-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VeH3BNOaSdWEGcXf2Rz2UmLIOCf8ym7dBzPRuRguduRwTBcnkJ0Mq/Lol17bnJ6n
 2GT7EdNHF3bFn5QCqCAv6Q==

<SEC-DOCUMENT>0001047469-09-006056.txt : 20090529
<SEC-HEADER>0001047469-09-006056.hdr.sgml : 20090529
<ACCEPTANCE-DATETIME>20090529165206
ACCESSION NUMBER:		0001047469-09-006056
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20090528
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090529
DATE AS OF CHANGE:		20090529

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		09862434

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a2193304z8-k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#09ZBT14501_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>FORM 8-K  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>CURRENT REPORT<BR>
PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF&nbsp;1934  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Date of report (Date of earliest event reported): </FONT><FONT SIZE=2><B>May&nbsp;28, 2009</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2>(Exact Name of Registrant as Specified in its Charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Delaware</B></FONT><FONT SIZE=2><BR>
(State or Other Jurisdiction<BR>
of Incorporation)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> 0-15006</B></FONT><FONT SIZE=2><BR>
(Commission<BR>
File Number)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> 13-3191702</B></FONT><FONT SIZE=2><BR>
(IRS Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>119 Fourth Avenue<BR>
Needham, Massachusetts</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>02494-2725</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>(Address of principal executive offices)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>(Zip Code)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Registrant's
telephone number, including area code: </FONT><FONT SIZE=2><B>(781)&nbsp;433-0771</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check
the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction&nbsp;A.2. below):  </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><FONT FACE="WINGDINGS">&#253;</FONT></FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Written
communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Soliciting
material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR
240.14a-12)
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act
(17&nbsp;CFR&nbsp;240.14d-2(b))
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act
(17&nbsp;CFR&nbsp;240.13e-4(c)) </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="1",CHK=587423,FOLIO='blank',FILE='DISK134:[09ZBT1.09ZBT14501]BA14501A.;4',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca14501_1_2"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ca14501_item_1.01._entry_into___ca101874"> </A>
<A NAME="toc_ca14501_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1.01.&nbsp;&nbsp;&nbsp;&nbsp;Entry into a Material Definitive Agreement    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On May&nbsp;29, 2009, Celldex Therapeutics,&nbsp;Inc., a Delaware corporation
("</FONT><FONT SIZE=2><I>Celldex</I></FONT><FONT SIZE=2>"), announced that it entered into an Agreement and Plan of Merger dated as of May&nbsp;28, 2009 (the "</FONT><FONT SIZE=2><I>Merger
Agreement</I></FONT><FONT SIZE=2>") by and among Celldex, CuraGen Corporation, a Delaware corporation ("</FONT><FONT SIZE=2><I>CuraGen</I></FONT><FONT SIZE=2>"), and Cottrell Merger Sub,&nbsp;Inc.,
a Delaware corporation and a wholly-owned subsidiary of Celldex (the "</FONT><FONT SIZE=2><I>Merger Sub</I></FONT><FONT SIZE=2>"). The Merger Agreement has been approved by the Boards of Directors of
Celldex and CuraGen and is subject to customary closing conditions, including stockholder approvals. A copy of a press release announcing the merger is attached hereto as Exhibit&nbsp;99.1 and is
incorporated by reference herein. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into CuraGen (the
"</FONT><FONT SIZE=2><I>Merger</I></FONT><FONT SIZE=2>"), with CuraGen being the surviving corporation of the Merger and becoming a wholly-owned subsidiary of Celldex. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the terms of the Merger Agreement, other than shares of CuraGen's common stock, par value $0.01 per share (the "</FONT><FONT SIZE=2><I>CuraGen Common
Stock</I></FONT><FONT SIZE=2>") held in treasury by CuraGen or beneficially owned by Celldex, each share of CuraGen Common Stock issued and outstanding immediately prior to the effective time of the
Merger (the "</FONT><FONT SIZE=2><I>Effective Time</I></FONT><FONT SIZE=2>"), including shares of restricted stock, shall be converted into the right to receive a number of shares of Celldex's common
stock, par value $0.01 ("</FONT><FONT SIZE=2><I>Celldex Common Stock</I></FONT><FONT SIZE=2>"), calculated pursuant to an exchange ratio described in the Merger Agreement (the
"</FONT><FONT SIZE=2><I>Exchange Ratio</I></FONT><FONT SIZE=2>"). The aggregate purchase price payable in the Merger, which is initially set at $94,500,000, is subject to adjustment based, in part,
on CuraGen's net cash position as of the Closing. The purchase price will adjust upward if CuraGen's Cash at Closing Amount (as defined in the Merger Agreement) exceeds $54,500,000 by $1.30 for each
$1.00 of excess until the aggregate
purchase price reaches $97,500,000, and thereafter by $1.00 for each $1.00 of excess up to a maximum aggregate purchase price of $100,000,000. The purchase price will adjust downward if CuraGen's Cash
at Closing Amount is less than $54,500,000 by $1.00 for each $1.00 of the shortfall. The foregoing adjustment is described in further detail in the Merger Agreement. Notwithstanding the foregoing, the
aggregate number of shares of Celldex Common Stock issuable pursuant to the Merger shall in no event exceed 58.0% or fall beneath 32.5% of the shares of Celldex Common Stock issued and outstanding
immediately after the Effective Time. No fractional shares of Celldex Common Stock will be issued in connection with the Merger, and holders of CuraGen Common Stock will be entitled to receive cash in
lieu thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the terms of the Merger Agreement, Celldex shall, at the Effective Time, assume all CuraGen stock options that were issued under CuraGen's 2007 Stock Plan and such options will
fully vest and be converted into options to acquire a number of shares of Celldex Common Stock determined by multiplying the number of shares of CuraGen Common Stock subject to such options
immediately prior to the Effective Time by the Exchange Ratio. Celldex shall not assume any of CuraGen's stock options that were issued under CuraGen's 1997 Stock Plan, which stock options will, to
the extent not yet vested, fully vest and terminate and be of no further force and effect upon consummation of the Merger if not exercised prior to that time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
in connection with the Merger, Celldex shall execute a supplemental indenture (the "</FONT><FONT SIZE=2><I>Supplemental Indenture</I></FONT><FONT SIZE=2>") to that certain
Indenture, dated as of February&nbsp;17, 2004, between CuraGen and The Bank of New York (the "</FONT><FONT SIZE=2><I>Indenture</I></FONT><FONT SIZE=2>") in respect of CuraGen's 4.0% Convertible
Subordinated Notes due February&nbsp;15, 2011 (the "</FONT><FONT SIZE=2><I>Notes</I></FONT><FONT SIZE=2>") currently outstanding under the Indenture. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Merger Agreement provides that, upon consummation of the Merger, the size of the Board of Directors of Celldex (the "</FONT><FONT SIZE=2><I>Board</I></FONT><FONT SIZE=2>") will be
set at nine members, consisting of (i)&nbsp;Celldex's eight current directors and (ii)&nbsp;one additional director agreed upon by Celldex and CuraGen, who is expected to be Timothy M. Shannon,
M.D. (the "</FONT><FONT SIZE=2><I>CuraGen Director</I></FONT><FONT SIZE=2>"). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="1",CHK=494048,FOLIO='2',FILE='DISK134:[09ZBT1.09ZBT14501]CA14501A.;7',USER='CDESORM',CD='29-MAY-2009;15:32' -->
<A NAME="page_ca14501_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the terms of the Merger Agreement, CuraGen is not permitted to solicit other proposals and may not share information or have discussions regarding alternative proposals,
except in certain circumstances. CuraGen may terminate the Merger Agreement under certain circumstances, including if its board of directors determines in good faith that it has received a Superior
Proposal (as defined in the Merger Agreement) and otherwise complies with certain terms of the Merger Agreement. In connection with such termination, CuraGen must pay to Celldex a termination fee of
$3,500,000. Similarly, Celldex may terminate the Merger Agreement under certain circumstances. Celldex is also required to pay to CuraGen a termination fee of $3,500,000 in connection with certain
terminations of the Merger Agreement by CuraGen. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of CuraGen and Celldex has made customary representations and warranties in the Merger Agreement and has agreed to customary covenants, including covenants regarding the operation
of the business of CuraGen and Celldex and its subsidiaries prior to the Closing. The Closing is subject to customary closing conditions, including (i)&nbsp;the approval by Celldex's shareholders of
the issuance of shares of Celldex Common Stock pursuant to the Merger, (ii)&nbsp;the adoption of the Merger Agreement by CuraGen's shareholders, (iii)&nbsp;the absence of certain legal impediments
to the consummation of the Merger, (iv)&nbsp;the filing of an effective registration statement on Form&nbsp;S-4 with respect to the shares of Celldex Common Stock to be issued in the
Merger, (v)&nbsp;the execution by Celldex of a Supplemental Indenture in respect of the Notes and (vi)&nbsp;the receipt by each party of an opinion from its counsel to the effect that the Merger
will qualify as a reorganization within the meaning of Section&nbsp;368(a) of the Internal Revenue Code of 1986, as amended. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, which is filed
as Exhibit&nbsp;2.1 hereto and is incorporated herein by reference. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> Cautionary Statements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Merger Agreement has been included to provide investors with information regarding its terms. Except for its status as a
contractual document that establishes and governs the legal relations among the parties thereto with respect to the transactions described above, the Merger Agreement is not intended to be a source of
factual, business or operational information about the parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Merger Agreement contains representations and warranties made by the parties to each other regarding certain matters. The assertions embodied in the representations and warranties
are qualified by information in confidential disclosure schedules that the parties have exchanged in connection with signing the Merger Agreement. The disclosure schedules contain information that
modifies, qualifies and creates exceptions to the representations and warranties. Moreover, certain representations and warranties may not be complete or accurate as of a particular date because they
are subject to a contractual standard of materiality that is different from those generally applicable to stockholders and/or were used for the purpose of allocating risk among the parties rather than
establishing certain matters as facts. Accordingly, you should not rely on the representations and warranties as characterizations of the actual state of facts at the time they were made or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ca14501_item_8.01_other_events"> </A>
<A NAME="toc_ca14501_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;8.01&nbsp;&nbsp;&nbsp;&nbsp;Other Events    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On May&nbsp;29, 2009, Celldex used an Investor Presentation document in connection with the Merger Agreement and the Merger, which is
attached hereto as Exhibit&nbsp;99.2, and a transcript of a conference call regarding the Merger Agreement and the Merger, which is attached hereto as Exhibit&nbsp;99.3. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the proposed Merger, Celldex will file with the Securities and Exchange Commission
("</FONT><FONT SIZE=2><I>SEC</I></FONT><FONT SIZE=2>") a Registration Statement on Form&nbsp;S-4 that will include a joint proxy statement of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=3,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="1",CHK=726109,FOLIO='3',FILE='DISK134:[09ZBT1.09ZBT14501]CA14501A.;7',USER='CDESORM',CD='29-MAY-2009;15:32' -->
<A NAME="page_ca14501_1_4"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>Celldex
and CuraGen that also constitutes a prospectus of Celldex. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE COMPANY, THE SELLER AND THE MERGER. The joint proxy statement/prospectus and other relevant materials (when they become available) and any other documents filed by Celldex or
CuraGen with the SEC may be obtained free of charge at the SEC's website at http://www.sec.gov. In addition, investors may obtain free copies of the documents filed with the SEC (i)&nbsp;by
contacting Celldex's Investor Relations at (781)&nbsp;433-0771 or by accessing Celldex's investor relations website at www.celldextherapeutics.com; or (ii)&nbsp;by contacting CuraGen's
Investor Relations at (203)&nbsp;871-4400 or by accessing CuraGen's investor relations website at www.curagen.com. Investors and security holders are urged to read the joint proxy
statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the transaction. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Participants in the Solicitation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The directors and executive officers of Celldex and CuraGen may be deemed to be participants in the solicitation of proxies from the
holders of Celldex and CuraGen common stock in respect of the proposed Merger. Information about the directors and executive
officers of Celldex and CuraGen are set forth in Celldex's and CuraGen's most recent Form&nbsp;10-K and Form&nbsp;10-K/A, which were filed with the SEC on March&nbsp;5,
2009 and April&nbsp;30, 2009, respectively. Investors may obtain additional information regarding the interest of Celldex and its directors and executive officers, and CuraGen and its directors and
executive officers in the proposed Merger, by reading the joint proxy statement/prospectus regarding the Merger when it becomes available. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ca14501_item_9.01_financial_statements_and_exhibits"> </A>
<A NAME="toc_ca14501_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="5" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="48" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="393" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Exhibit&nbsp;2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Agreement and Plan of Merger, dated as of May&nbsp;28, 2009, by and among Celldex Therapeutics,&nbsp;Inc., CuraGen Corporation and Cottrell Merger Sub,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Exhibit&nbsp;99.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Joint Press release issued by Celldex Therapeutics,&nbsp;Inc. and CuraGen Corporation, dated May&nbsp;29, 2009.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Exhibit&nbsp;99.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Celldex Therapeutics,&nbsp;Inc. Investor Presentation, May&nbsp;29, 2009.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Exhibit&nbsp;99.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Transcript of conference call, May&nbsp;29, 2009.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=4,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="1",CHK=612324,FOLIO='4',FILE='DISK134:[09ZBT1.09ZBT14501]CA14501A.;7',USER='CDESORM',CD='29-MAY-2009;15:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="page_jc14501_1_5"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc14501_signature"> </A>
<A NAME="toc_jc14501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="205" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="20" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="216" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> CELLDEX THERAPEUTICS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;AVERY W. CATLIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Name: Avery W. Catlin<BR>
Title: </FONT><FONT SIZE=2><I>Senior Vice President/Chief Financial Officer</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Dated: May&nbsp;29, 2009</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="1",CHK=769144,FOLIO='5',FILE='DISK134:[09ZBT1.09ZBT14501]JC14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="page_je14501_1_6"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="je14501_exhibit_index"> </A>
<A NAME="toc_je14501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT INDEX    <BR>    </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="5" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="48" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="393" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Exhibit&nbsp;2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Agreement and Plan of Merger, dated as of May&nbsp;28, 2009, by and among Celldex Therapeutics,&nbsp;Inc., CuraGen Corporation and Cottrell Merger Sub,&nbsp;Inc.(1)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Exhibit&nbsp;99.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Joint Press release issued by Celldex Therapeutics,&nbsp;Inc. and CuraGen Corporation, dated May&nbsp;29, 2009.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Exhibit&nbsp;99.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Celldex Therapeutics,&nbsp;Inc. Investor Presentation, May&nbsp;29, 2009.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Exhibit&nbsp;99.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Transcript of conference call, May&nbsp;29, 2009.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
schedules to this agreement have been omitted from this filing. Celldex will furnish copies of any such schedules to the U.S. Securities and Exchange
Commission upon request. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=6,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="1",CHK=901796,FOLIO='6',FILE='DISK134:[09ZBT1.09ZBT14501]JE14501A.;5',USER='LPALLES',CD='29-MAY-2009;12:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="09ZBT14501_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ca14501_1">Item 1.01. Entry into a Material Definitive Agreement</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ca14501_2">Item 8.01 Other Events</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ca14501_3">Item 9.01 Financial Statements and Exhibits</A></FONT><BR>
</UL>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_jc14501_1">SIGNATURE</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_je14501_1">EXHIBIT INDEX</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>a2193304zex-2_1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#09ZBT14501_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kc14501_exhibit_2.1"> </A>
<A NAME="toc_kc14501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT 2.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> AGREEMENT AND PLAN OF MERGER  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> BY AND AMONG  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CELLDEX THERAPEUTICS,&nbsp;INC.,  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> COTTRELL MERGER SUB,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> AND  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CURAGEN CORPORATION  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> May&nbsp;28, 2009  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=776259,FOLIO='blank',FILE='DISK134:[09ZBT1.09ZBT14501]KC14501A.;3',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="page_kd14501_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><B> TABLE OF CONTENTS  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" style="font-family:times;"></TD>
<TD WIDTH="10" style="font-family:times;"></TD>
<TD WIDTH="49" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="361" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="18" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> ARTICLE I DEFINITIONS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1.1</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Definitions</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
1</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1.2</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Terms Generally</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> ARTICLE II THE MERGER</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
8</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.1</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Merger</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
8</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.2</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Closing</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.3</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effective Time</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.4</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effects of the Merger</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.5</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Organizational Documents</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.6</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Directors and Officers of Surviving Corporation</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.7</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Closing Statement</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.8</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Disagreements Regarding Closing Statement</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.9</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transaction Expenses</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> ARTICLE III EFFECT OF THE MERGER ON THE CAPITAL STOCK OF THE CONSTITUENT CORPORATIONS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
11</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.1</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conversion of Securities</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
11</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.2</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fractional Shares; Adjustments</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.3</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exchange of Certificates</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.4</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Treatment of Options</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
16</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.1</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Existence and Power</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
16</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.2</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Authorization</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.3</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Governmental Authorization</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.4</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-Contravention</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.5</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization; Subsidiaries</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.6</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Reports and Financial Statements; Cash</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.7</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Undisclosed Liabilities</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.8</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Absence of Certain Changes or Events</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.9</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Litigation</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.10</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Taxes</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.11</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Employee Benefit Plans</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.12</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compliance With Laws</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.13</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Finders' Fees</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.14</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Opinion of Financial Advisor</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.15</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliate Transactions</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.16</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anti-Takeover Provisions</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.17</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Voting</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.18</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contracts</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.19</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Labor and Employee Matters</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.20</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Environmental</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.21</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.22</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Intellectual Property; Software</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.23</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Insurance</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.24</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Business Practices</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=707307,FOLIO='i',FILE='DISK134:[09ZBT1.09ZBT14501]KD14501A.;4',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kd14501_1_2"> </A>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" style="font-family:times;"></TD>
<TD WIDTH="10" style="font-family:times;"></TD>
<TD WIDTH="49" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="361" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="18" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Suppliers And Manufacturers; Effect Of Transaction</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Government Contracts</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FDA Regulatory Compliance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> ARTICLE V REPRESENTATIONS AND WARRANTIES OF BUYER AND MERGER SUB</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
31</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Existence and Power</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
32</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Authorization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Governmental Authorization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-Contravention</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEC Reports</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Undisclosed Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Absence of Certain Changes or Events</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Taxes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Litigation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Environmental</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Intellectual Property; Software</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FDA Regulatory Compliance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Suppliers And Manufacturers; Effect Of Transaction</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>No Breach of Designated Contracts</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Finders' Fees</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Opinion of Financial Advisor</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Merger Sub Operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ownership of Company Common Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> ARTICLE VI CONDUCT OF BUSINESS PENDING THE MERGER</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
39</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>6.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conduct of the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
39</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>6.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conduct of Buyer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>6.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>No Control of Other Party's Business</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> ARTICLE VII ADDITIONAL AGREEMENTS</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
43</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholder Meetings; Joint Proxy Statement/Prospectus</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
43</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Reasonable Best Efforts</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Access to Information</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Solicitation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director and Officer Liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Takeover Statutes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public Announcements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notice of Certain Events</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Employee Matters</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Listing</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Matters</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholder Litigation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exemption from Liability Under Section&nbsp;16(b)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board of Directors of Buyer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> ARTICLE VIII CONDITIONS TO THE MERGER</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
53</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>8.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conditions to the Obligations of Each Party</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
53</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>8.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conditions to the Obligations of Buyer and Merger Sub</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>8.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conditions to the Obligations of the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>54</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=3,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=555535,FOLIO='ii',FILE='DISK134:[09ZBT1.09ZBT14501]KD14501A.;4',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kd14501_1_3"> </A>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10" style="font-family:times;"></TD>
<TD WIDTH="10" style="font-family:times;"></TD>
<TD WIDTH="49" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="361" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="18" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> ARTICLE IX TERMINATION</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>9.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
55</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>9.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination Fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>9.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of Termination</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> ARTICLE X MISCELLANEOUS</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
58</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notices</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
58</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Representations and Warranties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amendment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Waiver</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Successors and Assigns</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Governing Law</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Counterparts; Effectiveness; Third Party Beneficiaries</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Severability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entire Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Remedies</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jurisdiction</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Headings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Further Assurances</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Authorship</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> INDEX OF SCHEDULES AND EXHIBITS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Exhibit&nbsp;A&nbsp;&nbsp;&nbsp;&nbsp;Form
of Certificate of Incorporation of Surviving Corporation </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Exhibit&nbsp;B&nbsp;&nbsp;&nbsp;&nbsp;Form
of Bylaws of Merger Sub </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Buyer
Disclosure Letter </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Company
Disclosure Letter </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>iii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=4,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=181115,FOLIO='iii',FILE='DISK134:[09ZBT1.09ZBT14501]KD14501A.;4',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><B> AGREEMENT AND PLAN OF MERGER  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This AGREEMENT AND PLAN OF MERGER (this "</FONT><FONT SIZE=2><I>Agreement</I></FONT><FONT SIZE=2>") is made and entered into as of
May&nbsp;28, 2009, by and among CuraGen Corporation, a Delaware corporation (the "</FONT><FONT SIZE=2><I>Company</I></FONT><FONT SIZE=2>"), Celldex Therapeutics,&nbsp;Inc., a Delaware corporation
("</FONT><FONT SIZE=2><I>Buyer</I></FONT><FONT SIZE=2>") and Cottrell Merger Sub,&nbsp;Inc., a Delaware corporation and a direct wholly owned subsidiary of Buyer ("</FONT><FONT SIZE=2><I>Merger
Sub</I></FONT><FONT SIZE=2>"). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> RECITALS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties intend that Merger Sub be merged with and into the Company upon the terms set forth herein, with the Company
surviving the Merger as a wholly owned subsidiary of Buyer; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS
the Board of Directors of the Company has (i)&nbsp;determined that it is in the best interests of the Company and its stockholders, and declared it advisable, to enter into
this Agreement, (ii)&nbsp;approved this Agreement in accordance with the DGCL, and (iii)&nbsp;resolved to recommend the adoption of this Agreement by the stockholders of the Company; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
the Board of Directors of each of Buyer and Merger Sub has approved and declared it advisable for Buyer and Merger Sub to enter into this Agreement; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
the parties intend to adopt this Agreement as a plan of reorganization and for the Merger to qualify as a reorganization within the meaning of Section&nbsp;368(a) of the Code
and the Treasury Regulations promulgated thereunder; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
the Company, Buyer and Merger Sub desire to make certain representations, warranties, covenants and agreements in connection with the Merger and also to prescribe certain
conditions to the Merger, as set forth herein. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> AGREEMENT  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein,
intending to be legally bound, the parties hereto agree as follows: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ARTICLE I<BR>
DEFINITIONS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.1</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Definitions.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, the following
terms have the respective meanings set forth below: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Accountant</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.8(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Acquisition Agreement</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.4(d)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Affiliate</I></FONT><FONT SIZE=2>" means, with respect to any Person, any other Person, directly or indirectly, controlling, controlled by, or under common
control with, such Person. For purposes of this definition, the term "</FONT><FONT SIZE=2><I>control</I></FONT><FONT SIZE=2>" (including the correlative terms
"</FONT><FONT SIZE=2><I>controlling</I></FONT><FONT SIZE=2>," "</FONT><FONT SIZE=2><I>controlled by</I></FONT><FONT SIZE=2>" and "</FONT><FONT SIZE=2><I>under common control
with</I></FONT><FONT SIZE=2>") means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of
voting securities, by contract or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Aggregate Exercise Price</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)(i)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Agreement</I></FONT><FONT SIZE=2>" has the meaning set forth in the Preamble. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Assumed Options</I></FONT><FONT SIZE=2>" means all options to acquire Company Common Stock granted under the 2007 Stock Plan outstanding immediately prior to the
Effective Time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Book Entry Shares</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.3(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Business Day</I></FONT><FONT SIZE=2>" means any day other than the days on which banks in New York, New York are required or authorized to close. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=585357,FOLIO='blank',FILE='DISK134:[09ZBT1.09ZBT14501]KE14501A.;6',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_ke14501_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer</I></FONT><FONT SIZE=2>" has the meaning set forth in the Preamble. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Balance Sheet Date</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;5.8</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Common Stock</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Common Stock Per Share Value</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT> <FONT SIZE=2><I>Section&nbsp;3.1(b)(ii)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Designated Contract</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;5.15</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Disclosure Letter</I></FONT><FONT SIZE=2>" has the meaning set forth in the preamble to </FONT><FONT SIZE=2><I>Article&nbsp;V</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Intellectual Property</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;5.12(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer IP Licenses</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;5.12(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Material Adverse Effect</I></FONT><FONT SIZE=2>" means any Effect that has had, or could reasonably be expected to have, individually or in the aggregate,
a material adverse effect on the business, properties, assets, liabilities (contingent or otherwise), results of operations or condition (financial or otherwise) of Buyer; </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT
SIZE=2><I>however</I></FONT><FONT SIZE=2>, that in no event shall any of the following, to the extent occurring after the date
hereof, alone or in combination with each other, be deemed to constitute, nor shall any of the following be taken into account in determining whether there has been, a Buyer Material Adverse Effect:
(A)&nbsp;any change in the market price or trading volume of the Buyer Common Stock, (B)&nbsp;any change in general economic or business conditions except to the extent that such changes have a
materially disproportionate adverse effect on Buyer relative to other similarly situated participants in the business or industry in which Buyer operates, (C)&nbsp;any change in financial or
securities market conditions generally, except to the extent that such changes have a disproportionate adverse effect on Buyer relative to other similarly situated participants in the business or
industry in which Buyer operates, (D)&nbsp;any Effects generally affecting the United States biotechnology industry except to the extent that such changes have a disproportionate adverse effect on
Buyer relative to other similarly situated participants in the business or industry which Buyer operates, (E)&nbsp;any change in legal, political or regulatory conditions generally or in any
geographic region in which Buyer or any of its Subsidiaries operates except to the extent that such changes have a disproportionate adverse effect on Buyer relative to other similarly situated
participants in the business or industry which Buyer operates, (F)&nbsp;the announcement of the execution of this Agreement or anticipation of the Merger or the pendency thereof, (G)&nbsp;acts of
war, armed hostilities, sabotage or terrorism, or any escalation of any such acts of war, armed hostilities, sabotage or terrorism threatened or underway as of the date of this Agreement, except to
the extent that such changes have a disproportionate adverse effect on Buyer relative to other similarly situated participants in the business or industry and in any geographic region in which Buyer
operates or (H)&nbsp;any failure to meet any internal or published projections, forecasts or revenue or earnings predictions for any period, or (I)&nbsp;changes in Law or GAAP after the date of
this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Objection Statement</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.8(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Recommendation</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.1(a)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Recommendation Withdrawal</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.1(d)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Registrations</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;5.13(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Sale</I></FONT><FONT SIZE=2>" means any acquisition in any manner, directly or indirectly (whether in a single transaction or a series of related
transactions and whether effected as a merger, consolidation, sale of all or substantially all of the assets, sale of stock or other similar transaction) of more than 50% of any class of equity
securities of the Buyer or acquisition in any manner, directly or indirectly (whether in a single transaction or a series of related transactions and including by means of license) of assets of the
Buyer (including securities of Subsidiaries) equal to more than 50% of the Buyer's consolidated assets or to which more than 50% of the Buyer's consolidated revenues are attributable; in each case
other </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=538672,FOLIO='2',FILE='DISK134:[09ZBT1.09ZBT14501]KE14501A.;6',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_ke14501_1_3"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>than
the transactions contemplated by this Agreement."</FONT><FONT SIZE=2><I>Buyer SEC Reports</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT> <FONT SIZE=2><I>Section&nbsp;5.6(a)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Securities</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;5.5(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Stockholder Meeting</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.1(d)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Termination Fee</I></FONT><FONT SIZE=2>" means $3,500,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Cancelled Share</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.1(c)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Capitalization Date</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Cash</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.7(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Cash at Closing Amount</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)(iii)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Certificates</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.3(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Certificate of Merger</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.3</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Closing</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.2</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Closing Balance Sheet</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.7(b)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Closing Statement</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.7</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Closing Date</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.2</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Code</I></FONT><FONT SIZE=2>" means the Internal Revenue Code of 1986, as amended. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Common Stock Exchange Ratio</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)(iv)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company</I></FONT><FONT SIZE=2>" has the meaning set forth in the Preamble. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Acquisition Proposal</I></FONT><FONT SIZE=2>" means any inquiry, proposal or offer from any Person or "group" (as defined in Section&nbsp;13(d) of the
Exchange Act), other than Buyer and its Subsidiaries, relating to any (i)&nbsp;merger, consolidation, liquidation, dissolution, sale of substantial assets, tender offer, recapitalization, share
exchange, business combination or similar transaction involving the Company or any of its Subsidiaries, (ii)&nbsp;acquisition in any manner, directly or indirectly (whether in a single transaction
or a series of related transactions) of 15% or more of any class of equity securities of the Company or any of its Subsidiaries or (iii)&nbsp;acquisition in any manner, directly or indirectly
(whether in a single transaction or a series of related transactions and including by means of license) of assets of the Company or any of its Subsidiaries (including securities of Subsidiaries) equal
to 15% or more of the Company's consolidated assets or to which 15% or more of the Company's consolidated revenues are attributable; in each case other than the transactions contemplated by this
Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Balance Sheet Date</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.8</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Benefit Plan</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.11(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Common Stock</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Common Stock Per Share Value</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT> <FONT SIZE=2><I>Section&nbsp;3.1(b)(v)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Disclosure Letter</I></FONT><FONT SIZE=2>" has the meaning set forth in the preamble to </FONT> <FONT SIZE=2><I>Article&nbsp;IV</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Employees</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.11(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Insiders</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.13(c)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Intellectual Property</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.22(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company IP Licenses</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.22(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=340037,FOLIO='3',FILE='DISK134:[09ZBT1.09ZBT14501]KE14501A.;6',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_ke14501_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Options</I></FONT><FONT SIZE=2>" means all options to acquire Company Common Stock granted under the Company Stock Plans outstanding immediately prior to
the Effective Time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Registrations</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.27(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Rights</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(a)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company SEC Reports</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.6(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Securities</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(c)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Stockholder Meeting</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.2</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Stock Plans</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(b)(i)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Termination Fee</I></FONT><FONT SIZE=2>" means $3,500,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Confidentiality Agreement</I></FONT><FONT SIZE=2>" means the Confidentiality Agreement between Buyer and the Company, dated as of March&nbsp;24, 2009. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Continuing Employees</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.9(a)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Contract</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.4</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Convertible Notes</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(b)(v)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Copyrights</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.22(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Current Policy</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.5(c)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Designated Severance Obligations</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)(vi)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>DGCL</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.1</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>DOL</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.11(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Effect</I></FONT><FONT SIZE=2>" means any change, event, effect, fact or state of circumstances. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Effective Time</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.3</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>End Date</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;9.1(b)(i)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Engagement Letter</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.13</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Environmental Laws</I></FONT><FONT SIZE=2>" means all applicable federal, state, local and foreign Laws (including international conventions, protocols and
treaties), common law, rules, regulations, orders, decrees, judgments, binding agreements or Environmental Permits issued, promulgated or entered into, by or with any Governmental Authority, relating
to pollution, the release of or exposure to Hazardous Materials, natural resources or the protection, investigation or restoration of the environment as in effect on the date of this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Environmental Permits</I></FONT><FONT SIZE=2>" means all permits, licenses, registrations and other governmental authorizations required under applicable
Environmental Laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>ERISA</I></FONT><FONT SIZE=2>" means the Employee Retirement Income Security Act of 1974, as amended. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>ERISA Affiliate</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.11(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Excess Cash at Closing</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)(viii)(B)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Exchange Act</I></FONT><FONT SIZE=2>" means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Exchange Agent</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.3(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=560272,FOLIO='4',FILE='DISK134:[09ZBT1.09ZBT14501]KE14501A.;6',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_ke14501_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Exchange Fund</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.3(a)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Exercise Period</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.4(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>FDA</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.27(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>FDA Laws</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.27(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Form&nbsp;S-4</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.1(a)(i)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>FTC</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.27(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>FTC Laws</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.27(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>GAAP</I></FONT><FONT SIZE=2>" means United States generally accepted accounting principles. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Governmental Authority</I></FONT><FONT SIZE=2>" means any nation or government or any agency, public or regulatory authority, instrumentality, department,
commission, court, arbitrator, ministry, tribunal or board of any nation or government or political subdivision thereof, in each case, whether foreign or domestic and whether national, supranational,
federal, provincial, state, regional, local or municipal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Hazardous Materials</I></FONT><FONT SIZE=2>" means (i)&nbsp;any substance that is listed, classified or regulated as hazardous or toxic or a pollutant or
contaminant under any Environmental Laws; or (ii)&nbsp;any petroleum product or by-product, asbestos-containing material, lead-containing paint or plumbing, polychlorinated
biphenyls, radioactive material, toxic molds or radon. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Indenture</I></FONT><FONT SIZE=2>" means the indenture between the Company and the Bank of New York, as trustee, dated as of February&nbsp;17, 2004, relating
to the Convertible Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Insurance Amount</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.5(c)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Intellectual Property</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.22(a)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>In the Money Options</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)(vii)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>IRS</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.11(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Joint Proxy Statement/Prospectus</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.1(a)(i)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Junior Preferred Stock</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Knowledge</I></FONT><FONT SIZE=2>" means (a)(i) with respect to the Company, the actual knowledge of the individuals set forth in </FONT> <FONT SIZE=2><I>Schedule&nbsp;1.1</I></FONT><FONT SIZE=2> of the Company Disclosure Letter and
(ii)&nbsp;with respect to Buyer, the actual knowledge of the individuals set forth in </FONT> <FONT SIZE=2><I>Schedule&nbsp;1.1</I></FONT><FONT SIZE=2> of the Buyer Disclosure Letter or (b)&nbsp;in the case of an individual, the actual knowledge of
such individual. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Law</I></FONT><FONT SIZE=2>" means applicable statutes, common laws, rules, ordinances, regulations, codes, orders, judgments, injunctions, writs, decrees,
governmental guidelines or interpretations having the force of law or bylaws, in each case, of a Governmental Authority. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Leased Real Property</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.21(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Liens</I></FONT><FONT SIZE=2>" means, with respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind in respect of
such asset. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Material Adverse Effect on the Company</I></FONT><FONT SIZE=2>" means any Effect that has had, or could reasonably be expected to have, individually or in the
aggregate, a material adverse effect on the business, properties, assets, liabilities (contingent or otherwise), results of operations or condition (financial or otherwise) of the Company; </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>,
</FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that in no event shall any of the following, to the extent occurring after the date
hereof, alone or in combination with each other, be deemed to constitute, nor shall any of the following be taken into account in determining whether there has been, a Material Adverse </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=383112,FOLIO='5',FILE='DISK134:[09ZBT1.09ZBT14501]KE14501A.;6',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_ke14501_1_6"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>Effect
on the Company: (A)&nbsp;any change in the market price or trading volume of the Company Common Stock, (B)&nbsp;any change in general economic or business conditions except to the extent
that such changes have a materially disproportionate adverse effect on the Company relative to other similarly situated participants in the business or industry in which the Company operates,
(C)&nbsp;any change in financial or securities market conditions generally, except to the extent that such changes have a disproportionate adverse effect on the Company relative to other similarly
situated participants in the business or industry in which the Company operates, (D)&nbsp;any Effects generally affecting the United States biotechnology industry except to the extent that such
changes have a disproportionate
adverse effect on the Company relative to other similarly situated participants in the business or industry which the Company operates, (E)&nbsp;any change in legal, political or regulatory
conditions generally or in any geographic region in which the Company operates except to the extent that such changes have a disproportionate adverse effect on the Company relative to other similarly
situated participants in the business or industry which the Company operates, (F)&nbsp;the announcement of the execution of this Agreement or anticipation of the Merger or the pendency thereof,
(G)&nbsp;acts of war, armed hostilities, sabotage or terrorism, or any escalation of any such acts of war, armed hostilities, sabotage or terrorism threatened or underway as of the date of this
Agreement, except to the extent that such changes have a disproportionate adverse effect on the Company relative to other similarly situated participants in the business or industry and in any
geographic region in which the Company operates or (H)&nbsp;any failure to meet any internal or published projections, forecasts or revenue or earnings predictions for any period, or
(I)&nbsp;changes in Law or GAAP after the date of this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Material Contracts</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.18(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Material Licenses</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.18(b)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Materials of Environmental Concern</I></FONT><FONT SIZE=2>" shall mean any hazardous, acutely hazardous, or toxic substance or waste defined and regulated as
such under applicable Environmental Laws, including the federal Comprehensive Environmental Response, Compensation and Liability Act or the federal Resource Conservation and Recovery Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Merger</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.1</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Merger Sub</I></FONT><FONT SIZE=2>" has the meaning set forth in the Preamble. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Multiemployer Plan</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.11(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>NASDAQ</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.2(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Non-Voting Common Stock</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Patents</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.22(a)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Permits</I></FONT><FONT SIZE=2>" means any licenses, franchises, permits, certificates, consents, approvals or other similar authorizations of, from or by a
Governmental Authority possessed by or granted to or necessary for the ownership of the material assets or conduct of the business of the applicable party. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Permitted Liens</I></FONT><FONT SIZE=2>" means (i)&nbsp;Liens for Taxes, assessments and governmental charges or levies not yet due and payable or that are
being contested in good faith and by appropriate proceedings; (ii)&nbsp;mechanics', carriers', workmen's, repairmen's, materialmen's or other Liens or security interests that arise in the ordinary
course of business or that are being contested in good faith and by appropriate proceedings; (iii)&nbsp;pledges or deposits to secure obligations under workers' compensation Laws or similar
legislation or to secure public or statutory obligations; (iv)&nbsp;pledges and deposits to secure the performance of bids, trade contracts, leases, surety and appeal bonds, performance bonds and
other obligations of a similar nature, in each case in the ordinary course of business; and (v)&nbsp;easements, covenants and rights of way (unrecorded and of record) and other similar restrictions
of record, and zoning, building and other similar restrictions, in each case that do not adversely affect in any material </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=530237,FOLIO='6',FILE='DISK134:[09ZBT1.09ZBT14501]KE14501A.;6',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_ke14501_1_7"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>respect
the current use of the applicable property owned, leased, used or held for use by a party or any of its Subsidiaries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Person</I></FONT><FONT SIZE=2>" means any individual, corporation, company, limited liability company, partnership, association, trust, joint venture or any
other entity or organization, including any government or political subdivision or any agency or instrumentality thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Purchase Price</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)(viii)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Pre-Closing Period</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;6.1</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Preferred Stock</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Proceeding</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;5.10</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>PSV Policies</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.9(b)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Real Property Lease</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.21(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Recommendation</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.1(a)(i)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Recommendation Withdrawal</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.4(a)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Representatives</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.4(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Required Stockholders Meetings</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.1(d)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Requisite Company Stockholder Vote</I></FONT><FONT SIZE=2>" means the affirmative vote of the holders of a majority of the voting power of the Company Common
Stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Requisite Buyer Stockholder Vote</I></FONT><FONT SIZE=2>" means the majority of the total votes cast by holders of the Buyer Common Stock at the Buyer
Stockholder Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Restricted Shares</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(b)(i)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Rights Plan</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(a)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Sarbanes-Oxley Act</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.6(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>SEC</I></FONT><FONT SIZE=2>" means the United States Securities and Exchange Commission. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Section&nbsp;16 Information</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.13(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Securities Act</I></FONT><FONT SIZE=2>" means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Severance Amount</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(h)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Software</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.22(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Statement</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.7</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Subsidiary</I></FONT><FONT SIZE=2>," with respect to any Person, means any other Person of which the first Person owns, directly or indirectly, securities or
other ownership interests having voting power to elect a majority of the board of directors or other persons performing similar functions (or, if there are no such voting interests, more than 50% of
the equity interests of the second Person). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Superior Proposal</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.4(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Supplemental Indenture</I></FONT><FONT SIZE=2>" means a supplemental indenture whereby the Buyer assumes the Company's obligations under the Indenture. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Surviving Corporation</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.1</I></FONT><FONT SIZE=2>. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=648274,FOLIO='7',FILE='DISK134:[09ZBT1.09ZBT14501]KE14501A.;6',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_ke14501_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Surviving Corporation Plan</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.9(c)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Tax</I></FONT><FONT SIZE=2>" means (A)&nbsp;all federal, state, local or foreign taxes, charges, fees, imposts, levies or other comparable assessments, in each
case in the nature of a tax, including all income, gross receipts, capital, sales, use, ad valorem, value added, transfer, franchise, profits, inventory, capital stock, license, withholding, payroll,
employment, social security, unemployment, excise, severance, stamp, occupation, property, alternative and estimated taxes, customs duties, fees, assessments and other charges in the nature of Taxes
imposed by any Tax authority or Governmental Entity, (B)&nbsp;all interest, penalties, fines, additions to tax or additional amounts imposed by any Tax authority or Governmental Entity in connection
with any item described in clauses&nbsp;(A) or (B), and (C)&nbsp;any amounts in respect of any items described in clauses&nbsp;(A) and/or (B)&nbsp;payable by reason of contract, assumption,
transferee liability, operation of Law, Treasury Regulation Section&nbsp;1.1502-6(a) (or any predecessor or successor thereof or any analogous or similar provision under federal, state,
local or foreign Law) or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Tax Return</I></FONT><FONT SIZE=2>" means any return, declaration, report, statement, information statement or other document, together with all associated
schedules, filed or required to be filed with a Governmental Authority with respect to Taxes, including any claims for refunds of Taxes, any information returns and any amendments or supplements of
any of the foregoing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Trademarks</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.22(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Trade Secrets</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.22(a)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Transaction Expenses</I></FONT><FONT SIZE=2>" has the meaning set forth in Section </FONT><FONT SIZE=2><I>3.1(b)(ix)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>1993 Stock Plan</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(b)(iv)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>1997 Plan Options</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;3.4(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>1997 Stock Plan</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(b)(i)</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>2007 Stock Plan</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(b)(i)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>2009 Budget</I></FONT><FONT SIZE=2>" has the meaning set forth in </FONT><FONT SIZE=2><I>Section&nbsp;6.1(l)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.2</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Terms Generally.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The definitions in </FONT> <FONT SIZE=2><I>Section&nbsp;1.1</I></FONT><FONT SIZE=2>
shall apply equally to both the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall
include the corresponding masculine, feminine and neuter forms. The words "include," "includes" and "including" shall be deemed to be followed by the phrase "without limitation," unless the context
expressly provides otherwise. All references herein to Sections, paragraphs, subparagraphs, clauses, Exhibits or Schedules shall be deemed references to Sections, paragraphs, subparagraphs or clauses
of, or Exhibits or Schedules to this Agreement, unless the context requires otherwise. Unless otherwise expressly defined, terms defined in this Agreement have the same meanings when used in any
Exhibit or Schedule hereto, including the Company Disclosure Letter. Unless otherwise specified, the words "this Agreement," "herein," "hereof," "hereto" and "hereunder" and other words of similar
import refer to this Agreement as a whole (including the Schedules, Exhibits and the Company Disclosure Letter) and not to any particular provision of this Agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ARTICLE II<BR>
THE MERGER  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>2.1</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>The Merger.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;On the terms and subject to the conditions set
forth in this Agreement, and in accordance with the General Corporation Law of the State of Delaware (the "</FONT><FONT SIZE=2><I>DGCL</I></FONT><FONT SIZE=2>"), at the Effective Time, Merger Sub
will merge with and into the Company (the "</FONT><FONT SIZE=2><I>Merger</I></FONT><FONT SIZE=2>"), the separate corporate existence of Merger Sub will cease and the Company will continue its
corporate existence under the DGCL as the surviving corporation in the Merger (the "</FONT><FONT SIZE=2><I>Surviving Corporation</I></FONT><FONT SIZE=2>"). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=12,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=377978,FOLIO='8',FILE='DISK134:[09ZBT1.09ZBT14501]KE14501A.;6',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_kg14501_1_9"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>2.2</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Closing.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise mutually agreed in
writing by the
Company and Buyer, the closing of the Merger (the "</FONT><FONT SIZE=2><I>Closing</I></FONT><FONT SIZE=2>") will take place at the offices of Lowenstein Sandler PC, 65 Livingston Ave., Roseland, New
Jersey, at 10:00&nbsp;a.m. on the second Business Day after the satisfaction or waiver of the conditions set forth in </FONT><FONT SIZE=2><I>Article&nbsp;VIII</I></FONT><FONT SIZE=2> (excluding
conditions that, by their terms, cannot be satisfied until the Closing but subject to the satisfaction or waiver of such conditions at the Closing), or at such other place, date and time as the
Company and Buyer may agree in writing. The date on which the Closing actually occurs is hereinafter referred to as the "</FONT><FONT SIZE=2><I>Closing Date</I></FONT><FONT SIZE=2>." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>2.3</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Effective Time.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of this Agreement,
at the Closing, the parties hereto shall cause the Merger to be consummated by executing and filing a certificate of merger (the "</FONT><FONT SIZE=2><I>Certificate of
Merger</I></FONT><FONT SIZE=2>") with the Secretary of State of the State of Delaware in accordance with the DGCL. The Merger will become effective at such date and time as the Certificate of Merger
has been duly filed with and accepted for recording by the Secretary of State of the State of Delaware or at such later date or time as may be agreed by the Company and Buyer in writing and specified
in the Certificate of Merger in accordance with the DGCL (the effective time of the Merger being hereinafter referred to as the "</FONT><FONT SIZE=2><I>Effective Time</I></FONT><FONT SIZE=2>"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>2.4</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Effects of the Merger.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Merger shall have the effects set
forth in this Agreement and the applicable provisions of the DGCL. Without limiting the generality of the foregoing, and subject thereto, from and after the Effective Time, all property, rights,
privileges, immunities, powers, franchises, licenses and authority of the Company and Merger Sub shall vest in the Surviving Corporation, and all debts, liabilities, obligations, restrictions and
duties of each of the Company and Merger Sub shall become the debts, liabilities, obligations, restrictions and duties of the Surviving Corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>2.5</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Organizational Documents.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At the Effective Time,
(a)&nbsp;the Certificate of Incorporation of the Surviving Corporation shall be amended to read in its entirety in the form attached hereto as </FONT> <FONT SIZE=2><I>Exhibit&nbsp;A</I></FONT><FONT SIZE=2> and (b)&nbsp;the bylaws of the Surviving
Corporation shall be amended so as to read in their entirety as the bylaws of Merger Sub as
in effect immediately prior to the Effective Time, in the form attached hereto as </FONT><FONT SIZE=2><I>Exhibit&nbsp;B</I></FONT><FONT SIZE=2>, until thereafter amended in accordance with
applicable Law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>2.6</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Directors and Officers of Surviving Corporation.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
directors of the Company immediately prior to the Effective Time shall submit their resignations to be effective as of the Effective Time, which resignations shall be a condition of the Merger.
Immediately after the Effective Time, Buyer shall take the necessary action to cause the directors of Merger Sub immediately prior to the Effective Time to be the directors of the Surviving
Corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Corporation. The officers of the Merger Sub immediately prior to the Effective Time
shall be the initial officers of the Surviving Corporation, each to hold office until the earlier of their resignation or removal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>2.7</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Closing Statement.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No later than three (3)&nbsp;Business
Days prior to the Closing, the Company shall deliver a statement certified by the Chief Financial Officer of the Company, which shall set forth the Company's calculation of the Cash at Closing Amount
and which shall include the items described in Section&nbsp;2.7(a), (b)&nbsp;and (c), below (the "</FONT><FONT SIZE=2><I>Statement</I></FONT><FONT SIZE=2>"). During the period between Buyer's
receipt of the Statement and the Closing, Buyer and the Company shall seek in good faith to resolve any differences that they may have with respect to the matters specified in the Statement and the
Company shall afford to Buyer such access to its books and records related to the Statement as Buyer may deem necessary to verify the Statement. The Statement shall become final upon the earlier to
occur of (i)&nbsp;the resolution (whether pursuant to the procedures set forth in </FONT><FONT SIZE=2><I>Section&nbsp;2.8</I></FONT><FONT SIZE=2> or otherwise) by Buyer and the Company of any
disagreements they have with respect thereto (the "</FONT><FONT SIZE=2><I>Closing Statement</I></FONT><FONT SIZE=2>") or (ii)&nbsp;at 5:00 PM, New York time, on the second Business Day after the
date the Company delivers the Statement to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=128398,FOLIO='9',FILE='DISK134:[09ZBT1.09ZBT14501]KG14501A.;9',USER='MSULLIV',CD='29-MAY-2009;13:37' -->
<A NAME="page_kg14501_1_10"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>the
Buyer, if Buyer has not notified the Company of any disagreements with respect to the Statement by that time. The Statement shall include the following: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;(i)
bank statements for the most recently concluded month and (ii)&nbsp;a roll-forward of the balances shown on such bank statements showing the amount in
cash, cash equivalents, marketable securities and short term investments available in the Company's accounts as of the close of business on the day immediately prior to the date of delivery of such
Closing Statement which is not subject to any lien or right of set-off in favor of any third party, calculated using the same methods used in the calculation of Cash in the preparation of
the Company's audited financial statements and the process and methods described in </FONT><FONT SIZE=2><I>Schedule&nbsp;4.6(h)</I></FONT><FONT SIZE=2> of the Company Disclosure Letter, including
the same methods and assumptions used in making good faith estimates in respect of cash equivalents, marketable securities and short term investments for which market valuations are not readily
obtainable ("</FONT><FONT SIZE=2><I>Cash</I></FONT><FONT SIZE=2>"); and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;an
unaudited balance sheet of the Company as of the day immediately prior to the date of delivery of the Statement prepared in accordance with GAAP applied on a
consistent basis using the same procedures and methods as used in preparing the audited financial statements of the Company (the "</FONT><FONT SIZE=2><I>Closing Balance
Sheet</I></FONT><FONT SIZE=2>"), including a schedule of anticipated payments to be made by the Company during the period following delivery of the Statement to the extent liabilities for such
payments have not been accrued on the Closing Balance Sheet; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;the
aggregate amount of the Designated Severance Obligations. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>2.8</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Disagreements Regarding Closing Statement.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;In
the event of a disagreement between Buyer and the Company with respect to the Statement, Buyer and the Company shall work together in good faith to resolve such
disagreement. If, after a period of five (5)&nbsp;Business Days after the Company's delivery of the Statement to Buyer, the parties have not reached agreement, they shall promptly thereafter cause
an independent accountant of nationally recognized standing reasonably satisfactory to Buyer and the Company (who shall not be either party's independent registered public accounting firm) (the
"</FONT><FONT SIZE=2><I>Accountant</I></FONT><FONT SIZE=2>"), to review, as promptly as possible, this Agreement and the disputed items or amounts for the purpose of calculating the Cash at Closing
Amount. Concurrently with commencement of this review, Buyer shall provide to the Company and the Accountant a statement describing its disagreements with the Company with respect to the Statement and
what it believes to be the correct amounts for the disputed item or amounts and for the Cash at Closing Amount in total (the "</FONT><FONT SIZE=2><I>Buyer Objection
Statement</I></FONT><FONT SIZE=2>"). In making its calculation of the disputed items or amounts and the total Cash at Closing Amount, the Accountant shall consider only those items or amounts in the
Statement as to which Buyer and the Company have a disagreement. The Accountant shall deliver to Buyer and the Company, as promptly as practicable, a report setting forth its calculation of the
disputed items and amounts and the total Cash at Closing Amount, which shall be final, conclusive and binding upon the Buyer and the Company. Upon delivery of the Accountant's report, the Statement
shall be modified as necessary to reflect the Accountant's conclusions and the total Cash at Closing Amount, and upon such modification, the Statement shall be considered the Closing Statement for
purposes of </FONT><FONT SIZE=2><I>Section&nbsp;2.7</I></FONT><FONT SIZE=2> above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Buyer
and the Company shall share the fees and expenses of the Accountant's review and report based upon what portion of the changes called for in the Buyer Objection
Statement are reflected in the Closing Statement, as follows: (1)&nbsp;the Buyer shall be responsible for an amount equal to the total amount of such fees and expenses multiplied by a fraction, the
numerator of which is the difference (if any) between (A)&nbsp;the Cash at Closing Amount shown on the Statement (after adjusting the Statement to reflect all of the changes called for in the Buyer
Objection Statement) and (B)&nbsp;the Cash at Closing Amount as shown on the Closing Statement, and the denominator of which is the difference between (C)&nbsp;the Cash at Closing Amount as shown
on the </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=319386,FOLIO='10',FILE='DISK134:[09ZBT1.09ZBT14501]KG14501A.;9',USER='MSULLIV',CD='29-MAY-2009;13:37' -->
<A NAME="page_kg14501_1_11"> </A>
<UL>
<BR>


<P style="font-family:times;"><FONT SIZE=2>Statement
(after adjusting the Statement to reflect all of the changes called for in the Buyer Objection Statement) and (D)&nbsp;the Cash at Closing Amount as shown on the Statement and
(2)&nbsp;the Company shall be responsible for the balance of such fees and expenses. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>2.9</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Transaction Expenses.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Concurrently with the delivery of the
Statement and no later than three (3)&nbsp;Business Days prior to the Closing Date, the Company shall provide to Buyer the amount, in the aggregate, of all Transaction Expenses that have not been
paid prior to Closing and shall provide Buyer with a certificate setting forth (a)&nbsp;the identity of each Person that is owed such amounts; (b)&nbsp;the amount
owed or to be owed to each such Person; and (c)&nbsp;the bank account and wire transfer information for each such Person. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ARTICLE III<BR>
EFFECT OF THE MERGER ON THE CAPITAL STOCK<BR>
OF THE CONSTITUENT CORPORATIONS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>3.1</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Conversion of Securities.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At the Effective Time, pursuant to
this Agreement and by virtue of the Merger and without any action on the part of the Company, Buyer, Merger Sub or their stockholders: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Each
share of common stock, par value $0.01 per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and become
one newly issued, fully paid and non-assessable share of common stock of the Surviving Corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Each
share of common stock, par value $0.01 per share, of the Company (including the Restricted Shares) ("</FONT><FONT SIZE=2><I>Company Common
Stock</I></FONT><FONT SIZE=2>") issued and outstanding immediately prior to the Effective Time, other than any Cancelled Shares, shall be converted into the right to receive a number of shares of
common stock of Buyer ("</FONT><FONT SIZE=2><I>Buyer Common Stock</I></FONT><FONT SIZE=2>") equal to the Common Stock Exchange Ratio after surrender of such share of Company Common Stock in the
manner provided in </FONT><FONT SIZE=2><I>Section&nbsp;3.3</I></FONT><FONT SIZE=2>. Subject to the other provisions of this </FONT><FONT SIZE=2><I>Article&nbsp;III</I></FONT><FONT SIZE=2>, as of
the Effective Time, each such share of Company Common Stock shall, by virtue of the Merger, cease to be outstanding and shall be cancelled, and each certificate representing any such shares and each
book entry on the Company's stock register representing any such shares which are non-certificated shares shall thereafter represent only the right to receive (i)&nbsp;the number of
whole shares of Buyer Common Stock into which the shares represented by such certificate or book entry have been converted, and (ii)&nbsp;cash in lieu of fractional shares of Buyer Common Stock in
accordance with </FONT><FONT SIZE=2><I>Section&nbsp;3.2(a)</I></FONT><FONT SIZE=2>, without interest. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Aggregate Exercise Price</I></FONT><FONT SIZE=2>" shall mean the aggregate exercise price of all In the Money Options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Buyer Common Stock Per Share Value</I></FONT><FONT SIZE=2>" shall mean, with respect to Buyer Common Stock, the volume weighted average of the
closing prices of sales of Buyer Common Stock on NASDAQ on fifteen randomly selected days during the period of thirty trading days ending on the trading day that is two days prior to the Effective
Time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Cash at Closing Amount</I></FONT><FONT SIZE=2>" shall mean the result obtained by subtracting the sum of (A)&nbsp;(1) the amount of the
Transaction Expenses </FONT><FONT SIZE=2><I>plus</I></FONT><FONT SIZE=2> (2)&nbsp;the aggregate principal amount and the amount of accrued but unpaid interest owed by the Company in respect of the
Convertible Notes outstanding as of the Closing Date to the extent not reflected as a current liability in the Closing Balance Sheet </FONT><FONT SIZE=2><I>plus</I></FONT><FONT SIZE=2> (3)&nbsp;the
amount of the Designated Severance Obligations </FONT><FONT SIZE=2><I>plus</I></FONT><FONT SIZE=2> (4)&nbsp;the aggregate amount of other current liabilities as indicated on the Closing Balance
Sheet from (B)&nbsp;the sum of (1)&nbsp;the amount of Cash available in the Company's accounts as of the Closing Date, plus (2)&nbsp;the amount of other current assets, property and equipment,
net and </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=684093,FOLIO='11',FILE='DISK134:[09ZBT1.09ZBT14501]KG14501A.;9',USER='MSULLIV',CD='29-MAY-2009;13:37' -->
<A NAME="page_kg14501_1_12"> </A>
<UL>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>other
assets, net reflected on the Closing Balance Sheet less the amount of deferred financing fees included in other assets, net, plus (3)&nbsp;the Aggregate Exercise Price. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Common Stock Exchange Ratio</I></FONT><FONT SIZE=2>" shall equal the quotient of (A)&nbsp;the Company Common Stock Per Share Value </FONT> <FONT SIZE=2><I>divided by</I></FONT><FONT SIZE=2> (B)&nbsp;the Buyer Common Stock Per Share Value.
</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Company Common Stock Per Share Value</I></FONT><FONT SIZE=2>" shall equal the quotient of (A)&nbsp;the Purchase Price </FONT> <FONT SIZE=2><I>divided by</I></FONT><FONT SIZE=2> (B)&nbsp;the sum of (1)&nbsp;the number of shares of Company
Common Stock outstanding immediately prior to the Effective Time </FONT> <FONT SIZE=2><I>plus</I></FONT><FONT SIZE=2> (2)&nbsp;the number of shares of Company Common Stock issuable upon exercise of In the Money Options outstanding immediately prior
to the
Effective Time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Designated Severance Obligations</I></FONT><FONT SIZE=2>" shall mean the sum of (A)&nbsp;the Severance Amount in respect of each Company
employee or officer who will not be a Continuing Employee, </FONT><FONT SIZE=2><I>plus</I></FONT><FONT SIZE=2> (B)&nbsp;the total cash cost to the Company reasonably expected to be incurred in
connection with the loss of any federal Tax deduction for the Severance Amounts by virtue of Section&nbsp;280G of the Code; provided, for the avoidance of doubt, that any reduction of net operating
losses as a result of a lost federal Tax deduction for the Severance Amounts shall not in any circumstances be considered a cash cost that is included in the amount of Designated Severance
Obligations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>In the Money Options</I></FONT><FONT SIZE=2>" means each Assumed Option with an exercise price that is less than or equal to $1.67 per share
as of the date of this Agreement (without giving effect to any adjustment to the exercise price of such options arising from the Merger or the other transactions contemplated by this Agreement). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Purchase Price</I></FONT><FONT SIZE=2>" shall be defined as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(A)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>if
the Cash at Closing amount is $54,500,000, "Purchase Price" shall mean $94,500,000;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(B)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>if
the Cash at Closing amount is greater than $54,500,000, the "Purchase Price" shall be adjusted upward from $94,500,000 on the basis of the amount by
which the Cash at Closing Amount exceeds $54,500,000 (the "</FONT><FONT SIZE=2><I>Excess Cash at Closing</I></FONT><FONT SIZE=2>") as follows: (X)&nbsp;the "Purchase Price" shall be increased by
$1.30 for each $1 of Excess Cash at Closing until the Purchase Price has been increased to $97,500,000 and (Y)&nbsp;the "Purchase Price" shall be increased above $97,500,000 to a maximum of
$100,000,000 by $1 for each $1 of Excess Cash at Closing for which no adjustment has been made pursuant to the preceding clause&nbsp;(X); and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(C)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>if
the Cash at Closing amount is less than $54,500,000, "Purchase Price" shall mean the result obtained by subtracting (X)&nbsp;the amount by which
$54,500,000 exceeds the Cash at Closing Amount from (Y)&nbsp;$94,500,000 (rounded to the nearest whole dollar). </FONT></DD></DL>
</UL>
</UL>
</UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Transaction Expenses</I></FONT><FONT SIZE=2>" shall mean the sum of (a)&nbsp;all fees, costs and expenses of any brokers, financial advisors,
consultants, accountants, attorneys or other professionals engaged by the Company in connection with the structuring, negotiation or consummation of the transactions contemplated by this Agreement and
(b)&nbsp;the cost of the tail policy of directors' and officers' liability insurance referred to in </FONT><FONT SIZE=2><I>Section&nbsp;7.5(c)</I></FONT><FONT SIZE=2>. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Cancelled Shares</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Each share of Company Common Stock held by the Company as treasury stock or owned by Buyer
immediately prior to the Effective Time shall be, automatically and without the need for any action on the part of the holders thereof, cancelled and shall cease to exist, and no payment or
distribution shall be made or delivered with respect thereto (each a "</FONT><FONT SIZE=2><I>Cancelled Share</I></FONT><FONT SIZE=2>"). </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=537542,FOLIO='12',FILE='DISK134:[09ZBT1.09ZBT14501]KG14501A.;9',USER='MSULLIV',CD='29-MAY-2009;13:37' -->
<A NAME="page_kg14501_1_13"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Convertible Notes</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The Convertible Notes shall remain outstanding in accordance with their terms and the
Buyer shall assume the Company's obligations under such Convertible Notes and related agreements by execution and delivery of a Supplemental Indenture as of the Closing. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Limitations on Aggregate Share Issuance</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this
Agreement, the aggregate number of shares of Buyer Common Stock issuable pursuant to the Merger shall in no event exceed 58% or fall below 32.5% of the outstanding shares of Buyer Common Stock
immediately after the Effective Time, calculated on the basis of the total number of shares of Buyer
Common Stock outstanding immediately after the Effective Time. The Common Stock Exchange Ratio shall be automatically adjusted to effect the foregoing limitations. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>3.2</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Fractional Shares; Adjustments.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;No
fractional shares of Company Common Stock shall be issued as a result of the conversion provided for in </FONT> <FONT SIZE=2><I>Section&nbsp;3.1(b)</I></FONT><FONT SIZE=2>. In lieu of any such fractional shares, each holder of a fractional interest
in Company Common Stock shall be entitled to receive
from the Exchange Agent a cash payment therefor in an amount equal to the value (determined with reference to the closing price of a share of Buyer Common Stock as reported on The Nasdaq Stock Market
("</FONT><FONT SIZE=2><I>NASDAQ</I></FONT><FONT SIZE=2>") on the last full trading day immediately prior to date the Merger becomes effective) of such fractional interest. Such payment with respect
to fractional shares is merely intended to provide a mechanical rounding off of, and is not a separately bargained for, consideration. Any payment owed with respect to fractional shares shall be
rounded upward to the nearest whole cent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;If,
prior to the Effective Time, the Company or Buyer shall declare a stock dividend or other similar distribution of Company Common Stock or Buyer Common Stock or
securities convertible into shares of Company Common Stock or Buyer Common Stock, as applicable, or effect a stock split, reclassification, recapitalization, stock combination or other change with
respect to the Company Common Stock or Buyer Common Stock, as applicable, the Common Stock Exchange Ratio shall be adjusted to reflect such dividend, distribution, stock split, reclassification,
recapitalization, stock combination or other change. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>3.3</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Exchange of Certificates.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exchange Agent.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At or as soon as practicable following the Effective Time, Buyer shall deposit pursuant to
an Exchange Agent Agreement in form and substance reasonably satisfactory to the Company with Computershare&nbsp;Inc. or such other exchange agent as may be designated by Buyer and reasonably
acceptable to the Company (the "</FONT><FONT SIZE=2><I>Exchange Agent</I></FONT><FONT SIZE=2>"), for the benefit of the holders of Company Common Stock, for exchange in accordance with this </FONT> <FONT SIZE=2><I>Section&nbsp;3.3</I></FONT><FONT
SIZE=2>, certificates representing shares of Buyer Common Stock issuable pursuant to </FONT> <FONT SIZE=2><I>Section&nbsp;3.1(b)</I></FONT><FONT SIZE=2> in exchange for outstanding shares of Company Common Stock and shall from time to time deposit
cash in an amount sufficient to
make payments in lieu of fractional shares in accordance with </FONT><FONT SIZE=2><I>Section&nbsp;3.2(a)</I></FONT><FONT SIZE=2> (such shares of Buyer Common Stock and cash, together with any
dividends or distributions with respect thereto, being hereinafter referred to as the "</FONT><FONT SIZE=2><I>Exchange Fund</I></FONT><FONT SIZE=2>"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Procedures.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At or as soon as practicable after the Effective Time, Buyer shall instruct the Exchange Agent
to mail to each holder of record of (1)&nbsp;a certificate or certificates which immediately prior to the Effective Time represented outstanding shares of Company Common Stock whose shares were
converted into the right to receive shares of Buyer Common Stock pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)</I></FONT><FONT SIZE=2>
("</FONT><FONT SIZE=2><I>Certificates</I></FONT><FONT SIZE=2>") and (2)&nbsp;shares of Company Common Stock that were non-certificated shares represented by book entry immediately prior
to the Effective Time and which were converted into the right to receive shares of Buyer Common Stock pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;3.1(b)</I></FONT><FONT SIZE=2>
("</FONT><FONT SIZE=2><I>Book Entry Shares</I></FONT><FONT SIZE=2>"), (i)&nbsp;a letter of transmittal (which shall be in customary form and which shall specify that delivery shall be effected, and
risk of loss and title to the Certificates </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=378828,FOLIO='13',FILE='DISK134:[09ZBT1.09ZBT14501]KG14501A.;9',USER='MSULLIV',CD='29-MAY-2009;13:37' -->
<A NAME="page_kg14501_1_14"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>shall
pass, only upon delivery of the Certificates or Book Entry Shares to the Exchange Agent), and (ii)&nbsp;instructions for effecting the surrender of the Certificates or Book Entry Shares in
exchange for certificates representing shares of Buyer Common Stock. Upon surrender of a Certificate or Book Entry Shares for cancellation to the Exchange Agent or an affidavit as provided in </FONT> <FONT SIZE=2><I>Section&nbsp;3.3(h)
</I></FONT><FONT SIZE=2>, together with a duly executed letter of transmittal, the holder of such Certificate or Book Entry Shares shall be entitled to
receive in exchange therefor (x)&nbsp;a certificate or certificates representing that whole number of shares of Buyer Common Stock which such holder has the right to receive pursuant to </FONT> <FONT SIZE=2><I>Section&nbsp;3.1(b)</I></FONT><FONT
SIZE=2> in such denominations and registered in such names as such holder may request and (y)&nbsp;a check representing the amount of
cash in lieu of fractional shares, if any, and unpaid dividends and distributions, if any, which such holder has the right to receive pursuant to the provisions of this </FONT> <FONT SIZE=2><I>Article&nbsp;III</I></FONT><FONT SIZE=2>, after giving
effect to any required withholding Tax. No interest will be paid or accrued on the cash in lieu of fractional shares,
if any, and unpaid dividends and distributions, if any, payable to holders of shares of Buyer Common Stock. In the event of a transfer of ownership of shares of Company Common Stock which is not
registered on the transfer records of the Company, a certificate representing the proper number of shares of Buyer Common Stock, together with a check for the cash to be paid in lieu of fractional
shares, if any, and unpaid dividends and distributions, if any, may be issued to such transferee if the Certificate representing such shares of Company Common Stock held by such transferee or the Book
Entry Shares held by such transferee is presented or otherwise surrendered to the Exchange Agent, accompanied by all documents required to evidence and effect such transfer and to evidence that any
applicable stock transfer Taxes have been paid. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Distributions with Respect to Unexchanged Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provisions of this Agreement, no
dividends or other distributions declared or made after the Effective Time with respect to any shares of Buyer Common Stock having a record date after the Effective Time shall be paid to the holder of
any unsurrendered Certificate or Book Entry Shares, and no cash payment in lieu of fractional shares shall be paid to any such holder, until the holder shall surrender such Certificate or Book Entry
Shares as provided in this </FONT><FONT SIZE=2><I>Section&nbsp;3.3</I></FONT><FONT SIZE=2>. Subject to the effect of applicable abandoned property, escheat or similar Laws, there shall be paid to
such holder at the time of surrender of such Certificate or Book Entry Shares, without interest, the amount of dividends or other distributions with a record date after the Effective Time theretofore
payable and not paid, and there shall be paid to such holder on the relevant payment date the amount of dividends or other distributions with a record date after the Effective Time and a payment date
after such surrender, less the amount of any withholding Taxes which may be required thereon. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Further Ownership Rights in Company Common Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All shares of Buyer Common Stock issued upon surrender
of Certificates or Book Entry Shares in accordance with the terms hereof (including
any cash paid pursuant to this</FONT><FONT SIZE=2><I> Article&nbsp;III</I></FONT><FONT SIZE=2>) shall be deemed to have been issued in full satisfaction of all rights pertaining to the shares of
Company Common Stock represented thereby, and there shall be no further registration of transfers on the stock transfer books of the Company of shares of Company Common Stock or outstanding
immediately prior to the Effective Time. All Certificates or Book Entry Shares presented to the Surviving Corporation or the Exchange Agent after the Effective Time for any reason shall be cancelled
and exchanged as provided in this</FONT><FONT SIZE=2><I> Section&nbsp;3.3.  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Termination of Exchange Fund.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any portion of the Exchange Fund which remains
undistributed to holders of Buyer Common Stock one year after the Closing Date shall be delivered to the Surviving Corporation upon demand, and holders of Certificates or Book Entry Shares previously
representing shares of Company Common Stock who have not theretofore complied with this </FONT><FONT SIZE=2><I>Section&nbsp;3.3</I></FONT><FONT SIZE=2> shall thereafter look only to the Surviving
Corporation for payment </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=18,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=104114,FOLIO='14',FILE='DISK134:[09ZBT1.09ZBT14501]KG14501A.;9',USER='MSULLIV',CD='29-MAY-2009;13:37' -->
<A NAME="page_kg14501_1_15"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>of
any claim to shares of Buyer Common Stock, cash in lieu of fractional shares thereof, or dividends or distributions, if any, in respect thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Liability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;None of Buyer, the Surviving Corporation or the Exchange Agent shall be liable to any person
in respect of any shares of Buyer Common Stock (or dividends or distributions with respect thereto) or cash from the Exchange Fund delivered to a public official pursuant to any applicable abandoned
property, escheat or similar Law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Investment of Exchange Fund.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Exchange Agent shall invest any cash included in the Exchange Fund, as
directed by Buyer, on a daily basis. Any interest and other income resulting from such investments shall be paid to the Surviving Corporation upon termination of the Exchange Fund pursuant
to</FONT><FONT SIZE=2><I> Section&nbsp;3.3(e).  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Missing Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event any Certificate shall have been lost, stolen or
destroyed, upon the making of an affidavit of that fact and providing an appropriate indemnity or surety bond by the person claiming such Certificate to be lost, stolen or destroyed, the Exchange
Agent will issue in exchange for such lost, stolen or destroyed Certificate the shares of Buyer Common Stock (including the dividends and distributions with respect thereto) and cash in lieu of
fractional shares deliverable in respect thereof pursuant to this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Withholding.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Buyer, Company, the Surviving Corporation and the Exchange Agent shall be entitled to deduct
and withhold from any consideration payable hereunder any amounts required to be deducted and withheld under any applicable Tax Law. To the extent any amounts are so withheld and timely paid to the
applicable Tax authority, such amounts shall be treated for all purposes as having been paid to the holder to whom such amounts would otherwise have been paid. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>3.4</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Treatment of Options.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;At
the Effective Time, the Company's obligations with respect to each Assumed Option will be assumed by the Buyer. Each Assumed Option so assumed by the Buyer under this
Agreement shall be subject to substantially the same terms and conditions set forth in the agreement pursuant to which such Assumed Option was issued as in effect immediately prior to the Effective
Time, except that (i)&nbsp;such Assumed Option will be exercisable for that number of shares of Buyer Common Stock equal to the product of the number of shares of Company Common Stock that were
purchasable under such Company Option immediately prior to the Effective Time multiplied by the Common Stock Exchange Ratio, rounded down to the nearest whole number of shares of Buyer Common Stock
and (ii)&nbsp;the per share exercise price for the shares of Buyer Common Stock issuable upon exercise of such Assumed Option will be equal to the quotient determined by dividing the exercise price
per share of Company Common Stock at which such Assumed Option was exercisable immediately prior to the Effective Time by the Common Stock Exchange Ratio, and rounding the resulting exercise price up
to the nearest whole cent. The adjustment to each Assumed Option pursuant to this Agreement shall be made in a manner that complies with Treasury Regulation Sections&nbsp;1.424-1 and
1.409A-1(b)(5)(v)(D). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Prior
to the Effective Time, the vesting of each outstanding option to purchase shares of Company Common Stock under the 1997 Stock Plan (the
"</FONT><FONT SIZE=2><I>1997 Plan Options</I></FONT><FONT SIZE=2>"), to the extent not yet fully vested, shall be accelerated such that all outstanding 1997 Plan Options are exercisable in full for a
specified period of time prior to the Effective Time (the "</FONT><FONT SIZE=2><I>Exercise Period</I></FONT><FONT SIZE=2>"). At the Effective Time, each 1997 Plan Option that has not been previously
exercised shall terminate, and the Company shall have no further obligations with respect to any such unexercised 1997 Plan Option. The Company shall take all action that may be reasonably necessary
to effectuate the provisions of this </FONT><FONT SIZE=2><I>Section&nbsp;3.4</I></FONT><FONT SIZE=2>, including without limitation providing written notice to all holders of 1997 Plan Options by no
later than 30&nbsp;days prior to the Effective Time, which notice shall specify </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=19,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=358921,FOLIO='15',FILE='DISK134:[09ZBT1.09ZBT14501]KG14501A.;9',USER='MSULLIV',CD='29-MAY-2009;13:37' -->
<A NAME="page_kg14501_1_16"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>the
Exercise Period and indicate that the vesting of 1997 Plan Options, to the extent not fully vested, will be accelerated, that any exercises of 1997 Plan Options must occur prior to the end of the
Exercise Period, and that any 1997 Plan Option that has not previously been exercised will automatically terminate at the Effective Time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Buyer
will reserve sufficient shares of Buyer Common Stock for issuance pursuant to the Assumed Options under this Section&nbsp;3.4. As soon as practicable after the
Effective Time, Buyer shall file&nbsp;a registration statement on Form&nbsp;S-8 (or any successor form) or another appropriate form with respect to the shares of Buyer Common Stock
subject to the Assumed Options and shall use its best efforts to maintain the effectiveness of such registration statement or registration statements (and maintain the current status of the prospectus
or prospectuses contained therein) for so long as such Assumed Options remain outstanding. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ARTICLE IV<BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except (i)&nbsp;as set forth in the disclosure letter (the "</FONT><FONT SIZE=2><I>Company Disclosure
Letter</I></FONT><FONT SIZE=2>") delivered to Buyer and Merger Sub by the Company concurrently with entering into this Agreement (it being understood that any information set forth in one section or
subsection of the Company Disclosure Letter shall be deemed to apply to and qualify the section or subsection of this Agreement to which it corresponds in number and each other section or subsection
of this Agreement to which the relevance of such disclosure is readily apparent on its face), or (ii)&nbsp;as disclosed in the Company SEC Reports (as defined herein) filed prior to the date of this
Agreement (other than any forward-looking disclosures set forth in any risk factor section, any disclosures in any section relating to forward-looking statements and any other similar disclosures
included therein to the extent they are primarily predictive or forward-looking in nature), the Company hereby represents and warrants to Buyer and Merger Sub that: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.1</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Corporate Existence and Power.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company is duly
organized, validly existing and in good standing under the laws of its jurisdiction of organization. The Company has all corporate or similar powers and authority required to own, lease and operate
its respective properties and to carry on its business as now conducted. The Company is duly licensed or qualified to do business in each jurisdiction in which the nature of the business conducted by
it or the character or location of the properties and assets owned or leased by it makes such qualification necessary, except for any failures to be so licensed or qualified that would not reasonably
be expected to have a Material Adverse Effect on the Company. The Company is not in violation of its organizational or governing documents in any respect. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.2</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Corporate Authorization.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company has the corporate power
and authority to execute and deliver this Agreement and, subject to the adoption of this Agreement by the Requisite Company Stockholder Vote, to consummate the Merger and the other transactions
contemplated hereby and to perform each of its obligations hereunder. The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the Merger and the
other transactions contemplated hereby have been duly and validly authorized by the Board of Directors of the Company. The Board of Directors of the Company at a duly held meeting has
(i)&nbsp;determined that it is in the best interests of the Company and its stockholders to enter into this Agreement, (ii)&nbsp;approved the execution, delivery and performance of this Agreement
and the consummation of the transactions contemplated hereby, including the Merger, and (iii)&nbsp;resolved to recommend that the stockholders of the Company approve the adoption of this Agreement
and directed that such matter be submitted for consideration of the stockholders of the Company at a meeting called for the purpose of approving and adopting this Agreement (the
"</FONT><FONT SIZE=2><I>Company Stockholder Meeting</I></FONT><FONT SIZE=2>"). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=20,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=434863,FOLIO='16',FILE='DISK134:[09ZBT1.09ZBT14501]KG14501A.;9',USER='MSULLIV',CD='29-MAY-2009;13:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_kh14501_1_17"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>4.3</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Governmental Authorization.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The execution,
delivery and
performance by the Company of this Agreement and the consummation of the Merger by the Company do not and will not require any consent, approval, authorization or permit of, action by, filing with or
notification to any Governmental Authority, other than (i)&nbsp;the filing of the Certificate of Merger; (ii)&nbsp;compliance with the applicable requirements of the Exchange Act, including the
filing of the Form&nbsp;S-4; (iii)&nbsp;compliance with the rules and regulations of NASDAQ; (iv)&nbsp;compliance with any applicable foreign or state securities or blue sky laws;
(v)&nbsp;such filings and consents as may be required under any environmental, health or safety law or regulation, or any health care licensure laws, reimbursement authorities and their agents,
certificate of need laws and other health care laws and regulations, pertaining to any notification, disclosure or approval required by the Merger or the other transactions contemplated by this
Agreement; and (vi)&nbsp;any such consent, approval, authorization, permit, action, filing or notification the failure of which to be made or obtained would not (A)&nbsp;individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect on the Company or (B)&nbsp;reasonably be expected to prevent or materially delay the consummation of the Merger. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.4</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Non-Contravention.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Assuming compliance with the
matters referenced in </FONT><FONT SIZE=2><I>Section&nbsp;5.3</I></FONT><FONT SIZE=2>, the receipt of the Requisite Company Stockholder Vote and Buyer's execution of the Supplemental Indenture, the
execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the Merger and the other transactions contemplated hereby do not and will not
(i)&nbsp;contravene or conflict with the organizational or governing documents of the Company; (ii)&nbsp;contravene or conflict with or constitute a violation of any provision of any Law binding
upon or applicable to the Company, or any of its properties or assets; (iii)&nbsp;require the consent, approval or authorization of, or notice to or filing with any third party with respect to,
result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both would become a default) or result in the loss of a benefit under, or give rise to
any right of termination, cancellation, amendment or acceleration of any right or obligation of the Company, or result in the creation of any Lien on any of the properties or assets of the Company
under, any loan or credit agreement, note, bond, mortgage, indenture, contract, agreement, lease, license, permit or other instrument or obligation (each, a
"</FONT><FONT SIZE=2><I>Contract</I></FONT><FONT SIZE=2>") to which the Company is a party or by which the Company or its properties or assets are bound, except, in the case of clause&nbsp;(iii)
above, as would not (A)&nbsp;individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on the Company or (B)&nbsp;reasonably be expected to prevent or materially
delay the consummation of the Merger. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.5</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Capitalization; Subsidiaries.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
authorized capital stock of the Company consists of (i)&nbsp;250,000,000 shares of Company Common Stock, (ii)&nbsp;3,000,000 shares of Non-Voting
Common Stock (the "</FONT><FONT SIZE=2><I>Non-Voting Common Stock</I></FONT><FONT SIZE=2>"), and (iii)&nbsp;5,000,000 shares of Preferred Stock, par value $.01 per share (the
"</FONT><FONT SIZE=2><I>Preferred Stock</I></FONT><FONT SIZE=2>"), of which 1,000,000 shares have been designated as Series&nbsp;A Junior Participating Preferred Stock (the
"</FONT><FONT SIZE=2><I>Junior Preferred Stock</I></FONT><FONT SIZE=2>") and have been reserved for issuance upon the exercise of the rights (the "</FONT><FONT SIZE=2><I>Company
Rights</I></FONT><FONT SIZE=2>") distributed to the holders of Common Stock pursuant to that certain Stockholder Rights Agreement, dated as of March&nbsp;27, 2002 (the
"</FONT><FONT SIZE=2><I>Rights Plan</I></FONT><FONT SIZE=2>"), by and between the Company and American Stock Transfer&nbsp;&amp; Trust Company, as Rights Agent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;As
of May&nbsp;27, 2009 (the "</FONT><FONT SIZE=2><I>Capitalization Date</I></FONT><FONT SIZE=2>"): </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;57,194,682
shares of Company Common Stock were issued and outstanding (which number includes 150,000 shares of restricted Company Common Stock (the
"</FONT><FONT SIZE=2><I>Restricted Shares</I></FONT><FONT SIZE=2>") outstanding pursuant to the Company's 2007 Stock Incentive Plan (the "</FONT><FONT SIZE=2><I>2007 Stock
Plan</I></FONT><FONT SIZE=2>") and the Company's 1997 Employee, Director and Consultant Stock Plan (the "</FONT><FONT SIZE=2><I>1997 Stock Plan</I></FONT><FONT SIZE=2>", and together with the 2007
Stock Plan, the "</FONT><FONT SIZE=2><I>Company Stock Plans</I></FONT><FONT SIZE=2>"); </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=21,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=856854,FOLIO='17',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_18"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;no
shares of Company Common Stock were held by the Company in its treasury; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;no
shares of Preferred Stock were issued and outstanding; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;(A)
the Company has reserved 6,000,000 shares of Company Common Stock for issuance under the 2007 Stock Plan, of which options to purchase 3,643,632 shares have been
granted and are currently outstanding, (B)&nbsp;the Company has reserved 10,500,000 shares of Company Common Stock for issuance under the Company's 1997 Stock Plan, of which options to purchase
1,493,348 shares have been granted and are currently outstanding and (C)&nbsp;there are no options outstanding under the Company's 1993 Stock Option Plan (the "</FONT><FONT SIZE=2><I>1993 Stock
Plan</I></FONT><FONT SIZE=2>"); </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;1,460,061
shares of Company Common Stock were reserved for issuance upon conversion of the Company's outstanding 4.00% Convertible Subordinated Notes due 2011 (the
"</FONT><FONT SIZE=2><I>Convertible Notes</I></FONT><FONT SIZE=2>"); and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;&nbsp;no
warrants to purchase shares of Company Common Stock were issued or outstanding. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>All
outstanding shares of Company Common Stock are duly authorized, validly issued, fully paid and non-assessable, and are not subject to and were not issued in violation of any preemptive
or similar right, purchase option, call or right of first refusal or similar right. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Except
as set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.5(b)</I></FONT><FONT SIZE=2>, there have not been reserved for issuance, and there are no outstanding
(i)&nbsp;shares of capital stock or other voting securities of the Company; (ii)&nbsp;securities of the Company convertible into or exchangeable for shares of capital stock or voting securities of
the Company, other than Company Options and the Convertible Notes; (iii)&nbsp;Company Options or other rights or options to acquire from the Company, or obligations of the Company to issue, any
shares of capital stock, voting securities or securities convertible into or exchangeable for shares of capital stock or voting securities of the Company, as the case may be; or (iv)&nbsp;equity
equivalent interests in the ownership or earnings of the Company (the items in clauses&nbsp;(i) through (iv)&nbsp;collectively, "</FONT><FONT SIZE=2><I>Company
Securities</I></FONT><FONT SIZE=2>"). There are no outstanding obligations of the Company to repurchase, redeem or otherwise acquire any Company Securities. There are no preemptive rights of any kind
which obligate the Company to issue or deliver any Company Securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;Other
than the issuance of shares of Company Common Stock upon exercise of Company Options, from the Company Balance Sheet Date to the date of this Agreement, the
Company has not declared or paid any dividend or distribution in respect of any Company Securities, and the Company has not issued, sold, repurchased, redeemed or otherwise acquired any Company
Securities, and the Board of Directors has not authorized any of the foregoing. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;As
of the date hereof, the Company has not entered into any commitment, arrangement or agreement, or is otherwise obligated, to contribute capital, loan money or
otherwise provide funds or make additional investments in any Person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the date of this Agreement, the Company has amended the Rights Plan in accordance with its terms (i)&nbsp;to render the Rights Plan inapplicable to the
transactions contemplated by this Agreement and (ii)&nbsp;so that the Company Rights will expire immediately prior to the Effective Time, provided that no Distribution Date (as defined in the Rights
Plan) or Stock Acquisition Date (as defined in the Rights Plan) shall have occurred. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;The
Company does not own, directly or indirectly, any capital stock or equity securities of any Person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Section&nbsp;4.5(h)</I></FONT><FONT SIZE=2> of the Company Disclosure Letter sets forth, in respect of each officer and employee of the
Company, the aggregate amount of severance payments that are payable or may </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=22,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=190978,FOLIO='18',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_19"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>become
payable by the Company to such employee or officer in connection with the Merger under an employment agreement set forth in </FONT><FONT SIZE=2><I>Section&nbsp;4.11</I></FONT><FONT SIZE=2>
of the Company Disclosure Letter, the CuraGen Corporation Severance Pay Policy (for each such employee, the "</FONT><FONT SIZE=2><I>Severance Amount</I></FONT><FONT SIZE=2>"). </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.6</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Reports and Financial Statements; Cash.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
Company and its Subsidiaries have filed all forms, reports, statements, certifications and other documents (including all exhibits and other information incorporated
therein, amendments and supplements thereto) required to be filed by them with the SEC since January&nbsp;1, 2005 (all such forms, reports, statements, certificates and other documents filed since
January&nbsp;1, 2005, including any amendments thereto, collectively, the "</FONT><FONT SIZE=2><I>Company SEC Reports</I></FONT><FONT SIZE=2>") and all Company SEC Reports have been filed on a
timely basis. As of their respective dates the Company SEC Reports complied, and each of the SEC Reports filed subsequent to the date of this Agreement will comply, in all material respects with the
requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act of 2002 (the "</FONT><FONT SIZE=2><I>Sarbanes-Oxley Act</I></FONT><FONT SIZE=2>"), as the case may be, and the
applicable rules and regulations promulgated thereunder. As of the time of filing with the SEC, none of the Company SEC Reports so filed or that will be filed subsequent to the date of this Agreement
contained or will contain, as the case may be, any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;The
audited consolidated financial statements of the Company (including any related notes thereto) included in the Company SEC Reports have been prepared in accordance
with GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto) and fairly present in all material respects the consolidated financial
position of the Company and its Subsidiaries at the respective dates thereof and the consolidated statements of operations and comprehensive income, cash flows and changes in stockholders' equity for
the periods indicated. The unaudited consolidated financial statements of the Company (including any related notes thereto) for all interim periods included in the Company SEC Reports have been
prepared in accordance with GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto) and fairly present in all material respects the
consolidated financial position of the Company and its Subsidiaries as of the respective dates thereof and the consolidated statements of operations and comprehensive income and cash flows for the
periods indicated (subject to normal and recurring period-end adjustments that have not been and are not expected to be material to the Company and its Subsidiaries taken as a whole). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Neither
the Company nor any of its Subsidiaries is a party to, or has any commitment to become a party to, any Contract or arrangement (including any Contract or
arrangement relating to any transaction or relationship between or among the Company and any of its subsidiaries, on the one
hand, and any affiliate, including any structured finance, special purpose or limited purpose entity or person, on the other hand), where the result, purpose or intended effect of such Contract or
arrangement is to avoid disclosure of any material transaction involving, or material liabilities of, the Company or any of its Subsidiaries in the Company's published consolidated financial
statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;The
Company has made available to Buyer a complete and correct copy of any amendments or modifications which have not yet been filed (but which the Company intends to
file) with the SEC to agreements, documents or other instruments which previously had been filed by the Company with the SEC pursuant to the Securities Act or the Exchange Act, and the regulations
promulgated thereunder. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=23,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=737725,FOLIO='19',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_20"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;The
principal executive officer and principal financial officer of the Company have made all certifications required by the Sarbanes-Oxley Act and the regulations of the
SEC promulgated thereunder, and the statements contained in all such certifications were as of the respective dates made, and are, complete and correct. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;The
Company has (A)&nbsp;designed disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Exchange
Act) to ensure that material information relating to the Company, including its consolidated Subsidiaries, is made known to its principal executive officer and principal financial officer;
(B)&nbsp;designed internal control over financial reporting (as defined in Rules&nbsp;13a-15(f) and 15d-15(f) under the Exchange Act) to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP; (C)&nbsp;evaluated the effectiveness of the Company's
disclosure controls and procedures and, to the extent required by applicable Law, presented in any applicable Company SEC Report that is a report on Form&nbsp;10-K or
Form&nbsp;10-Q or any amendment thereto its conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by such report or amendment
based on such evaluation; and (D)&nbsp;to the extent required by applicable Law, disclosed in such report or amendment any change in the Company's internal control over financial reporting that
occurred during the period covered by such report or amendment that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;The
Company has disclosed, based on the most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the
Company's Board of Directors (A)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the Company's ability to record, process, summarize and report financial information, and (B)&nbsp;any fraud, whether or not material, that involves management or other employees
who have a significant role in the Company's internal control over financial reporting. Since January&nbsp;1, 2005, (i)&nbsp;neither the Company nor any of its Subsidiaries, nor, to the Knowledge
of the Company, any director, officer, employee, auditor, accountant or
representative of the Company or any of its Subsidiaries has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral,
regarding the accounting or auditing practices, procedures, methodologies or methods of the Company or any of its Subsidiaries or their respective internal accounting controls, including any material
complaint, allegation, assertion or claim that the Company or any of its Subsidiaries has engaged in questionable accounting or auditing practices, and (ii)&nbsp;no attorney representing the Company
or any of its Subsidiaries, whether or not employed by the Company or any of its Subsidiaries, has reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar
violation by the Company or any of its Subsidiaries or their respective officers, directors, employees or agents to the Board of Directors of the Company or any committee thereof or to any director or
officer of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;As
of May&nbsp;22, 2009, the Company has Cash in an amount equal to the amount set forth in </FONT><FONT SIZE=2><I>Schedule&nbsp;4.6(h)</I></FONT><FONT SIZE=2> of
the Company Disclosure Letter, which amount has been determined using the process and methods described in such schedule. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.7</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Undisclosed Liabilities.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except (i)&nbsp;for those
liabilities that are reflected or reserved against on the balance sheet of the Company (including the notes thereto) included in the Company's Quarterly Report on Form&nbsp;10-Q for the
quarter ended March&nbsp;31, 2009, (ii)&nbsp;for liabilities incurred that are reflected as current liabilities on the Closing Balance Sheet, (iii)&nbsp;for liabilities that have been discharged
or paid in full prior to the date that is five Business Days prior to the date of this Agreement in the ordinary course of business consistent with past practice, and (iv)&nbsp;for liabilities in
respect of the Transaction Expenses (whether absolute, accrued or contingent or otherwise and whether </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=24,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=61535,FOLIO='20',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2>due
or to become due), the Company does not have any liabilities, commitments or obligations, asserted or unasserted, known or unknown, absolute or contingent, whether or not accrued, matured or
un-matured or otherwise, of a nature required by GAAP to be reflected in a consolidated balance sheet or disclosed in the notes thereto. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.8</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Absence of Certain Changes or Events.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Since the date of the
financial statements included or incorporated by reference in the Company's Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2009 (the
"</FONT><FONT SIZE=2><I>Company Balance Sheet Date</I></FONT><FONT SIZE=2>"), (a)&nbsp;no Effect has occurred which has had or would reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect on the Company and (b)&nbsp;the Company has not taken or omitted to take any action that would, if taken or omitted to be taken after the date hereof, result in
a breach of </FONT><FONT SIZE=2><I>Section&nbsp;6.1</I></FONT><FONT SIZE=2> of this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.9</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Litigation.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company is not a party to any, and there are
no pending or, to the Company's Knowledge, threatened, Proceedings of any nature against the Company, in each case that, individually or in the aggregate, would reasonably be expected to have a
Material Adverse Effect on the Company. Neither the Company, nor its business or properties is subject to or bound by any injunction, order, judgment, decree or regulatory restriction of any
Governmental Authority specifically imposed upon the Company or its properties or assets. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.10</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Taxes.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties contained in this </FONT> <FONT
SIZE=2><I>Section&nbsp;4.10</I></FONT><FONT SIZE=2> are the only representations and warranties made by the Company in this Agreement with respect to Tax matters. Except as would not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect on the Company: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;All
Tax Returns required to be filed by or with respect to the Company have been timely filed, and all such Tax Returns are true, correct and complete. The Company is
not currently the beneficiary of any extension of time within which to file any Tax Return. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;The
Company (i)&nbsp;has timely paid all Taxes due and payable (whether or not shown to be due on the Tax Returns referred to in this </FONT> <FONT SIZE=2><I>Section&nbsp;4.10</I></FONT><FONT SIZE=2>), except for Taxes for which adequate reserves have
been established in accordance with GAAP, and (ii)&nbsp;has made adequate
provision in the applicable financial statements, in accordance with GAAP, for all Taxes not yet due and payable with respect to taxable periods, or portions thereof, for which no Tax Return has yet
been filed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;As
of the date hereof, no audit or other proceeding by any Governmental Authority is pending or, to the Knowledge of the Company, threatened with respect to any Taxes of
the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;There
are no Tax sharing agreements (or similar agreements) under which the Company is liable for Taxes of any other Person (other than the Company). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;The
Company has not constituted either a "distributing corporation" or a "controlled corporation" in a distribution of stock qualifying or intended to qualify for
Tax-free treatment under Section&nbsp;355 of the Code in the two years prior to the date of this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;The
Company has not participated in a "reportable transaction" within the meaning of Section&nbsp;6707A(c)(1) of the Code or Treasury Regulation
Section&nbsp;1.6011-4(b). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;The
Company does not have any liability for Taxes of any Person (other than the Company) under Treasury Regulation &sect;&nbsp;1.1502-6 (or any
similar provision of state, local or foreign Law), as a transferee or successor, by contract or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;There
are no liens for Taxes (other than Taxes not yet due and payable) upon any of the assets of the Company. The Company has complied in all material respects with all
applicable Laws relating to the payment and withholding of Taxes in connection with amounts paid or owing </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=25,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=558820,FOLIO='21',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_22"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>to
any employee, independent contractor, creditor, stockholder or other third party and has duly and timely withheld and paid over to the appropriate Governmental Authority all amounts required to be
so withheld and paid under all applicable Laws, and all Forms&nbsp;W-2 and 1099 required with respect thereto have been properly completed and timely filed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;The
Company has delivered or made available to Buyer complete copies of (i)&nbsp;all federal, state, local and foreign income or franchise Tax Returns of the Company
relating to the Taxable periods since January&nbsp;1, 2005 and (ii)&nbsp;any audit report issued within the last three years relating to any Taxes due from or with respect to the Company. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;The
Company has never been a member of any consolidated, combined, affiliated or unitary group of corporations for any Tax purposes other than a group of which the
Company is the common parent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;No
Person has granted any extension or waiver of the statute of limitations period applicable to any Tax of the Company, which period (after giving effect to such
extension or waiver) has not yet expired. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;The
Company has not been a United States real property holding corporation within the meaning of Section&nbsp;897(c)(2) of the Code during the applicable period
specified in Section&nbsp;897(c)(1)(A)(ii) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&nbsp;The
Company has not changed any of its methods of reporting income or deductions for Tax purposes from those employed in the preparation of its Tax Returns for the Tax
year ended December&nbsp;31, 2007. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;&nbsp;&nbsp;The
Company will not be required to include any item of income in, or exclude any item of deduction from, Taxable income for any period (or any portion thereof) ending
after the Closing Date as a result of any: (i)&nbsp;deferred intercompany gain or any excess loss account described in Treasury Regulations under Section&nbsp;1502 of the Code (or any
corresponding provision of state, local or foreign Tax Law); (ii)&nbsp;closing agreement as described in Section&nbsp;7121 of the Code (or any corresponding or similar provision of state, local or
foreign Tax Law) executed on or prior to the Closing Date; (iii)&nbsp;installment sale or other open transaction disposition made on or prior to the Closing Date; or (iv)&nbsp;prepaid amount
received on or prior to the Closing Date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;&nbsp;&nbsp;To
the Knowledge of the Company, after consulting with its Tax advisors, neither the Company nor any of its Affiliates has taken or agreed to take any action which would
prevent the Merger from constituting a transaction qualifying as a reorganization under Section&nbsp;368(a) of the Code. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.11</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Employee Benefit Plans.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Section&nbsp;4.11(a)</I></FONT><FONT SIZE=2>&nbsp;&nbsp;of the Company Disclosure Letter sets forth a correct and complete list of
(i)&nbsp;all employee welfare benefit plans (as defined in Section&nbsp;3(1) of ERISA), (ii)&nbsp;all employee pension benefit plans (as defined in Section&nbsp;3(2) of ERISA) and
(iii)&nbsp;all other employee benefit plans, programs, policies, agreements or arrangements, including any deferred compensation plan, incentive plan, bonus plan or arrangement, stock option plan,
stock purchase plan, stock award plan or other equity-based plan, change in control agreement, retention, severance pay plan, dependent care plan, sick leave, disability, death benefit, group
insurance, hospitalization, dental, life, any fund, trust or arrangement providing health benefits including multiemployer welfare arrangements, a multiple employer welfare fund or arrangement,
cafeteria plan, employee assistance program, scholarship program, employment contract, retention incentive agreement, termination agreement, severance agreement, noncompetition agreement, consulting
agreement, confidentiality agreement, vacation policy, employee loan, or other similar plan, agreement or arrangement, whether written or oral, funded or unfunded, or actual or contingent that
(A)&nbsp;is </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=26,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=417035,FOLIO='22',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_23"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>maintained
by the Company or any of its Subsidiaries for the benefit of any current or former employees, consultants or directors of the Company or any of its Subsidiaries, or their beneficiaries
(collectively, "</FONT><FONT SIZE=2><I>Company Employees</I></FONT><FONT SIZE=2>"), (B)&nbsp;has been approved by the Company or any of its Subsidiaries but is not yet effective for the benefit of
Company Employees, or (C)&nbsp;was previously maintained by the Company or any of its Subsidiaries for the benefit of the Company Employees and with respect to which the Company or any of its
Subsidiaries has any liability (each a "</FONT><FONT SIZE=2><I>Company Benefit Plan</I></FONT><FONT SIZE=2>"). The Company has made available to Buyer a correct and complete copy (where applicable)
of (1)&nbsp;each Company Benefit Plan (or, where a Company Benefit Plan has not been reduced to writing, a summary of all material terms of such Company Benefit Plan), (2)&nbsp;each trust or
funding arrangement prepared in connection with each Company Benefit Plan, (3)&nbsp;the three most recently filed annual reports on Internal Revenue Service
("</FONT><FONT SIZE=2><I>IRS</I></FONT><FONT SIZE=2>") Form&nbsp;5500 or any other annual report required by applicable Law with respect to each Company Benefit, (4)&nbsp;the most recently
received IRS determination letter for each Company Benefit Plan, (5)&nbsp;the most recently prepared actuarial report and financial statement in connection with each Company Benefit Plan,
(6)&nbsp;the most recent summary plan description, any summaries of material modification, any employee handbooks and any material written communications (or a description of any material oral
communications) by the Company or any of its Subsidiaries to any Company Employee concerning the extent of the benefits provided under any Plan, (7)&nbsp;all material correspondence during the past
five years with the IRS, United States Department of Labor ("</FONT><FONT SIZE=2><I>DOL</I></FONT><FONT SIZE=2>") and any other Governmental Authority regarding any Company Benefit Plan,
(8)&nbsp;all contracts with third-party administrators, actuaries, investment managers, consultants and other independent contractors that relate to any Company Benefit Plan and (9)&nbsp;any other
documents in respect of any Company Benefit Plan reasonably requested by Buyer. Neither the Company nor any of its Subsidiaries has any plan or commitment to establish any new Company Benefit Plan or
to modify any Company Benefit Plan, except to the extent required by Law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;None
of the Company or any of its Subsidiaries or any other Person or entity that, together with the Company or any of its Subsidiaries, is or was treated as a single
employer under Section&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Code (each, together with the Company and any of its Subsidiaries, an "</FONT><FONT SIZE=2><I>ERISA
Affiliate</I></FONT><FONT SIZE=2>"), has now or at any time within the past six years (and in the case of any such other Person or entity, only during the period within the past six years that such
other Person or entity was an ERISA Affiliate) contributed to, sponsored, or maintained (i)&nbsp;a pension plan (within the meaning of Section&nbsp;3(2) of ERISA) subject to Section&nbsp;412 of
the Code or Title IV of ERISA, (ii)&nbsp;a multiemployer plan (within the meaning of Section&nbsp;3(37) or 4001(a)(3) of ERISA or the comparable provisions of any other applicable Law) (a
"</FONT><FONT SIZE=2><I>Multiemployer Plan</I></FONT><FONT SIZE=2>") or (iii)&nbsp;a single employer pension plan (within the meaning of Section&nbsp;4001(a)(15) of ERISA) for which an ERISA
Affiliate would reasonably be expected to incur liability under Section&nbsp;4063, 4064 or 4069 of ERISA. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;(i)
Each Company Benefit Plan has been maintained and operated in all material respects in compliance with its terms and applicable Law, including ERISA, the Code,
Section&nbsp;4980B of the Code and Sections&nbsp;601 through 608, inclusive, of ERISA, which provisions are hereinafter referred to collectively as "COBRA", and any other applicable Laws,
including the Americans with Disabilities Act of 1990, the Family and Medical Leave Act of 1993 and the Health Insurance Portability and Accountability Act of 1996, (ii)&nbsp;with respect to each
Company Benefit Plan, all reports, returns, notices and other documentation that are required to have been filed with or furnished to the IRS, the DOL or any other Governmental Authority, or to the
participants or beneficiaries of such Company Benefit Plan have been filed or furnished on a timely basis, except for failures to timely file that have not resulted, and are not reasonably likely to
result, in material liability to the Company, and (iii)&nbsp;each Company Benefit Plan that is intended to be qualified within the meaning of Section&nbsp;401(a) of the Code is so qualified and
has received a favorable determination letter from the IRS to the effect that the Company Benefit Plan satisfies the </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=27,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=554256,FOLIO='23',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_24"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>requirements
of Section&nbsp;401(a) of the Code taking into account all changes in qualification requirements under Section&nbsp;401(a) for which the applicable "remedial amendment period" under
Section&nbsp;401(b) of the Code has expired, and there are no facts or circumstances that could reasonably be expected to cause the loss of such qualification or the imposition of any material
liability, penalty or Tax under ERISA, the Code or any other applicable Laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;With
respect to any Company Benefit Plan, (i)&nbsp;no actions, claims or proceedings (other than routine claims for benefits in the ordinary course) are pending or, to
the Knowledge of the Company, threatened, (ii)&nbsp;no facts or circumstances exist that would reasonably be expected to give rise to any such actions, claims or proceedings, and (iii)&nbsp;no
administrative investigation, audit or other administrative proceeding by the DOL, the IRS or other Governmental Authority, including any voluntary compliance submission through the IRS's Employee
Plans Compliance Resolution System or the DOL's Voluntary Fiduciary Correction Program, is pending, in progress or, to the Knowledge of the Company, threatened. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;Neither
the Company nor any of its Subsidiaries nor, to the Knowledge of the Company, any other "party in interest" or "disqualified person" with respect to any Company
Benefit Plan has engaged in a
non-exempt "prohibited transaction" within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code involving such Company Benefit Plan. No fiduciary has any material
liability for breach of fiduciary duty or any other failure to act or comply with the requirements of ERISA, the Code or any other applicable Laws in connection with the administration or investment
of the assets of any Company Benefit Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;Neither
the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will (either alone or in combination with another
event) (i)&nbsp;result in any payment or benefit becoming due, or increase the amount of any compensation due, to any Company Employee, (ii)&nbsp;increase any benefits otherwise payable under any
Company Benefit Plan, or (iii)&nbsp;result in the acceleration of the time of payment or vesting of any such compensation or benefits; and no such payment or benefit will be characterized as an
"excess parachute payment," as such term is defined in Section&nbsp;280G of the Code. Neither the Company nor any of its Subsidiaries is a party to any contract, arrangement or plan pursuant to
which it is bound to compensate any Person for any excise or other additional Taxes under Section&nbsp;409A or 4999 of the Code or any similar provision of state, local or foreign Law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;The
Company may amend or terminate any Company Benefit Plan (other than an employment agreement or any similar agreement that cannot be terminated without the consent of
the other party) at any time without incurring liability thereunder, other than in respect of accrued and vested obligations and medical or welfare claims incurred prior to such amendment or
termination. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;All
contributions (including all employer contributions and employee salary reduction contributions) or premium payments required to have been made under the terms of
any Plan, and in accordance with applicable Law (including pursuant to 29 C.F.R. Section&nbsp;2510.3-102), as of the date hereof have been made or reflected on the Company's financial
statements in accordance with GAAP. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;Except
for the continuation coverage requirements under COBRA or other applicable Law, neither the Company nor its Subsidiaries have any obligations or potential
liability for health, life or similar welfare benefits to Company Employees or their respective dependents following termination of employment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;Each
Plan subject to the provisions of Section&nbsp;401(k) or 401(m) of the Code, or both, has been tested for and has satisfied the requirements of
Section&nbsp;401(k)(3), Section&nbsp;401(m)(2) and Section&nbsp;416 of the Code, as applicable, for each plan year ending prior to Effective Time. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=28,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=439328,FOLIO='24',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_25"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;No
Company Benefit Plan is maintained in a jurisdiction outside of the United States or for employees outside of the United States. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;The
Company has identified each Company Benefit Plan that is a "nonqualified deferred compensation plan" (within the meaning of Section&nbsp;409A of the Code) subject
to Section&nbsp;409A of the Code, and each Company Benefit Plan so identified, to the extent subject to Section&nbsp;409A of the Code, has been operated and administered since January&nbsp;1,
2005 in reasonable, good faith compliance with Section&nbsp;409A of the Code and IRS Notice 2005-1 and the regulations issued thereunder. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.12</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Compliance With Laws.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
Company is, and at all times since January&nbsp;1, 2006 has been, in compliance with all Laws applicable to the Company and its business and activities, except for
failures to comply that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect on the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;As
of the date hereof, the Company has not received written notice from a Governmental Authority that it is a target of, or the subject of, any action, proceeding, suit,
investigation or sanction by or on behalf of any Governmental Authority brought pursuant to any Law, nor, to the Knowledge of the Company, has any such action, proceeding, suit, investigation or
sanction been threatened in writing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;The
Company has and maintains in full force and effect, and is in compliance with, all Permits and all orders from Governmental Authorities necessary for the Company to
carry on its business as currently conducted, except where the failure to so maintain or be in compliance would not reasonably be expected to result in a Material Adverse Effect on the Company. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.13</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Finders' Fees.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No agent, broker, investment banker,
financial advisor or other firm or person except Piper Jaffray is or will be entitled to any broker's or finder's fee or any other similar commission or fee in connection with any of the transactions
contemplated by this Agreement based upon Contracts made by or on behalf of the Company. The Company has disclosed to Buyer all terms of the engagement of Piper Jaffray (the terms of such engagement,
the "</FONT><FONT SIZE=2><I>Engagement Letter</I></FONT><FONT SIZE=2>"), including the amount of such fees and any right of first offer or other "tail" provisions, and the aggregate amount of fees
payable or to become payable to Piper Jaffray is included in the Transaction Expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.14</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Opinion of Financial Advisor.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company has received the
opinion of Piper Jaffray, dated May&nbsp;28, 2009, to the effect that the Purchase Price is fair from a financial point of view to the holders of Company Common Stock, a copy of which opinion has
been delivered to Buyer or will be delivered to Buyer promptly following the date of this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.15</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Affiliate Transactions.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except for this Agreement and the
Merger, there are no transactions, or series of related transactions, agreements, arrangements or understandings, between the Company, on the one hand, and the Company's Affiliates, on the other hand,
that would be required to be disclosed under Item&nbsp;404 of Regulation&nbsp;S-K promulgated under the Securities Act as currently applicable to the Company that are not so disclosed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.16</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Anti-Takeover Provisions.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the
accuracy of the representation set forth in Section&nbsp;5.19 hereof, the Board of Directors of the Company has taken and will take all actions necessary to ensure that the restrictions applicable
to business combinations contained in Section&nbsp;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Merger
and the other transactions contemplated by this Agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=29,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=999267,FOLIO='25',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.17</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Voting.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
Requisite Company Stockholder Vote is the only vote of the holders of any class or series of the capital stock of the Company or other Company Security necessary to
approve and adopt this Agreement and approve the Merger and the other transactions contemplated thereby. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;There
are no voting trusts, proxies or similar agreements, arrangements or commitments to which the Company is a party with respect to the voting or registration of any
shares of capital stock of the Company. There are no bonds, other debentures, notes or other instruments of indebtedness of the Company that have the right to vote, or that are convertible or
exchangeable into or exercisable for securities or other rights having the right to vote, on any matters on which stockholders of the Company may vote. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.18</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Contracts.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Neither
the Company nor, to the Company's Knowledge, any other party, is in default in the performance, observance or fulfillment of any of the material obligations,
covenants or conditions contained in any Material Contracts to which it is a party; and, to the Knowledge of the Company, there has not occurred any event that, with the lapse of time or giving of
notice or both, could constitute such a default. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Section&nbsp;4.18(b)</I></FONT><FONT SIZE=2>&nbsp;&nbsp;of the Company Disclosure Letter sets forth a list as of the date of this Agreement
of (i)&nbsp;all agreements or contracts regarding the acquisition of a Person or business, whether in the form of an asset purchase, merger, consolidation or otherwise (including any such agreement
or contract that has closed but under which one or more of the parties has executory indemnification, earn-out or other liabilities) to which the Company is a party, (ii)&nbsp;all credit
agreements, indentures, and other agreements related to any indebtedness for borrowed money of the Company, (iii)&nbsp;all joint venture or other similar agreements to which the Company is a party,
(iv)&nbsp;all material lease agreements to which the Company is a party, (v)&nbsp;contracts under which the Company has advanced or loaned any other person any material amounts,
(vi)&nbsp;guarantees of any obligations, (vii)&nbsp;contracts or groups of related contracts with the same party or group of parties the performance of which involves annual consideration in
excess of $100,000 which are not cancelable by the Company on thirty (30)&nbsp;days' or less notice without premium or penalty, (viii)&nbsp;each supply agreement and each "single source" supply
contract pursuant to which goods or materials that are material to the Company's business are supplied to the Company from an exclusive source, (ix)&nbsp;each exclusive sales representative or
exclusive distribution contract to which the Company is a party, (x)&nbsp;agreements under which the Company has granted any person registration rights (including demand and piggy-back
registration rights), (xi)&nbsp;all contracts or agreements purporting to restrict or prohibit the Company from engaging or competing in any business or engaging or competing in any business in any
geographic area, (xii)&nbsp;all employment, consulting, retention, severance, change in control, non-competition, termination or indemnification agreements between the Company and any
director or officer of the Company or any other employee earning noncontingent cash compensation in excess of $100,000 per year, (xiii)&nbsp;all labor agreements, collective bargaining agreements or
other labor related contracts (including work rules and practices) to which the Company is a party with respect to any labor union, labor organization, trade union, works council or similar
organization or association of employees, (xiv)&nbsp;all licenses, consents to use, non-assertion agreements and coexistence agreements concerning Intellectual Property to which the
Company is a party and material software used by the Company other than non-customized software subject to customary "shrink-wrap" or "click-through" type contracts (the
"</FONT><FONT SIZE=2><I>Material Licenses</I></FONT><FONT SIZE=2>"), (xv)&nbsp;each contract to which the Company is a party with any Governmental Authority, (xvi)&nbsp;any contract which
provides for termination, acceleration of payment or other special rights upon the occurrence of a change in control of the Company and (xvii)&nbsp;all other contracts which are material to the
Company taken as a whole (collectively, the "</FONT><FONT SIZE=2><I>Material  </I></FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=30,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=501309,FOLIO='26',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_27"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Contracts</I></FONT><FONT SIZE=2>"). The Company has made available to Buyer a correct and complete copy of each agreement listed in </FONT> <FONT SIZE=2><I>Section&nbsp;4.18(a)</I></FONT><FONT SIZE=2> of the Company Disclosure
Letter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;No
Material Contract will, by its terms, terminate as a result of the transactions contemplated hereby or require any consent from any party thereto in order to remain
in full force and effect immediately after the Effective Time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Section&nbsp;4.18(d)</I></FONT><FONT SIZE=2>&nbsp;&nbsp;of the Company Disclosure Letter sets forth a list, as of the date of this Agreement,
of all agreements of the Company with any executive officer or director of the Company. No officer or director of the Company, or any "associate" (as such term is defined in
Rule&nbsp;14a-1 under the Exchange Act) of any such officer or director, has any interest in any contract or property (real or personal, tangible or intangible), used in, or pertaining
to the business of the Company which interest
would be required to be disclosed pursuant to Item&nbsp;404(a) of Regulation&nbsp;S-K promulgated by the SEC. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.19</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Labor and Employee Matters.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;With respect to the Company:
(i)&nbsp;there has not been within the six (6)&nbsp;years preceding the Effective Time, and there are not now pending, or to the Company's Knowledge threatened, labor or employment controversies,
including any Proceeding alleging unlawful harassment, employment discrimination or unfair labor practices; (ii)&nbsp;to the Company's Knowledge, no union organizing efforts are underway or
threatened as of the date hereof with respect to any Company Employee; and (iii)&nbsp;there is, as of the date hereof, no strike, slowdown, work stoppage or lockout underway or, to the Company's
Knowledge, threatened in writing. </FONT><FONT SIZE=2><I>Section&nbsp;4.19</I></FONT><FONT SIZE=2> of the Company Disclosure Letter sets forth a list of collective bargaining agreements with any
labor organization to which Company is a party and a list of any labor organization with which Company is currently in labor negotiations. No "mass layoff," plant closing or similar event as defined
by the Worker Adjustment and Retraining Notification Act (WARN) has occurred with respect to the Company during the six (6)&nbsp;years preceding the Effective Time. The Company does not have any
liability for any payment to any trust or other fund governed by or maintained on behalf of any Governmental Authority with respect to unemployment compensation benefits, social security or other
benefits or obligations of any employee, contractor or other service provider (other than routine payments to be made in the normal course of business consistent with past practice). Each Person
classified as an independent contractor by the Company has satisfied the requirements of applicable Law to be so classified, and Company has fully and accurately reported such independent contractor's
compensation on IRS Forms&nbsp;1099 when required to do so. The Company has not entered into any written agreement, arrangement or understanding restricting its ability to terminate the employment
of any Company Employee, for any lawful or no reason, without penalty or liability. The Company has not, directly or through agents and independent contractors, employed any unauthorized aliens, as
defined in 8 U.S.C. Section&nbsp;1324a(h)(3) and has complied, or caused any such agent or independent contractor, to comply with the employment verification and record-keeping requirements of 8
U.S.C. Section&nbsp;1324a and 8 C.F.R. Section&nbsp;274a, as amended. To the Company's Knowledge, the Company is in compliance with the Immigration and Nationality Act and the Immigration Reform
and Control Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.20</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Environmental</I></B></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;(i) The Company is in compliance in all
material respects with all applicable Environmental Laws, and possesses and complies in all material respects with all applicable Environmental Permits required under such Laws to operate as it
presently operates; (ii)&nbsp;there are no Materials of Environmental Concern at any property owned or operated by the Company, under circumstances that are reasonably likely to result in a material
liability of the Company under any applicable Environmental Law; (iii)&nbsp;neither the Company nor any of its Subsidiaries has received any written notification alleging that it is liable for, or
request for information pursuant to section&nbsp;104(e) of the Comprehensive Environmental Response, Compensation and Liability Act or similar state statute, concerning, any release or threatened
release of Materials of Environmental Concern at any location except, with respect to any such notification or request for information concerning any such release or threatened release, to the extent
such matter has been resolved with the appropriate foreign, federal, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=31,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=476685,FOLIO='27',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_28"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>state
or local regulatory authority or otherwise; and (iv)&nbsp;neither the Company nor any of its Subsidiaries has received any written claim or complaint, or is subject to any proceeding, relating
to material
noncompliance with Environmental Laws or any other material liabilities pursuant to Environmental Laws, and no such matter has been threatened in writing to the Knowledge of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.21</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Property.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
Company does not own any real property as of the date of this Agreement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Section&nbsp;4.21(b)</I></FONT><FONT SIZE=2> of the Company Disclosure Letter contains a true and complete list of all real property leased,
subleased, licensed or otherwise occupied (whether as tenant, subtenant or pursuant to other occupancy arrangements) by the Company as of the date of this Agreement (collectively, including the
improvements thereon, the "</FONT><FONT SIZE=2><I>Leased Real Property</I></FONT><FONT SIZE=2>") and a true and complete description of all oral Real Property Leases to which the Company is currently
a party. True and complete copies of all agreements under which the Company is the landlord, sublandlord, tenant, subtenant or occupant (each a "</FONT><FONT SIZE=2><I>Real Property
Lease</I></FONT><FONT SIZE=2>") that have not been terminated or expired as of the date hereof have been made available to Buyer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;The
Company has a valid leasehold estate in all Leased Real Property free and clear of all Liens, except Permitted Liens. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;Other
than the Real Property Leases, none of the Leased Real Properties is subject to any lease, sub-lease, license or other agreement granting to any other
Person any right to the use, occupancy or enjoyment of such Leased Real Property or any part thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;Each
Real Property Lease is in full force and effect and is valid and enforceable in accordance with its terms, and there is no material default under any Real Property
Lease by the Company, and no event has occurred that, with the lapse of time or the giving of notice or both, would constitute a default by the Company thereunder. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.22</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Intellectual Property; Software.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;As
used herein: (i)&nbsp;"</FONT><FONT SIZE=2><I>Intellectual Property</I></FONT><FONT SIZE=2>" means all U. S. and foreign (A)&nbsp;trade names, corporate names,
logos, slogans, trade dress, trademarks, service marks, and trademark and service mark registrations and applications therefor and all goodwill associated therewith
("</FONT><FONT SIZE=2><I>Trademarks</I></FONT><FONT SIZE=2>"); (B)&nbsp;patents and applications therefor and all reissues, divisions, re-examinations, renewals, extensions,
provisionals, substitutions, continuations and continuations-in-part thereof, and equivalent or similar rights anywhere in the world in inventions and discoveries including,
without limitation, invention disclosures ("</FONT><FONT SIZE=2><I>Patents</I></FONT><FONT SIZE=2>"); (C)&nbsp;copyrights, copyright registrations and applications therefor
("</FONT><FONT SIZE=2><I>Copyrights</I></FONT><FONT SIZE=2>"); and (D)&nbsp;trade secrets,
know-how and other proprietary information which derives independent economic value from not being generally known to the public (collectively, "</FONT><FONT SIZE=2><I>Trade
Secrets</I></FONT><FONT SIZE=2>"); (ii)&nbsp;"</FONT><FONT SIZE=2><I>Company IP Licenses</I></FONT><FONT SIZE=2>" means all Contracts (excluding "click-wrap" or
"shrink-wrap" agreements or agreements contained in "off-the-shelf" computer programs (whether in source code, object code, or other form), databases, compilations
and data, and all documentation, including user manuals and training materials relating to the foregoing ("</FONT><FONT SIZE=2><I>Software</I></FONT><FONT SIZE=2>") or the terms of use or service for
any Web site) pursuant to which the Company has acquired rights in (including usage rights) any Intellectual Property, or licenses and agreements pursuant to which the Company has
out-licensed or transferred the right to use any Intellectual Property, including license agreements, settlement agreements and covenants not to sue; and
(iii)&nbsp;"</FONT><FONT SIZE=2><I>Company Intellectual Property</I></FONT><FONT SIZE=2>" means the Intellectual Property, Company IP Licenses and Software held for use or used in the business of
the Company as presently conducted; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that, with respect to Patents, the Company Intellectual Property includes only those Patents set forth in </FONT> <FONT SIZE=2><I>Section&nbsp;4.22(b)
</I></FONT><FONT SIZE=2> of the Company Disclosure Letter. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=32,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=1014527,FOLIO='28',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<A NAME="page_kh14501_1_29"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Section&nbsp;4.22(b)</I></FONT><FONT SIZE=2> of the Company Disclosure Letter sets forth a complete and accurate list of the following items,
to the extent included in the Company Intellectual Property owned or exclusively in-licensed by the Company: (i)&nbsp;each Patent, (ii)&nbsp;each Trademark application and registration
and (iii)&nbsp;each Copyright registration and application. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Neither
the Company nor any of its Subsidiaries has misrepresented, or failed to disclose, any facts or circumstances in any application for any Patent or Trademark
registration included in the Company Intellectual Property that would constitute fraud with respect to such application. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;To
the Knowledge of the Company, the Company owns or possesses all licenses or other legal rights to use, sell or license all material Company Intellectual Property in
the manner used, sold or licensed in the business of the Company as presently conducted, free and clear of all Liens, other than Permitted Liens. The Company is the sole owner of each item of material
Company Intellectual Property that the Company purports to own (including, but not limited to, each item of Company Intellectual Property listed on </FONT> <FONT SIZE=2><I>Section&nbsp;4.22(d)</I></FONT><FONT SIZE=2> of the Company Disclosure
Letter). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;No
Company Intellectual Property is subject to any proceeding or outstanding judgment that restricts and/or conditions in any manner the use, transfer or licensing
thereof by the Company or which would reasonably be expected to affect in any material respect the validity, use or enforceability of such Company Intellectual Property. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;To
the Knowledge of the Company, no Person is infringing, misappropriating, or diluting any Company Intellectual Property. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;All
material Trademark registrations and applications for registration, material Patents issued or pending and material Copyright registrations and applications for
registration owned by the Company are subsisting, have not lapsed, expired or been abandoned, and, to the Knowledge of the Company, are not, as of the date hereof, the subject of any opposition,
interference or similar proceeding filed with the United States Patent and Trademark Office or any other intellectual property registry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;To
the Knowledge of the Company, the Company Intellectual Property constitutes all the Intellectual Property and Software necessary for the continuing conduct and
operation of the Company's business as conducted and operated by the Company as of the date hereof in all material respects. The Company has not received any written notice within the two
(2)&nbsp;year period preceding the date hereof that any of the products or services provided or sold by the Company, or proposed to be provided or sold by the Company, or any method, process or
know-how used by the Company, infringes or is alleged to infringe any Intellectual Property of any other Person. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.23</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Insurance.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company Disclosure Letter sets forth a list
and brief description (including nature of coverage, limits, deductibles, premiums and the loss experience for the past three years with respect to each type of coverage) of all policies of insurance
maintained, owned or held by the Company during the past three years. The Company shall use all reasonable best efforts to keep such insurance or comparable insurance in full force and effect through
the Effective Time. The Company has complied in all material respects with each such insurance policy to which it is a party. Each such policy is in full force and effect and will not in any way be
affected by or terminate or lapse by reason of the transactions contemplated by this Agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=33,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=720709,FOLIO='29',FILE='DISK134:[09ZBT1.09ZBT14501]KH14501A.;13',USER='MSULLIV',CD='29-MAY-2009;11:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ki14501_1_30"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>4.24</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Certain Business Practices.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Neither the
Company nor, to the
Knowledge of the Company, any director, officer, employee or agent of the Company has: (i)&nbsp;used any funds for unlawful contributions, gifts, entertainment or other unlawful payments relating to
political activity; (ii)&nbsp;made any unlawful payment to any foreign or domestic government official or employee or to any foreign or domestic political party or campaign or violated any provision
of the Foreign Corrupt Practices Act of 1977, as amended; or (iii)&nbsp;made any other unlawful payment. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.25</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Suppliers And Manufacturers; Effect Of Transaction.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Section&nbsp;4.25</I></FONT><FONT SIZE=2> of the Company Disclosure Letter sets forth a true, complete and correct list of each supplier and
manufacturer that is the sole supplier or manufacturer of any material product or service to the Company. Since January&nbsp;1, 2008, there has not been: (A)&nbsp;any materially adverse change in
the business relationship of the Company with any supplier or manufacturer named in the Company Disclosure Letter; or (B)&nbsp;any change in any material term (including credit terms) of the sales
agreements or related agreements with any supplier or manufacturer named in the Company Disclosure Letter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Since
January&nbsp;1, 2008, the Company has not received any written notice of any plan or intention of the Company's material suppliers, collaborators, distributors,
licensors or licensees to cancel or otherwise terminate its relationship with the Company. Without limiting the generality of the foregoing, since January&nbsp;1, 2008 the Company has not received
any written notice alleging that it is not in compliance in any material respects with development obligations under any material license agreements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;To
the Knowledge of the Company, since January&nbsp;1, 2008, no creditor, supplier, employee, client, customer or other person having a material business relationship
with the Company has informed the Company in writing that such person intends to materially change its relationship with the Company because of the transactions contemplated by this Agreement or
otherwise. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.26</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Government Contracts.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company has not been suspended or
debarred from bidding on contracts with any Governmental Authority, and no such suspension or debarment has been initiated or, to the Knowledge of the Company, threatened. The consummation of the
Merger and other transactions contemplated by this Agreement will not result in any such suspension or debarment of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.27</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>FDA Regulatory Compliance.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
Company is in compliance with all applicable Laws, rules, regulations and orders administered or issued by (i)&nbsp;the U.S. Food and Drug Administration
("</FONT><FONT SIZE=2><I>FDA</I></FONT><FONT SIZE=2>") or any comparable Governmental Entity ("</FONT><FONT SIZE=2><I>FDA Laws</I></FONT><FONT SIZE=2>") or (ii)&nbsp;to the Knowledge of the
Company, the U.S. Federal Trade Commission ("</FONT><FONT SIZE=2><I>FTC</I></FONT><FONT SIZE=2>") ("</FONT><FONT SIZE=2><I>FTC Laws</I></FONT><FONT SIZE=2>"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;The
Company has all material authorizations, approvals, licenses, permits, certificates, registrations, or exemptions from the FDA or other Governmental Entities
required to conduct their respective businesses and produce, market, sell and distribute their products, in each case as currently conducted and as presently contemplated by the Company to be
conducted ("</FONT><FONT SIZE=2><I>Company Registrations</I></FONT><FONT SIZE=2>"). Each of the Company Registrations is valid and subsisting in full force and effect. The Company has received no
written or oral notice that the FDA or any other Governmental Entity is or may consider limiting, suspending, or revoking such Company Registrations or changing the marketing classification or
labeling of the Company's products. There is no false or misleading information or significant omission in any product application or other submission to the FDA or any comparable Governmental Entity.
The Company has fulfilled and performed all material obligations under each Company Registration, and no event has occurred or condition or state of facts exists that would reasonably be expected to
constitute a violation or to cause </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=34,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=1015276,FOLIO='30',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_31"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>revocation
or termination of any such Company Registration. To the Knowledge of the Company, all third parties that are manufacturers, contractors, or suppliers for the Company are in compliance with
all applicable FDA Laws insofar as they pertain to the manufacture of product components or products for the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;All
products developed, manufactured, tested, distributed or marketed by or on behalf of the Company that are subject to the jurisdiction of the FDA or any comparable
Governmental Entity or the FTC have been and are being developed, investigated, tested, manufactured, distributed and marketed in compliance with the FDA Laws, including, where applicable,
pre-market notification, good manufacturing practices, labeling, advertising, record-keeping and adverse event reporting, and to the Knowledge of the Company, have been and are being
marketed, and sold in compliance with FTC Laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;The
Company has not received any written notice during the past three years from the FDA or any comparable Governmental Entity, or from the FTC or any comparable
Governmental Entity, that alleges that the Company or a Subsidiary is not in compliance in any material respect with FDA Laws or FTC Laws. The Company and its Subsidiaries have responded to all
observations made by the FDA during inspections and have not received any Warning Letters. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;No
product has been seized, withdrawn, recalled, detained, or subject to a suspension of manufacturing, and to the Company's Knowledge there are no facts or
circumstances reasonably likely to cause the FDA, any comparable Governmental Entity or the FTC to require (i)&nbsp;the seizure, withdrawal, recall, detention, field notification, field correction,
safety alert or suspension of manufacturing relating to any product; (ii)&nbsp;a change in the labeling of any product; or (iii)&nbsp;a termination, seizure or suspension of marketing of any
product. No proceedings in the United States or any other jurisdiction seeking the withdrawal, recall, suspension, import detention, or seizure of any product are pending or, to the Company's
Knowledge, threatened against the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Company nor any Subsidiary of the Company nor, to the Knowledge of the Company, any director, officer or employee, or other Person acting on behalf of any of
them, has made any contribution, gift, bribe, rebate, payoff, influence payment, kickback, or other payment to any Person, private or public, regardless of form, whether in money, property, or
services (i)&nbsp;to obtain favorable treatment in securing Company Registrations for the Company or any of its Subsidiaries, (ii)&nbsp;to pay for favorable treatment by the FDA or any other
comparable Governmental Entity or the FTC with regards to the manufacturing, labeling and marketing of their products, (iii)&nbsp;to obtain special concessions or for special concessions already
obtained, for or in respect of the Company or any of its Subsidiaries, or (iv)&nbsp;in violation of any FDA Laws or FTC Laws. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ARTICLE V<BR>
REPRESENTATIONS AND WARRANTIES OF BUYER<BR>
AND MERGER SUB  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except (i)&nbsp;as set forth in the disclosure letter (the "</FONT><FONT SIZE=2><I>Buyer Disclosure Letter</I></FONT><FONT SIZE=2>")
delivered to the Company by Buyer concurrently with entering into this Agreement (it being understood that any information set forth in one section or subsection of the Buyer Disclosure Letter shall
be deemed to apply to and qualify the section or subsection of this Agreement to which it corresponds in number and each other section or subsection of this Agreement to which the relevance of such
disclosure is readily apparent on its face) or (ii)&nbsp;as disclosed in the Buyer SEC Reports (as defined herein) filed prior to the date of this Agreement (other than any forward-looking
disclosures set forth in any risk factor section, any disclosures in any section relating to forward-looking statements and any other similar </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=35,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=383231,FOLIO='31',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_32"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>disclosures
included therein to the extent they are primarily predictive or forward-looking in nature), Buyer hereby represents and warrants to the Company that: </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.1</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Corporate Existence and Power.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each of Buyer and Merger Sub
is duly organized, validly existing and in good standing under the Laws of Delaware and has all corporate power and authority required to (a)&nbsp;carry on its business as presently conducted and
(b)&nbsp;consummate the Merger and the other transactions contemplated hereby and to perform its obligations hereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.2</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Corporate Authorization.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each of Buyer and Merger Sub has
the corporate power and authority to execute and deliver this Agreement and, subject to the approval of the issuance of shares of Buyer Common Stock in connection with the Merger by the Requisite
Buyer Stockholder Vote, to consummate the Merger and the other transactions contemplated hereby and to perform each of its obligations hereunder. The execution, delivery and performance by each of
Buyer and Merger Sub of this Agreement and the consummation by Buyer and Merger Sub of the Merger and the other transactions contemplated hereby have been duly and validly authorized by the Board of
Directors of Buyer and the Board of Directors of Merger Sub. This Agreement has been duly and validly executed and delivered by Buyer and, assuming the due and valid execution and delivery of the
Agreement by the Company, constitutes a legal, valid and binding agreement of Buyer, enforceable against Buyer in accordance with its terms. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.3</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Governmental Authorization.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The execution, delivery and
performance by Buyer and Merger Sub of this Agreement and the consummation by Buyer and Merger Sub of the Merger do not and will not require any consent, approval, authorization or permit of, action
by, filing with or notification to any Governmental Authority, other than (i)&nbsp;the filing of the Certificate of Merger; (ii)&nbsp;compliance with the applicable requirements of the Exchange
Act; (iii)&nbsp;compliance with any applicable foreign or state securities or blue sky Laws; (iv)&nbsp;compliance with applicable environmental, health and safety Laws and regulations and any
health care licensure Laws; and (v)&nbsp;any such consent, approval, authorization,
permit, action, filing or notification the failure of which to make or obtain would not have or reasonably be expected to have a Buyer Material Adverse Effect. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.4</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Non-Contravention.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Assuming approval of the
issuance of shares of Buyer Common Stock in connection with the Merger by the Requisite Buyer Stockholder Vote and adoption of this Agreement by Buyer in its capacity as sole stockholder of Merger Sub
(which Buyer shall cause to occur as soon as reasonably practicable following the execution of this Agreement), the execution, delivery and performance by Buyer and Merger Sub of this Agreement and
the consummation by Buyer and Merger Sub of the Merger and the transactions contemplated hereby do not and will not (i)&nbsp;contravene or conflict with the organizational or governing documents of
Buyer and Merger Sub, (ii)&nbsp;contravene, conflict with or constitute a violation of any provision of any Law binding upon or applicable to Buyer or Merger Sub or any of their respective
properties or assets or (iii)&nbsp;require the consent, approval, or authorization of, or notice to or filing with any third party with respect to, result in any breach or violation of or constitute
a default (or any event which with notice or lapse of time or both would become a default) under, or give rise to any right of termination, cancellation or acceleration of any right or obligation of
Buyer or Merger Sub or to the loss of a material benefit to which Buyer is entitled under, or result in the creation of any Lien upon the properties or assets of Buyer or Merger Sub under, any
Contract to which Buyer or Merger Sub is a party or by which it or any of its properties or assets are bound except in the case of clause&nbsp;(ii) or (iii)&nbsp;as would not have or reasonably be
expected to have a Buyer Material Adverse Effect. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.5</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Capitalization.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
authorized share capital of Buyer consists of 297,000,000 shares of Buyer Common Stock and 3,000,000 shares of Series&nbsp;C Preferred Stock, par value $0.01 per
share. As of May&nbsp;27, 2009, there were (i)&nbsp;15,820,593 shares of Buyer Common Stock issued and outstanding, and (B)&nbsp;no shares of Series&nbsp;C Preferred Stock issued and
outstanding, and (iii)&nbsp;Buyer Options to purchase an </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=36,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=538538,FOLIO='32',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_33"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>aggregate
of 2,784,068 shares of Buyer Common Stock, with a weighted average exercise price of $8.42 per share, issued and outstanding. All outstanding shares of Buyer Common Stock are duly
authorized, validly issued, fully paid and non-assessable, and are not subject to and were not issued in violation of any preemptive or similar right, purchase option, call or right of
first refusal or similar right. No Subsidiary of Buyer owns any Buyer Common Stock or any other equity securities of Buyer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Except
as set forth in </FONT><FONT SIZE=2><I>Section&nbsp;5.5(a)</I></FONT><FONT SIZE=2>, there have not been reserved for issuance, and there are no outstanding
(i)&nbsp;shares of capital stock or other voting securities of Buyer; (ii)&nbsp;securities of Buyer or any of its Subsidiaries convertible into or exchangeable for shares of capital stock or
voting securities of Buyer, other than Buyer Options; (iii)&nbsp;Buyer Options or other rights or options to acquire from Buyer or obligations of Buyer to issue any shares of capital stock, voting
securities or securities convertible into or exchangeable for shares of capital stock or voting securities of Buyer; or (iv)&nbsp;equity equivalent interests in the ownership or earnings of Buyer
(the items in clauses&nbsp;(i) through (iv)&nbsp;collectively, "</FONT><FONT SIZE=2><I>Buyer Securities</I></FONT><FONT SIZE=2>"). There are no outstanding obligations of Buyer to repurchase,
redeem or otherwise acquire
any Buyer Securities. There are no preemptive rights of any kind which obligate Buyer to issue or deliver any Buyer Securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Other
than the issuance of shares of Buyer Common Stock upon exercise of Buyer Options and as contemplated by this Agreement, from the Balance Sheet Date to the date of
this Agreement, Buyer has not declared or paid any dividend or distribution in respect of any Buyer Securities, and neither Buyer nor any of its Subsidiaries has issued, sold, repurchased, redeemed or
otherwise acquired any Buyer Securities, and their respective boards of directors have not authorized any of the foregoing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;All
of the shares of Buyer Common Stock to be issued pursuant to the Merger have been duly authorized by all necessary corporate action and will be, when issued in
accordance with this Agreement, duly authorized, validly issued, fully paid and nonassessable and not subject to or issued in violation of any purchase option, call option, right of first refusal,
preemptive right, subscription right or any similar right under any provision of any Law or regulation, Buyer's certificate of incorporation or bylaws or any agreement to which Buyer is a party or
otherwise bound. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.6</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>SEC Reports.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Buyer
(including, for the purposes of this </FONT><FONT SIZE=2><I>Section&nbsp;5.6(a)</I></FONT><FONT SIZE=2>, all predecessor entities) and its Subsidiaries have
filed all forms, reports, statements, certifications and other documents (including all exhibits and other information incorporated therein, amendments and supplements thereto) required to be filed by
them with the SEC since January&nbsp;1, 2007 (all such forms, reports, statements, certificates and other documents filed since January&nbsp;1, 2007, including any amendments thereto,
collectively, the "</FONT><FONT SIZE=2><I>Buyer SEC Reports</I></FONT><FONT SIZE=2>") and all Buyer SEC Reports have been filed on a timely basis. As of their respective dates the Buyer SEC Reports
complied, and each of the Buyer SEC Reports filed subsequent to the date of this Agreement will comply, in all material respects with the requirements of the Securities Act, the Exchange Act and the
Sarbanes-Oxley Act, as the case may be, and the applicable rules and regulations promulgated thereunder. As of the time of filing with the SEC, none of the Buyer SEC Reports so filed or that will be
filed subsequent to the date of this Agreement contained or will contain, as the case may be, any untrue statement of a material fact or omitted to state any material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;The
audited consolidated financial statements of Buyer (including any related notes thereto) included in the Buyer SEC Reports have been prepared in accordance with GAAP
applied on a consistent basis throughout the periods involved (except as may be indicated in the </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=37,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=814858,FOLIO='33',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_34"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>notes
thereto) and fairly present in all material respects the consolidated financial position of Buyer and its Subsidiaries at the respective dates thereof and the consolidated statements of
operations and comprehensive income, cash flows and changes in stockholders' equity for the periods indicated. The
unaudited consolidated financial statements of Buyer (including any related notes thereto) for all interim periods included in the Buyer SEC Reports have been prepared in accordance with GAAP applied
on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto) and fairly present in all material respects the consolidated financial position of Buyer and its
Subsidiaries as of the respective dates thereof and the consolidated statements of operations and comprehensive income and cash flows for the periods indicated (subject to normal and recurring
period-end adjustments that have not been and are not expected to be material to Buyer and its Subsidiaries taken as a whole). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Neither
Buyer nor any of its Subsidiaries is a party to, or has any commitment to become a party to, any Contract or arrangement (including any Contract or arrangement
relating to any transaction or relationship between or among Buyer and any of its subsidiaries, on the one hand, and any affiliate, including any structured finance, special purpose or limited purpose
entity or person, on the other hand), where the result, purpose or intended effect of such Contract or arrangement is to avoid disclosure of any material transaction involving, or material liabilities
of, Buyer or any of its Subsidiaries in Buyer's published consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;Buyer
has made available to the Company a complete and correct copy of any amendments or modifications which have not yet been filed (but which Buyer intends to file)
with the SEC to agreements, documents or other instruments which previously had been filed by Buyer with the SEC pursuant to the Securities Act or the Exchange Act, and the regulations promulgated
thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;The
principal executive officer and principal financial officer of Buyer have made all certifications required by the Sarbanes-Oxley Act and the regulations of the SEC
promulgated thereunder, and the statements contained in all such certifications were as of the respective dates made, and are, complete and correct. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;Buyer
has (A)&nbsp;designed disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Exchange Act) to
ensure that material information relating to Buyer, including its consolidated Subsidiaries, is made known to its principal executive officer and principal financial officer; (B)&nbsp;designed
internal control over financial reporting (as defined in Rules&nbsp;13a-15(f) and 15d-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP; (C)&nbsp;evaluated the effectiveness of Buyer's disclosure controls and procedures
and, to the extent required by applicable Law, presented in any applicable Buyer SEC Report that is a report on Form&nbsp;10-K or Form&nbsp;10-Q or any amendment thereto
its conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by such report or amendment based on such evaluation; and (D)&nbsp;to the extent
required by applicable Law, disclosed in such report or amendment any change in Buyer's internal control over financial reporting that occurred during the period covered by such report or amendment
that has materially affected, or is reasonably likely to materially affect, Buyer's internal control over financial reporting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;Buyer
has disclosed, based on the most recent evaluation of internal control over financial reporting, to Buyer's auditors and the audit committee of Buyer's Board of
Directors (A)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
Buyer's ability to record, process, summarize and report financial information, and (B)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant
role in Buyer's internal control </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=38,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=378933,FOLIO='34',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_35"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>over
financial reporting. Since January&nbsp;1, 2005, (i)&nbsp;neither Buyer nor any of its Subsidiaries, nor, to the Knowledge of Buyer, any director, officer, employee, auditor, accountant or
representative of Buyer or any of its Subsidiaries has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding the
accounting or auditing practices, procedures, methodologies or methods of Buyer or any of its Subsidiaries or their respective internal accounting controls, including any material complaint,
allegation, assertion or claim that Buyer or any of its Subsidiaries has engaged in questionable accounting or auditing practices, and (ii)&nbsp;no attorney representing Buyer or any of its
Subsidiaries, whether or not employed by Buyer or any of its Subsidiaries, has reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar violation by Buyer or
any of its Subsidiaries or their respective officers, directors, employees or agents to the Board of Directors of Buyer or any committee thereof or to any director or officer of Buyer. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.7</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Undisclosed Liabilities.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except (i)&nbsp;for those
liabilities that are reflected or reserved against on the consolidated balance sheet of Buyer (including the notes thereto) included in Buyer's Quarterly Report on Form&nbsp;10-Q for the
quarter ended March&nbsp;31, 2009, (ii)&nbsp;for liabilities incurred in the ordinary course of business consistent with past practice since March&nbsp;31, 2009 that do not exceed $250,000 in
the aggregate and (iii)&nbsp;for liabilities that have been discharged or paid in full prior to the date that is five (5)&nbsp;Business Days prior to the date of this Agreement in the ordinary
course of business consistent with past practice, Buyer does not have any liabilities, commitments or obligations, asserted or unasserted, known or unknown, absolute or contingent, whether or not
accrued, matured or un-matured or otherwise, of a nature required by GAAP to be reflected in a consolidated balance sheet or disclosed in the notes thereto. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.8</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Absence of Certain Changes or Events.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Since the date of the
financial statements included or incorporated by reference in Buyer's Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2009 (the "</FONT><FONT SIZE=2><I>Buyer
Balance Sheet Date</I></FONT><FONT SIZE=2>"), (a)&nbsp;no Effect has occurred which has had or would reasonably be expected to have, individually or in the aggregate, a Buyer Material Adverse Effect
and (b)&nbsp;Buyer has not taken or omitted to take any action that would, if taken or omitted to be taken after the date hereof, result in a breach of </FONT> <FONT SIZE=2><I>Section&nbsp;6.2</I></FONT><FONT SIZE=2> of this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.9</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Taxes.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties contained in this </FONT> <FONT
SIZE=2><I>Section&nbsp;5.9</I></FONT><FONT SIZE=2> are the only representations and warranties made by Buyer in this Agreement with respect to Tax matters. Except as would not
reasonably be expected, individually or in the aggregate, to have a Buyer Material Adverse Effect: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;All
Tax Returns required to be filed by or with respect to Buyer have been timely filed, and all such Tax Returns are true, correct and complete. Buyer is not currently
the beneficiary of any extension of time within which to file any Tax Return. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Buyer
(i)&nbsp;has timely paid all Taxes due and payable (whether or not shown to be due on the Tax Returns referred to in </FONT> <FONT SIZE=2><I>Section&nbsp;5.9</I></FONT><FONT SIZE=2>), except for Taxes for which adequate reserves have been established
in accordance with GAAP, and (ii)&nbsp;has made adequate
provision in the applicable financial statements, in accordance with GAAP, for all Taxes not yet due and payable with respect to taxable periods, or portions thereof, for which no Tax Return has yet
been filed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;As
of the date hereof, no audit or other proceeding by any Governmental Authority is pending or, to the Knowledge of Buyer, threatened with respect to any Taxes of
Buyer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;No
Person has granted any extension or waiver of the statute of limitations period applicable to any Tax of Buyer, which period (after giving effect to such extension or
waiver) has not yet expired. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=39,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=456311,FOLIO='35',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_36"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;Buyer
has not constituted either a "distributing corporation" or a "controlled corporation" in a distribution of stock qualifying or intended to qualify for
Tax-free treatment under Section&nbsp;355 of the Code in the two years prior to the date of this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;There
are no Tax sharing agreements (or similar agreements) under which Buyer is liable for Taxes of any other Person (other than Buyer). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;Buyer
has not participated in a "reportable transaction" within the meaning of Section&nbsp;6707A(c)(1) of the Code or Treasury Regulation
Section&nbsp;1.6011-4(b). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;To
the Knowledge of Buyer, after consulting with its Tax advisors, neither Buyer nor any of its Affiliates has taken or agreed to take any action which would prevent the
Merger from constituting a transaction qualifying as a reorganization under Section&nbsp;368(a) of the Code. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.10</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Litigation.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As of the date hereof neither Buyer nor any of
its Subsidiaries is a party to any, and there are no pending or, to Buyer's Knowledge, threatened, legal, administrative, arbitral or other material proceedings, claims, actions or governmental or
regulatory investigations (a "</FONT><FONT SIZE=2><I>Proceeding</I></FONT><FONT SIZE=2>") of any nature against Buyer or any of its Subsidiaries, in each case that, individually or in the aggregate,
would reasonably be expected to have a Buyer Material Adverse Effect. Neither Buyer, its Subsidiaries, nor any of their respective businesses or properties are subject to or bound by any injunction,
order, judgment, decree or regulatory restriction of any Governmental Authority specifically imposed upon Buyer, its Subsidiaries or their respective properties or assets. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.11</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Environmental.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(i) Buyer is in compliance in all material
respects with all applicable Environmental Laws, and possesses and complies in all material respects with all applicable Environmental Permits required under such Laws to operate as it presently
operates; (ii)&nbsp;there are no Materials of Environmental Concern at any property owned or operated by Buyer, under circumstances that are reasonably likely to result in a material liability of
Buyer under any applicable Environmental Law; (iii)&nbsp;neither Buyer nor any of its Subsidiaries has received any written notification alleging that it is liable for, or request for information
pursuant to section&nbsp;104(e) of the Comprehensive Environmental Response, Compensation and Liability Act or similar state statute, concerning, any release or threatened release of Materials of
Environmental Concern at any location except, with respect to any such notification or request for information concerning any such release or threatened release, to the extent such matter has been
resolved with the appropriate foreign, federal, state or local regulatory authority or otherwise; and (iv)&nbsp;neither Buyer nor any of its Subsidiaries has received any written claim or complaint,
or is subject to any proceeding, relating to material noncompliance with Environmental Laws or any other material liabilities pursuant to Environmental Laws, and no such matter has been threatened in
writing to the Knowledge of Buyer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.12</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Intellectual Property; Software.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;As
used herein: (i)&nbsp;"</FONT><FONT SIZE=2><I>Buyer IP Licenses</I></FONT><FONT SIZE=2>" means all Contracts (excluding "click-wrap" or
"shrink-wrap" agreements or agreements contained in Software or the terms of use or service for any Web site) pursuant to which Buyer has acquired rights in (including usage rights) any
Intellectual Property, or licenses and agreements pursuant to which Buyer has out-licensed or transferred the right to use any Intellectual Property, including license agreements,
settlement agreements and covenants not to sue; and (ii)&nbsp;"</FONT><FONT SIZE=2><I>Buyer Intellectual Property</I></FONT><FONT SIZE=2>" means the material Intellectual Property, Buyer IP
Licenses and Software held for use or used in the business of Buyer as presently conducted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Neither
Buyer nor any of its Subsidiaries has misrepresented, or failed to disclose, any facts or circumstances in any application for any Patent or Trademark
registration included in the Buyer Intellectual Property that would constitute fraud with respect to such application. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=40,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=677991,FOLIO='36',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_37"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;To
the Knowledge of Buyer, the Buyer owns or possesses all licenses or other legal rights to use, sell or license all material Buyer Intellectual Property in the manner
used, sold or licensed in the business of the Buyer as presently conducted, free and clear of all Liens, other than Permitted Liens. Buyer is the sole owner of each item of material Buyer Intellectual
Property that Buyer purports to solely own. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;No
Buyer Intellectual Property is subject to any proceeding or outstanding judgment that restricts and/or conditions in any manner the use, transfer or licensing thereof
by Buyer or which would reasonably be expected to affect in any material respect the validity, use or enforceability of such Buyer Intellectual Property. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;To
the Knowledge of Buyer, no Person is infringing, misappropriating, or diluting any Buyer Intellectual Property. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;All
material Trademark registrations and applications for registration, material Patents issued or pending and material Copyright registrations and applications for
registration owned by Buyer are subsisting, have not lapsed, expired or been abandoned, and to the Knowledge of Buyer are not, as of the date hereof, the subject of any opposition, interference or
similar proceeding filed with the United States Patent and Trademark Office or any other intellectual property registry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;To
the Knowledge of Buyer, the Buyer Intellectual Property constitutes all the Intellectual Property and Software necessary for the continuing conduct and operation of
Buyer's business as conducted and operated by Buyer as of the date hereof in all material respects. Buyer has not received any material written notice within the two (2)&nbsp;year period preceding
the date hereof that any of the products or services provided or sold by Buyer, or proposed to be provided or sold by Buyer, or any method, process or know-how used by Buyer, infringes or
is alleged to infringe any Intellectual Property of any other Person. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.13</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>FDA Regulatory Compliance.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Buyer
is in compliance with the FDA Laws and, to the Knowledge of Buyer, the FTC Laws. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Buyer
has all material authorizations, approvals, licenses, permits, certificates, registrations, or exemptions from the FDA or other Governmental Entities required to
conduct their respective businesses and produce, market, sell and distribute their products, in each case as currently conducted and as presently contemplated by Buyer to be conducted
("</FONT><FONT SIZE=2><I>Buyer Registrations</I></FONT><FONT SIZE=2>"). Each of the Buyer Registrations is valid and subsisting in full force and effect. Buyer has received no written or oral notice
that the FDA or any other Governmental Entity is or may consider limiting, suspending, or revoking such Buyer Registrations or changing the marketing classification or labeling of Buyer's products.
There is no false or misleading information or significant omission in any product application or other submission to the FDA or any comparable Governmental Entity. Buyer has fulfilled and performed
all material obligations under each Buyer Registration, and no event has occurred or condition or state of facts exists that would reasonably be expected to constitute a violation or to cause
revocation or termination of any such Buyer Registration. To the Knowledge of Buyer, all third parties that are manufacturers, contractors, or suppliers for Buyer are in compliance with all applicable
FDA Laws insofar as they pertain to the manufacture of product components or products for Buyer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;All
products developed, manufactured, tested, distributed or marketed by or on behalf of Buyer that are subject to the jurisdiction of the FDA or any comparable
Governmental Entity or the FTC have been and are being developed, investigated, tested, manufactured, distributed and marketed in compliance with the FDA Laws, including, where applicable,
pre-market notification, good manufacturing practices, labeling, advertising, record-keeping and adverse event reporting, </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=41,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=610621,FOLIO='37',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_38"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>and
to the Knowledge of Buyer, have been and are being marketed, and sold in compliance with FTC Laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;Buyer
has not received any written notice during the past three years from the FDA or any comparable Governmental Entity, nor the FTC or any comparable Governmental
Entity that alleges that Buyer or a Subsidiary is not in compliance in any respect with FDA Laws or FTC Laws. Buyer and its Subsidiaries have responded to all observations made by the FDA during
inspections and have not received any Warning Letters. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;No
product has been seized, withdrawn, recalled, detained, or subject to a suspension of manufacturing, and to Buyer's Knowledge, there are no facts or circumstances
reasonably likely to cause the FDA, any comparable Governmental Entity or the FTC to require (i)&nbsp;the seizure, withdrawal, recall, detention, field notification, field correction, safety alert
or suspension of manufacturing relating to any product; (ii)&nbsp;a change in the labeling of any product; or (iii)&nbsp;a termination, seizure or suspension of marketing of any product. No
proceedings in the United States or any other jurisdiction seeking the withdrawal, recall, suspension, import detention, or seizure of any product are pending or, to Buyer's Knowledge, threatened
against Buyer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;Neither
Buyer nor any Subsidiary of Buyer nor, to the Knowledge of Buyer, any director, officer or employee, or other Person acting on behalf of any of them, has made
any contribution, gift, bribe, rebate, payoff, influence payment, kickback, or other payment to any Person, private or public,
regardless of form, whether in money, property, or services (i)&nbsp;to obtain favorable treatment in securing Buyer Registrations for Buyer or any of its Subsidiaries, (ii)&nbsp;to pay for
favorable treatment by the FDA or any other comparable Governmental Entity or the FTC with regards to the manufacturing, labeling and marketing of their products, (iii)&nbsp;to obtain special
concessions or for special concessions already obtained, for or in respect of Buyer or any of its Subsidiaries, or (iv)&nbsp;in violation of any FDA Laws or FTC Laws. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.14</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Suppliers And Manufacturers; Effect Of Transaction.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Section&nbsp;5.14(a)</I></FONT><FONT SIZE=2> of the Buyer Disclosure Letter sets forth a true, complete and correct list of each supplier and
manufacturer that is the sole supplier or manufacturer of any material product or service to Buyer. Since January&nbsp;1, 2008, there has not been: (A)&nbsp;any materially adverse change in the
business relationship of Buyer with any supplier or manufacturer named in the Buyer Disclosure Letter; or (B)&nbsp;any change in any material term (including credit terms) of the sales agreements or
related agreements with any supplier or manufacturer named in the Buyer Disclosure Letter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Since
June&nbsp;30, 2008, Buyer has not received any written notice of any plan or intention of Buyer's material suppliers, collaborators, distributors, licensors or
licensees to cancel or otherwise terminate its relationship with Buyer. Without limiting the generality of the foregoing, since June&nbsp;30, 2008, Buyer has not received any written notice alleging
that it is not in compliance in any material respects with development obligations under any material license agreements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;To
the Knowledge of Buyer, from June&nbsp;30, 2008 to the date hereof, no creditor, supplier, employee, client, customer or other person having a material business
relationship with Buyer informed Buyer in writing that such person intends to materially change its relationship with Buyer because of the transactions contemplated by this Agreement or otherwise. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.15</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>No Breach of Designated Contracts.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Neither Buyer nor any of
its Subsidiaries has since January&nbsp;1, 2008 received written notice of any breach of or default under any material contracts of Buyer and its Subsidiaries filed by Buyer with the SEC as exhibits
to its Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2008, or incorporated by reference therein (each a "</FONT><FONT SIZE=2><I>Buyer Designated
Contract</I></FONT><FONT SIZE=2>"), other than any breach or default that has been cured, waived or otherwise resolved in all material respects. To Buyer's Knowledge, no other party to a Buyer
Designated Contract </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=42,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=1022005,FOLIO='38',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2>is
in default of any of its obligations thereunder. Each Buyer Designated Contract is in full force and effect. Each Buyer Designated Contract is a legal, valid and binding obligation of Buyer or its
Subsidiary and the other party thereto, except as to the legality, validity and binding nature thereof may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or
other
similar Laws now or hereafter in effect relating to creditors' rights and by general equitable principles (regardless of whether considered in a proceeding at law or equity). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.16</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Finders' Fees.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No agent, broker, investment banker,
financial advisor or other firm or Person other than WBB Securities,&nbsp;LLC and Brean Murray, Carret&nbsp;&amp;&nbsp;Co.,&nbsp;Inc., is or will be entitled to any broker's or finder's fee or any
other similar commission or fee from Buyer in connection with any of the transactions contemplated by this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.17</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Opinion of Financial Advisor.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Buyer has received the
opinion of Brean Murray, Carret&nbsp;&amp;&nbsp;Co.,&nbsp;Inc., dated May&nbsp;28, 2009, to the effect that the Common Stock Exchange Ratio is fair, from a financial point of view, to Buyer, a
copy of which opinion has been delivered to the Company or will be delivered to the Company promptly following the date of this Agreement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.18</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Merger Sub Operations.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Merger
Sub has been formed solely for the purpose of engaging in the transactions contemplated hereby and prior to the Effective Time will have engaged in no other
business activities and will have incurred no liabilities or obligations other than as contemplated herein. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;As
of the date of this Agreement, the authorized capital stock of Merger Sub consists of 1,000 shares of common stock, par value $0.01 per share, all of which are
validly issued and outstanding. All of the issued and outstanding capital stock of Merger Sub is, and immediately prior to the Effective Time will be, owned by Buyer. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.19</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Ownership of Company Common Stock.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Buyer does not,
immediately prior to entering into this Agreement, beneficially own (within the meaning of Section&nbsp;13 of the Exchange Act and the rules and regulations promulgated thereunder), or will prior to
the Effective Time beneficially own any shares of Company Common Stock, and Buyer is not a party, or will prior to the Closing Date become a party, to any Contract, arrangement or understanding (other
than this Agreement) for the purpose of acquiring, holding, voting or disposing of any shares of Company Common Stock, and Buyer has not within the last three years owned (within the meaning of
Section&nbsp;203 of the DGCL) 15% or more of the outstanding shares of Company Common Stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ARTICLE VI<BR>
CONDUCT OF BUSINESS PENDING THE MERGER  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>6.1</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Conduct of the Company.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except for matters set forth in </FONT> <FONT
SIZE=2><I>Section&nbsp;6.1</I></FONT><FONT SIZE=2> of the Company Disclosure Letter or as otherwise contemplated by or specifically provided in this Agreement or as consented to in
writing by Buyer, during the period commencing on the date of this Agreement and ending at the Effective Time or such earlier date as this Agreement may be terminated in accordance with its terms (the
"</FONT><FONT SIZE=2><I>Pre-Closing Period</I></FONT><FONT SIZE=2>"), the Company shall (x)&nbsp;act and carry on its business in the ordinary course of business consistent with past
practice, (y)&nbsp;comply with all applicable Laws and the requirements of all Material Contracts and Permits and make all voluntary disclosures deemed appropriate to Governmental Entities and
(z)&nbsp;use commercially reasonable efforts to (i)&nbsp;maintain and preserve its business organization, assets and properties and preserve the goodwill of its business relationships with
customers, strategic partners, suppliers, distributors and others having business dealings with it, (ii)&nbsp;retain the services of its current officers and key employees, and (iii)&nbsp;keep in
full force and effect all insurance policies, other than changes to such policies made in the ordinary course of business consistent with past practice. Without limiting the generality of the
foregoing, except as specifically set forth in the proviso immediately following </FONT><FONT SIZE=2><I>Section&nbsp;6.1(p)</I></FONT><FONT SIZE=2> below, in </FONT> <FONT SIZE=2><I>Section&nbsp;6.1</I></FONT><FONT SIZE=2> of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=43,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=646841,FOLIO='39',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2>Company
Disclosure Letter or as otherwise contemplated by or specifically provided in this Agreement or as consented to in writing by Buyer, during the Pre-Closing Period the Company shall
not do any of the following without the prior written consent of Buyer: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;(i)
declare, set aside or pay any dividend on, or make any other distribution (whether in cash, securities or other property) in respect of, any shares of its capital
stock or otherwise make any payments to its stockholders in their capacity as such; (ii)&nbsp;split, combine, subdivide or reclassify any of its capital stock or issue or authorize the issuance of
any other securities in respect of, in lieu of or in substitution for shares of its capital stock or any of its other securities; or (iii)&nbsp;purchase, redeem or otherwise acquire any shares of
its capital stock, voting securities or equity interests, or any rights, warrants, options, calls, commitments or enter into any other agreements of any character to acquire any shares of its capital
stock, voting securities or equity interests, except, in the case of this clause&nbsp;(iii), for the acquisition of shares of Company Common Stock (1)&nbsp;from holders of Company Options in full
or partial payment of the exercise price and any applicable Taxes payable by such holder upon exercise of Company Options to the extent required or permitted under the terms of such Company Options;
or (2)&nbsp;from former employees, directors or consultants in accordance with agreements providing for the repurchase of shares of Company Common Stock at their original issuance price in
connection with any termination of services to the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;except
as permitted by </FONT><FONT SIZE=2><I>Section&nbsp;6.1(h)</I></FONT><FONT SIZE=2>, issue, deliver, sell, grant, pledge or otherwise dispose of or encumber any
shares of its capital stock, any other voting securities or any securities convertible into or exchangeable for, or any rights, warrants or options to acquire, any such shares, voting securities or
convertible or exchangeable securities (other than the issuance, prior to the Effective Time, of shares of Company Common Stock (i)&nbsp;upon the exercise of Company Options outstanding on the date
of this Agreement under the relevant Company Stock Plan in accordance with the current terms thereof and (ii)&nbsp;upon conversion of the Convertible Notes in accordance with the current terms
thereof); </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;amend
the organizational documents of the Company; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;acquire
by merging or consolidating with, or by purchasing all or a substantial portion of the assets or stock of, or by any other manner, any business or any
corporation, partnership, joint venture, limited liability company, association or other business organization or division thereof; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;sell,
transfer, lease, license, pledge, or otherwise dispose of or encumber or subject to any Lien (including pursuant to a sale-leaseback transaction or an
asset securitization transaction) any of its properties or assets (including Intellectual Property); </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;(i)
incur or assume any indebtedness for borrowed money or guarantee any indebtedness for borrowed money, other than letters of credit or similar arrangements issued for
the benefit of suppliers and manufacturers in the ordinary course of business consistent with past practice and reflected as current liabilities on the Closing Balance Sheet, (ii)&nbsp;issue, sell
or amend any debt securities or options, warrants, calls or other rights to acquire any debt securities of the Company, guarantee any debt securities of another Person, enter into any "keep well" or
other agreement to maintain any financial statement condition of another Person or enter into any arrangement having the economic effect of any of the foregoing or (iii)&nbsp;make any loans,
advances (other than routine advances in the ordinary course of business consistent with past practice) or capital contributions to, or investments in (by property transfers, purchase of securities or
otherwise), any Person, other than a direct or indirect wholly owned Subsidiary of the Company; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that the Company may, in the ordinary
course of business consistent with past practice, continue to invest in money market accounts and U.S.
treasury bonds and other securities guaranteed by the U.S. government; </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=44,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=1018579,FOLIO='40',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_ki14501_1_41"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;make
any changes in financial or Tax accounting methods, principles, policies or practices (or change an annual accounting period), except insofar as may be required by
GAAP or applicable Law or, except as so required, change any assumption underlying, or method of calculating, any bad debt, contingency or other reserve; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;other
than (A)&nbsp;as required to comply with applicable Law and (B)&nbsp;increases in compensation or benefits required by the terms of agreements in effect on the
date of this Agreement and set forth on </FONT><FONT SIZE=2><I>Section&nbsp;6.1(h)</I></FONT><FONT SIZE=2> of the Company Disclosure Letter (complete and correct copies of which have been delivered
to Buyer by the Company), (i)&nbsp;adopt, enter into, terminate or amend any employment, consulting, retention, change in control or similar agreement or benefit plan for the benefit or welfare of
any current or former director, officer or employee, or any collective bargaining agreement, (ii)&nbsp;increase in any respect the compensation or fringe benefits of, or pay any bonus to, any
directors, officers or employees, (iii)&nbsp;amend (including by reducing an exercise price or extending a term) or waive any of its rights under, or accelerate the vesting under, any provision of
the Company Stock Plans or any agreement evidencing any outstanding stock option or other right to acquire capital stock of the
Company or any restricted stock purchase agreement or any similar or related contract, other than as contemplated by this Agreement, (iv)&nbsp;enter into, establish, amend, modify or terminate any
awards under any bonus, incentive, performance or other compensation plan or arrangement or benefit plan, including the grant of stock options, stock appreciation rights, stock based or stock related
awards, performance units or restricted stock, profit-sharing, health or welfare, stock option or other equity (or equity-based) pension, retirement, vacation, severance, deferred compensation or
other compensation or benefit plan (including any plan that would constitute a Company Plan), policy, agreement, trust, fund or arrangement with, for or in respect of, any stockholder, director,
officer, other employee, consultant or Affiliate, other than the grant of stock options or restricted stock to new hires and newly promoted employees, which grants shall not exceed 50,000 shares in
the aggregate or 5,000 shares to any one person and shall be on the Company's customary terms for such grants or (v)&nbsp;take any action other than in the ordinary course of business, consistent
with past practice, to fund or in any other way secure the payment of compensation or benefits under any Company Plan; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that nothing in
this </FONT><FONT SIZE=2><I>Section&nbsp;6.1(h)</I></FONT><FONT SIZE=2> shall prevent the Company from making bonus payments
up to an aggregate amount of $1,156,833 pursuant to its Executive Incentive Plan (provided that such bonus payments must be reflected as current liabilities in the Closing Balance Sheet to the extent
they remain unpaid as of the Effective Time). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;make,
change or rescind any material election concerning Taxes or Tax Returns, file any amended Tax Return, enter into any closing agreement with respect to Taxes,
settle or compromise any material Tax claim or assessment or surrender any right to claim a refund of Taxes or obtain any Tax ruling; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;initiate,
compromise or settle any litigation, proceeding or investigation that is material to the Company (other than in connection with the enforcement of the
Company's rights under this Agreement) (this covenant being in addition to the Company's agreement set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.12</I></FONT><FONT SIZE=2> (Stockholder
Litigation)); </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;(i)
enter into, terminate or amend any Material Contract or any Permit, including any material Environmental Permit; (ii)&nbsp;enter into any Contract which would be a
Material Contract had it been in effect on the date of this Agreement that would be breached by, or require the consent of any third party in order to continue in full force following, consummation of
the transactions contemplated by this Agreement; or (iii)&nbsp;amend or modify the Engagement Letter; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;authorize
or make any capital expenditures other than in accordance with the Company's 2009 budget as approved by its Board of Directors and furnished to Buyer prior to
the date hereof (the "</FONT><FONT SIZE=2><I>2009 Budget</I></FONT><FONT SIZE=2>"); </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=45,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=438103,FOLIO='41',FILE='DISK134:[09ZBT1.09ZBT14501]KI14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_kk14501_1_42"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&nbsp;adopt
a plan or agreement of complete or partial liquidation, dissolution, restructuring, recapitalization, merger, consolidation or other reorganization; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;&nbsp;&nbsp;pay,
discharge, settle or satisfy any claims, liabilities or obligations (absolute, accrued, asserted or unasserted, contingent or otherwise), other than the payment,
discharge, settlement or satisfaction in the ordinary course of business or in accordance with their terms as in effect on the date of this Agreement of liabilities, claims or obligations reflected or
reserved against on the Company Balance Sheet (or in the notes thereto) or incurred since the date of the Company Balance Sheet in the ordinary course of business consistent with past practice; </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>,
 </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2> that nothing in this </FONT> <FONT SIZE=2><I>Section&nbsp;6.1</I></FONT><FONT SIZE=2> shall prohibit the Company from repurchasing Convertible Notes in privately negotiated transactions from
time to time after the date
of the public announcement of this Agreement for a purchase price in respect of any repurchased Convertible Note less than or equal to eighty-five percent (85%) of the principal value
thereof (it being understood that the Company shall not be permitted to repurchase Convertible Notes at a higher price without the prior written consent of Buyer); </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;&nbsp;&nbsp;take
or cause to be taken any action that would reasonably be expected to prevent or impede the Merger from qualifying as a reorganization within the meaning of
Section&nbsp;368(a) of the Code; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;&nbsp;&nbsp;authorize
any of, or commit or agree, in writing or otherwise, to take any of, the foregoing actions or take any action or agree, in writing or otherwise, to take any
action, that would cause (i)&nbsp;any of the representations and warranties of the Company (1)&nbsp;that are qualified as to materiality or Material Adverse Effect on the Company to be untrue or
(2)&nbsp;that are not so qualified to be untrue in any material respect or (ii)&nbsp;any of the conditions to the Merger set forth in this Agreement not to be satisfied; </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that nothing in this </FONT> <FONT SIZE=2><I>Section&nbsp;6.1</I></FONT><FONT SIZE=2> shall prohibit the Company from amending the
Convertible Notes and/or the terms of the Indenture as may be necessary to allow for the
assumption of the Convertible Notes by Buyer pursuant to the Supplemental Indenture. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>6.2</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Conduct of Buyer.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except for matters set forth in </FONT> <FONT
SIZE=2><I>Section&nbsp;6.2</I></FONT><FONT SIZE=2> of Buyer Disclosure Letter or as otherwise contemplated by or specifically provided in this Agreement or as subsequently consented to
in writing by the Company, during the Pre-Closing Period, Buyer shall use its reasonable best efforts to conduct its business in the ordinary and usual course consistent with past
practice. Without limiting the generality of the foregoing, and except for matters set forth in </FONT><FONT SIZE=2><I>Section&nbsp;6.2</I></FONT><FONT SIZE=2> of the Buyer Disclosure Letter or as
expressly contemplated or permitted by this Agreement, without the prior written consent of the Company, Buyer shall not, and shall not permit its Subsidiaries to: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;adopt
any change in the organizational documents of Buyer or any Subsidiary; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;issue,
deliver, sell, grant, pledge or otherwise dispose of or encumber more than 50,000 shares of its capital stock, any other voting securities or any securities
convertible into or exchangeable for, or any rights, warrants or options to acquire, any such shares, voting securities or convertible or exchangeable securities (other than grants or issuances
pursuant to and in accordance with the terms of Buyer's equity incentive plans, employee stock purchase plans and stockholder rights plan or other current Buyer agreements, in each case as in effect
on the date of this Agreement); </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;sell
or otherwise dispose of all or substantially all of its assets or securities, including by merger, consolidation, asset sale or other business combination
(including by formation of a material Buyer joint venture); </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;declare,
establish a record date for, set aside or pay any dividend or other distribution (whether in cash, stock or property or any combination thereof) in respect of
Buyer Securities; </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=46,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=331085,FOLIO='42',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_43"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;adopt
a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization of Buyer or any of its Subsidiaries, or enter into
a letter of intent or agreement in principle with respect thereto (other than the Merger); </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;acquire
by merging or consolidating with, or by purchasing all or a substantial portion of the assets or stock of, or by any other manner, any business or any
corporation, partnership, joint venture, limited liability company, association or other business organization or division thereof, if the consideration paid by Buyer in such transaction is in the
form of shares of Buyer's capital stock or any other voting securities or any securities convertible into or exchangeable for, or any rights, warrants or options to acquire, any such shares, voting
securities or convertible or exchangeable securities; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;(i)
incur or assume any indebtedness for borrowed money or guarantee any indebtedness for borrowed money, other than letters of credit or similar arrangements issued for
the benefit of suppliers and manufacturers in the ordinary course of business consistent with past practice, (ii)&nbsp;issue, sell or amend any debt securities or options, warrants, calls or other
rights to acquire any debt securities of Buyer, guarantee any debt securities of another Person, enter into any "keep well" or other agreement to maintain any financial statement condition of another
Person or enter into any arrangement having the economic effect of any of the foregoing or (iii)&nbsp;make any loans, advances (other than routine advances in the ordinary course of business
consistent with past practice) or capital contributions to, or investments in (by property transfers, purchase of securities or otherwise), any Person, other than a direct or indirect wholly owned
Subsidiary of Buyer; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that Buyer may, in the ordinary course of business consistent
with past practice, continue to invest in money market accounts and U.S. treasury bonds and other securities guaranteed by the U.S. government; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;take
or cause to be taken any action, whether before or after the Effective Time, that would reasonably be expected to prevent or impede the Merger from qualifying as a
reorganization within the meaning of Section&nbsp;368(a) of the Code; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;authorize
any of, or commit or agree, in writing or otherwise, to take any of, the foregoing actions or take any action or agree, in writing or otherwise, to take any
action, that would cause (i)&nbsp;any of the representations and warranties of Buyer or Merger Sub to be untrue in any material respect or (ii)&nbsp;any of the conditions to the Merger set forth
in this Agreement not to be satisfied. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>6.3</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>No Control of Other Party's Business.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained in
this Agreement is intended to give Buyer, directly or indirectly, the right to control or direct the Company's operations during the Pre-Closing Period, and nothing contained in this
Agreement is intended to give the Company, directly or indirectly, the right to control or direct Buyer's or its Subsidiaries' operations during the Pre-Closing Period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ARTICLE VII<BR>
ADDITIONAL AGREEMENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.1</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Stockholder Meetings; Joint Proxy Statement/Prospectus.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;(i)
Within 30&nbsp;days from the date hereof, the Company, Merger Sub and Buyer shall cooperate in preparing and shall cause to be filed with the SEC mutually
acceptable proxy materials which shall constitute the proxy statement/prospectus relating to the matters to be submitted to the Company stockholders at the Company Stockholder Meeting and to Buyer
stockholders at the Buyer Stockholder Meeting (such joint proxy statement/prospectus, and any amendments or supplements thereto, the "</FONT><FONT SIZE=2><I>Joint Proxy
Statement/Prospectus</I></FONT><FONT SIZE=2>"), and Buyer shall prepare, together with the Company, and file with the SEC a registration statement on Form&nbsp;S-4 </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=47,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=928237,FOLIO='43',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_44"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>(of
which the Joint Proxy Statement/Prospectus shall be a part) with respect to the issuance of Buyer Common Stock pursuant to the Merger (such Form&nbsp;S-4, and any amendments or
supplements thereto, the "</FONT><FONT SIZE=2><I>Form&nbsp;S-4</I></FONT><FONT SIZE=2>"). Subject to </FONT><FONT SIZE=2><I>Section&nbsp;7.1(d)</I></FONT><FONT SIZE=2>, Buyer shall
include in the Joint Proxy Statement/Prospectus the recommendation of its Board of Directors that the stockholders of Buyer approve, as required by applicable NASDAQ rules, the issuance of shares of
Buyer Common Stock in connection with the transactions contemplated by this Agreement (the "</FONT><FONT SIZE=2><I>Buyer Recommendation</I></FONT><FONT SIZE=2>"). Subject to </FONT> <FONT SIZE=2><I>Section&nbsp;7.4</I></FONT><FONT SIZE=2>, the
Company shall include in the Joint Proxy Statement/Prospectus the recommendation of its Board of Directors that the stockholders
of the Company adopt this Agreement (the "</FONT><FONT SIZE=2><I>Recommendation</I></FONT><FONT SIZE=2>"). </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;Each
of Buyer and the Company shall use reasonable best efforts to have the Joint Proxy Statement/Prospectus cleared by the SEC and the Form&nbsp;S-4
declared effective by the SEC, to keep the Form&nbsp;S-4 effective as long as is necessary to consummate the Merger and the other transactions contemplated hereby, and to mail the Joint
Proxy Statement/Prospectus to their respective stockholders as promptly as practicable after the Form&nbsp;S-4 is declared effective. Buyer and the Company shall, as promptly as
practicable after receipt thereof, provide the other party with copies of any written comments and advise the other party of any oral comments with respect to the Joint Proxy Statement/Prospectus or
Form&nbsp;S-4 received from the SEC. Each party shall cooperate and provide the other party with a reasonable opportunity to review and comment on any amendment or supplement to the
Joint Proxy Statement/Prospectus and the Form&nbsp;S-4 prior to filing such with the SEC, and each party will provide the other party with a copy of all such filings made with the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;None
of the information supplied or to be supplied by the Company or Buyer for inclusion or incorporation by reference in the (A)&nbsp;Form&nbsp;S-4
will, at the time the Form&nbsp;S-4 is filed with the SEC and at the time it becomes effective under the Securities Act, contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein not misleading, and the (B)&nbsp;Joint Proxy Statement/Prospectus will, at the date of mailing to
stockholders and at the times of the meetings of stockholders to be held in connection with the Merger, contain any untrue statement of a material fact or omit to state any material fact required to
be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Joint Proxy Statement/Prospectus will comply as to
form in all material respects with the requirements of the Exchange Act and the rules and regulations of the SEC thereunder, except that no
representation or warranty shall be made by either such party with respect to statements made or incorporated by reference therein based on information supplied by the other party for inclusion or
incorporation by reference in the Joint Proxy Statement/Prospectus or Form&nbsp;S-4. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;The
Company and Buyer shall make any necessary filings with respect to the Merger under the Securities Act and the Exchange Act and the rules and regulations
thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;Each
party will advise the other party, promptly after it receives notice thereof, of the time when the Form&nbsp;S-4 has become effective, the issuance of
any stop order, the suspension of the qualification of the Buyer Common Stock issuable in connection with the Merger for offering or sale in any jurisdiction, or any request by the SEC for amendment
of the Joint Proxy Statement/Prospectus or the Form&nbsp;S-4. If at any time prior to the Effective Time any information relating to either of the parties, or their respective
affiliates, officers or directors, should be discovered by either party which should be set forth in an amendment or supplement to any of the Form&nbsp;S-4 or the Joint Proxy
Statement/Prospectus so that such documents would not include any misstatement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, the party which discovers such information shall promptly notify </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=48,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=219735,FOLIO='44',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_45"> </A>
<UL>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>the
other party hereto and, to the extent required by Law, rules or regulations, an appropriate amendment or supplement describing such information shall be promptly filed with the SEC and
disseminated to the stockholders of the Company and Buyer. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Except
as otherwise set forth in this Agreement, no amendment or supplement (including by incorporation by reference) to the Joint Proxy Statement/Prospectus or the
Form&nbsp;S-4 shall be made without the approval of the Company and Buyer, which approval shall not be unreasonably withheld or delayed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;The
Company shall duly take all lawful action to call, give notice of, convene and hold the Company Stockholder Meeting as promptly as practicable, and in any event
within 30&nbsp;days, following the date upon which the Form&nbsp;S-4 becomes effective for the purpose of obtaining the Requisite Company Stockholder Vote with respect to the
transactions contemplated by this Agreement and, unless it is permitted to make a Recommendation Withdrawal pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;7.4</I></FONT><FONT SIZE=2>, shall use
all reasonable best efforts to solicit the adoption of this Agreement by its stockholders in accordance with applicable Law. The Board of Directors of the Company shall, subject to </FONT> <FONT SIZE=2><I>Section&nbsp;7.4</I></FONT><FONT SIZE=2>,
include the Recommendation in the Joint Proxy Statement/Prospectus and shall not effect a Recommendation Withdrawal except as and to
the extent expressly permitted by </FONT><FONT SIZE=2><I>Section&nbsp;7.4</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;Buyer
shall duly take all lawful action to call, give notice of, convene and hold a meeting of its stockholders as promptly as practicable, and in any event within
30&nbsp;days, following the date upon which
the Form&nbsp;S-4 becomes effective (the "</FONT><FONT SIZE=2><I>Buyer Stockholder Meeting</I></FONT><FONT SIZE=2>" and, together with the Company Stockholder Meeting, the
"</FONT><FONT SIZE=2><I>Required Stockholders Meetings</I></FONT><FONT SIZE=2>") for the purpose of obtaining the approval of its stockholders required under applicable NASDAQ rules to issue shares
of Buyer Common Stock in connection with the transactions contemplated by this Agreement, and shall, subject to the remainder of this </FONT> <FONT SIZE=2><I>Section&nbsp;7.1(d)</I></FONT><FONT SIZE=2>, use all reasonable best efforts to solicit such
approval of its stockholders in accordance with applicable Law. The Board of
Directors of Buyer shall include the Buyer Recommendation in the Joint Proxy Statement/Prospectus and shall not withdraw or modify the Buyer Recommendation in any manner adverse to the Company; </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>,
 </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that prior to the approval of the issuance of shares of Buyer Common Stock in
connection with the Merger by the Requisite Buyer Stockholder Vote, Buyer's Board of Directors may, to the extent required by its fiduciary duties to Buyer's stockholders under applicable Law, as
determined in good faith by Buyer's Board of Directors after consultation with outside legal counsel and its financial advisors, withdraw or modify the Buyer Recommendation (any such withdrawal or
modification, a "</FONT><FONT SIZE=2><I>Buyer Recommendation Withdrawal</I></FONT><FONT SIZE=2>") if (i)&nbsp;Buyer shall have provided the Company with written notice that it intends to effect a
Buyer Recommendation Withdrawal pursuant to this </FONT><FONT SIZE=2><I>Section&nbsp;7.1(d)</I></FONT><FONT SIZE=2> and describing the basis for such Buyer Recommendation Withdrawal and
(ii)&nbsp;within a period of three full Business Days following the delivery of the notice referred to in clause&nbsp;(i) above, the Company shall not have proposed adjustments in the terms and
conditions of this Agreement which, after having negotiated or caused its financial and legal advisors to negotiate with the Company in good faith such proposed adjustments, Buyer's Board of Directors
determines in its good faith judgment (after considering the advice of its legal counsel and financial advisors) would result in the Buyer Recommendation being consistent with its fiduciary duties to
Buyer's stockholders. Nothing contained in this Agreement shall prohibit Buyer or Buyer's Board of Directors from making any disclosure to Buyer's stockholders if, in the good faith judgment of
Buyer's Board of Directors, after consultation with outside counsel to Buyer, the failure to take such action would cause Buyer's Board of Directors to violate its fiduciary duties to Buyer's
stockholders under applicable Law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;Company
and Buyer shall each use its reasonable best efforts to cause the Company Stockholder Meeting and the Buyer Stockholder Meeting to be held on the same date.
Notwithstanding anything to the contrary contained in this Agreement, each party, after </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=49,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=289097,FOLIO='45',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_46"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>consultation
with the other party, may adjourn or postpone its stockholder meeting to the extent necessary to ensure that any required supplement or amendment to the Joint Proxy Statement/Prospectus
is provided to its stockholders or, if as of the time for which its stockholders meeting is originally scheduled (as set forth in the Joint Proxy Statement/Prospectus), there are insufficient shares
of its common stock represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the meeting, or if additional time is reasonably required to solicit proxies
in favor of, with respect to the Company, adoption of this Agreement, or with respect to Buyer, approval of the issuance of shares of Buyer Common Stock in connection with this Agreement. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.2</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Reasonable Best Efforts.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions
of this Agreement, each party will use its reasonable best efforts to take, or cause to be taken, all actions, to file, or cause to be filed, all documents and to do, or cause to be done, all things
necessary, proper or advisable to consummate the transactions contemplated by this Agreement, including (a)&nbsp;preparing and filing as promptly as practicable all documentation to effect all
necessary filings, consents, waivers, approvals, authorizations,
Permits or orders from all Governmental Authorities or other Persons, (b)&nbsp;defending any claim, investigation, action, suit or other legal proceeding, whether judicial or administrative,
challenging this Agreement or the consummation of the transactions contemplated hereby; and (c)&nbsp;executing additional instruments necessary to consummate the transactions contemplated by this
Agreement. Each party will promptly consult with the other and provide necessary information (including copies thereof) with respect to all filings made by such party with any Governmental Authority
in connection with this Agreement and the transactions contemplated hereby. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.3</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Access to Information.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;During
the Pre-Closing Period, upon reasonable prior written notice, each of the Company and Buyer shall, and shall cause their respective Representatives
to, afford the officers, employees, auditors and other authorized Representatives of the other party reasonable access, consistent with applicable Law, at all reasonable business hours to its
officers, employees, properties, offices, and other facilities and to all books and records, and shall furnish the other party with all financial, operating and other data and information as such
party may from time to time reasonably request in writing. Notwithstanding the foregoing, any such investigation or consultation shall be conducted in such a manner as not to interfere unreasonably
with the business or operations of the Company or Buyer, as applicable, or otherwise result in any significant interference with the prompt and timely discharge by such employees of their normal
duties. Neither party shall be required to provide access to or to disclose information where such access or disclosure would violate or contravene any Law or, in the opinion of its counsel,
jeopardize any attorney-client privilege; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that in the event that a party relies on
this sentence to withhold access or disclosure, such party shall, to the extent permitted by Law and the protection of such attorney-client privilege, notify the other party of the nature of the
withheld information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;No
investigation by any of the parties or their respective Representatives shall affect the representations, warranties, covenants or agreements of the other parties set
forth herein. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Each
party shall keep, and shall cause its Representatives to keep, all information obtained pursuant to this </FONT> <FONT SIZE=2><I>Section&nbsp;7.3</I></FONT><FONT SIZE=2> confidential in accordance with the Confidentiality Agreement, which shall
remain in effect in accordance with its terms. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.4</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Solicitation.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
Company agrees that it shall immediately cease and cause to be terminated all existing discussions, negotiations and communications, if any, with any Persons with
respect to any Company Acquisition Proposal and shall use reasonable good faith efforts to cause any such </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=50,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=469688,FOLIO='46',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_47"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Person
(and its agents and advisors) in possession of confidential information about the Company that was furnished by or on behalf of the Company to return or destroy all such information. The
Company shall not, and the Company shall use reasonable best efforts to cause (and shall not authorize or permit) its officers, directors, employees, consultants, investment bankers, attorneys,
accountants or other agents (collectively, "</FONT><FONT SIZE=2><I>Representatives</I></FONT><FONT SIZE=2>") not to, directly or indirectly (i)&nbsp;initiate, solicit or knowingly encourage
(including by way of furnishing non-public information or assistance), or induce, or knowingly facilitate the making of, any inquiry, offer or proposal which constitutes or could
reasonably be expected to lead to any Company Acquisition Proposal, (ii)&nbsp;enter into, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any Person
(other than Buyer or any of its Affiliates or Representatives) any non-public information for the purpose of encouraging or facilitating, any Company Acquisition Proposal,
(iii)&nbsp;fail to make, or withdraw or modify in any manner adverse to Buyer, the Recommendation, or recommend, adopt or approve any Company Acquisition Proposal (any of the foregoing in this
clause&nbsp;(iii), a "</FONT><FONT SIZE=2><I>Recommendation Withdrawal</I></FONT><FONT SIZE=2>"), (iv)&nbsp;grant (other than to Buyer or any of its Affiliates or Representatives) any waiver or
release under any standstill or similar agreement (except that the Company may grant a limited waiver of any provision of any such standstill or similar agreement solely to the extent necessary to
permit a Person to submit a Company Acquisition Proposal), or (v)&nbsp;enter into any letter of intent or similar document or any understanding or agreement contemplating or otherwise relating to,
or that is intended to or could reasonably be expected to lead to, any Company Acquisition Proposal. The Company shall promptly (and in any event within one Business Day) notify Buyer orally, with
written confirmation to follow, of the Company's receipt of any written Company Acquisition Proposal, which notice shall identify the name of the Person making such Company Acquisition Proposal and
the material terms and conditions of such Company Acquisition Proposal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Notwithstanding
</FONT><FONT SIZE=2><I>Section&nbsp;7.4(a)</I></FONT><FONT SIZE=2>, prior to the adoption of this Agreement by the Requisite Company Stockholder Vote,
the Company may, subject to compliance with this </FONT><FONT SIZE=2><I>Section&nbsp;7.4</I></FONT><FONT SIZE=2>, (i)&nbsp;furnish non-public information with respect to the Company
to any Person (and the Representatives of such Person) pursuant to a confidentiality agreement with terms not materially less restrictive with respect to confidentiality of the other party than those
contained in the Confidentiality Agreement (a copy of which shall be provided to Buyer promptly after its execution), and may (ii)&nbsp;negotiate and participate in discussions and negotiations with
such Person concerning a Company Acquisition Proposal (including solicitation of revised Company Acquisition Proposals), but only if, (x)&nbsp;such Person has on an unsolicited basis, submitted a
bona fide, written proposal to the Company relating to any such transaction which the Board of Directors determines in good faith, after receiving advice from outside counsel and its financial
advisors, would be or is reasonably likely to lead to a Superior Proposal and (y)&nbsp;in the good faith opinion of the Company's Board of Directors, after consultation with outside legal counsel to
the Company, the failure to provide such information or access or to engage in such discussions or negotiations would cause the Company's Board of Directors to violate its fiduciary duties to the
Company's stockholders under applicable Law. The Company shall promptly (and in any event within one Business Day) notify Buyer orally, with written confirmation to follow, of the Company's receipt of
any written Company Acquisition Proposal, which notice shall identify the name of the Person making such Company Acquisition Proposal and the material terms and conditions of such Company Acquisition
Proposal. The Company shall promptly provide to Buyer any material non-public information regarding the Company provided to any other Person which was not previously provided to Buyer,
such additional information to be provided no later than the date of provision of such information to such other Person. For purposes of this Agreement, "</FONT><FONT SIZE=2><I>Superior
Proposal</I></FONT><FONT SIZE=2>" shall mean any bona fide written Company Acquisition Proposal that did not result from the breach by the Company or any of its Representatives of </FONT> <FONT SIZE=2><I>Section&nbsp;7.4</I></FONT><FONT SIZE=2>, made
by a third party to acquire, directly or indirectly, pursuant to a tender offer, exchange offer, merger, share exchange,
 </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=51,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=993512,FOLIO='47',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_48"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>asset
purchase or other business combination, (A)&nbsp;more than 50% of the assets of the Company and its Subsidiaries, taken as a whole or (B)&nbsp;more than 50% of the equity securities of the
Company, in each case on terms which the Board of Directors of the Company determines (after consultation with its financial advisors and outside legal counsel) in good faith by resolution duly
adopted (A)&nbsp;would result in a transaction that, if consummated, is more favorable to the stockholders of the Company (in their capacity as stockholders) from a financial point of view than the
Merger, taking into account all the terms and conditions of such proposal and this Agreement (including any adjustments to the terms and conditions of this Agreement proposed by Buyer in response to
such Superior Proposal or otherwise pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;7.4(e)</I></FONT><FONT SIZE=2>), and (B)&nbsp;is reasonably capable of being completed on the terms proposed,
taking into account all financial, regulatory, legal and other aspects of such proposal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Any
violation of this </FONT><FONT SIZE=2><I>Section&nbsp;7.4</I></FONT><FONT SIZE=2> by any of the Company's Representatives shall be deemed to be a material breach
of this Agreement by the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;Except
as set forth herein, neither the Company's Board of Directors nor any committee thereof shall (i)&nbsp;make a Recommendation Withdrawal or (ii)&nbsp;enter
into any agreement with respect to any Company Acquisition Proposal. Notwithstanding the foregoing, prior to the adoption of this Agreement by the Requisite Company Stockholder Vote, the Company's
Board of Directors may, to the extent required by its fiduciary duties to the Company's stockholders under applicable Law, as determined in good faith by the Company's Board of Directors after
consultation with outside legal counsel, and
subject to the terms of this and the following sentence, make a Recommendation Withdrawal or enter into an agreement with respect to a Superior Proposal (an "</FONT><FONT SIZE=2><I>Acquisition
Agreement</I></FONT><FONT SIZE=2>"), in each case at any time after the third Business Day following the Company's delivery to Buyer of written notice advising Buyer that the Company's Board of
Directors has received a Superior Proposal and otherwise in accordance with the notice requirements set forth in </FONT><FONT SIZE=2><I>Section&nbsp;7.4(b)</I></FONT><FONT SIZE=2>; </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>,
</FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that the Company shall not enter into an Acquisition Agreement or make a
Recommendation Withdrawal (as a result of a Company Acquisition Proposal) unless the Company complies with </FONT><FONT SIZE=2><I>Section&nbsp;7.4(e)</I></FONT><FONT SIZE=2>. In addition, in the
absence of a Company Acquisition Proposal and prior to the adoption of this Agreement by the Requisite Company Stockholder Vote, the Company's Board of Directors may, to the extent required by its
fiduciary duties to the Company's stockholders under applicable Law, as determined in good faith by the Company's Board of Directors after consultation with outside legal counsel and its financial
advisors, make a Recommendation Withdrawal (it being understood that for purposes of this sentence, such term does not include recommendation, adoption or approval of any Company Acquisition Proposal)
if (i)&nbsp;the Company shall have provided Buyer with written notice that it intends to effect a Recommendation Withdrawal pursuant to this </FONT> <FONT SIZE=2><I>Section&nbsp;7.1(d)</I></FONT><FONT SIZE=2> and describing the basis for such
Recommendation Withdrawal and (ii)&nbsp;within a period of three full Business Days following
the delivery of the notice referred to in clause&nbsp;(i) above, Buyer shall not have proposed adjustments in the terms and conditions of this Agreement which, after having negotiated or caused its
financial and legal advisors to negotiate with Buyer in good faith such proposed adjustments, the Company's Board of Directors determines in its good faith judgment (after considering the advice of
its legal counsel and financial advisors) would result in the Recommendation being consistent with its fiduciary duties to the Company's stockholders. Any such Recommendation Withdrawal or the entry
by the Company into any Acquisition Agreement shall not change the approval of the Company Board of Directors for purposes of causing any state takeover statute or other state Law to be applicable to
the Merger. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;Prior
to the adoption of this Agreement by the Requisite Company Stockholder Vote, the Company may terminate this Agreement and enter into an Acquisition Agreement with
respect to a Superior Proposal, provided that, prior to any such termination, (i)&nbsp;the Company shall have provided Buyer written notice that it intends to terminate this Agreement pursuant to
this </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=52,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=522388,FOLIO='48',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_49"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2><I> Section&nbsp;7.4(e)</I></FONT><FONT SIZE=2>, identifying the Superior Proposal then determined to be more favorable, the parties thereto and the material terms and conditions of the Acquisition
Agreement, (ii)&nbsp;within a period of three full Business Days following the delivery of the notice referred to in clause&nbsp;(i) above, Buyer shall not have proposed adjustments in the terms
and conditions of this Agreement which, after having negotiated or caused its financial and legal advisors to negotiate with Buyer in good faith such proposed adjustments in the terms and conditions
of this Agreement, the Company Board of Directors determines in its good faith judgment (after considering the advice of its financial advisor) to be as favorable to the Company's stockholders as such
Superior Proposal, and (iii)&nbsp;at least three full Business Days after the Company has provided the notice referred to in clause&nbsp;(i) above, the Company shall have delivered to Buyer
(A)&nbsp;a written notice of termination of this Agreement pursuant to this </FONT><FONT SIZE=2><I>Section&nbsp;7.4(e)</I></FONT><FONT SIZE=2> and (B)&nbsp;a wire transfer of immediately
available funds in the amount of the Company Termination Fee (it being understood and agreed that any material amendment to the financial terms or any other material term of such Superior Proposal to
the detriment of the Company shall require a new written notice to Buyer pursuant to clause&nbsp;(i) above and a new three Business Day period). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;Nothing
contained in this Agreement shall prohibit the Company or the Company's Board of Directors from (i)&nbsp;taking and disclosing to its stockholders a position
contemplated by Rule&nbsp;14d-9 or Rule&nbsp;14e-2 promulgated under the Exchange Act, or from issuing a "stop, look and listen" statement pending disclosure of its
position thereunder, or (ii)&nbsp;making any disclosure to the Company's stockholders if, in the good faith judgment of the Company Board of Directors, after consultation with outside counsel to the
Company, the failure to take such action would cause the Company's Board of Directors to violate its fiduciary duties to the Company's stockholders under applicable Law. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.5</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Director and Officer Liability.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Buyer
agrees that all rights to exculpation, indemnification and advancement of expenses now existing in favor of the current or former directors, officers or employees,
as the case may be, of the Company as provided in its certificate of incorporation or bylaws or other organization documents or in any agreement shall survive the Merger and shall continue in full
force and effect. For a period of six (6)&nbsp;years following the Effective Time, Buyer and the Surviving Corporation shall maintain in effect exculpation, indemnification and advancement of
expenses provisions that are no less favorable than those provided in the organizational documents of the Company in effect as of the date hereof or in any indemnification agreements of the Company
with any of their respective directors, officers or employees in effect immediately prior to the Effective Time and shall not amend, repeal or otherwise modify any such provisions in any manner that
would adversely affect the rights thereunder of any individuals who at the Effective Time were current or former directors, officers or employees of the Company or Merger Sub. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;In
addition to and not in limitation of the terms of </FONT><FONT SIZE=2><I>Section&nbsp;7.5(a)</I></FONT><FONT SIZE=2>, from and after the Effective Time, Buyer and
the Surviving Corporation shall, to the greatest extent permitted by Delaware Law or the Company's certificate of incorporation and bylaws in effect on the date hereof, indemnify and hold harmless
(and comply with all of the Company's existing obligations to advance funds for expenses to) any person who is now, or has been at any time prior to the date of this Agreement, or who becomes prior to
the Effective Time, a director or officer of the Company (or any of their respective predecessors) in respect of acts or omissions occurring or alleged to occur prior to or at the Effective Time; </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT
SIZE=2>, that such indemnification shall be subject to any limitation imposed from time to time under applicable Law. </FONT>
</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;For
a period of six (6)&nbsp;years after the Effective Time, each of the Buyer and the Surviving Corporation shall cause to be maintained in effect the current
policies of directors' and officers' liability insurance maintained by the Company (or comparable replacement coverage) (the </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=53,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=298302,FOLIO='49',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_50"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>"</FONT><FONT
SIZE=2><I>Current Policy</I></FONT><FONT SIZE=2>") with respect to claims arising from facts or events that existed or occurred prior to or at the Effective Time; </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT
SIZE=2><I>however</I></FONT><FONT SIZE=2>, that in no event shall the Buyer or the Surviving Corporation be required to expend
an aggregate annual premium amount in excess of an amount equal to 200% of the annual premium currently paid by the Company under the Current Policy (the "</FONT><FONT SIZE=2><I>Insurance
Amount</I></FONT><FONT SIZE=2>"); </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that if the cost of such tail policy would exceed
the Insurance Amount, each of the Buyer and the Surviving Corporation shall be obligated to purchase and maintain a tail policy with the greatest coverage available for a cost not exceeding the
Insurance Amount, on terms and conditions that are no less favorable to the indemnified parties than the Current Policy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;This
</FONT><FONT SIZE=2><I>Section&nbsp;7.5</I></FONT><FONT SIZE=2> shall survive the consummation of the Merger and is intended to be for the benefit of, and shall
be enforceable by, present or former directors or officers of the Company, their respective heirs and personal representatives and shall be binding on the Surviving Corporation and its successors and
assigns. In the event that the Surviving Corporation, Buyer or any of their successors or assigns (i)&nbsp;consolidates with or merges into any other Person and is not the continuing or surviving
corporation or entity of such consolidation or merger or (ii)&nbsp;transfers or conveys all or substantially all of its properties and assets to any person (including by dissolution), then, and in
each such case, Buyer shall cause proper provision to be made so that the successors and assigns of Buyer or the Surviving Corporation, as the case may be, assume and honor the obligations set forth
in this </FONT><FONT SIZE=2><I>Section&nbsp;7.5</I></FONT><FONT SIZE=2>. The agreements and covenants contained herein shall not be deemed to be exclusive of any other rights to which any such
present or former director or officer is entitled, whether pursuant to Law, contract or otherwise. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.6</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Takeover Statutes.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The parties shall use their respective
reasonable best efforts (i)&nbsp;to take all action necessary so that no state takeover statute is or becomes applicable to the Merger or any of the other transactions contemplated by this Agreement
and (ii)&nbsp;if any such takeover statute is or becomes applicable to any of the foregoing, to take all action necessary so that the Merger and the other transactions contemplated by this Agreement
may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise to minimize the effect of such takeover statute on the Merger and the other transactions
contemplated by this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.7</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Public Announcements.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except with respect to (a)&nbsp;any
Buyer Recommendation Withdrawal effected pursuant to, and in accordance with, </FONT><FONT SIZE=2><I>Section&nbsp;7.1(d)</I></FONT><FONT SIZE=2> or any action pursuant to, and in accordance with,
such section, (b)&nbsp;any Recommendation Withdrawal or any action taken pursuant to, and in accordance with, </FONT><FONT SIZE=2><I>Section&nbsp;7.4</I></FONT><FONT SIZE=2> or (c)&nbsp;any
action taken pursuant to, and in accordance with, </FONT><FONT SIZE=2><I>Article&nbsp;IX</I></FONT><FONT SIZE=2>, so long as this Agreement is in effect, the parties will consult with each other
before issuing any press release or making any public statement with respect to this Agreement or the transactions contemplated hereby and, except for any press release or public statement as may be
required by applicable Law or the rules and regulations of NASDAQ with respect to which it is impossible without undue effort or expense to consult with the other parties, will not issue any such
press release or make any such public statement without the consent of the other parties (not to be unreasonably withheld or delayed). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.8</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Notice of Certain Events.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;From and after the date of this
Agreement until the Effective Time, the Company and Buyer shall promptly notify each other orally and in writing of (i)&nbsp;the inaccuracy in any material respect of any representation or warranty
contained in this Agreement, (ii)&nbsp;the failure of such party to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it pursuant to this Agreement
which, individually or in the aggregate, would reasonably be expected to result in any condition to the obligations of any party to effect the Merger and the other transactions contemplated by this
Agreement not to be satisfied, (iii)&nbsp;any actions, suits, claims, investigations or proceedings commenced or, to its Knowledge, threatened against or involving or otherwise affecting the Company
or Buyer that, if pending on the date of this Agreement, would have been required to have been disclosed pursuant to this Agreement or that relate to the consummation </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=54,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=29806,FOLIO='50',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_51"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>of
the transactions contemplated by this Agreement, (iv)&nbsp;any communication from any Governmental Entity in connection with the transactions contemplated by this Agreement (and the response
thereto from the Company) and (v)&nbsp;any communication from any Person alleging that the consent of such Person (or another Person) is or may be required in connection with the transactions
contemplated by this Agreement (and the response thereto from the Company); </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that the
delivery of any notice pursuant to this </FONT><FONT SIZE=2><I>Section&nbsp;7.8</I></FONT><FONT SIZE=2> shall not cure any breach of any representation or warranty requiring disclosure of such
matter prior to the date of this Agreement or otherwise limit or affect the remedies available hereunder to the party receiving such notice. With respect to any of the foregoing, the Company will
consult with Buyer and its Representatives so as to permit the Company and Buyer and their respective Representatives to cooperate to take appropriate measures to avoid or mitigate any adverse
consequences that may result from any of the foregoing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.9</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Employee Matters.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;For
one year following the Effective Time, Buyer will or will cause one of its Subsidiaries to maintain the Company's current severance pay levels set forth on </FONT> <FONT SIZE=2><I>Section&nbsp;7.9</I></FONT><FONT SIZE=2> of the Company Disclosure
Letter and will or will cause one of its Subsidiaries to use commercially reasonable efforts to provide
generally to those of its employees and employees of the Surviving Corporation or their respective Subsidiaries who shall have been employees of the Company immediately prior to the Effective Time and
who shall have accepted an offer of employment made by Buyer in connection with the Merger ("</FONT><FONT SIZE=2><I>Continuing Employees</I></FONT><FONT SIZE=2>"), a total compensation package
(including benefits and equity based compensation) that, in the aggregate, is no less favorable than the total compensation package (including benefits and equity based compensation) provided to
similarly situated employees of Buyer. Buyer shall notify the Company of the identity of the employees to whom it intends to make offers of employment no less than 40 Business Days prior to the
Closing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;With
respect to any accrued but unused personal, sick or vacation time to which any Continuing Employee is entitled pursuant to the personal, sick or vacation policies
applicable to such Continuing Employee immediately prior to the Effective Time (the "</FONT><FONT SIZE=2><I>PSV Policies</I></FONT><FONT SIZE=2>"), Buyer shall or shall cause one of its Subsidiaries
to assume the liability for such accrued personal, sick or vacation time and allow such Continuing Employee to use such accrued personal, sick or vacation time in accordance with Buyer's practice and
policies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;As
of and after the Effective Time, the Surviving Corporation shall give Continuing Employees full credit for purposes of eligibility and vesting and benefit levels
under the existing severance and vacation plans or arrangements of the Company that are listed in </FONT><FONT SIZE=2><I>Schedule&nbsp;4.11</I></FONT><FONT SIZE=2> of the Company Disclosure Letter
(but not benefit accruals or any other purpose), under any employee compensation and incentive plans, benefit (including vacation) and severance plans, programs, policies and arrangements maintained
for the benefit of Current Employees as of and after the Effective Time by the Surviving Corporation or any of its Subsidiaries for the Company Employees' service with the Company (each, a
"</FONT><FONT SIZE=2><I>Surviving Corporation Plan</I></FONT><FONT SIZE=2>") to the same extent recognized by the Company immediately prior to the Effective Time, except as results in a duplication
of benefits with respect to the same period of service. With respect to each Surviving Corporation Plan that is a "welfare benefit plan" (as defined in Section&nbsp;3(1) of ERISA), the Surviving
Corporation or its Subsidiaries shall (i)&nbsp;cause there to be waived any pre-existing condition or eligibility limitations and (ii)&nbsp;give effect, for the applicable plan year in
which the Closing occurs, in determining any deductible and maximum out-of-pocket limitations, to claims incurred and amounts paid by, and amounts reimbursed to, Current
Employees under similar plans maintained by the Company immediately prior to the Effective Time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;The
provisions of this </FONT><FONT SIZE=2><I>Section&nbsp;7.9</I></FONT><FONT SIZE=2> are for the sole benefit of the parties to this Agreement and nothing herein,
expressed or implied, is intended or shall be construed to confer upon or give to any person (including for the avoidance of doubt any Company Employees), other than the </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=55,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=162848,FOLIO='51',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_52"> </A>
<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>parties
hereto and their respective permitted successors and assigns, any legal or equitable or other rights or remedies (with respect to the matters provided for in this </FONT> <FONT SIZE=2><I>Section&nbsp;7.9</I></FONT><FONT SIZE=2>) under or by reason of
any provision of this Agreement. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.10</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Listing.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Buyer shall use its reasonable best efforts to
maintain its existing listing on NASDAQ and to cause the shares of Buyer Common Stock being issued pursuant to the Merger or issuable upon exercise of Company Options assumed by Buyer in connection
with the Merger to be approved for listing (subject to notice of issuance) on NASDAQ at or prior to the Effective Time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.11</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Tax Matters.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
Company, Merger Sub and Buyer shall use their respective reasonable best efforts to (i)&nbsp;cause the Merger to qualify, and shall use their respective reasonable
best efforts not to, and not to permit or cause any Affiliate or any Subsidiary to, take any actions or cause any action to be taken which would prevent the Merger from qualifying, as a
"reorganization" under Section&nbsp;368(a) of the Code and (ii)&nbsp;obtain the opinions of counsel referred to in </FONT><FONT SIZE=2><I>Sections&nbsp;8.2(g)</I></FONT><FONT SIZE=2> and </FONT> <FONT SIZE=2><I>8.3(g)</I></FONT><FONT SIZE=2>.
</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;This
Agreement is intended to constitute, and the parties hereto hereby adopt this Agreement as, a "plan of reorganization" within the meaning Treasury Regulation
Sections&nbsp;1.368-2(g) and 1.368-3(a). The Company, Merger Sub and Buyer shall report the Merger as a reorganization within the meaning of Section&nbsp;368(a) of the
Code, unless otherwise required pursuant to a "determination" within the meaning of Section&nbsp;1313(a) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;On
or before August&nbsp;1, 2009, the Company shall prepare and file, or cause to be timely prepared and filed, on a basis consistent with past practice, all Tax
Returns required to be filed with respect to the Company for the Tax year ended December&nbsp;31, 2008 and shall present such Tax Returns to Buyer for review and comment at least 15&nbsp;days
before the date on which such Tax Returns are filed. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.12</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Stockholder Litigation.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each of the Company and Buyer shall
give the other party the opportunity to participate in the defense or settlement of any litigation against such party and/or its directors relating to the transactions contemplated by this Agreement,
and no such settlement shall be agreed to without the other party's prior written consent, not to be unreasonably withheld or delayed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.13</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Exemption from Liability Under Section&nbsp;16(b).</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
Board of Directors of Buyer, or a committee thereof consisting of non-employee directors (as such term is defined for purposes of
Rule&nbsp;16b-3(d) under the Exchange Act), shall adopt a resolution in advance of the Effective Time providing that the receipt by the Company Insiders of Buyer Common Stock in exchange
for shares of Company Common Stock, and of options to purchase Buyer Common Stock upon Buyer's assumption of Company Options, in each case pursuant to the transactions contemplated hereby and to the
extent such securities are listed in the Section&nbsp;16 Information, is intended to be exempt pursuant to Rule&nbsp;16b-3 under the Exchange Act. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;For
purposes of this Agreement, "</FONT><FONT SIZE=2><I>Section&nbsp;16 Information</I></FONT><FONT SIZE=2>" means information regarding the Company Insiders and the
number of shares of Company Common Stock or other Company equity securities deemed to be beneficially owned by each such Company Insider and expected to be exchanged for Buyer Common Stock, or options
to purchase Buyer Common Stock, in each case, in connection with the Merger, which shall be provided by the Company to Buyer within 10 business days after the date of this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;For
purposes of this Agreement, "</FONT><FONT SIZE=2><I>Company Insiders</I></FONT><FONT SIZE=2>" means those officers and directors of the Company who are subject to
the reporting requirements of Section&nbsp;16(a) of the Exchange Act as listed in Section&nbsp;16 Information. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=56,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=694030,FOLIO='52',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.14</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Board of Directors of Buyer.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Prior to the Effective Time,
Buyer shall cause, effective immediately following the Effective Time, the number of members of the Board of Directors of Buyer to be fixed at nine (9)&nbsp;and the person identified on </FONT> <FONT SIZE=2><I>Schedule&nbsp;7.14</I></FONT><FONT
SIZE=2> to be appointed to the Board of Directors of Buyer. If the person designated to be a director on </FONT> <FONT SIZE=2><I>Schedule&nbsp;7.14</I></FONT><FONT SIZE=2> shall prior to the Effective Time be unable or unwilling to hold office
immediately after the Effective Time, the Company and Buyer
shall work together in good faith to designate another person acceptable to Buyer as a director in his or her place. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ARTICLE VIII<BR>
CONDITIONS TO THE MERGER  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>8.1</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Conditions to the Obligations of Each Party.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The obligations
of the Company, Merger Sub and Buyer to consummate the Merger are subject to the satisfaction of the following conditions: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Effectiveness of Form&nbsp;S-4.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Form&nbsp;S-4 shall have become effective in
accordance with the provisions of the Securities Act, and shall not be subject to any stop order or proceeding with respect to the Form&nbsp;S-4. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Stockholder Approval.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall have been duly adopted and approved by the Requisite Company
Stockholder Vote and the issuance of shares of Buyer Common Stock in connection with the Merger shall have been approved by the Requisite Buyer Stockholder Vote. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Injunctions or Restraints; Illegality.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No temporary restraining order, preliminary or permanent
injunction or other order issued by any court of competent jurisdiction or other legal restraint or prohibition preventing the consummation of the Merger shall be in effect. There shall not be any
action taken, or any Law, rule, regulation or order enacted, entered, enforced or deemed applicable to the Merger, by any Governmental Entity of competent jurisdiction that makes the consummation of
the Merger illegal. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>8.2</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Conditions to the Obligations of Buyer and Merger Sub.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of Buyer and Merger Sub to consummate the Merger are subject to the satisfaction or valid waiver of the following further conditions: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties of the Company set forth in
(i)&nbsp;</FONT><FONT SIZE=2><I>Section&nbsp;4.5</I></FONT><FONT SIZE=2> shall be true and correct in all respects (except for </FONT><FONT SIZE=2><I>de minimis</I></FONT><FONT SIZE=2>
inaccuracies), (ii)&nbsp;</FONT><FONT SIZE=2><I>Sections&nbsp;4.1</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>4.2</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>4.3</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>4.7</I></FONT><FONT SIZE=2>,
</FONT><FONT SIZE=2><I>4.8</I></FONT><FONT SIZE=2> and </FONT> <FONT SIZE=2><I>4.15</I></FONT><FONT SIZE=2> shall be true and correct in all material respects and (iii)&nbsp;in any other provision of this Agreement shall be true and correct in all
respects (in each case without giving effect to any "materiality," "Material Adverse Effect" or similar qualifiers contained in any such representations and warranties other than those contained in
Section&nbsp;4.6(a)) as of the Effective Time as though made on and as of such date (unless any such representation or warranty is made only as of a specific date, in which event such representation
and warranty shall be so true and correct as of such specified date), except where the failure of any such representations and warranties to be so true and correct, in the aggregate, has not had, and
would not reasonably be expected to have, a Material Adverse Effect on the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Performance of Obligations of the Company.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have performed in all material respects all
obligations and complied in all material respects with the agreements and covenants required to be performed by or complied with by it prior to the Effective Time hereunder. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Closing Statement; Company Transaction Expenses.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The amounts set forth in the Closing Statement and in the
certificate delivered pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;2.9</I></FONT><FONT SIZE=2> shall be true and correct as of the date of delivery of the Statement. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=57,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=91177,FOLIO='53',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kk14501_1_54"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Officer's Certificate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Buyer shall have received a certificate signed by a senior officer of the Company
certifying as to the matters set forth in</FONT><FONT SIZE=2><I> Sections&nbsp;8.2(a), 8.2(b) </I></FONT><FONT SIZE=2>and</FONT><FONT SIZE=2><I> 8.2(c).  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transaction Expenses.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have paid the Transaction Expenses in full
or accrued for such Transaction Expenses in full on the Closing Balance Sheet. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Material Adverse Effect on the Company.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Since the Company Balance Sheet Date, there shall not have occurred
a Material Adverse Effect on the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Tax Opinion.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Buyer shall have received a written opinion from its Tax counsel, Lowenstein Sandler PC, in
form and substance reasonably satisfactory to them, to the effect that the Merger will constitute a reorganization within the meaning of Section&nbsp;368(a) of the Code and such opinion shall not
have been withdrawn. The issuance of such opinion shall be conditioned upon the receipt by such counsel of the Tax representation letters of Buyer, Merger Sub and Company in customary form to be
provided at such time or times as reasonably requested by such Tax counsel. If Lowenstein Sandler PC is unable to provide the opinion required by this</FONT><FONT SIZE=2><I> Section&nbsp;8.2(g)  </I></FONT><FONT SIZE=2>to Buyer, but Wilmer Cutler
Pickering Hale and Dorr&nbsp;LLP has provided to the Company the opinion required by</FONT><FONT SIZE=2><I> Section&nbsp;8.3(g)</I></FONT><FONT SIZE=2>, Buyer shall waive the condition of this</FONT><FONT SIZE=2><I> Section&nbsp;8.2(g)
</I></FONT><FONT SIZE=2>and shall be entitled to rely upon the
opinion required by</FONT><FONT SIZE=2><I> Section&nbsp;8.3(g).  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Resignations.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Buyer shall have received copies of the resignations, effective as of
the Effective Time, of each director of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Certain Consents and Approvals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All of the consents and approvals identified in </FONT> <FONT SIZE=2><I>Section&nbsp;8.2(i)</I></FONT><FONT SIZE=2> of the Company
Disclosure Letter shall have been obtained. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>8.3</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Conditions to the Obligations of the Company.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The obligation
of the Company to consummate the Merger is subject to the satisfaction or valid waiver of the following further conditions: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties of Buyer set forth in
(i)&nbsp;</FONT><FONT SIZE=2><I>Section&nbsp;5.5</I></FONT><FONT SIZE=2> shall be true and correct in all respects (except for </FONT><FONT SIZE=2><I>de minimis</I></FONT><FONT SIZE=2>
inaccuracies), (ii)&nbsp;</FONT><FONT SIZE=2><I>Sections 5.1</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>5.2</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>5.3</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>5.7</I></FONT><FONT SIZE=2> and
</FONT><FONT SIZE=2><I>5.8</I></FONT><FONT SIZE=2> shall be true and correct in all material respects and (iii)&nbsp;in any other provision
of this Agreement shall be true and correct in all respects (in each case without giving effect to any "materiality," "Material Adverse Effect" or similar qualifiers contained in any such
representations and warranties other than those contained in </FONT><FONT SIZE=2><I>Section&nbsp;5.6(a)</I></FONT><FONT SIZE=2>) as of the Effective Time as though made on and as of such date
(unless any such representation or warranty is made only as of a specific date, in which event such representation and warranty shall be so true and correct as of such specified date), except where
the failure of any such representations and warranties to be so true and correct, in the aggregate, has not had, and would not reasonably be expected to have, a Material Adverse Effect on the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Performance of Obligations of Buyer.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Buyer shall have performed in all material respects all obligations,
and complied in all material respects with the agreements and covenants, required to be performed by or complied with by it hereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Officer's Certificate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have received a certificate signed by a senior officer of Buyer
certifying as to the matters set forth in</FONT><FONT SIZE=2><I> Sections&nbsp;8.3(a) </I></FONT><FONT SIZE=2>and</FONT><FONT SIZE=2><I> 8.3(b).  </I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Buyer Material Adverse Effect.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Since the Buyer Balance Sheet Date, there shall not
have occurred a Buyer Material Adverse Effect. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Director Designee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Buyer shall have complied with its obligations under </FONT> <FONT SIZE=2><I>Section&nbsp;7.14</I></FONT><FONT SIZE=2> with respect to the appointment
of the designee to Buyer's Board of Directors. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=58,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=151614,FOLIO='54',FILE='DISK134:[09ZBT1.09ZBT14501]KK14501A.;5',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_kl14501_1_55"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Nasdaq.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Buyer Common Shares to be issued to the Company's stockholders pursuant to the Merger and to be
reserved for issuance upon exercise, vesting or payment under any Company Option shall have been authorized for listing on NASDAQ, subject only to official notice of issuance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Tax Opinion.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have received a written opinion from its Tax counsel, Wilmer Cutler Pickering
Hale and Dorr&nbsp;LLP, in form and substance reasonably satisfactory to them, to the effect that the Merger will constitute a reorganization within the meaning of Section&nbsp;368(a) of the Code
and such opinion shall not have been withdrawn. The issuance of such opinion shall be conditioned upon the receipt by such counsel of Tax representation letters of Buyer, Merger Sub and Company in
customary form to be provided at such time or times as reasonably requested by such Tax counsel. If Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP is unable to provide the opinion required by
this</FONT><FONT SIZE=2><I> Section&nbsp;8.3(g) </I></FONT><FONT SIZE=2>to the Company, but Lowenstein Sandler PC has provided to Buyer the opinion required by</FONT><FONT SIZE=2><I> Section&nbsp;8.2(g)</I></FONT><FONT SIZE=2>, Company shall waive
the condition of this</FONT><FONT SIZE=2><I> Section&nbsp;8.3(g) </I></FONT><FONT SIZE=2>and shall be entitled to rely upon the
opinion required by</FONT><FONT SIZE=2><I> Section&nbsp;8.2(g).  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Convertible Notes.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have received from Buyer the executed
Supplemental Indenture. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ARTICLE IX<BR>
TERMINATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>9.1</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Termination.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be terminated and the Merger
may be abandoned at any time prior to the Effective Time (notwithstanding any prior adoption of this Agreement by the stockholders of the Company): </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;by
mutual written consent of the Company, on the one hand, and Buyer, on the other hand; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;by
either the Company, on the one hand, or Buyer, on the other hand, if: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;the
Effective Time shall not have occurred on or before October&nbsp;31, 2009 (the "</FONT><FONT SIZE=2><I>End Date</I></FONT><FONT SIZE=2>"), unless the failure of
the Effective Time to occur by such date is the result of, or caused by, the breach of this Agreement by the party seeking to exercise such termination right; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;there
shall be any final and nonappealable order granted by a Governmental Authority that makes illegal or prohibits the consummation of the Merger, </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that, the party seeking to terminate this
Agreement pursuant to this </FONT><FONT SIZE=2><I>Section&nbsp;9.1(b)(ii)</I></FONT><FONT SIZE=2>
shall have used the efforts required by </FONT><FONT SIZE=2><I>Section&nbsp;7.2</I></FONT><FONT SIZE=2> to remove such order; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;at
the Company Stockholder Meeting or any adjournment thereof at which this Agreement has been voted upon, the stockholders of the Company fail to adopt this Agreement
by the Requisite Company Stockholder Vote; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that a party shall not be permitted to
terminate this Agreement pursuant to this </FONT><FONT SIZE=2><I>Section&nbsp;9.1(b)(iii)</I></FONT><FONT SIZE=2> if such failure is attributable to the breach by such party of any of its
obligations under this Agreement; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;at
the Buyer Stockholder Meeting or any adjournment thereof at which the proposal to issue shares of Buyer Common Stock in connection with this Agreement is voted on,
the stockholders of Buyer have failed to approve such issuance by the Requisite Buyer Stockholder Vote; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that a party shall not be
permitted to terminate this Agreement pursuant to this </FONT> <FONT SIZE=2><I>Section&nbsp;9.1(b)(iv)</I></FONT><FONT SIZE=2> if such failure is attributable to the breach by such party of any of its obligations under this Agreement. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=59,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=567598,FOLIO='55',FILE='DISK134:[09ZBT1.09ZBT14501]KL14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_kl14501_1_56"> </A>
<UL>
<UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;by
the Company: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;if
a breach of any representation, warranty, covenant or agreement on the part of Buyer set forth in this Agreement shall have occurred which would cause any of the
conditions set forth in </FONT><FONT SIZE=2><I>Section&nbsp;8.3(a)</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>8.3(b)</I></FONT><FONT SIZE=2> not to be satisfied, and such breach is
incapable of being cured by the End Date; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that the Company is not then in material
breach of this Agreement so as to cause any of the conditions set forth in </FONT><FONT SIZE=2><I>Section&nbsp;8.1</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>8.2(a)</I></FONT><FONT SIZE=2>,
or </FONT><FONT SIZE=2><I>8.2(b)</I></FONT><FONT SIZE=2> not to be satisfied; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;prior
to the adoption of this Agreement by the Requisite Company Stockholder Vote, in accordance with, and subject to the terms and conditions of, </FONT> <FONT SIZE=2><I>Section&nbsp;7.4(e)</I></FONT><FONT SIZE=2>; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;if
the Board of Directors of Buyer or any committee thereof shall have effected a Buyer Recommendation Withdrawal or publicly proposed to effect a Buyer Recommendation
Withdrawal or Buyer shall have failed to include the Buyer Recommendation in the Joint Proxy Statement/Prospectus; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;if
Buyer shall have materially breached the terms of </FONT><FONT SIZE=2><I>Section&nbsp;7.1</I></FONT><FONT SIZE=2> in any respect adverse to the Company. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;by
Buyer, if: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;a
breach of any representation, warranty, covenant or agreement on the part of the Company or Merger Sub set forth in this Agreement shall have occurred which would
cause any of the conditions set forth in </FONT><FONT SIZE=2><I>Section&nbsp;8.2(a)</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>8.2(b)</I></FONT><FONT SIZE=2> not to be satisfied, and such
breach is incapable of being cured by the End Date; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that Buyer is not then in
material breach of this Agreement so as to cause any of the conditions set forth in </FONT><FONT SIZE=2><I>Section&nbsp;8.1</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>8.3(a)</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>8.3(b)
</I></FONT><FONT SIZE=2> not to be satisfied; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;(A)
the Board of Directors of the Company or any committee thereof shall have effected a Recommendation Withdrawal, or publicly proposed to effect a Recommendation
Withdrawal, (B)&nbsp;the Board of Directors of the Company or any committee thereof shall have approved or recommended to the stockholders of the Company a Company Acquisition Proposal other than
the Merger, (C)&nbsp;the Company shall have entered into a Contract (other than a confidentiality agreement pursuant to and in compliance with </FONT> <FONT SIZE=2><I>Section&nbsp;7.4(b)</I></FONT><FONT SIZE=2>) relating to a Company Acquisition
Proposal or (D)&nbsp;the Company shall have failed to include the Recommendation in the Joint
Proxy Statement/Prospectus; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;if
a tender offer or exchange offer for any outstanding shares of capital stock of the Company is commenced prior to the adoption of this Agreement by the Requisite
Company Stockholder Vote and the Board of Directors of the Company fails to recommend against acceptance of such tender offer or exchange offer by its stockholders (including, for these purposes, by
taking no position with respect to the acceptance of such tender offer or exchange offer by its stockholders, which shall constitute a failure to recommend against acceptance of such tender offer or
exchange offer) within ten business
days after commencement, or the Company or its Board of Directors publicly announces its intention to do any of the foregoing; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;if
the Board of Directors of the Company exempts any Person other than Buyer or any of its Affiliates from the provisions of Section&nbsp;203 of the DGCL; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;if
the Company shall have materially breached the terms of </FONT><FONT SIZE=2><I>Section&nbsp;7.1</I></FONT><FONT SIZE=2> or </FONT> <FONT SIZE=2><I>Section&nbsp;7.4</I></FONT><FONT SIZE=2> in any respect adverse to Buyer. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=60,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=344891,FOLIO='56',FILE='DISK134:[09ZBT1.09ZBT14501]KL14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_kl14501_1_57"> </A>
<UL>
<UL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>9.2</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Termination Fee.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;In
the event that this Agreement is terminated (1)&nbsp;by the Company pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;9.1(c)(ii)</I></FONT><FONT SIZE=2>, then the
Company shall pay to Buyer the Company Termination Fee in accordance with </FONT><FONT SIZE=2><I>Section&nbsp;9.2(e)</I></FONT><FONT SIZE=2>, at or prior to the time of termination, or
(2)&nbsp;by the Buyer pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;9.1(d)(ii)</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>(iii)</I></FONT><FONT SIZE=2>, then, no later than the next
Business Day following the date of such termination, the Company shall pay to Buyer the Company Termination Fee in accordance with </FONT> <FONT SIZE=2><I>Section&nbsp;9.2(e)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;In
the event that (1)&nbsp;this Agreement is terminated by Buyer, on the one hand, or the Company, on the other hand, pursuant to </FONT> <FONT SIZE=2><I>Section&nbsp;9.1(b)(i)</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>Section&nbsp;9.1(b)(iii)
</I></FONT><FONT SIZE=2> or by Buyer pursuant to </FONT> <FONT SIZE=2><I>Section&nbsp;9.1(d)(i)</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>(iv)</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>(v)</I></FONT><FONT SIZE=2>; and (2)&nbsp;at
any time after the date of this Agreement and prior to the termination a bona fide, written Company Acquisition Proposal shall have been publicly announced or publicly made known; and
(3)&nbsp;within 12&nbsp;months after such termination the Company enters into any definitive agreement with respect to, or consummates, any Company Acquisition Proposal, then, on the date of such
execution or consummation, the Company shall pay to Buyer the Company Termination Fee in accordance with </FONT><FONT SIZE=2><I>Section&nbsp;9.2(e)</I></FONT><FONT SIZE=2>. For the purpose of this </FONT> <FONT SIZE=2><I>Section&nbsp;9.2(b)
</I></FONT><FONT SIZE=2>, all references in the definition of the term Company Acquisition Proposal to "15% or more" will be deemed to be references to
"more than 50%". </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;In
the event that this Agreement is terminated by the Company pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;9.1(c)(iii)</I></FONT><FONT SIZE=2> then, no later than
the next Business Day following the date of such termination, Buyer shall pay to the Company the Buyer Termination Fee in accordance with </FONT> <FONT SIZE=2><I>Section&nbsp;9.2(e)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;In
the event that (1)&nbsp;this Agreement is terminated by the Company pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;9.1(c)(i)</I></FONT><FONT SIZE=2> or by
either the Company or Buyer pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;9.1(b)(iv)</I></FONT><FONT SIZE=2>, (2)&nbsp;at any time after the date of this Agreement and prior to the termination
a bona fide, written proposal or offer to effect a Buyer Sale shall have been publicly announced or publicly made known by any Person or "group" (as defined in Section&nbsp;13(d) of the Exchange
Act), other than the Company and (3)&nbsp;and within 12&nbsp;months after such termination Buyer enters into any definitive agreement with respect to, or consummates, any Buyer Sale, then, on the
date of such execution or consummation, Buyer shall pay to the Company the Buyer Termination Fee in accordance with </FONT><FONT SIZE=2><I>Section&nbsp;9.2(e)</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;Any
amount that becomes payable pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;9.2(a)</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>9.2(b)</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>9.2(c)</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>9.2(d)
</I></FONT><FONT SIZE=2> shall be paid by wire transfer
of immediately available funds to an account designated by the party entitled to receive such payment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;Each
of the Company, Buyer and Merger Sub acknowledges that the agreements contained in this </FONT><FONT SIZE=2><I>Section&nbsp;9.2</I></FONT><FONT SIZE=2> are an
integral part of the transactions contemplated by this Agreement, that without these agreements the Company, Buyer and Merger Sub would not have entered into this Agreement, and that any amounts
payable pursuant to this </FONT><FONT SIZE=2><I>Section&nbsp;9.2</I></FONT><FONT SIZE=2> do not constitute a penalty. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>9.3</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Effect of Termination.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement is terminated
pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;9. 1</I></FONT><FONT SIZE=2>, this Agreement shall forthwith become null and void and there shall be no liability or obligation on the part of the
Company, Buyer, Merger Sub or their respective Subsidiaries or Affiliates, except that the provisions of </FONT><FONT SIZE=2><I>Sections&nbsp;7.3(c)</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>9.2</I></FONT><FONT SIZE=2>, </FONT><FONT
SIZE=2><I>9.3</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>Article&nbsp;X</I></FONT><FONT SIZE=2> will survive the
termination hereof; </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that nothing herein shall relieve any party from liability for willful breach or fraud. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=61,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=759938,FOLIO='57',FILE='DISK134:[09ZBT1.09ZBT14501]KL14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_kl14501_1_58"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ARTICLE X<BR>
MISCELLANEOUS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.1</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Notices.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All notices, requests and other communications to
any party hereunder shall be in writing (including facsimile or similar writing) and shall be given: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>if
to the Company, to: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>CuraGen
Corporation<BR>
322 East Main Street<BR>
Branford, Connecticut 06405<BR>
Attention: President<BR>
Fax: (203)&nbsp;315-3300<BR></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>with
a copy (which shall not constitute notice) to: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>Wilmer
Cutler Pickering Hale and Dorr&nbsp;LLP<BR>
60 State Street<BR>
Boston, MA 02109<BR>
Attention: Philip P. Rossetti<BR>
Fax: (617)&nbsp;526-5000<BR></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>if
to Buyer or Merger Sub, to: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>Celldex
Therapeutics,&nbsp;Inc.<BR>
119 Fourth Avenue<BR>
Needham, MA 02494<BR>
Attention: President and Chief Executive Officer<BR>
Fax: (781)&nbsp;433-3191 and (908)&nbsp;454-1911<BR></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>with
a copy (which shall not constitute notice) to: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>Lowenstein
Sandler PC<BR>
65 Livingston Ave.<BR>
Roseland, N.J. 07068<BR>
Attention: Anthony O. Pergola<BR>
Fax: (973)&nbsp;597-2445 </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>or
such other address or facsimile number as such party may hereafter specify by notice to the other parties hereto. Each such notice, request or other communication shall be effective (i)&nbsp;if
given by telecopier, when such telecopy is transmitted to the facsimile number specified above and electronic
confirmation of transmission is received or (ii)&nbsp;if given by any other means, when delivered at the address specified in this </FONT> <FONT SIZE=2><I>Section&nbsp;10.1</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.2</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Representations and Warranties.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;None of the
representations, warranties, covenants and agreements in this Agreement or in any instrument delivered pursuant to this Agreement shall survive the Effective Time, except for those covenants and
agreements contained herein and therein which by their terms apply in whole or in part after the Effective Time and then only to such extent. Each of the Company, Merger Sub and Buyer acknowledges and
agrees that, except for the representations and warranties expressly set forth in this Agreement (a)&nbsp;no party makes, and has not made, any representations or warranties relating to itself or
its businesses or otherwise in connection with the Merger, (b)&nbsp;no person has been authorized by any party to make any representation or warranty relating to itself or its businesses or
otherwise in connection with the Merger and, if made, such representation or warranty must not be relied upon as having been authorized by such party, and (c)&nbsp;any estimates, projections,
predictions, data, financial information, memoranda, presentations or any other materials or information provided or addressed to any party or any of its Representatives are not </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=62,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=692562,FOLIO='58',FILE='DISK134:[09ZBT1.09ZBT14501]KL14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_kl14501_1_59"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>and
shall not be deemed to be or to include representations or warranties unless any such materials or information are expressly the subject of any representation or warranty set forth in this
Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.3</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Expenses.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise expressly provided in </FONT> <FONT
SIZE=2><I>Sections&nbsp;7.5</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>9.2</I></FONT><FONT SIZE=2>, all costs and expenses incurred in connection with this Agreement shall be
paid by the party incurring such cost or expense. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.4</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Amendment.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be amended by the parties
hereto by action taken by or on behalf of their respective Boards of Directors or Board of Managers, as applicable, at any time prior to the Effective Time, whether before or after adoption of this
Agreement by the stockholders of the Company; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that, after adoption of this Agreement
by the stockholders of the Company, no amendment may be made which under applicable Law requires the further approval of the stockholders of the Company without such further approval. This Agreement
may not be amended except by an instrument in writing signed by the parties hereto. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.5</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Waiver.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At any time prior to the Effective Time, any party
hereto may (i)&nbsp;extend the time for the performance of any of the obligations or other acts of the other parties hereto, (ii)&nbsp;waive any inaccuracies in the representations and warranties
contained herein or in any document delivered pursuant hereto and (iii)&nbsp;subject to the requirements of applicable Law, waive compliance with any of the agreements or conditions contained for
the benefit of such party contained herein. Any such extension or waiver shall be valid if set forth in an instrument in writing signed by the party or parties to be bound thereby. The failure of any
party to assert any rights or remedies shall not constitute a waiver of such rights or remedies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.6</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Successors and Assigns.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Agreement
shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns, </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that no party may assign,
delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of the other parties hereto (and any purported assignment without such consent shall be void
and without effect). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.7</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Governing Law.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be governed by and
construed in accordance with the Laws of the State of Delaware (without regard to conflict of Laws principles). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.8</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Counterparts; Effectiveness; Third Party
Beneficiaries.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be executed by facsimile signatures and in any number of counterparts, each of which shall be an original, with the same effect
as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective only when actually signed by each party hereto and each such party has received
counterparts hereof signed by all of the other parties hereto. No provision of this Agreement is intended to or shall confer upon any Person other than the parties hereto any rights or remedies
hereunder or with respect hereto, except as otherwise expressly provided in </FONT><FONT SIZE=2><I>Section&nbsp;7.5</I></FONT><FONT SIZE=2> (which is intended to be for the benefit of the persons
covered thereby). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.9</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Severability.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If any term or other provision of this
Agreement is invalid, illegal or incapable of being enforced by virtue of any Law, or due to any public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full
force and effect. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement
so as to effect the original intent of the parties as closely as possible in an acceptable manner so that the transactions contemplated hereby are fulfilled to the extent possible. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.10</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Entire Agreement.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement (including the exhibits
and schedules thereto) constitutes the entire agreement of the parties hereto with respect to its subject matter and supersedes all oral or written prior or contemporaneous agreements and
understandings among the parties with respect to such subject matter. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=63,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=538654,FOLIO='59',FILE='DISK134:[09ZBT1.09ZBT14501]KL14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<A NAME="page_kl14501_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.11</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Remedies.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The parties hereto agree that irreparable damage
would occur in the event that any provision of this Agreement were not performed in accordance with its specific terms or were otherwise breached. It is accordingly agreed that the parties shall be
entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in addition to any other remedy they may have at
law or in equity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.12</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Jurisdiction.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;In
any action or proceeding between any of the parties arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement, each of
the parties hereto: (i)&nbsp;irrevocably and unconditionally consents and submits, for itself and its property, to the exclusive personal jurisdiction of the Court of Chancery of the State of
Delaware, or, if that court does not have jurisdiction, a federal court sitting in Wilmington, Delaware; (ii)&nbsp;agrees that all claims in respect of such action or proceeding must be commenced,
and may be heard and determined, exclusively in the aforementioned courts; (iii)&nbsp;waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter
have to the laying of venue of any such action or proceeding in the aforementioned courts; and (iv)&nbsp;waives, to the fullest extent permitted by Law, the defense of an inconvenient forum to the
maintenance of such action or proceeding in the aforementioned courts. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced
in other jurisdictions by suit on the judgment or in any other manner provided by Law. Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in </FONT> <FONT
SIZE=2><I>Section&nbsp;10.1</I></FONT><FONT SIZE=2>. Nothing in this Agreement shall affect the right of any party to this Agreement to serve process in any other manner permitted by
Law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;EACH
PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE
EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II)&nbsp;EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER,
(III)&nbsp;EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND (IV)&nbsp;EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </FONT> <FONT
SIZE=2><I>SECTION&nbsp;10.12</I></FONT><FONT SIZE=2>. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.13</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Headings.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The headings contained in this Agreement are for
convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.14</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Further Assurances.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each party will, and will cause its
Subsidiaries to, execute such further documents and instruments and take such further actions as may reasonably be requested by any other party in order to consummate the Merger in accordance with the
terms hereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.15</B></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I>Authorship.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The parties agree that the terms and language
of this Agreement were the result of negotiations between the parties and their respective advisors and, as a result, there shall be no
presumption that any ambiguities in this Agreement shall be resolved against any party. Any controversy over construction of this Agreement shall be decided without regard to events of authorship or
negotiation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=64,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=513088,FOLIO='60',FILE='DISK134:[09ZBT1.09ZBT14501]KL14501A.;6',USER='CDESORM',CD='29-MAY-2009;13:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have caused this Agreement and Plan of Merger to be duly executed by their respective authorized officers as of the day and year first written
above. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="213" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="22" style="font-family:times;"></TD>
<TD WIDTH="12" style="font-family:times;"></TD>
<TD WIDTH="213" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>CELLDEX THERAPEUTICS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/ Anthony S. Marucci<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Its:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>President and Chief Executive Officer<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>COTTRELL MERGER SUB,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/ Anthony S. Marucci<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Its:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>President<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>CURAGEN CORPORATION</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/ Timothy Shannon<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Its:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>President and Chief Executive Officer<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=65,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=164724,FOLIO='blank',FILE='DISK134:[09ZBT1.09ZBT14501]KM14501A.;8',USER='MSULLIV',CD='29-MAY-2009;12:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="page_kp14501_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
EXHIBIT A </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>FORM
OF CERTIFICATE OF INCORPORATION<BR>
OF<BR>
SURVIVING CORPORATION </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CERTIFICATE OF INCORPORATION<BR>
OF<BR>
[&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;]  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FIRST.
The name of the corporation is [&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;] </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECOND.
The address of its registered office in the State of Delaware is Corporation Service Company, 2711 Centerville Road, Suite&nbsp;400, City of Wilmington, County of New Castle,
Delaware 19808. The name of its registered agent at such address is Corporation Service Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIRD.
The purpose of the corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOURTH.
The total number of shares of stock which the corporation shall have authority to issue is 1,000. All such shares are to be Common Stock, par value of $.01 per share, and are to
be of one class. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FIFTH.
The incorporator of the corporation is Eric J. Weiner, whose mailing address is c/o Lowenstein Sandler PC, 65 Livingston Avenue, Roseland, New Jersey 07068. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SIXTH.
Unless and except to the extent that the bylaws of the corporation shall so require, the election of directors of the corporation need not be by written ballot. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SEVENTH.
In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board of Directors of the corporation is expressly authorized to make,
alter and repeal the bylaws of the corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EIGHTH.
A director of the corporation shall not be liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except to the extent
such exemption from liability or limitation thereof is not permitted under the General Corporation Law of the State of Delaware as the same exists or may hereafter be amended. Any amendment,
modification or repeal of the foregoing sentence shall not adversely affect any right or protection of a director of the corporation hereunder in respect of any act or omission occurring prior to the
time of such amendment, modification or repeal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NINTH.
The corporation reserves the right at any time, and from time to time, to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, and other
provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted, in the manner now or hereafter prescribed by law; and all rights, preferences and privileges
of any nature conferred upon stockholders, directors or any other persons by and pursuant to this Certificate of Incorporation in its present form or as hereafter amended are granted subject to the
rights reserved in this article. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=66,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=507195,FOLIO='1',FILE='DISK134:[09ZBT1.09ZBT14501]KP14501A.;4',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="page_kq14501_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
EXHIBIT B </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>FORM
OF BY-LAWS<BR>
OF<BR>
SURVIVING CORPORATION </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> BYLAWS<BR>
OF<BR>
[&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;]  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ARTICLE I<BR></FONT> <FONT SIZE=2><I>Meetings of Stockholders  </I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Annual Meetings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If required by applicable law, an annual meeting of stockholders shall be
held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution of the Board of Directors from time to time.
Any other proper business may be transacted at the annual meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Special Meetings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Special meetings of stockholders for any purpose or purposes may be called
at any time by the Board of Directors, but such special meetings may not be called by any other person or persons. Business transacted at any special meeting of stockholders shall be limited to the
purposes stated in the notice. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Notice of Meetings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Whenever stockholders are required or permitted to take any action at a
meeting, a notice of the meeting shall be given that shall state the place, if any, date and hour of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is
called. Unless otherwise provided by law, the certificate of incorporation or these bylaws, the notice of any meeting shall be given not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days
before the date of the meeting to each stockholder entitled to vote at such meeting. If mailed, such notice shall be deemed to be given when deposited in the United States mail, postage prepaid,
directed to the stockholder at such stockholder's address as it appears on the records of the corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Adjournments.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any meeting of stockholders, annual or special, may adjourn from time to time
to reconvene at the same or some other place, and notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken.
At the adjourned meeting the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30)&nbsp;days, or if after
the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Quorum.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided by law, the certificate of incorporation or these
bylaws, at each meeting of stockholders the presence in person or by proxy of the holders of a majority in voting power of the outstanding shares of stock entitled to vote at the meeting shall be
necessary and sufficient to constitute a quorum. In the absence of a quorum, the stockholders so present may, by a majority in voting power thereof, adjourn the meeting from time to time in the manner
provided in Section&nbsp;1.4 of these bylaws until a quorum shall attend. Shares of its own stock belonging to the corporation or to another corporation, if a majority of the shares entitled to vote
in the election of directors of such other corporation is held, directly or indirectly, by the corporation, shall neither be entitled to vote nor be counted for quorum purposes; provided, however,
that the foregoing shall not limit the right of the corporation or any subsidiary of the corporation to vote stock, including but not limited to its own stock, held by it in a fiduciary capacity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.6.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Organization.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Meetings of stockholders shall be presided over by the Chairperson of the
Board, if any, or in his or her absence by the Vice Chairperson of the Board, if any, or in his or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=67,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=377405,FOLIO='1',FILE='DISK134:[09ZBT1.09ZBT14501]KQ14501A.;8',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kq14501_1_2"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>her
absence by the President, or in his or her absence by a Vice President, or in the absence of the foregoing persons by a chairperson designated by the Board of Directors, or in the absence of such
designation by a chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting,
but in his or her absence the chairperson of the meeting may appoint any person to act as secretary of the meeting. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.7.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Voting; Proxies.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided by or pursuant to the provisions of the
certificate of incorporation, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of stock held by such stockholder which has voting power
upon the matter in question. Each stockholder entitled to vote at a meeting of stockholders or to express consent to corporate action in writing without a meeting may authorize another person or
persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A proxy shall be
irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy which
is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary of the corporation a revocation of the proxy or a new proxy bearing a later date. Voting at meetings
of stockholders need not be by written ballot. At all meetings of stockholders for the election of directors at which a quorum is present a plurality of the votes cast shall be sufficient to elect.
All other elections and questions presented to the stockholders at a meeting at which a quorum is present shall, unless otherwise provided by the certificate of incorporation, these bylaws, the rules
or regulations of any stock exchange applicable to the corporation, or applicable law or pursuant to any regulation applicable to the corporation or its securities, be decided by the affirmative vote
of the holders of a majority in voting power of the shares of stock of the corporation which are present in person or by proxy and entitled to vote thereon. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.8.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Fixing Date for Determination of Stockholders of Record.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In order that the corporation may
determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or
entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the
purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board
of Directors, and which record date: (1)&nbsp;in the case of determination of stockholders entitled to vote at any meeting of stockholders or adjournment thereof, shall, unless otherwise required by
law, not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting; (2)&nbsp;in the case of determination of stockholders entitled to express consent to
corporate action in writing without a meeting, shall not be more than ten (10)&nbsp;days from the date upon which the resolution fixing the record date is adopted by the Board of Directors; and
(3)&nbsp;in the case of any other action, shall not be more than sixty (60)&nbsp;days prior to such other action. If no record date is fixed: (1)&nbsp;the record date for determining
stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the
close of business on the day next preceding the day on which the meeting is held; (2)&nbsp;the record date for determining stockholders entitled to express consent to corporate action in writing
without a meeting, when no prior action of the Board of Directors is required by law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken
is delivered to the corporation in accordance with applicable law, or, if prior action by the Board of Directors is required by law, shall be at the close of business on the day on which the Board of
Directors adopts the resolution taking such prior action; and (3)&nbsp;the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the
Board of Directors adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the
meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=68,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=610522,FOLIO='2',FILE='DISK134:[09ZBT1.09ZBT14501]KQ14501A.;8',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kq14501_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.9.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;List of Stockholders Entitled to Vote.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The officer who has charge of the stock ledger shall
prepare and make, at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing
the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the
meeting at least ten (10)&nbsp;days prior to the meeting (i)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with
the notice of meeting or (ii)&nbsp;during ordinary business hours at the principal place of business of the corporation. The list of stockholders must also be open to examination at the meeting as
required by applicable law. Except as otherwise provided by law, the stock ledger shall be the only evidence as to who are the stockholders entitled to examine the list of stockholders required by
this Section&nbsp;1.9 or to vote in person or by proxy at any meeting of stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.10.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Action By Written Consent of Stockholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise restricted by the certificate
of incorporation, any action required or permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote, if a
consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to
authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the corporation by delivery to its registered office in the
State of Delaware, its principal place of business, or an officer or agent of the corporation having custody of the book in which minutes of proceedings of stockholders are recorded. Delivery made to
the corporation's registered office shall be by hand or by certified or registered mail, return receipt requested. Prompt notice of the taking of the corporate action without a meeting by less than
unanimous written consent shall, to the extent required by law, be given to those stockholders who have not consented in writing and who, if the action had been taken at a meeting, would have been
entitled to notice of the meeting if the record date for such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the
corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.11.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Inspectors of Election.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The corporation may, and shall if required by law, in advance of
any meeting of stockholders, appoint one or more inspectors of election, who may be employees of the corporation, to act at the meeting or any adjournment thereof and to make a written report thereof.
The corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. In the event that no inspector so appointed or designated is able to act at a
meeting of stockholders, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall
take and sign an oath to execute faithfully the duties of inspector with strict impartiality and according to the best of his or her ability. The inspector or inspectors so appointed or designated
shall (i)&nbsp;ascertain the number of shares of capital stock of the corporation outstanding and the voting power of each such share, (ii)&nbsp;determine the shares of capital stock of the
corporation represented at the meeting and the validity of proxies and ballots, (iii)&nbsp;count all votes and ballots, (iv)&nbsp;determine and retain for a reasonable period a record of the
disposition of any challenges made to any determination by the inspectors, and
(v)&nbsp;certify their determination of the number of shares of capital stock of the corporation represented at the meeting and such inspectors' count of all votes and ballots. Such certification
and report shall specify such other information as may be required by law. In determining the validity and counting of proxies and ballots cast at any meeting of stockholders of the corporation, the
inspectors may consider such information as is permitted by applicable law. No person who is a candidate for an office at an election may serve as an inspector at such election. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.12.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Conduct of Meetings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The date and time of the opening and the closing of the polls for each
matter upon which the stockholders will vote at a meeting shall be announced at the meeting by the person presiding over the meeting. The Board of Directors may adopt by resolution such rules </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=69,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=749895,FOLIO='3',FILE='DISK134:[09ZBT1.09ZBT14501]KQ14501A.;8',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kq14501_1_4"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>and
regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the
person presiding over any meeting of stockholders shall have the right and authority to convene and to adjourn the meeting, to prescribe such rules, regulations and procedures and to do all such acts
as, in the judgment of such presiding person, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by
the presiding person of the meeting, may include, without limitation, the following: (i)&nbsp;the establishment of an agenda or order of business for the meeting; (ii)&nbsp;rules and procedures
for maintaining order at the meeting and the safety of those present; (iii)&nbsp;limitations on attendance at or participation in the meeting to stockholders of record of the corporation, their duly
authorized and constituted proxies or such other persons as the presiding person of the meeting shall determine; (iv)&nbsp;restrictions on entry to the meeting after the time fixed for the
commencement thereof; and (v)&nbsp;limitations on the time allotted to questions or comments by participants. The presiding person at any meeting of stockholders, in addition to making any other
determinations that may be appropriate to the conduct of the meeting, shall, if the facts warrant, determine and declare to the meeting that a matter or business was not properly brought before the
meeting and if such presiding person should so determine, such presiding person shall so declare to the meeting and any such matter or business not properly brought before the meeting shall not be
transacted or considered. Unless and to the extent determined by the Board of Directors or the person presiding over the meeting, meetings of stockholders shall not be required to be held in
accordance with the rules of parliamentary procedure. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ARTICLE II<BR></FONT> <FONT SIZE=2><I>Board of Directors  </I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Number; Qualifications.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors shall consist of one or more members, the
number thereof to be determined from time to time by resolution of the Board of Directors. Directors need not be stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Election; Resignation; Vacancies.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors shall initially consist of the
persons named as directors in the certificate of incorporation or elected by the incorporator of the corporation, and each director so elected shall hold office until the first annual meeting of
stockholders or until his or her successor is duly elected and qualified. At the first annual meeting of stockholders and at each annual meeting thereafter, the stockholders shall elect directors each
of whom shall hold office for a term of one year or until his or her successor is duly elected and qualified, subject to such director's earlier death, resignation, disqualification or removal. Any
director may resign at any time upon notice to the corporation. Unless otherwise provided by law or the certificate of incorporation, any newly created directorship or any vacancy occurring in the
Board of Directors for any cause may be filled by a majority of the remaining members of the Board of Directors, although such majority is less than a quorum, or by a plurality of the votes cast at a
meeting of stockholders, and each director so elected shall hold office until the expiration of the term of office of the director whom he or she has replaced or until his or her successor is elected
and qualified. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Regular Meetings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Regular meetings of the Board of Directors may be held at such places
within or without the State of Delaware and at such times as the Board of Directors may from time to time determine. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Special Meetings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Special meetings of the Board of Directors may be held at any time or
place within or without the State of Delaware whenever called by the President, any Vice President, the Secretary, or by any member of the Board of Directors. Notice of a special meeting of the Board
of Directors shall be given by the person or persons calling the meeting at least twenty-four hours before the special meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=70,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=560121,FOLIO='4',FILE='DISK134:[09ZBT1.09ZBT14501]KQ14501A.;8',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kq14501_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Telephonic Meetings Permitted.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Members of the Board of Directors, or any committee
designated by the Board of Directors, may participate in a meeting thereof by means of conference telephone or other communications equipment by means of which all persons participating in the meeting
can hear each other, and participation in a meeting pursuant to this by-law shall constitute presence in person at such meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.6.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Quorum; Vote Required for Action.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At all meetings of the Board of Directors the directors
entitled to cast a majority of the votes of the whole Board of Directors shall constitute a quorum for the transaction of business. Except in cases in which the certificate of incorporation, these
bylaws or applicable law otherwise provides, a majority of the votes entitled to be cast by the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.7.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Organization.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Meetings of the Board of Directors shall be presided over by the Chairperson
of the Board, if any, or in his or her absence by the Vice Chairperson of the Board, if any, or in his or her absence by the President, or in their absence by a chairperson chosen at the meeting. The
Secretary shall act as secretary of the meeting, but in his or her absence the chairperson of the meeting may appoint any person to act as secretary of the meeting. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.8.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Action by Unanimous Consent of Directors.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise restricted by the certificate of
incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the
Board of Directors or such committee, as the case may be, consent thereto in writing or by electronic transmission and the writing or writings or electronic transmissions are filed with the minutes of
proceedings of the board or committee in accordance with applicable law. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ARTICLE III<BR></FONT> <FONT SIZE=2><I>Committees  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Committees.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors may designate one or more committees, each committee to
consist of one or more of the directors of the corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified
member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether
or not he, she or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in place of any such absent or disqualified member. Any such
committee, to the extent permitted by law and to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in
the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Committee Rules.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless the Board of Directors otherwise provides, each committee designated
by the Board of Directors may make, alter and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board of
Directors conducts its business pursuant to Article&nbsp;II of these bylaws. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ARTICLE IV<BR></FONT> <FONT SIZE=2><I>Officers  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Officers; Election; Qualifications; Term of Office; Resignation; Removal; Vacancies.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors shall elect a President and Secretary, and it may, if it so determines, choose a Chairperson of the Board and a Vice Chairperson of the Board from among its members. The Board of
Directors may also choose one or more Vice Presidents, one or more Assistant Secretaries, a Treasurer and one or more Assistant Treasurers and such other officers as it shall from time to time deem
necessary or desirable. Each such officer shall hold office until the first meeting of the Board of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=71,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=548768,FOLIO='5',FILE='DISK134:[09ZBT1.09ZBT14501]KQ14501A.;8',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kq14501_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2>Directors
after the annual meeting of stockholders next succeeding his or her election, and until his or her successor is elected and qualified or until his or her earlier resignation or removal. Any
officer may resign at any time upon written notice to the corporation. The Board of Directors may remove any officer with or without cause at any time, but such removal shall be without prejudice to
the contractual rights of such officer, if any, with the corporation. Any number of offices may be held by the same person. Any vacancy occurring in any office of the corporation by death,
resignation, removal or otherwise may be filled for the unexpired portion of the term by the Board of Directors at any regular or special meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Powers and Duties of Officers.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The officers of the corporation shall have such powers and
duties in the management of the corporation as may be prescribed in a resolution by the Board of Directors and, to the extent not so provided, as generally pertain to their respective offices, subject
to the control of the Board of Directors. The Board of Directors may require any officer, agent or employee to give security for the faithful performance of his or her duties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Appointing Attorneys and Agents; Voting Securities of Other Entities.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise
provided by resolution adopted by the Board of Directors, the Chairperson of the Board, the President or any Vice President may from time to time appoint an attorney or attorneys or agent or agents of
the corporation, in the name and on behalf of the corporation, to cast the votes which the corporation may be entitled to cast as the holder of stock or other securities in any other corporation or
other entity, any of whose stock or other securities may be held by the corporation, at meetings of the holders of the stock or other securities of such other corporation or other entity, or to
consent in writing, in the name of the corporation as such holder, to any action by such other corporation or other entity, and may instruct the person or persons so appointed as to the manner of
casting such votes or giving such consents, and may execute or cause to be executed in the name and on behalf of the corporation and under its corporate seal or otherwise, all such written proxies or
other instruments as he or she may deem necessary or proper. Any of the rights set forth in this Section&nbsp;4.3 which may be delegated to an attorney or agent may also be exercised directly by the
Chairperson of the Board, the President or the Vice President. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ARTICLE V<BR></FONT> <FONT SIZE=2><I>Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The shares of the corporation shall be represented by certificates, provided
that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of stock shall be uncertificated shares. Any such resolution shall not apply to
shares represented by a certificate until such certificate is surrendered to the corporation. Every holder of stock represented by certificates shall be entitled to have a certificate signed by or in
the name of the corporation by the Chairperson or Vice Chairperson of the Board of Directors, if any, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the
Secretary or an Assistant Secretary, of the corporation certifying the number of shares owned by such holder in the corporation. Any of or all the signatures on the certificate may be a facsimile. In
case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before
such certificate is issued, it may be issued by the corporation with the same effect as if such person were such officer, transfer agent, or registrar at the date of issue. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The corporation
may issue a new certificate of stock in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the corporation may require the owner of the lost,
stolen or destroyed certificate, or such owner's legal representative, to give the corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged
loss, theft or destruction of any such certificate or the issuance of such new certificate. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=72,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=477721,FOLIO='6',FILE='DISK134:[09ZBT1.09ZBT14501]KQ14501A.;8',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kq14501_1_7"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ARTICLE VI<BR></FONT> <FONT SIZE=2><I>Indemnification and Advancement of Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Right to Indemnification.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The corporation shall indemnify and hold harmless, to the fullest
extent permitted by applicable law as it presently exists or may hereafter be amended, any person (a "Covered Person") who was or is made or is threatened to be made a party or is otherwise involved
in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a "proceeding"),
by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the corporation or, while a director or officer of the corporation,
is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or nonprofit entity,
including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys' fees) reasonably incurred by such Covered Person. Notwithstanding
the preceding sentence, except as otherwise provided in Section&nbsp;6.3, the corporation shall be required to indemnify a Covered Person in connection with a proceeding (or part thereof) commenced
by such Covered Person only if the commencement of such proceeding (or part thereof) by the Covered Person was authorized in the specific case by the Board of Directors of the corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Prepayment of Expenses.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The corporation shall to the fullest extent not prohibited by
applicable law pay the expenses (including attorneys' fees) incurred by a Covered Person in defending any proceeding in advance of its final disposition, </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT
SIZE=2><I>however</I></FONT><FONT SIZE=2>, that, to the extent required by law, such payment of expenses in advance of the final
disposition of the proceeding shall be made only upon receipt of an undertaking by the Covered Person to repay all amounts advanced if it should be ultimately determined that the Covered Person is not
entitled to be indemnified under this Article&nbsp;VI or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Claims.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If a claim for indemnification (following the final disposition of such action, suit
or proceeding) or advancement of expenses under this Article&nbsp;VI is not paid in full within thirty days after a written claim therefor by the Covered Person has been received by the corporation,
the Covered Person may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim to the fullest
extent permitted by law. In any such action the corporation shall have the burden of proving that the Covered Person is not entitled to the requested indemnification or advancement of expenses under
applicable law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Nonexclusivity of Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The rights conferred on any Covered Person by this
Article&nbsp;VI shall not be exclusive of any other rights which such Covered Person may have or hereafter acquire under any statute, provision of the certificate of incorporation, these bylaws,
agreement, vote of stockholders or disinterested directors or otherwise. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Other Sources.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The corporation's obligation, if any, to indemnify or to advance expenses to
any Covered Person who was or is serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, enterprise or nonprofit entity shall be
reduced by any amount such Covered Person may collect as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, enterprise or non-profit
enterprise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.6.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Amendment or Repeal.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any repeal or modification of the foregoing provisions of this
Article&nbsp;VI shall not adversely affect any right or protection hereunder of any Covered Person in respect of any act or omission occurring prior to the time of such repeal or modification. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.7.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Other Indemnification and Prepayment of Expenses.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Article&nbsp;VI shall not limit the
right of the corporation, to the extent and in the manner permitted by law, to indemnify and to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=7,SEQ=73,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=733539,FOLIO='7',FILE='DISK134:[09ZBT1.09ZBT14501]KQ14501A.;8',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<A NAME="page_kq14501_1_8"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>advance
expenses to persons other than Covered Persons when and as authorized by appropriate corporate action. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ARTICLE VII<BR></FONT> <FONT SIZE=2><I>Miscellaneous  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Fiscal Year.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The fiscal year of the corporation shall be determined by resolution of the
Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Seal.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The corporate seal shall have the name of the corporation inscribed thereon and shall
be in such form as may be approved from time to time by the Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Manner of Notice.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided herein or permitted by applicable law,
notices to directors and stockholders shall be in writing and delivered personally or mailed to the directors or stockholders at their addresses appearing on the books of the corporation. Without
limiting the manner by which notice otherwise may be given effectively to stockholders, and except as prohibited by applicable law, any notice to stockholders given by the corporation under any
provision of applicable law, the certificate of incorporation, or these bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the
stockholders at that address to whom such notice is given. Any such consent shall be revocable by the stockholder by written notice to the corporation. Any stockholder who fails to object in writing
to the corporation, within 60&nbsp;days of having been given written notice by the corporation of its intention to send the single notice permitted under this Section&nbsp;7.3, shall be deemed to
have consented to receiving such single written notice. Notice to directors may be given by telecopier, telephone or other means of electronic transmission. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Waiver of Notice of Meetings of Stockholders, Directors and Committees.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any waiver of
notice, given by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of
notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not
lawfully called or convened. Neither the business to be transacted at nor the purpose of any regular or special meeting of the stockholders, directors, or members of a committee of directors need be
specified in a waiver of notice. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Form of Records.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any records maintained by the corporation in the regular course of its
business, including its stock ledger, books of account, and minute books, may be kept on, or by means of, or be in the form of, any information storage device or method, provided that the records so
kept can be converted into clearly legible paper form within a reasonable time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.6.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Amendment of By-Laws.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;These bylaws may be altered, amended or repealed, and new
bylaws made, by the Board of Directors, but the stockholders may make additional bylaws and may alter and repeal any bylaws whether adopted by them or otherwise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=74,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2",CHK=970380,FOLIO='8',FILE='DISK134:[09ZBT1.09ZBT14501]KQ14501A.;8',USER='LPALLES',CD='29-MAY-2009;11:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="09ZBT14501_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kc14501_1">EXHIBIT 2.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>a2193304zex-99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="58%" valign="top" style="padding:0in .7pt 0in .7pt;width:58.56%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="204" height="76" src="g145452mm01i001.jpg" alt="GRAPHIC"></font></p>
  </td>
  <td width="41%" style="padding:0in .7pt 0in .7pt;width:41.44%;">
  <p style="margin:0in 0in .0001pt;"><font size="3" face="Times New Roman"><img width="240" height="37" src="g145452mm01i002.jpg"></font></p>
  </td>
 </tr>
</table>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Celldex Therapeutics,&nbsp;Inc. Enhances Precision Targeted
Immunotherapy Platform with the Acquisition of CuraGen Corporation</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;Conference call scheduled for Friday, May&nbsp;29, 2009 at 8:30 AM ET&#151;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Transaction adds 11 oncology-focused antibodies,
including CR011, to expand Celldex&#146;s Precision Targeted Immunotherapy Platform</font></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Increases potential value of both CuraGen and
Celldex assets through combined technologies and intellectual property</font></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Increases Celldex&#146;s pro forma cash to an
expected $96 million at close; extends cash resources into 2012</font></b></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEEDHAM, MA and BRANFORD, CT (May&nbsp;29, 2009):&#160; </font></b><font size="2" style="font-size:10.0pt;">Celldex Therapeutics,&nbsp;Inc.
(Nasdaq: CLDX) today announced it has entered into a definitive agreement to
acquire CuraGen Corporation (Nasdaq: CRGN). The acquisition will add a
portfolio of oncology-focused, fully-owned antibodies to Celldex&#146;s Precision
Targeted Immunotherapy Platform. Celldex will acquire CuraGen in a tax-free
stock-for-stock transaction, which values CuraGen at approximately $94.5
million, subject to certain adjustments described within the definitive
agreement. In addition to its pipeline, CuraGen is expected to have a cash
balance of at least $54.5 million net of certain acquisition-related costs and
CuraGen convertible debt at the transaction&#146;s close, which is anticipated to
occur in the third quarter of 2009. Concurrent with the closing of the
transaction, Dr.&nbsp;Timothy Shannon, President and Chief Executive Officer of
CuraGen, will join the Celldex Board of Directors.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony Marucci, President and Chief Executive Officer of Celldex,
stated, &#147;The CuraGen acquisition fulfills a major initiative to identify,
acquire and integrate value-creating, synergistic assets to fuel our Precision Targeted Immunotherapy
Platform and</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h2 style="border:none;font-weight:bold;margin:0in 0in .0001pt;padding:0in;page-break-after:avoid;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:9.0pt;">119 FOURTH AVENUE&#160; &#160;NEEDHAM, MA&#160;
02494-2725 USA&#160;&#160; 781-433-0771&#160;&#160; FAX&#160;
781-433-0262</font></b></h2>

<h2 style="border:none;font-weight:bold;margin:0in 0in .0001pt;padding:0in;page-break-after:avoid;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:9.0pt;">www.celldextherapeutics.com</font></b></h2>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=1,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="3",CHK=145269,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MM-01_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:42 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">enhance Celldex&#146;s
antibody-based technology pipeline. In addition, this acquisition
further strengthens Celldex&#146;s intellectual property estate and balance sheet,
providing cash resources to advance our clinical development programs into 2012. Further, on behalf of the Celldex
board and management team, I&#146;d like to welcome Tim to our Board of Directors.
We believe this transaction represents a combination that clearly exceeds the
sum of its parts.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Timothy
Shannon, M.D., President and Chief Executive Officer of CuraGen, commented, &#147;CuraGen&#146;s
Board of Directors considered a range of strategic alternatives to increase
shareholder value and concluded that this transaction represents the best
opportunity for our shareholders. We believe Celldex&#146;s immunotherapy expertise
and platform technology provide an excellent fit for our antibody portfolio,
industry collaborations, technological assets and intellectual property. The
deal also offers CuraGen investors reduced risk via ownership of a broader
portfolio, while still retaining upside potential of CR011 in the combined
company.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CuraGen
Corporation has a portfolio of 11 fully-owned, human antibodies that the
Company selected, optimized and advanced during its collaboration with Abgenix
(acquired by Amgen). CR011, currently in Phase 2 studies, is an antibody-drug
conjugate that targets GPNMB, a protein that is highly expressed in metastatic
breast cancer and melanoma. CR011 has shown promising early evidence of
anti-tumor activity, including objective tumor responses, in patients with
breast cancer and unresectable stage III and IV melanoma.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Celldex&#146;s
expertise in developing novel antibody-based therapeutics will enable us to
seamlessly integrate CuraGen&#146;s antibody programs into our Precision Targeted
Immunotherapy Platform and selectively identify and advance the candidates we </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=2,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="3",CHK=263134,FOLIO='2',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MM-01_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:42 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">believe
hold the most therapeutic promise,&#148; said Thomas Davis, M.D., Chief Medical
Officer of Celldex.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics is discovering and developing innovative targeted
immunotherapeutics for the treatment of cancer, infectious and inflammatory
diseases. The Company&#146;s focus is on the use of tumor-specific targets and human
monoclonal antibodies to precisely deliver therapeutic agents through their
novel targeted immunization approach. Celldex&#146;s deep pipeline consists of
product candidates in varying stages of development, with lead candidate
CDX-110, partnered with Pfizer, currently undergoing evaluation in a Phase 2
clinical trial in newly diagnosed glioblastoma multiforme (GBM) and CDX-1307,
currently enrolling in a Phase 1 study in epithelial tumors. In addition, the
Company recently completed the successful preclinical development of CDX-1401,
a candidate for study in multiple solid tumors.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
acquisition of CuraGen adds to Celldex&#146;s clinical development program a number
of important milestones anticipated over the next 12 to 18 months including:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Present
  data at ASCO in June&nbsp;of 2009</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt .2in;text-indent:-.2in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Phase 2
  CDX-110 ACT II and ACTIVATE data in GBM</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Phase 2 CR011
  breast cancer and melanoma data</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Phase 1
  CDX-1307 combination data in epithelial cancers</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Continue
  development of and/or enrollment in core clinical programs</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Phase 2 ACT
  III study of CDX-110 in GBM; design of randomized study in GBM</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt .1in;text-indent:-.1in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Phase 2 CR011
  studies in breast cancer and melanoma; determine next steps for CR011
  development in breast cancer and melanoma</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Phase 1
  CDX-1307 novel combination therapy study in epithelial cancers</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Initiate
  new clinical studies</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Phase 2
  CDX-1307 randomized study in bladder cancer</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Phase 1/2
  CDX-1401 study in multiple solid tumors</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=3,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="3",CHK=403148,FOLIO='3',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MM-01_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:42 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">File
  at least one IND resulting from recent business development and licensing
  activities</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
  <p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Drive
  internal research to fuel an exciting pipeline of opportunities for future
  years</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Transaction Terms</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the
definitive agreement, Celldex will acquire CuraGen in a tax-free
stock-for-stock transaction, representing an equity value of approximately
$94.5 million. The purchase price payable in this transaction is subject to
certain adjustments described within the definitive agreement, including a
collar of between&nbsp;32.5% and 58% of Celldex&#146;s outstanding common stock. The
transaction, which is subject to the receipt of CuraGen and Celldex stockholder
approvals and other customary closing conditions, is expected to be completed
in the third quarter of 2009.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CuraGen is expected to
deliver $68.6 million in cash, net of acquisition-related costs, including
transaction fees and severance payments and a closing balance sheet adjustment.
At the close of the transaction, Celldex will assume $14.1 million of CuraGen&#146;s
4% convertible debt due in February&nbsp;2011, resulting in an expected $54.5
million of net cash. The Boards of Directors of each of Celldex and CuraGen
have approved the transaction and unanimously recommended that their
stockholders approve the transaction.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex was advised by WBB
Securities, LLC, Brean Murray, Carret&nbsp;&amp; Co., LLC and Lowenstein
Sandler PC. CuraGen was advised by Piper Jaffray&nbsp;&amp; Co. and Wilmer
Cutler Pickering Hale and Dorr LLP.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Conference Call Information</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A joint conference call will
be held on Friday, May&nbsp;29, 2009 at 8:30 AM ET to discuss the proposed
acquisition. The conference call may be accessed by visiting&#160; </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=4,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="3",CHK=696081,FOLIO='4',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MM-01_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:42 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">www.celldextherapeutics.com
or www.curagen.com. The webcast and telephonic replay will be available
following the filing of the conference call transcript with the SEC.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Callers may also access the
call with the following dial-in information:</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.88%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Domestic phone number:
  (800) 299-0433</font></p>
  </td>
  <td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.12%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Passcode: 10533463</font></p>
  </td>
 </tr>
 <tr>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.88%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">International phone
  number: (617) 801-9712</font></p>
  </td>
  <td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.12%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Passcode: 10533463</font></p>
  </td>
 </tr>
 <tr>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.88%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.12%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Callers may access the
  replay with the following dial-in information:</font></p>
  </td>
 </tr>
 <tr>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.88%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.12%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.88%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Domestic phone number:
  (888) 286-8010</font></p>
  </td>
  <td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.12%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Passcode: 97792467</font></p>
  </td>
 </tr>
 <tr>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.88%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">International phone
  number: (617) 801-6888</font></p>
  </td>
  <td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.12%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Passcode: 97792467</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About
Celldex Therapeutics,&nbsp;Inc.</font></b></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex
Therapeutics (Nasdaq: CLDX)&#160; is an
integrated biopharmaceutical company that applies its comprehensive Precision
Targeted Immunotherapy Platform to generate a pipeline of candidates to treat
cancer and other difficult-to-treat diseases. Celldex&#146;s immunotherapy platform
includes a complementary portfolio of monoclonal antibodies, antibody-targeted
vaccines and immunomodulators to create novel disease-specific drug candidates.
For more information, please visit www.celldextherapeutics.com.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About
CuraGen Corporation</font></b></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CuraGen
Corporation (Nasdaq: CRGN) is a biopharmaceutical company dedicated to
improving the lives of patients by developing promising pharmaceutical products
that address unmet medical needs.&nbsp;CuraGen&#146;s therapeutics are based on
research into novel drug targets and mechanisms that are believed to play a
role in the underlying disease. CuraGen has translated this research and
understanding into a pipeline of protein, antibody and antibody-drug conjugate
drugs.&nbsp;For more information, please visit www.curagen.com.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=5,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="3",CHK=488573,FOLIO='5',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MM-01_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:42 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Additional Information about the
Transaction and Where to Find It</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This communication contains &#147;forward-looking&#148;
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements are typically preceded by words such as &#147;believes,&#148; &#147;expects,&#148;
&#147;anticipates,&#148; &#147;intends,&#148; &#147;will,&#148; &#147;may,&#148; &#147;should,&#148; or similar expressions.
These forward-looking statements are subject to risks and uncertainties that
may cause actual future experience and results to differ materially from those
discussed in these forward-looking statements. Important factors that might
cause such a difference include, but are not limited to, costs related to the
transaction; failure of Celldex&#146;s and CuraGen&#146;s stockholders to approve the
transaction; Celldex&#146;s and CuraGen&#146;s inability to satisfy the conditions of the
transaction; the risk that Celldex&#146;s and CuraGen&#146;s businesses will not be
integrated successfully; the combined company&#146;s inability to further identify,
develop and achieve commercial success for new products and technologies; the
possibility of delays in the research and development necessary to select drug
development candidates and delays in clinical trials; the risk that clinical
trials may not result in marketable products; the risk that the combined
company may be unable to successfully secure regulatory approval of and market
its drug candidates; the risks associated with reliance on outside financing to
meet capital requirements; risks of the development of competing technologies;
risks related to the combined company&#146;s ability to protect its proprietary
technologies; risks related to patent-infringement claims; risks of new,
changing and competitive technologies and regulations in the U.S. and
internationally; and other events and factors disclosed previously and from
time to time in Celldex&#146;s and CuraGen&#146;s filings with the SEC, including Celldex&#146;s
and CuraGen&#146;s Annual Reports on Form&nbsp;10-K for the year ended December&nbsp;31,
2008. The companies do not undertake any obligation to release publicly any
revisions to such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=6,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="3",CHK=239639,FOLIO='6',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MM-01_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:42 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the
proposed transaction, Celldex and CuraGen intend to file relevant materials
with the SEC, including a joint proxy statement/prospectus. INVESTORS ARE URGED
TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE TRANSACTION. The joint proxy
statement/prospectus and other relevant materials (when they become available)
and any other documents filed by Celldex or CuraGen with the SEC may be
obtained free of charge at the SEC&#146;s website at http://www.sec.gov. In
addition, investors may obtain free copies of the documents filed with the SEC (i)&nbsp;by
contacting CuraGen&#146;s Investor Relations at (888) 436-6642 or by accessing
CuraGen&#146;s investor relations website at www.curagen.com; or (ii)&nbsp;by
contacting Celldex&#146;s Investor Relations at (781) 433-0771 or by accessing
Celldex&#146;s investor relations website at www.celldextherapeutics.com. Investors
are urged to read the joint proxy statement/prospectus and the other relevant
materials when they become available before making any voting or investment
decision with respect to the transaction.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Participants in the Solicitation</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The directors and executive
officers of Celldex and CuraGen may be deemed to be participants in the
solicitation of proxies from the holders of Celldex and CuraGen common stock in
respect of the proposed transaction.&#160;
Information about the directors and executive officers of Celldex and
CuraGen are set forth in Celldex&#146;s and CuraGen&#146;s most recent Form&nbsp;10-K and
Form&nbsp;10-K/A, which were filed with the SEC on March&nbsp;5, 2009 and April&nbsp;30,
2009, respectively. Investors may obtain additional information regarding the
interest of Celldex and its directors and executive officers, and CuraGen and
its directors and executive officers in the proposed transaction, by reading
the joint proxy statement/prospectus regarding the transaction when it becomes
available.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=7,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="3",CHK=859405,FOLIO='7',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MM-01_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:42 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This communication shall not
constitute an offer to sell or the solicitation of an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of
any such jurisdiction.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Celldex Contacts:</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avery W. Catlin</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics</font></p>

<p style="line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief
Financial Officer</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781)
433-0771</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">info@celldextherapeutics.com</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex
Investor Relations:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sarah
Cavanaugh</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MacDougall
Biomedical Communications</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781) 235-3060</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">scavanaugh@macbiocom.com</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Media:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dan
Budwick</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BMC Communications Group</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(973)
271-6085</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">dbudwick@bmccommunications.com</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CuraGen Contacts:</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sean
Cassidy</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Curagen
Corporation</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice
President and CFO</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">scassidy@curagen.com</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(888)
436-6642</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CRGN-P</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=8,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="3",CHK=692962,FOLIO='8',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MM-01_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:42 2009' -->


<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>a2193304zex-99_2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<div>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit
99.2</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi001.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Conference Call
  to Discuss CuraGen Acquisition May 29, 2009 </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=1,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=1003465,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi002.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Forward Looking
  Statement This communication contains &quot;forward-looking&quot; statements
  within the meaning of the Private Securities Litigation Reform Act of 1995.
  All statements other than statements of historical fact are statements that
  could be forward-looking statements. You can identify these forward-looking
  statements through our use of words such as &#147;may,&#148; &#147;will,&#148; &#147;can,&#148;
  &#147;anticipate,&#148; &#147;assume,&#148; &#147;should,&#148; &#147;indicate,&#148; &#147;would,&#148; &#147;believe,&#148;
  &#147;contemplate,&#148; &#147;expect,&#148; &#147;seek,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;plan,&#148; &#147;point to,&#148;
  &#147;project,&#148; &#147;predict,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;potential&#148; and other
  similar words and expressions of the future. These forward-looking statements
  are subject to risks and uncertainties that may cause actual future
  experience and results to differ materially from those discussed in these
  forward-looking statements. Important factors that might cause such a
  difference include, but are not limited to, costs related to the transaction
  with CuraGen; failure of CuraGen's or Celldex's shareholders to approve
  Celldex's proposed acquisition of CuraGen (the &quot;Acquisition&quot;);
  CuraGen's or Celldex's inability to satisfy the conditions of the merger
  agreement with respect to the Acquisition; the timing, cost and uncertainty
  of obtaining regulatory approvals for product candidates; our ability to
  develop and commercialize products before competitors that are superior to
  the alternatives developed by such competitors; the validity of our patents
  and our ability to avoid intellectual property litigation, which can be
  costly and divert management time and attention; and the other factors listed
  under &#147;Risk Factors&#148; in our annual report on Form 10-K. Neither Celldex nor
  CuraGen undertakes any obligation to release publicly any revisions to such
  forward-looking statement to reflect events or circumstances after the date
  hereof or to reflect the occurrence of unanticipated events. This
  communication may be deemed to be soliciting material in respect of the
  proposed Acquisition. In connection with the Acquisition, Celldex and CuraGen
  intend to file relevant materials with the SEC, including Celldex's joint
  registration statement/proxy statement on Form S-4. SHAREHOLDERS OF CELLDEX
  AND CURAGEN ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC,
  INCLUDING CELLDEX'S JOINT REGISTRATION STATEMENT/PROXY STATEMENT, BECAUSE
  THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION.
  Investors and shareholders will be able to obtain the documents free of
  charge at the SEC's web site, http://www.sec.gov, and Celldex and CuraGen
  shareholder will receive information at an appropriate time on how to obtain
  transaction-related documents for free from Celldex or CuraGen. Such
  documents are not currently available. Participants in the Solicitation The
  directors and executive officers of Celldex may be deemed to be participants
  in the solicitation of proxies from holders of Celldex common stock, and the
  directors and executive officers of CuraGen may be deemed to be participants
  in the solicitation of proxies from holders of CuraGen common stock, in
  respect of the proposed Acquisition. Information about the directors and
  executive officers of Celldex is set forth in Celldex's Annual Report on Form
  10-K, which was filed with the SEC on March 2, 2009. Information about the
  directors and executive officers of CuraGen is set forth in CuraGen's Proxy
  Statement with respect to the election of directors, which was filed with the
  SEC on May 19, 2009. Investors may obtain additional information regarding
  the interest of Celldex and its directors and executive officers, and CuraGen
  and its directors and executive officers, in the proposed transaction by
  reading the proxy statement regarding the Acquisition when it becomes
  available. </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=2,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=379227,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi003.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Expands
  Celldex&#146;s Precision Targeted Immunotherapy Platform with a portfolio of 11
  oncology-focused antibodies, including CR011, for use as monotherapy and in
  novel combination approaches Increases value of both CuraGen and Celldex
  Increases cash to at least $96 million pro forma; extending runway into 2012
  Fulfills a major initiative to identify and bring value-creating assets
  in-house Benefits of CuraGen Acquisition </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=3,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=1041191,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi004.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Transaction
  Details All-stock transaction valued at $94.5 million CRGN to deliver a
  minimum of $68.6 million in cash CLDX to assume $14.1 million in CRGN debt
  Minimum yield of $54.5 million net cash; increases Company cash to at least
  $96 million and runway into 2012 Net of acquisition related costs, including
  transaction fees and severance payments 4% coupon; due in 2011 Timothy
  Shannon, M.D., President and CEO of CuraGen, will join the Celldex Board of
  Directors Anticipated close in Q3 2009 </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=4,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=381111,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi005.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">CuraGen: An
  Ideal Strategic Fit Robust portfolio of 11 oncology-focused promising human
  antibodies Vetted and selected from target/antibody deal with Abgenix;
  fully-owned Phase 2 Candidate CR011 (breast cancer and melanoma)
  Antibody-drug conjugate targeting GPNMB IND-track CR014 (renal and ovarian
  cancers) Antibody-drug conjugate targeting TIM-1 CR011 and CR014 also have
  potential as therapeutic antibodies Nine other novel antibody programs ready
  for or in preclinical studies Extensive antibody-focused IP portfolio
  Anticipated $54.5 million in net cash Synergistic technology, IP and
  resources </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=5,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=546736,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi006.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">The Precision
  Targeted Immunotherapy Engine: Fueling New Treatments for Serious Diseases </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=6,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=830195,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi007.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Celldex
  Therapeutics: Leader in Immunotherapy Precision Targeted Immunotherapy
  Platform Primary focus is oncology and inflammatory diseases Lead candidate
  CDX-110 in Phase 2 study in glioblastoma multiforme Vaccine targeting the
  tumor-specific molecule EGFRvIII Partnered with Pfizer CDX-1307 completing
  Phase 1 study in epithelial tumors; will initiate Phase 2 clinical studies by
  year-end 2009 Antibody-vaccine to fight cancers that express hCG-&#946;
  CDX-1401 entering Phase 1/2 studies in multiple solid tumors Fully-human mAb
  targeting cancers that express NY-ESO-1 Additional IND candidates in
  development </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=7,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=827860,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi008.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Significant
  Value Driving Events ASCO 2009 data presentations Phase 2 CDX-110 ACT II and
  ACTIVATE data in GBM Phase 2 CR011 breast cancer and melanoma data Phase 1
  CDX-1307 combination data in epithelial cancers Ongoing
  enrollment/development Phase 2 ACT III study of CDX-110; design of randomized
  study in GBM Phase 2 CR011 studies in breast and melanoma; define next
  development steps by YE09 Phase 1 CDX-1307 novel combination-therapy study in
  epithelial cancers </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=8,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=965765,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi009.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Significant
  Value Driving Events Continued Initiate Phase 2 CDX-1307 randomized study in
  bladder cancer Initiate Phase 1/2 CDX-1401 study in multiple solid tumors
  Ongoing internal research to fuel a sustainable pipeline for future years
  File at least one IND in 2010 </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=9,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=23153,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi010.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">= Significant
  Value Creation at All Levels Combination Exceeds the Sum of its Parts
  Synergistic technologies and infrastructure Ability to drive exponential
  value instead of sequential value Programs in the clinic or promising
  antibody-based therapeutics Cash </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=10,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=702675,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="587" height="458" src="g145452moi011.gif" alt="GRAPHIC"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">www.celldextherapeutics.com
  </font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=11,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4",CHK=31883,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MO_ZBT14502.CHC",USER="LPALLES",CD='May 29 22:44 2009' -->


<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>5
<FILENAME>a2193304zex-99_3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.3</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CORPORATE PARTICIPANTS</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Celldex
Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tim Shannon</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">CuraGen
Corporation - President&nbsp;&amp; CEO</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tibor Keler</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Celldex
Therapeutics,&nbsp;Inc. - SVP&nbsp;&amp; CSO</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Chip Catlin</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Celldex
Therapeutics,&nbsp;Inc. - SVP&nbsp;&amp; CFO</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tom Davis</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Celldex
Therapeutics,&nbsp;Inc. - SVP&nbsp;&amp; CMO</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONFERENCE CALL
PARTICIPANTS</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan
Aschoff</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Brean
Murray, Carret&nbsp;&amp; Co. - Analyst</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Glen Gechlik</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Needham&nbsp;&amp;
Co. - Analyst</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jason Kantor</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">RBC Capital
Markets - Analyst</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">David
Sugarman</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">CQS -
Analyst</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Richard
Mansouri</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">DellaCamera
Capital Management - Analyst</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Thayer
Koboroski</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">CCS
Financial - Analyst</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan Van
Orden</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Dominick&nbsp;&amp;
Dominick - Analyst</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jeremy
Stoval</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Polly Co. -
Analyst</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Scott
Middleton</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">AM
Investment Partners &#151; Analyst</font></i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PRESENTATION</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Good morning and welcome to
the Celldex Therapeutics,&nbsp;Inc. conference call to discuss the proposed
acquisition of CuraGen Corporation. My name is Erica and I will be your
operator on today&#146;s call. Before we begin our discussion, I would like to refer
you to slide 2 and caution listeners that today&#146;s speakers will be making
forward-looking statements. These forward-looking statements are subject to
risks and uncertainties that may cause actual future experience and results to
differ materially from those discussed in the forward-looking statements.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This communication may be
deemed to be solicitation of material in respect to the proposed acquisition by
Celldex of CuraGen. The directors and executive officers of Celldex and CuraGen
may be deemed as participants in the solicitation of proxies from the holders
of Celldex and CuraGen common stock and respect the proposed transaction.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Please be advised that the
question-and-answer period will be held at the close of the call. I would now
like to turn the call over to Mr.&nbsp;Anthony Marucci, President and CEO of
Celldex Therapeutics. You may proceed, sir.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Good morning and thank you
for joining us. I am Anthony Marucci, President and CEO of Celldex. Joining me
on the call today are Dr.&nbsp;Tim Shannon, President and CEO of CuraGen
Corporation and the Celldex senior management team, which includes Chip Catlin,
our Senior Vice President and Chief Financial Officer; Dr.&nbsp;Tom Davis, our
Senior Vice President and Chief Medical Officer; and Dr.&nbsp;Tibor Keler, our
Senior Vice President and Chief Scientific Officer.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As you know, this morning,
Celldex announced that we have entered into a definitive agreement to acquire
CuraGen Corporation and I want to welcome both Celldex and CuraGen shareholders
to this morning&#146;s call. We think today&#146;s announcement is a significant
milestone for both companies and we look forward to walking you through the
transaction and the resulting benefits.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Now as you will see on slide
3, the strategic acquisition expands Celldex&#146;s Precision Targeted Immunotherapy
Platform, or PTI, with a portfolio of 11 oncology-focused antibodies that will
help fuel the development of our new therapeutics in the field of cancer
immunotherapy. We believe this transaction increases the value of both CuraGen
and Celldex assets through a combination of technologies that should result in
increased value-creating milestones and partnering opportunities. When the
transaction closes, Celldex&#146;s cash will increase to approximately $96 million,
extending our reserves into 2012.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=1,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5",CHK=1886,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MQ_ZBT14502.CHC",USER="LPALLES",CD='May 30 01:12 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Importantly, the execution of
this transaction fulfills a major Celldex initiative to identify and bring
value-creating synergistic assets in-house that can then be leveraged through
our integration with our PTI platform, which I will discuss in more detail
later in the call.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[It&#146;s] Celldex&#146;s growth
engine [and] works by combining synergistic technologies to fuel a rational
design of new therapeutics and targeted regimens that maximize the beneficial
aspects of the immune system. We believe CuraGen&#146;s antibody portfolio is an
ideal strategic fit for the platform and in a moment, I will turn the call over
to Tim to tell you more about the CuraGen assets. But first, I would like to
outline the transaction terms on slide 4. This is an all-stock transaction
valued at $94.5 million dollars.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At the close of the deal,
CuraGen will deliver a minimum of $68.6 million in cash, net of all
acquisition-related costs, including transaction fees and severance payments.
Celldex will assume the $14.1 million in CuraGen convertible debt, which
carries a 4% coupon and is due in February&nbsp;of 2011. When taking both the
cash and the debt into consideration, the transaction will yield a minimum of
$54.5 million in net cash to Celldex at close. As I said earlier, this will
increase Celldex&#146;s cash to approximately $96 million and provide us with a
runway into 2012. We will also welcome Tim Shannon of CuraGen to the Celldex
Board of Directors and believe he will be a valuable addition to the Board, bringing
both significant clinical and scientific experience. Lastly, we anticipate the
deal to close in the third quarter of 2009. With this, I will now ask Tim to
tell you more about CuraGen.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tim Shannon </font></b><i>- CuraGen Corporation -
President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you, Anthony. I would
also like to thank our listeners for joining us today. CuraGen considered a
broad range of strategic options to increase shareholder value over the last
few months. And based on the synergies Anthony just outlined, we felt strongly
that this transaction represented the best opportunity for our shareholders. We
believe Celldex&#146;s immunotherapy expertise and platform technology provide an
excellent fit for our antibody portfolio, industry collaborations,
technological assets and intellectual property.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Let me take a minute to walk
you through CuraGen&#146;s portfolio on slide 5. CuraGen has a robust portfolio of
11 oncology-focused, promising, fully-human antibodies. These antibodies were
thoroughly studied, vetted and ultimately selected from a target antibody deal
we executed with Abgenix, since bought by Amgen, to develop antibody
therapeutics against the most promising antibody drug targets within the human
genome.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The lead candidate resulting
from this deal is CR011, an antibody drug conjugate that targets GPNMB,
approaching overexpressed on the surface of cancer cells, including breast
cancer, melanoma and glioma. CR011 utilizes antibody drug conjugation
technology, which links vcMMAE, a potent chemotherapeutic, to the CR011
antibody resulting in antibody drug conjugate CR011-vcMMAE. This is the same
drug conjugation technology used by Seattle Genetics in their ongoing Phase III
program. CR011 has shown promising early data, including objective tumor
responses in patients with advanced breast cancer and with unresectable stage
III and IV melanoma. The candidate is currently in two Phase II studies, one in
breast cancer and one in melanoma. We look forward to presenting updated data
on CR011 at ASCO this week. The second candidate in the portfolio is CR014.
CR014 is an antibody drug conjugate that targets TIM-1, a protein expressed on
the surface of certain cancer cells. CR014-vcMMAE is being studied as a
potential treatment for ovarian cancer and renal cell carcinoma and is prepared
for IND-enabling studies. In addition, CR011 and CR014 may also have potential
as therapeutic monoclonal antibodies using non-ADC mechanisms. CuraGen also
brings to this transaction nine other novel antibody programs that are either
currently in or ready to enter preclinical studies. We believe these programs
will be highly valuable to Celldex&#146;s Precision Targeted Immunotherapy pipeline,
particularly in combination with the antibody-focused intellectual property
portfolio CuraGen has built. Beyond our core clinical and technology assets,
CuraGen also has a strong cash position and will deliver a minimum of $54.5
million in total net cash at the close of this transaction to support the
continued development of Celldex&#146;s broadened Precision Targeted Immunotherapy
Platform, which Anthony will now discuss in more detail. Anthony?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you, Tim. As I said
earlier, the PTI platform is Celldex&#146;s growth engine. It works by combining
synergistic technologies to fuel the rational design of new therapeutics and
targeted treatment regimens that maximize the beneficial aspects of the immune
system. As you will see on slide 6, we fuel this engine with three fundamental
components &#151; immune system modulators, our antigen-presenting cell technology
or APC and our therapeutic monoclonal antibody programs. I am going to take a
few minutes to walk you through each of these components so you can see how the
CuraGen assets fit into our overall development strategy. One of the core components
includes immune system modulators or drugs that activate or suppress the immune
system. For example, this includes our TLR agonists, our FLT3 program and our
antibody programs targeting CD27 and CD89, which we envision as part of a
combination immunotherapy regimen.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The next component of PTI is
our APC [plat] technology, which uses human monoclonal antibodies to deliver
disease-specific antigens to dendritic cells, which then direct the immune
system to fight disease. The APC technology overcomes the cumbersome need for
specifically manipulating each patient&#146;s dendritic cells by directly targeting
dendritic cells in vivo. This novel technology is currently in Phase I
development with our lead APC candidate, CDX-1307, which also draws from our
immune-modulating assets. Our therapeutic antibody programs </font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=2,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5",CHK=620528,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MQ_ZBT14502.CHC",USER="LPALLES",CD='May 30 01:12 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">round out the PTI platform.
These are based on a well-validated approach using antibodies to target cancer
and other diseases directly or by interfering with critical interactions
between the patient and the disease. With the acquisition of CuraGen, we have
significantly added to the antibody component of this platform. We believe some
of these antibodies have considerable therapeutic value as single agents and
others have therapeutic potential that can be more fully realized as part of a
combination regimen that draws from the components of the PTI platform. Celldex&#146;s
core competencies lies here in our ability to leverage these unique combined
assets as appropriate for each of these three components to create novel
therapeutic regimens that harness the immune system to fight disease. Turning
to slide 7, I would like to tell you a little bit about Celldex and the
programs the PTI platform has driven to date. While we have assets in both
inflammatory and infectious diseases, our primary focus is in oncology. Our
lead candidate, CDX-110, is currently in Phase II studies in glioblastoma
multiforme, the most aggressive form of brain cancer. This drug was partnered
with Pfizer in April&nbsp;of 2008 in one of the largest cancer immunotherapy
deals done to date. CDX-110 is an investigational immunotherapeutic vaccine
that targets the tumor-specific molecule, epidermal growth factor receptor
variant III, or as it is commonly called EGFRvIII. EGFRvIII is a mutated form
of the epidermal growth factor receptor that is only expressed in cancer cells
and not in normal tissue and is a transforming oncogene that can directly
contribute to cancer cell growth, which it does in about 40% of GBM tumors. Our
second candidate in the clinic is CDX-1307, a dendritic cell targeting
immunotherapy designed to focus the immune system against beta hCG, which is
frequently expressed in epithelial tumors. We are currently completing a Phase
I study in patients with epithelial tumors, including colorectal, pancreatic,
bladder, ovarian and breast cancers. Third in the pipeline is CDX-1401, a
fusion protein consisting of a fully human monoclonal antibody with specificity
to the dendritic cell receptor, DEC-205 and is linked to NY-ESO-1 tumor
antigen. NY-ESO-1 represents an important target for developing therapeutics
against multiple cancers and CDX-1401 is intended to selectively deliver the
NY-ESO-1 antigen to antigen-presenting cells that generate a robust human
response against these cells that express NY-ESO-1. CDX-1401 is expected to
enter Phase I/II studies in the third quarter of this year. In addition to the
lead clinical programs, we have a number of additional IND candidates in active
development. So as I believe you have seen in the last few slides, the
combination of Celldex and CuraGen assets equates both to a robust near term
product portfolio and a longer-term pipeline of opportunities in future years.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As we look to the next 12 to
18 months on slide 8 and 9, it is all about the execution and building and
advancing a robust clinical pipeline program utilizing these combined assets.
In the near term, there is a significant amount of value-driving news resulting
from this transaction. First, at the American Society of Clinical Oncology
annual meeting later this week, data will be presented from all four of the
clinical programs we discussed here this morning, including CDX-110, Phase II,
ACT II and ACTIVATE data in GBM, CR011 Phase II breast cancer and melanoma data
and CDX-1301 Phase I combination data in epithelial cancers. We will continue
to put a priority on the ongoing advancement of the Phase II, ACT III study in
CDX-110 in GBM with Pfizer, the Phase II breast cancer and melanoma studies of
CR011 and the novel combination study of CDX-1307 in epithelial cancers. We
believe we&#146;ll be in a position to make decisions on next steps for CR011 breast
cancer and melanoma programs by year-end and are also working with Pfizer on
the design of a randomized controlled study for CDX-110 in GBM. By year-end, we
intend to initiate a Phase II study in CDX-1307 in bladder cancer and as I said
previously, a Phase I/II study of CDX-1401 in multiple solid tumors.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will also continue to
focus on driving internal research to fuel a sustainable pipeline for the
future and we will file a least one IND in 2010 resulting from our business
development activities over the last year.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In closing, on behalf of both
the Celldex and CuraGen teams, I want to thank you for joining us today. As
outlined on slide 10, we believe the acquisition of CuraGen by Celldex creates
a combination that exceeds the sum of its parts. As Celldex&#146;s undertook our
initiative to in-license and acquire synergistic technologies and adjuvant
products, we developed a list of criteria that an ideal transaction would offer
and CuraGen met all of them.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">They bring synergistic
technologies and infrastructure, which will result in an increased value for
both the CuraGen and Celldex assets through a combination of technologies that
should result in increased value-creating milestones and partnering
opportunities. Importantly, CuraGen also brings both promising programs in the
clinic and promising early-stage antibody-based therapeutics with a significant
amount of cash that will help further the development plan as a whole. As a
result, we believe Celldex&#146;s acquisition of CuraGen creates significant value
at all levels. With this, I would like to turn the call over to the operator
and take our first question. Operator?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">QUESTIONS AND ANSWERS</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Operator Instructions).
Jonathan Aschoff, Brean Murray.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan
Aschoff </font></b><i>- Brean Murray, Carret&nbsp;&amp; Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you. Good morning,
Anthony and Tim, how are you?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=3,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5",CHK=509583,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MQ_ZBT14502.CHC",USER="LPALLES",CD='May 30 01:12 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Good morning, Jonathan. We
are fine; thank you.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan
Aschoff </font></b><i>- Brean Murray, Carret&nbsp;&amp; Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">It&#146;s really nice to see the
cash runway for sure. And I guess I just have three questions. That was &#151; the
first would be could you discuss 011 and 014 against the closest competition,
as well as which of the other nine products might get some aggressive
development at CuraGen? Or are they substantially more on the back burner
compared to 011 and 014? And I guess the final curiosity was what was the
strike on the debt?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tim Shannon </font></b><i>- CuraGen Corporation -
President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Okay, Jonathan, this is Tim
Shannon and I will start with the CR011 and CR014 questions. We are very
enthused about CR011.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">That is not new and I think
the combined company is very enthused about it as well. The target GPNMB really
had emergent biology over the last year and a half that has increased our
interest in the target &#151; as a target in breast cancer. We alluded to earlier in
the year and then have shown in the abstracts that came out, an abstract, that
we are seeing clear evidence of activity in breast cancer and we will be able
to update that at ASCO for both companies&#146; investors.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In terms of competition, I
think the beauty about this is this is really a new target in breast cancer,
which can carve out its own space based on that target expression. So again, we
believe the target of GPNMB is expressed in about 25% to 40% of breast cancer
patients. That compares to HER2/neu, which again is about 25%. So again, that
is a very nice target and that is a definable population. So we are trying to
work out the scenario where expression of GPNMB will let us select for patients
who have a better chance of response to the drug, which certainly theoretically
makes sense. And if we can do that, we think CR011 will fit in very nicely to
the existing treatment paradigms in breast cancer where treatment choices are
very much made by selection of specific agents based on receptor expression. So
again, we think CR011 can be very competitive in breast cancer.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In melanoma, that space
remains wide open. So again, GPNMB in melanoma is expressed in about 80% to 90%
of metastatic melanoma patients. So again, it is a target in melanoma that
should be useful in the preponderance of patients in need. Again, we think the
activity we have shown thus far is very competitive with both the approved
agents, as well as agents in development.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">So again, we think CR011 can
be very competitive in the melanoma space as well.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan
Aschoff </font></b><i>- Brean Murray, Carret&nbsp;&amp; Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you very much for that.
How about the other products beyond O11 or 014 or are they substantially on the
back burner comparatively?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tibor Keler </font></b><i>- Celldex Therapeutics,&nbsp;Inc.
- - SVP&nbsp;&amp; CSO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Not at all. Jonathan, this is
Tibor. So we certainly see a lot of value and opportunity within the other nine
antibody programs, which have all been selected through a terrific scientific
program that has really allowed the development of antibodies that target
important cancers, both as potential standard therapeutic antibodies,
anti-angiogenic targets, as well as drug conjugates. So from our perspective,
this really provides the Celldex team as an opportunity to develop and
investigate these and we will be actively looking at how to prioritize the best
targets to bring them forward clinically in the near future.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tim Shannon </font></b><i>- CuraGen Corporation -
President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">So let me just add to that. A
frustration of ours has been our inability to move those forward just because
of the constraints we face. A nice synergy in this combination is the fact that
Celldex has internal capabilities that can allow these to advance in a very
cost-efficient fashion. Those are research capabilities, analytical
capabilities, animal model capabilities and manufacturing capabilities. So
again, we bring to those assets capabilities that we did not have internally
any more or even at certain points in the history of CuraGen. And again, we
think that is a very valuable synergy in this combination that will allow for
cost-efficient potential development of those assets.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And because we can do these
activities in-house, Jonathan, it is not going to have a significant impact on
burn at all.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan
Aschoff </font></b><i>- Brean Murray, Carret&nbsp;&amp; Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And how&#146;s about the strike on
the debt and you don&#146;t owe anything on these products, correct?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Correct. They are fully paid
up of milestones and royalties. And the strike on the debt I believe is $9.69.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan
Aschoff </font></b><i>- Brean Murray, Carret&nbsp;&amp; Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Okay, thank you very much.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=4,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5",CHK=382356,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MQ_ZBT14502.CHC",USER="LPALLES",CD='May 30 01:12 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mark Monane, Needham&nbsp;&amp;
Co.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Glen Gechlik
</font></b><i>-
Needham&nbsp;&amp; Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hi, this is [Glen Gechlik]
for Mark Monane. My first question is on Celldex&#146;s combinatorial approach and I
was curious if the combinatorial approach for the CuraGen assets, will they
include ADCs or do you think just the naked mAbs?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tibor Keler </font></b><i>- Celldex Therapeutics,&nbsp;Inc.
- - SVP&nbsp;&amp; CSO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I think they will likely use
both technologies, so certainly we are very excited about the data so far with
the drug conjugates.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Clearly, it is an approach
that is gaining a lot of credibility and effort and certainly we will be
pushing along those lines. At the same time, we really see opportunities for
these antibodies as standard therapeutic antibodies. Much more is known about
these targets than when they were originally developed and clearly there will
be opportunities to develop them through the use of their effective functions
or blocking functions. So both avenues will be pursued aggressively.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Glen Gechlik
</font></b><i>-
Needham&nbsp;&amp; Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I have just a couple
financial questions. The first is what do you think your burn going forward
will be for 2009 and 2010, just approximately?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Chip Catlin </font></b><i>- Celldex Therapeutics,&nbsp;Inc.
- - SVP&nbsp;&amp; CFO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Well, I think we are going to
be doing a full financial &#151; this is Chip, I think we&#146;ll be doing full financial
projections after the close, which we expect in the third quarter. But as we
said in the press release earlier, at the close of the acquisition, we expect
to have cash in the range of $96 million, which really extends our cash
resources into 2012.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Glen Gechlik
</font></b><i>-
Needham&nbsp;&amp; Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And perhaps you can review
just the financial terms of the transaction. I noted the collar between 32% and
58%. How does that work out going forward and when does the investment
community get informed of the decision of the actual final deal?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Well, Glen, we will file the
S-4 and the way we will work out the final price is we are going to use a
15-day random pull on the average 30-day close prior to the close of the deal.
So we will take an average of the 15-days on a random basis.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Glen Gechlik
</font></b><i>-
Needham&nbsp;&amp; Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And the day that the deal is
finished, is that written in stone or that has to be sort of just agreed upon
going forward?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Well, we are going to file
the S-4 as soon as we can and we expect to close the deal sometime in the third
quarter.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Glen Gechlik
</font></b><i>-
Needham&nbsp;&amp; Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you very much.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jason Kantor, RBC Capital
Markets.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jason Kantor
</font></b><i>-
RBC Capital Markets - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hi, congratulations to both
parties. My question is really on &#151; it is obvious that this brings a lot of
critical mass to both companies, but how does this really change the resource
allocation for any of these programs? Where are the synergies in terms of cost
reductions and which programs on either company are going to get increased
asset allocation as a result of the transaction?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you, Jason. This is
Anthony Marucci. Well, the programs that are in the clinic now we believe are
all doing fairly well and the data to date on 110 and CR011 and 1307 all have
early good promising data. So the allocations there will not change at this
point in time.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As far as prioritizing
programs that are in preclinical development, since we do have the
infrastructure in-house and the people and the expertise, we are just going to
let the science drive which programs make it to the front of the line.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As far as burn goes, as I
said prior, we have a lot of the expertise in-house and the infrastructure, so
we don&#146;t see a significant burn while we are able to bring forth additional
products going forward.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=5,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5",CHK=272362,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MQ_ZBT14502.CHC",USER="LPALLES",CD='May 30 01:12 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[David Sugarman], CQS.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">David
Sugarman </font></b><i>- CQS - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Yes, hi, guys. So some of my
questions have been already asked, so just one quick bit of semantics. Can you
guys give me an updated number of shares for both companies as of today?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sure. The outstanding shares
for Celldex at this point is 15.8 million.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tim Shannon </font></b><i>- CuraGen Corporation - President&nbsp;&amp;
CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And CuraGen is about 57
million.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">David
Sugarman </font></b><i>- CQS - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Okay. And that includes all &#151;
that will &#151; all options that will vest on closing of the deal or are there any
kind of [tag-ins] around after that?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tim Shannon </font></b><i>- CuraGen Corporation -
President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Well, again, it would be 57
million &#151; about 57 million outstanding and about 3.5 million of options that
would be in the money that are outstanding.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">David
Sugarman </font></b><i>- CQS - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Okay, great. That is it.
Thanks, guys.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Richard Mansouri, DellaCamera
Capital Management.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Richard
Mansouri </font></b><i>- DellaCamera Capital Management - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hi, yes, thank you. Just a
couple of questions. Just as far as this transaction, is there any breakup fee
on either side? And also the share count with the collar, that refers to the
pro forma Celldex shares outstanding? That is my first question.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Correct.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Richard Mansouri
</font></b><i>-
DellaCamera Capital Management - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Am I correct?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Yes.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Richard
Mansouri </font></b><i>- DellaCamera Capital Management - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And in terms of &#151; is there
any like breakup fees, termination fees, anything like that?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There will be mutual
termination fees that will affect both sides equally.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Richard
Mansouri </font></b><i>- DellaCamera Capital Management - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And then separately, what is
your position on the potential partnering of the compound CR011? I mean I know
it is just early, but it looks like there is some pretty encouraging data and I
know that you guys at Celldex have been very successful and you alluded to the
Pfizer transaction that you did last year. What is your thought about
partnering a compound like CR011?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the opportunity comes
about, Richard, and it makes sense for the Company to do so, we will do that.
We are impressed with the data to date and we fully intend on developing the
program to create even additional value. But if a company comes along and makes
an attractive offer, we will certainly listen to it.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tom Davis </font></b><i>- Celldex Therapeutics,&nbsp;Inc.
- - SVP&nbsp;&amp; CMO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=6,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5",CHK=1003525,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MQ_ZBT14502.CHC",USER="LPALLES",CD='May 30 01:12 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Maybe I can just quickly add
that it has cleared the first and major hurdle in cancer drug development,
which is getting clinical responses in early phase development and that, of
course, is very promising. So we do think with additional data, we likely will
be able to even further increase the value in CR011. So at least from my
perspective, I think its value could increase significantly with some
additional work. There may be a fast-track to approval if these responses are
real. And with that said, it may be something that we want to keep to
ourselves. So we are keeping our options open at this point. We really need to
define the potential better. Just so you know, this is Tom Davis.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">So Richard, at the end of the
day, we are going to do what is best for the program and the Company, whether
it is keeping it or partnering it out.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Richard
Mansouri </font></b><i>- DellaCamera Capital Management - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Understood. Okay, thank you.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Thayer Koboroski], CCS
Financial.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Thayer
Koboroski </font></b><i>- CCS Financial - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hi, gentlemen. My question
was regarding the terms of the deals and the closing price you are going to
use, which I believe you already answered, so I don&#146;t have any questions. Thank
you.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Richard
Mansouri </font></b><i>- DellaCamera Capital Management - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And in terms of &#151; is there
any like breakup fees, termination fees, anything like that?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There will be mutual
termination fees that will affect both sides equally.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Richard
Mansouri </font></b><i>- DellaCamera Capital Management - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And then separately, what is
your position on the potential partnering of the compound CR011? I mean I know
it is just early, but it looks like there is some pretty encouraging data and I
know that you guys at Celldex have been very successful and you alluded to the
Pfizer transaction that you did last year. What is your thought about
partnering a compound like CR011?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the opportunity comes
about, Richard, and it makes sense for the Company to do so, we will do that.
We are impressed with the data to date and we fully intend on developing the
program to create even additional value. But if a company comes along and makes
an attractive offer, we will certainly listen to it.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tom Davis </font></b><i>- Celldex Therapeutics,&nbsp;Inc.
- - SVP&nbsp;&amp; CMO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Maybe I can just quickly add
that it has cleared the first and major hurdle in cancer drug development,
which is getting clinical responses in early phase development and that, of
course, is very promising. So we do think with additional data, we likely will
be able to even further increase the value in CR011. So at least from my
perspective, I think its value could increase significantly with some
additional work. There may be a fast-track to approval if these responses are
real. And with that said, it may be something that we want to keep to
ourselves. So we are keeping our options open at this point. We really need to
define the potential better. Just so you know, this is Tom Davis.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">So Richard, at the end of the
day, we are going to do what is best for the program and the Company, whether
it is keeping it or partnering it out.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Richard
Mansouri </font></b><i>- DellaCamera Capital Management - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Understood. Okay, thank you.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Thayer Koboroski], CCS
Financial.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Thayer
Koboroski </font></b><i>- CCS Financial - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hi, gentlemen. My question
was regarding the terms of the deals and the closing price you are going to
use, which I believe you already answered, so I don&#146;t have any questions. Thank
you.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=7,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5",CHK=917690,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MQ_ZBT14502.CHC",USER="LPALLES",CD='May 30 01:12 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Operator Instructions).
Jonathan Van Orden, Dominick&nbsp;&amp; Dominick.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan Van
Orden </font></b><i>- Dominick&nbsp;&amp; Dominick - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hi, good morning. Thanks for
taking the questions. What is the exchange ratio?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Right now, as of yesterday&#146;s
close, the exchange ratio would be that the CuraGen shareholders would receive
about 11.5 million shares of the Company.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan Van
Orden </font></b><i>- Dominick&nbsp;&amp; Dominick - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.5 million shares.&#160; And can you kind of simply walk us through
the collar and maybe provide an example of how that would work?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sure. We have put together an
upper and lower boundary on the amount of the stock that can be issued for the
fixed value of the transaction. And as you know, these are customary in these
transactions. So we basically are looking at the 52-week high and low for the
Company just to get lower bounds and top it out what they &#151; 32.5 on the upper
bound of the spectrum if the stock price goes up to approximately $12.40. So
those are basically the ranges we are looking at for Celldex&#146;s stock.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan Van
Orden </font></b><i>- Dominick&nbsp;&amp; Dominick - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Okay. And in terms of
regulatory approvals, what is going to be required?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Well, we will file the S-4
and go through SEC approval. We don&#146;t believe we are going to need HSR approval
here, so it is just the normal SEC filings.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan Van
Orden </font></b><i>- Dominick&nbsp;&amp; Dominick - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Okay. And have you spoken to
regulators about that or is that just your assumption through your own counsel?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">It&#146;s my assumption.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan Van
Orden </font></b><i>- Dominick&nbsp;&amp; Dominick - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Okay. One other thing was &#151; in
the press release, you had mentioned certain closing balance sheet adjustments.
What are those and are they going to affect the terms?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Well, again, we said that
they will come to the table with net $54.5 million and we will have an
adjustment up or down based on whether the cash is higher or lower.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan Van
Orden </font></b><i>- Dominick&nbsp;&amp; Dominick - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Okay. Can you be more
specific on that?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will do basically a
dollar-for-dollar band on increased value.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan Van
Orden </font></b><i>- Dominick&nbsp;&amp; Dominick - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Got you. Okay, thank you very
much.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Jeremy Stoval], [Polly
Company].</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jeremy
Stoval </font></b><i>- Polly Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hi, thank you. A few quick
questions. Have you received any feedback from CuraGen or Celldex shareholders
about the transaction? And as far as closing conditions, is the deal subject to
anything such as minimum net cash balance for CuraGen? And lastly, were there
any other bids for CuraGen during this process?</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As far as feedback from
CuraGen or Celldex shareholders, not yet.&#160;
I am sure we will get some after the call. As far as the CuraGen issue &#151;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=8,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5",CHK=783873,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MQ_ZBT14502.CHC",USER="LPALLES",CD='May 30 01:12 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tim Shannon </font></b><i>- CuraGen Corporation -
President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Yes, again, I think all I can
say there is, again, we had a public and very broad process again trying to
identify the best option in terms of value creation for CuraGen shareholders
and we think this is it.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And to your question about
minimum cash, we are looking at this as a totally synergistic deal. So we are
fairly confident that all the issues can be addressed and dealt with.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jeremy
Stoval </font></b><i>- Polly Co. - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scott Middleton, AM
Investment Partners.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Scott
Middleton </font></b><i>- AM Investment Partners - Analyst</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hi, my questions actually
have all been answered. Congratulations, guys.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There are no further
questions at this time.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anthony
Marucci </font></b><i>- Celldex Therapeutics,&nbsp;Inc. - President&nbsp;&amp; CEO</i></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you, operator and thank
you to everyone for joining us today. I would like to encourage you to please
visit either companies&#146; websites where you&#146;ll find pertinent information on the
transactions and transaction-related documents. In addition, we are available
to answer your questions and look forward to seeing many of you at upcoming
events. We will continue to report to you thoroughly throughout the year as we
move our programs forward and thank you for your continued support. Have a
great day.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operator</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you for your
participation in today&#146;s conference. This concludes the presentation. Everyone,
have a great day.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=9,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5",CHK=100680,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MQ_ZBT14502.CHC",USER="LPALLES",CD='May 30 01:12 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Additional Information about the
Transaction and Where to Find It</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This communication contains &#147;forward-looking&#148;
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements are typically preceded by words such as &#147;believes,&#148; &#147;expects,&#148;
&#147;anticipates,&#148; &#147;intends,&#148; &#147;will,&#148; &#147;may,&#148; &#147;should,&#148; or similar expressions.
These forward-looking statements are subject to risks and uncertainties that
may cause actual future experience and results to differ materially from those
discussed in these forward-looking statements. Important factors that might
cause such a difference include, but are not limited to, costs related to the
transaction; failure of Celldex&#146;s and CuraGen&#146;s stockholders to approve the
transaction; Celldex&#146;s and CuraGen&#146;s inability to satisfy the conditions of the
transaction; the risk that Celldex&#146;s and CuraGen&#146;s businesses will not be
integrated successfully; the combined company&#146;s inability to further identify,
develop and achieve commercial success for new products and technologies; the
possibility of delays in the research and development necessary to select drug
development candidates and delays in clinical trials; the risk that clinical
trials may not result in marketable products; the risk that the combined
company may be unable to successfully secure regulatory approval of and market
its drug candidates; the risks associated with reliance on outside financing to
meet capital requirements; risks of the development of competing technologies;
risks related to the combined company&#146;s ability to protect its proprietary
technologies; risks related to patent-infringement claims; risks of new,
changing and competitive technologies and regulations in the U.S. and
internationally; and other events and factors disclosed previously and from
time to time in Celldex&#146;s and CuraGen&#146;s filings with the SEC, including Celldex&#146;s
and CuraGen&#146;s Annual Reports on Form&nbsp;10-K for the year ended December&nbsp;31,
2008. The companies do not undertake any obligation to release publicly any
revisions to such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the
proposed transaction, Celldex and CuraGen intend to file relevant materials
with the SEC, including a joint proxy statement/prospectus. INVESTORS ARE URGED
TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE TRANSACTION. The joint proxy
statement/prospectus and other relevant materials (when they become available)
and any other documents filed by Celldex or CuraGen with the SEC may be
obtained free of charge at the SEC&#146;s website at http://www.sec.gov. In
addition, investors may obtain free copies of the documents filed with the SEC (i)&nbsp;by
contacting CuraGen&#146;s Investor Relations at (888) 436-6642 or by accessing
CuraGen&#146;s investor relations website at www.curagen.com; or (ii)&nbsp;by
contacting Celldex&#146;s Investor Relations at (781) 433-0771 or by accessing
Celldex&#146;s investor relations website at www.celldextherapeutics.com. Investors
are urged to read the joint proxy statement/prospectus and the other relevant
materials when they become available before making any voting or investment
decision with respect to the transaction.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Participants in the Solicitation</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The directors and executive
officers of Celldex and CuraGen may be deemed to be participants in the
solicitation of proxies from the holders of Celldex and CuraGen common stock in
respect of the proposed transaction.&#160;
Information about the directors and executive officers of Celldex and
CuraGen are set forth in Celldex&#146;s and CuraGen&#146;s most recent Form&nbsp;10-K and
Form&nbsp;10-K/A, which were filed with the SEC on March&nbsp;5, 2009 and April&nbsp;30,
2009, respectively. Investors may obtain additional information regarding the
interest of Celldex and its directors and executive officers, and CuraGen and
its directors and executive officers in the proposed transaction, by reading
the joint proxy statement/prospectus regarding the transaction when it becomes
available.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This communication shall not
constitute an offer to sell or the solicitation of an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of
any such jurisdiction.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=10,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5",CHK=832071,FOLIO='',FILE="DISK106:[09ZBT2.09ZBT14502]14545-2-MQ_ZBT14502.CHC",USER="LPALLES",CD='May 30 01:12 2009' -->


<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=LPALLES,SEQ=,EFW="2193304",CP="CELLDEX PHARMACEUTICALS,INC-NEW",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g145452mm01i001.jpg
<DESCRIPTION>G145452MM01I001.JPG
<TEXT>
begin 644 g145452mm01i001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!,`,P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HH)P,UY[X_^(<OAJ5=.T^V+7LB;_.E4^6JGT_O'^573IRJ2Y8DRDHJ[/0J
M*^6M1\1:SJTIDOM3N9B>QD(4?0#@56M=4U"RE$MK?W4,@_B25@?YUVK+W;XC
MG^M+L?5U%>.^"?BEJ$FH6^EZU&]X)F$<4\29D!_V@/O#WKV*N2K1E2=I&\)J
M:N@KD]<^(WAW0KAK:6Y:XN5.&BMEWE3Z$]`?QK-^)?B6ZTS3H-,TUBM_J#^4
MC+U5>AQ[G(%6?"W@&QT*R0O$DMZPS+.XRQ)Z@9Z"JC",8\\^NR$Y2<N6)07X
MPZ(&'G:=JD*'J[PK@?DU=?HGB/2?$5L9M,O$G"_>7HR?4'D43:/&\94JC`CD
M,H(->8>)-'F\'ZW9^(=!A>,B4)<VT*DJRGV'8\C'KBG%4ZCY4K,3<X:O5'LE
M%0FZB6S%U*XBBV>8S.<!1C//I7#WGQ9T2.Y>#3[6]U%E."T$?RGZ$_X5E"G.
M?PHN4XQW9WU4=8U:VT32Y]0N]_DP+N?8,G&<<#\:YG2?B?H&HWBVEQ]HT^X8
MX47:;5)^O^-+\26/_"':B`>#$/\`T(52I24U&:W$YIQ;B:EQXOTRV\*Q>(I/
M.^PR*K*`GSX8X'%;%E=QW]A;WD.?*GC65-PP<,,C/YUY)K3'_A2&G#/'V>+_
M`-"->E>&I$C\(:2\C!46QB)9C@`;!S55*:C&Z[M"C-MV?8V*0L%ZFN%O_BMH
M5O=-;6,-WJ,BG!-M'E?P-26'Q$T?6Y198N+&]8X6&Z39O/H#T)J70J)7:&JD
M&[7-[P[XGT_Q/;W$VG^;L@E\I_,3;S[5LUYI\&O^01J^?^?T_P`JZ/Q%X_T/
MPW/]FN)GGO/^?>W7>P^OI55*3]HX05Q0G[BE(ZBBO/8_BYI:.OVW2]3M8F/$
MCQ9'UKM=/U:QU:P6^L+E+BW;HR'OZ$=C[&HG2G#62*C.,MF7:*S-/UZQU*ZD
MM8F=)X_O1R+M/OBM%W6-&=V"JHR6)P`*R3OL.,E)70ZBN?T/QCI7B*_N+73/
MM$WV?.^;RL1_@WO7054HN+LP33U1B>)M5;3=+D>,XE;Y4^IK`W:3X]TG^RM7
MC6.]49BD7@@_WD/\Q1XY<E8%SQO/\JXU':-U=&*LIR&!P0:Q=64)W1P5Z\H5
M;=#CO$WA?4/"NI&UO4W1MDPSJ/DD']#ZBLW3]/N]5OXK*Q@::YE.%1?YGT'O
M7O<$EOXK\(7-OK4*2[`RANAR%R&'H:R/AO!8Z3X#.KPP(VH3([R.W5MI.%]A
M7L0QUZ/.UJ-4XR::>CU+&@>'-+^'>F"\O2ESK$JXR.W^RGH/4UN^%O$$VL?:
MX[G:)4.]0HP`I[?A7G]Y>W&H737-S(7D;OV`]![5O>!RPU]E'W6@;/YBO'E7
ME4J79%/$-U5&.B,KQ:V_XJ^'!-CR=R]>F=Q_^M7KM>8_$G0KJZA@U*P5C>6#
M^:H4<E>O'N"`:Z7PEXXTSQ-I\9\^.&_50)K=V`8-W(SU%=TTYTHR731G9%\L
MVGU.IJI<BV@_TB>6.%0<;W8*/S-3R3PPH7DE1%'5F8`5Y+XPU<^/-<M/#&BO
MYUJDHDNKA/N#'OZ#G\<5G2I\[\NI<Y\J\RU\6-9+6^G:2ER(K:[DWSR@Y'EC
M'IU'.:O:5XC\!Z/81VEIJUO$BC!*HV6/J3CDUD_$G36LUTK4X8!+#ISJLD9&
M1Y?&,CTX_6NNTC3_``]KMA'>:?;V$L3C.!$F4/H1C@BMGR^QC>]M=C-<WM&<
MGXKUGP9KVES0'5+>28(3#+L.Y&[<XZ=JIP:O-JWP:NOM#EY;4&W+$Y)`*[?T
M./PKJ_$Z>'O#6ERW=U:6)E`_=0>4NZ1NPQC]:R=::2;X67%S+IL&G//%YGV>
M$8`!88)]R*J#7+%).UUN*2=W=]#-UK_DB.F_]>\7_H1J7QCJMS'\/O#FDVKE
M&U"&&)B.ZA%X_,BHM:_Y(CIO_7O%_P"A&F^+;&XD\#^'M2MU+/80PS$#^[L7
M)_,"KA;F5_YF3*]G;LCT/0/"=GH6F16MO&JL%'F.!\SMW)-4O%?AN'5=->&1
M`90,PS8^:-QT(/UK8\/>(;#Q'I4-Y9S(Q91YD>?FC;N"*I>,?$-EH6E/)-*K
M7+#;!`IR[N>@`KC7M/:?WC?W>7R//_AYJ;Z+X$\0WG66"5F&>[!/\:K>!-2\
M+6%M)J6MZI%_;%Q(S.TJEF09[''4]:?X#L7U3P-KUH>'GF*_1BO^-7OAT=(O
M-/;1M1M[2/5;21D9)XUW2#/;/4CI7;4M^\]5>W8YX7]TW+SQGX-G@:-M8MY4
M889'1B#^!%<SX%U"RL_B!=Z7I-T)=)OXBZ*,X1P,]_3D?3%>AS^'=(MX6EGM
M+".-1DL\2`#\<5@>#M3L]6\37RZ9H]HNG6?RKJ"H`SMZ+Q]?PK"#CR2Y4[6[
MFDD^979<US2ITN%OK0E+R([@P_BQ_6N?\1ZKKWB^*RT338O(BGXO90?NX['N
M%[^_2K'CSQ1/?:@OA;P^/-OYCMGE0_ZH=QGU]3VI\>B7WAZVM;FWN'FN[9`)
M6;_EH._X=JQY71M5[]/U,JBM)N&W4[/PWH%IX<TB*QM$PJ\LQZNW=C[UL5G:
M-J\&LV*SQ'#CB2//*&M&LW+FU.J+3BG'8Y'QA9-/:EE!+(=PK@*]BOK47,)&
M.:\^U+P^\-\K1IF)I!O3T&><5C5@WJCCQ=!R?/$BL;S[+H$@SC>\G_H-9W@R
M\_XHZ.US_P`L9>/Q-4-3UF,K):0PI#%$[XVL3N[<Y^E97AO5OL&GP_(L@"LI
M1B0"#]*]6GAY+#\CW_X<(KE2CY&R.E=MX"L&!N+]Q@,/+3W]36/IVA-K$MO-
M#&(;22)78@YY[@9KT>RM8[*U2")0J(,`"O*A3<9:]",-AY*?-+H%S:K.OOV-
M</K/PXTG4[@W#6[P3DY,MLVPD^N.E>@45T1G*#O%V/0E%2T9Y9'\*+.1\7&H
M:C+'G[C2\?C7<Z!X:T[P_;>38VR1`_>(Y9OJ>IK:Q153JSFK29,81CLBA?Z>
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M=YCC,BI'L&%P>I[FH='UB\?4HHI[B26*6`R8D51S_L@=!]:MXF;5FV2G3NGR
M[E[0/"MCX?L;BVLUD"SR>8^]MWS5CZ]X!TW6KCSYX7CN1TG@;8_X^M.36[];
M9KXWX9DN?*^S;!AEW8QZYJ?4M:OCJ-XEO,8DM@NQ0$VL2,DON.<?2I5>2?-?
M4'4ARVL8,7PKLI'`NK_4[B(?\LY)_E-=K;Z-;Z9HYT_3T%K'M*KY7!4GN#Z^
M]5FUF4:@R/(D<9L?.VDCA_K67=W=S>VNAS27#(S2H68`=3WISKSEN[AS0C?E
M1:\,>#]*\/7-P]N6DNY?FD>9]TF/\":Z&[M%G3@?-6#+J<EMJ^HNJJYCLPZ_
M*,D^Y]*?IM_<J\#S:FEQY\'F-"5`*GU7';ZU,JCD[LN,TGRI%C2]!AL-0>[B
M,D;MG<BM\C?A6[7(Z-K%[+JD"75TS+.7"@*K1MCD;2.1P.]==2BU;0=)Q:]U
M6"JMU91W"X(YJU15&ARS>"M,9B38VY)Z_NQS21>"-(CP!I]J%'81"NJHJN>7
M<5D5K.R@L;=(8(ECC0855&`*LT45(PHHHH`****`"BBB@!DJ>8A%41I-L!*/
M(C_>_P"L^7[_`-?6M&B@3290.F1;@XC4.%V!L<A?3Z5%;Z+:V\C2QP1I(W5E
M7!K4HHL%D4?[.A2V,,<:(C$DJ!P2>M4HM!M;8B2*VC61<[6"\BMNBE9!RKL8
M-AX<MK<[WC224.7$C*,C)JQ)HEK/<"6:".1EZ%ES6M119"4(I6L95QHUO=2H
MTT,<FW[NY<XJ1])MI(DA:"-HDQM0KP,>E:-%%D/E78SSIL7F-*(U$C#:6QR1
MZ4RWT>VM=[0V\<;OU*K@FM.BG8+(S++1K6TN3<);QK*<_,%YK3HHH!)+8__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g145452mm01i002.jpg
<DESCRIPTION>G145452MM01I002.JPG
<TEXT>
begin 644 g145452mm01i002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``E`/`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#UO6=8G-T-
M.L,B8L%9QUSZ#_&HAX6N'3S)+\_:.O0D9^N<U5\/?Z3K\D[\MAWY]2?_`*]=
MC0!SNBWE_#?/IUXDDFWI)C.WZGT-=%110!GZVS)HURRL58*,$'!ZBJ_AIWDT
M@,[LS>8W+')J?7?^0)=?[H_F*K^%_P#D##_KHU`$^ONR:+.R,58;<%3@]13/
M#KM)HT3.S,VYN6.3UIWB'_D!W'_`?YBF>&_^0)%_O-_.@#6KEO$\DHU&U2.5
MT#)CY6([UU-<IXH8+JEHQZ!`3_WU0!/_`,(U>?\`05D_\>_QJ"&]U#1M4CM+
MR8S0N1R3G@\9!ZUK'Q'I8!/GL?8(:Q'=_$6MQM%$RV\6`2>R@YY]S0!V%%%%
M`&'XFOGM;..*&1DEE;.5."`/\BJWAV]N/ML]G=R2,^,C>V2".HJ&Z_XFOBM(
M1\T4)`/IA>3^O%+K0.F^(+>^7A7P6Q[<']*`.JHI`0RA@<@C(-+0!DZ]JK:;
M;JD.//ESM)_A'K69#X=N[Z(3WMZZR.,A2-Q'UIFJC[1XKMX6Y4%!CVZUTEU?
MVMEM-S,(]^=N0>:`.>A_M;1;^*W.^[@D/`&3D=\9Z$5U-9W]O:7T^V)^1_PK
M1ZT`%<7!;W.I:S=6ZWDL05G8'<2/O=.M=IWKB;748],UR[FD1G4LZX7_`'J`
M-+_A&KS_`*"LG_CW^-7]+TF?3YWDEO6G#+M"G/'/7DU3_P"$NM/^?:;]*V;&
M[2^LTN45E5\X#=>N*`+%<MXG><:A;1PR2*63`"L1DYKJ:Y;Q(=NLV)'8#_T*
M@#4T"_-[IX60DS0G8^>I]#5/Q7+)'%:^7(Z99L[6(STIDW_$E\1K,.+6[X;T
M![_KS^-'B[_4VG^\W\A0!2T4BP\226\AQDM&,_F/Y5V-8NLZ']N87-LPCN1U
MYP&_'L:I"[\2QKY1MMS#C?L!_7.*`.B-S`MP+=I4$Q&0A/)%2USVF:%/]K^W
M:D^^;.Y4SGGU/^%=#0!G:[_R!+K_`'1_,56\+G_B3CVD;^E:T\*7$$D,@RCJ
M5-<S'9:UHLCK9J)X&.>F?T[&@#6\0G&AW'_`?YBF^&_^0)%_O-_.LN6VUW62
ML5RBP0@Y.1@?EU-=):6R6=K';Q_=08R>_O0!-7*>*`&U2S!&05`(_P"!5U=<
M_KNFW=YJ-K+;Q;T0`,<@8YS0!:O/#]E-:2);VZ138^1AZU4\-7WR/ITRA)HB
M2HQ@D=P?<5T-<]K&E7/]I0WVGK^]+#<!Q@^I]O6@#H:@O+@6EG-<'^!21]>U
M3(6**7`#8Y`.0#61XCBNKC3UBMH6D!?+[>N![4`9&C31Z=IFIZY=?<@C9R?4
M`;F_I532]8;QA\/+36'"_:D)\X+V920WZ8-8OQ5U'^P/AQ;Z4C[;C4'",!UV
MCYG_`%VC\:PO@5JZ.VJ^'IV^69/M$0)_X"X_(K^59.?OV.^&%OA'6ZW_``_K
M\CU[0+K[5I,63EX_W;?AT_3%:=<[X=L[RQN;F.6%E@/`<\9(/;\*Z*M3@.3U
MK-IXEM[ION'8V?H<&NCNK&UOPGVB(2A>5Y/?Z5#JVEIJEKY9.V1.4?T/H?:L
M6)O$6G(+=8!,B\*<;L#ZYH`@\16%M8S6HMHA&'SNP3SR*Z]?NCZ5RYTG5]6G
M234'6)%Z#`R![`?UKJ0,#%`!WKE-$56\27H901\_49_BKJZY-;#6;34[BYM;
M<?.S8+%3D$Y]:`.I\J/_`)YI_P!\BG`!1@``>@KG?.\3_P#/"+\E_P`:O:7)
MJ[SN-1C18]ORE0.N?8T`:M<KXF_Y"]E]!_Z%755@:YIUW>:C:RP1;T0#<<@8
M^;-`%_6K'^T-.DC`S(OSI]1V_&N8O[TWNBV>\_O87,;Y^G!_2NWKDM6T"[;4
M))+.'?#(=^`P&#W_`,^]`'6T444`%%%%`!1110`4444`%%%%`!1110`4444`
M8VM^$]"\1RPR:OIZ7;PJ5C+LPV@]>A%5]*\#>&M$OTOM,TJ.VND!"R([D@$8
M/4XHHI<JO>QHJM11Y5)V]3H:***9F%%%%`!1110`4444`%%%%`!1110`4444
#`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g145452moi001.gif
<DESCRIPTION>G145452MOI001.GIF
<TEXT>
begin 644 g145452moi001.gif
M1TE&.#EA2P+*`?<``"H<%C4D&SDL)P\\?A$^?UPJ'$\U+6XX*EI$.7!&-FE=
M6G)42Q,_@!E$@Q)WB2-,B2M3CB]7D#1:DR-MD2YBEC!DES-EF3AGFCMLG41<
MFDAGG4!PGT=UHU1KI%9YIV)\JVQ\L@">10"?2`"@2`>B3`VE41BI62&L7S"Q
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M^OKV\_KW^OOZ]O[^_LS,S"'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``A^00!``#_`"P`````2P+*`0`(_P`M"!Q(L*#!@P@3*ES(L*'#AQ`C
M2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ9-EA-N
MZMS)LZ?/GT"#WL0@M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7KV##
MBAU+MJS9LVC3JEW+MJW;MW#CRIU+MZ[=NWCSZEV8<Z_?OX`#"QY,N+#APX@3
M*U[,N+'CQY`C2YY,N;+ERY@S:][,N;-$HIY#I^TKNK3ITZA3JU[-NK7KU[!C
MRP9,>G;JVK9SZ][-N[?OW\"#"Q].?"_HXLB3*U_.O+GSY]"C2Y].O7I<W-:S
M:]_.O;OWAA6^B_\?3[Z\^?/HTZM?S[Z]^_?PX\N?3[^^_?OX\^LGBWV___\`
M!BC@@`06:."!"":HX((,-NC@@Q!&*.&$%%9HX8489JCAAAQVZ.&'&?8'XH@D
MEFCBB2BFJ.**88G(XHLPQBCCC#36:..-..:HXXX\]NCCCT`&*>201)I'P7L5
M7'!7>"$I:9"3"D&9D)0*'6F!E1P=-Y&6"U%Y$)1>CA3FDQ-=,"9,7%IPID!:
MKEF1EVXBE.:7#;DI)9@=5<!D07,:U&='<=;9T9\#2:#0!(@FJNBBC#;JZ*.0
M1BKII)16:NFEF&:JZ::<=NKIIZ"&*NJHI)9*0:F65H`JI`ZTZNJKL,;_*NNL
MM-9JZZVXYJKKKKSVZNNOP`8K[+#$%FOLL<@FJ^RRS#;K[+/01BOMM-16:^VU
MV&:K[;;<=NOMM^"&*^ZXY)9K[KGHIJONNNRVZ^Z[\,8K[[STUFOOO?CFJ^^^
M_/;K[[\`!RSPP`07;/#!"">L\,(,-^SPPQ!'+''$$TQL\<4+KZ#QQAQW[/''
M*[@`\L@<BTSRR2AK;'+**K/L<L<KORQSRC'/O''--H><\\T[LXQSSC_W#+/0
M1`=-,]$\(ZVSTBTSO;/1'KL@]=145VWUU5AGK?767'?M]==@ARWVV&27;?;9
M:*>M]MILM^WVVW#'+??<=-=M]]UXYZWWWGSW_^WWWX`'+OC@A!=N^.&()Z[X
MXHPW[OCCD$<N^>245V[YY9AGKOGFG&=]3#.S['+,++.,;HPQLQBS"^G&'(,Z
MZ:.3+OOLLK^.R.N\I,ZZ[K7//DSLR?0^>_"ZMTYZ,KFC/GKPIA_/>O#0O[X\
MZLFX/LPPQ@R3>_6S).-]][!#/\OOU'<?//;7O^X]^J>G/TSW[O]N/O;)#).,
M,?73[_W]]B^S/_[^VU\R_,>,_070@,E@1@`)Z+]E,'"`#W1@`B7(P`8RXX(%
MQ*`S('C!!BZC@QQ48`@]^$$0.M"$)=S@"46XP@!V$(4@'&`,2[C`&4I0@0V<
M8`YQ.$`=]I"'S_#A!_\3Z+T*_G"!$RRB]RZX/Q'^L(!'5*(`,[A$*"Z1B%04
MX!6U2$1E*(.+P>"B&,=(1B)ZKQAB_*+WPEC&,:*1C,`0H!J3H0PK<G$?]<BC
M'NL1#WBXPQ[Q`.0[X/&.=]3C'?,89#W\^`YWP&.1\&!D(<OACGJ4HY!^C&0Y
M(DE(0@Z2DY&<1R(=2<AZS&./C_SD/#H)CWT8<I7RP",\[#&/>YPRC[>T!SQ.
MN8]'[C*/\+A''FU9CU[NHY?!-"8>ZW&/?-3#'NFHY3SRL<I[6/.:MA2F-?=Q
M36[VXYKZP"8_Y-',>_"#'^;D1S_.><Y^N%.=[W2G/.?)SGKZ@Q_^N&<]]\G_
MSW[Z\Y_MW.<Z`4I0=@ZTH`9%J$(7RM"&`C2?#K6G/AV:3XC^TZ+^M*@^V(E1
M?%;4HOG4QT=%JD]_Z$.D*!VI2>]YSXVZE*4P3>E&(5I1D>(3GQO%*3](FM.5
MSM2C+[6G/OHQ49/RXY%Z-.0[Z&$/=[ACDD_U9"<;^52G#I*2\"`'.=S1#6VL
MHQSF*(=8RZ&-=VQRK/`0*RDY>4E"BE63FDSD+D&YREV*DI.0%*5>][I+=^SU
MKGK%*U\CB<Q>WM66YKB'/:P)#W,<=AZ+=:PMT[&.REXS'=A,+#;#B4UQYN.;
M^8"G:-UYCX&N4Y[\O.=G(\K:UKKVM;"-[4Y9N]*)_U+4I@#-:6I/:MO=GG.B
M*=4H;TFZTY,:E[<F=>E.\W'<Y.ZTI?K`QW&G2UWC\D.Z+T7I2=59W>UVE[H[
MQ2YUDSO=XNXQ'DJE1Q_M00^GKO63FQPD*9VZ53]*XQ*LX(99S4&.;93#&^X8
MZUG/&LD`LW679BW'/#;)2<B"TI>$3"0D@5G7NOKUCZ+TZU_WNDAK=CB2BUQD
M+!\IS1+?PQS?%"5F3\R.;(KR'BONK(QG?$UT6C.TI?WF:4/KSL^&5IU`_FT^
M2BK;(AOYR$@NJ$J-NE"2UK:W[.1I/8.+TM]JM[:Z#6E-;4I>YY)7IMK%J761
M^UV7EGFZV!7O1O'!YC,7=__,W\5'>(TK735']\W1S:F<[7QGX^91J7R4KQ^=
M2H](#O+0A6QD6IV:UDV.0Q%5D(0E6"$-])HU'`9N=%HU[=2SDN.MEUSE)S_Y
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M/GR_^]WG,:<9XOLF.,,7CO@]U[FX=<;N(>&A\4/6PQU,U:5[#XE)3%[2K`;&
MZCNN$0DG1.$)5!"#)5KAC4NVM=-J%3G-W6M[42IXP1QO\,T#&TH-S_*7HASD
MAN>!8;XJ79M(;:4V@6[+?%!SKYK-Q]6S2>S.!O/YC)6'_SPX:\YRHO/\T78V
M^OG!X\]Z]]J_[4=HAYKV^MO?V^/F+4-Y"F]_#I>X739OYW9W!\=W9U9>U25X
M!6=G]T!P`]=FE9=YAP=Q$!B!%BB!U25>XC5PU\5F'"B!%8AYB'=.B2=>$Y=4
MA60/A]14F81Q[14/3A4/8$55[N`-VL`-U7`-Y%!KTI`(0Y`$5.`%DL`*A?1I
M+N=R#&96;#5@G+16;+5*ZQ!)48A(5.A+KB9-(&9+?\5)MK1,>A1*PC0/Q&9,
MK;1A5UAL*%9L\_!-MA1)G55L6B=CH-5U[/=-Y\1C)R5_^-1M&V5]W`9E]Q>(
M@MA03A9<6-91[293[)9W]N93B__XB'>';U]V<'B6@)$G>9CH@2!H>!4H@?=P
M@9D'B@T7@AC(<(IW@:?8@:.X9ZL(BA`(<7MT2/%`>K/D@N[E7IQ$5=YP"9.`
M"9-P"9$`#>-@#M40"4KP`T`H"9@@#;6&#=P`5@RV:4R(2&E55S@72J2628"E
M8:-65Y#48,RW6""&5[CV:Y5E5[DF38J%6-;$:R^V?>K(3=?46"Z63<]W?M9T
M?C;6;#AVAS]&?^L$D']X3P<UB`9YD`BE987(9<X%=_QW9?(&9I.(@)%X@.^7
M@)SX>`&GD8E'@9)7@0W8B8C7BJYH@:,X@8_'B0.WD:#X@"59>=YE>"<EBX:D
M1Z!7:.W_-6CLY0XP.$GR50M;0`53(`E3$`5.D`BTH%69X`0_$`0GMXS2H`B8
MP`U:]0Y;17,%MFF@M`Y."$JD%H7V$&Q#QU>F%&*@E%=UQ5B1)`[J`&/M$$V\
MUH;&]&NB='WJV(XP]GQB.&-P&(<TQGXW9GZA97W:QGX[I8?<E4\_AI",V9@<
MA5PX!8FVY8B,Z(CZ-EU=]F65J)D6>8!VEI)_5X(-&)(OR6:?&(JE:9(+.(&0
M%XHD"9,1V(H="),/1W%Z1`^%Q%219(N,EDFYF$C5L`5-`'M4\`1)@`1&8`:?
M0`[7D`A`X)22<`F)$`5>@`DK1PY4!5<$MDE?!5==B7.AMDFP_P981I=7Y3A+
M\U!KU/`&9S`&+S`&9Q`(KN`*D>`*OA!,K41.M@9U9QAU6KA-:GAKV%1LWQ>'
M^YB/->9L>LA<L^5^[$=_\^>8$LJ8AYA_[39EE%EE&OJ(BQB1'GIP!0A>?W>)
M=*:1K=AP^P";%(B*%M@.J?F2I[BBL?FB+WJ2XG5>2O4.@,1YNYF3GH2=12@-
MD6`&5H`$0(`$06"<0?`#0V`&M-`-9O`#/W!R5="47W`)17B5`09SF^947'F-
M4JA+]E`.7R57G*1+9RE,B[1AOO`&"J```A"G`H``;UJG5O`&W8"60/=KS*2%
MZAB@[2B/=(F76H=L-59^Z71CACF8=?^X6GDX=D.F3XLYH92*=O)6;Y0I=Q`)
MB??F4V+V?QX*9WY7B746DH>WDJSID@XWD@U'FC0:@2[ZJC/:D:0HJ[8JDYKG
M>4K55('$>;=(2N+WH_)0"\<(!$0P!`=P`$T9!$&0!$-@!(E@!LI*G%(:!<HH
M#>\0#ECE:6_5I7#EFV"Z2F9*5T4'CJ>4K6ZJ``8@IW&*`.[ZK@N@`&>0#>7X
MIQNF6&KXG_?`3=VW3?M*J&VH6?)88P-[3>I'A\VTJ(:Y40-U;>T7J94:L6?W
M9!)IB)-8@$9%D2(:D_]7B7'F4MB%>1&GB299LK=:DO?0#M:$>.S`LJ79@;,Y
MFRV)#Z?)9O+_4'DU*ZOZT`XS67&;!T@X"7KO$$B)EFA:)0U6\`/)FJP&D*P^
MT*Q)H+3*^@-/`'M*&P22T(O=@%9-V&BD))[?"J9SA7-F>99ZA0UGH``-P*X"
M$``&X*X)`+<)$*]O$`[L$*#45TNFM%?VV$NX)JAX*4W=UY?8-+#+AJ@(6D[I
M9'T)VZA"1I"'B6X2.[E%UHAXIW_W%HD!J+EFMKF=N9$?.ZN@2WDG>X&Q2K,6
M^(FG>ZNO6;H7>+.5U[*H.),YNH+V\$F_>F%%:Y77T+L^>``%$+S"JZQ)$+4_
MX`-2&@11D`3(:ZW+N+5AI59;RH2EYDCS);:1A*8/EE?P,`YG@`!L_QL`;3NG
M"5`$"I``Z+L`=/H&Z^!8>ZM]?OIK@?IB;[B7_<I-A"M]C#5C!]M,/S:8UF>8
M[&=]+L6HV.8/1`6(E+O`$15WB:B0'(JYF0FJ'MM=%7QFJ_IP);B)&;EFKHMX
MIYNR;+:ZZ>"RL+NZ'^R*^E#"^(#";":[ICFC.TMQ-9E'M\MY+MA4O3E)K#17
MT&`&R"J\PTNU2RJE1GR\/^"\K3",2_A62JB54/R=8*I+XGJ-90"G<1H`````
M;GL`"S`$3K`%7(`%3J`$1C`$\>H*B54/Z;"W^WM*]*N.!4J__XI-S&1B_IIU
MSF9^Y>>/=SC`[!1:W!;`VL9M[23(BNE1%?_%P(Q,B)CZ?YC*;LYE=QEKB9Z)
MB2*+JR7*FB+9R9X,BC#LBBP,BK$JNZ'LBCF+LRY<>;$ZRB@[DK&ZL_CP9[FI
MHVCZJWWD5,PGC0.62+60"$<`O`4`O,1KO,'K`\DZS$!0!92`"=:`>F.EA%S[
M8+V)O5XYKF,+#ZZ`Q7&ZQ0*0`$.@!%6P!9)`"99@"9,P"6"P!4PP!&,0#HS5
MQB^V:_%KCV&HORYVQS16;'WZE\MF?8S;=08,T`$\4T,&J9%Z6B)UT(G<R`[]
M4`KY;I7\N7@VD>/E;W@&<`KGFC)ZDJV;FJ><LRU[ROA0PJ7LRJFIJK*:RA;(
MPBB->`UX4LQ5<?;_<+OMQ5Y-]8*Z?'J\3`\>%TG%J`1`<,10R[3!J[3#G`1>
M8`G+2$GC\')OA8L')G(O9\VFAG/[0`Q6(*=<'``(L`!.4`5@\`7E;,ZI<-:K
M8`E<X`1%``JX9E>'5:]Z"[#;U'VFU+<OUJ_QJ%G@U$WYB(_JI'X'"\AXJ-!W
MR&6*G,"+_-",+5&*.-&0',$5R9DA2M$:B(FC.Y*T&8(?;:LN++LO';LE>8J>
M_9+MX**A37@C'$X]RUZ%]$<L"'JW"(.,)LWE((/=^@[C(`_-Z01#W912FLS#
M>P`^``1/:0W=$%5IE6!7Z4<_#:9.6,UXE6N^I`?@V[8!X-5%$-9B+0EE_UT)
MEI`*J[`*JK`*DX`%:/`-M>9\S$1L)8;'!4K/]8B7!5M+"FJ'APJ8@NV_@`G(
M`\7?A6G(AGP/"`Q_)O59"MS8C%R9E8FIQ06BH-JA<%;9%PEXJ\F*WC5GF2VZ
MGUR:I[G*$3C*J?W!GPB[AE?"+NV*+1NK+GI2#<BS*'B[5;6;O^JKZ*5)3Z4-
MX]`-/+YR15@+1V#$4;NTQ)RLR!A[F*!R[J"MME=S-?>MC!:-!1:%V%M,\'`-
M1Y#%6EP`17`$W+T%8%#.80#>XKT*K=`*J[`%5T`+.Q=,(K:F95C/^?J&`[K/
M<$A.RW:X@(RHA"W8"BO`0R52BDU4'O5<!:G@E/]+F?1FF3/U4A)^F6=&X0:8
M@06G>`NHVC*ZP39:NNVPXJQ\@22=PJ#>TOC@Z:+=LC4+>==&>A<'2(`4#QAW
MD^Z@#0#&<>4P#N_`#9-@SIB`"9=P"<[<@\4[U$0@M<%K`,-\`$@0!5]`":Q0
M#6`55ENJ::#&8-*]>\XMQ:7V!M>MQ0:P`$:@!$K`W6`0!I00!I-@">,]WJS`
M"I)0!&]`3F)(CG`-QWSZ:_A9CO:<KW>]38:*N(FZCW[.YPG+WPQ*F(>Y7"Z^
M=HC>R(IH=Q\*JA!97,^%L=4EZ>659AHNLJH^@JZ9PJ'^HJ[LHB$OZFR6#B5?
M>:&MLCN;#S#^9[7X8.W_U6DZS'N.A.O7,`E3,`5?T/-"*`G"*:7&^P-$(,S#
M"P1)$&G.O+4"5NVY:.W@*H75+.7!MY8OT,U;?`!&<`3CW@1-(-9A3@F4@-;L
MO@J8<`1F$$H=]L:S]MY*UZ]U#G7SW9<%6F-LN,?0!FW]K?<#3(>`;)B%/';[
MH)AOU_`2J^AY)\F)WUPH5<@31X`"7N$;^Y&8K8&O:'CF9.F))[,O6O(KJ[(G
MK_(M7-*E[K*E;_*B79(H'<(M/L,\^TA`6V#J)=N^.NLU3DF))@V9,`E5,`54
M``7%:YS%FP2_'=P'T+3$#`110,Z3D%_=L-RH9V!1/E;D`,712/5TM4NU%@M8
M_[S%WVX$X>[U4C#.89_N9;[NF)`(8R`.9&MJRX=9F)5SWR=U@7M-<YYU>4[P
M!0_`?ZU^?6Y4`)'/GT!^^O;YXT>0WT*&#1T^A!A1XD2*%=,5RU-GAHP8'V#(
MF$$FSRMG^BJ>K.@/H3]]+%6VA,E27\R9+67RZY<.73MTZ6:R+*BO7;IS.MO5
ME#DS:$VF39GBFXD/:E1]^/CQ1)<U'52I5:5^]<J/ZU>R9<VV,YM6[5JR8MF6
M1<MV*]FY^.*NS3?S7CV^[^J]L_>.GKO!].`1=A>OG#=WC<L=;CRN'#EWU:!=
MBN3$B9(A0(`$28+DQY`?/PX<,'#Z-!(L8":E8B6M6_\Y=^4FNX-'FYSMW+G7
M/3Z\SC$\XKWAO2M>W)X9`P(`/#]`Y(@2)9JU;/$")DP82Y92K0(?/LT5:L3O
MP;MW_CR\>O/<OY]W;UX]]/+?R\=O+I]^_//JIP=0'@#3D\>J`>_AYYY\%%PP
MP03S@9#!A/)):"$*!^)G('_Z00@E#S\$\4-_G+$#!@D>8(``%0E@(,45&XA@
M@QD$(2?$#V.2R26:=H2)IF(XT""#"SQ`)T>6ZI!`@PLDJ,,IDYA:JJ8HJZJI
M*Z_TR0>J/"Y8,H,9%.QJ++*\^NJ>M]ABYZRTTJSKS+727%.J-J6"DRPSR\0G
M/:&X.DH?OOYZ)U![#H,,LL;_#D4T4>#@(>>=:ZHIQ0PE2O,,B,XZ.\V``DX#
MPHDM)O%NE5:DJ<TV=]ZA#3?>'BO''E;=6:<XWN`Q)[E8:=7F`^>>,V`!(XR8
MCCHEF&ABBRW"J,2[[U9)I956$L&"FO6*HZ\X^*Y-)[[U['/OGG7ZBT_;`?\;
M,$$`'4QOP0@9E)!"+"F$,%Y]^@FJ'RQ;LC%??4-\108(&E!Q@`$`5K'%%0\F
MH($+R'!FWXETA)BF#(WL$:&6AB&8``A*8LJ?&58<8(:DFEIJ*JJ<--DI"NL8
M@`"!/\A+3)G'//,N.<V:\ZNM;+;9S;?JC%,MM.Y!JYV>P\2GKW@$C0<>P^@9
M#+=$_Q%]YU146;5M'%3=Z283,X`X(`BQD>@,"--4`T*)+20!%3Q6K.E&,=O,
MV<TVX.RV3;A869V'55FMM46!YP`0``$BB#"BB`422&#3!(!H(CLQP@##6"X4
MP401,ZJ!1Q[ZZ$L//7C"O1:];+N%)]MTVI,OGW#3,R>]?=(YL';;TU4P][S>
M3<BD>'^?%Z=^Z+77)(>/1YZA8#S(6$6""6[Q>815A&"&AI-G"$<>=7RR8J3T
M">:!%24H4JF9:`@XY*1&=K)[KJCJRJVQ9JKC8`^L1!JL_*?"T^>UY@(:.\QT
M-)KY[W_]@U,ZBJ8_M`CE'E%)6E_H,2C<1(TX33/4H6@S#O]W4(8RC<G-J=P1
MCLE<(Q)'J!02DK#"%2)!A4LH5A@H48EEO4T:R%&'-DA(G%79QAZ.J0VL>O.8
MOHW.;O5XPZX`T*M?$6%Q0V!<:A(0A"QH(0Q?8()GD"`%+B3"#-GPC^B24QSY
MC,X]M!M=>K35K0'%[C[Y^-;M;F<N!)E)7;I3U^_T.!-[N6M>*[&1\;"'O'3$
M07PLFAX#'A`!"$3`D0V`Y/0")@$[="AY%GM)AFB2(^_!I"#^`,8A"2`!9XS,
M8^DC0X^<,J64D>QD_*L*/^JW(ACD*7]4,J!9@$:GLN3L*[MDB_QR&;2CW4DJ
MQLS3GJ#"GJK9(S#V>!IQ<!./J97_XQT<1-0'@WA-1I&#'->0AAF,8"DD*"$)
M4:`"%;RP!2U(P8HS#!5XK"$;O*TJA.KH86[*(9PA^HU6\T##X)8X!"<<H0A$
M2,`!"F"`U!P@`4P`@QBR$(3'J6T29C`#,L*8G(U>:Q[K,`=\SD.[^[AG'=^R
MQ^GP`R#:W4Y`!S(7/A;$K@="R"IYE)>]*I00#7G('SIQ1E#180YZ%620(7(&
M!R39``S$H`Z"*,8RP)&.=`3U%7F800<B,+V!P4`<V+/))G^B/4^&]2?#$*4$
MP)$CJ\R@92I*9?ND)->301!^5)JERSR0)0BNA4QO\AD!RY(F8`YSL&MIAS';
M-+0R)?8K_T<Q4U7X`K5`"890\3`,;@)SJ$!9LX.'&@=E-MB8JEWCF]?81F:,
M,`05)H$*59!$%9I`+"U$-%G+6@4K6L&-;G0#-R2L)VWR:3?CW`T>ZQ#<<P2P
M@",<X5=#,$```("`A!X`"$R81"6RT#C&*6$26UA#.>(C.O<0I[SNB9T9UY&.
MT9UNO.%JZ3K803J7UK=V,\T33?<(H2?U`T+[@!?Q)M*/90@B#C#P@`8<V4@)
M)(D%(@&&58YZDE=(8'H2B,$KVA&1EW2(1!UHGHH\<+WC<3)B'?Y>4CYIDO"M
M*`+@Z-%"R/!6]<W5QD]Y2LJL8M>@W,,?>1T`")!I,OU=R;"'U?^97?`!)Z`5
M2"J"W=^1GTP6G@TP+63B"SQ^N&6GQ>.'B/&R8X2KJ%*5:C+D&,<UNO$.<H3#
M'=>XA!F<T`07-H$SW6W".Y4%GE:PXFV\+8<YS!%HX>)-.'8#Z:H$+6AX-".Y
MA&-N<X>P@-,DP`E8*!L6NJ,%A29@`4#0@ADB,3I:U8J\HYOO2?]YQGM0]8SU
M^=9'[Y%JV,U#@-Y*#SMB=Y[\!N@>+P50/M)T(`,M2"\(RLON%O(3H#SD'L`@
M0P=0E+Z6O75%T;M`#/+PU0E'1!!;/1@$:%`,BG2X(?@0!/,0U@$2[VNL)T8*
MBL.ZOA:KB'Q(R=",71:R]K&O>U6Z:Y7_W@>5']MO?F7IJY1YB3,TT:FP4?8?
M.P*H9#O%Y2YW>F!5CO*5P'BY:N]H&C7MH0W<D%P;M)E-JCX8W*Q1[1IL9K,W
MKY&)2&#4"41P:-K<*<-D88+/?6Z%-;CQF$&'T,QS^\W<!"W>Y%1C#`@HP'2)
MH!DG_,H(*H3"%)H`!"-LP3M@$$(0G)"(*FPA$K]0!^WDD=YTA+3M@O96[-"(
MQGG8XUHGC?5)Y1,[=N`=UW&$W8#V(2`[#8A"4J&CN?91$&07!!_[Z-A#P%$'
M#D22JP`;6/1:Y*(&2&`&P+!DM_E1#`DTSP/!R%"Y51+ZA112E"KZ@"#UA>(3
M:_+=8_V)0&8A_[X4O9A]^A:8R'!/5Y--">"P3)`^@%S+*XGEKU*>4YTF/N6;
M*?S(5B[+G1:H9*(]\"M_65H\``5R>J0*,8Z1FV?1;)N4F\JW&_PX!U-E-VUX
MPQ>.6``"/LV$*6BG$JAP&]UREJ#C!F^P&^#*&M'2)WVB#<A`CFIP`DHS@`0X
M`BN@NBJH`M=*IRI0@F)Y#4OP@BB8`DGH#FLH!_9*#E,S!^0@-=+QC_-ZCY#R
MCWP@#GD@(]%1C[93#QS<M=C)D[G(M9EZ(#,A0G-)B`=:MF63L'II"0(C@])K
MF<V3PBF<0DEZ``\0!-;#'G30@(-I@!G8,.3Y-A=1D3H0$9>`-^WA'O],VI$<
M0:M)`H?=^0E]4Y$9H*L[;`I8PB4J4;X&$)@!N)^,,POG*Z!A`B`WF0LH2XLL
M80NB40M'3+($>@N,.XH_^1._D)H0PIO*,K_::+]W>#^\\:W(<`?)&`?)*(=M
M0,!'*`*'&H(\.Q90698!'$"XL0TWTZ=284!484#:>,`C&`(H&H(CD#/-2`1)
M0$9DW((F@"V?6X5*`(,OH`1+8`5NZ)PQ>@\S2L$Q$AWVB@]S8"\$$1!]^+56
M(Y!RW`M?FS4!`C8`@8=;&\)YT`<G0Z8(22:HX*N:L)=^.(<X`#>7H<*`I$(O
M=)X&@`%R.RI_B('FH8&B0AY0@H!P6P8/83;_V@NKH%C#X=,DC`0E48J`\F$)
M?/`8:Q,^4\)#/D29*\D+64H1/V2!OS(RPU)$75JR)T,F1W0R6ZI)ZU,+7R(+
MB:L^FC&(R@J4>6!!_]BG5E$57>Q%O$'`>I*,<*@;O"E%0NN&$W)%)J@M9)E%
M6@PZH?,M5.RA0>LAXMJ-:S"#8$P`(K!`.:N"8T3&29"$+7`"#)R$\&"6[VB%
M;J"JXI#!;*&5;!&T^R`.J@)'</0U>!#"EI('JN(U;Y$XO5BRO@.0,DD/P&-$
MG32FI9!#/MRI?A`$#0"8YTD1@11(20HW.Z@1Y#&)/R!#`I`!!,$>E="#YHD!
M+>0PVT/#%4/#-LP1_XR,"7ZH-P)XL11SJQ6QPY-T"OZ1BGSH!QWS"A^K`T@2
MF/LQ,C)YOBLS(";KI<<ZIOY1"V%"N$;T3C59..I[LKNH"AHTE7(8AVVP#6W0
MH?G4AFW(AF_(AOS,!FI`!F2@!OQ$AE_(AE_X!5\@T`#]A6;X!6H@4`)M!O[T
M!5_P3P1%!E<X`NJZ+BWP`J[\.:_<+6[83V1HAG#H3V0(AW`841-M!G`8T6;X
M!F*XAD08@M,P`B>P`HPR`[A$1MF:,[OL#DL0E:!S!W4(!W$PTB,5AV\P4G,0
M!W,(!W4@AZ(PTM1I4G-PAT5+AR8U3'%8!RT%*79HN[Z3K[9K._F*'7F0A_]3
M["U`BP]V,!J@3`_:82S'X@HB)$<*$0<R>``:"QC3-$W41!@.0$B'\0=XZ,(5
MT8!TF+`-^9@5@8!A0`DU7+U)E;=-XB3<Z\B6@9'R00H:H#'AN[%_JZN?R!"=
MJBM88ID_K*6!FQGF?!^5P8?G;+@D2PN>X<E:_<Z?Q%6?&=!C\(5CV`4#]05>
M(%!@W85CM858@`5EC85CE858F(584%98@`59>`5JE05J759F7599<(5`"`1J
M=85OA85!F(4W.`)*`P(AR#,NR"Z]]-"@DP9<V`5HE599P-=\Q==9X%=>Z-<U
M((+28$L<-8,JH(+8<H(?(`*S^8%SDH0OT`)*R"W_:[B&89@%8R`&?M7861B&
M8N`%B^W8CDT&8CB&84@&BSV&8R"&9$B&9DB&96#998!99GC9EX79FCV&F'4&
M9E@&9Q@'RU`%5;@$3)B$8U2%:@"'9U@&=3@'<5"'IU6'K'B&ISV'HE`'HC&:
M=EBO=A@&#W`9/QS-*/33/Y6DS1NE/%"*?<F#C'F`+,3-V5L(9_A'`B`#E)C4
MQ=,'=!B&5Q"$/]`#00@&<$`'AMB0>VG#&!M.\O$O*3E.N.H8/,R0?4"'8'B%
M/\B#/!`$80`'"1LX^@&9#TBF[)29L0*'O;5<S`5<9T"']'`3F^F'FM*^(Y,2
MQ#)/BNM..]')J6B';$#6_UVPA6`]UGH-WEAXUG(=!%<8A$#X5G`-A$%(WD&@
M5N<%5^?%5EB8WN8=A&QEWD!X!>8=@\5Y'";(`B\0@]MR&P^UAFA(5N3=WND5
MA&IM7N-]A(0]'"?`J"J8L]>B`A;JC"0H%DD(`RH804RP!FH8!$%PWD$XA(UU
MWD,X!&.8A00VUP6>!4188&#06&"P6(Y-AEG`X&'08`\^!$0P!@<&AA-6AF$X
M!EXHA4L8VE4@VD3PE$OX!6;@69F5V6=@!G6XX67@69Y56F9X!G1PAF40AS^X
M`-0$F+$E6^EAD<V#I#AX6Y1(AT-5$1CPL2EVF,8=@`Z0/8DP"<D5!#+P@!.!
MI/\S;H`'&)(X$(0BF=3M`8I0&A\8RR1]H,,:4Z5EB[QV>`4X\(`+>(`&8(`S
M?@`)\(`Z&`:K>-VJ*+B`^0#OZ]Q:?84X^``+>(!`'LTTCH`.F($\*(;L/!IG
M,(9D,(923H:Z2,3<E8MA"`96;F5TF$0HVZ6=.8L'*H<"/59<^%U?\-U8L(5G
M159IG59P[8,^X(-C/N9B3MY`X(,^"`1G?N8^2%YG+E?K!5<^:%]7.`,%P%`E
MD(+L>-?PH$5K(&=LP`59<-Y72%Y!D`7L%01P!80_2-YBU(QB;`+^]5\,K`(O
MD`1,:`5,J((E\`)*8`5J0.`#-E>-/6@%!@8)1N!#4.#_",9@?IWH#=Y88(!@
M8$"$9)AH9=!@8Y"%7*`%H<4$2\`$3%"%6J@%6J@%8E`&97@&';;9'Q;B'L9A
MF3V'9W"&9\@#"Y,D@7EB)J;"$$L8@^G3NM47UW0>!GB%U1.]5Q"E!R@EBC")
MR<,`HD9-!M``,B@&#NF>EQ@K?GA#>P-)D_"'.T[..^0'=*@#$`/4@AD`"(B!
M"(L*63(XL]A#JTB'//"`UP/4EI%K06!=[BL3?4`$$T#L$D#L/3`+["L+81*'
M&'@`"+CD!^B`8L#=8^J9-O%)508+?=@&;,C/"#T&7,"%E/5=6["%7-B%7O#=
M;!T$8^:#,GB#,B@#-+!MVN:#_S<HYF@NYF)NYN4EYF,&!&A67E=XA`M%`"!`
M@CP#@QFB(7$>9VFH!FK85WQU7D!HWD#0@S<`!#[0`SVPP'JV`MEJ`BHP&R)0
M`,_0P"J8!$S0`M?Z`E;(!7ZEX(AF8(G>V`[>6`_F5Y,=AF%0AF68A0Z&Z`L&
M!HYF617.!55@!57(K57H#DJ8!%78AIV5:9O&X2+&X:E=AIA6AZ55!Z<=!@NX
MO(0I&*$>R!>Y-LX;F`;X@WSIAQAP'@+P8J?NMG2X@+>"<2TN"#OPZ8#)&&LC
MR%&*@[)F-E(=:XV!L:8`OAHSOI_`ASS0``88&$0B0Z#N4P:``#AXAII8OO<1
MQ+(0!/\0T_*W!IF$@8$(ZTZA:(<]*($0&($1"`$3``3/QFL[T8=&=3%!@(N=
M])FY2.4\H=.NR`9?P(;2/@9;@(5CG59AAO18"(5E;N8^*(/=/N;V!07K+>90
M>.9FQN8^`(5/?X,WJ/1`>&=8`(7O=44EN([M,%_I%CJAFU=&_]8_>`-PU0/F
M3=Y,L`(%D`XY:X)ACP(D4(W26*$G"`(D:"<AH`(Q4`5>X%MTYMO^CN`1UE@*
MYEB+MG9B*(9D.(:)%H1M)X9R[P5;"%I5.&F\)%IDO`150(:=EMEC0(9C6`9B
M@-EFD-F@"O&>?09QD-EP<`9Q>(9F,"063R055_CT:8`84%3_&Q$'"R.8)A&]
MAI@!",!X"+`#BG`&&,!J2(*`!HL`3+8V@M&`8/B>%)-C>UNK[]&W%`%5)_$'
M<I!L:@/JR6XPRA;D`2!##_CD?<@K`H@]_1D3=(@#/[QR,DSCG`_D%#=J2BKT
MP>H!$ICS.3<!1(A=-SGZ<,N#G_ES0']$S?:*HSB&4(`%48<%4U=[8Q;UW^[M
M4R?F0%A[9@;749]6:PZ$47?[/C#U9OYTXRYF-%"`A+(4\;4B,9A&(.W0K[0&
M:(B%/M!N:,[>08#66:@%/5"`Y;("+)"M*)`MLEDA*OB"@ZT"*9B"+)B"+YB$
M6ZA@X^WO04`$?H4%01"$$^;8B^4%_V-087Y-:%GH5UXXAED(7E^8!FAH?#]C
M!;>)<+<IZ4F0RT2X!&JX]Z"ZZ>HO8F>`6G7@<.P?^!&W@XA48H5?>!5Y`"G6
M%T%H20)X`-2K>(9HAZ@*JH>/B&6PXA?1@!O(@V!XAJIRAF$PL+X&"`("!T;(
MX\^?/GT'%2H<]H!`@P81G"5$J'#&``(,",Q@F/"C0F<>!D(<T.#"##NOBCES
M5@Q8'C@<'@[44(Q?'9(?].'KR?-GOG,Q(F8D8#("C#J"@K5T%DQ0'1@2-&X4
MV(`,NIX]V_6\AR\=#Q(CQHXX8:SK5JU:\_FTTX!D`SMJY])E1_=K3[MI[R:\
MI\]7J%"@`O_!ZO/F39\^@P*%@N4X4.+(@2#WX</GC>4RF,LDIDSY\N7#?`Q;
M5B-Z-*S)KES1>G-EP8$#0)`PR>(E#"5*E2RE6N6[%7#@T&*%"C3HS^1`KF#)
MFE4+V!D!"*R8<=(D2I0FVK53H5)%$B5,J<1\$:/*%K!#LP:M'_3*>'-!@^;/
MFL7KV+!9Q_0/:\:+5WW#Z.*++[5,`PTTP*G""H.ML.(;@Q$RN,J#$$)SR26T
M$)-,,KP4LXPSSX`(8E/BB'...NHL`Z(ZXCBCHHK-Y"%!46\Q\!95#.BX(X\]
M^OCC1@_4H0\_11IY))))\D/#0`-<((^244HY)95*%J,!7`U\($C_.T@>=%"1
MP<P``4D$0"`(0@M9Q,\P#60T@`3H6%31#"1U5!$_(*$S$DD#:&`'.!XEU`^1
M^J`#3`PT,8`!.#D-Y$%"6O&$CS[IQ&#5`"9I4$<QE.;I$SY^Z>-,'1=4)1`#
M,[`S*5WJ[#""6".$@$(R;-VE%C]Y1`!7'+?JE=>M^.AE5SOI\'6/7UM]X\LN
ML<`R2&*C);;<+L=D@XNSL,2R"RR7[5$&N.&6\>VXFAV&&;J@)=9)'XYX:UIB
MH,"R"[>QN'+&$;`E`,00M6D!AAB5"(Q*;\$%!PTNN\C"GK:SQ#)+)J_HH0`"
M1UA11179-6&==DET-\4D#U("QB2D#")(_R#RO5)?(*^PI_(KS<TRS#``UC?+
MPO4A,DLNM"!HC80/3B@A<`T^:,DDDV#BX"70+)/,+P`.\TLRQW"X(M99:[VB
M,\NHT[77@F!0E$8#`7DVCSGV2$`$>O13)95\"@2#/W#;?;>4[7!0Y@6"O)VD
M/OWXDX^1_@3C`8X"23`,0GGB&<P#;PT``3H5T=GDG2`I=(\,93Z`5=V::^[7
M/8)@*5`,CLX]#Z6L\A1'DPU\CLZGP?;$CS-DT&25'3QQY=56^C"30JQCI>!,
MJ,'Z(\BN`S4P@['XR!/LKUI%'^SU[=S#%3Y<Y://.-3X(HNSG476!R[:F%..
M-L@<<PPNME2FF?^XEJ%;QF7XP^(**.>/U@9FVI"8-EPF,;"P!2Y\D9H^Q"(6
MD3B#`A)P@`0,H5]2T((7P!"&,%2"8!0R6"NLT0N9.:R!LG!%(-Z0`2)@P3H9
MTT[&,%:%+4BB-Y60Q"1H@4*4`4(^.)//(&`AGY0)8CTZJX\L9/$L^<""%JI8
M$"8B5+0I@K!HK$C%#;6@!4FP8A*2D(0JH/$-$XD#'.'H6C-61`RNC4AKS&C)
M,L#A#!.E"!@=,!O:\H@V@5A`$%$BG-W2,96!Q`%OACRD/\A0)@_<1$UJ8L@C
M_=&.&22.`!ZX1Y'FY`]@/*`H$`#'FHB$D8&0071$LL-&J@*!/)@R4I3_:IT^
M""<2@3S@C@(9P`>2]4I\Y$,0NR.`!/[`#[383BOMR,,O(Q",N^CE&"@(`5E&
MT()PV(HN_`C&(`<2@W14LYC`ZIZPU'*]Z&FO*_H053O:,8YL8(-9S<K6`;%1
MCG+,@Q[:*`<VHK&+^*VF#Z%83B@6$PCRQ8)\MMA%.WUAB\#T[PT$!`4N;K$+
M!";LGMLH1S>F@8U=Y"(UJX$@`B;(+R$T(0NV^<(&>9,*$%IC.#A3V,UV,8L'
MFH$(2&@"%+#CA.]\,8JJ2$72:I&+0:BG/H,(QLWR@[,D!B@92<W/?8BABUS8
M`AH2LD8(L5I%@QTM:8EP`A"`L`6@TE`2EX@'_R;[D8]\F,,<901'',\A5W4\
M`QUP=`8B=C`(=:1C'29"1SK2T8P/H.IL:M.CCJA"@`L$XX\\0(3=BK$K&]GA
MD):U&S#(]"AG%,EREDL32.HV3$HZ+P^99,@U.[F1"%1N3OP@0U$&,(,Y)80?
MX)B*C@;P@#P0ZB>1TMPK8XD/?^SI5*C*97`II8X.D"T"@G"=-R6%3)W\BGN2
M,@8*HCF"':@C'];5RI46B0[@V:YZT:5+.\Z97NTE!![C"$<YPC$.;6B#G=JX
MZ#R],4]M3-06MH!%1.&7L&/\0AO'J.\XQE$-^M*W&M7`!C:0$8WW05@;[F#?
M-\+A#7=<.,'P>$<YPO^7BUQ0HQJU,,,")"A2)`C!I%D`F,!6VHK?M.(4IXC%
M+?PKBUW4XA?7J$4DG#`$("0A"=C!V!<E@0G?7$*B]2'&+'1Q,P#QHFK'^`^'
MTM@,9/SB%\1H!C5V$8UH6*/,#"HSFLL,0BFN(A5(FT2&I+$((B3`"))`A=(R
M!(]^]`-9YT16.L@16'.P@QWK,'0ZV,%7'LP*$8,#M%V"(@,;(1:Q).D`,93D
M#W6T8`0I`"257O&64?OQLJ:.DC\NE5@)...1"@&M16#]ZG2,Q$8:`(?C\L2F
MW4D@4'A*Y)MDZX_6Z1IVB6W`D#3W/5,Z[IR\#.\B=^F3/"2N`7D@+ZNB>T[_
M.)#D`8((9_72>0]$F"":)."!.GC)O5%Y@&P$T`!%J#<7\UHOG.#\[N_.^9'T
MPB/$[D@P-N!7&%`0_!@0AC`N'(.(P,`"?@AU,#;HFXUL7%0;V-@&A^<9#OKJ
MMQSP<(?%L3%Q;>AW'-M(,,H3/,]Y5B,25E#``4*Z+R`$H3;EV8V,9TPAWSSQ
M%+V81C6N08YJ9.((0/C!#X*0A.MTIPI@D$0E6"$-:AQC&<AP7S.:T65D?*,9
M&<Y&,\1!CG"`@^O;J(8TRJP*KH;004!+<P@CY)M5($T2BKC$*;(A#WV0(Q)C
M*,(6Q&#6;NR]S\@Z_#W4>H]\(/X>YF!\/HQA@A`T_[K/:R62/]1*!DI7>H\"
M\0#ME*2.[)*@!'N`FR"J_8I3LQY)Q7C(C1B@!S7QXTN0A*2L%?(*137@#Y_=
M-8Y82UM]P-8HLO7(<,&!I:IXH$NP].U/\/&I27TD5[\<``R2BX]U,-<D!-AF
M-VU'7JW<0QRV1%U=DI</=@RBW&,I_1ZZ!SQTP,#=&1A&^,^+%V;.Q5C`^^XY
M?1S[3(,"O4$9O``"JL`5]$'$;=1_.0LN6`O%:8-\;</)H1PYA%C*D4,WK-Q^
ML4_(_4(VW)<%9@/7?</$4=R%<=A\:0,HC`$"&(`!R,9L0$$7=$$8B$%OK$)P
M\*!OR)@UR!,R1((9#$%L'/\`T@5!$#P!%$#!%'Q!U'4#.3A#.(`8/,P#/'2#
M-X0#/<R3.;@#/'R<.W"#-$C#@DP(#\Y8%;$"5U6(FZ%")4Q"(MR=-)2#/>Q#
MG[%#/O2=$R3")*C".S2>.6!AXB7>V]S#/NR#(?*9/3`:69@`'_"9)!I)/]1!
M)[F;\W3>CLA`.D0)=D43"IA#E:2>\ZQ>ZYTB[*!*!U3?E.1>FAS$I6@3/]Q#
MK+5)4?0:;262G7Q$FNB!FU@%FBS;1P07<`$7/[2#W`C$3K@2/^P>1#``!*R>
MM.F?="6.!"R#6HR?5NR!^U&>Z2'+5PR%]PT`!;Q"MJ%73UR/.*7C7:CC=]&%
M`&;_@R_0`A^,@0*\@`JH@`*HP!O<0@)-5"P<E"]0PS>\USC\F\HA)(==H`:J
MW'[15SBP4T)=7#ED`S5<9`H69$..PSR]PS6\P0+,8`$D0!`L0138!@>APMSU
MX`^N@C5X@SU4PQH0P=$A(=+Y@`\HH0V*@26L`H(@2#=PI#MT@S5P0U:5636$
MT!.AX4JJ(7#X8(7,W0]:0B50@AAP`1@H@BILPYXABR+:@SWT&3G4PB58`SSP
MA#LD(B(JHB(>GB+V&3](8C]('C0]XA[D@UP6"9_I2IF01.>9!`T0B9(@P@EH
M%PGP097\0;4!PRF>HMS$!=R\FD>`EN[11`.PVBOZ@T/<_Z*O\6*=#,1L@00^
MR`#9-)]HFA(Q@@HL41M)>(!:$$D<))8E:1\UJ@4ZG`Y$L-)6<,6PI.,>E$!=
MAH`)#()W;1Y)0(#OU68QV84ZGA<\H"`V_$(LO,$+W.,'O,`*O`!BQ$(NT$LN
M^,(T7"0U9(-#9IS*)=AX)I@%HAP(UA<[$0B!4-PV6.0OB"=\G=PVD(/*65B(
M18("&$`!3%`2"`$49$$7E,<./J7.K8(FK`(W<,.%.`%L(-T/X.0/,.$7H`+!
M*((?8D+3.!@W`,U*265+[B"%L.%6M5DJP&%5YD9NA`$8;$$B)$*3H17I)&(]
M($L]#!.1U`,>\H0\X&'B!4Y;NO\E)L6E).Y!<)(%">P!.V3>W_`9/PA"-O4E
M8D5$(44)'[B?=GT:E:3>J#5`J36FJ2U#\Y@)9U&)(^5)XX2./K`#;C+`*V@2
MY.`(J]V>/C#)+84F0]PF2=C!L+72;PWJ,+;.;9%$]I%7.Q#6C@"J<M[%/2@2
M*?T?741/.O1`-(7`"2""..!F;C+>H\[%.U(C]U1D-KR/*XS!"XS!&:@!N)P!
M'X""L\0"+>Q"EXE<-F@D0J9<RN4J"I*G.U3#"`9<=+H3`LEG-G3916Z#?&G@
M>M[3/;W#._3"$0"H2`G!$J`DSM&8SJ6"C+%A*1Q!;"`=S4$!%8B!&!",)F1!
M$=P=AU[_PMI-R%.J:$N2J+VJZ(J*01AX019H0;]N@8Q"0BE(PSNT92(JXB#"
M@SG``SG<#B;9BEH*:2'VF20N(I^-7EUJUPCP`#N\S=\8R3!H`-G@B!XU``/L
MUL<>23_\9@@4#UF4@#&$6D18A3"1J:F1XN=EGIHZTI<43I'HZ48DFT5`3D9(
MA)R$UF=F2N8H!.0,Q`,T5K/55NOX!)%X"M5Z"C_$HC("3T(XPU1$1`/@'^-!
M7Z2L%7GEWT_@K"6M"EJ,*CZ(`P]HEUD`0_,@&VWZ2J7>RO402SI:UZB:PWVU
M$RV`PAN`PFK$0@K)RW0^@BL,I*\R),I1`P960_B,)WE2@SM8_R`%6J3X%(A_
M^<)\:H-XCL,WG)Q^FER"(60'SA,\5`.*S>"^E&04_`LEH$(KC.CM.F5PL,(E
M*`%.^L`34$%Y:"CQ+@$0.,$E3`+`_J%1LF2;S9T;WBO=426,\NL2(($38,$6
M1((J5$,@W@,\R$,]P,,^U$,]S`,67B$\I`.A-5[$(B+\.EY;4JQ<(H++:BQW
M3>*1%$,'R.8SIDUA#80$C*F7]$`):&PT]8!H18E#_*G-FIJCN$D,-(,SR%'7
MV%5+%`,X6/`SI!&)/(-+$$-3U$'BS-::-/!;X.*0%DGQ"009((1?3&GB6`"N
M.<[SG2;T/9_TJ<YL@L3KW2(P+$,Q#/_Q$+N$$!/Q,JP1$0_Q$1.Q(&@6`5A`
M5H2*V^K%,[P**";#$Q,`'-#;7N#M-]W%=YF7V];#.ZQ@.7#8A6D<_$1G+00D
M-I0NZ9YG@E%NRIV<>"[K.^CG/%G@-GS#+Q#(+WQ#-<37.DEN?F)<ZG+D..BG
M!78@.;B7?Q[AOB!!%'1!NJHD<*R4B;:"4989%PC!$XPR)FNHMWIK%P3!#S3!
M)%2"X%F"-71#\]ZNMTKO#WJK)5`E>6A!23F!&2Q")-P"-?#5.H#O/"RL(J8#
MLJ`O,SO>/)SO/.S#,\-#(8)OXU$S6])O/_"`""`P681`"J@#DB*)."".7P*P
M8@&3*28).\3_;<:.Q3NC`*@IR:$.!`T\\&5)JE$\``3TLS]'`$#W,S_[,P1$
M`$$7=#\#],PJ(R^FUB]B9J[=PR@)!)^>4N*L(D@TVPW#$D?[!#\HYD!DGT_L
M0^H-0.PA-$$']$&O]$`CM$$G#@1T2O_M7U?<PS&D0)>&@QW,`/=PK3E18[C-
MFU9XL5K,PQG;`QC"`SVX@SU\'#R8<1BNG$*Z`SG\&X?I9^;JY^E:X#5@X#B<
M\;_Q<8+!5UCOZCLT\E>?L<=1-56G+H@M[#O0@A4<H6P@@11X0;K*F+?2LB:'
M$#>HPA;<X`UFZ"E[:R5D@1`$017T9"UKX8/B:RT_K[<23"X+#'ED_P$42`$6
M0`(TC,,5`MHZK(,]H&\8SN+AS8/CW0/ZJC9JFX-74G,TYZA;JF57(N+;F`,*
M=+/&9NRLQ*R2B,-0X!$`5X5-(`F1]`.GZ?8W:ZP)^':4X(.G>D#*XK.1X(,@
M",(K"`(P'&F13'1?&L5W]^6;]`E$D`0'\.(F)0YK932P[6E&\S"D"*KFV##U
MN9(_B!I5?,`NZ0-K?G>F8&)XUPB`TY(PR!\XI:-=5$\R9%<T<=>C_HH7_TIS
M-N<7]X0]O`,]-'4\(#6&<SA82ZL:J_$9GW%5GW55N\.'HSB'?=Q75W4:LV`:
MI_%7IZY52^M!AM@\A3A8]YO'26LUG$%(QO_&$"R!%(!!!ZWH[:ID*H2![?HU
M-XR'8&-R;YPR57H!%#R!))B92WJ#-VQR87_Y&Z*K&/!K$TC!]DI#CL[#.F#A
M:C-S:[.Y;"\>:KMEG#>>5]8YLL0ELO"9Y"DW/",P"CBWRN[##9#LVCS*-R1)
MYB6W"+PS`H?`Z4E)/V@M,+$#=2>)8H(M!TB?D5!ZF?QWIA@?@(_W+8'Z?VM`
M.]3B`ZP:*'E6\2EMK.$$2<3`/."P]$4?1V=;V0*#R6Z$?FN%/U";R4J.J?^W
MJ!>[L2-[J#?`*VAC,1E#839X.IQC^GE34*\C.HHJ/HSV.]C#4C,UA]'#QR'U
MA:7XBH.UCE,UNI/_PQ[;.(J?-8=U0X?]6XB=\5>K,;OG^XKG^(A7]8V/^#A$
M`A',X`&4Y(LQ^9=70@99`AMR0Y>/AYCG=6%KZ!=0P11<@C=P`P\Z_(RA0BZ;
MLDJQ*'EX`<#.(2V$0_L.HINO>30SL\HW,VHK8FLO'N+90SZ\;UO>O%<NWC[@
M)1_<KS?+RJ;J;^&0<'C/C:4KR2<&O6'R`)78`5RL\Z4721QX'P'``))H+31J
M``=H@-=[_09\_=>'O=AS/=F#/=IK0`QT29ILYD;@8FCI,T>$ENH,``M,;:$0
MFVAN]*"*VLSF4K+HPQ^<R@.4O0:<_>&/O>(;?N)_?0=LMS9&3X*G%SC0_T`P
MD-L[]X`Z@.-R"O5,5[A>\.:H6I?Y7K@8NL-2GSZ'66$\H/A!HCN*LWN(IW6"
MV?OI8J#0,?(\G?B,P_OKJW&.8_6,N[@8+FPO8`%L'$"_9`$7M')E8Y&_4L+&
MTX-1CD<'9?*7PR$EW$8:`L>#8I'`'+EEH^L7D'PB,$)GRX,\%+-HPS;ZLCS,
MH_8\V`-K,[,RKS:AH:]KNS;\,MY7LB5`W-O7[UZ_?CQ"C%"X<&%"AB%*[,G7
MCU]%B_SR/""PD2.!!C/P7>1'D1^B$R1(,&RH4B$*?R)%!M/(\09,FS=QPF37
M8<"`C7%$DMG(@`"<>_KPW6O7+FE3IDSU+=67#O]?TG91VRE-=\^J/J\5@3T8
MT(!!!&?Z_*%%.Z/CC+1?[7C<Z`'?5Z]WD7JM>[<JWKW\!#4@2^!#W;Z!.6H@
M)B]=8\?IU*%[G.Z<X\J0&Y^3W!A=9*I5F5;-5Y4T/G,Q"&A8-LA$0Q)[#)>6
M/5MV:-KX;-\N'1H>O'?OW-%S-YP>/7C&X0UWE[Q<<G?DGL,CY_O=..7N@(^K
MKGW[[W':OUN'9YU<]?+#MU^'#IW\<^O-R963#Z_:&R('#@!1D@5,F$F5**$D
M#"FB\,(25KJQQQYOK%G%DE0>3*655%)9A4(++:E$PE9:884;;E*A1(P`*Q%#
MC##`V&*+1":YA1MW[HG_<9YUX)GGG1GOF:>>'.>9YYYUYK&G'W-D7"?'='KL
MT9P9UVFRQQBAW/$>=@@2:)^""+(G!8=8ZC($B"0B221!(N"H`8_BJ.LB?UYB
M324N5V+H!'5RTD>#CBY()Z<]^:QH%L%\:D`0D>+B2(:*T&(SK8K>6I0?11%]
M5!])TV+SJ$KY&68F`B1`!R^O:.!H@!GN>NF/,S?2X!Q^/OVJKU;Y$JTN.Q@@
MB@`82/-*)HXN>`8IPW[MJRJN2"-6M]APVPTT=JIBAP94/7!FCQ(8BBA888_-
MEC9V/F,6--K@B<>XX-R)9[CC>@O.N>N6P^ZW<W\[#[KJL#NO.^NXLTXYZ^@U
M_T\[Z.1SA]_A!EYNON;D>2>3,19(`(@AM`"C/TG`Z&()**J0Q)INNM&F.&M:
ML9!""2OD,.155N$09&NXH6>5,+X0H[\45U1$E6K&2;(W>-)99Y\D@0;:GB2)
M'!K(>>`1*,E[>EY'02-S_!E*>_+Q\4J!8NQG'A3@?,C+$4CHH9Z;7I%@(\'J
ML,F??O8XH<NW&3(AF3WCZ(B`//K,^R8X&AB+@`O:&=-6`CQXB=)$V53+HL0O
M0NO1M]2*/-,'SAP@`D]?\LH?M@CHR:U2->7H@6$@A]55I%A]E9^D])FAU@$8
MH.NN?L`Q>R,(BAFMM&NU/3:WOCYKM@Y4-YHAG1Y26O_(A$'T.>KWV[R=[3.J
MV(F^-*5TL^<W>^KY+3E[B#L7/=_**0\XY:8KYSKPLOL.O7SQ%9A=\-S99CC[
MARM??>?&@0X>_=W1'/4-AQS46(,"$C`$)4S!"V!H8!>@D(0J7*(;U8@$-*3Q
MCGITPQJL"!DK4F:RDYF,9=V`QSZL(8D&@H$+B8A$*3((#W.DHQX_JY$,>W./
M&OVL1_5XTM',435XK,,<YAC:T&1XHR"IHQQ,7(<2GY0/ITD12@/)QSV.X3:%
M=.UM7.+!0&Q2!XYXX";^F%87X::0$B!B3\,H4V+NH3<Y5@0=MML(&3+')GX4
M`P(<Z12E%*662C5*D)%SG*3_#C>I73%@`!#P%%_X,0.?W!$O_JA=1_)0ND_M
M)5B;S$LZ.E`K1GK`-E/Q@)G^T`]LD49WNJ/-4F83HV3-<C;\L`.@>M*`.B2%
M!RHQ`2+RD0_>]4Y;UL.-/+XE&P5I3X/OL(=PTL4NW[1+.>\*8/\$%B]^F>]?
MVR!'P9[#GN>\CV#9P0X!Y2/.=O5&/NK#9G(B880##*$)6IA"Q+Q0!2=$HAKO
MD`8T:$&+:M2C'O3X$#=,%D(.>;`5W/!&/&JX#VXH(A&*N`0TL/$.ZM1(ASQ#
M6M)\5(\;]J9'2)K'DGIDCWVPLT8G+4<VCG$,;,@T'.'0AC9L&HZ6^L@>/P*2
M/6AT_T5^'*,U:?S2"+J6D!W0:5(7"1T!TB:2?K"#!R7@8AH90@)$B.DFJ.E(
M5.>8M^&)[A6,JE0Z[D0`!@CJ<9HK9#\"R;A[^",?E>H'.IR1UT=B*BP<B0`X
M*C4I?9!AD@3X'%Z\NI$8Q`I6G-0+L*H"F`>(<@"DC(T^:%#8&;B2F,]+"CB6
M40QG%`,=Q=H-5_2AATVAB33JV$'R6F(,UEV%F(TI3?!DPZS<[+8J!%7B=<QE
M+FTD9Q[-61=ZWK$>@>FK/-IQEW/9,X[R;:,<U"V'OJ0[7?QE4SP!#*#ZXM/.
M[*JO?`0;KBX8!@0D2&$*8)@$)BXAC6I<PY_5D,9]37BEXO\<M!4@4QG+Z%&/
M?HBT'N60;S>&DPYSP$,>O5GPSDA*T!B)=!X\'*(YFG-2'Q6WB4S4!C)V$8M0
M@"(0L(`%+G81TYCZ(AO-.5J2CG:U?AB#!%?%*I=2L`ZN[G$F=K#)'I"*5;B1
M0`1LS,D^@M%'N4!@&&'MTS#L.(!#(4I1_A`*1V#@UL05<I!<-IP__@"!"$``
M`C`XRETFYT=/L>HE5I[DJ/`2QT+=KAB(:I5C\P)9O<0`=J_+LK'T(0A1,D`"
MSC`6,6FS#`U$8,P:"$:S(`T5?`C"CAXQ7FG4D0*5H"`9S>N=,6T3/-SB8]2S
M:4>/RN$]>IQ/N,5QUSM2G<UQHF__N>'QUW:<>UU\55<;V]B&^^0S#FI08QO#
M'D<W=!V>^,$:7]^4WWOD$XY7G$$!0`!"$K1PT?E6(Q,9M.\[KE&-?BZ''@HJ
MCC?HX0UTJ[O<7MD'K,O!CWH@J3GWL,?_!%B.!^],I!#^*$N!J(YL@(.(ZZAI
M,V;1!SXLO`^(Z`,L8E'B71AC%]EP8H^:!%0=0LD8U&*)C;MD`G7L>!E*]K%4
M=P!RK[$$)7O8$YNNS!$.Z,G)-^F'/$[)$28O#E.OL!4#'O"**B>*RUH^9$7R
M\8&O`C+-'OFK)@G;N5%E3A]U)4:E2867U>6%ZUN'I%>``0&RO,X#7$F=/M!Q
MIUH5Q97#_^S=/>9<V5(7"Q@7L!L,1MV/9J!`)2E8QC"C9TS=\%99R20-ON6#
MM%Z7PQN,+P>"U[<O].3//>YSSW*KD;]Q9./7W]!&-K"1C6Q\7O34R`8U=@$*
M5^PB]-+UM:\WO_EO$#L;L5<VOG`J##U8@0@*3$0F,A$)6@2_%N3X]CNZ\9OD
M!M`WOMG'\U=:#R%5?1_U6+!+G3/$)B$^AR1-6@Y%FJ/_*0EIW_B%+';QC2*6
M`QS-",0;RE"&A0>"_K`P1BQB,0A8[*(9X6@.2I_D'JYHQCQNBT9`!!`P`15P
M`1'0!);!(N1!'OB!&":+`7Q,`LUJ!QAP`SDP`0>A3]!*,#:BLO_6K.9$8G/L
MA@QP0A].:>P\`!VV++`&J<L2QW`"`U4DH!E*QQ_Z:B,D`+".HA_60K/BB%7N
M0@;.A@""S@@]22\8*[+$(>>(1W:`A1_$R*_*RK3<3C><00-@QR/R(#2R@I:*
M0>W6S@/`X=!(PQCXCB%:0!PX*UNB9^X$3PUEXV#*01MPH0]PX1BR(1Q\+9WV
MQ7V6[[J>(V#<YSO,Z9O&P:9LX1%[0::P81*1`1M^P1=LP15BP17>X`WZP!9V
M`11]`1MZ3=E\+1N^8?-,[QM^+3Q0\1J"+Q(B`?AJ(1-H015DL9^JH1:4+V$T
MR(<*K!JZ(:*"4$CZ0:6N9,',(;S6@;S_7,JX=`0>?`C"&.P>=F1)_L<<PD$<
M?F$6Z&\6FJ$9B.$89"$0^&`0Z"\0!D$6!B$6C&$6RG'_PJ'_RH&(EB2(3FI)
M8J&H&*(#.?`$'C`"Y8$<Y$$8*K`.!M()_:$%_+$A$]#(^*0'1]`#ZLP$+0(?
M7*<C/``#;P(QU(H!\*C*&D52(H>0^`$=.D`NH$JP:E`B?Y#JT"*S1I`,!,L(
M>5#)B&(#G$&3FA#/[H%S[FZ5].&29,X9:&,+9^-9Y*(#U,'M],$9<BXQB@%[
M:LDD5(('F,4.<XLTGD?P9HGPJL(2L\$60N']/-$6.$\;'B\<JH&\#K'8PNL[
MB"T\[*=\OF,;_T[/%WPA%OK@#=2@$]\`%VY*]([!Q`"S#_H`%$S,%4!!]?H@
M%D"1&L9A]GK!%W9A%W(A%WPA%W;!]*CA%RZQ%H1A-%^A%O&+VS*!OG:1ONCK
MW:11P%:JGT9"1[!DP`:"(&K*_^I1WZCQA$Y*'N;AYOJMWV2HG<H!&<C1&]5Q
M'6=A%MIQ%F!!%MA1%F:!%ZP3.7E!%DS,'9U!'<)A29IDP=3!'-3!&$[@J!;"
M(1?P!)Q!'M`!':[A&M#A%2H0#N+S/=&!'/Q!`]6S`[5*;S+"3/Y&$)JJYJ"2
M*&JE`2[`&?;D'EA@K6#G`>+@*KZB!HMNR]HAL0:``S!GR_IA5S;B<O\^Q<UF
MDB<'2ZU0-%J"R72\0ICXP>SD80;.A`'LCB,^X"B.HEBN<(Q\!2ES!3<$$!]N
M270$833$L"_(`0;L1@*`X45U0Q\0H0`5H@?6`=&V\K8@C2J80AX\ZQ)W@3%=
MP140DQ9";_0`T;J$C1IZP15H81HV+Q=HP15LH1<DLQ&_HQJR`3/CM!/CKPS@
M[PW:%!M2[S`UD<3"]%`1M3'9U!8VD19J`4YM`5)#,4[QKS1?X15&T[[$#1IF
M435KH9_>`:(2!OHHHGO@H1^NQ"#Z(1]NLQ_2H1';J4;<P1Q\Z*,:C!ICI*44
MK(B**!S*\0T"P15D(1BD<Q:.@1CZSQF2H1G_>($8EO48D`$9VB^FM#,6>*$9
MOJ&)UD$=Q*&FO@$99H%KX*0_$]`$P$$>BJ$8[E,0ZO,:QN$9TA4&$8)<-U!N
MY.B6B$>M8B`8(D5OTJ$.S&9P)*#)]J0?BD$"1,DC8F`G]>A"]Z%1G$%)1Q`"
M!&'+-(<?0)13=M*M(JDG/*=42@4<4A)%&:`#@,&3]B)EO6(8/`!5.@`.-/)5
M^H(?VD%B$X-`?10?=`?MXF`FR((,D*4I2"U4.@("7B%G)^6,%N(U?B?PY'`.
M?6<WPN$79LHR+Q/%1K%,OX'S9H\6;`$3;6$:]%(O,],7J&'VLF$:Z)0:D($:
M?&%-$9,/$+,/7"$4_V(!%D`!,'%!]+!A$_&/%B"3,WWA%R:U,GN!42-5<,V6
M<!F3;B]5#_0@->WKOH"/%LIC%WF18]XA82KL-JVQ.4B5(`RB(-(A')"AIGAS
M2<H!:3H*PE!JP:*M'`Z.%Z"3_JC3.H]A&)H!&<2A5[\U'+\A'+(A6K\A>)U!
M>(\A%W@!&985&9SA&)K5.GEA2\:57DU@&T<S>S.B5N`@>T<3'?B!/^EU/>E$
MCNI`(_+U`3X@#Y;!<'+B'H"!#"X`51)4`\HJ)VI0$)2,5^R`'!YE31XG<=`!
M8'MB*/#&0K]"4W`0!MGL4:*N<[(.S30G&.R(*"*`#(H!'];&+MSJ'HJ!#/_>
MB`&,=LX(`Q_FH9:Z<"B(`@)F(!B:)XZ"-A\JHAWT("H5:^Y(C6\ZX@'R(%NN
M!<@:P@1@0RNQE)9,+9:\$A_*`6=$#_1F:A)KK_2:&!O,-CQF;S*I>!?TTFW?
MMC*Q@7BS83-S@5$!%_\>$11_81HF<8U]`1=ZX3+U$AO"0?;*]#,Y,Q?P+S.U
M6"\O4Q=T(1,@-Q/F2[Y0L_C>81>E@37?X=W&X81NDQ]VQDH*0@`-(APLTQ>0
M8?2,BZ3^[3N4$</*01S(H7B;X1=R019T@1B(H5EW%QE:N1G`X3MYM8C&$W7#
M(7AK2AN1,QQC:G>;X1B281F((>42PB'&]P2.`1S_1E,T=6^R&@`$O'<T%W)\
M&1`%PLH?!*%&.V(L),`#X"`/!$&T\LH9@$$0["`&-&"UB*(!HH5/$`<C]O=L
M)&`&!&$9/`5[TL$97B$/9$`"^D8$'\`.)F4'7V(89G0`"JU5)(DC#NM36(5,
M2'8L(B`&\B`8GB$=EL(<GB$8\@`&(H`LR`(",FE'2_A7\@PI@L$,=<X#[``8
MEN$RTD$<R#D/:$`#&*DC8@"W;.,>SG>'[4`V<+@OV*$'?`D0N,)8DI@TO,6S
M/B,W<&L\&K&FJ`L;BE>JMU:Z)K,1MZ%X3X\:+'&/QQ8T!]=M?X'89F\2]3)M
MO;CTN@&*MT$;J@$OJP$;_TSO#^UT,K/!2R\3,\<8,B-UCWL!<B/W4^VK%C.A
M%A+F&FKA4^7A&KI!'NHA@&IH50FBP9X/5565(+[A,G\ADVOJ?T#;P;ZC>)&A
MJF5WE+^AE:$U6DN;&OJ/M:,U-[OU.]4!2,R!B'+3_[RU6\6!WF!W28"X'^GU
M!)+!&81!$(0!4_5@[.#@4IU;&/AA7JDY`7G`0&5@M4;P;!K@`<3L`2@G7^T&
M`N)@'_J$Z!XEFS^R(QH``BY``SB@`S3@`B*`<@+%;R3@#R[T+L*B<@IM!Q>Z
M>$:TDE)Z<*1NNR-``SH`OC]Z,`I8I-'B"LD"5TQZ=_;(`]8NNX%.`C1@`]Y[
MT?^^N["4\`:V(I;P(4"_*GH\BS16IUEZ24X0`7J46C=PBQU2?):80S[4<AMR
M2AM@57:#[?90D;2'[6R_@:X_DZHKL?3<EHK'-FM+3QM,#ZZKH==&[_/PTO3P
M<ARVVA(OV6KAN,E]@18B(9!K0;$/&_@&ZI!K$51_0Z2PPXH,HGN>+VM$]Q[*
MH1E$3QN"USCY_)OD`\-R679%N5<%O1Q2$9=OV71KJENCM951EXB01AWR41MY
M%1[8@4B(1(>BM'K)%2#UN1#T0!`*X7S7"@1>(1,*X14$@5]3;GR)+`%=KN;\
MX15:5KUM/0GM1G1DH$GSI@8-QQEB`+Q%I8!S/9=BH'W_V\PKA#!1)L>^-U:0
MB!;`#<FAG6$&-L5O/#;;M[D!3+9Y]&%'*VLV3'I2P"$.]A>\L]UO[*8#!`%*
MQ%U_[68&D$E;>.<>U*$%N$0$4,`85*F8#"_&8]Q;C.E_OJN=_"\0O\,XOZ.)
M18\N:V\R3U'TMK:KD:&LAZV)B>T47R_CL?SUTK2N6U'9&+ZKNWK(J8$3([<T
M=<&P@>\:(M"^#IL<R"&#(/LWY.&R456#^.'Y7G1TYT$W^=PX_:_'YT.&/EG?
M9D0^FE$^U$$=<"H/95=UA;?_3)?JQ:&)UF\\<P1*GF3#[B$<N$:X^S,$1(X8
M0ET0!$$/\*`"04"P01VZQ7<#_Z]*`4O`&/1(U@6AGU&%>,:"V'-]GN_7(BM"
M$%A`(P+E(R$TW940!BJ6D!"837JPD7:2"5&0H4VT58`!!B#`[R&T<OJ^`2R@
M#M#AS+Z]L,@(6"8E:/4A&&;@C7*]V->*`^P`'&J#U*JB;+0]!DK+*HB%*F<I
M=7)E&31-(40@!#B-B&4<J*4'7-K)'9!M&Y!-/M!TCCL/+QD^%6\/KQ]>V-K6
MJ\]6]%KQUU[O]3A/XWV-V#(>]K1<QZU8RR&^]K;Z]``9<DMS%T\]YA-&W&J1
M-5U^'WPQH@"BWSYY\O89%-A/X#QXY>`Y-.>0(4-SY<)5+$=N(L-R$,V9<U=N
MW3J*ZO_*F3RI3MTZ>"75A7L),Z8ZCQ5G>DP';UZZ>??NK9LW;\>(H2%&B#B*
M-*G2HR>.#<L#58\>.`\8-``A-6LA?CQ"+$4Z-&S8I"CJ^?/'+ZW:M6S;JG66
M)X:&"`T($!B`=X!=`@T@:(B1!YW;P83;!HOC@>Y>!GH;-'APX4.=8OKT\?.G
M#S._RIDK8T9G)[2=//<L<_;WRDX=U<!.<W[-F1^^8G4\7'C@F#'>QQ(\Y'$&
M.U^PT'7J"*J,+[ERY?J2-R]FAX4$Q7OM.H[0@88@=K*3LUNN/,\,,C?@S(#C
M+'D[\.S;XZN<K$</'O-[('+_?7DZ\.OUX^NO'GCO=',2@2?_'3A....,D\TW
MV2R8383:5/,-@PM2L\TV#RZXS3??;#-.A0LFF.`V"F:8X3@8HJ@ABAQ64XZ*
M(RY8H88<?DA-A-_T\HI4K[Q22RV9#)G)._*\4\TU0DKSSCM,&E1/DP899.0^
M_?24D$(-.=30.PV9M!%-%5%$$T0<A53.3!Q1)))))1WXDDLOF>.2.#%Y1%$Z
MYMP#U#WF\&0/G_/P08)87QW*U#'%X"$5HW`TP``#6#4JE3XM>'6H6(8BU4-A
MGA+6CS."Y%$'#3/$$`,-<=@A2'K[6/9IK&N9QH\SP0AB1QQP%,?J,.A8AMEK
MP6(6[&EIG:49L<9>!IMKG+UW#[/X_SSSRA_%D1%''7D`TPP^:2'77&G#(O=>
M<\RQ9QD^Z`"C1ZYPP)%M'J\XDXZYWKEWCWOJY8O//0#J"]ZSW2V7'\$`'USP
M?_,<Z`Y(X7A3#H@Q@JAAA!A^&,Z'("Y(SHP-9I-CA")O/,[&VC`888HN;DQQ
MR>2PV/&(,;X4XHT@CZ-+)H($&>0K0]9"SI'75%--D.0@><T[5"I]Y3Y2]L//
M/0?M<\^97S9$#D4G642F231Q?>"96HOTTSQDIUF1..6HW5)*)='I$5#SF)-.
M3W;WE$\^X:!0U%"('FJ"HGK4,?A4D$JJ!QYP)*X'/SM@^I6F?2-%`B*R7KZ9
M6[!BSKE:R/]>AE9;IB&;F;+CENZ96LU6MAGJS;9>;.NQ70:U;)K)UARX[^VN
M7'?VYKZ<N;]W5IH^_>B3C[T'_Z<<O^TE[)[RR^L+_7[)66^]<M;_:T_#()7C
MI4D0F[1-C#/2F*!%XYA/<H@BWTQ-R1V&V"'%&E:#XHHLEBQ__^.X<SX1A>A$
M*+L&,?0@B!]E0DA#(@9!R%&-;BBI%M<@Q]#(L31X6&D@];!2U`8BD'MLQ$M<
MPLCZO.8.,ZU):V4BDSG"\4*4M,D>0!F)F\[T-I7@R1PB\1.?>K(.'_(I'_;H
MREC^IA02G.`:KUC<5!1W.*S4P8EZN,8,0@`YI82E;YI*03XZ!\;_,(IQ,\0Z
MEC_Z<9;2F0YU:23C:8JEK-4)2XYR]-;JRE4N<.5.C\K3W?"FIYQ_+4^0^$@8
M]-@S,'WQ:SW.>UZ`M*<?=F2//?-P!T.\]+WO-223Y`#)_TY8/O/YKW\;HD:%
M,I8-BFE#&QE:Y4LRA+\.94,;V<"&RMIW/@:94D?($-DWKL%$GQ$I$WH01C&<
M-C1@2B,3U3A:!(TDCWI(<TK[@$<'$[*9:IK$(A>!B"5/TA$QP8.%5O,:#&]X
MH)*LPR3KL,G;/,*2'?)P3W\R6S[6D0^>S(,=[#"&"8Z(1*2$X`3%$,:[%/>N
MW(#@70QMW`NRJ$5-:6H/8ZRH13U%NED1_VM<Q6K6L.#8F<[$<8VP.1X=88/'
M9_W..?8:&+D.!CQ`&NQ>!<M7P?)S2)FVAY"%Q,<D`<;3G^(#'MXK:CGB$8^P
MG00>_P-@.0B$HHB]3&4D*MF#'(0-;;SR&Q$+AX96^0U6;F.57UT9B%X6/PB!
M#&38.(8OL.%+:E"#B7H0IETQ^(YK2"-)RZQ%DX@6#VG*(QY*VP<_B.J.#EJI
M24U=4,36!":O[2DBXW3(0C[2-8[8*6QGN^'<0E)/L\F-)WKRX9]\$D21S,,>
M[`@*0`,J@H%>PZ`,36BD%OJNJ<!!'UU!E$3%@@+N7'2XQ&766=8RTN*9[J,A
M]0QL."I'S;Q&=O]UW$Q*4:H[ECIGN[YK3C[`XZ]]Z#20_NEI(0^94WU);[S\
M9,]^OG-(0?8'L>Z(1WV]QQ!O?/.I36W8^DPTHG"D<AMR75$L,T0-_)7#0:ND
MI3:0L<I9SE(;687K*FTY8)6E544.0H:#=&3*"NE(@3[RF2Z4EM=:5"/%F4B:
MD\;QC@YV4(/\*$<$I=DD:92B%*J`!C2B(8T)K2]CXA"'UKY)V<O^:9UTX@@W
MPZ%.M)UMG3:!2-F`LA.?[*F'<2.;G]C1$T24P&^PC:UL:U%;.(#@<!U(LQXL
MA<5,_78H%"VNG2L:4HVB#HW*<F-(X^B9V,%&=AUUEFG2Q<?IYI&EN-O_8_"`
MMUY\?#>FXV6OP=)[+IWRE+P`>R\DE],]>-`C'O1%JDD:=NJP::,BV@AK.!J<
MH0IC8]:T]@4NCI$-M^)B%[NPM2]^_6ML3&,:M93P^W34OA2E,D<HDVN#'-0A
M$B\P$Z\@AM+J,;0DD4-(U3A2!.-!D!B_`Q[\B`<T3M&->'`#&JI01"(2H0A(
M7,(4I_!Q*2+A"EGP@AKDX!H,,SM.,9F#'$Y^DYI.8D,Z^7N'.P%*F<@&<2[_
M$!X\('.9!]H,09"!H2``P0,(P(`VU[8.]WB<;W\;`A1$Z\XL=\M&ERO2F*]Q
MHX%V+NMB;NC3&2\VAA[T25FZ1T>G]%S"XY?P__3U78#IHQTY36\[DL=I]6JZ
MD<FAND_!D[V;YK0=]%BU?LNA#7J<VAL-+ON%(4SA62-CUM7(QC1\$8UHX`(7
MO8C[KW%A"US$@A:QL$4L^FX+6^PB%[W8-;!_30VXUG+6B8??.#KVC?@YR)2]
M3*7E":P+GY6XQ=%,<9*0M,`F#:U)31IL-Z1Q"45P01'W3H09L'"%(UP!"V:X
MPNK-8(8C',$,;Z`%-2KR$LCB"9SRS"R>N/DF.^TP:S>9FY[FQL.(>SFTQCB!
M4<H<6Q,L0Q`QV/B[0,`7`HA<S>]R'$23PD6Q5*[E[&?+<D=*NIGC_,]J3",<
MU6$,8[2CT!W5^4D5W?\L[Y$\*D4N0O=2*\4<D59IRY$O`.(ORV`,B*`.,J6`
M[&%US$,]T_-38$=6W=`-%V9V()AVV!`-QR!W<X<+;P5LTX""=Y<+K@`*@0`*
M?Q<+L&"#L%"#KN`*?Q=XMM`+O6`+N0!LU.`+OV"$:Y4C,'(A(S(_$.(BQ"`(
M4D%M"70-!8$D*I8T2I()W3!820,/I%<-J>=Z67`%97@$15`$"J``1>`$LH>&
M5U`$"[``5\![M'`-,P,32L5"90)#+5%9!V<.1N81XJ`G@H@G.L$GI95:J!5$
MI]43>T`"V!=;!"4(,[!0EU@7#=!F'0<'&U=R<18YZ3<4.Y`/M=-^[&=_-9?_
MBC(G<W'D9\N`"(/0#I5A4O[0`R5P`LOP*H5V4L%"7734:,\R=)#F:"N57?RQ
M:<GQ7?S"+]"C#HB`",D02,D#""9@`O?1/,GX4@M8=3V5C(1$2-LP:ZPT@F8'
M=F"'#&MW#"9H"J80"Z$0"K=@"V\U#=C@"[N0@KZ@@X'0!_T8"*Z`@WF7"P.9
M"[L0"P19>+O0"[N0=[N`:Q*B>+D4/W*5(@MR(@HR#L2@>765"<)`#CBF8I_W
M#D'2;>\`8W^%>HIP!4[@!'"(!'$HAPN0`$.@>U?0!`M@``B```EP!8JP!I'0
M"QX2,QGS#3$!?.%`#AY2E'?R0C`T$L6W0T8V6C]!_Y409S>+R!/J\#CG=R@#
M)2H@0`:7N&9\T0%B>1[F=W*:@@+J8(JGV'*E`SIJ)%(?E2STEXJ7T0-*M`QK
MQ`,B8`+&<$:NT7]T9%(_MSI01XR[<W2*"5/(,TC;M1SKD0^(8`(EL`>/!HDD
M<)GM<('1(VG+TX#\(9KEY5/;\VGXH`VX$`WCF'8-EE7:<`PA>`RV``NX``OP
M^(ZUB7>NT`>!4(.@\`;\&`C_J(.P(`N\QFO`9H2']PNY]E:*1TN6MR$?LU;O
M\R$EHPTQ0PT](A7"H`>Z``_VX#2]@(5_%23OP`].(@W20`N1D'M$4`1G6`0J
MD``[&9-PB(9%L`3UN9.[Q_][D:`+2?D22;F42$D.`BH.(=)OX/`-X``.XO`-
M148.AD@W.Q%P#@=/-[$3=-,G(L$.0>03_7(/Q\`W2\&5`U4->M!Q*SJ6XL>)
MG,@.._`WDG.-;NF6];>*,`===9D9:]$5?_E17!$"0)H/:?1GF%&8_%"8_T='
MLSB`Q:A=Q9@/ZX&`SI$WS0,>29=T_S*+S2%F(=`#P8,/Q[`'>[`,C]2-`<.-
MYN4O[I$.V3-)`/)3H/`)H8`(MY""LY:"T8"/-NB;O69KO!8+@<`'?-"/?/`&
M;U`&97`&9?`&_>B/@2`+."@+M@"0@@>HOH!KV"!7G%IL#^9+8I4C&"(RH]H@
M*#/_(JU6,LBPD0D$GN)&DL#D>=W@))$0":Z'!44P!#&I`'+(GSL9APD@AT"`
MAKLJA[L';[20E`07?`1'$0,:(_W6E`P:#M0*$QX!0Y55?..D$Q@*?=$7<1XA
M$NF@!R;P-UB$KB9`#2K*HBVJ`>T*!^E@<NB:16(1`IIIHVY).JH8?\Z5BAQU
M.VGQH\=0+%_4`T,*F.NP#!/(BY[1#NJP#/O7B_J0$GB4-\@#L>J0/(W&.\[!
M#^K@#.H`9L?H'.RPL*4!F9RV=/U22+/X'YSYI9<92/<P@%/*'@\+#F>ZC<R1
M$@O+LFFJ+T)U+^TQ2?O1#F.@`F5HJ)\`"J%`IS#X!FK0_ZAJX(^/2JAH\`)C
MH+4O<`4JD+0OX*B]2:D$>7C`1FO(QDH:TR(,PB+Y0V"19S'N8WD.XB`JD@V_
MT"-O@$#5=C1?&*LN5C3MN0;O.01I*(<*@``+H).+FY,&D`"/NP!%`(>1>Y^T
MMP;@Z37C)*UG<JUI8B=V`A-%%@Z@NUD#^F\!MZ'-9S9^,A*MZQ$?^J;F(`]\
M4`*'0@(H@+LHL`(I<`WLNJ(=4!<$D`'PB@][@+LI@+LGD!2:P@-MF:\L]WZ@
M\WYVR4:!Y@][L`,H,`(ED`([@`B84:0'>XU[D`(G@`+>BSROD0_J8+SFVP)[
MP`ZPT0X]T`)\L`P]@+O+8%W\T/\.>]`"*'`")Y`">Z`.PP,(.\`#QF"\)H`"
M+3`(O",\[%N^`@R_P>,,//"^FW$/_3`(+=`"LV`NR<`#*3`4#;P'XE`NB+`#
MWLL?*@S`*##`A"3!+]P"B(!I@O0=R7AU"?,O6#L&9=`&H``*L!!X[]@'B*H&
M6JNHC?K#C5H&:%`&:O`&>\`'CHJH@8"#LU"0RREB#8(B'R(R%O9JKX8B7H4B
MOE0_$6(A&Z,Q;#LBW\"==?4*+E8/Y$`+6,@DVY8)9X![1Q"3BJN3<KBX.FD`
M.5D``:"3":"K<1BLCUN&8[`&N;`E$,$E&S$F3Q:Z,"2M`[<F$^I"3=9"H_5\
M(\&('TK_RK(K#WM0NTJ1<LL@#N20#@=Z#9G0<64)`L!K%\/;KO5"-?O!6Y!#
M%"/``_;PO*?X<C4WEZES7"05+.$KBGO01C^:`B10`I&8<H`).^HPS=1<NR2P
M`P7,&>K`-RV0`E[QEZQC#CS0S=5\%"U0+\@AI"9`PB4P9B%0`CU`I<ZQ#-,\
M`M3<SRWP*\KH3R+``TM7I'QP%'R0.\90ST2!`NC@+?RP!T<!"%7'F:I\%-6\
MO=]L+OG@#"T@`MM;S?:\!_WQ+YTYM";-'CAU/?@`"T.<=Z]Y887GM+SY"3H(
MG&\0@Z"@@S#H"KF@=[D0"ZX0>$*XG)Q:8&W;2M%)5DK-/_(S_V"Y9"$DDB%>
MI2`6Q$3$)`B%$`P5)'I!`DR?M\=]C+@(4-:#C-8"T+@!H-8'L),)``1#``1Q
M/01&H'MC8`:]<"`2`286$1-_C2=ZHB<K=$,VM!*CM65S,S=7V4/W8,H]43=[
M\$]DEG+-\`?>]WTLV@'`RP#">\NVC%L-=0]]:69#00(%7<S&7+WV%W_#PBPX
M9SH1>"F6&8U*BAFD?<^(8`PR2M#\D#S^T`Y"80(]$($\4"C-2XOB[)>W2Q_J
MT*6$(@(I`(TJ3-'6]1X'V\_>J\#_5`*#0+.25G+;:Q^(8-S"[#S)8`(AP`/,
M`0@BH)FY(PZ`L`<C$`+UBPCMT!^0./\">[!TZR%FM\L'$4C"^VU2$GW<NKT'
M)X"PX-%>6(<P;KH<(;C4$<*G@9>"O?8+]G@,O0!LR4F$1?AK;^=L(&-*!(:=
MXI@A:HPB8N4B_7-+&"D_,1-`)E(AP$17>]O5M)I7"P1,"U0+D8#71B#(9BT`
M:HW6!L#6B?NX<\WD<XT$6;`%8%`%6U`%2F#75K`&U"`FBAUP&;I-`CIPYU1\
M(@$/JF4VZR#8?W(3<2.N:NX1?J+86";9%G<"X5`''?`!GUV6FUW+D"*\>\[G
MF[WG((`.!UO:][PYJ?V6Q\5&@^DZ,T=2O#4"@9,W16H9/7`4/1`ZRZ"\*/#;
M_/#?_'T6X0W_I)6Q#B@06RU0P,E3/#U@OH"9&>@=`OR=.T(Z`JI^//Y`F2&0
M`NS0I6*VWYP1W-MK#)-V#.F]WLX!W8`0+M$2L_T02/H`"$-Q']^U#I=RC;E#
MHBFW#DO'#YA>`I;S18#@P<;PX/CA7BU-7JWU5!=1U2C25F[E5D5XA)XZXBE3
MJLJ&(2&S(4NMU"VR,DQ8D0._(3)"/^>C($A#3'I`;;I`##JN)-7&0'ML!7Z\
M`(B;DP*``#G)N`$0``80N4S0!5W`!5TP!2<_!6!`"9:`"9<P"9B0"&UH!59P
M!K_G-9#5$"010P4:YBOT)^P4$F2#9=^Z$!>J)S^1$]`W6D!A38A0_Z)8A`+4
M<.>`+NB"G@&10@`:(.AZSO7DT%O95V>*WGYSV:^L37/_*IB>47$G`.N9@48_
M^KV6<0]\$URTV!6YJ`_\I.MC1NL4RS?7N*25X3:5\;"0*`(ES1Q=00(*[1SI
M@.V`^1YKGPS^\G3`O@=))^O)GAS0#<W+\:5A:G3Z,-\C@`A3>@_H/0([`!Z(
M``CW[1RCCP)[8`S/L,'H#N':TQ]&Z^`M;<EAL^)GNWB*YV$E`\8`S[8?)DL>
M`B(X\FK8(#\5\^_^8S].;>+26;?^(T'<F4!=[0Y_Y3.UT"-G<`960`2]JKA%
MCOY&;@"'[/$[*010,/)B(`9?(`:4(`:54/\)EL#RF,#_BD![9P`08]Z$*U?.
M7,%R!-49+&C.(3F#X1RF@V=NG;EY%LNM6[>Q(T:,\]*ELRARWCV,]^ZM2W>R
M93J4,"L>:U$B1(@3U^ITX-G3)T\"03/\)`HB'8\0(D2D,,;/Z5.H4:5.I5K5
MZE6L_/QMU>=/7U=_6KV.!=NU+%FT77F,,)&,JSY^^GJ$,&',:[]Y*4*@8-<U
MG]X2*5`(1H%BQ`@>7OFI0['WWE?(7^^I`]1C!PH3)$2$V,,/'V0>).KJ^XP/
MWYX0)1#%;==B1.#"A$>$X$':GS$3M$FWTP=(,Q_3[4PCLKD'G_#/^OB,(+%'
MWV/B(XR;-BVY-#[_=2U()"V!8L<>=-3%CZ>./#AYT^R.4U=/'5Y!;^6ZE=NV
MK>"X^MK"U=^FC3_^<;X)<)QL"LQ&P``-_&:;`[?!;QMJ\/./O_\`=/#"^NA[
MD$$*"XR0&FH*!'"<<:BYIAQJ7M%#CU>$T>6::]ZIII9,],BDQC/&Z$"!!190
MP(``!!`2`2(%,*"``()$(`$@H.BB"S'$H.0+2JJDQ!(L+<$$$U8B2>0,,\R@
MAJ&$##KH(#,=<DBB@RI:9YXWX>1HSC3-(<DDF$Z:1\][]ESIGI?ZW-.<>\39
M`P424`@'CIZ&(BJ#!A@@0`*B>'+T`W+6,J$'=K+R]%-00XUJ*U+?,BLM_Z_@
M(NNKL=[R!ZFV(O-JKKI2Q4<O%"+32[03>NT5A1.,^XJQ$%+@+;*O$$%!J1-0
M:&&'[?;(A[2O8#6&M'P^V^,U1/3)IYU=?147A1ZJ2\8$$6HSK1]`E.I,/.)"
M*)>ZQ[8E`3A\^$%$,^/:N:<Z?_"YAS=\\E%GCQU,L"D$$E(XAKQTTA,O8NHH
M1D\\]82+&!YW"NK88_O&0:@<$@ORCV024R910`=5)E'$^A#LKQK]6JZ/Q`LW
M_(^_;.HS,!MLJJE/Z)['"6?E!:M)<<46@WGQFEIH7#&3'(_@L4<$!`C22"(1
M,,``(K\NX``@IN@BC"_"D.0+2:K,<DNX64G$C/\UUJ`E(H3,(:B@A<AA4TV'
M%C+S37OFG-.<BN#<,W&'^D1ISY,(]5-0E0A5R1@>4%BFC@P<[:#SSS^'5%()
MA@(==-$_0&>/%A#I1U388Y?]J5-9+=754U-%%:ZR8#V&5%6M)17<O=KQ*I\=
M]C*&'76:=UZ]81M+`5FXP!4A6'78R2=>:4OCAP<15`LXN;E*:,JTY$\PQGEF
MFG<&.7YP2_??>_K9@]_QA[.I!\^JZ^TP0%#'&/LC3740P0=$].4\^F"',Q!Q
M*,W,ZV(3-(W%(D8Q\V",8^\IQSL0X@YWC`.$)!NAR$9$LJ.I3$#9(-""6$@@
M&%X(&]F@&85NMC.?80C_1"!26L^`-J&"V`=E"'+'-LBA(D%D0AA1(T8M:%&C
M-ZRH:@I0``)^)"0!$$D!"4!``8YD``&,#0A/R$(7OG#&+TCI2EJ"VRK@=HDP
MK2$2WS@:0>P8$754A!Q^4Y.9RB$XCMC#(^6`QYL<4A$[.01RA"(43%I".3Y-
M3B7W@,<QX`$'TW5.DYN,U*0TL,G0:?(#S;M'6&9W2E1B!2S`PUVK:K<JLSCE
M5+[S"ZNLQ;N_B``%^4C5ME33CWYL!7,\,$8_NL*8I3P&6<?(#0_R,2U][$L$
M>WC,9[YWDQX8DS3K:(SFGJ,/7W;K*_T8IC&>J8]SC6`'PN'E_4@`B/[EBWOG
M_^&-O::##W%TTSR,&8&Q>',/A/5`'=F*WPE$T`(*XL-B%1P/<B*FGH6*QQX@
MI&@\*`I"$=[G8P@1&<I<=J$5,LA"#Z+/-E*H,FV4%&<YVX;2ZD,-".$P0_S1
M4,M*1"(5Z4$8P7C%*W3QBAM%48H@J&+8O@;&+")@`0G@XI$*`(0@0($*3_*"
M%\R8QBMA(A68<"-7,6$-3,S-#(_(QAU'UL>1-81-'N'('T=VD8@`#B0I"4E&
M(-<2Q3T24)+<QS[(<+I,<I)TH-QD!C30`70XY76I9&QCG\(5K9QE+)'="F5S
M-]G(:F4MJJ'66&C5%'[LHQV(RA5D<#."%BQC6NK8`?];W!*]@_)&FUTY5[$&
MFH]E[$`I/9C6M/B1/!&8`!'MR`<[0D.;@N6#G";HYS&^DENV7"MZT<V6LABV
MAWY01U\E2)<X*#8M/I#@G?1""@DXI0]U].`PSA'8;\.W!W_A`S?(Q4=[+I9!
MAE*08A$3#CSBX5]WT..B&_5@!\L!0G*8,(0N8[`1;7BS$=FLI!I*V4SI@S(,
M9=A!+.S/A%CHH7&00Q9Z$$1/>YH)H.KA#"JF&A&ZYK6D8I%'3*6Q$(30!"E,
M80I5_8(7SM@V2Z1B%5WE4I'AB(4W1*@AB?,CFC!BD(R\R7!MY1M"%B*X/YZ)
MD9"#G./TQ(Z[=ODD*OEK80O_*X&@$``"9BYL!YSA6#C'.<Y@X<>VV(("1%3V
M>]$EU3UPQ8Y4@=,FSKJ,")IC%GV80WK)B<P]6J`4[^S`H,QR#F1:*YH2[.`R
MVU%?7$ISOQ&<0-.&.?17/M,#9NV@!2?(S#0+^)EEY*8[/$A'MO"Q'.EDBS?+
M('4*=I`"$HP`!0,U8&8RK>G,"-?6"848L\E#CW)H8\`732M',9I@CX:8P2J[
M884L-%,*X>S;#^8/3&&JC6H4:(;8F*&''$0.7;!(&#U-XHVD"`<]@(`(1:VB
MD8X*-BXN:0%%*`(3<KSC*IQQ"FA<(U>WZD96;.D2D5C#(ZJ!R+P5!")HRIM#
M.E*0_T"JPW"%&Z1']K2.QZGD(B]!^9@A":<^V6E/^\"D83OWR4]V3@(/X+D$
M/BFZF]N\`^`PI9R-?G11M4H=*2B!>/>@&'[T@`0G>.USF&ZL1N]ATDE!@;!8
M=0]$K1/1ID544J;>@Q1L9@>,;JT)#E4"YB0JSY#)5SNTKA01A!J^QRG@,FJB
ME,#L(3.`R%]]!6]H%%@,$"7@;,'P<9N:W"0U+4B&MZBC',/,ACDHX,._T#,P
M\>"WH?7-F,38H;$#I[0<%AVP!SWXGHUV;,$J6W`U$ESA"H>[/N&@8>\+E&X>
MTFQ!W<YPB+)!C70?W_CI+A$U%C2.:^BB$"8N,5"I%@DXK/_8"@H@0->0"D:P
M><T`"2C"`H90\"94H0I9\/$9V]^VK,9M2V"=>"1\0::$Z`TA$@G''?N_M[T!
MI+<Z'(Z0D[V2N0*4G'O8!Y13B7R0G):($Y4@AE>8A9[Z*5T(!IZ:A9\"*@W4
MA5I8HFL@AF`8AF$@!F+0"J1;01:\BK+HAW8P!D1`!'7H"J=0!V,PAE(R+42X
M%MWYBG#@@SW8`SY0!UC*!QFL.LBX"W5X(")<!G]8AB$4IZ]HNV-HPB$<A&6`
M#&AZ)GY8!B'<`T"H05.;EL](!R<<PW680778!VHYCAA$A$$P!O%0AT&@05-C
MCP?J@3U`A'1XM3K<PSZL0>1`#L__^Q?\LJ_SR"^%8L1_@0=ILRAI`R%XH`=X
M>`],Y*`#RRB,FKV.4ID(B2D2@:F8H@9TFP;EFP9JP`9?F`9?4+?CRX^?,3<(
M*1H&41ILT`9M4+Z><9!OH$!A$`0;23$I4K$SL`*O24:D$A*P`9+Q,S^"8P(F
MP#$=TS'WPZHU$K)58`5K`"M64(4WB(1K0!S\>P\M0Q-SK+*TRB./*)Q+7)R-
MB$>YRHB02`>6@)P']+))6@EX4`E[Z*M]!,AGV@<5O`=YD(<]4BQ@TK,6;$B'
MC"RS6*Q6@8H?O!U$0XM`DY7:897(X*588A5^>)W(:*T3<"[+BXO(*`W;^(I\
MX(=S,L-J__*??7BFXUDVQPLT\6A)R<B@1BN@/,S)8SD60!2]1AR/AV*VTL.'
MB9HV2H2'=YB'=^"8`S,PBB*1!'.'VULI<GBI$'FIGJD&7VBW:E@W;/@%Y)L&
MM&0W7P`1"$D^Y*M%#Q$:!NE%_WBA4*0&<@#&3)B^)%*Q-SB#8[2"#A`_L,$B
M,"*2)`$X\B,X)6""):A&'D,C^-N2(6,%;J2_2\!+CCNKBNC,,RF'*+.(CIBR
M=BQ`NPH<0TJ3=7@/NZ+'EC`'=B@)CG"<EILD/IFD?'#`^JF?@WP=8%(N7N(E
MJ%@LL6#(ASS.V.$*X%E"N*`=5PJ+4W$*W-&'8!J[BZ0>[!PG[/],GRWDG>S,
M3D:C.VIY0T!\P^H0&'T@&/(`1/&@N\OSR?0T#=`;O80R#T6<F/H*/:4L!P'K
MSTL$L)%Q!PXJL`.C*$)J,`C1-@8)$>/[!;/T!5_X!78SRQW:(1IZ*0WCD*'I
M2MW;D`5AT'DKA$SH2QP!3"O(@!_Y-RR*L20)`+#ID:4:`B-8`BB`3(9S&RW9
M1F[D$F[LAG<@AV_X!G'P&W$(4CJ2"+PAB,VLMHU0'#C!""F[!WO@,HR(P#ZY
MDT5*G#=A!WU4"9<[B7[T1Y78AWUTBGO@A_IY"M\<3E,")AM$3C@5E5<JE3>5
M3HY\SN9<E=T)-(R\SE:")9+L3ECZ3D+_Q4[/<,_QI!:"\<GK&(]7:X?X0M3T
M_"9O84_R0([VN,_T:(]T4,1V:(]_Z1AH\P;9"["-\IA3U:@2\L11;!`/^1EL
M.`9L6,49DM"UY!`#62D`(1D,[44#V1F=0;X@A9%7*+$5L1$]J(,5@0,KV#X!
M(("OR9H````L:M'$5,PA`((ED`(JT#$M\`(U>ANO`BMOO`15Z(9P:(8@I=!O
M^(5O4-<`V:,C!4"$&,W%>1./@-("C!-ZE)/9'+,WL<<^:<`_F20RW4>$/=A\
M^,?Z:4FG<,,S]4*''<[("B;BC%.,Q0J+U!WC3(M7HLA7JIU@TE..M9U"W0,^
M-$+(B`O%V$AD_T%)ZH%9\.2=F#1#2UW/\#RGZ_"7@7D.?R'*\N`OAH(HHUS$
MB%$)B9*VE(J]E(J/A!`9^]#%^X`(E_F&X_L&!@61M021XS.0&0K2=ON9_-"]
M#<50<B.0!_M$`;D&86`19)4BP#P#$+`"%XO69<P:``B2%A62`F`J($"")NA6
M*CBX,[(223C<28";+4D$)\`"BTLA.C)29#`:.W(R=02Y0HH3T5P<>.#<<K"'
MNFI-Q?$RNZ+-QYD</K&'!5Q=A.T'E7B=@W1)8.H'Y?*'V0W)4G)3VVW.C.W=
MJLB=D04>BK3=Y]Q=J`A9W3&FC.13CEQ"Y;Q3ZF1>9%E>R)@M[Y19F?^%)N],
MCN3(%LEP3\>SR<_X%Y\42L@@KDJ%5&<;#W;`H`D2#HW!AVC3Q92B7_I5-W8#
M&E9TQ1=Z6@+Q$*Y%!FIPT!W:VFQ`10\K$%2<Q5AL2['MQ0RUH97JQ01)$6&<
MFA6K@S/0X&.DHF8$HZV95B.Q5B\R@`,(`B'(`H-K`BB0`BW0@BS8`BW`@B:0
M1B;0`DG0$C```J:Z@EXH!XBHMD.Z1(,(I'B,1XYXCXZ8A\(Y.7<834+RB,Z%
MDR;F,GBP!Y$K'$*Q!WMXID"2TL*9)"Y&B7MXIH4M+H,%SM^478>EW87TBGWP
MAS/U!UXBWJ+S78R]'<B:"K`H)3J^8XH,)E[_JDZ/;:4ZI9WI75F('+N29<Z5
MI9[7R<C(D%GL#,_K2$EE2D_M_99)+:"8+(_Z#.6B7(_\E$]M8#=4/@9<0&7]
M+4L'189?\(5C@%"N79`@51"D::&NC,O>FTL00<L%!KZ>X=H90K[?TU!2S!F=
M:9ERJ(8@G;=C71%E5;%D/0,RX+ZO$0!J-4P@L=;$3``;6P(:70(<8P(A*`(@
M2&<>)ILDT()*F(0JR-8B0(,Q(:3_7(@VP9N#,)Q+I),E9BLDOMQJ"X>%F+)"
M8BO)P>+"*9Q\6`<N=FAVX&)[Z`>';N@NSLTR;MC>^DV.#DEC6DB+#=ZP`&0\
M1D[E+$ZJ*!7*2FE7_UE..];C6'HLY71I5BKD2=8=CTR516[>'YSD0D66S_"7
M2874K_`7[05JXF*V0F2/1E3?B"KE_(+44Y;5:,"%:)#E6(5069W06:V/LAS@
M6/:%7(#0",6&X8M%$6FAH='0<N./:E`:!B6:N51@KE4^4ERI&^)5<KB&/1(&
MO[:W:`YL9Q62O#VJ`BB`,-+;)$$`;65A<:YA).!AICJ_R$YG*`"#*JD")AB"
M(\`%@R!B)O48T(0V+.Z(SE4'07H3=?@8U1,<70P'7<Q%;4`&9-#%;-"/E"((
M^A4<=T!MU%Z'*\/B>OA<AU:'>BCNA6YBR\%HVGTFUPU)V84+Y0KIR?KCB?\M
M:3C58^,\7NA<):JXK#FEWMV]X^*MG47&TXJLR+)(Y$=F[Z]`29B564:3K?.%
M)O.M#MY03V;[E_T:9?^>(,^SWZD^963`AF@P\&,XAFDX!@DM$*S=(58D:[#6
M6K*F4'6SV@<N$60^X`5^$/U%MPE9T'`;D0=Y$!BYAF+PZV"`YNI#,:8IA#.X
M(@#(6Q<]`*8Z@*.:UKX=`L"5`LA.9QMGDO/+UB`(@B@``TN8!"W8`B>(!*-!
M"$UDS7G8"$1:[0)%"*E5O5/6AF/(\BYO!OU`A@07<]KF\F,@\S%7!V3X/VUH
M!MG&;=C6!F\@:"O[(T$2N7V-,I3CXN;>S=PTX[#_4-ZNH-V1MEWLSN-5HK.I
MT&,57'166B6.)15"/N2S@-[GU5/GO4[K?%[FU.GW]NFQ@V_2H&1*Y<)*[63R
MI*!$1,JBO*!1%H[89N7:YG)V*_`"+\M95;X'C64+M6M?Z(5=D/!9965VVR&A
M>>MM@%!;Z`6TY%`;@N"6LB$4BIFQG%48(0:_SO9B;1%M[ZE"T(,..`#"IM:^
M36>F\B*M81(DF$8I8((D0((D2`)U!H(H<((JD((JB'<JR&$P`(-)@(9K>,=#
M(L?_G(>*0(A8364$-_,(C]4$E]5CB(:'3_!=2'")?_A=R'A<J/AC*!`Q5P=:
MI^H$=WCZ_;_^`WDLLPB+_VCB?,@(UMU',P9TEZ3CD!SI0X]328?IXM3N[99I
M[0[>ZA0+2&=I5!%T/QUT3B=D3K?(37>E]A9U4C]?EN1DEC1?S_O)2Q4.366/
MIV8/3`T.AO>%4^XPV\8&9`":;'!0`(Y0MH_07Q!@V@[K"@>17.?J`N_*Y@-F
M582I8X9%=KL97HVI#5U%_?T%&`E!MIVWGFK;%E&1;1>$[4,J<B<;<T\`)!F_
M(A`"<HX"'(N"'8L"&XL"MI$$+YB"?(\"+ZB2+YB$2[BXD8'M_E/'2XSM:(B%
M4+A]6`B%C;?J7;CX78B%C-\%7#`&6+"%WR_^8[`%8]@%XX>%W'=^6-CX,2]Y
MAO^/^(@WA@2';9!O\UE'>2J7LCU172_=$Y*X!RXUX\>(>5>Z^>SF>5-R?U)A
M:7V(8^5M%?B'.JEHE>"5K%(9V8ND:8#0YT^@OX(#"0XT>'`@OX(-%T+4QT\?
MQ8H6VU7,EX]BNW8;,>(+J2\DR9(FV;$+F<XDOG;X4N);R;+=O7+:M&&[>3.<
M39O:OF7[ABU;T&WCB&+[A8W:+VI.LS'U]:NI4Z#;LN5\2O3JMJ[4?#EU6BU;
MUW#;=&(=VM5HUZW9?&%5B@U9TF+%A`F[^VHO7CVO\&;Z*RA3'2L*#`@`(."`
M#R!(@@@!D@!!@@5%L#!I(J5*E2E>/G>9TN6+)$J4)%7_29*D"B5+KB_ARA9.
MFVR@V+Z%X\FS7#ELQW#!"B5\>*Q=N'8A_VVK^*Y8L)Y##^3J>2SGL`+!ZM,G
M%/90B&(=.V8L?/AHOW\;#S\T_$UUO,NM4Z=NWKI[]NS;WW?O7K[]\_KOQ]]^
M^FBD44/Y]",1/PLRV*"##T(8H8034EBAA0TJ9-!#!?6CT(8:0IBAB!]RF%"'
M$28D$$(*45200!T:]*(_'1)4HXLJMIBC1#I.A*-%"R%HD9`:W7.112*QE&1*
M+L7$I$Q,EB132U+RXXXVO'6ES5D^Y68345\2]4U43#4%5%!?BAG4-^/,ALU2
M8))EU%9KK37..-N4LTTUV-!Y_]0VU,395E)I'9---<A<8]<UUPC#5Z.O9(+7
M7WOID8D>"B"06``'_!"$%$@`$5EEE@F!1!-1>*;%9U^P2EIKK4D21114L(8)
M*ZI`4R@R1)5#UFSEA(/,;\[9`@HH?0R";"BP[&*,+;N4=TQSPFFWW2#95>L*
M=H%4JQT?W`T22G7CPE(=+,8TAPNZTA9ZC#;JA+,.?.O0NXXY]=[#CCTHV3./
M.??,LQ^`^^$3H,`:):C@A0LSW+##%XH8<88P@OB@/PW)*#'%&:*8H8H)E>CB
MC2R";&.+("<T$<@J$\2R0Q3UV*.0%.6#$48UT\P1/B,AF61(,+$$$TQ2_IPD
M/;S=9/]33D;QN<TW3F=S%%#:A/,67$&9I9MLOATSUTU=^^9+-.9AXXN;2`V5
MDYM#0>6FV=&L39<O9I=]3#1SXX*>+[C,95<QS^@E3"V-"A-,,(07#JD>8RQ@
M0``&&)``$E$`T>D0DEF&A*FG3N&9%U^((89IE&""R6E4H$Z%))=8PPHTU0":
M4S;"&K>++;9<UP=VVI4;BRWAS8(<+]`^QVVWV@7"+1]]P#++==B^\489;?"Q
M?"#)<L=MN<Y7A]QXR1V#3&[FE*...??^F\\Z^^9KSSKSS)..?_SUQTX^]PUL
ML(!!&B@0B1<_+(`"?%C$!L@@D7EL1`O;F(U*1K(4N8A&-/K_6(Q09J,$N0AC
M%SN(_P["LIT9:2,YHXA(2,BS$\[D)$![24Q4XC.8^.0F:R,+G&B(E9W<9!NS
MV5(XOB%#X^`".+B(11!C01Q<G"*(OCC&W.CFFVC8(HBWPP7NQ&6+6P0QB+W(
M(A6[B,50T,(6LN#%7=!1#&+@97!XD=0K#(>78.BA#&,X0N,"((`$)"$*H`+"
M$"X'A"(XQE11D(*JP"`ZTY2N=)9`315H)8E)V,H:M6C*$FU'B^G``A33698K
MJ`4=9CV+6-)R3B=G49WD<4=WH9`%M(YQ2CY$KPQEB-YVN'4]X6"G=\C9)7O<
M$Y_<A.-\\)#??^ZAG_NP@S[P"Q@R_PN$$G8$")H&*Q"!\C&C(LU('_UHB`&[
MZ<V.;6B;W4P@.0%XH8]M+&(K4J?$(#*R=WZ,1_Z#68M8)C,AT81`'OE(D3`R
M$I"T)$DN6>&23N*D)I4$)VO#QMC@=C:V865N:[M)6K*!$['93CA&I-9P.D$<
MXD0QBU&,!2B"LYU0&,M8RUII2'%QBRDN9SF^@P4M8B&+90CC&68\'%[N4HQ7
M%**-AC-<+2)QABL0`7(`V-1JFG`Y)BBACU+5W!*D()K/2<(2I6,%*U9ANB^D
M9C62*)TUAAA*6'1R.MV+1?+ZL#S=E0LY,LW%,8#R"_)D(SS684XK1XD<5W2+
M6\O"#KF>8_^+\1SC%\C853C442]ZI8,WYRO'^=:1S/>]SV#GFY^^[E$/:>HO
M0!K1ILHVU!`,?C.UJ978.$74P(I92)T/62?)^$$CD<639`C19HQ,%I&*>-!'
M][0(SO11)`+IPY\[6RYS0P*E@/JL)2LTB9.T`;=HW$(XI\`BWYRF);?-S3@2
MQ8;M@GB+6\0BN\,)Q78ZH1U-:,>]\57I[6PA+I0.9SM]<`4H0M%)6+@T%K0H
MXNT&+&`LOI2*Q'`&.H2QTUH$@QAV>=0K:D$,71"#&M*@11KH"#D!!*``0]#"
MIX#`!"8@0:I#2'$>HY"%+'@!#*3C:E<Q@1K4)4%UI;L$+:Y3'.G_4`<Y;#T>
MD,/S"^1(9;'8J-I8LJ$T\H0/.7=%URZ0X:SJA,<8U)F%>'@)Y?`%Q;'OH6PZ
MS&&^\U46?M)4YCW6`8_Z[&=?T)3FOPI6L`'Q1YLJ.A$"Q:G:/PNP@-TD2#I=
MR["0%;IE%6RG0F"$HP>>#+?!39'+8!8S'W%$A!W9"#Y$F-P3/I<D+LE7"X%&
M-)*L!&@P*4]V1]'?4'#7*;\PFR]J%\3TU'H7>Q-B$%&JTDZXMPW::8,:B@U+
M[1CK.;>(!A71>BRT3H>_H'C6WFIJG-OU(HJYF,8N>O$59#@#<`T^X^'0B,8T
MOD(7UR!'-[IAC48XH7&($4`!$@`%*$0A_PFFTAR_^Q@$)KPX"U7P0E9+MPI+
M7"(UJN-,%<:JBN4P:Y?F*M<GGR,+612'B>&3UEV5\HUF4.U*\+#)8F>'C*E(
M)3Q5WC@RFJ%R\@B+/<T05LEQTZ5@TL=>YO#7/78./S@#;#]PSH<TDQF@>=A/
M0`(K4H\DZ`\$/?VV@)[ZPPIMSD"W<YV'%A&,'N+U`\XVZZZ=$00A2,'<[H@A
M*KKTS)*K:9IYI"(EX5G0H"N3Z3JW:*(."3;4&XHK$C$\R*!&V9IXZRZ&-(K#
MNMW<8.$)[;"W6L<Z%A^$_8GX[A?`M<8=LOGKBNI\WA:]J'6M\S9Z7TS#*;[H
M12YR(95PF]%O9__,B]^$<0UB7.,=[_`&-ZRA"D68X0A%6$"F$+`$*%0!#%%H
MPA+XG6+'"&$)2\C"%*KP!=-8PC222`(05J.:)FP!#)/`Q?!DD>M=$A8YN1AC
MQ\-C-I/O*DS::,;XYE$^HA0J&W<-;W)VF62B+$/5-(-%Y<:[[(1[O`>:Y9R]
MT$O`Z(\#Z@^]M)DR61;1]0.1(`P&;<1`7.""&!K5`9K"Q%:C.80!]18[E2#$
M;!#*?*`'LB`&H5/9&03%[)9NU4C:X8C,3,1P&5=&()<_Z<Q()%?>$6%TQ41!
MP40[#`U)H$<H4)&NF0UM+,4T,%%XX0U,45%]4=O>Q)0Q&!&`44<L\!?_M`'6
M?H&"[]B"M+F"*Z3A[907%)Z>FSQ%6,Q-+D3%,#!#[!'#'DX8[2U*[M&#-PAB
M-W`#-*@")"B"$2Q```0`$$@!JU2!'C4?BJ489`#<$G3.YU!"Z)`&%:A&$OQ`
M]VW!%ER"5/S"[,S.S.V"+*Q?+NQ"Z^G:+Q##5"S6`*8B450-U>S&>WR#F.S?
MW+!+<IQBH51-+@:+-K3<N\A'^;P9^L##OZ`9G$$@S]4'!/;<O51C_4#3!1)(
MGF%0PFS3GG6@GX$@A7A(;(E@A;`6A)"C.4K,BOC/PGS,@2#0RCC(Q%00!>F6
MQZB(1SC0/>T@Q@C)<'D:W.E3/H!0<Y6$2X3:_TLP23M(B4Q$9)1H@[M("]T`
M2E<(Q9<PT5Q<Y!*YHD114GA5830T1TP=1TQ5QR6MX71@VQ0UD>HUT328C59$
MC9W(&NKY`NQ0PRP$0S&8T>U%6#%<`SHDBE'J'CTHI2`.HC24`A<0'P(8`!!0
MP6<D01`@`8I1HN8P0?2ARN>(`:MX02-501,X@5DF`AB`02GL2B_B!FTL`WD0
M0S+P0BX$CRO&HF(1Q6)5#;"4#V_P!`+F!IL`!5`,H+`HU@"&0P"&@SCDACHL
MEOB$1V,]IOG0BYF=S\]E9L"P0SG`SP0VXV9%4X%<8('P0X%8T`4>1#\DS-J5
MXX0XQ-4]B)_)ICH*FO^#L":(P`QMNM.BU>/6L=8YXB9P15`"P2#)4$P_#`,>
M,`,"U:"/,`1NM69%[-,(!>%S-:1$OI`1%@W)^0;:F`74Q%]$F1SAA<53S)HO
MW$XNV`(L/HOMV`[ID1Z2Z5I(-I%4F"<=8H6A:$G45,-:?`557,.?4,,W+)@S
M.$,Q.(.$G=$>?@,YO$,\O,-2QH,W5"CO<8,J8,$1',:F'``0`$$0J,:)(8$0
M"`$3+,$E9L%HA(X7:,'"24*,QF@E3`(T].(XM&5D(L,LSN(OZ(+ZY0(O\((O
M1"8JRD8S],1?Z@:PW)QLA,/,":"[S,:3.N;YB$,OYL;,0>G-F8^__,LRP<__
MSHFI9EUCFT$3O4`3@!1(S1C(:<F(@JB(,A`"(?S!G!8",#P#/MA6.X9@.\S(
MB4Q(<OG#/H"@/S!#(12"G1:"(1!"HC8JHJ+#`ZVC"GH("Y)=A<`C/%IJB^##
MQ0B"#BB#V2T$=$K$;Y'0@@CAS7Q:<77$/W&GW4%7E.2=J;5#3\S0EUP%5'Q)
M4E`%H!3H-R"#;8QDZ]VG5-QGM^'"W$Q%V20%W>CD')*)4Z0>4=P)63C%GT"%
M4XP#-6PK->@)-3#HA=6"XK@"-52HA`9B-\3#NEYH[XF"*%Q!`H!8B(6HOBW!
MB9X8BD*!%+P8BWY!%W`&K:!.C%[")%P"MP[>8CG%_V(-J9#JPE3,XO#P`I<=
M`R^4W%XZ:3.`W&[L(F^H@V*F(OT!$V.>3S"9`S#1'S(^J<;B1F9>)CN<#\PN
M4S]$4YO5!TKD"YS=A_[TQT:HIC4!4&QRQ!_4``[(@0[H0`[<P`T00CO85CGV
MPR',@3+85CHZ2#L4`ATP`VM2G3\`0QSD0-CF@`[8``Z,;=+F0!PH`VT99\/4
M8Z7"5H/P)@O2ECYJ2"'@0*@69V^55@Y6Q($0)'*]W9$(U*LZ9`LI"4F,');(
M"0U51:Z.)Z"TS1P.'IF,Y-P07GK>9U*DC>3.D-MD:U@0A>@""NQDPS7`SI]0
M1;>*15+P@BS4@J6\02:P8?\WT`,WM!LV=$,UK"M3!B(W`.\E&$$"%,!2=4KT
MI2CR2L'R5M6*MLH4+$&.-4'#K4[!JD(UX&BPSLY<#.G)R6*!-H5BA8^.SL['
M9</,'<.4C@-N`"9@`E.P'&;+`9-\D`\PG6QC`68SP$N78.-E/N/.[8=^[`>:
MQ2P[P-G-AM:::M,%JB:?`:V>$:TAA!LS/(/4W@`>.&VAZ@/1%D++H$@[W`$.
M',*,@.`]/,,S4/`S`(,-@"HS,(,R/(,S^.D^LB!PQN;8U::?-L@ZZ9G(8%#9
M,8@AY.T^UH@&0>=`],=$>)JJ^B#=&6ZLIL.IL804CUP.Y8E9T)#XF$72,"F;
M!*O_F%##KC"%Y)YG@)IB4Z3-V1`%;4P#36(#3=+D>;;Q-/!DZJ5>&9-Q6)A)
M-:2>+]2"'D2"*]!"+?3".&!H-4@#-+S.-G2#.URH-]R$-UC#)F#!$#B.#T1?
M$J2H]$D?%+P8O[*H&"B?:E#O)<2H)4!#F3S%R2V1+#8#C_9B,WR<^*C)%_M0
M^$RIR`*3DM(&*D8F_6GL8ZY#8[*)_:J#+KJ'8YZ9O?1<,]-L.CB@.:2#.*S#
M.:Q#%-\LT"G=?MC/:)VF-7F@-0'MG^J#'\A`,6S3GX)P#1Q".19$.RA#.GAP
MB.0#.@Q#._#I-_4#H2Y(@O0#.^3`':2CHS%:/"[,#7<0_\@`*H,\`R&@`X9P
MX#K=5LAD4(<<`JA.M'/B5CW]K47T2*=E6MQ]FL\TI`N5Q!*VD)0<%#RX@YVX
M0SG<237`]/J>29BLR5XJ;&2"<<*&!27-FNB.KASJJM6T\=RTL;120R],@[?Q
MY.@N]1U7!5#@,:WY@BOH@2NTWCB\0S<DLB+7`A]WPSAT0X3Z[NVV0BMP`?$>
M`&0\`2=O<HH&7!9L@>B$9>JH3HQ6`2:\`SP<!50@@U0TK,5.Q2^X90^YI<T!
MTV)MW`#.W&'W(OR)CQ;/'_TYJ6/FAF4_YOA@)@'?RSU`<_QX:7V8P\B9@SB4
MMCK(S[]H\YS1CVF>IFT]'0"5*O]I;7`-,$,/=X@RW$`>W`.#+/2&S'.(P-:?
M4@AO_2EK<NT]1D@^QY8UB4,.S($Z".1L:=U$.!HW`3>&=-`]7@PY`JI!'$(-
M`,.#S-,*DIT'$^<V'4+>LJ:FHMT.TE/;$5=!?@0)`51TE?1$/A?1\#5,S_0X
MD$-&MD48O\GH%NB7Y'&OXC&8`$J:G&=30`58A"XUP`[J40-4E_'J2?B$(_54
MA`4M!(8N4/@X(#(MF/@@OTZ[M2M3`B\WC`(6(,!:0\'Q25\61%]7QG46T+48
MQ*@7#.SJ8$(WV,/(Z=\O),,O""F1>N\W*%88)VR8A`,Y`*N.NIS"BLF3V]S'
M`;/^+L/_9,_&_NJ&R9IL9OXO9\/#,\+/,U)S:;,Y-4L@2IB#`;?9THG61HP6
M191FB9P(/A"";==(ARR##MR!GEKWU450U^5SA_PV!^ZP;WO@-XJ303.(08M3
M<J>SU48(0;2##M"!TY8@T$8ZAR0(U'5W.!+W`;4W0X`=<CM$;L)VU-:`,/2S
M.+6Z1-R6U&V3HI_(IRH#`Y5(;HWJC6`W=5[$:`&A"8F$S3RQWDUQ2K0T@-O)
M57"KMSINMMH0@A->3B_%'!:XMZH>'H,[6.!G3T^#B%.#+A2U@N,Q3?9"N[N>
M+L#.-+A"B%-X-RCR(->"--0"+DA#(S>R[V)H[S5")8?*O=DX_Q0`W(EFP14$
MW/5)`FE(`L$17(P&N3WL,SR\A9!:;"T>=K#JY6!7+BUZ[R^[I187=@_9HL9F
M`V,N)K"4+)J-^6ES=C3:2YA&\<Q7\V7^B]!Q<VBU=I'8.6QKA,C@`]$6@\K\
MZ2'D`"%H$SRH0W(5PR&$*HVT`S`8@B'@J:$7!#LHPR$0`C!$ZD"TPS,X+6ON
M`SIX_2$\@S[L0VZR`SJ\B,H`SB'<*48D-S^T`]SS`]H7PB'<]H6T`W1[.LFP
M@PHO*C"HPVAM!#J(0S^T`]U//8TP`S`(`IXZ+3H\@Z/#<Z*JO35MTPGW>2&X
M\#,D]STLPR$<`C#<MCFIG3,`0]\K@_]+%((.H+/+]"9PX<@/\Z!\>UH)+==]
ME[2H*>%)FS1)_+>=1`VW&L6:0$V<5$TOAD4SA'&VQA\8B^Y]]FKETD6&TZ2"
M\R1/?@50<VN$IUXN9%L8N1Y87/@K!((L4'@\6(,U0$.^5P,M0(/]5T,U=(,@
M!B)38F@K`$0D)4"@%%PB),L2)DR$-,S")`L5252^2+)XT2(F;O;LU;,W+]RO
M7[YX(6M&3>2W;R>1A4.&#"7,9C"1_>+%Z]BQ9MI4J@S7$VBV<,V:A<MV].<W
M=>',-34GSEPXJ5*C.G5:SJJY<NOF654G+MVZ=>G8L;NWCMVZ>V;OM6UK-E]<
MN?GZY>-'EY__/G_]^OG3]Z<&,W[^^-5%-Z>&LG[Z!-EY]N=&C3OM%@.3HP.S
MCCG`"/.]JVQ.YAPZ_E`.1D=P/WZ&YN2XG(,09;^%Z#S;RX_?(3JC=8PNU`XW
M;F!TE!UJ+2='#C_`50=WCEN?.LWZ\OJS[O>Q'!N8X\Q1=CW='S_,\N2H08@Z
MOV)W1.?(P^S/'7WZ]OECAN?&:QV&@+?+HP.'&F[`+`_J]'GFCOP`U.&WP?8Z
MT`\=\LOAACN4,40'P1S<ZSJ_]+*N.@/]RFL^OSR<+Y]V\M&GG7OTP:>=^>;#
MAT9\7JP11QK;H3&='&OLD49V8*01GG'**8><<;891TDFG=QF22:__\GF&VJL
MI`:9;*BI\BADJKS2RI%Z\07,,L,$<YI?RB2'&BW'`7,;,WWQ9<PQY_0E%S*G
MI.855VJAYIUNNI$&FFJNJ:8::&JA19IJ!!VG&W?B\88;;RSEQAHL@!`BBH*H
M6,*@A2!:*(LLM@`C##%4I8152S"QYIUZZ+&GGWK@R>:87781220O5?HE&R^/
MHG(<E4PZ=J:6FOE&*F;'28K9I'B*]J=GI[H66ZJL8LH<<IYJZBRPQ!*KJ;+2
M2DLMM=9:UZVYJ(M+G[KZ&FPQ?_(X#YA#E`'&$#ED(`2?Q0C1C(Y"F$%GL4-R
MN`.89\Y1!KEA[!*N.V6>N=@/V/11N!B_E/_1X8Z#F?'CAD.H\X<0.9CAJYU"
M0%;FG'.>(61A=`KSYQ`=\)BC$&?0:2;!0O!YCFA^VM&!#N"(/D0.@]5!QS(Y
MSEE,'SPTL^,09M+Q)Y]^Z6CX&68&#DT.RO2!6(Y#GD%'F8S1:Z<88.ZHP8]#
M#EEF,8CW<^899?*`XP^]XF6&CC@,OG@8.C33H6/"GC.QKQ(%Q^U$$@67$?/,
M8Y0QQQM]Q!'('8?D<70BW8&G'">53%+*;51Z,YLXVYR2RMJM1`:;H]K4\DQJ
ML+%2]S:O_'WW*Z^Y!DIJJGF3FFO,1.E.,J_44DTP?7$E%FHD%1111^,)M)I&
M$=5&T$DIO;1243;_[;2@@IJ`8HGX2Q4"(E/#"*,25"S9'Y-7N_%H5APQ1S9L
MPJM?U.07+*'2E*"5K)?01"HPZ<E0ON&K*5&K63X11SC$,0Y?284<4AF'.,K!
M%&\UA2E8*=<ZH)(.<8P%+>I@ASG$LBZSU+`M^;B'#N-"-7W(Q3HEXI`^"%$#
M`=G`!C?(SR'841U"V$`.SF@./Y[1'>"\ZQQSB,,S</,,.=0&-ZIIQS#4L9H<
M=(R(-U@97]BA-NC\00[/4`TP2-..V_!#'0HK!&$V5@,<<(8O_6B'%FU6-.<<
M;0Y#(UH[G$$=ON`L!X;@HQ\D@[#;,$,.<\";:OKRL1K,@3+MN(,<OG,=_W7\
MX8_S.D0-@.$@HXV2&7MA&2%2Z8]VV$$'PHA7O=`Q-QTH)CW.\5"'+F<BP071
M<C.RD8Q6)*/-S>A&HOO<Y]HA)&JRHQSN<,<XMJDZ)WUC'+%;TNS:5*QP#BL;
M)P$6\U0")BU5D'=;XIWNM'24<52#&G%*WI7B5#TR24]XT\.G2.9$C5Z\HA;C
M>$<\NH%/[S%44`V5QD2ET8UXQ(,;]*"'I2RE"H9`X0GM,TC\F"`%A0R!"5C(
M`JKVYRI,K`(3K+"&-3(:P'[L(R2[X(6:FF'`9A#C)<N@X`-?,A.B].07QL*2
M!5<RP7",\!OB(`=4ID*.$(;#6]RR"CS2X92N=O_%A5T1QSEH&)8:H@6&:'&+
M6_3A(GC1I41YB9Q?)O8'&]1-7X<`QCF>4\1"\.5DA8C#,BAW'67DX!!\`<0O
M#9F;&W`FC1VCU6(\XX\_9(@?]YB#U!X91E'J@(M]S(,B@U.(&W"QL;A1!P[F
MT,3&WL:6<PA<9BD)C,@MQ@]Q2(US-I:#UO;CL*V\#G7.$8?`$6:5I12.#@YQ
M1]5XT0_W@.0>030B=&A'&8:LKA"-.:+Y#":9T'3F,\?+(F7Z2)K3%!*0\&%-
M?*3.':Q[DNJR8<Y\AO.<Z*P@3(!'#>:%B7C/ZR_PIC&-83DOGU9RWG]'<B<[
M60F@*,%G0:GAB^PM=%#_OS#4-<H7T8@BRJ(<U:BEXF$-+824"@5YPD'@%[_X
M*6$(#EEI)5K*/U9@BJ89I=4^ZE&.7^A4),00\DUV18QFY`09Q+`)45ZB9*`0
MHR?(F-9,AF*29H`#G,OB8%:9M4&J0`4J5[&*M[IZCZ:$.<Q=G>$,Q5*6<;$E
MA^V"*]7\TA?*&HV2J"VLXW!#R^\,YD5SF,/!VM$.=*#C',P`65L%K;3GS,=E
MI00&:P^!CI,%\P\Y$(RBT7.=P@+#!L,8##!J8++G',(&&DKM.9!61D.RB!G,
M<$8RY."'?-@2#SBP9&&NBX=@!D<?Z-!,C"($#&?$[!F%9L8<DG9K4G.FS@,[
M_T0[UM8.=5#[#J#41X2X"")@^]F0?2%F=X]YHF&F)W.:R]PR681>'8VNW:`#
M79'D"R5OAA.<NG.=Z]`YK/[2+L`"%O!_JU'/</I7=M:;4R]R,8T(@ZD7#I<>
M-GZ1BW'4HZ$.=12D&'I1;UP4H@SUAD9'3`]N<`$*5*`"^UP,JI8C`0A(6$(3
M3C6)25B"QI>PQJ5:(8U*Q8,>]>@Q`7]QC)L0^>@W.>`Q@.KD!!+EJ#W%4@:-
MM1(O$>,:%'3J5)LEC@UJF2H@]"H\G$)6KZNC*>,RJ[G4NM:UOO4N/Y019>.5
MEWLY(SC>=DXA<*#GO&A'#I?10>![\\E\J",'?^"S,/_]X;)&]@,?_1K\'0BQ
MC&#2C+#"L($R].*<H3V#--0!=79/?0/2-U:0.+@#:7FKC#_L)O!QP($?!H,/
MJ\FFBS@P!%Z<(\B=L4,?<]A.'#`C>!W4(`>;6R4P/J2/.PS?^)C!00Z`G\G&
M%@.S11-W$(=[S!`=4T;^V`?F\-',=&_.1NF?YN>L*3IK]@@>VGR2?)E47RB!
MDW;`.TK^L?1.W^U_2XKG2R",3/!)>:S'2@RP3'JA&AP.)0RJ3+3$`'7!3JK'
M2A8J`9MG'#K.?";%XP2%'BR*Y$:,&U!A"E2.Y>('?EHL?HP`"9``(K1`"\"`
M$B:!$E8AH]Z!4JRA%6C*&][_@1[VP1ZT821V)>E^(1F(X1B0H20>Z*=$HJ<0
MJ*><C*A6PJB^(:FH2AR6Q4N^;@M=PB14PNLX:!RB(LR^Q1S0#NW";!W,H:O2
M"BW@#,[*CX=VJ"[NPH?F@VK\``=4K>[ZJN\`S1_2X3((H1`.H1`*P1`1,1@.
MA`;\X-?RSA\P1#'X`A^>`1CR`#'BH+EP`XX$HQA*1N_"2-$*0?0V;VE8*;4&
M@QU\R]&`#4,,9QCZAH[^`!_\XO;FA1^6`39N;?$$2="`[PYPP!`/<1$+X0],
M)EY6J7'\`1^&D1`(81`2D1H%8=KT@0Y`R9!RYO0>A_N&21`EAX_R(IG8S;SD
M3D5V_V3=UH^:<"2]:*0<MD&;W"%U[FT;[._^_NMY+@A+OJ2>@F?`!*X:?*'@
MIB'!P$0!'Y`:#++"1J(A$]`@[X2@JB%0H$$7$I`B`^7C.,I2!&4C1Y`$K6$2
MO.`$4ZQ]A"!4%J()%D()FD`*MF`+N$`2-L$:NL$;ZL%\9DH5?#"`C((D;((7
MIK`F2N((>4$7=&JG"@@H2<+*H`XH7@<HH`X9OI`HP&$HB"(<P,$JK?(IO*XI
M0LCKP*Q<UL(<SN%<<&BM\.$>RB_.VN*'>BA>XL66`./T/*.O:D#/!"D;5<07
M3T2,,BE&B,8Z#N$&.L8N;:D=#BMI<,-EEL$?0`\]B@;4FO_+'YXM%;O1D-H!
M!Q;S.4`/#Y[!D8#Q#NRB:G0@'73QNB:#:/H!^T#)LG2K,TKDM@;SCX9K8&(I
MW?2P'^`(-(MF8#!3$@GCW$P$T$2DF-+-1>3N',\Q1FPDO=[QW7XD1X1$2+KE
MWKPIW_*MONI+_R!,37#G2@P()N+)3"SP2@PL=YX'P2RP&GI!%R3.X2+.H*;A
M/7NA`GUA%[:A&Z8A&HBA>0RE&Q;JXT#NHB+*4F8%08%NY+J!%23A"Z9@"J)`
M0N'G?59RI;9`$41A$Q1!$A1A%52!&T*4&RS*'C8J1&<J1-W!'LSL)8CR"9..
M%W0J5W9!%G;A*'G!R(!2)X*2)'S_85F.2B5^%.J,ZB6DHAFR02N'U"J]#AR:
M80R?%,S.H0V=@LW4@5S2XBS8PAS<0BU=Y![V88>44P_]@I+\L&@$(1##B(@R
MQ-,<I.XL*_N\,6<,4Q<-9&#PCA]H!C>9C?6@@SUL1A\FK95.#157\6CHH$_Y
M01`2HS/EH$#R(D+0`43X0A`8BV@``Y3ZP1`0ZT.X9B]<Q$26[T/Z(6>$B_OF
MCE01JV@($0>`$SHZ9-S"L?.^*_QR<SG-4;S8L72D$Q_8"T;HC9N,Q)O\JW;P
M+4[HR4HH+CSYJ\%V0>(@+%G5<SW!Y$T8C!K>,TVJ(1?L9.%Z81?N1.*^E:!T
MX5#:DSXU_[!`"?2BWB%$1PXD2RX><+)!O8`*('3E)%0*:`X,O&`+(L%$6Z$'
M*Z4;1+121NX'<0Q%@PX>PN'HF'"G?&$D1((72")&)W9BF<XF@.I8=HK)AM0*
MC<KKAE1DF4PGHJHGG)2#PK*%UH&LW'`LU.PLS0)+[X$L9'8MNY1&?BCNN"9>
MVJ&(@"D2"X.(^M`N^>%C)D,X\^(0\L".]$'1[D!2"R,OA,$V"B$'LDL?#&':
MKJ,=\*!L!B/3-&13`V=4^P$8;@`]Y@@'#H%R!(<9ITC[$.D5<6,8$,LN]:$0
M:N"X;"\'3I//1.EJ[8AE#.$&;,`UGZ%PF$$OQ$T9[D#/GHU#^O\!'1)7-?8B
M'UP/3T5)90Q$+\YA;EI5NP0QB#JU^;Y1<F@5<\SOF5*DK6+D9J-3FJ!S=-;K
M5[FIF[K)F^QM6/2Q@JHD2[;D=WXA>$?"(`FJ=P0N`Y\'GQAP&NRS3BIL3G)A
M6^V33-0$&RCNQPA26Z]5P39P`]7UHD(4)$N4Y#B2&RCA"QX40J=`"JK@);?@
M"[0@$2)%HPAV1`4%QT9.07>P!Z4!Z.J!86<A5W)!Z8@AZ6HT%Y!21GT!&8SN
M@)JA)![8J$86673"RJZ2R83JRI9E2<'A2;L2S%XH':S4#=.A9K>T+=3B7,Q"
M+6MD+>7B76B5DBHQ:/."$&[`&?9A,:#_0V'L8!@.;69RP`Z`PR\L8P[4)FP(
MP7!Z"VOQ@Q"*`1V>P64>]2\P"_)0:3S0@=HR[0[.07!`;5"M@R]6J1/#K1^D
M0QL;50>`01WZ)@_H0/5NT?9N8!U&$4&,RQ"*8S=VIFR*.`XXT="D^(]53='\
MX!F6`30OUS4J+8H+X3)0RQ^4(0Z:)MDPT0ZZ`W2+!E;+38B:CT3XZ-(\)+R2
MDYE6I#ESMJUTU1US))N,A/Y:IYV^@=_Z37>P$"5$PG>JA[_*Y.$0LDP8LDPH
M,.(N\DZ@MT[HI)BA=TYVH19RH1IJP3UUX2(YC.-`3E88JAK>E7Q',%Z]`1/2
MER3K=0JJ8`J\_P!]MZ`6X`$:,HI21M0;!K:=6P$:=JY\0W2>::H;Z*$<CB$7
M9L&`E\&`=4I7I'<6*O8F?$')<D+)B+(DB.+I1A:BH>X+F[1)JU(K559E.:@L
M6^CL7FAEU\YES2(=W,XMYH&9]/`OU"AR--FT;./1<D8S0B/QHI9RZ,@U9)H0
M)%40XJ`8<`,=\$,SY$#U"HDQ4.-F6H;X!`TSH'9RA"$'A&%IXL!5GZ,=XD`U
M'^UC?$N+[$`8[L`.EBD/XF!K?LT?T$$0Y@`'MN,.U&9G[@'0E&$WE'IA%%=J
M?38_Z*!`Y@.N8_HR0F9BN*9Q;[HWOD:)DT&[ML]$3G6[O&MR4!=%5O\$L@L-
M'>^A1539LHF$27`W=YLD=O)K2VA"66\98M7$>J]D3WK92JI$'Q7R`*W$(!G2
M`9V73L:DPIH7H!S,%5X!473!/X^G>0+%`__WG?/Y74>P1-^A'+SY"U0E?<LY
M?2E!#*(@$>"A'Z*A%2YEIFSR?$0T8`]TH]X912TEIY"2&&ST)@+:H(^.Z2"8
M8I=0R8),))*A*8=T&2*ZHE>BOK$,&3S823':*S%ZJLB*9<-"':P4'=1!2M7"
MA$<:1TCDUO1P']0A&<RFAODABO\P./JB'8!!$=4F4?U!'2Z$$`S!\GJ6&>@"
ML)@!$0N!\^J.17I3W/3!&80A&@U!<8<K+^C_^CG881GF=C6=%D][SY;0X1`$
MX1#MJ(WW83#:@1EP3Q*C@QDL1AT@;V=DPR_:01@441":_(YP`\L-$>\>Y!R`
MH<:5P8["*'+@)A'U)4;:X1Q\O+#H9=RZ2[$OC42^SSGE+CE5!$74+T>>\W/8
M"YO&X97+87F61)9CASMOYTQP62%YY9;-D\*NY"+-Y+4'JAI(VTHJW:!ZH<(\
M_3S?LY@E;DYTP15TH1JD^5K]T[_BH9HO*@2UP5V-6YOI`1Y:057$`'W3=U6F
M(`@2H2VXX1(J!<<*5D0%A0>A0;M%C-BQH5+@X1MH=!:D.>F0$D9Q@BA)PNB4
MSB:L+"B1A8*'U"6(_V(9/E;<53:J5+9)Q6$ELC*JVM"%P&*L6FC-V@)GR9$Z
MW)IS'Z3"5U$0R9%R`*TYB+,X9:EH`5Z3Q<T7XT)JP6O@)X;Q9"FUX%:[)H?B
MPXAH5J0P'HDOKBLR]RRN5K-R'6GC!^/6`NFU),<N+WY#P&^X1M>3TPW?G8F9
M^+Q%VGP^1$=VV[%7VPNSA55UV&1*\$N6GP<91MMW<,<\U229:UMZ-*S`?IE[
M,_U*EK?`#)*V*^R7[=-*J'=;I??4I5F:#45YNN'506Y@$;2XC?L=[*$$5R77
MQ:`2HAL($J$^JD$1AMT;9LKG!#9$(VJF?)`COYM2`C0;I'T6IET7IEU7B/_A
M)R?6)JS]H)>L&7P4"7%TO7$TR>J;R8PL&894)YJ!\T4?@[4R*J\LW3UXK$PX
M+,]!+$U8K1B\A?FA1N9#NA9W<L(-]8CS;G73<>Z60T;W.91<DR>U0X1)R`6S
M7OS=W\5X3!>O:%X$;DWD;)7Q9NKBNR;>D"9&%U_M00Y>,#MUSL5?'$59<N0J
M=4OYAURDT/R\1G;>1X"DE55G2>J_OKA$=\P3/+&A)HC'(?\)(*CY&DAP(+5J
MTWQ16[BP&L-IU'1-FVA0ET1?O7(95"A08B^!&`?VRKA+EJQ:%BW6(D;MVK5N
M\;IYB^GN73=M]'+JI&<O9T^>^?;UH[=*C!A*1BG_5:+T)<B/+>_NQ8ND2!4W
M:UBM<?/FK1LWKUNQMN*VE>M,LUOA:=N52Y?)M[IVR9WKRU:L6+)FO<V[:U:N
MM[EFQ27&BW`S7L<('^/UJ_"L7;PB$VN&K)GE<,[$.0/'&9QF<:!#BP9]CIRX
M=.?$K4N7CIUK=O?NX<,GFQ]M?OSTX=[MCY^_WKN#"Q_>KQ]PX;_U]=NM&W?R
MW_[T'1^.'#KT?+^I:_=M?/KV[[ZE6_<NO!\P.\RFYV,VATZ[X+^[DP=/G_IR
M^N/UB=>?7'KX_?_QIYM^^N6C3S[MM*.?@@02.-N#$.+33H04XI,./.-DF.$V
MXVSC(8?9=/A--M1@\\M"_R92@XR*"_V"S"_8;+300+KXHA%#$>'84(W52(30
M-+H(U,LT0RIDD(Y#3I/+C`L-^0LQQ+R"4DJU-/32._'$LXTV64JSDTX_@6E/
M<4.QDA0E:*))11!()!+//N]($\DETEBCBBJM:,455F2!Q2=99G%%CUGVE/.+
M7GK==9<MLMAUERNN!"(+7GN9Y(I)KYA4&&.%[4*,27KE-4MDPQ3V2S/$?+,,
M.,M8UDPXEGWC66>TSDI:.J"QEHXZJZW#CCGLI'-/:[3-EML]^N"S3X,$UC=<
M=.19I]UXT#E+K;3.^E9MMMOULU]VV^ES2`XZ$/),@N@H,X<.P-SGW+?<QALO
MM/_B/4=O;]`^QU]XN1T8';,'ZH<L/@T2;'"%$CZ8SFP3SH:AAAE6TR&((V;S
MS38ZLK@0,M@P!.,OOQS9RT`:'4D-1!PY1.3)#NF"D"\A@V3DR#.>Z`N1"1F)
M,LC-.*-++<$$,R7+U+SSSCC5=(,E6?8T_>5.38]9W#[6&%7)U5>+L68BUL13
M3]/2J`*--6-#PXI57?W9)Y_6>-7-VUEZHY,[Q[P%2RR1!@)IWH%(6JE)L(#J
MJ62$$0.9+K,0@[BIQ"333#)/?N.J99.=*KEEX#3#F>::=R:.9[FR9DXZHYLS
M;&N^P@8;/OS(5MN`ON6&;W380:?//;-CYY\_WL:7W;;_SUXKK[6V7YOO\/59
M=U\_PM"1@QQS1)\#'8?XASQUMDNGO;[@$K_]<_+M5Z]X`>(&\&P$WL.@@\E2
MV'#"\./##H0/0US.AQQZ."(U(V*,XXK4`%D`!7*BG!&D9`2AQL@4,A&/1&0D
M$/Q(018H,XPL!$@084@N1J*17Q3C&5&J!4JF%"27=*,:U3`:-Z#A#:>%*4P\
M:5H_\E&<;BRE$I;(VA>64`569*D>_9#*VZ3!"JQ<0FQ[8D4KZN0G/KGM;3+9
MB38F146]14H6DLJ48`(#F+SD)3*\F$6H$&<14SUI,I-#U::@Q#@HH;%6E)N<
MY#@3&M:H1G3`<DWJ[B$/"-FF_U\#:I;O]L&/WAGOD-KBW;2,`Z_K?2=?U*J7
M(AVYG>24)QW),(0?_E`(8:A#.?.YGG3DP[M20L=;W)(D?^@EOO[XIT&N+!B!
MUK<@@B7KE@C+Y6S8`0]R0,Q#X\A&-;(1(F(:,QL`'&``D:$0`7)$2`4AB"XT
MDHL-8I!($>P%+H8TDFUN\",G,\A$AJ0+"0HI@KX(AC.>48Q@O$(7[_P92QQ"
M#6U@R1O0P$;4G.:3+\GP'@;RQBIP>#54B&$*4E!%/8Q6R'TXU!UA,^(E+F$-
MKK0B3UAI8MN^`D5!R2T>==N+%D$E*C`B)HQA[,NHW&(2E@I&,H4AQI-`=KA=
M6`0R9O],8^9FY:J==N8;N2+-.<ZQ&M*E8S6O@4T?8S,;V1BL60+3UBBC,\/L
MD%);\F%D*(U'R4I&DJM=Q5ZT&*F?Y13G'NX*J[V,1[YL%>]?K3R>=0(9G7[!
MM4'[(!@M&S0A?;Q/E^F8T/SP40Z(32P;VC@FB19+#1+A"&0@BV8";P:S@H1L
M@1;!639'$I*,?'.!&*DF!'.1,R7APA9%ZH4N/O@,80C#)+5H2S5J,0T4*FU0
MT&"A#/<!IJ?]TUOO&&C6Q/`%+:B"D.^8!R$=VH]]2..(K+C$G*#!#7IPXTY%
MU`I9LG*5MZ%%)]GX6UY8RI:XC`JED8',X<2(.,&DA#`SE6G_9,H(4S>>454]
MPQSF=MJYS8DC-:<!S3K6\5]UL(97OV+':OCHU#[21C;ZR0T_L!-$W^!N=U=5
MWEN[AYSQ<3BLS(%D\20)XF<U!S[3Z9UN0HD\2*YRE9;,EBKGNM;M":@W-I;E
M[=*WH![K1Y>Y7%@[W+&-^V6(F-M`<C@2:TR/G2B``PD90:1\P('LPLI7WL5(
M=H&SSG83G:$%K4AR88M<X$++%.F%+6Q!BY'UHA;%6"<[W5F+6$P));Z`23R\
M(0UH:&-,48-:;WGBT&7IPQJ6$`,J#.J%2Q`2'@NM!S\*O0]XR&FBBD@$16'"
MC4M@0A6LD(:HLZ(5:7@W4/0H1TE8_VJ2O[2:%]6L9F1RL2E>X-36-GUIITP5
M&<'X6A<@DZFPD2'LR9VJ&=]PQC4D-T?/R&HTY##'.<PA#G.LXQQ'U96PY#$L
MU]VC=:S[,53KFB_L)))W*R;Q[Z8E+>.4N#HTMA>_WLT;X/7+W;@QCR%H^.Y3
MCH>4^`Y>]WA7G'S=^%[?HI?LZ!K(!AF(0`92GX(F'C\@SR8=]\M?DHVIC8L-
M4[$DBE%E?5$CR5:3+5K>[)8Y*Q`%JARU'`1M!-<,08*HN<R06HDST,%S=`@C
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M-HC96"=+-IJ]R/)IS:QEU*(VS#D;63E[`0UTCFR#-E*S_LM<9C)GA!:T(`NY
M0`NND`O%P'//P'/"(`BO\$ZY4`N^T$)%UPU]U@V`QG1+UQ,],0__3K</-$04
M!F448%`-Q;%0[T!(4U-HXQ`)D9`(6*!IJS`6W7`)BB`)GG8)DI`(.B@)F`!W
M9C$H\>`+LG`I@?`*KO`*@5.$)X$I@.$7[F53O39X%B$8>^=>NE`XM=8,IX)&
MDY%XJ:(YX[!?L"(KX/`-DB<.X2!@TU8ZYJ`.>;1MPE(L394L?P0[4&4<^7!N
M^5`[X6-ZWY$/?R`'Z?!Z]?95I81ZA`@MO2=AT((/=S`'U@-B&H9(VI%PN)$/
MS_`'P?!6XP,OW!-AL,0L"H(@$^=7"Z(^T:=]V8<P1+8-X?`AV;!QL9ADXN<Q
M'1-9Y^<+5Y9^&]1_&:%F^)=_Y*19V/1E_]T4"P#(9K3@*+6PC&0&@*Y`"Y$`
M*;(`#NF`@.C`3J\@"/"4"]D`$T!8#4,"=1?H$TL7#_:07/7@4/E@#ZT0@F(@
M"6\B#_(0#^^PCA6&@O!P#9%@!DKP@I(P"9C`"IB0@U6P!5M0!5$`!5&@!9(0
M@WJ2$][P#K[P"GJ#-['P"GA#19ER%U0D@*TF@%2(%[!0=QWY"E;(7I'1&(K'
M1HQC&<<P.<XP&3ZE.6<X>?]5;=+FAKH2+.0@+'R$#P[&5-^&/N*&8^9&8=!R
M;OO@;XH('NUP!S5P#H3X+FOU556)+2;F#^VP+NW`8L/S/=_3'8@H<`:7#X50
M`W<@(-_22N'Q'/\+9TELZ7`!LX>W8Y?MX%06MS`)4UCXXR'5D&0'L5@=`V4$
M1&4A82,E4S)RP5G&J&6ZB!'&J$TC40LCH8R0DHS+N#>00@J@\)FN`)JR0`P'
MV'/H4`RNQ8"UD$)Z=D*U``WC4`]?LT_DN$]9\@[T*`^X<0_6<$-'T0W\(`_U
M8(_P4!SY5D@+)0U6,`1$4`7.Z9R2\)S/*04,.05?8`F8L`H9-2C>X`M]PS>9
MH`>@$`B@L#<7.83B)0L-2(WC14:*8X6)%U]@=$;$@`PQR3G7H%^:$PYE*`Y`
M=8;1II/8IAH$]AJ9EP[ZP&T/4I2>%VZP,V&CQQV^,Z%AB0<Y\`S!06+_B21C
M\@8>;`66UD)[W8$/RN`,H(@/T4-#V\,M&W8M]4)*H>1A_)&)P/!BW/,?':HO
MVB-AS((@!3**$O)P^5`A?!DA19IQQ]18V``1VY`S(9,0TW`,)1)-;'%^9*:+
M9Z9E6@IS&[1-G+5!*4>9T-AFIT6`KB!VH/`(>O`(G_`&G]"F?>`*NB`,IND,
MQ7`-KB4E+_$V-B$-LT4-\L!U3M</@>9TL]D3?(J;@?IMW)!#1B$)TB`/1F./
M0E%(S74/7/<.U1`)1+``0U`%5$`%3T`%S^D%SJD$2-`$52`)2H$)`]DV,^&=
MW\DW>O.=LQHI&GDI?[&K@9&28!079#0JMP8E_RR)*J[B1JZR&9>3.9T3&J!#
M&K<R8-,F+$8E#[?#5'+(5*US2PW"H['#2L43EE))E;M1'+4#>[7W2'-EG-WR
M.^,1+L1#8^I0!WG0'/W0E3J`#P4G?-]AH\KA+=_3E)848V)U2L5Q2S4&?"/V
M2J$(2`U7(`&C(,B2EWEI<1#"ET@J3-HP3-K@(20R$#ES91L1F8HY?]2T<EJJ
M6IYE93?S$2-!)+:P3;&@3;B`"[5P"[=P"J-0"J3@"6_Z":,`F@3XF9F0":Z5
M@#UW@*TE)=6PITIS#2AD3_0@FU$CFS'$=5:+)=4@#49SCX44#P-%":1J#9+J
M#N4P#V:%5H6V4-60"?]F0`0)0`1),+>J*IU),`1(H`11``:48`E^^ZI;X9VP
MP("R4'>08H3K"2EU-X16%#B4(@OJ=5Y@E`R%QT8R=1B\$$>NLH6<\PTTJ3F?
M\Y]E^*RBL1JG852MP4<7LFVQX52U42S?UARP8R#>LJ]:!:+4<3M2^0SW07#<
MP1L'8CZ%-!^W.TI5A3UX^#LT-$FUFV^]MXCOLBSOT@XYL)8\NBXK5BUUU2WF
MTX>'^'O[BF/@XBXK=IR*V!L'JQRE]R[[`K#/H:_#*R"YX:!"6B"Q82`/9[$-
M,UC8$`VUM:1+*GX_LJ0%$0W]ZPO'L`MGMF:XX`M92G+`1G(D!T[S5[,-/#+_
MU6#!T0"``!@)G]`(:Q`)H[`(:#`&9N`(G_`((DP+MT`+N``-#5RSO1`,PE":
MUU`,.'R`KN4R<-.T!T$--4$/_3";LOET.6'$'1@/UO!<H=8UD,8*3!&JUM"U
M\P!0A10;E#9;F<"I"T`$2``$0]`$<SO&28`$2#"W5="WKHJ=JU!$T.`*@H!%
M5N0*)=DW@7`WF>)%'!DX>R%&D6MKOG!>GO(D@->%Q(8J+M*%L9(JQ.`,<E0K
MGU-M0V5MJI$K/%DZK%$.IY,.W-9'2Q5NR@(PRR<=V,&'%9H#XM`=7QD=S[`,
M[\$=^G`.S_`,^^(<9M4.Y\`,Y]`<7#G+Z)"N7!E)_PE2KOB0',^P<ZL<'+<\
MR^<B8874#LN0`W[P'E_9E>Z1#^C`#+-,5<IL'.W`#,SPRY9JO]+QS<P`2GX%
MSLO`#JN4&Z_L#^I@I\R@(.X;'>A#5:SL#/-<S%(5'?>`#OH\B!$&L*!(T.O3
M#@9"2PCR(-A7<1`"#3M+"Z4PT:.PLZ/PII$`"K1`"J1`"Y_9T:#@F:Z0T:'9
M"RT<C1Z=TAWMT9&0"1>MPF_P")#@"8[@!HY0TX_@!I&P!HNP!CZ]!FF`!F:`
M!FK@!FO@!F_`!C']""H,M*"0"T&#M#R7PW@J#"8$M==P$!SR#E-+M3TQF_&@
M$UP]G#.8@SR("5,L#]8@"?^B2@63\`[!::F8ZE#KR'5M6PN18`5$L-=$\`-*
M0+=-0`5-T`1FC`11P*I^:PFKD`K9R8*"D#>3DL>`DYZB$BI=U%XX95.>XG?"
M%I_"1I^54Y^*W(7-9I.1_%^F(0Z/!SK4-CKL(`^N+0^DDWFQ08]ZV7D#`GTJ
M%J&.I`]W@`,"#0QY<`[)<`=RH`,Z\`>\IPQW$`?D<@?*@,[`\`?,H`Q^X-QQ
M\`>[K"[(K0-V$-WF4PQW\`SK)B[*;1O3G2YX@-S5JPP'NQOM0`@Y0"XY,`>'
M$+O`0`=T8`,XH-_CW0ZZ]PR'(`?S'0=^P+O3T0Z"L"[(_=UDX@_%D`?+P`QW
M<`/_=&"B`KXN<@`'<F`([[$<S/`''_0'<S#?T',(O-<=-/JO_N`,A'#<.A`'
M=V"B4O4,@!`'<G`#<^#ATF%HI`RQ?N6C^(O0#&*Q"',+HB`*I3`*HA`)30X)
M4/X(;^`&CW#34G[4;H#46?[3;[`&;:`&7?[3/FW46;[E1RWF/IT&:(X&:.#3
M9S#F/JT&:#[G1OT&#2@,2*ML..Q:Q2!"34M/*#0.$]G5@&:U4[MG,]$-UL`*
MB0"=`OFJDBH)3S#IB0#7SMM<:UMITI`)U^"V<$L$S#G8HC[897S&2>`%DI#8
MC)W8C?`(ER)&PU`2(FDX-O(6H9*$0WB$AUMWL?`7*>%>_XIS4W]'&(SQ(HJW
MR)Z;[&B$;#L5R8\W&J)!.J<Q.C\Y+-PV+-GJNIX7&P0R>J2L+93DVQ>:&X50
M+G1P!X=P"'Y``W]P"#J`[H=`",@=W=XB"#I@".=N"(?P!SE`",(@!^@^W7&@
M`\K@'(5P`\H@+?KP!S>`#OV`#^5N"'5P!X9@"(5PW,E@G/[`#+KG!X40[W.0
MW<4\#']P!_Q]!W_@!^IP#^LB[^V^[_6=#L?1#GY0O>DN[SE0/;D!#'+@!_K]
M!X*@('E@\\!0"+]=".H+##K@!R7N!_I>""W_'KVA##F`]#/$'LF=[M<M!\6`
MOE&Y],!P"'-P`X+@>?Y@2W=%E_^E.*0$8R`,K4OM(&2WX.2>X,&1\`B<P-2.
M``DWG>4U;>9ACN9O`.9R+N=B3N9F/N>*3]2&'^=JH.9`_=.&WP9B_@;`0*<\
MYPQVBIJH:=506R4I@4)&,[525[5/ER75``VJD&F-+@FN+Y!_JS324`5)\`2)
MH)N7B.ETO8[O4`N7T.EFH-=[;02B_IR$;<9)X)Q]FT.HD-B6,`F3</>N$`NG
M-?W+F'=8JF9OT>MZ%QC3Y!=`IY%[H5*$$0R+XT8QU4;(JLB>VS/*QJR9(RMF
M".V@80X_23JFHRNJVV`+>MNVU'``T<]?/GX%#1Y$F-"@/GQW=)SCI^\0#AR$
MVO7KI^__3PX<?]H5]`=,QQ]]&0_5R/'G7D%]A'"DO)A164=]$0W94`:RIC\\
M.M!E+&1#1Z%V)?TIRY$''T9T<^0HJXDQG2&:^/`]TX&G73M\_M;-L4$G6<F,
MA&X$PU@V1Z&H_I[=R<&LH#(;'<_I\Z=/'S!@!?OQ:Y<GSC-^_2;BF%.L:\%T
MA(;JV]</J2&\S^;H4(PQI)PY,8'5,+24W[,_A^[ES:LWHU[6K//IO8?OM5Y\
M#+E:M7H;]VY\MSY]\A2<4_!'CQPY8M2FC1OFS->X61,].G3I:M0\7_-FNG/I
M;JY+3R-=//CP:\JO0:/&3/DTUKN[`O8,W7QTSIP5*R9,O[!:_[6N7=-%EVJH
M&2>>>.BI)T%[[*$'07J\@::42!+9HHHJ)-D"#$DPP<022B:YQ)IW+JDBBDO(
MD<>O?"+K9Y]]$'PG$_\R.<,*(A(80HDF=N0Q"B:28&+'*BPALDA+*BERDD06
M*<Z1-MYHPY,V/GGD-U`B`<454$"))1=;NLPE3%_&_,6777KII19::C'3EU_*
MW*667,;TA1<S>=F%&&2^R>:;9M[T\YMOG*$&''":012<;PQ5M!EPQ!%4'''(
MD=0<2]-)!QYS,)7GGG3D^10?>43%YQY33=7G'KWRP4@O?Q2"-5:6[L`!(GX*
MJ>&.C_[2AQD<?#*HGW:<4B<C0VKH#/^CPIRI08=G\A*HG3OD^(B?0VR0RQ]M
M"_(#AW3ZP8>07)?ZRY^&<OBVGT)N..35@Z0=K#!U<KBC*W_ZN4>'&@3)1UN,
MGJ'WWGZ>B8,D93%:)@=":E*F!CK4*4RSM/Z:2X><^`%&J&+N??5>:>60JY]A
M'MM+!T-:;?60'`XIZ:9BE-5GJ];PBFCF5=N93=6B<&.(M]UTLRJ=WH"+Y!%(
MF"PN:>86>3(Z[=IP[XPUKE.C#:G74`YJZ-I@@XTUNAXONN_&9D.--,R86CHT
MVC-O;3769CN---[(1!CZR*&O&&+T"R;``*F91I=>JKDFGG?H6;">!0]_YYUJ
M,EDC$2PLK%#_$DDFZ9`2S3'O9L0J+GE-8!<+<G&?>J[I[YI,,K&1B`6(4,)'
M))80LL0FEI!"$B.)1))W)1=AI`\V^NA$.>/:<.01X]]PI(\J/?DME"VSI.46
M5VBA)19:KI>>%E"V)P7[6[#/'OM8=L$&FU^H\06;;\89I\]OK@FGF3W#*2<<
M<O87)QQSP@&@.<I1CDUI:AZ9NL<!.R6/G8UJ):7JU*D.4I)\5+`?K(H8:E@E
M$&UQ##7\<%=$\%`K@1SK$`AIAQSP4).#N`0=A3D)RPYR#AW<@84&<<DY_G(2
M82#$'X3(P3,$$I17;,L@A<"!$(=%AVI-<":%T!8-;;@M?5P&'3>,_\@<Y@#"
M?A@B!\6(2&UL<X?.^*,8%0$A7@36JMPP0PXGQ%A%])(099BL(,P8"C_R@8<Y
M/*LVN'&&'/S`,!S<@1GMZ""KS(47F[&F**YY9#XBN3.K](PW7!':T"`!B:0A
MYQ'0:<[3FJ:<J5%-#6=PCWO>0#6QH>%K84M;*>46'K:A1VYK6(\9TI,&-,#-
M;7)[@S"*(1]YD.,_U\"/,(+1-P'IHA;.'%PW#-0@>RBN'@UZ!S=4(3DG6,A"
MB0"#ABS!H7%2`A/2J(8T+@&-?K$J'_<8'3]<Y+C4U4(/9K#1`A9@!"4$*0D[
MDD(5=L0$*8"!$D5"4B44>J1*4$(23&-$\?_:4+SC&"]YR/M$'Y)7G#=0*6E5
M`NEO/A&)D7[B2I\8Q?2V1`I0A`][ML`>+FR!"YK6=$RV&-,TJ#&@;%"#&GQ"
MQIY^RJ<!YD^`EK+4/`Y8C]B42E3P.%545_).4^$+@P29&,=*HD:!X"N$^KB#
M#5XHD1KT<"'HT`$A7M-";X'P)'UYER"QR(\_V$"(UK(!&!>B$1M`[%9YI9E!
M_I!$?J!#803Q83MTD`=V^*,=.<##4O(R+#G@`R'ZX`PB^3J'.]P!#Y_]+`YN
M@(ZCV*`072V,8Y]A"#_<@0YTD$,-X"@292@+(5BYPZN00@A^W&,..,##'5KK
MV=;FJB3M&&P-"0'_C"L2A#49B4C-9O;(5>D%9[5Y)#Z`YC.KE,)HCVA$\A;A
M!D<L(A+-<<-RVC">55K'O=5QKQJ>-I[KH(V5UMEEV^"&GE[VTFS]E=O:!(R&
M-Q#C&<68#S+WHY]7",-OO7!F+:AQC7<8Z$`.:A`]XF&-2#C!PU5PPA8J)XF#
MCG.<'))&-ZZ1XMJDI70OE@?JCAD)?+I.GSKBD11VA`0>-T$+)482)1I:B4DD
M=!**8(0FB%>\3ASG$9WH0T0=43Q&3/D-&CV.)Q[AO"K]!GHB->E*64H*4HR"
MS&8NL_1N08KQD9D6;*8%+FXQYU[4M!?0Z,68L!&-]OEB&NG+AC8$M8WW_[UO
M'/C#GSO,`0]R9&I3BTY'`>\!CWE$M47WL.`^W)F6CJD1A$8$UPB=`90:7,P@
M:/5#"`OB$L+PXR9R"196_%`N=Q%"K`6A"JQ!@H_!5BLHSY@K$I?!CV748&$)
MZ8<Z.(M(Q>I*(#&;`QVB8I`4SD$<KPHK9^?`1\YV]@[KD`P.3N@J81DB#C7\
M0R$(\8<\6LM9SU:U.FI8DCI"D1TZP`$=O.W9;=/!8(X%QA_F$`=D045;^EBK
M=%LSFY@A'.'4I4TE<;-=J[#C%A]EQ"<=L8:-,^(-S%DOU*2#2OF:TCUB@R]T
MP":>\E@G/&;[;W_3HTL`\[*7+>>E?(6)GP3SY_\5@GB%'@01X?[4HA?3J$8W
MI'F@:B:H0=V`!A9RY,UN6DYS1.H0AU#\CFNH"B,KJL>+]\&/&!^S%C3"IP+T
MF:/;\5@)/(;[A1#:4,T16:%*4D-RVL"(X`5/>5)2'O*.<YPF+_DWG;!2E\$<
MYBU]@J4M;2F9R;QFR<^Y>J20\_CF+&=HT!1-?.9S^[!QC/15(QNFUP;\WK>-
MHI)C@`*$1^QCKU3:TQZ>]V"'/2IX*H)LL":AZQBTJ$TK(?H#5Z8NB&))@I`<
M%N0D(?/+,P1IV0[^L%;.+_5!S$5\7->@U6P=]KP&J9!TC`0O]Q[DP?$A!SG,
M%;.=*8QC#EF4=JA#'^G_V,I?BF$#0Z01(\R(@SI8AA9S"SE@BS@"!@YBH5>1
M-6VI-TG2HF=HAW1@!_SC"IF!-WU`!V8`HH=8#4:JB1!TI%51E89[C7R0.$NZ
MI*#IKJ1AA$4HK_%Z@T68P>H0#_<BN?CZ#K&Y#I%;+^KHCNK8I?20N2*\.;B9
MI5I*@S/0@P4K!KP1AE<(.CT0.EEX!?(Q.C5)NFE"D&O2,&M0A"-`@B;HIA#;
M`JL[*'*RA%58!4RP!@I[![]XL;!K$7DZ)F/*A$BH$2*PL2$P`B0``B10`B>0
M'22(`B^H.S&H!#$0@[HKLDF0!$70!"9+LHGJA"<CGC98LB?K!"8KCDO\,BM9
M_[PP2RDSB[SPD3Q4%)_JH05;F#-8P(67JJEHJ*EI`+T_FX8_PP9=W(9MR(8^
M@1_X*:JBBKURD+W9L[U*LP=V>"?=>Z<-PJ"N0HV=,(KMLP$=(BOD&PT=&#^6
MX`<7LHD;`".*$19NW(F#L[6[.@F]HC8YP`&(Z0>7&+:(J+4:&+5VP(,X4(>!
M`(D6R1C*X(=[LR&0H*RNV`=WP0<MJI8ZDB$N4J.\X`=?*81@Z0=V8P:\:!5@
M6)F*L2&\Z)>,R`>5Z;^(3"N]<(QEF"MZ#,$/BHA"T($$9+@YFJ[6B*28I+^(
MRPWNP@<)^:Z,<X1(6(/S>@[O0`\=?!OW2H]46B^L(?]*Y;B.1<`.^D+*M_&O
M]C!")#2;Z#B/2&"P!M,/=,@/*:1"0<`>5WB%6%"3\($&:=*P+FP0",$"(O@G
M*>BF+4@$JT.2K&M##K$&:6@<O^@'>S"=TBF(8OJ/>2`'&CD#?#J"M0."?FH"
M)$B"?DJ"RCS$+P@#,`B#S61$(3L2,$B#K(&R3E2.3KRHBB+-)H.RC*(2402%
MDDJIWTBIQC/%QR.%4'@S[#$%6L!-S=N\FO(\7.B%:!A.7XB&:?"SY`0<;/C%
M<>A%YPS&81S&V!,@VJ,TI:H'I=H'>S@5W=L'3/LZ/8(6#]*,5"&^"SH^BBD(
M=)`K@Q@(6RL6?1"$&F#'@L#_BF/#R):PJ[]X(NW[#!S8%21*!K^H-1QPAGV0
M")AX%35"!]AZ(<#(`3^("7\P!Z<@BQ!4+/@;C3BX@Q=J%8`3(LDP+7($JQR`
M"('1!T``#;S(&!P`!H%)+72X@SA8R*'("Z3(@[EZ!F!`I*M0!D0"B4-X2:-@
M)(6KKM>(I)B1#9Q109W4+G:P"E+8)$ZJ,N-P!#?X..X@N:1T+ZA)I5(ZN>B`
M2NP`0OC"+R*\2B,,#S:0&[#QFKI9L%H0)@6;PDR@!1EQ!5BH!5*(!%>HAFK@
M0J>+AVZ(!",8@ARK.A(KL2+!A%30.A$Y%8PHG;"+C'U@-')XAV*JA4C00RMP
M`AM;_X!!?#L>6X(@68(HR`(OT`(O\((O<%6#$K)*``,N*$W2;(-)5,TI"YY.
M'$WG@9[BZ(-/>(/7O!)0"`511*E12"F66M8S6[-G'9]0&)_=9+-9Q`5HF`9<
ML$5;-,[VT<5L8,X!&9!Q()!@'`?I-$9CG#W94RIS6`=S4"KNO`?!Y,X5T31\
MR0@7Z2H%](=[<`AGT"-#$$?U[`=TB(-N!`G'"-&32`;U+"PY6+Z(*`N[*@C?
MDH-GP"Y@^"T=`%A]0")8.QB78`9M02Z%L;^M<`:X@*O>BH,^:CB++0K4$);,
MXI5K,23K>H8\R($7%='3^@N,4!F+R(U"D`/3J@F1T`$Y8/^N?6B'>V"&.=A9
MFJDW$$*N&R@$H7$L91BX9]&('#"$=-`+9J"#.&`&F)D9A3M!A-,9U[`-[=+)
MV[@-4NA)X^@D1H"$CV-*I_%2ZF"E4HJEZ9B.,05"[SC*J[P"F7LY]OB:-EVY
M6L"/_U@P85`P0:!"5U@=5W`%3K73/^T&;S"0!(D';Y`&,X"=':E+2?@"$ML=
M3-A+5L`$5O!+%NF'!*'4>O@+>'@'3,W4L].#3FW,&\,")U""X?W#?LH"+>@"
M5FU5+M`"+=!,,9@$2MB"--"$X4$>)5..*>/53GRR3_0$Q(.>4+22+1D%QYM-
ME@J%5)0\W$Q%:36%6S`%5YRS6Z#_J<ZC*5JDQ>+<1>3<Q5_,AFV@!@`V5V$\
MUP&"AW0]X'F8/7NPO7M8AWD]%1?!M'<Z&%=9B0\:B#L8+;W`E6%P6/:,6,&Z
M`<+PAY,8!H1(AY1PE]3X`QH@X7Y`6C\@A,L0A(U(AXB8SU;K((VX@9'-"W38
M"$$B!+AXHQOR6,3X@SO`6`N5+GR)`SJP+.LR-SG(@R'.@3@0!$0Z"JOMQX&9
M@USQ@SR0`SH@6D*X%Y%(XAR0`^&"BS@XA)C%F#A@"X1#!S](VC\0N%]AF;P0
MVQN8`S^P8QUHR-6(KD8J"B1])X1[C4IJJIQT4BGEA"EU0?!B!#>H9%(*&\*-
MI>OPFJE1_XXQ903Q&%/^2E,UY:7V8-,TZ!I5[AHV:`-9.##\2";]N(;]T(/5
MP>5(>`-.[8\MO+"W+(4K*`(C,-TJT((+N3H/(9)4:,,V'"=K2)"TJ`?98Y%[
MP%1YX+IWH(:STT,S(-TA6(`CP`(L4`(CD#H@`((BR`(LR()VW@(MR((E0`*"
MRH(M"(,MX`(VJ$1-T%XHPU5>!85."(Y.#%;$`P7H.6B3*M^6DI[:1+/U55]I
M[<WYW3SZK5]<B`9H(,YHN,5=I(;TP09JZ*EJZ,5>)`=A1-=R<`=W4-=WC3U[
M6(?92Z`$<I%*H^![N*`6V:#4VF%]&(:KO:!E*(1BZ:#>.@1MC/_(0F"'OWB&
M+(ZN@F"'H[Z7@V`&I?8+?5@&@9N#TNB55RA!H4X'B#2(93@$L.V@=A"&/]"W
M._@#8+LL0[@#._@#=,`'8&`9>#,)8)`LC,QJ+<(#0AC94RN$92"(\42'0B"C
MK2[;0SAA&%Z9=@@XU[H#0@`V%$6'0R#LB&D'96@MSA($MV:)U2(CM@8&O(`G
M5VFDF#S!$I2D)G7DG]F-4^#41XADHZ%2NJVHY6@.4LH:+`4YKOGD3H[*11C3
M6PJP(P2P_DKE]I`;LV%3-PW--M"%9Z!N^4`'R=6/_-`/7%X=7=:#ZZ&%7NA<
MS[4P:5`$0PV2)J@"$?N"9%;F1FW452C_$A&APWEB:7@H'6PNIL9!G>ZF,2O0
MIR(P@T1P@B)P`BPP@B(8@B$0@B%`@B%`9R`(`G0.`B$0`BDX7BS0Q.-(LNT5
MZ-'LA(`.<?$U*>@)A?-U//5EUO0=A3:35MZ$5OFM:(N>Q3H+O=!#SO8YO6R8
MAE\,8'*MAG*(S@(>QG5@Z7)8AYA.\G5@8":?5V7DSN^T*F5QIX$HB0R"EJZR
MH)S>UX18(Q#RQHA1#57[((%@B0H$/IU@I+00\^K3C%?9"LU2-6I#)`54I"S'
MR(R`44G:BE>Q+2T'S%;)!W5XI+]`K(FX:TDB="XJ#$;JESF_ASCG&/<D674P
MAZCXP#FZ%YMI_VV9B1E5F0TG]9G;.`51B`11\`11,'5.VJ3BX+N*<@.)RAHG
M40Z]TSOF$&[H@)+B%K#VB*]3GJ7K:%/GOJ56_IJN":;JKH]8%J8%>X5(Z&[S
MR@3,-3IN4#IO\`;'"<-A5N^`RA!%Y9UE=E1'G>]H_@O3:9S&<9%ZD`?#Y+H_
M/;L\-(,%2(`CV`)O3O!Q'F<D4/`A2(`#*(`(#X(*%P(H0%4ND,0^Z`,E\_"!
M%NC@"#,O`[-2;*F'/D459S/)JQZ*?E^*!DX\(\[AQ`4ZL<5=%#WF#-<`-C1S
M%7(B3W*6?E=S<(<DAX=UB%=S>*=*BRJJJJ!H-`H]9Z&#B1@SG^K"0/\V'UJ-
M-1I/2B_/U-B6HDZM?H$5]232U$A)A+"M-F<D57LN[<N(K/_0"?)SH)<G@]#(
MTK[R#GJV:BS/.9)8UN@8EO"JGLX+,8J(F&PX15;;W'`XUYXXWH#2=H"&45#U
MPE?U1R`.OK-2X^!5P4,.#B<OO>.:I7$#XE8$6.)!-?`:-IV:\VCN56[ET$\#
MJ.P#`XOEO,F/_$`F>])E7<;3ZX$&:>`&\I:&#N,G)]""'<F0,-"<12V25+`$
M<A^G;@B[PBB=='^'!)FGQL'F_^@/[(D$M3N"`3<#!,>"-%`$+L`"82Z"!4"`
M@!?X@H>"*>@"NUP$34#_3AQH3QB%[_W>4%#_?X$.UMDLQ90*A1,'!64=LXLG
ML_MG,XD&"%JW0MTJ6!`7KEO0HN%B&.TAQ(?8IE'$9C%;-FP8MW$<YW%<.7+E
MW)4K.7+D.G@JY\%+N6X>S)?W[-V[MV^?S9OY^N7CM]-G/W]!_?$K2I1?T'Q'
M^Q5MZO1I4W]"I?+SIX]JT:M#M?:[JC2H4:E'H4(5.Q0I6;)BK4K5Y]3LT[9C
MC;IM>C4LUJ+]@.DX9/6JOL!BKX[]VS8PX:IKT=ZK"ACQ7\22`[=#7-ER/GSX
MVFGN[+DS9\VW1I42-4H4:D^<5GN"!(F1:T>0'#EB9)MV&T9M=C-:Q*8-&S:+
M>C=:Y&;1&N3*UP3?_QW\.?3H;-)(#ZYHT9M,Q9X]0^?]>['PPL*_BO3F4797
MF=;7DN:^6S=IBIP<,=)$2I4F3;2`$4.)4B66"!A@@`):0HDEUM2SCU#]]'/3
M/O6\,R&%[VSSSC[\3'C--=540\L1"UR1B"(EFJC**IMPX8020R10P`%`R`B$
M$%%0T4477("A22<]^AA*)Y[T**0GH83B"9*='.D)**",XF0HHX0")2E56CG*
M*+001-`MI&QIBBVFG&+0F`4]=`M##3DDT4/3>&B11MALHY$VV8S343D@@612
M.>N,Y(X[ZZQC3TOEP`033?7,TX\]^]!T3S^0[N1@3UWIXZ!4]UR:%J>=*O]&
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M8Q`UXB@R&(KXV(DH/8Y2)))'BN+)UU(RB27:44;_*:4I5E9I9)>DM"UW0:08
ME)!!T1QT2T,+1101G(%7DY%&V7#4T38?D402GWZ6`\_C]@@*SZ&'WC-/33@U
M&ND]/74N,U.^*C;7JIX2-9AC5*UU%NJE<SH4Z9X":]:LJ9XZ:UI!`4L8,#<`
MHY6NO![FZO"&U>Y87<1*5IFQ[5RVF;.!Y5.99M12*RT^T$2R[;:K<3(;([)!
M(NYMNIW+FVZYI3MN;FO<2R^^NM'[;[_"I:M)O6S@7V^]\!KG2G<*)H\!@B<\
MX8D$`C-1B_5,#!KMD<8M-%8$CC&A"2#C3QC$0+(`82(5`4K9%[Y0"6N\(S!!
M<5#/(B2/"+V#0^]84,]\_[8@>*Q!`6:`A"JLH;12F,)HW/BA*N:3@`,$`0A!
MJ!H4LM`%D7U!$3P*DH^Z5C:R?8V*9_L$EMQFBE!8:8M;E!M!3+'%@K3M;J<X
M!=Z@82:&\*T7#G%C-+`11XE,`T[5F,C@M'&XQ"7.(^[8DTD(];C'P2-0+:&<
M.>R!N4?9@R8XB52DD!))I$S%**%SG>F(=SI1R44QE\3D4W#G.E"Q!7;`BQU4
M1%F6W=WE&8)`!ZAF)YB[B*IV8O$5KR23NL@42Q^7N0RSFE699]UC,]B3%CO8
M@8^C:8M[J/$6)QH!B4B\AA..X,UP&N&(>(WK.+:IER.NP[_\U<\WBK`?.H,#
M,/]Z[6\1^VM$'X"!#N[`4A_R0`<YT$%`=(RG%GIXPQM<08M,5*P6M(`&-&BA
MB(TYH0E*N`]_^K-!2ZPB%0)*V<HF88UXW$,>DD0*A$*ZCPKU0X8+\ME((V&$
M1(A"%=+@1M-:<8I66..'W%!%&H80HR+2"`I16"*.G+BUH?Z(;$L:&Y)&\0DG
MN4V+3?72+<1HBRY%M2!HQ!O>\K:FOTE$CF^"4T:T(2<[]1%G'RF'-O@T2,@-
MRI"5LQSFS%$31T**)Y/*!Z0NE114@O(MF]S58C1IJK[BA:]IH54LY6(56-V2
M++/3G:]F:9A=_DI7=QE6JMS"ELA&]C"3`>;R*&.L8Q[_DUJG:*8S1;&:3JPF
M$KT)5_C&Y9KP6;,VX9/F<!91HMZ,CW_?7$1QZ"7._&F"#5R@3G#PIUS]0<(5
M!`L@/O@A#W)0]QK?$09V,P%0]1"4%@(IQ276<`0B&$$)#;V/%+2P!3!00A*4
MF(0E4E%13%0B99.X!"OL@5=X2#)F-\F)/.#Q#IS)HQ[WJ$<C&66/>O2C%$X@
MFBI^"`UK-$V'W/`&3!MA!!CQE$9"R((2<_2;>&G"$9TP\8]&H20@20E+14);
MB[G8U+F),8QD)&.9T*1C,ZT135R%R!T#9Y$\9D./B,O36<-A$D"51"4J<4E*
M**<SG;%CD9"J2>?V,2F>(,4M_TJIRF%O*6:IP(YXI`SL7VD5JEPIMLRV;)6:
M*[L[LZCYA&3F)"GGK-A>M063>W[,9*D"&;=,AI>3D9XO+<,LZE5/6M>35CJR
M)XI2:&L32-O$:E0KS=<L(A+BF\TC9#,NV[ZV-_1R!+V^>=MQT:L1P;5?<?"G
M/]W6"W_G=*<B'B'/`'J4'_@X&#F(`8Y[7N.`>EC/>EX1BTAD(A)G"%$1E&#>
MAGHLHF$`0Q@*5%&+MA=!$?[O39@BE`Q%"!XL)`?.S+T/1I7TI/N`AAD4,6&8
M_C`:UD"H-;RA;U5@X0`%F)$1/SR%*62!"USXS6[B11L4K]@T70M24J6TMBB!
MHDIB;/_;Q<EHBEN,J4QJ-`C(=7PFKJIICD#&AE@MPI%J['$;>7+'A<K1#3XQ
M;I"$I!P\)"<H0='$RC;Y.4X^EX])`>63;XG45!H4V$M112FJ&U6H=)?T5+EJ
M=E0WI=6[0N8S:S)7@*8Z8!&[9J_OV;".52R:/2OHQ1(%,:D[=**'?NAE,1HT
MQXQT9T[;TFU9>FRJ%<6F&?&(X3RB$><Z\<))[4U3I_HUYH)$X5T=+N"ZFE^3
M=^?^-*$))VJ^\YN/A#"ZTQURL*,H]V08,<@Q#W1<0QAZ.$.S]>"*AT7L#2$:
M0GF=X`0M@`QD8/C][^';00%)0A*38,6]J^$.>T0J0Z!S$`S_ZT&.:Y!#W2&-
M_CZJH8A(7*(1BEB:-<*O0VA<&,.JV'",?!!P*`P\B0@O5[GXP*-M8<E'570Q
MEK`(8[21XA06Y_@9617'Y4W(J5%"E,F/080<+6!788.':`,$0N`V5$,W*,Z1
M\8E*]`DAP82431GFZ,Q<T95-\`0)Z@67'1;KW!)82%TE)=VGA!V=[0KLM(K4
M<9V;H1VHZ([4:1T,#L56,)UE@5ED;!+N[)F?S9*<61;529;HP!UBX%6B24:S
M+$LP&9/=58MGG,*DH9;W?(]K%,<:7,?XL`OZM(%MF0N[G!IMP$:JN8'D21[_
M!%>X5%X[M1JMS8_FT8(S[*%W4!<\_\@#.YQ>)@@#/BW,&YR!*\C>`JT!(X[7
M$.">!7G,%FR!%O!>);)7@<!7)6B"*G1#/-A#-4A#-S`?3E0%"4)*A(S4@.4,
M#,U,N#%8-4!"2UU!`C@!%RB"T83?#WE#/,2#-T""3LF(^@D!^V4!%'!!NL`+
MO,B?YZ&&D8A"E`2)BUD1%ND?:8P"*93"&8E1_YW1&4%#QW4<F8"<&IV)CSU$
M0_@"F\A1'`5.1MR1AW1#1WB$RR5..83#S-&<(>'</!C*H:S#3'S@3.S#/.`$
M7FF979%@S#C(6]R%TWD="PJ6F9T9#V86#JZ999U9GB461@K/UUUD90G/$E+=
M$1[%2%[68O\!6A,J3VCY4K)0C[),(6E=(6BD@Q9.&M)PBZO)HBPV`JS5%KN<
M3VWD1KNP3_F4VG`01W"-TU+JUOX,EZMYGSLMPBA8UW>0`SB`PS6`0R$20RT0
MHG<40R8<F\4TFQF<@1D0P2,J007AQP51HA:D%Q@0R'NE0DT96#Y(B#14@[G5
MQ$*Z(@NY`SF\PSPPF$B%5"TH`BM`PX850`(`P15<`1?@4"MH`SW0`X9A00*H
MWS`*P1)DP1)L0;SD!HGQ2.>%@BAL46IBR=J4S?[MGRE@8Y6,`L9QXQF1`BWX
MG]U$58YAE4+H#4*@24(D8!W5$34<)\M5@Y%50SGLT9VH5>,X63G_F(,YP$-U
MQL2@S,0]5-E`^N6505+,Z-4E^8.QK,Y?F2+:9<JKE)G8Y9E<Z`Y'8F1(LJ<M
M::15F%(MB>3L(,]?)9:?Y9)<`!I@T,6@><6EM&2SO"1E3,9,-NC1',VE;0(D
M;(*$NH9KB`*GQ5:YA`^\Q-;WI&&JC<LW]5;E`5>]-&4CU.%31B7^=$(T^-H`
MY9.,5A<X$`/#%$,^H<-Z9(<_F8$5.(%:/B(2+(%^.,$%5:(4X(<DQ-<D'!\W
MT`2CV$0]A&(WK)O,"$51A%LA`0IA0HAAON(^--LE*,("P,@0/68"3!`6I$%+
M<8,U*,(0`4%G@I@48$$RPA^\=((F](&>_VX"'XB")B#-UJ"F)Z"&4B$)%HT-
M;+88I97"4\G-Q7%C_\E-;AX4&M$"0J0)+J@C1%!$-$"#F]31.^Z1/!;9X2`9
M2*05=$[G!O(CHEP.K&*9K/*$=TX*43RD])`G>>+2*9GBJ#C=G6W2Z)1=J^P.
MILR2I=R9UM4.\)@0?`)A9C'=@8ZD1U:K9"W6*`T/+F4%L/"JV_U%9#DAHH$6
M8LAD%9;6KS5:I-TDWW7/)ER"A5IH^-!&B<56)ZS+;=2&&MY&B=)A</UK'&)>
MYYFH-$7E)X0#C$Z7=PR0P1R,C;["*PB#=56,`F7"LVV,$B`!$Q`ID5;BQ_!>
M%,AE@+#"A14FS?^@U#M(PS5@"#\TQD*F(CQ0USNH1+@!)@ME`FPL5`)LIHP\
M)A!,#>YA`20X@6/*R`\$`11\9L$5UVZH@1K`'[V6F)YJ`A_T0;RLAFEVPO8\
M@B=\0I)X`M=^@M<JE=AV;362[5)]@I%(29-$B970`F["+2UL'"X(A$`T!$)D
M:B_@0B],`RZ(ZAUI0S50@S900S90`\N%0Q\I63BHZJH^#DR80TR\E:QF#EY]
MCE_J%99.Q;JI3GFV7=/=65AP7=BQ69Q-9/"4+MBYI[1>G;#4H/'L"BYA9.HX
M!B@)J!(2RZ?,68$J&K.TI"]5S[DVJ&=``_?T7=]%D[Q"`B?H:6V%FB/_<`*^
MT@:X.,(CQ%:X/`(D+,+V+J6XE*@=CA-P42B%CH^KW<(\^)ITW=,]H0,[>$=6
M7@,P1*PP^%-V-%M]D%=Y)<$2;*Q^9$$E>H$63$$53$'(3$*$O9`BP0-*+8@\
M7(,TO!!#,H7+/LB63HB7>BD,<4,DN-HC<`$M`MR,')$0!,%G#H$!'(`*#R.(
M-4$B4*WFE<LUF2&>FN:>/A%K^0B2[/`CG-@C<"T0)Q78_O`/?T(D?`(1(ZH1
MBVTD-,DGD,*3@$+:5IR5',3>0@-"0$,O8'$T^`)%3$,V3`-R5H,8W]%&<$0V
M?$.=>$3CAL.>A(.2L>IUSH/D5LX]R-6C/-*#_QS+T.V#"7'65]SJ5&B=4GB%
MKJX=L\YN\5@=$J+N$/Y9[,J2M?+JZIX.V4E6$F(2[A`:)S>A[8KKH;5#'T>A
M:,7D\-(D,H5&.A@-]W`":L3K^%@H-#'O;-1&-(6/&[1+4=+K:VQ3;=0K'N;6
M<`A'N&A"5+ZK-%D:IKG:=51#,6D&^Z;#/DU?,5R#/[T",`C"&^C!*[S!&(Q7
M>2&!?@A!!3&!%(!8)8*8`&?!%J0"-]##.\1#S3`8#.U#-U3#."Q(RTZP@\B#
M.U0(@ATFS4`#(V@>)Q17$1@1U0@!0X=8%V0!$!0`C/B`#U3-$D"!$'"!YDUM
MCW3>#-_I1G="&XCT;O]`G-B:QC3N<!6)K5*A;346L=@B\2,<<1,?\5*-@DTS
M,6[N9A9CZJ=.0S3T@B\$KG+6B9P([@36B7+>B4?821LGSC?$L4DXSN-0YUN!
M($`&7:W2*J6(VY?M*E'`[IZQ()N%)"WERMOI)T>:M44RJ^T$Z.A4EF)0,B8+
MJ&:]]611%B2[W:&EI*$YH?,H"X-N1MT]&FE%6F@H$[OF)"=<`K>X!KRZQFIH
M;VW5AC;5!FVTRQK:AO2*Z+@8,[I0GJL9<_AH'O/V'89JPB9$Y2(\`CGT`S[L
MDSY=I7>TGC`(@AX(@\5FQ[,907U(V_\J;18P`<$ID<AX`1AH%"_"<SR\$(+_
MN>*45H,^8XJ#-$8A#:8_KYMV>VD_=,,H''0C<(+57L$0`(&0,G02X0B.!(%$
M^\`!^,`/$",38(%&6ZW5:EX?],$UX?<VP;"/]/#4[G#7MC3:6"-I>`DV%CC:
M@$(DD.V4J.T3P^W;T,*3N`(IQ$)"Y&W?(,071P-0!QE1)[4>&=DV?,,>J;$V
MM+$;.V[CK$,=OP1<5>ZZ^:66[82DD&!/D.>7*86Q6(I>-6M&HAU=#T]B=%9G
MM1U*7A9*\JJW+F%@>*O7*8]?]\J`@NZ@\=)<\#5?*S(C/WFX@C*B-8]@!X:F
MB+)A3POQ+C9J.+9J?0_@19,U<?9JY*MGVT9L1.]!_]=YOVC>:&>:9)LV^4:E
MH(L+*,A#9S"LP<0V^WH'=KT"-[\>6H)S>3U4$T0!%@AWDB:1%S!1);3"@O6B
M<\M0"MDS7Y*;E<Y,(4T(2MU$HZ3B342#)DBOYW$!$QQ1P!&C>G>!&`B!O[WW
M#\1W_U[!$W4>'X1"2.NIC]RP)O2P:G1T)WP-XM$&UPJ)26,1%&.)$UL[*51<
M%E5)W-""H[H-W()<5O%-%J,C1>R"A\<)1J!<-BBG<J;Q-F0#6J5XO9-XX_2)
MH+#$5=.$/7"G5GLGI+1L7G4%3X2U5G39L?[%LKZ*)4<YD>.NJ`QYM696[7YY
MN'HDQE^Y[7"R[FZ69GE\6_^?#I-K>2<C(=R!%K(PJ"]!"SX8RS,W:&BHLC+A
MPTU>`H5B**;1LKS&^;S:1E%>MB,T0JA94_-V@K?X\FT4EV]TWJ![WJ#WJ^31
M`B!*<V<PBZ_<4SYQ2*-KEQ58P1%,$'#K!WZ`F-DKD7&+3"6H`CW`0R]Z8CTT
MMZB'VSUW0SWP3%UIMSR4PSMD]RNZ8B.)`N:)B^8QPA68-Q(@`3E#0:Y_01;X
M`(P<P`_TE!!@P49[7J!VWM9TWB8\49+H:=<(R<(A/=(+2:@)^`\C?0\_`A,C
MD+5C8]W\'QIM>\CQS=UH>-\BU!?#NP.^2488CG*VW#9`8$FXW$GX24J4A"+-
M0_+_O\3.P2I`YH2L&B0DB0Z7[3AY(J'!KR[*@WR31[*42P:2&P^4@ZOX\]G)
MASSH(@]G87*?6?R@S2Y_/GGO)@_]>_R7.^%+,D\P'=KTG#)`X!,XD&!!@>U.
MB1*UJ=$FA:(@<8+T2&(C1I`P0G+$R)&C-A<[<F+DYB*D-IT\,A+)B"7'12\7
M-;+(J%',1IH6X50DDZ<BFXTFYD(W5)^^@47QZ1MZC6DF/7#.6"DRU8@1)TZ:
M9,VRE4L7KU^_>/DB)A4W>_:ZI7VW]EV\>O7@[;NW[UVU;N_X[9.[KQ]?>/#>
M`=;+M]X^>_O>;ML44U-CQU>*``$R1(@0*5N]?ND"I$!G_Q]!*C-)T\DQI\:;
M'*)VJ+"3*$VA0HD:->JAPE&E;G^:[6E4I]F?.'WB+?R1)DZ=VGCZM/S1*-V/
M=(\B-?W4+>NF2)DZA=WZK6C6HT7KA2O:M%[EITU#CPW;-&S9L%6KIBV;_&WW
MMVG3KZT<?__E`+0'P'7^6L<>>,J99YT$UYE'P0;7R>>>"2?,2\)^[N&G'W[R
MX<=##_7I)Q]__"FJGQ)1/+$H%$ODA\45BX*1'WU:+&K&&V/49\8:_0&11AM)
M7+''(7_444<<48RQ1AE+E+%(%UM,<L<89S3R2""%=++)HO;)T<L<\RDJGW9R
M))/,&.\Q*JE[!FK'H#<'2D>@4_]444@UC$3AY!).)(($J(E8VF@1-SKBB*5%
M'.'D$98T:8DEBV1J#":89'JI#4H9NBDGGB!A!!1BAA*(S8'XD0<=4Z\11A@]
MHCIBB"*J4D*)K)S(XK*MO/`J5UV_^"*,5>@Y*ZUX[&IKG'<*TZN?>L:Y!MG!
M-NP+L,#@F8NOON:QYQY[;BFM$=,:@PR(RHJH[+(NQ@H#B`,*.."`(()H`@N'
M.FFMDU!>TV2AV&*C3:%0-L%M-E&T,Z44ZTXI16&%9;MM%%.D*^64B1M>+C?I
MIIL-XU.R(V7B4VBAI3M<;B&99.N@P25E:,(+S[WX7L9&&YG98R\;_/CK3V=M
M!`000'?_%ERPG'6(AL=!!>?))Y^DUY'+V@DEO`=#I3U4>L017>PGQ!RUUD=I
M*V'L$48:Q8;2R"2#=-'L*K=L<DL<<ZS2Q;!MM%%NLL%&LLJ\X[8[R[&#O/++
ML??.$9\PR42\J#._-'-4?-IQLZ#(WY23'8'D%*A.3A:ZI!&%,O(3HS\[BHB1
MCS;Z2"6.5G(T4)H8>8D-2GFJZ25&<*(T)T4TV6F11UQ!)YW,Y^JQ5%/1N>85
M5JUP@@@BDHAUUB9JU6*K+,#:M0NQQ$#%FF#I2:L;N^*)9YQXD(T+L6ON2G;"
M#??YZZ]Y!JNGKWJTA6>4TB)RC`LF*C,N`%ZO"V$(`Q-\D(`$_XP+"UA0A&L:
MXQM\Q>8AIB!8;1[R,%-8<(,;3)C"#%:*#D),@]K9S@@]F)U;:(<4(IP.=JA#
MBXE=ISO=J8XI2I:R\[0L&O-13S5J%I_VU`<;^<E/.<+QGW*XPV="@P<3A[8.
MH,T#'O;(UCKND2UM3<AI]LC'M:16M0QQB(Q?"U$_M-8UK:4-;60+4I)^%#@<
M^:AM6\*;E=HXN+I1R6UZO-N/[F;'N#5I1X6;&]@0^:7",<XH8=+CXF*4E':D
M24T$D1R<W)2.R^%CDYS$QRD@8:=,R41THOM3(QR!2HXX0A,;626?.+&11K'D
M4K*KR>Q\4KM)Q>XE-:F48WK'"%<48_]X2<F+7(YWC5IDX@UF.((3C/`\)!#!
M"$K`"O6:H`5M8F9[7>A*9L3PJWCTPQ[ADT8\I&&7;IAOG>JKQSNZL8VX+&L?
M_M"+/`(3&'OTA9QZ.8PV2`-!XP!37$(H5V6PAZXP<(&A5^#"3O3E"<ZU1J"N
MB<T&_Y51"XI"A!:<C0@)-K&.BA`W$)-8PCQXPH)Y[&/4V<X+JT.*%>*PAMYA
MV2V@4;*6J4<][%'/S(0H1/UT0QOW*>I^_),SGRV1:%$LT(.V90\LYF,=YJ"0
MU*Z*H7MTR&IEY-#63(0W0LIH;U,R:X[@F-9`&LFL8D/K(9?TQ[W%%6YN1>2-
MD+3'OHT5CX__C%'7]-B.KPDV1HQTTYG&=$DX61*3!ZF3*&L7NE)"Q!$:"51'
M6.E*UZGN(VSPK$QH4I/8V2XG;=#$I7`B*4W<A`UK6`0IFM&.8N)#'O@H5:F*
MD0DS-.]Y5?%M-97`!"9D(9M:^`H!OY*9,*#"+&>)1UKL(HVT'*M8^\C+<^\B
MC\$<\R_R^`MAR#F7>=0#%[C3!"J`Z;]R3:8R0AAN`9>;)],LI%[ULI-"\G5!
MC&X"8`1339T,]A"&@5`5VR$IP3K:P8\M&(4CW,Z"(3RQ[X#G.Q/F832X$40-
M<R/#0$0J4O-35)TM]6=$`]J"#B35HVG+0%>%&CLDM(\O1DL?8\R0_]?"NK<T
M@G5*:*52D>#XI2#S-<A/*E+=;@18MGH)1XX4')-_#"8<UTW)(((;6`=G1B='
M4I)E8EQ2%I<FQ;8)<HLU\^5.$0E(C)(A?;J$0OX$D8P$JI6G:T-G/[((U>GY
M4FP(;6@7P8C9R0XFDIK4(GC72EK$5A^R[62IEKE;)RB!"$KXK56"BX4F,*$)
M6S'N<1/Z%0-.HA5G*>=SHRN?<XZO?7IY!U..M5U73VN>B$',/>IQ#URD%YA<
M:$QD`MA>*<!7$:MQB&GL.\%-O&8AF]B@0T:(&GQI@@M8\'5C%E8P$29DI!XU
MV,,B7+`1AO1CMXCPN:N#LE-<&!O18(^[,_\\,Z#*.S[RUL9\MA&.?(\80`@2
MVH"B.`]S9,M!4L6B@JYJ10J)B$(<RD=?MJJU,(4)L$Y>$I%T)+:V74E*7P+L
MDOZJI+Y*;<H39[*2O?;5+3]<D1[GDI'`S'*_;ME+3D[*S1MG<J1P>>=F)G.9
M/9E).5TR':`4Q252$Y&C9Z1/<A8M&SYR9T%'7>J;76VD>CE:FS1F=H,N="/8
MT#M-T`(<I\+'\-(A#P]=0[=..(*L?BLK67%:N$V0PJU"W05N>L6`O^(&/0`/
M>&I40QK0D(9TGWMX9[D:GG<9S&`"@\]:ZP4>^GC+*7BMB64_9@A!&!<2A`"%
M<X5!-:+H!+@T01K_8/8W%*9P-FI<SU_5;*+:15B`$*Z0>\TC&#<</:DJ#+;!
M!$],W-LA&,12ZD%S5R?".(5P>+P3GIJY.XA`I=F]:U94(^YG&^7H_E(%]`[P
M$ZB*!9_'/5JL+7:<9:LQGDN:T.AB"CU<:1*O$LJG%&2VL560(']DX09G1E#N
M2YR,Y@A03`#0*/2A2P:G;/3(R1+0<$HN3`3"*!BIT1J'<<;$YWRNDS;IDA)"
M(9#N<S"(3R!"E1;!L]9`ZN[LSJ#.M%IB(UCI(V1BT`:MZN[LM%)K=JY.$\*.
M$XC)5-(!'BZG5-K."(X`N"Q-5M[.FCAM"8C+5O+.*S`CU,*@++S!&SC,_QON
M[?`*#QJJ`7W2Z2[R`C#&H1J>14,H;RW@(5FDY2W,`1ZZ);VNK3&X(`V`;3)`
M[U8,*-'22_4:`V!20_9:;R$V"%]0HS'2(/<28`$4H`AR#PL^YV$6XH(NJ!1\
M3V%.H14:#(4F!OB>;\%J:MTNC-TR;/K>C3VXP=[@@S[T(QS*P1M@\3^X$(K<
M0:K*X1V(AF@>!$*LR$#8`:K8`2XH9![2P1C-8>#FSVJZ2N;PBF^.K*S\:AJI
M48_`[$L.!QL'YQJKL1O%).9BA`+7I$P4\'"<[`+)!,PJT"#&[,Q$Y2`*(G-*
M04]0`X-J0\U,PK4\:W9.YW1>\'541R5B*74$+?\-]M&T5LNT/L('<\>S&.,F
M0.$:A@(=R`$=/*0:SL!YX`[N@$MZF$#31$\*HD`*IJ`+2M(KGN`D,6.Y5H$;
MK,$E+X$5K,$+"X\6I&$M"&^=UE`^GN7Q\(D-U=#6JJ@>H@$GZI`'[O#:V"`R
M.@\T0@\*#:@Q..*TPDX''4,U!/$4'(*"]&4A(H)S<&(1<\_V(G$1C`W:>$]B
M-!&C.$CXW%+XMJ/`)L8:RLT[THT4H8_=K$]FM"$:^C+[KF\^DBIG]H/?EBA`
M`L1`5,R*"@Z+SL(8[:$>UH\=CC$9$>ZJK&:KTH3B=,21KFR/=F2-5B0"O;&P
M_"H=33.2MG$UIY$;2W/_YP8G<J81-5/3L"J)`^$D<Q3KDC9)%4APS3#HE$A+
M'SV+LU0'LP(EEEQ'T!8!#3R+Z]J@$5C0M/@Q!6TB)F*!(I.G&(H!'6K!F8A@
M".1N/,E35H1@">XN"J9@/4MR"JB@/:F`FY8K%51A%53!&O`3/Z&A%J2A%L!P
MG0ZO%KJA+^*G&L;!\?1B+J9%'MP0+N`B,J-A,=(@#1HJ[!R2"ZX@")!`,MIK
MN+1@H7+",:J2"ZI2\S9/]E(#OV3/.(Y#E'1B+!UJ]^I1P!;F8&:J+5OA^!0&
M^!+,A*)AW:!!PDB197ZT.GB(&S#,W=RM+_T2&Y"4/?1C/J"T,/OC/_X#098*
M_VB&YJD:)%O0;Q<;9$RL*!D'[ORX2*MD3$*8D1GUZDKF:&]D[I$N$))JKAOS
M`1SO]$[1Q$THD+#T]!K'I-%,CAL-D$X7AP)W3FDF*4?$S)$4U5'/Q$TP$))N
M;ATG!^@8:^@(HI/BY"`VZNA68T]&AY=>0A_3(`59D)8"[75HR<Y4!^P8\E)J
MJ1_],<]&"^PX(1:$H3N+X15>0;>24'K*4^XZ[3R;``J0E0K4DSW7TRNF`'O`
M8+DV015*H16L(2VD(61HTB:KX1K0J1:R00WK02VTJQZT"S'>`9_J04-PS5S?
M8A^B@0T:*O>N8$(92EZS(`$Z#P@T-/2X`A6N+42Y3O]@-T_S3F-&5:,Q\`1<
M5*,1Q/(*S*`A+@CX%*)&3^KX%,(4@*_`1*'`0*@M9Z@53B%(%RQ(K<&F\/)(
M,RP\9D;ZEE0;N&$;IO3#D`H>O*$__J(<SN(P@V9HD.9HNM2+#`1I%B09K\I,
MH48SVZ_]),1(NN;*X$8:7W-J]8B2(E4;:XQ.-5!255-.PU%,<*P"$V=2$>L>
MMM9LY]1P*O5.&>OG"")S!((=#NMM*;,@,+$2'V)T.H4G)D4?<P(E&&%1/((D
M&F6U6C7U'@5W](PE]I%68\<?4Y`G..$55$5YHL(*J&D(@`L)Q+,\D6#3E@!9
MI0!9H4`]J8`*GJ`+4M<]L\#_"Z)U$E0!&KBA?-;B"VFR/VT2G<!0+]Z)*=:"
M\A24+=9U'[0K7=^B'J`A!1MJ*A(@]TZUVB0C>H$`"98`"L>""U+0H;"7VM*K
M7J\M86?O-!;"-&X")U1#T&;G6YP-@S!QP/!68RUHVRHV8S=(+I>O2*&!9#\F
M?UDF94OQ2=M-9GIH2:\/J0`DJ:JT,*%(BGJV'."!0(#V09!&Q1Q$:<X/:>=O
M:=>T:?]ORJKQ&LG$;,G14-$Q;3'0YB")34QS4"=5;;.1L`1K41L'`PE+`14'
M4L,Q4,,D32IP<:Y1'3%UL=J1(![G[`QBD^ZV-HYMS4B))QZWE_*L4`XE<6,'
MZO3L_[06EY;:8!]G1R'O3,^*<Y8<P14.@7+UP`H<T0A@!0FJ`@G<>'-EI7JK
M-_1(%PI2\CW?$PK>4]0J(140[RT2+W]IDC\SP?#DXQKN9RVZ81S4AR_B!Y_.
ME7?;$'_Z@1LVSW86D4*-T@BD5S*0@`E&#T,5(/<8R@[50!,>=A'4X%[3:]E\
MC7<2K38XJ#8X@017XVZ3&/A*KV(Q<=DJT?@\B!--B$X8#$@I[,*05$F95/K:
MK65H9F:Y,(%G)L1\1JE\!FC@(0[-P4`>^(J(IA[6H1^LZA[&&8/E3T0VF.9L
MBS6KD9*20L:N]H>U%BG`C''FM)ZO5@'UN='R.5"SUFO\&?^@PU9,QC9001AK
M+=!K*G52#[IM<;,=S99-'H=3\4$5($$5C,US:H=OK7,?U6`-/,L-UF`-T&`-
M7L=V<&>+B[,%5=H&<<>\<A"8<*<30&$6@(%5%&`(PG,(V-@(.!=6?-JGW7@)
MJ+=ZZ[B.45>/3[*`*,$25.$NWH$NWN'P;+(6:D'5",\F^Y,:CNG5%KDG,00N
M?G<PYB%=;8T;4"_S-B$--K23@R!TMV*AN``-KF`1KL`.Z[`.V6`12_E@Y=4/
M97F6-29O%T(F1.%S("$GPE=?..C!0(BCVM+!("Q(P:/<DME)F1E)EYD]I"'[
MJ*_Z/FQG8/&:2:RT_T(=""1H'*3_JL@Y:M[OM<_/M946:CB8'^8A:U7X-'/.
MH`6:-4T8H6'SM[^L3AV5;,'63.A4YURSGE-SG\NQR\Z$(&X3-]]$<BYIS#()
M'YK-3G0"T2:%#11A0KE8!=G`#;;8(`/M)G@II4_K=*BRI2]%.CN!4<RK,6I'
M$SXA$U[A#!1@`19@"`"<<S<4P'G:C9$`7@X<]$+O"4B7P>T86=4S"WQ%#/J8
M&^JA?-X)GO*7\`YO/ZL!&EB!/]'0?OIA+=@G,-`(C>#BNW@W?J):+^A!H#*O
M$;"`7X'`!Z+W/*-@*WQE$O0E84T4OQH#@PY6R'U/B34!8CAJR9G\(1IA)QH!
MZ1RB%"A6_\$>C/@83+)G"*>BKV76K<L#^+.IKV7''*E6D68+4ZE&6V<=V!W^
MPAW,X1;E!T%@T6BNZ&@F9(O.#XLFQ$RM*A]R+3.9<<>,HDL*1Y"R;$X5/<H,
MU34ET*^X\2CT&<S,MH<WDVT[<T\M<.($:Z%G&#:[%FS_64<DB;H;B\RLNQVC
M@2[I\F-TP_=F(V%D0SM&(:8PAA1@0SHX!A<XQF-2ZA1P@606S&/L4J56R-R6
M[V.BX1J*00_,X-FA'0L2`0O,0-J?G=JW`-L3(1'`8-L92A(DP8`8*@S$8!(F
M`152(15602;?85F2!3"J81O8ARFZ`=:NH5O)X5KZX2?59T-"I/]4$"/%^>F8
M^D$=BG2#K,/97(\4$F$+S"#;&^CAMUT1)D$1U-U(?S3CK8-D6H^'LN$8DC29
M>:B9B?1(HR$;6D8:E#0\1I9E^A)F8;;=D#3#."SF:;[F.0SGM4$+85X_M)`+
MM<$=?%X;Z"'HX4$_WH$_XJ$-XT'HZ<$=H+X<Z&%^$F1^RK2*]DFJSB(?S,%^
MM,4<M,6+PBO/UX_^'@Z=Z4^K9NSLJV9KY.9#V,;*`$G(J$0`WVH`W88T1].O
M[.J1^(KN$>GO3:3O?2R1O(3P_8_1]<@??E@@^,'1_8&2:BPI)LY%2`7N/X1$
M,%]#-K_S/=_*-E_S/Q_N-Z3SC8?T1S__]3UD'CK?;N!>]%5?[4(_]4D$]C&_
M]#&?'G#_0_AB\]%H\_?)]U/?'E*?'E3_0W:_\XG_^/EA^3__]V^_\Y-?^)G_
M]4^_^J>_^K5_^[F?]E/_2(Z_]J]?]6V_^\T_\\'?]&O__#\D_3%__#,?_ME_
M]&F$_<M__CT$^M\_].%?_LU?_`&"G\"!`OL1)&CPH,*!"0\V7`BQWT.%$B%:
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M>_\./KSX\>3+FS^//KWZ]>S;NW\//[[\^?3KV[^//[_^_?S[^_\/8(`"#DA@
M@08>B&"""B[(8(,./GC<1DZ=E9@^%%YW(5@90NB1.(+0$4<=>3@CX4_+_!%'
M''FPPU@R>=01HB#IH"3('X*PR,\R>>11C%3`[)C''T(*,LLY-Q%4X_\?,Q+F
M88IQ"-*,/R4^E8X@=J1H!S#R@)6.D'EL&%67>1PR)4'#[.C,18<$:<YG^MC!
M@044S&D!!W3@T]0R+%10`048#*-8.G'$R:<%=?ZQED+ML.`GH/S$8:@=%Z%#
MAZ,LZ0/#G)H:BH$'=<@D@Y^"#/:F!QA84"@'<;3#U9LL&(HJGRR,RA6DAOX!
MYE/%8$`!"V4.1`,%%?S!$S!Q@*0/HQ@0XUD^<5!@Z`8<G`HM#;D"Y4\<%=0Y
M`PVLAG1M6^C`@*H%TL**`1T0>240IHT*5,>VZD(DR+2T#I4IK!?$RN<,W_(C
M@Z&ON.5/N`/I`RFT&$P+K04R=/025.W08&C_!0MSL*T%&.3QJU#FO&HH#(F:
M-/)"RYS*PI$AV8JH/^F0L?"WR9IKZ69TR,F!'<,X`PS%T!(KU$NA6I`'R26W
MY4_`%7C`XS*'!$SS0NS>].J?\/(I*40R;'L(3@;G:T<PP`#SQPP88#U0,F,O
MF93!+1U]T,T4<%"',LX,$\>I1//CTK5N\VWK!G$`X\PR@KPZ=YHQI70(K!KW
M>-31*^D3S"$U9\C,*Z^@P_?)%K"P4C&O`/.O27_?Y0P'?@)3U+,4P(`3.\,`
M\PQ"_."#3COXZ"//,L.P[<^X?.:1#K+\W%T,.E(2E,XYZ?1SSC`X\AV]]`?Y
M<PX[WX(3S#)$O92._^_.Y+,0/L4$PPSY&!V"\C($M;,U!7'TI`_VP^PL4[+O
M/HIV2\^02[1UR"1\PW@&GC#B#W)A8!8(^</9.*`\?]PC'>E0GT#4,8Q@#*,=
M6/''W9;!082@XQQ!"9[V"'*/9!1C&.AXB$OR\8P5@M`CSO"`Q@Y!$'S$00*O
MNX=+T)$[@IB#'482B#_$<8[Z,<-[`VG',E;H#)DL(TX8&!52]#2GHK7K)LPH
M1C':\1!]I$,<':'<,'*5M`I<P(86H,-9/'@_Y9EL9P(YASK203\*-D0?ZD#'
M2BC8#IF@XW[+\!H%R=<.]E'``\Y`!R*=9Q1]^*X82X*8/]J!#CP>KQA,'/],
M'@Q%!H6<(PY9,E,.3+6P&3C*)7G@0,X.`8,-+`QHP)C6MER9-6<,"@.=RH'B
M^)$.%G``!G\P%0R>I\MI+2P.G!,(.H0)`[Q-:P,RX%S]7!8'5&(`!F3BR1]8
MP,MAXG!=%+,`T,Q$ACRX3R##D($R,<`"._0$'U5C'?\JD+6##&-:AG+EO/21
M!W#RD@6X4@D`[7FPK9F3;S-PI3W5D4T,7*!3-/@EWP012PQLP`/,'`@=7'G.
M0[@R#@+!AQT$NC`96,H?LY"!+#5*T`,N)`]SHL%$1ID'8.`IF,.\AQ%SP`$/
MV/,/_LQ;NOKACX#R,J66JH.A:+`00>1`G3S!*"__-T#0H`R*`T(2Z*Q"DKI#
M;:`"H%,(,-RI,0_0H(@"<88,PCDX#W#@83>A@4,'0M2<">09<I6!^H`!`P[L
MBP,$7<E'N>J/.FR`4T%51C[<R8)UWNX/,)`H/.UP39?%@+#2U*@,+/J78%G@
M7A;QQROBY*?%F@M1`K&#G.3*2SE=0!#^:)SC*A"'?CB#47ZB%@MJQP]T4!%C
MO;K',^<4V\\QHV"IL]BK5%N!AW4D'3-`U<*02RM]W"Q:<MK81MBQIPV`UH@$
M>0;&S*5:"V"6;U53AD"TA4^.`$-OL2(I.T*56CE9@`;3NUZF+L#`@^2!3V0H
MV-!&=0_\:E1.O6HF/P1Q_S:+Z9>NC\HB7N4T@_>6BY=SXH"C:HE<U+;1(N4D
MK=3.H3H.L#5?]G1MG?0FST_ZB6%S>X8^\I$I#(SS;01Q('>A%8=]=$2T*+5N
MS69J`0E8Z[\F!G%OY73,O?)VHI]#%>P$LK4*T*H?-)6?0$[6*U8!8[$7V,!B
MA56'GH@V#_XH)[K.R*@+.$H?;N:GPUH(3-7!<\%RHO!?](<!A%KD'(S:+R?I
MP"L.N)<?+KY`10'[5'^8XW"&HL,AW"=:&@RC&#Z#JC["NBUASH\,%'#TILF`
M89B$U0(>$,0R;F8QQ3G5`C"8Q3.<VJN.O()7LW(&41.WD+!RH'0\(8BMZE`X
MG__)`"8SPP#DXC6!?'Z$TA>H`^&R):Q>?W-.=MB(_BP@:($(@D_+UL?6+L"Z
MQO6*<,#8T]YRA#$.J/,0'H`6K5R7-7\(HL_'>Z`@[C8TJ/)C!D!>AC/LD.CQ
M\BW'1^9(<U4\D*'9\Y.<$N8PUL$!"7!`$,]X!1MQ)=RY2?8F[6@'!=EAH>.E
M.`_-.(2RQEG.=#6CEI56"::XIH\_S&D&05F4G^BPC&"`3)[9DA,+7K$,A%L9
M)%`KQ$#L,">2\F-7O6)'T@I^\`O,31PW(?7>BJ'TC;\BD,IR%,6Y>@Y*>YD?
M[5#=(EV-:#]![L_*6O1%=.XP"R8LE(R&%@O4)^,KFWO_6P-3^>=VYP]ZBCRX
M8ZT`#49XCBGVJDU4$SGVXC1:ERS*4#CTN=78'@<:T&%&.;!W0KHL[8$L8[$>
M(/9"SF2';PU#ZRQ@%:`=50<)Q%=J4!N5)*EHJ?EN76KYVO%`@$'N^AV8'Q1G
MP3#P-`L[_$%QKJT`W_LA"!H,[KW0TN*#,3QU5'&@$"Q"A_0=-;0X1)$??\B#
M(&2:P[J')!TI+N)CH=7B;541'TG$QX=VC&KQ17]UXF#M$%C"%%0R@"<NED^[
M)@$Y(!#E)`,#,6L"!Q'#P&OK8'@<(%DZ1P$\)Q`]\R27IS$(109\<F4#9RCW
M(F-2YPR\MCOYHG[XP&7N!Q)K__9E&[!(^,!L5=,CFU=%JI=BR]`/`VA.4J)X
MHP48_;`H%M-P"K%\QP>#_0!U%`"!(2@G,0`3_7!NX_0'J!(#P#`+8Q,J.A9<
MYP4,-F%;W#0V[;2"_@`.<;(!WN,/.$9X_-`,O/8O-J$/]"0!&/`'8_@C_*80
MSK!8PT82[5`,@A`'B%-6^5!V[]4_"O%8AF)/^^8P*^$/,>`GQD<0.19N_'`(
M%Q!=4B)Q_("!"L,"-)`'S$`04#-.]7,0KG-.7T@!4!5,?=(I,Z`S05$'=#),
M3_(\$*%XGZ<2*%8G1<2%^-=:<Y*"[7)$T0=4D9)G=5))(;<MLE(_Y60'8S@,
M$-8K>/]23M[W!WQB@1SA.O-3,#0P/`.!;]?C$ACX.=/3.&2E/KWW=,(R+\'`
M:U9G*PL#`W%P"*6C+0LU=7HH)4`(*+-@*"P`?T-#+`.(`71X=4H8&#=P*PM!
M./63+&H48`)!?Q7``3/B6A10!U+X.DRW@@)!<1:P+X:B*44C#G'"`<`%4+"2
M,153`44C;#B20%S##\!@95B!C.@"*[G&$7MR`7,W$/D`#.I0,&QW4O35D+87
M`R4H$'0PB5!H,5X8=42!@PZ10-!2>`31@E@V)[1B!ZK%0Q2P`30`#@MGB1;Q
M+._V?1:08:)X7GQB,=$$DF^E*="2,Q123JQU$)>6<B$YDA'_MRT39XX'L0PW
M(%A]DHV2LHF=.!#W$`<R(`,`5'OW``,Y>91NR3EU28Z1AA4^1VLW<`,T@#@P
MP"K^0'`6Z1"C6`'/.`M]DH(*Q8)\<BPYTH_!!4";$D_J0XL&L2MK9'4WP7"B
MN'-Q(R<G.8`0AY86X(E]47WG*!#)("TSX$>A:0$?^6DTR2+;)76HR"N[N9+L
M)WXTX)[O.0.L8U[6>&%U\I[O>0,XA(R+N7!^\@K],%^W:13[4(T8(`/NV2TT
M,`/S<A!TMBW>AU<7H"I(%7,!&0?[P@(LTI&?%R^[MQ"]9Q`R1@-@V7T+X2Z!
MUJ#!0@%`,S0[]FK"I'6IQ@_%1Y=R_W).^_:!1P(.=N!.I(@J&=HN4@5.^A6$
M2':+.)$Z&S`#:2)<(JD.1J10XV0'ODD0-:1&'+"@698UD();+<$+*),/F!(R
M"@J?J\(/8?E@_1(Q!_&%#"8L?*DQ@-)F-FJBP4"*SRB4KW-`7?AT?9);!QF.
M-W$/V0=.#3-;$6AA!_DY(52,@(*C$VALJ"(I;5<GOU2&)M87Q;`O&\`Z^F`0
M=/:CZ;`/-]`G)VE$:P@3<O,I`A$,(:.2%JENR\8W@FH3YZ"#'."3@K`O#^,2
M^W`/]T"@_+"?#A8J%X!##P=<S'<#=G`.]!2G1H0/[&!!"M&FD<4\Y$(!$SA%
M(@D,'0%FM?]7>7\"$[](`:F74)R'5,!`>ROA>4\XEBA*$)(WD=5I1>G@#/?P
M:8=03N+%#SD@)QPC$,60(K3%#UZ73R4Y`_73#O?J#^H`#(C&)SB$#^H`#OU@
M/I2%86<!9IS:.G/B`9PSG5S'=DH98-5WGGVW7W@&7UDS9B+YD0.A2`XYIPO5
M-\5S@R4J$+8XHA0AFX+I2M+B2H:BCN1ZGL\@>H*@#^9%5D]Z$RZVF]M"L!76
MI?T6J/H`1&QW)J_B>-SW;M^*([?7;ZS&M/S0#_E"6\*5C!%G;X+1#P4I;\N`
M#IRF-T6C#Z/8*^LT#P"4-5!G`>>9IS`0<9PG$.:08O:T##```S?_\*2I,S=+
MXC)[$F@N(0XLD+BL(FPS4C\LUI_#(A!Q:"B`8BN_F2TL(`.A*!`&*"N"``[I
M`&E1(Y2?LR10)P&@8R%E5S#OR'MOB#UQID54"&6NQYQ^HB3I@`XG@C@["S#0
MPD!P0C<I-Y\<0"+@"`,XDHY<*W#I@*T)6PA]9;-V6`&O@`_NQ`'VQ&5R@KP*
M0:XYXPSI,`PTH#=WX!(A>0%.]V`1-G$U)Q"CRFT%DXN[YZ`B23QA^@QV8$/A
MF'.HPJM)1;E`(UJUB"KG6Z6GP@&S,$;.XPP01E:<,U^PVXS1I0^@66I:Q`RO
M"1*SJ8[/Q"?SDHH."3^N-&=5*'5U"33*_\`KK=<N[16\;;0\>8`R,S*=P,6%
M@BL8^9`#?+DP$69]W]*S<U,'=+`GT04/K16=`S$,4':/J'(O+J8J)Z5[>;F?
M;,-H?*(J=:"U?B6L*<8V0S,((:AU'$`&)V4H=#6?!FH'[BMW%C$NPC)1_"0O
MSH1Y"VK'BS0C_H##_%.N4\,W['B;=$!;/H8!I.2^=9*&4L-;0,L!&[`O9,56
MH?*]07DV>)D'=!`P.<H/W@L#('(JGV=;&$`#=@!`>"FL'J";=&`'9C.[K.*V
M*C(H:PL1]^`S%D-CCN936(8J'G`EZ=5B%"`!)RMCJG('(%,!JPI,^5(G+"!,
ML=*WIUMHI[S+1?_J=;7()S>P$+[K,!Q!+IR;-`U9!V2@.EKF$FWZR$Z\+2F9
MLYQ"2D\\M9Y3>S/K`;3<S;32P`815H^,;(T:@JK%BWGCDK1"?W/C8#,@`;09
M&.90!X12*!L0>SQ!7;RB*='5227)H'\+$F9[,&1`BGT"+3*P3B^H<6",,!%&
M)Y^U5V@\$)E2`?:45!RM7]8J;JBE*?)&0Y(Y)ZD"L#>AE2A-:Y$(B=`".>](
M%?[PA7TB`2`()VXZ-[2U%9DRU!7`0^8BTS4M+#@$U<05F#`@6<Z@U90)B`>C
MU1W6:2'(6X')`O:$#Q1#F<K\R&MQ215-F7VB*F`L4L+BDC/@;LF,6PW_P0YM
M[2?N*Z`#(0XYH#=]@BH70%#_,@R(HRGI`BQS<J/"<H4'<0^%AJEA7(K\H`ZC
MS"=^<I)]PZ7Z!YAE%5P@,R>DZYO(>38LX%/M4%VIK8L,JJ):1&?0,B>'X`_U
M9HSU8M5K+1#LD&)QR3=9UDV$@0XHHGUYD*Q&U`]U2P.(2P-(BR2A=R_/@"4#
MD0<Y$`<C5ULW``.D6U"GFR)N9%9Q@+@RT-[\8`YT<`._V5IQ``=,:2SKS8K$
M=G"=*0-S0(0BH2.A]R0D5!2"0-@RD`?XT#,Y4'@@0@9,RX@T8+I&]`>="0/W
MDG0R0+ETH'`$<24YH'WNJ2+%D'+D[9Z_M`R;_PG@-W(0YN?A<7!DE(*X=>`[
MH7=.ST`',S#?(S)M\DVZVR<2S_`',++B%-$SI)L'[?`'VK=.QD(#GJCC`3D+
M]U#'HU<48->9I$L'P;`372+B,$`&DYRS[OF1G-;="R$H^<T.&:%+-/`I'=$.
M>2#D`8G3,`'5VTT#L_`*KJIZ\BT#=L"ZH3=.@M+*])-](BX#<1`,2&+>EB(H
MB#L#[@,B<<!6_##`!$X'3(DPHL=!K!1Z)1X8:SH5[=*'B"P2%V*QRQ,3933.
M)'%C%^&IPZP5GGH].9'=3PTW#!$2?=,2^,"#I56'4N.IUV1$5-'B.K$[SQXT
MS$ZV8&(0^0!_%U&'Q_^.[.2#R%,3K!"Q#\'.ZI&DD>D922`1[@W*$=+N$:W^
MZA("$B]![APR(:E>[]*1BL_X%QUC[Z?AZMPA?#"0[?]^'_DN'<7@2GYF\/@1
M\-R!#L^@20U/\<EQ.A6/\1FO\1O/\1WO$PCO\2'?%-EM%1=OZ\T.%?XN\A""
M#J&G?68*L]J7`S-P3DXQW>XYYD;!#M1M!R-7$OJ0X4_B>K-@X=Y]$.F0!]4]
M7O=P"&1P`W20#"NO\:E()Y,N$/>G*2#8%$#O;L@U`U`9L)A=)WDPK2%1#)4%
MI\Y'$(C&8`;Z#.$^#&PDQH:9(]A::A<@3U)?\?((DPP:5D,-P4K17,`,*[__
M&4R,Q2G7:1&H"\QZ$V7UZY+\1`$WT!--:"Z$P@&0XRX:@WEVJ??_3L,2]CH]
M@8EZ<[XFOQ`NQ@+)$W91)&-S?0X\'*@B(8\<<`CB(%)0RYP68P?/`&)6`U"Z
MF0S.L-M25XZ2C/2JPP*4]_GV7ON,`D$:MDT/W'-D8P=Y,`P-,3MJSC?%,#9:
MLRU`HWAR5I'W$BS&Z!'5QW?W)"E@EH)T`"V2LHQF"&]DY:FE9Y#]`/_6V?S_
MOBMD!1`T*%00Q,\?#`H<XERH0(/?PUDL+%2H8`$##&4/<U@$]I"?.@X5/*33
MY]'CL$-_Q#W4QX("AF(M7P[S^,>"A3\F=>IT)NA/_S&/<2CFT6?30AR/@C!0
MF,%/GX>$Z!ZVD[AAF3X9%2X4?"C(`@4Z.\6.)5O6[%FT:=6N9=O6[5NX<>7.
MI5O7[EV\>1\66PHCSTVDRS90D&'GID-^Z$)>8,$"PU<9^?H9)9.4(E*TRI:R
M*(GPPB&/=BA0J/.6:@68_.A\M>-QV6,6_IP-9H'OH;^L&(+QFU$QYT.;%!#K
M)5[<^''DR94O9][<^=EAFX-QL`"CGR"&<6PV].<OSV,ZMI5:X"`U'746Z?SI
MRT'!`E>SZ6!4#,LOSN@8Z/8-<RG<GUNA*I#A'OM&:^TA9S9KAR\*:BN)'QEN
M*LBP"EA8!I]E^I.AG^<Z]/_P0Q!#%'%$$N^*S@(6T&&A`@Z>$0HGKRR8H;MT
MA@$F'Z>*H6X#9S2R:!9_TH'*`W7.TH<&BF!HYZ%E0F*1!0Y&$XXM??JQ`P,6
M@?*G#O<.Y.<U"CS`A\'T/*)!0GZ$=(\#*+4BK$0XXY1S3CKKM'.LZ!K$!TF<
M9'CI&Z,<^H^?GN*`@3KRENGJJ]*PHR".0<E*I[<*%:TI2HK(.XPM?U8C#[[[
M*,C#(S(7Q)*SVR)\[Z%#$!V(@Z5DN'-66FNU]59<S<J3LSPJDB%*%N:)45!T
MXHC2O0MNXO$A=3Q`L9_[+#@D4K'2R:I"FG0:A@868+#C#_#8BN,F#N#KQU,O
MD^G_2Y\F&WP0-]1V>X@9,F!@@0ZE'LUU7W[[]???XXK9H$)V'[N)`C+\V<XA
M?:)5*(]6R>OQ(:$X`,:EVLK":B(8I-K)GWSR*>D/W]3J-%D/@.DNJ:\PX^>0
MB9J2QP,6)Z:*`JMTTL<VF"WP$F"@@Q9Z:*"C8PP?JFZZ*2>2&^J'':@VR!8D
M"Y9U"IC'9%C*9;$:GJA,#EV+8P8Z]%FO-PPF1NN[A&8QZ+^2-*,`!MOXJ2-9
M.[KS$P.N$G27T#AH@)0?:&<B^G#$$U>\Q.@(/E+IG`6A*`=^SJ&.;Y`-(P\<
MCUK*%(-9'A1+J8I8R($&P6E0%)AD-Q!DF2L%#)L.U#W>_\ER<E'7O:!\8$B6
MCF4$"0FFD4L'9ID91JNC),$LRF.9[U!<<G'JJ[?^^KH:K\T[I3-NFH:=5>5@
M!L<FPB!;BBM"D<"QX+V)(BDMZ.@>/RVX8`-RL]4'H0K0UTGS@TD)+,!)ED4N
M,)HXA$U%-\'`8Q)B*7X(1%GD@@_V+'A!#&:0+Q)`%5^^<H-^%&4BB&F&1$8C
MHP#]3#,4^=E.$J2^B2A--P8!!@R^XAX6=.0A^7!):G;2$H90)%,3.9!W$&41
M&4R/22L:B`529A)TV'`T+`)-!JUX12P>KAT^X0H^?/('9CP$'7GX`_K&6(<Y
MA"X=?R@C%(?GOYVT@XU_^"(=R?^8#J<$21!QT(X2"7<(,OA0)UZDXQQ]0L9G
MF*08=HB#'52VDW0(H@YT^,,YXBC).OS!=EGD9"<]V:^PD264+-$)A\8#`]$9
MQUCJ24L_1EF75'Y2EK.D)>*>YA.)5*"%>CD7!NJPLK3$LI;#)&8QL9B@]\$`
MC\B)0]F`:4QH1E.:G6S'H5@0!V=0"SG/G&8WO?E-Q>&#).`D9SG-^<U7GE.=
MZV1G.]WY3GC&4Y[SI&<][7E/?.93G_OD9S_]^4^`!E2@`R5H00UZ4(0F5*$+
M96A#'?I0B$94HA.E:$4M>E&,9E2C&^5H1SWZ49"&5*0C)6E)37I2E*94I2ME
M:4M=^E+_F,94IC.E:4UM>E.<YE2G.^5I3WWZ4Z`&5:A#)6I1C7I4I"95J4ME
M:E.=^E2H1E6J4Z5J5:UZ5:QF5:M;Y6I7O?I5L(95K&,E:UG->E:TIE6M:V5K
M6]WZ5KC&5:YSI6M=[7I7O.9U1-S4*[^T*5:^ND683NE:87]H6)T9MCOK6>Q?
M'X(/82[6;(L=BSXLJQ/)-G8LD/U8=R8;V,=&UK.:-=EH*=LYQ)IDL*M-+6H/
M6Q;(7M8CF3WM3CB+6=."-H_`U*UE8TE;W=[6),!U+%IP]-K$(E>UK24E<HE;
M6=$RMK8ZD^UL<UM<X5I7NL&-[F>+ZUW&OFU0W!0F(,Q[7O2F_U>]ZV5O>]W[
M7OC&5[[SI6]][7M?_.97O_OE;W_]^U\`!UC``R9P@?WK`@0G6,$+9G"#'?Q@
M"$=8PA.F<(4M?&$,,W@%&>9PASW\81"'6,09WO"(37QB%*=8Q1@N\8I=_&(8
MQUC&,Z9QC6U\8QSG6,<[YG&/??QC(`=9R$,F<I&-?&0D)UG)2V9RDYW\9"A'
M6<I3IG*5K7QE+&>YRBW6<I>]_&4PAUG,8R9SF<T<8RZ?6<T.3O.:W?QF."NY
MS1Z>LY/K'.<MX[G!=R9QGO7\9T`'6M"#UC"A#7UH1"=:T8GF\Z)YW.@L0]K1
J"I;TI"U-Z$I?6M.;YG2G/9WB3']:U!&C)G6I37WJ)X<:U:MF-9`#`@`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g145452moi002.gif
<DESCRIPTION>G145452MOI002.GIF
<TEXT>
begin 644 g145452moi002.gif
M1TE&.#EA2P+*`?8```P,#!45%1T='24E)2PL+#0T-#P\/$1$1$Q,3%145%Q<
M7&-C8VMK:W-S<WM[>Q)WB2I?E"-MD2]CES!DES)EF39HFCQLG4!OGT!PGT1R
MH4EVI$UYIE!\IU-^J42<HE:`JEN$K5RNKF"(KV2+L6F.M&V2MG"4MW*5N':8
MNGR=O6.QL6BTM':[NWF\O(.#@XN+BY.3DYR<G("?OX"@OZ.CHZNKJ[.SL[N[
MNX2BP8FFQ(VIQI"LQY.NR9:PRIRTS:"WSZ"XSZ.ZT:F^U('`P(S&QI3*RI[/
MSZW!UJ+1T:[6UK#$U[+%V+;(VKO,W;/9V;O=W<3$Q,S,S,#/W\#0W]/3T]O;
MV\32X<G7Y,W9YM#<Y]/>Z<_GY];@ZMSE[>/CX^#G[^#H[^SL[.3J\>GN].+P
M\.WQ]O3T]/+U^/?Y^_[^_@``````````````````````````````````````
M`````````````````````````````````````````````````"'_"TU33T9&
M24-%.2XP&`````QM<T]035-/1D9)0T4Y+C"`\B]6F@`A_PM-4T]&1DE#13DN
M,!@````,8VU04$I#;7`P-S$R`````T@`<[P`+`````!+`LH!``?_@!2"@X2%
MAH>(B8@5BHV.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&R
ML[2UMK>=C+B[O+V^A;J_B<&3Q,+'R,G*RY7&S)H1S](4SM/6U]C+T=F7%=7<
MX*O?X;?CA.:[Z,CJY(85$^WQ\O/T]?;W^/G9[/J1_/T``PH,]6^@.X,($RI<
MR!!3P7(-(]9Z*+&B1504PV6\R%':QHX@0XH<2;+DL8\F4ZI<R;*ERY<P8\I\
MAG*FS9LX<^K<R;.GSY]`@PH=2K2H49TUCRI=NC,"/)!)F9J**C6AMZI8)5[-
M:HNJP:U=N>+:)K:L681>!:5-1_8L1K=P_S6NC4NWKMV[>//JW<NWK]^_@`.#
MFRNXL.'#B!,K;MAVL>/'&`E#YB59:>7)F$==SLRYL^?/H$.+'MUN,^G32_D]
M1<VZM>O7B=F!A4T;[^I&C6OKOCC[Y.[?'".8!DZ\.+WAQI,K7\Z\N7-@SS%)
MF$"=@@3KU[-53T3]]JCIV6E)N!X^^M\*'T"H7[^>@S4+ZC]\ZZ#>@BD+Z3\D
MVJ`^`ZH,(*"`P@D?V'=(>?)X9]XU&G1QQH,00JC$-!*,4,894QA(R`053/$@
M"0A^(L$'8IRAA7^'*/%@"B%^8D$.6IR11AIHC&'%"(9D@`.*D$BP`0X:]D)=
M!260H.""SV@PQO^,3#9I!84DH)'&%D$.8@$6,YK08B<CRBB&!H@T,2,.6W;B
M0Y--CE$"(2EH,89[D%2`0Q==\"AD!TR<L<.12"ZS@1@T*O'#H(2F(,R6$D29
MAA95"G(EC5J2,L$',M;98@J#@E#*"#*>T40.*?0`:!IU"J)D&F-L$`D(,G)A
M9REE%K+=($+,N&>?#"Y9Q@;C86?(=19DX%^+!F9@06^):`BLL/8AJ$NPA01K
M0852,GI(!5BF44*LU@7[*B'+#CO(I&6D\24AC29K+((<"FL=-8E(P,.,3+Q;
M8;EH;$L!!TN^"2X%PG[+*:EV+MNLND%*BXBW[YZS507&%K*$K<CA&LK_!!H`
M6@:<B7S@`Q9=<,$$"M,Z&H0538P@1!=6M-R$?H+XT#(.@DQ00LLZ"/+!#R!W
M@440,$L`0A-6^%#"%5SX8%\&/%SA,PXG5&N!@A9<`6FL&NA@!9U-[(@@"4)H
MT8460N!8\P?EBN%?!B=;P8-]6ENQ9J(M\Z"!#V);<4(PZ"D1LA(?X-"RH;_V
M,*,5=O(@!`\?2(##%5*B<<6-UY&PA-@L\X"B#EK,>,85+PO"P0]B:W&$V118
M<'(3`6ZM10X5:$`ZRRB`JZ/37#1!LB`2<-#$%$!LH(/36``Y@>^C?M%$#Q9+
M<^K&9:*P9)-H*(%B!ES0V'D:9V2?1@[793QC_Q8&UOJ]T*,V*08(XYTPHQBC
M6A&LF$UN3_ZUV4:*R`C;-WD%QQ;H@8R:=(:W68=2Y@+3#]['/@K0CTR.FY$6
M^I<&,]1.$"``@Y1FU`6KI<$'(9)`"3:H!1Z,0%S9"0*:TL`B'`S02?ZA7Y-&
M4*$NH*D,A+.`#=/0A!>B00C9\AP*LJ,!*Z`)#4%HU@BD5(8I4(\'$P#!$:\@
MF^;9XE1H:((2MKC%G`EB!$O*(@Y$-:,@.*I_:$"#%G`@I298)VHS*D/C,F##
MC3EP1DK``0]&Q3P1$A`-/)#`F;CW`QS(T%JR>I2VMK0![V$A!SKPGORLPT;N
M"0$'0N@4S4:4MJQ)2?\,-!3$`\>#`R:)@0<YV.$4&%&U&7$A!SS8X0>))4/N
M=8$)*>!1"53$/4&!0'QGZ$$*@B`C-)"``BE@0AR%X(,-9*!S:%@"#GX@HS*P
MSP+;0\,1!,>D,P0!!]N;)`6.($%8[C`'UEEB''V`@VS5Z6X[_!G-K*@,C*4/
M35<8!/V$,*U$E>L,-'SF^U`P@A,TR%RJ&N2,6#2P)V5`9DN8%@3FE89Z20".
M/!P!"CB`/1JA4P(9\.#]#-'*?&W)<&FX0@;&PP'OD8F.--HD!7(@)4NAS5PZ
MJ*:^!*',-$`P!7%DGP1D4-.5*FI]Z2S7+!&Q@1ZND`LGX)T&RI4JEBKA"H'_
MO,X#K<,J4C5+!WA\%UC38$8+>.\(%1#:`'WPQJ*J-0U<T,!X++2H:0T,#2RJ
M4*>$2LXTZ``"?.)(Q80R@3_%L0QC0.P8ZD6!#2SI##`3A!)FQ`.`;8^MV2$G
M&D[0R@NE84(4!9^5`)0"#[J1`B7PG%#?^B7RE+*NAN!0MG8:+2QM-CP4K=<(
M87M&&H$(@6@8H!?U.292S@@+]HFBC,"P4HI.:!!&_*`B+#`"TKTP#64PFV-1
MI2HK64`#(]#!J,A$@:ZZ2I1C"MC`&&76&9T@?(!"`PTY::Z5OM9ZPMH`EL[`
M/G6*H;LPY:\@^CI<>BKC5&<@P08XL&".?E%*7%#6_U@GA,T9#9%W*"@C!\IU
MU445D7N:2AT*FN"@)EDTM7!%D0BE=`4#)4IJAVCE(@\AOC)T8!`OKFL.Z%6(
MGH+OIDTZ+7%].AX9S.BT42P7<R>@PC14=A`+7.JOR),Z$*2`EVDX@B"V^R8B
MYL`*8MC@C$0K@DK9I\*H@A_\XKB!"LL7OMC53Y<(1H$HGT'-8;8PM>#:K`"'
MN*\[@,!/!LL2+G.`RN%19X1QO.//IBY[\B6$85\GI13,ZPPI6!)R4W>$#99A
M@D=^XXQ:S#M%;5H0BF(4U6QK`D34F&,44">C)ER(R9X/R,'EWGN'#,'7(KFK
M:J-`DWN0'0E$&80D/8$.?/_`H^N,U54^ZE=W-Y#-,5QA5*+M:JG0/`8\PT\+
M&G"SV8`I9P2J30)-OK.WQ7`"""AZI0"SH8#'.:,"&_@8A=78H7^U853!VGP@
M[.B;":%,$W$W2FJ44E9)X*44;$!./%YQ2G4A@3+7EW=`Y6UM9T1;0@C4F,7V
M-050(*53IVY[[T4@66F:!BSPJ*<0-#(/SU:IE8Y5R!:(+EMSM$/R\FY@Y^47
M=GE%`8I>H03AMC5YM>V?"D0WEP$+V,EI-&Y]7^>FK:7H$:(N]3TO.MX@O@Z!
M`WMO7!26#-B%-;JB6]GK=`!0"99`>P>.<?\%*WT"EL!8F="K*+OQHJ/64`;B
MFU?_"]`/D8:P;53/G+I!-+D)_0SIF'T$]UU?U$MRQ7J;C8@&T=Z1R!&<.04F
MT(&:4^"H0J6KE&O-01Q=)P.V/BV7B1Y='$!`[MD"WUN[T$^4:GD\)#A"#XXY
M]_G6N-R8W_.)QK.!(_@@!7:%\/7D_>=Z"[KL^#:L'0]$<N[Y0*/;4\*9(1W*
M01AV1LRC0$];WJS7C@$'(_#!`/\.1U(/8I!B@+\02)@N17*A90#8,C0$`F&D
M!"10`H>'(O@'?SD07SDS9^<V,%T`)NI77*%W6JSE'SG'0;"49ZN'8P.#*DWP
M`T>P0VAP0<"$`R7``;:F!250`A,S9AA430.B`01(2".0_P([5%D?%TJO=D!I
MHX&F]8+T,TE`5RS4=QU-Q@0'2&AEX82+``L(Q@%\4@$\,$!B9@5RE3HV1'=#
MEB^4Q"0[UUC>0R/FTBH9,`'NPWY/45@>1"-J)$%30U)!)&9,<@+P(#TSDD:N
M-`+P,`$7L`0;-(C\-'K`AB(`AUX^11TR]VM>`F\C<$]:0#]C:`@NM$+>-S43
ML(%PF`(AN$$[I&66M8=GL"TY@(5,T@0:"&E&@C&/U0'486Y@4G%=D$9B]@4@
M0!V*=@&"D`%?D$8B,`$2D`*#2$78)PPAY3/==0B;>`)-4"*?ICE60F):$&*$
M,"<L@R(?(#9<@#I1U`1C<&="T/\!)5B-%<(%72!^&\*"X?@%.T`"6J`\C;*)
M?D,G]O@%]MB*L:8$7_`@71`$5$@(%_`XX6AM,C"'QY,%V3AZ'.`T5Z`J04`G
M>*B&=&)&#)DW*O8!1\`%7/`#LC,CR+8_2L`%%W(&RL-9JP$"5O`@8I`"$]`F
M%\(%.@`"3H,XUU$"6G`A7;`FJ/6,#Z(%.X`BAA<RN0@P6Y,%JG(\>8,!@]`!
M*\.2XU@S((".D->+U'AC@!@$)>(I<WB,OG`!&<"+BC`D_,$!C2)UAX"6O>@N
MT<(?L^@M4P.7L54!'-`!&M`N$;,P`8,!&)`!?2DLP0`/-M@!WS)ZFT@?9ND=
MPB*6CL+_+*GCF(\9EAZ7EQE``B"P`>$FC.;C>0<",!WP`1_@'W^(+O3Q<(["
M`:'9F':"'[]4"/Q!F(4`EL;R%+(YF1?`-Q2@`?2A`>\P"!`CF8,@F\2P`1W0
M`>GBE=?`+9)0)K,R>I&P&F17,['5G#73'8TP'4>2G>/BG(;9"*QR!F/P`Q8`
M'ZP8";%"G0V3GO^""-HI*[$%'=;!)]%9G?.)G,NA2&IT!=,C3OA0G_;YGT)S
M!=>%!E8`B_]YH!$!4B.0`SW0`R9TG`@:H0-1;-,AH19*"E!XH0J1H1K:H1[Z
MH2`:HB(ZHB1:HB9ZHB@*$_YI%\;P$<KI$9K0HJ+`H=A0#>KP_P_.\`WF8*-J
MT0SP.0G7(:.9D*.-P*/7$H5%&B<_ZA!+BJ2.$`%0&J52.J546J56>J58FJ5:
MNJ5<VJ5>6J4/\*5B.J9D6J9F>J9>&J9H>J44L*91JJ9N&J=R.J=T2J9PNJ42
M4*=9^@!\VJ=^^J>`&JB".JB$6JB&>JB(FJB*NJB,VJB.^JB0&JF2.JF46JF6
M>JF8FJF:NJF<VJF>^JF@&JJB.JJD6JJF>JJHFJJJNJJLVJJN^JJP&JNR.JNT
M6JNV>JNXFJNZNJN\VJN^^JO`&JS".JS$6JS&>JS(FJS*NJS,VJS.^JS0&JW2
M.JW46JW6>JW8FJW:NJW<VJW>^JW@&O^NXCJNY%JNUNH!Z)JNZKJN[-JN[OJN
M\!JO\CJO]%JO]GJO^)JO^KJO_-JO_OJO`!NP`CNP!%NP!GNP`*L"(1`""KNP
M#ONP$-NP"ZL"$NNP%`NQ&)NQ#]NP%:NQ%[NQ'ANR#"NR':NQ&<NQ&%NQ)6NR
M(#NQ+,NP)?NQ+QNQ%GNR+CNR,]NR*UNS-UNS.VNR$BNS(INS+XNR1(NS,%NT
M+&NT.:NR,=NS1WNS/\NS3;NR/ZNR4-NT68NT7'NT3SNT%CNU43NV9%NV9GNV
M:)NV:KNV;-NV;ONV<!NW<CNW=%NW=GNW>)NW>KNW?-NW?ONW@!NX@CNXA%NX
MAGNXB)NXBKO_N(S;N(Y[N`H;M$@;N3Y;N2XKN9AKN2,;M)3;N9O[N9X;NI<[
MN:2;N:-[NI^+NI2KNJ+;NJ#[NBB[NJD[N[);NZ6KN;;+N:-KNK1[NSB;N[A;
MNK'KN[UKNL.KNL0+O,C+N\I;O,&KNZX;O;#;L\R;O-9;O<PKO=K[NMP[LEO`
M!5L0ON([ON1;ON9[ONB;ONJ[ONS;ON[[OO`;O_([O_1;O_9[O_B;O_I+ON"[
MO_[[OP`<P`(,OYA8P`9\P`B<P`J\P`S<P`[\P!`<P1(\P11<P19\P1B<P1J\
MP1R,P'S8P2`<PB(\PB1<PB9\PBB<PBJ\PBS<PB[\PC`<PS(\PS1<_\,V?,,X
MG,,ZO,,\W,,^_,-`',1"/,1$7,1&?,1(G,1*O,1,W,1._,10',52/,547,56
M?,58G,5:O,5<W,5>_,5&'`4Q``,Q$`-1``5F$#EH?,)44`4&C`9A8`9K;,%Q
MC"91X`4(+,=14`55$`-X+,%2<L=[>`-F8,!F<`,;),@%'`90H,AH$@9VF`9U
M#,AAH,!R#,=HX,B.3#UAP,@=[,D-C`8V8`.1T\E0@,`W4,8T\,>2?,H&#,D%
M#`4NX`"D[,!5$`5P?,D([`51P"1M;`9Q[,H%C,ES?,!10,8Q0`4K%`8TT,L.
M?,B17$&%C(E00`/3G`9>H,QI``5F/"/<W/_+9D`#,6#-!GP#E9P&4<#(YWS#
MW)P`"Q`#4+``59#&:$#(%13):3PC9G#-:%#(_<PDTWS-:)+/5*#,_ZS/A1P%
M+E#/4K+/3'+0`#W-$%U!,_("IXS)Z.S&]XS03.(%"^`",=``#N`%$RW03>+0
M^DPC9N``-["'\BS-$8W-"S#-BGS-!,T`#=#2>UC)8=``_GS.#J#-^:S/:633
M8I;/4/`"1&W(YMP`8<#2L*S(L.S-+Q`%#(#2&TT]A3S4$(W5_PS*!SW1'!T%
M"&`#5&W56#W5,Z(`#A`#+J``E6P&7B#,#WW.+M#+$QT%"E`#-J``9IW58@W0
M!9W4T`S3*MTD-]#_`+Y<!3<``V&@TT,-TPI=V%XMT`[``#'P`@F@T;`<`PJ@
MS&H=T`V-)C9P`,Z\T3%0`R==R&&0`#`PS520`(I]`Z[-`%#0US#``%%`V^.\
MSFA"!0>@VFE@VR^MPS!``Q7DS@KP`F80`V$0`PO``'^,!C2@``L0!52P``KP
MVC'@`,O=`)]]`][M`)I=`S?0TK=]`R[```O@!3<`!5X`WB\0!B^@`'[M`@1P
M`S00!GVM`.8\RPJ`W#/2UPMP`U[``&S]W&_M`E5@`+J-X`Q0!39`!33@`@O@
MT_'LW_I,`ZE,`!'NW4Y]`^P-`VE``\C=S&^M`(W<``P@X@MP`)#=WC=@_]^J
MW=\VX-%>D,PV$`45?N&';-U!30,UH,WQK0#C/``UD.$.``4%X-06[@"/[0`?
M[0()4`-H``,+(,^RS-Y5T``%(,;1C<?-'094L-!04`,T8`,#``/>K0`,$`9#
M[M8+X`#^[.4Q@``,D`"(#-T+(-0O`-ZYW=Y=OMUF``/VO<JSG``W3@-4X`#@
MC<;>W>)[:.C7[0`%8-9H8.=X[M]HP.?:/-S:O`"RO`#'_=YIL.,VH-TO0`4%
MP`!4`-X+/2,S3M*\;`86W@!>L-(*X`)GG@950`-=CMDVX.7<;`8UD.518`8O
M<.'GG-A,<MX+8`#5W.EN_MKU[=>6GLK&;M__[?\`5<XDM$PC!?[4<UX%"(``
MQVS=;=P`[RSEY)T`,?#0+@`#)$[=;GX#Y][L]FT#-4``+R`E8>`"(IT&#J#:
MLMP`9JW>(7WC!DSO#B`EMNWJ._P"R&T&51[;4=#G"%`#-?#'>ET%?,T`P.[?
M`7X#!U#FF1WAP6T#F$WB-?`"T%T%;4W&\UX%JPX#Z5X#"E`%"A`%"7#&/W\`
M4##CA>P%/7\#->``+G#@,9``P/[S"T`#WQS@+E`##/`"1I_8+F`#PIQ&K?WR
MN.X`,/#GV6WT">#14``#C5[P.[\`0VX`B-S/HIX`C4SW=._S/M\`S$W+5V_T
MJ3[T!4#28E;=-[#C"$#_!?P.!67MUR$=!6+_`BH?\E"@XB&][#)_W/*\\1T_
M([1,`P30Z-!-!>@NTAYM`RQ-ZCSOS#0@ZB=O]9//S0P`\`B0R@A0!0PP[#`0
MSS6`\S00]%&0ZE:-[WW<`##`X`F@U&DPX[^.V>T](ZMO\E3@^I0?^^+N`C2P
M[,!]QBWNTWV>YE!@VGOM`E7-`,*M[`A`Z#30`++\`L5?!62LV,&_V?2^^MFM
MUTA_W65=`^<,!0[`)&0,`X#0$+4`I5#UDN#U$@6S4&.X$)40!35Y$'6C8):6
MYH"P@,!@!N,0U4#Z8F-(PV"34!5CB!!3N)E&Y>#5$$9E6%/3\++IE0`E:8,0
M_X7&:7;CD,8*Y;(0PP#EP/"BX*)`Q?G-&=;@59IFS5`%KK[.WN[^#O]"DV:V
MX(46:4_SZ9UF\YPFC((P:6#$:$"ER@)H,&#,0T>E00P8:6J\B!&#H4$&_<*X
M8*!``91=CAIP6F!C`9HP"PA&8<`)G[<:V-)Q='#C)8,#-%(Y@-(IIX($-=9Q
M;`!TI,,T+EXTR.:"W(($#BSB\]*)QE,HK6"F.>6UE0$#11W8$-0)!@,T9A1@
M!:<+P0N%S1@L,'`#88-/"E[(2[.@"A4&,0PL6!`L8T]GT!!TX^3,03".]EJZ
MN)'F!<T;#*)\!9K&V>!;A`TO$!5P(&,7-1PO4-#S]?\DF%6L-6!LREJ:B9QZ
M!G0$,+2+EZ0+'T:=1L$I&%Z\+#`S.$RK!F98W:V"-.34C&F\A`G#V>F!PRYP
M0C9IZA_#&RY8UBAPV.V+4.E"F^3DT,8++PQHN"#MQ30*+)"7>R;AD])*FG#B
M0`PW%`,87S!H1@-%[CU3H3E4.&<+#.,98`-C::#QURT+?57#<^`P%@8,#;BP
M"RJ[;-(0.S<8=L`+GW$$3X\^_OC.7VW=DP\5-$3T7QI1N`5%(S5XH8`-'"F$
MQD0.X2,88;LX<!%%%3K48(O34`&#2"T1D@`5D@QBAG,$$4,%%4[!((Y:WAPE
M)0R]^`<,4&;5$`4-"=@2TP+_9#K@T0L&I0&%`085T"1"DM7P7W_$V%!%%2Q5
M$@45"3P8YR0B&6(64E_1T`T4![SU#10V0(%`)E4D8$,4L5KS@@-5U'##E1"U
M8L@-%2H&0UY>'/EB.`F(9$!4;I%J`U.;H66J?5R1IDH5-\2PC$#-/&,68;"4
M244,LZ6A$%=Y,7I*>PM0%)I;-4SWS5G$#98)%5!P.R*/G'!(7`P(/(D`%*K6
MYLQ<,7A6$6I2'K2K#3"T%\,+]L1`((8PG.5<)?K&4,61"\QCGQEAC!(#30K=
M<#%LAI;)E4`>+PF%2E#:8A[+9KS@0LA0:):)%_.>!8V.G7$8D#55G%6(%_M>
M].\D_[/63%"]SS#BT<+,-0@#%&&8A<8RWZ!AEF#V6!,8D&JOW2,-T9J1"]FX
M5.'`@`RC4:8"0FUC1L_DH/'++V1[447/AS5`PR_^T."V0@J4`A)BGM*`**H*
M/.G`2@YL`GA(-3B>2\],P4+-@)<[N$A!4*`Z\CI^@\3`L6^+M"0OKRW@@@T9
M]3(5:(,_,G+GEW]M1@T-_>S-"ZX.:`"KG"R).W\7F?[S40,::</@A>\<D@V*
MVW`DK75'\DU3;7F-Z(O*[]8K\IDQ[.G$Z+K`_>7A;-ZDZH,H]]*`G?U'CB@H
M3T=4B(I=#@`O-'`C$@+\AJ=X-K_Z%843HOM7Y@IXBT0H4/\!("'3.3A8GZ^=
M1@%1$,=K2M@`#D;D<2[('_@\11,SQ`(V_#E-?6SU&A>X31*4JI\A(H>0!%`N
M#):S`3E,MCG\`$6!-ZBAH=RVP4C\;'%,V5`2H_"?L.DJ;S=P17T>`9NO58T3
M^1/'XTP&$OJQK"_-`(T%;3'`*.B*;72LXS?,(#9;;,(6)U/'=YA1-3S28T1F
M$"3G]G@RMAPR;/0(PS),QI9&\I$@D8SD-_[82&8P(VR.-%DA\6C(;HT1'+98
MR2/%1DD]=M*2GQ3;(`,R1DQ6+9&&W!D-8D&H.SHRD[1<R8CZ&,I*`O.0`=E$
M'^^XQT?^LI:@/*4N];A,4A*2'LO_,.4OV<)*;!Z2/2F)5DP2:4EF%%*3Q1R;
M(.\XS8!<LI"<9,LNP:&FJJU$E8AD)S&_,\EO$FHEWCF9,4]&#DH]`Y+U#$<@
MTTG-F'`.F-7L8R3'2<R$;A*6X7`E)G.93C3<(R8;S20]<AE.18;3CB0MJ4E/
MBM*4JE2EKB1C`\JQTIC*5*5A<`H-,#K3G.H4'(![D?-V"M2@"G6H1"VJ48^*
MU*0J=:E,;:H[6NK4J"H5JO"@ZCL8*52KTG&<V$3GC[#*#K`&1*M251M.[0A6
MK(XTK*-$JRO/V8ZWEI4=YURK27-YUK%ITI=Q)6N/VEI'L985"O7Y1A7<2$<T
MV""O,5&L_QA]1-A]U7&QZB#L5>%QV![UHB@*?$N51IE9=NS*'87[!JKZH=<1
M4=:.-F@K%%!+1R]@9AUAR%Y4PKK:'X&O7B23TU4_`EBVP8!A?0ON\W0THA@8
MMQUFR)XZ6DO23KDC!B2[P0O\RK;/?>,%L%5'<]%``T788QV=\EX=&U%8.W*W
MK$:*0EM@@`;LU90!WZG!8N-[@R;2P#/-"&]\H5`#7B0C#/8EE.R@4[#+T2`=
MS:4!09;FC7ILC`&_P./J;F`&P1QI;#=X4A4.`(4&4T$@,#!#H#SCA4!5(0H!
M1A<-,!.&74&!1"WQF2N--&-N,-@1&Z9"FUZ\L^<0\;Y4`)0W0O^FC&,%F`HG
M"@,"Z!0%!X5-Q1_VW857XBHSK"Z]@=I0K+1,`Z]E`PTAPPQT:D#8&GA#:-F#
M3A?#$(LP'&O&D$D3C]=<@_!6H6"&W2\]?O$=K+2)4DJR"'('80/GLIF15#A`
M#?J;#ME"5U/H`O,-L+S8#C-@MD,B<(MEAX9K:<K'*U[PGV]`A3QZKQD(T%2>
MFQ,K-`BK"F0&L-`N'6I3:]C'V0#S3Z&TH6[D&L5O&N.Q+DW@!9,Y4*P:L6)5
MH8P.W^.P3X)5G!J]X&%0D@$NB$%5G-M>>GCOP2\6FQ=F`684`SC26/'.OF;L
M-`PGFA!2[<4+.F.`SO1E`18[0$2<PMW_`[A@62Y`@")>A!"!,^`V!'`1-KPI
M$&RPA@`Q.``#')"`FCH`1L38='?&\QYM=$T!,*`5`[C=:DZD:.,W:/B]YZ.J
MKEA,3H\[@`-PIQ"U&$\N")`2B/F=-B4E`!$T6`"(1_0)C/-G,!_AS"46@`U=
MV9P4O>"&E&#4&:]0@0`-4$7)T;P-!<2@X9`A.:U@,(MJ6*P^]FX%`5)A=AH<
MH!OOHO`-!!Z*N@WFWF'.45\:8(":C0D_!$`&[E[![8<W?!E5+\93GF(1X5BD
M$"XHP*$)<'/F9*,_R[!!P\LT<.QPD'ZST,4CT*Z?!#3DX@,`33VPTX"G5/U=
M(SF+="3QTH%(_^8N5;LWXL8.C(WK[>T'N3<5$'#SH5]B7A:K(<P=@[&-0Y4S
MB//'T">1BH),D#_<H-R+9"&9!7V%$0LG`)D0WNB/$*;P$B%`4S+2F8`XY@4&
MF`^@@/ZSV(>W[B2+`M=KD``#)T!4L1879P8,T`AH)PT)4#&LQS!.=7R70388
M5@.Q4!7*@T`%EPE58C1WYQ<\H0`:Y1;V<'/A!1DP`6SV8`CX<'<NX"&JP"JY
MLR[&4H%/IANZX0]/YE[V$"@P8`!RE!?O@CLZA`9,(A&JET+=EADI\P("T0"/
MQ@E0DQ>\,2*/422G$6`6,0BIL8%*01'>`3X-4`QKP0D<(31H1PK1XO\=`_$O
M-5@Q-(`&"7`*"-!;"'`9KW>&=)@[^T`*EV,27<<2:%@W4L(N_]`63U@U@]$6
MWA`)PN()SO$6-9)BFH`/&Q<:%V@6F8%<A4!FU/!D&#<,E>$-W884FR*'E'(L
M`L,G6`(8(8(I!$*)N/,,4'(#!7``M!8)AE`/&Q@&B1"%#)@ISR$L+K`JAD(5
M:*@:,%$5QTB'-R@-(:*#[%`W8>-Q%9,[F3%!Z_(=JT.,M3,DG-!U`U&$-V"'
M\X%+4/(2]3`(*:9O<)1G_]$3W-`(IP",?(AQU10870<-+D"$UA`2>1$R'D(3
MCV8(R9%?T,546@9S/Y$2WJ9#74.'%1(P%-'_"K-0(2RC497!"T4'$$0C$.MH
M#PABD7K2$M^`$XRA%/U!#3Q2+;6%<0J!'3J$`+B0%T]8+)I1A"EV"K#!A/-`
M75;!"`-#01G!%17##.A@#H,@&+'`A-?2%H1X#8M"8.]2)B]131Q1#:S@(ICA
M!4Q6-6I1=!53`W'(&L/%##]S*U[@(JCB']O"D[_P'SC!$D1'7>IQ#3;@`FC`
M"$+$"8J8-BA!E8E0D@5A(3IC#LGR#Q;!&KMQ:"@8=]35+2J8#HJ"%O(($I'"
MEKE3A.GPA#R#:"H!&`XPBU&"`*>`#X-P,H"Y$K[8'?/"$>CP+@+C'`]D$2P#
M'L_`&D,GD?&'%*G@_Y*L"0Z^@0:ZX1^+J4.<0#3-P&_[@)KU\!;AB!45"0/&
M@Y'.,0BG&9(GAUS8F"$6@0T5B"FN62:W!(<CDH^802F+&0NY<CDV=3EWZ!;F
MH)@_A52#8"[7X`"-(#!504)]41Y;R!N&(IJ-4#,920RLD"L``27WE@L#XQ8R
M\2)J405L2$%/^`PC(1F%H1:>42VL8"ZSLIXO0`!RY`!L20@X:82><A!O6!`Q
MH`HU@S$35`FQD&<)])>#\!)JX:)I\G<(L1!Y(0D8(X884S!DJ"'W5AAP9RX/
M4IX9:@!B61"$82C/0PV?(G:QYX,5DQT'L3'@<@.;<J5=RB[D6)2M<PL_1_]K
M_<&`.W&@S\.`(W-QTT".%CAYJI<CSU,`:C$7JL<EX3`0"9@F:-%R6(0`7W,*
M!<`G!?$ND,(,/[1Q'*%ZW#82,I,/1((+Y5$`6*%`_,@1=#@+@`<E,?`1&%,+
MC&$6.FHHO)E_+E)R3I-+OE$18E<,3"F4W4%R3S$+#E``M2,0;X$KV;"K&4H(
M0M8-MU(S6%$#`_"`>JHCE)()K*"8][8D7%HHN\*`GZ(9MU!X,5``V)&?B'J-
M]P8#C!I5S5`LZ`(RU/FE(.,%&.$=F!$GH5%?>@(>;(%A'48F#F98T[D)'89A
MLF8R%>)C&&98M*!N<.8@4/"EC/(61*0GH:%FTVG_1+#@-!MC8K2&86$`%&02
M8%&0#G$"9_IBL:U2+/%U-PO;1!C&"(\6LFIY4^#1'4`A0)E6+$8T6_(J0PD;
M&NO38=V"$;7BL>+6-7G4*YBQ.NWZ8AZK7/F:89X!!5[0#&3F$'(&%$Y#1%&P
MLJ5D7P3[I4V2:,TPEL\SG2OAKOY`"X3EM!O3#T+#.)M0!5/+#)=6/`_;1`'Q
M:/H2$-25$Y95/"[J61E;MAS;)C*KL."!1U\J,257->T:`\A:*QO36JM36\,E
M:[6F)+0F,4"QL$\+"T6F)P`+#BL6$YE+#XQS`X7UMC?%"(DF6V%#L(QR,HP3
M8'/K7G)+@2$B6YM0"0;F_R!'EK:/QK@?"[<C@K)=<[DC$F!>H(9ZB[6"QCA&
M-%=2)5C12[W5:[W7JS8*9!?7%5C8BU*5,$'>*[[C2[[E:[[G2U(FYAG8A;XJ
MU97LV[[Q*[_S2[_UFU/3:[_Y.[YA\("BU0]:!K]C`UC+]2/CM`Z%E!!UE&)&
M!3B(!20;4D>"L39R1I\^@K7_VQQ0I64:J[$Q83`-VQQJXS1TUAW>\0Z.%&+P
ME%X'?%8:F\+H`K4SI65>\R\F[$`KW`XEU"J)B+7,T!P=+%J"@<,"G,/2%1`A
M#"3\^PT+C"Z4P%&$T[]PD1#=!0\S3,#7.Q(3-5&P6KF$Q$AXU%*"-$4))0Z+
M5/]-R:106`7&P[%)8N,@&%%786-7$_4/<LQ3>057C251=B5(Y'BS=#4V9[R8
M:Y7'YE0T@F7`KX2<B4-.A)+(ZC`1)+,Z_-)8S3`8UT(/B@(:B>--CKQ/KB1`
M39BW(/-1ADPWH#M.01M2MI`R"-4=?I$.""MHCBPV<YQ0M'Q)3>$-X/5B"640
M<'56\5=(_F(\\&(DC4MG:B5#>K++GJPD23)2D:QRBD-75#42C[0NH3$APX`1
MP`!6?:PKQ&55<)4H44R^(\$]Z-`W'"0T<\$<X54>]O,("%A-*1$)NMHDW9.L
M8687B\6>U6`/NO`N.R./5%``#H`+8K<,7C!W`W<8NY+_#35#0]PB0YV3#<@`
M$@]8"&&4$7`6(/0F0XZD7$6'#B)$/\R@#:\9>'EKMA5Q#<JAL0MG"J!0*R`Q
M6^!E0[42&D^;0@;Q"5,Z(GGS:-J`*)#!.-<`==H`AQ83):X2&K-E,/VP.@T1
M8WG)8OMU#MB\L!61.+K0%RW2/5C409QP6'2&L.4R($\2S_I1>`[&,H10*\#`
M;R8&$@VP9VEB,>/P+PIK3!A19*]18B2=)9<3!=%2V'*4U&('#8?!,.#QPLQK
MT^;RT&94.>F@9APQ"#LAU<;0EWZM9C!"0B(T"SGAU4VH#2BAJY3P&MX4:J^U
MR`81:A3Q*K$0"2'3'6%&'4Q]_Q_Z`AJ,6P/CP1%58D/.@`E]`W5$E`[AE2+T
M%A!\W;XCD2)O^X2!D2LI8@WH>`F9L"1D<@!R+'9JABJ'P`@DE&"\0M[;TFJH
MW344UG.>T@O@HS?.-9P-D8]J`0,3JF:70ZS;77&M(=V-:@,P]!S8[5ZI<3+%
M^@N%,QS]@9R!P:KT10^!P0`&MW#CD)]JH0LQT&@T81:SY60)OICRX()OJPV%
M@UPU%67GW6*-A3%[YB#RD>(U<X!_S%-,X3WFUVV1<`Y/I4#WS5W#Q92&T!1Q
M%1!=(RA1<`FJX$6YB`G^<19V36'@8RO_<!&",.1A%38UZV\#\SE.D5^^@9?A
MS8#:+?\21<=8:/!2KX)>7),+8,&A>5$S^64`0SPB>KEI,\FE/:-Z#C'BW+4(
MC7!:41(T[G"`N-`\A.$+A``3^-)UZ'!R3]4H+-8*A.`B>&D1!R%'#=&XA"`2
M*<)8Y7L-?^$<58$NZV=P+'&=SD$3&<DYK2$2U]`W(#&"5&`:G](26:Q#R[(=
MV3D84<`?<F$+N8,1#%&*"](4:Z'J)J'J%WH?=)$6R)X/J"2.^O`)2Y(`K\$=
M?Z$0_K%=3H&`DF&TIY`1:9,[UAZ^^V`HX5H-_>`;A);)(#$H!1<[D$R1"=$2
M3)T`PXDJGYX7V&!\.LX5?A5_`<'4L*$C>/D..P/OQ%$;Z>C_"$;*&N:Q&'81
M>-/I"3ET5=:Q*N@>)T/!.`?_D$G)'S0`'X=!P.:^*#UA*C7YYI.^"4"=PYN&
M'@L'%!BQ$2$T#==^#550\FGR#EJ:#8CS'_4`#*01ZO-P#>]PS7-I&,J1F$[!
M%]R%.,52\O%)O]!-7RNZ"P?A'Y1CG3;#Z4*#`*"D9O>6%X^`UA/:"ZA&DN!A
M$JPA+K3PH#]D,#=@;11T2XKA%"&F-U`"@(>58,H[,,^0S3+C]\$R":!)#R1D
M*T6&)%S2K@S#"G#VA$FB)/5'\OK1'CRS*&%R.:\"@,:D9AOG%RQ!.<I%"A3A
M[JI0+FF2W^'+";S1&0J!]F52$98W_R+NT(LB87.HKNBYWP[Y"6?<@-9&21/`
MOPX>PYQKD2X#P>EQ0@K`T![]<3G'URL38=?VI<CJL&>8X&]J]B)V[PK5X!$E
M:C2^3B!ILB^%/#9H]@A04R$\DR@41@R<$>=[EFKN\!+K8@KROQQ:`0@T83`N
M"U0P"S<,7@E0AV%H:&F3E)-5!PTU!C%1"EXV"E`*832)F0QA+PV1E950")\,
M-0M5-S4V#C4O+PY>-3=F#0E45,-1,:RMRLO,S<[/T)51+\$*AM6T-C1H#;A4
M#FA>#H,+"@EF:6@OUC=5"3$,"PNH"R^S"BYA#6;3:3".\AA4&8>FUPL&H!:X
MD)2F!KX:#?]IO(B2YH8"!3#,N%#@`%6,BPALP$C3;]*-!!@U<FSPC2$:&`D<
MT')@+4H5!M:J3#)#T]"-D3L5V"@6Q@O.130@4K&6P-9%9&EX7HP2)0$#A%7*
M.:`1HV+7-$8#WE0@L%4-&FE<5!&7-6"X`E#\Z63VPH694&$<?*/BP@L,ALK&
M-H@2;UZ-KC=B5/FJS*BU!5$<@'5014&,7@X3T(!QPT&"!0[,T&!Z`Q24!N5L
M,FXEM=RWFC90PO`BKT$,;6FIB#.#2`&-*D"5H7&X($;2B(X;>#F).HH+*A;+
M+:;"C"^4%R3[QM-,PT96!8/E+6"9P,8]:C&\`*Z$A@$-1E74783_4JV!@VE2
M%=B+NZQ8:I5"00&##3&$@9,"U,T2"0Q/^;5>-!!&**$S:*`3#CKI>&$A.F:$
M84:%DX01A@NZK$*)AB&:889Z8435HHB2M`CBAU&IET:+444"R8J`H2'BAC16
MB"-8*HY8HHKI8!BBC.%4Z&0E'EJ(8H;K-9ED)31B:&4R'=(H(GL>[N2A)#R"
M".).+$9B(VL<DNFBCV$XA,Y[S2#YH8].JAB#DLKP6*.*2%;H!5K,-+GCE5W&
MV.*'W0RI(9)CAED%H<M<2..418FIXHQNWOCB:LI\::>4#/WXI*E#%?KAAAFN
M2J:-/+Z(3J9IT,G,G4IZ@:./FTJIX@W\_PG7X9!?YMGJ3DI^&094$S;K[+/0
MUF#?7-!6"^&#E-C`P',28FMMA"Y]*RXS50PVR9H3ZNAM-&0..6X-U$'8X;C1
MS$OO,NC>RTR^](99Z;/8VJOOP`07;/#!"">L<*'L+NSPPQ1*LNZW$T-\+;W)
M6*SQP!E#@^0D%3_[<3K=/CARA#0"?"<E(;<22<LNIPRRRRV_S'+%,G<[,LSI
M\+PRR#P#G3.;`/?H4L=D!LW:S4:+NZF^'??\Y,44;CPN%5#<``U#-[@;#0U:
MNT)M)8>\(.,--WAAK4V6P#!;.FB/[0P,%)WX`@QS`1OO,E5`L6S(:-C`)R6'
M?;4<,.P"8T/=$?\>1F@44`0[20T0/9,84+7<,/$-C$]"!>-I+Q.%VR^B/?@R
MP#831M@-&3<)Y*Q'\P(5@E32]TYNUQVYY,Z8EVWEE\<8]S;L";YU7^G`$$/8
MD#O">S11Q,L;W9-$WKDR73O3=>J5+._V\\W,SC<4HULM;@TP8#<I1690_F$5
M4=3@A1<(``-%#3IY$?]R-OA(10T4(1$:H$"#*(3!,FFH0@V@P!#:[>E&+IA=
MG`27J:+H#W]1,4^+?-$U!E`C@3$H4%1V09];H",*-(@7"JG3`&#,Q0LA5)L9
M=J&Y^^5O@;Q9!!7,D#E?4"<,VJ@"%1!`$0)2RSPUD,0TJ,'!2-R`3O#_DQ_]
MVC$_!5(D/@FLD`8)=YR&D.Y_%(G!7PC(0"_\;V]/)-Y/S%8%&S"O@`FL(@!Y
M$IJH^,8,!-R;`]%!A;I4H8U:XX?@4'A%M:VP>N^I00)P=);*H0\&8;#BC:(P
MR!2FPP8V@,P.S8#)0:`B*L:IFQC1@L(;]B]3*Y((26K@`J"@$"I5\.,.^U:#
M,`PQ"@/$7SCBIQ-.@D(G:#`.?Q[I@GWXHI8\E%_\J-`BVNW0@QPR3KQ&&449
M/E%7(4F#,\%RQC"$9"T#I$%<<I$4_H2SC`ID(!I*`QE*'/(@VL(D.A2H.3/\
M[W3F:PPQ.N&"!$2A`0P`*/T<`-`;$.`%\#@(_VVN<@`7A`0&#0V%/1SR`LT8
M@`%1J$<BEK0K8I2KF"_(RC^UE8"-5,$%#D@I;6@2@P.,PD5J2P<QO%!,62CB
M!8;0%DZ_48-<B&E(,Z6!!P6RK05`@0$&N,%@&HH2AXJC`1NA`0%B4`,/TH*C
M(?K<2A6`/M`@"`$=80`4#OH"7.`#`:=1#P/ZF-)]+`E#9OR?`39"H.5A)"3Q
M<"I6;T2,&Q2`)F`K:2,&M!&'0B$!L$A@`3(AV+J)"$?VI((-#"`3L#64!H*%
M`E5O:HA9R(0!!:B;KN!*#$W0E08(L(=5^QA0`A"&+P!U`5*I$PY(6((*;<0'
M@CA2#_15Y`6;$84+"O\`E,?NQ*,8;>AX;##5JNX4/#2A*4`+H+;:,D2(G3@`
M88K)D@,XX"/#Y81&;X"`1<*4$D*D`@-BX@F<TH2Y+[B!1@FCD)`4H)6_T$]3
M2%04KNGW!A4U+`Q:6[?8]!,*"SA`#.Z+$=H<Y!<-C6D^H8%0L(CB0PL`A8@\
M88B2P@`!0K6)`H*9/NRPTAX*A"@N!(01U$P,"@=(WP&`.-?VV"`M#CC`W1"`
M4D^YX,;.J*Q1&/`1G#:`03!PP&)Q!M8/QV`\M=3%3421AKNE@1;W>X$!J+``
M+X`')J!JA0T:<*/*Z,0!#-HP;6C:4XALA1;MN8&.(7J]5M"`S$H5HR]B@`#_
M>,1%K-I;@#8-TQ`'V,.G#J@K)1IP5*W%`#O-R"1)%B"M-/ATS,J["H,.<D6E
M/N,R%3DR=N;!(-1`HA$,D*^*VNB"9[00+)7V<OK28`,2\>+&K70&;3J!AJRL
M^<L)8!`5T*``BW0H`7)KA1@#=^=&+(`;N(8!0!$1P<HU8Z/?]40:&B#4<A$9
M-(!.M4"4M^<#L!+()SJ,@H%;90:I1P%UZT:M;*V(-)PF!L%N`%<E,V$(51B(
MST9#AA?0H2X;(K42>>U-TA!"MQ7:'L7$[)BGL0"N6'L9,*;!9LQ@T)$`FA=]
MWDR2HW)2=)/KR:C9"F=`$]P&H";96$+X[`[Q#EW0_^:H5>X*9+;%YXP>T`4)
M=T9/H]()M:&9X`=<,\0U1Z(N"YR\,)"(A)<1@U;?6XS?A@<+P4>)>E<FU;0V
M-"NU]N,0+OJH%*%!JR--9BZKW=(0P?2352Y?BGR"S,ZH>JC-SG(8.*1%.[>(
M)!2X]D(!&H9D/N`N&@+T6_LC./C:.5@,[N7&RU>MJKX+S"G!%2Z[#=X,V+;6
M[A;0S0#XXLMH9RN[#'>B<GM`&-WV48&#]=&<NQ4#+H5$;KR+!;0H]FD`.RMU
M`07)G(9!7$E*X?O]#%$\6:@N*`27.^0)RQRD%.K%K:#%"%$&7:>JK2S`F%UP
MDCO_9F^M."`A])((HY8#)O]4@.J`.P$/0K`$_>PQ=,0K;E3=0\8!MJ`<=48)
MJO!D1U5_#H%@A.$/VY`([S!<0R02[@$9!K0OEN%!LH5O%V8&7>8;)`*`:$`B
M#(!F6V8?3Q8&%;@,-&``#%)7!!4#++A6P1<]4U<)?O5DM_$.37%HN$8@OC<)
M/&<9C?!'S'"#%5=K%?$.0A%U_D=`Q>$;"$`,7D,),/@1!#(232A;,``7AK`M
MLJ5(G[,NLX!OH"!M#O`*'T%WEA%C:V&!&=5K7?90$XA@ZF$(]N$"!@`_^%0K
M7*49"X!6H2=?"S8@_`=@BS"`Z6`-,'%2#+"(EN$0I:`(U"%6Q8%0)E@`:F=R
MEF;_&YM`(E4F$1X46I,CA*7A&V1V&L5P9[>Q?,SG#-=Q2N06.)$@.`04)R\0
M%UVS.MHT.F@6%S;A%]U!#`4R#36`1Y02&"$$/W&!-8T(`]0Q*,ZH35$72=[3
M#+2G-C905K,87P.D'@L$>:R!/@Q$C!T2`UFS'"1!'5TS.I2S',68C8Z&B-)(
M`RJR&3O4/X%CC%#0-VJSCW[12:00C=2C@D>F-9^S++>1-2V2-K]0A,5A/"*A
M-3:QCR2Q%GCC.>DA$A3Q1,R@+;?!0_P!8'$!7.L47Q^B"U%@!N88C03)&6CP
M.9<T(!5B'/(##(,P&\MR'7L8.+<XCRT2D=&SD7XG6:A'_PD<AXZ<M$[%J`O`
M@#@49!PVX`5FLR\Q`!UEY1U:`QP#A@P`UC_`T4=[V(S4(1H7J5D<-R!'61'Z
M(TZZ$4*+PS90XI94H1/1(QI)L2LB$1?+8@-Q@8ZC(PBWTXH`XRQ^-R%"U"PL
M`2'ZTR]<=S!04(,*XS?,P!41$@60:1*L6"V'B3J9239H!0V2J8)AUBP<-S!P
MR3&(,R&=0!,PQW'>P@WX)YBR.9NZDB[.4@5[.)NZ^2VT8BT\I#"]B2_#5BW!
MN9N"R8^WF9O&N9S,V9S.^9S0&9W2.9W4:3#T(3KZ,X708D;/DH(#@T<2XRRD
M,!<J8ID4PI?IIS0GDGS+HQO.LO]._?,MUQD5C9E`TL-`$G(R(6(MVBDNWAF:
MRS`R^MD*BVF4^/DL87"@Q/D@WHDL!>H,[Q.;8N(RK=B?(*.@_68AV?,RK/"8
M,K@S.`,8&,))K78F+",SR5`AP+<3WJ(DK#`U&:.A27,S1ADSDU`(<S$1/\8G
M%F(2]=,S4=$+PB$Q>^@7#1!CM5:,+J$D,L,G0P01)KJ3+BHQ87!5"41P.5*C
MM0(4KKD36HHEDM!%D.)6*-HI0%JC>;$H@R.@+,H:V,)H&"*942H)9T&`%&&B
M1@D_7GI`0X*G5Z*E%9(5$\.D2WHS+G"G<1I3&+(\7L`?*8.GS[%QA=H0%_>B
MDWHK)XK_J5]JE")Z(W5DHU5JH1"C$0I!"G[!4O$0)S<!'>5@-L]W(US9%8OS
M$6LU$&*U#O@@#I9Q7:@A$&JG$"\Y#]H5(C)A%^*DDC10K)QD'_]4'`,D#WY#
M$Y"T)\2QC\4$;R.B'PP1%B%E`-I6!8O5$Z@@#O7P,DAU%A72'0=5.[]1"LL3
M#['3"O]TH]:`"NKE&[0F#[HA$QDQ"2]0``M4#L4X8-?P`O,C3C@Q#D+U#_.`
M`'.1%:)1$RJA')NQ&(-"4^]5*Z0&,IED5(@%'.P@590S#Y8I6]\&#D=%:2-"
M$Z4Q5?3%.L11(#C55<J1+?J*0?`2#[NJ3/&01*"0:HBE-N#:_P#EHA]P50C=
MD1<+,!NC4$#J16DVJQ]2^5YH,!KE(#&"4+7`L1$C@6")4"[.*E0-L%CTI1Q#
M\:MJX5)0(#B(H!Q/6SE#RV?R($0X01Z)]1(LA1K+@1,AA0PPA+5D@37ET!?T
MJ)++,A[S(Q,?Y*DDJQ(N$`,$H'$Z`2^9U&`_V&]14#^"`!F:&X49!H`8U1VO
MD+FU%!5K=:1&\1%4``_DM;I$"QH.80N4H%D9]1%XXVQ\N67^>A_<EE&&QIK<
MEE+EPK!'90^45&SR`QG^!`HU$(4QT$)-48R38&A9\63]>A?)2K0($4%'!:7S
M-V*[5C^&$'R'!2]"`0J7:6^AMXDW(?]4XA0*Q0%`W)MADQ`;G;`X_A0254<%
M!$`Y)+)`:&492U$:!J`>O296PS"&`A%]0F547A8%V@4*G=!'""`QF@$O*C41
M#$*ZH2!4,!9_:^5/E&81-A#!\!:%4.5&(,,9-A"%!T!`&,4+.W'!\3=.F409
M0B%6[B$*#O$_R5I'9J`9#J`6%><YVM53H&`+7C;$,]1"Z'8;Y%7"QYM1AU#!
M=E2'I%L,G9`U\&".H2#`FI$85=%3\N6,H="(N*`MSE$7+10V!W08"G!2\55`
MY8%2'!(2-'``ZM5(,$;%0T<2<0PVE/,*H%!P$?@>AG940!9+_P1T1`M<41A[
M+<3"1'2Y$\;_$V!U$SYW&FE!QH.A+0M@`!DE8>DS;;8Q$F\L&9Y8:T:16A@2
M?PFF==LV"^@`?`OP&1AA:06@$7$WQ/WC4G_H1BAA`P;"8[11:>TQ<J>A#SPF
M(U<E$0"X:,[!>Q_Q&9HQ.0;[;%6Z9C+(:`)!!04@#\/`#/.:%C<F8^*\MBAQ
M$M9,*.H%L7#G>T:A"@25-5=A`$>%6R,F<-KBS6_'@;*@340V`(NT:Z%G%,EZ
MI1+3O/`6=3-4#IX@"^$L#_6F/,$W6?.0`%5UI;2!1PF@T2`##PDV?2]P`.5@
M(@V!`$;%:):F5''A-MT`S"6%=_[`&-Z<(&NG7A4Q#@R06I<`L"]I_P[$,QSQ
M8`#:$@X5)QF"&A5.!QF^Q\\,0"8R754L1!6H8=0`:"Z,5E8W$'TFS1&=H!D,
ML5:;T1"W6-2)02AWD:!D!ER@O&6@.$R%]]:95'`PI-+%T,Z6T!%@]6/G0G"Q
M!X!"I0#:9<GY9$4:C5&CX&D_!KHM#"R%+6%4X%V:D%\`YVF7L;)1`"Q1"(1F
M+,LME`CT4S?1-RD`06DHE1=5US_N,1VS"F^+$Q)&%<=5D="H&-MA8QOZD*RL
MDVJ>"%QH!D-U8W/(]@I>QF5I@U:TP`B.`$G>@G.=G'.4]I7P8F2SP0FOLPCP
MQMRL=Z2BD`",@-MK=4#1$X6XA=R>8!&\,/\(6W$W?>%^<'AYF$4F\%),;C,+
MAQ#'0H$@M!MZ%NVQ-W`(\@6'C/`)\7,.VD1$4DQPW>8[45'?+B<(Y4%D!C)F
M)`P<Z'L,#@>$G5$@MN$Y@?C)F6L1HE`+:XL`&X16A!S5-^<)L4$FH5`%E:PA
M'HM;434=,IAJQ5$,9"S)4`!TG='@OW#B.")6JM13%5<,(@%I:XUS=],4'^P%
M+H4CHI"@%;4X!P`*GQ.%\-(`JG#==<,+W_!=H:%QHR`+C*"!<N9SS-<6`J$7
M#8""+_`2`.8<?406C2"D.S'=X`T@Y--J^G`1=&,-GQH;MZQV.O$<AW7+\3(6
MD/%CWJ;2<<X9]E;_#HO`(%S5"8@[#A\1(-AAY]80YYYS$>/0DY-`;8XV%.5@
MI2(1@AR!"O:!6<TAI`ZA'\MR.GQQZJDN"N.1"A>AZG/K.:T6&QBA#S^I`#PQ
M$@QRRS^N$PFA;9,Q0Q?1-?I&"V<1#-X`#EZP#SCUT2^S$8EP$AT[#XJ'Z579
M:L=!&:"`#RTA#@8"=)\!%?HP#_`6&DK;%#NQ$<5V6*CQXQ>Q$!AE$1RQ+.:`
M29WM#^X''C@R$/8V.Z0^$.UC#]8PYU$![D*Q$+NQ#O/`$/@F$_'G(9CQ%*)`
M%GE!'0>Q[!I]B]PR$0ZA"_,>"K7^%_Y*9&B1UDPAS&,Y#L[!<-G(%-0!_QI&
MB:L_P10"$A,"4>W18^DQQ>NVCO1+&QNHT1G6`&]NQ7Q^XBIYLBFV]2@^DGZS
M<B*LTBJSDB\_TB$QHB@HBB*0M16PPA`K0@E?4B,QDB$RPBI^8I1MSS(P$A6D
MDJD7(B.08"I!0BO:>2:C<B,V`B=HTB,X$O>[LBC;&B6VY2GN@B-3XB<S8O8C
MRF:\`!BU"1:"TO7S\OEJFJ4P8B8<$OCN\O<?<R'IU_A1HB+J<=PU<B*-KR4R
MA"Y=/R,V`O@^HOL:XB&`?RX"`R>KLI^(O_A1`3*SOR.NDB/&3_=+PAZ/PO>>
M`BD8`@F93R3E&0K4;_F;8BG'\B=8PB+D/R^G;_\I?EJ=R[DX[$\R[T\PPS$M
M\6\6=E'_[!^"S(+__-___L^<@("&ED98:'B(F*BXR-CH^`@9*3E)66EYB9FI
MN9DXR/D)&BHZ2EIJ>HJ:JKK*VNIJB!;C8F98Y94:!65ZHTM)56-&U4GEJ0C%
M&T75<`/S0FOI5:5(=7/(RYMXTR`L615F$X7I15-E(QK[7'.+:%M58VG3L(YI
MTYM&,X\8%N-I(RT9I1@A;^+^,<)6*0PW16C"#5RVB,HS1PW1X)L69I$9&A/3
M[!N$)M@K3%4.V`@SR(P9!QQI"4(3#684E(7"1+E%4V6P?V:B2$.CT);'F6G,
MV,R8I@JQHC<-]2064BG_(2]47L0@!)28S75*S81,$_*&`R@+5/HL5$7!K2I1
M.MJ,\<*+%P<-;""X@89M2J%%%9JA.LBFM&:"J'`+*DUPFAC-.*9,J>!%&(4R
M,QIM"Q@K`QLN:#1-XX5H4HE,\P6[L4`AZ+9@J50)Z?5KUZ$9T1CV9%@M(2IA
MC/(NY"(&%`:&"6T=R-KV0C,)8OPE"I.TRJ)`ST8'3:5S(0;A]+8F5F4!;-Z^
MD78MUM6+`FE4VJ)A4"VT9<!57J^V'.P6#!>5%<'@IY`7-GD5AE(@)0.60C$T
M4%A`40E#A0*UN<!`%4_1TI.`"@C#%H:V9(B66O!!UYY*"S@4$A5>](025"H6
M_[@A,5&D-I(E,1#P@@/"O&"#`0K`\$X--="`@`,V,,!``TAY@>2)-L350`T)
M+*#`20XPL,`-423`P`LU4-%D%5=2Z84-"BC@0A5-HM@``VC>D$`#"-@0X0(%
MT$!(%`C`UV1["RS@`A0OI!$%CPZX0,`-+[C9"PT#T&##E`P@1<4"#!C@)0P'
M(-#``$!:ZH`9;EZ5A@M4*B#GEPHPD``-"1R0'98U5#'E?VFQ:@,-<-&09AA*
MID$%`0M$RD`,7*X'PZERDEI%`4DBL``"54!QK!<U4!D#DUARLU*T"A0:'I+[
MG`D#I&D(B5IDOKKI10Q(.@/#F08@]4(4;?Z9D1<')/]0@P$,($!.D@M,^Z<S
M%"Z`9QI0#`#?L57`D`"::3@``QHNF(FK776M>N=V4;B*:A@ND`NF,E74.V9J
M-2BPP`'_I`NDI_%B"04!?"+I19N2(@`%F#C/C,"6)EG:0$>%E'O#JG$JX`"M
M5'+4P`+\4C'E`05`8>H"8Z$*,`P#O!/&`0?<@.2/OE+IP@`N2&EI&`XDL!^C
MA,3PJ-1DCKS`,@,X,`C5_T:]P%QAO'#FAOXF\(+7[]1(25I,AM,`%$;^MU@S
M+Z"Q`(\*)`P#?'2)VBH4"-B$<)4O+'!M+/LMTP"%-;QGPP*\,9,EA2G5P`R_
MXM5`%S`+D!H[&HO:X`!+"8#_HPVARXPU:60V<*76`E"\MWAP:#3P7PP.?!EX
M<Y&:.3TA#*AS@+4.6$N6"S#`0*T-QB9M1@TNH`\H#>O7L#[9('$'__C"P^"`
M&(1!6O'8S@W4AP:61,EBS=C,R39#%T(<"0TK@T+D$(`[]0A(4#2(10QB4"6?
M`.P&5,!@#3`HH1(B!3Y90L.W"-$9*"C`#&1S`>N"$T(]Y6IT'ME0`SKX@A>H
M+PRRFU(4*E2#X02';YLQ`\+J$P;X;,B)\0J#>FZ`@+ND(7)5PAQJ5!0T0L0+
M'!J\P0UJ`"OXM"YVA(/"ELQ@E>(="8`5VQYCL)A$@1R-!C1@`.9F=2($1$,!
MJ8N"_P+@QSLSV.`&,4`A&LA6*7H),(FFXEU#9F3(Z8TO2V9P'O2(:`/,'>,&
M-'#9B0@APY4XXUM9DI#HMJ00!9#%:(Q[A!?*0IPM8HT9>&),N=#`I>)5HU0)
M*-Y5O,86!O3P!45R@*$JYZ;><6>+9K*,"XI)L:DDJ0'\<D$:M#'-<A%"+!-C
M&DO",#/>*6QY8%(>P*82.-U0CIKW6!^O_!&X`S2`+L,Q2.2(J,A`:2TRNNI1
M\5Q`MC1P!C4-B,P'RW7+'VJ&"I)[3SCDAU`GAL&"A6A`%"Z6AA?00';WB,LU
MZ6).4LDO*0P8CD7.A!I!P+&7,!A<R&+7*@,4ST@+*(IN=/]9H31,,Z1);(#R
MHGE.PHWO``>M386FR1F0OF"?#6B`<`;:F:M,TRJFLJ"9:&%#HWIQ7U=91BXW
M0R.2>H1P\D@-A1S@,BXRH'@UJ%`[__,G&W+&'%ZRWT;(E(ARU6!0'KWEC$+R
M(P?XM("<6=?;U&DO,'FB7&JZ%UR,<R(:6267]L(@/$4%.>+M4Y"Y7"=1,3>C
M`H:!E3`YD3)K.0GUB.H%-S#`1_$JP\:4R@51<(!#KB6H&LP(!LLP@**VQL@8
M$*]R??SHD2"G#=H62WKB5%@"L`8PQ8K%75`X`/`4>ZU""0D&>.39E8A'M>P<
M4+&@08`R$'I=0@`7;N6Z6'A$Q3[_'0VLHU"0;53'DH#@>#0!9WS!<!3J@JE2
M*SB[$FH!YL$="PJ/B\2S02?#D#SQ:>\=(E5PE02K@!A(STL#(?#(+(@U:J&&
M!C7`GO1^5-#K;DW$-!!+6OAH@'6T]*P.$6+RCMA'K.5*N3RKDOQ`@JR6$G)M
M"B,`_@I0!1O*,#@P2`-QN]M!0>P8!I&"4ZY8F19[#4<8+<5>#0K`C0]*B6HG
MS!64BY6CWJ)&*3W]#W%[*V2BTJ`NM`W:B@XA6&]RQ[`%L$'GJ,:,'2M4>CQ[
MP0%:3*@*)>`?(@5?0PUY0,)%%TXSDH@#UCL5]T[3J@2&@0'2$DJ%*7-M+NRT
MZ0YP6,-._QJVDM@'L!J0N&EMPP4!-*,N!L<`&#S#(JVK`@UT\9]BSD^A^S3,
M.XYA!G=)AASWL,5YB7T^0IBA<^N#@CE^L>W6]>(71>GC_.:RP`7%@`:_<%L-
MCI0F;5O%"WHM!!J(BU!>@.,C]&8`1P18"')$NR'JH(N7E$'1JOH$3U$H.*Z3
MZ.M[]+00V2(W'/U-08DXA]SC#&`X>`'''S:DJE#82.OF4<,84($&P.:',O[)
M:_**J2[;#G8PSGOK!#^#'-FJ=I[J\@YC1[M+!:*+.2P8.:P(L.8=!$=1SA>%
MBJ';2\<HRE0#A15\S+P:P]'11Z#`QY7?@AR2<X![=T,7O*P/WO\OJ(*-N;T/
M*^()Y)V3C-/K485EV+"#ZCA$/:)@#H''8$O%DT8-ZX.GG)&R2P8..D>TH]"2
M3S5QBF3`_'@U<W/TO*[QMOH'Q[YRQEMK%DG!$SAB404!QN-MJ0=*MB!/ZUIR
M-!5ZC'WLDV8.1-3>]KSGQ.XE\?N0'HI&O4^$9!\AB$T$7_F'F&WKEE_\5FPT
M^M0OA;>A7_WLVSX,0\I']8%B#^U?PM@U0(KXSX_^]*M__>QOO_O?S_L_0R(O
M9I`&%%GSB<EHQ/LU,;_N[=,)H>`)]`>`AV`A8*$(?V%OS`<)"G@(OV=%"]@)
M@F`0#`$*%(A]B"`7+^$%M6<M?0<)'[C_$)"@(DYA(?P7"?51$[E2@8U`0\>V
M?`Y8:T+"?Y.A?\;A?X=P@_"G"@(Q%BG8`.500MJS7Y_@1A'!7HB@*XL01;2T
M5AD("=X&%J(";HF@#L*E"$]"<2U("5Y0,9"@A89P`[F'"(J"%9*1"*FG)LG7
M"37%":D7/T[8"%%`A^K@1X=@2+RV'H\0(<[4*I%@%V0(&HOD396@)PES2X<2
M7XX015TR5\%G+Y.0%GHX@N?R'PEC98N3"$O(@_:F#34595%"0[1P`S:!:Y-!
M7&1(;.6'%X_4$(>2,W310=JV('&!%647.(IR`#1@`"X0!GOF<LU0%1ZE4'MF
M#O82%U'F6X5@_Q@-1S$JD8K#X06Z,(VQX``+4#%[-HLU$6`Z0D."<$;&18NG
M2`6RT"Y1@A:#-3_AQA&L<@OO00W?L!^2(VP]PU2*A#U>T6*M,Q"8,CCH:(#%
MPQM390[*N'*V106P:!R\$P5B87>SL"!IPBZ]M6S[R%Y04`#`0%R:&`,&("53
M%1`.22D%,'C".%7.D2L0(3F2@4[8,QF\%G6V=0,WYW7X$X13H0LDI#!N9'8+
M1HQ@L1ESTS,08AC-<#)6Y2NYEWK`PFN\@3]-,XW:)C7ET&P;13QLD10^88[:
M6`SQ(!EPY1#[,4[X\&O]I3TKAVM>>#E%`8HV)!$I"04G8W*OHVT;2?\HB3,(
M`21?KQ,/PF8_'[1MU_AO"_0\:)`KY7=E/(AID\-E[A4XF!,A<%$H%W-*A,(O
M]5(61!0A@^4N\,$S/T<V@Y(45<(JP\%,:/0?9O4DAU0LUU(%"``DUU4E`A8#
MUX(4_Z%I'V8DX[,\Z]1'/0(DJFD(8="+-+`AF4E(!M`+]H(:C$%@/M92\C4V
MN-8Y7M90M9%95&``-&!VD3(<<()0GJ-<GLDWH'$`JP,GX2<J'\1KGY8`R,AE
M:#1<!K8;'AD[!\1EO&56-I19AL936,1>46``3](PPU1*/6(_TE,[HJF=\I,E
M<(%%=N$ED[8Y]2(62<.=Y1)`L"8[(09"-F#_$C;4-PQ@!IS").HS,@)J/PH@
M"*OE?Y3S06TD"W`B8K2@%+;@;[\YH#84&MJ&)?9"H%ZU-H,R6$3"#)\&'ZAT
M/*US3=PP5*AD5$=T`R81#Z&92S;!&ZTY,-YE++U!+8/U#(L")^"D"TY4@=\9
M0/CS0=IC`W>B/61S1KCFBTQ'*N]W66"!-0Q0`#,B#;+#3"Y00I:RBU-Q)C%P
M7T0$:80`$9]F',2%`(6X4F!B0>0T,*S"*@E6?@8@J+'3@=C(7E7@+PP`:W,#
M%^_P'],T<LF#=,C6.5P28,,I(4(5.T:16<_@!5-UGI03,?]29>?B3<0S347:
MJZA5J\O%.@DI*`?@_R9S]3HK)3Z=MABB.1`LVD.#`22<D@S*!`-%\@^58F7*
MRC+RTY((8!60XB]2,S[GPEY.=$O20`.B:2_A`12``J[4RJY,%BL>F1J8$V5%
M$@U3A2FQ.G).="3BTSG`(AY`>2T(8Q7*-3\L2D09$;%8@4Y783_B5!67TCE>
MD2QW$:H(L"#`\EI'PP][!E-UT1F#PAGVDP;H2JYB=!7AX:Q;Y!!%\6.LXQ'$
MQ52Y="3>%:IC4Q;L"AIGPA&$0%+RPZA%480AX0+@"F<?M%7&N2JP^1[S@DI[
M(HCMUV)Y(25)%#3K$08)0%'V$C7LQFXX"2?&&4MF`A/QH`M&0@@Y(CF%&/]3
M,C2IBD4<A_(+'!2V=&*HCXDP9>&%=Q$%`&=EI7JX=?%-+990+::7ZN-,>SN<
MD[9:25,@[YFPI>);N+9N+0L#*_=;WB06Z)@X[XH5F758G+%%VB!F[D(%-F!H
MEZ,]'I.DP6$(&A0_\?5#=$@X,V(&//E:1R1Q#0F[">9;SO1!G`9V0;08[+5:
M3%(-ZI,G%2(>MY0LU+`XF'.KK_,[6W(M*[(A;F1YAS)<&T)!1T)$EKM:(7M\
MB^%=/?E!G'%+1C%#0)E[NK(^#"1.V&A(C&L<AW1='U-`PFL(_Y$T4"!B0FI)
MLL"RN+9RO:`]CS0^A6AEHBDY"74DY`22AP(7^_/_/H4;241T"]-H%[T0E)`[
M3*4"/.I#'+#[EQMV/7WTN<*E'N^Y&V`G2/#7B*W2)`:0'4PC:FX"*:NRA\"R
M-$>4-PG@-E0"0+J`4/(5)P=0B&80-2QSMT*E%*AR74"R&*L2.(])'#K#&)8R
M*7-C/Z9Z;$3<8EX0)WGC-[NX)=S4D`XQ0%3B#&["3264,,;9``=0KM^DQ=R@
MA0=$+6Y2#F=G4=Q!HJH[%MMP.C/"3>HPM11<55+"+E!@#_&B-98<.%G3=AAD
M6;MA5!'5*D]BR5)L%_;B)G$QR=KF/-6R&[#I1TP2+IMSNBX`4M=X*76%$L11
M-C4`0@VPG2N#)%'P:`Q`_V\L4R]&I0R>`*H?@P`;(1P8-,ME;%VX/&FBTU`?
MA">F<BG@@";)HB19\VF*93(<R6Y:+$N?!JB<0E!5)D-R#$]N`KO2JAZX=CQL
MC"5Z=RZH(L51A#T-=:M$HR:]02-Q7,1PPBY/O!M,<TW]E<0VH*:>P26/1BUR
MO#UD0PLKTR9RF'Z_*PP;51]F,=)/,0C3XG_3>`N_&PU%T3,P8:,305$MK6UQ
M>8(1>(#3*`T"<L,QG10A\=*V47(U(1?YDA$H77^KT=*A(10Z_4W#E!?MD1+]
M]1I2T1HW4=0X.0\1B--04!N?82%A[1$C7"!F810],Q4^L=5M,2VD*(AT:*-#
MW?\3`0$L%O+2VL83:&U%MG$3KS$3<QT8<3D//8K2AF`8/R$-('V[-V$9R=`.
M)PU^PG!)<@$L0^T:KW%)45$4!F$;0)$8'7C98%&`QG8162D7//T4E%TFPN$2
M)9+4]==Z.)@45&U%.(W5$0@:_36<<3G6PSDD2Q$:T9#4P-+7-JM<M4%17H'8
MSJS;:.'5H)'2OVT<O%W;:^$3^=)?G0TLK3W4G>C=L$40WYT(E"W>Y;T)PVW>
MZ:W>Z\W>M@>%[0W?\2W?\XT5'DW?I!`2[ZUM^OW=7P%\]IT)TW'?`PY\ALN'
MFG@(KUL(@!<)I,$*AEDP1O,+#(Y**8P("EX)_(T5XZ#_X84`@J@T$]Z`X,C'
M*Y02-4'%APV%.AE(0P7R$8M`?APB;(S`AF!1?F*H(G(QXH>`.QD$$H6P$6XR
MXX]P+:A2B=80?H\0;7^RC86@;S5+)XO@=(CPX1I8I]QG;.4@$KJW%)'@%\!@
M"!9TY`7B#O*M$"@A/0Y>(IO=@0:B#:ZA;4VQ7`KB34<!%C$!YX2ZT_AG''">
M%9;A%T4AW'#N%5.('1.1-#Z!/451@F*Q4@HR*&=.'46Q4E0Q$;[A(:#-+58-
M(H<NVDL1#&0Q@+-1UU,A$?[M%:<.Y[8@"ZK1$S_Q%Y58'"5!EZNE#C7Z#%Y1
M?[UQ&XA*%;)$&WWQ&P$G)$T3_R,I48(_EW3;R@VV\0\CG=_4$1`@8@OKHQI!
M,84E&-!04#$U'CNN@3!?\1*4(1^+=A-]E.KV$>OW%K-=/A"@/NSNDL7F8.>X
M^0Y4`;>A02#RAB<&PHR]$>C*D1>R0PRA/BG3,BDN\0R.,QH=8>E,00SQT!.,
MWLMI`A+I@*3%P>A<R(-,\B=L'#%E,3.!(\3)@C`8^2_E]R<$QAGA@BDS(BXO
M$&#)<CP2-``&-B6!,ZVL`LPY[X4^+_,HQ2^YLAACF%?/L#U]OA)88D;;TW9_
M@BEJ@B7&9JACD0Q_4IZEPC*3,C)"I`#-H1Y/<TM2$Y=_4C3N@HU+C`#4&E);
MCTY?K_]R+#,G\<9;:7(ZWR(D"F!<OA@UQV-(<I(P]W8F(J4V@U!`K>$VO9$F
M3W.-@')D4U$@?;(H[JAM06@G("HU?,_TT^W5*X$_8'$Z_&*<4I,=*`&H\T,A
M&U*;"#`VDH$E!#92_Y(+%+5%TYC"2>H1;G<5W*[0,^-#-2L1G;,Y]XPX/@$S
M%!<Q:7(F9;HA4Q$-8;)N%R-#=L(+1",R6A(HY8`MA4!;23P+C=\T/A)B](9B
M^T$`$?Q1@^`HD"(I2#$C@#+V/](`!""_;5(E!>"AB_$.HE(`IO8OS@$(#@P+
M-VF&AXB)BHN,C8Z/CE$(-5!F"I4*5#<W-0=1"514"#8U"#3_"V8V#30-:#<,
M-2XP,&8.+@PO-@LTL&@++C=>AF$*50PV:`XQAEZ4#0ZV:+(.+V8N,0TU-PMH
M40I1"V$+WC$V"85I#%&(-@HV,.XN-2\O,<GT#:HN7@L)-88V1D%!8VA!##/9
M%MCP%J:*@AL'O%!1\,(!&AO'!%:95`I&JQH*"%[D=`"*@C!>H&0S8Y`!E710
MU%$,]H)&C!=48#$PX^V&`C/;#%5)X,7+PY.&8L!`9,D+RT]5S&B#D<`%C315
MH-UXT>`&M`;VCAG*B::&`R\(O#BDX0Z>F40V'(`+,[%A.RIHP57Q!64!E00P
M;(1Q\0Y&%%BM7KEP@>;%4C20"4,V_\2R"J)8:;S68-#-AHT#-18(BPO,7RDH
M1">^?:%P79HP":H0HY$@#$%Q81!QO=%`ULW--\SXP^6SQL0$4`RQMO'2T+'8
M7HC:N!$#090#58R^4NFUKQEUCH4JX'<#339#M!>&H>1"80-^HF+<",/@AD/X
MALR:-!,3Y+N0D`0HX(`$)E*6`M\P8!EX##C@23A1&`"-`S0XD$84#<"P3!6[
MN."`#6G$HL`"#G3E0"%4-(#`4J^)YE<:-+Q@2%\-D$A8B!Z"&*,#4&#6%%AG
M'?!,`\U]2-D-,!P`32X.S&-DC`TH4.)5+A0@S&LQC)@;3&G,0J1*:?BB2Y@+
M,'`5AV%D2?^(A$NZ@!4W:5C3X`%CQCE.ES&X!)."ATT"`PTUP&!,C*^YT\"%
M#!@"CG.ZO)69A8;<4)<OX)CA10.8)G!3G#<LYD`")6*3W(UI@&G#/JB(\X*2
MU!"$2`,)+$#G8>*]Q4!?PHPC6DP)G&I###2D.$L:_%B5AE*Z787(K<-PXJ9F
M+Z`1`XFCZ*F)IFSRR!ENQ+Z00`-O.420`S!P1MD"EF&EDI2K_/E":);)DT"#
M]:&A0`*N>N$"J*X>DVHF@L`*#F0*W9J/"QB&6&-S_#2,YS#PW,I``PS4YP!N
MVR"@4G*VH`(0PH=B&(.2#41;X,DHIWRA"ZCILE=&-M!@`#A%]>K_ZZ'<(9<C
M80N8Y&D4<C4P$##EWI9`%!Z:!&(:7)D$3<\/.0#UQG\AR9D-!2##``PJI>L3
M7AY^`@4-,&@F#]0U@6=#7Q6]9<,+4"#0W`)"'ZU.=#%_8T`->9H#A2U;Q5U<
M=^?L*Q0"U!DP40TUE'PK`GF67=(XP'A8$R_@H+955XG26BCCH"!%;*]>F+-6
M)PS%#<4+"'!80U$E;Q8%DX48B15GFZG&3SM0((M(3K9U[0XK"P2FN$$VS#P.
MCR43!H.VJ/U-S3*^&P),&%N&Z->E<".'Z3SVTI#\#;I0$8;F[ISJ#1I&O06L
M.;FQ5$ZO<!KB416#8IZ+AO)4!-&I"',`_Q6PL8HP`:L&M6'43\3AMU5%B&^Z
MXHY<B!*&`P"(6'+K3?3R4[:J]*Q&VY@(TF(BJLP0@$5IT(4J$&62L:%093",
MX2+"\(*MI2DW,:@"1A8SP-Q@J"M4.!,-T,"+%X0A"C60%@,(0\.MF2%8F6E0
M<]``@Q?H:Q7Y*E%-`C9$+A+Q)1AQ@&6\<!:LW&*(AI#6`A3PGA1.+!0UB`(R
M/`(,,Y1K'S"@@AW'*`@TIH-BR*"!95XAP(U`@PI$Q`5*SM@-08!HARPJ"R[V
MD2)UF($K"@@6+EY0A1@THT%5N`$4JI"/9>Q0+6=:AJ(P%04[.JI4#%``LV)2
MQ4Z:P8Z;-$.*UO]H1#/D:1]0C&,:&Y"=;-C#E6%LSB%Z1!D8G.^-EW*`W&C)
MR1B$@1?[6$A.8A:B)89!E)E!1YP:\$UEA0D>"G!!&"X)%DJ`*":VB((D1X0,
ME73%"_9(TULJ*<X4"0V?KGK-"Q!4#5\VR`N;4(\+>@.VK7G!B`_U(:;$28,H
M',2.:=ID%19#I#15H:(U"$.3T+"U0S0&!OJ"Q2&R`HO!X`*EQLRH.@7YF@,H
M\U+`(I8]-D,D&?KTIP,**%!C2*HTG$B&MQRJ(AK@&D880Z@J@VHB_J142*#!
M-@)RU3H']*NJID.9`9+J(KA)A>0PY959Q>HBQ$J@I'KUIT^,S5N)52+_ML[U
MKGC-:X"B<*4+]56O*8-"]F8HSKM&(5V`!6PW[*HRP5;5?&%B;&(G6]6R--6K
M7J#!7RG+V<YZ]K.@#:UH1TO:TIKVM*@%*OLL%29BH?5D^#,I:U/K4[LZ)4RS
M]:IDTTBLW=YV0%X8+&L)LI>@LD^RJYWA8&M+H-_&$*JY-6F`\+((Y[86$=A+
M1':'B@;$2A>T7A"K1'9+6Y1Y04$AI<7K5+81&!`$"C8@97EC2(E&V*`948""
MF[Q*OD-`41%4O)1W9W@.`DD*$3KT@GM#*J!.IN@1P3JP(O([U#"X=T`LDV%_
M$=&,1$3!G(V(VS\4D6'T@/5"9CW$#2[KT_.B_]65GS7/B>UTL?D&R"O.U)=<
M7%$A9`!MH"G!FBA1TK3,-`Y$/^XK;_!H@.1\YR$)J`@8R>6HB\2`9;*P5$76
MT:FU*:,07C'B-5U@&5=`8QVJB,%AKYQ9"KWF>6"N$)+.4A8L]JA)L-G)A2QS
M7U=`X2_92&<9(_6N))>%0D")`8_20`4/609#.(EE;KQP`'5B(XDS*@!(<M0M
MN5RF-[>!\Q,I%(J7E%HV4O;"AV=6B:P(,`SO$"!07)4D!$KY0K8(+[$J#864
MR%G1:@G%J0JJ:)IR.&QV/,]#!8@UL_JR9"DQRQ`M[(*'C.4E5:`"$A%-0QZ9
MF19MCA5"#WF^TKV`S/_2A,(Z4G((53A31<U)]C^>\2%*7XP5^\@V%6)!B\-R
MPDCZJHFCHC`+!7=%H%9!*&3L$P[IY7=O.A[(5@Q#K('$"1O.W#>%>'S4U=5@
MHP)D=[D72H/OA((:5[I!`6A@X8.O#L0VGH@J,/(NN2'@74=30.,\<0P#;`<7
M"/R+/%IG$+B-I5<+3=(ZOM.SE=?P%7%1I1D.``,7T*E7Y`J-*-ZE<P1102'T
M@`B#PY`-&!#"'0C(!N*P@9%Y\&PBRM@;`V+0N%?P-"`F`5>(K$@`9^1#2LF+
M"Z304)70!$J`_MB'+/UF)EZXSC&#$`9:Z$&(7BEJ;Z`J!2EA$)HK)6.C>UG_
M3..F]9E97"4&O_$0L%1"@\E-Y$\/V5L-^4-K.AF`;'Y1R/,(,OD/32P&MR\9
MV;Q5G,W4H`"J'.:?J%&?<U0$6#=H\HRZTI)\6&<Q-""`69$%I><@31[4CPOG
M)S&B;;)&)9_1Q[Y\<DD6W:!7N/A4<YY^#EBUP]88>D5-9G$.G=<CG9J7(3!`
M`,W1'IV2"WZ!?0.@"]BC*Y<2*)<@=SBW=2!A1S*2&5V12:NB"R"A$#D'#`KP
M)W9S31KR`C>@,>I0/$:7&7M3(GA'-RPV7YO273]A5/!"4KO'(8?!#PC1#KE!
M(>CR5:PC1OGA)@QT*$D1`SEQ.](42^9"#.=S*+)@_P`50R?A0"B'`7R#H'.0
M$B=F<2_&$A?SD`[SPD8'4":@X1+\`"/E,B^@H@YI(#3OP@QF(B7O(H?3@3-(
MZ`NA1(4,``IKY$POXB%^>`!YDD:H=PA"`X>882?\L"#)4X5F104&X`(KPH=A
M<G"S0%6H]RX!(31=LQ,*`2<9DB@<(E08PB%O4@-^B`!;PE2$(33$D`I6,0O4
M4R[K4`_8A11/`2.$@0"WPH/,P!4'4!$<TWEQB`[<MQLV*!KG=`"#L`"8`2Q$
MY``(@GX6\C>G$H?EHQQ7D1.$0B8OL2,Z8HPMAP"UJ"''HA2G`(FHX`L%B`QG
MV`!4AQ2P$`Y/$0YFL0!IX?\72-$DSI@0KO%0]'@3ID0QN9@G5"`N,'$B3(4T
M#5``,4$%,(``1-@B1B$,7A*#\]4X6`$24>$OX35WW/`7A^$0W^$3+Z,+X34.
M^?4,`,$9,H>$Z[B$',(5<K0TEA"%:7`-O6)1'%(Z'R&-X\`)7K%,E\`6]'`L
M3>(F#%4#[5!1FK20W$`VMK!O,;$.<CABR3`*_7`I2.-EI7(H!(-01W,#F@4%
M[Q<:Y8$+R/%AVV`&L*:.AB`T^<`T%T@,CY@.[[<0GJ0<\L`+XI`<NG`5CJ&.
MU_`NVD85JO!U+.$3ZZ0`AWB*B*`27T<L'A@%:.DJ0A.+@H4*IV(3G*AH\Y9\
MA8+_2.T`(HY15C$`B(ZR926S:``Y$(20%#)21;(9&O)T*NK`"9BA(3[1.Q\4
M%Z72E"D$C(Y2=5$4CNF@FL\S1-<@-'FB7_)@B^M8$T%8'\4`&P681)GT8>"@
M1[UR$M$!#N_'"421"<4@)L[X?A[3DW(Q=TM9=<=@'KF3D9:@"70C#C&@.NJ@
M;B7"#"[",:S`D>5%'W_(-[+T'@PPDE0@-?>"(6B!#18E2PQ`'PMR&+&D+`B:
M27]S"`CDD<8P$?9W+N=C(821)9$G&M_!``AP$F4BF4=Y=%$2&W2C)&/H#;#2
M(VQ4#$3R5&2CH]ZCE5``#U?2"9>2*#P"#S3@)A\:)@J"_Q"QA!/?\@WW4C&#
ML0#[":%_TCJ&X$AEF"Z6P!H+0I%E$@XMLB4\T@Z#\'X-8`!<8Y&:PGD1PR-B
M-`D*,E`DDC#&L!ZN0@6&R!G&D*04X2H!XQ51(`ZI4!.H=WI*R$8$0`-_YE\C
MD@]56@5F=U"F@!YF:(P]23[S(GT7DG8AN&C`P*8I&"7BXR:T@4"?<@DGXJ0\
MX@EF`*<K)4OG$"@J%J9->!*WD"4J0B&-NHY_0DQ?-2T,0(#*`2(@$255`!+)
MNBZ?<AB?$"5I$8(1<Z$-&B?%>`C`"J>KXJQ7JJTO,5`-(I<',$04PP`^QU04
M8Q##@`K0*AI,96.*<#XOT0V5@/\5X7)+41`*9F`9V185*&8&W45<:,`?B'0(
M^!HGB,43L16PKS&I:;07#4$LN5%6N;$7^.0D$_L2*,%AHQ0*G$<-(5MQZ5(%
MO<:OW?4:DC=*_,JO/+$END0LPA`5$&L9$CL6;\$?\H2ROB!*;]$-K10FZ@89
M?#4,K:2R@U4%AQ4ND*&QE(%81<%H\U%QPZ)MLA%<1'M+EA$*44&T":NS46%$
M:?2O9::S4?"SPS!*#6&PEH$2*!%<-ML[*C0=B)!?^^18/+&O3GNV?(4_DY:Q
MAY4]VE84!$NWFI`;^'I5PC"S*BNXLD&VW9`=H(!=,'NR0N%8:N%8YZ-+O;:U
M=!M<P47_L+)1`X!"%,RP)64E#*A[%_R!/Q(;N1PK3WK+:)!A%$U%M-GA&+U&
M4NH1L_KZI_'S9Y-[2T=;L00AM01KKRA#7J4E4EIJH-55(PKBO"9%9JC%33^%
M!@M[5U]'(@&[7-C;"/SP0I05&O#J"+I0/,C5"/1A,HL@/H>@O>5[OP<*O2:U
M5?C[6J3E5LRE5W*IO_A+OI2U78\@ES*D5HM@L(?@P/@;P1(\P:1%P!1\P1B<
MP1K<"%*EF1P\8P)"!0N18FJ9"%4[5Q_7;L_ZK`UAP"?,"+[DOVMU$,^564$%
M0W[*81^W-##D*D2T61P&Q"G$D42D3I.E2U*!Q`.B1^NU"'J4_UCK\0A/K`BZ
M=$W02T1T8<#7]5W>"Q0@#`F:)2!A3"#/.@Q^E%IC*PQ79;&0]1H#5`T$D53C
M]7790Q=#NY!Q'%MNW*1J\1J8NA2J9AO&DL7,L+`O1EV.8K"6TE<2(0Q-\L1X
MH0[F<RN)+!+&HDM_Y;UU$;"/2QG$A4A0Z+UBFAV)D&T]2Q<BH0F)<@CCY<:Y
M<55ZA,H)&\L+Z[UJK$NP;!LOH4M[<1AOBSU;DFT!-<OQT\?"#!GXXQ>N<L?"
M,,AMW)/!LB4282F3P#Y/S#Z2][V%W+/4-;;K],0!FRZVC(%9_"(24<Q[H<=V
MDA.2(LV)VHL5JT>S+)?495*(+!()J_\6J6S(^+/+]?RVA3)&SYR5Q8!(43M@
MV1:9QI`<=APFV4'/=PS*Q2`;B1PG]=S**\4AB!1;DY&PQ/+$<"C,<=+'#EU<
MNK1"6#'1D85;I/4):R0IL=*^1\,/"V``CK$._6D24N("`S!BX8LN-3(3;(0X
MYR4KA/%Q(V(`Y2!+>H,<%8,N?4$1`!6O_;`ZY8HT@!$I3)TB9]B@AJ$.A$$`
MQ-&3+^$%!A`;@U!@YX0@$2$(E\`XQ](C6FI$HH%.AA$K[E"_E7I>47(Q4O.B
M[88@"(/7"J:E0TT#;+%&L.),;JUN\X(16JI?9,=+U!H8_6!3I^"^88)`:_2L
MH().#B`5".+_<VZB+X-Q+ZUG'15SH=9SAJ*A"TL4`P.0"PD@2X,!&)DMOR9!
M-Y=R+RN&JU&B#GAM`[402[Q!`*=2`P.`,",B&JVI#&LT8C<P`-98VU<H2PI!
MW2(!H6>Q1JPP"%/4'M^`$TSS"@2E1`8A#A1A1&F]8K'"9P/`-;'BC#U)`"/3
M#]%20SKGK=B].P,@-%I*3M6V4$XHO;]@`[-=-ON@+X2:7W--J35MICI7I"%"
M"65R,>J`0%+B$&MT$/H=4H,@),Q@``C2GS+25:,5-^<SBI<4+17B&.;A(;6S
M&94@2C5H5$-D'Y1`%;PP:C<A#;5H%=_!-=-1$E:Q&]#`%@OAT4D!_RZPK97;
M@`R*H@W^4#+)(&<I^'5R)$8)=.6-`Q0>HQIQPQ9(TC/:^@E0>0X]0Q3100.N
MN!]ALC:M)PIX(9FMP!8BD0FP9B;2\#S.)#>J<&YFH#']\1!F%QKMYV?Z6*1'
MTQ7@(E)D-@D!,7^<<67T$!UZ)(T3;87LP^+:9A62H`V.XB&-46WSDR4<TI:A
M<5\)(#[6`:7E$3,[H30_D2'$$!!'I'/G``^;\8B9@$73X%X-$E^4D0D*\13P
M]1G;X!HCX>:?8&'UL5"4`1CWI0[V:1VWWBNG012'L1E@WBC#4`R]H`PSXA=I
M,1$M0QM;DE`/\G4Q88*9U`O(80E(U#NM4_\,L>H99[,56^,.KD$,^#,)HU`*
M<P'@9:-S&=A*NR`W1A$0I!!E+H!+S&!3Y0G4A05:8$(,9F%4R)`3=^DDHP(O
M84(6SI$<W44Q48(9G2(/*73D!Z<4>>(@JZ,*H+(*-"1+:%43;W(GBZA,/#4*
M1[4CKW"2+B$.+G"!/?DK@%R#M*(J0M(;9*=H56``F)*"&.$<'E$H\1,PUI$J
M"["42ZCU<0*'`$3<#4<-220:*3(R6D2<1M)=?H'REU`?AU(A`4OUF)(NZL@;
M?S*+1F5VD'$,G,$/&Q\G\D!$")(N+(\1P"@(O>Z,7H(75%\B^:K,TB(CXK#Q
MDB&-B>+T6N0532'_&F2_&"!"2E$6Q^BB)UU1+@YRDL.`\D?##9]2(BC$*XVC
ME:%A&ULS^0#NO7.W%)G?A7H9A.&8BH,OC1+R#/'#&JTO^I+0((XN3]GY-Q-#
M%.%P(M)3I&F'<ONB=^V3#C"0_'Z=)V@Q,73?#F]!+N]H$-E"[F""F6^!+N<F
M.J(%!3[G/X<"$I!&X^D4-G1"#8``Q6"3X(66!M,0U>"2`.6"0..29N-PHR#H
M0`-#PQ"5X*)`8V,`]?(2X_EB4Q-S@U#EE39[">7@TO`"=7##0#6+M@!S<U#3
MP`"E<-/0"[50M5"3]D(`-9OFHHOIXC#KI6`3<V"#N9E&8W`33&,+_<D*_Y[^
MTC!+A0`E'K40%J:L''H(#0,8@AHH4E##A0TS"L)`R44C6)4HR,K%J'3.DP,8
M#&HX@B1H60T$-ZA`JV$KS"P8CAC0>$'#S`)7"2A>3)?@1@P$G_"]R/8HV8U9
M+A8XJ\$@1A0'SL(PZNE+)CL'LM"X<&'3T;QE:1S48$CJ1J)D4#9=JJ+@FRE%
MT12B@1%.P2&&-Q9$23,H00U2R6P<BG(/Q@%]:&K8Y30KC`M;N'2-.W!1`16$
M-UQ066"&(A2M#6S02UR3F]!943#)]6(WIPT7A[P@8&6@-+1*6!U0:0!%HL`8
M6@]XJ>E@H0*YEZ+$B$&#QBM99I*&5;8:#10#,?^ZOEA*!5G2S3<,U*!A%[J+
M6L>\>:^AP`P5`I.NN7\//[[\^?*A('!`E0J--&\'ANFO4!6,7!>&`QT5&%$:
M9KPPD!<<G7*#-/JAD8H+*"W$T7B98/40%15Z<=L@7K`&3"<NA)%=-A[*0AH#
MM]P@B4MHT.!A%3%X48,#9MBGTBP/56$BBVD(<I49-C#0P"\"JA1B3##LB&04
MF^''(H4,7$4%#&B8\212+L!PC8`'NI!485&\I=Y>UL`0AHV%(4E%%-)PR<`+
M5;#YX`OZZ1?#`@P8%:(T*RW0@)8V6".F.K?=XD4G,1B*Y$2J#&3&+`D-A$85
M!MZHI1<&UD!A%6D$>DC_&HJ5B51^^]5P)DT-."#JD4EZT4`-;,;@PHBHWM6+
M(M?$L)$L-%1QY"U12%)I?S]YB(:5L);H8A79G3*EKXL,$H:6;GH)XG[`P/""
MK@F:NE$,:&2+QC+(7).J93&$00.L+PAC1@Q5O/5?#%G6>2*X-)ZSWXPN4A&B
M#6&^2M5##`Q5H*BZ/FEOHE7<EV0:ZMY@AHG5F<J-+\V21%_((H_\WD,CETHR
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M?(C*2#?R`B]BX8`&F,$+,0!59FA@-GVA@0JEL@$"+D,#?96-!NHS@Z@R141U
M,(,*FK.@`J8W,1/&<&HZB0)#!KC%!F:J63"D0@:GZ,,TV*B!@''C=V1!O6%1
MX0!06&$#K]$H>TT1'[*P42JN`:\&>E%!,#P6B\+0"I,@)";J>4BW$E"%(9YP
M8@L)AP&E<Q$OQG")3=2<DH[#`&"XD0H^K`(AB7BO\/#C.RJQT0WZ4413W4LL
MZ@A.8H[%,"C<KXUZ-,XOB-A("[X&AGI,U@((EL986(P&42B=3J`0A@3<2%3X
ML$:W;@C)1C:RAA>9XG]L`$7_8XQB<_"Z7[I<X4477@,&+HC!V<KI'@_E9H4W
M*MM%G,*4!E1!)5X0$CZ`*%#^L&(0P(!1K6+QQ7OAXRY>B)"+W!;$8<%3<SH9
MRD388:HL4A%>TD-#H[Z2)AL`Z2Z8E"0M^3B8Q$V&(UY@@*A\@8M;".8%KYD%
M6EX`#C*%XC<&0@!1;;``!2RUA@RR`0'\M0">*(!!6#D`3+;:`!RY#08%L.*5
M0)F+6QPB#`P(PU(,LQ-;+",*024`16Y0@*N`ZIJ62@!+:G``!0QQ`4E,$@-<
MZHD#..`N9CC`E7RZ@'G4B@`O<<`\7(,?A!3@):_:&!H8T0A;<N.:D46``G*'
M)`.9_^PVT[$347+A"`(8Q#*XZ4PV"F`8(W4C#5&XZKQ>`$H?*>"OXVG.9)1Z
MFZ,B8`&)N>8!<+$P`L3@!1MA`&KT(:"K6&:K"HB!`1KP$HNMHKLD4<@LT(%4
M>!Y`:,/EB0N\>D;J,N@WN<AK<!CR1;L,@@"G,",U6#&32!R@`8_:#'#%@@`8
M@.P:BV#(B:YD@+\RA2-)1*\X@?$J1ER"-TBI$RQ64@"DWJ`7,+"+42.;U"NE
MY;&$2(!GPLL,TG2WNPYHKW&N1(#!&88:"?&,M#HS$+L0E:B%F,6?'.!5<<+U
M'@TH+?LL6PC\,"`V`]E(%)*\`$B,Z"J*,`"#@D/9Q$WLOO_/P,LE/N<@,#W*
M4I-H4UK24*MGZ&,:?;*&`W:2C7$LP`LO:(4KZ/$-J/(6`>-967;PFX:9>/6]
M++)$GX'T@F)8@AD-80AV?2$(9Y3**&F8[GA(PURZ+,"EX2E5.',)A7`TH!#.
MO0HOTH*&,^Z#)3#P'BJ1/!E^"&,2O:B'7((1`WIDI]?7*(L+TI&>?ASI(:M9
M!)PK(2B93$94FDC,)A)<F1M8(I;*=LDDCK364G\#-?:P;#$\L;!%*S:$I<--
M0BCA`B`))B&#BY?%D@(F3D^WVL&^3Z2A^M,>,N.P_+'+GGW*"4_`N7LO,4`E
MY$1=:50"%9VN&6HOL8#53+?3U"7_ARP:U0V,Z#$]YVJ4@CEB#=RL)(0Y:O*\
M=KMQ%#7$S$VF(3<5JDMKLX0;!O,*7RD:C+O4RA(P\+/+I0H31'@++^!,P`KM
M]))QQ+@SQD['J('I50>\AKD47P`Q\MRG4>W9:XC;D8+K(JJ,IV=4%#<'!KOA
MD)G7RKI)$YJ)[XR`)L+@,GQNQ2@`#8Y8FN$&1#UA/1@@$T,D!0$6?!(MCC$B
MKR!DV^10B5&>$94_#6U=GA[<G&4"U27*VM1O#O*CTN)<+NY]'S+11QAPU.2N
M<>**F&'K3X84RU']6ABQO*O.PA#9D9#C7(%G-E;H<8DW*^B:@L6&MSB"%#8A
M:<3<!@=X_R<AB.82!C7DSKNMLJ,/*W+Q46VF`E/>G:-YH*?'L\"5Q0A<'<Y'
MO-,-\/[J<PG#J'HKZ&/G<R>$GA!>X6**8"M>00F%LA_'\1Y(54/@L&:5Y7&C
MLG&K851K)S_@)0P5HW*(`":>X2*M,#@Q=PDJL3#ZL56<X&P.D&77T`DTP`B6
M@`V&\0LQ)A#68"&6D!V^\"H@V&=*=PV>@!J%<1625PEVU@F<D!-R`4R,EQPF
MDW1>=P#C=R1Z-';#,S>EP1L*`P,&8'Z,4"?5L68C-R\UI&+0X`5)@PH*@&(C
M4BB"U5T60@-GM%57DC1UP1M2XC;V@':)Y@S<X`"E8@;W\5GUE?\C<\55!:`/
MJ/$"%$(`AD<#?@4<]2,3^!%64J5UA)$8CD4FA!`#"E`(C)=$\P(-I6,7C,<-
M9'(($Y,(L5%[<HA4IZ4@+F(@]L`@F/!["4!=964`N&`9R&!;?=18N<<?W?5;
MP34-`^%EV'``9M`/O$@158"+:N@-!D=JKA$C,"!8!E<%5X(+I5%B\6()":8`
M&?8"N&5>YU``V!@.8.(1++$43A4:A?(,>Q9K6@(#!%`E!O<-_@)5//8JY>@9
M=_8"-P")8@&&>V=`O04%6Q@&"K@)N,$@8QA"(O=9M^`BR,@10G<VD<824+!A
M7F=4?C43!A(*VS@/J)!QL70#`T!!)2;_&-PP%`H1A^6H8\.%6Y80:[%$#IU(
M>-)08BP"A'*1$/]XDT;H5PU0`)J21'856;>0?3`1#(O"(+UFAHR7.(/G3^?B
M"K]$4"#R"W5C5$VD0U"4+LQH#023%(5#1+\@)U&P4,/"1`N1-UCI1N$"##5P
M`X5D,4N4'.(#!;_P4B41!693.A8$/86D'X,G%QJD18.)2$W$)/X$3M73#W]D
M,5LY>-"S0V4I'9G9*&1)&JY@`QW5+(KB"I29'"KA0E`0-_MS$07$"C'A$&=X
MABN4&QWA'LH4/?8"2=\!!7?10V'Y%7GC(8>2.^"D#H,G'5\1#E2$G"[5EQ((
M1`W41MW$18+)_R(NB%)U<T]WD0W_LI9ER5O,.6K`@)R9P2H3<1S*T)!X&4K<
M]`L`91*C0@4V4#\*`D1GJ2348P@[-!%E$T$I=2,S])O@-"0L0DO^Y"/XY)H+
M84B-U$KQ<Y8),#6&!`6_*0MN^3S*424P4D".F4*HI`YNN44L`DX[DBG=U$0E
MP9J\!2*OZ07AP!NOAQS\8`TD6DB89"]YXQ#I@D[+LS450S;2@3E;0P@41#9L
MA3]`BC-F<`Q6R*0CDT4A\VDBXQ'E(Q_DP`#6U3/S&:4R@X5?RC5%$5EBZCCW
M8J;SX04&A#8NE:8^0P5+^J8CPP]P`Z5K2C(3`:5S>C3J4:26,T54Q/^G@TJH
MA7HZ?VJHB:JHBZH\__%+:7.&\B$+I4,?FO.?:-.:IN*B*<.,D>HRK#`?S)@R
M;NF8[B$^[J&<)#-XO.-%,&0KG"`+!KH_;#HJ,&"K+"0?_R$R4G(VJ=HX+4HU
MNGHR-F"K>_<U$60</SJ?SV-XC.JLDD,K.Z(2Q:,YD`0?E)H[]/1NOE,IYH<-
MUG`NH7,(`^FIPJH@J2.JP.`V6R)R3NHIT%,JY\(T/=(*E5"MV:JNI%%4Z7JN
ME%`SV$JMG6,A@[DE,:0C_9H[T,`[4_-Z7G.OQ:-'Q_$;J*""TMJO0O,><7@<
M-X2MIK(E8<4?4Q.P&!2&*(JPD)0Z$)L8L</_LC:CJQL(/(F!,B);H0WC'AU[
MK_R!B\?Q3!6:+*+3.6C!7%3@5PBQ3]4Q+Z?ZK$NK.#0P`,EQ)PTPAX)%*UGF
M-@4R'+]I(&=D!J&0`+N%!J^X"=)5`+Z@@CJ2(WX2!0;@==!38V%5&7\21`&*
M'EL%-@[@5XJQ`%]+"P/0@`K05A0A"J724PI`%0JP7@<0584T+W2WI;+@`KB%
M'I'U/,-A&+&!5-=T&UXGM19G(=WC#,IPCQ#$`**0,5'E=/Q14/;2@*PQN13:
MN-(BMQ%K+WNF1X5P(Y.;)=RD)>T')G,1"LJP((`;`_RUC8:[0EEF&)@@)2?4
MD+:P:@$:A^QI+@VY_PA\%;:6JY0Y80NE2ST&DVKZX"=.<3:;2U>$TBA2ZP+J
M$57K"QX*P!YSD;D$DT2.P!\2L3_M>[K9@+>U>$)682#G$$))LQ*/8KM,B\"+
M\PG;N!GV>0`"\A)8X1)&M7>X@!X.H@EAY2*Y`P/&X6*@U!82#(X]A11<U$]A
ME0T_N1%UVGXC=@!ZN%,:_!FNL114L0`MF`P19%D]]2C!@;O!H0J2AZ87+)J#
M(1G*E`@>UPF$P$28@$Y]MFVK("4@S`X((5@TL(P%]PO(H!?02`Y`4@Q&D<2"
MM3*!.!P))A!8V#T<P5?G90!;.I@=7%76Q47``0,]Y8+A(@S2\QZHX1%,M/];
MT#C%FH8:C^@]V6(<9_3`AA&'?(8*8/(2,/(.&TB0-H(;V6`0)$Q@J`%5^F*_
M%I,62PQ*P98[":"&ZYL4G-P@KV$##UQMLA1+2:>PG[.%!'!!"8S+AH,:S9&(
MV8$(G9@`4;4QGK*WM1)"E6$A\)88M5@3L60)GBC,YM5GXV$#U#44BX"QX;4Z
M?;(`+\QZ?B(-VM9<!3(4+["%"["W9Z-PJV$KXFP+D195FA!"/M(`5M+-X-8L
M-?#(91,-<,<`A.8V4`Q!GFA"UL6V[=L-WV!-/R4(/Y4(97,EBDLHVWJSY4"A
M44D(F'"/,W=>MD%&GL(`"3`0YK)\Y(9!UCPD">#_8GW<ST/R&=F7:%!%:CD"
M2461M;&4'6NV&N:@S[TP99YQ-N)<?U&U%>=0%++P*(J`OQ7'SS1M,L-8$E[`
M$$B="&>R9[Z,&`P62Q@+#=]X=LV7RV']-VC14\X@*4J7#39R-ARA*;7R;5X1
M5OA!"PG@(361'H.0UNQ@7C>X%R?,9_T$R8M8*A/CD49,BO.%"[DC6,;43]%P
M)XWV`DZ!'`K1#2+Q#*Q`T3]R#\3P"00#$\&Q9TO<#:EF'R=T@ZR0R*41:%4P
MD()E1<D"#H3M4P*!'K04"9>]%[N%JC-W"FE,([@@-/ST*Q:7"NS3$6W5"I*Q
MPBX!@]S4B2OCQY7]&=`8_R<U`4H$2=.T(!E9B-,NP7(6$M<JR$T#>#88$6Q5
ML!>,0,*IW!$J)QFS`%6-,@BC_1E+C1=0E'&X(1%U-S2\I9+6!2QM`C;5<23_
M@:ABC>"5NFOLLZ:3,`K'ZU/U@,Y9MD$+62#H_*^ENZ5HT0I&(;4^I:"N`!Y9
MY!1^@B,2IQR26!2ENQ3_`2LU)@S`<`NZT&EY&<\@5;K9DPRVRELOT+6+NT'U
MX..A4+K$8KF?0'AJ2#U@4AI6V\($$8?1\`W*T;[P`KB(!]]?"U2&$&]QN*6*
M,1QY:7&^,T!.\3Y4D+EEL1!""D]A,N$Z$KQ+T8O(BT"=F''O42#$VN,L.!Q^
M$?\*N*#GWO`G43()[]/F.H$:2,)%:J@,U^$C8(*U=H&W5GL94K4@=Y%$HA,*
MU[20:"`_,BXDE;Z^>H(&5/$^YW#+_-.U:FA`S1.V>Q&@"2[K6\.,M%,\31.N
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M\W/$'TI[+VLEIZ@3(;2J(%)=H4H;K*S`]9+*"EC/.5\?'TOT-RX5K_>"IEQ3
M-E!*.68_-W"?]:^'JF0/J0!O]W,S\GHD]IXC)/P>'RR<*4.Z-<?#,B`BU553
M^,OC!0X'T;#S%>^R"G2*)(V`I+QE">U#>&D##?A!UR-3&K<`#FRCV^]Q`_=)
M&J5O-TJ:&#Z%JV5O*'F/0;&.0JJ/-K>Q/[""^KC_-Z/I'E(B,__B,Y,?4!>V
M-;R/06,.'T7G#;<\,JSR'G(2_ZR]:S&73Q_]@-+R(?U'PTV,;P!IL<NL;1N#
M%P6;%53^4R\&&`6V>@CQ4BF=+N=NU1G=T')_6`G^\Y<68Z(Y(@U\IM^F``@U
M:6DN,(,U-515:8I4,#!5+PTT80PW@U$QC"X.7EXV+RY>@V8W:&90838Q#E%I
M-PX.#*\.,&%>-`X)"UZP#E11#&@V856<BU"U9J0U#:)5H"YA4:-0HVEADC=A
M"B^_W%Y0:<DPIC?.5#8%-ZE4L55FJZV#80D-\0TORVGQ+E!1#EYX"4;+EID8
M#6QEFP=0X"`T-UA1"2.N%)4$H08R&'C0@8U@4:@P$LFOF<`H-AS$*&4&XCXH
M+V@`?/_FJDH4:\9HHJ$QR4RZ0F86NDKCY8`TA#70#$J3DM*-94]S1F*@;)"+
M`U&JO.L7`\VG-#8!.H`2KU4R%PN6UGBQ<Q(:-`AIH'E1HQ?%3S!<+,H5@^2X
M6E40-`C33*\#!%ZHN-`;#\:+9%T5,[;!,TH-`Q47**`8\!I$%S?<B:I1(.4V
M&`TNY72'F!X,!T^AG$K%2I!E%S&\('`0)I>-I<"#"Q].O/CP*@OR>EE0*08-
M!E060#%`PX4"&PDB>I3>@('L-`U^+T5>XS64U+`7V-A]@X&-25$6/`\S2(%'
M!%2<U4APT84K-`OXA88+@L!0W0(1@88`#0N\E5@5R]6`D`W_![SGP"#+!16@
M`3'`H``4URFP0'PV%$)A#2+F!XIT#+P@$`,T/%=%`M61E-\Y!%;(``PQZ*,`
M2;&L=\,!#M#PXX@+5*%`#0P@%IX+[AG0W@T*=!C@`1TJT)(9"<"6P'LN8,BA
M#>J%<AZ)A9Q#)0T(Q1`#>:\M8P:1*-[0(')1$-"C=^A-Z)Y[#:!AR2!46-(B
M6MBIJ21]:2RPG80-0"$,@9&V6$YY=2[Y0HCEP:@)40BXZ-YU@P16@PO1>0%@
MH1V&\B6I<R%`I9L_8JE`%#04X(4+N4C('W4HDJF`6G1=)Q^#-BSI6'B%3G?J
M=C88\`(]-/K3913A->"`"PD$(R%T_P8P^24"DL8('98>7N:*&0MXET`-#@3*
MSP'E,``I#5)ZE!>9DG;(20+7N/`"F<%4`0LK-GCG@'KO)N!"LFOM8]S$%%>\
M7"7/16$``PP<8.=RNPKR0@R:-8#`:Y<,`MM29ES6P`)?HD=7&J>Z@``#"LSR
MP@`D">I*`RC2AQL#B_"3),L$IF%@THHQP*$P<VD6+<<((#3.+$0MH&%\:%12
MR#@)'="`B*>FX>9.#BCP(0$&5$%%`1P?D!]&C(:!T&YK,:67>L+PH\`H+FZ6
MAGLCPGAA=&;DHG:&"<T"()E=,Y?&@#?P"):61`T[-0,QPW```YI%T@"64-P,
MQ>8(T&>&`O^+-$Z4=VFQ^]XY#/Q7:!@("H[-W=N*7,/!84Y>>Q0%=(=?[;PT
MD(E@5-"@S2OYT&!V#*4/.DBEKI3-#^<P>+'9XVE-/K/EKZ`:_JAHK&6=C"DM
M@$!\-(<9WPT$.K_R.:G1LG.#A9Z31C#A,=NT)G>8%X3A81VQ1XF(1S4[I<%Y
M@XO!QII$I<AQ;1`&*ALWZ+-!*,"-@K-P0`T0L`"3+8P4)2+%`=I5(0,5*V<8
M>1@AX`6%&<E'*17+H0Z#@QPS1`$!_)%5)E+%B_$]!P:X`DC*'G@A1HCP5E"@
MP7E@X1BS"4QY-GB*R<0SN)\E2R3V(MI2<#,(^HTL#46B"X"0F!W_[Y1*`3=(
M`!2B""^P4:L8W=+:<E[#%!B-R`8V*!N/0!01Z23G%^3"53B@D)Q!Q,`[G,A;
M"@_SJ=6YHA:L6YV=2#0+*B4+"C%@G=8:$,J@P%%K&U19("]D)Z4@9QA0E.(D
M_@@O_^R("J!$`(IN(A=^\(==#$)#%&ZE)26I*5Z"N`&3E(:`X)DM4IR084Q6
M1ZZE0"<*<HQBXA80IDA%(0I0<AX9JQ.3Z0$C!JF[WCE^4T5LS#$!'JI"/:@4
M!E6(4&F?@L6BN&$G,]APA+_(SGZX]AZ(C*@&40R%)G)1)"N&PCW]:\#_G*&)
MQ9!BCCN"S7-@`C14D2N*\(/@)#[:EP8M_X=K2N%1>QB!N=5-(YLR$89'JH2K
M9(4A'M4A!8UPY;9V>>&6,@'-#&%3A=/A9X=(U>%/E_&"`YCA!>UJ`'*6$XH"
M25$!8P/G$G&7$!I5`F=(1(_WFJ07^WPI!N8K&G3`@ZL$<*P2?NG/"^1X`\'0
M:&!HD(73V*&`0C@J#`OC)BPF2@K0-8`_#:H$<CBWD1(J@`8IW,]^=/&A>W34
ML,@9FWBP8S*@32N%-B!`T6CFUB21L*\_O5UW$B!'>R3@;U537F!?4`4&:&@?
M4!TFSL2SU*]V`R#+&1N;L,HA(S6@`3_%&5OF)2+>Y`QG&N.<3%+C#ZPN2:)4
M(,`2]S.Z@/QF9O]-W0<:&D`%,W3'46BH@I3`DXP%)*<\%\DJ#`3A)N/>0V7N
M<2U)E#0V*%C'9)%PK\"L6D8'Y%7`M6T)58IR`_XJX'W"\&WX:`:#^/('FX=U
M1`V0<XYD,(*\Q!T@-S0+51K80S!U!0C'?B$,&A@"FNUB<5#.)8@'=HMC5:('
M`\(P7M"QF'+)&EN`N;F>H1CW;VBPSRNPVBVA#@RJG/U;4J<\,320Q">3NTE+
MJN"5K-#'"_0IZBC`#!S"Q"`*2D$%FOUY"Z+4<!$4H8*5ER'/4M&Y);B\,W!P
M00,;>9G,:JYS%<KS'1]&P0S^Y,=H*5(%>"PBO5U[LSOEW&8?%N/-Q2#_"I>U
MC(T&XY`1F![%+>+1(.#@DCY4P.5;R@NA^<)`&$5U6WH5T9)_K/HM7+YH4!J\
M%$CSP]:)CO-;;N*%39/EUV@FQ8<.[<Y&^P08BLZTP53%91`QBE`XJ3.8GSI`
M._.#TXRXLYJ],@HQ$^7+JKK)M2GBSU3LN8:_EK4PR4)F,F-C%./V-808X:`:
M3J1H<5[TF&]PC5Z,.<S%SK0_HP"#A$F/'E`0";MQ66QAIILLZ25*N5NBY8Q;
MV<I7CL)-(]YK.4_N'XA>!)FG?7+96'PIIRY5P0D.EB_7DRSFIK+.=\[SGOO\
MYT`/^E*H)(X=F@$MTA&ZTEG&FYT/L\84(]EH_Y=.]9U_NNI@,>PUL,[UKGO]
MZV`/N]AWCF@JWW3L9+]Z4D^AP[*C_>UA[YK:X4[WNMO][GC/N][WSO>^^_WO
M@%?Z/WI>9Z5C"][%^?B&*Q:%)6)HZWM^^)3=473C%+YBV7#.M87C"9BG;^I_
M3P;H<^A*'U8>&TE)O%^"DSB))?7R@8^][&=/"BI<PR<2:W1Z555LHLB9[6\Y
MQ41PSX^)".H28;`]/WS"J,2D6?G8*.^>C<\``MDVO8].OE*\YP6@301#TE]*
M\GOD>_J\``;"WWIT9#TY14S.GT'Y?O1Y'"_/Z#[:DPN@3R`/?RN/`CN,)&>-
M]A#*1T:9TWTV('^)X?]ZR5=P)L=\_$`*T<9FV$<*^Q9]RX!]5R=KJV-`[T<*
MIW"!B4$?PL=CEC"`R8=H<N9/MZ<(5B8Y]S<2NN-[+:$4;)=\),A\>24(*4A[
M/OB#>!<&+Y,=V!0@CJ0VSA$1]H$B?;4*XU`.(F)=O/$R"$(`M0-#-_`"H/,W
M(&(?7B`+TE%;);0/5+);!;`+!&`#K[8D4.!6BU`#`X`:-\.%4<4H8B@M<80S
MI?,^YV4C!@`SZ`<E</1/'+,1P^1>4'``1S47:M,]4@,6!1`@[G4K;W0=L@!'
M#%``3$(%6K@D1P<S-*"(_Q>')J,9X1!C=CB)N*0VR#6$_C4*J#(V,*`9:^'_
M7EF4,[+R4Z%#,CDV"-A10C=``)+#B6!!(.U"+GGX(UJ(,\%H+QLF(B."*KMP
M';BC&6XR`!)BC6;@(0IP`(QB)U0!3F@`2M'Q5K/(C`5P*^XE+T#8CNX(=@E3
M"NJ!.0?8"S&A$I84!C>04_3#)*OSC%2P(-L@'5Z`4-Q$2H+")&2AA%F((`A@
M`]_Q/[^C2ZDA*6T82`E`,BUQ@`A).%!88^=G7B^`$G4%"AUB"?%"*`DP#0RS
M"G"4`&80"^WA#5TA,$7B2@#C!:VE*L)3.2Z0.!+%""M9)[/($^RR'Y3Q)5KS
M3;BQ?7]#2F;P)R]`)2#)%CQA":6`$(:6)`""35F!_QAQI(2OMA.%P!8W$$>!
MU!JK0Q8+4`,C,@B2P@@,@!!HX!@D^9!S*2@)`TIY00.ET!Z).`U_@U!H006W
M\B[K85,_I#H*\)$;\3#.T!ZO`0/FU0Q9])`1^8Z:N9E"UR%94T>E4FI/=2I/
M(67I$R8EDC?*<S%D<F.XY%C>(`[&N`A/123Y8#>+,SD,X@`5,A;8<@,&H"U%
MXDRX(X3B($)N)0LIXQ'Q\QR\63G580\)02BP!B-B$YD253*34#MZ(T/_XSB$
M(S'0)`C109UF(S;>=2$[$IRQD`ND,#/8P!PK(T(W<US+^1OQP3K\\`CTP`N-
M$A^WT"`U<)VX\5F1='+LB?]<V"`X([-6WRF7GGDJ3#(Z*7&<Y]`\J"$.PN0=
ML\`-DM(=1.,=["E"L^!2V/`YL@`%C[`1S=51ET`78[&-(@)YG%FC-II4;<A1
M_D,/2V(A\&(#XP4#_7(KQY4WWG%2_B`?]A(+(.("^2-"`1$,H80KU/,8[S,Y
M53(D%3I,A)2:380-_/&D*>$?OW`(2+(P,0"</LDD#%=CY8DG<K06<8D:6D6G
M;9DT1/$E`Z4UUD0#NY0/A)(6(!)%,9`2>@E'"R1'/;(82E$/OXE&)3*2\_!`
M(Y(0VX(M4WI^CP6<\>$)"F!E<<HCTR*AM:,2UT$_&;@C.>J@`>E?56((IY*E
M%1+_*9!J+QV"$)@JHEE8)$3*.MVR)+!@F)3AC?DGJ6YC%&G@#>"4#+]!("I1
M.:5##7-WH]1:K<+AEJ+0/*;&,:<#!37@"MUG+T^U(P@E"#0@3[;P:@8$+]CB
M##$B$M\*6&W9,@Q`7KLRER]!%1HU$2+4'MYA&;UV?GU&,R(')91)"J]&()*R
M+?]0.X_D`$7C!5TAL<-0KUFA"=M8??6DA5WQK4L!0")WL+Z(7(_D@431%>E3
MKZDF%]U#.[+1'N15,.(3$_!*#0:[#QFK#P>$KQ,:#BU"6PJ!?A!1KW.$GTF1
ML!31'5P4KD#:/0_Q2"IU"=U*%?XPL#*1$C5@`^-:8=2S_QN=L+.%`%C3Y1Y7
MLRW[8`SX.B"ND`TM0AC9`P7GH&(QT!NN9ZUV>[>D%QS32AR?MK=\&W0VB$-]
MVW-^FWB3<[B]1C%^6[B)JT-S=W6#:[B(2V6,*QR+"QR"BRW#(;AYN[E_B[>@
M&[JB.[JD"W844;JHF[JJN[JLV[JN^[JP&[NR.[NT6[NV>[NXF[NZN[N\V[N^
M^[O`&[S".[S$6[S&6S&5>[S*N[S,VW/-$R-]QFQ95K=<-X!\BVC)-KD]YT.5
MR[T]-PTL,ZW)-V7"-`U7)W*(!K[;2[V$0J,B!WY8MY'#`;<VB+UPEQC39W1#
M\;&(9@;XNT/CRW6G@`I3AK[Q)_\<'+=YFWML.@1]\,MCTGNC,($`W<!(7I"!
M3Q%\>OMIKA>X+/,0GQL2$@B"F^`2DP.Y&VR#'WP<6L/!:J<AJM.W'#S")]QK
MY_$0$`O"0^<`'?S"P"$G`6(*_*`4UI"FX="X$6BY)UR_2@%9-/QMCX9#M.IF
M#Z%V;U'#;^%Z$G/%)(PJF*L4`?EPE%$H\EO#7]RX5Z?%O1:Y-IA"2S%7U[;%
MF$L*0DR&82"D-O'$7"P<-ZS#:[S"58S$DWO%JU`*)!S(Q5'$[&!@?:L7RK/%
M=4L%%?+'3_RQHW#%1:48)KS'VMN.!N)+.+,2E."6"CHY*$)>8M@5U5$E"X-+
M:!$X'W'_"8T'$QP3#B*W,.GJ7O1#`-I$)@CR5-918]NX,,\Q&,&`6GYI-\N@
M&Z`C&R13RJ]PC/K(,6CVS(D!):9J"`GC'7`A(EB3)P*1-C]91C=#-'!10I[!
M(,9,B^S2/*16.Q!)P:?C!=X`1Y1*2DNQRJP0((7B*#.2`%4PB[P!$).0:C@S
MA45'!3<0!9)P-/SP2#'2+O``5?J`&NHQ#.V2/25$&@8V"$92.R]0&G[C,8(!
M1W6)SO30T"('54I(-/[%3?6T,#]9!2]SM.@<-4I&#Y'IT5AE,%C5/7*1.%7@
MER3#&PCU.7![=/9!$<M(HW")7/6\1)*B'@>TU+7XD\[#35;V_S)R82<(L@`'
MX*W=?$V2($:O@&:0T!O?>@!+,H=#D2=0HADN,(Z@XWB.$3QB6!<RC1(BL=`)
M&`QA"`KKX)=4\LNAL"2:^<EFL"#89)@701G7,$S-PR05)D>-&2T`X1CGXJ<[
M`JLC\R.DM#0OP(F<J*+R<238=#K=XC%QM`QAX#$P@!]P5`,R02[>T1[;IXE4
M*1VOX4JW$@-R,]MMR=OW89C68IC*--SY$3ZZD852-9=P60"9D!HCX@W;]Y!]
MMB2IC3S#9!D_F@_O004&8!DC\B.Z@$.-"9S^U7"U#28\X5\C$R`>$1'8U&&^
MB)R200\/Z98JFAK900E8@DW)LH_>\?\C;/(N2N&5#&)BC^:D41#6***0H5`J
MI?%)6($BCI`/_%$+J%%;)PE(>UE5Y.4H2[$*XAB`SA&GXZTEN!,?/[2/E<!(
M,7`J,A(0H90?GQ(<YR')EO&I1G.6'2)5C5-6C#3:<D1*C(0BI],CRB,=_'%$
MYCU`*5$%>@(+J=$B=97A&/*0"V#D9/([4H8-R%6F]@(3VR+)U>$['I$/"(6U
MB)7:<?3@-X`=[#M[Y<0NJH(D7A#;1L@4391*/`(=R_%`CR`]28+CGNTFA![H
M),&VKW4>1QF4A!,Y'*0E@P4;4XT9*7%/8-$@@M(Q[M4W<8D[I#&)HZ,9]A(F
ML"$[D5@RFG#_PV]!-,H#/066-2[PASEC@[%M"7S**\C3#$L1*0.3#(62=>07
M'3A4.\N1/H_Q,E(R7[PIUYZIL,YNWWH#06[L4A(4ZMW73-R'1@WPAYJ1%]9$
M$F6S.N^1SY"0%K45[5CE2I[.-V9C",M!1N?!G1>J`-7R.5AU3RGQ$#`#U@49
M/`31XJB$)`<D&+4%$-[J#?B9$`O5;<!![+/P2I<CQ:;PH>*0&K,>'FSM/E"B
M[AX^+;AS?C0C8G-9KQXQ%L,N47T,(#1]23`@[D?U"AM#+ZG414KC/-]U*A#Y
M6H#D'_?0EE@SZ<7YCG?."UT9((D`J/^S&9E`C7RC"&GA8I]\Z'/)_QL"H^A6
MSPHK@58!XB&2@CMMZ#8?HD>2PPUE@481WJKUT!I@@0`V425)HDPX:1/DTBV9
M("/*].^IX:%Z[QP[]D@/\2-`(3!EM)()XY8&4V.$42C6D0JG%!]MF!BHD86R
M5.P<QAQ&DNS4T"`'TF?9P2,(`0VK8`C&*/KO472P($E_OAED4E1]]A%?DAW>
M8R3G9"<4\4A%9VU4LJ,"]*8+\$BF/SE5<`!S'Y=DH@I=OF,N(C!']QAPVTQ2
M%4BY\%1-5"@A,3*,1!'6@?<7@??QD0Z&B1`J4B)QDA>6XSQSM^.P5FK<0`VO
MH0^A0*NPP9WAT995D*:L$]`]@AR`8*,0=O^S``.35N.2QNAR4)@0U@#E0G/C
MD`;5P&BV0,4`E>9`DP!%!1.6AM90$W7#X*5P$P;#@,I`XW)+XV!C$Q6CH!C%
M$*8`E5!%5;I@%K80AL8X35UM?8V=K;T]'5.39M;@)4K54-6P<,R(]J*08`.E
ML.`0YE#EM5E#0U.#YN!%Q465!`P8>*.1:%^-*NDF+7C(@`H"&@W"!%-``Y^S
M!F;22#)SXT6:%U!@R$-P0]2":5X2+'A7[Z4-:6B"I;.H0,&+>CGAB209SF(Z
M&&8<Y,2DRD$#*NE@,8J"(%V4F.\8A6'P,(J-!#KK4:$7+$&-%U%J8'SQ-4T5
M!V9<O%0@+8T+*OC_T-B(81.!KU+HCNE+`^/N21MD&=T('"/-84X5B\JD(H]!
M%00YB;9+$,/,91LNBH%SD?-&P&DWQ&+R\J]!:$95#J2SL19-T9S`7,/RTM3+
M5IWXTLUBX$YD&F^L*[:316K!`2^@'7BRA]73W!@+8MR25X5?PANAJ$41B.E<
M7+,*8#!4`,M%E)&4J,B-$F]!,1KN+)EN&_JO#42,H"`(X\(BZIE%@TC?3:/4
M4NR1YT)'=34"WU%,*4=#%`0ML!\4-EEBWD0579011Y)4`4-<W)R(8HK;F-&1
M1ZI$$PT:7J0RC8PTAC&.1VB@D0J++.K(HT=>^-@1D>!44>20,(8131HS_UH%
MY8NJ%.D@DV8P9`,U3.;H)(TL,<G(DZH\*1LX'='H18YF#-DB.%[(-N0T+(II
M(S5U"FE5D'7&.*,9>N+H`F<.Q-5DCU6R*..<5)K9)8M-FOGCCU'>N2:+GGA)
M)YEO?BGEES>.Z25#9#:9*&`QQ.EFBSBJ0BF;>4[#)YJB)@ICJD"Z6BFC1MI9
M:Y`L;9IKH8@RBF-<:88)9I>ZMAEDI#OVV:F;A4JSZCI>_EBLFR\@A*.?3::Y
MXYG)BGFC12:JB&ZZZEYS[KKNOIL-&C"\T":\U;1K;[XHUL2`/?K^2XT9J`#,
MC1<E:F-#2@1?(W"]"Y^([\/H1FQOPO_**''&&O]OS''''G\,<L@BCTQRR2:?
M;*^?[%),<)GHJHSRR"S'G*YL,\.LXLPOZTQSSS[_##0WY2Q@3C5F9!0#H4G;
MR]TT4:@F#HI/H]</-U"L1\T])S8-CGO7G&/#0@BAZ,78$U/!,R=H7Z-;-51D
M6?!,:-/@I5556+3-*^A5P0X##1B4QM`151/&-]B@03?;&1F^#7,/=4<-#=G1
M6%/=6BY=3=O44*$PK%6D6/BYQ[*M3.<HWDWXY^ZBX3447-K+^KFQOXLZBC3X
MS4K0UQBS$'4=*<.C`E$LL",54!#/^N<_NNP1%7S+1E>85502YCL&<]1BD52$
M8085[L5B@Q=1*.!>&-O_@V,^IFQ&[\`WW8\#?8X`;<L(4]$H4Z-2WA/3]>M7
M1N.\-/#O?>"@2?'6MB:T#:]%\>M>D:+PN06B`7A=PY\9(&B7TU"A31TI4P*'
MAQM3>"D7#/&>-`AHE6-X(0;T>`=\[H:1LC4C8&A+H-K>I``D<4(5QH-&#:N@
MNO3%!0VVJ((@Q@$0/RU@>'Q3Q@+>%,#E,81%4X&5>PCH!;Y=Z7/S&F(6)^@U
MUJVO>:D8!8\V*+YH'"*+S8/?E?Q'%W_TXX)\J\&@`J>Z+;(N%1/DFYO0!AGN
MN6!(T3NCC#;H(C/1I$U`O-(@NH>V6'P.(">D)!"M$H4BF<]/#>A<]_)(R6G8
M_^*%3CK?FI"TR2^>S`:;>,K1'@(#W`PO)@A(0%N`8X.OA.$%"L,-`\02C%]2
M87@+*(#A<G%#MA0%,L+H"PRL,XV[5:$@DG$`5@;!"!K<13X)N($!<OBW)5)'
MF)`IYMA@,("Q5"9,!W@$28IA35E8)1UC>4@KX(D5*-3@&S"XQ$,$HH`&)&!>
M`X#;#="3`*CY,@$T0&<-:E&=6"S@!2]8J#;G\I`[,N=HFWCF(=+)%7D420$&
ML($!7K*3OPDOA3%`THS(ER:0M#)P]9K>^!J`@,R@HYL,B`(]_+&6ER2`"F0)
M*`(6(H\#&`XR<=E>(?IUE>.M,"<&F!YP;N!3`"5,$O_`41U1O8"54FA($`S0
M2P(.H+H7).`%M5!`THY#OD&&,PH'>`=!3/)+9!P`+Q(EGUG*BK6BX/*;3`$.
M=0H0!1@\)"/H0<!.#?:0&!A#H+I(9Q5(XA*Q$L0F3^2E3XG#2T;8(!TQH,$`
M8-"7%]3@M#60CPNN\LN"(&"8\H%%.'M*@!G.AJ%5".A`I\&*)Y4SAZ1P@'/D
M@5/&D0R:+!&+#1``A9YBB`%V4<!6[A()%R2`+6&J`124XH(7^(,B-NC$V.C'
M$@4X@WP)F)%WV]&+P!F7$KUH@%O*NX#NP"`7XAU%^VBP@)`P($!H<`$+:V#>
MIRQ1`6E*!B-&P9"GF64_ZO7_"`*\@`SLWH`5UC5)=)]1A1K<(`8(L!!`CC'#
M1%!7&+T-\7>E:Z%]EB(2FBC<BSES72C0!!0-.`!3:M"`\1D#"F8@7S8%TE[(
M!",DQ'L*3KMIA@/(8P'Z$,[70#&(Z`(9#5$8WBS-RP`SF"6Z!S4#*PUL!EOT
M9Z:J*(\@:M!3!AS4?`>@#W9WN5T'3>0&+=($1=#P"D7\.09LM3(#:B"1?>H%
M&OX9GD0L40\1-^-MI7DH#,9"T9HX``:#HJA5<CJ+X'JW`:QP@$1L0`IDT*(!
M1"2%HI&11>&IMP8)LV6@PXRAHM``,@GH\A-SV`@&Y+*W7O`N#)(A/(9NI32<
MLV4E_QC`2T,<PQCE4%@\'%F:,(PO+F4E6CV2-B]=I'DART&FR6R`%,5`P0"D
M=@@Q[#A!7!S`N`V"@@#@)D"_S4.UINKI2,96H'6(IAG/&%Z\P_E,CVRXK4JY
MG7LFP8C]!FHDBC@,`I0"`Q?P,P;^1N\GHJL*3S2B!B%L0`SF[0!Z.:D9)J6W
M)DZNE)T8)#6D[O5*0DA=1B@B#9-XQO'0L91)&,"X#C@>EX.L[P9P1F`NH1%%
MC&M?37RB$Y_S=R)>P!`9#?CB*9<&AA6.;"3Y:<.D>=W'&1`X@PBGX(^<Z"*F
MJ0ET9X+4H6`N4^)R-<=:,[K#&VW(7X#R!MV@H-,8+72=G/]PAN2BH5?'"W!-
M,73CPMDC2VQ&:X<:J$ND`<`.."H-8D"8^!+#\8PWS`)0XH*!`WTLZR;Z\3:/
M"(-$ONC$*SCQ!BEWAB@"#0OX'#05@(`=#9C58=*N/7K?[O9ZX@`-4,HLG_9O
M>2BEM54O1W=8"8[IJB7%G?P1*-*`;GX'^1EF7H3)P*<;9(O8'L+S1#=?4&)9
MC`4WBLU1+7ZN<5/%8!(384TWBYU#[T`#!V!P@O!=R&8#83!->!%DJ>=O$`<8
MN?`-V[)I!Z4AA(80S[1__C$V`X$,^X1-<D%R^85E4%!ZL7`EW<1Z)<AX-&``
M5U,*@&=P$=9>.K<(H/`,+P`*!;'_#/'@"Z8&%Z.W1`6!;AF"`*I3!0:0>@3`
M'4N1#+U'1%CC<,0#/L?@>$X"$_$`&:+A/<80/J414_5#@FD7#U!`49X@##7P
M"+*@5F2V"7XV"0?`'VEV*A;R-&1A:J"`AOI@``=U`_-G"$^D%BX078DQ=Z5!
M"1I7"2(Q%OO7(CUG79?06X1!@$M$B,*@"W)G"%"@5"PD@4-H'8E!:,6G"9QV
M"#O("A%A79QA<`$G;*LX%W`1"Q82$H#V@BEG1Z)`B-U$$2:7".G4#3(V$,=&
M"1?&##$@=4\$<MOR`@[P'87P)IZ`"_XW8OFU$EG'"-\7<=*E"-\`"K&`!CMW
M,M$E#Z'P_Q6')C!5D#2OH`MV06I:\0VT5GS0Y@VA``]M$76DT13K80.V8!Y)
MLTO0)EY/\Q`[(3`#%@:2LWE>PQVM`'Y0H`DAYC=&%`HWP&<OT'S=$6G1Y8S3
MT`H6H8YVX3=>TS"*07<K%(ZDYAYKP3VU0%%4`)"GTC[]D26[9@8MU1DO(%GM
MHPER9B[9P1ST6!:H@0LF0A(;104TH&NG,APY`C8Q*6;]XC69`!SYY0_4U"##
M(P\I$0-8LT+JZ"1)`V?V(%FO,"]AT(^ZD!U)J1:2XP("98AJ`1S"X"2=D1DM
MA0J?$""$X#?PF`A9(B_01B.:@#@(6190D!)0D$N#LY!S)V=B5O]S)$(+T&8&
M<?<-3V-?HF%RY54+1&&1F0`W1S-@&-:`]`AW/>DZB7$#6=)23^.3)2(P`-))
MX)=0.U$6'M$9-;!+:4(O7H!63O,W%TE1`DD+,'"."(8*8`D/`8D*`W,JK$0C
MKV`/*Q26<;%K<J*#F0$/FW<W)7*;*,,C/!,Q)I(VA_,H\<(K#J,[&5.>.:,N
M+(,O\<D]Z[`C.P(K<7$#JK,PKQ`,D&,5ZEDS#&-<*=,`S7A'[)(O[0DO<H<B
MY9!NZ%DC&Z.@ZPD[%&JA%PHT`*HO@`8#6.,Q"?DZ[J*.NHFA)R(^*3(Y):JB
M&[JB+:H-$^JB,=JB,-HR*4*C,OHSNH'_:&R3#6B):%YGGVK")57095'@=45J
MI*@2)X2P$&'2)N*#01Z!I#A2I"T28N%3#8?Y0%VV-E;QAY_#.D4Z(UZ2+%+:
M91TT3%TV(SE2+9Q`*JHC(Q/49?KI--Y%+2VB)&(**W53%K,`#E-Z)591-QC#
M&EQZ)DC*0)L2IT1ZIE[:"D?*I3(2J2PQI6I!:W6C;5W6(Y7J),8RJ0'#)9OB
M)M8`I9G4/$5J)93*I6WZ),ZP#GYD(T@*IVD:JK[`)8?I=7CJ#&NS1]V#JA.T
M#C,BJX%SJ362IIFD)&2*J)F*-H1"(UKC)$C"J)HJJM4ZI4K*(X@**V%S197*
MI'3J,U?A`-IE_SJ*@0``*J[D*AYR*0V"T".1H0"=1A#]PAS=D7I@-:X8(1>0
M(U#`P18V<`#4%!`7`@WC\Y8,M@Z*A9$505<%00]A,@\.T&N^24V^8&4/-0TT
M@`!8(1FM4;&?,"3:R`@ZZ'4EY21A!AS`H7(1MP"@T5_VBI@!^TM8XP)((2\*
M\)9/U+`%@9@&,`XA00TW<&$AAQ[Q*B\;.Y&LD7/3U`GR030\4A!N(5[:Y;#X
M@![ST")P=@`;JY@MZQSZ"7\%P6`[^WV30;,74A'48!8]XA3L6@T2&QUF)K,]
M%5H/-J]%%V:J$&0CD;=>8+)@10PD!3AJ(;/R=%`UNT3#,5$Z46`*D_]Z,$``
MDT0`9#&WD&>.2'=6AR8(.N@93H*TYF!J-1"7)%80Y@`#&RL?T2D28>!8X$!J
MHLL`WX1TXY!F.:*U7&MJC+`4`UBZ0=0OY,J)U#05$=MK07-MQ)HU"'``EO,4
M%58663=!R*,46=()2)1=RN4`"I.]!L8:.92]C^>Z86-EHI`2O%<2PO$+_0$-
M28&,;#:RZ"LY399-5E9ZPX$(-3$7:$<-+)1IL**23B)E:=(,_G85"D-LN"D)
M"C,)G!%QBP!6DI%O--*5WT4--E``@\*@JO"6W\![GQ,&R9!PU8"-4S0X9@#"
M_+%+;8%O/!<*X:!<_"9)V313_)8&PJ8)U;#_?\(17VT1ET6A=."`L-MGG^!K
MO@R,(/CVO9SP?9"Q$0KBFPR&&WYRP]-P=US6>XD+?JKHP:^5Q-D+`P:`$#5@
M`"3!9E1P4N9#71FDNP"'A/(;A?5[A2/+P6S%&L1S/#YD7U7C;]4+Q*^3?S6,
M-1$1QTY3851`:P^:<:(5ESZ39CA[`R:29@#&O!Y!68^<A`61#JPS%RX@&]N%
MD=3E%O.BE/W:`"4EB(V`;IT#@9Q1`VNEDUS5C`RV#!,UE7'\-/Y!45@3A5ES
M`!1EG&.1L5;&7--$5Q2%%B&WO#6":HO!$!1%PE(H'+E(#1"8O<]%4=V4"+26
M@8D!26'`B86F&TIA_Y'I-CVQ@08!]<DWRU:94<?2,$7HC`X@UCQHXQP410.K
M<'T/FG]D-T\TXK+:506<."\5512H,0X3-W=4C!:<S,=IURY_$\NZ@0!LA0KQ
MI;O0=FF;MPB'`'XQ,&+;Y\PS-,7UDW,\QW%R4ATS)0U=?!A^LPH%*M`4!1`M
MVU)-IGF*X1(M%4T'H`LI(<C\`1BNG!GH10PT80XZ.0FBBUX09P91\3<^2PU_
MG!-/G91"32-IE@"I!VARR%:`:Z$\8H8Z@6-N(;0>RBLEL58>J$]P`5]HA08#
MA5,'C0O:%`XP<#54=LJBD,K@"W[M@Q'\(`DI]X)NPADH$7%Q^31"NP]3R?^8
M79-3^Q!BYK=YPLP?$?;8"ME;)48-6"%05P(-N##`7A-PX"?9.T+-JXD9<MAF
M?J->B?=+=CT1^X"6`E$=DGVZCK`>.N$`OZE8^U!>JC!-._+.S>C6O:=B/M9P
MVH3/HO6@_';3'A&"G?'%B1G;=,.)CO`-"`UR(YO5:-70V#C-@LV/#`78",US
MHZ!-:L%@*\79ML005P%@TC#2#IV-)\T)U9%N'<'2IU@(A(8,"@$0Q8`+.7?3
M5P)D0\4:CQT*/07'"Z`0FC$V1<T(WA`1!4(6Z+7'+@2&0XS0#@Z1Y$,?#^ZF
M9CA06P'@5@<.07,#Y@<9^D0)6$$`BTP:+"X\2PO_"PYN1T0AB`V`$.;-P@^V
MXF-C#&NARJ&P"OLTOM\;`YS\`G"SY/V1MR-AU^XKY?V1OVI+OT#-7+SP"0'#
M"A\FAOLD9[B!!OYA2R4L;/6#3>$0$!S<4\#\?%0&9U?3N4M.P86W"#$P=$K,
M#^%%1)_#O?M%JMA4U!#,O3JY#I9H.A`W7E']#;BA.ELFQXG`$<\M%ZK%<?X`
MF'1,>?RP:=\MOPC"E8L@CD`NZM70?-3U8W!V`V1NYATQWTRAYL2LOH&4%%&P
M+=(`"JKU`A/%>BK=Y3<@9>V*"?Y`LX8(WH`,QXM,P_-"Q0_1/0&E&8;#U$^T
M(WDM@JK`F#TUR(8A')!1_^J`(1S?=:,:\PR;5AV$`PU54*[/T`"*%0.?X,Z'
M9GY@9>_;YP5J170!X;BM'J_PO@KQ6G2JX1QLH890]UTM#`H60E'JH`J]SFG%
M<.=9$Z]JE9_,UWS\,&\\KK'-)[H75Q!`Q'S&]7D-(N[2(.B9`!T=X0+!EU$M
MVR:A7!!EOE;69!?"46@<O.+L8`@6SXG-IW0,;,)(<>?/`%;?DT,QD%#-I\O6
M9!+],#B2A!N;IAK,$5#&=0[Q.@]U0\-FD7$B-^FKP!THMVF=VX`!Y3<T8L3V
M3A#&)>S-M[)%EWV*N?'9:Q09:11$]SDV,``9.#;?Q;0%%GPJS\M*85W@5Q[M
M$/\*[<"Y7%;S879I4#``JTD2(]\+\A[PHF5^6S$O1N:VNIN4%\<*)*84SJA6
M?].YX(``B]#4F$##>\O'#3WI->P>JQ#ZS2?WE(?N'EWWX?/O,*%<-%,X'MTN
M$\0CX.H1=_'(K,,J]\`E&Z1#@8,C%FF1"FBEJ3#\6,/N%IE%%FFJWDS]]R`K
M;1GO=J(A)!JHI/IY5X28W@_^HD$(%NE4W-$C[8]5B-0U[GS5&T22@.3]L@,(
M-S$V9FAI43$T86AA7FEI85149H]H5&AHB#%5:68WGS=5C8]>G&E>CH^3589I
MHEZ@-ZF=-3!0AE64KHYA-H-AKK%A59^WC\=>P(^(-;/_I\JE85"@4*:NC<6Z
MI[.35*!>4=F/HJ3)TY^EH%7$H)1F4,#D:99F5(_UAF;6G>?65#0T3*&!\FL>
M(D7/,C'R\@[4)5.1'HU2%2/&+#2LCN4*X]#+.5D>;\`[IDI9%4?)QE'":(@E
MR92N=.6"]>U8+UN,/G+R4B-&E$XOM)$<2K2HT:-(DRI=RK2ITZ=0HTJ=:K05
MU:M8LVK=RK6KUZ]@PS:M)[:LV;-HTZI=R[:MVZU6FV)Z*S7N4KMTN[8\9A55
MJ[A66YK1-C<P,B]X&[4:S'@>R;B-*Z$9C"GP8IA#%\MS;)AR(;Z3_S+65DJ7
MYE2C"TW^S/?8Z+D2<[6N1%*?_[+7M.\QKKQ[,NA.O2WCUJUM-U]4LSL!)MEH
MY7"KGGD/SLUY]#S`UC-/EPZ[>=79PY2MGJY[M6/:H54_;OFW/?7SF?W:E`U?
M<.3,]1]?EWR=]3SDE:B'B7&9";<:7GF]%)0+-#P"0RXO**"``XV\H!$,N,!@
M1@,*+,``%&G<4$,8"^ST`AI><.BA-6;`(&$#C2P@XP(U5`'#,53<J$H",KJP
M"`,=+F!+4&C`<`,,5$0AHP(QQ)5C&E#,V&`4&C+P4Q@O1`$D`@NXT)**"C18
M`X\KFA&AC"`^6`4#"R@`0XH+<.E`%!TJP(`]4'H9X@()\%@##2#6,*,-(39@
MB(C'1/_99D!;*G`B&BZ`:(8#<2K0@))!U@`%`O:@P8"/;<I(@Q<+.&)CE`KP
M&$.(-P#I(3Q!+@"B%PYT2&$8+G!R)`R$IF&#CFC$4"<5@O:Y`*%54)@&%6UR
M:22/'5+QP@*45('`-&0N0*P#C]3@2Z4+_&13J`Z@(J&,-:!!0ZBFW.""1"Y0
M@J4G2]:0A@M!.B`OAW)2.<Z)'';XPJ^JQ!NBO68P<&.11YJ9BA<G#D5KFX_"
M(..=:<"@8PQ03(N`G9S88.&R54KJXSAO)M!@&L*&42NZKC309KQFA+I`*%LN
M<*(9D3YR@Z$'KXL`CR`F:)07"IBAP`&<6$D#`V&X'`,5#+3_HJ4A6BI=S0T*
M\/2"%P086@6U#L`0AADQO-LM`\FXL(D")S&D9:(,''-#J56\0*$"4:!RM@.#
M0.T`%`VD6T4#SOQ,!=_ZW/RS&04D32(J-L`MGJS@)(#EFWZES9`-AEKI`H8I
M]AU%`E2`T[47,1B*1JWVZ`-#N;AJ6F(]"OPS@+TTC)S&L98@[D7EY-"IIQ=4
M)-!W%7#[;8,`-U910(G-)T/%`-PRJT\,;"_B`IU45&&#MLT+NF$,9F#I`!HU
M-+"X)%V'P?<X79M1PPO#./`U)3`D0*@9/"E1&&A0+K\P@`#VH($`_N0"5#`$
M!@.X0<9B,`P&C$HHS$L=#%RP.`>&_X%.N8C!^EZ7.T@DS82DND'PPL``&SBP
M%9E+'13JMBRH\<UO\KL%`^Q50TM\#("R8H#23#$VH=PK7EY@@"#*98;*A:$!
M!/B)`US(/%D,AD.<(%P8#*"`LW51%6R+'"844(`4JHYJ-4B?"WR4N^%UT8W%
MF]`C:+`[=>$O118QHM&002T&-&!]5K+2/2)1M670,&NE>L0+:G"_L>V05,P2
M3"H\5;3T54%Y48C"!PMYB`8DRI.=T%8";I!)E"@``9R@`I9HI,JX0,$!--!1
MB!QP`PHMH`$4_&(D^:*`&D1A3%CZ7A146:)*(,9*-0A3*TT(C,5ET@7<JH(+
M"#;'D4USD?_'B`$,:L"F*O3N&"Z@42X,0;5C\"I7]TCD):&0R5[825V66F<[
MF76S<OI*;1!#VB*4E#QVOJ`!191(J2!U`!ZVKP$K,Z$+K.B@E;D,"FJ#$BAI
M<*E,ODY(:.#0GRIZ"1C(+`P5>40#BO:2!+#3!2]@'CLU^8)5_6=9TUP5J8`A
M/Y?MD!P6S.0^2$4)*B"`!C4(I])L4,I#?"JB&_)"[^YT@Q=HKYBN6$!<Y)>*
MJ&%,I.YR@!!I.8^K1F&1]M+B+<V62*,RKT3,@INV4$0C&IY"E*2,`;6,:DX;
MH/-II;H?)ES`PST6I8A6<D#[9KB/7=+5J)-S4`P:J:T@7@T-TVK_P$JN.@X#
M,."RF73KW!Y!N'1&@4M^_-_2E$$+!B``1B0AW`L2&H4&_(Q$5+M;,SDY#QXA
MP`"W>,$!+INK$\J5;9="`^@0P#9(+*"9!6``%QTAPLKIXIOWJL'@CF'76%;7
M=V9X&@+T=5CY@6YE-3.591OP(1MHM;4>K8)E+PL%JFFI58:P:[=&9``9^4^]
MRDT`\MSJJ8X2H&B>DBI)\G9*'K;49S<KH43G.-YR-0`&=^H2(]=+(1@`Y`4P
M<*EKB>*%]1[`!E18[Z6F.90-)C-]7R31V>2*@'A)Z+(N)<5Q#W&`%[R`368`
M[0X5>0#29@QT4,BPD=94,R(*F(_%*6L:_Q9YS;01"@W:>@1*!340R9;H0S,V
MZZ<J,BVD0<M(H`PE%79[`$Z!T1#>Q64:8AE4Z)+8KT69Z9T6I[PICH,&]JRA
M(<.+U?N1"IYJ!89'OOBZ7E5A:@L@R687S%E0,F]L/H9!2]<W#PI"HH6J@-(4
M(TJ#2.VMB1*:;6`$**N,]=535WK?2$?5"<"9D!)SBY(7_>B_:DK9%[)DT/TV
MY*A[H,^$$MSLF,@[5SZ/S2IV%:$2`7ID/0M+P.95I"KY1HYC*PD59=5GE+CF
MB&#)<ED\/!W_5D:I!B3`I9U=\[==VP"46CB6),EPPL[]"*X.Y=C+"A=MH8LV
MYM$:'C.>7)-,./]#/$ELQINE&I]3&V;.4DH:"Z#04U.!;]=$&4J@DV!7HT!+
M$M6ZOY!(0`,:@(`H:+&+E=,<&,?6*B66Z%@G<0745$&]8<#MS+X2.8YCF=$$
MZ(BO<(YS'W^B0&\H@)0+F!H"O'4#^=&@M4TZM\B$V&F>UNP`P?K05Q70BAN,
M<H8/6KH-?/E9ID/!?S7X!-H9@#Z5>0L*XUL$+.?A`/=!87Y*"VJ\A$2%RGEC
M;\!H0`&:V6PH9[&+_[2!XF%Q]'_HUTH6,_FQF)EO1;Z@EHTVA)N;H4QA*=5"
M52"`VC(Z)Z[98VX)^TE&):@T4XE=4T&E`@&RQ`!K><L&[*Q;&/KTB&C_>\%+
M2--&0$68=9.SG51$!YK&7O)3*G"/?ZM2^%N!,<-'R%7Q-CA<D*.XVG5AWT:K
MBL(`-*SQ28QCZ=)U@$^]Y<M+^K+N0?69H1J0I7\FC(/$T]GM27/"S69-ZC9P
M`Y20;C9Q6IVP6_EF!@!8=FFG"W(U#4=W=R!F?W;V/$\699W6>Y$"(U_D``2@
M#%0#:4,C/V-C<$MV*5&B""?4/K!6-1DE+JMF(;)G37T5=#:11B[4"1;A*S"6
M/B^P1AK26@H##"(T.LT$!?9#3C2`">W#`"E%$J##=CZX1@P",6NT"52(A6OT
M/QL$A'A&"DLX&1"F1'83<2CA`@PP)\%@/Y3`_SJ&,#R/,2+=XA$.`$T<5"@1
M]Q,NI"Z7E2ZTT(:],D"D=`]I=`A%TUXP]2FI5#2X9Q-C6#1PF(3+`"+LXPX_
MN$9XID)(T@MF4H=5V"N_-`X2Y!&T8!6]<`^*P(>%DPDJ-`_-<`CB@B.44BZ<
M90_>4`DY"(<P98?34`H:TEY4X(ESDDG=(BZA,`]/"!17&#54R""=Y(0<@2=)
MF"*?P@LW]B%IH'<H15I-!(BD8`/!8H<:X@J]0A*`TBT@T@OJXHE?!82W\30[
M9`B$,X0AP@GJ8H\V``S'"`DU(H"%R#JZ,#QAD"[>PH;Y6!O<TP#_4XCJ(F@+
MJ0LF1P6,6#0W8((V>/\7^)$<&,D?"8(@&7D5L$$4>W&1?N611V$82&&2:R&`
M>D&24:&2+>F2,CF3-%F3-LD4,'F1.7F3/-F3/OF33[&30#F41%F41GF4;6$&
M49`)J;`*C)1VDR$RK-8+C'0+:%"1W^@.2\F/3PD%I3`/U<4+11,1BB83C)2#
MKA`#+V`,40"15,E(K3B07?F5I\`*8\=(!D<LWN((O\1(32EI1=.7!WF5+?67
M:PD)=UDC;[D/RZ`-TH(DI`"8Y-2446,/-C(PD]$W3^E+7]E$JR66:&:1&N$,
M8Z%'4T&60Z%*.*D0<69P=!D5JA2;`<F82(&:J#D4_G$4J<,71H0\1M%3/G;_
M%#'W%:;91*+)%.%@%[>9%:99%CS5(9C@-`F`4HK@`H4S+540!0>P1F&"!EQD
M""\0`/9P`P=@F3=F`'S5.Y!RG:4B?L'6<+;G(-,93JIC80K#9S5#)8+G-M5R
MGNDY,HVTG3^H<6G`6Y1"*D[((>^0=.NRA!YBG<=U8_<#-XN3"*.DG2CU/>3)
MG02Z+`>@<5RC3:@S-JNU``WR9M-42_*S36&R)M*R`.B):Y-2./0)!0/P$P18
M8BMCDB@)`^*R'/#A&NM1"3G:"K1D&?I1&46T%ZT@7ZZH-D+Q%TA1#2-U5>JI
M'P722:V0;E':0.^1&XO4=2XU%U4`8+6A+T?Z&YF!_TU!ZI%2^AY;"BSF.#]O
M^J7[82U+V!JM%9)1"J<B>2@QEA8\%2?V<B<AQ5E"Y"!9`DK<I("HE##E>2\8
M=@RMU2UKR4D;I)W'M6AK!DV&8&&/("L;9D+7%DH[T6S+P*@TTSMK@A<C]0C+
M%CM\4VJG`#>U%ZK/-T>T-&/9F:.8!R6)ZB!K-`\WTWL<QT/ZA**XIW[Z!0FA
M,%>O-$=@U@H:`P4'0"TY&F]/YU&UEWV^`@N8I2YY:``P,BT4$@5H^$J3-P\S
M)"1>L$$W$RPR`DI7>5F'TR/U(#,^`CI&@EE><%K`(U>(8U<M0C$%&R\<-S@R
MHW%0`")3DUT@5J5X0@,)D/^&9V,Q)U-I'D)*Q%5[A)-UM`@E!(`D;))017)+
M$&,G^,,`Y6DQ5N(-.4)>[4(`%(6O5"`SY4@K#)``S4`II",S@/(3)M<Q.F,Q
MX/@TB!-DY)4B!D`E.B,O"5!R$/8M%%(D%GL,@G(G,%``/%2PEP>P2"A7F'-C
MKY2&FA1.&'(/T_(A+$N;SME'@I)$SG<`(W=H,48U4&!9?$((MX1G;)(Z#J8,
MF]4[VH0C'_)@/NI6DR)-/P$#=,LG8S,+@I5(?,930Y%N-3`]"["='>9'EW(,
M]'<#-*!6=A)/<X55"O,MDJ81QV5N)OH.Y#IR?W</72,1Y>(`HO!%E7"K(H6N
MO9+_HNOS`L[2.`,X41K#6NS64MEZ#-V'.F432R2B)&.G+0C@"Q4J*,'((+EC
MG6-7"8NU*3;PH97#351#0VC`)$_W1XLC(CZ!`'>SE@HPO=HY=O&;.XG'5Y>B
M`/C+<=JD+0XP1;U".%Y0`#XZ<AEGI4T[99=2-O`29'Q3`**[;*W2,6IC+3;`
M=J<C+GYGA\IC03>&KNBJD`SBO",S9C.D?O&[0UQC"B@5!08@71P4OX`#46[#
M,AH3+@<`$%@69/J3.[CD(C?@ON@3G7/RH=P#48LT4BBU(U#0H*BS-E3`(`=`
M$&SS/3<6Q.CZ/0802Y&"::[P/?\[+<%I%LR3,/^@5<XW_U+P4+BI>G<G/!DT
M\L.&NEL&`(J,NEJRU%I:E*")8ED(8"&S,PTN-PL*2;G%%%`,IZLG(6E>\'5>
M>0Q`4H<_8:(T@$HJ!LE*$G%.Y:0UE`Q5("BVH``-BX311GF^8ED'@#YEU3@&
M%R[*6DN6=,'N4TB_6A&'JFDJZH3<4A06=C_9F"LM-#B:BTK"BS@C9B]44[C)
M$R:XR"9U+%6D4L,_4PDUP"4<)T'3U%HP^C.9E%QM<C?&5<.DHG>$$E0DQR>C
MLRIGUTMHQG9^Q%<+);&VIB4-<*T)L,LM`B2BK'O'HC_U]4YB]D6KI4@-,C9`
M5TOW@R4[VT)\92'Q9UPN@\TP4/]?<4*)4<8@M]II995AZ@:JI9+,_ZPSJQ)+
M[C(IVP4,13(B7*=;;?)'UVHIO<<M0^560$=75*/0/#+-@M12J<(G+O5[<2)8
MOB.H0Y<P!>!\,?9HK>83NL<XC=7!,T1*[2./-,18]@@XL59?E>`VX0`U'/TZ
ML92VB[,F(,(\@G:ZGV1KV9A2U!*2:?"JD&P/(L0SZ-9%E(4T]C@ZTN4SAUL9
MPK4^V04T;^U+%SPI*X-ADB9<%M,B-Y)ZM31#/36KAP)*VL0LG+`A@.))-U``
M#:>MOAQ4KV-2ES1,FP!B"N-:<TU1W]2P-H``*'&AU0O-22=9W(.+TI*&$B18
M87(ZH#/_3)CD$[+]?-QD5QO$,Z.#NVG'T>Q4S<J@6Q?LVE,DSVLF1"*D-^+3
M*WXWNF?'$<>"4+6'*)W`-Z),(AI'4?9S5#RS31A]V]?URQ+1-5P%.$=W:*E0
M."3"36F$2RV$-OHS*<=K>%1#/%!0"R,-9N+#VP3]9ZUSW0NN>)S5170"7PZB
M+U-70]AK,=,,2TK3.@_R=`[B/M#TT&J1(I-BBTP#$'.J5?J"KCY#(3#B`@E@
MV/@,4,NRRP0SNK.HE&J#AA*!6DLF"%QB)ZAP6;4B038@<DSRAI(U%!S7>SKR
M*__J(3K3"CUS#.K7"5:"H+4"(E>.M1/B1U;E1Z*LG6QBHM9Z_S$4M^1I,">+
M<UFE\D1`8EG#H'.2U3&3$G&]E")8HS8]L683TB7OH#9UAS9&M%B^$"(W<N2%
MX"*.DD1MXK14$RV'/B9=D@\O4[WKDR(I(B&[3$*]=)B7)RRF95>-*R$I92B:
M+C.BW%0LE"IOPB9\@^(4.^6<A0!8XDF7YVFFT-IM<A*P7C1GU2&;PB<G]41M
MTBND=^03H@LL].@QP"7'M2G/=L]-=>A'DDX_""*7ETR6H@N+$R>DQ"-00R>6
M<G9L4A'V@CC!Z#)\\B=BHG3K(B.FL%A/A"*P+@ML,DI;+2$@MLN7MBCO$HS?
M;B<0E6\P6@/TI&!WQR>#4W)KP0B0`/]#YC%@I-02XH$8P`!`D'`V-F'Q@R2*
M6PGQG2`>W&A)ZZ`+2BD+.%*1IF@7(D\>E+$.ZS`+B\`<K1`U_-!T$F$7L+"5
M.6^/,J]*^G#RKE'RSCH2!N&5W@H+2#CR\]!W>'(;MR$3+._T3D^:P)$^P/%2
MY7`/Y,`2^N`.T+`/&!$U6@_Q94]:&,$+[E`M9E_SVX`)RH#2Y*#UMN$.=3^;
M@>$(TW$VBP#WZ0,3ML$<&Q'X&4_W/@9`*((8M2$;4<,0_V%)Z3/Y8N\:R2`O
M\I(1-G'YD*#YPX!F#-$8BX#V>;_UR3`,VL#QXB$/@\\77Y_XHH#V-%7XP/`K
ME<-Z]!$;6@__^6XAE$CY^T?I^\`__&B!DCA)DLDBA<2__,S?_,[__-`?E+_O
MUG\:_31)_6S1G$B1F];?_=X__)?PBD>AT-W96B.G?NP#)$TRB$[1D..?1II?
M%`/I&JG4G*2H\QHYDWV'#)1"694P*H!`8X:69B:8AIBHN,B8:$.5&-6PX!#6
MV"BYT'!SV>E5T]E8X]481D.89HJ&&NKXZ778VEC%V0H%J4CE$"5;6F56P]J;
M1K4Z?#P<!JJ(5ESJ]8G<6E,E[2R-G2U;I1"V<&N&Z/6;2--0%;401<-P`P6E
MK$!%M5#S`EI5A6H<7H@61F60/'V*`*ZBXD5!M7'"TE19D,^,#0=F_QA$^1?0
M7QH:-\)42F,,S:!"B/J93&2FBJ54&=,P3(1&93@S"$$B,L8LWRHST$I2J>&B
MY((856AT<UD,C;JC5:ATBTEJ)$Z6ELRD7#G.@0U$51+8J.+"@4B0,W_1),7M
MZPV%+LE9)9>(810&^7R2^J>/IJ5O+>LF'(1NP:JZ(LGQLZMN`2F08:H![/<2
M*LN0A'0FJN*EL"4&#KSH1=3X[5M"`$E-#'/Q;,F>,'5ZJU:2<,R5L>^FM*V2
M\4*WC0G=YM5,GY<%86(21`0#AL&K*<,U6WP9EYG>B3;UK7:8I$O%2!MJ^RXM
MQ@`:"Q(H('YCP0(7_<C#"V/*!?SB#*"(0_]7Q<8"!300U:AAQC=>O``%`PPT
MX`4"YKF`2CKK>>%"#0.\H-]ZPE1AP`((O,!``3`,X(`+YS4@T44N>`'%"PS6
MT``:,21`!3=>1)'`*0S8$(9\J3B@'HH+'&C&6@J(!1(,"B2@V"0)W/!?&C'8
MAY(#"BA`H`(-('"#%PPL<(`#B*33H$3JR9>8%T8J<(`7#C"@P#ORN0`E%`JP
M244,ZBD4Q7D%;)4&#"^4%`6$_[C@U%#G)0`%##%<%D9ZZYFQYIS]0+$?#%1D
MF`!1A]IP0P+U&<A`0E,29V0",`R7XY$(F,&A`E]-R0M'9B@0!5@OS$7I8C4D
ML(F!#80AIY5JLAG_!10QQ,#)"W6JUQ\BR,*PI0(W%)#`7/M%T6D#+NRG"0(Q
M.,7`DAW><"*;;<IY)9]H2*F`"S9,2,APY=5`7KBX:+E?#7+N!P4-2(;JKU;F
M(6CN"V&P"8-\!BH``PT#Q%"#>C#XAL`!-L"09[A2,I`CF[4X.:7!!R9`9!KA
M3AE&#"'78$.`4`B:AH0P[-JN=^#=W`HWW@"X0'K(+GE3J1314(!Z=$'$R)HW
MX"()%1X"Q<`+:[W8,JW^N0K%0]SD^3.47"'@A5/FA$'K`C!4%$Q,?V+<`!0-
M'$`%`R[`8,.>*C)PJ0LW>.D2`C3@R``,:[$#CPV$.`6LMPP$^<VOW*&D_Z^1
MY!GB0`PO0,KW1(K,RI&XZ:R5N%$WJ`SID`W6T&D-#IS=0`WMF.$5(NXJ\A`:
MPT6!0&/Z+O""`YQ0$9:</]L@+=FXO-!S%%3D3FD5-4CB@#EH-.![U`NTO("_
MT"#:LV`V+.F5Z$^EL7<4!<1``[0%IK.8BA5)/=3K-H@.P_5Z=Z:.5S4@`-L]
M#<1@AM8UP`8Q&-K_2.0"]B#@'739'87.,906V8`!$:-<2?1%`_ZQQ27Z<D`#
MW!<]T-``"FNRP:HFZ`(2O4!%E^M916*P0+)!`4;T4$:*Y$&K!+`,`<?#6#L4
M$$#E\&=)I'-)`C#3)AXF9#'U")"_D!B#!D3!`/\S"XI#<D@%LO$"9UR4Q7`J
M`HD!'N!`%D$$/%+2@(:Q9Q!H*&,J:E$%!R2`087@C`L,U"E-4)`[O@/-"SQ%
MC^%<BHRXX(I@A@.4-E:AC(KR#X`HPB+J.<`!B_S@)*I`O3L.T!%'RF,#]A@5
M,S(@%;R#P7:T5,!%>.&3;*)!4/9VCS1H+@T%B@04QOC)]=5CE-YXP0$:H"U9
M"L!K$;L24#CA`O)48W9]6A1(;I".[<P%#05J0`)6"`HOZ.<%""!C@:KA1C61
M;"X.^12;DFG*_0"3'6&$%B)N1$&Q#(<&!@!F]1)QL!!-0A*48A]R^H.D3T:L
M&F:`P2\_>!H&6&Z*P$3_$"+NT4=W.2!%H(A;#$QY#Z7,:!.:,!6YAN."1<WS
ME7SSR('`]KBXL>F#H&@D,0ST(\T]Q`&@F`B%T*"`S"2,.":+6&/PQLJ<JJ.>
MGX3-L>*VMS2X*T"^M&<XZ$&(&Q''&XN18AI6QP!"##"3!H+2[023ADUT<:R>
MX%\9>Q6#*%`2.:'*$?H:,(\LL@,S#OB3B_Z3@'[`H`#I6%5=@0<%!`CNB(@@
MX`S3XP5$*52M7@A#/VJ'2.)(BQ)R>L\+T"'2+MV``,%@``]_N9$"N.T`CFV,
M"])10&6=-HUSR6)";F#0[T7A!2VB)R<<BXA.S=9O09F(?N;"MUG5`%@P6JP#
M_^B1#J?,SV*TJ@$,'@*ME0SEEC30BE+M<5J+(8(*U3(%1!8(0S!-4D[*:E,8
MYKE80D%$*;B@`<N\,DIZ>#`=T?M3[V9[`[SUU%6R7<KH$)`G*%RLEHEP00&<
M`L1/^3,-+UA4B*)PVKI*0F7KB('F7F"`++J*7/V(4!]IVC;BJ?4%-/A3,G$Z
M(SO2"'X/J0&MPJ*Y&S3`C`LT:&*W"*VY?+`_+HV!13YI@P-`V`4O*!M00/'!
M/`79PO(@3HM??,1J*:"#*TG87&1\5>P1#PK.!<V4=4N<62VF/F%U\7O-Q-?R
M]",,B.)/IV!#UCBC9&Y$<5*,>`3`DB!O2,":TX]NP/^J*7V$EGA,A"X,T1\(
M\2X,O>O9929!`S.Q2EF?C(&+MFBF?UBJ'07\$05ER64T0%-V'>F,+%^`!@(Y
MY%<72P.V"KJ>\_+H<JND8!0,Y[HK>=?4F`R'I?0L-ZF!8AUH@!9-(V&NBJX)
M@,\]6X%"I`P#1:%)R!*EMFSPO)C!8TV[N(F+SP,)\OBI"J:DPB>32;YH72Z.
M0RDH*>KL:@-]1:1$.3>RML)HN7FASD0ID$7",+$)UE667:V",[\D%HC9N=DK
MX50J[DAK/!OB0%18AZLI0LM)+$/;-(#$\SIN!CO)1\#:+G9COF6@""W2N2'7
M][2)T:R"RDT^"8O7FD*J+UG_UF)8<_L>]1C]HXGE?%C#Y55]"LH3Y=R1R#EB
M&P4;1,&T]N=Y!0W#!,G\I:XBO>K."G?%NTJ,H34+)'.;2SODC'9FV(P1\($)
M(5;A&]K`1,[[R&TAYVZ3-EX$[ZQHR-KQW@I6!'&2-V%&;N%LD\0;?A'_Z$?A
ML=%W:4SG[XVPG>,5?XFUVZSNBT_\VS_?1<W?;//9B#PCA('Z84P$%1D]/6F(
MX_?*/U[VIZ<]Y9%Q^[3K_AA3V7TK+M^)COB^%U1HF-P9,9+A*W_YS&^^\YN/
MCD@@_O2`?K[UKX_][&M_^]SOOO>_#_[PBS_\T^G\3:##>#E[1ANX'4;YF8%^
MY=/D_^^22<9QD/&3O:O2=C")?S:H8`/ZUPOY(7S8`(#5UPGMAWS'-W[I1U8B
MP8#',!_'EQEQD7L-B('?`056E`H')T(V4P-W!QY(-PK:0"&+<`,?LPBM1CLM
M(F<%Y1WK\CB-$%A\(@NS@G'(4#\B,C&;@S>+(PXD`AXJ(R4]*`M&,4D;=`PN
MIDG`IPAP<@DW\"=R5A1I5X5C%8)2^!W%HG`P<0XW\849*(8X0T+*05YG4P,&
MH#P)!`5F``\WX$JX$`8'X`)%<5G5I1RW%B$.L4*9H3JG(DM:80,&X`[P<5]!
M4EU;E`HV4(?D`D#W`'#1XPWH$3WAP(@A$@E$YCV5,P@3,?]<4+`*;[A0)S8@
M=2AJJH,MHC4@+[`8EQ(#IF!==6)I%2$/4N@F9T,^(=4/=?,(QQ*)G#!M$V4Y
MB]$5I*`FYV5E`9(.-$%D0`0\K(@BQ"`=JA,,=A@.Q>@2G=&&M`0L%$(N=:@U
MB"`KU-@,Y!(+B_!I+D(%H$A-,4%D:A(BI^`(D\0>U;45(3=1,Y(*46!U#49"
M6P%ARF%U,5"'!H4.(44;-H49]J!-T8,*C4*0U5"&`'<`L(&/+\,+J&&'QA(#
M^S91M,2(.#)'KL2/KK889D)3P"(2;?B'XU!\-)`RE=-+IQ4@F*$B(CB&.=D*
MR\,B>D,`U14AA%@Y+X)<!D"06=7_-\F$`-@V0/RA"?MC;BOT"/`$/ZZ#83)&
M0C2%*`>0'$#T)0;P'_%D.?\A,!4R02S"$?5`AUPQ9>7Q/?J!++ND'].Q`*X8
M+OOC-L>"-UQI)&DH8T2V#$[C)_6P)#QB.&W4)EQ)'A/A0W]86`8P$:[B0;M"
M7S!@`.+F'QQ8"*NC3(DA-F_38C"`/[]U-<3C7%YAB7Q#%DAC$7-TEG=48B"1
M#\HP0.T@(KNB@HZ```T0:61#E_1`D%$T90N46VI9.80Y.JU#03,F"3<`EI[B
M+^F`7;?$(G4E9`I`D%OT$!/A.P=`+_"T#%-477"E0]3C2_T3/:WC)6X#`_#5
M,PD4,4Y!_U,+A``T-3=G(P_.XBX+1!<D-!<31&+)\3<#I$-(8A3T8&[HPS$Z
MR:"MX$HN,66C=#M9Q8@,(&2)L1VH($5`X1*B>0`^Q@MM`T.4%)/UN8<\`41-
M:0FK(Q@R1&+YQ6"_-";4``,-0(CHXP*[^2/']J`QXR7RU1_`!0H\L0!T"28<
M^C\&<"`'D!Y&6J0C*AV*449`85W.`D!`%`,R2B5:6AD+<%UI@#0-9A$)@0;V
MD)FMH:1ODQ[TP"(.40_U9*'`\C#5P0DRYE*RQ($BP9JY4J92,A1_LDHDHTYS
MM(<DU@@IP0YEXUC7,THB85U[J%13MR:QLB:0X(;,V0XS%B%*8?^9GP1?+T5"
MZW)-BT$YGJ(YUM0`5I)UY420VV$#,P82;!$D7B()C:05:(!+WJE?%N$[Y/(0
MZ=$@M,57#0.)!80`Z-0P`^(`EZE?T7,C:2ID#2JMHC!C]*`?KN:9^E,MZI!5
M#]$/;6.FP1,X9P5-)#2N)$1DY3:73:D/"E6DWK`.-N`V3E(?-L"(YE`E%Y,^
M(68#+V!*"9-;HY0.*Y1N#48,Q'->VUJF0?$_2V(L]&`5B4$3&PA6`:(E6^$G
MS.0DRD$<Y'%KSF41V"8.@K&I5I.>@2(8L4D,7@DI-["44?`MB0&LRH4H<!AR
M:RD[BX*'8Z<S(#%1$#$K[+,6HU.71>K_'\!T6L\S.X:Z")"""VG4#8FU%E8A
M8\C$)WZR$4K#8!S""5PV2OF55$ME*%``AUAV92V"+;SC']]`6YH3%M-6"^04
M-VVJ7+"J%/;1+Z/TJK8*:#4"LW$#"7CC.XP85IDB%$^"*"JU;_41(LZE*'5%
M*79B'_#DLN[PBM.*N?AD)?P!!?6D0U[`E4/")7,Q3<.!"LNV-D-"15:U"6L2
M-;OB`%WB%-9D0N8`LT8'L=[0#Y)P15)28E!CH_.S)$,R9=QP)594$>;"7=:T
M-%8B+AT%56:Z"7=T(-[J#<M372DG%%Z0+?*@-XEP+`%R7IJ`G=S@NUR15;/C
M+ZFZ2B@;,U,H_X,^ID*:`!&)$0:?I`!@<R#KT3QGYVHD4RT-\X1F\TEF("*Q
M.Q<S0C((H`#%-A3M.4)#@B@G>`\W,'U&83GRL"4.`#9KPCM]=()7=+S=FQ^;
M.T.3T`Y>(K9QDZHP,*^2$`460[_-TBD<?"-!P5URQ">\&S?#D:HT$,-0XF*3
M<,('(L!]1(0*H5]2Q"&6(TL$`!O3<R"BE0:J"KMT2`/'4F*:8)138B`'4P7(
M\TE6%X&9.X:-DI'K"!P5Q[WS\!B6>@TH@AF%\`[Y0`YF\0[A@"U^\0C$H#R#
M\&K-<!`/"1MH;#N>`4T($23P`4V5L330T2CSX!(6S!5+\T9-01-MX?\05D&V
MQ9$4Q5!QP+*-VW4X63(;<4$*SL"]>V?(-U$,N>%JPF<6D,`:('$Q``(2V&()
M`6&I2V.I>3S'XW`9-F",Z!<D,U,5OFP0Q&#!21$%BJ*=EIP;T`#+,/',=1;)
M29&"ISS'XK`TU4`%6;)=Q#S)LUD-N5$,HOP6A5`,M8+&N=#,C>'-A93)*;&(
MS@QG`(@6%IP/:&$)Y9C*3S4=6:,/^L$*:%P3W;S'"`$-GE''^1#.NSP(G4P,
M3FC&%]V`%XC1&QUG&LW1.?D]7O/1(TW2)6W2)XW2OO=^*<W2+>W2+PW3,2W3
M,TW3-6W3-XW3.:W3.\W3/>W3/PW402W40TW_U$5MU$>-U$DMU"*AT4[8>^#Q
MU*YW@XUE>[47>$J-U5FMU<>P/`C`P(K("`%XOR((J</P#I=PIXO@/`QF2J%P
M`P<`US98'?]!1X;&,7V\.9$6-V6\U7WMUT<-!0*`.@H2$P%8""@R+093@K=6
M#=#$$^\0+_(J$N/P%7/X*]HTRN03!3QQ:RLQ/6GR(WGL$'@-$KMI)GD5)("&
M!AL2SHL(BI]`!01P-E8'BE$P`,0,(-1$SN?E#A;]U[\-W#4-!020&2X`-P>`
M``20@@10``8``)PE9$2#`!EF-D2C``5@,&AR/I>2`'!-`P'PDU[]H=41(05P
MW6#E!040`,ACWN,1_\,)0(@W<=V6`A\+8``&T`V"92>)=0`%D%TO``"BI=T)
M`P`(4`-I8F#(#2'X/2'![>`//M-1$`!>70""<%$#0#?#Y`5&Z07*S97`D%C^
M6@"F0-S.I:14,`"WD.)TV.$;HHA/2=Q$\\_6%"!Y9314=``*<!D+,``"X#M0
M7`4$8$)^8N`%$#8IR%<5+A&6J0X#@"T$,-PMPY57$D`)`.%7CN4H#04/0\EO
M_0(>4C=6`99A(.1&23X)XJ\&0#X>GJ-X,P#Y0`"X$W#+FCN(0`GTA`9ULQ)2
M`J8S!E-<B6Z%8,$I(P`&YE@%L#]^4B,&D!)D2P!.\Q7'VDU!OHZB%>=IL/\A
MDW!5.I[EG>[I%SW<T"$>#B``=#/B9G``B*+<+E!/?'5-,!``;],S`]``18/B
M<#Y#2PG`JX((5D)/P##B#R7DJKHE-4``<N1,9N#5$\%7^,TE"4+D55``%MHV
MCYXA$E+K"@$BQLX-N\E7FBY'GR[NXZZ3Y.9X(7</CX"+>U-\GE%`]C%"ENDG
MQ7%DD2:0IZ)6Q9)`<(8Z=1(31@@A]KH5]IKG,FEHJ?H-#K'O:#!"_>)J<X.,
MC4))C$@OAG`K9X.2O&"OY+-QY.[Q'U_2,(``W^?1(&_R)]_3T8?R*\_R+>_R
M+P_S'O\3_T$-FSV`8</7FS-6:""`4`W()2]JM2+_KSD_#`#XD$?6>SQO!OK'
M\R4_#-V<,_Z7#5#OVS8_@LT@=V'#>Q9=$X>:R5./\XJ@]4X(&%(?"A*!D[U0
MDK8`BL@`$)<`]5"/>Z/&%7X"UEP1]MM%]!B]@0RL-Z&2>HSG+B_C>:8W.K/G
M>58]>__`4X#G@(@/$E2`:BVC^'AG0OKA+E'L^&\GU6QV.2!!/:[C)7#'^!`K
MFXT:U8O7=VOG+H'/#`*,>8%O>C<!J6!Q$WV'-ZZ_^05!$>)L#!6'^('/$8B?
M-8@O^5"U#T\=^`U3_#91!5EC13BA+,`?^U9-8>9W^XQ0@+/O$-Y2>$D/$JS`
MB($?2[*C+K?/^0[HLGSB_Q2*`C2)=P_?Z[.UX/0-*L"P`VD\7VCBL"9+:<$L
M`@@P40T,-VE1#(4,!U0Q"PU552\,4"X+-&F9@PLN9C4P"R]H4`L,"5Z950Z7
M9C%>7C1>+PLP9F&6,5&&5#8N!5`U439IO+>T:)EHH`Y>BR\$+S957@T+-6:S
M+V90#@Y0U5"9:5`,"U`V!#'(Y,AAZHB%80M1"V@UB0KVB554-6DVX=)(8N#`
M40PSH"A)2U.C2J95QZA4\Y?IEBD:QF"@\>*`@3H;LV)8BI(139B."2C"^&6C
M5$`T"A+50"-QP;!,-RS50D3+2PP&#0C0D%:EF@TJ4*),ZL3Q495/#%YX0:!`
M%O^#6CAYP6#0*9,O&@@:*+B!QD8B*N)N[#-CR468%S1N3)M(Y<:+`KK*Q:!2
MP!M)2]H^T3)3L>U4!`[MN6!`0Q^,E@RH4&E\XX8-+S5MH%'+P&&:%P9JV&CP
M@N=,D=8(H?H7=@$58]I<U`A#",'E51\;P.",-@W"!0ZJ+`KH`-,X&]A"H7E1
MP\7E!@T00&EZ+18LPN*R:]_.O;OW[^#!P_6-(`84!%2LV:CZ$`84`Z.A*("1
M7K2"*&-KQ)A5XSZ,!C8@$$4,8S66"0WF2:=`:0G<H``4-!@01AIH..">.31`
M]XDW#-3P0FDN?/B/;`FD1P\V'KY`SDW]4='-8E`<,)K_#055\H(W#=`PB42R
M&9*&%PW:D(`-!P2T7W9A=-@2/?3(%X4+`CX80P/-S+):@/BY`$6)+BAU%0QA
MG/*0`NG1P)A\:"W7Y0$TP*`E`R!IN8!:+MP`WPLNN+EBB%'`ETD-#28`C`(3
MHI&``_A]$Q>98U+!&`TTG$>D#3<<,,@-.4+QPGXQ6&JA4O1LU66#7-V`P`T'
M>34:HF/]V>`!-]3@6H$,$&:&`C'0T$AD'L'07`TURN8`H%4\9FH4"'P"PW_I
M$<A@;\Q>U8`#A2K00*+SW2`H#81&M8!PBCI(!:XT1.%J>B^4N644"2!H:8>9
M8(DGLY<P]RE\>9)"2KKDFLN0_VLN.+`8*FBXEET,..I(@W,-F%?`#18Z:6:.
MX55L\<48;S?>K5Z@`:<!"RP@H&_?IN$`C>10407((M-0SY^;PO"C-0X(I$`"
M&F7R#0,&I)R&;@RD$09[9AR@@,@S)9!`P0@LD,".![XPXB!#GV16%4H['8-7
M_C@:@T8+G"3K:@PTO>!XYREP$R*9P+D`=LV)XT6?(9_*`"+`"L18`2$KL(T`
M-_WC0(4WF/'M)`E\>TG-#PUSC]$B&^*QN9O>[#0,"1R=`,)0#&T&Q)8_7;)L
MF4B$*84E%XQ6GI!+QS5#=5930$NVA#TLH3!_/4YG'1WP7Q05:CI;=&ZIZH`A
MSFD"2?\]7EC#M],3I@'6/`V$\PU<LBUP99<-E%6.`<(U\KO@D?T<4/5I0,Q<
M,N5OVAG$:,"$F0#^?%PW,$W[RW;UGIL\]B!I@(%Q>C$.0IA+?2YSR+`RA[2[
M22]_F1A/%>HECO)1J!E->QIS9,.>!M2@=3.A"C(R1L(2FO`SF#!<Q\PAJ$84
MJD.W&HU:7M.@1N!G&KER3JW,0J-#W.`\:+E5,.QFK@XI@!\(*)0UJA"#*LCG
M/@YXP5,498:%-0`;;Y)'&+3E`H_!H`KER@3"JI@C;1#J9'-J!2>FN+X;1($&
M"2`,UB(AJ+"5CCW-VQ(4&C$N>C@H#.L1%Q0.X@`%#"Y>+C#_V0WD`0HJ@.)G
M?GJ(-J*H-B:NIB!F8(QNP(B(+Y:+?V_KQ28_20/#481)5:&"F&!B`WFL1QJN
M>$@G7.""(2&+=E4#D#G<`0/W(21@Z8H*^AI@EX;8@%T^$E8X3J8S7FUD3B4:
M$#+,<$P7-"!$"'F!`&4#IU8@#!%5D(ZIA#,@A-4B1`ZDA%=J\:'U44@!&(%3
M9/`3!G:]Q5J9=!`LJW"4Q6@B:-4S0P)(,A;ML6T\@DO?M,[IIAIX4(@>`:-$
MH%`6*DQ"C%?,D([$X29D`$M@;`06#X?6$AHPT8D*N,\)5\K2[\3`'V:@$AH@
MT1]#8H==(JL$-]#"+9L2"&?GP51*_Z%0B7$<K0&%>L'13N6`U0U(<]%S4"DD
MH@M$]4TR"XB)?$+VQ60A-0RG.L312O:C<I#)!@=!JHJ>>*V^#<@?!)H/1U/J
MBBLF`P;6F@\:>LJ,!DB$+2EE@#$V1R.KX41J6J+-5F/R#PF)XP6)$^QZ2A&]
M*BRU!NG):A7P$[(J)+96=AE75B6S5!^%TT,I-8['4MK%FB+5*TUC@!=<L-31
MF.%6>-)%2H<5@TYU=K((<).YNL2M]91C-8]1T6=,&]R:40,;-U,'A0II$R^,
ME8DVV`U;03*5#-7-LQXQZ=%XY]14C-4G%"G8;F-:A>6DE%)(%18O4DJE0JJM
M=(/KTC\2Y_\6*KDH#2\][#CX%3(O/$:TTMFJ]A!5H912)$FC1:O<$F&**$PP
MJP,"25*62M3Q4A5BV&FIB%MZVXI0*`S(\$)[D>2%,-C")"-\18Q7TV(T5*%0
MT0O#BI,Q#1>C6&@I;C&2JG!;&IN$R!5!<AB\<-N-U'@C(]1QB'US8]^@>$(N
M%MJ*S5#E+#M9.Z\XL79X0848K[ACE0U#H<*<95MDPLTH-HF6U?R60U9$RDD>
M845:;"LD:YDP/YZ0F[F,'1UG><\_6LV==ZQB/;O`I,BPL9K=+#0^:SE^O/2S
MBFT1Z/BU%\]OM@6@]?R*.'?LR]F91I)M]>)+P[C&-X[SC?L\:B#_BP//A_;8
M=-H1/QNCV58U_M&*42WF'PO;Q(/&SJ`%C>02+SG+N(YTF,7!94%'[\U06.2;
MJWQ;:%M:RAO)1,=&3.YRF_O<Z$ZWNM%]M76[6QQAU#/&+//N<\N[W%^LM[[W
MS>]^^_O?``^XP`5^[XS%;^`(3[C"%\[PA!?\A`_W3L3=/7$35ESB%+KXQ0Z>
M#"%C;-H#USBY16ZQ>Y,</!4_^79ZK9V+JSP9+T]&R1M.<XM%0=';D47,#[$U
MG6$#Y]ZA3RS"PP]RO^7A+__<7J]=L6;D:HTR-V%+>E.4K!HH/-0X*M!''*N*
MO5'$-?#1-KH3*9:J["G9:<64OS,W[L""_SNC"$.^26A@M(L##3$(0^?`3)*K
M6\P,`EM[Q=R(\JTPO>8G],)1*)1M+-=%[^;2\0TP4[@?+=X,7B`JJ:410X$L
M7B"3GZ!)UK[%16ZD+H3QP@UHP#@@D<(&"]E&Y9,1!7+LT190('*V;>5&;`R.
MGT%$BAET<>UM+$3RJ/C<>K!#D\N$^T>6]TP5)K_L+6%&S6+FIV<J<LR]!BH7
M*"9JZF\0?"@,?_::N`QN7WB0<;T&T+:(`DDJ@^*&J5F;EC<7YI,RPHTD98L.
M87Q,9FT'<CR]P0LXIWH(\R/DAPR\X!`ZUDJH9WD'"#'&H2WAIVT/$0.35SH=
M^&:JER9D)C1(H?\;*A9]-(%YM3=^YK=_YO<3MO!YOE%F<V-^%3$6'K00/H1S
MQ&<2/T03VN,0BE=F5``DN]!]/Q$&-'A,5J9YU/:#,1(02R87)&A^NX=Y%Z1J
M=4$PNY<*,J*$%"4,J!"!2HA^B)=S0#$6>)4(UL4`NU4D2E4V#H`S6-,`0Q(@
M4/)@P&$3!%`]AR(H^"$6-S`/G9%V0`$45(``A>0"EM4`!M``.#$`D)57LP4=
MHG`@I4``W$`/EV!-I'$2;@A9L&(M=W@`!5$*4I,)RY``$X0/U."&!X`=:M$1
MIJ,C]+`*\I=7&_4DS^!0W[`9I<$)!O,CI)@A?=&'D>$(P)$>N%@#")#_)Z@(
M;]9B$WR#"I95:&P1#B^0$T]#"-6`""-D"\)A">>@B,F2"HJ8.-$A"\`Q)#73
M)G_2APU""I8@?=9B`,$AC$3%";)%6W*X.1-$C@X2%!3Q#-D5$[7R$(]X1(.X
M"E>RD)61`%!2"0G@B`K@(1,DB'YU`.4@18:4+<]8'@SP"P3!*,3@#>G8<U$P
M`*M0D:QX#QT15=;2"?@03$^2D0T"(`1P/`I02_<`'WYE2'=HCA212:'X##T'
M`P<@%HZ$`#=2"E1"";WU&*3@D#^Q`#U7`Y((`\_(+7/H63&1DF?8'7FS657A
M,>M!!?B!0L,B4*IG(5)##JS'$*WGE(5S-RZP_S4.-2S$0`4'8``^<G<VX"%1
MPF6A(#-3\F9'9`YI<`GET2D!>$2W0@[XH3('T%L'("M'-I52HQ9S"1:Z(@[G
MT"F563`_<0AQA#K%,1^)2"B+82;=T#5Y\PV.(@_DQ#`YP@D%>`@THSH`<I94
M8`D9HAN)A%>A23+F4A`.1`P,(&_'DP:R`2";D5VV`8ELP0E*Q7J7`(EY8S/*
MD$BN,9H&0`^.$A!FDC[EL)HR$T"(:2'P!!'JV98(\):@X%WJ!"^'(%MG.2?M
M$4"SH)Y_TIPI4P,?!"S^T",6(C-8A2PM=E9F(4^"TPMA4B<W50CU0`[)X!IP
MD@9PTI-P1!'.6"ZDL/\18T$)#9-(D:`]KN$%!(HSO=`\>+([#D67.L,\)3I"
M(0)@>!(+^UE[!Q`V<$$0W-)+%^D96M1+'&H(VG0R8*5XC#.6VK$P%$)//W,/
M<Q,TV(,<8:,^6U,F4D-`C.<`I^)7I/,-`"(T4<"1ER@.XTA;]"`0G+`U/40R
MS8`6NG$`VO0"6,8>BD`/<X.GO606X@8#7X,)CK)186`FN`-XNB$=VN-%D&A=
MA`$3NJ$B8<"1,T4+S$%,0C.7F.(H!?,4`Y,(@2I&4C-!P.(Q$K$>$T(-FJH?
M,N,.(6,K1_094^(OUA55W&`()^,-21)%`F)'T\<)\P$7'C(BI;,``"8S)FK_
M(8CQ'W8D/5)##Q792P$Q'KU`6[W$+<2YJUJ4$]H*%_,`G13A*-?X,\GD#PMC
M2'KR)S43*E>1$G4"G0`112ED(OE@FJ$`'03$#7%3">=X",0$B6R#.D61G,Z8
M)_K5J>7@4/%C$R:Z+!0R0<(!1MX2`R_*%5W:B>G#.*/A&VK3G%Z!"<#B')+*
MH=/QB,OAE7KB$];2#GXC0`5C+OOAJV\#,5"Z':KD4/]1'"52%0<E4K>R17XH
M*[XB-=TI'+)R#X]QD?#4$K+B"/(@%]$C*0WP+C8&3?T!B;Z1$@9CH81J5]"9
M([\P#]HS-+D"";AR(ULA)%&[42(!1UC6+BM!"@YA_PZXX@*QJ(H`0@D6XD']
M,2-+2PO)L@_!.@T&(#4N,R.:X%7.43.N43T"XS+%Q5LRLZVI"9T=,E#+B0;6
MI`L#-0D?%!^GY0(2\@+7$IR%H#;%L5%SFA[+FJ1T6P`J`PWP%AJ7T+;J-`[M
M8BWR02,((D^[.K0H<Y'%X0@U8`#&D8B(\&AB8C(7*2C_818!D;Q1>TW6FSP!
M4[Q,ZQH%T$L-HS9'TT,0LQYXXQ'_=#H8^DYF$@[$%##WT!NL!RCXL1]W0PEW
MDQ*ZH3@9,BR^XR"DH"U,&S=S"B0B<3<O`YW),A:R43"5(QQF`A+!2[W:!`J`
M%K-;LQ6`\@V+Y#=SFK/9P?\->?<6Z6(/F#<,22$7]F!CAI`3I804H)<,S5%*
MF@)(P^)1P\*BQ*`?_J(8D()VGK`9CQ8XV841_Z!B'^(O0K,LKE`#+"I'N240
M(8+$=?%H9@##!J8EHED0370-#*&$>7EU530L8+01I=0+!V$/;=D<L-<*!#HA
MH>G#(58)!S%]7WP9;Z%?.9%WM?<C4?QF(A$.EW%K"6$(;^$K=>$0O8`@+F8F
MH8`*.0$#F!$.=5$1_B!_#)%Y>>D*AA(0Q+`?C5%%LA%B+DP6$)-WGM"6<A'$
M=KS'**8C>_%FCT'"O9$^(C$,8SP3?Q(*C>%9<)%M#F%1]&:!88!9.",5K2`;
MF&7_"-,G"]F6E]BA>':L>&GA*Y!,9+=,R%I"$WG28L8T#@51S)_S11\2%V\1
M*YM1'%<<#G9<.GFB9A3Q&5&D&>3GQ^F"=D]!?J(\$Q:5+F\V$TGA&R+1PD0V
M$^T,PE`Z'0B]T`Q-;J^X<PQWK";4/!!M;Q4M8N[4T!J]T1S=T0GW.8>WT3IV
M0E?LT>:F:B:=TBJ]TBS=TB[]TC"]4I2V'3,]TQFCA'K6#\!3<E%0`S;(T(>F
M'3;-;RA-(5@(<#8]U"@W;G(392$-'DI]@HDG>.`1U-\A;_'#U%6->53M;ENW
M4E"&,32A9M/0U1B#T^*@TRO'9(KV?#575-QA%VF1B@:7_PC1XPC:JG'NM1@)
MN7`^\1V^PAVZL&ZQM!U8LYXZ_:3^]E_BP*HH=W>EE!VS85)]/&]TG0HX4T)X
MMT6U;#&($AY[Y1FMD"1/K3&6L7W>`1#DEDFEG3%@Y`EFS1V`LA[AS%(%0RT4
M,@NT)5VW%AEB6Q07O6[R@2>HP`VUT$,T(C`CTLMM4BPN4,NR\-Q](EV6)83!
M$0[;L$6E`:Y.E)#*0`6>T,#GD#QIH<ZG?,+,`3'F=P/+\B2-D<?F<@[/61%N
MT@B,$-UH(0E2Q!Q;)&_\,'W:5&B]X$28M%=ULD6]-"%/`B;@G`O*.T+&+7>6
M$D$+["8.L>#1LQDBT5YVD10ALO]D()$JP'M;K!<.&#X.M!0TR=`1/A*<DGS(
MBT11<6=^3Y)W>X2GDJ'&_&P7J;(=A84JC*B4%D9+'!X-["T(CR80-^)&H7%S
MK?"<PD`Z;\9Z8')-\^H.QS,*A''C.?,>_0$#SXG?X;@?:G-S48#('X(*-=Z(
MQ7S#8/1%]2TW8'X-P/#9OLP>0A/(6_0CYB=2OE'B13<WG8(4FX6F8QR8>\6D
M">`1\&%^LB!%=&G0S=U+V^=9C'@#!:#+XS(AJH!Y>')C9CM\(7*S5AP%:*'0
M`@<%!="_R.)0=<*3'\0A9J$?0V)-O?5FH4`@R2M='TRBM3/=Y-`<7`%3D5#,
M'M2APX+_&#5Z#Y#%M$3BC.%+!<KK-,XH$3ZK2H\VGQ'4,%\SGE$1`ZSH$>WT
M'[HL#AX2`[8!3YJ@O/<`+!P(3Z7QO=:$JK0T+@X%&CV7B'OY`A/NN<FRZ@ZP
M/,UQB6&`CP12!;XC)*SG0:ON$0*,E;*B(_7!)TZK`&G]W(DT-%1.&BOAIS,[
M*]]4"'CZ-8&K-LT^)-S1"WVR\$K9$MIT1+Z3O"YSD8CQ(<XH\\XAN@-5"L[H
M+RN"E:9`O]8$*(.(8G/B.\A@)Q^4[=20*X(50<4Q.]Y@2!$/YI9%Y3$!1^O1
M)N[([>)PRZ?B.Y@S00CC6)^1/8.0(01Z[*AR["+2"TJI+\U)_ZCS.ZX`IC8I
ML>@P@+N=9//R9!=#,BWN-#3+<I&A@0Q'0FT-DT"N,2OW(!T=DB/T,#8#]PWY
MJ3O-`RSKTQQ0(A:Z(3,!@CXV0QAN$SU@.K%O(P_T$#_-L5O#0`\(H*AVN!A%
M%!"$FMLR@ZHU0TRJKZP;U:$3,BPE,XRA+W]J2Q@-4P_Q\P(#D,#F'C/2^D^?
MT1ID@@`=\J:,](ANZ"9&358;E?E/JO)!XS5+:0H7/"$V$4HU<RM@3@S`@0F(
M@"QP$B&$<,R[\U@+<@#=/;%^`Q,>C\"`4-6@`./%(!A%`]-PDV;C\$*3!A.3
M9GGIZ!+%D$;%<.-0M8"6QF"C8"::%O_S4AH%]<)@$+40YD*S4#6Y")7FT)@6
M!N.`\,(XZ9*;]O)2BY;+0&49MN"EX/5L8\#0,)MFIMQ@TP`5#670P(`0XY"&
MAO;R:),&U4#IB$!^265L4%,+S@:G,->^(5C0X$`-+P4:I%&@H$$"%PRB?*/1
MRH:F!M2\D*L(42(,=Q73U'#APD85!F9,+3#SC4$"B2XBF43@P&*G4:5LO+2D
MZ)(9*ML2WEBPB48[*@N(-5C```T,`CHQ6;V*-:M6K/721&F@U.N"DS!&QJA)
MKL:-&)6H0(&1($P::]@6^/1BB8H"N68<G$JE@!::4VOM-B`%+T8#333*22NY
MRD6:E9*AC)7_3(Z@8(RE;BC0Q:#&H30+I$U^F^!&`R]QP='8:P84Q7F8:KQ@
MFX:S5TXQ&$"Q8<,+E!H(:"0`_!K*#1HU'%8YJLNDPR@*QEW2^+53:`6_:Y`*
M@Z`*N*.QHU91H#C-#08O1@H43J/8`N4UE*)9/VU!#*4Q!(=Y[849@5VC62[*
M*1`+(HHX(`D--=4P22578<>))_54T9H"Y*D2PTB?*$###0C0XH4+__3B@F(6
M';,,.0T8`V&*2/D"`X$)K&2:%]54\XR(-D`1@US/]&(*(X=`@0`44#`751A0
MF)BB20[<XQ9<,($#PPT)_!/&>*BPQE<"C=%0!10'L/1B(N4T`HMD_V?5(V`8
MHAVV``R)Z&3*)"^D)(J77:['&"P0NO4"*IV@(B!YEM!R)2,(_!@#4YL(Y!6"
M%=5@0U\*;<5IIYY:TM57UDBDE@L8-H"`"WHY4!UN,"#$DB6%<J.C7)8DHQ@#
MU'"#@"=H0)&``PGLY4`#9R6@I`+".I9&`SJ=)VR-$@$GF0-04+,)&D$Y*RT#
MAH!FFK3.'G##K!S%TM0+-8A"!6TF15))4%XYIRR(GCE@5T/H4?/4"X8,$L,"
M+L!$T""-M0,J`HMTLAI""[02S`%0.:"C&6%P0T@-#2&+H;`WG((O4X/`4'`"
M"UBBD24KA9'.P[,:0`6K#ARPR:H*B":(L?]V!IM`%.I.TIAIUVW$,"AHN*``
M`Z'4LM(JE9`#ZRP(NG!##3-=XZPOO:RB[`$N2#2(%U8_)4A3!QCB`,$*\WA(
M+.G8:D.P!:CF6$OI.'`QP#5JN>Q^DR#4`$QHI-.-:%U6@^\"!]CZ&JM'49'B
MO3U[-@AQK*IZ@$]A>.&/(\HF8!K?H,>S4DM5-,,-%)^_%>/$B"4>BJ[N#,Y`
M;X%3E(XHM%S,`$0VU^<`4]%]2GSQJ02CBQ<W2!-&\LL[+XT7>)FAI*W?*`D3
M%:18$AL,-<@5QO)4#)77#55(TWT,T3TGS?B3P62)%S9$OSSRDX6!QOC1XR7>
MKS=D#T#N*<<,:(C_@O8&Z`[EH*$*>*$"%6"PO>9);RYX^89IPA>%=[3+"TR!
M@O:"<0,H?.<&&11.!$EH/TO\*@JZ(%_X1#@-[D"!@!<D(1IJ8*WUF<\=4;@!
M7EXX0BJLKX)>04-L1/@KRXA'?$-!@_(R.#XG54$7STD>7J17!>M-0SPMI$+S
M$CC#_!EQ?YVPF/B:!X4L=N(&<G&?&L$XQ?/Y<%%L_(;XG#C#O'B0%.,K8!TO
M\0HO9M%]U,LC$)W4O!U.D'K_NP0&J<!!#;Z#A!\LG_309Y$JJ"0OP5GC%+WB
M0%)$P5::'-X:^=>E]A$0@>R;S/00*,`P"NT;-H!!IA)81_V!T(%SL4$&_T?I
MRN()<YC$+*95MF?,9"J34^^P"OF4";EE"I-E\,O*#48B36:&(IO<[*8WOPG.
M<(ISG.0LISG/B<YQ&C&=T^"4&:I)3ORQ<Y[TK*<][XG/?'(3GOKLIS__R4Y^
M7@69`"VH00_:3_D5;X'P,X--!BH>&A`0$Z_(2LR:0D3N+<0[[Y#3[`@Z%PAA
M15L9[11!%8JR!CC`+\3T@A8YU9R5NJMXFK0$#F-0S?H)8Y98J9\E=KB/F183
M(_/;)%86DA7YI4).('6IDC@ED(>%P18K_<6\!/;2K6CD2B[8VE9J:I4H0,*4
M[G@$R:3#4:5(P@M[JHI5J``,H=R#F%6X#UD[9?]43HF'>UGTCJ<V.M&O"M28
M3#5H&-"W5T?6564_5(8C>C:9Z#A1>`H0(C*G^(XW!N-F#XR5%Y(W(%)403#W
MF]U/'=(\>$;A`!(RXE[1T+QWR%:VGRS')1Q`-:M99*GNB&W\%NM$0WAU@7AY
MQP0O4:<;*!*X+K68%2]QGS/1(P$^$6D:3-22M&%BG<T\&IG:*)?/JF<U1-Q>
M0^?B/@I>H@J/\N(Q?$M!R"`&,8=]A#4P>PD3=>B-O,U+8&(6*>HJ5XBIB1G"
MXO=!UU;3!0*P"!0"T(JA"&ESR+L/>2_!&HS\Y!):$H@MJZ.A4Q`&MP*YJR/:
MX=Q?)2FR*G1I<!GZ6XO_Y<*+R+M2*N!Y6+DP(K&?%9P*6Z*3FE6#N265'E*B
M0$"7!M,=61Q<+PX+/PJ+%Q/X33&3RP'2?CYP)0B!'RT4X`(T].9F-QB`9-#`
M@`+4$B(Q,(0"%C``&"`@)/`#SC]D8IKFJ'"&N-"/CG:'M#F'H1D:BH(+!ATB
M0W3Y$C!0BES0]9D&#`)OAS:#J09!B$W<M@9FL$8:&0#J$D$$;YZ)B"V21H"H
M?`-IU+6,.KSZB7>J9UBWLY1,'*`.TY@!!B]HATVZ<JO>#,PJR^F)I5&U@!LU
MACK*TH8Z:!,B:D!276^N!BZH:XD8#.`V]5#.`@1FAE,LH``6*9&V'"!F5C"`
M_P`VD%@"(.:%`TQ$8B,R1*CSDAJ7<K`64]43]S*(LE'WI7>Q6D8"1O("A>E%
M)E&H041.T6P#+``!(B6?->`I7E"P]!%6'4=!?C8A52&D.`XH0`UB,"R2]0YU
MP5K`7F+PYM!L.P;),C6Z:N'?9)=#8API]6HJG9(!!,X7!(`!O2%(:'<Y7`&S
M>,%*;O:JZAP-(B](-5-<7H6QX0(]C'YS`T16'$LK8,Y9UF<]?'2#[;TFA%1X
ME&XK:U-G)>"SR$(`!T&'K##<*-N\'EB4G(8)UF`*64CY!$O6GAJ8]T59,$%[
M!*-AK5+@-#0]L\;NP$&%&KR%.PZQQ,P28(`PN^`7+__23TL<SD93:(@:P%!=
M&*@#`Y:P`[ES7HV&`E(=\+0K+N+`!"BN.X]-2,_2!3#Y57!T@%_@=F`,,M$G
MP@"<O>A9/3DIP'Y>\!L1E>,7IM&++1YQE!AXYA\LI-D[*I(03S2G.5X(#Q7B
MXGE%!*X]QJA'F$GA$P1$HPH%J/:3A/H-W$$-A"$@IH$2WB(P,)!UJM-W+<%&
MT1=NG"`4MX`5*_$5O5`/6:,:7Q,?$F(5V!$7ZR$0[\=`=7<^"#!H'%%9-O`Q
M!Z`Z,2,:F1(:#"!1"P`,64<+QO`"9@`6IM`2`7,XY[$UEM%VY\,=J6$<X%-9
M54`S2`$ZP%(U6\(2/30?S+#_:RX``W[W"3IQ0\.1.7-G&0)A!J]1=OD$)S52
M#=/@`C.A#9+6`*)0011B"2XA8SI2%]'!%C:!&R8A&:!R`T4!-4D19IY``^B@
M4O<A`,"P:R83AQ*'$\W2"P[P#W5Q>?.1#KUC6YZW+C98"C-1.R7!:SAW&]'0
M+#J!0]_@,IEP"<\W57NQ#+TQ/K70%2GA>^U@(F+Q%$_R=7"W78N!.S;P,Y%@
M(LHP&.T`;-1P@!6!"PGQ:>L@6J.0$@U0`V<":G]1BD!1+%4%!7[A`A5#$+:2
M$KBA"#*1#A)R/D[4&Y>'/W-U'S!Q<==%`Z-!BO!H+#IC&:C2(=[Q&65EC!(8
M#%.2_V6>T`A6I1H=9RK[(8U8H1&AXAO!<S(]\1)-@QL5\2H)02+#B!=ED34L
M4@X247^1D899Z`S08!I?(0I.-!:&R!%SH0"D4!%(\1)MJ%*S%Q,QPR8,<`\>
M,1&D8&F\0BDKP0K:48;XU&TP`"Q;8P,TEQJI<0/=&!@H0S'4%3?483$C<@W/
M@(=E(0EE$3]YYQEZ\2.J$AA.&`4UHCJ_40CL(3MO$04KYF2==@CZ((T\4AI2
MR5J!@329Z`OSX'V+\$!'D1/(@I-'28IC@6]+4CN2\0BKR(4X&06".3Y[,8O6
M-5Z.4!KV8#%'`R%',5751`-SDQ"V`"'":%9?,0STT'G7!?\S"A`76_*'UU08
MSZB9I-<?JE([Y_`LH6<#!!!"XG`(J/"-MU(6\7(;7Y<EH`(ZX8842^A%[S=*
M_R`X^O&82D0:.A&.)H<1:7)PD8`&D$`%]M"/,:0JV(`-BU(<#!2/ZI>>H<$6
MU)%%_/0(FK8)JD$0:M$SM<`4J^`A(O(Q4B-6S?$"U+$>*P(,BT$=L9`3&F(/
MU"%B[28*M$$=U.%$@8$LP,B3"Q`BLP"3S5.A`=HSK&`7L&@/]Q`#-F`U!,1>
M7D@I'108+Y``0WE/5-!F^`)!*@-J,7`?U0@/8>85DK`>OB$,[U`3+[".%?0Q
M+.@(<55JG%@.H2$,50!!_P`))@'_:K]!`V(V#UZ`:S#@CCL(%&LA#8W!I5(A
M/P]C*A0!"5'@@32@$^+G4!@%:J&Q0.G@'860&RMI$@CA%A"2"(PV/((@IX7@
M4$,1+U[5"94@%5AU"9J7;6M1%2M32R;1"RRH>1Z!H4MRJ)>PC680`Q#B$RKU
M&U4Z#1#$II%2!32:"MSPABID+1YQ6&02&ESJ4-NS'L?Y,6]*,2JT=:6A(]]6
M)S<$$3.2%Z!6IQD9'9HG"F4R/Z`FB3_B1/C2'Y50!1+RF-]V:/X"%"9C>LTP
M,);V,*GP%(W@2V%%)M(:K?10I8/6:>XQ#PJ("ROU0+<0!1Y!@V*F"S30?7=S
M<KB&HX!Z_Z5'L2?_@3?!,*+!`$$"\0G[H*I0>CKXQP"<Z!/10`.KT0P[B*1-
M2AMBUA364@E>$*7I@E#;DV4$A4PB.U(JU$S,A`D6`T\F6[*S)5O0);,JI!4P
M6W:(<4S;1;.N0+([.U`SRTPXZP[$D[(^^U,\M5TWF[-`:[1%:UI+FQ4@-5],
M&[,ZNUV=)K*SQ3WRE+1&Z[4DV[-#*[8?10K?@[)%&[9>2[0F.[96B[(SR[9G
MVUTZ&[-LJ[5BZ[1C*[1M6[([^[)=J[5QBU"#2[B=,D>%FQ6#A;B+RTT$I;B,
M"[F1*[F3RTXP2KF72[B6B[F;R[G=9#'"=&.?59[*]$4"U$F?\O\K\_,I74)8
MBY6X+^5$6B$_8?0IRG.X6L&Z5\%!0F1,U*.Z]#2ZGQM.FJM"6;45QNM,R/M5
M+]4EN5M.H^M$!.6\QC1%V("\PHL5P8N\TUN!+$@P#N1`!*-<CXM0))1UPE0C
MIW`+Y.LI!#%L+*,T3]DI+",P"**YZU(\/Z)"W&"\ZQ*I@4>9OJ<L3<&^BQ(1
MR[(5\8`5+O>PPP:Z=Y-ODK"R.`6U?X6TB_H?6>>!WD0#%<2I@U4%^)J:\RL[
M6;$N/21,/F(57854G!(%`#A-!3>&!!4\RJ0EMM246?&_1_4?7D`#$BP4.)43
M6W$OH+9K!T$KJP(5)65.AL:E5&`10N3_!6<1/<PP6FUT'E]G0`TD/5DX/)S:
MJE[C`N0R0U6`A0%R$HT@HV3"#$0$.41:`P8`#.Q0MD%B$:\G)R\@HPPB9CQJ
M"YOCQ=1S$E4Q2J=CIXN2(EWR)@(R=%!@<F'P)E[1(<40C^UA*]03/JP0'0+2
M"Y;F0%R\QE":$A>S-6M!#^NK/&4!R6S$:Y)5&IO50P'JQ,T3Q5&P6S"D%]G3
M(0<P1;VF)`:0*0Z2=B_<51B!#<+L%4VY$,4@6KHP1TK"A)3`'ES*/>4"Q2E"
M0&G</7;*#R130"E"!:Q%"G\X0Y%L"7+F<%[L%9:,85[\C:>#K9`#`VVGQ]IS
M$MX!5[<!/X-A_R(7LX_?T"&%Y@5EJ1*M/!GM(0C7L(TX)3].YR``IT)(%CYS
MX1E9B&0B!#E!XHNT808EU`M39&BJ8@8G`4/@$!@OW`Y-*5&9@%N+@C__\WH>
MQ%J]T1[P<PX;2(L>:RJW)<'J`W(D`2'P$%?G)`HGX71V41J0$(\KT7?Z((E)
M\PB*@&9?P18E'`M6TVZXE3FEH1\.P!:2B!3ARAX*/!<)<!:U`\PD,5RAP@C^
M,`PV\"BDV#Q99`^]$<U6,H>;L"<<30B:L"<GDC1R<0,%X""A,2+<0`->4XC_
M@$T68@!*T7DGB;)6%8TV^-<4QPE.Q$"T<%/3R-A=LE(/U2-E,A\'8/]+8J)2
M#SH?GZ$:W-,[5",5-(.%QJ$QM036GH"3!D#3$TM^3T$<68U_AZ;;5W<#!W`;
M!X`+$D(4)3H64Z(Z#UT`>_*&&+HG>M$<+F``-3K8&D&#D+4,"F%]Q2(*#M*'
M/"C-R5H[BR`*[##&M^`]-P-U6W(S*"/?`?//HQ<#O$D.RJ(:TJPC66@,U"4F
M.-EN-?`JK$!0Y+";'OL"QETCR0HB8`$5\8$^N=#@82")8!$+I^`@5^)RS0$*
MY=`<(3(67B,K-1`%5'$2G^#@"L%UZJ%FWQ8?VT@).*<>^M?!UZ4?WF,-REM.
MA9@.QU$#`V`#85`4K,43/!B)L/`CL5,SADC_,P&H"QH)Q8%C%Q(H(!&A,,<@
M9SM=F0)"*7D-7:W]%=;AL0[PV*28?T!N%+#ABJX`%U[>G>_&7F9C&[31$<J@
MD;V0%HJ),!92(:HFV:PZ#R9R##[3#;VQ:F^6<$^!H7X.%#AA&FC`FM_F0RUY
MBCUN`P,PF@XBP;!5+N_6%>4B"TS!&B.G&->"Z4@S<L,PD(^P-880-U,2>X)`
M!9QQ$HMR,C%P`.E06293`WIA1/J!#NIP%N_0$A=4#1\G(=N8GRL!Y.H`$U4`
MY0(AD^O@$._@++9!D)!0"1WB>?-0#W,E('AA>$I$[9*&W`\YAI0P$D5MC/F0
M=K7!#`/N>@+"V=G>_Q)\#@R4P"J:<Q*L^9BFL#V-]A5-V>@3`R$.`BK&<G!&
M@B/@;AOYH>2^$`-0KA.I$(\WT@R4L(G60[S=Y'#=(16Z#1Z0<N]'T0A5J'F'
M@6MD\BA`PA<SXM7.4@^L]Q+AEFEL&GD]A&ND8!D3NAX%CTV&AA_K\7N+H3H&
MWEJU$_/X^A(=,8<>!`H2Z$?Q2W-D<HO!L.P6D2(;.1P9T8<6XA!,\1V\:$LL
M)0[6`@[BEQJDF#^6\ALFV@J_UPFP8"C/@&3/Z`CTLFNZW0D),'>(K#+587N8
M,B*U@!Y+\IWSNNIU<B>11WI>)2P;7S/.@NMCSPFXT!W"01S&T6D@@BS+T?\<
M>%0:I%`K3\D@/Q4\G+`2([\<HA7SZF,73$D#`@'JE])K#3(E6RDA4=(<>P@.
M&?0)'S%%LZ\Z[[06C589ES$70&)W@?=F8U,KPW_E(%02+/*8QE(,JF,#KU$F
M%'[.;,H(4^(;P-$>D<$]'_YFU(`C0:$;%^?4*`<I0J()\4?6:FU3&VQ..D*C
M)08("U$O"PX+7H0,#3`)#@=0,0HT#FDV!E5H+HH,9FEI-8T*50U140YAAPT,
M"R\U"@X*5`Y0:`VJ+IYF#*LO5`QHGE4)+C$)-5X(#0L,-Y0NA07'A30NL9JJ
M50MF9@MAG@U0#KLOGF&*"S0TKZ(P"MZH8:`-HJ3_:0X-,>0VN&E5#%`-TOCR
ME$9=#!<)O-`8=L#&+&ZV"D2QH0!&C`4NJ*RC44,?KDR*'`!#PX`*P6QHPBB8
M%^,&@VQ1T"A8`"P-*@<T&+B(TO#5`@-4$L1P!8L**2\T.U*$9>I&&A<.&W2J
M=`F6+EGX8'PB)Y!!OT(*8D`9IN!&@7DPS"ES@8HE`Y$V$:0+Y<43SQA>_2$U
M]&+DM9>I5)U25?%>#!A1&B6(`H-&FA@Q["J&%-D3*`<%;I!Z"5)5&'$Z:R"X
ML:[&OD\^O=B8FF:7EP,T4)E!%86!%T45P=ESFL;,L"H%H`1%:&Q=W32-HS1H
M5J6T,$?\TKQ`$";!"VZC_QS`T-JQG-QZ#FY<ZV99:#LJ+Q2X<)#Q1@(8+Q83
MG$^_OOW[^,/<@&*&2MTJF$!Q0UUH0+%:@5%0$89^`-H412X&>N,)&E$,*-!L
M5*"1(1HWW-`)%394(=`[^[&F'RW]S>?%85`$<P.`88AHQGY4B!C/"S00*&`8
M%**AX514S%8B05[L!PR(=>GG37_`5.A-D&D4V6",N2AH4HH30F&1CL+%^(X-
M"3Z9SPW`%!D3E53VUJ&$%Q+$I$U@"O1?D`S4,-^-JZ4AG&I46$D+B"(JJ*%-
M@8;8CS=5A%'D5&;$Y$6@9DA9UZ-5>E(D+1J&2,4"4-!BTY!AV$!+D351$5.%
MQ_^E@>"5)IW(6H$W\/C@C+%^.NH--?9C:!63IEK%KJFF4:&584!IQHYJ>CBC
M%ZH]2.6Q%L+@JTE1F*&ACT%F>.*/AQ+D'X4?:MJH#:DRVQ^5S0+S:ZZ6FJ3@
MA9)&F2H571X**YO";F?2KS;T6Q=C,8B(W\`$%VSPP0CC5U/"##=\W\(.1RSQ
MQ!3?9\8]^%:L\<154+(QPA!_+'+"U1X<\L@HIZSRRBRW[/++,*L<!FLQLXP&
MS37GK//.//?L\\]`!RWTT$03[&/12">M=,YHQ.!8/PX(3+`9-71B2@P9AQ&#
M`S;T-DG78;S@P(-5O/""U/2]Z#`F,$/Q8"YH]\.;P?'_U%0%KK14037.^%'!
MFVKTF=%8Q%XT^O9\)T],M6J)(ZYW#1FG';>B#)L1M[<.F-0;7LS4ARNY!!U3
ML=^YK*:WPL?D2?#I(`_LA9T:*QHJPU!DU)@-D7^\-]%H)*IJ2JFB@8`!WL`0
M0(N/=E(3:]D88+DQ\$'\0IT)0$'#`JZ8@I,"M[7"0.Y<^^A[32/Y3B@:2+W#
M=DJ(LNFC%SP6;NGZN1#4>UW;G>Z0JKRF9!+Z&>N?I:*@#<LYQ`OTDDI,Y)4+
MRO6&5Y_@1Z-\1#GWM"A&(X$?\*(DH1A9"QQ3.MW[W!<I\4U%44?SDJH6U#N-
M>"$F&^3?-LH!F"BPC5#S^5;O_SJ!HP=ZXV9UL=Q4F*6G!BP,@VEH@`..\X(&
M^"T!5SH=UW3#+`8XBVU3(=_]1N)`R]&`*XU"A8B(J"*DF,I:A;O?A!)%DEFQ
M#H5DG-"C?!3#WD%A`67\7?V0R,"C^>@P8:C62"P5K"AAP@P568C;.D%&)`(0
M@/9)GJI*.#_N#>TS"JC>IAB`@*ZI:@$)(!,G#323!5"!+5YPP51H$`DSV"`@
MW`A6R5Q0@WH<A#P.:*4]6E2?\-1@%]5[@:)>X`5#F-(?KZ#!`,22@`4T(&S6
M@0$H>9D-!H2B&Y%PYBF%!<9Y*``2!EB`*1F0&65((@IB6<9H)E0-!5PG/0E(
MB#*28?^]!A#`!L*$9PT(V(#1W`:4_>)'%6"P2034D@`U<,\KS%"-Z5G3$`FX
M6REM4(`ZU2`;XE3(*B)JEYD`1)Q5T,@"$""@9BY@H.IIAP(0@!Y?]),&#,VD
MQVPP`(0H0`&<L($X^^()&FAI%:8\`$N5\1**_&,5S[S!`L+B``+P,@HW_4<!
M$F(34=@%@4C]C&8$-!,#5&BG8<@(%'AZL9O&8%/]/,8J#L"/L-'4!==+@"=1
MHP"@G(T!"JB!-!5@@TS<%`8$<.)23^J*!EQ/$@1I1R'0F@"8&@(!>.SI4G.T
MQ!K00*D800-%*F(#.]V`$0?X;`P>=+:+Y)4@FW7!#08`R@+_X#,,ZFCL'3$2
MTQ=(4S[SH8@XC=*`89@A$@HX0.YX9@-.*)4B\?"*JACP@HSLHE.B>L1R:N"Q
M<FC#"T)YP0$*F0:7W,8DQ=7&4VH)UX;8)SQBN]C6;H#/ZXVU`:#8CS"RL9HZ
M84\E+["0L!(0UE.((J$V.,"FT%.97X:*N=^#`2T;H)!!+*`9%#'#)'+ATV(H
M-1[O<0!#X?N"XGKAF]S32"3B\4P:F*(!I^G*6`[LX6^B@B(#8BDHPH!B`T&A
MD\PXC`M@P-#FJC*7GB"-X/ZQ'OB&H9,3N;%+]NF.&R"`@%%`@!?NZ!+8)L!2
ML>"K2J`@"?>\;8HQT(5X#O,/]L1`_RH-<`$4&'`09GQ5>74R`S[B_!6(L6?-
M!WFE4J/P&BY?MGJ;U9R$&?--_KK$;')NZTD50$#5:DXE(16P(!`@T1NHH[AA
M$!"G7/!.L_UX.6]#0PV@4(.&),0EQ?VM`BPE5QM06AVF[')>!:&:[6P%/K7I
M"%+&TEFJ(A(*+V8T#9[)*>[]:@$P((U.<?<>_1+$0#=HR).QR^4I"W=H^:@J
M=845D$\6U[;AN5X##A`%@'2.2.XH$`Q<@2]1OZ0U)AFV>+E&A<:<FS[A6?=C
M6K*>L2)@'-`LR2$L>9AZ$-"@=OE%8]!@2H=NEQJQ\,1AHH01QP!D'UY0A3B;
M40-<-*,<H/\Q!B5N`]?N.J`CX4!%+3\)`TH`Q!=X13$_:J,9;C=#)=YX`5[T
MUHUP/*6SSC2`9JA``QCHIAFM0$YE/NZ`?S/WI..MP3)"2XK:V$001_T*-01"
MDZLC140,L,0Y-`<5W>2;N@E0A46T<E-5'*.?+P#(A*#^Q5E8]X=5@.I*ZA0>
M^)(G[`<X1[4,H-PH:?R;`7%IU[I35:1@%0$Q4)<VVB@(FHC]+0?)Q4MT`Y"D
MCP(!8-0$)U_9E6Q;72!GV06O"'"=`S@3>^)M&G=T?M:7,&`[4#"`+;Y756_`
MM:@N8+A.RQ1X9;C$)'?L)'TN,FY,<Z.XO3G$T,;"&&8$9,US-PK_4$YNC!L8
M@#\(H,Z=W$%C=$J%38K46\LW55P31[05U>81OF_00XOX)BFFY,@-Q#*:B"Y"
M(RY1+7$W/0DG'9'Q8"15`P;P*.%4$US&&`V0'D9!`\5U$:90%ESC<=U&?3#`
M4M43`P85"[;0<7<$$PF85RZW""6Q"QWG";Y0<S1G1`LP6M5S4CA7<[0D"5#0
M$&%W&$;G"]1@)Q819`&1$U0P%)P6!0;@"J/6$.#P83=0:@2$?3#!:`@!#+YQ
M1R;Q#]@3!2YP'"=G=O2'(R4Q%!/G`AD1=Q1H`W*E`%/!'AKA$'.S"(K"5V*#
M'N&@9VRFA'=$`Z?D!2UW;A3AA=_D%4`H_W!MQ3W?!`.0T'6(E%!>57G]L1B?
M-19$EQZ?M8+YX!@QT&L?DH`\J&*,EA[EP%>UDTJ&4!MGE1%=J(*^0`P[X14N
M(&#8U2&JU!M[6(._$GR"P%>:,8.GY`M!$G<N<'ZY8`P[R&Z(!%51>&U#(VXA
M%1D#-2'24EQ-`R+.!![5E0O7\0G.Q"QD-0_B!&Q\H2&K8">U(0AH$!O+-Q%.
MT2]*IRHPL`LUH@Q8HQVC,(-H``,B(FYO,XTVX!3\>!'W4!<S:#_,IQIK83E\
M5P@O@$[6(RR580:$X`"GH%/L\5O30&JWT1$SL@RE$!E'F'%OP8A/`XCHU`^C
M)8TLN(^%<QTIZ?]32F4+]60:8<4*5-,B`6D7D2$XS@0@MM`0,PD.9]5=SA0U
M!*45@*B1>#42S45,R!%2JQ!F/85.)C%:=\08/\E>-O$,2W1'8=>1EF*/OZ4Y
M48)7[I027@E;Z`0@BM``(:4,!,46@]`)G_$6.Z$5`T61S@0[84.1.+$,O"0L
M;UDV96,MO_1@WEB&2_0,UY%0>K(,GK2/A;`<2@D#Z^B0SW:.@\`A9R67_7&.
M)-D*!*17>@(7+K$`<^4+V(,&PA21K[D*+Z(,PL2/F>E$*>D).F4+]&<MKWF4
MP]4SC3,AQ$D^N4`:@VD_RFD3L/,[=$2<RPF=)],X"P,QU0F=B&,?QJG_*I,$
M"H5DG-;)G<6IG=D)GMSYG.*9G>=)GLMY-.(9GNFI1]@YG<LY"9'P/]N9GH.D
M*AEW9EPQ(?E)G^^)G>HIG_$YG/"CGM:YG_MYH`::G_0Q$B&C1?J).-L9H!/:
MGN-I/PVZ/!P:G>ZIGP(*GR$JH+]BH?))H4L3,11H,GQ3H"MJ'[^5G#%:HS;Q
M132:,&/%CC;:HSZ:,B$*,B_ZHT1:I$9ZI$B:I$JZI#$#(F9I,$52*QHS&T12
M,"D1*3HS,R)#I0DC1,S"70GC!</)I3NCI2I#I@H3G`F3$N@SG/1AIDQ*,;,!
MIT:CIA-BI_4AIG?"*'AJ'_*WHM($"S3@1P-#_QJV$'$58P,3F2.5<1\95P7-
MB1^_-:0.DU\1&C$752$,\PQLB",-FC`Y8A\50G]&LS)#40Z-FJA],C?X80H:
M4PM5`%-&@S6="#.32A^A*C$"LC$U(!:'TS=O1T>?JBHZ92T'(V$T$R(W8$-S
ME3!PN:(N)!"G`$-1D&F,.`B]@`J:4P,UP"&TU#NBQ1JUPX]W8W^:U41:T1ND
M1FZ(("W>LF.'4*WX-&5PY2/44"'?!X@N("):LJRTE$7[@#55H"5A)F'2-)FU
MTZTV)"PQ`A__H7,O9#55`'HA53+56C;N6@X*5B,&8'2+\2!>&!NPM1,2:0,$
MEC%\1FJ],"'*<#VVY?\-M2.KZIH/,T-_(/*M=],*-W,0R..P>@)7G=`1#/`T
MEA"2(=)<_&%I9]-=4($^"D8F&#L<?:)9WUHD]M=1VV$Y(M(@_<!*(]LB`Z5F
M46);$05LI)81>D*:P7``'9%F,#6RA_,K'=8[O?JU!<(C;E,7[*(U9^-]4%`V
M:O8:828>W9JS[(6VA(L^HG4;O"<00S%04%DV/C4C.P8_-E"-8G,V(45_@ZHU
MG:@\"`%5\)$A@Q!FY",.O%$%Q*`H%A$K%IMI%`*T-K02><>T,)6S@VH7/*(L
M=_2T_>"PQ])Q3ZHS7V0_J""FDZ9F;$8(^X,^B;)D/1B")XD.Q0B"KD"!Z&#_
M`%R!%#$@=,RE6EAV/4_V#P;`$=AC6&=V$300#3K1#E7`5FPX;`*3:\A&`W(A
M">E[3YYP1[7D4V%W4FQF=-SK`(10%\S`5H?1"E>QO'!1"[DD5P4P/095$I+`
M87"U:%S#5+]*$@&F8%U'$F%1OJQ0FOA@*07`:25Q`-O16'G5O=<CM`MA"IQ6
M`YO2OSFQO@66&:_0#!812@>P-4[46*>@8*)Q1UO3=">G6L7!2M)K%P/0<F67
M1)X4'_AT<H+`:?;K#\U5`)O"$_#!:)(`62[8L=,!"I=[P0(#`^5KA\:@"?:+
M3CL&5R)Q;NC:B:[%:<60>QU6)V''"-V+AEQ82[T:_X*F)2$L.(,"C&P,(&FU
M%!ZPH;X=VQC5$%_K\0(#\#]-EWL>7)K:X2T/&7PJ<69&AX:1R"-8)V)1<W(X
M15UC<3T*EE=RY0F-005.Y1!I!X)&47!4H,*$X*8M4[QWZ@ZZ`%4\L@^<M&TT
MMA*]!0N+H!43IRH=-Q/95G==`Q^64GFN^1M$*!",EG7384R"T!MFI`#`$';"
M+$Y8@ZHN@`!P10[494I2[`GK;$S200`)HGOCAA<K!'6F1`IZ!1#-X'WWL%U1
MX@Y)]$NO0TQ#&WSH$WB.('49X@#O44C_.QL&O8[)YG($C`"&0,[]X(;"AT<G
M5T36[!)691$@:#L'T-&<8O^`P<`)\#Q6BZQ37_%AZ-`H360`^NPCX;$/M$32
M6@',!%15V5!MGM!#S=1T8I'3P[>,O9@2K*`5+C%WDHL<T_$6;"O+6N$0/03/
M61M<"U)L4R$:8R,;[[6`)2'1L*`=!^B6R[P2MO9%3D,05D0%!C#09_;1"H$0
M84<)7/,8.A>$TI$>WA#.6_%A4*U=XN"&1\T*4E9SW.PCC'8(W$!`R)06L]!A
MX:!S78$3TO$TRK$0+5=<6]B]04D:*6'0/'-'6#@VW*,2!!1(?+40FW(<=W0/
MI"9:!<$5RC:/$]<1)6?-%$=`&J(9W3;5&@'0`3$]I%9<3E%NL6;*SC<1B/48
MS,#_'D470?\0S]+Q#Z:!!@X@=%0P&ONG5"E!$7HC@E'P17+F9N0MJRIAP![6
M$?ZP<JJ!C+6'"1.A$XCSOZF]2AEM<O/8W,'`7RJA5$\1&:^D8)^P"@]"#'[S
M#`/>62B6X"ZH#2>%7::!8U^1::(A=2TA%#1Q+,NQ#YR]X)$AU'C4'!3Y"@2A
MLQ5A/:1!@:-!?I--0+.!;+CP2U0].%]<86F\X]HQJ"U-#!_&40@1'?02'YO2
M'#3N#[(P"Y<UA"?UBN!@&I!1$-O1J%8491W2$K\@8@_61*?AV?`AR5UC6Y2-
M6[I&$T@A30;2K5=G$8:%?1@V,XOQVHMQ4M2]-6,U:KE$_PYW]-,]%'UY=5-B
MU!H69FG$C124ZC*UP&:VT-Z.X`O%0A8(H)&041%0!0O[E^+I.A8V]=N]T`@J
M?,WC74NJ`$:[`$K*\7$:,<E+L1AR80BNT0T?!@N>I`ZS"%>SYQZ8X4FQGE>3
M8-FJ8`L91YNP,(L=DQ7(<0"SL0D-G![*X'CT?0A@L>FP`.4W@0["0=?%"@^6
M@0`,'@[-40U/`QRTZ0L4,AG=*]%1<!FB<`V9LQ%C$=XGR;89_@H,8`#0YPM0
M50TN$1'AL`J`3`U!(=&?OMMV<19A(1`#,%=)1Q0@)@Z70`@-`!18E^/9T'21
MQ7#-92>0H0[;+LMW#46#(^^RP/\1"C0`@QFH#$;N/G$);\%E`K]P+P'PZL%7
M65YT"W$<I"!GMO!,A\JVP_!OIY$8CF`17R2$K.1,!*`YKC9\VNH3Z9IBOG`;
MM$GME[`6DJ81NCX+D4!=SR%723<XLDP=PT`2(@(.NP>7-"'N/4,UK?`E8;)`
M5$##"Z0EC*@N<0)!E&(7)FM#DU(H"ZLJIR*O'D(0H1(F5F(IHM(DAD(O'.(A
M/=(/^V0_!M(GE$(I%<)G)Q'YU2HGM+(D`;D-RUHM4C)&;Z,?BS\A:P(O^@TG
MF#(1D!(ED;^3+HA`B+\\RVHC)J$:GO(51D(AP6"RR*%:\PLZKL](D2\08)(J
MI0`ES<+_9ZR2*<$O*M7J2AZR^KH2_(6?"Q6"*4'!)A`D+(92_37K-L4R0112
M!4A877?C'_T@IK:?6/FUM<<Q$84#0\"6&(!@EC9H=G,3EA8%Y643%67F=6-6
MU8A6Y95H9D:51AEEB>E558B91H58>&A&0Q.C8!9E0T4E.DA)5759A7AI0U.3
M4$5X,XNVB<8(A69;BO899G.#AF:HL"M[2F79:!H61BQ\VXEY.9CF%66*^6BJ
M:1AVC*9M3E]O?X^?K[_/W^__#Y#>LH`$"QHL6.X@/2\-!N+[I3"BQ'I1%-"8
M:"X,@P4+T@&$Z*]B#8P8T;A8H,"&01H*%KQP6-)!*9($I]&\_XDSI\Z=/'ON
M0Z1/D\^A:9#AM"0HH%!_9H`2]8?,:<$P7F"2E/HTJ]:M7+MZ_0HVK-BQ9,MR
M#9/.J1=.8M&NK5>%;2>Y9NO:O8LWK]Z]>+U`J>)@8`T7-@G12YK&C$.;B`LG
MMJ?X7F2_-QP06D8#ALT8,`SS_0PZM.C1I/=6J0&#P(U!-1`L:.`EC`.7D!HL
M@&'&%0-<+A@TB.$238T%N\V\6.`B*4,%#$Y7I>'%U0(;7FI4#G-R`976K\-P
M-G,R>>GQY,N;/X]>'Y0&-Q*4JG&`"@P'+UQ$83`8!I47-A10B<'`#0A0\5H4
M"?0'!0T,0('`#30`!04,42P0PPLU5/_1W`M1N`)%@`[L%T4#+M`P8'V9S1?B
M1>FMR&*++KZHU7I4,&#.8*8LD$`".,*@W2`5IA'&`C4TD(8+-J#AD@$H+>"%
M`PC`-@@5#3!P0`Q1./#=<0HDL%YE33*`P(@O),(`9V#B.":,:J[)9IMNUB/C
M*ZPI$`8-#=!7!0TI>L<C-`O<0*0+-2!9@W\)GE:12FDPH)\",:#!0##]_:=`
ME_0U0(4##@SGG0N<U><%#<J\26JIII[*5Q0N>&'1(.VAE,N2<:$$FPL*5*IJ
M&C!((M,+MT+'$0.E](=C#&D`>`Y'Q*D*A88M*6"DCM;4`!T#+5'!#:K:;LMM
MMSP9`R10FGC_D10DY9(["+IHH+(,(E$1@FY&Y`K2%+Q-:2(45?B:FQB]Z"[E
M;<`"#TQPP08?C'#""B_,<,,./PQQQ!)/3''%%E^,<<8:;\QQQZ59Y7'((H],
MLD`1@1P0R@"I_`_+4)GC\GDQ\S,S237K<[/,)^^L4,XT%Y0S$D(/37311A^-
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MSW___O\/P``*<(`$+*`!#XC`!"IP@0QLH`,?",$(2G""%*R@!2\HP2(\P0@8
M[*`'/PC"$(I0@"QXPA">0(01JG"%+!Q>]%H(0PNN(`1)2&$,;XC#'.IPAP)4
M`1*2H`(>"G&(1"RB$97G!"0$\8C;>R$3GUA!)Q91BA(<`AF>\(061)"*'^0B
M%+\X0B]VD(MB5)X*6,""%LP0C!(L(QO?""W'.,IQCG2LHQT#Z,8[ZG&/YLLC
<'__(1S\F4)`>)"0@#XE($!H2@(M,I"/O%P@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g145452moi003.gif
<DESCRIPTION>G145452MOI003.GIF
<TEXT>
begin 644 g145452moi003.gif
M1TE&.#EA2P+*`?8```$!`0L+"Q,3$QL;&R,C(RLK*S0T-#L[.T1$1$M+2U14
M5%M;6V-C8VQL;'1T='Q\?`!&C@-*D1I:FQ)WB2-MD2]CES!DES-EF39HFCML
MG4!OGT!PGT1SH4)WK$5YKDEVI$UYIDA\KU!\IU-^J4^`LD2<HE:`JER$K5.#
MM%B'MERNKF"'KV"(KV2+L6..NFF.M&60NVV1MFR5OG"4MW.6N7:8NGN<O62R
MLFFTM'"WMW2ZNGV^OG>=PWF?Q'ZBQH.#@XR,C).3DYN;FX"?OX"@OZ2DI*RL
MK+2TM+N[NX.BP86GR8>IRHFFQ(VIQHZMS9"KQY.NR9>QRYRTS9.RT)VXU*"W
MSZ"XSZ2ZT:F^U(O%Q9/)R9G,S*?`V*S!U:[$VZ+1T:G4U+#$U[/&V;;(V[O,
MW;O=W;C,X,3$Q,O+R\#/W\#0W]34U-O;V\33X<G6Y,W9YM#<Y]/>Z<_GY];@
MZMSE[>3DY.#G[^#H[^SL[.3J\>GN].WQ]O3T]//V^??Y^_[^_B'_"TU33T9&
M24-%.2XP&`````QM<T]035-/1D9)0T4Y+C"`\B]6F@`A_PM-4T]&1DE#13DN
M,!@````,8VU04$I#;7`P-S$R`````T@`<[P`+`````!+`LH!``?_@!>"@X2%
MAH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&R
MLXL8M+>XN;J[HK:\O\#!PL/$Q<;'R,G*R\S-SL_0T=+3U-6.%+[6VMO<W=[0
MV=_BX^3EYJCAY^KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O\``PH<J"L=P8,($RI<
M2,H@PX<0(TJ<2+&BQ8L7'6+<R+%C)@L>0XH<2;*DR9,H4ZI<R;+E(0L:75Z"
M*;.FS9LX<^K<R;-G+@P@X\7T290CT'@6@A9=VA$H3*=#FT6]\%1IM6Q0F6IU
M!3-I5ZO3P![*JDWIUZUH57TE>R[IT;)0_]VFG6L*:-RIV[KB76;7+4VZ@$.Y
M[2MV'`:G>:LB#LRXTUJYZOSFC?NW,5^_C[M:WLQY$^'#:]]V'DW:$53*GTNK
M7OW2:6;"K&,WCOF:T%G9N.<6%O2Y\@6VN8,S'GQ;4%7AR`/7MBTZN?/GT*-+
MGTZ]NO7KV+-KW\Y=N^_NX,.+'T^^O/GSZ',FK<"^?06JK;Q:>#^?/2O[[QE5
M6+^[E/T+_ZD28"ON0=+>(O.E%XL%)]A@0Q(/0CA$#";LY8D)35PAA0T<K#!$
M$B,48J$E'"0AQ14@)E+!!S%$H6$2)JQB`0<Q9'C%$S%\H,H'#]J@XWT@0!C#
M7B<D`2-SA,3@(/\(N!P6G@52_"'EE%/N,08(^9EBP0MY5#E"%U(^,0@&-$@Q
MXB0?M$%E$ED2@H$-<U#YQQY7?-"?)Q@D,8<?5/HQ1Q)G6F+!$U-&T28J%<0@
MY1L9-%)!E'](,>8)5S#YFQM2QG`H+-@\":F<5*K!02ID2)E'&V%P`.8?3;P'
M0JEM!&I@$E+VX48;)XP5!9]_^-$'KW^T,6HG#F6`!;!]]$&EF*9D\,:4<PPK
M8`Q\NM&H?I!*>D$&4NRQAZ488/I'#"UA0,$_4$JI1@WLTF!#&,K^44.;\Q4&
M4GX@[>:5(1G$*2]-)K`[`GN*!IO.>^9&LBF`5TB)Q6$.T?I''UU0&$/_%_%J
M:YPA8"5EG%CG'M*$E'Z,48,)1<8AY1XL<.SQ(@,JLF6\F2Y,%7O][?=Q(2^/
M&;(%'[#;0B$'&A+PR0""H,<?>F`I2`LUT/`C(>_9W/.=!#GI3[J1NE<!!J7^
M\42;(+!PPM2\<?#!CV57:!5(()QP@J6\C4#'Q#DVFH':>DOL!@C#5I"!"2RP
M`$(&6/-6]MENJBKE%1Q(.\B*<?K!!(#S80`I'2"`I/8'V7Q^+08?@+`!!B.<
M<.VV*)]0898@W.W'$QC@-X+*?UQAV^`KF(`X(1FLK;?<']A<R*I=_A'&(5^#
ML,(*:!,2M^\7K`VZ(!R`<+T@&6@_>N09^"(X_\HLC+`Z]^!OR\(><YZM]]KI
M9#""V:.V^;DM'_3^NX*3))5MU0"ZP!BDQ*:D=8$.OJ)#%SI'%1#$(0]O.$$7
M\M"'/9!A!$&Q``BP0$$_T`$+#+1!'GBUASPP`4IYH`.@R,`^*=$A#B#(TQOV
M\*L]N*$&M8@!&?20+#I<(405`,$<XM4'.I#A8#58U/FJUX4KV`!Q''!#'N:`
M04%<(0]YJ,%\:D"'/'3A"=[JPF%L,$,_^$$/;B"7(`@5K"5>(`9C>$++>%.#
M,N[A#3;(QA.PB*,X]!!0B_C`W?:0A*7E@6Z#.,$.?T6',,1H$!FX`AV2E886
MN($.5/P-&5+(@J!$`?^+)ZS`"[HXAD9AH`9NH&$%\2B^/>:A54]8FI3T0`=R
MC2&%+\C/F]K`PS[,00I3RT`;IM@"*2!P#VU80>+X]Q)(+7`$T#3!$Y1%AQ!=
M``3/ZA6OXF""I(B`?;Z<V)34T"@-XNY74HK#P"1&)4.MBG:X\U(2B$A$&_2'
M"43DU1Q84($1T&Q1!FF8V%2$O2[U(5>""!N;*B`Q'CKL`C;@%3J9UC*P$=!F
M`6H"$6L5!5M80*!#-&.MU(B("B3Q#]92:)M8<#=Q2FD.ELK`JL1)!W">P`(9
MP)VFJ")00R5*B2;-9ZTN!R!(Z4Z@5,*AN-2H.8GRZ@W6Y(#LXD2S:#%3$ES_
M\X.WO!6O/#!U561H`0L&^(<Q`.6;+DS""2!U4)B`]04M$(.4S!JDY$6A!@-[
MYP5:`%(;Q,"!O8K""5H0AG1NX"4O`.<53A`#-:23`QEHK)3(4(,7&`(#CI67
M\;!WMSZ8(#]D7>@0IN3!/<2@7W."40Q:.C8.4'6.Z(O<!CAPV`NL@'UZ:,()
MAF#0%B3%"E,*`PM6*Z4PQ,2B?V!"!6P@)6M!,IM=&&XV=6=2/O4!"D62I6=Q
M^BP_Y-**4O)IP=Z`@0R(RPIRPX(+=50!@4JA`B;`Y\284(,8BHL&`&+NG)[`
M6-R5L@)279EN-=JK&"QS(K(*RZ=`]0<ZU,`6)F`?_QV*!V"5[0&#(I#E0@59
MLP@WF,*N9=K`4-L'?@I"O6(CF)3:`*`/+*T/3-`1!Z1P5S?^1JZY`]"*<&<#
M]O0T9K]1DV9E%N"##D*E#)U2$SA@`LB:Z'+L@106`-S9$^0G`VF@@Y:UW`8[
M";15[)$8%@`$W#_$(0/L&1E*-5*!$RA+#R'B<(D%\5,SH[D"+6C#&)A@B[!1
M-\D3NVE.I?3="_040-3Z`Z.*_(089B`*4>#0>[*5M*7IH7B7RM2VNDM4^'8V
MEQEH*138XRPI->'`5S4.I.;0A59W80S^ZH.F3OJ&%MB:!9F=5X;G9,UPU>RD
M;A!KX82L1=3ZP<07T*M)5_]L"_-.R8A1>`&:7R)GA`)(S<LS='@7AEDIX=`0
M]NOL9P41VC"O-U\Z_@`+DC!!AU5@`U4.2H"IE`?0<9H%+2B2LAC5WH<*HF!N
MB`D4)CL(%&NK`E%XG)L&$>(^?%>#+^YFJ;U;M1^_$:#(_<.IHG#:R?TOB(8$
MUU+AJZQ#$F)5A@JP'W::;"F=,-6/X)K&WL,!@0:<"7V2TZC1VC2$C5S-I%V6
MX%3FAZ$)XIWO.6FLGM;2*?7A#4-*AP4\7._)`=P6AT8$B@UEB!942!!R?N0%
MD"RQI0]B!)($EKN[_8<><Z\+;6@#[NH-;P:;JGAEYGJBJJ41#N`N#J[.YAQ^
MM/7_30%-W/*.]Z`I#MX_1`'12KS`"?Q%VCG8@,[N=17[3)[I<8DRG:NK`!N[
M8(&Z]V$%@\#QRV'>"*Y=H4T@9QH(<,XT,MC>]FD@`PTJL&O.^]KS:LX#&=0P
M_-MK*L3'KMJJP*ST;,R>EU3:PTUY1G5$-E_;CE\8H`-NF]CM00U6#GM^D*S?
M(P[B`_ZZXQ4R.V8+)/P/8G#38:C^@7F[H?BX[\(&^MTU0="@N1H1`_\$*O/"
M?UPW.?O!87O036#7)0O(7826+Q:7:.0%=DF@!B/D=);U*%+R7M=D:4[S>[OW
M`LIR9I,S>J776<BF>JB6:C('>V[&-"S")VT0/K\!64ZR_VM-PQOB,@-U1DX0
M@X.V@'Q&UW(I5@'_9S#84SH8``(Q(`5VM2D;4#DLAWW4E76',`(OID6$`"D+
M2&43\TB_MU`20P:34W:^8P$#]P=35@$LH"Q]@$-*T6:;!SJ8X@<S\!09<#H>
ME7D``FP:L2H5Y"UZ0$-S53MJ9H8M]B(<@`'=M5-N"(>"EDTL1U:/5V?D55Y,
MZ(10T%+4]3\7H(6RQX,U(XH7EB5AHUQ%IDR"P(*CD&#1`(O)("M<TP76LS8L
M$#8!!P*]!2`CX`9N8(L6P',Q)62:PHMST@+L\8O!J",DIHQ'%R;LH72"<`)Q
M\$)8\AZ%E7V'4&:BPAXG8%`[9?]QB/!^>Q`%)O`!)G`%\:([%Q!B?[!0+=!"
M9$APQB%0I"<X0C9FO[$JN74XW:,G=X=P<X5F@Q(':G!Y,D=G5P=NR!B'(#`"
M(C`"3OAF`Q.#>?!9@&95D/)?&;"-GM5Y/G4"+<5U%(@Z;Z!E&LE_5]B!K@*"
MI.AYR(4%UR*`3/-9IC=]1KAZ/B&+MT"0$X-%0ADO?F!/%P`I>2`%38`[-=A/
MFQ>"2R4(FW,%30`'*Z8W5.5;5+%\[/$"?*('4!`%(V"59@8%3(`%X`1;5&,W
MS=4$QB0E8L0PX:4(QE(E%#0E;V`GY&8J4`"%4V)/%E!^@V`!$D,G3R`N\&<<
M'Y!9&O?_!F^0/%<Y=2VE!DV`!<KB!S20%.X5%`U)-!(3+?G!'A@@9*=FA''P
M!'XY4'0X64P0-F'8>'M`8TUWB>-57IE%!U'`!%?P8C-`%570@4GQ`7?0*QK"
M`K_G@UO"/GZ@!KK90LS2<+"UC<K%>HZR8*"R!TW@"QRPC53"38(``KCU(XZ8
M*9Z#8U0"!PRH`?ZBE4;(+.A'6B=P.]?9!(HP2J"2*O?HDG29FDYW08206%3R
M!KB3!$E1AH0017W2!NP3+?GR`6(P@"X4!73#17+2!QTEEW]0!9P)4/PB+@=(
M"+07!QH`-(Q),F(@+?/4G1&W'R8`F6;FH>]1,'#0*"*`F$YW_Z$6\)L9"A(8
M8)[Q.)Y_L'N"4`,N.C%2<"TJ9V5[F5PMF&HU<'M02@9AT`0KD`TX50.P-@=M
M\`13\P%=0`:VR!M10`9C8&T98`-9Z@9-,#48<`5D(`;6=`%)8'LD=0*P%@=C
M(`)`TP1J,`=S\`978)R+,'MD@$EB\&!*80.V]VV+,`),\*5C$&T&H4-SX`90
M\`&M208OD!0O8'OT*3U2\`9S0`8<,J9=4$54@0$L(`5]6JE88`.()`@F$`5N
M,`>`9UG&H:BZ1V>*1`876@@?@`52.FZ%(`)?*@9,,B-,T`:V2JK[\V]D4*E-
M8`)5-@@L$`9_*@4@H*OX=0$F,`:^ZO\+F$H&<6"K6("K5*&K1@DT5Q`'<=`&
ME@4%MJ>3H4BK?UHQP..F81"G<TH&)$6=C*`U/",6-!<^0-9ZY14^/0,)Y:4!
M\.$6&I`!-I8("8L)^Q)`K2&QDY`!&A`5"`-9C6(\&!"QK``3&N"PN]&(AQ>&
M65*QCN`Q$5M."+(M'2LSO[$!$SL6`+NSIE!D2LJS0(L/1<:`05NT].!W>T`'
MQ&JT3/L.36@"YM.T4@L/FS6U5GNU6)NU6KNU7-NU7ONU8!NVTM"DGD"V8ML+
M9CL3:9L(:ZL*/JD-"38452LB9=NVB&"WK/"VIZ"WB,"W?-L:2F$0%E(8#@$Q
MEU4+BC"W?:O_LYU``8[[N)`;N9([N91;N99[N9B;N9J[N9S;N9[[N:`;NJ([
MNJ1;NJ9[NJB;NIL[`:K;NJ[[NI8[`;([N[1;N[9[N[B;N[J[N[S;N[[[N\`;
MO,([O,1;O,9[O,B;O,J[O,S;O,[[O-`;O=([O=1;O=9[O=B;O=J[O=S;O=[[
MO>`;ON([ON1;ON9[ONB;ONJ[ONS;ON[[OO`;O_([O_1;O_9[O_B;O_J[O_S;
MO_[[OP`<P`(\P`1<P`9\P`B<P`J\P`S<P`[\P!`<P1(\P11<P19\P1B<P1J\
MP0Q<`A[\P2`<PB(\PB1<PB9\PBB<PBJ\PBS<PB[\PC`<PS(\PS1<_\,V?,,X
MG,,ZO,,\W,,V?`,J`,0J,,1$7,1&;,1"+,1#K,1$S,1'O,1-_,12K,1.?,1,
M7,5/?,50+,567,0W@,5>S,5<K,5C',9!?,9BW,5;C,1HG,9FW,9LK,9A#,9N
M?,9T',59+,9D?,=Z#,=3_,=U7,9H#,1\#,A^+,=?',AD?,AO7,AR',1\[,AQ
MO,9YO,9)',B8G,F:O,F<W,F>_,F@',JB/,JD7,JF?,JHG,JJO,JLW,JN_,JP
M',NR/,NT7,NV?,NXG,NZO,N\W,N^_,O`',S"/,S$7,RG?,G(',54W,:$K,S.
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M@CW8A%W8AGW8B)W_V(J]V(S=V([]V)`=V9(]V91=V99]V9B=V9J]V9S=V9[]
MV:`=VJ(]VJ1=VJ9]VJB=VJJ]VJS=VJ[]VK`=V[(]VU>]!K9]V[B]!FIGUGBP
M!GB@U'AP!D=P!&O`!T3M!VS`!E+"!VM0!SQ=![Z]U,SMW$7=V[GMV[L-U;U-
MW3X-W<:MW==]W=D=U]-M=\BMVX,-W>/]VG5P``+PWO`=`.]-`&B@UD<@``Z`
MU'7P`P40``````*0`$<PU'50``?PVT@P``S`TP\@`$:PU$@@``U@U$$`WQ9>
M``NP!E1M!/@-U`P@``,.U4(@`/)MX1?.W5Q=!T+PVT<=X0O.8'5@``.@_^%\
MS0=&<`92@@<(0`#*3=M_@`<$```%8``'0.1$?@`(0.-H700`\.)%O08'`.`(
ML``*$.0!(`1"S08#4``(#@`*P-,-``!%L-1G0``+8-0_`.!%7N0&(```8`!*
M#M5'<`!``-0_<``X#M5&<.0'4```$`!&?@`)@.):C0<)(``];M1'``!G#N,$
M$`#US==`$`!C_@=\T.9Q+MMU\.AGP`>>C@=\`.K?G=9&```37MU1G@!G<)EU
MT``!,`!Y_M-:SN5_@`1>#N9BSM1`T.A$#02,+NJA?@91[N11S0?K+2>>+M5^
M\.EX4.H&@`>@C@?';M5X4``#D.A%O>A?[NB0WO_78?[@/X[I/O[CG-[3T`XJ
MY_[C?,+<;##>>,`&S3WJO0+JE@[O\CXET/W;I4[L?`#OA`XJ00``!T#HAM[D
MNPW==:!VL_[;VMXG\/[;85[I4V+=++[<TBXGT+[L"O`#5-+OS3WM:4[L4F($
M`5``SNT'TH[<*([<;)#P#.;Q%9_C\O[NT=TG%T]:"(_NQNWQ]\[3BW[@=L?<
M:\`&]V[L?E`'*+[=.1[SO9+SI,4&!2``-;_<MLWT$Q_=B\[K<E('`]#M\RXE
M3M\K#T\E]/X'8<_R,1_JR%[Q:O_CS6UW"#_S#```*Q[NB&[V;P\J'O_O%Y_<
M'0_O1(_QQHWVI-7VI'7_\V;-!2B0`HR/`DIP[)ON]7;W`P;P`,!2!`;``'AP
M!`;P`TC@W@.@`$A`)?LMXP(P``A@!+R"!@;@`$>```,@``<`[F#O`%%?`$`@
M!$U.,D4`^P)@YK&.\09`]PR&!`R@^E."!`H0^Z$_^E*R\+5^ZU*"!E4N^T<0
M\?A.^>]-YRR^YPM0\6>```FP!M3?XWY@!`D0^V;N_`P6\J"R!J^NW)PO!`TP
M``0`[D=0_<TO)^@?^P7@`("P]O=W9``TB`=T("!0X"`X^&!P-OB'I#`@0,"`
M5HEFX'"$D(E@5'F*2@A@P)=:]["H6>HW>&;X,$`@](?W4Z#9<(;`T#IXA"DP
M_[!`^6<;$%"@@,=;=)#I"#GX^DOP4P2PD*I-$-#IQW"P%L0-Y+>V,#!P<#3H
MMX"P!O1;$.2'ABF/WB`'!CI5^F$`220#1WPE8\#FU)H&OP8D.$(+CP(!``84
MY&-`P)D&!!H]F%;/2(),FPS^66/H!P$"A_`$&97L0)!B=1`L6(/L0)&,"1#4
M.17$0!!Q3)LZ?<J4!X2I4SO08HJ'G$MQ:`8$$-CUZQ\C``Z4-#"@HT`\"0`$
M,!#2K4`D``C$0PM`@,(_/=T:(&<`0(-!0IX1L%9W:Z4UR;(Y+5SW;]XBV@84
MF$9702T"'=$V`D#Y#YL#>>%RE,:+]`]$I`_Y*38V0/_DM`.8I0("+M41:-/(
M%H!&0"%D`I(%F!H41#9QC@>.?AOLQX%?`[(/H%P`0*`1VG$+,-MMUV-:O5!W
M&T!9B6WIN&)5_2Y`H`@>[,!7E2T&Q+#D`?3.")`M@'5\,.!6`7$9`(E&I0&6
MFSAU:/4''P<$L$`C!;BEB`!X#=`)'B%56,"%`2`D7EV"^*$``'L-@MUQV+WW
M&P`*%`/3@F[M@L>$>0V`!$AO01.C`_7\H!]GP=420$GP"<%'`].E%<!2+^4$
M)(9_V`/`<1%.*!!47GX)E501C!F!!U<YR)D"#:S)9@-:)E<`&W@@`,!J8P&P
MRAEXL$%@`M,(418:>."Q!FG_#`Q"%P`,K$%H6X?^\4-9>K+A@&R'YAB`$(.^
M`\`#XARQ"GI-K9%+$77P48<0N43$AF73@!J.'VTM("<:;8%V)0,!-"`H'F>T
M)>497F$D'6JG\(%`E(/R*1A3D3ZZ&)T,T/*-LJ=V%5\=>*2:RU%H,!+$H)\`
M<,AS+^5RA+@3AH8=/0\&X("V:Q"(P*N6,KJ&M.65)>H?002ZJ:&(RG:2MD8D
MF6X=1-[73"/R[0F$AGCP@49)2!Q5&`)(3+R&=`O0\F\!&[\B6S@.>M6)A!T9
M,:AT`"2`+VE+>5@7RW@X&8`"^`:VRQ\IKO@'@2Y.-F@1_RG$1XH*H($JD0,(
M4@=V_T"LP0=(=:6;2%U'(?$6UFP0:5TSLL6K+=<$8,WI`:V0VI&FB03P])T*
M7'4&;V#>C3<J/4!`)@1F-O4@GH(/+B0B!"X@G9^#D"52)750U\D9#]CV!VX)
M&)/D48N__-J$*_+A*"^_R:>-$8Y50I;:4$7:<R6X[5)'(YC).&4!FI^+*V/U
M2B0/2LD9DN3IJ66*$AZF.UL7`\HSH`!G'`[R3=B1X'H*ZY`"4'@M"NQB+F.U
MT6B$YNW^\4T"L'D8@$*@$G`[60CLRPHJDE-N.:(`V%X)=J'ERK"36@Z4)=$-
MX"@2BEMZ$""`-?@A65I"$>W05(XMU<D3SW`);E9CM4,@*?^!!R'7E7YV"J&Q
MJ%.5D%4`&4,`QQ#(3OY#1&"D)+H(+B!]J&B`6.I&@(@,8@T_^!^H+G.N*)60
M0+#[!20BE;V\*?%+/2!3!/QVIE1DI4Y%J*(5B[`5-HB(`"XA2P*B*)W6\6(-
M9Q`"G>9F"<Y1\'ULD-@I<#.8/^#,``TH@O`J`2K5.<6!"5B`'Q>@`#J%HU5`
MI$LXO@&M0;2%,KLIP!_]B(P$I>@9^T.%=-["`#LZ)5*#PY,`$-`E1)8P`0%(
M@`(4`$E]@5`<YLI17@X0BMO]87Q.$N,?I+,4KGUQC5'\%+^P0D8SRH@6H-(,
M(@HP`!UN3FT++"4@_T@:(>$!F1'_(94`3OG("X4O%Z+ZE\E<@3():@D-T+@=
M;FH2F"[5[3P=U.`J!T$@@;3H%$ZBS#>^:8P'UG,0(.'@(/J0+*I1!Y607$!@
M5H.&LO22%VPX0Q%F",0V#O`4]QQ$+;?4GB5J]"E2H0H$.M`'P$$(*H#R(.H4
MA8I(:?`,#/B%;/!TN30:<Q#D?%_=$!!%LCR*#142W``6Q94D*1,5@Y)@)]V2
M,[ZX2A6:^9>=*K'/D@[NI0)PB7_`L5!M]-23"U",ZP!0"B.(]0B,HFBS^$F:
MH[IE`7V8D%>A=U8T)$MP!'B`^+(S2[PB98*9.<49U.@44,5/?@P(R4M?EL^9
M9F6B%%0;_\W4VJQI)O,/W\*3;%XJ&R&T48_Y_!@$S>%67GX5@]3)QDW/I-)!
MO#-H`<QKE^2(*T!YRJ^EI,4^>1&2;+2U'($[*L'$AE.)$.0_@@,B8]A9B;X2
M(F?^L-M&G\L4+[@`!M1U@1.<DI4`4(XI?,".HF"CTY1Z$`FT.8`"'M`G6B@7
M2>^K*6S(AU)/``$!Y/@E4:GSVDJPP0#XD%"FC@#@`)-5-$LMYA]D6\/8O@P)
M`@:PGNJ1G[+($A7N`$("ZFN`"0_B64\Q%VNB=`0&B_@(:/!#:$]Q%0_S0G*C
MP-.T7)O7_UUO->NE;`""&UC[)K>\YR60,=<K65G2Y0!^F&:F&/\<8@`C01#3
M%("WH&&$!C.X#L<5%:R8\JZ432@;[AUMA');B=.V\X,J"F%KQP?5``(JB6G<
MY6W[F8UF"JHD14"R@",BYAT&1D,)<,`#0B4:-^(QJ;A-9J2>"MU$+S&[;T4%
MH.P2@*$L$ST.1((#[8J22.VRQC7EBUV&*IU#N<,@?JB#$7Z3WRLE[KV#P`W^
ML&/+4K>"D+,+!UUBRD\Z489K"&!U46N1B<`X8*&CYF<=CJ!-<7#8*2K&4B6O
MA(>0ZN\4;#@O'LQ%L02M00C)B,CX(C7;2J1HUP]D;U9/89Y^I>@'VMKP,%7Q
MS3G1\*O,3%%^BYP1:GK:@.G!0Y&-6+W_!KD"0OYU24W/=,$O"T"9?WW?F'VF
MUPBU96BOW>=N>OW&L[XY),J4LXGGW6]:'+P2?UX4'VCAFVDPQI^MGJ"[YZM=
M1<M<B5E^RAG(@82#I7!SD4ZN['QD\`O]N-S`]0.6'G"5-7!F,(]['B*2!;3%
MI.4D)=R.28OPEFSPP0'Q(3`0#5R'WV@)Z[BB63N2&XUIU*$U89%Q:AI7B;:D
M^GJ)9.59X8J@2FR]ZX`R2@<U8ZZN-$>_=CG*^'"8C2,P0A`USG-3\OA>]!F<
M,S&ML>50@H8+J>Y?!U`F'AA``%-(5H<$8@!ZV("`O#O)`<70HL!148=P^I?+
M`2"RESW$<G+N__+E(PRWXO6*9HL&,+M:JE%H;HM[W896T[>;3P'Z<^,SI4A+
MJ`=T&[&7=.K8AIR_D=[,O^^EP#'@`>0O/_D5,B<2]L%),[I37AQ0!%P`8"E8
MTDD1')`6L+;"P&&.?L,H5`3ZP!&BYB0%\`!%(`0IXGVH0'8'T$-"P`"G43QT
M4E<(2$IQ$WN%]$#Y(0`'B`NR$1J%D3-"<']IL1K1(2-_`@U#!4`5*`0SE&'B
M@!OX9'=QQ!IU<8!"0$H[UQ<($`1%H"ODT4IT<@!`8`0W$5_CTUUUX0WRAW26
M0&@T55M/(5CO57\_B']X$ER&=`J/LPH.0!)XHCI>6`#><!,KB%OP<O\$?"`L
M9?&#0!`8[1<6VY,4'$&#CD-PBT!["!!2+4=:+.=XJ75@[Q=_=G%F$0=;H?$O
M`E!'</@R*)$X\@%G)90LG>!Z!F"&=,).@7@_0%`$OH`G[$-@:Q6`@;$`L`$Z
M>()HX,>*6,$9D(4]?_!GN\,7+W0G"'`K>?$`Q9!Y@X.)R;`U1)=G1?"*JU!R
MVI`BOKA=*&8$@3$XC"A+^7)8]R,0L?-U#\0'#W!8?D0]?/`#^>=)#C`-6+=S
M$8(=Q$!4,^2+<T=W'79W.S17Q=4E:Y"+'2$E'C8N@P,S(U2-ZFA9XIA8?@56
MYX9'@'8*O2@XOYA#3(4*:*`C'6%#."97G93_$)7@,A-U:IVD,WA4C&7X>ETH
M>UO66`@W0<D79H!U/1JD();U`/,$8Y5`(*'AC1QA60F@3`>#)T4PB6@50<V0
M5H)S``;A>&LW.'7U&Y2`0OY((1/V+S'7BD\I#GQ0!$$@!$%@E599E4'`-`CH
M&&@0!!BA4S;1`#^P7>K0`/!W%$<@!$=1!U]Y"G@@!!BQ&$#0`$#`!FP0!+:!
M!T?P`&=I*E!A:GW9`%JY4'O9EVB9'D5@!*W0EBOB!Y+3`)IR!D'@&&8YEF=P
M%4>0EUTH!)J2"GS`EWZI89ZPF4ZA#LMHF*))5$8`AD#@$J?I./?7``^0+LD5
M!+<#FGU)EF>2*J_5_YN`&01&L%!FB99^H)9L&9?'P@N::4>[@4_&<YCA\Y9!
M,)LHD2I@2)O]8I8_L`:-R5T(.`U^8`2>B0AQ>2;J8`[CB1XV\5I>F0W7=I88
M@02W:0QKZ5>4>9`_$)^B(IYG66+JB6[VB0BL.9LLXSC)R9E@&`1XAI]59@2S
MN8:ZH6-02:&*%EX5BJ$9JJ$;RJ$=*@X.L)$DYW(>2J(EVJ%M-%A-X20:9*(M
M>@H7ZJ(Q*J,S2J/?1R]&@`9G\`.,L(PUZJ,_RA0HVB^.@P;<MI!`VJ$PBJ1+
MRJ1-2J(U@E1Y84M.2J4Q6F5,@9,!P*)5"I5H4$=<"J9A*J9+Q`9`H``'T/]G
M/3JF:PJ5>.``/\!JBU$40D"0;&JG=XJG>:I$)Z>G?=JA1N>G@2JH@TJHA6JH
MAXJHB:JHB\JHC>JHCPJID2JIDTJIE6JIEXJIF5JIH'D$8A5E`,:"9U";8!)%
M;"`$/T">0(H&!OJ9(5:G3IHJJ#JDJVD0;#!@K;B7/S`U>X0$+'@L1S":,KH&
MTOFD0>`-<;JD:`"LFOJ4T^1;/X42$L)R3]$Q#/>*"[>D]C8(E&(0#P)$5=HQ
MKWDA;M%HR45H"<>*W?526YH*![.*2-%S0"H=SZ:A2/"*C$6E\<2LN$IYRN-'
M"6"'K;!;=Y0*LM*3L&4(.KFD$`@)!+(7L2>*53K_0ROR9V68JDRA2\;``.P(
M774C``ZPJTQQ!%/'%$8#`%,ZH[?5H=A1A))6I2*TK^!7<R6D>#0T>U[R<=F@
MK6!*2LSP(`0PJTC:LVE&KQA+=$])%C,E#C:1?^]*,CF)I"J[H<T4=?G:6C$[
M<XQ&8>N&48[!!B*F0/P$$P%@.H1")T)05MK`8`^F=XSB*QO#!]W)%Z"Z&$?`
MMJY`-6V;M_6P!A%!9563+R=+-3\[**(:MD]Q;`!VN.+@#GZKN`X"8()R+&YK
MMU1&&FA+*"DR->B1N$QS"IF1$6DKMG0+%10#8+?C!WCY,G*;"JB7)%Q[D('!
M7]2#N)$K*G'+EH_K"I'+_VIQJ[L62;L1HJS+F@IK`&#3<)=&QP:+.T:C22@3
M8CJP40<,)KFNL+;K*;IC)"K&2V)#B@?#ZZN\P&""H*]8.W/OLHQ.XBD?UZUA
MB"<_Y2WY]Q8/0),!8!P1H@^7!4J+L0FZ`B_^P0#.4#-X0+]N$93B0+^M0UX"
ML#\C.RT1>`;OXA8IA`>YT(R>Q`#!RA<D\5+P&Z0%`$K.6%?HX8WU54HKTA4.
MX+\+$"-)LJ.7)0`X\@`FG`"VH5S<QJ+_<%D#0'5-82LT.<)\T<+7M%`CVP#J
M,*+(45=U,*]/D0@TC,(#L#WUQ</G(W]YD0"ON1%N,0``*7P-/%=)`@3KF86K
M4/\$]%4'?;`26Q$$'2B#F,4?$2(3^DLY?``$)KR_E1/#IX##VE#&M?<_2$!*
M7!PO)20$,3(`0."2YJMH6GLL=+(4TBH(2=,1J#17@R&-]Z,`0:`C!F)ID7)C
M!J464L@("9``=78_!7``"T`:!%`A?906YB.AGG4]=^<D2_$S;,$1("PGY)`+
M"S#(;)8>V"'%#'#)6>4]=G%*8Q-2*.A,%U(;2)()IFQANYP`0K`(D;&8.--'
M%T(`S,`UQH2N:^#-@%0R0=N+CC3(Q*`1G*$APX:WR$%"$@$)3=P4T?$,W=P1
MS$!._V$`]W`CAI,7J'0A,5@CKKS%QG);;?C/<[6+_'/_3<A@OQ%Q:'J7+',G
M!-1Q/P>`F9>DS]%\)=KH3(&Q<X(HS^OK)%(LRDY7L_^,"8\(/<_@$[^1%F['
MR!KU+CU2-7Q`*7`SR2+)-7G'"Q4[#9C"-$5F;R?W+<9!"Z\`5BK'$>U@=%PC
M&&I'&OP14OZ!K;"'3$?13&]1U+_0"=JJ'K49.#9Y)7`RJW53``D2*=^*"JUR
M/Y0@GIG0"5S#'TWM)+)<-_,7(7U0UOXV(">[?PC3U#[6"J!;.1-T#N`0$7Z`
M!*/#N-BQ`$?1!_9*MKQ`%J>(K'OUKD3K%'4S`$804DS\U&*#/46]UR@'#9@I
M&G1R".QW(L[0,_N$+-A#0",;_W.BO1=G`,T1\2W?2DY`R[CRUB-0F-<;_#*M
M(-H1.A^Q:-+^0D(/XG0W(P#H-`"D(QJPAEMUPIA.@H@WO5&!8R`'`!=0HD$%
M-[=;@4/3<+.J56;78X/#@Y1P<SOKHTP>HW=@E@KZ^B#\%0",=V.M,$,",;1*
MY91*A:]=:+>TM>"+\1__(QV'\&?A%D.1DR2BDB*VT4*WE,0/PD'*E7"QQV^#
M>(<$5N+_\BB@4G=,X50J&KRI4.%O^1L8'K%BHSI$E)]Z4A);\0UHM$_!+4LS
M_F>(=C#8BBSS!D?W3$H&(1T6'G815-'Z]0/T$"DP)-V>\BYV&5*$\BI5/2@3
MXQ]?Q/]KL,$&G&'3XITW@6._]IL,",`D/!EGQAM_K>S5(@G?>[&S:;8+:U![
ML#%DL"$=3]5/X6LN7#.;N#+E.TM*#]LMZ?$+&OP2:@D+6B,.*"1+FPU0(`=/
MN.)X?]#H,!E`[(L*XZ/8"?=7N[=#@H9N1TM.JJ.D3?$O%IY@15L/I)1?,6EC
M./82?_[>\C/@U"8[B0A?=7=KE2;LDR7=0I+D]&`\GFH$=$TGTI[@G6X*>RY>
M6_KB?@#>\O`#Q[W8'@$7!F`@6H-@HW2U:JY1Q+<&[=Z=[R7)B`*P@J,<!(3G
M$$</)K1=?[84KP[H[P9`K5/H)W,>_U($H-(`F,(,.[OAXT#_W(CP:4SQ*\3E
M%I9>O*PN4TFN&$U<-[BF2"#70CN99J80SG[(D-2V5*C`XJAP7/L77T\QZS!N
MZQ%2B99TLKM^GG_>9*/9\43UZ$V\9@UY8WW0\)"^U54FY*@M.#AEL)3PZP!$
M&6W1:-$=\T,]KFZ!`)0`RIG`",G@$0IC4J+.L>K^)3/+72(9%@8P?IV9X5=R
M8CXS;PK`Z;#5Y[5W)OP7\.G!WZDP0V<P0V@0>T$I:(P>WQ"[GEU]Z9RA]@_`
M]C<N[,C56<VT7=.6ZE'4%K:AZT:-"M.W7&B4<+H418P!UP6IM#86-K'NXDE<
MZTP.`-NEZX[GYVHC\MK`AG_..T"T_T\JED]?M%K>HTQR?P:X43ALT`#+PP"N
M4?.27^JX$NI=V`I4/\^ETP`(%"I(=)?7?_V+C6A8DN9D7_8C=?81)!U>?"?$
M/;#BIE=(]):>T^NV9S]*&T;[7>(OVBD&,C&C,/[Y$]\'_K/-IV\R#@@`#GA_
MA48!!'6%BX5K`@%HC`\`07\.`#^,=08!9W]G``E^BWX)`)Z%#0!&J0!`F@60
M?T@`"H5`F']L`P-LC$*UC(N.B8Q!``N%1P`,PLZ%QYG/E@!%TX67TH5XL9YG
M`0BCC0$'?'\*U8QG!0UL!`)KC$:AHZK6WP:$BY,-?Y/:?PX)\&4(0`,$G:[]
M\8,PTA]5`/^Y);ST:I@!!7A^Y%H$\0^>(ZP*\4%#`-*R!'T8^3GCBQ;*1=Q6
M*9Q)LZ;-FSASZE18IR2J:7X.!(BGJN+*`@"*\1'J\%R`(X6^#4`B$E<!16O(
MI2Q$R]:B2T)@&H`W;5?)9-0&/%V$#JJ?MH7J#""@SV.!`8J<=5QXQD#2O,+6
M#*B5%\F[>$<0H<H(X`"A;Z)(*5A;B$&Z@`$*.,0S"0&AKK=R^5E@4-\:OY6<
ME1*D#XW?L`&1U3SVX)H]A8D)+-:8[P\:<.+^."KW!]B!>![1/?!CF8'I`QLO
M6<,C](>^,R6A_AYPI,]*O[T6]53;6R&"4UP5;YOD^$_B`HM5+?#_8SSOD<&U
M=PF@VJ@`O#JQ6+<-$`$PX,<F`00Q"A^3``#53A!&*.&$%#J#1TE-/;/44'\4
M`8``"SBPP",`#!`/0P`@("`Z_/FA"H@/(!2`-<*18XXRP7P%`&P>C87<,Z2Y
M4M!?;#E8"&D'6"=7,=O<19`P100@@`(/C!B`E#\R(MB5!CC``'X+6B8``S%^
M&-(WX3""Y`.$6!82'J0-P(`#0@GP(&A_X"(-&H-U^64H=0ESQF`'//`G1@4U
M0U,TMETV#1^6R>G`>0*<"=PPY!""!SH$-/"`7P7X0A(`739`0(IYW889.(8*
MP(P^EX"3P",!A*<C`+4IQ%!"?T#ZX9S0_]DIDBIRECE`)(*1ZN4`?M7F8HD+
M/-``4@86%T!C#DSZX8-1!I#``[,.%E*%Y)9KKKD`"I"A,WP@0!8>#;@*`#A%
M)!``?T*X*LL"]\+DP&```%``C<()@,"-GP2`5B$/S+C(4K8^(X24J&S9SR+\
M\F>$ODCT5%Z/3`H#[[7S'B"$O0\*PX8`!OP@[P`";A-OP*2.^YL"P74X6+\-
M!#!N'3,';$#*W\R79P`5S2)4P&,^^<P1G##-`&")*3I3$`$`)(P##BL$K[P!
M&&"S`)$U,L#!<3$`-@(_G;'TO`L\R37!1OC%]"`P_5!29D`0$+)[5_)W32GJ
MPA1TV.-ZY("\I/^F+,2I\SY`H#1?TSQF7O0A%3#BI#R^^0\,4';NZ*273I,?
M:)P1Z#-KG''C2D4(<00A;)R!^1E"%$%(ZZNO$?L1@/5Z1H9XG)%E[<&GOM4S
MQ;M>".JV:ZGZ\V@((00>*Z$1'/0("S/2[X34$;TSCN2S1NY9#O-[\,6G_TGN
M6"$1J!^^RQXH'D@@)S[[2.2N/4T?L=[_8&*\FM2A8]>HW>JFX;L@`(\1[6,$
M'X8G032`3V3]$\(9<J9`31P!?1#$W@%55[Y`)>9CU^!=8-;'.A9J*78;W!\I
M&EB$->3L#W7XH!`0J#(C"$%[*C2=$(=(Q"(:\8BD*R$2E\C$)I[K!P7_2`TT
M9,.(O3CQBEC,HA:WR,4C*K&+8`RC$3TD``<4H0CQ$I8NBN`R`KA/C'",HQSG
M2,<*E:][=<RC'A_%-9J52`CB0,*U`L"C/1KRD(A,9!/Q(`0CW%"1D!3C2H#0
M@`8$(4L9:4#*(LG)3GKRDZ`,I2A'2<I2FO*4J$RE*E?)RE:Z\I6PC*4L9TG+
M6MKREKC,I2YWR<M>^K)TV(O+#VB$AA\(KD)'^`%RDOG&<ZWA!YN,$!N#AQ,\
M!`&0'@$"-DV'AR(X0`$+^('S?O&#<CZ@G#\`PNPL9(1RKG,:9P#"`A<A.YV<
MH0$*:``U?VE$/^B#/O+DIQZ-D`""_.8`HP"&_P/,91D:D2::I%N&U2*TJY_D
M1(E9,0`>S54W/\[+.6+Q*,W(D2$T0&=S"7@C&PR`EVD<8F$V&133UB70(:YA
M`6_R44WIB(>Q$,2:CBR.(,REBI`<(0A.*QT;U$FABD)(B4!]9(7H<Z4$R.X(
M_T*&/JC#C"!X%0B4'(QGX@*=`P#A4X`*S'G^M@@C#`:F-;D$`HXPSIT243HB
MT:E=X\@'GTILJ.5RDR)+P2N=W)&(?$I0]X[@JM3TU4B"4@M_CI&`YXB.#T6(
M!9$TT;!K3;0FJMIK$55%';*(%IA'`$(ZY0<3NJXD"#\PPE:+,``!!($J'T&%
M0OF03"&X#P]&`.L[&?^!!MAVIZB%0(,1D@?;(`QP$=7[P6WG.8TZ&,$A:S`"
M&X`+UN?&I9U`0,+K[.6)W$+0M:W]@6\S2@C>;E`XVN4N$&BZ!MC*UKIO?-9G
M&:8P<RP%LL(P15CX8(IC`N-B#RG1`PC04O'XQ0"3@"M/CG`>!V@7NK#UK4J.
M@`9&`N&-2!CN)X9[OM5NM+C2;:8'51N$]SXLGNKUKC!"S`=&#C,OQ54G'NO`
M1B#4U3?W9>,EG<$&(;O8#T@PA87QT->!L$$(-R8?E)T;G(^L@0U>1<Y(8`N$
MY3[L"%1!@W!OQ-LC</`(*@8E$MXVKY2.HTM@2X`B!$DSNOP&;1YB0)`^%+/_
M3YPT8`AH"H/`IN?+A.Y!0&.<`!J@CS[\`&!M3C,C)%J('P3``:9@&A""8P3-
M17HA"/&&MX(SG!NAX3P!(P`06&:.4O]!(YBVW*:?%P1()X!KN1)9=IXAPQX!
M.*33<1)Q;;20!3"@PWX+WAJ2E$-FW&0>?GP%'A9',YC=:!<(0$<M;K@4TR[$
M7I'PPZ-'ZN:T*1IOT\BL'PNDCSKPRW+H%MD![/1G.0<!;`U`6*='JH`G\0NM
M`1O`N/P0!,A]5!$QV9R9Q](WFL''7XP+@#Z3&P`%H+HV=9B,'X=6B%T8X-XH
MC4=ILV29I)62#4A)0#K5!MBL2$D!E'15;=:@MHJS_^G."9T7B(#`\M2LX51)
M^L&#D8.+10-A,M=RJ$SP8)DN`<$!2&G`*`XAI[-22ZK.H/2KYT4`!P#!%+*8
MQ6`28/5:\,&IH"A;P8BSB<;\X`'^"5NK!4"<22#"ZZ8HW*H6``0KX>H94MDG
MN_QB!#X8WO!KX!H!?'%8\21[(748!3<:+!)]S$/"UT`#`X#.`"3XX1)&#YV0
M=*&6,CX@<2(1RH^<FI@!-*#L"S`'G)3U]%-)'?"/@/D/-`Z;211`<@T83"$?
MQHD").D!A!H`WT/7+_>XBNQP3Y$^2!.V<_J%2=V">59CSQFD'(`!-O0+W<N9
M<O]:AAVP3\EO$/$`!X@7'?\0KKWT"R8`EKW]5`HPQS_$XQ])=]*M"U`7&D$<
MCH`TXG`,"-4C`T%Q:`,,"2(.$],;J@!2R3%4`-(U?D`@,O$'E@$5AZ``@%$'
MH99@26-2`5@3RX`6DT``FW$>K_`6F'`C:^`?D4!>":-V64$<P(``><$&T-$;
M.:A_28$<>.""O8(0/P"!UY)KD]88U`5!T&%\"'``4S@8`D!,X+`\=D%Y<<%@
M@N<>SH83R.4;`C`5S[,Q;D1ZE'`-&[)Z(Y@-PW``B!(E)]AQ#?$,+K,<ST,:
MR=!3A9596K,-T%%9A1`EKC`*HR$D*/(#,@@=L($D!`$@2\<)"I)<L?`@I.47
MB/+_"?6'&-X2@O9"%=_@,\-```;P(ZT7#[N`*OW1+[]1'O.0`!LE2GBP!H#A
M!QZB435R%</`,IK"4@3Q#0EH''71+IW`#7I'<?D@2+(($T@1$H(5.NNU!M2(
M"[7!&S\D>[/X-&&H$0B6)[E@%L%S!NMTAVE':L3V4+]`*JU&;).P4(N@$9F0
M@W6Q&DRX",O0'C/Q7U=R)0'G`#^!<Q#DA2)S%U^8@CFA*L?PC7]`&M:P"R;"
MAJI'"B-H%3^D*>(0.C5$C=0HC\RS!L488=]6"T9@0QXA55PU+H$7CT)"#,'C
M(5Y!&E+$@>D@2/H8&A=#6D*1,AL2"5QS21Q97T/U&[PH_Q)L\"2H\PBJ^`C'
MI!&U482\4G*KQ`:IU0"SPHXU<@#+LS(%H"G^85"7<F#"8`\K@T*35P?`<(^D
M`8T.@B)24G^T$@PSN#D'`)!8YPR75VEKN`AZDC`X\PQH-VJ8@E`]Y6V^(7=9
M*80SR2AXL@]_YPR"U)4`A!K4>`9<HQG#AC;.&#';P&!)A8]4=!-CV%#"T)=R
M(9F/,I'/8X-S63+N)WG!<B5P>2V8UPCMQ`#NDB.&6"(JUTR/E3('A3"X\`H(
MJ26LUI"_=AMBJ0[TD&`T4IA/T@=,L1IO*27^*`H">5Y!\$VG0A:.@)HXXA76
MB$.'D4H9:'"UXH2)N0@>YY6F=?]GYJ!0PC`)OD5L8M$+C%)%&^@F02$P!W``
M!@"@`9HK:#`M)*,P3]B$*KB74Y0)R_"7JG$>HI8FXU`.D^<T&$5WYJ`1,]F7
MQ<F7CZDR:O%&F'4$L@<=*9.!`O,C[<D(NP">3<*%\A"&HFEH&[@(M$%Z,.H]
MJGF$O+(&!KHY`?A8!A"@10J@2<(\U,8TKH(6?G`$"@!I`S!KWJ-7"4.A6T><
MH=EQOHB<FX1<:2DH@JDJ3>:&LG`>QA>@2%J7OM&<;64W\U)Z\?!%4>$MC<!J
M)W&7H!0E8])E%M08YA"<[-FE/64K`IEGPN`F7!DH<H$7\LD(Z*!TK(`0XG5X
MAN<'.9/_0S]@+SN"@MTX>@UZI5I8!QWV!^;HIH>IE2,W;+H8A/[`H."8"2Z1
M,Y9QCR)A"B8'7?47"?^U27A@"IM8F%F")C=T(3(*FK79*#2B"L,W":_PHD\8
M%!SR/",H'LG$J0HB%)5JJ9B*ATGA`$%0DAH!5T5&)Q]"4V4*79>BEZ\PJ^J0
MCLF9#H@ZHUY!IE:Z*S7H,Y9Z>*.0G<*A%C!7!&<P*&2Q,G0QHXKR%IW`K*H4
MJ9*`E:[:<0,@F<AH4"F2<T5)GO"P(9LT#PCUBG71$QNXEJ\*C]"E84;0`*OG
MC9Z*%AS*"*99GAPA`&$Q@OB`,,9A#JK0H1#KCK#**#WA;6UG_ZN%B`CIPP>D
M08B]*@Q\TJE'XK1Z::MG.0T?:A.J`I-5MI,Z^H3445B[(`M'T`!-H:+-H`KW
M6#V_-18_D8A]&`1L`A,.6Z7>YJ\:\0J-FB4:H2CJR!'IX)+ZF2OVZFW2*0LL
MJR5#AB8(LY"3AB6Z\`A?"K5Y=A?^YTGH$%#6Y"KM$;'_VAM^Z!`"Z8#Z=""6
MD7];=P"NPP=(X!>OT"X&$7GN%C!L"15G\`A`$'D3!!W6<`D*8$,'0AH5@0?!
MQ(V*,@F+*1JCRP9^@%F[:JJR\+5"<'9]`:B`PQUG=P2G`H0:^JH\*PV7D`"J
M@P9!0K0>80I#@SU\0',?PA^_Z0S'D/^&F`$?-78?`F!1G7FL./)9-;:-"182
M/X<TKGL)O%@'`K"CPH`.SN$';&`9"3$)NXNI=2"5WV!;MHL$L8!Z/>(S(M1'
MR?!?/Q!YJ,,)]*N`/T*L+/F"HVM#'Z$6(;&WK6`-!,8,*)PO\]L*L]9D2'F'
M:/`('=PK)M6I_HH+"Q!Y']&=<THHVL-(`K!XCG<M$(I*$T,J"8`4:M%2FEN6
MA(`B!>`<=Y82P.`?!9``I^*^O_HA")";FRA37WP7S_BTK"!NU_+%"%$+NR/%
M"0#&I$(0TT)3..*RH/H'.:H+T#$`";`TF8`BX49]96PPQ,8'L5+&F8&8]*B]
M,+L1=0`=B.#_*OB10I8,QU8H13WU:X+(#`M"&@:S-'JH:_8;&W`E!`4P?/I)
M,(9H`%%<(B$!K0IAB%]LBMT@'."!`'8<*@MQ"0(SR$TZ3W9W``DP&$!G#H<P
MS+G)`!N5KLEUL27<"+V\-`YP(RSLG%$1Q@G`"5DC#AHAR&C05].Z$$Q1:=="
M``F0FX2(!M2<7*[RQ9Q0?VNQ,F_YS?,RD\_B**C$!WIS)0/@`&B@`)@Y@TV\
M4H08$"7A1C]G-$9``,-4$E-B477@`'M#``\PCO:""$6`?`^"T0_"!T(P%O/R
M>W51T#NC?,@Q&H4E#/<!C[5&,#HC132G%ID1!-K,@G%A)0.]#J3K_Q$!/26I
MVXP(;0Y]0]-",`!2Q`90-P#'!ZO.4`="-T@#H`";5`K<\0R&\7`X]"]7(M'S
M1!T'\(5(,-#",#&!N`];W59"(24)D#*;,%:#TS=5!;Z8Z1M1&J<+(&A!\-:9
M\;;,$WQ74@`_8%(&H`A^8`2`70#Q)D'?_"0D42W00``\<E,X'45U$7P6!=+0
MI0"T8@#/&X=74@2E8`!(:=!:5@2`W74X5@!&LPA%`,Y7?0:/%A9E63=7<@!!
M-:,1R4KB,SYX4`=73-S"4`?!4SO:<R!;9=SBLP:S&-R"-Q+1,]PW8MT0U#IH
ML$_G.[#(JPEL\RC&[1'CO0WEW7$#RSZ1-_]#!<3<QVT\YC#>[DW>]V/<$X1P
MQBU8,U&+WOU(PXUUR,VHZ3TXP\V&Y^T1#;#6YHU'_`W=Q_V%[UVJ_\W>+/&1
MPY.@Z+W=YEUEK3,]UX#<VW/>PST_RKTZV`T3==`]]'/A%C*PX;/>*)XS_*WA
MFK!/>)`Z)LD'QEU"Q5.JS@`,L7U:D+1LG_E)+]H4V&&8G/06%BSDKV3%7H,0
M3>[D>[2=IL0'G.(I?^(`>GI(!0WA5*Y*C><,EFD*=!WFB`2\I[0&&A=P@OU)
M.H[FLK0+-PG3;QS"<I[G%?(]C32Y>O[G0C02,@839U3D@'[HB)[HBK[HC-[H
MCO[HD![IDC[IE%[_Z99^Z9B>Z9J^Z:[$=(\M'M'2Y6+$!M&R13^P`"IV='Y>
M$R:IUS/I2Z0NOIQNZ0)\L.23O88DJ%BT&GC^M,<4(=-&U_.P7[RDZ[.NZ;;<
MXGI,1_"I1:;0Z[[!6A2RJ-N`9C5U4*)^[(^^)!CNY>"@O_T4BD4DP`4`[L\S
M$]D>2LVN[:>U!GVG``R`5'FC.T7```J@3('1=PR`9A,[UMHT"DAPV,\$3D6@
MOVQ4.]_4`)ZG$F?P`.`4!'E!TK4+04`0!%LE!/;>`(6GK@G(0.]^V`S_30P@
M!+<H!/)4H`K@`/&`67HV\2,YL`T0+1G23KZ0$==3[^&4/F*V`/`.\8W`_S4"
M\`#6\$R;]$P+D//J(/"GO@"ZHQ"\Y?`IW_0+8?(?8>\/L'HF?T#X]`!-`52)
MAU.+T/`]3TUHB4_10K_`A4\:WQK@P$@MGSYU$`0\[P`F"D$8GT]2S^ZH1%L>
MY=5940#:%C`%@(J>)G%S,4^"RL"%WP!:2`JFP'*;PR-^T#`;YPF)2-."A#9N
MLVY!3'$=GW4&]T<B86F5WR0T:W":T3,TLXGV$C0?4HGG8"1_'_BDXA`9R#A"
M$P_`0#,(->RR#6E),2X:H0!P6B#;R'0D(Z2_*``N4VTTLB'-'W"P<9HGA3,`
MG?RD$I!PRC12E'&<OSMAT^:D0OB;,R^,U@A_%O\P!:7WIY3#EW8$J74J:)$5
M)0)-K&P0<8$4.&4$&D?`ZVEW@(!0=-00$(#TEZCXYY<`$+!@9*0`0%"7*!0@
M\'!4Y%AP:020X*?8``#TQV8`.2B$`,!0NA:`T+>HB#8`>408,+#V%P0PX'!D
MY&APB5<00,#0:5!9`(3T(P!@Q$@9<#!8*(#XMP!P](>&/?"#%%00FXBDR7GT
M,P#P\+?V\`ND+<H`3T``:$<6_#J3Z,>C`T*..#!D#E="``6"]"H40!L>5K6,
M%"06C,^!A8/(`?M3AT`E(4809A)@S!,`97_PC%0PJ`BL`GC^\"%GH&$0E3_.
MI7N`1(@[!XG0$`C0P&/_$&GX_IQ*4"0I58E<NWK]"C:LV+%DRYH]BS:M6K-'
M##PHA0G`@9[H,BH298"/,``*>OHDQY,KN@-Z'\B]M`T5UT:Q]*)L9FYC@"**
M\#A*Q>PD2@("@BE,53E!`(1H:CG&=<H!7#X,!A213#F19<4;&R<293?1J2")
MDB'^XP!`@T24$*T1J.UV``,]A1@`G<@P*90#`O_YEXC<VT1\@LOZHY`F(W)%
M)?IQ8$`<(UA%^4@[@/BG8I&'N3,`4#0E@-@UI?&?G<H:"/25BP`"H/''&0$4
M$$PB1PR@`!^E3:9($7+I50A_*!D`C$@!1)2@`KRM16*))IZ(8HHJIN@''JO5
M_P&$7#W18ET^`@1&3G(.+N@7+K00]H=A54U4'BZ,@?@')>:4QMPB1P20@&X`
MC'C$*'XT$D`0'DEBQ"FIE'8`7(MXB&!E:^`!9H_7\=5?.8HH6*-"O#$V8B+'
M!:9D/CPJPH8`3=:D"!]U!#=='3?ZA5T=!72VR)T]*<24(L,,B4L??K7(!GL^
ML:)A/*30IZ&""/B1D@!LY-*-FE4J()MC+3X8`(*3+N+'&I?0\J>-S&TT`$M<
M&I'C.!1Q\MN*QAZ+;++*+JN(']8L@(!*%]H(I)T#,.=A@]82H*8B/Q8&@!"+
MQ`@=K8Z4F1T`B%2Y@(]^]N1I*?=AY@X`]MYK[W!@BO^I2$K<<H5=H]VTR`I"
MB9PQRFF&C2B:>C45,,"IY!C7S6E]6H<'/0L<(&V4JE2'Z#L_JKF1J>`I)ND]
M7M51A`,*<&@O9JQHJ\JA9"Y2QP#<YOSO;0"TV^B[307!0`+-`'"@5?MUM:^W
MR_'!ACWXXEO4&=(Z$TFWS&[-===>(XL'`P'8>Z,T>>E9;<W8&L!HOSIK;120
M"X^+7U>B&4R<NG]4"5#03?)Z)F<(,A.``@P<CC@#E)4VJD11U[A(P-[ZR4?)
MI\+#EYAS,X;WPR?E^2V?(*.DP-B:%"#-=(^'#%#H@;+M&<J)S,K5&=(\(@#'
M=5N^R.K9XORVOSU*;B?E?P#_(?4O!VB"X"DZX@*FWU`;N$#BB$>TQ@\(8/,(
M`W!_#7[XXH^/2XP&!($$&GB(,A?:%E_K8ND.TPAWZ(:)JTB,1=(*2^?DF!,/
M!)QF;U""RV>JE`"]V"167@'3+7"A*,TDH@Y"0(.G!HC`_ICL8%!:A)P8X8CG
MK4Y8%$M;GYH4'(8@X4S#4-WHU@20J%DB:#,DUR)HAPL\P&(!13C#&N33GH(M
MHC0)]-#\!L:SWP00@P`8U1D,](,CH*$.46.@8<IUG2/@@18"Y-.[4A*QKY1"
M0D40VX?(A\8TJG%K>4J$'^X#)#!93&@*:8"8%`(Y5,EM2G3#HAL1,)I%Y*E4
MG4L-_ZH00(XZI89?16@`@ACW0%I1HDXG:T!*`FD*`#"%=P<;Q2+FEJ2?W9!-
MH33'C\2T.C\L#UUXH(3'HO8G[#`&?[.STLG*-8S].2U7:U!)*MRC,D48ICTC
MB50B8H0/GO6(D(LP9(R,^8=,!"`8HD!`CXXS@#HP#I7&HP06@^"`'SH@`9=+
MQ'UHN<9TJG.=:"%'`VR%AD+,9$:YFV.3UK"+'["!@MC(8_'VB$[]+48TZ`JE
M.()C`"VRX0>&P!L?1&,@="DH``Y0'QN`()!'#@Q@ORA"'2BX"T2D4*$,%0!"
MF+'!!-ER(G-R1``>L$\A["(B$W.?Z'CB!UC`%`]G((<MH_\V@#/T)&"9((`0
M8KH+_'UFE)02G0`\6H<CC&1WTLC21S&:-/H$``A4#(*!$"*\1:30"'A8J"9<
MTL0SU&$-&'W$X*3Q3IXZ0E\5FUR3C*")'YPI>[]@@Q\HL0"AUL$(@F.G80^+
M6(D\B1B<D8LF3N6ZFEDG$XP=Q:$$4]?@4%*@YNF?(/6&$I<2P!X!$`*_AI&P
M<9ENM(\H3]/,LX]*J.2EI:B#:$EKVH>U3:73B0X?&5.Z`9#V`8X!75T3<;'F
MC$UG8UO>OVHC``7X(6!\.$4E2.L`QRPU94W-Y"]4DCM12D8:K!7`B#Q$7M*"
M1IDXNRW2<LL&=SC#'@5027*LAK3_I\@E&*]5FU[X$%L!-%8`^#N#?`DPV^TD
M=L$,7N-T$X!@!`BA#@]``(+8D``[]LMPISF"`@A0@'`J8`%PP["&7X&D(GAC
M,>.DF?;PAH<?'$!G"S@"O_*A@`,\CQ$%J6\!%'`$QV!8-5WQ@R<B+(33X`$(
M'")`C0/%``7\1D"4>D5R*HR&J1!`$*?1WH4S?)HZ<)@1K]!9`HQ0AP8DH$%2
M)4`">(H`Z/!!"!!V<Y(KA(#G&4$07<'#`SA4@,"N(0$,X(-[PM$`!`,Y4,M#
M@@,4;6/9C+A;2YXQ`1:=BP5`S`#ZU`DMU]"`^AJ@`9<;=';[16A7%>'#((;&
M$$-MYCLW_WC6M!8?J>IPFES?^$I&^J@;;TPKN/AA@(P0XZXC69DZ?(\1P.Z7
MKW'!AV8OH@\?);9LE&V>&T<;VLUR#!YP+1%=&XE?@JJ#F`;X;;]L>]H?!3:O
MF_7N/F/;C;<X]*F43>X#,*K=XY:WB\R3;D7TX<8!IQ6R_S!P(Q5<(M\V=ZT?
M#O&(2WSB%!\+)QF^/)I5?.,<[[C'/P[RKUT<VOK6>,A/CO*4JWSE'W^H`<H)
M;04PB.4TK[G-;XYS\O%;WM;.N<]_#O2@"WWH1"^ZT8^.]*0K?>E,;[K3GP[U
MJ$M]ZE2ONM6OCO6L:WWK7.^ZU[\.]K"+?>QD+[O9SX[VM*M][?]L;[O;WP[W
MN,M][G2ON]WOCO>\ZWWO?.^[W_\.^,`+?O"$+[SA#X]T/QP!"":7.EL+ZC6V
M,N"=T!:"$)8MEG7C04MH68,0&L``!Y"5:WPX0Q!`WX`*2ONP=>#\5_B`!"`<
M;AT]]\J<[PRC'3>J&H@'2T[#A77.?FT5]]IQSK*IEH)<3D%A*@L>'""U>R64
M66<0S=0$P(!B+5A4JT=#Z?`%I<9W!8R70)C'N&*AX?3>*[_7$-5S&3XA4*0A
ME$:P]LG"R6V2Q;;$:$`1C``$(S$`2&(L1Z`2(?9_0L``V$`@#69^TH8&[L!I
MDO``*@$?%F=_O"5MZ;=^[`<+[C=UPN?_-3B40PB&>5]1,HBA?V-A&`=04'@`
M%">X%O'U,S"W-RJ!3HG%?5QA$[%0+&O@#AH6%F&E(.<G$1P8>'M`!TNXA'D@
M1A\H&T>P!GZ`!D(0!&=`;%1HA6A6&4=`12QQ*548!$5@@S5A>D$@!&?`+WC`
M#A9Q?X,5!$&`!L0657&(!-^3,9"7,=I2AV-(,[2S!EK4.UZX"!ECAS((AQ54
M&4AP"@NP0A)!?IZ7AM;F>5I23AG#&6E(A;6@A5=8>_D04A+12P*`/7?8*(*8
M(.IS!'+H1FM0!'%(B,+41'#30CU2*Z]8!#0#>VAPBQ9Q@CQEA9/8A5-X!E:H
MACFTBA[%.%V1_PGBL0A%L!P_^(I"0#-)I(']8@2^*`KJQQUGR(51>(S>(H5J
MMP028([FB`)/N#0)`B4.P#U0T2-XT`#<0Q&Q\20-,%6\P08+>"\$``2G<0:`
M="^0@!@",C;V4@#\P0?M,)`+4$Y&4"^/@`"=PR<@5BQ!0%%D%I%(\P..P5EB
M@R0/P1]2-9`3^15"("U(XP!T<9#Y`HFC!017HP#:\GS11P!!4`KQ<"\\@09-
MU%:/0&)=,0Q=9"1((%3;<`B+(#;:(!*C9B]S(8_T.!,1`1OC=X5PD6;TJ`Y^
M<1P'<`WV4CCWEPL""98*<#E/H@`/`98K^2;+8R_/44#F00FZ%(53*/\;]7`O
M,.$7_E)^*P61]Y(`=90+WX>0R1%?3_4FPD619><#$!`!CPD!'K!Z[;<CFJ``
M/_!]^,,:_?<`E&!2:^(,#L``ZI,,#?`#"R`0(P*$<O$`G3DV^#`;!^``#P!1
M".('&"D`"_``Z#&+^?`4@<F;[6,DE/`?@+0NAG"9#S`29[07Y?$_S;2.1R`0
M"=":SB5^T`@E/]`:P@$U#"`-/Y:#-?$4"^(`CS8*/7$>2,,`/R`:I94/!@$E
M#8`FAB``U,F/?F1.P006Q:&4;B(9N>D`0.`'IT``IIEH,W$)I3%#80&#%&&:
MK?%2=D*?]HD-W35![]&:"H`-D8(;T869AI#_'*MY``_0``.`#;U5B$]!@%S1
M'96PG@=::.*)?$58"F=@#]2)FMB@?L0GFYB)'(D`C3/7@_A)=CS@F)`IF>SG
M"+&!!(^`/^DI701$`&527<*Q)I]Y3,+1(TXQ0T60FY<2'*-R)XCQ?`D)B@4`
M8V(C+A:R`%B9``;0>*+0IAP4&&*#D[*A*7M1%<^9292A0P*@(WP`!%`!;+41
M!(YAHTG9G..G$@A0:JR@#0HR`.(P9PNR#(O2(*6!'P^D$"C:+(X0GEPA/XL0
M+#THA'5@`%/Z)@*!$.Q#;-$6;7[P0-"X`%,&.S82`!U92\*)"T8079>B$$!2
M)13B$XTX$5)V,.Z`_P!<T2>[Y14!Q(?&N1DS5(2,<!_RZ2`ZJANYVB/2V3Y^
M0`Y]$1P-F':-^9@1$)F3"85_T*2Y@C"-<T6%6`0(4DVNLCU(P`;YND^GX*=3
MM`CR%R8Y\U)'63FE('\/0$7Y&E4=)`HW>28U\6\O&48GPQ2D,H>!HAU9ZIQN
MH@C!L3B%HZ_Y&H$]LPCQP*LG4Q4DF**Y44O#\4QCX@B1P3:7HZ"_D2:=M8YB
MQ)^*<!\RJZB,L`8%Q09/@1`6TCB*@`0(<`!*BP`($`RE@V8A^T'8-&67Q7#^
M6B'SM"9$N3=LP@?2J@B="FSXY*Q=<3\)FZ^9P!1\J8%X,%HPYTX/,Z5HN_\&
MI6,PJU`XSB!^17JNCYFD1;:N31JE'+2L2?*SO?H.$^0.!B)<!O*:_;**G6D/
MS1<<CU``BN,7P<&XC=M/>-"#2".;0>85_-H?A[L&`*AFC[NHPH(DI&LAFM"X
MPN56$C$,T$1`40I_7$%^BR`J\D&`\<HK-,N)=J4U?\5'8;&S^:D1,YM#:%`$
MVEE5ZR(C3F((AF`O:B@-`F"BC3LVK9,[/3)"?<8.DCL3>L$N)<LF8:4("`1L
MEP1Y7.$(FZN]V#`J1.A)C#-`\C<<QZ$)VFNB`@%\RO$(NG=V/M"W$1`"ZAJ=
MI$2XA@9(B^DS?4,="V(`!8`Z%\P;@JI?N",7I5#_:2TY?01ZP19<P03"!@YP
M-(]`3EV!ENSX)UDYD*K[D1PK)90A?S="PB1\`":7NTAK2ST,01FH1[Y;/K1Q
MJ^?01&+2E3UG&-SH(^/X!PW3GS+KK`'9D@",$,?AK&@2M$B@$G?8#!8LQA7,
M:38U059K)$,QD-AP5XF+.:P2ODT1E]`&"P2<(%K$&""6PQ8\'&Q;K0_XC%8Z
M(2-L`&2L([61*VHW!V/`R&,@!FX@1DOZQD-4"TB))+42"F[LML#@N9WLN4"J
M"0OP`VDX#`<023P%!`M@@<^'"I[<R<@65;2IK3P(.Y#B1J=0``W0#VAP'RE;
M-ZP+G91A(=[CRH;&%?J+_[BLHJ=]]K:\6T#!`IV\@5+">[2ZTG-/LJ"H,1!Y
MXS#!8F_]T@P(\``6835)^;6RDT/-@(4%X\IX8,Q+?%-P@U>Y^0,])']GPS>\
MF[ZC52Q/4LUB]3.%R@KB(AID5<QZX<<=!,\IL[]^HFSM+":#ZJ1^1YGLRL#L
MV$5",D1;MCYN/$NX<`9<*!H:$JRD,LK-,HIL8"$))*^\B`:<T"QXE3:X<$5@
M>WS:<LY5P5GD0$N@HB?9S`@>86VE`3FG4!Y`C#,JH2$:/0P27+J(D!G4K,3?
MRX,CT5TVF@V)<<C28`Z'IBULNJ6L"LH$X##]\A2(,"\^0H9H`[XOA`L\33=M
M#/\TDXPESR,=S?9$I"@1,4(`I]+$N*#2P8`'.M.7I(!2Z`*N5BH9!(@$HY<@
MPO40JLIW%2VXE&P+[/H+HBMFF@1#S_@+1O!?1[`H".$(AUH37B47?:#%@L@'
M#\(3E^0`E^`'^\C9%K+#8Q0C<RT1<+(<?@%4:CC;UJ73ORP=YA9C8T,9#\47
M=GG<UL1P@!3;->&EF*2R9CT3O*AXNY#%`H%[AD$3DE$F*VC-78%7N>IPK>T.
M#7@*R.IG8T/%Y;32/5%ZRVDP#3H`0.!7C#!8L,!`3_)4Z&D[9[30'^-/H00$
M/8$'7JJU^>S#RGS/MBF=GK08!/H:C+!DV``:=1$$Z(G_!K`@+GXLX=(1$I2E
M?N&!!`KDI00@V",AH%<A@W!'V1>]@WZP#]T@<Q1!36Y<$]QP``H@D!HVJ+6P
M`-*P"Z``'(9P``M@?:`!C96@`!^&XS4!"_698YJPHH$""YSM1I0P``GP8;\@
M2JNK(!218P3@'P>C$EU^XWK-%4A`7QMC"#\`%TAMU@(&(0(IY\>$Y"]##!%Q
MS@:PDCU9S;A2>W[`4,3@Y6X)I^L[-@;P,F:>U5[M+?3EXP*!#?\A3P.`2!"&
MD'>VF=T`+6,3(7IR-F=<X-*4Y*P@$#-$/)6]XXB>`'Z2Q'U&"3/QY/7B/<(T
M-C^6`/;@W""N.B-Q:8`$5Q,T_Q("@$C+DZN,L-X]40<L/MD*,`#W-0!.[12#
MNY!'`R5E\B"VZV?ZM2`_X!<U:2\#T``!J:K?7KW4,#SZ5NX*@"YKL`"[L!!V
M+"DZTSF#9CK48(!O%DT#4"=*L>M'\``#^";23C8(<.5(NSV6>Z>8(`!$NA'I
M(9#4<!I^X!RFH_#/:`\1TTN#JPIN]HD/1N_.@+"T,A2-3@@&_[4%`'-&P!&U
ML'@"L#]\,`GT3@P'@-^%^`/:3@!LF0\%P-(7ZMP,5X&&4.W51P`(\2!.;*/?
M@1(E"I2$M0"?^,%@R1!J,F>L\`CF?CFH2A.Z,*?O*1`4Y:5#P@8E:CKG8[YF
MKBU>O/_H>T=%ZF8KM+)/.70&4IAK=0^)>7^43WP&EU-6888$1_#WA6A!*[1K
M:X`$Z?.)@;(&9<@'C*]6$Y3?6Z0F484$R_"PD-_XG8^"@5CY8P+ZCK,,9[#Y
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MZN"AA0?(CX6'ZBA,%+#.P4T2!?F9^"<@1(/&^*!!P^8B05Q^%A`P<E(0`P)H
M'OE!$A.4GR-K$*$AP,#4&I:)ZC@P$"#``2`0!:%A4("`@1]U"C4\,(!`@B*;
M\!PXL/`,3T%%"`01Y&``DF)K$@@`8"!J2Y0(`&`]Z2<!@+..A`28^PE(`*"&
MS@!(8!+4&@(+@L8-("`````*(!X9_P`@`(&U!W(*JF/7,N4`8S-I1=!UL*`@
M`!Z0)8!7F)\&``8D:##P[2T_<?G^JQO@S"/8NCLM`'`$T9D`A$D=`9`8T0\`
M!Y`L4""$\M@Z!B"?J;/F08`%_?PP@(X$#QOO`S1CP@,1"?)^0`#\$,0'3^%?
M?0[\]7/?-JG^AN`&@!"#\/?'1A8=XH='A?#1#WM2<12@1/89DI!`B'C4WX4`
M%K*@A(34!V*!`=4V2`*]=32BA[`)41B#CE1DXH'#&=&?8,D52"$B%R9%R(<^
MW@29@1XB$$!Q#33P1UBJ&<%64GXH($!,:%BF7I0"`.;A024.DI"/!PXBF`*G
MI:;1?3#^R/\EAHK4MA&8?]0&84$K2J4?&B^N*"=$1':I49U_4%@8D?-X`0,/
M/,@@PQ2+Y*84`C^<L4!3"K0FB*1-/>76&0@4\4,!!@`E'0%./<!&04(D0&H!
M"AQQ$!]%J$K``0^X)<AY5!6P0'&#U/$#558)`2<A9S`U@*:#X!&$K*RVYH<1
MJ@YP@`.:U747$`<X]=`A>#!`60$(U'2>`004P(!OBAPQ*:D(!+$0'@M\FX!Z
M8KY''[2D'N5C'4`@L.H"Z`IRA`*D&M"`9D$4`(``[09HY%D,*+G10,_-1T@1
M`_X1GVJ$L('&L&DY(%13"?AV!L'FNH6'`@LLA,1@_:!F<;\!H]'_0*8/J%>'
M`@S8W%2G`*(!*1H$\U33'T(+`40!!<Q5;`''UHJ($`>L94`"-:D+]0';/JHT
MTT6$+!2I"OB&A*H%-&`K'JD2,`"KK@H";\OT\`#!W7=WT*&`<[U,JF5K#1"P
M$8$3X!@"43E)U&4V`E'X6@74Q`=L`53EV%\'_N"8Y0"0II3"`KA=&1`/*E"9
MZ`$X`"#AL1G>>53PGNZZ`'@%L;GK;1V(HI%5/=8`FME5=N0?:QQP>N"\'E+$
M[6L!X$"@"E<F0,!BFA9G`[<[EL"I@7;V-P`P"<(ZYP7DY(!CE3UOR'-81US(
M`P"$-@C&SP]W!!](`!'$&3,64J4!"P`<_UNJ$SK'+&`@=:A*:100,_D(HD:"
M0`(!%N:Z\FU&``)8W%KV@HCE'"`[EXD-7EY6@,H)@$"3H:!C,G,(S3VF*+X1
MPEH*.!BWN,<``AC`"?\7P!`>@(`39,Y`\$`YSF$.>@6P53SL%H$F0L`#>W/4
M']RCG3J<P7@]^0,;#)>S.B`A.T#X@Y-2PQT\("%T8<,#&LZ7@(4L9R42X11D
M`G69(BCDBW+I"(H<@(8ZL"$LT_O#$8RRG3H4`8/T&L06`]#%,V1G/D)@RQ$D
M@D<EX8$H0HAC7,+X![L((`AL8(-?!)#(`ZUA.#_XV!^&DP`D<,<!X.->(>I@
M.""P`0]K@`T!2O^"!KL``0W]^P..^A')`TP2#Y)R'GR@4\@C*$PU?-"/+=5H
M%]7PJW-]C$A<,&C,I$2R.8.`#0-P(X`CH.B%"U`B(="`&5>B(3L".)@A&1,3
M6A(@*B]CX!]0PS'[=20[/4.FZ=JH1<H88)*GA$XP!>D8.";4<\<)@-K68![#
M'<R,=@&/(:Q(E"(`$PT#",`/*'H$XZEOD`"8J!J+$AUD*BQU:S`D(AD*1V3&
MA4RF7$.'UN$#"#0Q`D^,8AZG6#E9.@D!#1SG()"`@#`ZJ0!)84``++7*%)VA
M`5HJIA_6$#H\74H(.1ED%@<Q2"5A+`&V,D(1AH4:C5ZJJ8)L0/(T-D?_-@S`
M+`=90Q`T8Q?UQ<EX<R4$+.?"U?1XR73R(T0='O`#$]DU`)H93V"7BIR.9(M>
M6AG`J8S0`.K!LB=X**&-!*'7K#%'$?PBRF,,((2!'"8`0+"(LM;"`#XLC@`-
M^$$#)DA00[!S>(*(CP'XI!_?))``+ILC72WFSZ,F!3M3+2APB1<Z=0JL,LF[
M9(K\9JM(*L!$AYF2@HRDF>>,%6G5G2+X;%6EZ`KB.5P11'X"$).K9A4Z.WT'
M$YT(Q43P[;HY$F8`D+I*`&@I3N([K=R($K$D)6F3/^*.NO`;S=@D(%))89^#
MDR15`X@$<@L0`C`3,9X#@RDA:S"G::PEFP>4_Z=`=IGK<*@:SJ%B[+QB!`".
M/83+,V@.L@\DCG%,LX:[;K@!#E#87%%LA+AD<3P,<[&/E@-.BB@`7)4AT!_T
M`@!P%8!A.KYDY]2SDR/ZSS*VBL]8K55/4BVP@?TT\!]@F=@YQZ^@R.V5VZPK
M2.CXB,[J#?!X@@.<0\PW)GQ`T5RM51SW),!$5;KG(-1<(",=+4X2'LX!%BH/
MN^$-`GKSKUWZ%@!]*F7`_$'1I0GAI+$F\#&PCK7ZNN.OYD&G#U-4;64,@)0_
MP";6L8;JEH.XL*L$DS?4*\0:')`M]%D/#?IY80&DUDD`4,^?AQALF3A6KP"C
MZLJ->8QX"SS92U7V./_`CO5<;$859V<Q+>BSC`.X1^5&)(EM`<B='X1`E'P+
M`6,/T,IT@YO20_PO*?&QF.Y2=%Q\5G:Y02Y.B0LALX(*6VZDXG.]"<%/]>)4
M$':AZG/J+%_]Y"2:0";$Q/-YD8,/HF*53A'Q?E!K6!,8'U@(`0IV3@(?*.*_
M'B<6JG$C<T.T6L^?+(+2EQXVXF4G``4X``/&<W,\&($!./3=:U+*]*7?[U9"
M(-CEM/PC(R5;3!,4`+@:8#I3F[$!68?,0.QR;2$?HM#[-!,AEN-MN0W',@90
M@`,P6!-L!\8TQVE:UY5^JA2J'0%LU[&7CO"`N!-TXQ%Q2Y(L2]]DK4&5\!O_
MBP)23E8%GQD!)JJX1LQ.QSP/,^\6D^P?)DZ(C07J;<_-^"&6\_$RS6=,!XG2
M70H!:`M9^J^D=XF<\RET!-0>`)P\T/'7`+I935VA_B"4?Z7(_'H1>#QD[P@#
M&GMTN1770[41)T4'HE4_L$%E:-#<`*[IUV3)C:('LB+5<5V(%A4DM[%#+7@P
M$/&1`)NA&;@$!"$5$RA2=^5F9W,Q2-X6'TIB=/GF2@M19*04<4-F@&R07C\R
M$'Q@)#E3(9^5?PBX!D)@.,6!><IF`/&U>0+71T&@)0+G&]X16)%4?X.P!@-F
M(@E7:=9V>WGF:+ZG?,7Q'-P69`1B5Q='1_.W>_GF_R.PP1+=)PBPD5C6<F`:
M<2<'8CHV2!1F,R2#4"4W1U?11W1X(DX?,Q`8<P#Y11=2Q'O-1TR=DQ2H01CE
M1Q;,D11\@'6^\3"*9#QPN!/Q)3=?YC&50SU&4`"0-`"_0U:H9@C%Y$UW2!1'
MLP;902::F#OTX84-2`B&UW]#M4C)@QU#50BV1Q^P-&ZC*'2$(7P/P'_=,R]X
ML&=H)WEXX"]7HFA]5F4%H3"DLWEZ,5R))TO+$U_'@5:]HA]<B#0_.&D.I!&J
MUGJED1Q!6&!6"'7J<08+:'%)<8N29@C+P4%*<5>GPG*#8`3Y9BM'D$.E%"?'
MEW>]M210YW"]=QQG^!QIR/]Z@G@KQG.&_O$CHQ9!9'AJ!%8'QG,5E-<8++&'
MQ$,9""`$1U`$II,[5%<$1Q`$P>-A6C$8&FD$;=<'X@$^#W`$1S!XF/-;#&`$
M2,!OT,<M<<&0/^"0PI<`1G`$0!!$J)=HG2,$2&`$P^$Y(2>*=F<(L-0J"_$<
M!/`#%4F(P^(D!``$%7E.G3=[.O9BA?!Z@U1J1?"2QO-=(P@9.?D#E'%:)6D`
M08"2V),[)&0$\6@[W[$54A4`!(('=H$`9>F0]`$;!Z"111`7GN-;1G$1V:@[
M0]AP`F:`L,>!?'"1:[DT.M8/'_B$]J1QF^.403!!''.%'1$7/W0$/S!!/.@E
M"##_;JC8*91'&9SDF?IHF-,H?9V7D3H9//'%!__&:;LQA\IE;C=7/"]4&3_0
M#Q`I2-$#:P6`%VAPG+%1%AMX!LP)'36Q,\`F``]0&]41:]\Q+,1C/)51&=<Y
M16?Y&`1P/I(&G,&&+G1GE`_(CH^!%43D;&.6(:8#:W.9,?MT.9/U>GX0!./Y
M&`B@&:R#G&VY$&P0%[%&`+RR18^Q8QUQ/K$F`$!0&\L9H1.:+%(5:P&J$X4I
MC0I'=,:E0(&V3'&VH';QG=MY04]XBU%(CFSAG97!`.UA/3V(H"_4`-R)<D?S
M3MKY``>ACDK1.1?!CP5B/%3"G)"H0SG!HGQV$D60,[?R_P-:XBNZP38,('C)
MLP92:@AL$`17R@"91`A:N@`+,%+/\@/<TZ73P0!V5!`IJ0`*$"G^\P#3X0!&
MH)L=(017Z@!QHQ0/P#*V!"M0L1E>RC-!8"N>HD1&,%(\(@1DBBY\\*9@RIUR
MHZ>"AP0BX925RC*K%B@_H!MH``33T0!K12P.8*@*$02]EJ=7N@![12Q7&@3]
M,1.C^4.)Q"]DFDH6<@1LQZ:42J47X6,!XP>)VA%!$`0(]*E^BBZ4IQYX4`1L
M)U?A"`2MY27'.BQ4YBL*(%>.):4O4@1[^G6(0*R#VBN%Z@!G<!%LL*6]HJQB
M(J?S4ZYCN@!`H%.><BIX\`.>./^0_(H/[C.NW.""S-`A0D.I_7JP[:!TYB"P
MU.`'#E"!"!NQ$OL,=)@-8#6Q&)NQR$`TT:>Q'ONQ(!NR(CNR)%NR)GNR*)NR
M*KNR+-NR+ONR,(NR>(H):'"Q@B0LZO"L?=H(,\L(=7`$0D"1<.(':%`$0AL4
M;?HC/_%O7A6S3BL:#T!RG``_!`*BZN"#P]4(ST(;E+!OKE,9"$`]1-0\`W9V
MU^-><O,`X_D=3?JT;ML(D;2$GE!\0F`J.?L#LMH(=I6UD^">"?"P(%03#AL;
M##`4;*%.>``_13>X`K``#N`M@V&P;SNYAM!QH4"U+<%5'C8)*+>JG.$\EQ(Z
MZ/*Y'9O_4)71&H65/-`I9Y3[LDL[2<DR$OMR!FNP;#JV'<GRDAYE$FMP!NP!
MM$9@775@!$*0KJ%'6OQS(",1*,2KE5Y2M$W7NPNE1K=D!,&+-"/6@R,F$C&Q
MM+Y[*]]+'VB`NQHQ$EP"M!0I2VQ`OF68O`UBOAUQ!J=2M#;+O):!$^MDM,YK
M"-1WB`9)8$K8?+51!)2Q`,;3&H0#L>^E=ZV[LGA0%K`F%D,T>@I7!T:R+/89
M&B45;PJ@'M@#!*/W&`60/%Y[H_X7)9U7!TRSF2^D`+)4!PO0/&)!%;*T3@)P
MI8\1<.1B*]%D6'9U`"Q<&>FT9:E3AB&E<&<@`(^V;R44P2Y"_\3U5V3[VH/2
M,A"#Y+C-8YWL%V^/%B@,0+8(0&,]F$AFB&NF,U>AI5F"\`!_N3)HBTLUG'=R
MV\`FRP?#P1.GVA@6D\2T<R"PT3*?`CX)T(*-@0"`>[C*ET,1HS!))#Y%\;=&
MLA9C8;6TQ!@&X``Q7'!Q,AR0N%N-L8&!P1B0N"MIO#95DQ-%QAC3$L*JH;D0
M$4E"NL!-4A2"=S,+T[T@F'<.JKD#X208)'@H@CE'L$T(X*,K0[B&&SZ.`#_/
MHQ6@3!^AJ$40L9X4$6-TK+++X\)E"#6:(5SS9$%RS!^7-`"C]:#3.!S@3'UR
M)G"-%2=^D3'(1D=A)@AZ(6GN00#H`O^<:AS*=IDL4"-+`H?*E.$`"]&?3Y)H
M,B=5.70J(]@;*)RW6I0=H1%`<V$MP4%:&;003F*70S0>[Y;1],P6-=$M![D(
M[S@`,5'*A7#&AF`Z8JP1SS&8UVRR*7$D$D$AF-L1;2=:@Q"W$<2V-UT'()6U
MP]&Q@P:-?/M/&>.3QF4X1T-+`G`J\-.Q@_3,0K>B_^PEIZQ%\*A((DJDET0`
MHU<<7"5L:X`$%R%\G(0QS<%5XZAL&=3+G6,B%<O+0:8;6[3/Z1)2H9'&<<S2
M/S+6X^H7@C/3*"MF=^4V;K,6$+L3CZ$Z@V"YD50YBFTY&TA[?$@@3J+`OG9G
M?W!\BHF(:NS_THJ%CH?PFOXL`*:\@:[<*R):)0;(5=1A)I&DP&RPD0YP3IQD
M3Z>"&DK%OP(07Q#9?79]259M+2_=TXWAHQBGUT%&8Z9CM@_,&,]HV"$;6N!#
M*MK--$LX'%9MN?$1.MJMW2PD>S6&%3OX/G<F($V=9XBHVG\P>I826E%]VI,H
MVCQL<ER=U,>U$-$4U4XR4@SCQD!1!PVPMHX1?<#!&]7=VL.M7%RU:1V1U80`
MV-RB.9]T$0$=(O-8(-'-I>B<W-;]L<;MNQZA$',B2,T#V=M6)FKC$>PQ)Y@-
M@3F&8R<<BJ$]X:-]E-1EU=VFX13^3ZP=UZ[MWL]1!.=S/^2R$U'X_X?@,WY%
M<#(Q*3`!P`!ES9UV_>`X]8%92]_TTM!FVQ$]Q(6CR*0>\N'K%)"=.N(BFQ*>
MW8.P&RCZL5O39;G'D=1Q<@3IBI5SY7]7GBS94;6L9T_AF-7/47_+X]QE&,N(
M2'IVM8%<;B+]?6H,0,.S)U'?T0]E[:S&$WUA#4N<+:8@K>6:#M(%%GZ%%<=R
M8SH'L.:K2.427@A%V8,`U;9L_K'/4CEWJKSZ41Q;%QFV4P#<@QKJ\Y$-P#WY
M6FH#`4&#H&T^2=`=X4*A`=HBBM\]OE9XX$P+H^J+>1%C&9XD/>3\7>V[&%($
MAAIK05BAHQD&_A@="S^-\8#4M;E:CM$7M_\\!;#G,%S2M8<<.L4'``_P2I%#
M<9,6;^[A0T@?HR<R?A#P`G_K(DO2`\8`"5#`"[$\!'!RPU%;2[(P"W`6[]AE
M9$H4Y:1\6@)+6N:-T%'IH0//ZYGC?DUP^=9OC!&/KR>-R+$`!M`40&;7FU'M
M?_`<H"M@L8&`<8$8*K$P0W]J74:I62YYI8=3"80<810[`L`RC+SF#!IU6]'U
MD<&'2ISTB',(U,Q0+]KU6U&:$*^QB1M$E:,V3D?.M#X`Q:&0CL$QPQQOQA1.
M)3\(#Y`E9!5M`O`#WH$548+2_Y346M'(!\*1W"0$33$L(&5J<M,`S1,=O*A%
M!"#3*IS4WMCWSDS_^=!V.04`!`3\7::IR8AP&*BGX@J<Q%GD!][Q)`]ZELBQ
MYBK>&$6A^_>8MK;?P8CPQ0'C'1C$&$51%&ZU]B'[LSD)T+4[2S$E-RCIK&B0
MDZK4*_B'_3YB1CBQ(-G/!FLP$%N52+7;#W[D_>'/Y</"!VN@ZD2;DP:J4Z84
MQ\_O);7K6-%?$&>0DVY1_LG2ZX#P)SA(Z+>V)HBW5D?(MSC(=V9T1KAV=(3&
M1[BIB';X^:DY:&F4N4G(MH8W6'?H";K&=CI+6VM[BYNKN\O;Z_L+'"P\3%QL
M?(S,^R/P0_@#P)`L;7L4<+`ZG:V]S=WM_0T>+CY.+EP=L``$I!`@<%0N_\Q7
M]%,0(`2/GZ^_S]_O_P_0%A\@`P`8!$#`2$!<?A`87(!MH<2)%"M:O(@QV1HA
M/WX88921T)$?12*&/(DRI<J5+%NZ?`DSILR9-&O:O(DSI\Z=/'OZ_`DTJ-"A
M1(L:/8HTJ=*E3)LZ?0HUJM2I5*M:O8HUJ]:M7+MZ_0HVK-BQ9,N:/8LVK=JU
M;-NZ?0LWKMRY=.O:O8LWK]Z]?/OZM>H'CV#!=0CC$85+<*$U:.KP4?SGL2C!
M?DY2/G8Y%^13@4WRRNP/]*G-TDC_82PKGV1:CROO$LVO<UP\"`H4((`[=T+-
M"1"`9+-@0``#1@HT$"2$P+T_#@I0"MG\>;$&SO\U*S``DL\1;&@*1--5YYV@
M!P203`L?K`$!Z9O\*#B0FIB?,X@B7T]=)WB``O'+&2$0!"U!$%"$,@2(YP\2
M!3@05QT$`"```0,,@-N$"B4F86H.0'@``T<0<-P?0`#0S!\+`(`@1@T,P-XP
M*[;(&@(&R,+'`@2DA@8!#+AV"QL&).":`P.D:(R/"O#8BWHP)F)``/41(X0`
M!?Z!1P(S"O*,``=`E$\0`#Q`RP,`!+@+>43N<P0`"\PFW!%UO`EG89H5,``C
M#050!!]^\"&GB"0*<N*9%>'A&&:%:E9'97AD*(@??>)R!@`(N$8H8L<@`0"0
MP%3*V@$"/.DB`!?^\6;_9>Z-R4<?^G@)YBS/D*D+I_^DN29<#@:`QBU(<I+A
MG@@$<,:N?I88:".FU=*99[.X)ALDA\WRV+,,'>ML+X)9R@F=_7$VV"9G!)``
MMG\(VR@GTM82:;BCX4%N8JOP8<"GFT3+F6NK#>('`P!,V5X"`9@WKK#M.GLN
MM\H*TMH?0GP9YICC%ASPP^3:2RV5$0U,RZ[=BJ1FN9P9C'%09O!`,LE4V'+K
MDHDPP$!$?#2P`"-XT%F'$0D(`,`!"GB2`!""C%BB`B@*4L</M16P@!$#XU&$
M`K<9P(#*?Q21P!%K+%"``0\<)D1M"!3!8]$(X(:``_']H,"3>`1Q=-2#X.&`
M_P-')%#``^*BC0@>#3"PQ@\'%("`$/;"W(J_`2#0,AL*_.!:'4$D0$`!!S20
MZ]0'0-CS'X^C@0?+)J&AP`.J^H'$`@8`#L3!E@,P0`)D^G&$TP4H4(2JM`"1
M0.7S,6";`VO$^V31?WLG'1\.++`&$'\?$(0F>A=DP,Y^'(_'W`4=D$`1"SA@
MZ>."DFITY`<\$!_5ESAM@-F$U*%\`56SVG`0<Q-PP`\@B;C`&5C'+$0"E/1Q
M/#0`86P(",+G>.>=Y"4`5"OCTBA"IR@A.(U^#*C<'VCUL]P1XG'2P4/7;*,`
MI26%!Q`H80D[,+!;6?`4=:#0_68F`%DLJDX_",!!_O^%J2,-"U!#JQ(``C``
MG`4`5IS0%Q"%PSJ5/8,!\2K(EVHH`"%.:0V7.Z)!#@`2H8D'#T)C'<ZDQ*0!
MU$,`ZMJ$%JE4CR8%\8=DPD.\V/`M@^P'#Y&:%)42\,,)&:0`B'C&0=:D+R/P
MP2$I>@:8_%!#""$Q`=L:ST&@,:Y$KC$`W*/%&?]@A(((`'H$D-<?T&"`/'YQ
M.?"R!A"%V(R9W1`)?*@'&[QTPR`TR8*+PM4LJ"C**X)$3)X"HD$0@`T?`K$=
M#FG5*<2$``$,,U,@6<!PVE&`.C1@7Y$Y@"FC:)`275"3!;$-``!&B#[@<51^
M8A`>3M0.)[)($!C\PR4%$<C_1`CME#]T@.V,TH,(Z#,"$/``R@A`274$`0A!
M$$(P<1,1&,J09G5`0I.$<`8\("$`"O@9`'QFHJ$5X7!(2`40`D"`^Q&B"``H
M@!'8$)X"`*`!Y'I&`"K(O@``40B'.)&FIJF`,[0B"#B;TB7%5(`BM,(!0,R5
M&P%@`/HP4!!",X\JE9,*?15@%6Z,8?6"6(H_?$M3SSC`$=C`AO_\R7'60`(B
MXKFP6E')FI0PPGZ*$(O2K706K\Q91R_8#B#$(@C"X9<9OTFJ>C3@$,F!4-Y^
MU0"=KH&O`L@5'RXW@""D8IHA]0/H2!11>%D5"9<+0D2?H<TT(4!<?\"I8J,D
M*D<&_V"P;!!"02[T#`-\%0E=-.8FQ)0IG1XAE*TZT0",P)C24O.QK)/L&HAZ
MH[6J"0VM+<B_9D'2!=C+FN]8&'%0>@25,NB"'7/GT`8Q385,#P`*^"H;BM`D
MOQ*E!Q#89S^7]J!'&B2&1'/AVPPP`!E*""2_JEP.*P,T'KYC1"T;A!`,.HLC
M+"!%(TI`PPP0S,L9$PW6Z(,?@H`\0@@M:("M0SVDXX=I@NFHR[$D8%59XA;*
M2Z%HK),@OH4`06B//=,,T58'$4\VV/</$[V&'VZV0MIXTEO@:M2),(H<29&6
M'>\P0J80LS!Y52-$@]@HF(B+Y)D!2Q#A99(GV0$P"E^#R_\7A1:&085'C"(3
M,=-,9;P0Y&$`;/<4STBN("8*X8S.6;@%ZL/ED.SA+5<#F%66*3C7QRBM#F<5
M1EBP,\C+SNZ>Z-#Q7,,`"#T(-)`Q9#QAKWL]D$*`,J`CI#8@T7#S0FU1:;^1
M^=5S<FA18@7@'=5`:@-.FHO`K$&N#IZ%F+XSKLLAB,*C-=8:C!!*GYWJ'1,M
M]B`F"B3-+E7#)R[`D!^[8OPNE+Y:S122='T$A]CX<**(YQ_,+28PM7``#GB`
MN]U].?6^&%R5<=``0#7#1F;T'1LJ\1]T+"\QA>[=#V"`-?CPV"TW"H^5T]>4
M-)L:?XDGX930\@JAI8CBE/D/8M+_Y@[7<'!"B+AA>Z;-ED]$SFD6B.+X<O4?
MGH%D-`)V%@YWY)XC@P<VQ`[2W*W5.\^=6B>/S]WM%E)^'46HPJ@.)R0T(010
M6`L51AW5]Z7OS%Q\)__R/,#[CLPR#C(`1].B;W13ID%T2&>&-<J:3Q*S:Y#0
M@+'AS"`8!3,F(5F)X3P&>+8XX]5?R'=IMQ@D,'8-&AY0F[G/]9/TAF=J[QX-
M-VYY#8J7K\-.D2Y!Z#C/D+#FQ9DZZZY#@N_ZLOP>#\/VEBN\RU3BNW>E`[]J
M'("T+XY[)P^BYLO'FKL5W:#:TT[$KA<+O-3T0^H'X2]*B,G??,#CH45"T;4^
M5Q!K>`#=_YS(\W9.6N2IA:7IG?0?W7B<)U3P@`="8'X>A-J6M'`0`1)J[85B
MO;]W)B^`_R3Z3P[0B>Z817=^2#\*(#2:`GR=YR299@V5401?1$')QE2`E2;`
M1GUZ5U7Z-@AV=W7Q(7@5V&*I<6,\YESTLP#B]F*2XAKFYGX-90VK`'(`4E`O
M>&#3ME65H6-3U0C']U?O,'P(0WK04%!"\(-"H!`)]R19YWA34E6(<"K207G7
M,$W!-U(,.#D.^'*ZMT,3U7N#`#^^9H4991X[R&?5=(`+!P"4T&\W.'VCH2T4
MQGG_!U(=@D>]IWW?Y7@*X26N`X0']H-X$'ZY,7X\X0>!&(BW4/]+4F-O]V-O
M^I5?X^)R/+9U^%<LCE`9?*!S>*16A*`O,+4*#48+KX(OGH>`DQ)H>O4L0J-L
M3*9H8S8(3G8D'%@+?D<S59<W^)4WL=AMT?8K#]`8FK`AXT:`YC9>0I!NI[:(
M[4$+Z:(H\;)"EN9BI[!]8A)S*H8('7<*HH!M1<AP9'8A$/>`X.0>`8!L0[8)
MHZ@*FF"*CD1$7M(,E,=Y9&9;A"`F5-9Z!PB&*O<'?C:&XY)\?F);+92&QP0`
M'"%GC2(TE",GSR"'';-L^"(T"I$F68@ODQ@G%9,44D<+M01.0@!$\F<GC0AK
M?H)1Q<)7,<>*U3A+@\`&E]-K!2@(^-C_=@G(ACQR!`51=SW4)*/"17_"C:]8
M;<4HAK-H=;9X8X>8:0\R;C%6A\\&+DWR''YP(I6T,@@@@YF"8P,Y",^0`/=$
M;;0V'/<S(O(R402P0LCF,WB`@S]6AMKH94KH?(2@D=:$=J?`AHAQ!#B#49XX
M"`%F<B6V!@_RCH,@)@3P)!LU>_D7AL:7CVA)"9HFEHWB4M_#8TL9>F@T9+^3
M?9*V<9_T6O\&4.2$!I.S=$]12Y^'+R=R`)/P`P!E=:RFF'<6?3O4==4@``^`
M!&>`7@')&4)37F<0!"IE@ER(9$0X"H?C*`#E`$B`!`_@1*W25!8U`#]P!CO'
M1ZW';<L"B\U(_YU`N5`!``2Y`F.M!PU'@`1`$%_?06$'<E:/)WTY$Q$3A0Z3
M0#7L.0O?@IX@^%+BZ0#*1$X:]ES-)RF3\`#*)"]\(#0%``1GD)Q]]9.J5SG3
ME#][QVU"PQX.8A!0R`K&B9S*F4WH2`A<MU',(`G6]'N;X%+$<0;+@"<"QGU]
M!HH+MV4A5E(_($$V](^<\"N+1H8+QIN^V6OMY"61=09"$"_45(6S69N].:)5
MX8]2`X(W]`#QMVJ+V!``H'6:PG5GA$@V]$,_Y$";,)-RQ#H&%U*NHGO"*0AB
MIBH?M:5(=2*]=TG&0Z-[!#`P-&T7>&*==#^E!)3U47I354<**$0VY/\=\ED'
MH01IYH8E!F%;?H!::YI4[:=2Z*"`V`<A0=`NEX1+6XHU8[@&>+2F`?``D]@D
M1=B("_-#1Z"GX]*<F&A8R))(6FH`;5H9>+E[D?$`<3JH?^E(3+2E`?`#ME./
MPW66#O$<^:&E.<.4MC`B(UJ78#H`8KH*[50'#J&I#9D(#:"E--JE5H$'0/``
M(N5_#I``"]:M/_`N0&"NR.$`O^$`4W(&QRECOM,H1]``"9``MT9[6B6N"?`#
M:W!AWYI@#@!B00"P1/,`EAH91<``XQH$A?$`0*`)VS>O]:H`0!`?%Y:NM5`$
M\CH0&3LN!+L*?H"NV'!<"<``=<`&#R`X[!3_=Q7+!GC0$=B@/PD0JD8@KZ/0
M;HV$!FC#L.#J+2/(.&?Z``I`LTRZL<&S#@I@0"#[-D*PL`D`KUI8L.,B!.N*
M,(_C/R*;L1N[+5X2E\MB!`R```M@0'5PL)IP!`)+"._JC?2*`)2#!G)#"VGK
M"?7J(3QRM(1@L[GRKR(EC/%1/>XF5,E4I]3W`#?[;.*Z.&O`!P3+",?%+T5#
MM`:4MD^B'?5ZKT80FF'!:?+1N>/"#9=*A_A2#A@3,I^[+*@K,*C[,;;`NL:H
M"Z?B;ZXK'[[PNKB`!!Y2"12RN:ZKN@SQ%S71"DWR?,$[#82R@-'4$VF2$&]R
M!GC$4L9K%NY1$&,J_[W:0!`R9:$WD9.L@T0(8('7VQ4$2@`(`)GB2PP?4@`(
MZQ/=.C;E:S_H6Q;7(K_:0)$Z$1B'4K_[R[_]Z[__"\`!+,`#3,`%;,`'C,#=
MH`B%"Q2,D:^XP!BWF\`33!.O)+,"\+4N@0;LVPM`!@R/96<4+,(_01O%N`8(
MH*LKT9>%V0O&LT";\D8C+,,],4/W(\$4X7:_,(@P7)TS[,/CX`C,Q2.!H2>Q
MP".=X*^S@,0FT9<#P#E$(PI]4"@+K"Q4;#&FRQB/T!YLX`E5C!JDU0DBQ0<]
M]BAUX`D^:RZ4$K*,@<:$D(%^P,5H;`B'\&VF01I!S+A*C!HW_,-_X0=&D/],
M0+0`_F6@#;!)]R`/@3P`.>7&/Q`O[6``J:-5`(40"8`'W;$C4V.@0F!M`F"^
M(]5+7A4=&6,SP@%2?#,(^B,<`A#)V)#(RG1I*;(V37+*]5%8('4<>/"D,J4C
M=9HO!H`(TYH`M*5,!."QH_%F#%#,#F`2U@-$C$PT"&#);Y,`6,1.BOPU/,('
M0M!+84>:?=R_&EE28U-2B(`I:612?B`FP_$WK+-%\W0`Y&P//!9?EQ8)5*DY
M"+$?GH(0];%1)>4I$3*Z;BFH!]`DY*4):Z!2]'/00>M6^T'._4<E)\+*"-!-
MN8):0+0C^J(E_&S-LT"LI"(<0630=%<+DF=M!FW_0W-F!#A#/P\R)/7U?F_#
M:DB`,X`3J0^W(<-!SN4!S@%L:4/$+ITZD&G"G=<B>]OA*#R59]5@`)Q#B2<R
M*7W0EXV5*#.8S[Z:**!49H&V-9%018*B90;5!QXD4[E"8(G"-*R<*/YB0(Y"
M5-\1!.!R!GJ2LO8G4<.A"I0GEH]!1>"X+/1'H0B0"7"#5*IS5`6`!(+Q46,:
M9]]*B1LR9CHVTXD0BR=BKH%10SJT40@048[R4:KXT_WK)?*X!@QP#^<<$<Y$
M)%V6/"DB=,XCE-Z6SW9D4<=1#66D:)/)"0<6-@]""0B9QQ>4"<9W4<%D-=5T
M;Q%#H`=(;!.X'B3K)M#B_W)+BI(3TL8D]C;U@`A.IMNT,30M9(.)P"A"\ZV3
MF-P_)@"4P"P&QZ2C;;R(ZJ4\-X_2;*_VREMN;`EL(Y\9.&^]YB5[1E+'0:O@
M>;XY9YO8^EQG@#.7]@/;<94&00!*BP:N`7#W?=\/4B`@5VS@/1RWUL:,N&4M
M9+T=^&]G@`8H#M6NUVJVM"'!!UHB/=Y1R@BF2@`]$RQ$4P\8;J\J%7/PC;X_
MIG"G@"EJ%6>?2J/;=0:\(U,',68U7(*:HHXC-5=B$GRKRD)^8W9R9!Z,6@]R
M=``K"S?81T;F`7*]^D,T>@]B)@IHX"]@UP!R+-B\2],NADXR!2RMY)/"*=\*
M,_^0)`Y_+@:S\?5#GZQC-W1#O@KD_(OE"!-I:K4H`C`)9T#IE2X+.8(08_L#
M8I)G?Q?E@K"%,E;E5DA<8BTT6J(`#C`@:4DT],K/@$U]0F`Z@IH*^W$$E8[K
MC$!LVKRSD&,0F=P>U4WGEKV(1H,`QYX[.QEL\E)S'<HPXIU0B?9OVC.D3KQN
MMX[KE![BB_X7&Q*-)EL]]'TG1,(IT[2NHD!2A>GIBB;E(SK@?@[LIP%0Q1N9
M!U#<(OU<.A=,IPT-AH`$E,)9^Q+I#/0FJH*F5$(?"%,'48*=#"K2E4WCC2*(
MHEJ=PEG:FW`B]T#9]\.,C\M*B7`&#M$\;,4)^LOMXNO_5M,Y+@T&.^C@[`>@
M-@IP('\P3ID62D_>21[8>*$^-7/%!IUT(9USJK.05F\S3<]UJW:CA2LU2+Q]
M*@KAH!S_-XB0PPR.':.P8X4PYQ"_[FI8G8B9*YJV3NP4148%4.+1!X&9*.S@
M;_IR#V+"2*P`.>]]\GMQ3D@EHP87>NU$-*%4-QQQ\ZL`5"HK)*<WC_B*C/EL
M6^_N)QC<`)<S])BG3*BM/'+T#M]"4065G\_U#`/0`$#(#E>/!M`CHT^J)I5!
M><RPV`YA`#+JR"LE+$V?*X"^W3[)"3&\=@<(H^PF!"MBE?F"$`<K\T!4X^V`
MVK(.4HC`!BKU]P\02M-<]^AK_ZQ@1R9\?Z9O+D>$'<V/9*#65CE$Q3IU\($\
MS_A\H*$0,H)#7@BW>A`"<#Q_PJB4.@!`H"C8^D@&`$Z[]4CHD!H^)"E]``AH
M"`"$``$+=7^*BW]^"`%H?W4$!'B+>`4#B8R7!@-LBWP'`6N*>`T!A0(.EHIK
M!H4$0IF)?`^IA05&BV>CA0$*I9S#Q,7&Q\C)RLO,S<[/T-'2T]35UM?-?$@_
M#D'"DD5GPWA'W#]'K:9%#P]%B6=%H']X0@Y`>'A%2*Y%WW]L12+YX?-GC9&`
M>`X(\,>HS[9NI>J$6[2FW@,A_OR<`<+.R*9%=8P\L'>&($@@#H3XF2?R`1`D
M)HDA*?]B"8\1(RL5^3F"KMA.(^G^S$RG$2602)SJU`.RAL\1(R;]H`GBH-U'
M4^4<G`N*K:O7KV##BAU+MJS9L]B.'`#""(V``ES1RIU+MZ[=NWCSZMW+U^R9
M``$>'#DS"\"#OH@3*U[,N+'CQY"G^;E%"!>#N)$S:][,N;/GSXQW.DB0H`%4
MT*A3JU[-NK7K13E?RYY-N[;MV[ASZ][-N[?OW\"#"Q].O+CQX\B3*U_.O+GS
MY]"C2Y].O;KUZ]BS:]_.O;OW[^##BQ]/OKSY\^C3JU_/OKW[]_#CRY]/O[[]
M^_CSZ]_/O[___P`&*."`!!9HX($()JC@@@PVZ."#$$8HX83_%%9HX8489JCA
MAAQVZ.&'((8HXH@DEFCBB2BFJ.**++;HXHLPQBCCC#36:..-..:HXXX\]NCC
MCT`&*>201!9IY)%()JGDDDPVZ>234$8IY9145FGEE5AFJ>667';IY9=@ABGF
MF&26:>:9:*:IYIILMNGFFW#&*>><=-9IYYUXYJGGGGSVZ>>?@`8JZ*"$%MKD
M%X@FJNBBC#;JZ*.01OK%%HAN06FED5XZ::6::NIHIYPFZFFCH$Y:ZJ.E6BJJ
MHJJRNJJDL,8JZZRC,IKJJ9^^VNJFD.)*JJZ^V@KLJZC.:NRQM(:*::_#+EOL
MLKO6NNBMQ.;J;+#35ANI"MQR6T*W_^!^"ZZWXY);KKCCHAMNN2JHRRZ[[KXK
M;[OSUFNNO?+&B^^^Z?9[+KP`_RNPOP0'S._`!R.<;\(*,ZQOP=WJ*['!ZS9,
M;\(/\YOQOAOCV['']L;[,<,DEVSRR2BGK/+*++?L\LLPQRSSS#37;//-..>L
M\\X\]^SSST`'+?301!=M]-%()ZWTTDPW[?334$<M]=145VWUSUJ4D<757'?M
M]==@A]VU#F!D(<<-8J>M]MILM^TVRCADC?;;1(],]\QVWZTWU'D'G?4.>P<N
M^.`+$VYXRSEHH0(86QSN^..01RZYN#B487D.DF>N^>:<U]RWRC?H@$/GI+O\
M>>FHIZZZYB>GI]WZZK#'KG'@K\MNNNT'UXZ[SKKO[GOGO??^>^K"#V^\\<6C
$'@@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g145452moi004.gif
<DESCRIPTION>G145452MOI004.GIF
<TEXT>
begin 644 g145452moi004.gif
M1TE&.#EA2P+*`?<```0$!`L+"Q04%!L;&R,C(RLK*S0T-#P\/`!_?T-#0TQ,
M3%145%Q<7&1D9&QL;'-S<WQ\?`!&CP!(CP))D`E.DQ)WB2I?E"-MD2]CES!D
MES)EF#9HFCMLG4!OGT-RGT1RH4EVI$UYIDE\KTI]L%1^IE-^J0"`@`Z&AA*'
MAQ2*BAJ-C2.1D2J4E#"7ES&8F#N=G42<HE>`I5:`JEV$IUR$K4>CHTBDI%.I
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M\>GN]./Q\>WR]O#OXO+QY_3T[?3T]//V^?;X^OCW\?GY]?[^_@``````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``L`````$L"R@$`"/\`-0@<2+"@P8,($VY(R+"APX<0(S+<@(&BQ8H8
M)6K<R!'AAHL@,5+L^'`AR9,.,WC,H!)AA@TL7Q*$Z1&ES9LX;9J$N#-GQYX^
M@YX$*K1H0I%(+1K52'2HAI!0,2R=JK"EPHDM90Z$^9)F2YI4PU)M*M8GV;)H
MTZIU&/4BT[4=DR:%2[?CR[M<\YJT6K>OW[^`MP8VBU8NR,%!VV9$3/+LT)AY
M(;/LZYBQY<N8A5:F&W+FXLPD#8,.RK?DY*TLN785N_EFZ]&P8\M>.G>@R(.O
M(^9NF#OJS[6[<4/4JE5@9)A@!0<./KNY\^=%.V_]#)VAZ.IHP:9^JKKG:>S@
MG2[_#_^7^=;#MI62QRUWO>[2*?5.3JV2;W'W-0F+Q\^_O___<-GGW7T2F8>2
M@8,A"&!:"B+6X(*,(?B@0?`95Z%@%T*HX8;&2674A!R&"%U/9!$H8G_,@9B9
MBB>VZ")!&184XXLTUFCC5"QR]M9X!]('8T'()1=6CHG=:&1V1RJ79$,S#D>4
MD#$U^1R1+5*YY$96CGAE8J6UEJ6#.7V)4Y8JBGF@F5CJI)^&:&[IYIL[-@;G
M>FW^-F>$!9:DY)U\"M>GD5+^B2=H=<HIZ*&Z1<=1H8DBVB>C13HJZ6/5$0DI
M=I?"EBE<FZ9YX*2@OMEIJ(V2NJ=!E1DXJJE#LAK;JL9Y_XHHK#RYNBBHD(I)
MJZT/56ABJ1-9MBN2*)(W;'/'7IDLKT`R"QRN#9ZU+("Y^C6ML]B&^6JVVM:*
M(V;7YL?MG*,&.NZYC[(6)[K>GDICN.S&*V]1YLZ[I8)DVJNOCOOV.R9G9,';
MK+^:$ER6P`8G/+#"#/WZ8Z3.=8HPL;S=RC"F5;8;IH<7=VSPQ(3B5)''($-L
ML<D%TWD!?R5[)AVS+4.88\SB`O8ES71=M^U5(>+LL:)TNLMF>ZWNZW/0-:=\
MKL-%"Z3SSU!'C:UB+R,M]=5L=EL@?$^B;)!A3V.]HMA:JW6T2^6!7379+*LK
M*J<=JUT;L&PC>R)09]<]G6*I<?_L:MYZ#VIC4]/*_=%V@2=\+>!T9U8O@W)W
M]?B_;C(>GN6R83Z;X7==J/E3E$UIZ(>)G_LE<0)-;N_G/<_&J+1P,VF5?:J#
MFP$&N&,0I52X0]B[6+GGKH'?5-VNNVW$ETXQAS.N9MQ.'_'7`QA-5&']]6`8
M8<00C!//0_8EC#6$$6!DG[T1/'Q@UVXT9$^#2B"0#T33RO<99>ILU0Z7(+OT
M[___NWB%^M8C`SC(8""!Z%\8DN<3#X@"@/W#A2C$P`&F"&$-%80('/IW!I8`
MH7^7$)C$;,:G3"V$:>'A'P3]APL!ZF\Y98`%+FB`P/Z!@8$Y<>`*_2>'##X$
M!('`Q2?_.#`2AVQP%QW$`!!PL0M,^)"$>DH:6P17/R"]\"\Z(((6C<"*7>"B
M#%HD`A#V8AT<#@]Y1Y&=&8>7O`X\\!8T\!`-AD"$\'UMC6ADB`Z_2$<BE,$2
M3-S%`@O"0"6"4#VI^QU!9#"$(80O`Q]LXA.K"*9BS20A*/S46G+'`5!X40?!
M>XH'0*"^#]``!%L!@0YT0`,/Q$H#'0`!"!;B`59VP"`<D,$J9WD0#^B2!B%H
M"@AH0(,2<*`EN22%%X'@@85PX`,?Z$E%2L`#&@R0(![X`"]-28-)%J0#GH2C
M!7C'@3/T#Q37K(@,B'G,@7#`"$S<1`BBJ0'XT8"5UQ3(,S]0_\$,"*%_F-@)
M!X@)3"LM9&4R&XNM6E.:V44O=4T2$JHT)B8/>!(7//";!R[Q"E`881.X`$4<
M90"(5]P"%[<`Q1DRN(&2OF((8`#%+6Z1"2&X4PR;D`5*8=$('A"$`V(`A4YO
M`8M!T'`@($B#*$X*"T/8-`-@>$4@8?$*,&@`#J]XA1$X-H1!P&*FHH!#"+82
MB*P.00Q+O<4EYH<0#R@3%Z#\Z2:\.(2!`,$2.I7%)L"0P4#`(H(=E0$&0`"'
MI:+T%7)`I4#*D-4PW&Z)DGP*&'**"USPE*V4O.2AS/6=RG2.3&';2">]F%&"
M?.`57NSB+F`AR[EZ\1;^@\-`+''.RO\&DA4'U$`:_'?2_LG"!RTQIQ<#N0M0
MA(`E'VA$!&&["UD,P0)B@*`8,)!`07I(#(&L[#F/NH%+]&^NQ'U%"1BH0SCZ
M#0-'/(-4C""+_C%W%W#XB'?_!\<-#&*Y_AO$"=/[6(`N1+B[Z&US,9M92>U&
MHD_)2E;R\J&/$.V5$K$H:?UV6O^QXA6#T$`9^A<(5LJ!B:!PY0:4Z\4TM*^]
MNYAN"+IX"S#0P`?WW85^,U""O[Z4!D;XZRZ&()4C8F((/,##=ST0`C#\]8MU
MU$!U%X@!'\#V%FG0`1!(?`D1S_<69V@?<V]X$#<&6`>$#`.'-5`"U-ZB#'-\
MX"Z(H`$>[#;_@-O;P!!`6,TRP%86X4,O!^L)V8""@,5BH`$/8FP)"148/&62
M7>KV(I.'UO.$>7*(X5`R6KA2&+6[N$0)0A`^'I0!#B"P@`5D`%M6C'4#M-U%
M(,X(B/[)`0,T>#(17!F"-I2!>QH`01C@0(3>J7"!('AC1C'P`4$((@T@P``'
MWAA'E2Q9*BI,`QM!X-JM=M?59ZQN&I*'@3W&D2`8`$/_!*'A_L'A=A88`FP%
M09$^CX0&8H`##<;Y@0=BM,<<].!W-T#J`!-!?82]->M&)Z*!2Z1YAW,H_BAT
M153)#242MK1IU<QEIRE;!D0XPWQ9^Q02<QD#&X:O!NH=05$,0@P\_RCB[7+-
M@S`$`L4+Y$$\??C$#USTVTJV(09"8&:<EWL7>-``!^:[U>&]6;9=?F-<"2)N
M56]`A67@@=2)T%Y1?$")\30)[C90`B&4H1%,Q&@]^0M))@;4`ZYMX2"B7L30
M$1QCQEJ0?"PTD1P9;F0=X<!;=<"7"M^BM/H$`R;>VS]8G)K$O5XLMC5`!!WS
MUA(^&(@.RDI<!::[?X5NJS+-*Y#JWC#6`4PG$?K7"/G2E7=OWG:7-[]TIZ5^
M`YA@8>5O,5X?^'<@0VB$XR.8T0RDE\_^Q<`0,,W;2T1>>3>[5Y0ZQ_R%[*3A
M#J<:'AD"SD_V_8V"'4C(0RH(.,"6XR/N'_^;%0]?#\F@#)?8O2B.2P-,P\(2
M;<B$`H5_2$(.SZT!/FK.!6F!$L#V%8HE$$9`>D\Q7SQF=.;65DKG-ZAF0QH0
M>[NP"8TP@8,P@8&0;)"U"1D$3_UC<FF`6AC%$F379QE4`N@G0_[S"F.5,:L3
M'I*3<"]83S)(&])W$A''=Z;5<QX2;`%F!+367N"7:HD'<HO'`;+$=4,`!RAF
M!+['8<&4`<^F`_\7@)\F!F/E;35D723W=P1Q1+(%>_US@+K5/ZI'2%[&>4[C
M9*L5/M5E!%M!3\/C`V970=?V1>I3:3P@@OD&20!5048X2UT'!SI6<8>V,,K"
M%,N7&EPA(R:!8`?_<G<D@8>7UES9!VO?%P(6`%5,9&H=)WZ\$W)PH$2@P%,>
M@`$6T("[X(8Q-ET9$`*>9%T<$'NX<$,8(`/M=6_EA7//=E7C5HH8P`-_Q85U
M>(`8<'3D]49`($L@4`)&H&:R%6Z8YP$L,5F6$`;M=GL5A@L^@#MJ&()-B$0>
M9'8:``2C:`G)9@$:X''3-RL+912/@Q=!`AD4`E%UTB`V]TD%07*R@',@@&G5
MB`<H!@OC%7YK]HFNMG.K`$)BX'+_-UY'Q`II<`:NM0ME4$]54'AM0`;RMPN+
M<$P<X%J`4`8V]6P90`-J=@EB\('FYGP&B'K]TP850G*K]0JL``LHM@N9_T`"
M+$%MF$<&;3"(MZ,#3(1E9U`"J;8)8M`&F(8+0*`2Z:4[D>1$K@A"9!`&@/!]
M):`2!O<?EK(SV;)LUC<0&="/`99;`H%=_P,*KL5FJ%AT1+@+<B`0/)"0``0+
M;DACK^A>8+<+C6`<9U!Y$2@#+?%F9`B%"E0?/J!F+"0'KO04$$B,;?"2\)$!
M,@E!M]`(6=D2/*"8$=1#*N$!&TE:0$!XL#!?%?F-'>1/_9,)Q[29$`0+4R"6
MP5*(F#2;&F.;#,,!;3`(@9"5/P4'O`D"5K$!1C`(H(`):1`","8(5K4!92`(
M@P!X734(;EA/)7`&EK`)H'`):6"6&D`#<K`)F_\@"$#P`<#)F(\F!($`"MM9
M!L(Y$!]P!IBPG6P6!M#9E`,1`F+0"&H9"+CFEX,@"#AG!-#)A`?!`<`9H(.P
MH($0==YD@I;0GT+0$S00".(I"`<$!(*P"9D@!R50`H&P=@M1G()`!"I1H8)P
M!B=TG8T@GLAI1U:C-#<!?1RRE5X#.A[!`<?T%1JAE1S@`3OZ(SIZ%BJAH^V$
M2SIJB(\&I.O2*R[Q$OPT@P7QH]_D34(CI!S0`59:HY:D,%Y"F_Z2+`%#*([(
MCA,%IF@J*!>226G:IF[:@I7SII>C,&P*1858*#3Z+(%CHW*Z%"+4IY)2IX`Z
MJ$;"I[)2.H;ZIH*:$XO_RBZ-2JB02CF-DUF)&JGS4JF6ZCJ7D:<<P:F@\HXL
M\AVC(:KNX:G8H96FRC-^HJIBR8!2U##K*#1CJED01B(W@4>$0ZMK`F$I@7<5
M,QSK^'PF`CNUR:N]<:91Q*OS:*RLJJ0P0A2DJJPXVBNQVHB'>J6K&A$<8ZO"
M<1?3&FFZ2A`7,*[D6J[F>J[HFJ[JNJ[LVJ[N^J[P&J_R.J_T6J_V>J_XFJ_Z
MRJX8L*_^NJ_]^J\":Z\!.[#P6K`&FZX5L+`,V[`.^[`0&[$2.[$46[$6>[$8
MF[$:N[$<V[$>^[$@&[(B.[(D6[(F>[(HF[(JN[(LV[(N^[(P&[,R.[,T6[,V
M_WNS.)NS.KNS/-NS/ONS0!NT0CNT1%NT1GNT2)NT2KNT3-NT3ONT4!NU4CNU
M5%NU5GNU6)NU6KNU7-NU7ONU8!NV8CNV9%NV9GNV:)NV:KNV;-NV;ONV<!NW
M<CNW=%NV,'"W>)NW>JNW-K"W?ONW@(NW?0L#@QNXANNWA7NXBKNXC!NXB=NX
MD+NW+V"XCQNYCGNWE6NYEINY=SNYA\NYFDNY@.NYHANYH'NXI'NYA'NX-5`#
MB^NZH9NWE9NZL0NXIXNX>4N[D8L$.-"[OON[P!N\O<N[O/N[Q5N\PIN\R)N\
MPHL$R\N\P/N\S+N\QPN]QAN]V&N]VHL#U`N]U>N[TO\KO=[+O=@KOM9KOLT[
MONBKOL&[ON%[OL.[O<I+OMD[O]<KO\K[ONMKO_@;O_+[ON/KO_C[O`3<O],[
MP.";P/MKP`S<P`[\P!`<P1(\P11<P19\P1B<P1J\P1S<P1[\P2`<PB(\PB1<
MPB9\PBB<PBJ\PBS<PB[\PC`<PS(\PS1<PS9\PPD<O\A;O3M\O_3[O<2;PP(,
MQ#HLP#Y\Q`J<PSW\P_3;Q$U,Q.2[Q$/LOSQLQ$*,Q%;,Q$L<Q$:\Q53\Q#X,
MQ<0KQF"LQ5=,QEX<Q5>LQ$5<QESLQ&C,QFK<Q4G\Q5+LQG9\QG)<Q4Z\QEG<
MQTP<R&_<O5]LQG1<R'PLOHK_G+[9.\BAL`F?$,F2_`FA,,F17,F73,F9;,F:
M;,F8K,F8_,F3+,J;#,JA\,F5?,JH3,FGS,F;+,JDW,F@7,JCS,FK',JN',NW
MW,J9K,J2G,J\;,JN3,NEG,K$?,RW?,RR/,RZ7,N>_,O+C,S./,W&',O,',VR
M;,S/O,W2W,N1#`K/W,S>C,W8G,SD+,ZFO,OJ#,W!;,ON/,[6C,[:',_OG,[L
M',S`O,NYK,D[U,_^_,\`'=`"/=`$7=`&?=`(G=`*O=`,W=`._=`0'=$2/=$4
M7=$6?=$8G=$:O=$<W=$>_=$@'=(B/=(D7=(F?=(HG=(JO=(LW=(N_=(P'=,R
M/=,T_UW3-GW3.)W3.KW3/-W3/OW30!W40CW41%W41GW42)W42KW43-W43OW4
M4!W54CW55%W55GW56)W56KW57-W57OW58!W68CW69%W69GW6:)W6:KW6;-W6
M;OW6<!W7<CW7=!W2ME`)M@!`JE`)3%0)JE#0NG#0=^T*.JT*FQ#8'&T+DI#7
M#+W7@)G0ML`%3T#8_X,+E;#8_6P+C[T+NF`+KO#9ML#8!NT*E1#8?MT_IZW8
MB%W7K!W13R``4`!`$&``JN`*!O```ZT+7+`%!XT(`\`%_HP+NXW2MA`%7[`+
MMJ``"[#:&OT%`^`%#>T$!?#7`BT)DPU!M@`%!A```&``4?_@/Y*P``,P``D`
MW1`$!0E0"2ND"`90`.Y=``VPV0`=!0,@";J@W+I@V[C-!0*`"*W]WP[M"@=0
M``D@VKO@``-0VP30``.M"@2`VP:-"`#`V_VL"@,`X2:M"`'PW;LPW!WM!0!@
MW@O]``D^T"1.W?\3!0'```U@``8@`,>M"@8P`$_@!0@NXOWS!0(@`.I]W@"@
M``P0Y$Z`T(KP!*J@"P>0`+A@X0ZP"]:-X@`>Y0?-!07@!01PW/[S``2@X`R^
M0WM-V;BP"0/@`+7@/[9@"JH`F$NN"HPMX12."Z$-0))PX7F-"[I@V6"N"GHN
MVG%^UP:^"WH.Y?VSUVD.0'>-XE__$`!0D->ZP-RD3=G]<^>[0-I_WC^VP-QP
M;N:54`F0[@4!`-R9;N:5]^4`M.:Z<.)>[M>!I`L-0`!\7=D*8`"VL`4.,.=#
M#@43'ND,4.#^4PD&```\#D&XT.J"7NIY?>;4?0MZ7ME>E``)`.@$T.1>]#^V
MH.?$E>EK+N5J/0@]T.T]D&K_C`L+P`#WW>7]@^!<OD*5T.H#4`!.<-<'``#D
MK=Y>H``$0``*X-_]@P@+0``#H`#'[>:3_@#E_3^2$._DK0I/T``,0``,H-@-
M4`#CO0"*T#\/T`!0<``#8`!;P$2N``$2'^W4S0@-/P`.+PD1%`4:+_)?4`#R
MS@"NX`#2_ZX*#R#Q!O`$=>X`&*_Q!P#<LJT`U'WJ,(\+&3_>!@`%3`3BT.T$
M#X_:"D#ADL``-K_H_2,)K1[M#5#B`*0()>_P%4_BW<WAD9X`LAX%#J`+ITWL
M_K,%`]#CML``Y"T`*&_H24[H.^0%";`%XET`41#>[4X"><T%Z8T+2:X+#M[D
M7Y``%2_<*\\`%;\+>!\%#?_@Q:[M8:T&$9#Y$;`&`3WGT!T%KNX_#K#EKK#@
MP@[W3[`%#0``4*`*$!``!N`$JN#;1_\$!4``*%\)!%``3P`%MS_[`;`%MM``
M`>`$H^X``7``3N`*JY\`4+`%JJ#Q3K`%KU_@NK``R0\%4.#O*/__V@]`_2N^
MY`9``-/_``&P`'FMX@L0!>;?`%'_XXM^``?0V0P@`-_/```PY(0?`,[_!/?>
MXP"Q2R`4`%P$5AK`8!>4``NV0#D`P,LN+P$,,B"@2J"D`$YVJ3I0P,D6!P(@
MX`(YX`G$``,J"82IR@"!)UL>-,2UQ4"`!U]@#@3`H(%"F`TRPMP2P.<N)P"@
M.!'P\N='`@02#!C@0./4+0`*/(AB8(`!!U$4!)A(4-&N`PFH.MC5U:<7`0FB
M/"%@0&-7`@^V+`#P9.I@PH4-'T:<6/%BQHT=/X8<6?+DPFHF7)ZP1K&3`AI5
M$8`"\\$`5ZX(P)WZ>8&M7;:<&/R,FL'_`$D"%0F`^T0`(H%>"GA!%.!)@XZX
M!JL:`$$@<=Z[*BG8`M.!RUT+`C3G`B"Z@J,+G^B2I,"@0(RJ;+5U)?!!`E6*
M`D39A2N!VR\`E+=>X%+7U=J[HDB<JA(!&A"HJ^B<8("U7=P3S`L`C4IO%XX$
M>V*`M01RPB4N+#H(JZU@"F^\7<K;Q8'N?L(%+P`$6,`+XZ(((+K6%`"0K@9P
M@4JJGX*CB0L(!E00IO_NR\Z!7,#K:*$`%-DO`92RBDNI_3KK#0"/NKI/E0(4
MT(4R+[\$,TPQQR2S3,(LPTPSQ%PQ0`%$OO@B@0,4G$X5TPA4195*\K3%.@6>
M0$1!Y!YHK0`&_XR++P$#;%%@48%T4067X`(("M&I3!F`T%V,^A`76U1!9(L#
M!M"H45D$"@Z^I@YPPHL(X[.E$D3"(L`5`3T2R);T4DWT@%UTZV^7#5T\8,[>
M.$1Q@8QPR6^K3R7QXH'`*.*P`2J=$^`)^0J`HELHI.5BM`\;()6P6&<U@$H3
M/PQPM`&$^R@!`1YX8H$"E)*$@`,TRO&X+2YD:DFN`%@*$>UTT45`Y1BJ;;ZW
MA`4`D4%A8E.!*)?2I2U+S>2X8X\_!CED@="\+([$-A0@Y925$FA=TQQ@%*L!
M")3$*``".&"BV#Z"$B8&.CN`RZF"$Z```H+]"2%-(82)BZL$($``ZO\:5=`]
M^%SA#`"OH#!.U`&@AKH]`4*;RNKXVMIE-!T-CFZ^+G?Y`MF?_N,"N4,_,E%F
M*REZL#M)LLTX@*JJ,IJ+GU\5=ZJ<1AT@ZJ/J-&R+!B0YX*A*C#+`"88080"`
M!9YXXJR>$(M;1B&O$ZCT@TQ24A%<T-XY*43^%DP@^=R2W?8$%-A89-]_!S[X
MWT6)H_@X1$%,%P8,0$01Y[\H@,"T,[H3%R^VP)XW7"`-=X#.D(/+%4-_4N``
M5^2\Q79$9`U,D0%6&VR33)?K#I&ZH%@?\@4<W877[5WY@A,,L)LO"$`!49`8
M1EPQH9@@PA7^<QNPFH86MCCI6"*"B8`:8*#_UC#`)%Z0A/T\4A&#6"M"?W."
M?/:5)Q;:8EW2$0"[J'7`]7&J1"?*E>;\0Z`?50(7E?@4:R!`@$K(:V5:X\E4
M)`&%5ZGN)[GK7XQ6YQ&&-0E2IQ&64E3!.H'4HDT7RY7&A#=&,I;1C""CW50@
M0)TZ?49Z/U'%YV#BA`!(8F+5*9>$!K2+'_5'$@-P0G"B0Y#:_013]S&A0)X@
ML-9<I53\2Y4N'G"C*G&!COT!249LL24%Z:9Y[]E%D_A&-ETT("I-0E1],&@[
M957.,S-#RK0<-!%R2:4K@GG`;F#RA094(BGC$5\>8=)'@;!)73C<A2LJYTN8
M*:``KO`"`2;RD0(L_^"'DI`$(R11$B_(D(/JH<U48-0<)]ZJ=15\6%*^<!X#
M1"@X5V)9:X+VMC/6TY[WQ.=AB+FCL96(5'<:#*.R%:H")*`T5@D4713@!:?I
MTGT'X((7Y*4(7@FT.3$90`("94.(,>`+7+!.5'9!-=L``#X0`$!/)$K$KCC@
MHX`YRB)=&H4!*,`6[FF`(FPAIV0J8&R(@`!/=/&Z!+S-0:L4R'^"4LQ1;2&`
M!-@;"?T3E"^$96_Y*@`"H9"7/"4@JUY@0$MD^!^7<N$L1[G)%KR)L^59)S25
MR$M$%Z#+J?1K00]XB3()@,`?G42<J.N?=E:W,('!C@`$DDN4&'"]F=2F*__-
MR9@%\SE9RE8V>'U*T%0PBR/V[/0^2LR/U!90&US\R$(Y*<#7(`H3+QQ`:@8P
MB"(*,!Y)D&5CN,@E`10!`8/F:CI0HU<!UM(`:]IFMLG\K0!REDQ30@T"G*F-
M+?`BVNAZT`"58,#=)#$;X&H$%]E%%")^0YA*A$1$7AA@1K>0`$*)=R*VR*5R
MH6``LB'B*EA9P(6>(UH'[&LJKB"7<Y]@@-I\(6J?M1T4[H4SKO5F@,J=YE3F
M*Y5H-B<\7R.`$X+4-.$:=YJFH&]<"E`;\"ISA!VVA8)3EH"E^*8YW[V;964\
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M]\9WOO6];W[WV]__!GC`_P4^<((7W.`'1WC"%;YPAC?<X0^'>,=Z%W&*5UPR
MMWB%*#:1B4UTW.,?!_DF,!%RD(^<Y"8GN294SO&4AYSCFN@XS&/N<IF#O.8@
MSX3,10&+B4_V%K>0!=!E,?2@$[WH0Q?ZT8F>]*4C7>E"9SK0D\[THE-=%K"0
MNM.;/G6C;[WG-494V&T7G[&3W>QD%_O9C9-V2ZT=[2@:.R[<SO:WS[WL;\=[
MV.UN]K;SO>QV3[O?_2[VP,_Z%7@P`@U`X`$.-+[Q'7"\XR'_^,A''O*3KSP'
M,-]XQG.@\Y+7O.<S#_K*?[[RFQ?]Z">/^<Y_(`0\$$,CTH=/7&P"#D;P`0U*
ML/][WO->!KT'?O"%/_SA_Y[XNS=^"9+/>]T'?_G$-[X,:`"$,`0">9:M?2#$
M8(0A=!\(0AB"$,`O_NZ+'_Q#``+ZO1]^]:=?_>@W?_SA'W_ZU]_^[W=_^MW_
M?OQ[/__K'[\`[+[^ZS_PT[_U:[\!_#_U,T`!)+_PJ[_]`X,S:`166#51$`,0
MT(`-Y,`.],`/!,$0%,$0S(`.+,$1W,`-V``4],`59$$1Q``-V``:P(-3.:-;
M$`0@X``-R(`>]$$>W,`2[$$@S``,.,$8Y$`A)$(?_,$3#$(>',(HW$`C9$(B
M#$(FK,(F5$(-H,(2C$$D_,(8!`$PP(3)@@4\X($=#$/_#&##-G3#-X3#.(S#
M(J3#'FS#.J3"+LP`"[``+-Q#.03$0!3$.VQ#+AS$033$0YQ#-S1$#2@!,ORZ
MR<(%.0B!%[3$2\3$3+Q$%]1$$(Q!'RC#,MH$(.#$3C3%4[1$)T3%#\0`#A`#
M6+`G7`@$&N#"5;1%%%3%6]3%7>1%3^2`*K@^&8,%,*C%7C3&8S3&#P"$2/08
M6?P`9(3&:+Q$&@C%,I*%,"A%:=3&;>3&8\2`$@@$&9.%(>C&<C1'#^0`.&!&
M,\$%.,C&<X1'70P!2R@C5B#'>,3'?-3'#?0`.*BL6R#&?11(7MP`#@C'WY&#
M=QS(A1S!#`B!:@0>6!`"AJ3(_XKD10[``\J"`XODR!2T1`SX`!T!F4OX@%SL
M2([$`!IP-)'!A3!82(4\R9ADP0SX@$;()U#00)G424\4`B/C&%G@@9V4R2M8
MQS(9A!T4RJ34R0R8@94THX!4RJ3<`#Z@IX[!@ZC\0)@\1P]XA-^1!5K$RK#D
MR"RHRC(2A6<4RU742E[$@!]P2C+YRK2D2`R0@EKPG4"0R[S4Q;5\01(0A;(<
MHXW4RYCT`$8`S#%I!+X<S&[T`$I@22!`PL64S'+L@L,$'EP8@LA\03:<3&[4
M`KOLF##0S)DTR53L3!#D@#?(A9`!!0\XS2$\QM+,RPP(@EDX(U@H`4P,`1H(
M`1?<`/\/Z``0Z(`/X(#(;,424+P.A+P3W(`.X$3%1$VD-,&"5$'7Q$<,*()6
MD+B@O$00T($2V``D](!2+,@/,$^DS``.^`!.5$\/A,VTQ``KT$Z0P4M-W(`/
M&$\.5,\=;+P0A+QN[(`."$'-\\#_1,$-V#U.S(`-\(&<3$$5?,=L+$$([43H
M?,$,((%.L$S?:4U+#`$X$(40A8,/P``9V`12`(44M03NW``CN`12$(55:`,!
M!0%,D(,=S(`2P`0=<,(.J`(!M<0.&`0>R,4,\(!&T`$>$`3I=$],M%#WU`%3
MV%`O@85*9$$,\(`S`(40%83<[`!+(`(GY(!&$(4MW00Y*('_#*"!3`"#'BR!
M2T@##Q0"&CA!V91)#`@"5`B9,M!$#"`"46@$I-P`/!`%/I4#(P#!#3A4.^7%
M#`B#./W`#"@#2.5`-VA3%#P#6+`$ZTQ)08"%3<!&AQ0$2["$09`!#MP`,.#3
M#MR`,B!52X#*<\R`#F`$T"0C3&!2$3S22P""$!@"4<!+&I"%,N`!'QB"D1-0
M,("%,]@](U@%.="`$."Y*7!360"".N6!30#2.HW4'N2`30C3)=2`#Q"%--2!
M#7#"*/1"#@1#!9W"T;S0&>"$*:6,LWS!004%(G@]3+B$X'R%-CU!<@6$8IV"
MC=-`.'@%6@2$5\A-_<P$(8A!*>S6_QXL1=CD5BB<0G;-V-$,PTS,@!PHA:+\
M$C"`5UP$`URXA:#,T5>81`W@32L\P1(`@2H$0AE\PB?\P89,5T=LV"W,`#A(
M2"(<A#0HTIKM@$W(0!?D@$L8A$"``UB`3"*`A3(0@S"861[T@5L8!!/T`%``
MA#`0`^[<Q5Q%00[P`UL=HTL@6Q"46AGX0B(0!`^@`5C@`0O```L`@J_L`%!H
M`T/,`".P!->#!5E8A30M`5GP@1/D`#>0A3,04!^0`SGP@0\,@3,`!",`5PW@
M`#`(A#9(TP\@!1X(`7TU`K3D`7(L`370OF?D`"(P`C2-P164@30(A#20`48%
MP0R(`4I`V_\QZ5`6U`%8R$PVY(%&*($/^%<G]`!1((,^M``:>`71[`!,&`0P
M`$A5E-I9Q%#:#8-<W0`BD(-```,.H$DR"`1F+4'(!00B0%<=F$@-T`%2)`+8
M`P0@Z(`R6-\53%6G!<M+9,I26,V/(8*2'4$,"(-7N(0S*$+,W80XT``@H('O
MY8$TD(,A4$$B*($.F`(>`-K=Z^!9G8*2U.`/*`$B@-PT^``@D(,TL-(-+`%$
ME<$IV#T@T-PID`,XX$Z@G=7JFX)!4.`.!`'N=4XPD`4YX(&(#8%7T`$P*&$:
MP(`S&`05-,(-K%%8B.(DE`%1B.":C<<-V(/Y)*-+@$X\$&-4#4__816"``4!
M$/T`'H`%'8C8$MS!)#Z#51`$!+56(112K04!(B"%R'T%(E!.2\`$.+B$6R!%
M0,B$-A"$33A>4.`!(7#D33""!;6$,P`!IDT#ZN6`$&"%3<`#MPW/$A"%H=T$
M2UC;`M[=WA434$CE#C1@40`!))1B$$C>("37,G#"1KCC#'#C6PC:#B2#6]@$
M'WC(1H`#4`AF'@2#5Y"#&@0#1<V$359;'1"%R(4%(["`--C:#(!B#L`$4@B$
M0-#40!@$H,2`--@$VH5D`LY=>67E,AD"W&7%`SX#,594.;B$JQR$,MB`35B%
M.!@$W-P`3&!B6"CD2]B$09"#D?L`$%@%_QZ%Z!*6!4MP@U7`A$:0@V=-0B$H
M7`LH`8;E9@T@@TUP`SD@!2'XV1N5`]MKA,:MTTQN!'4.A`^(`V*NY`WD`$L0
M!#EP6PS8@$,X94P(U0TPYS;86G:5VD'8A$!H87CTXE0P(TN`SD$0!%84UE?8
MTE?`A&LU@E>8V0S0@2F8@M(%`5APW5LP@L--7`X$@DT`@0V`TPU,`[4-0C^>
M61ZXA2'0@4W@`=>;:0\(W;=.QZTE91T@`TLX7AT`A5YEA0%F5QDH@^+\50?]
MR%7FF$VPS@)69R:-0>0%6)UFWCK59W25ZUU0:73<A,PD@TSH``S@@81U0B,(
MUW'^5CEX:"+@`/\CH%L.R+TGWEK@!F=HY0!EUMQ-8.*4#DY`J,^L?.=2B&<R
M@6Q,C&4>``4:.%HBN`1H;01_WH0VF%5*W@!8+8%LM@`=N`4B.&^&!8%-D.B(
MEMHT5=82L``PT-8@[`!-$`,+*(-+T(`T$(3V#N$/@(.M[>!72%PZKE/[GEGH
MY8&CI>$.!$=9V(3)7EI+,`(Q^%<#!H40((.D#L)7%`,B*-57UL8-Z(-4H->/
ML6L6#(3$[$#7%-8R\(%FYE,_K5(C#(.1PP4@.&M!WFBIO58.](&S_(!54%D?
M@.L@_'"=7NTJN(48W00K!@%(EF0.``*&W7$.\-04!85K!`$M_L`)MC[_L-;$
MW:6%S-YL&-12Z:1.T*Y3T"4#)7QQ="6"*$=E#_R`U<X`IY5C<!53(Q!H6(#6
M,("%5Q@$"WY36)CF$@!N'OSF2R#9@IYT20>"6]A24GB%//](>/X87)CN2XSE
M$)!TZR8!2X#61?#N,`7G*=``\B[<'(WU$BA<$`C=#&AO'3""3"!?(M@$=!T"
M;:W3,L"$#\"$_09PO5X%@'X%;07:8$=+'W;"R-5I3/C14?1`H#Z#,Q"%:#Y>
M-H3BV,Y`.+`$RR;A(J2!57#;+OYB,RIC%@P#4IAE+J2!2Z`!&4!G##`"Q/W&
M88Q=#CA<'S=O6M\$1'9")3?/8NY!(""%;4WL_Q7T@-4V`E'P`1ZP^.,-72%P
MY:,5@Z'M\R&U^`8-`2W63"%XA4"8U+-DU&S$`,PVDTTP\2G,6R?F01"PA"$`
M;0L`0@X8[1Y<7@4.:3D(WE753SZG=@WHVGGF0!"5@S!H6LTM@=C+YG$5`CD0
M!5P]`T$H0BB6ZTJ?=%CU@5<8`HOG@7,5=4\78'<.00-^!0\`<*26:SG(`%7?
M@$RHY%;7`$D/@54(`5DW7$?>^S0-<QT@`ES-`%_O@,/7!"#E05H7`U%(4]K5
M@5<P`K(_5Z!]ZY+4`&FOU/H$YRK8<\CD0`]@7S$(`6[>@+CFPC"PA#*(<E$(
MNB7E0!#`T9&'8WS<`_^I+J-W1\&1'U$-``&FY@!A;>L-&`1>UP`X(`4=1/HP
M0.2SKN0,F`*Y:VL-L``AD.4-T&C-DX-`#4(>*-?OQ84Y1>M978/2S7AAAP.`
MAN-XSTUPY$V2=T$,@(-`Y8`T8(6K%?48X(0T?_F8!P@-&CA@.A1B(!Q8)3Z\
M$L/A@X>'HM)P\!!"SJL2'`:1`I%!C"P?&00.!$4$0QA1!XUD'#E0%)@,(3;)
MX0!H2(8/F\H(D>-!@Q%1'\I@X@#"TB&"8#!LP+1T@R4P(5Z!T;#AC!B26K=J
MQ3"#4ZU=8L>2+6OV+-I=1%QR;2LP0TH//$2)"J/ADAP-C<ILR&0D`P>_=\'_
ME%A5(D/APXE!D#*B88JL$D0R<<A`9%,'"Y<[L-VP2%:C#1G2"`*QZ<R&#6'.
M:(`CA_&4#3I@G7&9P8CA#4->T>BP20@&DB5>&1'#PY*<$)B`;.BP]X,.'33B
M6"JQ@0.'UG`X;`"#Z:?;\.+'<]WP9I:NM.K7LR][:0-Y@;M!-0*UB4<&&K#P
M:\C_JDP&'<3Q"B:-;+)*&AV`\,I:@`F"BTC"O=(("#IL@LDEH.B@U09MK-((
M)K``H<$9KUBRR2:]W0<$9ACX<$M1&GPPB"B6@#((!R&(0D-P5F$@1"R67'()
M*S*P%1\&,E`25GM-EK4)>.-A8*$H!HI"A`8@B/+*_R;VR:$3+"B*\EL&5=RR
MUD"-7/(!21MD2`0'@FQBB2A9M8F1FIO@Z(:)F&12`@V@:$)G&1K0\$HF)PK"
M@25&,!75HU6!T:<H/,2GU5=,.KGI6+B<="E)<`GU`2@*W967('QALA8'ESC6
M"&&;*"8K8K)J@.<EK^A`Q"653<;9$)ITH)4%1N`24P9G"/+8*Y=@L@I.;N15
MQ8>Y%DI2!W)LTL@JJ/GF0X]6I?$*7;:642,FEH"`00896%#&(0,%`JZ%E]")
M)JCYQL?!'K-P^F][EL!W:0C%&;$N8#Q\P%9T)-$`1AE&6)<P"/WEY`.;;?H@
M1L4EA!'&05MQ0(08)>BP\/\&/H0A50:R=="!#O!QX(-U`HU,!IP)<Q"N51L/
M`=W"^6(0PY(`-PDEJ""03)A`&_``A!!1TR!;U$+PX$'+-/`P<`8@8,R6QR)Q
M8`096V_507$Z5)C:Q@>W&P(890],@Q@TRZ"!V@+EC7?%3HO!M-`SE**IT4U^
MFJ],9NN@>`F&-J[V2'G3``('/%36@>4:P)Q=!U54$8(."FXH8\P:A-`XL3X8
M9H$&):!.P\>HN]ZS<26$3-+-S`%V\E9.[U6Q53R(843&;X5`@U63"P1W&,CK
M^_QX_*92./7N90<J!MEK=:0&VK_5+OAOO04?]UQ9T"Y7X*/_/?BBC63;^CYF
M/W#_<`.'VNX&/%\Z=-'5I[7)]9"4/>]UCUWJ.R#\ME>^(\6O30/L#_O8$C[V
M=:^"`@D7!@F(O4SYKSWX`I7[+);`'JT/?B64X/8@&#\48@L(>`G5_18XP?2M
ML'P:X$$',-B]EFU%ANR"'A##<YX.5N\]082>#8^HQ"6VQ7Y;X1_AV(.+30&0
MB3RT"A.SJ,7G<9"(:?%4$L,31O%M,3XYL<0B0C#&,I)GC6Q<XAY2D1XO`DQ@
M;PR/$^^H1R5"T4FCH,,MG`2*82V1A7L\Y!*]THDHTI$L."FC&^_8`=$@,E^4
MK&06]]"*1@*L5TK,(R:?%\DRYI%HC$Q+*%20!%D<C9"?_[0-*$,I2_%TD9-E
M>>0L<ZG+77Y2D[;DE!%YR<:6<>=^E)/@^T@2G`SH+W_)!&(?FQ2*%)@`!ZQD
M#V;R=;NVM.Q]HQ3F';T"EE^6Y7#@+.0Y[QA+MZP3A'$DIY/L>,0,@.$O]J-D
M&#Z(R!(,`A,T<$D'O",('S1M"'C`PQ#@LP$C!`(.=]O>!\00B#1L4VBF=-(T
M36""&\0"FP$<3PG<L`F*>M,'?^D,$9S'%2/PYU(=2(/K*,*#,G``#+@$U0?@
M`#SR,(4I@1LG/'<!1NA=LH=$D!2<8`J"-GCDC1VP3CO-*+RH(H8B'&I:.H_8
MKZ"V)YAM#!]8A0`$!`J$""U%W_\,#0G![ZTUAF\1*1&:J@$/#>D5X`H*'N0`
MBY.(011P&(2L2.B!06BB#9C`1/$LVK^TS'$7TT2`"1!@@U&L!VGDF4DF,*$)
M3V:`!Z^00\O(-X1;Q(0K4[B%HYY80+8.A#`L0EM16.I-%,ZP/QX`P[J"H\'>
M]11QM83G39M8G@-:["U`P)(@TL`8RX4!/&DM;GA8ITSI8H`,H.UA6K/[OC!@
M(H2L[4\)P%`9XE)0A")$:W]^J$S]98\MNV6B]+C*'D^.IVNG,X(.$#.%TH'`
M(R6HD,3Z$P+*+80(0G@($88P+`YH1',:^8#M6+J!@EF.>R4P@A`X$X)&!`)U
M,MJ$$?#_FP8C$$0,P5E94TS,@4TTP:<9&`(H2&"!G'HXJD\D6B<^\8E0Z'C'
M/?[Q)_2``HTB``$O"(5Z+'O5[1E!5F2@`2#4.`5,O`(.ZBL!*8YUI`VD(1.R
M2&V;:/"!XWY@`T*(:\LT`@12W+:[`P;O%(9PO868U,--D\%U9*`T!;NEIS;N
M(0V`&M0AZ,\M`<Q)A+=&8?B`0(W)7>X&)C8SI@'FOP9VI4!`X+K]#@P$0C#"
M0>)T"3MKC@><%D@)I@!J@72`"`&F9W4D[.!#,W@#$+ZPV0#SZ<9%6C)EIH$1
M@%"9U.B@"G'MG@<^_5#-N=K#/`!#YK:HR<;*]RQ>%>,9YI2)_U>DX42P^(L<
MVK`!06`(%#O*0"#(H(,/45D.Y(:%'"*]"3668-Y@F!.5N[T)6(3A2%,@Q;/D
MT($RW$(6.+(9)M)0!N<%:E=2$8@<`A$"'X""!R1L`R`>)F=HQH`32D#!"5`@
M\I"+O.0E/X%&4XX`%WSB?Q\-CV>-D(;46,4(-)`#:$6S$4%DHM]L"6@),`'F
M3..[2G+8=J\(X@,>;.(#4^9`NE\,<%$(HLR$O01=/%PK&>B`%)8($1S8Z>=\
M_9:<YMP?&$!AB6WKF]\6.`,@-#!1G?"@WAJ1`\!7$9-U@PC>6R'#)BZQ;R-8
M(.@HVL3298&+>&-+#JO8-E_``/`#+?]D$2AB$#T)M.\I(&80:C0N`/]M(%C$
MI`26(,6!A&`:%#U;%)BX49G5D'=,=&"P]B$.!I1S(5`,00,IP00I`/%R)6ZU
MVFFYMEM&LY\XZ2I.RP)$V(74:%#$1!!GT,$M'%*%8W&`6IIN26%"$`99"!L.
M(>$`=;@6`KU'NBX;^5*HF`Z+0(P("+`0TB8J-25RR2(0'PU$X%G"*_@?41'-
M$119D:5<9$469"T@`RX@`K"`(Z`%*`Q?$Y6(*)S!8;R%'%B9:&2;Z86!_@"&
MT&W/@M0$#]S"=O#`\FT"$/``*8Q-=PU"&7C`)I`!@^V$!EB")7S`3("!="&&
M*'"=+$B***S_"U>,'=D)&G!]TUN`P2V4W_G!P7NL02!D0')]0*64@"BD6D;4
MU"N`3A%V7T>0Q-LI1+8(P@;@W"25P25DB[J$RA2L@@YPP!0,`@C(`1A,V":`
M@0^\`@Z%0170$RSX`/J%Q@:`P"5EP)JAC8AP@!L(#!RH"P>T@1N$`"S05`F`
MPH&%@"6(P6"-R'#P``LR5U7$02!$1!ADPDQ0!`W`@0<46A"]D_&AA3R)QV@,
M@@:\W2"TRQGH(O1!A1A8P`8T@AAD``UV'0A8@#(RXR9H&JTD!AB\!ZR)QC1R
MS9HM3`;`P14&@ALP4$XU`H,`P9=M@`<$PB!TP"'(`0\0`2C\!4GT_]-!Z`"#
MR**4=-P!.B`$*B"1\2,#KD`AG$4%FA'>-((E:()<X5R[J(X/0$6_<852A$O7
MZ!^I6!S==0`I6`V45$%1)&,7,E,:X(@EB"!4D(%+8``7<EU'8``-'&$3]=8&
M,:%8R((A%$(A&$)-WF1.VB1/]J0G3-%9G)T9A<%[8,`U6L`UID$@;,!$F4;=
M=:%KC(1.``$-=`0SEN%;E,$B"`09+,('K,(E',(A7$)DI$%>:(5"CD1V0`<1
MI`'IA0#JP8&"(65W(66O-!`C`I!W;`!=ZL1)70=CZ$"QW,(@#((@5$DB\H`1
MF!\0Z(A?*9@'V(<@"((ER`(/X`$L#$(8D/^:$O'+)M7B6=RB&)%&?_RB+^IB
M!^[@,1:C20J"&BAC!EB(&BEC8B"&881!:,"%P,#:]5@&9K1+2,K=-[;)2M#`
M&32"#T!)]ER&#ZA$]ARG5@!"&O3(7MBC>`P-)QQ@`_JC/G(GD:F`'IB%DHE'
MC@S<3`PBQ.5<(]Q"(ZPG*7#>]A#$T&6)_BT7!GP`*>"0"S+=!QA!1Y;!7'C$
M1U@"H_2;,-H&"0RA#APA!@1H6R@AJ)3=+GP"-:&<1EFH":#<"5BHAI[`"P!E
M67B*=?99&.PF45JCP)#FH]T'%Y:`'`RG;Q"!,K;.*NP4B6RE!I`!'JZ"')R!
MCY(!")BE*V6`0MK_#"2N`B8(PBOT6PFDP;[A"!CLYC6FCQ!`R5%.HVF@"6"*
M@F!6`;>5@8\2P3F2PB4(@HB@I)-FYB:FBH]R#`<TP2"P`B!JT0;$$;6!IEC0
M%RZ29K+H8I]J`/3M8!@08R.8Y"!<7]-UEE6NV_>5@`4(01B6J&A(JFYRS7`(
M9JND008`PG`*&.*!`0UT6PAD@J5@0!D,`CWJ0'#(@2Z^11@,0O[8X'SNCY)H
MYSYVI\HYX'8B0`K8P9-88`]%:0B4P7FZA$+JAAB0`1E4B:4<B7SRC)98'`A4
M'`8XI6^\8`SN)0UR(1`0XR#DQ4BVC#%ZDXYP'8,Z:'G`Y/Y(Z"<,F3\F_R!D
MQ:O*N4`@!>6(<I.D&B4U7F,;=&,:>,`6DD()$$5E7*J%+"-L"@0O]L>I=H`F
M3*<%P`TD7M=;I$%1%-XBX`9SF,9F[N%"*<0UTM-=,E"5!A0U<B0'-$+860`0
M"$)+"J;JT,#Y#($/_"'RT``K^``)B)<&$`$LZ(`EI,$N@@!N54'CU)O0LM/S
M^!*>EH5H)E]PYN('`B,<0,48M(PE&.KUU:@%\$"-QF9'^$;0AD@(B(&)4B-1
M5H;-:,NITHH@=*I5.%Y[?IL&B,%IP`$K(!<HE`$>O`*A'56U6L(@B`&()%:^
MX&,"YBJN<N>NGL`=D,5X)A^6\>`E:$+($.EUM?_/2+).W;B$?!Y)M%9K?:Z"
M?@)!<WI`%0#0(*A!:]P@()!"S'SBHY`!,8(7*<@`#*Y+[CYH_O2N3Y&'A'J"
MNWJG=QK9+=RI6`@E3YEM_IRHOFZ`&P@"%BH7[`['Z6Q"JFS"4G;=;&+E+I[!
M5KY=(SP&O)4!373`&8A";`C')BP"450'39#!>JK;*PB"&"Q"(W!`VEH`=TW8
M&01-?U1I35WL7@Z!*,A!&JS")<)N@`!6&<"!WQX*'+@A+@R!#+""_0Z")7B`
MS^*!^0J"[95!&XC"6&E1\37M6""?6_@`EF@`"_>'8FK`$`C!0N%'#=^&#XB?
MAH5!98!`&'"&#@B"'`#_@1A\``]4@=Y416PB<:@,7"/(P3_U[(AHQ5"H7>_5
MG"`,0@L/12,(PA6?6?<$J<IRYOX8(+QV9P/&J[SJ8Y$!).0"*U?H@./!@9W-
M\);A5\M4@:4T#:B*C!BH$0?\,6#\<4W93AALP,-L@%D!!FX&0GXMU"/+UDA<
M1QCT%P]GR0^_I._F#T])J"SH01Z$LBB/,BF/<D">A8B6!R[J@!'D3[&)QBN;
M%%`(&\=$%-:XZ'/(A$-DB1A@FBS?T!18Q1#(@?LNC(L*'-C(02,HUP8`P2(,
M@A$0`9;X@#*3U"OG1U6`P"!L(*HYQ#4GL@8`02`8(P=T`,>T"P@<IR`(0<TU
M_P(@"$$5$!0/`((EM,'G"8$@_$[7I`&'37$6Q1<*IS`<IQ`,]9!YX8_ZC`?Y
M)#1TV=`5?=?W$$$)W"M\Z%";6-#S8&<^$N_B;B>12>"31$E]=4X>)9%:)5]!
MXV)_<$T(M0]T685[T0\G/]$F_^YU2J@M*:]"XX_[=%-")Y!M8%%*2PFVM%7R
M#8P3!37YL!7X<(!R&?0*B0\EU=!2KW1#IP\9E5`935M`Y^F?!9$3'M)7B\=8
MBP?B]F,:HS$_JK$+>()X#C1$GA/^]`Y".U%1Z4M-SS16M05.<Y).XZ)/B\9=
M9]4_DW$;$7:^G'!`JS`2/?1@([8N\8]V)NZ[>C0;'__966039(/*%85U1F]0
M*=B"6>!"*)2V:9\V:J,V9:$%H>%U8#^V9V_V4,NVM$U/5^_"TP*1=UDU;4=V
MQR$!`GKTKB*@`L9K#:RV>&):;Z,T-[&17DL)NZY`"DPW=5>W=5>W#=2K6?PU
M'O%T;>WU<H>W+GGF;>\"8XM23X./37-V;/.4,&$G%KB`"[1`"\BW?-,W"\PW
M?J\U1_V/2'\57C)T#!V)>D$T=@W7)#^34.^2.#%2NR9N<$?XKIK`"V@W6:0R
MXKB/`;4W8C=0%G&/AR-VG<K1;9]WOO#`U-`,!RC8!\A96`.!82N1UO`2=M*"
M+,A"P=WXC=N"+=Q"P16<)Z3_P'9:4Y+!M5:`0!7`P1D@#V"XFN?$<P`YS0.7
M`>J8&4$5%!D'")_U4*NI+4QCAS#E3_">@(27N82[P#5M][URDTR`P02KE'B[
M!0@(&S>5,Q!Y@!-Y6EE#I)'C$7DP;5>;.';9D!@<\DB6Z\T5SYJ+BSE]4X%?
MT`61YBYE``G(I'H\%F2M4F7]]T4K$P^`0B:,,U7<)[D<%B;TG\Q@Q+=2F6-P
M`"C(0A0SQ$/VT/IQ\_I8+UM`8G#E4H.;12S,`18P@;`/.[$7^[#;`8C>TJ)S
MQ65@@AQ<PBJT,!D9]$L/-5Y".A"%45X:+DE,@::65W/#,#*_1<G.-D8KD\T`
M0G[I_Y%BHW!NMP5V<``)Q&*.@`=V.&1*R@A):-KU7,>$V2BK90=W0-AC\SON
MV,Z1-Y@&D`:#Y1`;W2L)4`(M8)0*(,`)+(&%HT45D8=I^(15G`$L#-B26L5"
MW0*XE,%^V,RXA("KX_9:U@7/)**FK4*L+\1(+$;%Y$0?[M%7]W4CM;:^P*4;
M+!@<U"BK+02V)&+(A$#(7`>#V:@'_)=@IT:C"?PE%9,R17W&5)K"9TD)<$9>
MG@ZWLR%\/!7`-\WI$-*]Y7Q_#$$V35@(W).FN9+9+X\H)-0=`717OWNP!D(@
MB,(E#,%AWH>I9L6A=R$-@+!JF%LCR$"##@(>@$)C<`@<D/]8(,0!E>%!E&\`
M&9C;)5@*$&3"EF@^!YP+X%N<Q0X"@3C^%D%H#T7\*:'%-)T`%B2[?_/4$"A$
MC_2G@HPZ!E@`#<C"@8'"&82+#U,.J,M"H<AZN'"^?0""83P&\&5",`^'MJR"
M&&P`P1$'AR?2#"R2?$D[9T_!*S15UQC!L(3^*FP"3O`3'!P(&&3;DG;6M])%
M*R^4)I#"1#3'(<`!E6T'0!C!PP%#B$$T,&A0.&23J$U5-)08M&J5I1(:PFQ:
MA<F'!2&KY%`$DD%A!A^W9,G94.*20S`;%"K\($?4JTT\0FRZM>@#R0P,.W0(
M*6I1"`T<X(`B!4J(!A^81($*LP'_#BY1/A+&U+J5:U>N>UKIVC66;%FS9]&F
M53OV$@>O6C.<N06&QB588'1@DJ,!$!P-EL*$$%6"AR@01%X1H2&H+1!<:60`
MPN16X89+83B(PD3#""P>)!4:$66$1J!!("ZE*4'$LXS$,@*EP9!&%MU,?M_F
M?KL!`V^O&4A0JK76[*<5=7#A(CX6%.7<LYMKQ8#!PZM`1HR`L73)`PU8(S5L
M$"^>`R@U;6#1^"`J3-8,0%X9T3'H5HD2#TM,V:2CQ*V#4UX!0H=5W#!*MP,1
MS&T&3H9;SL&U<!DBJP05@J.MF#+(\+XS2BACE1)TN"60$M*X!0X=TECE@R%P
M`:0$,EXI_P&$3<@H`8P8.WC%$AW`2(\&5F3`H(E-/%`(`]?*D*&,34"08Q'"
M:`QA%3!*D&,OQ^"H4I,.?/I@.QDWR?)&\#3(`(R;2EADD0[:$$4(F!;:I(,T
M+*KRD`V,``4(V"SIP!(\2@C#$A"`@.4,$$"CD,(]9GG0T4?)N@3.W#*@4X/9
M&KGTC$'X\@LPP0@3Y8-`Y)A.!E%H`,(P#(``I8.8-@"L/",PZ``4(K+:0!`X
MIO-`!@YD``$$(5@AH@18`AE"AB+3R'0V012EL+??8A#.45;T4.Y!(@_$`(Y-
MG+L4`Q!>T6P37`(!`0,=9-%A.B$NV4Z(\L[P8!.+V)L0CD#*Y/\!E@XW"0,,
M,391[97/,AC$#0XV(<*":"'6#8,%&X348ERCS4`.2>'*0#\N.;A$#!UBM&#`
M$BR@895A8\R`@TQ>H@&$$)J`10=;A:`.%!_^2D.#76/"0(S),."@A`Y*"`$$
M'3(I\)5!ABCA`PV`6-D"(#:9NB0KKS;LX47D2!0$J:NT1(,I,)GTITWNDP,,
M,-J(T=<.9/C6@T8VH0L$#3X`A8<)(]9MCU0L+IRX"W6K%%H--M644SG@B#6,
M$D21@0=00!BDC(3ZYJ%5MUI]M3)9-\F988S#`RRKA,#0Q*%;AM!@"+M>26.#
M-/C%H/'`<_.MJPRJK=CPM<#M%@Q18?7_0>F[-/``CTU"R$`$63"VL0Q9Q*"7
M51/SC2DVDJ0LP0U8&KDD7BI7B;[20!@V(E'>X9^8P>$?'>)]!..2,R8.@/A`
MC$PS%!L=,,EDI$`4#0R(-<H,X@P;6!(H0-$N6V'%5D#`0.MH<)4)X:XD"O&!
M)3:Q"5FX@6J6@,4K%H:U#EPM:Z#1F!PL8(0ME2D->RE)FAP""[.A371E8D@)
M;+(=2SPI!(&`X"LRL0'8O$(6@U":*/X6'J],"D%4Y`!8Z)=%LEB"BK])`[1T
MQZDP=NHO@:E<83Z`!SQ<"H@R:)4'6.6J7,F**47;A(0JLZOI@*`,\*'2J8C`
M`1H8K0SI.0,8_[\(O]Y1RUI:3`NW#N0=C&&`![(`0G7`@($,@``4_-K`("SA
M%@Q8H#IBV``HSD`2.-P"%^V)21LXE0%_E>`,%]J`#L;FF8<)8F$-NY\B(28_
MX3DR+:BCD"PMZ9-"\<`(<G+9971`BA`4,'HT@)X07C%-#FBB"A\Q%@U>H9Z=
M;7)G!0'%("!YJ3!,)CQD\,%M<-D(-R`-:6%H%]80I2JME0D.,/3!ATBRB#9H
M10X6^4`:+J&!*F"BAQ;X8=XRL($/'`T.F.`!"`@FR`ZP3`VVBB(PN[*!P8F%
MF(9#'*72(,:47FJE@?"4&"AG.5$-(3X\.$0HAR!'(;@*5I<I#ZYL9?],Q("!
M!X'`!!%8(1\\X((()`L##<0@BA`DLE*<`NE6?,<5X#2RI&6)#H+@`(LPZ(`(
MH`@EN3)9)B)0;UVB:$13B2`(6,Q+%*G,P`<VL0M77DH'[.$!?4"$0AUDA`?]
M:00/P$`*'3#L#/M45!?A1[&NIH6I@$L0!T(R.2.L0A!&*QB*/A3-`ZXL`RH+
M`1!V(0<4,0DQ0/@K+GBP'A]DH((DP<,N9!,T!*9!!V5XA1`*UJ%;N*$$J^!0
M&$A1`A5F`+@]*0D<#*J7$HAA%;.MS"(.H8,I;.1L@X'3VN:T"B+PH*`="$0C
MR`H*)EE"$#KP`2C`4!W,7+4K6)RLQ3AV(##_G*%,3?"9D'Q6!C%H``Y#`($@
M0E":(IU)%((H`27EX!8=R*%(E8%#(.7P-\Q^!E89<>MBX>"0-."A"1@!A2@N
M$;O]*F3%],4?"1A$TONF4S<<.,,FE@('=77@$#GCS>T&<B0\B(+(@0#"40(!
M!I\\Q7Y:R=,F8!F](6""%`';0`@$T880&B$\'A+#+UV<.,G>]RQXA-B<&K()
M-SB7!Y?8R$A*$(B>E$`0B(KS!ZH6$HXT#Q"BT,09C,R!0+A+T#2XU!!D8>BM
M``$JFS#"!A@LAS2DH0,,SH3[)LRE*NTM)E@[!-(:89,IP,4'(6P$&>0P44QH
MPD"RE$-0OE61B^3%_ZUE2)<.+!&5-'"`*J,)LU88169(<?&R^X/548P-)^=\
M(`1P&D]XPA6>\4R;BA'M0`@XD"$-"*LR,/D`"#J0JVX#$[*Z"0XMA+V+XE&(
M`R'HH;1[\V/*],8#()A:KJ@H'JY\&]D*:?<^>6UO6`G\UXJ:02F&*6PS9TP#
MU_Z`VC;*)6@;V]]K^[9S-@`"#U"[3/I6B!CRNY5V9SL\WX8)92(.FAYVH(L?
M>'AX0N#<K41<V@UOME:X%%%F3XH#('"+OO\]<)9'J]Q<N2+ATOT@8D>LZ`5_
MR_U\$IZ$6-;I+^;JC*,=N!]3O>I/[SK^QIST71#AU]K^'5R`*_&M@#DF1?],
MC-?I:_8RP1U#;"^3W;_^%K#(6.QJ.6G>`1^T'P?^0%M->$E!46%%]F9:A'>\
MHC(0]G1'B.N!!P$/FOZ6#I1A"%E__.?S'NR^'R[SH#=]WH%W]<FN6Y%;W_KI
MC_WYR,^O[\:4/=XI57G8[QZD@QO]X3S/>^&'.?6')R:-><=XUQNI],./NPQH
M+_8F1TSN3Z\^_HZ->^=O/V)7;,7OU[)T[L.^^;HI=_'3C7RM*Y_]61T_2+LX
M>^-/UO8BSTT)JO#NB3J'MC**EL!];@-(X"@&,.\(;O>P;3>TC^A&"OS2XN_>
M+P(AQO#2+_BBI?W:3P*E*,P.;OY*JK(@9@/.0!3_;L&7-H!@5N&P%`((,L$F
MP"!!(@H.7N*M2B`3+J^SOFX#Y.#+=D_0%@Y6\$+W>,>^'/`L0DX#*:3\NJ[H
M@"/&A"WQD+#L]&T#0*/YJ!!!A&GTIN^8X$,,X,`-Y(1DJ.0,^B0G5$,,6H8K
M)F52-(X#,&$*3*O=8"(AJ&A"P,SC.JB+8&(1TF`!2X(DJ##J[NY](NH*[\XK
M$C#V*FA:-H`RRJ_H1.K[BO`LQ"\*%PD)SRW=OLH2KRI#?"*BYJXR@$GRTNT'
M\0<,,"$$R.`#`HD,J9`#+`$(JJ`M.(`#=,"QP,`(W,`2J,1"R"#;IL`'-@`3
M2,,PI@MT!N$2RH`@:*`,_[0C$&1@*T"@#2ZA$5X"TJ8`NGYQVQ`J#18AE6*B
M`\*@#`Z+2B**J!0J&RWA##I@"+CL!$=-`VHD!*B1%SN`!\C@Y,0`(2KCJ3B@
M#(S@O+@,#&3!$OZF-%(#CN!G`]Z@%;1E$K=("4%/(B72]"A0V%@OI#CQL7X)
M%`\Q^6:@$SRPI(C`#[7B/@;AU3+$&_T-$\)@7\X`$P:!![0B5FHG#6`!$]*@
M#6Y!"!+&=MZ0<H8%7'B`%-(@JOS""-`E##JI)A?A$L`@K'CF$E[A#&@#"#;@
M$#9!#.3@%L[@812"7#`!IBZ!#"+*)3.@$6!ATN:J"C2AW6!!3J0$")XR*O^E
MN/]*(`-(1@9`HWT^P";$(!"RB2#1ZU3P`!799R&)$"+9P@(WTA(ODLST)P>W
MSR/7KB1@PB2Y@A3)#`0?2P/^"A8RH0HVP`?$BI9N(0SD`!;<8`H``:#\S1+V
M8ACA(*(L00PP8!!LYQ*F@')"`+A`(!`"80.Z!@2,X!5`P`+.!..,P"@X"2(L
MH38M8W(&PP+6HP]C`@16P0@L8!B53'+2,FPR8!WOHP1*C6UDZ`.,("\%PPC\
MI`\M97\:Y@-(@59``(H8!@@L@$Z($YQH0#.Q:C$9\PAYIR(?,^Z")_T4[T!Y
M)Z(\T1"Q2@DA]%(XD\SJ#P8_P`VHJP0V`+G")&#D`%K_7&8LJQ`P;//+-N#4
M$D8--N#2A!(XH3(A!(,SB(8(,K($X`!O;@$ZVR-%P4"%%$+2Q$84=""B+J,[
M+R,#%L$L-6`1RD!R:J@1ID`.VB`#RD8G'.9,0@`37G!_+JUS,&`]>&`1!<%G
MCJ)AA/!`&I`Q&Y-!W13],-(Q&=0*,X0*F=`R%24+Q<XS%84'B.`#R*`#'$VB
MA&5&?"`-W``T-*=$PR"B&@%%'S4#!*&!,*$*BNNTLL82-N=(*L<()B,#;-0Y
M.&D0P`"X>/1$"P-1-"`U7&A&/L,RE$P#T'))`RJ5SJ`1+($(O+%T9F012G4T
M"D(4VH0OO=0(Q'1<_`9G,$"-_R[E/BT(?@04(BO133D13B5S02700"D%$"]3
M;0#42"KTODHR8VY$",X`0'1`!R[A:(:F`TIM3'V`%#@L=1HU1<6@.U64@8:Q
M-[,)N/Z1;3P`#C*!`XQ@8#%`AIR#9'0`3W:TC'KC-@4U4(%`%L`Q+!7+-E]-
M",0J+<N`)`Z!##``B-*G4$2%!W#$"&[!?31`#G!A$,+E=([U/GG@IS1`-`:I
M#`P#0PPT$MDT4H)/6R]Q]X!6#:DO.$:2?C:16D,P$+%*[H96`\*5_M*T*SI`
M$%[AA!I(*!Q"3R(JJC2A=M:05$E";'6E40$A'RUA/6V0T3C``P(A*OP&`X@@
ME#!@"/]"*1P;P2'PA@PTX!`R25<R:0@<`A-H1&S81@-B*"Y!Z"7DH%&%HE%#
MID^T<R_\9!4T`6\:E;EP@5:T`A:)P`,RP5T^P*(X8!#B@P.&K"'(3C&1KF<)
M5&FOZFD3!\9J@>^Z2OU@%W_$HT[ECG>_M22B]@-7]\R$8!`XU-]X0`@,1"%6
M8V&W(@0\`'PJ3..V;6K`30ZO[>2`P,#\;0`SP`-(@(HZ0`B`8*/VQMT4(N:8
M-VH.,#R.!C1*P`AFYE745P/J-P2,XLJTY@.$P`?,-P,LX)]"`'"NC.5*X.<.
M>-N&`"$VP$]C`)B\KV?'8EJ%-G=S(Q/CU((SIDX#<0T[+G'_FJX#M7!JI^@B
M.F;MP"Q1[,Z%N&(Z+C,43_CZ8EBK.D:%61A#?N<3*TT3<*.%+R5HC,2%C03^
MUI1-*5B#R8WXC%9!+?@1*\,3M<V)P2[ZDLX4'TMVG>YW06^3K.0#&@_VHG42
M(1")QR\R[RMIDU!I"W&-%]`/Y6_T+I2,HU#?M#C,.*`A)7@77C<"L7CWK'7&
ML#7VB.Y`&I'WH'A"19%2F#!X2VH+Y?B1`\_[;%>,Y72*TOCS^ICX$C2#(1F$
M=Q=/.RAP,@#ZCM:1XAA!P!*K"D^&._DQ2>(-&D6"C[B5\Z[I_GCU`IF6?R.3
M,821'8E/%85$&E=T.@#5P*"'9&EX_T$`U<I@>76Y]5RL^6`YC\?XF2URB9^P
MDJVYCKU"A&N/A+<BFAI!#DA!)3I@$38A)$BH3%2F-K<-$VX#$S"!TZR9$SF@
M#U)ADHMPC^OY\S99,K6YG^G+E[6(J290##K+`GC@0^(597R@.IL))#SH$I+S
M/AU&H"TQC/>9E[6NGS'@G\\XES'ZU_14[$XY-X*">0>###B&84:M"B8,AHY"
M:P1U7#EZI.VX(?79`3.2^RKRIG<C<.0'W81-%$1:EYFVX#`@!Z@XW3AW`AMN
M$01A`]S`AB3G83#`2K#*#3+!L7!Z_.ZY==GT%;SZJP-O!Q`NW6`A>G#:(T%Y
M\83@%$I9B__V*EJL<Q!2T0*TFEYC8J\KPPV(-(G-.I%!RF4201)[-M$&V_$P
M@`I0(1<F[Z,6.\RL(!7F.HMZ.%I*8(B,0G<6H26K`"S]>B8.=[*Y+P-"`!+$
MFDVYC+Z`6H[?`!5VFIC"P+3#C"%E>_3X.3=0X]6PVD:3L[B*M$RLA"2$HA%,
MV)I?N^HR(`=*@:@EF%]L^^M"@!%R.]VLJNL"^C&+;EP8(9]'[U\@)@UP01"L
MQ`W`S7P(IA$HXX4RX&!Q89RM1`=2>;I/+P.N`!6@NV=A(1KMV^FDX!006]AD
MP;__._F*0,#!KZZK2#6M!'+VIDHN00Y4-3165P@>?+X/'/8\(!'_'CN/QR*S
M-QRD/L##+WMX1!QV2<XB/<`/4.'$LPAW$P=QB?8Y@'C[ECMH#3D(2F&U$WNX
M1QRDK$#`9[ND;`:<@SPF$ORZ?Z^VD[R>.<`/3F&_\]@2HI>;@WP&)L$4J!R[
MMQNJ*[/L@`<23`'&M>@59@#)GYQ:AQP5'A+$=P$.5GS-I24$/'S`^\YVG"['
M"Y2D/:`/4`&\B]#*Z;R5=X`2IAS.RP(7Y+S0$Z0@`#T5;,$!<:$,'+TK/.`-
M3B$5(!LB`^&H+YU!<P`24`'/%7T7\$!=0OTM<L##7WP2'^/+;1NU]\`43L$5
MV%07!$$A5UUI=X#4!?W4RT(2?H`@>MT3_SW`"B@AT,V\I`9A!OXPR3.$`X3`
MNBT[CS%A!WJ=0:GC"I8]%=Y<V,<"%VR!#W[@WJ8NW8-XZL2%W848BN'=$]V]
MW7]X.E;G$^,=BMU=W;6MW^-]$+7-A>W0$Q6"!*@@$4Z!R'M6%UP!#7[E(V]X
M$*4CE"/^A@FQ@]Z:A:-NXS$>+BC>XT-1A0&^`W;@#4IATYN=S&2!#1Z8X'&X
MZ["<^&0O[SP@"*1<X<4=+1@>$KJ`"GX@!V8`Z'-`Z(=^!H(^Z(G^Z(V>!G0`
MZ9W^Z(M>Z)T^ZJ5^Z75`ZJE>Z9\>Z*=^ZFF`!J8^Z;E^ZH/@"O8@$DR!V8L<
M_'1!%?K`"G2`!/\\8.X]X`/H?NZ_#>_OON[W/N_K7N/HWN[OWN_W/O`+O^\!
M__`57^\#7_`%GP1((`BR(!%*(>UI8>V+L.WWH`ABP`-J\2@^']G<8O2![B@V
M("C(8]IJL1&!;O5/[O-=/_1'7_1+OQ9Y[?5O'_1GW_9;?_1O7_9%W_1/SO1Y
M+?8;L?ASG_=Q'_3)@S)V7_B#?_0](`1R8/)+0>USGCAJH15,H12\GQ,XH13`
M/_S%7_S'__O#/_W-O_S3?_S!W_S;__S77_W?W_W1G_W+?_[M__SK7_[K'_\!
M`A6J5*E:U=J%,*'"A0P;.GSX4%<K4Y0H,6($Z:+&C!H[8O3(T>/%D"+_1W:$
M1!)2))`L-Y9\*5(EI5("6]'2!3&GSIT0=<WJQ"A1GSUOANX9BO3HT3Y)W[Q!
M](;HT:)]G!KMPZ?HGJ5:IV[=FC0L4Z5?CV:]6O7J6;!IP4;]&E8ITZ90WY;=
MVA5KWK9>X<J5.S:LGT20:!*LA8NGXL6,'>K252NRY,F4*UN^C#FSYLV<.TO.
M];BQZ-$(<T6FA3IUZE8V4==JK7HU+8.T8ZNN/3NR3=JO41OL[1OX[]8&:=6R
MK1KX;>,X23MGK,OTK%FMIEMGG8HZZU;965O_GOUZ=>W5QX?W/BN\^.[;V5.?
MOOU]>OC;RT\_;_Z[=O;8M4^O=5]ZXXD77W[^_\WW77_UN4<>:[6`]ER$$DY(
M88467H@A0LUER&%$'7XX(4X;)C2BAQIJN&&)NY0H(D,LHDBBBRFZN%"+-?+$
MXHPW*F0CCPVI"&*00@Y)9)%&'HEDDDHNR6233CX)99123DEEE59>B6666F[)
M99=>?@EFF&*.26:99IZ)9IIJKLEFFVZ^"6><<LY)9YUVWHEGGGKNR6>?7$KB
M!4*N>)&80KC8\I`J6RCB'"Z(()J0*XCL@F@EDC@G224,N?*0HX5^J0JBJBB2
MF"V:'HE+)9]"),FJ"MFBB"*05H*(*I%RBA`NMOK):Z^,.2'`I)(D@&M"B$#Q
MT!,.,$J:+H^^^J@3JO]4PNQH4$2QD"L00+II`[MZ64D"BKCRP`/(<@$!DJXX
M4.Q#MG#![:L/.-#``[9\P8`##%RJ2@-<Y`J%`[X.3'"NKCI!``.V#&N+*LIN
M80L$"9RZ"R+E(C*L`[OBLD6YC"H"`02D>F$N%Y5\@=`7JGSA2B5./."%*H@H
M8D`4U.[RQ0,BN\(%%`]P4>B[$,3\Q`-;X'*M+5$X`$$E7AQ`Z!8./*$*+EP\
MX,0"[6ZYK@$8/U")Q@U<JI`J4$!AJR375DUV)=,J`@6ANL"]A2NP>O$$HVXK
M!'<4#%1RJB2VV+)%W@H)+LFQ7#2GB!.ZV-*`(@Y,&@75#1SP+RY/*-!`P9[_
M^UF)`@^,^/("4`RK"@10(-(`W@OL6LD"7GBQP!<+0+`KZXALT4`E#'"QM!<,
M?`$%U`XD-GGO$#CAA1.(."`)YEP\(8GL7#"`2,U?*,!L)09L(0D$3SSO!11;
M>+&LST\KPL7D3T"`[Q=.&+"UE)*TOI`3/M?:`!3Z.^&*3[FB`>];END@X`!3
M-(!33T"7`@*VN@5$06>5.(#^%$`KBB'"=`U(`+HHY0"706`+#&`6Y'S7@"A(
M,"&)Z9<BO+4+R:E"$D_8PHH2YP`@?6Z'<OH"`.BG$"<X01$'V(("AH4U!L#/
M"0GYX"Z8YP24(405/7.``ISH"O/MPA4,(!E")A?"_R@DX`%?D(0#($?%)U0.
M(>9J0&+(B)!*-,`6KABC$QA@KBVDL0$,Z!?D&O`R!4#@7ZKHXY6>`(`%*$1J
MJH#C[ECG,R=`RF((4=L3$-(`?#$07=B2X\^VV$6%[0*."FG@+GQWM5W@(I,)
M,%\#TD4I;S5@4EQ@8D)4X0`N](M39D1(#1,B.1X*TT[OFE00F?@$`TSLBE_8
MPA>:EQ`OP')HS$M(P+A`0B_N0A+Z`V7[,/D\P"'B"1X\H[>F5S@V+BTQ$#"F
M''6U`&=RH7R%^QD4>M<`74SM"]AT@@T+^2TJ5>(!QJ04`SA7@#GZTF>*>`"S
MI#G%)R!K%P[P@D*=4,M`%?^RHJILG<!&65"$8'07_?K@*KW02B@\(5"Q#-NE
M:IF0L/T+C15[@"]M6,F/#G.G>`K9%@]0`&T-+9.VVY4J3`>%UU73EQ5]P,08
M<*U9-F`+$/":`J(`!0.\,'P8]:@MNEBXV&T!"MASXRBE^,XG#K5\4`B915^G
M`$18M'E#9$#'#A`O+:EB$PH$VC:]!;,'D*V07G@>"=GWMRLBPH,/**%$N1"Y
M>[[PC;7BED7AE@`O<&\+!S`C^(:&D*^Z=!<P/>4"J"<X\4D.I[]$B.1<Q=/8
MPND+4H0;+EP1!>;=%@K5HB'U=N$%BID-HQ"KQ!-^VSBRRLR?NN2"*QSF/"KB
MC+?_DVK<$RK!,YP$5U"+VV)N"14KZ'H!7MC$1?/0%D,G1`%B88H"V>890PA$
MX5-?<(`#OF"U>BE"%_45'R*<T("IV4(7]X2`),R&$)MQ08JJY)WX<$M`J@W4
M`5"`E"W0AE[V(41X]GV`*E+7O^9PH:"5F*AL3XSBB!@RQ:,!D@X_-338-F1F
M&=(%+F[,XASKF">X^$)>=\PA+I!-)P$$LI&/C.0D*WG)GZL:1)S\HU`%E,E4
MKK*5G2/DGM2M4V!S2",K\:\KBWG,5.ZQ>RGE!9NA>0N5^"JR)'&^'U>B%I)0
M1!2896=$Z&)L;::4INS,NP^G"A%GML5X#TSF1"MZIW[;_UQ#I[8`.!,P<@>`
M'@.>X*^%V`)Z"IA:7(7W!-F%4&0XB^)I%;"`AE;P`9OCI@/FA]-%RWK6O#KA
M-A$ARK,E=<2Z(*@J$K#2*4..$0O0E!KA=THS2H*@.(.`([$70JV-,@H*-1JM
MKXUM/`V04[9@'4)JB5L&)"!\B'#4`Q1PR5=%;H&[N!;T5-FOL#'*8LO:YN3`
M9E;5??1:V>ZWO^%D+I?Y+;BM,]_]OC#(\,'YC,7ZZ@MM9;ZVEAC3`[VN`QX0
M!0-G[7GWPPG,6C>L6/][Y"0GTT`OW6T^0D$7]R.@>4/XA'QERL2:,RZGYND*
M`...:F8$9!1D@>FIJ<UA"*$NO?\4(/*2*WWI7.(6+C9TJ(18.#$\,Y0J-10T
MG!3JZ5=?T=6U+O6AZ8[I9"_[FAH&(GJ'V>QL;[LP9>SVN,M][G2O.Y,_?*%6
M?:%:$,%%QJ<\H2W;??"#-R6E$-4P`7++;K>2.J=PV3!<09E2[8H=?G51Y!4Q
M7E`E2GRD%A]OPHM^[K^.-`2FRCH&]`X1"/S=+3"-O5K<$:KF90!4HT"`\R$B
M;*J71/CT!87$Z,()!3B=OCQ,+IE'K`%C,Q8?QT95/I8[YAT$_.BOOW1<!%Q<
M68R9ZI)J"GP-2ZY?<)G,(EW"2L!/J;5\@BLZAE+?*R!WQ78`FYWP!/Q78FF(
MX!X7JA7_-ZJ`?^6B"A.$/JKP-!2#?0NX=`W4+XG!>ATD4=BR2TZ0`+.41?22
M63K5+[I00R%$4OZ2+JMT*OWR:ZJ7+PNP`,_72`E0;P@1@0G@!.T40WED4-;'
M@#F8;1CE1ZZP`":C/U%`@7^S>S$7,'465PJU8&Y40S`30ZV3+GMV*G)42"KS
M3$8C,R:#,<X66C_H,N^#,A9#520U?SIHAO]&5B\T.!<'`0<P@2$8._,2!;0#
M8`?@,O42;=.S8+?S@ZS74E,T1]=S1X6E1'8E"8*4:2"D,S*(;`V%2P]P.3AX
MAI-(9O<R0U/D!>5W8+:""XR"@.7F*%Y09[80BFFS>VDCBB05_S@6=BF=F(JG
MY`6D`HLAA8":B%U;="F#@C$_1HF]Z(N_"(S!*(S#2(S%:(S'N%-PAXS+B(QP
MQHS/B&+O=SJ44CBM(C@DI0JZT#.3LC)1,"IGTV:`PEMHMCK4.(ZAI0CEHRF&
MUD"N<(W3DCBG4SZV8C;H%8]><&%]5(!0H(#0Z(\$XVP^(U1^TU"30D8^XS?'
M<E6TDUO0<P"J<T3WE%2-HUXE%$<&H#JO$S"\DW&3,C0+@#6,B#L4AFE'E4(_
M*#'+)C[;\H\M.3!9<V>'N%[]4TN%%#KFPS1G0U*9"`7<(TH?9RNTTDJ\DVZA
MPRD8!2B0A5'2XBW[PD4MDTM(9T20Q?\HA8-PHV17?.>26[DGBM(`"H!29_,$
M*D-A:`-L*M4S-B0\^)=J"C5(,-1M*;52E616:N0$4_-JA71<4KAM86-$9S-$
M(#A65UF`#/`Z7(F8>8(+@Z0(T"9D!*4+5<4H&*=^;*56:B,N9D5&XA,^U[1L
M[O0]K-.80H9'%&4`K=([3RE'DH`]DG,_FF*5WC(TBG"8B6F;=2(Y_L)R]E5A
M-5@I\_($AH8R`T5`3J`V"`$^`M@_"S,OO;E-HL-L%C4UV$)"JH0VMA"<"(8^
M%45@MB)7N/0%K,-1MTF><X)C+-0I,9(KZODIJS(B'><0R[9V#G&>$:&,Y8F?
M.Z8H<%<XO)C_G_\)H`$JH`-*H`5JH`>*H`FJH`O*H`WJH`\*H1$JH1-*H15J
MH1>*H1FJH1O*H1WJH1\*HB$JHB-*HB5JHB>*HBFJHBO*HBWJHB\*HS$JHS-*
MHS5JHS>*HSD:H@WS83W:HY0BB:01*L[ACHH@"0?1>%KR7#_V83^F*SY:/SSA
MHTU*(:X0I6@7)4/J$`MCI/'"HU,Z>:I$+8H0I'U79S@X*F1ZGZ2Q,!@3I4&B
M*XC'B5JJ$%::$W8J&EAZ)Q!``'WJIWU*+$]P`&6Z$^^G*:I@0:.!G08P``(P
M`!Y4*'RTIDZ""PR0,"-2001@8L92`']:`++#&-[SIP1P`,[I'+;0_VD-847^
MF1/F%5(3XCW8PA`7=@"-^JAK]P"CVJ<%,&3]-P"_6@"XPQBV\`"-:DL*$38$
M(`".VCL5XC",NJP'$`6LRB&*0`"!X@0'X([?LQ"5N@`ZM"(-L`#4:BAR)5+:
MBB?'<C8'(``2!07P(DUONAA;(`">.``V)1I.$``5Q4\*(`"9DP!XE26X<```
M(`!#UFX```"PI!!>``!EZ3_LNJDZ40D"@%1GPP`!P+!L*E$-L0`&0*[Q*0`3
M*R&2$`#IIFX!T#I?$`7LBE,,,`#NBE5K\VT#8`!0\$P.(`!EJ!B*$`##,V6*
MT*EC*3\VVX]"ZJ_^LCL+$`#'.B0#Q2@.,/\`HQ(`)'LV]ZE2DSI%!?!14DNH
M<.(`!""OH=5PF9<0M[!Y11<`I*(*]TIYZOED"?,IJF```ANPCV.VM\*+=-00
M@],0:;N>6Q2RNI``0ZL0"U```K"Q&Q8`+#5%"U"OBE&Q3FL+"S"U4C=@C@=;
M>.H0C(>XW$)'\2)`G^*S).MX>_MCF(<+)HNRUG2R96,`!6`K#%``_BD)`[!B
M&R8`9M6W@.L%`3"?H94`!,!W7!``^-JM-4**&A*Z+*2SCAM+!_LJ@.MX%A*V
M[EBUA>J?0>.?;=NU`Q!`>4NV6NLDF-`$Y]L$F*`881M0O&,W4\-9!>!A6U"X
MS;HB]%L`P,8I6U#_``#@AFU+0+$+@L(S9+2#L&W+`*N"-X@2L&+TJ06%:['K
MAHC"FNAB`!AI*\3J3X6+/<9"NP8`@J35.@V0OU$`KJIT``=P4(52"?([`(L+
M7,"[$)(@`,BK$S3LM.VVMNO2DP5@0V84N\,330I0`%Q[*<2:;F94`*6J`"#;
M8$1L`-+B2S]#Q&!9,0D``%R[-:PCP>ZW1?U3/`E%-E9#Q!+4KIJF3'DE3;,;
M5`X!`9&[$&^LE=18N,"&*%GU0S"4$%^0O8:B7MNT``55-(/#:@Q@`)<D/$6<
M`-.Z337,$/=#-CD'5(N<&(LY2&7,8#.6:I7T.X+2/]4S*>Q;N@SQ,I5L_T1+
M[,6X,(,D95?)!,*FL!"Q$P`),U"Y1\0>=$MMF+]'DR5J$`$1,`$1L`;K2P`!
M]0`"H`JN4``#8$$,```!>WH_J[8RF+''PP4&```/U+8"((,-```,X"ROJTI$
M'%"5^K/!A:0:H@`!@)''++LQ-`#!:H$`@"P^1``+X`0*``!,9`L&$``/J;,&
MX)WQC$#,;"L0D,5,4P`!D,DND@`)L`4#0#81[04OS!"_&[RX$+#D.[D\T@!3
MN\UX5'ZQBS6U&BB(\*@O8]"V\*FGQ*C.1@#L+`OMMK-W.0#SIPM,>P`Z(P`$
M0"WZ;`#V<CA]NCQ8?$G;W,V)E!CT*H.6"P"M&_]#XNP0EAHJI#A@PG<`"?!C
MB!``LEI*`:``67.\NT"__JLQ"O'&"+L0/A1KG]O/8/TS7R``43P_,KP%`?"J
MFL8`NQMJBOMT"?#/SB8`[^P0/FM+4*#4,1P%B```-G2])CNQA&L`B0$%`4#-
M^_K7!L!R`7#36?.PJU)(LZPQ#Y#0)*"LD^*#`T!`D`O55*(&$P#;$S#,/-$`
MQ8S6`X!=RYR+!A`L"+$`Q:P*!*``B/<`>+T+4;"V)!7/G+C7JI(`3ERQ-AQ'
M>PT`S&Q@N;+.QH38_[(%6C5%]UPQB80HKE"W@\.H9*.ODV*Y[T7/3]3>%:.Q
M???0MRNK!T7#,(S1#$'_NV-[.+N;B3FKL;IBLYR""V$;R0IP`+7P!`S];;W3
MSXI4V2SUNR!;"??:''*-+$S+4EO0V%%-LM=L3,JL`,K]SJLD`&V6P@3NS5"=
MWP_1`/^<PC'^`+=%`)W#$!6^N!4^KB`4N0X;O+M@J?+*QVU=N_ULV^W6697D
MR!"`VY$".(!C*USPKPGQ!/5*N+V]"X@$O9J6U8BRU^_\QK02`(X]M:-L*`BN
M*_F+*\6-,@C.<MS,;0IPY+=$`!]%VK+*QY=$KRP5F1*-);X<V[.]$^RK$,4:
M*@4PX@CQW)#BM4,.3&=<V?:J4U5^*94]*1'>$*M[3PL]`)G3Q),TYJ'5,'`V
M_P"*Q,=>3;OFK0`B!@`L4^>18@"K3@+22U*O'A%9?0LJJ`NJ4`#7I;@7+<,+
ML=\\4;&<;:O!^GBV+N*S,SLZ"RC_/#ZXPM**]+$6=@":?=<K-3M<<,^X@+BX
M,LIF;BB#,T-;(-S*/>D'2\,HZT,L#@!;OA`-(``=-B_F4NLZA:QNV[#!#M_U
MS.\)0<)"SN]N'>O-<2@-`S?SO@M,3C$1_:L#P$2U?3[S5-G!E\(7_N^D?+#*
M'+8^%NL]%NI>*^X)X>9<[=4FRT1HCO()8>@+X;U?-`"PO`NHX->_/4^SL^!)
M-R6^#,S"3,SM$N8LS0`)$;",+K;&RV`5;E.1?DKZGO_ETGN[Z=+$6S-#&X*`
M19R-&PV#H:XTP_NK`6#JH>[;1?ZIA6*\P24`MA0=`9L+8?[=^,X0!)L`[5;,
M7R#1JI#VP)[1#WW"R#KOL6*DW]*V^%KAQNZHCAHM_?M#P3GMMG``B>[;DXU(
MRVJKI5ZY3AS5V#+R&H*_OYK-RHV\"YXX8M_(4*T(9]RM3F:I>_OXL'7Z$XO<
M));W+8[6)[XIG,+6";'?#QXI8>SY`F/I,85-4*#P^ORKCMJHE_30A4+[,];5
MB$``B&!!KX\S(2^V-$RR=WOVM^2V&WWZ*-OR96/KA+X+I:"XA!L`A]^H(XLE
MF#`&[S\&H*`8M1U005\`0S__S@)+4>#[NX[;T<@-$(IVF1KP8-?!)P(D[<+%
MP``B`1`.3MRU18`7BKN@!!"8X("N@X@`;-$80,$3+XH*+-CU)0#)@PL*N+)E
M@.5!+@&^J!H@\2"N`PEV01!0Z2!/!QDSZ@JZB]&`+0X.V%(EP(E2+P&X9)04
M4>G7@UVO?N5I<!=/!I+42JI4R=91+P\,`(A2<P&N!`E`,E1@0-?&+6O;JMJU
MP,#;78H"0$F\6&D4DR@5&5!PMN#$A)(4,PX;X$E&5P44()[HI0!&!C/!.E"H
M]$D`1!ES?IG8]7/6K1FSPJ3H(($K1"\G&K9E:^5$"`$80/&":$!2Q6,IJB*0
M5*8B_\&27.'5>]!E;K"N;#J9VD"!$P$"79)T0,#59J4*#N#"/;%2SUWR<4GR
M/+$]X>FJ.\B!`0"\3Z($#,!.K;9<`>M!"".4<$(*>R,`P(,@*#`T!B:2#['_
MNDKJH"@`V&HC@<K"+("%=N%"@`5@4TJ2`1@@;9<'!JA$%_V\$ZXOQ+IB*3C>
M'"J.LHFX`,`+6PXXP$&G!#!(0Z/.$O#!6_+2!2_#)*K$*]VTHLB6!@2(C<(O
MI<M(1;X,@'(7+YYPA0L&#!R@`>-8>J`U*P\+[K.#;'$"(P4*0$RQ*!I+E"(>
MW3SH/@5T87.7U[0C@`%<#H("`$`I>@V\75Q18("%4KN1(O]%[GPS,0)&RT@Q
MGS1:LB4Q03O`@"J]$Z!#EQ85STV[#A(O@4QW"2XI6Q@80"!4!4CJ-=H>A4`2
MIH@]J#X('R#@@*2V&*"`J6AE[T)%!.!L(ET\TN7+$2LR<1>/]A.@TQPQ/.JR
M7?Y[U"NBF-U%$@ARK7!@@@N64-^)<G2K@`X92G"O_W`I$PI)N-B6L$VA4&72
MS(XJ`(!PE4J.@2\D020Y![:,-Z21=F%`@,"\2```EKYH.29#\TP2`-HV<D`1
M1!)(;ZBBCKIR"]XF`LI:)P(P<Y<O??(BBDRS@L`+K*%0(``G0,)EB]Q4>4+@
M?=6<#M^*`E@`$4FB&"`!6Y1L`+O_IK?0.=4$$$&$`0`.LT6!>35K((!$B3L(
M/OX<(+O,F&>NC./67G.BXH_-/DMH"+#S8FO.E.4":]"](`P7*`10@`O-G"#`
M@!;'?)EBBW^#\UVL!C`@,$F@(*"`A>XSX`M%'@C`[Y5`LB4!`E#?X@``1JSD
M@)X0J001U:'Z=W<N*O$">FJ#VLN+=VV!XDS=`!"S*P#&6B_?`OD[]R>/;)%X
M,<H-4"7=C]SWK\`U6Y4$%P(9R"N*6)T7M&<``I#-8`MDX,#DLBHG%$`5KN#6
M073!@.X,Q7Y06X``!B"`!#!+$@78E2H*$"O=M>X!Z0.+H$CX00)`P$&X6$"D
M0C*`K:@D_P`#B*$"X.8<\#1@*L=K&)P&$!M;:.B#!8!)!*MD0HG0\`!*X=%=
M$O,V!U$'4`YPU!<^.(`O)F`+Q4H7IF@%JD<1H%-K.B&Z=.=!&"TDB6`40`R+
M<X`&7.N%"O#A6U3Q,A@ZX2T8/)3U1#4\>TUFAS%<P).@.)$4[L(6>ZIC`PCP
MOHFH@D!P-`#5!@1'#WX1/%P0&ACOI,!'=5``(&26<S#R%9F!<@'^<ELE%_";
MX^51CQXL`'FL"#5M?="##"`?(@[`28S0\)=>Q$@E8D@6!!KE;T>\X58@8#])
M$&!1%)$/2/ZX2A#&YH(*V,\ED;-!B@`P``10A!/0:<*Q>,$`</\\P"L;>$]\
M1D@5E2C64?BY+@SM,Y.MLX4BFG.C2G`!$;BH1$#_-Q'T^(LL7_B<O00:*$D@
M1A58,\H^<6&+C&;2*`S%$$@1LQ\O?.%-'OU)0T-B(Z6XE"&2`)`M9'I1D*Z%
MIGNQCRD.(HL'H'&FJTJG3#.)-44@%&NM,^I&OT"57(&THB*="$BAM%$FK6FI
MH>(G22?BBH<RQ*"2J(5V'J2]E*Y*%3K5Z8UL@0B.]O,K!3UH54/:0H.B[E22
M.*A`O7I4`YZ%;*KX0EQ!`U>5VB>J(?V+Y8X2UGTBQJ2"Q84NS)J1#P7*H(A8
MZ4@O2UFEV`)K&^-G2P.*"(42-9^K96W_:Q=8BTK81*ZNI:V$HN#8VE+$%0UH
M76Y]^UO@!E>XM<7%`^SI6ERHP@#6&FYSG?M<@P&0``.(%G1SBPA[#9>PUN5N
M=[W[78*)]E2LC8(!^@->]*8WMUZ``/G4^U[XQE>^\Z6OP>)BM_KF5[_[Y6]_
M_?M?``=8P`,F<($-?&`$)UC!"V9P@QW\8`A'6+\V9<MLP8(+*!5GKN,M6"U<
M\>$/6[BU-"'86K-K"Q#39+8:EG"+7?QB&%?H:PDPI0*."Y;E\9,![:((!!;`
MX8%!H`!#'K("H`#D>XH*MS@F(4Q_XA`BBP8*5TW`D@>FO1AG6<M;GN\D8;0%
M+T!AGD+-2*5T_[%<GDZ$`1>ZY\L@\(0G."%&9G$M=7@<H=`4@`L2K0D!G`!G
M.:N-,)-,V@*/1TXN)UK1BV[N%KC&T]BRN:HWRDRU^BD_EZFFJFF>D*FJV@`=
M,8K#Q1GO1\=DI3N/Z4:3JNH!*J.TC<0J(RP.U*A)4PN;S)K#IOZ)+3C-:&`'
M>]%->I)N'``@+SBDR@"JU"Y<?10(!`4*J8%2L@UP`"<0QA4/@`!B]G9C:E,$
M16%Y@),>T#I)2(4R=3G+`[;02(P@H@$VX<)SOB*)<A_@W,:*$</X[&I.KUD5
MA(::`[;@P]@H0BKZ9FJT]5T)5["F1@M1A<-_=A2#-_*I3DB0`L8H;/^0ASS+
M79&U4BRB;U`K@#"56MKEG-4>`:CFY`\`]0((XP0`,*820R9;N$%2"?DX*+;/
M`?4&LUD=N=`%:F!<0`/T]JT'+&``S8NI`8ANN^DI```$F.68*,-IR&#7WHJI
M$6\)6(`'M(=U9SEF`\J4`$F4*8ZJ:'M["+"0K@R@Z2?;%002X!B1!U[P#K99
MH:?#,,1\85Z44@A0*N-HF&1E)B;$T[46;PNIR_LB2F%``/*2E^F>27C1LEI%
M"G`F9W;H2U/9TIH7@@L(4#TC>WIE5@R"E-`^.R/?<<78U?:6OQT`0"/LT$9>
M&86+G/G5KX$)1!I@61#Z430@<04#UCAX[&?_7\#?>5!6GO`%1'SA"T@R<U,:
MH.GC&<K[XA<_93)%HP)P[2N=9X#;&T#C!QP)T0QQDJ_O9U.+88DO,0L[JXT`
MN+,F8:Y&H0JT:;7]FPB;X0(5@8]_<1;V0X0%N!##D21%V(Y<PP4@4;,+J80`
M\(F_"0#C&CCM6T$6]*]RN3Z&<)`2`2=AFH_R&XV5.0A+$A\`6"4ZBKX,Z1O5
MRC32()T`\(+>XS%JPP4NZ`L"$```4#W\@!JKR*0K^2H"T"4=G+P&#!0DR0A'
MXRS?XXS@\$%PXAU76S$DJ8E7RY#V6;S#^3L`N!.):D$[O,/T$H\'#`D#\`)'
M@P)%"$3L,(I*<[5;_\BL@U@S6X",*!#$0-R14-$Z:N(\3;L7&2H`+2R,PX",
M!("`+4"$XSB0?8D5W-,MAJ$(:F,U+VQ#_[B0`J1`6'%$[*`@&WH4_>,_YL*1
M`DF3,6DGP$$G/`Q&8;2N3QF3#I($1I`_2*(-,T.2?A&6(2LH962(*'BEY-`6
MV<D(3YN(X&",0@$0ZKB+!(&2KE`],$G`Q#O`C*`A"3*:!9"4+I0DW8-``<BC
M"307=Z0(+M@"70`U`RF`)PB670"U*L&U^>`/0-DVF,"%IJG#87Q(B*PM51":
M)V"+O6$AS)N72@`83J$4%G&\?QD`!<`.!P"`F<A(*-C(V&,,+W"66W`T"/^8
MK35K#KT1LP1*&P=0B\'Q@@NZB$KX`JT30##9!<@(F*"1/7T,`-Y*-S%117G\
M';UA+ZRS#.@`O*%`0;8HG3QRB;20A,[[`ERX-FIQB5G"-\?X$D`YG@$0'45(
M@':,2+B,2]:J!+E[0H!$C$H`)#!Z``>!`E))%ROR@B=\&X\0N@ZBH_RCNP,P
MBGZ<1/]P&AI,@&@1%#@:@"?(%$0@@'4B@`>('^J0CB0*I0RD,W1Q@B\:`"?(
M%.HH.4G:&E#"Q!8Q(8-(E6WR,CIB@)%Z(S!Z`I!(CK4DG>G:RUL(R4Y!A'GZ
MH#Z42^5<3@;:CWT4G5E3!*2!+$5XOUQ)*`E<JZK_0@2PB4U%"*COS(CI"41$
M4`2W2*>*R1Z*2*@M2!%&P`5<"$^EX4[.HBFPJ)@MR!5<8(3L"@N@`1K[5!JV
MX$![<<Y/1"BDB2H_K!+V;)WXM"@_A$[FG%`*K5`+O5`,S5`-W5`.[5`/_5`0
M#5$1'5$2+5$3/5$435$575$6;5$7?5$8C5$9G5$:K5$;O5$<S5$=W5$>[5$?
M_5$@#5(A'5(B+5(C/5(D35(E75(F-5%=P+0FC=+]^@*GJQ#M),K\>Y`H<``D
M@Q#+ZD\(484&N+$'X8)CRRVZ)%-]>H*^T#?W.HMI<P`N`#))<(+ZPZ^?\`('
ML#Y[082HFY;UM-,'6"@I_RW4GU@``&@`$5,*5^C$#%&`(3P(CHO4"#$-AX00
MQ8!!L$`/5,HG23``,GL028">!8``+C*78J$[TSFF!["PS&R5`SA`Q"@=RIA*
M(Q(-`B"`,U$)D40>3#)4'EU4I2`@(>LM1ID.,-D2".&U@MD(8XT0A*00HGA6
MUA)6LCB`TTM5ULB-IMF*2>*(=1P5@?C69KH4PFA)@Z`@X;N>NY@F+Z@LT[Q4
M8)W15QB$0[A76)#6!%"N->+.38B"!IB<LVB:!#@R[BP617B"@&T1[BR.3PP>
M!\BJL%!8!]`8?@.`JSD<)VB`S*$(25!8*%"\7X53!WB`+P`)3H5/5=A2XR*-
M+_^``(Z5*.H)V$M=V850A"A8V86U,.,#C>5Z"RZX3!\I-%<H50/\C)RP)VJC
MP%W@U/MHE]"PLGE]436@`*NE@#B8$!/ZC&@C#=:XE;\K@(W\&`%83$MRD'K;
M%AZ*C0!RA=6YMGG*TGI[F[G8UX280XGP%@)P2U0UE@)XFP*8"QC\U+(E(<8@
MBHX2FEN15:*,.>3!(4WAH<<U//A(#B?YN[L+UY#Q%'"=#@)Y5EK+BD31$`S)
MC)P@GZSP@JXX%Z"XB:FU4368`-F=@#68$&]9"%=*&`#@R[_(.7EQ``<Y6_$X
M@/]QC@[Y#[=-'Q0;O4:1HZ9ADJ91*6=J`,+0I&4!P0+_J,Y1S3FE8`VP5`4%
MN)"4%1Z[<87DF--K<Y!1G<WGJ%YE,5;XP+ECPP7(N+[0R,32J!5)D@L!V":P
MF,B;#+>#",...1S"X0DMA)1?>UT8C=W9A0,)H:'1P+`#*"+6:!%1%,6!=`\B
M*0V,^`_J"!F2VX\66<1W<5:-$("=V)A4&9LJ'&#N-<4BDDY7X%2=,1H;H;'\
M3"X'B=>-406(P*3*99%[N3/JP%^6X0U7>`*Y(-X'4848@0D!3AM$*&!C<0P'
M6(R-Y!M69&`958,(".,(J-T(*9>W"0HPJA*$$<6J,(L=#+ON=8\CKJH/U%/#
M@,(3(>*2Y*%<G3H'X#X#QB3;_U`*]"@%7K0@_;"8.2Q8PNB\7'WDW7T5QT#<
M>R'-4&&87\,65+F3!89B?-S"-R'@HC%@DH#B=2H`!Q`-:_5B%0V$$7CE$3@$
M"2$*!ZAE!RB3+>(?*O22*3Q;./Z)3&G;*[0+71`>AG&"%<IC@6"-)X@"*(B"
M*/C$")R(3.6*:=P%D"`!`2B%JI"U^#F+*,A``(#4EVEF9X;F.JS<4+,,2\XT
M#"F6/:$X>]E&CX6>]Z$2S"B*TTV2(Q26J<$NM&/E&LT4^)00RLL(P]$6.Y&(
M;M9!`K"%7H&D.FD/5Z`.YHH:$4$,)<GCA2@=\L$%[(J:G<&D.0Z)O$$/3@B-
M7T)@6__XQ*,0GG;B$VS&+DD^W%$NQ:3DC$I8`$#D.ERHA04PHS8YE><I@.K"
M"9U0,T-A6AN&,P@4#H$>TA>YL:1E'W#TBJ=]"^$52UT@(+A!WO@[,C%-#Q&A
M">,\X:2F$;A#L6YM".JRJ9GY5=9@$D^N!/2@A&)^":HXWR;A'11CC4HH%P7@
M)_/M9U29Y'4NP(RX!6;>F#WY(-$CG.+8"+.1F)P31.DYBP)(`+?("8E(OZ3*
M3"OJH(4"NK>,:B`%04<)$$4-H%$,E5@=[+.%D^F"'EVU:NK8'6Q%U5K@FVM;
M">Z5/`C0!6\9@%NI1Z$[I@/8EO-:3^4VW*9M#?`5``.8IY3_J0@P2A`X]$O`
ME9+9JMR;CL=0V9.]-2\/8K?I/FX&("H:,9\`>&^E'.`Z.J9]#8G:_A9F48FR
MS54U1>T=U04N.&H/CD\\;6D1@H`'F!XN*)8Z=8"Q"8DYM3,_;:],VM+V:NG8
M^)J*?;\G*-F3S:0.CX)*"`RRL'!"E4[$<(4H>`"3)8V$=8#V(J,7AP"P5`I5
MR,_$*'"7!HLJ+MGVA(#D$9:H:%D;AV8H>.8C+R93M5AJ[O"*7$\GIU;_GO+P
MN,(6-"HJSW+Z0F`M[W(@)3@O#W,Q'W,R+W,S/W,T3W,U7W,V;W,W?W,XCW,Y
MGW,ZKW,[OW,\SW,]WW,^[W,__W-`_P]T01]T0B]T0S]T1$]T15]T1F]T1W]T
M2(]T29]T2J]T2[]T3,]T3=]T3N]T3_]T4`]U41]U4B]U4S]U5$]U55]U5F]U
M5W]U6(]U69]U6J]U6[]U7,]U7=]U7N]U7_]U8`]V81]V8B]V8S]V9$]V95]V
M9F]V9W]V:(]V:9]V:J]V:[]V;,]V;=_V`<L#;_]V<`]W<1]W<B]W<S]W=$]W
M=5]W=F]W=W_W/,`#>)]W>J]W>[]W?+=W><]W?N]W?_]W@/]W'+@!'"AX@C_X
M@A]XA2=X@U_XA$=XAG?XB(?XAW?XAI]XA&_XAX]XA4_X@<_XCC=XCN?XCP_Y
MD1]YCR_YB?_W^!M`>98'^9-G^91O^8Y?>9BW>(FO^)O?>9/'^8R/^8I_^9[?
M>)D7^I4G^J#7>)$O>J(_^J5/^J5W^IQW>HJ_^)[G>9N_>JW/^JB'>IJ'>I7W
M>I=O>K%G^JY7^IS'^9)'>X;_^;6W^HLG^92?>[JO>[N_>[S/>[W?>[[O>[__
M>\`/?,$??,(O?,,_?,1/?,5??,9O?,=_?,B/?,F??,JO?,N_?,S/?,W??,[O
M?,__?-`/?=$??;N7>](_?=1/?=5??;#_>]/O^]?G^]C7^]EG?;^O_;S'?<37
M_;OG?=N'?-^O^^"G^^$O_"6H@]]/?N5??N9O?N=__M!'@D\P!.CSKW[KI_SB
M3_WLOW[N[WZZOP-/*`3O__WM'W_S/W_TU_SRC_P;&(-/L`-'0`+47__T3WSZ
MKW^\O__#IW_];_S^3W^`N(%C(,&"!@\B)$C'TZ=8<Q)"C"AQ(D4<`BMBS&CP
MHL:.%3EZ#"F2(LB1)D^B3*ERI<F2+#6Z?"G38L4YA&#.S$DPILZ>/G_2!"IT
MJ%">1%$:/>HSJ<8D2I]"C9J3J=2$5*NJO(IU*]>N0+6N!+O3*U*E8KV>):MV
M8-J3:=NNC2NW*ERV=.=N)%NW[E&^>%N.]#M3L$3"?P\C3JQ8Y-[%CA\G-@S9
..[>2@E2]'E8PY9,F``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g145452moi005.gif
<DESCRIPTION>G145452MOI005.GIF
<TEXT>
begin 644 g145452moi005.gif
M1TE&.#EA2P+*`?<```0$!`P,#!45%1L;&R0D)"PL+#,S,SL[.T-#0TM+2U-3
M4UM;6V1D9&QL;'1T='M[>P!&C@))D!Y<G!)WB2!?GBI?E"-MD2YBEC!DES)E
MF#9HFCMLG3=OISYTJBYBRC%DRS=IS3IKS4!OGT!PGT1RH4EVI$UZIE!\IU-^
MJ4%QST2<HE:`JER$K5:%M5RNKF"'KV"(KV2+L6F.M&V1MFR5OW"4MW.6N7:8
MNGN<O6.QL6NUM7:[NWB\O%^'UV"'UV&)UVB.V7.:P7^CQX2$A(N+BY.3DYR<
MG("?OX"@OZ2DI*RLK+.SL[R\O(2CP8FFQ(VJQHVMS9"LQY.NR9:PRIRUS9>T
MT9BUTH>EX9*MXY>QY9RUYJ"WSZ"XSZ2ZT:F^U(7"PI3*RJW!UJ_%W*+1T:W6
MUK#$U[/&V;;(VKO,W;7:VKO=W:S!ZK/&[,3$Q,S,S,#/W\#0W]34U-S<W,33
MX<G6Y,W9YLW9\M#<Y]/>Z<'@X,_GY];@ZM+HZ-OD[=GB]>3DY.#G[^#H[^SL
M[.3K\>;L^.GN].WQ]O3T]//V^?;X^O[^_@``````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``L`````$L"R@$`"/\`,P@<2+"@P8,($RI<R+"APX<0(TJ<.%`#0XL4
M,VK<R+&C1XX8/XH<2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^J$&')GRYX^
M@V8`*K2H48%$CRI=RK2ITZ=0ER:-2K6JU:M8LVK=RK6KUZ]@GTX-2[:LV;-H
M?Z9=NW,LV[=PX\K-ZG:N7;)U4V+(JP'#W;^``ZN5:R&OX,.'#2->S+BQ1PV*
M'4OF:3?RY,L."V-6:7FSY\^@0XL>3;JTZ=.H@W:&J#FU:ZL:6M/E_/IQ[=NX
M+Z_.S;NW[]_`M^X.3KRX\>/(RPY/SKRY<]W/HTN?+G$Y;.K8E7>USI)[]N^G
M_8+_#QO;NV_SJ-&/7\\>^][V\$>KCT\_Y_SG]^OK_YX_IX7]-_4'X(`-"4C@
M@0AJE^""##;H('0/1BCAA!3B5^&%&&:HX88<=CB3@1Z&*&);(Y9HHEF0G:CB
MB@3)QN*+,,8HXXP^@6B2C0/B2.../!ZG8X]`!EG<CT(6:>21J1%I'Y),^MCD
MDU!F=<$%&5R``94S34DEECA=.9*6"TWYI9AA8DDF5!BDJ9&66XK))9B2*9D>
M"TAP$884,Y`@WDLL-$$%%U3@P`).)N!@*`D>E=!$$S4HA`(.30SJ4:%-S+!0
M"39,P0473<2@`9<$J3<?!AL8:L,&%&UP0Q.0MLHJ#C$(_Q3#HB=$J=,*9ARB
MB"*)\%J'I2U=L,(9ANQJ+")EH&`3%<8^`2I%%\30*QZH'G2!%+N&X=$%-NPZ
M1[4'X;"'L;LB@H8)H)(@Q0W/4A0#%XANNT*QA92P)T0G%$+NOF@(9,:N3HBG
M@0Q4Q%NAG"RQT,>QB!Q[0TLS+%PN(KWNBH<)-)$@L2)T@)M1M-,:7-`%3V2[
M;;>*S)$0#@V76S'')0ATP0QX*")%NQ&1X`4B@<0L;[&#V#O1"<7N:^P9`IVQ
M:Q-^D1`&(GV(;"M+)=2L"!Z1]BEQ(";<.W)!]^)LK0D2]_%$#"O($$;%VHXL
MMK4:U?!R(K$:].S;LD[K<95:8O^K2!AX'Y3FW2A_>]`&=>R*Q@PKL#!%RT[(
M[,6N-\-M=Y4$"=MP("3@C#?.I,YPPPQ[#^3UR";HBX@3-=Q@@PVN2\K"ZQA?
MP$*O>VP0^-0B85"R(G648.65+`2RZQ-^;5!""1XO;S`))9"@00DL8(RY"2QD
M'S.7S"IR!PIM9B!%KX58/Y`),;#@<T4DM#\4]BCTI`'T4B.DM"*#[,J%0<O[
M3/T*I1L(R*X&+E*M(`;H^AW@!,B![)W@4V`CP0&K%Q)N>0LA1%.$(="%N2XH
M3B`E*,.N"H:H#9#`!!O0``M6@)$+2#!]*,32!F:PN164("0:."``#]>XF"FO
M!!U`R@C_2C`"@O@%>]53R`52IXAZL>E,RB,!JC8@-T4$PH8(>Q+B>&4#4&&@
M"65XPJ"^&(A!3$$@&(A!'P8!ARG.81!]P$$=H,8"884A$!0S1!\*!D+C)6(&
MSW(:%W!@,!-X`8\\ZP(',V`"/@RB#BP(PR`288@SU*I**]A#(.C0N81<(%_X
M:T+#^K"^#&P`#G"4P10"D0A$S$%2=I.!W@8R`SH8(A&!D$+WVF9*)^#A$(DH
MQ!R`)9`-^/*6P40#+`M7NB7J*Q%/0!653L"H066R93PK@_@&8<8N&,(04[B`
M,?&`S$&@H6Y<R!^OX!@#*LU@#K=$Q!V:T)>!Q&`.%.N#$W"P_T;`+5&3P4/C
ML":)RS.L("$F`)KY#)+.0>```U[0USK[`$O>G00#\U($((1F-[]@P&]>D)FT
M".C"A25"G89``0D2QZN6*2*D&9C!++^&.8&<X`Z[2D3%[G#)$S0,:KPR%AHL
M(JQ><6XA35#<!NC`*QP0A`3C2L0>=&HL/)12@+*\&J(P4(.BZ328)AN*!\NU
M*T,X52!3R.G+^E`K"Z8,(1I`0T[QP(4:U$Y,*W#I!;FPJT)4S%EIY155%=$'
MC-V/7#*X`,M<IK]JQ4"=7QV7(OJ5`130RUX84)A:=]6'@QXDH4T$8/LV0-J!
MR%413;C`:8U%MP*%*(L*P<`,=E6'NO]<:U=>V-)(\8`HJ!J+FW#(@!,4AS8N
M]"IJ%QBN(K3)OO8Y%U4:$.%D8Q"#^R'M`I;=52`$Q5=%(,*S*QB$/.M'D*7N
M"@?)W55P![(!R2)""BQX0L5JT*X!4LN4..78#&*P6G_BX+B"DD+#!H$Q$^2O
M$#98@0W4R2ZW&NX@+)"HL0J!AB;$BP0U8*HBSF"#6'7/NVNLGKX&40,6W$"B
M763!^)K8!!N0X`3&`R<+^,E%<<*!MON5[F0S@('L!LV4&C9##&2@85X6A(F)
MZ`,>\+"')G=A(/=S0K2FT*M!M)B\R8%M4]Q*!X9\%+<#R>I]-R`QGI;@H#%X
M@B*GE$%#G.#_MB\E"#_[0&<ZHS>OBMA#YUPXKD*\.;N)8%<&2F!20`YE!2M8
MJ-U&RK5/ZLL0*Y"AQ,)Y`0UHV%D'V2VJ1CJ(-[O0:MK2P!QX1=\I=3>UBAJD
MF.XGA2H53B$QH,/+<CH'955IK#>C4O<"+4'E-4'55#JMLS1GQ4[ZC0I3JD`5
MD9910]31A2SM%P8RZ,21[J&(MIN#&9Z0%%`:[:W^6MJ4;I=GW=%$R]+IS`6J
M6(<`[@G.,+6O[C1V/%")<P4UF(*L-?CFWS&W2K\CU\UNT"LZ4)>ZHU9$%[/K
M9J2PU-`/Z2XO_V6S@?CVCU@*0[TSK;<+)'7'`QDKX$J0/T/<X.!^_V,NE4H0
M`R>4H6C#9J9"-A"#*<S!KT(=R.1LAJ7NU39SC&QY&22*:3PC-P.GG<+!;U"L
MJ-W@@C(++&5]+#P%ALJ32,9#';:^=2I`6=RV.RZ6+3J2S`[XJHR4@<%`*M)9
MTON/H<(!'?2J0?!5\0[56C<=Z'!SRL$YJ+-V%M6+F3B,/X30M`V#XJV&]V+6
M#!'M%(C&%2'E18?L`H%]LLP42&RUOJS=&6!!&5BYKYA#_7(I>E\-3HN(05U@
MYY6[P"X+$H,R3++T4\+S4360WXJ]#!$F^#C29/9Q:5-=]B,\W=CH==`4IC`D
M]TMMV/,\=K)_!`,=*+2]J;R')U2)[7G3:O\&1A#5.@YDQ5)%`Q>*Y69'>[>B
M0]'`Y)]0@=^Q$0YP0(/^T4#?C`:-2AI0>!#'$!=`<-^64\#R=G63`?-77V*F
M.^`G$'X#.'CF2FB`?Q>(!EX77GU%!US`4KE6.$E1`V$`!Y4G,R207^CU>GXG
M$-V#;`/!@?@S!Q^X<2RP.27$4G>@?_FG?V>@*!]$?$'H8^C2/5S@-6+#1.63
M$%%&)2/5!P&D%>CF&V.%!B.0)L2C3OOS97^#)2A#+7SF73$@'O2&"$V`*B3'
M;P(A76A@;C*3`??C+#;0*W`0$E*$$8-G2@]G)C6%$*SW38!8,3#57KP"2]*%
M:2.C:8JU*W00$M+_-7(+4PB>-7XIA%:[<@8F\"D-Z&#-Y#=[4$J6MBN"!GM;
M\H($T3UED(D7<(CC-DKQ<EIGI0$F1%19%34#,7G2ED$$YG&*@Q$DT`54<(:?
MI2]+:#]@1VZY8WTKL0+&HPAP8%<F<`-6(XE7HEQX)TX4=U\C8%+FEP%M!CX9
M\%]JF`$Q4#3G)#TD$`-/XW=,!'E5@@)U0`=A$#-YN$6&1P*08@-3L0*J8U<G
M\(_1:%08XUN0EW$;-S(/F`$9A0B`9#L2!3@:0'%>-Q1><`=P8"FG53E5<SQ5
M\G3@9A`L4#26E$(F0`7DXUF3%WNF:%HM:`*2572N."4?-P>=U`1X,`>1_X-X
MT"00,R!1E*6+PM-LS^:1I'00H%2,!T%QJ15Z8K<[RL@1,@!9W.1[1V!/O9((
M9^`$<%`Q8%B&L%0"DD4'3Q!1Y3*)1X!-6K<'+H4(790!W1,(5"`%^?4&J`*4
M#K<KAF9T:`=PC$A4F+,!.)4(39`!(A!5"]B`ED=`0R%=@T`%4P`(Q@)3,O!3
MVV8&Y#,HW5,(4S`%^:4(E/9J"#%63;1UZJ0(^^."NW('4N!]*RD0W54(4B`%
M5N.9-E4LB4`%5&!#-9,(=2`%7"!1@RD^.84&Q-(RQ@<T/K-S?2`%C[DK9S2,
M3:1H!'%:2[F0N'E)3WD21#9K&H4$Y;5:WG4_R?^H@%S2!+/6!RQ5E0-Q`QM#
M+N9"3"5P6,92!Y&&70U3+TB17PU);H-`7B1@-9$S,H%56R)@4I&7`:P82[@C
M`@)A`AJF73?V-P/A!$4S8>J)`I*54UOY5@XV%4[#G;QB!CYS`9-I+'AGA`1Q
M`NV9"!NZ7G%%+ETD`^W)*UW@BY9I+![X0=-VGSXS`FC`G6B`93[51'N9-`!#
M)1N0<+O2*-F)$E1$!?KG!4V`=B5`!7>`!V<@`[BB@;JS`5R`!F:P4!I@`VB@
M=5R`/F>`!@$Z$"5P!&50!WN`!V@@!3``%*IR!DLV!T^P/B40!FC@!?&B`5.@
M?Y'&2&6`!EU01`9A`G[_FHH'@0)I"J@;`*5F8&L9T`3Z1TP%`:E<RJ96B@=A
ML`(SH'_!*2M=`*=UT`63J)!>4`=RFB==\*?"PU]H,`5CH0$ST`5TP&1TX`4S
M`!0X,`=[4`=4H`$XH'\/0Q`HT*JO^HM_&B\G$`9+!@>19P)2,`=+=@:_&BHV
M$`9F8&$X$(1]^JP#(0)(\`9Q6F%N:!`Z0ZX(X03ZEU@"L0+2N@?*Y)1-NBT)
M45KX^E11:!`;(`(,NA`"BV[]$;!*9$HB$(4FU(<4H0$%Z[#L55H,(;`+T;`%
M,3_29'%2P"B>!F<3J1`:FQ(8FR%3F*]-40*0"3S5(P.2U98H&[.A89+E@G/.
M_UA]^W&R,IL:&R`%?4!5)Q4&B[2S1+L9),`"-5`#,R"=1=NTDP$G3ANU4CNU
M5%NU5GNU6)NU2J&S6MNU7ONU#]&O-B&VGE%I=\&U9R&V:!LF<&459$L3;SL5
MRP%;<@L29GL0'#`18N,62=$?%O"W@!NX@CNXA%NXAGNXB)NXBKNXC-NXCONX
MD!NYDCNYE%NYEGNYF)NYFKNYG-NYGGNY$Q"ZHCNZI%NZIGNZJ)NZJKNZK-NZ
MKONZL!N[LCN[M%N[MGN[N)N[NKN[O-N[OON[P!N\PCN\Q%N\QGN\R)N\RKN\
MS-N\SON\T!N]TCN]U%N]UGN]V)N]VKN]W-N]WON]X/\;ON([ON1;ON9[ONB;
MONJ[ONS;ON[[OO`;O_([O_1;O_9[O_B;O_J[O_S;O_[[OP`<P`(\P`1<P`9\
MP`B<P`J\ORK0P`[\P!`<P1(\P11<P19\P1B<P1J\P1S<P1[\P2`<PB(\PB1<
MPB9\PBB<PBJ\PBQ<PCG@`B_L`C(\PS1<PS(<PS%<PR^<PS;<PS?\PSYLPSS,
MPT),PT1LQ#I\PT<<Q#"LPTN,Q$S<PT\LQ3F,PU/LPT,LQ$M\Q4#\Q%=<Q5Q<
MQ#.\PU'\Q4`<Q#@<Q5#\PUP\Q6%<QDW,QFJ,Q6>LQD?LQ6.\QE*<QW/,QV/<
MQGVLQTR<`U6<QV\<R(B<R(K_O,B,W,B._,B0',F2/,F47,F6?,F8G,F:O,F<
MW,F>_,F@',JB/,JD7,JF?,JHG,JJO,JLW,JN_,JP',NR/,NTK,EIW,2%G,N&
MO,MRW,NXS,N_',QI?,MD',?%?,R^7,S!O,S*W,QQS,S/C,S$;,R]/,S5G,S1
MG,VZC,W;#,W=[,S?3,W>#,S@K,WD;,[7/,[<;,C6O,[NK,[P7,["G,[(/,_3
M',[X?,[Y?,WWW,7B7,_(S`=\H`<$7=`&?=`(G=`*O=`,W=`._=`0'=$2/=$4
M7=$6?=$8G=$:O=$<W=$'O0<>'=(B/=(D7=(4?8`HG=(JO=(LW=(N_=(P'=,R
M/=,T_UW3-GW3.)W3.KW3/-W3/KW2(/K30CW41%W41GW42)W42KW43-W43OW4
M4!W54CW55%W55GW56)W56KW57-W57OW58!W68CW69%W69GW6:)W6:KW6;-W6
M;OW6<!W7<CW7=%W7=GW7>)W7>KW7?-W7?OW7@!W8@CW8A%W8AGW8B)W8BKW8
MC-W8COW8D!W9DCW9E%W9EGW9F)W9FKW9G-W9GOW9H!W:HCW:I%W:IGW:J)W:
MJKW:K-W:KOW:L!W;LCW;M%W;MGW;N)W;NKW;O-W;OOW;P!W<PCW<Q%W<QGW<
MR)W<RKW<S(W3B7`(T/W<NK+2TZW5@O`'U6TTTPU,-IT(?__P!S`=U$.=W3S]
MW>)MU-R-U(-U@.0=T^T=UL^]*^GMWO)]WJ?M!@AP``=@`/KM`'&0TG*0`&Y0
MTX*@!.\]TX>@!(*P*TI@``1@!`>8!`QP"(*0`$Q0TW_```.```N^+X?P`$E@
M-$K@``?NTVV@`.#-TX?@``10`/_=U`Y`!$G]`$.`TD/@`/:MTG&0`"\.UG^P
M!+IB!`MP"'^@`&T@TW)@Y(G``!#^VDP```G@`%*^``)P`"G^;6X@`!=.TT1@
M`"4>TTQ``'*@"(>@WT8PYM_V``4@"((P!#TNTTH0`$.P!-SYX0`@X^3"!`/@
MY4BM!`+PYCF=Y0U@X$V="`BP`$G_;00A?H!*T.0SG>5;#M9$<`"ZP@1%D`AR
M(`!+(--QH.F*0`2;_MI+$`!*0"Y$``"EOBM_X`9R,-V0ONI7+@C53>$Y)0=N
MD.(K7@!R,&L4[MUNT.'R'0>W;BS0+0AQ\`=&(`!M<`AR0``/T.&8/NR[,@1K
MK@B"\#*KONOL+>RX3@0#$`?D'0<*,``!@.=D3@0$4.4'?@C"#NRRG@AQ`.[D
M8NSR;BS97C%+\.TYQ>W[LNK7_N_`;NW9G>#*OMUN$`<!KPBV#NVR;BP-;^T'
M/_#Q'O#L#NX)P`#[D@@+[N\.S^S:'NUHSBO_/NP5/]T/'^U7#MV[LN""P.KD
MPNS@3NOD_Y+E;6#L(?_P9+[@&J\('(_I]<XKME[O&N_K5VXTJX[P#J_QTBX(
M#6``8T[K<3``"B[M]L[JL];R?Y#IFZ[RP?[S"N_RCYT(51`$9"\&*\T$I$XN
M;1``$)X(15```B``"P#>G>X`!B``!=#V#>``QC($"Z#Q#3```D``0W`(22``
M`%```VXL;7``U([WJ2[N@E\`BVX$"I```H```P``!##I`)#YUZWA@T\$NC($
M7OX'"+#UZ"X``\``1;\K<K``DP_AWL[Y1;`O#Z``3%``YH[?1F#W[^T&F"\`
M!I#J#,``LI_Y:-[@<:\`__WAZ3X`#K#@?O[?3#\``T#XT[WZ!O_0``<@!T.@
M`-/-!`?PYGX.``/P`(K`!)I?Y5N>X9-/!/!^`(N/^J7>!G>?^5L>X()?_+"O
M```A8`"#`PP4'3S(Y,`0`@(,*%%T2$$#`@3<''HP0*,#08KB(!AB0,"!-AD'
M+.C8P$%$!P,$$."HR(%!-P<>B"0P))$B00M<)IBX$Z$;`0Y$#AAR2!&#!PB'
M+$@49Z%(DBT%,%`JQZ=`!'$4+5E8X*41A`@%.6CH<(E'FP<T/CAD1`"``G&,
M*#@D9T`#G$5V'F(HL$%'14IP.A"P5@&1@X8%"$C@%6-#`H/+7L:<6?-FSIT]
M?P;-.5$'"*5I>%X2@,@?.7_<)"#@5<G_529&!BA(1%3`D"4+!+11E&`!P@8'
M%,DMP@0QDS@)!JPNNP0``2)*8,LYA(!`$B:^F2@B`H"!$B4-!#QH4P1R$D'F
MB2@70'9(@;P#DBA*$J`!$_4,A!Z4:``CF&!``"7:\&T(-RX3Y!!!"F`,P(YN
M4HI!`PQ(8@GG%DP@``:6D*L!1=RX#40!H"HB``>8(**HKP;PRCTF'A"@"$68
MN&J)(1Z38[8%%>&+L(/B:""`!YCXHX`#R-/.*\3>6R``)H@"3I$_[,L.`28,
M2\!!!)9<HH$!@%N@`",T%.\R)0`8H`@-"?A#$)&,4$(0(HQDT<4X`C!3"0(&
M6L*!`"`"JC`!_]X3%"(&$%"DC0`(<-,WX#(B8@D%`$C@OQ'YA/(W11`PZ*!%
M&PW``".2T*B!,*5,A`$!:SL)/P`P7$([.2Z[<X@M#3A`D#VI(S"`-EY[3A`*
MY7C,@24*_"[%%5M<20X"%%BB"`(`6"(1`YIJ@P`&MD0``4%PU'5'LD)#-UUU
MUV47H=$@B`""TSIC`H"7'AO@@.\220"!"N5R8T\'=I)S8.$0<N"`1'9<HD$D
M%9FO0H2DBU#:(MHP\"!!#ABN1:\,O?40`QA#-L)$%#@`,/KT4B([O`Z2Z^.#
M,+XO(@04.(X`(1F$$#,*,4O"4RMA"B[E@Q1`()$'"B`,Q#\,"!7B`?_^4`+&
M*X<`<(%>%ZT0L=8*P/K!IB[#T2N`#])KB#]RTIB(.#"N\DKVIHTC*B82\?.B
M0_Y`P($X[!ORJLNDL]&C-@\I(-0'13P(K3_B./0@BOZPLDU%%!A./?9NI)R!
M!$@]]^^Y(Y0ST[(<#5V`^T`ECE&BSF6`:2OC2R0)B"):@-'\OKM1:(1J`W"(
MJ2&/\(\:%;EIIV,%CZ@@.8<[:,<_K*5<D2*PU;:I!A#XXY!#VAA@B?R,</C6
M=L]'/WUU$2'--,^84#&)))SC_4&LT;8/\K5$[3*!J(N+2@'HLI^=A&1G7Q'`
MQQ*!@`90#V$&2`019%>8`=SJ08Q90@(18@3_.!'!`/6I$Z00`KG;'21HU8,8
M?6R#0IY%J"Q&D1A"?G:0!72)=9+SEP)P5A:]U*Q1OUE"!3'V(_S`Z``K:8P&
M$X8W`;CA#T-XP`.,D`@<+8@@_Q$.W"ZCQ<K=YTX"0``1;C4$/A6@`")!P&P4
M>$.$5&V-@S'`_4CXNR9"CG<)4XH@1(@YCQB`3Q_:R:BX*#<[(L1SFJ+20:Y$
M%C8*4F@`K!Q9$A$HE`5`=Q4\2"(OXX:GN&4`O@J?QD3XLV,-H(0)$]U0!$`@
MTWDD,=E;H`#,:,8`J.T`CUI`R]2W2U[VTETTX$`'.`"%]P'@=H)`0`$LV#-%
MYF^5AO37P1JG,$7(_X$("!B`:E(80P3*#%1$T)D,/RA!PLQFF5C+H,Q0]43Z
M&*].`D((LDJ8,Q0R)"YPTLP%?6:TR\`0(35<X/^B";V#1,64JFQ#!N50182@
M2BI(I."MF#``-RPJ*@>XT`(.,=$%;>\_F`-?E1`R2'ANM`%B,8`<=O0`(@QA
M"-5Q8T']IR88%114(KL?LO;WPX`]4R9&2Y*-"F6E(F"SEJWZ7$B;F82_\4X1
MN4.D3]>V.L8!*6E$N2-0"4"6EAA``0](@'&J9CXN(D0]!5"``Q8`IT+R1(1X
M1-X'YSC-5`:.0(P:4OA$UA0$C,RE1"`"<*;GG//XTK"'95<B$+%836D&?O\E
MQ)A_%HB;@V1P6)'C"=2"LT.)I`Q$$?D#RA9&G\$-2I&0RB#O7`:>"8Z5)SV#
MW+F6\D$#LBP1'!-*T(C8N]N=+%,<9&%9]'F9&9;E;)D5$1L]ZL]&,2`.!8"H
M>J@F`#GHI7!`8EIQND9=GA2$.@#RGE(82@1,6JD`#]#+N91F!(SQSE'L<5M$
M9F.[)HXT#K$59=0:$X#]60QQ]TL21,'I&I_"58\VXB-_%)&(/RS@@Y[[895Z
M:#^-&0"O(Q6:W#X%/7XQ2JE`HN8B2Z:4#A>Q>F6-"-0JE)''^500EB.E7'<#
M(([)J:JVB<.`][N$O<ZV0H=8PA_2LY,_4.2`B$7_<I+/5Z]Y)NHXM8P#$PK@
M+S>42@E$>J:8EI!C,"8B14:(LF:%UX882D=?;EAK'.1$DC@@!B+DW"][_AL1
M!1#@RG=B3,1Z")Y#Q<%/72I+=@K`'#*2987Y_"YQ/X@9.10@`6V(`[,^%35'
M^DTAO:*1$7HD.#<FPB=75@_6,)9+Q&@08@$H+]GJ^S<%!,PW;FA5`>X<@"08
M;P%1OE021$82:_XF20B`M'J*(!$[$RE-95G3F=,\Y\;%1PY!:T!4"JQ5QAS,
M"*J10QL.@!M'Q@UP-!J"$B[5RDQF&)Y:CL..7">T)0[-"%=J0!S<(*BDH8JL
MOFL>`@)&WN&Y>)0$('-(__(B2Z:Z^=1%\/-)I-UJL&!O6[V+][PIJ@0HNP$!
M@%9RQC6>+AS-<V,):)!51K*@YS*`,N=R@Q]/`E!!*$`C^?)*!A,3'<BXI`#[
M:X-('I,4\/1J2`TAPB$.$*&/"$0`EB%"KY($D?8\!HPR&\H!C`Z7XQC@R!H[
MP'6=XJ_,..8EC#D91!U@.G`^Q@""+=!C$B!1958S`?AB`&&,@%+?D#4`E,5,
M&^IB0K&,92=R<+E+D"Z0\V+H*WT?`-69<)2K=*3HD#FBFB!#^+4(W84-=KH"
M;O5<W@V!ZW(BRP(,(@A7:<0`3L*9&RRB2%GSQ"IA)?>("A"WUJ<<U0M80.H!
M?O\0L.;1\"T2B/^LKH0"5,\-LU=30_+E@`($;-`5)LML!L`B?S4Z=AKQ"T_2
M#IF/<5`@L6-"=K`609=@GR?F<<G9-[Y^]G,F+]Q\7(7\S`3"'"(.]E>"^13)
MA/`+PGS?.Q#"B(H@BPZ*2BC]LQ(FV#*S0,`>N14Y$!(`)"+_6S#L&*$#X2:S
MV)()E(/&<A<(Q`S6V(P_V!+]^P,4.L%X4@+Z0XA#<`,,!)"Z`9"$(C.TB1,U
M6Z?`\:'+L#^)^8,E6`($!$"9&<#[4[/]NS+AVA(9!!#^$X04+,"W(<`*W)G<
M@,&(N#^-T3\0A$(`9$$K"1D+I,*H>$+LT"$>S$(JU)C_)>B_D$E#*"3#3%H"
M,GN_]P,0,2R+^1.$J#@$/KS#CG#!(*-`/O0SJ,N-.8RA'[R(+`1!M`%"!'0#
M-@RN]J/$2K1$R8.Z2]3$2GP`DA"R`^B2O&"^2=Q$SXBI4F00!HJ#/P@:K4/%
M5X3%6)1%2Y2R3)S%6TP?J3`Z`R`YL7`A7.PZ`D!`6/0^EX@[8$3&9%3&9<PG
M6&/&9P0-01"?A@$0-O1`9?25#'S%'DF"&H3&;P3'<!3'<23'<C3'<T3'=%3'
M=63'=G3'=X3'>)3'>:3'>K3'>\3'?-3'?>3'?O3'?P3(@!3(@23(@C3(@T3(
MA%3(A63(AG3(AX3(B)3(B9S'_VN<R$1HD'JT2%_:R,/J2'?!C(]4%VT4C8S,
M#)&DR'=$,Z@[A`:0K<NHKB$A1:"YG_.1@P:82?=S@-WJC.\A25S90>T;&5X2
M!)[,1?U3@I?LR1HD@OLXDG1I`P?X2<P@DJO3C"(;QLU0@@=(A-SHB"3XQ<PX
M!+5"H7F;RG0ILIS$C)8\K\S0D4:1RE)4#I1,R?2YDE_$F)VZ#`4@"V1R*LX8
M@ATZGS@01G61DWGJ#`TYRZ.!*!.RLZQL%P=HS/0YA`3HK0502LY@`JYC`C([
M@,SLC"18--#0.[6$2>3[##]C"\IQ`,'4#(PYGLJ:(/41!/()#2;8#ENT'D8Q
M`G[2Q/\D\,VZ3++B$!*C`,0#1)MM*<JMZHA#A+HH4RF\,XN$<D8&"T04$H0V
MT,Z]*PL2_,(%B\2/.<S]"S]WB8,E6)!#\"`9')?OM)L&:TQ!&((#N+\X80[P
M7,`*_!X6/,_@$@3_J1XYD$2-*<KR/$\(K+^$JI[G*H*.X)N0H4$2ZQXW>!CU
MK`N,;)#/A$X>0D2$(,$X`$X'$9+N89`ID;(`[4R)R<X.;30BR@NA:,0G%(0&
M\9/P>X`%($%GQ(S6[+W*2BGM]$'T?,)XZE">>$+T%(H_P$@3;!`E#30)JD_"
M&%(B^)P0)=$*]$#O!,3J200QC),9_4$F]`CT]$'F"%'AS#C_\*D?L.&),C&`
M`K"1(DD\!4"UACFI-]6)G#FC;=ND-S6`Y\#(;3N`,R*Y076TPHPZ,S*`[R"]
M,^H9D8$(PWC3KC@_,P*6;!*7FGA3?8F(!R``)7FXB1&`4FF#!$B``A@,M#``
MZK@HK3F)^22``T#`+QH8AEA57H28!."5'".`"S&`:%$`1TT"3T.U^Q`W!CO5
M/VT`!Q'47GT;`K"D/V``(EB@OC*CVS$,,]*\PIBE+XF+EY$#^BR+E#.C4U52
MT=36S4NF51V8%O508+.24&V`(4B"6S.`64DW"_O3L#2O)%"]*@FBOIH6RLFY
M/1671#"""T$KRIE/77V.:J+/E%L+_ZFXL@1@(?`I%29(@/TI`H.X)OQ(F088
M&PTY(&TS(WW3-H(]J,I4`@<(EP+8JDYUU+@DOI,-3C0]K.P(%8>2"<T3!"4X
M`#<(5P<0,C.QDZX8ET65%B+XV=LH"Z7!43MA&CW2/#GXU:=:.SEX.P1TV1-D
MBEQ5L\4+OX?X@\]\P@;`#0Y"DB08-`]R@_]4FS^@TG&QLS^XMOCLQ%7TEA.T
M#?I#%4@K"A(4`,UCT.X4CA-$`/(IVZ9HB38@P:V:+H-@``:($^"\+PCI"`=@
M#"-`6C>BVNKZ5?7D18G0B0,`N#\PSB1Y`%_YU:<A6KU+&<)<D-Z4F,I<`#GX
MB$^*@X=XPO\%B+8B6#M!L+<DV:VO0J"4D1/^\)<D(``;-1#YG$V^4]($0"+I
MP,F<2PI0>1S3+4H#:!C`6PG$:!B&\+^Z``SZ5`"L>-$G;;ZRK9G`!`_>-`[1
M3`G]:AX<!3P%>)JU(".#T#LY,+DV:(\/`DXRLSCR:=UNN5F<#8V]:8WJ:HT,
M!*[+@0H;*P(C*(*>2=S7(C,$P$PCZ$T'2`*N>RK7Y`G74(+8.<&;DQS*14T_
MF=4!4!8(%+H/+@*;$)DE\!,B`&%/!;RQ\8A#"%'P&0(0)J^HA)[LF$S.=9#6
M>ZJJ4H`AD-W,NITHO@P&6`D&R[:$%9'6/`@J_2?*A0D,MI8I6A+_GH#7O8FR
MC'A;)VX`@SC3*+ZM^TE>XJL>H#6,ZA&XRFR*M,K#YG-,N860"V:^)CW/EH@#
M=]V@E&G-TUL"J^-<V:.<!]BAXT/`D]&7-HB=CE@"?#H.?>-.MI7:"S8"OL"(
M2E:FY_**_U22G`1:[SECB,&9H@+9O9&UPV0PUEC.C_G?!EA6X?"7&WUB'^V)
MQ+U@'9(RPA`X!EX7.2@"4B;E(UL;,`NE*[&P<$&`U;&1)"&S,\+F,*)2H8#?
MZ%C708V3YY.)>.-.518NYI.E!O5F;&[0156/;]:\!'!%X)RDD<#F!*@HB%H`
M(#X(6D[>B,!GXE!G"_+>HZE)45D)C)A4_^B2B5"9"82)-W[&9AX[@/MH`ZYK
M#F\>DP>Y(SCV.2O>:!J3'WY:O!NND#--NN/[2TN>&:91-VS&T8[VYMC@YC_N
M:'$K@HJFY?^5">B1Z1$:@$]]4UK["JMKC(<HOH1@FI;XYKBK:-G#7>Z\'GY%
M-JN#U.B9Y<]AXJ7XD.)#)C/*I:>NIKH`VIS+N<VTD06H7@/X@U/]Y@<XTUIF
M9G5)!.]I$`<A2;0UH,RJF;UID`T6Z06B5B*K37Y"6^$Z(NP@OAE%YS=.DOW!
M301<Q>Q$"VVS$<66$QU^ZKWN0..%F388XMA8L!>E9(2@WLLHJB;F'=^5*2G>
MN_&\G(9>BI7HY/\@DX@NAIYK(C$`9>&_<Y"'``\DTB$UD]V"!A*25@HY'CK6
M4\`)ZDT8_F*C:32MV9E&`]CB8^D%>T)^80`([)95!.06G(@#D-NPN@]:/KY)
M)FKNY+W3.\'0P@T[_N+(..\,/MH^7-*ASB1EDA:O"%>,TLVFAN6:&3OP`&NC
M(3[,V>NW"1C5^YC++ENTE0@&.+VG&IO%:[!HZTK[;+N>6\R\;I>)2KR",@K'
M?>0V6*"D>!!=FP\D40@E2!*UF0W73!*FK8E/$ND67HJN:`Y3DYS($-[BFP_'
M7;R6(=OS:HW6O*>&":(M(6N.:8VD$S+[F!XC<>VD21+>X:`@LPU(J^W_A;[M
M*XX[YG6BNP5PCX"NDM`/3],WJAE=`VA0!8"(!<+).*#3-N:=-RZ,E+KMVVK>
M(E,ZZ'*-7]V8!LBV,R*Q2YE,WY(#BQN>G&"-R=T8CAAR\^9)]<`9''EJ]QX3
MY(EO_9,3@5:CU&!TO1LVE#'M`6`:$EF-.)!MM0KPJ[Z_W`LMC;*_QC(,[[F9
MHL69CSW3!S&FM?1@W`6*0)JQ%'D9N)9-X:U;BV/:`\!)*5M@$]^E_T1M15HK
MF(U+X4D*DV./V('98V1;)0F*L@`G)4$E9*J2(8B64T4K6<U#[3"C;38YF!V,
MROP.PT#JRKL),]*)YU)O;?O4`AA6UIJR,+J,_WK%R$<#$.;+=[8(F038EVF]
M#-O`2=CPJLE=&(@""T=C'<#[5`*@.K0@R\I":I=M&'B%F)4P^)ND5LSQ4][)
M5@+`T1OQ4QWZ%RFARF0J@-RAG+E35.!@WC-R6231M\MX+L9`)L:Y"XQ,IC8@
M`L;Y"/W3N]TJ6_;:-C,ZQ@93DC+90Z-7D@6Y^B'A'CE`@!ZA5(K-^L$!-#]Q
M-`80$2,8#G&K$#$A19.=LH^IT1&)69FX'XWU'HI?6)X_(Y_7=L0*[T"+LC3\
MGE5N`S=DCC+%CB/;4!*]TAF=P8MP4N&B4/VSFXM0I`II3Q:*_'ABP?UL0"3Q
M_$"KGBM=L-4'K21%_?\#RHT%R4XZI)S8S[:].01HCP@*E9GO<2(>ND_/[WS"
M6*@9=="\<-SN!-+I5#,4`LZKR\[K]]#.%)+-W\/0=Y<KC1,"W3_H!Q`6>GSA
M:E+D5XJ-DM'>)`P2%&#SOWWK'%)%VD/TXD$4RK8O!0A%AP0)_*/HH(,%!Q<R
M%-2F#<&#A_X<4I2(XD%!$2<NC,/$3<6#?]K$X<CP),J4*E>R;.GR)<R8,F?2
MK&GS)LZ<.G>J;$-@B)('`YCP+)I2D)(#1(PRS2D(@8(E1@H\X"F(2$B;<J8N
M:>KU*]BP8L>2+6NVJ9$$!A(H.7M3#@(&$=V6=:/`P($A<W,FRFJ3B8$AB>C_
M$BYL^##BQ(I=#AR\F/'CL(?\+J8<^3+FS)HW<^[L^3/HT*)'DRYM^C3JU*I7
MLV[M^C7LV+)GTZYM^S;NW+IW\^[M^S?PX,*'$R]N_#CRY,J7,V_N_#GTZ"HG
M3W9LT;I7RPPO8L29:/!WE-IM3C3(D'I?\=@7KG<Y>+SP\#D/M1];7SK^E7$0
M'."?X`%!2CC@52)))'```VZ@E,@2=Q6`0%LW#6&$(D04<5(<"^S5$%$O'5($
M`@44L(""BBC!'XH-R)'1$`@D8(1?;3R`W2$.M)%2(D3$\<<"YC4E1XFE69C3
M'PS$09<2$>:WY$I,!/"`$48044`#B8#HE1(#0*F6_X\')3&``TPPT8``2M*D
MP(!N!'F0&P6LF)(1"KR4B`,$$-'&B04<280`141)!`$*#/9``40,,4`2"[6!
M5U:".!!`5R@IT<`A<1!PI%<++&4:`P/B)$<!:Y8EQP)O,GDJ0VT($*01`LA1
M1`)R),%$5G(HD420MBKAHR!+)&'J0@YX*D@!%"[T!P%52;2``A4)PD022T0D
MQQ]QX+K0(7AF6-4?YOVAA)AN"N1&$DJL^$<#!V#ZK;DH+2%`I(K(8<!2@&;5
MZA_$1CB$H(H888`!"(3TQX'PBI<`47&$NL2N&8VD1$5Q)#F70]%&]&P2;50$
M5P-=6F0MK1E!*^W'#K4K<O\2F,J;I'F"_.&&$GLE(G'*&5$+;DC9*I&AIP?-
M;/**Y`:),::@EFCKM8H(<C/)&27YYM+?TGH(PQO1K/(#RJ*ZM:HJ&S'`'T40
MP-\`#1PT%<"(*K)$`0`;<&,;!P!<@)E*AR3(`8DNI(0`*BMMT!\A'A`H00OT
M9\``%![2``%R%S"$(L(JLFC;!Q1`$>.6&R"Q``$TZX;<!M!]D@,&^)5OA05$
ME,@0JK<A[N27^RN5P`?%0<2\=2O"Q`$$Q3$``J(?H"`1<A_01A)X/:B@(`H4
M,#@"?R32P/,%,%!C``)`CFV=!A!P/5S/$[#`0/U93L"-<6A>0*)*N'V\B7@9
M$"__ZXU[3Q01`2/N0%]U'F!YSY1V``58+B_GNY$<U&(Y(B0"5#=*@OW4IH0"
M'&A\%0%=VT;W+P*"R7`#N%[]+%>`#O%N0UO+#Q,$0`0Q&2%0'X+7(5I8$@8,
M83(-$-@"-"0(!F`E`7J)X0$\MI#\=:EU)C11K+(U@!O=I23I,A$!EG"()#Q)
M$0R@5`(TE$`!_`$NM/H#O6H4O4/X4!!`]%$BLJB2(@1@`5=T'H668("(*,QK
M!_"+(.:'$G[93@`]^H,"%,(GB,3!`!!SU`(2T08$@,12.QN`%)D0JZ<X8"]*
MB&*V#*F$6"6""4LDEH;^<(`J*2`!^6H1Z)(PD"$D8(J0_S+C0IH'(T$D@`&*
M&`(,6R@')D11$%34FM+&U\7GR8&69F,``RBR!'7](52'6$`-%X>`1"@A`*KD
M&Q--6:,Y\@EB?")"KP80!UJJTI@B>=L)E5.I.,1!#NZ4`V7:$``"B,X`#%@1
MB`9C-*7)@7;3=$#9S'4(-X")"$002KS8,Y4.#5%U.'J8`P3`1&4EI4:V%`@"
MJM*I?9H(;(D0A,2(,`#($4%.!'6`H0Z5T%JN40!7/,!0!B-'.NII(4FH72SU
M>)(%*.MW-]J=ZHB0@,&T<`B&8AQ%7J8$7":AF0BXDWD4L+V%-."B\A+$1?`4
M48CHU`')'*%$;#520P'46J9#"?](EU`$`RB$E;;3TP,48I$$!%!?!TG`IA+2
M3!X:B@!%:.:-EL8$(R!@FNXC"+&6T,P.`3:?L0-<`0(;![7:4R((,%8ZC[.5
M*!G!3T;84`JEI9$A#E5>D;52VU#4EP<80`!^32%4$J``!8BJ1J,["=^`9:N!
M)N!Y"A``4:3J)=,MH&<\M:(#VO2F-N6+`6U3@)TJE(#="2`!LIWM3P^2+NRT
M`7\$(`C!FC4Y`YA'N0LQPAT;HE.&"%<1YG7OY=Q:(0&4<K;)E(/S!JBV-BA@
M`,`[4GL7<ER&N$%P_>5JI+P**K\EH;K7[5$2TGL>0JVELGQ41!VON)!.,02,
M1$EC7N__"3SKSE:QH4I=P/JCB`@[RP!,6'!&YB?4P3!!=D9S5-MZ:S:+7#:S
MR:$/=>B#DA2*2A&PTF>HY$"`)&"U1=FBB!L<0+<36P2>YTE7D4V[*82HC@$*
M@*>2B>+#@[CO$`^0$T8UZH#%DID`?Y@*2`Z!`)).UU(_G9E?L!E+!%GINP=1
M%84`>[:SG@VG,=8=AS&\1#)S$\U)<*A`5O0`!)0$C$S6V!_D.""\DJY?_C)"
M#N%IYSPFN$>&S`A*92>0.!1(P@OA)1.PRH"VHKF.K`0/7=7;%1`?)*[$TAN&
M#V$T4#'Y$"U:<7J)%>O;6LH-L#H(8"#K!EB;T8T2R9N/EZ2J_R(3`0$',9JE
M?@7!.S++#7(H'L$2T`8Y#,$`P,*E$;K+!(^)%'=QP.6%9@LD!0`@N-NKJ$^*
MP.XJ=BH1#&#D(KE8A%#%X0$`(&D0#U'*=;>[2\^DFQS:P`#T&=G/%F&<'!+!
MK#BXP0`!1"\>USO$6E?7#8L:T*U-ZP!V,DN:[&P``'!%`",`Z:F*4$`#]N(3
MGK,M3J6R"P`T5H!2*P++<B@=Z!9P\U96%+=1?)4?;UEK/;G!3N<.0%W!J@A.
M*R*N33_`B__5!F2YX7>_RM(!5GQ64EOQ>!FZXXR!2A"C+8$`+RZ"2\^9Y6PW
M)VY^.]M%"5:2!Q"`@F<&*0(:?^HX0/]71,`62`+H*:+;8FM*!6@\`\?;.`<H
M(%$-N-#:Q+MP"BI@*0Z`''[IR0!3$DSV#:C*ZQ(`TLJS#R5%$M'8(D78N<CA
M`!3:S^=[Q!`E)/(\"LCN0@IL$+@X=T0&,<*.UR9"^*F/G@DI0HXVKZ&.!]!?
MHJ/*(0#3M@>P1>(_)<*`>"0BM$\N1/0DBA+$>YZ-%P!-URO"CB70BOS+@[1>
M0ZB;=AD+_"F"_(D(5BB>F36>#^E>@S@+`I(*`8R-@B3!1;6![C%@`HS3`C1>
M<5W/VK02X>%'8X@'Q53$S("$TKR'FLQ%I;B!$&E$MVB$=@C"#':8#0J$LX3$
M1QV+&^@@$$K_!#L-1$:PTW=,"PS6H!`M!)#`H$1LR&B-2TF<A!)N!RR=A,@E
MRD?-3!8*Q%[P8!'&DKGU142,!*OY##OY7ML1H4%,AMU4H<]D',60W$8<T3HY
M"QGZ#%:)1!%N82PY1A<28ARL'2`Z!CLAUA]FA&/48,ZL3B#&X*IE842<7@IN
M(B?J1!N03R<BAALH7RB6HBFZ1,V<(ETL`?2IHBN^(BS&HBS.(BW6HBW>(B[F
MHB[N(B_VHB_^(C`&HS`.(S$6HS$>(S(FHS(N(S,VHS,^(S061P-%H4JXC-(<
M$4M<!'RHA)49!NJ@QGMTAU8PP<XTBARPTXX88LC%TIN<X^D4$S^A_R,V1B,Q
M$A0"S*-`\)R_F,T#E!]C0(A,/$4KGL4SZ0Y-*,%`I@03)-1.+$'"F))-X!CP
M*0"F%,$`;)X]$03@*4GRY`M,81;>"`"%`-[F%<HVTN,OE@X!&*04UI0U5M5,
M',*IQ02;>>-),@:VN039%46/3<1]M,3%-95#]`=!``I)2`P!P!P`J-K7:$0!
MT)=CI%``+,40H`_)X1)#H20M)H(==*4?M$0>89]<[4X;8!^,'`*?K)E'--T"
M"`@1^$@;.$`#2)'M#($#R!'$Q`R;9"6;9(T<,0&#M$$#I$R$'$+#"()9B@E*
MW%L#P,B?"0M=(H4;V.6'+<&*/(33;,P0S/_ESOS9`]S>BEP2B3!@$?"0Q]38
M\Y%FIT1*&TSF#P&@$2@FAFVF8U[2\R&%&2$D`$+,8]J(7NZ-1*4*I=U2`63%
M=N$2F%3$U^1+_[G;0;3(XZ3.W4275M:B':1`"(``$/SDBKE9WQU)(D"7`C"`
M`#P`(`4`(PE5Y`@`@JP%04!0($57FR#``AA``$",\1U$@$$;`6314](*P$!3
M\CC+TAG<]QP`?9T$V\1%4DY1H"S``"R%'`R`/26`1"5"?L+D8XD2@A3`5*[-
M``!=P#B*`+`/P2#`#2'`N[E6$>"-`33`;Q'%"`*='&P<`R"HG,3->-J3L94H
MKER.3([(`@A`HBS_08A":-\PQ`U11DBT3LY8%^O0B\&T4+[\1'X>0EX42H40
M@+G=SG!6)RW:00A\@`?XP$^&IRW)).J54D4,P1TI#/%,5YT<B<)`C`$HR\*A
MBWA145>0GFFUHAM5!!$$@-)15+*YF$_<B"BAF<^,9T4P@=0=@*?DZ>]<"-Y`
M3GYZU9]=3A$$T>1$J(EL"B^5A/&QC@(@%C2=!UXUT)H)1%XHP@+43J(RX`"%
MIP-LS`$H02(@P(4H5Q[QC\B1#UT)ZJJP!TO]69*T"RZ]'ON5"7$23.]0J2#X
ME::VR>O4RU)^7@"8()C.HAV`@`=X0`_\Y.]DE)3=47C^F^G4D72QY8;-_QR5
M+18"Z(U=\=)6S!&Y)`&NY*I(H$\>1<B`*HV+'1E",*K2B-VJ41FQK-NE'`0T
MR1F%:.CKX)?6C-GD$$&Z]`V&)DIOE5)OE=9"D-V;D9X*P:JGJ&>O*4`S'8!L
M)8"6*`*OQ@X\S61<"1J&4=E<R=7TR,V'\LEUS66OF0Y!#0$$,><*<9,I:6E5
MMF8<?,V6=2LL^@$0^(`/7,%/'LJL,0MP_9RZ5LJ)J:>&(A>[,N#2Y23>M`7>
M$$%Q^<O_0(A.+:Q,`NRA,@'*:IUUU*32C*VRP1C7[FK$7A1S#=C8+<54)$`#
M5"6K89N+&)1!U0VGJ<\!:$I@F.Q!Y)W6[17CWO_)KO:JF\ADI-1L9'T;ES($
MH6S$1/P$<9H0H;3I![D9L8"3(?G0(42GDU*5JT'M*WZ'?!R%R6$+BG(MF=T1
MC*FG`_2.P'Y6L?!G'"`3FQC,+67@AP59KE$7@$9*\OC.4-38D3R%P<K9IA",
M^QA+W[E33?U<562J7!5M\6`O`[TJB)*JZ3%J:VX'IQ5/BT%.HFFOTD!%VBZ$
M8L$LA?@JS9+/G)U-DD9?A%K'A-9+<>[1'.WO/%7I4C#+V\PN`PNA;'$G[M+B
MNZP)H.#7]@RHDKTE\6XK\SDGXT5)9?'2`]S4?;))`#SP27S)A!P`H<YNA+B!
M`#@`\P4`K=P%^WG.2;3_$!$PWSTR7A$D#P,T4,.:K]_ZBPH1%A?-RW\<```P
MD`+,ZUJMRJX:21N431*(U.6%)T5^"1$D@0($`.2LK4#<!>D)\=<\P*1P7!8E
MHIO\:\IV9Z<,P`&?5X@:P5*)R(T8T1XU\.YDCT9$5Q(`0.\<`NHNZQ#PB[-N
M<"\FP:TR1(VZ01%[)GVXZ1(L`>':Y0"5B""XJ:0:1('PAUV6");Z8Z$]U<S1
M28DD`GK-:W(Q8$EMIL'FHUI(G4`4SRDSH(H<1!'H:GX*P@-$KH#X#ND1UE)0
MG@%$Q0,\D%*D7G\4`64P`0+<:C+SJI08&;#]P1!`$XSR\EI$2%(,P=.9T0.4
M_T@27`@U(1.<H81@!H\/O8F`6$8^^PS&FM%=,B`#*`X/F\ALS58#\"4E,V,E
MGL=ZT.%V4(8#K81#3T=6N`&`8)XK5\=Y;".6`IN0D=FF@$IAFI!#?]1X./1$
M8T@E832VI'1*B\<0=,BC4>,*)K1-8X:51.Y-P@2''IP!#-Y,[%!PIH1/[.@]
MFD5/APA0PP2@S-I/:/!-1W5D+!6PZ,2YH=3AW<0?0`E\M(%=?I9;7#7NZ(1A
M0N9.2S5:I[5:KS5;M[5;OS5<Q[5<SS5=U[5=WS5>Y[5>[S5?][5?_S5@![9@
MC\:W[-UO*HU>YJN^:LQT0'5*[%)+C"P1N`$CZJN^[O^,=5C+87];5B\-CE#A
M3F3:6:]$)U$CD2R!8U\&#P[V<FR;OP``_QR$D1X)>?[/X*CL8E)*3;#82DQ0
MY"+`2`W&$`2`;1>`VIA(VP2,CP1.^3V3IRW?)?/$3,W'3#*%QN&C9@A"`RPU
M:_^&:QL!`/BP;"?I`K329"Q*\S%$P$I$5KRT0_-V2EC*`U3$A[PP:U'$1!!0
M^>B%*&V/!P(`,-T2`(!L+"7`FF1%>G@ADV;%="NX97PT>Y]M2KSTA+LW?6^T
M>+`$A`-A0R^X%JY'@J>T$G!K=Q<'D4$Q7A#$NQQ)>5M'EO@-Z`A`T'56%OV!
M@?1'$@S&5:CR%*67$5QTL$#_VB_?"&MEA=CP(`&\"8@,A`*P7P"QC75)BGA=
M=:ZB)7^TJAQLB?$YBP/P!T6NC0S[3%KT1X085+K<DY<DP)Q5-XOT!S@A\]%4
M$EH>",+\,HC82`T1]/]@<X4`(()4-4&SU?:VR"B[UP-T&T`J#:'G>1RD2P*H
MDHD402G)"G\824;`3XF;>+&VT+M`SHO#ZG0=RW%_6W_I!82>L9'*,4!1-O58
M"%6@W,(E5!>KA)2UIAO(D=E$6$2\CO2L2*+)"[W`"F4P@+*HB@+$FYOZ218-
M%'H:P58U7;%$F)PTN&R/5!(T@#B-G?9,Q1)GB0.@%Z1L!_44@=C,R/06#RU'
M:!(L_P"06DXQ3Q!($4`#!,50:/N$6`]N@4F<D%=5GO&!3!$`E-[&P1,#&$`1
M3(EYTF<8]UY$0<D$$:UUA42J9OIMA(?N$O6F?Q<N31MY/S>RH-[>I%<@V0YJ
M)T+7*58409N?*$7*G\>=JL1PBXAK#8%!P#>O"]BP!-*'$+BK1L@7*XBE:<2B
MJ$EP8BCX+8&"H*7I4#N&[=JL&BXQDYNGI)"9B+27J`[*>:][5:8X)<+D@KG+
M0$P#)>_O5LCM+L".B7/&)7T+(462,Z#?A1FT1<D!4,L?S%B7#T:62,NWA$1)
MI3;%GX:L)($1Z"L@;XAKBXU'*@#?L'BH]VOA(Y.*5%V32_\$\UD.I+S.7E"1
M?QU>&ED5>Y>=GL2!V,AM2-R\PRJ+2+U8,DO/L83N8TV.:VU>F3#772V%.*O%
M`-P1T\<0`3WEC9"=KN=DW*:*JBT8J'S$B0F"I`].U^?D=!NQAU*(\+M:1Y_$
M5530=_%V'HE)F*_GYM$3(HG$;UD/8!;::`=^:9BAFK1_-A>KXE.7RSH^0W2P
M)3?`FI49\/I+`3C`K"P=0+0I\$>1HD-QC`A8LF#!H8(/'1@0]%`1@P>*'AAP
MJ,@!`3F*VA@@J$C)@8D%%S@PF&!`@0(#`BC8J$A0`28%F0Q4Y(9`DC8_VP@2
M^#%1`B*'$B`@LH2(QB42*1(I,,3_R!(";109+9C$Y`$C!0494$)Q:,$X!=PH
M6M!@2`*'$8<D45(@3J(#20H^%337@1$F7K,2V7I@YJ&[#^/\67"`B!(C!01Q
M=5B32<Z3A]PT0`"T35H'#!X*6O(`@0"LBHP@F$F1=6O7KV''ECV;=FW;MW'G
MUKV;=V_?OW.W,8V:`,%$#@`(B*,V02*#<1#(9*U$HR(%0U`V**A$8<VOBI(H
M/9#H+%Z*;@8<592(.]Z,)_\4T!Y_;*(%H!^F+"C'37\'!^IZZ!`$S!.(H#\,
M$$P1.1SXPXT"B$J@"#FN,F@!`Q+1ZZ&B+@)O.*W`(\P!MT@*8*R'XBMBO2&@
MFJL`%0\Q_T!%18@8H*[#%-'+`04*$NXK$"6CB`'I$'RLOHXB(XPF`YB0HP#S
M4BN"KNU4_&R[!APJLJ`A%@#.RR_!#%/,,<DLTTS>F!`@K2***RB^`)9C0(`$
MDBH`@8]88V(`!P11H,,:&6#@``'P(H(`!AH@H(@@'UN.(B,&0&#'`;#$J+J"
M$KII"`(:4*#"_%1BC8CF6',@5`,Q'6`M`Q(0Y$&B$"AB0`-&-``RRR@:8@`&
M%A-@+"`U.BN!!@SP5=1#&2#@NS\($`#/1!OHU8T8S5NB@$.2V)6!T@0#4DG$
M"ACV``7^4,"`3@WP*,B:EJ`1V1?[E$_.*KM4Y"Q)$SB`*`5F//_3WW\!#EC@
M@0EN[0\C)HHCB9G:0%@1)HB(N(@E3F+MD"(:D(.)M`PR@H$AXF`"JT28:("!
M)<A3PCEL.29K"$27V*@-E4,S`BML&7#@M(=$;LV-=EEK@\0_%B[H$"8^(X*@
MR#9:(JTX'F`@":(%(7JUBS^60XFTMMZ/YC@<:&`))?#<4(D&Q'8N+YII(H(!
M(K1>CFPW%TXD"8O<:..FKNUE&[&7E5;DCY>+(/H/K5>>VJ`ET#Y1$(\;.%'O
MA]SX[`%'Y;BSX,TY[]SSST$/7?1#%CA1]--1)R)4U%EOW?7788]]S#8<6$WV
MV\?\(V/<>>_=]]^!#_@/M8,O'K=#*C;_7OGEF6_>^>>ACU[ZZ:FOWOKKL<]>
M^^VY[][[[\$/7_SQR2_?_//13U_]]=EOW_WWX8]?_OGIK]_^^_'/7__]^>_?
M__\!&,#.8<MTL#F$0^(PEI_@ACUEH\TAE#"2S2G!4;TY(&T2D3S@((\F1</-
MXXI`A"(8080Q2\)RY%`$)<SD<4G0X$/DL#,!SM![2@B`1V(C"`;([2(F.YY8
M;A,?&0[L.#?I32(>4$#84`5,B8B+O1@@0=O(00$(0$``!I"4(3!+14H`0`!:
M9H3D.!!%"-`.#='(O04HX`#]<DX&-W(6CCG$9!DDGM$TB+RP*!$V@CA$?(Q(
M$]M1!'EWM)@@_^[(P0T9I&*',.1Z!+01XNG1:(#!XR`#LR%!:-"/!;'C(3=B
MF!G=\9.AP60B,FB`!Z`R@XHBB0`(H""U$&``9'S8`0*PNC3N\G>$R`(6L+"&
M1U(D#@1@PA!44Q`BO,P`"HA#GP*`@)]AIP'#8I41!9$16AG'"`=0I5@$T0!'
M)4&61B/"`0[P@`*TX1`/8)$#D.8<03@@+6XP5TK*:9`B(,``"_A(-@VP3<$U
M@`C\?(`C'W`3(\PH#@V82$G.%3F##,&;!QC+`P0`1"8D@%5`>\@0!%"`KRB!
MH[2:2`@1D(`_Q$$!!?"38`Z1FGZF!:1/DH-##^$`(I@KBA,U0#IW9_\Q`V`'
M+*Y,PJ$4X!PYG*N6%EL`E\[(2ZGRS@X@\(`'>C#,AS0%,Y]*@`!4V$]!@+1!
MH^)(`!B@!`9`B"-/2D(_29(>)2```"A#`'8&U"],*8HK`&!G`>["A+=.I@`4
M&Y<2D)/4J,22I`B8ITBILX!$R$$`!*H17@#C0Y`,A"<.4(("`"`82/FE`1#*
ME@)^,M0E#&&=%)E+`IHD'R9`"B\+&(`*Y7#8!\0$-0:H2@,.\`<E$`"U//E#
M342:+>S4R`B/`6-K:D)4P;E2"0-(PI2HDQ`R)H(@:)OJ=V]GAQ!\X`,^T*I!
M#E`[04BJ(`K`CQ$TXJ3EF/4_$\EK3<R3$SG_Z&<GQBHH9J8D(!"E*2@B'<Q$
M*$.=D2B`1P)BC)N($`<#Y)<`<:"0$1,PA$0@X"N:-=`#%!L?P<2!G7NQD2(.
M$RTYK!A1K-&*:`ZX5.PP9#LB60^#!S2$%4/G*QS>"83"HJ`=&>8[2U!.:V+4
M(9H40##9<D.*/=M4UW@7O%5V754_X`'SPH8)-_1F2`ERG>T0QDEI&=5Q\%,1
M<0:X)B4QSQYW<A5DLH?!I3,`T``9HQ.MBTD[_6B#W=1:<#DJ+$VJ<'M7Z6,K
M;9:*TA6S(`IJ*^40.2LA=8FJ[@@B)5RH``(0#'_-NB5R$8``+GG)$`;TE5?%
M"&@@C@_'R@S=J:"(_[H#^(,#%H"@L3G+"&M<0`5;;&5AGXX06C`V&\Y++"7(
MA;;6(2IU#B%?&B5`$=$"%84<!4@?+ZD^"M",8([ISC;@*,]`#-%DF)2:C8R(
M(H7VY$\(P#$A2MO9=NDP?@R4,T\JI=IM7()5ZD*@K#2@/W%P`QFU8A7/NB'#
M:NF0N@NR(Q&[P>!N\&.L?BP'/6\IUS8Q2[RA.]30&-763/"M2*JKM0>XLVQ4
M'O;+;\=%BJSQ$&(^MQRG?9Q#/VB%Z76(5&[M6/`$`&@).3%KAN20(@2`G7?>
M#@ZYPX1B&N$0;2`N11*A@(9LE@F2^OE`8FV=1'_%`<G<U,'6B:T`'.7!3O^T
M$:4?$-R)FL>36IDS2#SM\(+P9&%63ZK6LZ0S16#<0(*P:$%`K!9RA1-.2)ZU
MFVHM!P3!->6O"3;,,?\Z2#F0._9\MD80E``WT'<`!UA``;9^5`;'<D$_O9"Q
M%C2G1SXH.L5BPL8%!]@A#8`)B:B1-Z].%CNMM7;#7;U@Z'V=5#]L3@M`0'%(
M!]AB":8C"\C7`+#"Q@@BH`#;^M1#2IL$)A`@`<XG@$KX2Z/2IXM'`CD``W[Z
MD0LEX4''=3I&>.2&@`9432&7KB!([B,:``!&ZLBF+*HR+P%/YV?N:"]B*-M0
MYF$>H`TT9B?:8`GZHF+:X`'@"8:(8`*78"0,(Y___N8!W(`)$"D$$<.=XB`$
M_\@-Z&]'6D,.5,>#-K`#:4()3J(-XH#2'J8OY"!FJD:PXD`K8JHO_J!)[.4!
M\.)@'&`(6@:&'N`KD`9D0@8DYLA!8K!>XD!U`F=!F'`O'$D%[04K_D"XE$`@
M*LBU*@B"/D*X$,B%!&>%7J,S%/`.RP>"`NPWW&`S7(7)O&2IZ(XUC,"93"R0
M_.7)@N)!2/`V$L$B-BDB7@@/*1&`.D*Z?N,02LLE%F`2<R.WV,HU_B`!"L!6
M4"U@-)$`;"77?.,I7())*C$69RB&SDLWR&-C:O$VA&(-H>L$Y2`7Q>06W0`8
M:2,)@T(6D3$9E7$9F;$9_YWQ&:$Q&J5Q&JFQ&JWQ&K$Q&[5Q&[FQ&[WQ&\$Q
M',5Q',DQ3"ZH>,ZQ'-5QV-AC,1#@`?!D(;1.ZXK@,GJ-`1#Q80:Q;3P1-Z#&
M=MH1G1P`3YB`(7R-""J&"7@E">XH#HK`D&)*BE[C$(9@B&I#A3Q'\OS1(9+@
M.WSFH'SCF1ZF$0=&$)8CIZ+0-^1@(B`&/#RR-B@2*X8@']?12Y#H_)1`*A"`
M(,AJ"**&4IS#4#[#F'B&4]I-3FQ)-ZQ%@S;%LXK@IPB""')IY1I@5YQCN'*&
M]<P"`;[%DX8@`&@2R<P--]*O8)`B+&&C#PF""?@H+R"C-];+S!"`&,VD"$`C
MIO^24C?^0)I`@NSJQ38VS@AXL2:!(TU,AR=4A+5F8E.JYDD*@E?60RKV!#$2
M@-224BC:8"3@B,0J9A<UY"&$@^YX0C#8I&)JY`]J+E2Z:2*6X``(H"OC2@!H
MDCPZPR$VCC8=2"B&L346X`&$PH'^X"?LJY$N(V]>:)-^L]TZXR3*8R-BJ&S\
M*#@G@CU`KI,,(F\"Y#,%A,0"Y#DRDS42P>IB9I]VD7AV,92B;5H$YR=$<),H
MKMWZ(Y00"2P.J)H0+)3R!I-B2#T%*3B)0CP/:")P+3E#HS8WQ.`09"RLTU78
MJ4#YDS!K(R)6PPVB\EH^"C)0)4<D(J<4,JJ48"9#D2+_3,XE"&`L,N="R(\@
MGJP4S25Y))28/D(J*D9*CJNP]L,`L(((%BJ9S()6/.XH211+#,,]3$W#;JD`
MB$LBG8_["J`^I`1)`21S.*8(&J((76(S6&,(J@A)'])>2-%.I@6T!F"%U,DE
MB"`1:FXQ5)'B"B``#$`.AD`EK!1)L6,IV^WT7J)V4K$4]6J];JAA7,H`!L!(
M2P))67&G`@H&;:44L<((Z`1)07+<7,*9=D*EUJ-T$D(`&$`08&LGGH\`$&`-
MVXE$+;53F%0'Z6J=DJ!+_H-)N_0O)O6?$B5<2M0Z%(A)16\G#N!*4Q)")Q(!
MTBQ+!<"=5`<0J>,D7@627,XY_WB"C`XA4"1O6PY"`/RI#0;`"#;LUP2"`"JF
M*/Z2-8I@6(<@3F<M[.#,.;I);?HDBG[T(:B#"80+^_0L#L;T8((K+!B`/PX`
M`6=I">1@6[BKC59*E09$,(H"U1*@0?[@`5J%(AH@`(P@A>(MZQ(@#EC*+:P.
M(?<I*-XU1@Z`XM[O8@@@9KRKH)Z)39(0*A[BK3A6.<8/7@NJ6Y?@6A\'8O^@
M1N1`PHQ@I11`)4#*7_=RBS('-(@``'3LJ'20,58J6L*3K39,:9SOF<1B0)R)
MI;:N1UW(ZK["4YK$^2!(60ZAH,ZJ<"`E*-Y/7T%#2IID`,?"*W+L<#I%$Q-@
MQ1J.,/__Z+C.\+A(:5]?0RKIA)8B$-KV+D0O;W!MZ0Q#9C$.`BW:"V0"3$8W
M!%A?8^D2P%/&%('8[/Y0@T<IROZ&*-H<)"%BQJ(HI'16[&A"<2Z29RVV`S(F
M:Z5*PF=5HYCZ@[&2@$UDB`%(I2B4ABA_3&IOHOR6C:1JIXVVA-H$8B)\2!!6
M;`-K23MI0O+:H$9^@E+(1B)?31&>,DO0`KZ20"XDD6'51O):$`&ZI"E.`FVL
MP@CDPE#X0R>6#]<,XL[.(MNB$'3=8+@$HV=K+-JF9)\X@D2RKB)QB"1$HFXI
M1&4"BZ]RLL(Z@@@HL!_#,86*H((KV&%FCMJ(:3E8*V%HQ3G_/K,L"L+E#+<U
MYJH4?VIQ'>4ZDA<G5':$>=0LYHM;)VM?E2IS/0KBTF0!2&A/@'.M`$LV#6,L
MN`*6HDAP,V[F0D4OPM96#F`RY>B_C.RGT.D`9,CE<B99<Z_`8L:)J1C5<,2L
M0J*[M,.>7,(U->:%%P1/!Z4-$N$Q8(E/*"+6`#CWW`"CT.FG%&"L&BP1GA*P
M"*!+M/3/$H**#^!.4&7#Z&5^EP!77&.>G#CO;`[:8DUL%ZW:(D=E'^3)S&/C
MO(([?NJG0O4/&&``!`!':C*#-DF/YO-1I,P@)%<J-B()%,)>#&"<NK)PDY@B
MX@-D!*$("*-^&_=!QNDM5_;H5D*R_TIS.XS%\,R#F!^BFQSB+[@2E]J5(S;C
M<`IK2`_"5=B$"')B)%1WYCKD*0[!*I)@)?D7*<I.,*QN6F)L-2!S)>`&Y.RE
MP@IMPU#M@(YK2)6)VL*YVAB@*!B`0L<O"-58=S.SF()B):?W6N>8<8M@:-8I
M9@.4)QM,:U?2VLYI(Q!E+E`3>3X"52A-?O?H+/#D#^HQF@MK)1_,3VJ,>26:
MVMCMQ@AX)*Q%#NJVS3;,+R#D@*(-=/]@"=9*(GWUD0]`])C7`6231HRYYDQB
M0/@DMW2)A..,C.AUA4("0X39V08DBN+`-9-GO:1IJ9MZF2T$*D9D)75W)B#.
M(/C91C=$Z_^JY@$`H/?$(B1B)FAKX@$.QWSOB+_THE'V0@!")5RGQ/`:X+A2
M0XH:P%<BH\*0@EP40S7"@B%9A)WZ<&%PI"U``H?0)D:&@'D50`"&VIC78UBJ
MYF$O$$>9%Y47A"CWR2'*C"<01G>P)/%R)-Y$0U5H!&)%PYB<9(OX>%I=B#NJ
M1";"8G2CZ-:ZLG,A+0!49)+)S.,LF5#VXBK"8JK-ET9P='#J:O`0I@`:!-)4
MBE=0\[J,^JA;`SI4T27,HZ-!LR<>QM3FEB),A36>3")3\:>VY7#TY3'=V598
M1>B(J3(7U3R>LF(>Y"N@P]1D*`E(I=VP5$1+S?3<-@%6*%%LQ5+_YZ+#>9$M
M\L*Q]O(U*W>@%\2E-F)$TR6?B"6@7L0Y))51+:0G!&$!5#%)D>)$B*!+ENJ6
M\]M0`HI8?L+`GPZP%D,'<7P5Q[HR9ZO!_N!CW87`;\)MP,)3#,!\D\I0=G4J
M./(5'5,32V\Q\**ZH@@!VF7<]D^&](]%$^`BWF;$D8<4G]R)N#)=C-1:;"54
M:>+TLEPLB@(O7#%=OB(D2E%9V/N!9@9>0X.,5LQ-E``%6>,,+>87D6QF/D+C
M)FLC*%UPEJ"A70,SE(`,HY<U'ITFV%(BJZ8U-KV]M^9N%\0V\U?2O8;6>?DR
M4KJ1_:AL-#(TQF8PT2:!UG`O2'TO3C)__QNTU4M]02)HU1,A?U%HUUU]&(_+
M(&:F02>=;%9]/33.:R((+"1($)B`8J+-]Q1`:Z)0N/Q50"ZP:J;S`H,:+%+=
M8!H9>0[D))@7TE?R0,Z0;R#=UJLN!+M])=V$+<LF"2DHT=E;E\G'LQ7^X<%'
M1],G"3`1XBT^>^BR>S+^XCF^XSW^XT$^Y$5^Y$F^Y$W^Y%$^Y55^Y5F^Y5W^
MY6$^YCF^E,!B93#I-ZP3=%J9-S((KG,C'<-'@K=S,(&CYP%&D?HQYQ\(3.9S
MYVN2$6'(BC&")/629L8U=$C'HW!#ZD"B(=3JYF&C`5[R>W0Z+P4D61@`['FC
M3XA^3`JRZCKQ-?\:8!]C8]/4?@Z!4:?/D%(AM`V2XS3BP%@L[$L<U3D8?G/\
M^></3RBT%P%RP^;"IYC,?N]&5NAWH^HLWTN@S56TBD)M0YIEPU%IHUDQX^[!
ML0T"8$X0J)8'WV*GEPX7APCD$#PA9F<%!_[<&&U>/Y288O8MC'U9B`)U5(+D
M@(1&YCNM'<'(B0YQ3T`@!H)EN`T6A24)`!XY?Y]&;_8%Q_C5-2<93L..D2;<
MF-T/!F[V(X%6>O0F!$5(B,14E`;'0KA$Z".J3O[K@BF,Z&B&'SP/#B,A:`@`
M0LDA18H.,2%"I`U!17&*&&%2((Y$@HG:"%IXB,B`)'\4R2E"Q`W!/W'_#LI9
M2-`-D2)Q1L910N0BQ3:'*LJ!*1*E39@*%0ERTX9(RX\A,1XT<C')@4."VB1J
M*L=(D9.*W'3T:"3APJ!$EB12I'3@PD1'3_YI4(#)(8L$)S(LD@2BG+4##1(Q
M<O70$B(<4?K]"SBPX,&$"QL^C#BQXL6$VP@@(J`(0P%+%"T8H@@M@@0"'OAD
M8"!!Z*L4'Q`0?>#F``$*#C4@L'F`9T&@12?HN,```@4R%2D9L+D`@HYM"AQ(
M0$#R`@<I(_Y)<+P`@T.'#B1!Z?HT@@%,%)F.W>#0@@`$E#`Q<,B(@.BWJQX(
M38"(3P7"#0P@<D@!9D5#%GQ-2<`!"!Q0@$)#_QB70!Q&`/>>0G(0B$`!`WB%
M&@-R(!":`0;((8APHAG0``+;54;$:02V-)9H"#0@1VZB\9;(:PF,J`@3`6)(
M@!Q*712'`2AZ9$``!2P!D8`$7+?$C4J@E`1L!'9G!((]`>F&(!I")T!W&!W`
MY79&U*CD>2(2\&5V"0CWAQ+HG=<4<!]VE(!DYQE91"(ESBC`EV&A=">!;BPQ
M0``*]*BE`PV`R:4!.<H142(/%`#=`2T-<9J&/S*&::::;LIIIXLYUH8#BU)F
M&7,,%'`2$04(8L1P\^U'4!L#+/D'`@XD,@0"%Z$EAYWHM6J6?HHHH*M8!"DA
MP))N<)>(`@L(<D@1!/_\D80!%PV1P"$./.L1`DD<8L"2"_VQ0'>')'"HJ'$D
M8L2T?QA@A%Z_`O"M'`;(MT`"T+:K8*-+!"!?$4L=@H!D"[D1@`-,+>`?I7,Q
M2L13^2;BP'#I!:!$(@<L0%T;"YS$:!*"$!#>N_KF%YX!0S#%@)8$5==:1NT]
M5X0@Y1:D0'@K+BR`''^DI4@1"!@+IAL$AW?(@8(P01G1/Z]\"`-#%R&`T?\I
M\K-%)%.W(DI6'O!'(D44\(=C`M4:L2)+@`TH$XG(D4`22BRUA+6.Q1L'F8HD
M$'$"SZ9W6P-?*E*Q(D8LM>4#3#6P1$:Z6JEE`].A2QT#/3-:DH\^.<!`A_C_
MT>:RIZ*/3GKIB_WD1NJJ$UUCU3\OL&QERV5VJ"+%D0MB`PT<=[7`8BDE=@($
M,<``01#AKGN(0RO@F5]J7F3E$C]K&?W/C2,0L8#)%Y"RN`LU980#`Z2[0'-S
M&5!9W>DASA]O!EQ7D'4,,*>(QO+EW88;$:'D!@$Y022(!RB`($M85:Q0A8#!
M=2AC!Q@<UO;2``&(#&B)X!M!.*<(!@Q@`4:X5/PD4\$#),\``P2?J%A4@)RT
M@0`MR=FY'G`UVY&-43WYV9^LY1>Y-.</0OM+UCI4&<(5#R,&,%B'F'"[J@A@
M`;JSW!(>4#Z"0$M-!D%/$@GV);YEC2(768L1'A`:_\,-;2P-V&`'!]+#Z1%$
M=XSZWZ(B8IKDB>8/&N0@54R'QSSJL71124(2C/!')?0F5E7SC0#$)SO/,*!V
MQU,`B!;9@#HMA`C".Q9Z*/F511[P#XYL8B2;!:N%S*TNZ-MB0<)EF084)P[@
M6I'D&B"0`WC/)PL0#@-$*$3S@6M)=6/5&!5!R7=IB6!%6$#SAH69<SF`"+\T
MWR:',$#?'$`F^HN#=5Z&RFNZ)S2OF:!"B+G&X@F"F0+0VU@26+\!0=(!2*DE
M`F[9@#CLCR$Y`DM:"N07_9&DGEA+2R_]\D^&1*0("8AA/RUB@$(-\66RE&*X
MV&0[`4!2=W'`X%C"PJ8D)O\"G7'"'$8.\2@$Y`L!8&'?RY@Y@`%\J5582^@%
MX\G"MD0$<PZ03O)6]H<A'&``1]JC3W\*5,5\9:B`<8Q($L&```1`=LS1G?'(
MUH`H>N1223"@=X1'R376[G9178@<6AA*2P[$2H*$5UL(H!`U*6"`+UQ('/ZP
M2Y0HH5$H(UP4]1D]M5EK;%=A8G7DT\\G*N`K5MI/E.Z53P'TQ'?]B55,#6<M
M)J9D5AL=G`/TE8B?>9,@<0KG(41V"#GLSEA8)$C.W'J3%":B60VP$OP`91;=
M-'.3/Q/7"N404+?ZCR!5%01!66?#(UYPH:?<3S6+PR.T4L1H0A,+2$;9RRL6
M;&__,7G?2!C0)+403GA[>ID2X"H'!Z`GC4"S3.>LZYL!_`%S1&`?200AR-!*
MC75!K:]][PL8IO4D;P"H#/,RN-55V6@(;9@K8$<BG38LZ$M$,(!(-%DC`1/@
M`04N@'P2$%;?X#"OCS+/C`;RLSP1I%TA:9=`T'NLC;3A`0$@'X#.-P1!J,\(
M`&!`&XK`'6`>R6-V(P"!&P"PD:S&@VY8#Q,,3+AH"F(S%?8,H!P@,``PT+()
M98("Z"5<<&9F.KMI@\<8<+7J#"Y)!*[J0U3,XO(]:@EJ$@"*&@"`#!?G)`U`
M'Q-V<XCG^>5<"#@RB(*&`(/^P7_"S8Q4?6(?([0A`:T!_V!!%B#+-M1YGPYH
M0U7EAIX"-H5L!>&H?#K<!JDQ80!%",IZ#&?2<RG`RPP8K!$<+(@#K%H]Q1,O
MFPUP.1;*4Y5K:^W&O*P`XN)WV,0.JAL2M!"E&(C!@'4#MPY7@`(X8)"V.Y/*
M!F+-X2`D)<]*1!(B).V+/`!^*`EU76R\N6@/:I*N*DB#"W!MUX1.6_!N`!%N
M983]R$$!'2E12*:SA$7"VPA?25JT$Y`3I11@`=A="+%8US^T%&!EACMF'.@3
M[F/-Z$!+8AQ!]AV@>[<S)PX0%TBJK>Y+Q2B(T2*0M*E34Q#=>W'PAN)5D#4E
MMRZ@(V>)]L=L-YV_M"C:K?7-K?_\0JXXT"8GV]X2:*1S$F?+1`Y//T`0[PQO
M_#!A.FZ83ARXY9K*..`Z@A`OI$2B*@-PL'-+:$`,CYURA@AH:01JP`/D(PBT
M&,#FY#K)$L#-`.*`^^?%+KSA]<@ZL=2D?F'&B,\"$UK2^.0DB2"MXTFS>+]4
M'B-7^P-<]^P707`((W_);%X83_KZ_:&+!:G)ZD,_%Z_!-?/G.O#!4.7YL<3P
M$)[_3USJ)\]OAGGT!2G^R\2R^8+XS*`%V3WQ1W+ZD73Q/X>CK_%'TBN*6%_U
M83L^8!3?>"(*LOLO0WKL,9)[BI0_^:V_OD\^#_V"EW_/ZS66Z,<:MM52Y/6+
M)^WR+\__?(<G@`-(@`5H@(&Q=08@><Z4&.WB`$,0&M1V@%AS(`Y4@.!";A.H
M@1O(@1WH@1\X&$IP,SY4,XKQ60N@`#'Q@72$'Q/(+AX$@C$H@S-(@S5H@S>(
M@SFH@SO(@SWH@S\(A$$HA$-(A$5HA$>(A$FHA$O(A$WHA$\(A5$HA5-(A55H
MA5>(A5FHA5O(A5WHA5\(AF$HAF-(AF5HAF>(AFFHAFO(AFWHAF\(AW$HAW-(
MAW5HAW>(AWFHAWO(AWWHAW\(B($XAI47@$W(?H*(B`<8!PS`,(UX&=MW"$;3
M*7F7<WKT$P2Q$@S1``MX&'&PB8>A!*(1.O85*M2F!$4G@HXX_P0PJ"F1*!9,
M(!JSQ"1#D`AN\(F)B(M`Q00`$!H)X(L)`$.!<3@2R!B@`U3;@HGRP30YH1C(
MPHI_T2%[=T?WE00]XQ</X&;\`0";X8L#D$*B4S<=825[]XP.<``5$7BYJ(Y[
MQ`084S^:1S0UH31C\7IC43^"0&V"0'[&1S3)]Q3[^!>\)WD%!W\5-%CMMXR\
MQSKZF'C0PC2LM'M"IU*REWCPYWXQI(\&I9#TYVWJY1=#8(T@^2..(6SOR'L&
MQ9`ZP11B,P"],FBVEY)KA#A$$Y/K:).:=P96H)-T4!C_(HOU4P3\5C]$P``+
M$@`((!*+1@#2QG,<M``$4$0@]I0$H/\`(B$("L`$^]83KH$97U<`!&`AT`B!
M/!66;:``K0(;2P(9K"$(0X`9H\9,I[&5#38`[_,?:W,:&M$0X9$2Z^96""`D
MTU%V7]EG+_-M=1DQXA%$%",9>?>5"3!,=-E0QW(`5#D$'HD2V'@2(CD6`I)#
M'%2952E%CY*6O,4YIU$``=!`"0``!,`Q`428A7*.9BF.$!@@&7.3N5D_'0`!
M$0`!-%`8[4@$<D"<<3!Z>1,>_Z)HN!9/\A0G!\(Q<B```\``01D`W?$:"`%O
MO*=25D(_18877((0ND%M+,9.V%@\2P``TE8$BD(M!#!A5SE`[2@`]F8`G$8$
M+68$"R!!##'_`'%B.6Y6C2A"*9)'1T>)'Q'$3@B@6&K#&L44`$B1'`QU*-@X
M!.TY+?PQ`.QD.4OB&`I03-,YC?P1DM;8%O7I%TG0FLMD'!?A`(=$4%E".(*"
M$`D0``R@!`YPE"NCH#':'>:8"+^QF2T6E,FBFS>9"!T0`;X)G(2QB].Y&JL!
M/^IQ($%W(`,1(C)A(VT@G;7S!_>A,?K"$/$R:%\B7A>A$1^!*F>5@79R8*"A
M%Q%J/-<Y+-&T5C4"`/03!Z36(6Z',TMQI@3!GV\5'SZ!2TBW$4H$6%;B'[Y8
M%P\@H09S-'L#-E@A>F12<`U04+=4%YRQ@)K)'RTV!`]04PW*)```_UA,HP32
MN:BRYB@FVBX\IS=[NJ@D%"/G**2#1C]\MGU'"HA)VIN_&9QYJ@1LI@2KNA!`
MMB$$`8'04IF_")A$\*7PTR&8,03DL0!],:T1I1:[D0@+\)^_B*)^H2!0-`!T
M,P`H$@<R>J=UVCH]44$+X!@N,Z!=PUO9&")D(:-*X$??LJT+<D?B)4^VYQ,3
M6C^X9`3D<98=\2_<>"8M>0#T8S@M^9$AN9[PIG9NDZ+96%S..$D$4';H,6(>
M6:9@D:X+<:7FF%YRH%\+L2"<Z*N!F`@M(`$U*P3#^I.3!``'R1^K`B[2P7!,
ME)6SXE#)E`0)$"B24K+>N:Y?H@`;Q'#$D_^!P)12),0EB0`HZLJN=CJ?'#LL
M\FJJAF1-$@LH(I&UXL44V^&-/I.HL8JR$6%.WV.P&L,<6/NTZQD'_Q)L4?L`
M3Y-L%)N9)6HTU!&`28"9U5%R`D`:TE)V[..V)?NR'ZLMN-J2#_FW(QJS@E@(
M@=`'@V`(.!L8RW(`_<D?Z-$LE50_1B,'1(MHM+@$ZT(MCR$(B4HX>T>Q@=H6
M@Z2KGP=I6'NRD]$=[7JGJBI%TK:G#E2@"_!+ZM$2WFD`].-YO;>M2Q"VRNN=
MHE0$+^E0A[($(O$'3U9DWD,2JO8?D+&`(+F97AL8U9@3<D`FCA%$F8$>YB@6
MCSN13.,RG`JD0EK_9.3V*,28N9DKG!)!P"<1:X$34Y32$@DKK3GE/](I+M5*
M,`C`(4R#%Q,94:SQ%>W8MZS"ND+V`/JH'DLAI"G!KKKBKKN8('_PHFY#'Q8Q
M:FZG!`#3%$&"(M@X`,R($JM['3^3(*SR&-Y!`$NP:<^B&YXW!'DZ+#[R$P.P
M,AA2)6[P3NP2H7\`$9B)LB6*N2D*``OP5N+#2EQ2)=6(&?0[LFZ061-I)0B@
M=-4H'[NSLN=B`!9!O1(;P'<\IP*@QWNL@*+BO6J79^2A%A$$G[+Q-N7A4/(!
M*-[(EC\S.-4AIT-93@0@4?W(8DL9&JN2M6V18P[`BRU2/DR#')1L,&Y@_Q\%
M(``47!"$?!J_VP:J:7V#!C]*0`",S"V<5$[KL<#3N7#2!B:,["IM@&N4C$\V
M(P`2@APCBKXDNL5,$@"*0LGP<\6H+)1F7",!,"L=,C@V<LQL23B!5L+"S,@)
MT,QX?*1+LP3IK,X6D3]NI19Y)A3U<Q"E]C),(!,VT199(4CR3!IN8,]CX08@
MH5V:!Q-XL31,\<\%\<^"D`32&@=6R01I$A*=EP1#L,_UW!5E(Q:K2[`8T0:D
MH2!=05HP\5TSP1<_@2)10007C34-W1<OLQ<?/=!>I5TLVZMG+!67HM("\7%3
M@K4A81"DL=-B\=`^,=!_H,\`;,Y+'8;C9*)#:/^X,,O44^VK<<"@=BR$44W5
M6QW`T8(41OB]-\W58TW696W69XW6::W6:\W6;>W6;PW7<2W7<TW7=6W7=XW7
M>:W7>\W7?>W7?PW8@2W8@TW8A6W8AXW8B:W8B\W8C>W8.%B/CRW9/)@$V6H8
MEQ@T!@,8^<8857(8=C*U'M%@<8-\#>V6TDJN25"X"($0Y2P8V^:)'3$$UR%I
M2ET8VI*SG$(2I*,MHSC9=0@NSRS66Y:,@E$$M*@8P??9A^I5HXO*"3,2M7R?
M#H82M2*RH4?,\%:)AK%MRZ@QA[)UMDT8N%TZ^7%,GC(R'?W;<X@LV#A+=0%_
MY(MZ^]<;R0??"QG9\_K_'T\A"((&+?8Z28JU$C5%',D"+?T]%@S`BQ)H-DR!
MX)I7$/"GCV,Q$`])M_5#DQ9ID@"9>OIWDM\G1=3FX-_SO`&XD;*7C^27WCXA
MWNMMA8D@!CI9!3Q9&-^J@!OS'V:)EE9'HFSIEMRVE"P"3,SQ=4:`M(6Y.8HB
M':*'`+SX)1<'GV&)-34U<<Q-$/];!`(AB0`;V01!-1I"7POR5L2X;T:@`%2I
MI@6@./R!&=2[+A%;(V!W(+<Y8@S08%2IPP71<)4M,'*Y9PTP!!(W;;&"'-S3
M$4`V/OUX.`%2!-A62W5)<6<!GUA9L(:RE&ONXET(K$QJ&-)IK8"K!.L)9??Y
M_YX^)@B,UE(6!I*MP0#"\\K4V><MH:#ADS#D(BA+8"\'`!(1F!FRT6``4#M;
M(0",)DEK])]U27#&(P!NB4-^(3Y/6T0&M:[2!AD%D()7YE]=*Q((JUX4DS!%
M6AD/```'@!#_29,3!TSC/@0E,EO@\J!`=C^0<MP+YUN(233(`J+C\2T($!_[
M&0#7\0#W\6[XB,H+4`1)%=J9?H5)NJ3"6AA4TQ+K"E@S_%H-ZBRF53[,:YI1
M0U((`V8>X6-),SC-TO$-"H%7T3^KBL&O'.P+L00*H,>K5C](.P3[::3VTAK-
MJGE/.V[\*8OKVCP1U!)?*A_#FZX7'JNKNQ]+)CS8V/\3EREYG@-,`=`3:8H=
MNE$7&Y,9*&P[`T`3>Z=Y>%808Y=WU"-M&^4J'X&/5#E6?Z;P6[CI#C\8U7%(
MAI+*`X$L5%%DW>$WIC5`\^474L.M#A=-;A`^,$]2H#(LP_Z+"4.]5`$N+3\6
MVT(@48<BU?$L9[XN8$1MM7CYNT&N$W+E(MLADC&\A03G+TN]S%@B`73=6OT]
MZ#Z/Z74IB.MP',/OT`HPU7'>6&.PV,$$1:"IT%T$V*P`?2'UZ23Y;__B-'L!
M$G"S3OK,[T$@=%K"2L3WY=,L`Y0O?]'J73\E^9(T/+4Q851D"H$<C$@\C&.X
M5+%1DD\=P*0$>QK:YACJJ;S_'4?YC!=D4I,11&`$$(<4"2)`1)$"!8J6"(AS
MZ$`#148&"%(B0(XBC$8("'I@0*"B)`,N8AQ8P""1`H(P*A%)4M$A`P]((G18
M@,&"!0P8,($IT^6?`4E<OF0@@,"!!0-D)E*B0$```W$$F<28"`'$H5FU;N7:
MU>M7L&'%CB5;UNQ9M&G5KF4+=M"@/GX,?6T@\M!=.00@5ASI1@"3@PLP*A#L
MP"-&.4/^,$"@J$T`H2\/.)"C],^A1`H:MQ'01E&#PXH2N1'$>0G&J5A).E!P
MJ(@2.0*,"%IP>K"".`X<-``MH,%(U+5G)DCD,HX`VQT%3C6(4!&3`6X4309)
MX(]?_R4D01]2CC'D'Y>'"@Q1A%*E(I;`7\:<F5!S<=%N[A[P25(0^Y5&*B91
M.=6!0NG^8.D!@HK`Z!`$&&AK008;=/!!"".4<$(*7:I,09(28<"Z]##R"[`$
M$E#).<Z(^$..#1?;+(`#2"/BK^.&$.0/(@)HS*\D#EDB`,7^D(@)00YH\8\A
M`%`-HQH?<."!I!HZ``&IDA`@.Y<>*."C/\!SZ(`H!8B,I.-L,VRY@@Y*B`D!
MW$CDH8@&N$Q(TBJ2J;LVU9N*//-6&B".\/`S$Z0`3*21`/D,8."\U0@`LHT!
M&JA("4'D:```!Q))@,O2"F*NJJLJ]/134$,5=512T4HB`/_`7-I1B0X5<6,`
MP!Q@40["1!O"*`(&,.(SXC@[8``"!!@BD4,<,*J``Q(P(-)@ASCD5@*";4`@
M)@H`]H`"_@MO@0"Z)8#*)0HP:@`'/B)IB-`6P*I:`:PM=Z@X8,4(W>4,,`BG
MY_:TZK\DK'O.6G%%5.2!`S[J%SR28#II63W5<ZB^6HMM-]@'$DF$6X%)DB.!
M=@7@\@^."R```0,$6R)7<1'X8].7.BWU99ACEGEFFK>2@Z>A#F%"#D%P'JB-
M_I(@0A`W^,2H#2**,#H.Z3AC0@DBVH#O$*B3R+(-@=P@`K!$VB@B:G/E,,((
M.8K.2N<$'$`8,2.VAL]"SSR4CNW_K<U-&$C$XN[Z(C>DZSEK/O_`FFXE/I)#
M:HP$MWMO10Z'[^^AV@#.[)>8(")J^'PTPNZ!EB""/]3:7B+2N<4F`E+1VEB;
M\II;=_UUV&-WG;.X054B5=ESUWUWWGOW_?>77ZT=U+>!-_YXY)-7?GG7!1F=
M>>BCEWYZZJNW_GKLL]=^>^Z[]_Y[\,,7?WSRRS?_?/335W]]]MMW_WWXXY=_
M?OKKM_]^_//7?W_^^_?_?P`&4(`#)&`!#7A`!"90@0MD8`,=^$`(1E""$Z1@
M!2UX00QF4(,;Y&`'/?A!$(90A",D80E->$(4IE"%*V1A"UWX0AC&4(8SI&$-
M;7A#'.90_X<[Y&$/??A#(`91B$,D8A&->$0D)E&)2V1B$YWX1"A&48I3I&(5
MK7A%+&9QA\738A=!:(@S.*$&-<"!%_H`/$-000I4F,M8+%:5+DA!"H%8"R(8
M%`8YXH%":5QC&VN&1RGL`2-T>((<#?D$*LR!BYY*A!?D>$8ORNP.,<C`!2QY
M@0R8H`N+E!T=,E"!%?@1+'1H0B$P$@@27(`$D#Q+()PPAP49`@68I`.%/'F!
M$]BQ9H4PP04T4`>,-.&2F+1D!C10@T&(BI<7V,`=(AFS0K``DQLX@0DVD`$,
M9*`,ONO"!C;0!+$,H@D;B`%\X$`"#93S+(GHP@DV(,BVX&$#%_\P@2DGQ(5*
MWL!U=[CF">:""&EF8`,D\.8U,Y`!<(:*#AJX0"B?";,P')0%<RB$(?!@@TJR
M0)>[*\0>]F!/L$S!D@E5!"(\2L>S++2A&UW+&0XJ`TXV"`>8I(+K(IJ!&12G
M#R3(``G0@(<]X($.-SAH/4/EA4K6X*$P$V8&:DJ20)@@DWKL`Q[P4#R+XJ$/
M%K.J(!-Q!S2@`:0D040=SO#3XB7"JG0L1%C;:`@XG.$.Q1F$58N3B#[L8:LN
MZ0,:SHJ'C5IT!IA\`F`5$0B@IA4/8:T#2X>2B#U(X:`QN`-(RWK6/7!R$'&%
M0S)=\H1*2@&O875FAH*ZU:^&=:P8,83_6=%`!U&6E`4'A8-+"D&'L][!L57!
M+1WLF-6Y5/6J+D%$5\/BA(-*`2-PJ&0,6!J($ER@!"C5RB!P>P;8ND2M6A6-
M6>$06T5L]K5V;.I3LX+8JR;"K'K$R&;/T-GJSN$,9VBL5OK`65:2)*N>+:E5
M(;E=MKJU*GW%+GC#RUG^NL2]]#5P!I&+TP0+%;4V\"8:/NM-'"2"#@2-`1IF
M8%`6P%,T7EB!04F``^K.@:!-0,,*>DJ'1(3!Q0)MPB!FH`$3"+(/UCR!9_>`
M@Q(<5*`S*.T4-"!D'`.6!0,%YG(_?-`-R*"66MGPD:'L!=&$8<E0MD%^!^$$
MJ1K3!%R`3R)B_X!)*32!ISV=`GSH4((-L,##(&:O:,JP98&RX`QOZT.0IXL1
M1'0!!58F9VU=,H<;3Q8/4_#F-BF\@3-D2`K>M$%,M7OF#%A8$50X*$DQLH=K
MFB#!9*7"":RL`11H6A$J)N><)5IG=H8YG7/`M*$?^V$3S&&<"$V$.,.<22J\
M;1!/^'6<5:V(/@!9R"5H`G45\01OFA<-E"Z.BC7`8A>3`)9WL,&:-2!GE[CR
MUR8(-DF&76QP>]"E!ST!%U:+$2=@$LL8P4.0-P!,+DS3F[_.L&@D*^9Y7J`&
MNN1T!EB0R@O<(!%36#9/8\!3?RH"#=A49R!6@$D36+.2)PA$(FH@9/]C:E2>
M&2B!9\,PSTSR%`,<UPH7K"Q0$M0A$9SVI<8O((,V]B$&V23!K[O07EGC^)K,
M+&T7LCG0#9C@R!>HM&B,7%19SUOBS;4C(II021P'F9FJ1L.:21#D%9Q`H+5\
M@B5_CI$^C]TM]M9C(C":`:DKPA`X.&C3']O4I/-4E>S-MT#W?="$DX3A14TE
MG*6;7W-'MP0!C?D@*-E3I1^4"X`>+.0#'G.,W&&6`G5G<^T)4$S:6@J65*XB
M\)F!AV.R!HF8@PFR60*M8_ZPF.ZYE<^.B,J7H/.J;#('$?%V=DL!\5VHY!-(
M$N\,.*$X=#]H#>I0B*M?0)UF8+=8Z2#V3(O_AJA%I4(9^G`'GFI@"HBM`29Q
M6AR1(A0C5,`D#@;15G>>(-)]^#=EZ>A2#.14$1L6:!<*@0=IN@#S4K`SN":?
MRJQIRR2QJH,9VR;<4[V/DJR54H0Z,"@30(/-6C--FZF#FH'G>S`6*(YUVP`N
M"(1!,#)ZLB>:2ZB"*X$P*(1`N#J#^ZT9LP$\"(1_RZ1D0JH+,#Z,`"U>`XLZ
M.+(5J+J+<ZJP0H,I>#P-.#:2F(,2P#$XZ"A,.[OMRX`:N`-QFJSBF#95"H-!
MN(.`DK[=6C5"PX$P0`-$X$`;'(1NRH`3,*6)D[X^,`0ZB($-*($ID#M,\\#;
MFK')0S:>*H'_JKP-_S0_$Y@"[PL$[)NC/K"!"Z@`'!`-#KP!/"@$EX/#9)HX
MU`N$V\+#1/R@-/HUDMND)ZRD252$/8@N$S@C1#C"&&@C?&(ZN9NM)A2\XBNI
M&0LQDFBJ?E,$\`LMT?@XN`NF#ARNJC($^!B]'B2)LLL`XW,[PB*),Y`!&]@F
MK9B#C"H.1'B\2,.(?+L`<)JXE4.I0ABC)Y@+I.HI6%($7A(H9P(]U+.G=5R]
M;D2S#'D\32N_8AP$[),Z0[BX9E*$B&JHSYLMZ2N.A<H`&_BT(,NQL""^P%,$
M/%BS@[(R\WL"3C*$/J`#]G*[@\*R5\0DG`-'2]*G1*@\\X*#H4O%K#B]#/\X
MNU6;)Q1HHT2P15A:QQ7PK?#"@T&PHYMB.8QPJ0O0/TY4)W<\`55RQ2-<@3K[
MMX'#B#J(`1N8O#F8IQ6PIYOTI5K229ZLJT(H0PT:!"Y`2&,*1$%,2$4H+[3C
MJ0U0-1FLJ84DP3*HR^V;Q#T(/U5[1PV8,MG"I&TR!+&[-XR@/BB+`2DHK:J8
M@6P*@\4$S,,J`0P8R`SIBM/3)V"\I@WHOC((@^AKR.@KO:IP"0XD*7Z"P^`*
MLNP+)DS:PR$D.6=KJI^3)8$")DYTJ,?,OK<;0&$2Q[94RV?<P[!@OJ<J`Y`#
MN0U8`3+CBD*``R]X@B;`0V.JI9TR)ELC3HI,)5'_@RK5E,FAJ,2WD2P,8(&Z
M#(,P0(%LLK`Z\+85>*4R@\0,$$YZNZ8B5`0)=`*2J,`+"$%!%"A5&\G5',T?
MM*08J,O.1`':RDPH:T]%*B$PFK'ZE#L$10%$Z+/]M">BU"A`FZT,J*UU!+QA
M\DWJ(T.2.,V:)(EWW``]DB=<:B-$@#;`$Z@GT*5"&,PF>T<2T"/FFL&P2`0<
MR*9`-,Q*"M$+P`$`=<)\/"A5*TBC/*@(-;/04P3C+,KB>3LL&SFC8CC?S$=?
M@H.1)$R2X,=Y&TE_LM"L#`O0TX!V'#V<"@,O<-.?$DO1Z`*IPB0-L,!-S"A=
MVLH,@*41M3MD"[*^U(I7_U32#*F\(24F3((E=M(Z.\4!4PI(KCPTABI"*-4F
MDN#!A.)$#?VT072V0S4_(NU0T>`"K:ND#;B!=[N@LH*#.I-*GEJEJC@S0D2N
M6\0("22IZB0!.CJ]%2@D*0#6)Z@E9O1!C-!&M<R\:SK1*=4_DL`#*6"!ESN[
MTXPX"IRGB"O(AD13%L``-<4('D0!.0+68*4HJ9)5^RH\5FHJX=12EX2NI50$
MB?2T&CTH6#+.\WNV2I+/_B2!CW(]=)4[%QM4T9"!PP,M#3`#L:C./TL$@\54
ML<!7$F@"N9)`_6-&756\7K4D_'Q"AMK.K,A+>N(O,ZN[<36D*0"I/J""AQ,R
M</\RA%X*6--KOO"*V3KC0,>TSTKJV$&2J#*\5!L@UV"=`C_J`RZ0SDKRM`Q*
M0*0\)<7C+V$B`2^(+F?UN(/*V:GCT2EU2;E[&T-T"3K`2C^*/IA2!.13KEZ[
M`WA"!#J8@4J:`8R0R-4#UTK:UA'%S,/R`C1`O&<M/)2:0Z72+UT2S'BU,_JR
MHQUUKEG%)`MSNVR2NCD@0CN:TKG%B*"<B[*[@-)CORW%""TMIQ3MO9OZ,V/<
M@##H)1F0TZR80W7"41'[BI3$)*S]4:<:QJLE"4ZUHUGDVJ9J6I>80V?%"/@\
MMD*XJXXJK>**/G\"*+7#B&@ZJ)]3*=Q<Q=JTW0SX1JG_G"?^E#N]':[AM2WC
MW0/DQ0,9M%8-&KD-F(*/&H0Z(,9?-+V::UX)A4>26,&V)+EVG(,56`'1JM<<
M#3=!Y0)$,`0N&#K\=%C&E3@>Z[W=9<UF=&#AK,B&8BOX5#ZMH+[QA(]!.%=-
M8\#V1`2KS0#'3(0RZ*<SLE^G[2FF9":_I+E4S,N>,C0Z"+,]3$E#500X.#(3
M**VNNUV'S29(300XJ%/%C5MV$ZAVQ`@T**17=8F"2RC]Q$VP*%E,300S,*C:
M$DSZ73],VM1**@%GBC&#,M:A2#\REM>72J:9,X$.ZX,2\RES8BC%K<2JB[X5
M2*:;.M,^D`$GG0O:5%';ZB4P_RXI(-0_B9P!4T($*F#CO7UC-(`/+_1=#/)1
M\^LYFS.!5^7$+GX;_8S#JK#2JOBW$L`!'"`!(+W6AA*E1-B^;^/0V]W@GA*D
M0J"]&VB"&IBG#:@EAV6W)B@#YEU-:32X)G`Q7'I=)X8R')@"$!Z\$P,RFAK*
M(SNQ)\N`R9/&"Y!);<R`^L12_H+/LZ-DDB-EK8O*#=X[RL,X4EZS)H`/XG-2
MI"U2E\CA2L*`=>;2#/!+[2+&>9-;LF@J9JL!*_-75/9DT0!E=UR!;#(!6S8H
MB'TL8L1&%.70%6B"&\,`3%8$YMN`&G""&U#->=LP3(J!Z$150^-$G`*RI=O6
M:HTMT/_"I9&.8><-*!:@Z$K"9'#6:">P`8_V($/8M6%"O=ZCMS4K@=<-`TL*
M7+E32H*5N^@KIA(P1:,6N/-Z/%6Z`;?4HUNRUCYPVY\V`:F;Q4@<O^@*V#Y`
MR&**@:`>BCJ(KDA4)T1P`H:ZI!(H-W^+:TN::VZ<I5^JWY/$B&:%#P!-XD'`
M@;BN`%]ROYYM49+8ZDHR;&9Z`LMJ@KC6@!F8L;BK3I)[U4%X6JT@7(+%`</F
M5["X`Z4L)AE()0UPIJA&:L+-@-Y#`[:N`-3#9<5T"9@ENJP`P$0UN"F;.[NV
M)!)HLZHH@SHMIE2#CUD>4BRD.P'TZZ/FHG-L;$PZ@6,3P]W_9H$F\^UAPH#@
MMC0+^BHNP($:"-HS`"_H.J@!W+\ID`);(^`IX`)5G@,I(",N8"4ZD*,D%HVP
M+`0SF((NV(,*1$V*7&_L+2DTD`(;(",O<+9$.`/Q;H(^&`0U,D44#0,<L(%>
M;C"2H(.<M@%5TS`$OP$N,&8->P(;N`$J$#'WAF^2@`,IF((IJX,7MS5$X`(I
M8/$,D6\;L`$I:%!ZFX(I4%CB6N(3GX*@#DM$@`,JH`(Z&`1;#.JHVM>A*`0I
M(`%)9BTJ>&]=*@,@-V:PB*P:8#%$"(,N5V_VUB\;%V"7N`,39[%`R'(USXHT
MTG*M*(0RL&6*564ZF`+Q%O$FSML+_V\"+Q@U'`QS-80#((>D/9\"6R.N,V@"
M#!_TK+!S/"]O[=KS/N>"/U>A@CM33W&\F?8C=[T@'UV!&J@S>9;BF=7F49LZ
MT>X@[_XA]NV"\(/H"I%''*"#.J""\&MT"NK-#JN#,D#0"Q#.0JB#J3TH6R]5
M$E@!4%VJ`SJ]33XJAKK(2@K""UKK8C(HZ4.I=;2D]P4T&\"!38?V`C+5I$M'
M44D$#S,!@BJ!&(AS#+H#'#@!$KCW]N2O+H`S$W`"`P-A<V>@1`B$/EC53TF$
MCNJ#0%!="C($O>H#Q^JU"`]XBJ]XB[]XC,]XC=]XCN]XC_]XD`]YD1]YDB]Y
MDS]YE$]YE?]?>99O>9=_>9B/>9F?>9JO>9N_>9S/>9W?>9[O>9__>:`/>J$?
M>J(O>J,_>J1/>J5?>J9O>I"/=:>/>BJ">JG_GE@?`ZS/>JW?>J[O>J__>K`/
M^S$`@ZPG>ZPW^[-'^[,O>[9?^[)7^[%O^[AW^[3?>K2_>[D?>[C'>[K?>[N7
M>[@7>\$??,+W>K4'`[_O^[Q'_+]7?+HW_,5/_+F?_,.7?+Z??,@O?,W??,*_
M_,IO?,J/?-#W?*UG_-('?-$__<?/>\P/_=7G>A>(_=A7`=FO?=JO_=G'_=S7
M_=O'_=ZW?=UW@=\/?N(O?N,_?N1/?N5??N9G_N'??=\/_N<7?NG_KW[>;W[L
MSW[@UW[N[_[IW_[HOW[Q#W_R!W_S[W[T3W_U7__C_W[V?W_XCW_YGW_ZKW_[
MOW_\SW_]WW_^[W___W^`<"%P(,&"!@\B3*AP(<.&#A]"C"AQ(L6*%B]BS*AQ
M(\>.'C^"#"ER),F2)D^B3*ER)<N6+@WF>"ES)LV:-F_BS*ES9T,P:L;$Y"ET
M*-&B1H\B38HQ#Q@>2EVJ>"IU:L.H5*]*M(IU(9^?04EJW2IV+-FR8<NV/+OQ
MRPXU8-!250MW+MVZ->6BU/'%Q9BW=O\"#BQX<-$<:@Y_38J7,./&=VDN=KPQ
MQX[$DB]CSJQY,^?.GC^##BU:9>31:$N;%DZM>O5!U!9=LXXM>S9+V)MMT\Z=
$,R``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g145452moi006.gif
<DESCRIPTION>G145452MOI006.GIF
<TEXT>
begin 644 g145452moi006.gif
M1TE&.#EA2P+*`?<``!861!P;1!X>2AP<4Q\@4R`?3"$@32DI3B,B4R4E6R@H
M7C,S6B8F9"DI9"LK:RTN<RTN>B\P>34U;#`Q?#HZ=Q1N/")X/R!M2RE[26D]
M%W-#''=-*DI,=&%O:#$SA#,UC3,WC3@[B!)WB1UHM#12CSQ7HR9AD2-MD2MD
ME"YHER]JF3QBCS!DES9FES)EF#)MG#MLG3-PGSMSG"-LMB=ON"QRN3AMHS5S
MHC=VJSAVI3EXISQ\JS=YNS]_P$I,DEE;HT)SG4UUED1RH4=XI$QYI4=TLU!\
MIU-^J7!QE'-TJ3:%2SN%84R345J59'"5='"L5W*I<#Z`KS^!L#^'N52)DT&$
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M5(BV<)6^8)>\:;.*<+O'-IW#5I;`89K%8IG&:I[+9)3$=J#.9:+,:J?1<=."
M6-&2;^Z'4^F8;O.48^VB?-?6&LO1*-_@%^OH#OOU`IZ>FHZ0L8JXD*NJMXZ/
MP(^0P).4PH>FPX6NU8FUUI*NR)JSS):[VJVQRJ6\TK:VU9K#EK78B+'2DJ[.
MLIO"VI7%Y*K$V:+1T:K4U+3'V;O,W;K5SJG(XJS1Z;/-Y+G3Y]&JDM"XJ.BY
MG_&SD\+?G,S2M,SDKO')M,;(V\[4U,G-X\;7Y\S9Y=3<Z-CHSL_GY\W@[,KB
M\=3A[-OD[=[JY]GG\N_8S._IV.3GZN3L\^GM\^SUY>SQ]NSS^?OKX_7VZO+T
M]_+V^?;Z\?;X^_[^_LS,S"'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``A^00!``#_`"P`````2P+*`0`(_P!="!Q(L*#!@P@3*ES(L*'#AQ`C
M2IQ(L:+%@S`N:MS(L:/'CR!#BAQ)LJ3)DRA3JG21<:7+ES!CRIQ)LZ;-FSAS
MZFRIL^=*GCZ#"AU*M*C1HTB+`DWZ<.E&ITRC<FPAM:K5JUBSTH0ZD:O6KQ^]
M1A4+MJS9LVC3SB2KUB3;MA9AI(!K]"W=NWB?KLW+MZ_?OTH!7[0K^"]AB8<+
M*U[,N+'CQY`CQTQ<E;)#RY)?8LY\E>IC%IQ#BUZ\>;3?%Z93JVY<>K5KQ:U?
MRPX=>S;DVK9SZ]Y]US/OW\`CX@Y.O+CQX\B3*U_.O+GSY]"C+QPN/27HZAJO
M2]>.7>/<S-R[%_^$(0.($!@P@,`08E[(#=#FJ:,_KU[(>92@T\N`R)XZQOKV
MG9>>$#+XMU9Z";6@GH%%G2?$5_.M-Q^`!I;'8%"U;7$..QRV<TX[[&QXSCF[
ML(#'B,5TA,(1YGS(X8CG4!/,@R2Q``,T[+03AD-AC`C-A0(5`Z*(.8K8#CDT
MZE71$43$-4V(8(0G4!D@IB@<4T)P,1`7&TX#Y$HW4.-A.QZ&&&([R(3UY#E:
MJL9%/_[$*>><_A!C`C%Q3B-E16_2.2<U28H$@SEQCK%G02B,$><Y7U+C)YWS
M!`J3$,7,4\:A#;5P3J$'L1!,G-2T!8,9YT`C$`M@+/JE2C"T\ZB<YOC_EAT,
M[,0I!@JJ'4&..>:4\TZ<\_!:CCEFL("G/\EXQ(4^_NQS#J_FS".GE1]]QQ(R
MO+;)$!CEE(/,E\1`:PZS_IPS;#G32#H1I@Y-$Z<9N%(TJ#_]C!$O02SLDJ=:
M*)@!9YHNL!`&G(PRM:<0M?K#3J\,\UJ,K!K=:`XY1RB$VFT9O?"I/]2@!P-5
M*&P,30K?W8OO0-8BU&<[`L)PA+O^L#R0R031;!!W*7!'%<3:L8MOO"CL>=W0
M"K7@L1"N]K,C>A"[`+)!-J,LT+U1#]2S"^44RL+06[/00LHU#S2O/V(@A,>^
M5A=DK=!!)W1HT.%M?6K`<A-]\W4F@[8QP"B`_P$G.X%6/75!*["`:WYS$9WX
MS2;GW36^CQM$:[-@L/2QQ[)**7C`+J"P>><&D5P0=WMZ3E<*^G)LD,A"!#/-
M-,$T:34,92!##32[R*XRLS)/?82T\QR!`A'$%&/&$<5,8\:6R4]3C+8#M8X,
M-KCK[@(>Q1!3L4!<$//Z-,1`;T3QRQ-TA/?3(#,&#->EP$7V9=!NN_8,L8`P
MO6%(.?[WQ%0^4!C9$T,8D($,_PD!?6:`P1BRMP7SH:\8.Q((\N21)V*,@6Y@
M:%[X#+(_Y0V!4/T0@^8V-@V!C(\8":P=-8@QA!00[W5F`$+7%OB\(;A.>0(9
M8/HB*,'LE<\%!R1&,/_8=[WB$8$(-]S%#<8#0&HX3ULP"$;6RB5$&`Q,84)0
MX?,,TD3808]XQ,`#\I0G%R"4H1A.Q)T0XA5%8A!#"!FD1@&W5+RRG>I]Q;!C
M09"&/\&U\8W(DV/\"C)`:A1C"\0K1C!:8*-@&%$@9LC>$5KWNETL!8FO4U]!
MP#C$P4@N)R@XFS^P`;&-]6I.Y]@>"XA`#3C)Z1QAJ!H7]A&S0!%!6ONHF*)B
M1@Y5N2`8TI+3/*B%`B[1B1T1')NA?AE,81)C:F*(DSE:`H-*S:D?U#@":$(6
M)W),PY4Q@QY"@.`J??!P(&:@!YWH$8Q3%:.;KO(',E*P!4+):1J]]$<P<(7_
MNF;Z0Q_?0D$9_&2J%A!#G<ZTFACB&2=QQ'.9B!)E"5TPT'(A8T[BH-*<O"20
MB_IC&O:DER)I&:=]M%,@HLR&9XY@#W_00P@VLJ>0-KH?@1!A&B0M*3(>=$LZ
MM<.*<))'*X5Y08%4,Z?^F,=)!0:G(\7IIT+X)IW*882M#4&=^BA&2^-TCUT$
M;)?E:$D+W-4/KTHN:;$,VT"(@-5B(+19SQQ(,'(ZS+_!%`:;\D?E8)!/9.25
M7AT;B!C^2J]TG>J*O5,+ZAHZNF/]DQK4(!<R<`4#F+4#&N9HZO8,,LM:Q@L(
M[_3L&.`$SC3YJUF056<_XDJ$3?7C'-/(ZSD>I$Q4_S%K'^3`%ISV8<==QBI(
M)24'-()YCB9Y*D[]V`=D23I1A4RN'_X;R.\>&UM@T2BTX%Q?/N>!SWVXLITI
M($-+]>%-:?4C16$8UU/-$0Q/P<D>D)66/MJYRGARMQRNK)>4\@4J@8PV3OJ`
M++F22XULD':9T$"N/#`KIW[(H[I8[-PNX"0.Z;:4'D2P43[U,0]H3%&_+'&4
M2U^'4&2T(*K!#):7KD@O=`5SF@(Y%G>I04M[&`I5X(Q3FD)[V<C&J1B@Z>FB
M8MN/?M@C?T#8E#VXL+6>WL-ZT4N:'`E(Y6(802!"".9KGQ0G>US9!:?UAS?E
MX4J6L2#)^!/(A[F;3W^40?^"YD57/`,K,%^V)06B#!6^-J:/-[O@6`6KJ#F:
M!`./4JMFG=5'^J#!Y1\+1`RN/$<P\BB$3>VC?&*0%N!<$%I`N6`(YS!R&5#0
M`A#::V/9R$@+D$&/=K0S4=*$03&E90\S4(5%CN9OL\IWK$T[U[51(D@9WF&/
M9Z[2O#M"06@Y%@QD#.&_](@@=MLY+Y,&+`SJG`>AIUB^(;C*'GXN`RW;(<.-
MM:-BA9831/>\+X$BE]HPZS-+\DF,K7ET'DP6,CN$QP751JE?H"(B2Y,*A!2,
MK;CVRVN*6'!:'?E7M9>"P;%^E!$6%T/68Z!E\%8$//]-6,P!@_2BFBV&L<XC
ME:#_.18Y.C>$8)9C"$`4,31:@`*/GK0,<)I&TUC"T$<E.\MY@FF_"T7JOF;D
M"'F5F0Q<*P:#BSB50)1I1W_,OM;BK\G%0`8Q5E63Q:JN(*9LB=\4EI$$]^.D
M+MA"2V',6:32"4F/1NZH<TA+&&?$4?5R03[G[@(NA&&23K/G&$RP,7MXD4E"
M\,Q_87RLY@J48#(4):-2T+>FJFN/Y02#R4YLA(\)80SF+5O-GSJ$>(468"G@
MHSZ+R2Q?N\"C?M[[HVD95J-FXY_Y@]E)5Z3:=5N-A/Y]*HTV5C`6G-[><8(&
M:%IP>W]8J=+T$B'#&2O!ELZCA2V@=]<\.EF]QZF]`PFM_ZE0<*QD4?Z*P<.R
MJ_;!!6Y^E"4NR($ZDJK-,"`77@,!PA%=``3DQ:D<+K`"+1<G?I8HEL<"G94-
M4]</Q7(0:/9/^J`/]A"!^D`/;<)6]+),V4<O>#`\\M4FQQ5A>-5'+R`./W8X
MIP=$Y;19&P-DI^(S8&$&_<5N[W=MM,0.Z#%%YH`-XB`.^.524,8]Y!*!]&`/
M1S(CI_)?UW<J&S,/!099\30C\K59D3,O^F5U<K(/[(`,(!A-8G9WWS<T0*</
M%0-\0EA+"F$_M:(TX:%`Q5`.\Y!?.\("'J5S`R%BX"<0V!"&..=2X@!98O)C
M7C-%EQ*"3D@-Y$`-P31$3'<=(_\(8@1!,L#'`KXU-1NC9\KF:*\7)\1`62)6
M/H\H?3+X=2YP!!I'6U.T3,8GB'S$?GCS7P6S-U-S13B(91_(:4\%B.003")T
M11BV2:YS#LT$@*F'2ZK44_300/,2/'S4#C"'$:XE1D<PC=38$CUE#]KD`B7X
M+K95+C2"8[5D(TPG$/F$?^2G8RQ@BO]$#MGPAWFE9WUQB09Q+``C,#=X'G]%
M6O32#_3P906Q,EQ@!$9P!$.P%"+'*-NT,3FVCV^D3O2P671C5(('&F"`#6_5
M9<5"B;'F`I^H':W(!80W@VG'.Y='$.1$+TQ&$$1`#OE%#^1R*ZOH?`31D0-!
M5KM@`J/_2"\-5F3(H&'T4HB.A5S(=78ND%?Y(Y%:`S6I4T(:^86=8X:X*$]!
MDV!U<H?O0ED@)(IQ@@T6YE(/LH%N!AHQV9/7F(TY]#<Y<(XUZ`*TF!'V4TY:
MXE'75&3[<"E7=`Y`@#*[T$S[X'(9,8#]>"ICN`6X$EIF('*F@A#0IP_1=3B<
M`T3JA(WYT9%A0$L%$S!@P#L9\8@1U'Q^]F?HN`4D15*DU0_D8"!LP74*`7"D
M*%?[LC5CQPY``);$$`8"%`9A``9@`!7+@H91PP)>R'8H\''F``:X>9QA,`1"
M0$&,&2]#@$CLPU=:8SBE&`S)H%Y8U)0PIGOQDH[`0P3#F7-3_].;[1"$X[%^
M1QE^BT(,8F`$X[B),CD0'A57*#`VP6`"%<4.MXF<3<)\!.@Y&T,.N8F;QIF<
M5MB`0+2&ON>:[\<"@D85(3A1F2A/4[=Z`O&)1L5TN#**%2806,`L2UA;`1-:
M*8)F;'@J@I81]#B+!$,C?*0/[1=:TP`&8E"@N/D@;2E=\J4\1S"**R>`N)2>
M&/B+I=A2SD-T"-$J**D01$!!#_D=S5<L1\`L&+9-^9F7H>B3_H!_H"E/Z4A+
M]%`&R.EW#>07\DB#:0*;=A63Q>`YP[,+[;D[:(@0P$DP1.0"7=!2Y`8Z9E`&
MN^D">ZA/6U-S%5AOI<8I84`,7$A99?_`+%Z6`L$I$*8D0WKS?QEQIGU'D@L!
M??T`/?<30I[#1R'4.22*-QM3>RB`;?327ABH;?%2!GX:G808-)GIC7)C!F/`
M!;+&?;/(+'DW.BDPB6#%2!&JGLZ'*_,Y$+W4#QW($GDE>J,(8\-I7:"1BF))
MH@(!,P"3K8+X2SKV/W;:.1])47"B4H8#!+BJ)75:+BT12G"R<@#:3;(V@,<*
M&J=UF1M(#]*26`9Q/Z[XF!$)1/)5IBY@@F%IHO`"&I9%6ZYUE`9[*3&&CB.H
M#V)@`BP`J680!DDB`_<!%[K67*?2>/$2FQ4'IF9`!%O`DA0*-9W%KZ.S>#PA
MG?)$D,'05.#_V7!B(`291H`QE8$Q:0XYVSJMMT:^)6NJ!PU$(`1F8%X):X;%
M-&XE*9C`=B_0YWQ"8`3(0%K^<WRG<@2J54!ED#""RI%YL@5"L`L:1YA@&0Q#
M0`1C@PQ&<$!_4WK_I0^[L`-<$%(+NC4UVZ`557O>6H-LBGQU<ATTF:5,M6MP
ME%?7U[/^4%11V9/`24OS)01$4`S>=0];4*D<,P05<Y<NNG[M1P3OD%S%<$2A
M57OVQZZG,HKRH+%CD#`KQP+T2@]FH+/Q%%>2.B>'=E:%53S%$+S!2PP9!G2Y
M-!"$"!JA92E<@`PD58O/%4$/*Y8K&I7G``9"0`:XY&=<P@[3D)=M_V$BH)(Y
M4`D&EDDC64LO\Q!,[;"Y!]&R48L"7GB9+I`"89!B6A97E05@[4`N@34VET($
M]K0/[1"'JQIW_@"X98"_I,4W4`F_T[&&T05<3X5584B'W1JR.SD/2?-J7!!/
M^EID\0F??9DF8K!5(?Q]1@4S_3`/%.BS-V.&?5@.$`J57#N?\;)W^6&4H%&U
M_=`.1@8G2X@U/$O!/1DDKK2^);4+A_-?+<PH.2JPS9*2'Y=4P01NG0.ZIR)D
M^@#$(LPR'@A@/TPNQ64^"$6Q"J%ZK]*IJ^20FQ6E02:V[PJUSAI]3E..U/NM
M45=2\L!<&9&J3:6:GF01H:0/_0"R3\F36_]B#\Y"3<1`9@"6#2EY$"SU6O&;
MF?W`=H)5#K149*[F&T+`:G)"#]!0>N287+=2BM304J35#KMP,6*P#^3%$V)`
M#O>`7*Z6$3F#!][57%P0AZZ7I*$V#\$6/3@%8,@P5X>,Q%G5,RT0#/V+6V"@
M>]?!!=E`+C&S=0.A(2)LAV+`R3K9#C\$1,?L#^]@!BS)6W)3,Q.VS(FR#[CE
MEFB[#\D2,,30#UG544465RW02I>6'_AU9&(9N\B5#0O<#^P@.^+`#Q1+O47F
M@DX3#*%&+_L`M%8#!%(5,T,P2Z_5$DG6EY-<!N<PFN?PF6%@#YG,$Y3(4.=@
M!JUT9)]&:\&@#KO_10X$:Y7>^&OXG%Q%UM,26#%#\`X<=@3?06/Z@*`O0P\M
M'`P9AX:#H@_[$$O][%T-:"P/'2\WU4SSL%-3`P8H;0Y1FQ(78Q$[1Q!P!`80
MB66ZJ3LPP`5@($Y$,`;!8`:ZBBEM'0;BU*]O?=-BPP5FL`MC("FXTJ.[4`=\
MO05O#;Z@L05EL`N'*02B`T1NS==MC0>`'2CVDP1@P-9NG=?O^]9.T0)@8`;'
MXS1NO3U$\-;6`P0%F=K;0Y,!T]:D7089QAU$T-ACH#M`X-=,?7EAT*<PMP5<
ML`7@:Q`YT`5@\&4R8)RJM`.YZ8]#D)NR8P2Z22,M<`1N#5-.<P2Y"11#_U`&
M&3N;D]T21U#=`['1FST>7!`,P<`%Q2TV8F#97*`@7##<?>UW0"$$86#9.4L0
M,,#<!A'7N-HD1.!W,#>`V)B]NQ`&LF805+FM"8'8NIF;;SWA[FW:H"U=YOUI
M]B'<,%>9K-MW>`V^U,T%20)'8>"/$M38=9#6;?W6>+'.=S/C4#,W#/$Y:=,I
M<$.GD8,H!T%Y"5$UN!(U.%X_;N/C5B/CE,C!V2!"*.!M_P0]7=/CHZ,Y`-LI
M=O,0-M,VD#,S5E[EB$+E-!,W0D/ED/,X9L[ED>B8-8X0CHGF&(B-=*,Y1E!.
MZ9F&4Y[G5T,Z,BXFYQ!0Q?J"75XS@A,T8",>Q_\Q<#%#0'E%#N^-Z#%!N]+R
MD$G:;.D@KRKA4?V0#<@P#5OUF3\.Z:).$,]\D7'"#IX]ZBMQ52[EO@=A@D)\
MYR<A!&TF)UDER*K^&^^#B.8`.QF6ZY$.6LA0#%%K!N4@#ESX$DJ+##Z([&*`
MZ\"^&W+3$C(>[2]AYI]4[2J!*Z@A%T5N[>`>[N(^[N1>[N9^[NB>[C_Q%WH^
MY2%A,S"H$4#CYBN1Y8,C&]C^$>X>[U%Q.-J.Y+L![0]A(]C-!05?W_5MGA61
M)29N5/6=UB%1X`%I$`6OFBB+\,)]\`8O\%HAVV7`!37E$2@`1^`]!IW'[]/Q
M\%N!\`\_W`^R>0_/\<W_45^&#,\V'X&(?!'!`-62Z[7Z,%LU@@P1>&[^S<D"
M;1+%D%Q0#<]038'RH/`>000)!!%E_11FH.(2(01#U2QZQ!$2=P[83`_8,,$5
M,0:,#(`RD8XN"<]*WVK0\$7]Z[)W(?,NT<:O`G(<H99,N3)AG1UR">%9:A)R
M^2KZ`/5/`4STVQ`H'Q%C`/9<<.@/<2PM?&[?GBF#/R?S<$X44;1I/Z5W/P^0
M:P2.^HSJSA`]U0_),.S!2T#C?!$AF)A#D'7:3!)RJ0^0&_@44?4%L4##C@S!
M9$@$]$8Y[A%W^19BR2Z'`OD$(0.U`J.+7Q`&2^R&/Q$BIVAS;4W^H,D1(3?(
M_Y/,")$S*-&;`-7[Y(!0#]G#PRLI\?[\U0$$M%;;+W@=1@.A"U&?'4L0U;L0
M-L(>2:H>#C'X`%%."`H70,[YZR>&H`L7*6`($<)0XL2),"BZL&CQXD1S_OR-
M81$RI(L6+5B0C$@1HL6%*E>>E#C&XSD9%PD*`2*1!0P@*3>NW*BS()`6$X6T
M\Z<OS$6@+3?"*.?1S%.(+F!.+(D1B$:*Q3PBLQIRC#Z$8"[V#*JQQ=:K%T^^
M;(LQ+<6'0K@&17&$;#N?+L!T]`<V:,BZ+(/BO,N0Q4V<12FR>-&S[\23#Q-;
MQ0@TZ&;.G3U_!HTQ16C.)HG,\V>/2%R&*<J(*Q?,\?\1:N20U61XI-BY=N>@
MF54<S".TDT:FV8X(HQBY;%S(4&O'#AF1BL'*M3,7C,BT<M.HNT7F43PQAC`.
M)H0)(QBY=NVHF;$H!!DY[PQ;%,LF;BK#,>*R!>,,*G_V&8.R[;*9)@QJV)EF
M")+&F*8]<HAQ4"(8(&RO'7&(26DWC^PIAQHBQ("-&".0X8V:+5PH(YOHIJ,H
M#&3:.Z>8(R8BAAQRQ`!C&G88O)&%,LC99R9RQDA!"&*R>2>Z:<JXK"$NLD'-
MGW/(`9`A+I`QI[=IQN!J.]L4;`>:R5P(SQ]L@$BO&&1,M+","-LIAT,+YZ,&
MC!FSV8(+<J@IIB(S%L2NF.__^/N3O-QJ0T8C(XKILC=HEMI,+W_FZ0N%,(J<
MAP@4ACANFI2&(*;+=\[Y\J(RH&L'R[Y@6)6W=O[S28A=6#WGO<2X@*8]<VS4
MZ=%(?1.#-&./1399T$(Z+;4C6',!!>'\F4:B,/KQAR^&PD!*/'_HR1(%8H;3
M$EMM86#'(VKVP=8C<G!SH9AVU;7GVQLW2I,>C^99T3R$%')!"&KF_<JB:3P*
M9C0BZO7''(V@0=@IBEH`#*1@Z]WGH$L=)(;@AI]E*!BRO.UG&HNB(GD+,SQB
M1^.9D"E2/'&X,D-?;]NAU`5J/,K&9H_:,4)<;STB1@9QQ&NWGT!M*F-H:ADR
MHTJD_Y%)B8LB]4DWVS/-:/<<8KB(Z"2GBAE9/'.,J`RI?C3NAPN9&K:(A2&.
M'KJ=,L2>MMIRM7;A")?%`[?2(K6M2&.0+*5'"!:(`,S;?11E"!F/RSE47J<;
M)4ERITV6J.:AYQ'CI".R]G:>_91%/775/5L<M7ZHF0:::6+/TH5IH6$(!3"P
M/6<@(<ZC9A=CK@XCI'']2<8J+O9*CNW@H6FW0!9'AL8,B#VBY]Z+TN1278S.
M*Q[-F8())NMB6,`#VVJ%%&^>&X^R%]KRHNI'>HF.D%K]Z;\M9CUW:SJ"ONA1
M##-H;A_%"\;!OH6,8@AA93\+1C$89J4(8JM^(>%"O>R!C/\$FJM""O1';"1(
M-!;(J$@E*T88IM4.8NP"&E<#`VN.@(PJD:,897#!&.I5LET4PV:"69YX]%$R
MMP`A&R1KQS3,X!,6<(U_P:#;S%``!-+U8VT7\H@Y)*)`%OKO4EP(F4?TY@*K
M:0T%:3H'^>C6J:"4$5,746`P6&"$>M%C""SP"@43^*%[[0);]""&%TW&@B#.
M8QAFF`:V]'$$%)0!6_,@(#)&9H:3<$%?^T"&"\U%G31E)Q@[NY3B5C=*4JIN
M<3X;&CE8<CS<-61W6F-!WDP2RZ]8Y79:8M[WQ`@#%,"`'$1CB`+!LI-\:8\B
M:2+&&*X&'_"Q((#9>A8A]=6.GJ#_9AYW3)-'[C8&;%&C,Q3SR!A:DA>;G4,,
M8PB#@/I1!A3T,BH'1`$7II&=Q8#3'Y0L(>\L0@(\?"@,!+D>OWKY2W\0XR37
M(\])DB$5@H!2(`19*+50P`+XM2TDW(/!:.:3H,W0C9T8H1LR8I`"%HQ!@%S(
M"\/,<<X8NN4(Y/#8VBP&@X[H`R0H^-V`8NBO2YGAG#G,(G_^B-)>"M.68I1(
M&?E"4X0`R`1`F`8UH'$HBEBJ'172"3)/^2T'T2U0!-DH2F&@CJ0H!*<'V0=*
MP4"-<NRBG>A""$BF)8Z(2(L^.!1?03%S/0`!!D!%)<=4Y5=*PA9V(ZW#WCSH
ML=AY<(Z6_]02R2O9$9$X0D0(8-!7[QZ+NWCFDJG],,-"TG0^^"E%,:^DAQ$.
MB\R\GL-O_VIB-R$RA"'\LA\QA%C]_$4/LH`EC\&0V,0J5M61[8*DSM27/(X@
MA"$((8^0@P$,AA`&8E0)GV+`EL.@ED7''$\<$M$J$)!B#S%8]H%Z4^#YPOBT
MG2!%'S'$HT?6A@PS<$$&P9W($?UQ-V?>XU+&C*,S8X;/S;"@!6-`$5G:10^4
M;J%>[5@N1)Y+48T5HR7<A-M]:JF839EQ%TA5GKERHD!]_&H,7##)9H+(E]%,
M!)GD_!8GY7L.^G*!E^7J!]`LFZ;:K65$Q+`92![8#P8%`PQAP_](NFP*$2"<
M%P8*W(<YD%&&+<3-L%?&\F&;95,B'.$(7?;)M))Q$A9(-KJ`H<<\U&PS>JR&
ME2L@Y.`&XJ_Z@9>$1A#@H8@@P*#ABV@P#DRZT',\?:A9S2,#[H?]40P'^P,:
M!^E=1[(W6(R@S&*MV?.`MC`:%F`7(6E>L_=<0(1@F&,>\P+M23Q]#I8\D!R*
M8:6="[K5;\U#'HK-HD5VUH]=2"1O#*DH&$?]MZ20XW07@8%'0[)JKL37T0+^
M%MH*3.:`<6$7V&A7H#Q]*4,S#'<YO>>%<^T"_896(D)`S3ZV("T0$S*7F!T:
M/;!1K(WDA2QOI$@<^R;`B'"A6X"C1H'_&BE?Q1YZPT8@1CGH@6J0&)%D)0X&
M#+;:#U"K>28P"(/4$#*//&4Y=5'R^$12T"SWM>0J+(BU55[9NQ9HC!ZW5G,[
MYG$.3Z5<J<W[%T%8H-6%Q9C,F<Y>4+1J.X_L0\&A([2:82Z/=N`!QMD)9WCF
M$0S4J-(S]+MT;O35*<CD<U\PEWD[P#(Z@I/#NNT4P\6M\D!O1NMX@LDK>?"\
M+T/'7)4LB*/.?XU3]W(!)D383=F2DK"X.$2_."SSN&'MD>0=@5-GBA,Q[!0M
M@N11BV_K1]WGT8YW(&,G@FZI5=YF=;I1\MSO2`HC?ZV\7))Q1@2C!W`N8M6^
ML,`@L)U[FQFR_X49"9Y``]]XW64>*'^775\7#%C"!:^T4;/9T.VX-37Z_?K2
M93WDUT=6E(:`FDD'Y996\30[+$+08%C6_&[?\,UUF1#%C/:L92'SM>RUD18,
M74!($X,)IB5]\[^D!3NSAX/`%&[J![^BM)VHF+;`GTOQ%.4IDG>(,/.SB#S:
MD2%(-H9R`6:+%K9KC;>3-6+`*>X+@_[#"88`)>`ZJJ<)&+41MO*XK&"`ABIQ
M&&CQJ(G*(`9LB>LY'\?CFZ#(M/VB#&8#@[TP`O-K+HG+J=N"B9(:-QV4B,YB
MP,?2FT[#EG<0I1:``2(8`V*@!IL9(^(*I8EH)',9B+EC(Q=4H6FPF?]7ZS!V
M(`(2M(CKH88P&`(92$#[$((C"(89V9<W1(I]*"^(>,.J*`\BH*YIJ)(OQ+Y%
MO`C'`(WM2[W!F!:'F:@\HB:4(Y=V0K!B*!!,?#8R\BR-D3W6TIF",;#K22VA
M(R&KZ##Y"IT5\Q2<8J!=P($4Y)D6(`)Y$`][V`)*PXCAFHAGXKKR.`B;&@DW
M,1&:PI8R,`&<RIJIH$*XF2@_\H=LD`@/;(@7^[^("8D]9#03;"J]`[%@ZR4N
M-(=_6@Q'RI;+<`B4F0H58*I9BQ8N0`VEL+>-X0RZ.8<6)`)0JA894#*0,#!D
M7`TZ^Z>8P)9R,`EUI+F12!-J,(E@R*ZX.1[_:G*N;"`'3VG&XWFUC7"C[^`)
M,>B6I:$CK@*"8F"K+3"!:)%(N!$"U#N@D+@/#K+`\\@_N>F6`OFD<L"G>-JZ
M&\F[=MJ%-^&"D\R/U5C)XZ$&D&/$IGQ$U+"'(VBQQ_`T?2"&,"@&__*'R7*F
M=$.&,#"#"DO!5KJY7CH/<8H<C["PDHH9#J*&D;$'U9J8N+N*;$J(7@(E<B@#
M,0`E<\@)0-.K;52\`"$HZQ/&U;A&"`(#RV$P%R`H<QB#,0"E>PH)^9N',B@#
M(>@G?_@NAL#&G0,F%OFCJPR&XRN#T0BP%-2;)$RF+?F9^I),$-N(7;.#T4`!
M:K2'8@`#/,@:SCJ"_WK!MZ!0)NR9!F2($(_0!WJK2#-8S#_JQ23,&:!J&&`#
M#',H`QGY(S"8J"XXH10BAI%9*H(JAS(`@S(`#!#<"$OI!W(P!QUAAY$YAPHQ
M0^I0H'-@SC$@J*7)(W78!3WYHR.(1W$0@R$1#[G"'B,3@S0IAYPH`TXAABX(
M!JV$DNI$)_,,3:=<':9<G6:)R\T0@L:QHG,P%XT0&?D2#W(0@M&P.6QQ!YSS
M!WJ+.X*H/Y)!Q/]21;V2""(@G6*)IW]K%]"!B18@J+MT@>-9-%_\Q7"J*N"D
M*AB8S'9YG&BI@Y%IEVX1#/A!B'TX@LWLR'C9L+@K#V=(&H3H!\PI17^0H_\4
MQ`:)B"B$(`8B("B$$(]V:,&+("AS8PC+(9F,C!8>/,.@:(&.<9JD@!PAB%,H
MS1+HG,JWT:+<8)L?K1U?0AHKJ<*(.`(?%0_*J;<@&M2UT1XC(`O=,P*7B1DK
M^0Y#'=,!04$\&"(YS3&U[*7KD=-]D9[Z:]6ID3@N<)EY$0@,]55C$8)R>`=S
MP"J;X((NU`<6"H,4X0K)G(=]L`=V:""&X*?V6!J_:96<L(%I>`=V:$%B:(\>
MPP/VT,LMT)>H/*QB"-=Q,@,::<$3:8=]V(?&,B9ID1#<T-7>\+O/B!!VB,Y1
MZQ)--8I@.`=[F%>]E(@8V(5ST(<`#(9\Y1P68=C_?6@',!@#SA,,>V6A:PQ7
M"]D%A8-6_N0*=;4;Q6C7=EB:OJ$&>]`'</F4W>`MBH61M)B1=K`?C%B5>2@T
MKTE11VT5R*,(,8@0EDW6+[D+&2"&<^`M>L@&^P$";-#7B>"6)`J38GC/S..H
MB=@":M!9=KA*WD#1W$BP>:T1H'6!466'#*&1:2B_B6`<.JDK(D"&]VQ9E*4J
M)6$'HYN'([$0@FW8-%K6=DB&C"B59\VQ::A3&!C7I<T.C2"D&:$':.797Z7<
MT+`LSX"!(P`;8"-$Q<#%+5@NNM",@+&+<X,(1RP,A@`#,/@RNT"!3.,+:$E=
MERA=H_`RJK*0T25=LV6*_]/M7:#-7"X@@ANK""]+"<MRQ#S\,A=8`=T=W=G-
MG2P$77AQP;YH@<NUD"/8@N%-#R_;`MZMWJ<8`B\C7M/54)70W-"U"8Q(W\2H
MBXG1W;>X74=\PN`]WMK-42]37\X@P=)EC8?(B>+E@M`-KCSD`M62&.75"(B@
MWLSM$^`U@@&.$B'HDR,(X,K%X`S.G<=`TF/J!WTX![-`6FPA!_I]C&/!+PV.
MEJ;L8-8QEA16X<$8B>MK81C&4!CNX,7HC!G&BRP[WQ@&8M51QTLQ!Q%%"-/S
M51,.XB4N)1N(84IS8B:6XBFFXBJ^,JK['&+X82OFXB[V8BY6XB\68]4)XS$F
MC?\6.((R((9B("!CDH@R-N,XEF(XEN,ZMN,[QN.P>,(\YN,^]F,_IN,__HPM
M%N1"-N1#7L1`9F)%1N1&-F-&OF-(=N1)IN1*MN1+QN1,Q@I-YN1.]N1/!N50
M%N51)F4NGLI21N5,)F0\;N%4=N57AN58-BP>IF):=LI3SF,6P&4\WF4I[F5,
M/L!6GN5?QCY;/F%`G<O/2(&6,&%)IF%B)HDL"XF5+`WZ^SB/L^%2<D1G1I84
MV&7ZY>8W%N=-/A9OKN;/:.;06`@X#N=SWH@HWH@4>($7^*9&'&=E80%JON;U
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MR);LK(Z"R;;LR\;LS-;LS6[JM^;LSP;MT/;KRL9LTH9LS[X`TQYJSU;MH8X"
MSS[JU%;KU]9JV0YLVQ;MW-YJ_]H6`=B>ZM8V:M^&:^$V:MZ.:N(N:N2N:.".
M:]*.`N=6[MZN;+8V;>9V[>@.:^L6`>T^:N..:N_N[>Y>;M_F[N+&;J2&[J(N
M;Z<^[[)N[ZR.[O4.:^5V[HJ6@B6HZ"'`;Z7>;]JV[N=^;?`>:]M^;MPF[26H
M[``GZNGF;@1?<->6[@(';@&':]XV[AUX<`=7\.U^:^].<-:NZBC`;P?G</3F
M<`KG\-3>\`4W;OE>\?&N;O,^\06_`!7';==N<:GV[QM_;1MG[A_?[^W>;A2G
M:A4_`=O&[^=6;[%F<`F7\:V^@"K8@2/'<!%(\M;^[R2_`"W@<BZ7`BZO@BX7
M\S$G\_\R)_,H,',N]X(T9W,S7W,N1_,VC_,V9_,YI_,[QW,Z?_,\3_,P-_,T
M$'-`SW,[%_,]3_,I(',_QW-"YW,Q9_0NWW-$;_0Q?_1)KW0M,/0RO_1)=W0V
MSW1.UW10AW11)_52'W-%;_0B4',O8/56=_57AW56Q_18I_5:M_5;Q_57G_5<
MYW58W_5>!_9@%_9A)_9B]W5C1_9D5_9E9W9B__5FA_9HE_9II_9JM_9KQ_9L
MUW9<?_9M]_9O!_=P%_=Q)_=R-_=S1_=T5_=U9_=V=_=WA_=XE_=YI_=ZMW=:
M[_9[1_9\#W8VT/=_!_B`%_B!)_B"1_9T0/B$3X=W4/AT<(?_AG]XA8_XA)]X
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MU6?]UG?]UX?]V)?]V:?]VK?]V\?]_]S7_=WG_=[W_=\'_N`7_N$G_N(W_N-'
M_N17_N5G_N9W_N>'_NB7_NFG_NJW_NO'_NS7_NWG_N[W_N\'__`7__$G__(W
M__-'__17__5G__9W__>'__B7__FG__JW__O'__S7__WG__[W__\'"'\"!Q(L
M:/`@PH0*%S)LZ/`AQ(@2)U*L:/$BQHP:-W+LZ/$CR)`B1Y(L:?(DRI0J5[)L
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M47YO.OK\^FO#U7P]NWRES3&'=P$:&)P>SUSSSEMR[?<@A&GU`]@S>L@1QX'`
M#4A:&VVXX8:':X@HHH=M7(@A>!D"1]^"]T7X(HR7R35/-L\4>*`;:Z1QQ156
M[(!##3C<D,(+0Z:`@@HG(/G""RJD<`,...@01119I*$&ARD:2(?_@K#%^"68
M3]VS3H6D:7GA=FVDD<844PBI@@HHH'"""2:<0"<*=>9IPIYYRKFGDG/.><(-
M-.#09AIKG`E?:,]D8P]^84HZZ4X37H/=A_&UH<85;@ZI))]U\ODGJ:/Z>:J<
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MEPSN_/7.]UQC8:8,9TJLCCB\@"_33)OLM)QN1UVRW/S6K32_+)P`-Y\PPXOA
ML2<"WO7$8!L.IFYC<VQVQU'<T*J2+.`].<HNR!GRW7/C?2?=?SXYA1K'!GXL
MQW+0L:"#AZL>8S_9[&%:V9FVL8:;*OA;M=V>W[VWYRF/C+22<%,NN=(GO'#U
MZ!JC>5K$]ZS^_(/]D!G'AVZ(+GJQ1#.+PI%.@TSJWI8C*2C<W@=_>>_<HS_U
MY=!R+[+(WJ>O_O_>W;]=_J@JW&#%&AY6;[WHK!<Q\D"O@,Z9D(VJ1[WK'2L-
MCNM>YM0GP?')27SRXY?\NG=!)#DM3M^S'_HF*#RIQ4V$&923_J9@(@4&\$-T
MV(.N#"C#VHB-;"PDG1O4$`4G<4]X&@PARNS'-/N5+VX@M)V<6)!!:$&P9!\,
MWI'BY#DB]LY[($N!"J:P!AP&SGHN?,8\9BA&O$QH&!K['P!S&(44!,I]'VS?
M![_70R1)T8IO_*$<U==!)"G)@^^CXA7E6,0_N>!\=^Q>_.PD.9#=0(L,HYX7
MJ2<'/61C'V.\I%GZ@3$Z0!*-($I#%9BEP3N*4(\@,V0@0XC'4<[Q2/7_LQ\/
M"TE$.Z8RD'7,ER`/J<M&;K&3:)3#,[R&R6%VY2WKV$/LT$B[&QRMEH%,@0N>
M64OU.8F6AYQC*Y^I1P_&L9M,S"7ZJBG-:YH2C[STI`('2,QU9D5L=/B?_SZT
MABL8*8K:3"4J>_A*4J[2F>U;'Q7A9,7U93..U.3@%>$HS1[B48\X2$,\/Q1/
M8.*,G1:5RCO,*%%/J@$'/`29Y;PITBNJ@`4N4.(X4WI%6:ITG-QL*4E32L=Q
MAA2*,'VF%DM4O3:(3@_E*-Q%@SJ4UKT3GB!R`QN$=-.1CO,$*%6H2AD*TY)B
M$60F7>@X68!2JBXUH5VU:C2?=`43R4&G1^62_XN$JM:AW,-&)?)?B>CYU:]R
M%:%SA6DAE0BG?;;T!.(4YUV[FB22ZF"L'3HJ8O<@S+4RME(9/>I;/Z3#%_`5
M9("UK$J=M,]J"A2+*+7E9Y_)56FZ@+//O*HMKXC2$X2ULY>UY65?"],8J%"B
MA^U0&R@)U,;RUB6MT\-M==H&N4*3I"AX`1V3Z]E`?K:D8?T>506J@N=:=KK2
MA!,W.:M9E+(`L$GB:F<1^MGQ8;&'G?4J9F5;U9+J%9I^?>A;@WLZY_6VOK]R
M9XGB@-L<24&ST>0AG+JK5>G"R7(!3H%>2RI0OR:IM*S=*QV[NU<$-UC!26*M
MA)T$X.Z6]J18=%*&%_\)X+V>%$YTK+!?.5SA)`U8;TB2\(-!6E5&JA"NN/50
M,.VKXY78XQD;W:^:/*J"%WP8NT9F<(KWBMU"EK;`1C9R=3T;X",'6,*ES;"%
MBZQD!FLVP`_6,';7^^0/FS3,12[SD[][Y-)&V:\[N/&/UZ#8W>ZXSADI8W!O
M;(4A*=G(A4RS@YN,72XK&<MI!O.%`RSH0:>9P1]^<(8_+&A"#_J_8T;TBOU,
MZ>D^^<_:%6@.#&M;W.IA'78^]4?>H0<0W;A#:XB"ISD-30NGV="'/O&A!7SH
M11]ZRD[N-;`Y_61;QVG8:=8R=HD=[,[>X`IL:+6KZ9`-.J.ZVFZ1GAY(U.K_
M*ZRQUTU:-KC#+>YQ+YG<P/ZVN8ULI&6C^\E2Z!]NX;T&.5QC5]:^MT/VL0XZ
M0+M#4[@!II_<[G03O.`&!S>RS0U;@L.WWVVPAB7Q_11^U",?];AXQ2U>\8MK
M'.,;[[C'+T[Q?/"CY/SPA\E3KO*5LWSE)&\YS&,N\YFK/!_2N`,;NO#LG;/A
MWS(@L+?##?!C0[G(U14X=@=^<*(O7=W`)I2X$ZZ"4#N\#<Z@K\29`@Y7+,,5
M7O]ZU[GN];"+'>QC-SO8N[X,M:^][5QW>]O9'O>WOSWN<%][W=V>=[7O/>QV
M][O=]_YV9:RB\(8W?"A6`86?*QW<[2;RAX?NI,?!_TGR^BMXD]"M='3'H->=
M-_*W0P^GQH_>M;VV?+E!/_E#-S+>KNZ0,;">]:2`PQ2J8(4J<J][5O"^][J_
M?>]Y__O?^W[XQC\^\)&O?./C/OFY;SXK4`']YZM"^K=_?O.O#_SL4S_[P2]^
M[Q=OO"$/>?.@5_J'M=SN])9>\^0'^OM+SV<BH[[RV)7\DTZ<^32CFXW[UU_Z
M,1(`WM_D/0GYN1^?"=30T5;_-.#K@1&US5Y/@,/VX=[W72`&9J`&5N#W<6`&
M8E_P@:`&CB`)EF`'FF#P.8'Y_5_\)1WY/4GZ#5V3#!W`U=__$0D`&J#H-0E)
M_57F]2`0WL#\(9WFT1_18?]1`E[:PK6@90'<T;U`%,A;`_;/,\B>!!(%!:*@
M%FXA"8*@]@G?\B&?\.$>*N1>&5X?*DA?])7A&::A&;9A&U9?&L[A'%:?'59@
M*E!!Z(4>D3S.'KH@NM73A_U@Y,%@^;T?D17)*[G@`0[)#*82#PZ)$/8@GPUB
M^^W@(19)$X+,^N5@`=(?#LI?:F$1ND6!&H2(%`Y#6EVA4/!#%HXA%X9@+'X@
M*Z3"\+&A';IA*M#A')X"*IP",)["*(B"**#")WR",8H",!XC,S;C,6X",T*C
M-&[")GA"-5(C-E(C)V2C)FR")FC"$WB"&O)>*.BA"C!>^:5`#&0>.S+)(>;@
M)-[_`"@^"0_"X/ZY(Y'%0!]*(CZRHQ_2GR1*(@PRDB2&F3R6WSTR23^&XK<P
MD@%^B_T)I`XB)),09$,"G$)"X160B+:U0>RQ(A82WRR.Y`CF7BOH7BJL8?3)
MH1SV(AU^`C'&9$R>PB?0)$V*PC-&HR=XPB=08T]^@C7NI"9XPE!RXS=ZHS=^
MXS=F@B9D@E-NPCBR`A3L83M6I4(:#Y/$8T;B(T*NFSQNY59R(E@2"9,8CT-F
M8I$,64!FY5<>(!(.B0LH)$+J(&55Y$!2UE<JI",.)$:6I4(Z)%@>C!J,"$>R
MP3.@"T@&!06*($FBH`=VH/%)GQOR(B_Z(C*F83$2(RHH_R,RUF1-XJ0S1N,S
M9N-.$B51(J51*F4W-B53-N50;I\J?$&29"19UB5"?B+D<6(ZUF5&%N3H560B
M_F5;6F61@"*?Y256!M(+.%AO#B`2$B<.TF-6,E(_[A]9-F1S3J=T;J4*X,!@
M$B:).$/$)69/\(,W/&8LHN<L:M\;\AX;UB$=^J(Q`F-FRJ0Q=B8QAJ9H_N1/
M5F,W6B,U6N-J8J-J%JA3.N4G!%\>WLE8YB5%ZB4`$DIOZF,!SM\/\N-78N23
M8"5P]N996BC]8>5M5J0C4EY;$LDZ:B*3=%Y6#B!M1B*)BN60<:AT]N%5WD`,
M/!1XBH@;6$,$DF=,O.)(HB=L.O]F\:7D\TEF&>YB?%*F+]JG9C)C3(9F->8D
M-O;D3F8C:E+C:BIE4K(F:V8"-([A*E!!7F8DBP9FB^J/F@JD0'*G'R9GAJKI
M7P*@(U)D#:HI#!9D7RKBF8[EY&UE0&)EB<IE7_XCD7`HB2;,CJX!&]0;D-[$
M>/J#D#:FI<JB!;JG](G"2KXG'19C+\JDJ$ZI*&P":(9F:?)DJFKI4;8J:G:I
M4C+E@6K"*00?%"`GCKII8.IC/.)I^?$J=8)E#!@)G;Y`#!C//\KCGGX+H7:E
M#B(K7^H/H1@)KP:F$"IK0;JCA)(HKU[>GV8E0+*I.YKBCJJ!M$7J3E3JI5HJ
M>Z9A[TG_9DM2YAPBXY.R0F9NYJCF)S1:*2>4)C0"J)8&;%)^Z5*VYH$^951^
M08JN([`Z8F!6TT'2YE<.:Q_69G%6Y+">Z8/B:`RDJ$3:Z;=.ISSVZG(>(*^^
MZ<,*X)D>Y,029(7*8XI:+%T6R0V0ZX[>@3J@:TXLYI"N*V0FJ4IR*DO**S#^
MXI/F:ZG*Y+[NY[^NZC0*["9T@I<6:*P>;"9P0@CJ85@^R;"^P`R4'Y]1J%S^
MY8T&JK4FZ@SH96#6*#UB9%\B9-I2I9WB8(-VK$)^K;$ZH1!>GJ"2Y3H&TI"D
M:$;&K7"2Y6S:['>*B!Y4E,[6Q'EV80FJIWK2(@A*YAJ^H9/^_^(O:J9F;B9,
MCBJ5/F-0^NO3(N6`<FFKNJ93ANF!UFKX:>W%/H[@YNT)9.RAYF7<CNR3Q*VX
M-DG'.NB=XBBXJF-Q[BE<@NO=SN`,#NK>CJRAUJY>JN.T5AY9$FZ-"N&P=FM@
M$F[@,NS$(JZ(<,H>(&;CSH2Z^FQC`I^[PN'0,NFG8B:^CNI-?BY.[N0QVJ\T
M]F0U`FS`=JGI4FW56BVGAA\0".^*=BSQ&JL"9^^*.B+#*J3MJL#"&NL#3S##
M,BRA".[L=JS'2K`$VVV>KB/V=FM>/O"*GG`'UVX%*W`-)G`-ZH^;`N`"XZ@!
M2F+7JA!'KL%@.L/)E:],/.X&+L/6<?_AY$9N\;6A+:9A*S`#.(##,K2"N\8D
MOJ9A9Q[C328M3-XO4/+D-&(I@/)O_WXC)QBHU5Y")IAQ)B2H\)W!L<)LWGXK
MKT(O!6NPW5(6F]KM!E,P"QM/!1,N!^MC`K.EPT*PL1(*BN(Q(<>`'R^P]YHP
M]'9>"!LAP.&QMY[PXQ0DP_:A%LW3B)SB-?BP3(`#IH:@-]3#*CQ!$1OQ!L*B
M2>+B>[H".J`#.#1#,T`!)\2O,L:OYZ9"*URQ*(""?O*D_NXO&!OEJ\+J4K+N
M&3OE)4#ENU*!!O.F"/MI("\L!K,PP$GH.FHS(U_P":-I(6<E!U,P\;9M<<9L
MALHQ(I?E"G/_+-<V\LA*L#IF;^?IX+?0,"*GJ+<^,"_IR'>JP1SD+"B_!!!K
M8"E#@1)@[<\6W^X1W^Y=X/"YY^V]YRY67RF[`A,H048K08)R*DX2(TT>HRA\
M`SCT)#%N`BCL*X`.\R=@@K\.,]02K&H:K#*?\25<`B=L7SE>\!\C,/9R+;CV
M-`.[(\=><%'_[CSSM`@;M1M;\QR+\+;"K/,*]5.?\P,3+Q[_,9O2L#I^\+72
MLS7+[CB'L/<65B>K@1JD@1Z$T4"WQ/F2,C]`@06L`MOQGBMX@RO8==AYPS+P
MWC+@=>Z)'2MXG3?X]=CAM?!Q'6"KP@"#0SU`004\P2=P`B_D]2F(_T(J//$H
M,`,SN,(2UT,\\((R@,(I+`,S+`-.CL(RC,(J=/8H;/9J;\(VQK3IHJZ!UK09
MY[8G;!\4.$X%*W7&%LDX__$<PRQ5"S5Q([<>G_-3*W=3`W=S/_4(ZV-/(^]O
MJV-10V3EZ;$W>VPW3^OQH'7XZK`:&,.DMO5)](.Z5J`J'+0%5$,]@$,LR[)\
MUT-?+T,]R#(ZQ+=\[_<RH,(R\,-_LX)CNT(JS/=\NP*`Q[)C`[$H,$,^-$-"
M1Q\XQ,,HU&2%,X,WR/(XN$(SU(,[-(,R*$-_H\,WC$(JQ(.)HX,\>`-)JW@J
M5"E,;RFLHJZL6BTSY[89JS'OW6K7-C<(W__Q<'LM<1LWD',W<"=YAB8WD2<W
M<C^Y4"?U=!.W</?TE,=CKE*P<8,PE(\LN*#U/WORCZ*W1K3%6P>?8T.V8Y_!
M$_#"/53#*H1"-:`#$ZP"/XS#$C"!,O!#-3Q!*J1#,S`!,_`#+UC`$SAV$R@!
M.K@#%#P!%*!#,X2"+*]"$YQ!:#^!NSHVH+>"*.#W&2C!*,AR*+@#,S#!$BA!
M$Z!#-53`$C0#.(P"$S@!.O!"*.1W$S#!AS>#HZ-#+S!!-\8T,GNIF-ZX,M\T
M&KMN+2KL4B-W\P*YE4,YM$>[[2:UM!_WD3\[M!?G43]Y]RYYU_[QEC-[5EX!
MF(MW&N`LF:?W/9S_N?!Y0UR_]ZHK`134`R\H@1(H0STL`13P@S)4@!+P0CV<
M@;][0SHHP1D\=@5P`J(K>C3X^Q.HNJ4OPZWS`J1C@";8H8?G=RBT`J170*V7
M>C540Q,\`<EW_+PS`Q3HNZHO08A70`7PPCPX@;^/0S-@`!.D=/\2*)<F)8[W
MO(X[Y3A"`32'.[C78+03?;57.T$F/=.+.[0[[\AV^3L+(9*/M513-<WB`+F7
M>UJ/;[J;A"M.;GO/0Z*#PZHS@2O40S-4`!.4<A,LP3WT.Q/@=[\?NCLP01/4
M0RA$]GXS`0:@0S%$MBJH.B_8`SI$0RRKO<U_*C/,PQFTO3LL`<"'@@4\_[H[
M@`,4=SPO\(.JCP,ZQ,,X-`'-^SN$[ST3P`,Z8(`27*-_GF9M3VTRKRXFS'YN
MV[1-;X).RT"54_6V+_7N_RZX<W!1]_[O:KN7$W_3<ZSR`__R-_W3%S\]T\"R
M=SF4[\!@<OVCCOG76\0K/J8J+'S(&WK:-X.A(_H2U$/=TWUDF_\]"+S"UT.B
M=SPJR_?!(W2>,P$3L#TOICCYS_L9N#I`,+G`*10O><J@H*M6(50]7DJ8,%DB
M,1VS"DR8Y3M3X0DZ=!@P;!*Y29,G32,UG229DF7*3)HRO=2$"5/,2S<SW;RT
M214K5JK.W+@18V@,HD9?%#U*],52HTII&%TJ]/_H4*%7B=Y(^F(KU:=?J8:M
MZE1J6:E*O9(M:G5MUK)4DY9-JO5K7;-8J^Y0LY>O&CCJ_`46/)AP8<.'$2=6
MO)AQ8\>/(4>6/)ERY<'@>OK4O%F5MWI0E#2K=N&)JWH6GX"KUV1)/646GBQS
MS5&UQ'?**IR*5X^)$G3-.+)2V"3=PR?'D;-JY4H5*MG,+#`!YU$9Q%:B/+EK
MAN';Z(3-+C!I\J1)*'D6,>)SPA$>.B48.HTD:9*DR)8K6<:,63-GSDO^=;H$
M%,U4^6*NK-AB:RJWUL++KK86[.HJK\)*:ZJXJFH+*PJ=HM"JL=`:"RP/K<(!
M1!$A+"J'*?K:*XT\[+'_3,89::S1QAMQS)$Q;S+;C#-O[@$-G&I@,PVX)[R9
MA[798F,2'7>:4`(<=Y1IIIYZEO`M&@LX806<="Y0)IUFP)F..514F:Y,CT:)
MSAM^JF'"`BC6C">4"LYP31EF%/JF3%=<P0>]C'CAZ!OWE-C$DY'H0ZD^33C)
M[R7]^-,OP``S^425GDZA`JP.1V30K;C24DK$LR;4BBX.ZVKP0P]/%/7#$U\]
M:@9:SUK0U%D;!+7$*_A*@R]K^M'1V&.135;991/#S$<?55D&G"8J4,8X5KPI
M-#9O>@/GSM+`686C9;A58A5O$%KE#"648$9;;'%K8AEK>5&&O%-4<849>I]@
M_[<TARI0@I-]>0E%H"?V=>*)4>CEA3QW+VKEFR<X8H89#"S0!!3Y%JUOI8];
MTF\_FFRZ-,!/-(.B5+=D%:JI#3-\-<$-Q7(9KYI33?7E6F.5^=2<?=9P0@1#
M5!#G6B?<0=B^TK@#,&:ACEKJJ:DFC,=GH56E7U4X4>()G[K^6I4FF$@E;+"]
M]JFW5%CIU^O>4.FW2ZZ]3N64WMAE0I14T'0;HB?2K">4Z$SY)$I_3Q&E-R9$
M8@+CB)ZX!+9//GD"@R=(BD@E^ECJ^*24\),))IC^(QU`DR_9[`Q2@9YPKIMS
M1I#HJ7IM/=6>B;9=]]R%BJI#W4NM\`8<AFY==@]U`/]6#6&9'^:>JJ&/7OKI
M)7,6ZZPWW93`S++/?GN?O/^I>_#!;RZ5[$]!!=_F4&E?_?13\8Q;V$ZI7Y3[
M\3^%DT_PWW@3RCW1"4U\8B0"5)1\1&(2SH$L9**SU'].ASI\^2057X`=[6+G
M.N'!3$&\"XL.:'9!!B7H5K8+E0='F*'<Q6R%P'.A4':@O&"M(1O4L^$-<1@]
M?ECO>L_27@]_B#7O]:A'V^M><S9EBNRYSWW,J,?$HO.^Q(D"%?@31>+X1SDM
M>D*+!/R$)[CX/P0JL"2?PP]^)"6R!Z(N<IG@1/920047CG!F-//@[388M#KN
M3F:NP@KQ*G1'H`G2:(5L6>W_A&(#&/+E"LR[PSQR&$E)3C)'F"FB$'N824UF
M\H@]81\KF!A*5+1B&11+5!6I:,7[\0]_7\0.%\'X2C`2\(`=DT]*%F7&EKAD
M=&KLCTXB>!-+8`(5/H&"#+32%*E$(0I-4:99H@"T'+S.*#J(`0BKB15K6C.;
M)KS=-KMINVU>!9S7#*=4N!F#*)@3A+>+00Y8-DZG@).<YK0G-W6@@RE<X0IK
MX.=>HE$L2@Z4H`5E#`\YLTF%+O1ZW>-;<T`)2E&J+VY/H"(J\8?15HJ"?US\
MXA?!&%)%$="6',,E`QL($Y&1#'67>D(G6N&3,S23F>ITYC)?4--FQB`I.=`@
M"'V*_T^JK#.?U<3G-75GS:$5E9U(O8%2GUJ6=J*SG$4E:C6E6A6?WF"K\,RG
M5XFRSFOB4YY&-0I1N1F%*["AGWN9PAR>9E"YSK6@"&7H77VH23B*3Z*H.!\H
MV=>^]+G/?JFL8A7KQTJ.NK*+(@5C+1^+P#*:9)>5]64F,`'!EN+D%#^!P@ZN
M\DR:WK0LZXRF4(#*5=6"M9Q4)4I1H3H\H,&VJ>`4*SA;N\T<Y',HN!UK4\]Z
MEJX*!9[V-*M9:%M;XY9SG_X$UAJF,`R!TI6ZU;7AU?3Z$[SFE9,$$M^FBAG1
MB1)6BJQ092M/H=B.;M$3V)%E2$O*J#*B!'22ZJ5-2F:RR/]=`A.B4$XHY!B%
M'>0TN$AA)DV12\[5/O4%OK5F3=_IEFVV\ZD*QJ:#@8MA=5XUPKM5;E--N\R@
M#@6>.?#P@]$9XMO^UK?JQ.J&^PDLY<&A'-:U\8VIY@V%EFD9S-F4*]#A#4`I
M5%JNN)XKO'$U[6V*;6@*K"C-B]CZI<^*A5UE>T6Q"??"U[&*6E1D'75&E5A6
MI93Z94LS14$+3LBG8A5K@9?Y3@53Q<$5'HI8[9SGX7*5Q>,4*IV7"M0"HQ:U
M%ZYS6D[+V]U&M;9#PW,[06CH>[)8K3)6`S^%\3P<;YK3QK(K^32##GXP`W`_
M`<<]T'$<A;[)89=DA6FJ\83.?E?_%:EP12O`"\I6,/&B[DME*NTWQ?.VEXOW
MBV5[$UA+!*(DEVA$HQHS6Y/_N/0F/%$.%+;*U:V*509AC7.("4W<$YNUK.I<
ML+9].MS=3O@H)8;T#=#Z5$AW6\1`NZT.3/S::[XYVQ/*Y[_96>%EGELHZ_3J
MOW6KSG\N7`TU[/3#(2ZC3S\+'?D@TM>`7(^%*(&(KN[,9[C$O9X`^4APW-0R
MT+$,?+7OHH,5A2E^G=Y17)'FY\UB1]^;92[#=]D@LX]]+&OF_)I,$^$-!6CQ
MC>[B;KBT+J:WB4<\8H3#EJGF[JJBH9[NWLKYWXM.;3IE$&EYN]@H6=?V5-'Z
M[PKK0`9$_U5MTHM[\("S_:RK-7%4`1YA:YIXG?N\M*7SL(^(#Y[PC>$'=GMH
M&G2D(TH?GPZ[\I7D'FL&R=X@USVBQ(QE^`3)@*I'-"K`"7().5_@X`<ZE+$*
MY8S>%>W3E[YZS`QO,*/U4Q;V*CFZY4V,8N>1!?.RQUS974+[S"8+;QS3;>)V
MPA/"$`ZN:<_^5)_&8`>_'2O=(0SUI$O?[G?_ZJ(7C&]LUA32@B8_NB'=U!(C
MU:I$T?[:`3[U?XLUZUMEZKJ[;D^U.M>Y#2_\_P&P,"9N,X#,&U!/8#S"`'O#
M,]#A2\#!R%"N`:?D,Y;`';P!<)X#%7ZC`GBA`3UB&5#N'JKA#/]6`<@\,.50
M0354T".FPUX^(=AR;Y6ZB)5ZC^?B2[(>)3\V(2942J6FK:7\2SF^8`?J+])X
M*]+&:IW&#N'6SNSJ[[76SL[>#?ZB,-*4+PJ#*NJ@K@JQ4.Q&S-_$S@CEK0GQ
M[0G'"@NO\-V.D-$`3JW2(`NR(`W2X`KR0-,"\`X);P`U`^7FQ3V:H!Z6P8F@
MH`G<`1RZYCOHI!Y6(2*J`?.4@$J\1C;6!1U`#PI<@3Q^0PF6P1V@H`*6H!KB
M81&9H!G<86#\H1F<``I.`V^\IN9P+_>T"#NTC-@>R_<8)<P^1Y?*;`>)CS\N
MI1/"ZYAPP.Q2"_[F[0B5BK?.KOZT+PS_J]`9U3#I@$KJ"$WMOL_KY$WLJA#\
MIH[]5$O;B(O"DD_YUE`;P]`<I6_1KJ\*Y'`.LP!8'`X/Y?'A$$^[?,0T$(+Q
MS@`=7"%/H(`7%)%=..%+OB`=O,%?O,$=EF`)T@$W.,$T)A$X'G)/-$X)_-$"
M5N$T_,6)SH`7YF$)*@`*W.$;QF,3GH`3K,R*;@ZDLDSG>J_G;BD7'X47)\52
M<B*S+L7:6"$4M$#<MK`,K;'0I%#MY*VKMO#]@M((RS$;Q3`;"TW\EL\+\0\,
MG5(IE7$-J[+KR!'KII(IJW(H%8T)02B&&FDO&JD.YS$M-TT/?6(35\$W>*$#
MR>,SH@$=F"#T_["%2I@$6S"O`AU2-K[`-X!#&>JA`=VA&I3@#S>"4#@"%2#R
M"Q12"4Z!3]R!'U&!?Z8LBUX1@%QI%FWP@$#SYQQ%!WGPLO;CS#+A^"SH&M,P
MJ*P2&<<0X=9-^8JP')F0*<52*=-1&<DQ#<OP*9'Q'(WQ-753^LHP"W?+ZX@R
M*:=N#+<2X1II#ODI#=B@QM3R.JFK'Q#JDJ(E()LA':J!&<3#'7@A3[*D2[Z$
M,`OEC3P#-*@D]"31-XC!-[PE--#!`I:`'SJ1,,^`2UAA&30""M(A2TS!KWC!
M',;A.#X!YC(J%CV*%K,,I&KQ]\+LYW2Q@6SR=#!AUE@!V[ZJZ\0/__\0[OIB
M\T-1"_]V*^Q$E#BM43:A\C5Q\T5#=$7E+T;E[T:!\PA%U/ML%$9Q5/YR@"P;
M:4BE"SN-U*!V2*^\(1^@P`*4P>+Z1157H0(?(A5D`QR>0#0$!N7F`33201HP
M8"#O85T:L@(/L@F>1`E:HU!6`1W&06!<036:`#*S1!5:08FF`P.88,K.2P8I
M1\L(Z+U$*C2!+Q>#3C_*#+-^,`A;(12J@"EI-#>#<^I6E$9QX$>S$ADC]49=
M%$2;DU-;%%1%550WM4='%=*"E)^F<P[_XDA==:!T3),\HU\:HAF4P$E=HUW&
M9#KX40D2HAIX%4HLH!E^@UCK(2)#PS6DP2/_V,4C>&$54&X<>!4ZS+-=/-`=
MF.%67S"QJ(B58M$S%P6DO.S+"I4D..%CT*@F$G6EIFT3V(855H$*+G54-_54
M7;1>[=4K[75?:Q14C9,Y3]546712N8I4=:`*AE0ZT\`8^.%5'3:'V/(_+S`W
M7$%<E`!;!B<VRA,*W"8VE.$,.'9=+,!*>6$\SB!+K`4^SZ`)H.`,+L`"`A$*
MF.`)5D%=SJ!?,#);E2`5]@5D'4=O;B\6%\O8B$WGM&Q<"14'95+X+DO:BLZ3
MAI!2/Q1?^754315?(]5&7=-J]Y5J4;1JN99?;V`'X%`ZKV`*[N`='G9MJ2=B
M>^()F"![5$T5[N9K_S@!;B.B2WXB(KP&;M\6<N#6%.#VC?`6;TWA%,B&":JH
M7_*V<&;V,N'V;_JTE58RB[3LE<3H3\M5-.MK^%2*9'A0$V:M%:!@"#AU!TX5
M=?E5=5-7!UA75*/@5&.7[_(I=A'N=<&65',@"OAN=_'-=E47=\'6=N5/=:5`
M5555#:YANMBV>:/F\%Q-B#S)'K=+>G_HA\++>]!$B0;K)]2'<IA(L0ZK3QNK
M8[+L@,Z746RI)$;34%NB4E(BL_H#97Z")Z=.>/.)=8GWWU`W2/$M>%VW>/-W
M@$6U?T'5=J/IW^85*(]S?^^7@"'8@0,8=7>@?V<W.6N34V.7@@/8=6WW:_\G
MN'C?$7FO``_LT'E1>%DB%EJJ%Z^FMYB<;+S(B[#2*W$T:J,JES,Y"C3_]!/8
M]Y8LE"6`KB9/4]HR81-4<X$K.(1=EX-O=X(Y>(F;F'\'F(*=>(D!&(MW0(+E
M+W8/;!IU@)DPF!RMF(F7V'\1CIFFN(.)<'>A#H%Y-WCQ=XW/F'>+EW6OF(2O
MP`JJ,X7]6%FVLX4%&=2V9]?`IWV6"+PFZA.DZ'[&5Y76ZT\YBA,B]&AI*6EQ
M$(V&CP=!%XG!YPS".(RS.(L#F'BOF(VA.'^C6)6KN)5=%P=4UXMK=Y9S\\"R
M3HW%^)2Q6)51EXM1.8SOCG?=V(T[&($[^(FG3HW_19F54[G22-@8F/>/I=E&
M5GB0J]>3PJM]?`*1GXR\TL?V"@N5O)7W%JNCD*TE1>)/;U`T@0YT-+G,U#6\
M.A0+3)F`+Q5UN6I>HP`'^+F?']B)F?B8J1B``QB6@W0'%EB@\PD'HJ`&^ID(
M+Y6A??>?CYF"^_E2-SB4J7B`YU4*(%IU^5D'0IJ*>5?`*GK^:!F5\3B,K<`*
MD-<*TG::9=I&ZM&:;9I\,D.>_6N\OEFPJ,CV?NT5C4V+9C%S_^>2PPB(V[F=
M-WFE1"$SXG6@I7@'J(`*@*`*OD`+7GFWJ.`+JIH**CBL!]J,Y;B)M1B*$1H'
MG*`42H$*UJV"$9BJN]JK_[VZJL/8=-?-=HG@K4,8=8F@JN=5?^DXK(<@!Z0@
M2.<Z"K[`"<):BW?`=`FXE^$:@OO:K(/7F54U"[!AICE;XK+KIEVX)V!XM,%+
MD4/IF_GT]B"YG#GS06U)G<?(8]XY9-:50U'A"SXXBW&`"MBZ"CK!%KZ`GZ,`
M"DJA%G`!%VK!%,`ZBG?9=0_:LL,Z[*::?RN8!RPA%W"!"J2[@^&M!IS@%HX[
MO'%A$T1ZEHVYL?L:!Z#@%DHA"%*:N2>X"G*@"G"@"DH!%Z!`$W"AK2E;K,]:
MH46YN4>Y@EV:A(4AFCL[P1NCID';FK5'I_N*IP6KD:>HBC23M5O[BXXZG1/H
MA_\YUV.$.*5X4"<[%(X;NX)Q(!3PFPINP1:V8+=-`1>PNQ9JX19NX0M2V;%/
M_+'EV+_#>@M2,0@0.A2PVZVMV(N9Z0MR(1=JP19HW!:>`-Z(-Z[+^,1UP!-R
MX1::`);->H.MF(*#=+>^P,:IP!1R81,$;,>K7(K3?(LU>ID;V\O-NL"1MPO8
M0<'QW#&JN<$;RHB6"$VJR'L1V9MIN+!24K$P?(MHR8M<$HPF:R8OM`=WT<E4
M815DV8Z_G+=QX0N(W!1P8`C,/!<JH0,X@`,ZH`."X`50',5A.:UYH-6;&-;[
MN0C">'C4&A=L@0I>_1*PNP-H0*0C.M:=X+B=H-1+?07_8`#8TYJAS9J?&_O5
M=_L24'UX\$VX_YN?>2!(U7N_J<`6;GR7T?NQ67G`H3MXAP"]7;<*K"`+UKW`
MI2'/X5TQ]IS/NVM\M/=\`%W"P3EQL$@E67NDPDASU;<DR`B(/R=2@DYTN4>[
M+_W$<>`+D%O3H>#6<X$2.(`$3&`%2(`$5N`&NAJLJUH(8'FNC3P*YMIUAZ"K
M7SR,OZ#E*8')G>`+<N`2CKL#@*#EY;7-O;O7.0`%4&#C8^#C3;[EXSA_YYJJ
MO1H'@N#45T`&6KX*%-NKJR#3<1ZA00$78IZ]SWW'RYWK?9RY=;RQ6YK=77H*
M`N]&!"_>CW3>Z9V3CJC)!%W?__<=!AF9<F<0EKQ(C!*(LG*IV8)8^$:'?G\"
MMR=;SE%<Q=NZQH?0S&NA`T@`!F1`!F``!FQ`!Z[>%#:AQ:NZ$XR;R4&!"BP?
MUW6="&P!%T2!GZ$`%VZA%I8<NS>=U_'[OO<;Q\.:!YR@UT?`*&P@!GA@$_8[
M\U4?%+9@BZD`%,#[%DSAOC.!!CP!N8.@VV]!$TKA^$%A"&!Y"#:A]'%=$WC;
M%K`@%&X!E-7\Q-N\L;=^Q\]__.%:K>C<"KK`'6QD'ZA!'M3>2!F\[>]J?%CA
MKXJ)BI"(B0#B%"J!`@>>.BA*U*F$"3\Y;.C0H:=/GB8ZW+3IDZA-GC15U.11
M$T:0(O]!;B*I*1/(3)DXJ6+5RA44+#MJZHAR(TK-*#IJ?H%"A<J9+T.HV,I5
M:<6-GCAV"&D**E<M7+A*!:F4JVHE7+E*`7%"]4N-+UQ+4<%AJFNGH[4J50IR
MB6NM6D=SV:)2LR;87)2<./GRA0@.3UEQV:J5*U<G'4/2&MZ:.!.+35F#&,UU
MZ];AQ)=P1(E:JQ,EJIF^;-E!Y4O/O#99MW8-F_7JV*ZC6+F=Y8IN;/YZ^_X-
M/+CP?<&([1../+GRY<R;.W\./;KTZ=2G]_/VDI7V[=R[>_\./CQX5=E5I4I%
M/CTJ5*K6IUH/W^#!@Z@^G?I4_V%#3@DY:>1TWR<9<<+?@)__^">2)YQ@Q&!&
M#9YTDDC9L;(*%3K11EM/.5#!524NZ%`%%*:`8@H40T1E5P<=.)'5$QR0T`17
M4`2!V"4U9$+5+6>5HA@(E]CU(@F6)$8)!QQTDI433>W`PUZ))7:+$S4@R1<'
M'?!H2Q!@X4()!1S\F(LE)'""60<R''5+!U8B5HH.7V36`0D46&)8$*OQM,.%
M&.[4TTU[ZKEGGE9<<5NAPO1377#\!).#.8D^"FFDDDY*::6_]0/.A.)MRFFG
MG)+'"JCE@:H=J=^E%ZIVJ(2J'JCLH4H>>ZN.RJHIKL(7ZWH3JO(%H('N9!,5
MM^0"2@PX4%$*5UT!$14N<9*`E2TO_Z[`P5&5`(%5)T`D:PLN3E`Q59R8`,E"
M"9A0%2<*'0R+R0TU-9E8+:784LI;-U"6)@DF#'E+$$C6\J*ZPUJ"`KX<!&$M
M"22L$&T0A-7201--#%F+:GSN,%N@.D7AZY][5F%%;H1:<<<\DQ)G0AG'6<IR
MRRZ_#/-RF&K:G::FIGKS>*AV>O-+K6Q'WL^EVDPTK#9K)[30KB"MG2L_)^W=
MS:W0S!T4'.>ETQ`U5<&:3D7@J0,.-"[;U(K6!@':BV<BM8(-.]R`91"9V+4$
M78#@4@E8`+L0BEU!P("#)EEQT,(-07!EB=LZ;:FF"110L((*@J?I@@U(IIF6
M+3ZX<"QBEO^4@&\0""-%`@XRI,TC5U2I[D0,?%Z=YPY:`SO[[#<QEN?50VR<
MM:^S[U1%%KCA5LZDBYJ0PC0Q+\]\\\Y+A\XRTD]/??767X_]]-YDSWWWWG>_
M"B^AA!(^^>.O`L4JXZ^O_OKFGY\^^N&G;[[\]O,"1151X/`[[*]?&`6M<0U;
MF/D"#G0``Q)0`BG,DDH0;C`$:ZV@*4/@45(Z8)BX4&)=MI@;)28HN%)TX`8\
M$)RS:L*A7%S";46`E[,(UP(5R"`'H;M!#B9W%;LHI7-A0L'D.C`V4+A@"#@`
M31`6:`M+6&*#G0!B3WAW$Y[P3HIZVECL9%<;V?B/8U5@#!<+=9O_*3@#49%"
MF0FXT([GJ7&-;%P>/]X(QS?F8XYQE&,=X5B/.]XQ'W:,(Q_UJ,<_^E&0?2QD
M'?,1#2PH4I%:P$(5J%"%1U8!"Q;2`A$<:2$+*1*2%I)D)RT4!2T,89*0E*3^
MJ(@G0%V-=ZR!P5[NL@,<H`4I_G)@3D#S!7>]*4PD0)AF<-$$$I2"+L`L@0XH
M4XL'[L"$'6B*L'*!B2BZL`,EP`$/>*`#'B"SF33,2@?&Y2Q9DB5,)K@<!RY3
MB1+L(`=IJ<4*H""59RE,81G+7>Y@5T4I1O&>5[S:[?3GIZSM@&M1`-EM@F<%
M/-Q#4B@[`0J(P8\V4FH?[WA'/\@HT8QJ_U1FB,+H1I6S#SQ,`8Q7X-J23KHD
M'L228Q>2I6=VTA26OC26GN&)#F3`4E1N;7<!7>5`JR`#!<H%%)<(!6+>DC8=
MZ*`);'("%(YBBPZT(`=(P@7$2K#`>,I@!WO)VQ;FUJ\;'(LKG5C*_KZ0%4H4
M-1.A<$(1+A>$IN`+B(BQQ?CJ(B:P!@$(B`&%NXH8S['9X@E^L803E#I0EA:A
MG[`C:$Y["JC9!7"@^V3E3D8*QBITX1V2ZD<P3`!:(!1O4O/`AC6RX=%Y6`,;
M]&B9,WCP!G9\=+:TK>USW@$',%J!H#6-J?]>EY=3<BR*0]AG3??GM9Q:,7:K
MM&+'7+`"2R#F2?]I;6`R>_*5J10FJB28*HO8YLK$5,('/1F=`\$Y0M0@S@8L
M_2YU[0($RH1S!X3I5PR>,%W#("X%EZ,K4E@@NW9VP`9-J,OJ0K%88%TQ3SV5
M70!Y<LJ`[H25PSUE/R=L&^$=]`K9Z.PN4`!B$XRA'I/"!@]FP`-L8!0;*!ZM
MI8PQ@QJLP[8TKO'S/*J<<F1A"CP>Z12<:^&O^92Y-?',<9>;T]Q)87>IY"<`
M[:D3KG%ML4)P`0DX@`E*:-D2:G)E)2AAIR@`X<JBH403*3#5'1RQ$E*501"6
MV($5@`@&;S;S5[0<UQULH1-YJRD/J.`62KCERT]8@1,J88D@Y*`(7T#_]`1A
MT($M=V`JEW!!HRGA`R!D(F\PT`NB6X`#:@%"T)9X0@=ZXE@`/AB?-BEH%)M+
M89;*H(M3!-87#5J%*Q@#Q]3QK`E`C((40&-2V3CQ#.I@LMYDHP8\<'&EC$$#
M'JC#QM1V#CZNC>UL:WO;W.ZVM[\-[G"+&Q_'X(*YJ;`%+FSA"$?8PA8L<P3+
M<*'=1_C!NRVS[GR+#MWT9O<6T/UN=_\[WI1U\#U9.E`'*_>*,FC!/.<IYQLH
M3'%=3.##92"#K\E@!0K;J@X<3@*<UL0&\VR!Q5U0DQQ8F00Z$/+''PYQBP,X
M"AOOKNR"JK"X.(MS'&^!#"0>\J_I0&$MT(G%_R&N5.6R4KB\PRD77PUEI4N=
M=X[=;:&BH%!^7-0?^WCCUN%XT;#WH^M<[X?6S?#KM&\AC9$R,;-K8`TR8B/:
MSH;4UOT!XQJ<H]I\5TXX9@'XP`M^\(0OO.$/C_C$*W[QKY#$*Q[_>$E(?O*.
MISSE(7]YS%N^\I)O_.1)<82"(GSJJV0ZPA$(`Y]C/"=#D`$,GCC9&[1@!3#8
M*L*!``-WZ40'-L!XE(G@>I\K%08YB)T0;F"#5_/$]3:`@?-UD(.;OCYW-R#^
M#D)1BDLX0;I(X<!27+_5';S`]C7!>`ZB4`0<5+\%[)<!DZ>.8=(O?/0'ES]+
M#5JH*V`!#\'HO___#_^`NP"`_X<'6V`"#H4"OT8,O#8=Q=8#=L!LT^8/<]<#
M,X8HI64,SI`-)M,/Y6`,UI!L_L`.QF`,:=0/[(`-']@.9`1C/#!C?0>#P-$-
MD$"#D6"#D5"#CP`).$B#DP`).EB#-7B#0BB$CP"$-XB#0PB$.TB#-&B$3*B#
M2,B#34B%0IB$-KB#6#B$63@)D3`)73B$./B%-_@(-^@(8(B$66B&4@@)@E`$
M/P9_J>9<209K259_L'9/7!-_.15)!9=31?!^]O=$$[8#0J986``9B8$W<1)^
M'&.(=O@U>GB'=0A_]I=P]D>'RJ4_D80%NU4%*0!:H2B*HQB*)T"*H1AB(2;_
M`W5''<O6`];P!C,@#,>!#370`^5P4=CP!C4P`RA6!\4#8S3`&UPG##30`^K0
M#[!8`\O(`[O6#RVX=S$HC?XP@S98AF5(AM<HAC>(AF@8A5)HA&08">%HC=C8
MC4:(CN%8AH[P".SXA%\X"8SPA8S@"/78".W8"(Z0C_I(C_5(C_<8"8W0"(P@
MD`/I")"0").P"(O@"`RY"`*YD(SPD`_9"(L@D0NY"(J@"`R)A&XH?Y=X-:8G
M>J0728\X1<JU6)$$?PEW<%+@DIBH6#")&AVP1%SV(IU6!5)0B4DF95(GDB%)
MDGS8DS"I=+'3B59@&[GV`@F8@&G7E+^&`J:8BFD'_Y5,"6Q-.08A6!UNYX'1
MUF&U>(O]@`T]0`-O,`S"T`,S$%OL@`:RB"CT\`8C8`?[8`W7)`S6(`S,IF+0
M.(W2V`W9F(X^"`D^^(5,Z(/IB)B)J8[7N)B-&9CV6(^3$)GY6)"-H)`1N9`5
MJ9D8B0B3D`B?N0B>F9&((`F?B0B)@`BIJ9J'H)J(<`BL^9JQ^9J%4`BQ:0BW
M:0BT69NA:8.3\`7!E9-RR(=11Y3%:9S'B9Q7<W3S9'W)>9P_"7^!Z)P%E6N>
MV$57R9106978>97:"6Q4F0+(P(#046PU4`[O$(O(!I;F,`^Q^`:<-8$G-@SW
M8`=J:3+ET`,U@`WM60.[1O^,<KD/QL!L+]B7??>72)B.@TF8/5B8D\"8#_J@
MXZB8"3JA97B/#JJ/E+F/_,@(\AB:\3B1&/F0B2"BJ9D(&OF9IFFBI]F:KNFB
ML.F:LBF;N(F;M'D(C7"#DK`%4^`:T#F=/PJD0;I\#><",G`3)BFD19FDQED%
M4]")D5125OF=W1F55)F=30EB")BE)D`%[O`HY5D\UK",UD`.MK@.^$D#S^`;
M]E"?;Z!:S$8.SUB6[X"?-7"7UF`-;?H.+4B@!5IM!PJ&ZKB@/9B#$BJAC'FH
MUFBHBGFH$\J.]0BI&3H)`JF0$(F1E9J9"SD)J;D(*7JBBG":B5":J-FBJ<F:
M,1K_HS)Z"+5)HS2ZJH9P"(YP@Z1`!#^5DSJIB:)W2BJI7%)@>K_*4KX:K)K(
MJ[K*ATHG7#KYDKC*12-Y?\W*=+PJ7+?JK,_JDSDYK,8:DD.YB7S(K+DZDB(9
MK5^T6U<0!:`HI5-JE;^FI=R9BBBP`@D8#"M#'6XW8_10!VII8A5H#31@GK\A
M##/0`_/`G\,P#W8P`K,HILO(L,O8`R,88Q+HIW_*A8TZF$VXH`[:F(TZCN6(
MF(OJF.CHCI-:C_@(J90ICP29LB%:D2*:D)T*FJ#JJ:A)JJ3ZHK")LZKZFJV:
MF[=)FYW9FX(@90=7K`@WKM5*G5+'K-_*,7!HK>"J7$X;_P7*JJP^ZJ.8"*S3
M^K13&ZP_N:LDB:U1(+4YQ;1(RT53$$EIRS$OH)U.2:6A&*]6FJY4:0*BE2A@
M>E'XR0-YT`/--G<UT&&]T0]Y,`-H,`_]4(R_V+=?R6S#\('.0(+8<`\M*+$3
M:V,SJ+&(>;$96X.'B8Z-.J$<6Z&!V8[M>(:/0+*5Z:&5N9D8V;*@B9&?ZJDK
MVIJ)`*,YFZHZ"ZNP6@@]6YN(T)N^*60[(:Q#J;17.Y+*:G]4^Y+3R;S+>IQC
MVZO(6;;'6IS-2WK?VJU3E[:Y5A,WX`+8N9WMNIT)N`)N^Y0A)@9:&1U@VAO[
MD)?7Y(+KP`-V2D;M.0-SZ0_%QO\#>0D'"U6GP^@/&$6YEDNQV2BAG.N#7IB$
MC#JZ$+JQB`FIJ*N/&6J/K%N0F4J1EYJ0H$FB,!NJ-5NJMVNJL1FCM3F;/?NJ
MNDF;BG"#KX`$.\!C^E.]QDK#57NLT^J2+GE*4O!C6KO#.JFUVAJN'!/$1[S#
MW:JU7PNMSDJMTZK$SQK$SCJV1VNL1\Q%FUC%R*JMW0NE59`#5/J=VTG&H-6N
M<_MKR%`=[ML;Y_`&_AJ6=A!M(/@.\:MB_L"??>N?^U"?K_@.]$"G)E/`!GRY
M:DB..EB8&*N@/_BY(0N8H/O`1HBAEKFA^XC!FEF9(0K"),K)HFJ:*CK"IYJS
M,HK"I>S_LZ^:F[1I""[LA:1`$T:<Q#;<K%,KQ+*\B3?,P[;,14B\Q+,<Q5A`
MRTC\K,7*Q-*:M%^[O45,S+6LQ+MZRT*IJ[P\R[J*ML<,K<[LQ5>@`U=ZE2=P
MOB80K^^*@-Z9I>]J`D00C=+!Q@,LIL:(B^Q0!\SV!OG9C"O3#\-``R/0`^G,
M#KO(;'W;`[QA#",@8X1\N8")CIN[R$5XC8RLF`>9F"!;H9(YP?;8H1TZJ:&9
MR2W;LB*JD)VL"#/[F9+`HJWYFC<K"2=-RK')JJJ<RK1)"#=Z@T(+R[GLRV0+
MKG"8K#N\M<F+Q=2IT[!\K$@<Q.+:Q%;<T\5<K58PQ=-LS%FL_[0_/<Q0J]2Z
MVH=<$Y532K=F_*Y:S9UN:P+!H`_340YO@`;.=K`]\`;3U@_S8`QV@`9O(`S9
M0*_^L`[S?"B_L:=UP`-J+0P690UJ+5L&;5O\<*`>NX."B863,`O=X+F:N\`7
M^PBQ0`NQH(;N",$2')F;/=FTT`VT(`M?^)"5:JD7N9`?'+N=ZIDB;:(V2YJR
MD-(Z*Z.[>P@UNJHVRL*'@(Z3D`0#]=/%^LKA^LQ675!2@`7";,U>7%"[$YR&
M>*O&K;9)F]11K,Q1QL7%S=-6?<N15-3(C*R;F'!17`3/[4C0K)*G5,W=2YW-
MS#$ID)U2.<95>8"@Y:YBK(KC,!W[0/^P.'8/^_T;^T`/]%#7@FL/\V`/P=$/
M!6[@9*3?ATO8-/:7@3J.D=V%/A@+\)`/W:`(.XB-X=B@@MD-\3`+])B%3OC`
M%!VILMH-^1`.VP`/\"`+K$N1BO"%&[D(G9G:-2L)G7KCK5F:IWD((0X+,7VJ
MN3NCO(N;*<S"-BK)DI`$/1`%CN22QRW$2(G>ZVW-SLK4Q9V3QXV4TNV)2?MC
ML?SEPAIEW*JV/VS,S7S>47`%.V"N^K-;T.JK9M[F!>7;W!W=W7H;TIVV<7Y_
M/]6\:BNM^C/>-WW>>WZN:1?.72VEYVN*;>O53FD"8"`/#X[I;738B`J/5$@+
M^``/V\`'P#O_A3V(@[,0#I9-V9*@`88`">[HA)!<ZO(8J8_`#>ZP`7P`".$`
M#Y+0H8WPLJ:-D1[ZA2+]P3/+FMW0#:\I";#0!WQ`"*XY"*J*"(30JKVKF[6]
MY#];F)+PAL%<Y])]K%L<W44]!2^9S&9+R\'9M$>\O3^I4L2<Z'A^WCS*JU_.
MW<7;YE?]W+[JQ=OKM"65.RJ)MILXQ?\.Q?,^S>NMDDL98I3NKN4[OO!*OEFM
MQIF.\<ZSZ8RLV`P,">$0#MP@#QO@!UXX"Y,0"[,0"UT8"^&`#[0@";$0"X?@
M!XD@\RHO\]>8\BN/NB>_\Q2-NI'`#>>P`7V0"-V`#H`0"%^X\J$Y_PN2,(^A
MV7B;VIFP[9F=^0JB"MN="0LO3GE^X`>4-PFQS9J65]MGO^W;WIE?2-/^'IQR
MG@5=<`=UT`59L-W*+>=3F[9!G`7!<`=I:^5#,`5W,`Q9L-XOV>>[Y>]6'?=R
M3P9U\/ATS_!\GI3/K+9(:>5ZOOC[OO=2P-0[@`?FX`R63]R$GMR*K^@,S^59
MG.A%6U`Q(-]?+:42GYVH./OG/-@9K_LO@[F/O(V#B0_=$`CX0`I]``FT``\A
M_^*.'>+X,`[:(`O!#PFHGOP@#P\^V`W6_Y>Q$/P@'_R6_>I"'P\DSPC=4`^`
MH`W6+PNPP.OPP`V>*0L@'P[:,/:\SNNT</\(VN#^[0_SX=`/\@`0V[3!PO=*
M$CQNW.#!TR9ID"2%X;AI@R?)4*%#API=O%C(XT="A1H]>C1)5Y$H4ZJLK!*E
M2A9L].S=FY<-3TN6+%WFQ+FSRA0\]\IAB>)R)Q9S]_`476D4IQ2</'=T47=O
MG]5]]O9)<WG%:%&O.Y@:O;*CJ96B1J&JQ'*E:4J68G&B'=:O7$NH*XOH;,K7
M9Y6\.P7WY-F7;]2^-U`L9FS"\>(3C1>;8#SY,0K*F#53=AQ,GS_0H46/)EW:
M]&G4J56O9MW:]6O8L4/SZQ9ITJ-(N4F6G`0I$B1:^&3U^;9M0Z)9^,(%DJ0M
MGL%P\0!M"(0/5I__A;,"D<('[T\@>-TDP8('2U)W07^<D_K#R%$DA1O\.`H'
M#U`O?-M@@><6"!##/\)9#I`^^),$$(HDD26_0`+9IJ*#C.-#$'H`"20>>`39
MSCI"N+$.$$'@P4>0/C#"R)"./@*)D$-VDX2**5R""JHHLCC'GVR<R<8?=^Y(
M*RV6IMA!I9RDD*(H,K(QQ@HFBS+K"F.DJ2,**UKZ"S`I8HPQR"Z@R2:;>?QA
MAQIJAHF1J9^8(C*G*,JB<J4M6>H"&VRPX(%**W;8ZRVTCAS&G[N*7,FKPPIK
MR8HL#65ST;[^$LRE&R*;#(433%C!A$I7J&PSR#3E;%/-)I.!&ME*-?54_U13
M5755TFK3;3>2?(/$M_HDT4`;>>2;)1]M,N#C/%TRH*B/#%ZQ+L3A^`@0G@VV
M"4>2/OR`9QM`Y.E5V7BTT>"02!SAQAU28.$F'EJ:998/4N`)A`\_N!F'./O\
M\(.BZW[%AQ3N!/%5$GE(D;:7#/J`11Y``,$G6&7AT>4_;?C(8%Y\`.%#Q8TH
MMAB1VQ@19(@UJ]C!BBS*\6>I+$B%9HHLLJ@"BY6J;*LHM%RR`HLLJDRYKYM?
MP@*+F%.N>:<K>%[9K9Q\WG$8EH)6V2>WKLB"T)Q5CA%DH:NX8AA^VNG"+2II
M1FP'FJVHRQPLI*A2T:31-A0MM=7^L2@94LAL[O]*,9L[U$E!_712QTP`HQY6
M`Q=\<,(+1\W52'#;[;=)>HM%1&THXH<4/F;A!Y:''^]5FX@KQT<;[FSUXY'Z
M^AA'N6^B"P<0<@-^_!L-1G^$FWFVV8:;ZS;X9AQ?P\FOOH4LA`>=;B;A9I]P
MG%U(%T$(UD`22<#E@Z&'NR&XCWL?CM!@??TP!-<-)L[(1(LOGN0W4JJVXHHI
MJ.HGF!B-\0<;,M1Q!H]REJIC&G7,,8:HF0DC&^Q(AS&$D0YHJ`P/V4@'->J0
MA6R8PT=6J(,TSH'`.KSD2WB`1CK,,0P`X@0+1P/;,+*A#G58PT=8\!('IT&S
M89CC'-`8QCF&$84N.,/_'.RP217P(`]_[*,=TLC"'::1CG5`(X,OP5\ZL#$-
MNP"&)V?C"=-8HK(J4+%E9]-BRUC21:?@1`9ZJTQF))4W,^X-5)8Y03$,]T8X
MQE&.JJ%-;NR8.)+\9E;)"0<I=`&+>/1"`P3!W"!B$0]N9$`7TO$<+!89"`TP
M@G3P\,,X!B2(]`#"';WZ0R3@$0X-\,$1WHK'!C;0!SY,+!RP&X1""J:AZ6Q@
M/--2B"`L%`@2-8]`"HH'*39`/3\LB$#9>PA#.I`A#1""$+@"A`9,I!&-E$^9
MA/A#(1"1&Y,4I@OEZ$<>:C0-?SCC#O=XQSSXD0<XG&,>V$C'/I9D!6?L@Q_F
M_RB',_Y4CBR0X1WVR$8Y[H"%>?1C*7=PQSY0V(]S/+`=^GB'.]P11*11,63^
MN"$$U0&-<O!#'5V`H#W2(90N&",KY6A'F)R!A7+P$QOVF,<=\,`.?_0C&]#`
MPSS>08UL&+0+4\C#/33*CL_@4VU$:YNAWO3%M;VI2C$;2Q5D<,:]?>HRC(E,
M9LH8JKK-S01;N%&I^C%'L(95K*5!W*ORV)M)=",>DO`5'RBR`>Y@[@^S0$@&
MN(/*Y,#"$KV,)%WAT0==A"-\\O*#)+*5N7B`L@_NX08Z3GF(1"AB$O`01_7L
M$RW"_B$1@WB0+B+VL#Y$:V#A*\0KY"&(#8QC&P_C7/\'6!<L0D3HE[WH0VR[
M@0]48D0C*;+8-$-2"$9,@A&2`(,6LV".?M`4&C0IPQWZ(=,[=$$:]A"&%;KP
M#G9T(2CSP(//[HD%8_0#&S[+0COX<0<K9".Y7>B">A/X#AS=`0[8L$L69*9!
MBM:(HUF`0SM!2*IY&`,.=S!G'K*`AW:$,[PGK4(>]D$-+`AC'^]@;S;L03)H
M]&,8-NJ',Z[0WBCR!(M$7>I25X+%064QBR9FDHI-G,4HL`RIA&G)&O&&F4M9
M1E.3J915)5-&QYCA,ZUY+FB*S`YL<'.LA.O'/KZZY+!VPS=VA!5:)QL.5#("
M./<2Q.4R8$A\))([O0A$<&#_<:MXZ*(;OF/6?YH!"UIT(Q;)Z94?(I%8#?3!
M$8^PGGQ&Z8C);D,#?YA$.,;1#6UT0Q:QZ$:C$>)6AB2Z>+0@&!\001!29*"Q
MNG@%+?8QS$S'%AX`HXA`*"*/#H@/FM*<IHH.X8A920(+4Y@"D^!@CB#J8Q_I
MJ.X=]M'2&KV#']F@TTSN@`Q_G"PE4<@#H`X\CWLHL7WOV`<>NL!2.,0(#[NN
M`SO.691MOT-E1)OH,';@M&%@U*003':,L"94F"1;O<2>AGK%G8=^I.,*9+"'
M/>B$#74DV]?O@(-+BE'?$W.1)U<PKHJMYL46LYC%*W:QBHERIA_EC5-4]?%C
M'G,I_X];ZFZ;,0$,P(D:=^9!Y2M?N3'L,`,TA`G*@<.&'40Z\SFZZC9FA43C
M8L$-63SL-S_W93A>D8%#,#KH?E@S*201CC/_H1L3@<4J0\EH@8@'(H5D=#=B
MUPA'=$/0\VE$(]*JK?9,`A;:$,@K_@`+VVF#$!E`4.0B%XA7<"-\&%O=\R8B
MB%<(M@_<T-=#NI%I/ZS=[O+([:HYHB+?>J2:+,)-)`11A2(PZ;C^D,8PK)TG
MYU(8AP%]ASK2H8YR5-`?QDB)NYUM!6&LHQ_ML/8[](&'@=MW"KYF!QRHC0>T
MA/L-7AQA?NN04G:4PZ3IS2\\Y]>F*T`CV0$O_>G5D8T#Y__["L[5J/7580P\
MS)[A8NN'.MPR\8?+.(LD3C'#'0[QEK#LQ1-OTH]:HH/*G)''=U.C92P5F:KR
M,4JQFRUXJ-.8AS>8`05<P`5\@SH8@9C#.5/IAW=XAZ_:!SN`0/B20#A"G#S:
MC9Y#JT3@`T/0C4@X!#X8A$/8EMQ0!':)A$%`I3]`A&V!A$'@`^S8AE2*A$;X
M`U2*ED08P3\@B4:0#[!SA$08-$<HNT1H!$)()D98!$1`I51*P3^H0C^`+$)(
MI5":P522!$0XA-PRA#[(LW6QM#%$!#_8@#\XA#7<@+?J@Q39+8KQ+64JA#]0
M)HSI.5TPBRIPGSPXDY5PKG;(MBS_V"<\P((N4,0LD+[Q6C9BJ"\K:!]GD*GK
M4HHN@#8?F8*Z*(?KJK:5V#:MV:)RJX(,RP:.D@9_0(8K()5B<#U\TH&2D;=]
M*(8LV*\N\"$QR8(ZF(<>N<6=P8(Z8*D[,(M*#)27($41NZ*5*8SSRR(98Q*7
MP9,6B[&(LZ^Q2`L7X+$<^S^-NS']PRJ[X9O*(`:4LP9C2,<>F($>&(9TK#F8
MDSD.A`UC0`,'BREK>`-AL(=Y?*/:.!]829S>Z+E9:80I(PE'4`2PDR2$5,A'
M@`1&<$A&H`5:F(59&!=9P,'*:P1%4`1)2DCWV#-%6(1)6,)&2(1%`+NRBT)$
M2,F5/`1$_T"$D50$1$"115B$($2$C4"$(,R(($R$0S"$G_0(1`@)G=R(C%"F
M5^@&\Z`(;>F#C%BUBEF10FBUJLQ#1.@Y24@"E=@\80":'2#$+J`29XBO.KB#
M*2&P?1`GM.S$(@J&D,*12P0^;``4EV*'?1B&N0S%"5,9+"I%Z:,&.$"P<&*W
M&YJ".J`V<1H&DY(P=@B&.JB#S[N#?AN&.J`&\<*#`4M$"$(H/&!,9V,)^;LB
MD'DXA=,\EGG&:)1&BRLQ:6P2&7N;HJ@;_YLJ`>P_,A)`K`("7#N-YVJR!!S&
MWWRY'@B3(B.-WWRRT'BRXXRIYC2RXWQ.T7BN?9C.ZEQ.)P,-#/\<@3JXAPLL
MI^ET3N7LQU,I*UAYR($D2-\(2"K+(Q.\HTA8LU4*AUGP@T'#HSN*E4?XL_T$
MM%&Z#9,L.P%MA)MT20)UR8C$291,!)E4T)SDR9B,T)B$R8R(24,(PXS(.T,+
M!VTHPS9<M6BJ0V6JILG+0T)H'$B0A"U`F8"#GT'9@?`C.)6`@YQBJ7OP,"LP
MAH":AWF8!ODQAY"BB7MPA^[ZO?8IAWN8B7V8AI01MCRHDFU#0(HSS"BHJ7Y@
M!W6`+VA@OE>LM6+0AWZPJ>5;KC#E43-IKYB"ACO@)IJ8!W:8$L+\-7/8!W-X
MFO-[S153N"L@&O?+B8B;/R[ZT]<\&]G_C((4($<;PQ3;U#BKZL:-FPPSN$Z4
M>\`ZD-0\@$`D4SGZ$HU[R`9AL(,\P(;KQ(8ZL(9YL(8\8(=3_=0\,-70(%53
MQ88\L`-A4#+M]%25<]5YR(-2?=4ZR`.;L@,>J($>^-5S,(8Z""_M?`=GF-4\
M4"_R-)4ZRL_=0"N"M(W%.<\/7)S$,<%)^`,"2:71,2L\VHT]^[-1*KLE'"4#
MG80!+5!X5=`"1<E)4(2?#$(I9%`)#<,)Y=>HY%="""U4>IAH"M'RJ<K?\@C?
M,H3@@@12>`EC4%-:.S\X@`9GV*DJZ8)TFP9Q:C$.@@9KP#T:ND5GD`85<AIH
MD+;V23=I,#"0_W$&):J2BG6&FK&9+!@&:?"1[8-9/."@[AH&;)@@)N&@^U$O
M8YB"*\"#:+"&:#"&7*R".BC9,TTW:QC9*HE::1"&J#6&I!'4%7M&/E6Q/;6:
M02U;/&7-:[22']$!N=&;CIN,%:!-J9(,3-F4D6L!Z4N-?7B#$7B#Z^RF&>`!
M.Z@!!>0!9?6'71U6Q056?Q`&[K0#&N`!3ZT!'N`!&J`!.Y`YQW7`857`'K"&
MKZ*NRNV!&JB!S'T''A@!80@-80C<=S`'RRU==LP&OO7;(+(&-*B!RYT!81C/
M:(6-?R37;:76]LS6]Z@\VYBRW(A(0^C(XE4<1L"C__RS6%#7=6V$*/^\20+=
MWI3LWGC%207%F`=-!##<UPBM4'^-RF@B+-UJWX,]6&J:IA8I"5U@DEI[3:Y9
M,11;-FF\`B-)DY]@$J_PBBKQ"BHA&EJ[7_M5X$G,T]*<Q!:;FBQ2":)YS2Z`
M@Y2IJ0M3"95HX-=,B:;9D@*61OZE1K,]810NVY?`WQ4NVYIES;=AVV^L#)"[
M32![V_R[*A.@`@,\C7V`@QFPW9C*@QF@`3101W:$J7XP!AIX`VPX!VOH`1H(
M+V,(7!Y``SM`,F/8(6,85FL`C=8EUF$@AV=``W94AR6N@3>P!B0K@BEFAQY0
M72,3!AKH@7TBAS=HXB1#P!FH5/&RW%(E!VO_$)G?+14/U%;WI++<@`1NS5;<
M&,C>L"-9D>1R1=[]+`ET?01&4$E.;IS@>M<#O<GLO<D%9=![O=>6W%?TK5#U
MQ5`*'1_W?=]JDCR%'5%J2H18^P)IK-GS&[\"9K@]!>;^71_\;9IA=AJR59D4
M3F']768!CH;J"Z@$<N9Q2S%!W5-B%F!G7N871F&R=6:/&8*WR4W.J*IQ]+_&
MB-L;XXS+F)L6(`9)+8T?YLZ_)6(>H*\TK@'0?0?2M08GVP?'K50FQEQJ@TX*
MY%L[J,XP/EQLX`'>?8<WJ($,>ZYGH('CD^+5!6-VA*]^R$`[N$"^K=1YJ(,^
M;H>O\MU"=HUIQ4]$_XZ567EI;4T<6!NE6>D-DCB?EV;D@S37<CU7FNZ6D`S0
M*!Q0[O5>>.5)4IX$"(70!S7?"7UEJ(:FJ'PF\GE?%3%1WTJ$6)@50>"9_OW:
M\;O3;]:\]0GK]1F4L@5F!][F0?5ED''K;'[-!<K2;-@P9VZ:9!Q;;&9KLC9;
MN$9AN+[392[4'3C4J=*;,Z)-33%G2MD;N3ULS-B"!/-A2N7'(8['F&('AY:?
MAC9=85"Y/'Z#=ZCB&B"'Y?0?.W@#A[;=UNT!F`*->WA`.\`&TK4#4.75P*5M
M.=9H.XZIEZO4(`K.?EB'=3S<E#85\]S6@)RS1NL&6K@-Q<$-2)@%.6.T6?^@
MLDFXR*E+B*F[[BJK5DU.*UD`4+!SUX4DZNT]R4D@23E;[TDHY5,^A/=.Y?/U
M5_M6WZE67ZJV:CR\PZL<441XY$D@A;:N&61^ZV#^9O<;VYH=M_,S<&U.YK?>
MY=<T<`BG</?3YKXV:Y\Q:U_NYG$K:[T&9@<GYI018(8#\08'F0IG<1:_\!=V
M&@U?<19?";%(B\+>E`!,5,B(*KW9,6]$HS(8,M/8VQ&``R*_U!Z@A\S>;'^P
MAM(=5LH=5M&N8AZPP"`R!M(MUM5VLM;>P)AZP#6V7"F7<B>.XS_A;8Y^N83V
M!WL(:9FZW+H\[O*<,H"LY,2!A%BH#XE@.TF8E7+_A83;B@6"H`6&Q2-9F(AP
MX(=OB)Q72`0MTU;J123(VL^4-,GU_F27%.63C(7/(02>#$*E1LF8-&5]-5\*
M=657UF\0E4K^AKSX?;5%%H0PL-,5'MMO7@DT&-3U0^NOCFL4'^L6^VO\/6L(
M-VO-"VNK(79?=NNGF?`:1^:'\\L2<VNW.';VZ5]>-G`'[F9C/VMM;IJ:Z68<
M;XD=4($SJN&Z#96^(;D:_C&[F=O*`(*`0[D$?`/F).+B!`UUV&SQHEQL6(=S
M,(=U,`<+-(81X('7[FQC*">2A@.%WN@GHX<$G&TO7@?4*W@L7<>,;MR-]NT9
M:/.][>-]*`<IEA\Z1^Z#_ZQD$-QS>(@%/\!!5!J$68&UA[PM_[".#"`$_'2$
M/B"%>F@F<=4R1I9>B`2T,(L=2#C715A"1GAZ`XW71)"%?`@U1@#*44\$I5YJ
MI^Y7KT]U_)[JCRA8BYEE/)R\:8K>W-A*!.=VIQ'F9\?FI['38!9F&9?[`Q]W
M!!?W$T^9%$=Q89[P9T=Q"R?KNJ_POR_-P&^:!,=FO!?Q]6,2KP9FKW;QLG9Q
MN!?Q]=%[.RVQ9_>8*-@!T1?]0R4Y'/M&2UDCJ_(QVM1A%#@XO17S?,=L,?%W
M.)[BYGPN*U?BU@ZH>ZA=?@SC+XXIVI[B=T`#&A`&(H^I>3#C7D1<DK[R('JY
M-_^X!W_X?9+GXS=`X]],^=<XY):^K5?`09$X24:8LUF(A9O'AS_H`'DH).A.
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M-NW:L_>]F5&GW^Q^>4;TF#=;'8\9QOSM$T:#AS!LY+`Y>]?/V`P>[/Q-KVYL
MG;'B;_;Y$S:#1@]CV:RAF=&#73_ES)UG,_9N7YX9-?(8RU-C^3OLPVJ\-T]N
MNTU7PPQO&&.-,=C8UJ"##T(8H803/M@-))-$,E2&0PUU83CP],$'(Y%@",DL
MX7P(#RV,=!-/((#@`TL&AFSXB(VTX`-('Y%T`\^'X<P"22P]HMA-+/#`H\TW
M\8032R,?<I.B+(HL0B2*VBPB"SZD9"`)DC]*DL@DW"`9)3Y0'K*(E^'$Y!),
M;;ID4YPWZ8333H7\44A/A/SA_],AD!#UB"!O>876%%+H555=A'*E&%I]P=75
M8UU!M=1A5O155U-=8$4I8$XU.FFD:/G5F%ZB`B;76H5.T=5=CN'%E%IJ1<K7
M8U9,$86NN^[0&FFOD0;::\..MH()G1$KK`DM3$.A/F^,\%UOOP4WG('#S#9/
M'CS0T&T-/3`XS`@U7.?/.V_0\"T:N;UA3WC5O5&#@>J1TT\_]`C#K8$`6N-/
M.6CLRX,=//#0GS_JI*>>.M!*FUP/\\X@#'@44ERQQ19;2")1-=HH9)(:_+'Q
M(Y.@&,L?VL!S,CY_`)*/C(0$VC$M\6S01X^T'/+'-N%(T@T^LOS11Q]_P!,/
M('^0$O^/-GYP@\_2@<"SC1^PX,--T"B3\LJ6&_@HB1^"1/T'-_$`#<@V_<#2
M"XA3Q\A''R^]"2>=-=5DYYUYYJFG3Q<N)$D2:'SE51=YX.%775N%%7BKAI/U
M*N.),EYH4U.TRA0T\PQ#JN%9!:YIX'*-2E46C:G*6&.5:GYX4Z?[!1?K43F%
MQ0Z5Z:!KKZRIYNL*P'Z&K*^MG;`[:;ZW9@8_%/8S3!W#\(:=-74(<T^V>=3!
MX&SV8".,'78(8XUPV-21AW"SM6,,]^64PSUXXO50CC5YV#&,=+39D\TPVW<O
M7#_J:"^,.>?D07R]*0?\C(&Y.ABC>?W(AO;.U[R+03""$<S_F,AL9$$A.>TB
M1(&$B?!!BT#T`1;Q$(0NXO&'#FPI`R'CF,]TA*)7]"$0VH@'*9+$!S[\X1"!
MB,<V-@"R<'QC`V,#1`;Z@+(-;`,>?LB`'UZA-!B10A#RD`4?0(8R0/BH#T6$
MA3P$@45`:(!,DF#BFV`2-[G9I$YWTM.=?+*("UT(##V(7!7V<`]UO*Y4>HR<
MX?+(1ZAT@0U=0$HV^N$,/OKQCXY*I")AQ[A&K:Z/?_0C9790NRCH8`>^^U5I
M0B,L7P4+E*<1C;),``1S/%!"]DKE*A]HKP;QYI6TD>4L%2A+80!G?JFL32MM
M0TM:UA([P.S-+B5HS&-&J!L5M*`%_TD$CUYL(!$;A`0M^@&/<2`)'K#0Q<I0
M"`L-T,A&&8)$"_N`CS-](T7:<(<@+@*)D55-`WYPQ(?ZD,0^:``1/A/$-KXA
M3T5$(FJ`J,<VX3%&/RA"2]HXAS:*F`@M"8(/S]Q`.+B!ST*@I"5R0^--9++&
M/>$I)XM8"$-T,3H^#H,?ZA@D)+TB&,JU:G&,Z=SDIH*Z2K44&N_0@U(8=,C4
MT;2F8.%C4(7*R#0T,JE*-1QEJD"$VNE`!\,B9;(^0\I@A;*JK2E&,9'IU0>Q
MSV!?'2M9RWHQ99)(G&JU8(\`,8B-=1`6?0`$($"8-)81-`-O9>8C<+0!/\"#
M&W2M*UWE0?\*/DB3$;'@H3QC@:(-]"(>^)R$SV0HC@W\01%'T@8@#,M-(B)"
M$=J(49(R0(B'XD,0&4`9V&#A-C.VZ4UIE(G=/@K2G"!B(1P4A&&:@E2_,"\=
M:KA"'48'!S@D10W'W=0<.+7<NCP7NH-$2A>0FP8X&)=3JCKN=*]PAWGPPQC8
MS88_G)$%[L9T"M6%0W<%>04VL.$*U0WD6KI0!^C"8;CR;</JZM`%_2XU<K^E
ME%('S+A*1J$*M9/![QK<R6)M)GBX4PVRE#4:+HS/K!H.SPAXT(X-@SC$9>4'
M6CG&04<0Q1&S8-(K)C&RA7S,#X/XPQ\JZTW37FB<Y,1'!VP&CYK__6$0?O#2
M-P(Q(D9,(K#RA$0]2XC/*N$C$((XAR`&T0B?P0(0\\@R/'2A@4$D&1Z!2.)?
MQY3:+ETS9?)D"9LWVE&ZS6V->MN3-$DJ"3`TDGGJN((PWN$,[Z4C#W<HQSS\
MO)5GS,,9TBBT,>Z`C4)#`PY6&,8\KH$4/+S#'&S(@Y^C8X]RW`$I<'!&.^XQ
M#VS<`0[KX,T]WH$'\EK#&N^PQS7NT*IA9&,>\\B&'JX`AW?8S\_#,,<[YK$.
M/60A#='Y\SSND8U03\,>/[W#.]2!7$0*V,`&-EP:`!S@+&!F5SI@L&M(2;SA
MI0986*5J)YDE8K-B(W[T>#>]ZWW6C7$L_Q8ICH2)H-2-;C2I1]OXMS)]QC)Z
MR.@/DX`C)%A4#QT=Z1L##T<W(`*/;W#CW['`QS9`%HEZSC!$4`X$$I,$)3]H
MF4LHTP;`M3E7>(A#&V32AVHE$8Y^')8/&&USF]T\VY^WL2="(<I"OG!2-'`;
M*7I6@S/Z88]W2*?5ZHAZ'J8`#7\46AW]N$<ZWI$.>V4N@>N(+QY,S09A\,/4
MZW!7-K*@AFOTXQW0T+HZ\.",>_3#')&^AC^>G@Z\MWT8K?XSU^%P!WO80]?.
M@$8V"'^/PEFC'_-(QS6T7HXV!!>YSO!'V[<-%6\'..E_1.JVK5#)J-;N!L3Z
M'2>INAK6KV"3OO\R@S[L_=6NVC[WNO='B9D9"10[0IR0>`4I2*$-;<`"H[,X
M/BE@,0A8=,,/&^C&&`G!-PZ:J!M"BT0L:'%\6+SBM+'8IC9>4>-O^H%'VM@`
M*;2O@2Q%OTO;!+\?-`"(;@0B`X%8OBY@(0E\^D$L')\@S`P1$4+3$-';\-P9
MT59.T$EMZ010],1($1TIS-%OI8$5D!Y4Z)D5--T\W$$=I(._S`$<E$,_6$,:
M],L[W`$;D!<+J@&#9,,5.`,_E,,53$'9S4,;Y,$^W,,PI$$>W,,]W$$/LJ!\
M%9(UL,'794X:D)<ZU($:I-1.J0,((@4T)$\7V,,"A9H:)!L<D!<TH,'_"MH:
MM24/'+2#/>3!%9P@$%[!;P&8YUW!&D`%!O+1!C).&B`=(B$85*F>54T8:ZS&
M5>4.5KG&:)S2[BGB(C+B!,5,,Z$8OO&;(@Q"B`C-GT""'UCB'S1"T#""(?!!
M;G'0PF&((_1!^A%%T+B-'R3"(R2")@I-(A0"#D4"(R`"'_C!(FAB(S2"+B+6
M*X8(+BJ"(OP!'QP"(PC9#>%0(B1")?*!+H@9FEF4"B7"2[@91\&9;;D1AI"(
M)'2!@6D@4FS@%"Q=2JT#(947#CZ#/UC:U8GA%5S=-=R:2DFA/YSC%>C!/KQ#
M%P27&E1!%[P#/^C!-/2#-"#5%#Q#/Y3#K_E&_ZN0ES-03AW,FC-L83JLPSKT
M1ZTE7M6E`1LX0SFP@_1@PQ5(@S]8@SA>W2'!G3-0VSM(VA5X6TPR3GR]H3B2
M'AS6I#@B!1W6(4S6)%(EFQ7,CB5A4A3\H6E8V.J-A@G$GE*>&VH40R-*Y512
M)6V0F"2J%1R18HYAWR@"BB/P(O`Y0O"-I8OYWB,0A#C5HD,PDR,L0B.,)5@^
M!%B^I5N.U%MZQ%OV(C/B92(@0EXR(TN`1,9)`IE8E-G@@R3<D"'XY4G`ED8]
MX`/232$8PAHA`KY-`I[5Q09*11Q>P=(ET`U>`7D9`PYN7MM=G35(1;]@`U/H
M&1L<QPT&H>3!01[PP__8K8MTY$%)GB12,<\Z`&1R$)(A(06U[8,S^&`V9$,Y
M*.<P>(&IV5H=T-W<<1X\^@,T9*`*7N<5"&$YW!TV"(87_E:R^:07VJ0X)IM@
MW"0>2@4&XF%.DB>`51)1ZH`**.54.=AH!`\AXJ<)@(%L5&6`"FCN*1,W<LS"
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M(?9.((Z2:1A+N;W`U0WHJ:(JB)78(SX"'"5H@RZ<5@X%AISE(U2H6A&=[]7(
MK<9EKW;HAP+KAWI$+PXK8';$(B!"B8;))!3C#<F32`"@(6248T*FSTEF3E3F
M3AA"(^0J*4R7&@#E7R`JI2K=_F1!;$(JD=)@=?8+-,SAU8WD9UJI&GS7/D"'
M=+@#'.B!/[!#?#&D'A@G-.3!W:EI%N1I.63.0PX7_[4))!:JPS#@@3!DCIN"
MX)2J0Q[HP8=E@W;>@S3D0>2Q(%,DD)7"`:2ZG1=6:GR6)Z'^1:7Z)*)"JKCJ
MEZ&&ZZ)NIJ94:A4,Y>Q$E7T"RPE(&%.>`&C\2E;YBN^81AFXBP3A7JHZK8"N
MZH%J):!,[58VTX-*:(1R(]:*DXN-I:V6I89.0E@&:]F*Z$?DY20$)C.ZQ)Y(
M:R(H@A_\@22L!$L8`F3&3=U<*V7RK4Y08-^$0<S:))OFI'[UXW&TW6@2I[*Q
M*SLB!9W*ZSFJ@37PP]9E0SN\P]GQ`SL@59;Z!CY*Q]:]PS"L01H(GN3=02']
MU)GB`1M<PSWXX-/=P1R8FO\>3(&J^:`ZC.#&7EVAX=T[Y`&A?I<_/$-.ZB0>
M@MYZ`MC,ON>/QBRD0B]2L*RC7H&N9-(0+%@*E)M5\:>Q#&W1LE[K!8$Y0-`^
ML`/ZH$\5?M4[8$.Y/.W[(E.!<DS';"6#OJINK177\E4DXML[Z2^)A"V&"O!#
M`&M'@"BQ]B*QJJV8?(28L,0"Y]8A!&:R4C";]5RUOAF-!H6V4N8?Y);&Q,(7
MO$&/DEZRP2SA(M4=.,,>I($*YP&DZ@%+%J<S!"\>/$/A7('=]5H+&\,>#!<;
M[($SZ$%M#@.]"G%G!C$=M,H=#(,S#,,=8.#`#D,;V!T4^]HP/$-\J0%^.#$>
MK`'_&SS#3WG7,$`L'!B#'DSN=:KP$__6%'P7$8HCN"HJ3KIL>@JNR?KDZ$"O
M?CGOZ@`EN;ZA?%I296"2#A`/[W!JZPEB)[W>9Z0`,400-J`!MW1+#R#(O!F3
M;]"`1,)O)T<0B0%*H&1(ABCH_2JHBVW(A$;HOHVE*$>HK8*MK\IRV0IK`@-F
M(I`H+N=RB=9M+U-K&3&@FP7%!A]"MF(4OCD"*;#LRT)ON((KFU).'2;JHLH4
MY="A3*T%4_"DH#8&I'9.-/M%!OH%Z#G%MH'SY`R8&J3F%$!JJW1;ZO:#I<'D
M38Z.R_(Q3)HPS+HL3,[L2:G!/O^S'#]S9Z[L%0RR):4>_^\TF(5Q$N^,:KG%
M1@0Y@WV\01W4`1JDBS`T[81H\AMDF">#-(6L*E_5[]0RW,+E;]8R$X8ZZ-62
M](7:ZJ_*Y=@&JP$7:UZ^)2\C:XGZ98F:1`6OQ"\SX!G5#67Z1-_.!(IQHR"$
M`3,_JAX_[\DZ]3,?+PD/US9++PEG-3]'+U739'G.(:2Z;,Q6*J&R:?1NX&^M
M@7ZM]3_WZ-OY@T'^9`L'Y#K4P13P\0E++_4V\[C"+#^#-?02-%7;,UGO<_6B
M'B;EP`V$ANR]QB$?[5(>,BDQR_%<3';4P`GV`SO8@7J0;S!5S*F)%8AM=$BK
M*J"8Y8-N4$ESHZSRU?RJ]N\YPO^%O#(D]BJ&:FB&TK(M([!'J*W:CE2RDN@#
M)^M)^*4O3^NT<M0#!D6V5J8A+`*^2<(8J.P\]S6B4C4]=UMZ/G,S-P5/KG7I
MHC5-+J]8]^CG!78@@_5YL^S,@FL^.^IPX?5Y?J;]]+5WJ4.MM?<<RS&;$BI\
MW[?RPC<^__58+ZK@JH%08FI4W<`+,&52-G0@<J_P/'9H**T$64.ZY.EL8,-^
M]`MVG$,V8(,Y3`QML`,V9(-TB#C>E<.(\P;[GD/<*>?X`-NCV<8]M/CE-L^I
MG>"N8</\T,8^J(-RLD.)F_98]1[6EC2_K3+7JK+^NO2&X+:%CLR%YO;8>FBP
MABBQIJW_F'AY3T\P2ASW<2?W!4.FG.BM3CQW(0!4AC@"(^A"MUTW&ERW>?\S
M!G:W/N?S7A_V'.YD>::U">=S?-%A?[?G/K-!G7MW=Q>T0!?X?W>;6;/!'9BU
MVYUP,WNA";^W>C\SG9?UH)KW'@/Z7ILP@2LXS_9LA>7.?4X8:)@&[IB`$'RV
M1*?+.F"'/V!#=102O@#,MW`:=NR#,?0Z@@!,F$)+'>Q#@>!'K]?!.I`#NM3`
M&VQX/Y##P*0+&A@#>&`##;R!-<3+MU@#>,2=,#Q,#:"!]1PYDHL,D].OJ](V
ME+\R;$,H;+<T;L?E0HSEA\ZTV28PB.XRF#^PB4HP4/<RSV'P_YQ(9C%G*R)$
MXLB00J-Z.H#G,T`'-('+^1Y7?%:K0>F*MUB[=:1;-:.O`4_>.<A'^E6+M1V;
MK%G[MWMW=:5Z]\4_KZ)O]W53JD!7^D#+N76+9WR+]5G+?%HLN"7E@/8V=(2Y
MQJMG%5,"(FD00VE'B#%H>#_L@UWKQCS0A[D+@[#/@!W0PW1PRQO8P1OP@+R4
M`VZ,P&[X@S%\"P^\`=G3`!I8,MS7P;RM`[H@T+;40.1EPW+T0`_400]4!X/0
MQPR@@3`(0QUL>+I_E?RR*K]='X*Z=&VG<JU:?FW;^RQG.;#>-$Z3Z+][^2X7
M?-U:8]P$<YRDT7,?0O`1G20T=<FO_/_)EKRFC[I@YWFDEC6XLO5>^S=@7[R@
M(Q4=BC>AZKX]\[Z<E[Q;N_7*8O?)PWSO^R0)"_;/P_ZEPRRYWKEYZGX>>SP_
MIVRH;W_I%D%4X0!]:M7W+N7K?1+W'J()1+0Q60-%VT'@NSTJ80,/H(%FE\/#
MI'ANV,$\`$2_=V]FU"BW[\V(.OWZ&:M10]B\><)JT'CSCIXP&CW*]<M#PPX]
M?PTMTLM6\<VZ>]AZS,@C,*&Q>_[T[?-W$V=.G3MY]O3Y$VA0H3B[08IT].BC
M1T<A38+4M*G22$J74GTT::I5J5JO6LVJU=$C1V,GC6UD=M)91XW8MF6[Z"W<
M1HLFT5V4"&__WKR')B%*A`AP8$2'!A<F?`AQXL2%"B$>=*B0H<B-8AF--&F,
MFC2;-ZO)TMDS9S6CLXQ6<T7SZ,V?27-.8QJUYBMK9H]&'?O*%="I.Z>A39OS
MFC2Z;\M6W;FXY]2Q39]V_CJW<^6IJ9.FGJ8T]M>OCW/?WIJ[ZN:I2]M^#AJ[
M9MI7=NAP__X&"ODFY*,P86(%??KV\9^P7Q]`_^KSSX5IAO+)&1H4G(%!'JSI
M9Q]A9G@C&W*RP08-&HS!YB%L;B+)((1HJ,,F8V;HX9R;S'GH07_6X6$&;.8A
M2)ARLLG&H1[,.8F&!_NY)R$2Z2'HC6O>.1#)))5<$JBBF,IJ*JBP_T+*JZJF
MNO*KH["2"LNEDJ)J2Z7(&HM,M=PZ4Y%%&'F+K33O6N3-N_SRZR_![)P3,<`4
MVQ.RQAAKK$]#%$'J*5VB,V^Z\KXKKSS4LF#.M,X8%4^YWJ:8PK77[KB#C=C*
MLVT-Z89C8U,XQN/-M.S,\RX\3T6#3;S7/E4UN_`432]2[S3KK;OCR%,T5^M&
MM>*]'7+0(0H5^/N/V?D`=%:_9>\+L`R;F+S)Q!J,*><9@GI@YYXZ9J"A!AYX
MJ&@&823LX<B;K"GHH"!+W&B>F]0YUT-_U&D)&W-Z(-=<=`WB,=]]ZACAC7WZ
ML::(@MXPQIYK)9Z8XIR<O`Q*+YURBDHOO_^J:DLH.\;*$2TO\])CK2Z;Y*HQ
MQQ3+K$?.9&2MN1BABY&F;IXDY[H2X?FJ1.!4<VBA;\9+$47P8D2O1)C."Q%%
MICR*E"W0\)52])K[;KS=PD,U5N[P>.899YS10S,XWGD'C^\V0PTXV-B0YAU[
MG-EU:^YTHU0VO8-M[M-4>?/Z:UR_%A9560>?#FM;#U=UBO=D<$\&99\%<+_]
M+M^\OON`,(?B=WDH9Z1L8!R&'CLF5)?U8;(9YL1V%X87(85*K*&'>O4]UQI[
M^5VG)3M85]>8=[)1T$,(#WYCIG[*$:8E;?NIF/KJ#^S&Y$FPFAHIC+WG/BFD
MN`??^^Y--A]]\;O_)U_\J3=^2GNHI-3^?:?FC__^^>&WW[+N)0EC<,)AG.(B
M=2K`F>8-AV/5=;IP#7[TPQX_RL8<YC"/?>AA-Z2Y`AOP<`?5.*,?\[@&VL3#
M!@.>T#2=4DT"6U.=P`G.@*P9#0M16*G$N;"&@N-.J*)PK/?H0`8IZ-Q]!#2M
MS$7+B,V*%@J(,;V).:,@ZQA)N&90AXE4D1X,R8DURI4O?\"N!N9`2!45EJ-Z
M]>-%->A=/_:EQH',P!A._)`_R*&@WOG#8!.RUDC>(:XWB,1Z@12D3BYV/D-N
M+WWN2]\B$[E(1#*R?)&(A2/U%S]+\J]^F6Q*_:2T2?K%KWN0B,4N<D@=_Q/J
M"H8U5!4*7W,-?V1##\-PAS^<`8=YW",/W0G/,^RVF36LHQ_#:-5P8C,<79YF
M-WLSH`D+6$IGKM*9T<Q@UZ[0PQ].+@5"S&8V4;"";:K@!-X,YS93,,YP;HX+
M[:C8NPSRH76QPW00><<]]C&/=_2#'?]Z0SGND8TWD$N,!+$#0QR"!MW=BP?Y
MRB<-L!&AC<CH'O9X1[VP@;R;Y#%A]UB'!3TR(4`.$J36*\I32&H42#R"I"AE
MBDE1^I25FC02+CTI26,:)9:FU#(E;>E,8RK3I>BTIS'=*<?.A[(G!55[Z8/I
M40FEI4>>]!&D*"!WKM8&`Q:NF=4YW`U-$ZHU>/_(&I@:!AKO<$NTM>$.>;C#
M'$9S!]+!\@[#N.<S[B"<-N!!#W=HPVO8H(<YK.$.<+B#'MA`A[R.QK!UG4UX
MOE9,OC$VJUD38&JN5DJL=HUOD;I"Y-Z3@V.1`1K3$.UH25M:TY8V#-.R3PNF
M(4>)0;&=-^&0&O<QC!K,``UO>`,:0M*0<_5@M_\*$4%(Y`]C;`20YV"1[V;0
MNSX6)+=OZ,$S7EF1@BUO'^O(K1WJ\)`XAA2\U`O'+,A;7O.>%[WI5>]ZV=M>
M][XW%I*0[WQ?45_[WO<5\JVO)/#;7__FE[_\M2\IPD";T82JAEL]H8*[ZIM3
MY68-KK3&9O;`CW7H89[_>("#D>YQCW<,0PW9F!X$C302@=P!#]FP!SW+<8<T
MY&$>V+#&/9YACG<XXQWU'(9<0^B,R483R*=BL)!1B&`@LR%RQ_)L#G8`#>KM
M(QB=.T&UJ&<-'G`$)^=X`P_&:@]KU*$'YGI8Q.YAC2WWP!@2X@$PNSM0X_+@
M#;IC!QIZH%`T)/0F'][RE>N`C7Z8#L]XM,.(ZIF'._.@#M;88W@9S21\/!K2
MD9;TI"E=:4M?&M.9UC0^X#&&('SZ")_>0A?"T`53FUH,IS;U&$I]:C&4NM6P
M/G6K2=T%,;S:U./YL9&#[$P%KP'8;&CM-:[0!A%/T*QPL(8UA@$-#^MA#^KP
M_X<YSN:,>_QY&!C^\S,ZLHXYY($?*U[',-(1PFP`4R#9Z,@]2)A#7O>ZJ_`^
MU8^=N88>+MFS0P!=Q?01C,Q]KGKV6`<[Y"@0=>CN1^Q@QT0+3H^UU1:W[1`(
M.^8Q/7LLW(EH!->'WL&.B'UH'NPX!T8NJO"/AQ#C(PEY.S[::)>_'.:!9$@_
MA(&#&^0`",?:P6]`U:FO(3@VH0H/L"'<*30`&\'`%O*[#<AT7;O;P5V-3H0%
M<HV.S$,/MN0'!M7`AC;HH=S/2(,KI:&9.4@1@]?X\U[G\`Y^G(TAT(##&MCA
MCVL`]DC78$,=I.V,'<;[P/)N>M(%'V3A7$$'^,[!#?^ZH#N*0=E9Q&BT%G_R
M#FQ@A![6:,E+3*P3US*:\C$7/5`^OQ/7EMXGGP]]3U#_H=6;_O2M]X<U\'V#
M&^R@V)II`S/5X-49!GLV1N9.&][`!I[/V\C"47X-X>";H4.=\+V/-[#;$&%_
MW,.>L%2#%2^HACQD8Z(V$;N$A=/VK:M!'?T0>QK8\*!K[*&>=.A]^O>0!C>D
M7YC6OT;4:VA5Z=?;-*PJ^D[(Z1+LW8H-V*9`\19/&/CAR?S-/M)I]'C"&*ZL
M!\*,!N!`VB:0`SLP*/:HX'!BT2`D]7*"!'$B]$+PHCP/!2G/!4'0!&7O';#@
M!F1@!VX.!V*C#>*`#;QN[M;_``ZJ#]A^D/K>H`V$$`A[C_B0S@V0+@X&,.F0
M;MYZ3PK_;S2.<#2.+O"DSS>4[C1^PT.R@0X\R.PL2`_TP(*N`<=H:>P6)E3N
MH-S0)OV<H3:<[!KR8!_>P83:X)Z$B0WPSS=::\("3^E\C^F4SO\,$<'\#_"H
ML*L,D0JC\/\*4?JBT/D4L/9TP,D>T`1.(`4,Q`,_I!P,[0(?INY"$153D1R2
MX1B2P15=L15?D15G419ID15C$19?,19741=S419;$1=ED1S$@1C%81B'L1C)
MX1B)41F-L1B3@1F3X0AL``9:``9LH`2*H`AX0!MWH`>*X!NY,1PO4!NC@`?H
M#!R__U$;JT`;IV`;BP`-M)$;K2#J!O`*KS`1><W(K(H1!7#Y?"_PC*_W#&00
M3:."[$$/7.GNUB`;V-!#[NX*VLXCU$#M].X*X&`=:NLEVH&M^#"8UF`.2"?_
MU&X0#_'=J@_Y)G$?K=`*UX`13;(255(FD2X-$F_);@X+4H1Z^,'?3*`,\B$5
M+\KA;DGV@M(H0<\7/D`IEY(IF](IGW(I00`$H-(#H-(JES($/L`'MA($N-(K
M?:`KP?(KPU(LN5(J/T`JIY($LA(M22`MW3(MI=(M/P`N06`NEY($Z)(NSQ(N
M28`'I+`0[1'P*)$1GXX2)=$1VT#"7F,-3*B"\D$/I$%?AO_A&6;"[YXAA*YA
M4^X)@V"L'Z[A&;*!']2!#BKL'?;*(X>A,:7(#TDR,!UQ"_/1J[PP^ISN,)LC
M$;<P)FMS"UUR-A!O\6Z2#&:">OK!WP#N*$TP.9<3YI+R*IOR+)]3.J>3.I4R
M+:MS*JO3.JWS.K7S*DN@!ZZP"]4`"7T/)6GSP"BQ$OO1$5^3'Z^A'L1."N?`
M'=CM#M0!^\I!)<2.#H#I'H9A#N*PV*)M'^QA'[*A;?3`'MIA#_$3Q."@(T:2
M'ZRA$E_3)9%N-B.Q0C-40RWT)<D3-@6P/6=3^3)4Z:I`\6(@!XK!>G@2!8*A
M*)E31F>T.)W3.V]T.JM21ZOR`SS_P$=_]$<GP$<G0$A!P`,@8$@A0$F/%`*(
M%`(>@$F;=`(>X$FG=`*4M$F;]`&F]$FW=$H?`$R[%$S']`$<P`'&]$S-5$F9
ML@2,D"4W=/HP5!*]T/\*TT*[Z@[V@`X(\PSK`"3/<*T."["@K0[Z*@_FP.N`
M$-KT0`Y"90[V(`^$,);^JJ_V@*U(14\Y5#T?$2!GTX1H$U1W\Q[;<T15\D[5
M<P=45$4]JPI(IWKZP0RV0!YHE%9KU7KZ81>@4SNSDRFC,RJIDT>!=$B'E$B)
M=$NU5$PE@$S3E%G-U$P;`%JC-5H5H`$4@`$4(`$4`%NQ-0&Z-0$0X%L10%S%
M=0`0H``0_V``"D!=TU5=U?4!F+((-!0+#Y/P`A,PJQ!$\S54,=2JNK`0?4GI
M`+8+12-4@N_`4&,\2U0?)PO!&!-#.S0]IZ\W%1$Q.10E"5%.1_0?*S02K2`X
M;2\&&,_Q*J8?B&$3;15E4W9);%17J9-7T?)78]8J=Y1F@[18;W9,N91,E[59
MG]5GI15:$Z!:$^!:O=5HQS5<QU5<S[5=U54`VC4`!@`"HK((I+`PZU1.LU9K
M79(?^1%#/[4Q/75KY=3XQC9KR_9LS79L(U%.^5%?J:\\,U9KT394NM9KU19O
M@>W>5C4'8J`8'+!Z]J$<1E9E"]=P8<\YX])7H;([GY-77Y8I@_^U1X6U6(G5
M22,`<R-@9]$43'O6`1K@<S\7:*NU`;K56HW66QL`7)-6:0W``,S5`)HV``*@
M`&:W`"8`+Z^F;=E6;7E70WDW:X$W;X>7>$&U>-=6"*FP/.D6;[$P/<U6>+56
M#6Y0!U3U!H:@(67N<+>7>UW/1A?W*B%W.L6W*76T1R<72&^V6#,W`KYT<\VT
M3)U5?D57=*55:+<5=5<W:5E77%W7?YNV=M4U`!*`1S^@!/@58DFT>)_W>!O8
M@1\8>I5W=Q\8:^T5@M?`"F[.]C18##ZN>S\8A">F'X!!9EW6.\E7*<U76(G5
M`]1W`MAW<WDV?D,W6NMW6H5V:+.56[G_55SY%P%<MW]=%X!IMW9GEP'@-1*/
M\&[--FX?%@F;6&N/D'BA&.FJCWFWEHH=N&O95GCCUHMG$PFCMSQWSVRC8(-!
M]@:*(49#F(W;V/-(&$<?URI16'S-%WW3UX79]TN_5%G+U(\E8'Z?=72A=8>)
MUEO!M8<366E_V'^%>(B+N`".>"FK%MB>T"7)D_K:-FN;D%\YV:NJ;XSS-HLS
MF92S]HFC.-B$\)2#;6RW&)1-^8+7P`U&&8OY-0T6[XQC8`>DR(U[V9=[@F5Q
M5)B?TD?O&(];V$G!U$HS]WW/U(_G%W2EE5JGF0$8@&BY]9`1>9%_&'9_N`!B
M5W8#V'8=('?G__5"5?F++[2*25F5U?F5U=F=UYF=,[F=VWF>[1F?VS:=SWF>
MXYF?X1F=^YF>^=6=[1ENV;D*SMCV4J`,//B7'[J7^R&8AWE79]:8A12C77A+
M8]B9.W>&!=F&I5E;\1>;L_E;??AU'9F(5YIVB;B`2P`-E#B4X5:*"_J@/SF@
MS[F>GSBG09FG+[FG03E1=9J>A="3N;:F:YIK;3JH;UJI?7J@:?J5GYJFY=FJ
M;O`&0C9D;^!D(=JKV1A7G7(J7W8KR_H'?D`KXQAF(W<I@W58D5E](T`"F'E,
M*6!*G=D!`#F0HSFDK96DCW9U#\"'#R"E_S><BWAVH[:`JW:JT3FIB?]ZEOFU
ML0_:IY4XE2N[LN,9LY?ZG8NZBJ>:J3F;GZNO"4'["$O;M$U[M`-:E1,UM=]9
MBH_P"A3:!FX`"]3IJW,[A'T!A9?R!U91',Z!%WU!'";Z1MUZA8/4<J<4ACO7
M!\1A%Y[YHWTVI*N5`:J56JT9=;-9FX.XD<$9:A$;L0%`DI6R"&1ZLCG;ZUXY
M"-<;JJ'ZGV.;LY.ZL4$;J1L["!_;LO?[M-\;J>=[H-L@"%URP%=[ON4[LQ'\
MO?>;P!U[#;!:H8-!'W2;PK<70HR[*<\Z!)!`'GR!`CB``^`!&*B4HE.8K=,7
MKJ^T6)LT`B@@"2@@`D*@%Y!`:#MWKVG8AOW_&EN#UG2]5;"[=9M?]UP-NP`$
MX&EM%P"*V,@9@$=)(*;1&\JC',J1>NYF&<K=>\K16Z>E7*BY7,H!/+;Y&[.U
M/,J5T,L7W,OO^\S#7+:S&HUOH`K(H<+GW'#MP1<*^"H]P`?P`0G(FP+(`1@*
M@)Q+W,23NX537,65.0GDP0?.-`(<H`!`%Z^A69"!]EJO>[N!W(?[=VD9&8#%
MV783&P`"X%V5L@3(4XE=.\I=L@FQ'+U1>\VEW-45/,W=(+]C';UG/=73G,O7
M6\UW?=7)_-:#';VG8*NW6@7*H.7HG-EI5**K\P?F(0D`0,_/X1B08!>2(0E\
M&QB2`1BVW0>^/0F._R$)?*$5?<$'/N`'Q/T8R+U'06#=CZ$7?F`"0@`8=N%*
M?>`8?@`)R*$?Q$$7.&`7=@%:?6`7>J$7DB!^^7J0L7N'2_>03QK(@UQ='?FP
M$QOC`T``(&"LA8#-:WW,95J6=9W6<=WDA9#D3U[E9=K*CS#E1=[EKQSF9[X-
M8!T.W&"VW5SGN[K9>YXYGYTZ?T`>^ES/Y8$<="$)DJ$=T#H)`!T8@($<DN"Y
MY4$<@.$'=B$)=J'JU=WH$QX8VB$)(.`'Q"'A>R'J0T`<C@%T]SP).*`7^!P)
M."#M%^"YM1T)D$#2G5721]=:,3W35U>1Q_5U"8"PO_G36QKQ11T!/"`MS_^[
MY;G\\1^?S$_^Y5?>\L^<#23_S'_]\OL[UI':#68Y56.`]+6Z"Y;=YU,_*(%^
M.G^`'I"@`"#`!\XA&12@`#R`''IA`;S]`P:@`=H=[<^!`Q@``924`8!A'!:`
M`^0A&1K`]X]!'#B@W2$``!*@%Y)![GLA`!C`!X8^`!9]`0I@]WOA`*!?`M85
M`?:>AOF^:/%WNP._TY?VT\49L44=XQD?!&`Z]&L>O>/`\VL>(-RT&4BPC1N!
M!@DB''B0X4*'!1LF+$@P3L0V<@9:M*B18L>+`A]2E*CPHD&$(4MZE!A2)$.#
M'%\R3(,CALT8+V+<*.:OI\^?0(,*'4JTJ-&C2)/_*EW*M*G3IU"5]O/UH:K5
MJUA_T$L"`(*/=L`*(/`@+AD'>,EV)=DE#AX'<;T"))CP`]BQ<_@X<)#'=0"$
M)/*0C$NVEJW;9'$=_,"'!`!@#@,HP.5P#DD`!`XR.V@@07.#S0U"-V"@@'0#
M!0E2JTZ`@#5K!+!C(R@@EK;MVP$"%,C-NW<`!A2JEAB9$.5$AQQC&D_I4:7"
MA0LM-G39O$U,Z<P%;J2.\J%(Z,[9G'3HTDW,\=:KJXQB\T;[%%S:19U/O[[]
M^_CSZS_:;Q?6_U=IA<0`'OAP#C`',/!!63[(<\PNN_P"S"X+(!;``[Z0<TP2
MO<BC%U\`//`!8+N<<XPN_Q!"6&%<#/B`SRX`(.%A`10@QD$[2!20V0.:918:
M:*(IT$`"IZ&F`&JKN?;::[,U6<`!3]*FFY2[Z>9;;P=8-=Q!YC67G7H0O=2=
MF.B51]%YTHWD74'G1902E^B51!)S,M%Y7$LR7:3<G=.ID<--@!;3SWZ$%FKH
MH8@F2A15``*H%5<>?'"@`0Y\D(Q9XNRB6VL&2`!7`)(E`X$`CYVE*0,>`",.
M$IGJEL```R@`5P$)_!!8`$G@LP"-XFRS`#R[%,"``\-ZYB.0HA4YY)%)MH;`
M`4S&5MMLM^UF[96\`=`;!%85P:=U'!F74!S;%=<&&\N9.YV<)QE'+D-[(I11
MN/_I@0OO<62R&\>7<.())TSJFOM2N"AM5.]'!+$'J$U8O#.HHA!'+/'$%/O3
MCSZ,-IH57P5X)0\P`RA85@.[P(-$"#[\X$,(<`'`LC@4^)#,/CXL(,\Y>B5!
M#C`/[#(.$ARD[$//)G-P3#Y)!(`$8PNPW,L!)2<1M`\]'IMLLJ0AR4"SSLHF
M6VW5VF9EE=CF!@"!58&`QKL(*??F0!F1B>ZXV)TTM[WIMFN>=O6*^V9#!B=7
M)YSBJ6OP1.#Q3:ZX&Z'K;TC[_NLNWBG1Y-Y--^ST<,6<=^[YYTE=S*@/&EOU
M`SF-%;BSL)8FH\`"JEY*F`_B`"/`7Y?V`@PY>J'5RS'_M?N```6[7'K,AEX!
M?XRJEDUPS#B[R!R7!&P=L\TN57^F?;*E,6MDDJD=T+773H8]MI79II_;`%J^
ML2]&&BT.D41Q[QOY0=*]KW>7>W/9DO_VV@Z<XC8O['2)7.]B6TKFL+^#B`>!
M_X,?`-\%L`1:AV_^`UP$$5BNZ0A$!S=(`:!2@`5V@.Z$*$PAY_K1#V"4[C\_
M>```(J4RUOG`!Z\"@0\X0`$*A,8'%.C8!VZX@`9P(`&420(2*>``6CV@0'HI
M8@(>$`(.%)$"NVH`RA:@``Y(X#</D``/%X``[?E(`E<+3?>.A*35P"8UXY,6
MM:AEK3J6S3?:4A`(0%"""6[D_X\`S(@<^G5`Q'FP?PW\'Y?J=DA"OD]Q;%A<
M!A.9P?M-<I#M2D]&II-``1:')1=,R2,SZ(8T9`Y0.2'&YE3(RE:ZLCXL;.$+
M_^,!"$3*`QYXHE4@8,M:\@@"$_B`!RI5%0]TY@$/6`Q7&/``9MJ2ESP:S0,B
M`(%F,F!8G^'1UD*3`,UL34B?\=&/TDB:K9$&?*J)X[.F11LHB>T`O"%;;[35
MF]OM$01%(*5Y+*G/12YR<9+4)]LHZ3_[\5.?,,$?`@G:ST4RM*`'A6A#(1A0
M4NIM#3L0X0M":),MR.>5(`VI2$.7L5F:U"JD.^D';,45$=T2E[B<@`=D.H$)
M//$!-?]%9@1VBLPP[L@!/.I1.-.HQM,4*0%MA",<O286`R#```8H0%1I(X"J
M!D``=RR;`D+P`1+TX)\</*A!Q1I14@ZRH07=9UK5*E%_HO6M>^/G6>$:N<AI
M00YSA>M;IP`H%<1`!9H;J6`'2UC_6`4$*DWL+'V0!!^$2)@PI>E,:TK9G.(4
MF1*(0$]["M2@!G4SH$&6D(ZT+#>ZYHWD>RI4H7H;`13`JEC-JMER4P`1?:`$
M[MMG6#D8U]WVEJ(`U6LE(=@_@(95MW4-[D'RJL^\2M*2P37H;\.*5^:Z8:[&
M!6[DUH`#OZH@)S=001<^2MCRFE>%4TF;>A7+7@#5DIF0A>G_9">;4YM:5K.:
MW2PR'=`9S73&C&EDXY#`UQHF1>NIL%GM5&U3U=C*-GUC^0`?%;I;WB:WPA@F
M;D//.D@,0S3#&4:K=<$:T>=6&+DC)B6((Q<%P`(6)RK0`33.2^,:>RZ]AQVB
MQDK07I6^-+[RK:R0)X#?_.JW:J`5)U%/DX"M(54UJ"EP:A.\VK`U.`#PS"H]
M>8.JJN0S#G)8\761N^+C<GC,>%TNB3DXR`Z7^<1G'K.<VRQGWIX9@6%^,Y?B
MG&8PB]F4X0UO3EY`AGG8^-"(5M14]H@5Q)J4QSW&BDSE2VF:6IJRU;3I-"6P
MV<XBV6K(4N,:D=1&U*96P5%=L&ZP_QI;!V\96P`0@!YO^P8ZX'FW<TVSF\F5
MYS#WFM?,/7.;W9QG7J/YNAW&*Z_]S&P_#_O9>][SK<&L9CKW6MG)7BZ'K;W/
M7R][7QQN@PZ\"]@0$B$;B4ZWNO?CBTA%^C\IXZKI7OB#>I/NEL*4;"WI:U^<
MYM?(/`JXIT$[S@`+&*E)3>>!95/E:L$6C^I[-?LD#((>3!O,Q8Y<G)W-<8PS
M&]G51;:<M5UL;!\;V=_&^*_#//*0NYS8OC;VL;V-9_.D>>9H5C:S8X[M04[A
M!3FQB8N#L8]U&_WH4,'QN[&2C'8DP73D>#J`9$8.V?F"JY2.;&4?`$Q-`[S3
MGS56J$-33O_ON1&U2XV-4U4;MMU8]:H/#@``SN9N?#H[YLMF^;!!SG&\]WW.
MNM8V_GB.<?_UN>]Y=W:UJVMMQB->Y"'W>,PAC_.;=WSG$)2#*8'NW1B@8`LF
M1+KH1W^4?62,T>M5[`_.`98$5"4)\_`%VOYSCF10@`.[P$<2>JGU(5_6IE\?
M.%"1_*-07Y-9I25P;*(%U:>V_;5O+]O<>U-;+77<USIW.>01C_V[[YWQ(.<[
MX4%N[>L3'ON0__YRS0_MZW)?UX&_N>-53G^5KT$'0!=Z>&T0#=+[__]`T1^-
MUBCR]D*_4#OBL``T!"+NAA4[\RI.,Q=`-@$A$`*5E6D4@$P9F('_G.53PQ=-
M:#0:#E!$HL89HO9DIC5ES>=\4W4^\G1'T]<`6I(&C.=XV`=^X$=^-EAX-=B#
M/EA_DE>#)-=S>J>#/EB#U-9]BM=F=X=F/#AS-CAS3?AS^>=7.5%H`)B%_U=2
M&O,#A+$+59<$=9$,P/`#5E$6/V`R"F(KNX`$QY`,)64@R8``"G(I'-`+27`\
M*_4[:>$#$^`5Q;,A$T(!P+`6QX`$N_"&T0,<O:`6QP,TQ=,+'*``$N"&QR")
M"-<L"H``1^(U:Z=@5G8ML"9W<D<K=5<$1YB*0YB*/:=RK(B$-UA=KKAM1CB+
MKWB+MHB+M_ARL(A7ID1N?Y4"1F`.6EB,_TC'0ER8-HY6%5J1*4F0#+7G"X!!
M%1ZP>DG@*2#C`8!Q#FU8(B5U(+1".\=``?``%TF0!/!P##_`*L=0@<D@#DF`
M!+U`#\<@`<D@#VF!!/'(*KT@`1)`#L`BC_C8AF7A`*S2ADA``056:J>E3@C&
M6JH&?3`X3[-W6[FXB[K(BQBYD:]XD1RYD1X)DJS8!MWU5YP'6()BC"JI;OU@
M>O^!>J9##V'!`%KA"TW6"^(@`1[P"^?@`P50,A)`D_+0"P(0,C@I4T-4>Q+@
M`\#`%Q2`CP?@`&5!`;""!":S-`,R`!P0#[VP`!W"`5,B)"5C166A``!`CLG0
M`+CB%E;)`7,W`/\%9EJLL8GDXU2HYG!6]8+JXQ<HA1$?^9>`V9&!.9B$Z8,Y
MMY%NT%W?!70OH`(J0`;TL)*2F6A*5SHL]1N+T1@0``SPL``U$A@_<`SS,"`L
M!0!C`7L<8``%`@_RL`V7D@2<(0\PLA>[,``$``$L`PPX*0$"T``30`Y="3RS
M89"_0PXT4P#CT`NTX2F]<#:VPD/B(`ZZ@$-LE'!S>6IVV7!2DAL.-HH!P"W"
MT0.%.9[D69[F>9XU.`6!UIA`YP);4`Z3&9^'EHR.,@])T#&V,B"I0@X+L!?`
MV0OWJ"FE*2*`\0,SY`-5YT4.\"JT"0![L4Q>`1=OV``(\`"2T94`2AO_2'`@
M/I!['("<RFD`%WH92],!9VD82(""9[=P"*9:VDE5K/9@5U$#Z%FC-GJC.%I=
MO^B8?A4#)W`#R,`/JR2?1"I8[39+I0D!^<D^3;D`5OD#4M4`.-D`+E*;E7(,
MY.!8W`*.`Y`92@HB$_`I#/"E$.(6'6,@&)H,!2`K:1D`@C`C\*"<P_,I"2`C
M'2`7","<<9F"=*EV#^FB>-F=I.@;"Y`V?92CB)JH<D`'BKJ+W.68+O!=BVD&
MAE:DEBI8E=F%NC=#F<FDYR`!;^@`!/!$N=(!/C`/)N,#&>(+#T``D6(B!B"#
MPM0@I^(+LLD!21"=%"`!<<H!==$/&"H.3Y(,_^,0-,>`#SXY*W/:G`BP&'J!
M!#X@&#"2&DFUB0WIB:"(&UB59653`!(0'+>%!HWZEXPZKN8:F&VP`SS:F-]U
M`EB0#I<:KR&%C,O8A>0`I72Q*@12/!R0%@/@>D.4*34"(0!Z=2%3%9G".KB$
MH$G#`"'PC+DC/`6`!+D#AD_3"[TP&S[PAHTH#AP@`(T(&Q3P(+3"*AS0`;)#
M(7+1+-?JIW9)1ZW%G5EE6WO$`X!9KH%)!SC+D3N+J#U;@S_+LX#I!BV6`M^5
M`B^0`BD@!-0@KT[K2OUP#[Y0KQKCAVCC`PU`(*1#(!,P`+:E8P=``1.@`+O*
M&@I2%3Y``FO:@$"D(_^UU$,+L'8.,`&[VI^9`@`2$`)B$484(#YD)`"[*A8.
M@$6T,KBSX8^[XBKH]!J=Z(G.)S8,]G!7T@#N1@(S<(M!>X29BY&;FZ.=2YZ?
MNY$_MY@IX`*-&0,I^;2JFT+]\`ONEE(:`U/%Y&ZR*TR2%BG<4DO@.;O`!&35
MU$O`!%H6JC(]5#(_$``*\`"AL5_D5'!E%!H&\&3+QRP*QZ*JQ78+)B4'$'V^
M80!7,04A>:X]&+KBRXKD.YAN\%>.:;1`EP)E0`]#NKKR6S&MNW18`6D]AF]`
M%EF318AP\8Y)H``!T`!@]UG**W9I1()JE"1(PHE]ZKBL93Z2&T_@6A6+RKG_
MY8M7Y_N1&VR^&#R86J`%/#K")S!>\WO"G<-"OV"_+(Q+MIMU,25DT:H7"KFF
M8`=4_94]VW,U1"(DB^N0?BI5$;R=<(='%;E2%\S!FFNN'?R*30RZHAL%(I"T
M2NN8)[`%Y(#"6DPQ*DRU+)R_^SM3^T93P*193*8`0,53G+4C015.2D94V]3#
M+,N)X_.)@!JS,DM;9RL<3^R#?4RN&[FY?PRTA-G$;C`%(R`"ZZH"+@`#,[;%
MD`PQ*OS%2T>[+Z5U_$9D$+!3G*Q?'?AI`,;#;*2BZ>3`V#D;0]Q@,5K$728<
M;Y#!@SG(L9S$Y4N2*7`"1LO(D8JZ\1O)OJP?4;O"_Y1<R2\<9&(L9)S,:5]W
MP\-W+,A")&H4QZ3L+-;[D$,,?0+`K5C6@!_0`[*<LQZLQ+!<7=^<BB2)RU2L
MM$J+!Y7ZR^Y,*/WAQ90LS^X%6<6,2UTW65UW66KLR6&7/6,7)*-%O7Q:EW9I
M9:X%=P)`=U=1`AY9SH&,HQW<QT$+T1F!`RZ@SBJ@SN[;SN_\T?DQM90,NST6
M`C`<PT-64_B%69_,TFXL3J)U)-^4B4JU)!",8%)E&P;@6FYW5;M[6QH\SN=I
MT9[[D>)V`AL=J1P=!N0%TDX-2QECAE=!TI$&DZ6COY5V:34%3)<U35[=@?_L
MS-L#)%DSTUQCTP;==@:P:O]7M<=5\<J$'-="O<1^',[@[,1U'=$7S=$;O=&?
M=PZ]_-2"S10N.<Q3+6&'1<_W?-)"AE/5-$T1P&F>+'QBS3VBQ@`#]L,LVGQ1
M!;-BL]`)P,U%L,$3+<Z"/-1"FZ@_NP8W<`*1JM0;?<7P.=BT'17T:=A7H=BV
M&\:6QF\XE5.:E5G[)7`_)7:A-M"IX60K.F4/B=!4<K^[2-1WC=>8.[X27<AR
MP-H<G=%*>P)$,-NU'=Y,,17<C-LG9<F7/%\IG6E&%GS$37`!779$DAJ93:VP
M8:W8FKW8/"5?:Y'F2;Y-+-VS?-U':$K<K;0'_I[BO>!+D:GF?=XNS-B-_7M?
MO5G_G/9I!$=40F(:I%;*+"I55,9@,.I:LFH5XGFSUDW.U$W+J;WB<QV8:-#:
M''W+*&`"1P#>#)[C15'8/4;5I5.`LQ3A)XW2*<W)1;;2DNW).4Q\Q!):2\9-
MI-5D4KX:E'L5J"C7+Y[!.)NY/1O@NZB>,Z[.GU<.@:WC9FXQM_W@:NYCBD6[
M5M&`EDRUW.SFB3T<+CZ>`A[4*D[7BNKE2!@%89X"*"#HWWWFABX4#K[FAEW>
MBF[>>P37_ZW7J=BY>3[IC"?+':P#,S[HZESHA_[I/D'>*J7;C=XHI)[;`'+J
M.?:256VS>A[=-5KIEL[BA9GG-3#H@X[+W3WFH-[K%B,._[X`#,$.#,1>[,0^
M[,6.[,A^[,:^[,S>[,8N[,D>[<P^[,Z^[+Z0[<^^[;LP[<3>[=J^[=X>[=TN
M[<2>!"20[NI.`B"0[CBP!D:(Y7Q^Y_->W>69YZ=]A'PU`YQ>NH*NM&%`C+[>
MZ[$42Q93\`B?\/LP*"QD,0??D@:?\!+O\+&T\`5_\!;?\!!_\0S/\1DO\1&O
M\07_\1T/\OTP#\0``X)>XR:`ZTA+@_*>Y?8N\X#9!E,@YDJ+ZX->!DT]\#[O
MU!KO$_M0##*``D8_`BNOSCL0[P-.Z[5>VDX/Q>>I!CAP`JZMZSK?`G@@#S_?
M]3D^#4-@]$8OYB:0`CB@!K#\L_^R#LCB?.FOZ`97D/,<C0(G8/0R0`R1Z?5Z
M7]N#4@Y@,/8UGO-C+ZYY7>^S'O7ER^4ICOB27EWJJO-)+^A```W\L/>6'][L
M4`9B[P)B+_9FKP;A6]&JC=U-?_B(:04RL-$KK_-&SP59?/FP3]LH+P,MS^F<
M7_=&6P7D]\=KS_AV'?-%W0:`+O:XK_,N4`;P&OO*+]C[``U;T/G0/^@XD`9S
MT.=X3O.["/<W$/W0?_=YO_S@[]3F,`8U#OC0KP(\X)?73^^^7^LS;_H8N08Y
M4/>=O_I&OP734'3AO_\@30_$(`,`<0+%0(($4Z1`XT;.0H8-Y=!QZ!!B1(H-
M)U;$6!'_XD6,'#-V_+BPS0X5!$T4'&@B19ET_ER^A!E3YDR:-6W>Q)E3YTZ>
M/7W^!!I4Z%"B18T>16JT'[4M*`02%*AR((XT(:U>Q?HPZU:06^G,:7/E!DJG
M!4T(*68OZ5JV;=V^A1M7[ERZ=8.VVW7#Q%X4*5"8>*H21QNNA3/2\6@Q:V+#
M5[/D^'N2[%\48LKULYM9\V;.G3U_!LVV7S]H6R1/WILBBD+$%!DWA@W;X^O7
M#>.HP5'PJ<F!,HC-"QU<^'#BQ8T?S]DNF(S39$^JOA);NFNLM:<SO!+E1/,4
MDK>;<&%9'W+RY<V?1Y^>I[YI82)3IGP2\(LH:11:O3@QL?6%__RO@_3O"ARZ
M,^LOOR(#`AFUU&.P00<?A-`N>H@)@J_XR$IAA^C^6TPZ_[9JHPH;HD))OLAD
M,..<"%=DL4477Z0),W7,8*XY^,I"@2K6.+RNM>H*<V.*&[8K4#+Y4@ACFGU@
M9+)))Y]$3A]JQNC.R)1,.NF&*=2(2#\>ORPLCK!V<.%&(RW<:PMDZ(&R33??
MA%,N>Z#A@D`LS4H-!RO6T*C+CS[4JBO&`'5HC2D@(](YWH@@IITX'X4T4DEY
MF@>9+1*]4K(JYZ.J,4+!_$B-*W+PZTC>3ML+B&#8F;155U^-M!]YBJ'"3JAN
MC.R$&*:8@@TYYO"JSS]!'1!'5!55-?\=S&!EMEEG89R5"Q>.M3&EDUZ0X8HU
MW(BCL$__<R,-(4NM]E2^@@A&G66?9;===].;!YHP7MBK.?F.'4@%'';8DR&(
MW+A/L0YABX/;-@R=081J[[4VLA2V*,8=?MZEN&*+B:N'FC*`,+-C^;Y#084;
M>*A"CFT#!C6C@L758:SN3B#2Q`*M34$,:-Q9]V*==^:9+GW,(>:(:67&<3*G
M3N(U"E[3.+E;/X6]R@TUQ,4!!Q4.O!<PU.Y4E9H%>P8[;+'7BG?C3(T>J,PS
M3=#.A!=NV&$**])08XTU"N[6:8KT;N-@-=38DP<>;CAH()#?L]=.P.J508QB
MV!EO;,DGI_S_IWW2*08,CNNU]K28X1-!8;Z.3.'M&V[`(0<9HHA""SD$CZ)J
MU'&XX86#"H]J=+2OC*]>%[8(IIRO*R>^>.-EXL>><H@)0X;W+IS9<,ZQK%=K
MRJ8(??&_OGO.PH81-^N$,E,2"`8N@J%&GIR/9[_]XI4O9HS-92::]TP/DHJR
MIZ(0W=;H]1_?S+)V$O,%HQK`<5\"%6B\>;`#&L'@@O.J!Y^38.IL%V38G11U
MM()TAUQ:>Y@9BF$.>JQO@2=$H=CZ,0]S0,,,6YA?_:#'FU/9#R4DLF%D.">#
M(XRA&.1HQY)2.$0B3FX?]F@A,<JP!1D4KEZ)\EX.[7<F\#VQ+RX(_P(9@H&,
M<LQ#B$4$8Q@EMP]YG*,:Q3!#&+80!!FHK7IO?*,.X5B]%+0`"%O@0AF*,0US
MN(--8@1D("FWCWW0(QWBF$8QB!&,,HAA"S"40213``,9Q*".+<!6)&5@A"V(
M80QF($8QH$$-<\AC'Z,19"I5:3Q]V(,>\Y!'.]C!CG20@QK5$`<URB&.;*3C
M'.QPASSD00][3&R5QT1F,I6Y3&8VTYG/A&8TI3E-:E;3FM?$9C:UN4UN=M.;
MWP1G.,4Y3G*6TYSG1&<ZU;E.=K;3G>^$9SSE.4]ZUM.>]\1G/O6Y3W[VTY__
M!&A`!3I0@A;4H`=%:$(5NE"&-M2A#X5H1/\E.E&*5M2B%\5H1C6Z48YVU*,?
M!6E(13I2DI;4I"=%:4I5NE*6MM2E+X5I3&4Z4YK6U*8WQ6E.=;I3GO;4IS\%
M:E"%.E2B%M6H1^VI"=FI5*0VU:E//2I3H3K56`E1JB[)F0G7M]69],.J-\FJ
M3+@*$Z5Z%:LQN6J$QOJ2LGZ5K&CMJEMK8DQ_K/6L8I6K2T[Y5JS2-2=I/8]9
MZPI6OA;VKFR-ZV$5.UB\+A9Y2C5F6L/JV)A$P[*7Q6QF-;M9SG;6LY\%;6A%
M.UK2EM:TIT5M:E6[6M:VUK6OA6UL93M;VM;6M5[`+6ZUD%O>[I:WNOTM<(/K
MV]\2M[?!]8)QD;O_7.4R=[FY;>YSARM=Z%(WNM0MKG2;&UWN(K>[TP5O=K%[
M7>Q6M[S./6]RT[O>YVZWO=Z%;WB/*U_SBI>]Y)WO>]EKW_T*M[_XU6]_!3Q@
M`A?8P`=&<((5O&`&-]C!#X9PA"4\80I7V,(7QG"&-;QA#G?8PQ\&<8A%/&(2
ME]C$)T9QBE6\8A:WV,4OAG&,93QC&O,V&M*(1HUUO&,>]]C'/WXQ'JKA#&F8
M&,!`1O&1D;QD%RN9R1Z.1CJD4>0G5]G*"7;RE;6\Y0='V0O9R+&5LZQ>+I?9
MS&>.[WG'C&3+>J'-!5XSFA<<9SG7V<YW+K`TJI$.//<9Q'1^,:#]/&A"+Q?:
MT(=&=*(5O6A&RUC0C89TI"6-Y1(_>M*7QG2F-;UI3B/:TIT&=:8_/>%1]S<@
"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g145452moi007.gif
<DESCRIPTION>G145452MOI007.GIF
<TEXT>
begin 644 g145452moi007.gif
M1TE&.#EA2P+*`?<```0$!`L+"Q04%!L;&R,C(RPL+#0T-#P\/$-#0TQ,3%-3
M4UQ<7&1D9&MK:W-S<WM[>P!&C@!(CP))D`I/E`Q1E1=8F1Q<FQ)WB2!>G2I?
ME"-AGR-MD2]CES!DES)EF#9HFCQLG2=DH"IFHC)KI4!OGT!PGT-RH4%VJT-X
MK4EVI$UYIDM^L%!\IU-^J42<HE>!JUR%K5R)MUZ+N%>KJURNKF"'KV"(KV2+
ML6F.M&60NVV1MFJ4OG"4MW.6N7:8NGJ<O6*QL6BTM'>[NWF\O'&9P7F>Q'RA
MQH.#@XR,C).3DYR<G("?OX"@OZ2DI*RLK+.SL[R\O(2CPH.FR8FFQ(VIQI"L
MQY.NR9:PRIVUSJ"WSZ"XSZ2[T:F^U(3!P8O%Q:W!UJK"VJ+1T;##U[/&V;;(
MVKS,W;;;V[K<W,3$Q,O+R\#/W\#0W]34U-O;V\/3XLG6Y,W:YLS:Z-#;Y]/>
MZ<+AX<_GY];@ZMOD[=[G\-_H\>3DY.#G[^#H[^SL[.3K\>GN].WQ]O3T]//V
M^?;X^O[^_@``````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``L`````$L"R@$`"/\`/0@<2+"@P8,($RI<R+"APX<0(7Z(2+&BQ8L8
M,VK<R+&CQX\@0XH<.'&DR8,E3ZI<R;*ERY<P8\J<2;.FS9LX$Z;,R;.GSY]`
M@PH=2K2HT:-(;>Y,RK2ITZ=0,RZ-2I7BU(97JVK=RK6KP:Q>PXH=2[9L4K!F
M(Z+5F;:MV[-OX\KUN':NW;MX.];-R[>OW[^``PL>S):PX<*'$RM>S+BQX\<F
M]T*>3+FRY8N2+SO,K+FSY\^@0XM^RWETSM*F#:/6N#JUZ[FM6\9^37OC[-JX
M<=X>O3NW[]\@-_3N*QRX<87#CZ-4SKSYV^+.4R>/#GRZ6>NUH;?%3KV[]\O<
MOXO_'T^^O/GSZ/6F7\\R//OW\./+GT^_OOVM[N_KW\^_O__X^8$4(%X#-E;@
M?PC>=2!@"R;HX(,01BCAA!16:.&%&(K68(8<ZK=!AR"&*&)%&XYHXHDHIJCB
MBBRVZ.*+,`(8XXPTUF@C4R5"E>.-//;HXX\\[0CDD$06:617''#0@0<=<%!1
M!U`2%"5#3HJ4Y)57>I"E0$G:U>5+4%8)YI<?*:F1DDO*9>9W'\`0A19:6*&#
M"6(V!((/3/@`@D`X_,"$"FD6U($)/_S0@T@@^,G$HHPR^@,,'K2P*`[;#40H
M$X>Z](*?-KQT9Q0_[.G1I9E:I`(3/U":5DHJ^*DJ=2^(_P$((;02,@@<.CS4
M`0NS_J&"0&[0^D.=`W5@PR"$W&%"2"W,6NNSM6[!P0^TEF%6HE8,!`.RRK;4
M`16T?O&2"7D,(@@,@9X)@R"$^+%L1=/2ZH99)E#QPY+Q$C(O=3#<4:L@[-(J
MB`\.[?H'(;YZ\$&PA`Q[D+'(SO'N1R_\@2RRT"*[10;4ZEO6"VX,0H:V[';+
M$@?@$B+&2RGD08@@+Z2;$0?K)CMQ1!UT;.U8'>@`!R%6.)GOOLZE,`>M<T0!
M@YO^MONKH#(;['0'"]/J0YU00GELLJ)*22Q%(.C@@P\];$'K'88:^D*^.S?T
M-9=<?MTD0F(V*7-#2T:=)@=1T/\ZQD`@]-`##ET/1*9!APNJ$`=3T+HR0W8G
M%+GD4)+[<LP%O5TLDYJ;H$,/N18K9N*9=[R&J'=+.:64!*TIT-P;P6Y0UJN_
M_@6M06O9@[ROUZYX0E42NZ7B:?J.D/%5H4PK'"ET2;,?M%)1O`<J+'WSKKT^
MS7`/52[)`@PO>+"MS02!T`+XA8.00@HWF[!^X89?N3LA;VCYI<X>@&`]XN;O
M7[[[RWH!#+H&@A?8P`8J@)\)%I@_`3ZM=1]000P&N),/L*]][IN(":Q0+09Z
M8($W$TCU8)`")AGN@TN#00CSIP(3@"!URE,90_HWP(,4$`8V8`'\%):"I8'`
M!-`#!.;_3'@^%1;D`P"DGA$/`D)++?"%)O`A\#JV+_6E8$_Z6R+U;/""PBWP
MBA[H81>9U#\6%`0$+2S<!2W%/H&8P`8U5!T(OF?$-"%1#+3"P@)SQKL2+*V$
M7RFB"=)E11!\X`5CU)+^#JB"#P3JAPS,8OO:^+\KINXI(#C:(+@G)2:(@0KA
M8Y(*MN`'<_GA"RS(&PL.YBLG,<QA'G@!&2P&"#'\H&0O%(@.W`"(00`B::*"
MP1S\X(<I".0'Q+0#I(#7`V2]`7Y4[`$<`'8'*Q3N!F6@Y1RH("H.].`/?N""
M%?X@B"],Y`=PL-@@_O"&T'6@7W]P`PS*T$L_8*%P+Q@#'P"&_P<MI"!O+[B#
M']Q0`B:5P`U_N$,7W^"L0?CA#29X@1WBV;5YJO.4+4A3"K9P!T&8\@LM(`@6
M\O"'*+PMAN)2R"Y[^<LH%(X)<^CE.MWPJOQIH92`<$,/_`6S*L%`#!83Q!VN
M\"X.V("898@".<L`OPZ\8)AN6!8(RN"'/>C`"G<PUQMN<#S\>0"9?M""#N(`
M,#OH``18P*D\J_0%8O:`"GOP91E4T`)ZKO,+@V224O-PA8'80*!,S1]"[W"#
MM`HBIS`04]C6H,X[;"&53IU#P`3AA[_Y0%[2[.50KYE-7\[!F@.A0A[\<`4P
M``(0V0(!%>S@T4'PH0S+[!DQOW`#AO\.X@Y4&`@I_1"Z_%'U#NCBR@MFY2X8
M#D0%/[,5QN80/NPA3'O"4A(+CD8K9%F,$';8T[0F&ZV2F,UI*FC:%A;B35K5
MKW4=ZZ6M:A6%-'VSNK7ZPIXZP`1:D9-67)@6Q@:!,4#8($GC`P1/HZ7=@%87
M8V\`E%&Y58(EE<!?@U#A'J#EKO%UJP,WF+!RD:8"#DSU7\M]X.T(0863INQQ
M"+GE@6FU!5%-`6,>M6]P/PQ?]0K123"`WH8)L89E<0`'M#HM[S)7,V5YF+IS
MX&^M[M#AV>D,!(RC%4F5C+`WK!=I[V*8':A,B#E`.%I<XB`A\JLE('=Y3R:`
M\)>1!D@/4"'_8%0&+@=>@+%:U>^RA`!$:VLE/5T>[&48$\-\L6!?C.7V"A>+
M\Z_R]8>#[3>W'J@O(5(J/G;-@01<X8`.G+E#@XRX##BPP1AH-3*I):QJA.#D
M=_WP*"M@K%LM.!AJ8>`#"'/2!-3=PG>91]YFTJ]P^=)7J!GVS$'Q%`LPZ($F
MF7#,6MWV#SW`]<NB\`(=V`%W6AH?PI@``RNP:Y,>+H/C;G"#-;"8218NJ+%M
M!2D=X)$0</A!KBP\2&D/X@LVT$&N/;#I9/4@V4W+ED"V<-@IF-AQQVM!$*T`
M@Q_8F@-ISO.C=DHK@W.`"<@2!,.9\.>>FL#*@^!"OJU,""SP:;]W__@#I%M7
M9*DF=]93"!@LI41%+36N6C?H@8XGW?!O<P_5@[@"#!`=Y"G`X+O*6I*8N<`E
M'$0,S4U3.0RH<#$=.`D'WT;V+I=7@L`QK`R#XZ-Y=6`#<?^Z`RFX]B"0K6Q:
M14$@A!:80&&@`E;V8%-_YEYYS_;O+2`+$.B*=;M\+&8L7/(I/."T0IPZ*R-G
MH`1'$Z)S?;6D5T+\X0(9\1V@7/@D9<#7(^/3MS/.U5X[TR"2_D,+DK0U/S2O
M;Y/64@9NP"XW0%G2)(ZH"W^`!6-F@`-Q%Q?-OFU2)XUX93=`%AR@G`$53'@/
MS=O:'1KL@1*H'5T9@/T8KM3RGCV]23AP`_\9F"WI.]A@3S?8`A4ZY<87M&"%
M7+HYB@4E9FDE"?0?9`(6F,"!WW\7"TYB=H:7)+#74_UF>_TG>'-0`C^&,5M@
M`BW09H;3<OF37..U)`+X-?FB!C9W-DWV;@OH2F[G).8F0QR0`DT#@!P@>)+'
M`?7W.DYW9NL&-$D"`B1G3!X@@)QC--'%`5P0/6B"9S=F5.SB>OGR-_UG`^Q2
M;'$G"-$V0"8P!5N@=SD8/4W2,8*``S7(,%:P)&1@*UKH`<$R"#=P>$W!`3RP
M/%>Q-W@&!SA`;N5F-1Q0=\]5>;3"/3`P*]#');[6+69G!39`;C[0>!/C=[4B
M<+UF7L#6,<O7),W_TBXE-&);$(@VH'//E2^NUSH09P-,T%;X)1`UDS!:TF]S
M``(W5P:!>`,X\#-D2#/(8@?O\F"V8@--<G-_`XHE,TAQ9W@DX5>3=0=BP`0A
M52>D8S@I0VD&\8>4V`.$J"5A=`-1\`5_!H`1)PC_Q23#E6=K<P5^<T"J>&WG
M\F,"LS:75#/%E4G"DB;?E3NEPSM11@@[`WR?*!!?2`@&)X:TPG_Y0UV<E`)!
MA#E+QR7))X.R.`@XD";O9G#^F&?!Q21B)BX=\(,TJ"6,J%V/Z`<=)HFIJ`/0
MTTIQMWQ?XB0J<`-3`%1`F"\@R22GR"0_H#&Q-"O+YQ7F*($BA`,^=G/K_U5G
M-,@K=8B/J98!,5B*7+(UI8B.\/4L@)!1(O1G&&F&?'AZZ$4K:S`1'7"1R\(P
M.>ELB45%A=,"'*63L3=\7$,R-A-W5_8L]R)]#=8!!8DN?$-J7-)]$LF.!H$%
M`5,KM112#A%#\U<^R;5?_[)Z+<`%I00MTI("LJ:7'_2//O@L8,D],9AT=$.!
M(,"*8<@!W]573E8M'4@(M^@!NU@EHT8(;X=J5[./ME)Z"YF43?*"3!*4>R*+
MYY(FHVEPV5A<7()G^S*7>:.;`_&(?U!"9I>5U?5?<<=TQ?)3U_4L);9W1+-W
MY[60I7AS=#D4F0$"$&9UK8-H=I!;-_<'95`&;O^P!F5`GMRS2G6(:C\P>Q%3
M5-('`I6Y/.19GN$Y!H"D7]6%@XGX:U$)CZ]SFR7$,'/@!N(9GN')`A?'F0/!
M@WGV!EM@=DSGBH,7ET5H`G&W!VM`GAE*GC<@H7904-4'86YIBV39+7-)+(%B
M`UL04\\26&YS8@@1GUT6G@1:GR807O;EH`QC<D"DC1HU88#'`9I7GC5*H(D5
M@S$YF;F(FH.@G1ZPCG)3<^]XB_)8<K19<228CDP:ACT*,U#BF@UX9A_$4PU9
MFQD`H'OC52<*);[))!?Y*P(JGC5*GJNWBP0!`W\63UN07,W)E7PH+Z)R.V0H
M;D&*'[I5+;G4)#G&8M[_A"RV-Q!=-Q#H27FFN8*]HI0)2C[U^`.`8P(IX51-
M(V.:8SCS<UX$83K_25S_]%TKAT3P29$*JB62]@8#Y(+ADFWL8HU/23\>`'OS
MYT)4*7V#U`%T.`BT^):>&9?<0B=B]C@GR`58$"H_E$8-1P89MS9Q`SPW]P5Y
MLSD>L*F=*BHILP8M`&5Q)RWH"&ZX>#DQ-%Z6TC6DV&FOTWWQ:9!5DID'L8&=
M2:7_ER;U:'`?4(*GF:X=NI@^V@$!29%/-Z;L=J7V>'E@V#T2>8&\J26Z296"
MYWH=L([ARB5V.A!Q)P:-U`'OUIQX9H1:TJQ<TF]B`#W/)!8*)R\ZH`(JX`/4
M__4':[.:E+*"</`&7P`H/$EY/CDL,MI7$$=R$H.L4:4D43"@D$9C;L`P4;6?
M+ULLJ(J-JKIWS*,D-NL&`B=I;0.:X;*%GRB68Z8E)J"#>8@P,6-4<.`&#_A.
MLV*-3)MQ(TIJ^-)R8JEZ!(AE5)!RXY4!S7<P/>4!G,@$H80X*5,&Z].XZS-(
ML!=52P)3;F!,$YLD'Y='`B&13.4DW]53TI=1''`#<_`&]Q2F29JO]$I=8?BD
MV(8X5/0!4^JQ>>2P)J6>2Y*N88B8VJ@D*5.*'E:/0BF;98JEK@N/=&(LA*N%
M$8D[3B)V^U*5O=(\OC8'S=,!RN:U>Q*:`_&'28*"0/_8`7A&8EJB`M0%2Q&'
M,?KI%3WS9^M4F+;";'!G7UA@!<F%@$$+**8))1AG*U]`!237922`=M=&/U2P
M!<XBOR^&,$NC8UVX>//C!CO!-@-QF\N2N?!F!5CP9]E"7['JP2^S!540P"OS
M3G!6!E-@=G^06!Z@>5>`57[S0B30--O$!7#V7YAH!=9$KR!8!6D%A#KP;2A,
M!5(;J$#X,"E#6>!$3,2T!6A'76]PP'_&?RD#"/4;P!>HA+2B!E0P!OV56#16
M33!,"%O@2&8F![GT,)1IF8=*"%=P-QOH2/+W.A_K`:/97E78,$Y"L)@;1*(;
M@YXY!2&#-%"6OBQLQU@Z9SK_%L4;?&Y,$G?;E%LU)Q`7^4\D0')PH,$.S"1:
M4+MM_`<O3%U`PZ;_\K_)9;V!\ET(HY1C45M@N0=,D!(FX,70,@>0(KT]27(^
MD+L265VC>0>8U@$X$*H"TV+O]&=]U0%5(#!E*#FENHA#%DOL$IR@*,K5)6BR
M&JL?%,#R0H@FG&?)%63R>X)862MN`"@JJ9/9Q&XBN7.`4#W+"B4I4,Z.(RI1
MX"S/8LL#\6[562PX"2V<*<S$;"LM=H+6K"^6YF)W"8^$ZY8LP,U;_$_B2`AH
M+#GF*%6L>Z^THID&T3$<V`$W%WJ8Z<F(;(]4\TH"890%2X>%2V-!-IK`VZ,1
M-A#__UHEPYPQ>)4FM%<KI3C)D3+-)?1.!ST(8Q#,G4P(6E`\+4#,@S#($BR^
MM+('UOP'-36Z`:,&0L(2'1`X6!">7/`G@I(H8^!E;D`%$V,"7U`&>"405A">
MM$A&4_`&=E`&.M`"8U`&6H`Z+&`%;F`'<S`&/%`2/Q">#^A&#XK"BS=/9<#1
M`X%-9;!R*9#6A2U*1#P'<U`&>O(ZCET%4J("6/`&=U`&/T`"5U`&8I!1%K;7
MH#T&-=4!),`$9>!E:L`$>9723.`&`TK;77W:`X$#L3T'>*4"=]UBEB+(EDT&
MH4(0Z2?7=E#6#Q1IX=E;@L(#!EK=!JJ?*L#7=S`'9'!6:?\R2G!PV3V`5J;]
M0#T0VV\0!1M5WGEC`K`MVTR`:6Y*!F6`!6"Q*\.-15U-!HD[V&!W-\82GE5@
MQN&)@SD3GO<B$"D,:FSMUBF]WZ%D`@_Z!6V6`E<@!W^-`S!PU_>4/P\JL@.Q
MX*]"K$3LUV(PWNGR`[@M!R97=F4@<&B7UESP+FA'!6O@UYB=J/Z=X*\SF!C>
MW1)>!C.>+VO``GLZ!URP3`01<:3IE%HQ)5F3$/`)94\"`B7@2,?C8200S`QQ
M(&;B0B;T.@OQJK-39`-,YK/C`20`G[4#)3_$$&!..2"PY6%^1E;NC!B1+GKN
M87%N$'>^$&M^2;D+GUA.$)GAY$3_\:J(+CD<\`&1FCIS+J]R/N>%[JV*,^?Y
MVJ9H+CJ"IWJ#L>@:`>I/\<TFXQ:B?B29$\%9@48M\&ZAA^I24@,E,\"PKAA#
MLX8!Y2R"4'JUSB3OY`>```?PU^N`X4VG]>H&D;YH0^R]8SXM8$;,?A@%%($*
MD6PX\-S1CCS1/AFNL^W>_NW@'N[B/N[D7N[F?N[HGN[JONX7(>HI$1NC*A42
M(2#+$1GOD=56@15!,N]A,15+(1E.N0$"/_`$7_`&?_`(G_`*O_`,W_`.__`0
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MIG_ZJ)_ZJK_ZK-_ZKO_ZL!_[J@\$-$`#M%_[MH_[NE_[MX_[0-#[O@_\NS_\
MQ$_[PD_\MG_\R-_[RL_[PW_[Q]_\R^_\U._[R&_]N__[UY_]V/^?^]M__=#/
M_<(O_=SO_>#__<;__-^/_<RO^^1?_N?__ML?_M5O_M.__NI?_[P__OCO_?)/
M_P!!@P80@04-#CR8D&!"@P07-F3(<.'#AP(K1E1X\6+!BA,W8@094N1(DB5-
MGD294N7*CRM=OH094^9,DRUIWL294^=.GCU]_@0:5.A0HD6-'D6:5.E2IDV=
M/H4:5>I4JD`=(KR:E2-6KA:Y7O6JM2/"@6*_GC4;5JU9L&C);IVX]JQ<(&S=
MVM5Z=ZY>NF_MT@7[EZ_>M(,=!G;;ER+AKH;+*MXK6')BM'@9_[7<=G+AS5@S
M7^YJM\YHTJ5-GT:=6O5JUJU=OX8=6_;_;-JU;=_&G5OW;MZ]??\&'ESX;D+%
MC1]'GESY<N;-G3^''EWZ=.K5K5_'GEW[=N[=O7\''U[\>/+ES9]'GU[]>O;M
MW;^''U_^?/KU[=_'GU__?O[]_?\',$`!!R2P0`,/1#!!!1=DL$$''X0P0@DG
MI+!""R_$,$,--^2P0P\_!#%$$4<DL4033T0Q11579+%%%U^$,4899Z3QP$%N
M)&00\'1LCD?M;L012!_O&_*X(OL[DCXACTS2N3[Z:+)&*>U[`@$KK4S@@3:X
M8R,!*)CK\@GMNKPR@2L1$).\0-`(9#HH%&`CN206Z(._0=+0@Y`^&%`"/R7.
M1"`!)/(DI(D%_P@%,TY"`D&B``+ZG#+2_)(`0`$&+EU@``,4S2X-!+Y<+DSM
MVFB@`084`.``!DQ%HSP'#&A3.B4`:!6Y!@:H<S\G!DB#D#8$<`"_!@)88-53
M!4@@SP<"V)*Y-@I(HC@T`D@@"4XEQ7:^)`*X%@H!&B@PC0`@/6^!`F*-3HD`
M:CWN5D3S4[=7/08(]KX&",@UQUFC?4"`9HLK,@T!HBUTW6P/%@\0,!8&(X[G
MMNW5N$$..&`0-I)X8H$&MF3C`0464`+=/I180($D\FSCB#@'>8*!!!AX0L>4
M(]9C3I,)30.)BRV-F;EIR2VNYI(7<*+-0#!V0`$QVT!"@0;24*()@/^=<-F!
M7@=1H@!@>^VCB:HCSK%E!938EEWC'"`@SS143B*!IX]V&M2UV6BZ`3;Z:)J!
M6M%`(E=&Q63C"*@M=<+'-!QPNV<H$@"`Z'D;R-CD?-/P>($F8D4C"2<4>`#*
M)QI(0(%!BVM"B30:$'W+M?_M^%I"W#U.#P(8(.0(?XL[7`$%K/:5`0`00$()
MQA=(HLW/$W"`726<:%H)ONEV^NZZS4984C<HD"#['1[F]K@^"E"`$'4)"+T-
M*`@@0($$!&"@SC[6-Y/:-0&0N@E-%S!``"0(^9D0/1!`%OSR-"L#'"!3`4B3
M<OIGG/\A:P$$"$"T^H`^`R1`"7HX`+(.4(#_`(0O$`T0@`$+,(#",4```#!`
M"4-H+@*D"0D!.(`"",!!ZKTN;>)+%0(4(``#,,``"A@`KPB!A!PJ`(8+B*$`
M"!"G(W1/3[,CA!-0:$`(2BV*`TA?_O:7!`(`H`!:0A_X#@``!^CH"5A4'_OJ
M]$+RT>F%!E@``N1'"`1H*E`"0(`>IK6_XH#P7WW$U7%^]8#:W>Z,Z5M?`=J`
MA@(`('T,Z"+X&!6`'Q*`A#FJ8P$$1<0#!.J(/U2BZZHGI3=@3P(0V)YSMO6$
M-K3R=`&H'P`:$`A:'B`!6QI$$P8FO@C>Z(5/F);4$E``]UGJ3N.J'2P'$0AU
M'0&'=.(?^WR&3..<_U$),M-D("9(@#;<R'9B"H0#*D6()P@@9/Y[H!X"H8`"
MY$F7U_05._O0A@'0Z4X0K"'L9F5/(N:1G`#8HBRA=`0`)*!.4NR3[9HU0=I)
M40%J&T#X^F```VQ)#PL00!H&\4(H#&)>!.!:`@;0AD#8$I=*,.<0`7"$96)0
M`77Z8`!ZQ;A9%@P)@T#``=JD!_`5R0&\:N4B=]BJ?FV)`8HD'0#ZM$=:JNL)
M@6"#`*#9!HI"28YH6":E&E`G@AHTBDH=);:NESU4/@P`043K`([0IB8`($U0
MB&`;V#!76P["7+GJPQ/T`%>I8?0(:.@#+?DWKHGIM#@EK=BLTA2("DX3:/^!
MZ*:>V%#`04QP`0"K:W'H&3YSI8$-<FU"`)Q`B+L20@$&2(-<VZ`N*#@A`*`B
MA`,,AIR?#M"MQ8$KI`9)"$J!Z@D`&"TAV!"`_=E.4;)K*'`!EM/!$FRP^XN7
M_P9`N^(@P5]/&)=<Y_K#(<YV$&W($V27U2J1-JND".ANJ[`+M.*(,ZU*A%11
M_;<E;:HK6E'E8VB_I"[E`>!+"(!5<7I;G-]:<;A\#.N4W#`!"#0XE<VAU!&:
M,&%6&L>UH)K5``2`5ACVP9;)@>MHTS#&`!3``7'Z62"@:!Q(CDRFA_UADQ9H
MG,,EP``#^)U'5_PXXP1"D@@XJX:#"(!HF:N6`7C_KU*MRRG^)N=6=8HN(?BJ
M60$X,PD"4-1OTS3<:"FT.`R-XFN7>X""P9:>A&SRO.K573;,:L,<UNF2C=.'
M.1T`@@;+*;I:?.;7C=3)`VN"$YR@5^-X.1!40P`!3A@M<1$LM$2]'6YA28A.
M\FA;649@<?";X$C=(0<R`/46'H;EY3RZ.+,ZPA.>(&A@GM='4(("_;[\!`<<
MH,1M$%?(5ER<HS)SMHQ-@&./`P4L+N`!33```BJ[XP)05T\]14`!!CUH56])
MGA-+(:M5K0<YG_K%MKIADZ4\:5]5N;L1P^Z6B5O(A4+1M6G"*7K?;1P^1Y>>
M:[;N:HE+[4&WJMOOPZ,#_Y0@6_(&N#BE5<`!VD"`!1SI7OE"CD('L:P#-"`)
MV[IO!),*Z7_%>K04X]$+T9UI0@C,N9Q&N7$@5FK_XF[=U>Q5.H.&@"1,JW!1
M.RREGI!K0@P3KYKD9:U*&NSE\)S%`U`48RL&YAR=-E<""]^M_J4')]3)R*2]
M8="JCMW@OHY63@[W;$-,92L[\;?!W;1Q-?VM,"<PIW<R=W%<*[7HJMDX+URD
MQF%>2$7%.@D\:B)Y_?QL!>C("=\2K7)@IYRBSHL!L?HMH_7>Y-!VO8F]LI*E
M2?U/=2,XY2E?N7(N?-@Z5MW%SL2N`_30!W$Z(9BF'0`4`J$'!V24YZC6@QX(
MVO\G<0-;V"P6P%-)E:IE.]NU=H,"D,,'5SA!%HAQ>N"67+L`DK(AT6V8*&KS
M.H#9MFL``_SVE,M==G3?MN0:;^L#]##\Y,([SX%(0`L#,6*DZMRC]+H[E@-1
M>FUNJ[B;_ZW.Z1KN(R\`8(#<6Y;@XBDO>A?CN)<&-(ZBHJ=;Z@,H&*.,>P"V
M,IB%.X`TJ$`"0(!`F!AEJRZS(SEQ\;S/X[0K`QOD,#5-RZ`"X*"'6I1^F2%@
M&8378R0!<)0!N"F!Z9.80I]O:9,H*ZG"*[J4,@XTT#`93#AB^AYP`9@C$++X
M"Y]!2((@&J$!(!@B>I0AVK`;^T+^T1I'`:`:0AOPBYC_UQL_W@)`DMNT]RFQ
M`L@4<#D\4!D$,]&1-,B?$2*`X$*##=L8_*LN4ANQ.226/.DV^)M#.$H\D;(S
M2UJKLS'`Y7C`Y:#"+6DB`C"`9@,6_S$`:M$#_2(P2](:U,(D$G3#D=NR75+!
ME&N#IUJ.6(2X/G""(T@U'\E!)#B"CM(3)R"4-FB"(T`"C=*3"LL1*$`"),`J
MS7J"7!D$*&A!Y,BK/Q(N7BR:6!3!G:.W/F`#)X""[[DLW%&"(["6'BM'N4D"
M<_RC-D@"9J3%Y&"#GHG'7R240'B".*G'O+I'9!R95*M`>:DZXX""9O2?852"
M/WJ"(PB9?*2W9_RR6^S%6-'&_SDKQX3$QVY*`(5[1^I1K%#I&>6H2'PD1HV2
M1DU;1LB"2,TJ1V!<0G;91Y=<%&1\Q9KT$+LZ`$)QK9-[Q3RL&.58)P.`.)LD
MRJ*T#EVBPQU"`&M409PR+"-!@O5A+Z.DRJIT#B@`'=&!P%<DFR,1GK^SRK`4
MRQX92^6(DK)$R[14R[5DR[9TR[>$R[B4R[FDR[JTR[O$R[S4R[WDR[[TR[\$
MS,`4S,$DS,(TS,-$S,0\CV4ZR[X40<742RA@@&)9`(U1@J$$F&5TCUS:2"M"
M#];K.OE@O03"CT$P1Q#;&.=(@X1K@-.4C^]"%_$(A`?H$U*!+<@D$$JQI038
M2#QB2O^[&D?V$)@#2![U\#!GHH^H(B3]8"Q5-`YD$Z7C**D!:``E:"SY2(*<
M+`_'\Q4#F$K<!!"(X9%`"*TUD\[85`\I(LWT>$SZ^!7DS(^)(3HCP4SDN+=%
MJ:#&/(\G*P^F:T_PC`]!>`,W(%`\X)X6/"]?<8+#&115TQ,E8`,T<(`'Z!4T
M>(`'8!=\?(`&P%`=&037&S@G@-`Y:X(6E$PR*AQ?28(&*$;O<8()[9F1X10T
M*!K_48(&<("!1(Y#JQ5WY-"03(ZUL;AF^5#/.H(<%9DFF%!?#)L'$+A<B2KD
MU%`':()\B48G18,TN!RHR9<VP\R<P=$JQ1U@;`(6_9>N<8#_8OPPY&`#,:71
MD4G3+4D9:DG(Z^2?(\#1&B5/SW+2+Z$<!^@9\F2#/VV5/V72*_U1,P*@%BTY
M)!A2@`&F@2L=L"'/&H+3)$@#`@"7KE$4NN%0@VQ4%KT6'Q6XCL-3G3D.(475
M+QNX!M#1PW2#"J``"I@`(CA0Z02ZT"J``K(^])H6&XO!(RB``]`P<`*A`N*^
M:"DI1S&`!J!#'EFOX_BILT*`/MA!.U-"/3"B3A0`0C(Z0FBQ/@"B`PC%!4!/
MNZ.J`=B@;O5*)2+6`F@5>J(H.PN`Y6P@`U"T_?D@'LR?6VK#00"A817%0AQ6
M&?R^T$J@Z'-!+-H@8FF3V@,P6RN`_S@1UQ`RV`0HDI4#(0`S`!1J@UT!`!Y\
M@AC*$>L:5@@*%GHB5V+UP0*"H#Z)JI7%(F$E5@&0FD&HO0*HHW4SH;.*%I0B
M@!CLE9*:H6;M*0*C)GH#(#O+']II-/Y!GW7E(R5@6$M*T?-1UU#43I0:5BQ*
MDRP\V1;2DQTB5P%X*<0LI>R1`")HS++1IGEJHCZ1(CI1ITXZOP)(@T,[*]D+
M1-J9%@<(+#885EK*GW!DO<%C@,'[LFUI`G5*M+QM@_+BK7&9/8P:U*1ML=^Z
M)KP!*>3@L2;JJ#TQ@`9D@P&XI34!P=D+(N&K(V6!I=D#HH\-`,`ESWIM0]?J
MG-H-%H$Y0/\7&RFFHR=G^[("ZJ8]Z9X',$!UHI1H>:&0T8,&*"@Y>3'HI5TB
M"AF!4;V)"K:%4P"+BEUZBKU`\!8!*!K!5;:H(@`VP2X2@JJ(NI/I"JPVV*`G
M25PV:-_318/4+:G7>A+YZC-K[)=L7`!9$BZ-2UR-TE:#*MT#_*[Z-2V0HB4B
M*IQD@Y(T,+&2HTX]^"X9T@/-C>#.A5536MNV=209=!0BQ*'@DL]C6DYZDD)@
MJRS9^[)A(MR?'+=HD9W@M#`Q$Q?XQ*Z_RS/-.IEOA22]90`/A*QSQ3^"4AE:
MBJSC8*U"DZEY"4[C&CH:NTQ(0A2?VRV%S1&?Z[8\]#.IXZ7U7!/_7&*4K^L7
MFJ$7GZ1(T\W8C'J=S7O/<B.D*S[C+ZN]5JJG+],D'K$QBY&F)PJ?XLB\"L2K
M!ZH3V-D6V+J\PL(<C>,I).PQ\%G"`'!:_7F=N-(F1>25)['671K4PW*MD,%7
M)^BFU2.$!_CD)RFG03-`)"8IM&4P[3$K%B5&3(V5%QS!D@,K7QF`Y?0]&P6=
M1H(5QBID/6FLN4N.>4LW!J(7IDM5O0-7?.F#!0@`2BI.^\0_^0W9`W@`4?JI
M?TFW/B#$[@*O<R8]YY1`<\NLXBBJ%HM`0THIF=M16L,?`3"8<0X:>E$Q9QOF
MX]!8?*$R0MHM9";EI`E%?]FM9QO'/#0`_T%&3J9S2AT9&=3A((*^Q-JJ)@0:
MA/P\K$J+5D&*._^!(H'9'PL.6>`Q*D>:(4<A8"E[`"0Z(=[#L8BZ3-/R(O1!
M'P#H'&PN,0>XS<*<@Q5``108`2O@GN@LLY#V56JR._P,'ZI:(2287X3./S:`
M)*8<O7G3K&"6YAPY/W)YN$7!RH4.3>FJ%UL\J@``X;/YOHX&QG->,CWH5B-)
MT$)C:'9=4W@>*7EN+S^;*.JCSN0(!!,"GP=@`(-AY691,VD>NHR=WJRK8S[S
M/7&EI`4X@AWB8V'FKN((Y$U[(NJ*M^]:6LU.M#R!'8XF,+=:X?P['<4MZ#F#
MH@/[,D,QYC;`*/\D>$?>KKE"`I\)_65W%*G&62<?].V+&UHH>)4`L%G$%!*Q
M5B4G2HX7W+]@,[JH1NA^Z1F<.A>LUC1Z*>SJYN&7N^%>UBP%6-"DE2%O/*<U
MB2C/Q3\:C4C;%6@Q*T$\H6MN\;'Y9`,%D,RL&P1V@BQSL^<!/Q<6!!C)K1T"
MD*VA'JP,K*ZOXV=@+J,@!N;Y5+D7T^*U<R;+7N8(RA79:J6[7A0Z-([0UN31
M)CTR>Z$:Q;I%OJ&RN3N9DD]!HI==F[,86[M,OBDH2).:4;+-RQ$/I*=#:>V0
M6=`<:8/%[AC%S<%Y>N_\I60`98[0(V\\M-L%ND_\##:"TY-M.68>/RS_(R(Y
MY)"B+UG67FF#Y^NND`FGU_H5@\)');)%(A/!-)@N^0Z6)BH<?*3F\'ZH.QG<
MJ`;#.*F]HC'>-)"B(P@LUTI9<VLK1__0V14NTV4#;D.R9M%S2D+/?T("6LI?
M-1X\N[,O;4+>*A>PR<Z5RK[K*YZ5:\)'#4MG8;9DT-:I*/5CTLZ\)HH97[LA
MJ1/D0<_4$(1AB3'SM(9GT=(FWP$7+@/7V%LFIX*ZXOVF7WD\J`*RD!E6^I*Z
M::$^/>D7-/BM4+]TX;5RY1"Y4L/O!$6#X29$'PN?0!R`B,57DKIUXYB5=A(]
M_,;:1'-%;0TA6RLCG"VQG,+7)S&B3N)$U^$Q_ZK.*=.%P"O362R*U_W6QZ4-
M198Z;![*H*5LP\.FI(]O%OO!HET=O#PD(^7H`SGJ)$U2K@J_3Y&GF!O3\%7O
ME0ZWXYWWO6<9^&1;EX86QQ2'%5U_HH=^.SW'HY4E-4KQ3C>L^/3%3_0ZCK;*
M.FI<>(J2)MO.U'K/H/9Q0_()Q5D2^633I`!P)J`%,!\L624:)AS$;(;?E'1O
M#B^=Q9.QL-&BLZ1S'H!I@C214`9``KE*@H-:3^R]>]9!`@:@4.]1@E5)T46Y
MT7!&@W.Z:,%G2F;JT17ED_J4:<P_K+XG1[QZ?$`=3R<HE9Q^T(@Y-`=@`#%=
M%/>V%M9>Y>ZSSR-@?/_`,AW^.2?)%[K'I]!!"]*<KOQ882:NV?T/W3+<5QEW
M[";1SZ4$6K7*PM3#:@(\G/Z24^S!=_Y%67Q("?S!GYKU'"XI9/DD8`"548(O
M&9F(H1O(1Q<+90!`C14ZF_]G_'MIP7VAYI$<5&S3!PA"A/HH:<``21N!"A<R
M;.CP(<2($B=2K&CQ(L:,&C=RQ*A$`)J.(D>2'*G$0!J!>@X@&"0P$`($@4K2
MK&E3HY(`(6_R[.GS)]"@0H=&A.)@@(*91)<.94.`@(,'!P0T(10HR0*J3+=R
M%8C&`8&D7<>2+6OV[-`G!A8D1.LV(QH&!@PH>*+0@0$D+M_R[0B%;MN^@@?_
M$RXL--!>PXI?*E48J/'BR`P12ZYL^3+FS)HW<^[L^3/HT*)'DRYM^C3JU*I7
MLV[M^C7LV+)GTZYM^S;NW+IW\^[M^S?PX,*'$R]N_#CRY,J7,V_N_#GTZ-*G
MQTYSI,]-/4?8#'629-`@)4X<.E$"V6&?\Q39(%&@P,$3I8&4'#GRX,$1)X';
M'+&K<%`32.@141OF-400=@KU\<012'#7T%7^4=0&$OCAE]^``R&QDU!].-$@
M&HE1%$B"%C6A1$5]()&22'JL2,@32:BW$!0R-I2&@!MEJ!B%#Y(HD!)5::A`
M`R4&ET0`+-:$1@`H"K5``>DAL(!#"A0PHT)/(/!@_T57#1"6E0(X,%,?!`@P
MEP$%"%#`>`,E,("23@3``)9N$F"D50X$P&4@#`10``$#.+E0'P8X8%$:``PP
M5P%J'I`2&P$@,50;4P$JP!$6];'`I!8-@L`!=2[DU*`<H0$`BD<4L*-##0P0
MF$)*`,"AIT<L(")A4`!051L)5#5(`K<2\@``"!1)'))<TL1DJ3]!B9T>>`KT
M;$1'"`#K1#DUT)8>#@"0Q$`%+)`>B6@@`))`3B&`71N-LLH0&PD`$.5";3``
MP)ZQ!I!$'[V^RM`@T5K$I(R/+8C4(&P(T&E0#`C@1!]Z^"FA1&T,\`!&H(KJ
M6!L;4\3L0-@V=-2[A.2DI/^G+$4&10!5G2JD'AF"BNMK@]QQ\QU_3(0DRO4J
M@03$/B.11!J)>8@$%"!#&*,2@07R!!)`)Z@'%'VDD433"UVMA![/#I*&DENW
M`:52;/Q,M$ML^*G$@VT$V$3)A.A10`*0P914'^(RU$982C4!P!&!9$4Q0T\0
M<,`!=RK$1J,)"/`@L`8HA88`X"X4"!H)46TUUB(3HK1"#`R@1Z0.)I&$LFY'
M'>+B/SO!:AH_QW<@`@PLCJE#L4L]4$X+0!$(&ZQ;!45;@Z"11!.]AIH&K<';
MG?E`3W">M4/&(]&$U2FET20A;:`A7XUL[W54&TX@,;O).KT4X^X"J9[U(%`4
M8(#_]`+%GL3O`L7?1H&H=Z\$T49UMJ(U9'-;PX[85)(_^Z6$27!#0@`<\#VP
M+6A^3VC+_1:(N?(EH0W.,]\3!O&T\S4F$%`86L_Z$H<05,`"%2C"S@200I,-
M8`".>I`2:JBFA:7+4@-``/?VYC@S$<`N;5"``)X2@`,DY"-0(L"?4C((:SV%
M48\Y@`((,<4O$2!-5S)9H`HP`![J"0!B@I&:Q&@`*#1$3D):2,P&0@#;,81\
M+W&8GQY`LU@]0`\-4)Q`GK"M9*F$``U04`'HJ!`]&)(0<H)2`0)`@!2"3B"N
MZH/"$&``,PV@389;TP`BZ!(G!,I,*+$*$G0H@`2(K`T[_V(2PV*E2B:F80#X
M,H"]OD@(A8$K$`Y(X@`2=X!!_+$M?6`)9-)0.4<&P$J1)``;)].`)!Z.``GX
M'/<>,+J!+$"2-?P.(7Z)@"\)0`%-3%+W'`>H)28D#6(LI?0.``!%V265Y!Q7
M]ZQY@$@60`F)$T`G!9($52Z3(7)BP#H5D(1UXC)]+`H$%@G!LB8X00#X6A<"
M%."4>2[3GF;")]\21P`E0,E*H3S"'Z'8@)D<D9H#.,(>T>*&"4A``A#8P<[0
MR1#*;:L/?UF7Q1+`!JNEJ0^#4,``I&<X5(U,`%Q#P_P"<80FQ2P)`)B4K!Y%
MD`A*5``,X%\#`&"`]!C@FBS;5O\;O"4YOFW):HG30QNF^3J^)2`-5D-``;!E
M+64Q)&]48DA..-0&`P`@`=):R%X8`$@M"@0)CTL7#U_"$A'U80"'=`(`#H`&
M/31A3@UA%GA$"(4!W"I2G?3IX4@T%[O&ZU6!,``3#W:H)PC@`6WP4-\@(KC'
MPI%NMZTH$IXF@`9PAUJ[E!0S'0#7>QU`HD$D&+SVY<C,HJ$/3?!J0SI[!`\N
MH+#81)$='[`ON"(Q)-YZE!X^@K'`#JM)$4/"MPBQ@$D2-2EL@&T:3!@`MNC!
MJIEJ`T#A)J?*Z0$-`[AF4(>:AJ(RY&^:[8.W"B`]66%5?58I*S:;,)^K=@R9
M]]4JR_C_"T&,68P`F=L4`+;%A@/LEPTMY8[H(-:&!VAE,&^@J4UQ*A&>-02A
M;1`A@'1BW<!,$ZZX:RQ3"46`O\+H.FEHTRX'<"A9M>FUUR290/)VI==FL9B%
ME)QU(??+A%@K(0,M&F(HURQM>B[+<VQC`"0$$P`P(*8,4:RT(/B@TOU'94H^
MY-^<!%$$?/9/,0'5F8H6J4-:<G2!<(*2(&C7^>5WEWHXZ@&,BI@D\!9">LH4
M0QCYJ)FD(2$`QIA\Z75<<"$T019K2:'J-JQ.VT^ZF+7<IX:)6`5(#K+7W!YX
M1Y>W!.Q%88?TEH2L-!_U/?EVAWJ3]!+&!O#$I-'%2\"5+);%_W#)1"`)`'/R
M%.(J;`7:*X!SGY0=^A*Z.-=E+;/*9`?A9SMJ$=O]PNZT_A5.G0:6#0/0BPC[
MD%$[EV6F-KUI3OD*$P$@#G&$!5?\DM"`<XWN"0&`<B57[9`"V:H``%BOA:V<
MZ\98B:S$GIE"2NX5B3ON6H0HLWR7V'#"'FHA,'^(7QO"7H%,U0#O7GG4E&`D
M/#?$L7N.K!8G"\=&=C::\F[)3@-@+`8TH`%<@RS#L/RU)#C@3>IS;``,T``H
M#")O#&^XQZ%\.?&.J2&#$"_#)>B^(QNW=(/`L/XT-JP!L,'*YU$FN##K=+TC
MDLE6_IQ3PSDZA3'L\/0FA&,+I-/T/O\`2A\G1!-"F<C9#9K:NA8(C?E7VW7_
M]:B]CA\2)@[0=W76/TJS&,AW<G@'9CCIQ(:)3$:ND#+K(=T"4?G>V]+9-#QA
M7@V?RF+Y$H<1B*#Y4HAASR`*%0=0/RK5=1@!:G>`BL=9(1D'=D.>H":Z^&G*
M(<=BYQ5"-K_')#'KQW[MQDGFQV:E`=6/"N$PJW:!G#`];ZZCOD%!.;4!`DQ2
M8SU%`3#10A`=0^A9(=7<A3%9(0%:`#B=TBU$QMT.P[C*I?W2X2R``J!3_.!%
M`$30W!3`_44%7W%3`#P`EL1/`T12"W;/Q4R+JI5.(!3`M@F$WBF3$D`70VQ/
MX'6?%J&<@OS_GQ9A&,B0#./UV95MDT#MR<G`B"D1R0P20AI(A0`TDU'%6_OM
MWK6<6I;IH$)\VV-D1?8QP/:1FX6!G]S4X!1>F%F]VZDH@0@=`+%]2DOH86)$
MGAC^GBZQ&9#H1/&]Q_T%UV`,`B#\`2``@B#D5`H!GU7\&&8AA$MPH!`J!&8U
M"X!!8!HT0!K@E5UUSQGMW.$Q($1%"9>E6H:DXJ,%P';-Q)B]G,L)HD)T3*CI
MH-T48+3H3;V$A4HD3CLAQ4R02!\<XYT10,D8G61=$V2!VA%>%@`,'M1A8!`U
M!)\)Q%'T`9,X`"Y*F@DEA-4@42A6XR3B2A\@D1T^Q`8-1"B.SA\:_Q=TF>$8
MZEH@)$`"B([(1,H0^H<>0@:PA`JZ7=,2CD[O,9K<O)F>*`F>G0Q$H01V*(P>
M@8U5L$%8V86?S5>)X!GLO009>MLP_8V`S,2X&=0T>D4068SY[43>9!'MT5[G
M/9U+S->.:&1'_MY8@9[+.50F+E+<9`:2A`B0N82L!(Y5/$`!L`<1&IAK'4!#
M]8&\-`NP$`!W[!94R1J$75X<'IZ<Z(4CK<EC8-BMC=*?7`4`N)Z9S!]WL`P#
M8,<@)$$1-815]5&63=6D^-5C/$8:.`X;$=//$0*2Q))#,.!"."#/=9\OR5!?
M61;F5:!DF2-*-HL&WL4`>$B2W5>2#%N"3/\3A7P+F<0@MA"+@,2,P/SB`LS$
M("P`/(X>(32`^OC250%FDQ!EL2@%DI03S?`C,PW>YRD$DLA(5A(D]Y!,:@Y`
M2`P"?%6%M[2=@5')R92)6/1!6.G1M[4%DI`=XM"F5U(.E?QAH3#9MR&G8TI4
M#;V+G$23&W9D)0()`+CDKC@7BD#4[7UA3FRG`'0G:Q*"LH&>OLG*]^P3BRP8
M0G:&5<%6PR6`'O2)U*EA`!Q2+9$6KT42=Z#!4RS`/B49!E8H$`6.MVB?S]F.
M?Z[;-07"-"6``H116(YHB9K4E3@%A*8).LE*`MBA>!D``R0`%WK:FBP`0C4H
M=IC=S*V)D'16`R3_QFX13C+F6;ZXSU0L@+PX`#H.@.W\C05"YN=@:'1MH$&J
MR0)`"6'5TQ+=Z.CI00CF(XM!H_L0@*+44`T-J!:)UP&(Z:3,C65Q8PTYJ3Q-
MRFZY1Z`()`UBJ4)LSZ1@EC\:H8)D19J8B7"B2$FZ$VGAZ&FVYI\$RZ)P1XB&
ME?:QV)2N"0,@%3YUTP+D5S=1:E*2(JJU9!E*CC(M6832&N:=Y)4Z22?*#8NY
MQ[D0Y'LJ3`$\P#&U1/H%`A*1*G?\H7X&XDZ&*!0$2I=^":UPQE<X@/W9'Z]:
M!4E-B1,HQ1,P0.V@018^2%P@P`.@P0/,D$6:Z+4.Q!'@(T(`$!;:EOY@_\U+
M)(&Y!@AB((&@R:L"E(>-0(&V,@`4L,$#<$<?/``"9,H@.,$"9)30/00,)H"Q
MA-!+(`'U22OUO"5=ULL#O!%Y(.).7:S[$*Q"J8=4C0<;>*-O2N:,S9#<A&N6
M7`<6:NL"7!#+/EK"YJM2]$$2*$#M0"S&IJ`#2.9\).P".,%>/($"L!*,W.B*
ML*R&!,L3`-!>`(N^[0W+`FSQL.MD>(@#;`<>=L^X-EF"`*R)+FR3H<'$F6R[
MBF.Z)L"ZVN$@"!(")`"_I(N3V@7.'JV[#L0#^./UQ`HX/8&3,@"W!FP0YFW*
MOD1_I$O7@2*\'J[)!$M_H<A;#LK=)D#>]D'B"O]$@!2MRZ:M_3R`PQ)N:^P1
MP5$$Z6)$Z3)6]3#L1H!'(J*%G:6N2-`,KL34'N6-(HD$M)9-?D)$[$:$["(6
MP'!$\)KN1,AN\1HO=2SO\A)$5C0K1UC5`OR,`<`)\UXO]F9O20@<`8`3200"
M$FR?-4&O]I:O^9[O@?QD1P2"*R4O^KXO_,:O_,XO_=:O_=XO_N:O_NXO__:O
M_YHO_[C=4(D$^WH,6;A$`6_OC\T&7+T$&NC';?G$(.#B2$RP`7</&V2P!O==
MO3S!$U37?[1!&FPP!WO0!K<9Q[BE*ZD$"O\O7SP``9!;4HD$XY"O10#L!6.$
M5(5$NT331@`L=B1!IF7_!.:N(&:DZTS0V+\A@.7PA!X8@&1J1+L@J4/<(T!=
M,;.ZC^A<\0'X1[M@<0V%R+D`U!@1P+0^1"VA2*$<RE$1FPLK1O$U<;TEGT:8
MT&%9Q!'TVDU8C%W8<4<L5!#3\<<H9F=XSX5]E=6T<(MT+TGXV_ZQXUQXL"37
MCQZ,TXJP@5I8+X#%["2G1P)*,L+&%QIS#R/1$>&],6%`E)_NTAG)C7<$D/[$
M#MLX1HP$#>9$I(LI@1(HR=;!<KW,U^PLR.FPS@8IP>Q<#=R46I;5\H#,!Z9T
M#`AGL-OX,N8D`<2`\"*Y"L3`91O$R`)U3Q/@SWE<Q;Y`LWQL%@:GU]4=#_I@
M_R$`$1`&HP'U^(PXVP__($]@&`_6I,X[NX0(/XV43E!;F!`^WX@'(0]BQ`B'
MZ/,L)Z2@'<\\)\P[NP\\<V/"S'#T($_)K*)#0)#:U1*)'1FA^.(87A,;*`DW
MZ@'XE8GM!*3[HO)60!"'3)7V&``H"8H6V5,-584>#!'#B?``L!&O[5,-^<=`
M/04C+T1.*$JIO8D2_5<!C-,!I!=`=5'BD2DP,1'?F)%MS;!<%.!.:Q$5637%
M=):B',^!/45MN014D=.Q!*HM58Z!L0C?C$<,%F`Y(8$8P2*0U)"9P%0X):H<
M8^$[W>=CQ,2E'$!5'@$7$8"0D!(YZ9$#;(G'L5->#/\$]BT*K>#>/U%?H#R,
M%GE@#8T'(\7G-(713@S4E_S;R^EQ$\2P(W/3:C_*9+`;A%R@_D`/@*&I1TH@
M(U&)JF1(#IVT=#'2(>D>3!/&K,JA2R!4=2F/\=06_WP;YB:5'CS!2]624(\7
MX[CDO\4,$AA@-IL8^"95ORB6D2$`__"-BBE`?.%%=<5+4M!6!_F;7?@)0@Q6
M2X"T!R$``*@=A$$3SM(9_]!DH2"RX92*,\,-Y>R$Q52%:R9!>BU14TN.OWV5
M'M"87;AFT^!)#`[50DT;BPE(LE[62/4+4MX67;!!M_"=5&`.5`Q5`6"54Q58
M(EW.]CU!MP``6Z3!DC'3$<#_E6JZTDA!'@'(F!JRKV45^*JHBM^LIET@9=7$
MBZPY1N+<!Y;;(;%J46)8S`%@N;OFS0$X`44I`5+9A3+9!:9]#?>P=+WU9G(O
MA<',^6,`#+58G)-DL-RD`=FHRM38E=@%*E`+=34V0*C`-_/(#V_G,4OE%R:%
MGL4XB1+$,&3QBQES*QJDDHO-L'W+EY\BI52IFL41CEX'L;[1%B8/0!,P3QKH
M+&103@-9+PV.AUS,1.]93GCCK+X5RB'%H%*($&7\TA'8U:6E'^3E5<*B`;<F
MN`"R9'4Y0*CDS5T60*:8Z.*@C+S]5;-/"[$E.;IQ3?=^2JARZW5!00X9T_<X
MN>:^_PH?YR`H<NN978Y-H\E<U%D3@E[<)D"1`MBBS(5F644DU5``M*=_0)3M
M6,RD@%\I\^`JQSE1L,_I),'0(*F<V#6ER\T1B%38]0ED,M)@:[=^,AFT"TX`
MC!%`-2A#J#O.XM48L3M&YW&"E$D'"0#-7S%(='JG.^GN78FVWB)&*T2I'WN"
M8'>!F)'-#[%"C%9*""!=JSHA:*M+])Z0E+JA-X;.3US:@,H![+M_+Q$2="$$
M8G<H!@#-CY&D3/J[C+RTATMP&0"J5<\!U!S3<SM,*-)K\:J@Y"#9F_S%/8`>
M[YYKPZ-UAY+)TSS%6!FYY"4-OGT2,(#HK%5MY:5\^%8W)_]28_CY1VA/FS<2
M<CL\48@PV(2^,O=5(K&W_LQ7`R2!($D.UNM/S"3U0*BT``BUR$O.`JR1LBN[
M7N6D-AT$U+A\FP1]/C7-Q>0^MP(/IX,V""H$J(^\_8!V8=(+7`[]XWR$$Q@_
M7\$ZXC6]74/=@S=6E/@]R769]T.K`R"B3TF%I,@;0F8>E1M_&G#6U';@,)7)
MM,-4W#L&JT"4W,NZD]XC0"P@-+!/@2-]""@)5&`!&H<.^QPI$&@@H3:!)%(D
MU&1`FS8"GN@9X.`AFC1]*A(*9$!!RHJ#$!C06%'!Q(\/7!(J*'"@DP`.!@U,
M,\#)@@,4TP1(0D@/`0:$!B4X$#3_9U6K5[%FU;J5:U>O7\&&%3N6T`,"#T`.
M;#-@J<J8@90,8-.S0!H%"J@V6#`4"J$$/`DYF)I$+L$':%P^D#G(0(.*##JN
M=3(0C8`F4)4`2!+H`-Z!4![T89-6,J$%"2H>D>ED0-]!#P`\<8F$`,HDM0<^
MD9M&@)**27RGA"(@#:'*LC<"F,P`0="FEPDA*=#'25I";`8<(=1@:M4'#@8&
M0K"`LP&4IH\Z(-!FH!X';(9.MFC`B>!!!9'H+)"?P8'S1Q(X#ZH#'"-DN.((
M80`U]=@CI+HG$/+-J//8>*`-W1`SK@`T:--CH`8B&T`V!!+0"(T'/*QH)=2J
M\NF!F?0X_T"FC[1S::>7&A"@+Y4.0&"`_`A)RC>$GH*I.[*03%+))9ELTLFM
M>!/@*()D!"Z!`*;3PP`#DJ"MQ.H64*(!I7CK*X&6!G+`@$':,&`_)1(8`,'4
M`D!"CP4(0$*)!000@(V/Y`N$`0$86&``S38*(,PC""#OH[VPF^PTJAZ8J(\X
M&5!`@-A<2J)./6@[[PD_!X'L`24&;:LB-`)H@(VF#%#BB`.42[`YBP8(+M0^
M$,A3"3?9XXZJV7Y2PH%<"3D@@`22@.PR-@@X((DD#EC/M.RH74_-0/#33[NA
M$C!6`/!>(O`SX@8Z[;IHE:`-@3[Z8,M``1!HMP#_>-T/B2W[>/]"43$)B$R`
MR:I3H%T"2DQI)0(<:-AAQ`)Q@%[@'"A``)QNRFDA--6Z]S\`T`T2T::*1&#*
M)U%.6>65629K$,&"H\S'`DY5@+TT\'2*O4&:.&```Y`(A(T$BGN@1D*2:"`H
MNP@@``'D4DJCVB?:4*!I!IQ0``T]%-A1IUF9)6"I092HEH`&V.NC`9VU)N0(
M<@E!E2+W.B-,OHK8\-&)HLY#PV:=*OYY,QOQQ.F):A/(NB\D@&)*`>3XOB[G
M!#),>MB4(BJ```.."&20SO",==4$`FZ;*?40[LOR/A:8+)`%H'NB5YI3'&B0
M!MI*(X$&W_Z,=)UU>CRW7AN=ZSH&FM[_2R6)SFY"`3VJ1HQGGX%7F+L#L,\>
MN4&R;KH`!I!K(UR-&<`II9YWS+L!C?*6C74@'5"ZY?GIK]]^)P>Y/+PVSO.\
MHC9J%QX]"$@C^7O)L`:A!SW,Q"6!N`A4`&B[H,RD#4[P7Z14Q#^7#!`J+SE@
MD)Y`E0-I;($=5!'F-%B50'!0)0^DB@%MEQ($]J$-"-2?C5+(&:"P\"4*U%\?
M2A@>"0YQ?P*2X;!F`D.5^/"#^].#_IA8$1K&T(1%M,H@`I%%+?H/A4:$R@U5
M<D,NAE%A5.&B$N^71C6ND8UM;-)06E>V`C0(2:-R@!.24(!WN7%E.N3C'P$9
M2$$.DI"%!"39_WPV`,HM*1#2&<``%F`\0R9)4$":Y"4QF4E-;I*3:73@`YM$
M0SIV$BQ9).4I49E*5:Z2E:UTY2MA&4M9SI*6M;3E+7&92UWNDI>]].4O@1E,
M80Z3F,4TYB9%Z1%0$I*'6W$@%+V8$^@I\XDIN1`;@'A,;6Z3FZP\PB/!>8"8
M:24029C3RAA0(*[TS$-/",X"U%F5/B3RD010`(*@0`!".6`!8.SF/P$:4#?F
M*`E[@Y-UM%*:EOW%*WH(H5^*Q-"K%.0`3FB"$VAC``^I9VMIR)!`01I2D<YO
M;0):RU-TXLXF&$]H%81"=8Y0PY.PH0D0DB(4E``%C4"/IL:K8!-&J?^'O>E!
MHN%)@T;:<%2U\(\-;#H`T:*R`.H`-2=$2DEFJ":5DWC$(AXU21I8B@8EV%0G
M?VK".4>:5K6.%$2U0XA`V$`]`1!@,D_0X\\(`#('M,&>FEL62L3W2`$LP$-)
MV-)(X@;.A`C%``(8``(8DA)H3680?(+8`4Y5`#TP````.`#7L*=/`GB-(-]+
MR1.4LX#.ML8!J$&"8QV[K/OP*6"[(X1=?42>M>Z6MP`%$1NRJ`=/*>%VH]5#
M7*<"!47!!Z8>$4`!J*:$`#1A$`HXP-:@0+/H`""F2<V.1\QR5*F@H0T.``!*
MPV.N@B!J*.XDP'$-0+1`7`D);4!#HR[W5F[_B<90;6"#`@P`!;4UQ[YH@,("
M`D#<BH4$#0?HIQ/.^Z?>3IC"M\1B%B\\Q@]AJ0!^50!*TE`<&BY`)LK=T4=D
M\Y&V(*2^N6+#BRM6SHX,1#%@A8]!,*B31KE$(GVX[W@&$2HEO!>B`TE``O)R
MI-(^=TM]`A)S!L*<835!`$BX#\U>S`;"7"@`:*WPE\&\RB=,B\S3@EJ:QG6$
M(R#A"1KI0Q(2X-<2%P97DUD+<O##JCX)MB/2.8]J!^#8`;1*-\:+JDO0,``.
M(4`Z7!/(D#V$@(@"ACLVVIR:CV#.QR!Y.PBHR!,81I'1[#G0Q-'-*,.<:E5O
MTKX>]2IY70*B:`H*_Y)'<`(#)C+"ZQ!EU_+)<Y6?$&PHH*&1TXFR`8(M[`O)
MR79%#8\!'J``!Z0A(71-;*11F@#TV@=S3K&*E&T5%&@I`*D#>$"RGR#@0J^:
MW>UFY=H"J!:Q-3O7S-YUBGFMDOWPU7RW34*0C1T=.C<R#6NI$5_16Q$U)60E
MU6(/I/TBD*B@5UC=3GA*P"UE-K!$0'TP``.HDH:@L4:2[C;YR3'9UJH:X`!-
M<-YS`S$J!'V$`04?6&FU@Y8'8'0`2@M5QV*5-44'YF)-2````//I`/@I00#P
M3%P\%.<V%Y4[#+1J53*.@$`H`.E',-J_/86U/'Y)`*A&^=G1SD<D!*@J4/^@
M'NYVEP8$-*@/D&&`^':T]2%5:JX-\)#S!*2[1QH`.GU`70/*)\TS4:0)A,]-
M`CPT9`.4M]](`#GF%'`T'A<("0WH`X`[[*8``7P`C6(/%&R;=M6O7HVFM(HH
MPY,_!K+)0V,<HVAJA\4&>H2!3*FA[C56P"12L(:N5TGOCV\5UYL27MQROA2Y
M:CODLY[ZU;?^];&??>UOG_O=]_[WP1]^\8^?_.4W__G1GW[UKY_][7?_^^$?
M?_G/G_[UM__]\9]__>^?__WW__\!,``%<`#;+^:.()V4H':T#`F0H$N4H*EL
M9\R,J`V2X,RJX@G.:1#0`#A*[CJ4(`G0@"HN!`K_TBW=!*R-*##>@@\J]B9)
MN*=+&!`)G(".6O!^N,?LLL+XMD++HLDJ:C!ETB`)^H<B^D`)O`PKGN`R>,8"
M;<0(Y6GZ6"T);D8)4,()'DHX%`(K<,K-Q$T(L^(^C*D-^"2^&NL`$"0SO"=@
M>NX\?*)Q5`+!F/"T!.!H`B%'FD9>!H(C2F]<*,(!`B`````0_S`.ZT>Z/JHJ
M[N0RYLLSR&(E`*##[M#:C`0*54:Z[F8'%ZDK/.4(<R(J."UE:./T;(M&NB(J
M9&*>+LXEV*!.<N()_B:5=$,VD"``FLH`/,TE*J8'*Z(!S,-!GB>Q.#$\&L"2
MA.E2!J`)4"+F-N?A8@->_VCH"`*``2CB9:9K()*`NZZ">P[%DC+C"*#'4.:"
MKQ+@51Z@&M-@;]`Q`1!`!>W'$+$B#0`@.**O$>,+B.!%[@K#9/P)9<II4RY1
M*R",M+1"NH)Q@W"0240C*&:1/49#\[1"*B@B@JYB-(B1QLI.E82&(EZKJ9X*
MB@ZR(J`G*)`G&8$+*SX";F!I$/Q@)?T`$`:R&J_JY@@R,0)@1^9ICK!CCU0(
M1.CK-Z3J,^(Q;@(@0SR.$3^-``[1FIQ`"4)01<2*:OX'N'!*>G`*"JCBQ6+.
M"0?"'55"K*A*)SSE`9I*P@(!#8#(HD:I7Q[0Q[QH)3BF)VH%`=YE*9LR/,1J
MK/]F0BV_TBZ58"]M1`$4*0#^\272H`F,T#F.0#.:JN"D2*F88BDIL,M\+"_3
M(-Y>#"H*3BV#42W)ZCKX9RDE20_2@$W&1`F<*Z8LJN0"`:=FL-ED(DCHB*:4
MH#6OH\I<H@T&908#H3+_9S2O`[C<"6*F$HG$BC:9PJQ":!#20`D.TZCB330U
M8C?/0SDOXB2B@U0Z\C:;BCHU4P2;JFI`8H`<<S>9L\U4`DR4:C<-LP-)*0Y$
M0`-"``.,X`OCK"U+DBO_YV(J8C@4P$<VLW5X@QB'Y;40HZ1VD<C^1[M:1`T%
M8'TL0E,"K0#D8P&^1Y^40CT"K7$`##(>R0$HPAWOQ+'_`N;?JB,0_8-$E!.2
MJB4`"``YI&:N[`FAGHU%]E,Y8*(`2&?0&H=KYFK0;(NHYFJNY%%3`F:Q<H(-
M%B#8!%.%T$*P/-130$:J"D"=E`!=[.J1<)061P4ZW,;>F@W)"H)$],DV<^)%
M`PW9>&0\P.D(%+(CRE&O/B(F]"G?\B9()=3(CL+CBN2;2@]+9&,5*W),0.8(
ML$-5U..)``Q/^D1,!,M\0K2>Y.,V?&;R^#30'!0[*O)!>B(`:F0H*C`M9A&X
MGBHG&B!+<)1T^J0M2O5.`%$`@`-=Q%#0`F`=J2T0YZ@.!2T[*!&3W(`")$`"
M(&`'LN+JK`(_T^L3MRLHL4+4_SC5)<C&4!X@?Z1B0&DQ)2H&!]<"`0K.O"YC
M3*00#7J%/52+`>##``+@GOZ+Z8[NNLH+`"Y#NOH"1("JO`:F"`/@`8ZJ1X*$
M18&*-4IDZT2D#>*B5A2&)5[H3N0B*@``;?ZKR\I"*<`K**%Q!J7&/%Z'KOQK
M4`3RBVYK27.B,AP`>B1F:Q(S";#)V[9R*`O"`,AK%B63(28(>QA(/+0.(>HD
MJ0P`-S"'Y:A&=]:#,P"`:)"T)MVF[-I@3.9U4=L@GV1BOJ`KJ0RE."!R(01"
MN<A5J`:@)2CR-AE`,/V+3`-C`**N56YLN?)FQOQ0"O%Q+JXQDMB`5?:J#<JQ
M+_I@I?]N$[%N)V@ULLM02Q9ID3,2!N-JHRFJS+XZS$.0!WHT)21FLAREL`T2
M4R%&92\PPE4]X@A<-95Z]5>#-2O6`B5S8B9EJ$>&Q5\$("FM8FLQASF<(M).
MYCHE"3L<\C<<5B<:@&H&`+W\)3_XQ'C\,$,R`S&NA"@+H"4(<BWR(RCFJ26$
M!"KD4CD!`&[P1#18D<8(5D4.0``4X$SBS#9A`D']Y3)P"F_TTP\MR")"D#=B
M1DM2<3\]UB50*V1UX@1]@FY15BC3P%_NANN*0V+F(BDJ$B::HRD^<1;1BLH^
M:C3^S0!F#%<<`W/G8B,M8K`43FR'0PDM@F'\8DUN)`5M)R;_!@%0<P)S&;)Z
MPS;JK&4[JC4Z)-.>5J59D8!3;BMZGV@U=1$JZI,S',X48VY)-_)SD#7*:B->
M"KA:#=1`9U*L\A,G1`(G$$)^5,*Z=G62-A=8A14KFB*>0K=VR^43M>21=#(0
MEI(YSTF$G95[QF42*T*"::R!<V(D$0TF=>PI:N(\'J"!FV`H_6(B*@)/`B&/
MT0"U;/'(9J8/FO=S/*UYA;AN`>"C4.L?5P*2%F"2#R,HC$2$/)8Z.L\`L#'1
M`N#CS#,S>D0=$T``7K/MWC<E]``!`,">3#,/B998"9*$:;<X*F,I,!>M:':%
MSJ:6<7%6U5$NSXLQ;@6'IP*"8;<V_X\&+4#%LTBYE)$,(F\$*G"JM0)@*LPX
M)="BA"VIK:+B9&3-&FE1D?5#(#:1(([.GJ0P*PB2VH8L),QMAF713P!7?^!-
M)-3IG!,W08B,*S69%P$`8_235?2(E/7I(R_)/3%``^3S"]^B@4!0*)/R<VUG
M3"SJ7M4B9P-&\U27B@8"P%[GE,NB@=W2G^!8.*[7JBA4([8Y987W==<&+O@6
M`"2-`6RZ?,HRP9RW.<@9>?Y8CW,CE54BOL#HFZD"#=SUMBQ&CQ#,?"JDL6A:
M8(/VIFW:RJSBD:U"N.*DE64C(.>X(@CRCNEH)@%WGEXW/)XWBWTY)<9$`:BZ
M`10BOE(B`?_61((EF!3;N`UBV*VIVLI`^JT<Q[$<+%J$!FQ3XR([^EBB#IP1
MU%/@0Z?#HWB19H69`DX.I46Q@B)_994=((_[PE_\EB.#F)_AI9?%>2[@&-[P
MUT"6>CPPFJ)9I:9O.C102259TB6S8A8%4KEPPEA9&'):!2IR!#FF*8@&HB'#
MHV%2@D(CPHU!FC)ZXRJ.A8Z`@S>.AA17VB(;)'C]0F>-.H\]"K()`B58Q3<0
M>5]C9B3+^S>N]]G>4H;T\3.FBS,VI`]"6#_]JZQ@8ZQ2N9G@5Z@)(@39)"Y:
MPJN)U8#QLQP1!`G80KQ?XGF)]9Q3XK7.:8$:SLU8(IE#=8*7N2/_ZE>5/8>N
MN26RH#$!/4<?._JP&1)L(<-U\T)L3SMCU`*QDH#I=.*HV,1?]Y%F)SDP.D.S
MY!EV@5A_$E>MK9'IX!B.-_%&MX9-]%,DP`.OQWN7]*``6!9OJF4NW#%_ZE:1
M1&US4D1+YBBSP99/=J0RGH)5HG5>^DW"+[!.@J(R/.\`QOPU.*6.\QJ6A5=9
M=Q=_5[9!X@H\UEN`E5,I'F.(L:>&-JZ]AWJT/UCK@-()`!MP`GH[",!XE$L(
MG:9!TH!SKD*Y!O.VHEL_4,.SA]H_=`(!NHSF(K(`:A<[`H8]S]O()QNM6(4!
MV)"N/H=@\]@WD%F"D3NOUP+R*&,__.(H_ZCV6AK$)XXBFRMBF]D$DB(R8!9;
M(U2[UL6C`.9B$":6A1%D5%;,%I5W^C!77D8EN#MVGD5UM$<R7M3)@"T=)52.
M(!'",R*FTBE:/`A@YOYBBF'I2J7-4/)-E(^L>VWK\W1$#J5Q(DV8#30'\7YF
M9]H:1,;\0]Q88_A$`4KUTF]K`*94`:*1(FJ"I2]2HOV"11<`,M8Q;@#@LSV^
M`=9&1&H3:.8ID0U=B-NI]"`KKR!9KCOQDH'R,CA+VF)B88WCN6`^6AX.Z4%D
MWZ\"JZ4I>Q=`,&0>M1#@WQ+S`%JK``"@.%X+`7B1`&IWZYP.^3YG*N(%O=S<
M=J!1Z_GDLSACKO\*9;!08B%9/G':H%G1C#UJW``<`#*T?8.Y9<>:P+,<`,`\
MGGHK$FF<S@DJR^FXHP!@G*Y?/$7.&0I>7E-T"]Y3?;`<``%NKDW&Z84==BUD
M&*M#=26*^="!J.?6V&'A&#86`*>ZOE2<[O,YV3&J_"STX+YRMV(LHY<@5RH0
M0"Q7I5!2?@'.C4+@6G^2YB/UX'8E2S"*GX[Z``E,QE6NJG.PXLVR'T$&`0KZ
M(UPT0E8TX@D<H&_0YMB=0"J\D3+6WSBNIP'`/PD0P&88T"(:P&N4X$4P\P$`
M8H&2)@&>$#IX,-"1)`@;$AJ$!,F@@VT:I"'4QL$!!$?:+#P(A<&!`P__VB`,
MN=$!&X<.*UYDB?$!@@,+H!P<=.0`@T"!D"!`H.1)`Y.#E"3@Z&0H0B4`E,"$
MB(10GP=-3CHPZ7!0DP4;D9@,="!!DY](^AP4JD>J1@=Z'!@\Z,2!64)/N)+$
MFN0(H4`/G`9*DD!GFKA]VKYMV*<!24)Z'AQ0X*2)7$(1)Q)J\B`0R*L'T8A,
MD&0NE`9I*<K4^;9-@J@L^3XP"Y'T038-5J*%F,0R0LD\J9Z4K20S1I%(T"AM
M/+)D94).?JY,XV`F`S0PJUN_CCV[]NU/`^GF#CZ[]^[A&_*$.3Y\`@.#VF,_
M[Q`^=C8*#A\1\+)\]?2M-;?^KM]-`.ZEFWLL_QGHD`,$8!4@>KH%8D`"!%['
M'X7^83?(A=KQIZ%^"%J7H4-).-5@B=6%^!]Y"*%H8HLNO@ACC#*6-\AZ'<XH
ME0$$).'$?0K<B&.00@X"11("."!D0A$.F&232?;!F9-23DEEE59>"5,#.TF9
MA@(##$"`;%B."9X#`B@PEY"!+(`DF6[2F.:;<LY)9YU)RB=E&VS$:2>=?;0!
MY(P5]DEHH88>BFBBBB[*:*../@KIC&T\\803E#[!H!Y/\)GD(&D\`45IVTVJ
M&1KY/66J?FE`P>2)X6EJUJJM;N>I39&.^@20FC[!QG>!L/$$&AU.NJE#NXIZ
M:[+*+GM0$@`,(,"7T?\>H5D3`E`G91\,",!M`8=EAX0`@#XV*U@*Z,=``9Q6
M)]2ZUA%DDP('!,J=O/0R&^Y*#155`+0#..!?(`U`*P`"^D)$\`&V,E=`M`60
MR&S$$B^:1`!.L(%Q&@T$X%03`"S<I`,!(,$&&@<,H&]V]ZV4ZG4MA\<``>ZR
M%//,,#D1`'5I8%OB>K/B*T#*!Z410`)HL"&R7H14?`0;3@R0@&9/!&`1%`84
MD!8:`AS`ZQ$#.#%QV&+W6;'0?10@(<YHM&&JAGVLBD:<>J`!!8,'S1TJ3'T8
MH(!E4`3`$$QM0)&&92LS-E<;?7B*AJA]I/DKK_NR`47=""V@[H&4IS&7'@K_
M$)`&3X`B5!A"@:RJ![Q2I3G(X*$C1G<;3*[WMN5[R;[BZ*;CGI#NM=N]%]P,
M%C8W\`C-O?;N@?1!N(:!H!$W$@$(3<CA>XW$4X3^54P=YG--7969+PVR0`(_
MCXU^^D)6?.H@&VD%0`,&<*L`5D_,+T``"C_D1+_1"@<1_Q4@-UDA'$*(QIJ&
MZ($!!*L?98)6HP4PQ@`,6``!`E``L`4B`0R@B)>BQ0"SM.&#`B``M0A1,X=H
M*V$V64``GJ6$-!#@+8-@0-0(09\O43``-F$``C2SP(1AZPD-BU8#^#0(!11@
M`5_:$5T(`+:#*($`('L"%)="`.H\X0#<^M=<TH``_VX)X&$'B4X8;[BO)!1Q
M1Q-Q`@$<`ZT$8`4-81P`38+6DB?HQD9M&(#2")$&`20A$$L\7I@(82.$)&%!
MZFND(Y-4MH9`X4B7`<##H`.`!^#0CD](@Q($8+XV$"`!4#`.`,#VR09`;UM5
MN4X#\,.2I*5!>@S`B;@@)*$^'@D-2K`C3]"V%R\I`0T/``"U7)B$3X7Q(MYS
MB/20,)@"&(!Y7%0"L"R&$"7R)`$#B*&9/H9(`WB'B4E`PQ8)L"<#*"P-#^`8
M2Q0`@`,X`0HNW!0!%C"1&F7.D/A\".W2`+5.AJL!@^C#`0C0A&@2("T-`,`"
MS,D2)PB``:4T$T.8<DD'9/\R1QDT3@#P:!TT!`!)?XNB5,+4QS^Z#P%)W&?U
M`G"J1\ITI@VJ&)L<X``F&L`D'F,-+EOG@/Q8\&T``-A>E*`X`TCP)O:R3L4(
MVI)#'N0!#>@)!/G&&*CYYP&WQ&H@E5;#S"`!8DX`@$'2Q:=78@L-3M!,NC13
MTFP6X'F`8RH`J*,`<0828J+LB``6H)E`6#,K\+35V21H)I.P@9()&H!B*=D`
MK"$$"8Z=RF&DMY*-Q30AY+K)`L3IL<`14D)3BR)8IF<=-NC()$\XI2%K(P"5
M_F1I@)L(&PH`4YKJ=K?@<58!1A*6DAS$8[8""TLI`@4E.&``ZNH#`N+9@&(%
M\@#_#="2_!Q;'24$0`'(`DD`6OF0@]Q'=ECMHR;%*ZY!1.@R.5N19?K`UIR8
ME1!#=0C.!J``:%H&K82``@#`FU?!YE:*X,QK40"@@.HR@($)Z`,\#=``)W3W
M(`EP*>;HZI2*@>PL[M0PA`C``.LFP+6,X>4##(#:!BST(7"#`AO:L+40AYB+
M;%#=]23$508=`;4P28..;-5:D_8A3(M-X"!F4M`$%,TNL.2MDY_,$O;QI$(X
ML]5*]_(`:!'@H#*+R?PL23@,_F3,"S">0K:[KJE]ZR"8Q25&_H60E4'H7.QC
MR?VB90`#S)>_#JG+```P4;/4-ZX'"7"^=L/#<$(DGF/^_\D#!J&'(Z#8DB;-
MYKP0,C`]X'*#TVP-WSC]N'XU&@&D7%K#"'`U6*:P1F)<0"`),.KZ$01;8)&0
MBAF$69A`H0`S/*``^#J`!^@AV*9[S$'Z<(0$+.`)7C,>E)]-TSK#9-8W"0M[
M'="X-<D,T@6=Y0`0$,A'MR=#G`J$R"8#$S0T!2%L4$(?\J7>7,(9O8#"JG87
MQE8V;!E3?2BK09J)F+1,:@'K3J%_HU@C]MAX:046Y[W'75#O:/ITBW2I/_>9
M1'%29@#6.B]+*&LMO1C7.^..U9GJ9M65I!"':6AY&_KH`(CSI"CMO1X"J@=2
M0K23>D\\P*G,>\#ONN]<=R.V'O]899D`0WOINS729H>;Z(=LA!!FTI>^U84&
M)U(8:P@H`%8$MJ6&/)/D'V(,VC1#/L>.5[WG`CJ]"7FNQ4+5N08HJV@9L.<N
M-\0!.QW:R.B;.9&RA@T#$*?<)]*'$>-5G#`.(46`<ML$QJR[\(QB(!LP&^8V
MF26$;]A+N'I9.7KL+7I`0&Y5/&%_HC,A.0T$M6],")$J30_SHYXH$2"[#$TD
M$'DE2M6IWN2*&>23EA>`QYF.?$=*FR7$K?8!V`N:$Y=0#P;]5Q)>&94G,!<)
M@/F[`@O`Z#$G4)';30(#`J#)'==;WFUZ*1OF7,8`,"`)"N"8'OIU!"0D@`#_
MI:_>$8+_,PB0!$AP4":Q,4?`.?/S`#XA`!IW'PM`?W\6+W.E<T4S@/TB+`EP
M)$E@)C'G$"-6`/E7``5P,/!T:4]A@OZA6O^B!-N"3X$T0$>```/07BO'$E#`
M7`M1?YJD7;2V)(/P2@W`@#R&$!H%:V/&772Q-=<W4D-#``6`!%QU0VW`:R+8
M=\F'A>KC!')4'5"0``?C`)JD$+R&`$W0!%S(!NFR98,$$I\#:TK0(6QP%"/Q
M$P<P?@FA!`=E`&5Q&?4#A)KD.1#3!-SUAPF!!#IR`$HP$4^``*CV`&B@`$Z!
M!&&W(DK0B`6@`-B2!@<5%9"X9<%157N!!",H$`IP$5056$G0_X@$D(D4$5FH
M=D(.055)H".FV!!,\4<P@8L-T09J:`!'D!9:<5!V^`2EA@0+,#.>^(9P]84W
MT0#GQ1<CV`#T!SQF-!,SD83,H8?HUE\55@`,P"">^(T\EX7E*#$_\QT(4AC^
M\1V%@43KN!\0-V[[07W[<A,KDA4"$G#.4X\/81FM$@C4YRN:=A,$&5ZDHP?Y
MI(^FTX_[>"*[EY#.E',PX34\!X\!-Q<%DAUZ8)`)L2_M6!H#HGOR:!X-N2(F
M69`V8XXKR9(MB27`<D^M`I/]Y)(U:9,WB9,F8B8'0(YEM#4]F9-!*91#69-'
MEWH(,3A'291+R91-Z91/"951*9532?^556F55XF56:F56\F57>F5+3ESX;$X
M>W$O%D(F>)(G@%*6*@DI@S(Q:&DL+\<D??!B91D(+U>67SE3B6<`&\8N*Z$'
M"6`01P!5X5%#=T@E@<``B`D>@>`$SH8>648`EL@S-\B%#N$TCA(L.`1NM/*8
MC3*)3%(1_7)/0D,;_5)X2!`HC/@ES:B7SX8S$Y4=HE05?Z%RQQ4>8-%^5J(5
M?@D>A%>9UR%WF)($D,D<V.40"[!4BW(V#!%(:V8=?>2;AM(`N-D0MP6%3D!9
M5RA#)A09+O1HG#=*2J!&/_*:3Y9$"9!EP],'IQ,W+"9(BT.0U?DVPL*+IA(G
MS\,Y!P`PO+/_.BJ$+`39.M"#+/4I-VUS;&81D`-J-[^2/%GQ!`+@!'-1GV86
MH1/*;3>Q,X^3%D_S8K;C7)?9$J;R(*OR.E*1D&S3H!NJ0/AY/*?3*QB!H)AI
M0F\S`*%R-`]2,N\Y"!':!.5&.5C1.FE2&)"V/"2:H'-3&G-SHLCU?J:S,\[F
M0^XY%[Q'@@@Q-4C">Z!C.MO"<XN$%;UDG.?92(&4!(L5.%2G`$S4@'&C9T="
M>P8A/VQJ,%+4,':DB76$.5=1=PFA`+NY-`CP/040-RK&+5<4>US4@&`#$000
M+7ZH`'KA!!#FJ%HW0OXB$=<)?@+0B8I:`.`%$G\V43Y&'7JP`-SR_QA]\S21
M%2U1H5'Z@RR-^J@F`48$PX5Y:*B3V1EA-$:*R##0<@#4D7A,1())8*MF\URC
M*@#R$RU&I1H)DP94^"RYR!ALZD?>T0`)('`((!<)4)T@9!:`,8-(,D71THPX
MX2\.I!J'&HN8IE304@`V$6[[X@34(7@MD003=@29DQ@:1Z:[U6PU\D,'07`4
M944_8B06T4=5T5`(``5-@(F>\E?FE&>:%AB4,F(Q1Q-#(Z$.,4EO$5E]4#'0
MQ(C-90`(`"J-J"G+RDO+"A:8QQ0(4*_[!RB?Y03>!C%2L6,/D`:T9P#!<JJ5
MZ1'H9RH"8!->4TX-=0"#4%;RA`9,Q`8^)O]/&H(SV)9*&Y1!GC0`F(<$`""8
M4-!U[8D`=8<&W-0&,J1*4)!7'$D`4$0X_Y(&34``NUD4`_!01/,P:"`R+<1Q
M@W%/[S92I[(F=8>S@/0O`H-.$$(U:!`N4=&U#>!BVO>(C/A#X::U47$$4&0<
M*.,0&_-01'1S!`&=4C1@*K-3\K,__SHQ"GF/*O1I@V`DV/)9<^$`<R5*8--'
M8/-*^F(MT+%/6I-0`_`6BX4DHY@6^]I=$()Y9X-Y:-!*/3$`*_L2;1`:7.$?
ME:*;A/!)0X0?`+4IC^-#WQ%(U&$MV,*\#@%0.G.C>W->1S8O:M891DL(:\H2
M"X";E.)Z+U%Z=-;_9!)5,@*0&OE:G8KS-I\Z9&U"-%<Q""^F0KIJIA313<QA
M6%RQ2<$)4!/Z.(JA&;W$1+6I3OXA/]"+%0K`78^#@Y43`!WA*08HO.UIGPV!
M>N(E,]KU=#B'%8WQ`&$8G-5SNC/AJZK+++S4!`-!Q!LV-4>H9YA'7Q(B7K;[
M-6_&L"=(>&?804IR!$V`G!"")/K65A!V&=5E$3HW5Q'Z%GJ['M'2!J.8G_R9
M%6S<2Z6!!@,P&`#0MFT[1L@22#9Q8A<2O@V1QX!T+;E;A$O[-%CQQR0<'P8`
MJ%+1@ET7`!*T2-_C6%/471I8Q_SW&KJZ%^=7,$C077K@1'_,&$[$M-6)_ULL
M]9Q]1L=U#"9IL2;QLWL&X'%8K`=JO!?S<\E-T0<$]VVA$7NX!6+0V<=+0P"N
M%W4?QV-M,+;@5Q94]8QCJ*"]-+I`_"B?<BF7$E-,%&+5=5!I43YQQG@<AQ$(
M10C5:1FYJVRF(\M8_'5LO$$4!<#50X<&H35/4+OANC4+0%71:\LWD;TKDKV4
M'+]Q:WQ)8-!*X`3B.P#4L<<(X4/H*[\`53=/?!"*P;2<"\CQ0G3J?'P9PD0(
M,'_&%LEG$30"[<_K8=`'S3E:MQ=/D"Y%HR&@[)PW>C>364-VM)B!8;AK-C4/
MD-(\HAF)!\M[40"SS,^9`R$"."(CLA*.^=*`A?\1JDB#.5O.N*G&1>9,`"-2
M$,,37[7+(X$F^UJEU$7-CP1S#0$^2VPX3HR[3SPP88H?M5L:@72S'?MF;:($
M2W0`L*%[QT83!8!Y$!)V6:8'3S.]F5@^EK$5>N#&C-1?<DS7"`%1?GPMVEO9
M4@'8Z$O3$OVR?KVTVF=UPCN_RYE-YB-%#'"AL4QG>J=]@[/0=[-L?)>1CRG3
MLR%L>^%TB.'`\CO*2#4`@5,CSR?1F@TQGS(17O-*8+,W?7,0(M$3^Z0`N.EZ
M;_,:.CO))-(&Q@;#2]LLVS:VH@)0YP(65^AW>@%Q+_426ES6RG?,F&T^B=W$
M=WDD+R?.#34=<HM/6O/_N0>`-1ODMO#4)M)Z?+*8/P;AOH1S'Y45(<'B)9.R
M2VZ$C&0]15@Q2:'S.0G52P..0!SY6YT4M!`MK_*;L$813TPK+AQK$'E5.`TA
M43R+WW+W*01W+DC`VD$#%ESC&=W[5Z4T,#VKR8OE:D\K6:0#8F?+V\.&5/>T
M,^<GW+&%+%L:0U.$>1&JFC%3;^B7!D;"$/TL4:KDB6PSJFJ[U_<10VY$K<-,
MXV81H3(;M[SV$MIG`,G$N`U3:6P63_5J)M.\WA%#/@WF$/N:$<NIBCRA`!/5
M!C^K<PC`I@ZDO7>:NG(8+?;[1RZTPY(-:Z+AZ/MJKYY:%;#KJ/C5*Y'*'`8P
M_]<&<!$C%"U_!3REUX10<#*]"B!I0*@XU)</L:^L&!@]>H6J11U&<J4K0N/F
M*CM>4T(+%C5Y*!H&\!R\^C`3`;'=DAL&!3&+Y#!KMB;;1:IW<P!5T4N/JA'4
M%T:%Z4%?8K>*LZ::D=VO$2'S$VR:H8H92>UCQ*C!SEPV@>J/RB</P-S:*ZAP
MP45?DKJ=84'IJD<LL:^9.RWGL^?*HCBM`2B/@Y#'1J*C\SCZJ2%L\YY0*BP0
M3[`#>R(-?SREA.[^`5\9CUPG6H]WN3N6<3HNQB1SHR_P93LL@3M&"DB/`R@/
MG:$/,3KN>2.N<R&4TRLJK_*]P_*HTZ)Y0Q$77TJI9__QNH,X)]\>N`/SK0$L
M*WZ7%_(G>P.,+G]LW34X)H\1I<0ZJ_*D`+H[YO$I39H[E>.??ZXNP`*4"S^5
MD_+;NE4CF=@&O<2804E(`ZXL^YJ7="^59J*MNW5GT.)X31D("-#WD>(3;$GX
M43DIDC\V1W>S"F^30SHQ?S+YGP_ZH2_ZHT_ZI6_ZIX_ZJ:_ZJ\_ZK>_ZKP_[
ML2_[LT_[M6_[MX_[N:_[N\_[O>_[OP_\KA\(]KP`\R<J;(`$1Z#\1Q!#NJ&=
MR)+&>@X73S<(#SHT`\@J-`^',-*>X)'&<[\=(AL1RH\$$G8W7G$EDVTZP]32
MW(<&FF\ZE@^`BBBRE0X>]3__)5E>&MW_%].)A_X/$(0$#B18T*#`04V<$-*#
MA(W!0$G0'.P3Z.!%C!DU;N38T>-'D"%%<FRC0(`!!0=.3B2D!`"!`C$)"&"@
M1Z"3``T&"0QD\DG&)P*.'%0B0,E`)0,&%!#0P.+`0`L&V!Q9,$T"EAW1#/A9
M52";``)BQCR9AA"4`$>]AF130('5`4[:(!!`8.:1G1P#,1CJ<9`"`X':$$BR
M=G#AM1U=FDV#P*R>`@\RMAG@(/'%0`82$-K:Q&`;`98+HG%\V?1IU*E5?^R#
M(&X?0H&@$##0IF6`)X'Z]&F#),""O`_2"DP"H._!A`,`(#&X%0#BP0K:]#DR
M7&";_P4OJ29N`B"KWC9/O;(16G'WDP$(`J$)X'DU<B@&`"PHF(1`&P=I>3/`
MW9&R:(\`"V20Z=8B$+;W"E(B`+,6-(N0`C'2H[+W,DM@$,$0)(@RR>H+X*$$
M0Q1QQ,0&P>-$/`#9:,&%"'(BKML>',BWKOHXH(`VTA`@`0T+VDL`!0)@;L,#
M`GB.N``FPA"EG:"(Z0`"MONLB21R&R@--OIP0J*=VA#.H9WZ>"*))FR[#DLE
MH-`##=C80&.]*GM,0XDF]&!#QH'`&G*@!P1H@STEV%!""3,%TF-,B<2;,\X-
MJ;3R("1V'("^@?Y2H(\$*(50@`X+8H-*)V`+Q`D@W\PQK__U"DV#3#T$7&^[
M1=\<2,Q!T\B+H%<A?'-5)Z3,,XU`QH1BD$'&?/3/O`9!PS8'\7N.C4#2L&W-
M/E9]`L$)&\A3B22@$*^@-K:4BR`QD^B5IP,V6P_!8)5X@KQ.KVL@K?"6'>A/
MB^X,MEL,GW!7O/4&!9$A:95P8L!%O25Q888'BB,$"R(V0J-!$C"@Q]B@C1%<
M"@7:*@$$","SH#X8<(*\/6-C@%/K&"A`PP:B)*0)!_"3F2@"!I@I@8?Z,"#=
MG#DE)`DC!:`O#95R+J`K!V`B((&@%HIY@0(("(!'0@9!0JD!#OCY6T)0+N@(
M/]E+H.H`"(#"8P/J&B"GG9I0:F?_,Y68:28$"JW4@23T0(D@/0A@K@U5A3+(
MB9QG.B!'`@`(`,<&7KYN`.8&Z3/G&PT@D/+8^M29)MCZ6,#M`?#RE/-(J;9Z
M<8.H7F`F`9"(^6T'+&J:JL$D<]`W`&@*W+(FFK)+@`,>HU#KN8'46Z`T#/B\
M@+4)0;JNE6+3C#,!/"O)[02$)DBXWFLFX+@C!K#-==AESQEN0D07@&O$Y#Y@
M*38B5<IHC!O67[4W)I!``@CL0".!8T!&%O2=V*3K5L4!@%HPDB\A$00)RTE#
M`!"3@`.()U(/>4H#IG(0-#2%#7IPDGH"40`AM8$-\VN#'H[PG.D<X`!J2H,"
M!F"6!@"@_V9M>$)[")'#!;"A#3GT#%H80#@&`"`PG@I`7S"4A@*H!PTO><*A
M@(2AD$&A#VQ8`(/Z\+06%H4Y6V%`EIY0@`2`+3:Q<<NM@C*R0<P+@3Y;G!Y(
M=81@&8T-@V```1!$GJ&@I0%(!$`&P3*4X!UA.D71UH+ZAIW[>"IVA)A@`M+@
M0N,81`$`&"0;#/`;(7;/-@[X((0&H#L&>8E>$[*,2P9`*/0H8!"L)$10:F9'
M`@"G(`H@`!K6E$LL<H6$!;C8(/X&*$((1PDDE$^\()2?,H&F4V0['R=5^$D%
M"-$D#ZD.$NQDDHET1SIW\EU#!-"B_:4S-6Z@P/\"J)'_&#!)!?\9Q`$0X,;>
M(?`B>AI(4!80K>%4+(,S$L#`"$%*7PDD<FW824($\*8"#/0V$\')1(+R!&*9
M<B@-**A`T"(U!GW%<#$STV`N)LDH)@!D.EO;%(^C@)>-*BO=J>(`$A`>SMAF
MH5E+R#P/<D)-'?2DE:K.`VXED"\>0&/28L@I!=)'!(%FHS>C3`9!@X1!(""-
M&7U`E(J#!-BL"6S\G&"-"%!`@OS%3PKMZ-!"BM#)289H#0IIMF8&@$[UJ844
M2DD?B*6UM4(E`6K+UT/8LR>7.,&8FV%/$X`Z$"?@U2!)Z"B'^+36T8%(.`]J
M0I+Z@,:\D*>5`&A1!8^((3:I4[6G<8/__R#PSHQ\45L8<9"/%'@=`V".7=SB
MUG?$!J&80(L]21@0`@YP*]_@*68)#01=["E#^1"W`)KJ3C@!L+87RO"Y`7C+
M<CU*VA_Z\3I"R2H""&*QL9Z$`0Q8``.28"9D"H1J3Q'4`WAYW8/V[@`/,$L]
M!6!<>\K'@22;+E0.,%N$5(<!^4MF6`[@`#3LA):$@*I(\7);@9PM$"B;$`'L
M:=P">*<-(9[N,@TB-K*!Z(MH)8B`!$+*NKVUE/&L[0&;"KS^".0)`*BI`SZ;
MG@^'&)T""5X`#-``*]E8I%A-UUG:`Q;$;,J9;GV(-`="34+`]"EZ%<@!I6I@
M\[J$):(#0'H<_[):-"<F#B,000A",+&,"!1L@^C61#G6(3X&P`DX$4T;H&27
MXX0M@H1X(?%N5.8%B&ZH!XWD0#S(7"@U0-*2AO!CB3S/!:U-.`N8=`,<<!3O
MG@6\%99R/>^)$!<3A)\'08L#J0:;K0T`)4'Z2;'Z&``A988`G?:T/GE28.:=
M<U;S<LI%BA4YQTDFGN']HU`"T>2!H/>JE#ERIQ]@FS8DH7L`*,#(^)EBI)Z5
MGNA]L?FZ'-)'3ZZ5(:VM795<2SWWH3*?+0"O'3`RSCB@;?,)1&V7O%C./-F"
M]_(>02AK%BL+!,OS%0B7)[KJ!)JWLUGI0Q->%X!7IEGC(AG$'_SP<?]!;(1&
M!=GQ4/P]HQQWUC)QS/%N^J"';_W6"2I5Z0&XS8!`1*I0*3GJ[0ZB9:@P]+/4
MG>?$[7POBZ3;R9X)]9==QBYBIC=E!&GL0.9+GB!:Q"48]25#T`"EDBP1(7HX
M*J[<,A#[F.E'6,5,U_N`A@28;\*DUM%08,HNKPG&V6</NJYBTX8%`6C)E&SK
MBC4I=AB?>R)P#9O0;&SCW]T5G0=DI:EO%8B$8JE]:>`/%':,SE8#?(IUZICT
M`C!EWU39<"_&K.22:>Z9)2EP"#:\DM\.&QYZ6(T;Y[UI(%.`"#,OM\Q*TE_U
M4!0%Y,O#5/$;CC+RVX9FK8*(":$#=A(49RK_O3[+L4@@CE``:`$[]N$,P-K(
MHP"J/($PX:7*1]D_WJ'@!*PY+Z34+U)U^19@/8.>"X\'@_.L>9T^(!HDZ+X'
M`+^+\)FWR!H%V`R!F"`D:*&7PQC(^*>G,I]ERX^U"80'6(Z6:*"X"8#C$AN.
M:A'1.8`!%("N$"U)8H[40ZH"8+&!2#7&JZWJJ+470B6ZF@A:<@FLT0,9PCP*
MJ0XEV(E`:(#:P!4,H@JB41,"0(#0L:$]NIZJDPJS.$+)\I#'>!K<8PK;`+ID
M"BP;L\*L\8VC4+(0ZHMGDZC>:\/30(.V28`&L"$"Z`J7,``$`#'E:9\@^0XH
M,)K=^XHF.H@T:""$_Y@7!6``65L>[2.7+I)#!,@)W1`_EUB;'CJ`)*`S(VN`
MT6$=I=LQS^@CW!G$/#.`W#J)L1JTYK".+'L9OS$:!C!%\)H7.>P>YA"=JVF`
M2"RVG^*[P1B2P"DSN[`+&<R:#D2`.12:'W.`-:D+!DB)3"H9HZ$:5#PD"%$)
M!4#"26*#G%FOX&*BH7C!]LDE@]`PUJL;[Y`>I7C&2+0,HJ$H`$``0AD`;>F.
MKHE%KF@J;=&#!."N!B@2HU*0390*"RR*(U,)YK`0SC#$MC@K!`BQ*>L.><PO
M9+R1C@)#AQ,SZ>G&[BG(=.1#?Z2+(7-#DC0,)%``K3J"@4&#!F"`EFR`(_]X
M%#9H@`'KLIJ1$`>('G"!,*A``I!Q`(.ZB0<(Q`%,B05PK-@X`@=*@YO,.62T
MB"=@@'2)0*%\"OPP"R<82D-Y@%H;%4^K(38T%`?HBL^X-Z0H0.F12@4HD[&,
MC21("04X&*1ZRP,XRD",#210"_PP$SUP`%YC@)J,#26`RR+4,94RBR=8``1X
M`#;@2J0Z`@2(RR3`JC[(24,Y`@QB`(SZ"@?(0Z`TB+Y<&RCP,9Y02GI2`K8C
MA*Q$$#2XR5I23*!TS-:T#>]#QCYX@(7H+"?HS`9X$`XT09^L2\4RB&)9@'1)
M`@0I3N%L*"0HC*O\"@9`1BAP3!]Y@`<;A#Y`@LC_=((G>`#80,VGZ$X$84HS
M84JM0D[F<4V&",X%(,N2?,_$&)"2++N/R"B/D,]*H<^/0((%,Q1@0@W]1`AC
M:QC]/*H`#="T*M"[7"W[5+PUTH@%18@"]8N-,-"UB-!*@4\-W5`.?0]Q&I1(
M=,\.'5$218J/+%$435$57=%THK,_0X"19%$9Y;TG*(T9O5$<S5$=A5#"0=`=
M_=$0P1`@'5(B+5(C/5(D35(E75(F;5(G?5(HC5(IG5(JK5(KO5(LS5(MW5(N
M[=+5X`TA4J$6>B"<T@,&.X@(Z5`]P*E961YU(A`,E5'!\%$6Y8UO$0S,8].!
M6%.P65/"$=,T?;LG2(/\_Q%48*G0A/)2'?4<KAD`!@A0*#(+!1"\!\+$$6T-
M`8@R2E(/H-!4U,@YLV@+G=11%X(-)TA"CG`A-WW/X+&^?KJAV8B7UH#"@F#4
M1CV*05""`N`:`T"GB&"*`?BO43T(;3M319U1CC*8/7,"?!N($#(+!"C&!"R`
M0-/0H(@H\7@`L;L(!0@JU""/#=0B('T1VR#7CD"/52U)E\BQNUJ;E=')ZHC1
M9%W6/;,-'4D`*&"#&GTHA:.)=SG5?/RI!7&]8]W1F,D?%=I3LWA60HC606`J
M0SG462F`"#28DAJ8M]L):0$\C&H7&>D#*!B4X'O8-6V",H$(-IF3B=`20JD4
MX_\L"IW4UG!I64^Q)UMAB#$)%*0JF(F0C32I%G8Q%E$1H_`@U+!I(2?0681`
M`W>Y/8CPEVO)DR8P&-P9H:3%$T$Y69Y@VCI!*C80%(2;6H4A%[()%;EA@Y`=
M6PC9DJZECNQ!V"VYV52Y$F@AU#DYEC:``JWEVD+9EW.YCJF5%05Q'`.@BLY:
MFQ$[`)M(`T>ESX.%E)"Z#HIM/%X$+DXM"#V@FI@PUH)=40_*GP:X$.)XF1":
M"(>-5D>[W%][R)DP`&X2.\0)CW3)K29JFO?AP;@+&KQX-@0X103<$`*`*:5(
M`JD0BY(JG<]BL0=(C[L9R7E1(CV`(IU1BI\XH_GY)T;_G1\>I,/T()P0$PIN
M7)L%^)F<R4?+>9^N"=A[Z9Z<N:FA21Y/Q,.@\0PZXQH".(HC=!L#"*>(<E0_
M^YQ+(8B@Z)T]`Y*@<=4F2)R30%L!Z!WWZ*==S9FAQ!2L00]""=Z@L4"IW-4B
M=`"W61J5^>!0=9Y@!4"""#SVP8GHP8FAA*E$);6"D#\-,5/""\IW_`P&2`,D
M(-C.[5`ZY2@'.`(A;I%_G!'2%0"S2(`"^CZ;")QJ]9FXX"&A^;ZGD)OPJ)HG
M:(,D.B(HH,>A.:<U%<7,R)Y#*;WQ.H!E00#C:(/.0@S*>HBNHHH.S"8VL)@>
M\3-+BHINJQ9[4DUKRMO8^1/Y_Y@()-2BK_NGX'DO\OB)[(C`MF"L4\H1FQM6
M4LIB4GFO&$3:3/VA-5ZA$:1'%;)C^P@5+LJ@[MBA\KDD7?T.M[V6R,JF(2HH
M!1RA+JZ=LKWC3#X^&-F*:S.`?Z*,*"Z*H^"/,ND#NZD3+;Z8$%*"MS,`YFB:
M2[*/D9FK>?F)R(J>.*()83L((!9B(0:K]AF=(U/:+-M6YF'%#*4D_>OA#@T$
M=W[G=RX(!^"VL=`)"CLU2B*`]1@`TRT@QK7F&^*I,*FW@4!=*KX)\\F,V2*5
M!\D4"+$5WEC>*V8Q!/!6RD",(Q"O$QH*WIT.G%"+Y061$!)1APZ;/=HBGF-H
MA9*HB?]SXC3`$B2X#W`-FWPTSKS0-PZ$779MG\APUGJ!.9`E`,F(Q:?XONR\
M&1*RD1Q^:;E!@^`!D>HX`D+54R(S-Y7&G@A;%NR$H@(R5X)(X$%]Z9*FK!O!
MMM"8P<VPZ0Q3@)=.`_1X`O9@`"VB80]V"#L5R$N*"3LJOWL),7N6T(S*H9@P
M@)C(&YYP@EC$..\D!')3M0CZJ['A879^3T29S"283!'UH/#0C:>(3B-^.WY%
MW8IY5,74FCQ$@-R8W`RCCR,8*G(]H2'Q:H?NM[,)5C_)C.,HZ3R!$4);HL\*
MI+`8QGBT"&U]BL"IR6Z]S(=\FP-037.K&$UA7#0@#P&H;MO_QI(!6)M_SK(%
M3*;`6``'I&GWI(P8Y3PH48ZAB,ZGV.$^T,6C^BR,>Q\!T+,$+JD@.0EP_NI(
MLN)@FP@V<(#SYB3G7IX)LN[JYM1G,T130J?B!F^D^J3[>9M,[).T:8"'8(-(
M%$'BPFL_=H##)8CJD!$H..VIF@[S>`K[?+MY88Y7&XVTN`K/O)6#GFP-S9&V
M;FM&O!F"B,Z\V.%][N<'!+[U:X+U8@"(<B(E3J9UGIF$IE:$-A.')IL%.`(G
MV)KP,``\T^W):1&C9B/F\*#FO.R5F8CBGIP!@^[8X"4&0(*H/"Y2,9,%Z.X_
M7);2@0([AX(W663QYFX^"0S/#K;Q_[[?6=DB#_NT,QIJT57GRI2H68(,N;YS
M-JGO67F"SCR]@N!OK]:193%%OGF"`^AJV)N1N$"#.P>1-&B<#J&,!P;PJ'#`
M9U.`.\=SFXB6D_POBQ`3`%?%<^NO>>FB4=V@*UDOFORA`<B?(Q0\WCVZ*RNH
M(5HO365O&K_14",()+2(OSCB)$:KZ""`H.1I)&?MF]'LC49H$,F4S&`QCKKR
ME[)HWC[HS_(F<2,XR^B3!RD*/$%ST%"+-1QPX@CH0)AG-C$`%H,"L&)<[<Y'
M!>ANZTP.)>G`46TNM.(CF@RL$!IJ?/;QL_4H`ZBARVU,/9`;JI`=GD#)H^)O
M_I:>APH*EO_X/R9?GHM"NX685;+Y"=!`*Y_1%@=_JJ%J`T5"`^D@#C\Y@@YI
M+EDZX<@=,<?Y]0_!B,<U"([*BL&@CQ$S;(^:%`2=\6AGT48\MP9H`@\ZXHGX
M=*L#@.XF%R=?;7AC`)K)F2ON"]FFC]<ADY4IJ!/J%"VG:2Z7G'=?$/?\"S\Z
MQB0H'Q.>P0*0BY\9E'X,#%(!D>9S@""9)Z)1^YB6)?+(839`^.[&:1O9M='A
M,06A":\WBC^4?/FP#!X/\I<S16Z)*#$!$F[YF8J#O05I`"<HGZG#"47RZM+%
MNB9``INC#]S7FYXH'2+/'LOA9STFG&"E21LR"_#.BZV01R4@;#O_V9%!T8R<
M"P`'R,H!\-3BD!&<\'R4ZW9'RXD'./_S7XA3/Z7>=YZN(!4#()/E_=V+Z/*L
M9]&3+-2F(0"^^:>K>`B`:'"$$$$E`)003$@PT`*$!!T,#'2$P``&2A3H8>@0
M38(V#P>R44"`P((F"=`,:IC0P0.%A-HD@%)P02!"&H\HZ./RR8$T2A9,)-!`
MI\LF!0JT@7)@0`$'%_5`Z9BP#0,#"I`(0&,SB8$!0CWV83#``4RM#QPD3,)@
MT$L&!Q)@?>(R$-<!!I`$&H2DP(`#21R@1=(@89,%.M.('+"`#:%!3@Z,5)"&
MT).<"X_P;4IT:H(!2J+J(<@FP60E?.\^_UC;!L&`)"ZI4C209-!HAS"5M!G0
M8.D!F82.H$WXA#4!!5H)/?:J@'&?!YD?;"8XG#'!00]Z*FR"P*/+A$@,@`]O
M8""A-`OX$D@@-R&:Q$VY=T_XLV;\^O;OX\^O?S___O[_`_C?(/3%IP=W]"'(
M%D%($!!:?`3:1&`?;;!%WR`*#IA0(`BV<6"%"C8&HH8*$9C7A@\V5I,>#L8W
M(5L3$H5@0FG(5),3`U!'R(0L-M9&'QF&F%"&-#9&&8XM^JB0@35E"&2*"G4X
M5X<@0JBCCR)J>"6$>1$$XT(+M5$E00;&N&4@N3EQ)H%.@DDAB6WH(:*7W;'Y
MY%SW#;BAGEQ6-_^AFRX-0N9^8@98J*&'(IJHHHL"V$830C$:J:2)*B'`$4\D
M48`"A/[GA``//&$:`IQ.6JJI4PW@Q*FKLMJJJZ_"&FN`-VXGJZV+!N*<`(KE
M>*A$!>RZW*W#`J@'`NL1FZRRRS+;+*YLD.JLM(3HP<:?BU9[[;32_KBMM]^"
M&ZZXXY);KKGGHINNNNNRVZZ[[\(;K[SSTENOO??BFZ^^^_+;K[__`ARPP`,3
M7+#!!R.<L,(+,]RPPP]#'+'$$U-<L<478YRQQAMSW+'''X,<<D)])'&<?4TT
M$5^H`R;AVR!$A1KM?VT@`=^,2>A$<A-REJRC$D<@`3023T3'*LF3T6S_<Y=)
M3(9?G(>R@02/_9%L<J)HX,PMEB)SS6@2`(QJWR`'(+`U`P3TH4<!+0720$N$
M.&#`U(<^`8"J+AT1`&-M"!``LB]]^M(``AQ5``$"'&#UJFP$@`1E`OQ-4!J-
MXYD$38<J,4#3,P=`GJ(/"-"KLA<5W;7IOB:@0`&^Q3=VV=V=K5.2>HPUIM*(
M/A'`W0IAQ1@;`@!@`'Q\#Y2;`WWT$8@>3Q@NNJF,.W[FUK\[?A\"!VSMG_0!
M$L_H$0+<3NQY,I\.\B!^X)$^(/M!00!B@RDT2!I).-$&V0FQH403L/V81IB>
M&N=,:5!0(*"@O^&E(1!8(YJ0?$(_!^5N=PGY_][>$">`!B@H-RWAV]MFI)OZ
ML*$)3`-1").`FQFQH0^80D.)5C@YQ_4!#4118<E>6)W\)6%_%T*#`5:G$_DI
M00D#'!FF3MB=&-:D#0E$@Q(8^"!,0>%WGFN#$Y+@Q#0,430H:0S6A#A!\(T)
M4T]@$1L2N,(,LG"!-6&B$QOCP"S&<$)!Y$X:6/.$\)5/9'$(@07Z:(3],*!L
M2B``?`+A``&,!`$%>%T2!N!(`QR@`&DCP`/80```!("0#D`;M1:P*T<ZI`&*
MX4L`$I`S!NR*``$PP&0BV)W>`>X(#_`;03@HN`XF1'5%TXLC!_>`"R'!D8<;
M0,H"@0`#)("4#F#+:O\0.8`$!,`U3X#<2Q+@3&BZ)E?"#,#JC`D``*3*D*D4
MP/&H94V*M*8[3<@*(1Z@F)$$``%S:X,"KADX0@P2D0*HE2BYTP>R!:(/GD3G
M$6I"P?(80)^L),AY%N#("^KD"!51YD0&$`#+]*$!B#R<`]8H@`488)AR44``
M`"``A^3Q=&Z8@`0D`($=Z*<-!4"('@C@&H(T(0`/:$-(`)"`\GS46@X`@"1I
MU]%I+B"!#6@0W*)9K7I.I@$`6$P;AIHR@QP!3I5""Q1T]\K0Q;(/X/&(!F_Y
M5=%UE0$=6D``T)"&H$*%`*,*Q`$`L-/1@!653EA>`0#@."?04J]\]2ME`-#_
M`#C=2`&TB60:2":`FNDA"8%#0@":T(?1%&!J!M'*4)?3A@<<I#L:50)4^CJ0
MMS*`#7P=E1,`<%,T=`YNGNG0]USSO3!!9HQ/D*M.%@"`GK3A"*$%K63H&8#$
MZ:$!M,1*$N"$E8&@`0`$&*.G$C`(F!``"J5+:<C<0(&6OE0_C>2.6^AS'J+\
M#@'M!*..#)>VVO6!`,$1)?**,R.=$D*C39,B(?)'G_@J@#)>=0EE*SB0W*'%
MEK9T21("L+F'$+*6#4B#'HPX"%W2M0#T:>T8:U<0PM:-:!XFQ-=<TP8EQ.@`
M!\A+`K`G5IJP91`,T/`L4?R2!+I$"0YN:M.,YY+X_S)`/@`82`.04B1/H:&F
MBFVG@]M`R2(%(@%ENVU7;TIB`(PT`+X1JWI!ZQN#W`VV2@A$`1C`)!D;0(&Q
M)8@N";$``I"/NQM;*03J#%/\T+4B#6@``MK:W@5HB&R#2$":$W)>HU+K@_D=
MP&6CJ2%-+=I!"PZ$$Y#@EJD*6((+TELL'^*WLI85;V`5TO6V-@BL.<":&J:K
M=:7C-S'?5YJOKNQ]JQ<(3/$YGBQ>\>_D2C8$J+*,ERQ`24JGX\DX8`"2'K'D
M'"T:2PT"`?O\M0%<2PBQA`F2"B3JKUG#Z-L>.]:$:#-!EMH<]NKX.+!M0J\1
M<#U@!Z`-L&:H)-U<;SF;+O\.(PA!"#0@A?Q``7'N)ML%_RPD@+:80+%#-*+S
MB[;)63D0R'0X4;J7A@,0#@%B`717-4T(6/*76N!!PP`V6/+NG#=^@G:)'NI)
M@`/,6)(2_ZFKG]!Q_#T6.5J.[NX89V)IR_5L98LV]GYW@#TC_0&AH9FT@Z>T
MS<J6.SY6R.10VKVE-(`!2&^`5EJK!-@.!`H^W;I`)`*^!N?HK:Y1'8&2W8?;
MXA0`ZJXLXXZ^=:6OV]`:MO=V\>VQ0?S!#X$71'Z*3*$+#6*3%+K>?^5Z;:82
M)`%H8[B'S3UUP0U&E)*VE)L'0+27D:2P'H=E]Z0C`&MN\)XXAY]"R)VK)U`V
M"1G_&;<DQ]9JG=^1\](!,99#3@BQNV:6>[V0BFO2XD`INDM+G\R9D##D'/LY
MV0ZB'2[-2I#H#H3M0G*3DF>I%>HI)&V_`1]@D05852E@`/`A=*[0[6="1+<)
M#5?^[VE-[][>V^_Z?PVS@>H:RMZ-0?P48"$!6TQ34=4.[<`/?479D>B%5RW5
MYK7$`1C`#SD?H+D2@8%5Z37&4-G5+2&>`BW%@Q5$`#A$:R'!(5''`2;/Q.W>
M$T2;D04"`Q!6^1%",H&%;SG.FWG$(.34ZQP36SB4;[2<*;G3W%6/?$2?^M52
M_P6"2#!&VSR?CA6436!&TZ!27]2$,;E/+<'<(-Q6;F!4__IYA`X:(.>!#G?D
MU-PA1/H18>JH&4JE7,KM7QT21(,ICC&M6!_4TP*(Q#[9A$8IP'EXQ7L-AEB-
M11MH'OR-!`.0U.705RT%CG`A`)\EE'6)G<?EC>^H'K745>H-@+L=$^%$3I=8
MDP*@T@&H$#<U@.J,1)RX(')@&2.6F2+QGER@`0&46219FXX90`,0&E/\"`TN
M`!JP04(M0%6<5'EX!0.<S0$\G=Q%G20&!]493B!=TD"$13P!8P"8&4&TUO,1
M1/M4Q(QYWF_$&XD=EUL(P$V15'$XE#RM%W=`'?R9($)]5)$MH]BAE/9U%NO8
MH=_]C)@X@0.$AAX\``(L`.S=5/\?($$")$`3#&1SK,<32!D;.,$#T$<:\%D"
MV!AR0$>7@(I-/"0"[-1`5I7S/(%!ZLA(*@0:-(!<-,>>:9T#U(]]Z$%)[A0X
M*@#,T0A9?)R5L8$#4(=Y5"(4.(!,L$$#%&4@-0!2UH@22-F$/4%(LL$"($#*
M?%:+,0#K<"39[*1+I`%09B2"N*18.B44N&0?7,0!*,"8)01"$J5"#.7U.,!Q
MK.0/.<$"P-P3T(<"&$!E),`10%!(E@=0OH0#]%A"'MUQ5-7F#"2UN`5*!61E
MUD?V%`F>8"9F7B9GQLJ%`(IG7F9^9`]HMD[\E*9H"HA]Q)F0B":6C(]-%(II
M[@=M6N;_;>+FQ&A?;O)F;^;F`UR.;PKG<.K?B1#G<2)G<BKG<C)G<SKG<T)G
M=$KG=%)G=5KG=6)G=FKG=G)G=WKG=X)G>(KG>))G>9KG>:)G>JKG>K)G>[KG
M>\)G?,KG?-)G?=KG?>)G?NKG?O)G?_KG?P)H@`KH@!)H@1KH@2)H@BKH@C)H
M@SKH@T)HA$KHA%)HA5KHA6)HAFKHAG)HAWKHAX)HB(KHB))HB9KHB:)HBJKH
MBK)HB[KHB\)HC,KHC-)HC=KHC>)HCNKHCO)HC_KHCP)ID`KID!)ID1KID2)I
MDBKIDC)IDSKIDT)IE$KIE%)IE5KIE6)IEFKIEG)IEWKIEX)I_YB*Z9B2:9F:
MZ9FB:9JJZ9JR:9NZZ9O":9S*Z9S2:9W:Z9WB:9[JZ9[R:9_ZZ9\":J`*ZJ`2
M:J$:*F^&0:(JZJ(R:J,ZZJ-":J1*ZJ12:J5:ZJ5B:J9J:AA\P:9ZZJ>":JB*
MZJB&:J>2ZJFB:JJJZJJJZ@S,``W`JJN^ZJS*JJS"*@W8*JW6ZJO&JJOB*J[N
M*J\"ZZP.JZT6ZZWZJJ[^:K+VJJ_VZK(R*[,>Z[,J*ZW^ZK0"*[02J[36*K)N
M:[5R:[<VJ[:*Z["2J[&:JZZ6:ZX6*Z]&Z[M>Z[I^Z[?&*[I&Z[$ZZ[O2J[O:
MZ[Q":[TZ:[9::Z[VZ[S*J\$6[+D&+/^[!FNS"JN^_BN_+JR_#JS#>JNV1JS%
M4JO`)JNX$JO`<JR^JJNWHNNMFNS)HFS*JNS*LFS+NNS+PFS,RNS,TFS-VNS-
MXFS.ZNS.\FS/^NS/`FW0"NW0$FW1_JRPVBS2UJS2TBS3SJS3&FW4!BW4QBS5
M`JW5OBS6QJK4%JW6MJS7LBS8KJS8<FW9FBW*DFW*IBW:YNS:GNW;JJS;FJS<
M+FW;PNW=XBS=;FW>XFW?^NW?`J[+ZFW@$F[A&N[A(N[/"H$9G,$9=$'B0F[D
MONW@2B[<4F[E8F[F\BP0#$$7T($07*[F/JWFAN[)EB[?ANW>%B[=#N[IBB[/
MNF[F>D$83.WCZ]KN[3;MU=YL[.+NU_;N[_KL&0A!TOHLTCJMUCZLY5;M\J9N
MY!HO\$YNS_*NW2*KV@IN]48OS(KMQW*M$)R![YIN\TKNY4YOY9:OV4+MZ9[O
MW:YOU^YL^PHM\E8![4)O_:HN]68M_MKO_NKL]O*O\OXM$``!U\(O\?YOU/)N
M`1^NW*IO_":N`K.O]A[PV!*M_\+N!-=MX)8N!(\NZ58P\V+PZ@(OU7)P"-^O
M!)OP[Y:P[L9M"C]P[KJP^(JPS*XP]L;P"W?P#?LM\H*P#F<N#X?O`L^P_DHM
- -$.>O#]MP!IMM0```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g145452moi008.gif
<DESCRIPTION>G145452MOI008.GIF
<TEXT>
begin 644 g145452moi008.gif
M1TE&.#EA2P+*`?8```0$!`L+"Q04%!L;&R0D)"PL+#,S,SL[.T-#0TQ,3%14
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M\>CN\^WQ]N_T^/3T]//V^?;X^O[^_@```````````````````"'_"TU33T9&
M24-%.2XP&`````QM<T]035-/1D9)0T4Y+C"`\B]6F@`A_PM-4T]&1DE#13DN
M,!@````,8VU04$I#;7`P-S$R`````T@`<[P`+`````!+`LH!``?_@!>"@X2%
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M-?T5?OU$>G5R5$#ZY=,-3_\!*,I`FK&V"E<%739?@K3MMQM02"5$T8"254>3
M?@-YM&&&#QH&'8@]&:5<<T3I!`I=`G[US2X\J9/20TZ=MAR%_Q6#5H4K3L<7
M/#S:0PY%CN"$&_]5GU@S69%V97,;6IXI5YQ(_LA3UUDK\@-:2[6MMLY`$!+6
M&$9A"N:D06U=>:.*/F+#SHCH&*(>@@>&-YU_:*XVHX]W0CD73#B]Z!Q1VW'F
MF*!ND2B7E(GM!N=5YA')Z&=EX60AH0SZPNB(8K(R:7^0,;A35,A<5^:9I595
MYWW*B948AW@]9JFHN-%XJ'NLJ?)7I.F9I!)OGV(58)NF#6;.1V0RRF"E!Q$D
MI&Z(25=LDC>V`Z@OD$[(2GW"-"HA+9\-.Z"MVN&HEU&T+CG36.5R]QN\QZEZ
MB%P=)HND1;J1I"B["V9[WK5F2?L6.P6IHQ9YGIKEY(&)2/;LIJ_,26__90T%
MR@A!L%99&(;;)1O.:`_*^!>(?4*7X3WB=+K>A9/R8N8]X\Z[EYD-'HJRDX<=
M1XID[ERF["HB]VO<2`0[#.QZJNGY5G"0C7JK4I0]HLC'X4&F(X&I43DUA2:&
MB/2^&7EF-6&CM8P9A$,[B!*PE?+K#V_X\?SK.2V"^M9*C7XY$=(ARTRL;W#%
MS#0Z8X<$$J<:)ZUES,2]%/*X<`Y)7^.O;K@G@3KNP^N/G^)HW8*5(WY7Z73V
M=DM3/F':=ZRD)QZ?5[8A66KB\*XN::IQZ2[02Y/YGJ*<C78HR^BH1O[E6GWO
MZ4])CB]EX)AI08_2T307S-+5I07^F][;84CM_^`\)JXB>!N^ZSW.HDDYWX2?
M3YL.K,S*;-QMT1:C^<6O1`9IVZ=H#9#8Q+E:_>QWB1I3SEK#O]`@S%O1XXAQ
MK(.0J!2H1%H;5'G(QPWV'`UE!U,?]$*'O>[U"F8)(U=1VF<?D<!(/M3YC%Z8
M`[F0I6L8X&E8/I)'L5JQ!W'DN9<B%A,NLWF0.>^A15B2AKE?*&8\J/%.=1"5
M/KXY3#U;(D0[</BB55VG;DT$5V>(EYM9W45N)Q1-"+-W$)8,J2,/1&#5G-<[
M68U/?-:3EJ;HJ$)'L>4RBIE:XW+B'"ZJ*X`V">`JMJ2O",YC0&\*T>@24Q8(
M_FQCG\`<3*8'K4+IS?]"%`H4A_@C0O>(!9!+&U31=O,O"[6E*W#QBZPB-4JP
MD"0N#Q,<L':92?PUR9,\?-`H@E6C;>F)<CM<#)X<Z1!E@`<D10.8AI:IRJ30
MQ1T.!)]"<KBC'KTP1+T,S\M2`T1YA9$I9[06@CHE%8'12YKR\]>[1%@B@YG3
MGJS+F1)M5K'8Y(J>VOKBUF2&*XPQ<Q'F2)+I6",=;%Y$%VI\*(K(]2BC$89%
M[2B?\,;)GY34#%G::E\OA%F-QW`H3P%EV%7<8J`X#D<[F8,HT+;(K7@V4GI*
M;&@UJ.>R@PXSDBGY4//\N*AC:K`_I&I/2]Y5+986LY9BA!B-XEC#_/5)0M#_
M;)]0$IG5V.VS*Q7\7<>*2B9$S1)G!.P0;PI%T<+!<2X40]XMAP*POIS3I_'Y
MIYI`,TL^2BQ<<!6:4[)CI>UY42J3#.1-5;>73K+JF97LU6$-B)4Q`M(C;T78
M[9CWP.11IHZE4M0Y=%<.$1T,+(!#$A^_IUG+'K47(/14JS`;0KPFQW1=#(MW
MV(3-@K;)88=S!#>32+:O/D5%]]L7N$R(+H@L=)40==-OC45<_*G4MT(2K7#F
MIK*4T?!HGT45X@:30A22"!K=,>A&0$?4UF#'F8NU+8!^-2,`?C>)@/EH;7':
MQ7S6S3;X%5#X8B:>\OWR)VA1XOVVZYTI:164G?-%_P!OV%R(?@>:NKL2+&.;
MC#AA-)U@.N'PLKA>U'#4;8O9',+D&PRH-/1%UP-9@_CR)\L=E39NO./!C,;=
M-[*E)\K]3_9V",["102',N3@/Q9WXINT+6I-,I<^!-LG6N(RRO+*G5U/6-Y&
M;EE6X_T:0%B+R^R^KB+K83'WZI3A3_+"R`$#Z^XXQ\)=H6E3]\W:!4?:'QY)
M!&[G;9VA/.<76"'BKMRCI)K.FLE542RLL[F0G&+"U*2^5,LW=*6$UX1B$^>H
M8'--E1X)M&CBR0C1S!R>%G%&$FA!@QM5HRRH&SO0!.,W.A%F;X(P9DX/)VN"
M`,V2L:19(9?0MH&W;M9]4__T:SY#<:0I7=^?;T;'?:DW8QW6,7569B8URT)Q
M"Y136YWB4%3#XJ_8!"\_=]H/)%I2R!P35[+YR8R7I>V&?:RK*K91;S3&B<WL
MY'8-M?N:?*%JW0NK)W6HZ]!HWY/$WC:%3/"-VJ!B<+M>$^F>1^UJ32,*(OE4
M:K$H.:<1/3I(`BRY2.TJ)#/J*67X0&E<3_-RR='R>4!98<F?<TO&K=#)<-UC
MSX4"[4A%_(";!`JH&$/P<]59AF?J,93W"9H<H7CD,UT)CV?;Z4,U6I7MG#J:
MH^(_&FZVYTSG%^QHMV_]7+:HK+(9:/WDHHV=VX$F,AO<_&IN;\];,&P7K$7?
M7)/_RN+K=,M!+EZX'6?PQ9>%A\B2I-<%.PN_-Z*M3E=Q<HC?`1[)2#Y#K3H<
M+RU4ZGM^B$^P;EQZVL>/N?69[JSB_>AZO+Z[I,WF\^#?7!;&#O=\T>26"<.E
MK=I7%A$-&MK6*,AY^8F4NQ!^;FWJ*]U?Q=.Z'Z;^>W@;(SDJ[R:69J#7ZY:V
MQJ8,9@C&^WN.[L^T;!.<)AFZU1*I51>*B72:S6_+++HLT#F+8^]D-'G!&6;7
M,,,V59NE>OH`9)PB?8H4?V3'@)C%.Z1C/T.G2[M":,=%41#W>NZS686`&XB7
M?F+&?JLF-80E&]3B?E;7=\?#4A`X?4R34Q!S4F-%9X+2_Q@KF'>"-C<!*$Q7
MQ&$B\R95\FPPE70UQX)(M2B^4GSJ!F2%!(0?(S5J)'C&Y6ZA`74/8X)7<PW#
MY7!J`V1!5X,"(2Z=Q5"YY$$A%3I@Z#9/07#197CF-RFXA86RI3\`%'#1A4$.
M`C1TU#\MI6[N,V+=9"SC97*%AD8^6'9(US_1Q@W7DFV=PE/7QDQZ^&Y<6"'-
M!8EKR&+P)"_!AC7N``[H@5Y;A(5A*$S]9RIG(2BW9FY)1W:W-!%8]W%20U=C
MXXF:DEF9&#%<!7<7E(ORQ4MALX,%=(M:=DQ9@WW+*&K7HQ/QMW&\:%O]9WPA
MR%<4>'`;5"QC!$9O)VS4^$XFTO^+$2,\OB)]K,5B9E5/MO974U=E?-5C<5=M
MDZ53("4\@*6.S#8_!]0OL]-Y$H.)](%1Y(=]UN@X+%(VU4&.,$)>_!$O'N9M
MP?0Y>`B#W94__7*'T7%^7':/XT9M%:F.8B*06J1(=FA!E;AK!OF`KF9-X>@@
M_<60D8=RK2.)!YDTS6)+2D5$!*9]*C5G@`>1DK<^"W:!<;9?\H5GC;AP79=.
MUX(I]M,69%%]:K8Y"B23W[1O.KB`,^%WHW:(MB8>"2B!BI0N;W5I7+,Z,]&-
M07(D-N:)TE6"=D(B*B=EZ8B3.1<K!6@\PRA.$_=I6/E</,1YAE:5>I=[.H8=
M=MB"YE/_<17G5AFTA$E(DYPE&&KF/?,W3)3"DS,V,/^7/DA$=S$FD3EUDUP(
M1@Z$9G%H6QT&;@&R<W2()Z7)A*=U47ID2F[$9YTI@T`XC"A8"JQ8'+5);*'S
MC_F59\2IB\\T.8$))&^XG$ZV+!)Y68GW61PY&$/%CQ34'/:T+A0G@'$)DY[9
ME_6C9#-997%S2HEEGO7Q--Z3AT9WF:61<<WI=MO`.#G5@8Z4'L)93S-203J5
M.XE49HS&*2YWBQY"3]/T$Q*I-BDYEYV56P<B/WP))=NW:6:91A%'%F@GEZ=Y
M.D9H/X+EE:-E*E:1C?R6&[1CA;>I)`U$8&"6&6Y'+18#%OK(_V85VGY3N$R#
M:(!0<G#[)W34I(O7@Y0RN7BFU$?\>7344Y!YN8BM%6F*.5`P5Z2=YF!P)#BO
M5'KR:1'J1`_](`YRME?",7(.IZ)AZJ'1@VXA&9AJB!\929*.4Y3>%6KN)6)^
M4:4YD6TAAZ:*B&7R%)YRRHWT`YJR4)M$0DOCA(,6VJ+0-XXKMJ%`!8Y8N3E>
M\XXYRIJTY1DVX6.6>7YV273S!Q.P.8$7=3HPB9_Z&4&<,T*:B3Y0`Q?(R8UZ
MIRJ&5#LN6)PJ2*E'ZI<617J]B5=3Z''(N$WY1XR\I'6BECD`9ZPK<J&K9(RY
MZHJV1!R'=DVTR*E`FDW4R@QWZI\G0_^:`5>?L<5-Q512AOF%Y=9@G]BNW5EL
MX050BD."TY*D;6I[1YB9U%6?,D5M3#I=Y/HX:BJ?_50RF"D-Y60>Y@B*G_9W
MET@T2M)VNI6<OLEQ6B4(%5`!%Z"QAI"Q'(L5'EL(&INQ&$NRC5`QGK.0\6"R
MB/"QC!"RR#<LO^"Q(<NRC6"S-^NRHC&R%J"Q/0NSF5AS3^)H4M*5)+=6NW1!
MP4A[<S6@K09EO)*T\NER$94!+8`$4``%1Z`"&5`(*N`#/D`"6-$!,N`#,-`4
M'F`$4+`$0^`!*E"V8IL<68<A_Y`!,>`#,N`!A_"V/E`"C4"V9MNU]W*7H]`"
M8'NX>*L"'[#_L8Q@MSX0`QV@LX@0`F"K`L@!`X@K`V4+MC+0`E`BN$M&.X?G
M-Y&*<7]F9W.K3H&$J>HY',5HF;22J=*#4T[3/BO`!GF@![JK!WEP!B7PL5>@
MNT<@N2NK`KGK!AVPL2&@!KNK!RT@!;J+!,3[35,UGHD0`E#@MX<P!M%K"!F0
M!KHK`]-+",:K!VH`NE'BJJ.0`6?0O+N;!W.P!,F["!W@!GJ`![_[LD:@NUO0
M&QG`O.[;O&B`OO31`4;@`QN1D%VTD_M#KQ"+D215)U$$0SFS/UGS"O,2F_JH
M8H:G`G2PNWB`![OK!MI[`<&K!\.K%!50`KE[OH*P!+I;!V8P!B$`_[UZ(+TG
MZ[IV$49'0`=YH`+$ZP.ZFP;S.P@KD+MS4,2*4+YN0,"EZ)*-V[X!O+M<$+F*
M4+]Z4`?YNP@5L+]YH`7^"\#NF[MZ<`9.#!LJ`+Y+,+[`:3COQ7_N9&)JV'F.
M1CF?=U7;)H`9N20#2S`$V<>E@`%:H+MG$`,E4`)&,`>Z*P6#4`(P$`,A(+)L
MS+B)T`&/O`*"RP6ZJP07T+6.'`.+*\G7%*/H,0@XRP'VFP=;7`@?H,AX`,2$
M``6+W+&4/`CEZ\*1MU(8VPA2O`2/'`-'T`5DO`2$\+$<FP$K$`,P<,:'\`'*
M7,*',+V2.[W_R[M*\,LQD,TQ8+E<3,LOV_^QLJP'2J"S0.M/X!<VZ!JQ0CEW
M&9APOP82IC=T@S6!R+6/#<IS@#Q,&=`&O+L"-+N_YBNX&=`!'4#`(:`"D7P!
M'>`!1;S0!5T!'7#(&>"R!#V_']`%PDO0G4S0!!S1)1`"Z-NS&.`!AUP">DL(
M&>`!'M"U''#(19P!)!`'O/L"!7T(FJP'Q#P(6)P'+<"Q%9`!!UT")("^MSR_
M#KT+*;W2HN#1H9P([,N[,!"R&&`$N4L'">W0`UT"H5S1G:S22MS)'U#3`UW3
M@L#0\WO0(M"Q,*T">IO2&GT('<"\/URS)IO2']#1"XV^(>#2A3#6R9L!(J"X
MA-`!)PP%;ZW0)7W_UY.,'N@,.83FV+OX8YC&=1FUK15CG4,R4T,JK$37QXB&
M`=6L!X:]L1`]!(8LN$LP!W/@`QSK`5+@PW5P!6D\!VD0REJ@VC!@!&X0PFG@
MN8)0`FXP!V.0`2K@!F2,!W,`!1>0VG,P!!S;`4ZPVWE`!V8``[M``E=@W'F`
M!V[P!!PP"$V@VGBK!GB0!VH0`QLK`W-`QG2PVN0<`RTLN!70`KD[P(/0`F;@
MPWE0!VD@`QA;U)T\!G-`PN"MVOX]#AVP!-(]!UP`S7W=OGD0U8[`O7I@!()P
M!0-N!%V`!W0`N68PX"'P`6DP!VAPTH(`!:H=`Q6@WLDM""2@!G/@NQ@^_]U<
M\`$?6P)=4`?PBP0P$-Q<<,;5/-<^;<HQH-K*/0@>@`:T'<HXKN-XH`9),-$;
MVP*J+=LYCMQ0,-$?0-ZZB]P_G@%*0-[;S>`.#B#2="P/Z[#09HI'YB8F997,
M5DZP=:Y^IYN#`L.ZZP92(`-##;0G?`2"T`$8W>7F6]6+FP%FD.=YL.BZ.P=B
M6P%,3-QD3,4F'+T:*^BZR^CWJ^(*+<6:K@=7,`@WK=V[6P=`?`0!C`1PK<@\
MS;$GC,,7L`)UT.5DG`?H#>GQW<FIG`*#,,@H?.F#OMV-SLW>"^$2;LI(H+NA
M?@&)K@>*S+LMT`&N++:#?N`7\`$?3`<V#M!<L/^Q)"#"W'V_5"RX)&"_O+OH
M`'P&&A/D,O`!(1`"(O#N(%T!V*X'VCX(,J"[73#15)[I9%S%&QL#C<[JNSO.
M(C#K`IP!-GR_9#P'99[+"K3F6P98@S<V%8]WYC`PY=:=="B=ALEU@_(!YKZ[
MU'T$'O"Q-IS"J&[O0U`"1R#"SA[*%)X'2U`",O#!OWX!Y=L&`QT#X`OJVWP!
M*:^Q2C#$,%`")ZP&D2O$>M`%*E`"2X#$-GX!-YT'4E`"1:Z[:TRY'YP'2@#)
MB!#.C'P!'J#(6JRQ&8#17E\"*B#%H8[KYOO7N\ZQOFX$1$_(,*`"4%#?S"S%
M/5W,\*T'9M"U%&[O;J#_]%B,!R10`8'?!1@+T&\/T&!\`=^>YS)0`N%<!R*@
ML5N0YWF_]X0,Y`",!W5`^G5P^G,`RS9L]X(PZ"H>U[P+!2K0`F@@O!HK\(3<
M`BHPZ$V<`3!`X5VPS24@PG1P^2T@Q6/O&_,CK>Z)82((V=;9G0EC;40S135W
M991=ID'&FFZ6SZ5``EP`\\VK!K!<Z;^.Z+:OL7BN[3]-X<MN_LJ]PKG;!LE;
M`3?-VAK[ZA!MOZ^<L1W`!8#`!>5Q48($13)1\4&G9T=2<;&EI]>545&Q1,EU
M49'AII=7$GE1:MJIDJ?GUE$1HVI9F@&SI-19X4-IEG&1JJ?&^ZF'IT)Z17E4
M_]$!6@<9.1:Z<FJ:<48)0UI:`4-YEI%A1CFGTE%RT3$W/+JL5S<*'MK2:;19
M2H(7&H/YD9ZWLM@(S[\+\/2<F49-#:6%#/6TB+0"G[<*).JL:B6C7H4))?"A
MN<2MG3-?=#YTTJ1'":86XEIPJ%`""A)Y"!%:P(#!@LY2.6_VQ*D30ZF@07_J
M),JS*-&C%W(Z[7GTID^I.R],_=F4J-&?4)4:/>KTYE"L-<N:/8LVK4T+8Z$*
M50NWIJ$N<U114M.AU#$]R?BU$Z'-UQR3%Z#I,6)*"24HJ%2QBL2%D@]CE)!4
M\(77K*<0,)"8484'DB1**N?5(PA*E.8."O/(TT))1O\V3.5D0`&EQTSC5;S8
MX4D1J<)>(Y?QN5FA(OE>RPBKA<)VJ@)+@Z4,2R&E+%UH3(KU6%:!+PVO"O3T
M:+&'KZ2LUO]6J!*OK;RWFJPIC;F"/[^4$+*L$:N`!"5+E`+%8LFIT$(Z=(3@
M"B7P71!"(^I=4*`>2V`2(25YN,&%$>9D<Q970RU%54]6`4655$!AE2)78HVH
MXE0E@C6B6VR=^%6,5VWEHE%)2157D$(&B=-82@V95D[17>#!"E+8I<\%4B!3
M@0CXS$%(*8SH08<'D82C1Y05)+%8)R6HTD9>%T2FAP^F3.F==)1\5%8&,IAA
M$4.AE<(F<9@,<1H[HH"($)G_>DCA%Y:G>*!$&_@P=%`OJF0FS'^EP,;7-@RI
M8I<>5Y1EC4,@DE=/0<1I@XY(D52DAWC=(1$?)>==P&H<:F:01B@J3!"#+J9L
MH\I\TWC26C&:E;=$!FBH4TH7&CZK83$AC6%*AB5%4N&%I1B1YT)V=&%.6DRU
MM92++W[E8E8GEAMC5CS*^"ZZ,[9;([LW*CEOB4[!]1:2_I;%UE8^_6N6!25<
MT05COV;`IBT7[)6,M8119-&$8(K9G12E^.(&!WQ*1@J<1TS0@BIT1A>)$9RZ
MT843%FTWVF'!`:H')^<H9&E9,%W9G<*R&(8'&E)@JINDOP236@JF8&H$R934
M,4;4_V-T,35BS5F3!W2G[)5$=91$64JJ>(SR<1XQ*$0'8*;IL44G]^@QQZVY
M^J.I0;QTTBMU]!5[UB+IJ!$#/F/<S2;+45,]-21Y%PUAQ29E(N`I)2B!1K>_
MJ'G653C.")15GKNK552A"QS4*3HRI6)8J7-NKRE*OELON4J-2W#M!*=XH^VF
MY^U.='N5!K$RJ0WDBBKJ96`8V(9>=YEC=SNKQQ"4Q=D1W%E><,@1']27AQ$>
M=Q#',*)-(G,G--LL3![&F@5/'A:YAIU[JZAPR>*\<-P;*#E#GTSUK)C2@6_4
M*51:,Y-VBH&\KV7#-R0P1=[0@`^;K:UMM+)(W-83C9W!C?\P%.K&W::1@6(%
MYQ8(@4T>EM4F4J#$86&[6X-R<[<,#083V0+@]C(@@AA(`1_^2%)7ZH6BHF0%
M+/`2HE6\LI2QK&M>,!*=Z%#TE-+MRQ1$O%?`SH7$J>ANBW#!(E6X2$4/X`8-
M)?A&![@5#[U4)A)[Z4)>/A`JBRFP$STS$YK4Q";IE0).EG%.]SHA@D:H;TMC
MPP0,5-&,2)#O5!4X7]A20[9C,>1DYO-@)."DF^8=S1.YRE0A\I0,7(5"!IWH
M0!?0P(4&(@0#H9)!!S[@@1#$H)-<N%OR3B$VT3`)-_G`3GG:1I$KW8IOHK10
M*4J0#KTAA'LQ\(`S8>D!6/:K9*'_V*`IJ*F&#QA2#6=0`DA\I27'=:)"I9&!
M&^90RXT(2AIHV<D4Y?7%S<T+14F1UXK<J96GU#.*]X2GDFJ$HQ,9B8KS+!<8
M#UH3$QFI2#P!H\HH80<UH(&78K@;II)1'`=IP0V/&DPI+D:*.AK-#<^CA!ZE
M5)E.R`"14#@""G<A##V@X0A0:`2S8L;(\J`/A5I0`DW*$LB%,.>:G+K"$;I@
M%SIAQJ+B4((2DEF^7+1#"D8`DQNN=PKGM&,.7+7I*L*%@5L",'Q[,H43%I*9
M6+'MF':PGBR6U<-&:D@,6Z##HX0%0H5LM:M=C8/2WKH0C5$#3&I(PE-)4XK%
MF>(#CL-$_X!^<80CJ,"F8X@L4B^'T,S&Q8K^S)UF/PO:T`XI`TIXU*;,P)]+
MK7%;W9I#$B2DS0N`239TI(3&-$G29IET>D-50J?N0C89F!9NH;):GX)3GBZ8
M`B4"(M0TV#0V$&)J(6=0D`@F@+^->56F*$P&09XPW%4,I#DH;$@HR.BZV4X`
M@-J)I`:-^2N=EL)*;B6(7@>2@2>AM3N1:@XOS:NK4SQ6?=,007D7PH6\O%!8
M(;!('0@#GH60%`907<@<?BK:#!.TB%#4L(<__&$5+,$,:G`#&JX0@P]>8`A<
MZ$(!8\(%)8B`L5PR20:0P`4NJ$`;,.A"%V@K@BUTX0EW.RH7QO\[A"YP`0:G
M:`$72FR&)'#P`CV6*!1"4((66\T(+7[(QGQL-64H(0UN,`,IS^+D+K`0EYXI
MLQ'.V.(=BZ#%1#;%"KA@XB1X@,5=P/`+M$#F;J:V+$OP<8N5'.,6J/@"25#R
MC@$(!2YH8<H96$*.57G-%@]!2UI(V-TJW84MJ*T4+9`"%X[0@4/"L":@SK&/
M7]UB+HQZ$5H0Q**99`0QN(%E*3:%"G(,J[!=@0M2P%P,S-"&-$"!%R48\:[/
MD(1!@QBT0E&=M4LW[6QKFXN1^(8`TR(#(\3@0QS!!S"&U"\A>9O5WR;8NFWG
M;>>:!0/?D'=6VRTD>X.X7QDPPA!@`)C_C63$/!ZF]ZV#]&YJ?%O?V[9=[D(W
MHX9+?.*AW4L=9/`!$F#J4Q0'(\,[#O(MAI`2;E#!!U2`0JN%?.44UQ&^?#)%
MELM\YF9109[R,(='T>'1-.^YST'\T&'8U4%8_;G1-<LY=47EZ$P/.0S.T*TZ
MF(&=3:^ZU?_5;XYJJ`ZI_/C5OXX6<_VH<V`ONX8S0((6J)T$!S>[V\V>@1*\
MX`4MX(_7WX[W@I8([WS/+"8ZT??`EQT3?Q>\X3/W%K(??O&,;[SC'^_X&U4%
M\I2OO.4OCWF*_S#=F>^\YS\/^M`CGIZB+[WI3X]ZQB,E]:QOO>M?3W.RP'[V
MM*^][3_[(G%Q_S[UN\]P[]7R>W^U'?BZNWOPX?W9XQM>^?-.*+57.8WC,]_Y
MKK-=[X'4>\XG/DDA\M?'F;_[[=>.`N0OO_G/C_[TJW_][&^_^]\/__C+?_[T
MK[_][X___.M___SOO___#X`!*(`#R'\28(`'B(`)J(`+R(`-Z(`/"($1*($3
M2($5:($7B($9J($;R($=Z($?"((A*((C2((E:((GB((IJ((KR((MZ((O"(,Q
M*(,S2(,U:(,WB(,YJ(,[R(,]Z(,_"(1!*(1#2(1%:(1'B(1)J(1+R(1-Z(1/
M"(51*(532(55:(57B(59J(5;R(5=Z(5?"(9A*(9C2(9E:(9GB(9IJ/^&:\B&
M;>B&;PB&(R"'<TB'=6B'=XB'>:B'>\B'?>B'?PB(@2B(@TB(A6B(AXB(B:B(
MB\B(C>B(CPB)D:B(,W`"E6B)EXB)F4B)E*B)F>B)GLB)G/B)F"B*HVB)I6B*
MITB*J0B*EXB*J'@"L,B*LOB)M$B+IBB*LGB+J1B*K+B*KNB+N+B+JLB+Q1B,
MM3B,E6B+Q_B+NLB,P!B+QYB,Q"B-O\B,I?B*G?B,TZB,T-B-SPB.X2B.XTB.
MY6B.YXB.Z:B.Z\B.[>B.[PB/\2B/\TB/]6B/]XB/^:B/^\B/_>B/_PB0`2F0
M`TF0!6F0!XF0":F0"QF,V?B-U/B0$1F-WBC_D0[YD+E(C1AYD1!ID15IC1Y)
MD1/)D1E)DALID1`IDB")DAV9DBV)C2:YDA\IDAH9DR&YB3+)DA9)DRKID2]9
MDS_)DR[YD31)E"4YDS:)DTF)E$L)DT79E+6(B6S0!FQ`E55IE5>)E5FIE5O)
ME5WIE5\)EF$IEF-)EF5IEF>)EFFIEFO)EFUYE5/IEG$IEW-)EW4YE@"&EWFI
MEWO)EWWIEW\)F($IF(-)F(5IF(>)F(FIF(O)F(WIF(\)F9$IF9-)F95IF9>)
MF9FIF9O)F9WIF9\)FJ$IFJ-)FJ5IFJ>)FJFIFJO)FJWIFJ\)F[$IF[-)F[5I
MF[>)F[FIF[O)F[WI_YN_"9S!*9S#29S%:9S'B9S)J9S+R9S-Z9S/"9W1*9W3
M29W5:9W7B9W9J9W;R9W=Z9W?"9[A*9[C29[E:9[GB9[IJ9[KR9[MZ9[O"9^?
MF0=R<`=Z>0?TJ9?S*0>_59C\&9__":#LR0,*$`0`1@8Z@``%8``+$`3\>:`)
M:@`-``;F=0<_L``%4``(H`-EH)=OP`,+H``.(`2;(@0-H``-T*`,`08FR@!`
M4)\+`08.<*(IRI=RT``/X)_F)0<<FIMW0`9]F0=DH`HVBJ,!:J36^08%```)
M\*(+008%$``(L``),``!L`,,$010*J4($``"\`,,408*```$H``+8``!4/\`
M!0I@97``8UH``N"E"]$#`1``!B```<`#"P$$56H``P``#[`0/R```("A`?``
M39J7<D``!Y"C#$$&!Z`#N5D&"`"H>WD'#H``]2D'!I``C7JDGZJ<@LH``A`&
M#=$``?`#+TH&=EJJ>D`&!$``0E"?=R`$!#``K7H'"6"H/%JAMCJAYN4``*`#
M;T"KMOJC94``!1`&=Q`&!D``'+JI`R`$<D`&NEJJKSH`+OH&.A``0,"7;["H
MGDH)0B"LN0D&`.``-:J@+_H&<@"J[[J;>&`'\EH'XKH0>9``!_"JZ;H0=V``
M!>"N@2H`>:H'P>JM##&G5ZH'0("NY@4$`:``%*K_``80L'KP``#@K3T```2K
M!S^PL7H0!'^Z$$(0`.FJL9%*"?ZJ`#D:I$%`!N":J0M1!D(0!+*:LAK;`#]*
M"7)`LT+P!GCIH_0)!D+`HY10!NTJ!$)JM$)`M`WQ!C2[K`W!LR[;*=1ZGTS[
MLWIP!PS+`$JK!W(0!C7+HWD0!A@:M4?KJ#6;M4;+H600!&"`J$\;!&%@K_!J
MMX^9!R:@`7NK`4S0EV%@I7K``,]ZKURJIBD;!C\K!PI:L3OKLZ&P``*@LYN2
M`))K7F]0M'J@`QBK!Z?:JJX:``R@N0!PN#!KL0`PH@NQ``30N)3P!@M`IP/P
M`.'ZM0Y0I72*`*7Z`P$`_P"$RJ$]`*6\6P!?:EYA0``-P`"\2P`\H`JYF@"Z
M6@#M^@!^&@`$L`-V$01GVJ4),+D_H+T"P`!9NP,#H`-G"@`&,*$/V[L%\*,_
M$+R$V@-Z4`9*"@!>>@<'P*1Z\`8-<*?PJR$3JP.WJP!9"P3!"[&9>[<)')EX
MH`$0X,`0D`-]:;L_&@2HRA`/*P`+T`-1NQ"`*[J)6@`'@*@+L0.<VZ$%,``<
M2J5%"[-YD+R3>[^LN[F'JP>5.[D:T@``T*(/,*@Q>[$*``0_D```L+)DP```
M@``\<`<A:P`]``0.4+T(K`=@T*5-#+S=JK4&L*0_T`-W<*HM*L1XJK\%L+Q`
MD/_#'_RP".#$I[H`];FYL@L$1]RI1@P`![`#/(NF3@S%*2P'`2R[9*"H(GP'
M1PS$/`"EWIH'"$"H/``$;7JER$H`3GS$#:#`E;S`#1P!#DP$WTH`"Y"R!A"S
M>MJF]6L`#\"CY%JI>%D&`K"R`.:Q'`M@<K``Y9H'!\"Z"[&X!G`'D3NYB<RZ
M(=O&XSH`ELL0@)N_>E#"")`'=_``"Q"PJPRP>H#*E``$"?"K>J#(J5O,7?JK
M5-RI_AH`J1L&`D#)*9L`!/`&80``GJRU.M`#RWP`!K"V.Q``!;JYY;RXMPRX
M_!H$":#-8EJ@=Z"@JI"DC`JX"A"P83``F7H'7'JPY.K_R>1:SLQ,O)9LT8O)
MP`Z<R47`EQZ[`V10!D8<`-><LF#PH7YJ`#]*LJF\I@/0J0#&L+`LM6(:S`U]
MRSL;PKM,S*&``.B\RTBL`P_0ISM-":_LI`/`J!KR!F[[`&CJKM.,RV0@!#U`
M`.%L7N?:RCP]`,3ZKP&KL0S``SNP`SPPQ#X+I0K``UY+!@)@QV*]`SF<KA=[
ML+[\L^?*KZ'@HU.MI`&]KE^[J'K``P`0O_\KN8F<PD:;P?);U1I\PQ?MV(>9
MT0^\R?DYQ%TJ`%7:L%\+R/=:!L&Z`$$Z`!%[N>[JK[H,8#.,E]4*``T0L(:]
MMH$\R`$`P[;LKC8ZS`;P`PIP_]@,4<('Z]<Q6P8-0`!W.JC1#-5WL`-VVJ5T
MJLT=7+(,`;M"VM64L+ETNMQP6J!"<`"\R\K93:=W:MD"D*Z;F[KXNM53G-EW
MP`/*W;\%FLN:&JZHO1">B\TWO=:B'02C'-I"4+>/[=]XF0=-0`1%4`1$`"9Y
M";@:J@,+K@,8^K,](`"#C<L8>@<QO+;FC`#N>JHDG;('L-L-(010>J@,0=^4
M0`:A.[JE2P#*/)]W$-+T:0!)S1"![=NP_=,)H`-`$`0#<,M0'=@&X``]``;9
M?-4ZS!"Z70;^&LVCRP-A0`9/_N0O2JL/L-T"(`3JO`!0#N4_2]XIV]-U_=QZ
MH+$%$/_D8`#06MO7BWL`H^O;>A#=M8S.B"W:7RL$5`X``\#A_ZWGC0G%S2WF
M@CW%`7#,1DL`IEW""JNGZUR?)(O0#1'8Y=P0JSH`%2VG'TL)&ING(9O*Y)JN
MS8KH5`SI([O:(QNE02H`QPRXQBVRAJVS_HJZQ1L`(NRZBUKATPVRH][!TUH&
M.I"ZR"VLX$JQ"_$&0<"A\NW:Z)VNYMWJ;>K>:1ZN(7O7BPNP-AVP]^VJ#_"K
M=["YB+[GW:Z8!=VZ9>#2>>#"ZQP&]!D&LTRP;W```J`#9'`';]`#`W"K"Q&L
M_DR?9,##[`M@.;P`3-NS'(JLR@JV??JCT3JM9,"E$TH&/+[_K`HO`'G>T*A*
MK4.LS`UO`$D>!HH<O=*\VA6.``(0!"Z>PZ_>$%0,`'?\!D><ITH>L'+0[CT@
M!SSKX&N=TO&>PT"0!\':`$E.!@I0SZ-;WE^.W@S@KKKJHF5PL:3[M1A:!O,9
MKF]@IS\@!V\0K`Y`[D0OOXD-N/H:[T=,P]XN]H7IL2B[*;,\H6$*`'7ZI@'0
M`$VZ\55,`&-*Z=I>I0IZI]S;TKW+][U;J7-:IW?*L3N.IE5:I,C<I6\ZZ3E:
MJVBZJ&Q-[CD\`&]Z`%!ZK56*`&6PNP)`QAEJZ=O\IK`:NJ3]KTT:XFX:`)-.
M"4W-^56M`/7Y!F(Z^7?J`&[,]%K]_[/(6L=N>Z?.NN*T/,0$X**%7I]!4-5D
MO*0<6LOG#;H1N_.)O]@C//;3#YA!\.X`%@8Z@*M/K``*\``VRQ!R\`,FN@`?
MC?TZ`*(.,/)X*0<[$-0/P."\KB$E>J+\7<PRVJ*_%00,$*)Y[J@R"@@/93P]
M>GIR/`L+/7)A.F&&0(IE>D$,"CID93M!AIYZ8`$-0@P+/W>&>3T\J)YD.@L*
M#Y"&=T$-"@P_<IYR/9<-07F&0CJ4AC\[K4"E9)67#V1R.T"&9+A`=X2N.KF[
MJ3^LAM/5>G=`N`Q`O)_M[N_P\?+S]/7V]_CY^OO\_?[_``,*'$BPH,%]840=
M7!AP&,.'$/\C2IQ(L:+%BQ@S+DS80*/'CR!#BAQ)LJ3)DP_#"'B`LJ7+ES!C
MRIQ),^,=335SZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS
M:MW*M:O7KV##BAU+MJS9LVC3;KU)IFU;=GKR2*OXIFVK>'*$!`ER;)S;MF7N
MZFG;[F9?>&7@?GKSIEV>,G/ER57\Z4X8($'(.)3[]V_C3W(_RR$C6.#-TI]&
MQRLC!(@0N'4[NXT[%Z>[T0[-D:XLV^T=MK(_QPM=$+>^O'LU+^XL_!#A=K%S
MJ]4I1,```=8'%!`79L"/B7=T%!@P0`$M=W=VC+].X$&K'=BO#R#_D$!(J@<#
M.J5R,*`</#(&^-<+`CI\4H8"Y!GP@W3M@%$>@WH`<0!YUBU`R1L'6(>=A@.P
ME)H!#D0R`!@&!3&`?>_DL<")[I31``$4*FC(#M=MJ&$!;Y11P`YZ.&!`<W$Q
M\*,G/0A0H"="4%AC?$%T)Y^&`H0HCQP%>!@/&#M`&`\/`SASSS0&<,B`EWHP
ML"%Y!#1P3)$L>J*B``B@-MU,0@#PP%Y!2!(`CPD5(I$.H@31`P$&'%:+F:.0
M`48#`3@P#*`]X,E#AN6\84`!QP01``-:6G,``'YZ<J"=GMRA``'4*!"`?N\X
M4``!YQE29`*9A0$?`F_DH5<0/PA07W+M_\A!``/(!(`B04$`P&H[81"09CME
M'(!J6T$@(,!W9."I:@]Z"7%'&496$L!WGY`Q@)3F(%"``7#)@:<.=N+Y!D=X
MXDDF/&\,T-%P"""`3Q@\4#8EHD*08>L`![!S*F9[/2``IWKT``"IK@P`0`%R
MSAE3LLO><8`!=X32PV.&.A<8:#E2]NW)MQ60P#(`D/L)$'N"QD``).H@P&%E
MJ'M,=9SJ6"@\JC@;\\P3!F"E$`'P8,@;!2B`;P$])(#N8.4I)K'3O3P+C[#$
MZO&#L?"LW-P=P^186HYY:+KL)P\D\`.FGS0@P+%ZE&$`NY_H,,!A9(1[AP$*
M2,<#V<04$$0!`O\BJ>PGH<A,S[=R"+MO7&64(9P<!R``E]GQM(+V(8G!<_C(
M,S=MB`(8URV`,X<CP#<R`^PML,8;!]`X`P0TTN@"SC)P3!F\DU>?-:=JITPD
M"!B/=RW<>I(0UY\D4`!E9/!`B=_WBBLSH#S<_+R!!3A`L\QR(+!`DE;"1^:+
M0,I*P!L\X.C)#C@7QD.L^5Y^V[#%&E\E$`"C-#5&#@G0P0/&DP`2'>(!,$K`
M`U;U#BKM@$K4*\,`PO8)00G&88`+EQ[<5RH$'.`N#'A9+""D*0%%KAZJF)`!
M=."U("0`30UX@ZD"$``#V`<(!)R/`^+W`P24(0\,:,`.##``!#3.')W_*XTV
M4*0`D'V"A#PPT@#.$PO6W0YW+W';A^(4B@W^H`$`Z`@"C00$OR7L#@D@``]^
ML`!014@`"NA!#YHG0+@A3E3ZDH?.NM>_7B2`AP_HE&Y`$8!0R>4QY_($`ZY'
MI`#$JA8(Z$@9"$"N/"3`BO-X@]<J"$"QY:]!`CA`#^@(@`)I$(\_<%B<\L"H
M!]!1`(]SQP\(X(P&Q,D0R7KB._##LY588P!'8F0&"5`($W5/#TQSX9[>4#EJ
MR@%"-%-`+"W6$9488)4,L%-ZYI.)ZJB2E3QJ!_XT<X``(*`'-)I?.P*7SG@L
MH`#2D,,;A&"`!:"B!\8JP)$VF8C6@9$F=6J`_Q[A22D]A`$`"QB&)Z_WACQZ
MPF'2*,\X[N0Q!;2"<X6+1Q`$X,]Y"J">[QADL*(V,P`0H&3O8)KD#*%!*['N
M+@!U(.3R8X@%)&`8@TM`/43IOV"5<FSCLZ&7J"0U#2;,$';+7"3-D8!<@D8!
M4H-FFW):#V*6"YFI6,`)H?HW3_!`GE2RDB=:"+D`",!9!'A5`9[GR=GM```A
M4FHM#"#4//1K&$!(P%)9JLX`D&9":[(J,'57JC"``0QA4$X=X4H`E]+B<&%H
MP%B!\+I[?O&@%Y%#YD8[VN9HRCIP30`0AB$R2?:N%F4`0Q$-"\<`*&`'84`%
M&6S+@][RH'GQ`V8J2_^V6Y2Z0V>&ND,!%E"J0P8@F7D;K6)>"*T.>>*>=QF;
M3CW!']<(P0$"@(3'A$H/HN+EJ'\$S6B$0".AY@M=ZZ39L23V-H?J2PBM\9IV
MN[HS`XFP$G?3`]286XL#'`"_0O@D9=CJB5`LP+>^-90&T16X?>5AO31"0![R
MT+G-K%=G6;WBZSBLX<4V+IJN@)$``C#6%>W`MPX@P`)X`=`PF`@2#(B39T$;
M$O;NX,=`ID9N--4#QC"FK:'B'2^J!2,*.8,,O`.`.X50QKC"]0#!+=(!GGF(
M4O*&%RHUD'4-`2@=F`E%9!@/C*@'S7&U:,QEHJ2L+`FM`@3@213S8HN:4\C_
MKZ%WN^,0#YH"(-0)W^]UF%TK!=LQP>RL^*5MGJES/EA65_Q7#@;H",U8Q;0S
MK?C$`)"FI-U!SZYU)#WC>2NA-_S70PAZ/K9UQSKSP%>'<,RDR;0,?F6'BINF
M[CN8%24C=J2''?/X(W<P<C49HQ@&NZ-/KAT-PKA5!I6B[0U`X(\/C<3L:KHC
M#_BS4#Q.!:3N."W,E=1/=?PIM`,"X0?POE=KJPO?UW%7GI\H$A#"P.\P3+(Q
MAWL>IB/J"?/Z.6Q(E;4H]JTW]TYUA*^3KR=^H%@!%X`!_;Z,``HA2H)_@DNQ
M`J%_H:N>`\DYSI#E-Q@.$%)%2S-4JX$SN#J"/W6$_R%:&B;QAO'7`(:[3-;V
M/L!/35P8`Z,&NWKP-2!94N.DJS:\Q3;HL5^"XG?,NTP$N(/$4.1)PY8A`?6T
M6Q@,X#E/Z$`'I>F5`S)&C$;=Q5101[=#"_!42_%RL8Z2Q]67CB35'8*O@H%C
MB?O^':CARDWP8K/!28GP],;EDZU025,?[K[`H2N<;]LT:!+P2T!)C@P$>.I%
M^VMIZ((>/U:JJ3JAWG=13TYV[*!XB*S7BL#]E,1QX;4A)*]P=@Y=7/4=&]H-
M=*E>@S(2;D[TH!30XI-/O27!A`>T#:%DIBD@3PO@(6F:QP,A+%_KA`Z"$!AU
MM;]#M`%);("D\^``V_Y`"/^S3><$=4"(\#G+/NQW\W[T#P_JBAE=IC(`W9=]
M)]9(13=TO6(`W6<)`5!2!1=(!Q=`[L`H.N!]!@``#E=OFL$?#_!=N+0L=54:
M`&4?Z2,`P<!>X_$\(B<JQO0)-],E]T-G7Z56T==@$`5AO?5$G'5]/5``:=0C
MSR4$DP(`.4=`02`'%"B$%]AR,<A.@W=KCB%+W!($KF(DPX`@+]9;=O-4B68N
MK;0Z4O=\*"$$<R5]C,-="7!-^/%6"E6&9(`@Y"%NJE``V$$`.D`98?`J!>0L
M:E4J/9`AUW$`IR`_E'4`#N`E_+1VJ9$`"1!<NW>&T'$`*$4&-S0?/,`@2_1,
MF4C_#)4H``)%&9P#7<&"`!ZR.)<T&`F`'0J80OIT`,G4`T.#A.1Q``NT77IC
M7'EC`.GT!JXB'PH`:'HP*3QS`&P&3070`)L1"Z6!1!Z%)#[T"6-'67#E@/E&
MA^WABGF3B@*@@+YT33]P'3]`!M92.[^0ANWP`P;@#+F`)&7X;4!$`*BU/O=&
M62#B)>CH#'<P20[D`"\CABYQ89UR87=1.:)R<W$A!ZT@%Y$E':,1!L%U!_JT
M;#H4.@:S&Z5"3<P6>!-9&+DR'-?T;0A9&`;SD+<#D951!OSV12&)%^P`D5IR
M$V'`"\DV#"MI#A]I#3$)D.JE)039"_QV1._@DNJ%&ALY_PYRTI.U4)-/$Y$8
MB930H0D"60L&(Y/7M&$H*9-3:0[Q(Y1(*91$@Y(.&2P1J4^!=Y,S.0Z?Y8]J
MN99LV99N^99P&9=R.9=T69=V>9=XF9=ZN9=\V9=^^9>`&9B".9B$69B&>9B(
MF9B*N9B,V9B.^9B0R9<K0UJ"P3+@H3GTT`A4IABB15JE4QB:TRF.V)'?9IG'
M]BV*Q`_4)!./P7:1277.,A_SH4K#T"RC=A#:P$0RQF7F\(<4LB.MP"5-!B/E
M(QQ"0$##HHEEUPY!,#3/5@"WB9NNP10]R)O\D#Y%U1)I!G/O0`8]X)JOB1')
MX@#P]@-58X#3%Q'XHTTT@F7?UO]^"]`D09!]1P(H.U">/:``/S@8A`)/3007
M>=`KSJ=5]O9L?B<1@5.,1Y%H`Z%<(?82Q249502>X6D1=;(LG`,RK54Y#*)/
M\4.6CD%-+UD`OR0V1],.-)-(I9)]D(!<H`$\E(!1Q5(I#7`=)R<'?D,>7`9M
M3@E4I'D(1=D+(AHL19D065(V0:J51;EA<9&D6KF,JPD:40F249H*2WD;`">#
MH(&6O2`P(#H.R^4F$;FE6LD@$*D83)H'&ZFF4.JDE:%#I2:DGZ-@8EJE%6JA
MH=8.2I80#_`BQ?DT/N(L"T`+Q/,JJM0*0L`Z,@:,Z<$JT^,8>E8NF:`'<J<'
M$Z09K=;_9?LB'OEY<D"`*C)JH'T:5P_`"^SW`*?"$BYB`*&'.GG3`*R:G-9P
M3P2```LR=BXU8]#Q`*SJ1$`U*<[B1+*R`$!P*K1)4X$JK'%11'$E/)'``!!D
M1,P91X2R/`EV1@50/NSP!@MTC`YS293X`S&V'67@*MJ*K*QZK`ZZ>Y,45PY`
M"?GX`,"J`,=B0\WJ)3U`K'%T8&%P*@KB$,S:JA`20_211>D4!K1:G+2T8@A@
M'V"@J%7BB'?*$&+4"T:7$"25"'AE#JK2`#P`7B>4!PA"?X=4"$DBB4M$`,!8
M6,^3+QST#B24"@"B89;C)B8T##@Q27`!&1"WHSR$`#O`*`R`_S8(8%LZL`X$
MY`")8(5W8"U*RR@O@T!VN`-%FQG91XN"@42BL`/MU`F`H@`\(!Y0YP`7\P#J
M039PIT098A]9!+8T-#0\<#$[,'R*)HF_=31`X%(>6U4\<@<+$"63LF*7Q#0R
M1K7N=%OZZ33I0P!*^[<ZD`?*Q5QI9H<:&R)4`B<[,$%\,U*2B!]/1;8&\`!^
M0W=*-![.,#8(T%L&L&CYQELK`@`\`GJ46T>.DJ,-P&_:H0/Y^8432Q%,XP!Y
M`@3G^1T/U8Q-2U%@QUVODR\$AH39T"_;RG**E"3-6"XU$P_PD@!8Y5.$0B*J
MYPD3^@G&UC<%VB`!8#]YH#-AP&&5EO]%QT),XIAD`U`7)O@TP3`8)V6@`Q6Z
M=^``0PM,1T.VY!(*!<(T7)-F.D!4#F$N+!&W"AHQTIHW@92W^P(U0I401P(U
M6FH(8```S9@0=2=CP2@`.H4?I,%2Q\EU1D<E=T>IEN17=&-*/$*V?@(O1Y*W
MU=`-GX'!A4%V[(!&/"($!U9@LY0`!S`,07``M(!IO]>[_I!L1A;%S08`V3&;
M"Z),DD1)D#L:-O0Z3;LI/:`<@:,+Y1E'CI@DZ4AJ^8N]&(A5%I/`-/5P(2B^
M`TJIY0N-SY4**G&)-_MXT%F>\%(-OS$:0#2_F/8PX>@0C]H.670>GPF19/!=
M=L0?Q_!>=DS_)H&A*;94G@9PQ`R*'M^")?6;M_KA5T<<LY:ZP5@LP1XR.%)C
M/:L$;YZ7!V%JD_,R-R"SK@%DR6`J-?R!KZ>$8EO,&F7&+`)`/7623K]QRZ&'
M-D:,"EO\!K(U`$WLQ/S`7CSP8]G\8ZNE:#S@%I9Y=4H&3<E3(\[0KQ:#1X[E
M5GM8.S`%!+7#9:+TLJEP,F$V=NXI8(SK)D8L'>-[:#[K)X^Q$GXU=!X3``4D
MFR8;1TK2&`^+2WCT9-<+-Z17+@WP*N0QR?@&+BQ1HY1!<:B%)B_SR:FA`ZQ*
M'@J1MUS7+Y9::1&CRC(5QQ["5`=-'K(Y`-\9I@$:1`/`8A!9RZ8$_P9Q:@@=
MQA^?P561)F"\:M.\2WB6QB.JP-,L-@S/#+E_V&2K9LW^T)F>B9F.4U^[9X#4
MEW6@)U"9(:,;YITW<V!*XYE91FC6&:G2(T>7C"0/(U&$TPL7UP[_3&9W+#T3
M34\ZEWN%XIF643N<<`UE!;EJ[4XW<:!F5[Z:`$?GLF_GTR.59FB4[`IDD+<_
MH#FEE0>'PV43Q``]`%D;%"&+9LIU/2.J/&\<70O+9<J@G3DZM*XTDP#=1XFY
M#-3:%=M[)35>]=*T4"?5@"@_$`;5T8=79Z2FI-L%<[.>%+(`E4<%0W:IJ=4!
MX6S,(M91)P<4=RS91P85%2IBYS)WT5NEP?]9#9"6FOQVV6<?<O<`)UJCQQ`*
MQ=C7E`J#!MIR`:<''68(X'4>8?"NA^-`33N_;^@?*U(7D(U\Y`)'"<"G9A7`
M\RO3)EH.':42EQ,>P*;*YO!S;:=I`+#2_J(I7".RKZU_WXMIPDW"#?:NZ\H`
M%VYQO4U@IN0MG<P.H<`21CUGQ:T[<C``.)ZWHLA4%<XCP/,9FW3$>O!)5RAG
MYE+-VETBC/4.#Y5D6:<I#``&I.!6A^4=EX'>X28$83!!1<4Y:?0`;/X`3W0'
M0FOF0:`J]5G1`G8I#NTK8-"<,7Q==;Q.6.Y6#A`&/4#-UQ3@#D4HR3TW.$)Q
M#>#E+Y@8K[)ONQ3_48&S`,IAL9QTYK`K2@80!&#@-Y.<V<:$:="968U$2XWB
M6#?C-"2="@C2`X1^@<0B<;EW`(<01Z?=?C`MUL"]KLW".&'`Z#K$4F5F8U4%
M,E2"X_L%4(^>Q'?WX\1-##'C,02P;_5#,5>D-&`P*+";RK@56`!PQ)Y$`*_!
M*+A51$28W57N#T)``&`]=S+C`)X#YW7(`#34"6!@+=8A6'&Q`RJ6)GC89$]2
M?K4@MM>A@,'9YY%`UQ$#CYY87_0N,/4#4WFH63VM`(TALAX'31EB'0A`(OEX
M[S0$"4*<'0I`"7*0?0R/BO&AB(,"\CPP0Y0Z)+EX)&'`[QV""G(08^PQ_WS5
M&5-A@MC:6PGF#NM9=2#6<0`7W3W-4@ZWB$G[<O+8T4#IHDF'-!]]6BA->SF?
M*EXTA!T'H!\F_1F[1`M@`.^58&<(,RG(6!AK6#[,-!C\+E!"TAB%WD@]<V=V
M+WKM;A"M63:6*5IZ7###P#*ZEEL&@E\P13*>^5F:^1JI`930(AS[%),5!%.H
MF2*!(0>0=1='5AG*K?B%[PR!?PBCGQMW0&6HH6OWPAI@@`I'1OBB\G;*+6'X
M)1R;_P[[)/F$O_L"IOO*C9"4[R:6^9EY\SFC#_HMZ>7P.CR?<_QFWBZ4O_NG
MW_N\$/JD)@1'Q#*:^?P+S/VH+_[`__?F?_[HG__^ZK_^[-_^[O_^\!__\C__
M]%__]G__^)__^K___-___O__@*`G.$A8:'B(F*BXR-CH^`@9*3E)66EYB9FI
MN<G9Z?D)&BHZ2EIJ>HI:F2?W]B;WFC>X>I>J=T>K>%<61H8K>,<:["OX6ICG
MNGAK7&P(*QN;%ZT76\I<")R)W0E,O6G]R;W<W5A\/&ZX>EZ[SM[N#E9`("^?
M`"085F"/>K>PDY@'),&``0(,],#58YX\`PW"",KCP``80COR*2I3CY"0!`0,
M/'@S2(Z#>`J""/J!(*5*!$)*/4@@QQ`/`V0HA=&WXT"93C]H+A+2\E&#!,,Z
M/3@0\\V/F/CT-;JCH('_'GPF$U%UAS6KUE%!`##@`78'`@$_I@+HL:\!@`>)
M'@A0\$/(CP0!_.G1$>`!6!X.Y`4E0^``2#U"WA8E]$;!V4%"!AC8X58!K3P-
M!C3886#`1)0'#J0D$"#HJ`4$8A82XF!P)#D&&`@*XL#T)AX!'"8J0X#MHQXZ
MU&WZ\8#6`P(@P2QV=,=``CUD'-A&)`1`V:W4JUN7%"1`54%O"ARX$R8`6CF'
M@94GW^PP(3`)!*Q%E-V!+Z@"'.H0L'-0&`,&3`/)JX<<!Q!0$WR92?<0`P3D
MMT,`$X4A@`Z"X.9:-'?DH4L"#OAFRX7&*(..'-V(.,@"!5PH&R*K'/**+W(0
M_[!`(NB%F`PMM!7X"XD3"J#;0\XL0@V(B=RBGI"%5%9<`&49Z>-\!BB`B'F,
M*2GC>44>-HLAVEPSGX[7?6E==DX)HJ`<X>GP`'\/F":'#@@44$`#!;[AP`$%
M)/`#-6`PP!\#.!(B(`(_#-`C(7DH0%PA8<AYUP!_ZO&?/I0%`,0#"")21@$*
M]"">?L]QVA)MSS60*"%IJ@:HFT]N)X0"WGTD2`\-M*HI+ZXF4!5I<Q6P0%!`
M,/!&'@_H$!"O$PDB!`-P(G#0&PL$,,`"9?S`0$P`)5```CN8MH,#0;BJ@&B`
MYN31`[5-\ZT!=P*1!QET$5`M0*ZNJTZWQS#P`P\',/^4WS5B9=M#+'<TP$,/
M^SJ0GZQR[``:`D"<^4`!!NA@VAT]8'L`#[0DMQP9O=[#IW<\Q"0$E<8`X6K&
MINVI;L:T>%RIFJ;)FZW&@I#1@+H+'%L&`ST@8(`0<AR5[0_J@8ET+=%M9TMG
MX$&;@`Z*L74'`P$LH(/5"%RX@&5N4DJ88P]$7,!SL@A=!H^'O`&O(O<]6L8`
M#@SRQ@$"!-#`T0$*D0<8)@,JA'(Q-5"`:J)J-,!TUUB]0,0"M!1$05D+`),>
M#03`D`,%'<#`<`OJ836\$6MV5P"]&"#``0XT4!#)!0U[@'1RA,Y`&6[M]$,`
M!^CP+`.TT&6``YI_;JC5G:/_7A^DNC\PDH-E*!:G'+DC@"8!R1>2@`&Z0/W`
M`EZ=4[4`6"N0US$$#%#`ZI0//L`;#`=0DM\#1)W`>\+"/[GOR4$975EAH.\`
M-P&`!WKPF^(&`834/8!\;/E?`6`W0,(`@``*T$'])*0'3B'@)0&0$!D,0(``
M'F``)B&#`*+E`#!HK@$6C&#27LB.[.@`*$(`PK/0$@8`$"5`=M(%]0:AN3*\
M(5K<68#1$H"4"?'J-H0ZA`GM@HBW76.)"`3``/JE"+^A!3%C&8`^3.0+3AW+
M%@K8VB'.=`\"Z.`.;RH0#Q"DEBTZ``"]R2``3,(`.L8",*YY6Q[L9AN\A.H`
M!2*#_V4"U#8]/."*<LB6M<S5$O)5I0<`&--4.AB+3)E.D0C(C]\DE#8)0:1R
MA`D``0NA`.VE+8E0:5\A(J>X'=3G10*8)!P'P+Z8^&V'`M(>A*"8NR#D03FE
M+$M/CL4V_OWM%P@0C"T6@)2>V(9M,8K.`FC!F@.L0G!D1(`<2%4@.2#Q#B9,
M0"Q>M!Q;?`6&[-P$,%X!SQ9I!``!."%!#&`SOYT2=`6("9'*T"H!],)NWBK#
M'@?`@"`H]%NE,D3<"C4(,M3%;8XJ1"-C](L\=FH0[_30E`YH"R%\:P`M,9%L
M<C?&DH%T$++$$1GD8,(>O<@UE<G/X?20'3Q6E$S]?%MR$/^`0.U,@SPP_8$`
M7--(URBR??J,J-JRAPL#%H('U].#`\Y%)#/1!I1JLP5YWA"&'0``BH.`:DP'
M<;LC)6ZAG-H6`1!`#;9)A50@<8`KFTHF`MSA/CU8Z*`V]*0"4FD6,`7"`)0)
M4A-B4`]E($,TB$J&0?'O.'I(Y=/V608AWDFD"F4=&22*P3O0I0%`Z$4[3XL)
M(>Q@M3S806MWP*Y!9&<'8:CM2P>AQ4&4:2I\&H@`!$H8NEC13WZ#UD`&4@`L
M$B)M$.4.`:22GKO@IQ!QFYL@:#.4`=B&#':2V!8%D=M#X"9&8!P$IT;5T$+8
M5;GA^2['+%>:ZYX+IV`S*5K;)\O_,NROBB:Q&`+.YQZD)M(M;^C*=N2JAW&"
M=Z-`=*5\';*P`1&$CLP9``;;9*<)[_,AE@UE@Y5+/GN>,$(O@F[3EE,9]B7I
MNR95BSU]F[?`JM06*"G`A*$D58TL\Q<U'@@`E.D4RY;,DG$S+D$&P@L!0#$,
MPHW6&%$+94C`]+-4_BP6Q82(]NJV-&2(AP-^H$+@VB*LY&-)7JI,!H-BJHGH
MP%:*F%,`M$B1$)&ZV0"V9D@S+DP'?'YRCO,@!+-E+P\ZV.E2!],=I1YBO8/(
M[!,Y&E@DR;=`!M8#:62#I`8Y]@#I5)Y)&J2`'00!#&V;J2#6.^1&RRW!VEOP
M=P7A%AQI_]IR5^.!2"/$6+7EP7@\4.A$46F`=N$:UE<L!&G`@.97()2CFH)O
M71.58]#IU:Y"0/,;WCMC3B5`U/A`K*(83$Z+!2!JHV[VC`7A*D#_30Z9C1::
M'2M1LI*3!PLH"*JBC&],Y#3+#%;6'7YP1]V:[@WX&@3KX*&`;OS@()CJJB'^
M0]9=AT:Z6"R#G4`B3@$<"^"+141X66-&/70'2EAN6LA3C8A@_B(!"LC4#@4K
M(;I.^C4!MUI0?JJ'E@[3G(+XCQ!^BHOP"%BIBWQ#VA0-!`1!U=6O--FA:O,B
MC.*4PAZ.FXF33E9!F'785BTV128^(1V\M".F*8P_9$XJ73+8I/])5UR;PG"'
M`TRV+$NO,)"I"Z-!\(``[&FUW4L9Y!,9TL0,8W)_9+NM1P>H`=\UE]GR#7E*
M=,62N%U[:;(CIS!<5:#)(4`0R!`X;^H```TA0X-,[%"'7^-9#4"V$"ZWH=+U
M5:$Y$8`^1K_/\(G+$.?.^5K($(9GF41`GF_.W\Z;B#>HZ_-X\0=>'@#Z$=9$
MTCF?;Z7SB``P+(I*#3(H,7M^QSP(Y/-`B!U2L^581E^.!V0(@L1`HF#!@E0.
M;RKM?4S'F@)4^P<%H+KX-!LT9)`08V4(J90''@9K`G!O798/H#<68?`BI!<&
M0F`G.Y%BM!8$=U`R+-9/=3,`/4`&8$#_/C]'3#-6;S_0?@CP8\5D".:R`^WW
M5G+0-2@8!"KH;>C6:JS#?H9%%+FC`,@V*$01;\SD12&X+V\6>4GX"(W!-(3P
M/XK3`$A1-<:E`(O4$H%C3PC@$'>P2,=5.\E7`!UG4<,Q8FJ$"[)T9`-`07Q3
M0#`R#!:'`/?FA(G#479%$'%&#?LQ8O*!5LFE"!1H7'FS>"-F`%41$::1$`7"
MA)9C`*1Q0CL0"PRC7P@@=4%`4H1A/>CS``@@&1`!+6"@`W[H+"-V`$&Q`"'W
MA(9`!@@`+:U!('HP*"<T,:WQ3`%0`)%U9(^1/L;``%N#&U`4BLI%&'9S3V7!
M-BGQ6P=P+!$!_Q*6&"&I*`A1&!.K:$\%P`,80HD%Y$5380#0DAL)L#5@L(V%
M0'"_E3H.`0_0\D#@J('C"#IFU#/FB``UD0=[=UP)4!.`L4]@0(RILWM*")",
M$&Y1<EO<X5BV``9`\'/MPB8U)#3+%00/PR$/49"WX9!8]`95%@;!$A(5V6BF
M19!O1@9`$`3W]@8U=)!T\R@L4D-AT`WMHI"RD9'4`%.X,)"-=0<)B2,UR5C]
M,I",I5`[D9&_4$.LD))Y<!,_UV@^Z9$A(5)EP)/,H5`@D5G$$)'32)(Q4974
M51/D)!LP%24.R2;/)0=!\)`&F8>EY94?&20W49)+:0L%66"?)W*.M?^69Z20
MOC"7-3&3=\E8.`(>>0F1#X,+#$D(&AB3`:F8B\F8C>F8BL`VBO:8DTF9E6F9
MEXF9)8:9F\F9G>F9GVD==_`PH$F:I6F:IXF:J:F:J\F:K>F:KPF;L2F;LTF;
MM6F;MXF;N:F;N\F;O>F;OPF<P2F<PTF<Q6F<QXF<R:F<R\F<S>F<SPF=T2F=
MTTF=U6F=UXF=V:F=V\F=W>F=WPF>X4F=TB">Y6F>N&EZ951!*]D)L"&,8'('
MK74A/+!&IL"1B%<40_-JFZ!"CQ>:2'B>YID'/T```.`=W4@`UQ@*FN.?\*DN
M(O*@I$!HDB$+G)AZG<8);[12U,%DE!>@Y?G_'P8`!")2EMVXGYQ0!F"@-Z'Y
MH''73Z1P!Q+C"[AQHG$#)9Y`21NZ%1KZH=@)#8R0?X_29<2#'HTEC(T5$S-"
M#,"7(N&`#5-6%&"U$]]@#+N@9DUR@!`H"T2EI=S!"TYR(IV7I+0@I139E%EZ
MI<1`"T8:41*C7R=A:+O`;I0#*)\E&^$0$G=JIX3`HQ2YD8<I(N24DEXU#9^%
M"U-V#E.6(L5@)BEY!V+5`P#:H\R)!S@``I<*`E&P"%TAAH(`J0&2`/T`&F;(
M'0PP`)BC`Q[!8P=03P9!#151$Q7Q,[^E``6R5Z`1ABRG'NQQJF1Y#P]4&;:H
M#Q:WB0&`5#H`&I1S_W,MVD-O@``^4P`"D*`$=ZI!$U&F"BVU.B&<@ZP!D*",
M%3L3I`^]&`MO$*P&<5@\UHT"8(VQT`,6L:W7!"EVXZT[@!"7$@8*<#<A-!CO
M>C'9:AL\4``_4&^4,Y(%`"T-,#,]@#RN&HT'P+#0`BPYYQZ&,:G1B0<:``$;
M"P$YL`B6\H^7Y!IL`P#E<JHMP0\_M@.*`0`8E3MJ%(JF%(T`X!!J@5!BX16"
M,'K:<CDE>QAA(`\/L`//(J_&(0`\ZZT[84+X<Q!JH2UV.!$N2AX/&C>O4VA'
MJRU64SC@:AD[4!G.5&03XQ8.(A*_Q0`3T4A4HQ;;5F\KJ`>TL3MB(;/A(?]U
M`,<6"30Q.T`7#Q`+/-IE>*.W+4L+8C4`![`#5F,`.V$I%+2R`'`P%>%"M$$]
M.L"J:'$H$^0`F$&`Y0<`U+.B%VN<&0L!$;"Q1+`(S\*>QV@^CW-=%!8=OO-,
M.=M(!+!=\5!7`#`1<V1=AJ1*C@$2A.:SQM`US]$@]A`=!O"[WM,2)D0\N^0?
M\(,A#_I''7BRK>M,3S<1Q2M;'21R!!%($12C?E<8+1$>%%HU*\@V+R<'B*)?
M`[(33T>"R)L@P,6C<911E>1[B3L-ED)`ED*AC70<)1,CN*&^[)M@+E0R"?>V
MEP*ZSRFZHPL!IJL(^IJZ;V4^X@L@8L4J+5M`I&?_*@$W1PXQ1\MZ(ET!17'C
M=W03&$``!#\`!-A52B8V>B7T%J^*O\Q$',G13U(;-]]!<SUB*1/Q7R[,PH,"
M5W$3<E@7(#*JLR_:IX*U'%W!`"S,PFIA#Z-7%KCA2_!#Q4`P1P24HSHL&]$Q
M-V(%11(%)98B*0C@8&E#<J37Q7ED#^TQ)_/3MPS<P,WYP!OKL8IP54\645>#
M2'"%+.]Q.<\A4:YAPH20H[26NV`GM8U,#$Q,""9$3P&`R0&P@B73(S/,'()\
M:@`@+L_B?6%J)ZPP/[)%@*'\<_UWR0!`3_TQ1)VVR.&[,<\*:Z+<:&]A1_3D
MRYJ,%B84(TEWM[#\RIHL_R$:*@=WU@W"['L']E:*I,O3P,:F84)0\D:_C,F+
M(1#Y,<MWK*-Y?)QY4`0LX`+GS`6+H,2&0$GC8<&%S!8C',@QPJE\BB!_;%6X
M^PNG#'#[U$@I?#,!@`!F24/5)D&=''#.G,OB0L'#M,.G/,NJO%A!'*.>1]!`
MX9(V2@U*_,\O0X?2+!HVNL`.4-!`\;O=?#D3(<4E;=#*'!C-+,ABY13'"-(/
M\5^#X<8C34,$#7]>]\UV%,[B?)V-=(O496-\>6>X$!UL04G[1$DQ4D[=8'/Y
M_,C'$G=ZY3>*YC<`O<0O^@M_NM0LE=#B8UZKW-53&Z8/^M-3!T7R3,=.N!-Q
M0__+!-C1&?2*L&C6T:%,J`=6N/!&`ONBY0LH<`?4><#&.,)QOM<C)3,W(&O3
MN+0CD\77IM7-W'%GK1O40FV=_W$`&1A2*F@7+Z)-\,Q8?B$'@</!;"0>M\#9
M,1'"5N4@#]&B8[$4[N*X12$L`)`:(F<N:,')@^#)"EUA?+<*EC(W8LS#=DQS
M$ZW+E-1R&,(I<R/7JNP/_QP3IT@-N$'<B?%CJV`W1M,N'+%=[.K!9&1*:UIO
M$]'(8A4O'Q3;8D6[!T@7+>'8U%PJ.<T:MG<AJ_B*E=V]//=&)ZK9V9D'/5"M
M2`0M]DH,A4L-80V+^WI".3L5".L9WEH5:B'"^FP+(*3_2P6:B9AS&&]0/W?2
M?PH`$F0,W`D-RK%R0D#CN#LAQL-4&F]`.1M-8:$<M6I!`-F#.361-CP'*01H
MV(Z;$!V7.T<+)^.&+`7J&:=:1]/`LMNQ'R7+$:1G(PBRO@8J$)CD>^>#+>53
MTTWC8&B\Y+JSY774'M[,S$'^7)\[X--)!JJ2``]@-G>0N=1`!E.L'P_P%86A
M:,WA&<Z!0%_X*P5":,$1=IV##SYL"&]@0<HQ,C>34++E)R+'>*<!35$S&(=^
M(6@"#)E[K:)1Z+_``TA$/?DA$OL4!I-.&`IP`,SS)WGP+0?0$`Z@ZG5R``L0
M6XS1.2E"!D?Q)$:#+`Q@&W+`_P-`LP">[7L]<!1PL=&5/@V0<:@.\%V+LB^Z
M3@U\P2:@;@O-+JEO?IT8,I&'(`301]U<(@F_+AK"?0CBC@D>Y0E,`B3PKB5#
MXN8?P@@84@@:;`OC_A3W?I@`#^[F&1VEV'[=V*#IKH:EM1&4M9W\/O`17PM<
M>#=W\X'^[@@#>JH5C^C="?$2#_*G$`:MA8*=$%D[`((8/YUE\)8A[_(O#_,Q
M+_,S3_,U;_,WC_,YK_,[S_,][_,_#_1!+_1#+_''T`JN<)_3<&W[@`R,D/3&
M`'Q=JO1'C_2M<!@S<@>JH:2?D"688":$K26[X)%93_51^F;'\.V_<"7-\/3(
MX260L/_TH@`>4O\)5#H)76\)QR#PDF`.R"D$\:`0>/*K'LKU/T,`<?*>LD4`
M6==S'/%;^/0R@*\0\I!8`^NI.A$@&_0(2I'VO*=_F,"/[+J2*$$0!1$PUS7Y
MK6$;PE(`3\8PA#\A#N-0`UW))E(`Q!X)_,>>BU`WG8JB[7&)H,!&UF4)79;9
MC7`5Y/`#B0\=GW^<4EPP/2"W..3PHJ!M/.`6WJ0BB')X%$$Y<8$RY2,'/5`P
M<[0`Y`^"WV87C+;,DOFQQ.,(DX<)#$`68/\0D1$7<_%K>*$#!<,7-@8(0GIZ
M9`0';X-"`@IW@XZ/90D`/X]ZD9..<@@$#SH$!665HI4\`6'_HZB9#T"IK:Z/
M/``[8(VOMJ-R!`NWK64.8+RI0@&4MC\"I[Q``$'!SL_0T=+/P\V9!@=W80$]
M>G=RHM_@E=]YHG*UY]CC/0"LHX4]!>^)`@SI=PP!@H[;W:AD!.P8]$!`J%P,
M4.61,VZ0@P&A!IE#]4U/D`#T;E5\I*!`.D<7'>!38$J/#HB/R!@P,"ZDGC<'
M")!1&.3```#_].0)8D``ID$_,"8*,/#5G48]2F9JZ.C;QW-/FS(=5>Y1P9FH
MY$STAN[1UJY>M=XID%#JUD<;N;8R=Y9KU(K#BE7*4W50*6`24U6\:&V:W[^`
M`X^ZF%$/`P)RMNEXL/+!.#DZ#A0H_]``ZQL'!@H@^#%1"(/,#)(]@DR/#%%4
M#[(M4/"H`<J4#D3K\9?*-`^"!O7D:B`J#Y`$!0PXF.DI``(@913PT\.C0:,[
M/!"0+16$C(*^UOLZ(M,@\P)@<A8,,)Y39T=$C\(,-RD`JZ-E[_(TP.B`6*HR
M!18DE5M&UWY'AXUS!P()F/.``VWI%ED!#A24#!@+@);,'3M(=L`.X,C!0#$0
M:O:#`SKHQ@`//$A6&571:=;#'7DX4```"#QPUH</Y,?0@F0ETUP0'25`CQ`=
M(="#+H.\D5H!"01A3AD+_+##2A@^*1PX9"P0Q!T-)*!E`@HH,),<%:I82QX]
M2#>B?960\?]9`=?I\<.+%VHH%Q`+A`*=B3OL$X9RCH#!IV"`!BIH)4(P@]8!
M!^0!1@`#)*"#)`]XLT``#.R@#P(LB@<B`O8)08`!#]18@&RCY*E=)@6$&`0!
MR<C!9H*BT`:00`2AA)`HBCCJ@``(R,%#`0$H`(2LA@T`C@X!+*`#`C<!D<L"
M$SV@E",P#=!@`0.$(8=K`C3YR!L$E(6*#NU54H:UU"(@0``-P#K('4+<L:A<
M<@B11USO$KA5@'HXP$!;6%(:V;JG>`JJ#I,!DV>E"P`0:1D".$#()P\T0```
M"5@RP``(Z,````HD**T"CP:@PQT(!UN4(_4='!ZE.\S7JV$!,/C_``'(Z`'&
M``9X3`"EWBA@S\"LF$:`HYPBT+$"LLS&38L+1"W)`&3D,_0"$9N3)\G,_I1)
M3*'V%`80!F#<`\02#X+L3-(JV[40;PP@[J[N#6KWW=($`8`.0@@1!!`D41(&
MR(W(<8`!=Y31,<OMQ;V+B#_<D<`!XY1AP..H[)Q`5'H`0;5N!42J<=JN;',;
M0*?U:RL!O%4B;3(],(#(0X@0&V!_]^B&@*$/S72'`9A6DN<[80P0LAX*()XF
MK:F06S?HF'<.``$1N0*&UX[@Z\VK+`^`"%VQ"B`Z?J;DH<`A11K`"`(L$13B
MN1(_!#O(&AOP/0.YI63/<U@3E[]5[AB$_^)"1)``S*0!`;0(`&YS&*SL```)
M6491WH"-.YAF9@$!!>@RMJCRO`P(.Q&`7'8@`##D@A&ZD41A!D?`*@DB*:>`
MGR-(2(9SY<YPAG+-0;B'MQ[Z4!P,8<@;&/*(0C%*``+@&0\:L:C3&08Q=/E&
M&8#4GCL<0``-0$XC`L*`OP4A"`D@`'I$`89//$\BYPL#&:I4`'#(\!7$BE4`
M3E>0@X1+%.U```]HT3U$=!!`!+@#81S1#E8,HQM-G$L"E#>(PR`B>4\QS<I&
M0:[JO2L_3?D8-T;#$!8]8EZX0M/O6-,]2Y)B6J\[EY6\J`#O(5`_8:C%N1[P
MNXP5Z6@O&4#K]/]`PTH$93D7H40=1?&`S[U+BE2<"0.\-XB`G.R.`NR6ZJJW
MMH"([E8Z45H>B-6B.0["-3\`PA>3PH-AT.,'V+,$`0;P@"",L12GB)OHV$,&
MOC@B%LT(IAZ&X40?^G-00MC!#G@P4('N("/#V($:U9B./S82,;.)T,8"4"XA
M),`G`U@`&1:5Q(UM3(.B6-6H4!&&=774)ZR0@_IZ`Y9!F*XVS"MF*,"URZ;<
M#``!.,`2I^FTG!SF#C#,GE!JJ8>KD.,`ME1;;CHR%9KVY@V-<)ZYT&67`#@@
M`=EJIF0F4Q[M?5*4*W6$Q<9(S-?H(2EDV$9'/0J*,N`/`+QJACQWTQ3_I([.
M$5)]1)[<\U*9$O-_86!``7"&1&5"E!!$F26J$K(`CS@B*&"0Y"W+DH<#(&";
MFQQ$GF0T"*9YU*,Z`,(^A"J7]QP@`--K0"B"^D9>MB>H@]!;,U0:LM[]\[:"
MDD,9UKC&W=;P$?8<A>T\0H;)/.`'83"J-\*P`Y(@0!$/X&T-RY"@8R"`5%89
MP`^^^+<#'.\PIK3<)..8)F\6-3?8%,4;@."B`-).9YE]HAQ^^9X$[F``8$!2
M6RH;/(>@!)**;&.:"M"-O+Y'*+/AF!P*,3,P[4`'L_AD.O>))CU$:$P)Z"\E
MRU55-5I5NC6<"!E^L$RJQ4TD;$)5QDX\0P.2_R)G+MWD,%WWFN)R`KG2,NPX
M`H(A76:"2/P:!`QY/`AL#@@!3CM=4!:0C@6P"L1R$&U?O(H6,.Q`$M""9RY)
M1\(R0/:QHRTJ`?)[/-R:^;:#'(5#GWB'H/1E4F1XPX;$*@`AL"D=/5A1)8*0
M4;)6PE7BTFQ%`\!91SP@@3$N3R5*6A2_II>0#-AQQ%17N]19L8VFF>>AWT$&
MX\6W-1S^7:*0Y]A*B'8'6\F#/@11R6]E!A%RN&@R@D+`5("24%XC83+Z4].0
MXL01)(DEDM+Q@Q[(`42/90:+P3L4UK2VET5,G4D"`(R3F+*HKT'GF\L59"*S
M;QS#2$@IEJ,`Q!#Y)?^LDXAE,=L-(32**>-V1!ETL$8L&CJ=+GP7<*!3DKB)
MJW^*$:NA$DR2PISYX'9+,QGC&R"]508,]:FB`0A0'2$`#V644F.>VC6:TSI`
MH!!>SB"DG"9VZF0^#!`"&82`\H^\%'5%>8@=`RUD`%0FN4*15A#D`*X""`'G
M;53U`'I`!AXT2R)3N[;.!)"`G\_G'P`FASX:H'+/6%5MW."N#@PP`&OH8(&9
M%,"I"/7IH<BETP<`PYZH/7+.D".,PR)721:F<7NH6@`\V&BYXXPN16Q&'AC;
M,EXYW!2L$KT'C6J$<A\A\]AF7#T!*$FW!1`BT38@#$(X``!V45P#!`'G,I+_
M++HI:]F>DF\'W`U"&?!#@!^L7%UD:!'>R8!X?`_@`"KW7$+:T0.H,LOU]VV/
MT(EN]($/:'I*1[CR`^/NL;NT]6*E7#XH:CQ/",+B';VN-T[B4=DMFK`416)-
M5=T^KRQ@9B@K0!(%P(FIA`'Z`"'`/Q`&:^&$XR$#8+\.S.'N2?\`9^$2(>#P
M!I,R`)31=82T>>[R?TA$`"?32!HV&C>S?@2P`[5`0OF7?P3P)V7$9)"`5'Z6
M'MH5*P.0$4"@?AOS#^:3#:)`!NK",X=Q"BCS60P0"I&P?@4@5Z$S<C9!`"ZR
M8JER3S+1@A>51%ZB62#U"/3W+OJP,20S`(+0`)33_TP5J!-&ET01TCK8MS$-
M0"4$<#HJE3;FPQKO]P.*L%;Y)SA7E'\&\`X:@D0':'!OTE%U,AO``BUV%@!'
MTP`%,!-O(#0&N$S+T0[1LWR&&!@6Q#G>0`8-\098(2_#PB*,6&1^$R\I\46Q
M%PX@MD9^5@8A^!*96"25J'06-!5H,8FZ$8IQ-@IY4$_5X0C;]'G-%`3V\@;5
M(R_5D8@@46&C\`9^8TFKUPJ^"`1P,QI0]A6H"`E5DPJM^!;+"`E^4S=AX('A
MX#=#](R6\#>AN%S$.$:3J'(+5@:`IA/)N&"PH@V1F`G;J(ZI-C:Q1`@#6#?)
M6$^QY(F9$(T348KR-D;!V/^*Z+")J)@8Q,@4VJ!ZNJA>0I".`A0$>#%%\6*.
M[P(&!HF-HF5PAWB1&)F1&BD-W\!4&WEP/U!K>",>M``F9?>1*'EPW[!(IIB2
M+OF2,&EF.Z!^BA:3=B,$R1<H^<4S/1%I-OF3>#.3(@241%F41AD-R05"1[F4
M`M0#('(E3!F5T``&JR"55GF56)F56KF57-F57OF58!F68CF69%F69GF6:)F6
M:KF6:>$,CIB,QQ1$6A$6IK@0+;F6>)F7>KF7&?D#!W!&KN`9V"(`#%(]+C(9
MDZ%'XW""!T`J+H)"?!F9DCF9E#DH0:!:P?`#/*,#?_,0!A`1XO$`($<2HA,+
M32/_;Q=3:I6YFJS9FJYI"XI(<&1U$:+3$>F0!TX6"J6@&>G@.9,1FZ\9G,(Y
MG&/)<JOE`)ZA/LYG6UXAFN80=9I5$DE13.[1``C@D<29G=JYG5NY5S1C``S@
M&L:$*J24"DR5!^@9"<%#'5]8)*DB6'?)G?(YG_3YD;WT,<6P#/U$""9'+6_P
MGW,Y*02280,P9D)60@M0(!:!7XT5G_7YH!`:H?[DG8[43)1G+A=:9)M``)\2
M"D*S``P0HLQ"2\QA0)HY$YAQ!XT%G!+:HB[ZHM%`H8?E3'\&3=X`!'EV41[*
M2-Y`'24:!N<2.:!B80(&HT9ZI$AJ"S(J:9-D'D6JA$NE_YJ6<*$PE`<)L`#N
M)@@-FJ1<VJ5<>I\SFJ'`93)G(1]+Q:,4U@U:Q@/ATCXKZJ5P&J<2NJ06VJ0Z
M41!6LGI!(*#@4&Y]TS?RH$%:5E*31J0.*J>(FJBL:70'5*2%8*?>T`,]L3&$
MJ0/CH`](U%%-)V2?(SD!8`T,,(6*.JJDRIJ)T0B[!8MA\(E%!@8_8(9D509A
M,*NSBHVG*D#O2`B`6:J\VJN^^JO`&JS".JS$6JS&>JS(FJS*NJS,VJS.^JS0
M&JW2.JW46JW6>JW8FJW:NJW<VJW>^JW@&JZX=13D^A2>-*[N\F>>6*;E>A04
M$9N*F*Z`,B8L:@O@PPOU^I/G*O\8Z+F4_>H*B?,&]RJNML8^AX,H*==,".!\
M";<`EF6IPM!8!7H=$^&7![L2"J!GS22%"(`AH@`$N;-H"I"35"$$A[IHSV42
MD"D-.J``)^M2N'=;V[2KT^""#,NR"_"R&QD)I04/K60`/="8&0DOK(JD>J,`
M#>(`+H*`:]9#QR`<DT*-I'![.Q"2/3%_$'0@#M`=>U,D-M$`4?L1GO*D6D5X
MMN`)).MKK,`#(2L-S9&O^X1H/E0\/0L8@U.3?A%D1&D:(CD*\\&90()=RJ>9
M@INDYI02O.E0L/*O7K&X[F)%GZD3R#)VBI"SZ?(YK48MP($(><(/G5MD;%HS
M#7$')TC_432K$V?Q7O9*81:I$PKA#.ZB-ZS@+ONE$`G"N!16M["(NU[!BCW5
M"A\AKX#$%+P+BZ_KN\;;&\+;&U/:MVT!G<R+O*Y`N[90"J=KI`KW4(E!%-&1
M`!H+5`I`(#H0$="185BZ'0^@)3H0@MOB1-M@I^)A2H%+3Y7@/%;*@H+''-:"
MG19A#PWP/Y4`!M:9`!XKJ<GB3K_P'@^X$^?W`$G1#$"PP"![G6ZG&\V%`"E7
M72=#&H#C*"%X2(^R`$J),A^2`)0`)N%[>4WQ`^'K*!%A)!FFPGX"(ZA6"6]P
M901B;-ZP`ST@!.>W'HG```C@`**UGR3,(WHD2`K@P7TRP#QP_ZD0M1-"G`!`
M','J@<%X\1(X_``100:_$!W*02%<4L$H3"`>JS,.H'0"/,1`D*%RT`/AF[!R
M,($,``1>/!-.$@;6V0!9["LIG,7I$1M7I@"14R0XK,(6$1OO\F!!"S*Z:[0(
M)A'LHPUZ>`"AVC3=A`!9`C+H^;\*P(=B9X>Z(!Y_Z0I)41BN4HCU"\":T$:N
MLDMYH#2-T#>&NAU*`FV+%HA"PPC%E%/(]6O:FP>E@,$3%T!.!@XD9,D71:*[
MH@""]:FBX&2)4Z"6O#O_LF=Z2!:G-1"N<GOZ(0="DP""17$Z41\8G``!L#F2
MDU&'(1,6!P!D\1&:L`A2V+5C`8,DD?\`X-#&X!D3P/QCGQ*JE'(YDI`V?$86
M'PH._%(*!]``)%$`B#`IZH,U0QAKBR`>?2@]P+-,NF#)P"((=[#+`MTZ;W)&
M!QVJ%Q,B*LITW5&"X+PN!]`#RR`()#'1-7,0X?P9"%@)[:`9SYQ26.7,@R4(
MQ3,S#\3#+](S+BJ\%Y%W:P1Y`[$H"(`(%(0XEN,<)V<0CB-`0A+2!H`584`9
MK5!<HKH=)M,*R-(`.K#6#F`3K*!8CK!('[&EPF.VAE82>7!E`MMXMH,8N:#/
MEE`VK!`@G282.D%"<)-1`I0`^VFH<9/1(6U6B0#/!Y&;8S&$PAS*+\&2%(35
M9BJK9[U/"YO_NVWA*3U@#H9C`'31$\!P!_412XA"U9*@:."25?T!S0/B$;2U
MF+02()*3`.CAHQ]S.NUP&['P#\/`&T<+#NB$/B4E,>]7PY(C8'51>!H4'DUS
M#,40'M1C/@)&<@USVLR!"3R@V>!,MFX"08U0/+M`+OSP!@@PA:7`-\;3"%HF
MH5'4KNX*$G"U?DE$HHNR,@&2!U"5BOC#B%PW"^B0!^=R>;1Z'@!A$R)7IV@-
MSY.!6HC<6GH@UX]`UTKH8GBT>5HT$7S-<(AQN#4WV(A1WL,RJ^XF$A.G`R94
MO+?C8]'Y/'JS,GPQ%J04RXU)JWD"#%"U$-QA0)U&8-I2"U3V+M2U_Q!A<#A'
MH5\C!P`J9U[2LY\GQ!;Q/1$!DE"T&@;JHVH0-42+^'7-L$SH060<WEEMI#?%
M('I.Q>`LDAB;4+004VN%$B(=H7:S^L"DU@BBI:4SZDV+].6?^PC:]BY(9477
M1:OD<@JX6:`@==\1&E`D0E"7KI23W4Y?A)-]8N)N]`#2,1[E$@3`$@"@\@:+
MPB@>Q2A*!^8[;<-410Y*I2URP&?4J.%K/@@>/GB`*6<8)2S^56D^A1A!(1J#
M!)\.```>E43)TCD&$'FA<VT_]6QVC>))-A:/XRK4MWY",6^C;KK,<3$YY;%+
M[E+6B2T`@#BT!69@4`W]8.5%EF[9=%F-Y/\1[;!^^9=3^0!18+)(/Q-`\-E,
M1$%4?41RLX%W16+C5XPM>AB?:^9,E45]E+I)`$9R46<Z8W%$K=ZS28$75@3<
MP')2ZV(-G>8UE`ZALOKEM%HWP25'/M5&%)11!_6_6''K]:P<5O6G?1,&"3*V
M$PZ+DYPFFT&_0$%H[W(Y3:'T'8[>KK6KK<@#K03-C;=F`4)?CJ?BQR9"/!]9
M118$;8TQ3]&@+*94.(YH_L#C1:89/-\W/'=%"W!0]6$90,"UO''N.T,6J#?)
M:G_T?8-H3:L;T,1?7&[L1-'UI^#;6),`QV4J%A:FJ&97?21;,78Z3E4(X8)Z
MY1:?Q,)CE64`;5__C,FSSU1>RXBU1-@0^G[V9=X`@D?3]B9T]`XS$2GOI872
MNGW=9I$\'W'V`/R`)75FH_ND)`%\-*<;%(IV:,U@8*H69G1-HQU^6'IEUR-'
MHDL7/\ST<@."&`&G-@(?2`CO#:XWQ[]_X)5`]K..R[$%`*1S%]J.1D\Z8E%6
M8;Q_QQKJ$>?N&H\(Y:,$9CA9J("@UP/0HV=H*$?`8)B'@'!GR$`@%Q:@<Z@'
M!*8G>5=Y:<@#$,19(&=()K"CMT!09GAW<)`7%$"J1Q;`8_A&T*"G$["IUSB)
M>=R[</@#<,DP\&I8]G.J8``)%""DIU``J5>YNU#P=DA&??PC#'N0<)=@_VJ.
M3D9PH""PK<<3$';L_P\PH,"!!`L:/(BP8*U;_L`$*!1I$A``#]Z4V2%``!DY
M!0R`D4/F@`$Y#BR5>?-#P((\F-Y9`@(32+]C<A*HVDCF00`&D'0(B(:*P",]
MM1J\(9-@`)EC#.(=\[G4WPX`.]Z\V?=#CP,!8.Z4&7`@S%4!INXH(!#D31`"
M`(!PFE2F0($@(!L$`,*Q0!B0"$8R)>!U@(-#.P)$/20$``$@:H7*N5-`F2%U
M"S8*,6!J8L4R/`083I5@(Q@""O((L70*4TEJ9!H`&`E9P:%LVQH(^/%&2`$`
MNS#U6D3L``*6;Q\G[6&QL+-)N1:<_#&@+2MCN/\$7*K%@,P;G;LFW@K':\"O
MPLC+Z"10C@Q>?P\$(`=SH)D>(0(2[`V#0"FW:YELL7(*7BT*B':`*\?TL`XQ
M!B2@ASK9R7%96?>$$9<!KX@"Q#<);<AAAQY^R.%"`(7AWB%-R2&'`@$0(!0#
M^&0R`%D#&+"-'`RL2$!]AQD21G0!!`````'\XD\9+@Y`P`#BE:/'#M`<LT\A
M>9RG)$28G.@/#_KYDZ(`+(J'30`#7-(960G`<TH9"'@YP#UN-1`/&`:LJ.0#
MV.28)(W^,#!2+P\0IM$Q])V5XP%+W6&`9,0XB>2,I-2DF%"VD<)HDH;J\48!
M]:6&2@$X*G!6&8@J"L3_BV^HR.(]5B)2`)&-)$`<G&G:E*0`#)QR8AYVL6C`
M5KO(BLH`J^2A@Y(Y-G!*+?F0"%&F@Y5Q`(X)+*!?#P+,A(D<"]"I@+"&]!!C
MC@5DM1\V+R[`7W52:HDD60PM\Z(>L926!T;MZME9;Z4ZD`<82C9`'(@"#TQP
MP0)!R.DQ=PC!)"YAL"0'$#O@M3"3ZO'P`U#]]L"#$!H>`J$0(H^\(R9YA/'#
M#CV0$7`90@0,BQ`S;=P#MIB0\7"1'@.T,`\\=,5($!T3$P;&((%!7,0_(XP+
MTKP(O3(FT^R0\3]D(-TO4+E]K`>$;Q2]'M$EG\,#8R`#4?8;%1-#=MBX8,SU
M_S0=>^7QR8<Q+2_:0D`(%"-@'!8&ME<G+00/-7^#,TMW"%WUWTT3MW`T>9#!
M<<Y=[PT+&)([KL?40=S!]*DV'[)XQWP?(C<00"5^^2FLRRO$ZC^D_<_6AP0N
M3]FGG+PS,6#D#$;9!@]/?/'&'X]\\LHOSWSSSC]O4!D+-`Q]]=9?CWWVVF_/
M???>?S\0&>^"3W[YYI^/?OKJK\]^^^Z_#W_\\L]/?_WVWX]__OKOSW___O\/
MP``*<(`$+*`!$9$P@8'N@`E!$8?N\`:8(:(<$)3#&RR((K5E2PX2E)<&&0C"
M$(JP@0D83,%V<`#J:4\.N#E(&,9GL#PL@`$=)`@8"O\`"M0A@(9`8)$/?0@1
MDAB```G(A[QX4"`$_*"&(VRB$QF8"$4-K#U]TYZ32A80.23J>'D0#A,%<@<7
M&3$/)=G&(!K`,9_Y[%"V:0`2XQ6,!/#``=YZHAWO.,#'0$:*=^CC01QXB`<\
MB1%^]$<>./B/QY".:_)"I#\*:8AB81$6BF25%!L)D$JVQ)$*<P0F$1*7`Z3F
M-*!0QS#\02)0T&,1J5#`-W9`@$GB<9:TC)\0QI&`'A!`,G?8`0(*<``>0*('
MSCD$#QCPBC`T`#,+&`85#7%+`_0J&C]@P"T+H(`@L.2608#3`8)0!F_V(&DZ
M.$`!E`@Q!G#,G`VX$%L0L*K_KI7SG#V`X+8&4!EP\*D`#)B)]("@`VGN(#5D
MV&<V'RD<'ORR`4LA@P*,&(8%P#`;?[H#`D0YF01EZ5J':,`D@B`=:0R`7+4L
MJ4G9YR\#Z$`2.Y&7;1:P@P4(P`%WF`A$$'4-,LC%`0$EP#8$^0I_%>`!MD'`
M*1Z@&`4\X``"(`4S$O6``@P@`0H(J#:Z=@\&[.`>.\A#&00P``3H8`$`6$D/
M/)4`DAIB*PS0@0*H8J,5(9,>0WW`$+=1"0*H=%L`DP,""/"`@'+E&(U840,<
M0(`"G&27Q-')Z%R*#XP841TORT,>[G!90WBT8?L0GW]$:L*3BG:TW\N#)**B
M`P`L_X(^5NK,WDBS34N4(AI^'0Y0\W"6J#!C%4CE2><*P"!F$(D9K@2';%-R
MBRE!XRL&*(<,G^23*D)F."Y=!4>4(4-R\,*+E=`+,6P3N`#\"1<';0D"`$`N
M4FI%/UJD;I$2.X#Q3@8`P)2%+!+PBG%HB+*IX-=\0TO:``NX>M=%'3[7^X,@
M*-A:EZ#64AR;B&PJ.`@N,@\TWB`>D&%3#SHYY590,@IH!H!<7_G368`PX<)D
M;*:'B"XP`F4R%3'@!RQCU2)Z(6$%/Z,,E0AM)9##H@>DY1]=3%<CAG.:0CAD
M%0`91',Q,0@%'-8!5'Y`-9S2H*O:I0$`G1.`!PSF,!^OQ/\:5@99P:JD&/UI
M(C]`U`'ND`HQQ2A<80!J*G)XY"G]Y!`(.D>"'$)B`3R@$0!(LY+<@V'Y/A,J
MJ+P'``3PT*XIHCIRCI&7<*8+`Z\Y6HII)V';$3!K]-$>>I8EI@23#HTR!<O6
MZH<</#I5Z.10S+2N]<!Z021)*T,20B"#KWU]"ARK]ZL,_749RJ!<BXR)=*!N
MSV$*X^=\G(;$\=5#7\+P:V!_-8<N9O0C*2=3Q1:8V-DF@ZC`@PKKQ$P'"0C`
M2EHBBV_D(0'\*9:<8!60KWS9E`#!R&&`*B^OD.$.@+:UP0_.H7D[Y32+0!!#
MWJ"#F3Q#1?V(!48-@;8[`-7-WR#_T6"0ZA9BT/L._)[/B*4A:`YS%!4Z.';*
M#2'(!^\Y6VXD#`#"L$=YQ7LVPJR$HO;1ZP7D0^$)Z^(@OT(D,K3I(0+!\+Y5
MC8E:D,NBCWA#`A2])81K?>L!R48#PB"$\RHC+@2@L1#:/9.)!&`H@G`WMJWE
MRF?NPP%@ST\_D%H`(.2$Z0C*!QC0*](_]<@`01#?$%TNWV[?I>A)H3$8?GG!
M<[(,00O`=F=<60E+J(>(@3E`KX.`3YA9%``*"`,8[I$/LQ2ZBL?0]X&H,N$)
M+\6O:"%#20KQCI%23CQ?Y+KO#9X'+8$5743"#UC)0M(W&$`5AZA7CI2D@%?H
M0+'RHF.,__(.<UNE60?8&,!,>A3RN(`B",N/D>=_R^0F&6@T0SJ&\96D)S**
MZ65.0G,^*]$-Z.M64S&*OL(4@`!GX24A]RVDUWN9(E\8=WR6IB0F%`;E-U,=
MMR9*<BN_9X&_-SE!@'/'!C)@``28(S4;T7I!(!/?`!(!(SYT$4A*\4)W,W"P
M(()LPRD0$@0@"&<S6&/@(!-<XH$@"#MFTSE"(!/$\6-E$`1`<PBY48+_<&PT
M6$521Q#:01/E9FP@(X0YB`A7V'L7R(5=6#S/)#\_-CR@,PX)Y(5GB(;V`W!A
MF&D&PP.>$D]I*(=SZ#YAD"'S$S&FUB%AX`!`L(5T"(B!*(B#2/^(A6B(AXB(
MB:B(B\B(C>B(CPB)D2B)DTB)E6B)EXB)F:B)FVAKE]5'CY%`G-0\EC40>7`4
MHF(RH-A'7`-)(,-("L-(K4@Z9K@]LF@\EU5#F"4PAU0\MH@_N%@0P,B)`B,G
M'2$7B7(+(4&`S','-1<007`62H(`?O@MF($9Y_0`4:%Q80%E!K",_O`&$H4)
MUR16#2,'Y90HPP`$H,*.H')*S*,F<5@\0G``[X@*!J!6""$'*DA^>G@0"W,H
M2K4^;W"'!P$$ET(0-3%KP]@A(+4`.@"1=B4`;O%W\G@\=^``%!$0&($`/"`T
MT=(;J<53$/D,!3`,/9(`J=$C1I5%#$#_"(>04D1E*RQ!1BH15=XG"!UAC6P!
M0\F3"@EX/-Y1)-;4(0]@#$*0'0-#'X\2&>O#)Z\8$/OP6/_0C!;)D`<A(JAS
M3I[`=+I(6+:868_4>Q$E`!KY#_3A6XA@$TOA8C`)3*FA#I?@5S@)$(\')"3U
M#%'1'OU`(N.E=+_@B7U4!@D`,`%!BE^)$&&)<D#9$AWDB_(2,%[9']L@F3S3
M09Z("0TP`+08<);9=0!0(TVIF"930X<)"U#YAYYY"*(6C"R!(%-I$*9YE00!
M4M\H"900`#N`0@BP`]]P!SR0`++P`+2E`WV13<31&K+@`*PG+WUA+8QI"*U0
M14C)EC"V#'<!_PLN$@2I995Q(4=,1S23=56O>0AE^!064B0-$`0]X`@ZD!IY
ML(X&H`!M1A0,=0C=M!3FT1?]%"P+:0@4U@[UQ`O%>0#VB0L-(`2[F2'%"4\L
MD0T]X`#M0(WAM`U!X`!@$*$*0(V8XDO"H0/E`$L!D$U@X&FX\`".L)S0U`!@
ML%2YQ$AA!P"\R1'S&9PIB@H.<%$&6@8.\`-G\C`_H`"R\'7_^77+)'3R\@`\
M`#DZT%4F$Y]RQ$&"!&E_8Z!-TJ1RT`/!"9'\``3(L@Q&D2T\VCGJR9YBQ9FS
M&76?!0L717!B@@`X*A]A)*(.H"+N8%JV$J'8&0:)U0`>90!85%-R0/]FX+A+
M`N%MYE!MTF```[`34-DU>%%P-!$&PE$.FV5,*P=-`R"/#B$IYS5>G7$`."I;
M(,5DQ2"H^<$`#K"HV[!M_E`J!M``")";7;,F"^!1!-`/(`5<<-(F"+!,V#D1
M8!&KF08>>&>K!+`.-:$2#I`````P.H"LTS@(_4`&B\H`SW``KS`(V.0`GO*-
MF6``KV%EF@*K9%5<.J4(<.)=G*H`_508;QIN($I?OKI\?M@*3/()QU`J;ZHB
M#8"1C%I$0DD,;*H5(KI,C&J'(65Q'R,'&997OGI>_H6F`9$8.Q`X8'<CNQ`&
M,7H*<B`27A&JL?(3&"899:``XV0-%L-/3#3_J,=P9X9JG;#0E,M0:/XH8OFH
MK`,0<MVP7U?%"$'ZB@Z!`.7@L=Y0!D1T"G<@4QNQE=7Q"X(T$U9W#:T*;RG4
M-<'YFR\)#BI!%*0'"2"%47^9"0!@M2G"')F&5#H06X)7`+UA%L9@J0BR"67T
MG^(E",[*$CT"'/IJ"X<D5?T@?_W0%-%0K;+Q=_22(L6E#Z#9)`"0DK_U"%#X
M8J-#+='@`+Y%;Z<P$4/G"),S4RRA4_QP77D[J[[A"\:%41[K%YQX62CRB7J4
MIG*6$3@$"0[1&\6!*7WT-3<R<(OZ``P#"7\)!F`@!*>G74SX<BY;N@#1EJ2S
M88S@&K?1F'T$,Y$*_S)!\`-_M0GZ=9VG!`8E\@^5D'Z=4`L$>!J_$BBB\#D+
M4KS#JQ/FEKSIEGYE,'#=P"GWFA@0\;*2M@@V-1O:D`N[X&R(<+J'I+OX@1YZ
MH)GE\)IYL""0TQ=YT'>P\,"!&2:D$!M\)@S)0+S%^PQ?TX9=PT$@H1.DD%H,
M(4DSJG-O=@R]I7<:PIJTP0@7)<'\<`@9V0^:*7TVG"VG*[XF0AV;F*`[P`.Z
M6<03$W7-,#)@T#!B&!&N$Z%)$@"!0H\_X@MEX!!B@F8KPIR=DZC(D&%<$DDQ
MZ\6AY2!_%15D<%&RH%;6Z[*39I[?PL/KI4*W`Y[%09[I=@F)H:1H@F%3G/\1
MEA8[ZC:.)P=O#-)B/W$:R5BZB="_/FMR-(:V@X1A1`(&#%`@G@&WF]EV>W&Z
M)F(*>8PHI=$`L@"K_<&4BF)*J9`1:`96F&8E$/=+C!IB_G:=/P4-/]QZ,E5H
MY<6SJ#S#MC5SG:P'#C%.PL$UN&9<5G*;PW@4..-KV.9K:=J3Q7S'G5`&B^I&
M0F`;VB@$)QH`110`=&=ZOX.%K??%)C-R+GL`A7"H=1MR]"!*/5)<VT%E#F!$
MU@P1=H,)]$8L@\1A@U1@=7G-@$%9YL!\'($`)/(+.':QO[.!A(P8@`<+HM*Y
M-SP`N1%2N<!DOS&V#)$8>C?)T:#,>]HJ/2`$9W'_"G$K#`-M"#PKRO(9?/=<
M"-F0RAJ,;0+P=;]CSFUZ4S8!4VCC']"FP9OPO3^PET1&!CQ`+8,5PSZ;9X<J
ME5US`$*WO$GHL"&LF6<ZL:?QK89@S$#,0B$6"8;Q!@Z07+8A!(4Z&QM:).F,
M">IPN\20D28<LV_P5Q2$>J'`&P,1J5J$;UT#7$2!G?*"M3<;$$Y<"KB90X-P
M"UOA&J0P;ZM;S#T@J!(M4KGVAK8'8[%@`+10V*G`9(X\MHFG$<4Z<Y4,##QL
M40F\U<0,#TR"8VTW#(B"R'P;FHHBMXCB7O/19DZ\9#9GPA0]'13D",`E0<$G
M7[6P"S$<4HDP')++"C<7_TFD0<:2]@OH]A9U/+'W&5(-4=`U-<[T&PP:D1<,
M,ZFBI!,.8&[60D,`\570*2\JDHU?4Q*%&0R:0+P*);V-FWYF$2\`D62!9!(%
MY1]:1"/FH;7$3-#,/`FYISI!\)9U&P!.01D4LA:B1+57<ALN4P\+(Z+FQAU=
MFXS,Q[]CNQAE``1M,CEH.W,-.QZ\P6,E`;?X<`=RFV7%9A=N$=.RX:J\@2(S
MFV7;$`P,-0UMXM.HX&[M'1V4\AK@U!DY-!4+KAH/0;];L0UG@7,D$AJV%Z.'
M]$NQTQD\W"..6SM9;24>Q=5HNI0CTM\*7!;W)!183A3\-R.;T(RN['_P30#^
MF?^$FMDN\94:A1'(TJA-X,!Y-V,`+%F7;_YJ:48`33H?4A4C_GK#!N+F:1X/
M:GQ\YX<(T1):]6(L`L"-7^&?TG-\'A$*SZ?3D-#FN%!'6O0+I=(*,8)?X*"I
MP(#ISM(YLIHJ>9D)8*4#*5%Q@K1]KDF7L7!)G2*BT+*WQ(ZDHQX:6SMU6X$D
M!R!(NU`8W5+IG*)TU]TYM*(D3;H/N:X32(+)^#:I8(5-=(E;5)Z$!3`8/:+I
M:SZ;E,"9!,<I/`8QV/LY^OXT/>`VX/`#/X"$`'$R76P.0-`#-.8;/#V\J,@+
M3.P/5^.HGE!T8"#P5:3B!O\Q]`M&>X$Z.;@P*)U`5Z/_0NIA\HP@%E0I!#V@
M@@M/8TDC\O+2\D3S"OA^#C&/\9UC.9-#TNOI,?@.33WP$3@G#U4S\?(VS5;S
M`QG2]%V#A)/S`RAM@C</.P(?0132)!KQ\I;#*J7!,R_O\#%3,T1C];Y&'`29
M,5^C(3I,9%SO"0W#[]UM]Y1HRX0%GX6]/)9UM'M[]X$_L<&`16%@$XJ[/&%4
M`+@J^(V/IF%@V>#H`,/Y/#R`H(Z/^9FO^9O/^9WO^9\/^H!8F824$)#CJ*0?
M^JE/B68!"B[S+0K`W0"AQJ20I;'_^K:O^KE_B&&T"Q8E&0-L$!M;"#\P/0)!
M1PJO^\EO@4S$1#D7T*_`_)B@_]UZCPEK2&1$%OW7;T@(3YK*[_WS\P9;]:91
ML1U"T*,G"PEWH`-XL14$L)S%8J$[9$1RP`,`.*3+3!161@Q`L`".D(UK!0@#
M97J$A7<_"P@-881W0(D)#X-Z03IA#P@,0H:("`Z,A$(,"`H_>81`/3R1=V$-
M"`DZ;X6TM;:WN+FZN[R]OK_`P<+#Q,7&Q\C)RLO,S<QE"`,*#`0%8'ID`@4%
MB0$.>7($"V\)`0,)9#H`!0D+`P.,<@H""0P%`T%Z80$]>@\"@W0$.-"@'(([
M_@39$HA@`8$!UP02-"A'CP,`!NH)@*<GCX,`#0<08,1#@`$&"00X0,@@0`$%
M#LAL8_^@8`""BLYRZMS)LZ?/GT"#"AVJ\P%$0F4.(,B3#9^>.PT"A)%3@(&>
M-R]/J7N`,$B`!WI*YM,C)X&!5OS\`;QS8$'%/`^D6E1(B\P`!@C!#'`@IRU"
MN'(?`-AQ"D@`'?I4(A0B0(?=E81X!,C7`,"/IY(WZ>F!@`S1SZ!#BQY-NK1I
MT'(,*`C#FHR#`63*"%A0*(R`'7?$/>5&2*#GJP0:Y$EP@#7K'0'`[..1<-";
MBG?*?-QD=%*A'LD+@?'\G*ST[`X$_"ZS-ZS<CF#*8`=B7$CY!G2!`$@`A,P=
MA*?SZ]_/O[___\:09\X`&PF07#:($?)&<%31UF!O`"G(8`'_`!#XCH'L!<#<
M/\[M8!8!`61772TCUO*&AP6`"-X`LUQ5G@,$M%C(10(4.$``M%&#DQSP`2!`
M*:<`*.201!9IY)''O"&-$$PR"88<"!:BY$J\/:C6)`LV<$<!"#39I!S[]%-=
M63_J\$-<U-%5B`[B%2*''.24>:9<KTU"G@-S62?''?_\X*40GC5``$Z$D,&#
M.P%<AN2BC#;JZ*.BW8'``?CI`\0=V2A0B%<_Y$;;EK3IP>8D<@S0@!X*%$`H
M&3^`F=8_;P@!0#^$Q'5-G;7\,!DA>=!D&'.U`G`K77=N%H!F>2S`@*Y`%)+'
M#Y[I&`I?A=X%Z;789JOMMKQ(U@`9_[$6<(`<LFGX1A@'&/!<561Q.0N'$IYJ
MF`)DR`'&`06<F]9KL0;00!EO]'!CFC(J6(`!4^GJ@*P.O*'>C<.V.*4>91#0
M6<"'E;%-$`Y_U"PU+?X`@"1RZ+H#MRBGK/+*`/(I``$$"'#`)MG@^Y`!FU!E
M5:\N@;$#70OBF<?/`Q2@33ZVB4E`&7<L$$`U!D35[`-+VQ+$/3$G\$;33Q-`
M4`!3QR@A6'H`873,"LP"A@$O/P19`ZHVPD#;`C!`*,MXYZWWWCKE$88J0."$
MH*$_M)C'=H3(H4IL0N!W^&_8]+`#$"W>(<0L90AQBB,[%)Z'$(.0T?@M9?RP
M0Q#XR0$$#_\_E''X()D':3GDZNTP>N)`[-`#*-B`$>130O#`P^U\%V_\\<@'
MD\W)R3?O_//01Z\+&8=);_WUV&>/LAP[\*[]]^"'+_[XY)=O_OGHIZ_^^NRW
M[_[[\,<O__STUV___?CGK__^_/?O__\`#*``!TC``AKP@`A,H`(7R,`&.O"!
M$(R@!"=(P0I:\((8S*`&-\C!#GKP@R`,H0A'2,(2FO"$*$RA"E?(PA:Z\(4P
MC*$,9TC#&MKPACC,H0YWR,,>^O"'0`RB$(=(Q"(:\8A(3*(2E\C$)CKQB5",
MHA2G2,4J6O&*6,RB%K?(Q2YZ\8M@#*,8QTC&,IKQC&A,HQK7R,;_-KKQC7",
MHQSG2,<ZVO&.>,RC'O?(QS[Z\8^`#*0@!TG(0AKRD(A,I"(7R<A&.O*1D(RD
M)"=)R4I:\I*8S*0F-\G)3GKRDZ`,I2A'2<I2FO*4J$RE*E=9Q=^Q\I6/=*4?
ML4#+6MKREKC,I2YWR<M>8L$*N00F+X7YRV#VDIC$M&4RC4G+93;SF+5T9C&'
M&4U?6O.:V,SF-'>)3&9RLYJXE*8RP?G-9X83FN:\I3C)J<UVNI.:YX3G-L<I
M3VFN,YWV1.<VNUE/;)[@G_\<`4`'*M"!!M2@!T5H00VZ4((B]`0-9>A#$SI1
M@$;4H16U:$4O^E".4C2C'H5H1C6*48DJ_[2C*#VI2DVZT9%^E*4@C:E+1>K2
MD(:TI"N=*$=WFE*8DM2G+\4I4'N:TY;J=*8VG:E11WK1FRKUJ5"-JE2G2M6J
M6O6J6,VJ5K?*U:YZ]:M@#:M8QTK6LIKUK&A-JUK7RM:VNO6M<(VK7.=*U[K:
M]:YXS:M>]\K7OOKUKX`-K&`'2]B[5N$+5BBL8A?+V,8Z]K&0!2@-UC"%-=@@
MK4Z-K&;!FMG->A:IGW7L"&;PA2^L@0:A3:UJ5\O:UC[6!EZ8@A=NX%K-=K:V
M/\6M;FM[VZK*]@192.QNATO<XAKWN$J=@1?6\`74BA:YT-UK;[$Z7<56-[H(
MG8$-9H#=M5Y7K2S?[:YXD1O>\<JUO.9-KWK9BM[UNO>]9FTO?.=+W_K:][[X
,S:]^]TM>_NHV$``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g145452moi009.gif
<DESCRIPTION>G145452MOI009.GIF
<TEXT>
begin 644 g145452moi009.gif
M1TE&.#EA2P+*`?<```("`@L+"Q04%!L;&R,C(RPL+#,S,SP\/$-#0TQ,3%14
M5%Q<7&1D9&MK:W1T='M[>P!&CP-*D0I/E`U1E1%4EQ16F!)WB2I?E"-MD2]C
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M]N_S^/3T]//V^?;X^O[^_@``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``L`````$L"R@$`"/\`-P@<2+"@P8,($RI<R+"APX<0(TJ<2'$A!X<7
M*VK,J+&CQX\@0XH<29`CR88F3ZI<R;)E29<P8\J<2;.FS9LX<^HLF!)DSYT8
M@0H=2K2HQ)]&D\Y$JK2ITZ=0HTJ=2K6JU:L6L6K-R72KUZ]@PXH=2[:LV;-H
MTZH-NK9MQ*YNX\J=2W<HW+IX\^JM>W>OW[^``PL>3+BPX<.($RM>[+$OX\<A
M'4/>('FRY<N8,VN.6GFS9[J=(W]>'-IEZ8ZG38]>;3,UZ]>#7<.>3;NV;=!G
M2\N^S5OQ[M[`@PL?3KQX\-_&DVM%[I2Y\JG.A4=_3KVZ=<33#V>_SKV[=,;;
M]8;_]TY^\_CRZ-.K7\^^O?OW\./+GT_Q/'WV]HOF+[\?-_K^]P68%X!>$3B:
M@0(FF!Z".#'8E(--8<`!A`JZI($&`FDPX08:7LB!AQ76Q`$&L85H%TD;9HBA
MAQ]^B*&)2\$HXT$O\M1AAQ3.J...'+KH(X]`!@G1AQ7=>*.02"89THL^_IA9
MCDHF-2)XX56F888FM0ABE%RR!*54$@KEX958CEEC;Q)^V>6:-!*IHH]D`J?F
M8W.R>5*<E+&XI9U\?E0GG0-IZ.**?1;:98U&3GBFH8P"62.<BC9JGJ1/=8BE
MEGB^1.FF[[F)YX6@@LKIJ(7]R1">+::ZJ$*FDNIJ7I8*_^0F9:GFE,$&MV:0
M04JZZGJ2KP3=JL&MN`)+E+$%88BL0LNB6&P&P^8:4;/,$MN2K[UF:ZU6PN*Z
M:DO#?GM3KU^1>22'H8H+4P<X4*%%%E/0T,&V-$#10PLCC=`#%#MP9`(46EP!
MA0DT[+M":PAUP(.])AQ4,!0N-*0OO^/A`(6]&/=`0\,-*6SO"-LFI$(/&KNT
M@[W[DKROO3C8E"E%';@`11994(%#!RQE@/-`-NQ[0L@VR0P%OF"Y*.M%3MYD
M`QZ&'.+T(8;($?%`8#@]A4@9N-#T'B/@JH(=3Q^"PQ96`]U2"UJT8+8;3E,1
M<@=U.-V#V<'2T+0=.ZLD1]A/&_\"R!4@*Z3!"'L<4HC:#4GA]!A>=@`VWV'/
MD7=,(T@!A;H-9=!"&86$'77+)W'@@A8GO!B'W'3/5/4A4Z1.U9@9!NH@#8$\
M74CG3N]!]`:KM[XD#9W;T?4&5C@M2!QFJ$`VZTM-$8@A-!R4`11.US'Y!C@T
M#<CPS-I]"-XK=;`WY$^7$;A!&1%N>`N89ZCX(66TY#CY31\BQ_4MT3#'(5>T
MOQ`-A7/:[9XFB!V0I`-7$(0@#D89MAUB;COIG>N>DB6"Q"E2-.'`&)PF!QZT
MP`52`(33P#"0%NR`!RJ@D4.`-H(=[,`&`RF#TZRP`9RY@`<H-`BU`@4MABRK
M`X4SA`O_OF4"$4*O(%IPVA80$C+OY8%[N'+(L&2ED/%=X80\H((9ZG>%A73`
M!CNXF4-.@,.I24]PB$I(",!F""M@D0<]P&'T%@*T"0XD9!E((O]ZJ*(+^?`$
M>7#:'"`&P@#NX032HYL?563!(AY"$"IXT0Q<R+$HWM&./J0,$XDEP;.L*%0;
MF4@'`FD(&T!K6.\3WJTZ,((1S&L@'%"!"U*X@1&8@'LB,($)<"8"%[C@>JT<
MP45,X,`IM+*&K9P<!T;@2Q5<[U8F\*4+H+B!7.YR<+X\7P=6$$0<N!)],N0?
M04;`1E,*1&>RI,$*<)81)[+3EL(<2`=N"4Q?(E(AXH/:#LBU_P$I:"^2M4QF
MS.X93&3>LB#SW&4-1?!-@=A2!`)1@3H-HH$.?!"1\VSE3]8(-1IH"U@)!:8M
M)R?+:2*TH!V0Z#T=NKHL'-.ATJQD0HIWB#B,(%P9H($(#P&%;:74!2V@9D!=
MN4Q?0E0@,:M=(6@@`IR!X)@38N4M*WK1@E@S;R$M"#-=@$@69C,#O4O+A#)B
MH/D=0@M=T]4(H,"#.6[@"H``!!0&,H(M/$\08*!!'0`QAX9IT`]^6-@>#%&(
M.H`N:WD`A!LZ`,#Z%0(06GAK7'OJT"OLH1"&"$0<#%A",.C!$(3=@TL'D@7`
MVJL.M[-##W#5@YT>(A!RQ2,/[K:S#/]D[Q#6RP@.XO`\0PBB#JO%E3MUY@9`
M[&%J'(`K(();2\MB%A!EV)U!\FF(?0:J`PZ4PJ[`,%DS%"(0/!B!'`"1!Q6<
M8*]]I2(8`,N##+06LA'=`R"DQMW,EF&E&G"!&03A-RKL0+[Q.\C\H(>M<^**
M!W&-[$!,,`=`U.&>^N5O(>Q0A5?:-JYY-</S((NSK^&.$(`P`P=`8(4\#`*T
M(3:C0<@)-1R$#`ICD`+1*MH#.4C8#E88WH2X"X@=2&&PA9A#RS3@O/H!X@\\
MX%U<=S"L]UYAMX)X+!5VUH$X^.&X+X*K'RA;RQ*CN`PJWD`/[(#9/4"ADYY<
MY$VN\+0];*'_!^OD)^_*5DLS].U[30L$QT[W/:@9F7WYW1ICZU>^.;-.K7;V
ML],&T=Y:CH^P3R.A0,*9!]#63Q`>G0+DW+;B;E+-:57(D`T$(<#Z&2+).6U:
M'D)0PR#.@%@;/'2=G09:IP'"K0;97W6WE0$JC+"!N:.U-T5XN`TDFKDGJ%T@
M5)"!]\5/`RWH'"$*ASOX9:0%`:SUX^XG8#;V0`7@7@&XG9F!$XAPV>?L@=/,
M(!`;[+36\$LK#VQMQ*?1<`6D#IL<0K`\11\"$(@S2+0/P34FRE,+IJZ?'.[)
M`3[;P=*V7D$&V,RW'C0<=1G0]+][2^NYUI"4<]3`\JB`H1&$$]Z`_X"A0*"0
M<-_262WB2M%*`,DWS4Y!IA+,N-,"`;$IX"X0&.6S(:X@LWRW3@-.;"4/XG8(
M,.P@>LOS'<7KL`,7K$Z5U#N$&VC@`HH#@F-DH+46:(!@IUVAW%`PHA6^C1`]
M*MB1@E#;1>S<1A?08'PD1#IM:PGR%\5:N\03)`Y&U[0YL'JZXW-QL&9;TPYP
MP(&/W(/PU'>X###>#>=\'PF;O3B!#)S@/1B=\23.@;`?(@]51S@'-8G0QQ5"
M@;`7Q*UOM3KMSAUJ<V.Q(<:.@_TQ3P/SYB`.:)!HO'5@!PXT0UM=0(C7WJOW
M(^Q)!G;@M#C@KR#3:YH@IG##QXV!G4(G>O\/FG\([;9`"J0NQ!1X@$@'ME?G
MZ[:!#7P?!X%PE,`"Z:2O#S&'IZL>;QF@`CM5!C1@`^,C:VJ!%&%R-IP#.7;@
M4;BR.FZ33X=V*Q0'=#7D0(Q#>TX363G5.7F`,QD03E!P`1QX"&Y#>1Z5`297
M!EK0,"[@+BM@@LEV"(/`/J6W;O.B`7H4/SI#2BY`-ZE&<"##>&9`93Q@!324
M`1>0==:W`=XC/*UF.#3P(A*D/G&G*X_78D!#@=9U1]1G/QV`7;9&`R/0`LM$
M;&HS`H$4=S5T.H:``ZCD-&3`(0-W:KIB;E!C2GI8"*:D,WS&;=,52.3C-(IG
M`TWSA"U0.USC7D[_XX,7X`*=(SG3MW-J,X08.'$SI"LX8&LX$`*:HP4V(SWJ
MIG4,85:7HRN+2(6`^&NW$FL*-@(B!$G0LH4/I"OO\W6Z4HH%IWMN)8$L&$B%
MX`(F:&Q<6(IU`#*:4SLHB$F>$8-F``B$)H6&UCIP)W'"U3E`=RL.1%D90%.1
MI7=$.&E.XXW`&(7<8Q*ZDE([0`5QT#2'@R&F1T.XDG4!QH90,T0),0)Q4UV&
M!D'CY`(]H`6$6']#&()\EX^<Y#3:!3P$-WPT0`/`B'CZQ&N=:#\"X4!@T$/+
M1&U$0U-NXY#6@ROO4X?0IHWW!#=[:%M-,Y+UN'H'P5%:!P8T69-;0$OY_[14
MO=:!&*)'8&!W-(`#Y\9LP>>2-0AT/6EVMZ("S&@(>U`&4A`Q9E.)&-D]G5-P
MLF)ZG,9GE*4!X"@0<$=+M@A![\-NN*(UIX<S`P:!(E<VDOB0$4D#>F0%>:24
M`U%,SO@D!&$"-@`&]=-H$H1O_U9))T!J7R<0<`A!&5`%'7B6JC8\)+B0A[8#
MA7=]-51C^?8TA,`^&Q!.@#<]C^A00)@ZWSA"CG28"U9BU59]'2".`(B/^*<!
M$A2&M`8UD491&Y!XO&:/;UB.UB*+A["9N-("I&8]()EYG;<!Q#F.-?0X'A5\
MF'=.E"F&W=91VW(FG,<_';`_P[@KB6:;X$E@T/\I@DSY6EVE1_TC$%+`C+9C
M!F$V$`Z)E01Q`F:(*V$HB`+QE1O`9XU6FF<%EK4#2;+"-GB8G8SCF$1846PT
M1V#5-K;5-X1&AQOP=\32H`BX%;-B%U9G!@IV$;<23O0H02I`:ACH-22*2+;8
MGS2U!;?B3A<1F;@2=1=PD9)C0<+"<E#SE`FT/A@2:][(FPFIDPKQEH"@GTB5
M:$$&!K%FD$GW<0J9?PQY`=,I"&Y@!FYPI5;J<0BU-[M6$JL3:AO@0``Y.")T
M@R]B9X4P9J]%2]E9A\K9.5^'(2I)8/>9-\&'G^.TH,RBAW;``YVS6.1X>E9:
MI5BJ-L$7!QE1F.9I@7;_*1!=-P?D5SU"54M&9$YWA'!V,%>W5:,#`8ZM>`B-
MYI6-N0&.1`@K@"%CJ2L:=Z!0N#6L=G]N-7(L^4A76J5F8*52,*$O9VA48!MA
MF(4$L3IT68W!N)*LE6<HRF<`N:+9>'J0Z9M0VHP#AYH;0`4U<P+\"#52T#7`
M::8;8'H>!YKPPR&Z%X3X1*"D%H<5BH@$)R]4^83N5$M!5(64P6>M\Y9/E#Z.
MEQ"^IWCGM(I"JJS$,CB%XZV.R']-8Y8D*:&:8Y@WU9S62:0<HXE5.5T+*BT(
ML4&&X'M<1G%=1%?[:GG5EQ'E"0CG.4.H"D\IQ0-@T#GJ>A#+<X1WY`+,V$6"
M_[ELUM*-GZJBC9D!88FJ8JJJR9DU5]DUH]11LI)H;C-P7#-68[@S-"5I->1[
MG$8;ZL-_O\1*Z-=BT>HV'+`Z9M`U)S`^)<J?N<*8_SF$>_!*,,JK.L.EJ;B*
MI60"M4,(03A]3>.MIB<%R@*DZH-_"9&=@I0WXGH_&+(\3+IW*GEH^<6,K3.G
MJS4X9C`'T25@XP,%MF0"*K!TC[@S9DM7:B@K?PLUC;:PAU"'F@.G7<,!`V9*
MBVL%.*-3'/1*!7%_/*!+N&L")R!3MZ4]E71;=O`STV<'<0"[[SH0BKJ-=;E'
M8K8'@5`&\_*#7*A#+6!$9H`#NML#A`@(S$:&9Q6]?O_Z;PS$9]8EJO])J@'*
M;,!VBP9Z3@Z)D-OIH)JS4Q.H:SW%@F8@!V:@-M,9"(BS`[AS-;6A`?XD0'8P
M!P%T"&W`3E&G*PZ)6V-P6;96.OOI-#S[GQHP`ZH&43G(4\0R<AC2`]JG!5-`
M?ZST.',P!5K`C,,HCPR9*_9X$?%["&-@!:!#(RO`GKT:*.QJ"&`P!5LTN.*8
M!QR\/(&@A*[5.MGW2%LP!>]X>B;0A>,C>W'%GKHC*&U@P8L$G)4W$!3GK'=4
MDASREGM@`C)<3A>2=8;@!F00"+B#IW3U.%0<5U6\!S,P$"+P.(>P1/+D<%5@
M!3ME!1QPO!>1O*6SD]]#!=S_5SMK/`5`?#>3RB$[T)2!P)YI*FHN:P92H`7Y
MEJL7\;F!=[Y_NP570`.IVD]#BY98J4='#,A/L\,B;#A;(`4.E`<8-3Y[8`57
MP)Y3X#^:T0%6L)JT%@>G*A"RJIZ9"0A5H&Q^);`<PJQJR\%M.Y'$(\QV,$0:
M$,M/,U\OW)G=+*X!%LJ->A`<$$[Q2!`=8'I/,UZO)7'N="&T$SF^YSL=H`7"
MO`?^BE"^!SD;.P,K<G$/1";`*42!\I;,BYSCJ@$KH+H7DL=[**=;0&AU0%-R
MD#!Z3#_TRB'[![@"L0),US?FPUHPN0$C^DCW],!$.,F0`P@M@Q0:,'\1"GIN
MP@$]_\">`G0%5/:Y_JD%'QPVN2JP\,>JWK,'AT>S85,'5+M*6"#,+$TL+I#`
MN$6UOCP3+X.A-'`%;F`'>3`'8-`#(D`F4%`&USNS6E`&5K`"R6L"&&(%8DVO
M&K`#8KU:&;`"9&`&.*V>95`&EAK69<!9`H$#96`'Q%L%*[4!<+W56B!+>2T%
M%Q'6UTLL.&`&92#`758'>1`'S(4^&@#895!AR3("5"`'Q"L%'0`%DCT#%[`"
M>7W7E$$#9;#55O`O>2V'2(4#8&#9<W`%#$3.;"W6OFW6./#56*)%9>#/!U<&
M8R!3")37`)4A@&T&<Z4!)K`%9;`%PKW<9%#,NS(VD]U"3?\#QTAU!9*=U[>:
MUV*=W2^BT-3-VH%B`E+0!GF0!V;0`SN37V*]P\L$!M7-/3S@!GE0!UI@0U<0
M!UHM!X1]*B*P`V7M@DD@4QRR`2MP!:)=!WE5$,2=T7`]WQ<AW5B@U7&@`]6:
MUQ`8V=`]$"HP!B[(3E`8V',0VWQ=OAQ@`UN`VU9`2R6T!8)-.H[-9,$Q`DWE
M+;+#>F(F!:$WR*G[/3J&/LE"*[`D<U0$2[C"NDUU)AGQXT^.-$*>$*P[AEEN
M04>3H;'SM+`D*&.5$3@RAH^"?5O>FNV#Y6,E*A:$Y9I"SEI.5F_.$6-50U/`
M+RFTBQ*JY9I$5JS'$:CJY++35+3_.^=0CE!<CLX-]1"^XJ'?<B&L)((51.>,
MSN9RSBHQJ4RRHR$=8.785T/X4]6S,=6&%@@]<`(M$&M2"^@4A1R$_A%YB:%J
M%A.KHJ"Y0P/TR;&UWN6<@>JX613B<B-&(R`TD&]^\W,0*!'"7AM@WAH%;#AN
M+*DA`B>F?AG//A([8&,$%`<J]Q`SO>U?$>TY<>L-(@5D1FN"4`8VKB!-$BOB
MX2>V8E$X<.\M8)EH9!+DKA5[DNT68N@XP8(N@`,Z@`/O7B'&#N?.(A7];A31
M`C0@8N[H0NBMHA+'CBZ"$?'`+A+8'NU[8AB",N:L,M,JH68A+QR"\DD(L>&:
M!/!L`1U7_W+Q.F$?*[_RR8)!B('RF(/N=](B+R\6-*_D/0+S&O\1#W_N2>\9
M$Y_R9C[T1`'TIV+S/N\52T_5B$+Q<1X61A_KRF$TY\)(L9,8"\\0&8_Q(R\7
M88_T\HX2@=+V9G'L5U\3<]\0.'(36B(X/4$@>;\3PAXIL+,2?7\J3QX329/S
M5>\1+.+Q9T_X2)/R9''W>0+UBLX2:X_U%(_S2]X?@?\0=<\3$+%(A[_D'='Y
M=O_Y=M_X;R_P?@+W=I\0DA_ZD%\2#S_5B;\D%&4IZ6TCC9'T/J_USA[D"-'U
M%&'ZN0_[Z8WZ@5+QOGSST^$I0Q+[.?_ZN&G\9J_\"X$C+S/X(O_A^H*NY%H/
M]W=Q)56]X>3O&$32%VE?^<Q"SMH?ZY*?$B`"\)8B_SUR_YFS_EY^_D=Q*=9?
M)@"A@<,&@@4-'D18<.!!#APT)-S@T"%$@@(W"%QH,"-%B@,M-GQ8,*1"@P(U
M6.1X<"3!C2(_IE1Y<2))D1XGMD1X,^),AC!];LC0<:?/DQXCEG1H$25+F1H)
M8H`:5>I4JE6M7L6:5>M6KEV]?@4;5NQ8LF7-GD6;5NU:MFW=OD5K0>Y<NG7M
MWL6;5^]>OGW]_@4<6/!@PH4-'T:<6/%BQHT=/X8<6?)DRI4M7\:<6?-FSIT]
M?P8=6O1HTJ5-GT:=6O5JUJU=OX8=6_;_;-JU;=_&G5OW;MZ]??\&'ESX<.+%
MC1]'GESY<N;-G3^''EWZ=.K5K5_'GEW[=N8LO'\''U[\>/+ES9]'GU[]>O;M
MW;^''U_^?/KU[=_'GU__?O[][?N((4`!!R2PP``!!)#`!`UD\$`'&U1PP`4-
MG'#"!PM,T$((+SQ0PP@WQ%!"""M\T$,*/_S0Q`8SW%!%!$%L,085!9R1PPAK
M!/'%&"G$\409>80QQ!^#'))&!C74\4@CB2RRPQV9)'%%&YFDLDHKK\0R2RVW
MY+)++[\$,TPQQR2S3#//1#---==DLTTWWX0S3CGGI+-..^_$,T\]]^2S3S__
M!'1!%I,DM,A"_P4U-%%$%W60Q1\=U7'0(0\UDM%&*\7T4DT?S312326=M$E*
M-QV54U(5S51&3RTUM55/747U5!]63;745VV-E5-0<665UUICO3544W?]-%=?
M9?W5TF`A%?9%4'_$0P\\IJ6V6FNOQ39;;;?EMEMOOP4W7''');=<<\]%-UUU
MUV6W77??A3=>>=,]I%Y[[\4W7WWWY;=??_\%.&"!!R:X8(,/1CAAA1=FN&&'
M'X8X8HDGIKABBR_&.&.--^:X8X\_!CEDD4<FN6233T8Y99579KEEEU^&.6:9
M9Z:Y9IMOQCEGG7?FN6>??P8Z:*&')KIHHX]&.FFEEV:Z::>?ACIJJ?^GIKIJ
MJZ_&.FNMM^:Z:Z^_!CMLL<<FNVRSST8[;;779KMMM]^&.VZYYZ:[;KOO'MH0
M-N`(^(TW]#7D#;XK_H,-PP]_XX]["U=<9$+>8.-O@/5V@HDU&K>W\,,-AZ,0
M?"''W%XXV.`#8#X&QY>/R/?]`_3%_X`]]C_X"#WC0DB'F'&(;R]=8]X)UIU@
MU6O/G`WB`0X^W^3)9F.`!#SW]P\##E"\$"2<J/>/`I[_MQ`FFC#8"0$"()]\
M`0QXH'$G`C@B9$.:.&!\Y]GPUXD$!```@``,0`+Z0XX87_D",``$(,$0]3)$
M$02P@-"QH0`#>,*_^("`!:2N`0088`+6<"__0QRA`.0S`!,.>`@C$,"$)R1`
M`1[0L34(H`@06U_['K:&`:QP8(9P`A(.UL(7#JP(`=@@P8P@@`CJ"PD!`%_!
M`(@]?35!`$PX&QL"<`#_\2N!13C@^HR0O0<8883]>D(`>DBP)@"```UH``,8
ML(`!`,`!GBNC##_6A``(0`$-0```"D`_P`$P``HP@A$8@+\Q&@$`!E!C&A$0
M```\`'I_.```MIB]!`"@`5_<%Q\JF8![%6(!AV1``@)``,D=XH@#6./XF'B$
M`[3R``@X0`$`,$:-/:&1$&-#`XKHL#6XD6!O$``#=NC+@3F!`:44V`,`L$M\
M'0$`213B,_>%!`#H_]!L4CP`(<@HR8(Y@9L%*Z,P[[4&#-(OCB"#I`"<<,`_
M%,&2^VHA`9CIA`$(((B&I&4AGO!!*-:KA0.X)P`.T#M^/2&2`%#`O;R9@-(9
MPI`VY$,!"!#$)P@``=HTA"$(40B-\D$!"3B>Q7II0Y>-])<!:,`P'9`Q=S+S
M7LZ$YL`,R<1\4=.:5-L#'>A0!SKL`9/YDB("#D@()ZR!$$\H0A&>H,U#&.()
M&V2#`P#`@";``8=!;"H;CI!4)O2.#<I<0%41N`8C%`$)J,M7.//5@&H>(HY_
M8()9D7D(.#0AJ4?@8[WTR56T'N(/3DAJ$T(*!P.DU%Y\((`!JHA`!0!`CO_V
M>H`8ZX7/M`H4<X:D7@L#X-)\`7``#1``)^VU!@;D%0YVK)<W5VHO!@!17P\@
M0%[QQ08GP%6I!^0#8(MPA#6,L!!%W>MM.XE4([#!I/;2JES'Z83;%:&X]6)#
M67M;K[K^S:E-P&YVF]"[0I#U`4SHZUZ-\(9>KE9YNMUNO=Y@A``@H`E_6\,Z
M,]>$O![5N>0-P`K9(-A[[9=X_O6K$XP'V.+^%+++?,-6G<#4_P&@GX?(;5*-
M,-WYFI4/,*TP$OC`A+:.U@C?):A3]Q;(N?9L$"2H0(HK4(+%SE8`!\`M`0[0
M`$;J[XU^-8`!_L"`_.6/"7\@``(\MV/\]=@`]./_<8]U^`?0]I@`,;V76O&E
MS/:%,X_Y&T`2.TB`'@-@`-8D!(U[7`":LJ&2/4:`;.UE"-K="[%4S-<;!D``
M@A[V<I.=I?(.$("\_J&2#L@C2?G5@`7LS7G]8H)D22A->U'SP?:JZ"1?B\K\
M"=D)LNQQ?F,\XQH'P`%,Y<,":DP`9:[V#P\HLAF/,,($U+"-`!!`$P"8OP!,
MTIM;U%Z7>PP^)M?8C#0-]:@C:][%-=;(&S1DCU>(`#K;"YCB#';^2.U+0SZX
M$`@00(G="54[BCI_`I`TOMP)6UHG8'`8/H03#-!E3T-O#0<5*(^3:&8CL]6:
M?!"SM).H/01<F98^$\0'_R`0@0A```0M[N\4M8G841K!"4-TK?84^P0>)^`(
MB9.Q-MV9@";D,)(5I#@`+/XWJ2:`"4\P0@&(V,2IX@N2KBTC``IH3,L>(IY(
M>$(3/DD`OG'8O4]0IH[]NF<'.,$)#GAQG?G%84';RYL)]9<S_UTOJ3Z:#5R6
M>4@7=T`X'%IY2!@D`^M%8]G:LNE_0$`!M"[5`1S!"4^``P%<:'0'U'&#B#6C
M$5`^O@T:@L<*<$(31'G+0[B3?P_'8#\K28`B."&R<W[`W@?`MULWE0E',,(1
MCM!8`UA5J@HX>0D!VE2V*@"[@R>VO9RY`*.S5<A1%2AO#<%L@KXA`,(T!%L3
M$/_X,^LW`!6$;@!$*^YE'H(-^#M\W2>O+W?*_/13/:`SH8A8%S[AZ'R',-$K
MMVX`8,_/EJS<0768>X2&G@"C)\2Z$5"YOII8X`0W.,*1V]X8!X"F[L1U`0R@
MS<K[-<@9Q2/4D:+]2[=ODK,%\)_F60`#*Z/U>[L<VB3%*2,#Z!U(&H"_80(R
MLY="V+,-4B9H*@(&*!T.>RQJ>BQX,B$UJQ<.,ZQ^H:Q\P;\ITQ^:`IC3&KY[
MJ2@;:YS60J;RPI=SXA>I(JDG,(#'XC$=8KA=<J?V.3X$:!RTNR4^F+-2JB@X
MJZ1)NK8\JQ<>BZ#^P\$YHY_C8X`O.KX*:L+&T21BPI?_UBJB0G``!U`<VS.L
MV6LV]?J]0P`F)\R>/%HI0CB``>B=:GNMXI.B"V2M[AO$@=I#`:`?#%L#`PBW
M(SP$#C.OJT-$;Q(G/)0E'1)#,AR`"I*>S2J:@".X@CNX?L&FA<LXI^,FB9/`
M;WHS;2($Q2$$U6$OH2NC2:+$P,LN`R``XHDY76LO/BHC6FHM/E(<0VB=)I"E
M"*(F`B@Z/OBB0;J>[$*"!?(7<GJB?6'!?WE!XGLL/N"^2^(@!-(7/D"M?.&#
M-2"MWU,<'APGPMO#`E`Z?)&J75+&IOH#.'""/)J^Q/*?7)Q$QWJI6U(M?+D?
M^KF?4CI&>VDIM_HFY#J_(CJB_P<(/%XL`+4#PGJAIM2K%W=2H2>0QOD3)T*@
M/6<+IH$L0<(31),$Q$&,H#*\%T."LH\DR$8C2.G+'G9Z@R>HI/:I.ZPZ!'DK
M/$2T%ZG2(6IZ@(YCRHS\`T)PRE'T``B@2@CX`/D+OHN"L/]C15S+,6T22/\3
MJM1B@`/`H/P1.F_JH>;3-5@KL0E,JKNZLWK9R*$,`,EY`T!3.5K;H#_X)&EC
M@+Z[LK8<RWUQ`KGSHGT)HP0PL*92/2W$%[9Z,/(SRP!XL%!+@,SD.'RQP7XI
M!"ZT2]DZKGH)HZ;+%ZD22CXH@@1X("7;RL*$R"V:*1R\)9NR1P#8H%9#G8:T
M2>SQ0O^ZBI\'4Z:V]#(^F,W14D,W.S,S:@`^DJ(Y/$D[K*#C]"=BDDDI6D#F
MPTWCN[V99#3B8R9;>B%T4\T$,(!4:Q\%$`"THLG0O!?;',ZV7$^H)$"B*80:
M``$0(`$0N('&G#\8@S`"^J+*DSC^N\E8)"'RV9X&4*"T_"9W8H#,"Z3,0P)@
M;#E^J<N&)"<S.H`(7;<@.JH&,`!&4B=#B!_GFE#,JTD$NL8LZY>N^T7E88#T
M6;2I\T,^LY=$BZWU*0#)@8,'$H`!&(!P"]`;=$R%XJ:'M)<RNJE#0$U_"4K1
MB:0!.(`%6,VVDD+8K#SJM#E?LLU[>=)6(RBR<\CB"TL(N\+_+U*F!IC00#J"
M"D4W?_(TUFD"!O@@,PK#[FRJZ,1#;.32XS($W72G1[L798I)/:V7.+T7)4VM
M/--)/IC2*BV"QDK/]?1.\"'3'&TKJ6+3-GW3I\Q(!LN;C.(H_YR_L40L+6W%
M''O%27JSK2R`RSD@8%*L`IPD$W2YXY&R?<E0'!6U(^`#C%JDNYNNPI&J"A(U
M-7M*P#$D`Q!*P/DD0H5(ZFFPJ5L?:J6K#QJ_8_4<-H.#TVFS>^FZ&SP"<[L7
M$E3)0BV^[&%5*-U.FWP`.&@<>WO-`>6F,S4E7[(E8IN]Y=--UL)1FXR@L/Q,
M-Q)59VI2OWI%6E)*?1F=["$M7WI._P0R2X):@SLLQO=40Q/\P_836.YLP45;
MT27T3BC",&=R`'FE.H*\QWMA*^QQIYA2)AU"V%SU*_T3U:D)*E6$38&4.#BZ
M22`3*BF".K]B*P>=I.,S@%)Z@PZUT$QD.2.\RT/X0X)RHNU$-6@2PWQE`,QI
M`@(X0;H4/H_-ES"*U7':1#RC);U9MWXBA$_*3KI:M[!U6*^#UQ%".]<Z+474
M1'I$2>#KERC=0M?R)RY#0JZD2V[JNJ6EI"A,P25M+VWZU[$+V*(<6((TA,A"
MP-G:GU)B@PXUA+CKT<;UR*&T)Z>;TXEM*@40Q4,H!+82)M&5G.\C*3G[(*B5
MP0BR/:A5U/\RQ=8?73Z=9*M=VM#V61\%:!Q+!)\68BCJ2ENE%4#0I<^<E9I4
MK->NO%D"]"8$`"\@HZ)0=(#+&[QFLZ4#`*]#4"85:@(CF%N6P]T?C$CW+#TD
M8()!8B3P61]2D[5UX[4\0H`C8`*D.]W4D24&*(('>(`#-H+C22!88P#Z=8`V
M8@#H,20$0&`$OA\W@IXC"(#1A30!B*U_Z4QG^Z`&N+P\:@#HD:H"8J7X5<M_
M>=)$%2@('@!&VJ(LC;)O,J0">%-L8TD]*H(`KB?L"=27'-R\<B?L$4@Z$H`$
MON#(,P2I*H`BL"M9DJ%F[6'\*5T.*P`CN+P/VB#;*P`DH)\=?E/_!6@CX,-B
M)/!A8CLS&LQ=[H3:]H1!6$L`)#B"=>LA#*.F`Z#?!ZCA//,DD6,"]L4?\*%,
M/#[/MHIB("YD*SX$^L1*IVG"&&-,[$T_:H74_%G@`M#*PW0R)!"UN[LR7$.U
M'AO2X_&FD$TK]G%90X2#P10`!V"O%RJ$(W@U+RN"QH$#UC6R)F!`\FG+Y>LC
M3,.R758]1O*U%ZM0]5(Y*,M<X=,ZZB*`HH4N[H,U.#PL;].?!@@=#I;6?(DL
MK/++&EN@:ZP@Q+KDU')EOT*Z_.GB_-*K(LCE`A"A>D%CU`$M)!9%+5HT7^NQ
M%_J#"$9E(WBDR()G]C)-USUE+$M,O\P?_V'Z/K1D`E3*GG?6(X766+_=EQ_B
MMI#EX)$5(^[SM,:A)EY+,OU9`"98(-Q:S@20JGWC9@L.`&L:Z%0;TB&;GFEN
MFC]8`SXRA)]>')',*C88(3BXO#<(ZKQZ`R:XGM+A@R=`0SQFVLMC@A++G"?`
MZJRN,_)Z0B<X@O?2J#6H:@">J^["8R>HQWI9QR=X*K=V:PICG2?0/+%R,[A>
M`[=^@RJ*ZF>%V+GDE^XJL;\"8*/&%[1&@C58K*CF:3P$;+]Z`B0@8\\1ZJ4>
MZA#3JJ[R:;1J:K>K,^/Z(J\^+*F&;*B&:[R&.^2ZO/?"%[T!8'E=`[(UOM5&
MIC^0M2#Z`[K>+O]]*B6]H5_81J95?E'2YNV[/AXXN)P-2^PO8NSLB>S)-CYR
MUNW9(6V]FN[<_FS:[B_#QION]FZEJ3O.2AI3_>[R-N^;(6R+FN3S9N_V=F]^
MD1XS$N_WIN_ZIN_(5D'[UN_]YN_^]N__!O``%_`!)_`"-_`#1_`$5_`%9_`&
M=_`'A_`(E_`)I_`*MW">68,0=(`G^**_>@`&:("+0RY@98,0+`(UBRX&*+HJ
M6B\5_S%G.RLD"/'&OO`:3_!"4"#]L3'/T:3RD;8@@M!`EF_5:Z,:Z]JF0H(B
M9R1SS5?6[>"UMO$H5W`Z(@`R9D9I8JL%^&G[0:@#<B<!:,XU^"0%.*#_,&H[
MVHJD]FDA_F&#)ZB[S:4F`2!COY;R.C_P0KB?77H"QHMBL8.N\U$<"#TL$WI'
M)$*N`G``OQL`V1KG?`5<.X?T!$]53`K6->.#-SBZ0_*<F%TS9H,=`U`[-X.=
MC-2\4F>K]OG22%=U`P>F1[\70F!CN>LQ:F54$_U%=38P.2/.VG2P5?=U`F_U
M?5$F`HK0(ZK5)%XSLYP=`JI;`VB"[V&"[Z&O?`WG7[=V^XZH^HQD!I6S`^#N
M`=2X=8WD6/J#0O#%$'.`!XBH4-]`E76T:X?W_N8Q.>*P0ONC;3ZD0#?*IJI8
M])VE$5H?D)(J9#9:"*+V>$=X^[ZZ8#("T`*H_U!<@`]3N5$J'4;UPQ@EK-]K
M^!K&GC>0)01(*O]5G'=/^))W[W<S,B9Z1%H[@"9H@-$;HETB!/-,WD6B:.3*
M8`<>G$1;49/W>;SQZ;<+G:@6,,5I':,W'G&M[?@BZDZB+0'K\,3Y^:FG^JJW
M^JO'^JS7^JWG^J[W^J\'^[`7^[$G^[(W^[-'^[17^[5G^[9W^[>'^[B7^[FG
M^[JW^[O'^[S7^[WG^[[W^[\'_,`7_,$O[W(G_`GG`P,F[WHA!`2&GDN_:"Q"
MGJWV%S98@,O'?`80<>A:@/GN&!P/YP_SG/6Z_.?R%^-4@.EA`/E"H"+`?,P7
M+NI"H[EB`Q!O[%R2[?_HJC,<(K0'D.O%V?"#:1WA#_%?8H!JSQ@G*#3D&J'Z
MI?S#*OZ,83(9`CNRK=/GOQLV$"CJS1<_S"8\/``9DIX$X/[/.0`B#9B8$X#U
M'Y]?6\'X!9D&]DC$JJ`F:*/V=]&EDZ4!D*AN;AP_!`@``0(($!!`8(,_APX9
M<@!`@<*%?Q``<&!H(<:,"^$@",!&(T8^!@!\7&CHP<&#`I"`_-,``$N0,C7"
M2?!@)DZ,;P(HR"ESC8`B/H<2S5D$@)-#A!P@(+2PB(`U0^'P+&HU)Q\!"2XV
M&/!FIL,G5\>2+6OV+%J<;`0<<#J5S\(F`(Q@A`-WJ).Y9>4J>./W#1N'!>#_
MRCV2]O"A/T<K@LS;A`\!`4?8L#$B@`"<F4X*%GE#Z(^3D4(/%3H0P,E?-DQ&
M,KAXB,^!N:X?`#AP5RU%CS+_+!`H=:&3``=0(R&`.>,?!@``&":[!L#-LF\$
M+!A;R"[BLT>3$BI@P.T?ST.G]\P^5:M$.&Y!.OQM_CW\^-G9"'=+J!!I/NHS
M$KIHB`D`1?1'FFLAP0%'1`S)540A!1JB7X(RR<6`1H8H`$`3AQ26&(*[P?%&
MA"9!*--U'>:T1@(`$``=>P/`@81>&-$6DT9_&!!`AAD]$8!7I)GV549O%'`:
M1D`-(-43`AR9TQ]&1#:`;B`9D=)O%@;@WA$Q&M+$_T@KTCA3B>L9\@0`#31(
MVGH2%<@0=M-59\B`_*V)49R%N'4@?C@-^(>)'$9H2(B%Y&D$4J\5,%B>>2IU
M$9\1PB%`>1CQ>1M.#_:9T8-\1,C'``F8E*:?A]#FGGREFHJ8(434L"H,4<RI
M$7T',*I``T\H,$"GO_'&0"%%K#B``4_\0:M;3S!``*X'&.&4DP``F]0A:RP0
M60$/4)K1A"#19IA<1B!A@``%.'`;'`\8,,!E#62VT!,)H&N`M70R@0"Z!R"A
MJ$:$'#!`$<$Y4*,!6[%1Q+K`!2A37@F`:D@1#F166I09P=@:1D<AP$9L=)TH
MG!,,1(Q1D@8H$.4?!!R0(/\<`RAP$60$(`'CER`QL2^P1RATQ*\&,&$(`PLD
M^`8"&D>[`*X+;%;=&@<T!YP!,1^"L6&&-+#`&@S@BD".(+$1=!,'"-`T(3,/
M4("`"QUQ`)!*]:P0H4Y@/%`!#1QR]D=`&\'EV`Y$]&BD<#A0P&4+E/23`M2.
MB]&6[@Z@]-Z=7F0$`D`V>6X!3+1W*N:9ER6(!Q!X#L$'^&H=``+X089K`0H4
M`$`!F?WAG6(#.%N`$R7+>L@34"*@P(UZ%2%[N$DY`>4!":R>0(AQ`4"A1LIE
M*%=DQ0M0)LNQ!9S`],@_30#IA5//4!$\)I#`BM&!M.5'S_V;T5JC:8NA3`XM
M/9/_O@(,KA.P"?Z1XO'):_1&$Q32@(\=0DA1N5P!J<,?`Q1`(7]@`EP`Y#2,
M!$<K[M(+S@`0+B08P@`$2!`;RL0NW;EK==6!C`$2I!RQ:$1]##&-<1(PDJC(
M)(3&*1Y!'+`X[,%D(6&1U*'8AA0VC"0`<3O$Y>A3@+&1#P`^2V!U"F@]!<#P
M?B$9T@%4]Y"('($@"+A@`YR2,D\=PF-?D9J*>'>9*VFNC6[,B2`^`($(1``"
M(!`=K.KSFA4=C@\I8HF-OE,(`!7A#X6PG2&LQ(3^$")+;1ED@/X`J`,0X`F,
M"I_[L+6\1-KI@9?YBEP$P`0[K0%7<(%10AC"!NY]Y"A'_[C(&QB8F;4DX`T7
M@</(6(B3-01@?1B9DA47PH:Q76LA%](E_;P6S-<)H&!/D]T`@IF3`=YO?SUT
M`!MQQR+$N>M:$L2)QZ"U!@(@0))D2@B<#M!`C-!';H1(0`"8H)`UF)`A'OL-
M'$R6/%[^RQ`448#K7F*^C/`RGOTY2@".T!\F5`6)`'!/(!6R'4/`X5":$A4`
MQ$*?,L'E#?#,$-\8@DV;*:4)6DD>C(J02#[0ZR-KJ60BMP8`)KP&/67437`2
MX#IL!@"9;_RI&^,XQSK>,2?T00#+C'.;;B4&=AJ*$61D-::L/2U<"LF+QH)C
M!#@1XC,'2"%(Y#(`!!P``0A87?\`-)8MC"P@`%]Y`Q+T1Q&I'*4!;\`/'-AP
M$92LH:L-XJ=/7,C-=<+J1E3-2(I\>C[3!),0X'(F9%A7S&E^K*X70>!S!NI/
M`GBSAS/I#<%@"23`*H6!(!3A6E:&D2Q%,2_16=!/&*.OB-&'>2T,0`+R-)VV
M2,1D3L&F>PIA`+"V32G><0M?GQ8`SA8I`!0**60@8@@[%<(!]@,)C`2G$#ZP
M@5DQ6@@O>S+&BWCL(]B$5F)&0BJ@LA=S<:0C4?'(/CU&M4!Y$<KKOO-4C2%R
M(818`Q.*,"T`@!6K"R&4=[YJ`*^Y**P",8YQ"F"T/#$5(V;421.,T`#3//29
M&D3``];_X!]X#O<`)A[)5D[$F+H,0&Z%#8!*/UNHG,PV;4!LL'^5<Q`7;\0)
M/GZ"L#1"38PP00#E]"%)P+M-D]"KLQ.,R_0Z583!D=:QA%6NW`S,S@!$$84*
M:>MZE=Q/!'R0G0*P+4$#P&,W2<ID>\UF>M>YG:;J%Z-2H4\4>WN`ZT`J6CQ2
M\%=7=-@"KHXM#K#D0LJ+'`86@E-D5#29*?62,+>WTO`IQ`?@&X&BJD4X+!NK
M??42T?WVMBE/@^=RPA6``A\,HV,[5`$(4(`#.%-Y"^"#IBZJR?D-^0_678X1
M#<)"6\E.(+?VIXH.%>$"4&R7O<P(0]$+'.X=0;Y/^6Y&^/`$_[@8XD<@F4Z=
M#P&C`C1A2%G+TG(T:,67E(0/JU-`$>(=FP9PL)T9*<V5%_)-G,QK>AK46[16
M;&40JOD0`)I?2'WH$4[M.;8WZ7:9%[(3-!=IQ8=(>&)\Z]#@#E>(W#GN0FBC
MT8)+:KB$""F9PJ5L6$N;G40#=BT/L0`!V'C@X[WI5R@9(01:NN?P,80:PB#T
M,,3A5?,U-6202D%1>P<_&]JCK-[I7"8\`3!?<XJ6"27//W"=ZZ!2'L4U\O1$
M7S=+"#B"V_S889.\@0D-*-\AL,>&KG?]ZRU<<AD'0"DD7&;0&ME1BC42OG]!
MS,8+0:5.N/>\Y0)I8/$N`DDS,N2+%_\[W>EN(&0"_QK':>3@/C$$&Y`P\YGZ
M>7W"O7((L]QJ87(99`%*Z4Q<J"_FLC[L3[/XH_*<],NN/<X>IW-$1J7<!12H
M9$T)Z7,80/>NYP0.36C`ZB@TZ6P3P``/ZE2B=>,N9T[?Y]YO[UIXN_NETR6_
M6(^1[0K(DU"O4\MYR;/9[N5@VV-D[#?5*[W2YFXV,J$O1>KSC&1;$2C6W?G2
MZZB6OJV:--6(:1S6&W"/6-0830P)M!#"A32`?R@'\1'%Y!4"D`&9CUV($4C%
M.]%<_>&=OGG6^12!\IW@OPC6'U#2;62)W*0,;YG-0P`1#BT@8$$<P=D>:250
MI-C.;\U858'_U9P%4IZ(G'(-A@M>G`)!AA-2D!$4DQ,H@'N\P>+,S>H=0G`\
M%^<-&6W0E$3<"*5]'QJ>2O@EE=(93/DYE5P\P':93`(90'<]T(JPFMY,4@`\
M@&?PP5%LH-@M3TY46/9]!#S)TW^E2$8=`J$L`((T"8N\%`2%QX7,ST\\&[LD
M%#L9!VI\R!M@AX3PB!%X!FBPQD7,UB?ZQ;=\CR-*5DB,Q),)&0%E!#8-3G:!
MR!J`2YCMFTPHQP,@"!^\!$TEGR3)''1H2A.LB(N]A+J`QHK`GT,`@.85H%*0
MV0]FHB^11YO=#HS4TA^P08H05Z%T1^LXA?"MQ?+H(N!(A1:^B4,H_\#<_8%)
M32&T42,;'!(2J)DA/*`H:<H34"`4IIBB:2$!U([?"`0!IB%#Q@=]&(#I;.'2
MX5?35941!9";$<)+?`WW4)()KL5%1LOJ`(OLV*&$$").V)^B-0'<``XY,<=K
M4`2PY"&0','T5-_T/)&*^=(#F""2:5!!*(D`\%B%(`$T,=!RW)I_Q490&H0&
MI5*TH$O+;<9U^02[X43W)4:*`,OTQ)A&P(Q:K$[UK8CVY),1&49P)-L`](:+
MP4%LR!KIK!_('`0F$A1CE,8`$!S\59PO85Q]7=Q(@DL)252A6(B*M,8/T<>3
M#$E:;41#J=VJC209ULB%<*2*E(1))=M`Q/_8HQ!DE'21$25+[S4D:<8''"Q`
MC+F$5PY-4E2713#$V10`$FAD:A:!.B7`$?!!$P@.0R#!5\7$&SS`5QT`P<P$
M&RC`+#Z-`DB;Z*U+$Q@/B+'!&RQ`3/"!<"Z8'Q(4`PQ7`L35>"S`9#:,HAB!
M`BC``IAG>2I`7;*/<'H'>*Y'(3P`>IKG`HQ@@1R!`@A-1A@!=0Y%<_+;`M@8
M()X5;LK7&BC`0@K3AA5`T-S&O!2`6JD.`C#!=$ZFWV#G&S#`_##3`A80>((/
M5+X&`TQ0A8:$ADI*`W@E&S0`=EKG:UYA21RGA!7";GY%;3VG`1B-:_`!`PC-
M'QR!#!E``YQA8A3_P5D=@`/<3]4,E]&`1P-HS!$PP+H8@A,83P(\`1,$:&EN
M:1IV%?W$B4G02:#\@=W]G"%5RIGNQC'V')SXSV$8G7D`"IQ>Q6>\RB$Y2)K*
MA)?*!'G,*5KXZ4QP'5$(ZGS)S9T.JIOFRYZV1)E6"IAR*:1&JJ1.*J56JD\<
MTAA:JG&2G*9VJJ=^*JB&JJB>Q0,,R9&):@C1WZBN*JNVJJN^:J6MAI:.ZFDF
M)ZS>*J[FJJ[N:J`"*J_^*K`&J[`.*[$6J[$>*[(FJ[(N*[,VJ[,^*[1&J[1.
M*[56J[5>:[$"!K9N*[=VJ[>6!1L4P'I^*[F6J[E2J_V=J[JN*[L:ZQ^D_Q0?
M.(6NB4B>"&HXVI)$2"<>A>/<:00?``H;P(%KY%6_MJO!'BS"9H<.:=!!3D2S
MX8[+:&4".$%'G!D?.(%I0$K:*`9C&H`1Y`D1`>ERK8&O<<^J*53"IJS*KBQ.
M%(%8(H"P2*3!X!>XD!/T42.#LB@U,HIR$$#/\!%^\!*P]`P?(%@#6`WIL:S2
M+BW"_H=L/`@YK8>!V4B`.,4P581"5%2#R04"K,L;Q(98".U'P(D'K<OP$"73
MIJW:?NO3_0&HD5]3X1A>ILW,?<4*:=(+YN!"0,R4X56BKBW@!NZS/MWXN2'P
M,1GMR1S-01REC%'I28Q*',`#=*C@5J[E'BOADO]3J)5?QS&9WK&56W5;OCE:
MP/E27%S0OUG;Y:XNZ^YJYK;A4]$L1"+N;5S8]LT7TG`J0R02'+@=E"1HZP:O
M\*YJYH(50[S$&];99MW&S'W$MF3$4="%8"5&SXRG"@XO]F9OJ,K%N,!)B@3C
M&T"%7G2'\2XO6WVDDC#!@=@D`7Q%$!9"BG0&'R1-56JO_=XOI:KC`-!4D3E+
MNAS,ZQ2`6_C3YRY$6P$)WSD+-(F3Q47+BBC)0+PF_DXP!9=F_R5`AE`I`R``
M`ZS!&QP::1C!5JU6(1%9O`@34]A$VOA-R['!`R0``C2`$ZAN!=>P#0/5G/BJ
M5232#NOP#?\P$`>Q$`__,1$7L1$?,1(GL1(O,1,WL1,_,11'L11/,157L15?
M,19GL19O,1=WL1=_,1B'L1B/,1F7L1F?,1JGL1JO,1NWL1N_,1S'L1S/,1W7
ML1W?L1M=[,N0K!M1A@];!67L,`X'\J@2<E'\L=8P`1(8WEC``1^3I@_/[]\2
M12%(YTR`'N66!28?AB23QAK4&KOR@0.L2+HUS22C"OE,UEG8R,D,1=C8JGS8
M2.F(:@RV\E!0J7Y>11,46R:1!4ID,OC)(5%DB=]=1<KLY155XV$XEBUK1T\E
MD*J6:TVHB`,H,M*VX*D8`A)\['L4PA&,<&!IXAN9'RV;%E&D3*1<12%T1#4S
M__)5\!P:XMLI1\ODI@7&^:OFOH<A&,$KI442/D`QEVLA*(>4(@[&="&L9A90
M$:&H6AD-UT6?D<7`'09P-:25-:II1C1(<`KLIN%1`.^S&D(=Q$$<T$%)^T1P
M&$`QE5*#T>,3$$(3/,`#/`&^\`$2.(`1?`@2W,:8-$PI9H03-`%^P-4;\,$1
M.,"48<H3R+03\`'5R025.L%%J`8?O($1X/2Z!`8U+K))/(%/W\\3.`$<%$&(
M/1#)-H$#S'1-QW1:T[1$S-K7T2AE/$!2%]!-/X`3I(E-.T`U7\N+I'7MW-L3
M7+4#($'!4/5-CQ)I>+4#'('DP,Y2`[3_6/6J(8%[5/\&3HL8GQX!KB"!4#]!
M`$E*$R`3&QQUB"F*0RP@(3!V8:LR:3C!5TL*$Y`*7*V+!\;V:QCE`*#=WJX!
M81]!P=1V8E`=/0+V6C\`4@>V$+XK3NM?/DN<:;LUB8QV<1>!>T3U5.]T^/:U
MO]YU:(=<(YHUN\C3&C3,3L/*40\@(H?J((#`!+SW!)"`GSI$+EM8#]E@6Z6;
M!.]BNA%`BN1(<AS$<NQV*LJ@N)7)D`PXM/B:@/.$5KQ*?@G1S2Y')6%4NI7?
M``F$!HVP/QE`1U3$=(Q/@S^`:Y2;Y96)`VF<OW;*ZI`>$Y#R<BC`7<#!2*3;
M`0S.BVOX0]P%'XR,CA=`24#_17Z?#(\*N(IDB'`10(8G)4I9GCOU9+H)P`-\
M';I1N!\5,!261R%8AH:K643`<TC`DY&;Y/E@4Y0W!S=B!(S05$,8N0!(KY$W
M17+X&X6S$#%OW@&TE8!+<$`"VW*TX*/L3KKM]D(4+F>GFW/Y3\D8@,<`6XQ-
M-*&,LHVGC1.T^'+HU+6-'/,H@`#\VG)TK4D80>5Y^:\.@AQ]#J=!-3R=(>*E
M#.O,MDVR40Q6!&A31&&^!-:L`<[@"$-$VH%S&9`IAZDYTFA#N3+[WB$<Q9D!
M66^LC`M3(X5BE`(T`8`U8*_7AA-4W734QFQ;1C1=7&2,8'G+CE@L^JM$%A8V
M-5"(_^L:&,LF'<)+.$"[$_147\81S/ORX$<\/L$:-`%%;.!1#``2\+M#'0"U
MAP]F.):SC&".MUP!34G3?`2A-`V`C00XZP3.$,`1-$$)%DS",=0!S/85!@CO
M4=I++`"_SPQ*_AW'Z#JN9$;N20SI\9+!KX%N@TAQ['92',7$KD&54B-^W+D6
M$IAEBSH;[=\(#K;L9,C0[[;+TQ!'7T1*6[83M)4$4Q^/6#<2"*2-"'"R"\3$
M/D%O+`!^#!,!)/T`0<37:SI#5*9U=TV,@+S(P]-`Y:I0T9$=J2XS@3*[Y&#*
M?#MXLX1<8&"AKP[3?\UM;`92,>Z!:T]ZN0A>#@[/OXICS?]N(.ZH<2A$"$4'
MIRB`HKA;6R!;UF@AX#L436W-_,A/4]T@]?5(HI4^$K'1ODA.`_0S`]1O[/=5
M`SB^<NG74?0EL!3,`U22PF<-C-3]1BA0W`[.*D7<O7F':W031*_,.JNTI*1R
M[K=$`ZC])L[R5ZX>$M@5%,D\2\#>X8E_!WE]0R3`;4Q'F=TYIY1^``)-)M&&
M4#P*KZ>@W.S>.QV'2=0M0!P2.)`/`0!'!CX)H.#0'P,&_APJ`N!`Q(8)`JPY
M]"#C0(D!G&P$\.30FP`,!"H`8"3APD.%$!3@,[!0@@%P/.;4N9-G3Y\_@08=
M]`%"A`@00!3JZ5``SIU/`#"$,P#_@5*!3``@.>2@XT`'`$(V`5#$(Z$$30T=
M(!`1R4&/"@3P,;G`(QL!"0SI=%B`D$0`30:F)3!S#8`'`L4R8()D,9,#-P\A
MB#OPC0"&`X\`8"*P;R$^;)H@</N'P(&\.?D,.-"W88$"2!@S_JJU`0`##YS,
M%/C'->/&7Q$:ROL'SI,'%)5.!"S0R5B/Q`T5,E#`XJ'"#G;"L2QP30"Z'FN3
MS,G;`&N;3@]I9U@9P6+?"T9N!:!1I_"&Q;]6U=E=P`(D;ZQ*SSN/VM**/__8
M.*VAZ5@3SI`_^'BBB`"H.R0SP+1#0$&L$'I).+F<2,"YJ2H:B+3R"D(@/=4:
M8XR!OW0J_V@P$P^@CI`"RCO$B)4\XM`0`PB`S;?CR)J()#9.$NBL-P::*H&2
M!$`@-B:8@"^DH+#,4LLM>Q+$`PC`A."#`.M#(``V>,*J@?2V&P@KK<Y"3T<8
M=UQNH`;.-`2!&=O:;""XBG..H`'PTNE&B/RZ\A#!(H(*.PL!B%322,^,;$:!
M*OM.H#X%@L.!/060E"7R6/,HQ=,JFW32P]X0+5("&D!S*E4EQ8X0)A0H8(``
M(D74R($XU>NAZM@`X-&<U&..1X\N-!3'B`RQ23<V&8**UD@W^PI-O9A(0%=>
M*2HUL`="!>"N)O*:BT#-%BVBW+N8R$LZO@0RI`D%#!A`T@J;3?_6S:PZ+0)4
M2<FJ[+)Z]X20`!61O-:M\196\!"XWB"$P40]*NP!TAQ>\U>34#KD/(+N.D0A
MA[7B4N656=:ID!Q0B!D%(236Z2N6=GIQ,R=[=&L!`9@<J$Y(_1R(@4K5FBE8
M)>/2V%1"=RH$Q[XF4E0PP@P3*+,&A!22B3_TO!1*30_AE(\#`%BX`2/@0XBT
M`\@4*+5"V32@:R&W)<2)!@P(M8`W4GOM;B30G$B``Q1XX(@`2JP:6':%192[
M`([UR-_FR/+(\?$>4BK:`:9-%JH$!F<")VUW.N[P!1XP@O&:!V+#")L`"``A
M@]<MFHTB:.?1X@HM#(#Q!!07@%]V>?[_%R$^1%N8`2->),M?@0I12V&&`Y!R
M\*!-C?BMN'Y7:D=%33:,M"`'U^CC)$5NJDFHNR/];B:X;]G^^[$\+2_8<^K.
M@&D'LH8!0$8[3_J75G94M$-8Z1#-J9Q#9F2]LD$N)4U)C882`@"Z/>=9<[):
MPJQC+,1D[3E\$`X"0$>9_C"+73MZ@`D%`IS6K"9&5#D-:8!7+SXHA0WT^<,:
MVL:;'"[*A%,Q`!M8@R1?Q4<@CO+(&QC@!.E(+H254^%E[&+`@2R@4N/I8/O0
M@Z3UE*R$>?D*?9YX."3FI3L($)?<G!`10KSA"(>#TL'\HI4(1:00<*AC>2R&
M*!RN@37:.1Y@_^;6,ZVTQ0$P](OT!$#%`AHB12LZ0$X(X<CG$$!LY/G#H2(R
M$9QI33/5$QL1\^(X)(5,`9#I%-0JL\&&`!!_M;1ERPQ1FP34;PUHPQD?R'@5
M@-D%`4YQ0J@P-``";&N"#`F;T@#VIYL8@HM,Z,L?5")+SDPG.6`)3-)">)CT
M$&``S'S#`1(`MCU-*U.Y.P2>%"7`T4RMAANLC1%.4P@'$.`)>BHG9@!6FR)8
M19_\1)*F_@`?`W13/(>0T;8,`1Q0!I!RV6D3(0X`DH$<DXHFHN<"`^"G7$;E
M)68J&C8-P"2NH#&```B90^$#-YVT)7,KTE#@=/,&`[`+*S4MB&E^%_\1D]#M
M#[4YY(JT>(@WB<1.:RB`<RH34L[<S*$V-(1*D'!#!A2`F28R"#Y)>1B'+/%_
MF,H73HZS,<X480`A.0Y)0,8T]$R%(361ZFYR5;];[I6O0?F#B&"%A",P(%0-
ML$CRA!F<XQ2``3^+U)5V1(`'(.%H`]#(U2:HP#@=@@T$6`C?(J7-0TQT<Z-=
MIW4"8(`CH"DS`^!:$9[*DF>JD&R<PDH!BH"$!@P@5-AYVQL=ZCV!=#8`"3""
M$52"@(CL"+=(<(`RF?0&SR;@"$<0444<$H#79C0`,RIMV2A4A"/$])/#:JD5
M7TD`(VB$"0(0@`..\-R[>C%'$Y2L=0URF2?_N'<!1S`"VAB@E#/J!`X%$,!K
M^P:`(6**``)@0'71%AR5'.`(1<@7P*1[$O_Z\B4'$`!N_I!1__Q7>`-@4K^"
MJ52W-(<`N94O`-:D'0$0P`%(4.A,4M07`2[$OR)*`'`+8JX'XXD`3)KHCFQ3
M!"/L-'-PV*EQQYO:F?SJH$IRI4/ODI?]>L>_HEE`W/H:9C$_QPA/I=0!D!"@
M@I"M"0%(&2&*X-G^U.9*A3""OFIW@"N9I4)(F.\"">"4)Y@IO%DVU`%*9`0!
M-%1D%4IHI+!C"",8Y%5&@):WV#F`EX)W,_H$EX.;0``%/,@`;HQ1`4:=,3-1
M:@%!^X,#RF6;IJZZ_W8*"-H3*)W:*@D`3:YCM*3QK$$TA;A$P_WP3B(:J07D
MA0EF5G"\=D)LUOSA:)$Z0*@UU82=1NK`NB$72S>:ZVNWLJL;=?8`'&`1-J"M
M=FN[JQ.V#0!T6Z2."OYAO`O`A`8L&KR()`";W?P2<G%[`4X@P(_A\&^.1`H!
MV^)#`;3H!'8+64Y>-0">&$X?C#;.6-L>0!&(A1%*)6!;[H*K:Q>U`+$E/-L&
M^'0#:#EFF8_Y#T^@$ANJ0STVU.\/.'<H'"C)A@1]%PY-8,(3<@Z'!#7$YTU:
M(QP(00BA$V<`J<Z)(=X0M,_D_`U+;X@3FL!,/CB!"4Z0D](59`@VR*GG%O\I
M!!N8T(0WI&M;.^>)W<>SAIO'#31'S_EH]<X$-I`)#F1'.M,CLG4"&WT-`>KZ
M<]@0\]W8'(UC+_O?<Y)UCQ1"[[E1.]MM+G<%*3X[9%]#XIL>([++?3RF+T3;
M"1+Z^AE"[_UTJ.$CTG,<^_SM/&^ZVN.^]*X+9^V<]_L3>:[WL/,ON&ZT^>$I
M$S0C\:$)K!\/W)G0>(+P?NV=&GQ@\#[YX,^<_.5GV1$(4+2SN:^6?#"``JJS
MHYJ:G_[UM__]\9]__9\**./3__\!D/S6P+UJ[+]@C/E4YJHTZ`ATJ[O*+0`A
M,`(E<`(I<*_>!@$'XKLJ<`,Y<">0@-+,Q;#VZ@W_%`!<*(+1.C`%57`%69#^
M'DZT=,+76G`&)]#RK(^OI(Y*H(\&>;`'??`'>R+\?(+T@+`(C?`(D3`)E7`)
MF;`)G?`)H3`*I7`*J;`*K?`*L3`+M7`+N;`+O?`+P;`%_Z`)BJ`()&]+_H`)
M%`?S7"8,W?`-X3`.QRS9:@<%N02;N$VO=&)OV%`._?`/`3$05R3]3L]^"L,`
MFD#[>J)Z%DP0'?$1(3$+5ZF6,"<H?J01C1`#(W$3.?$/]R;)EB,-&^L!F,D0
MD"#L&*`!4+!*-*@(D,X(R&=W`(>MT&TSUJ`(Y(0)CD`IG.`(WL`!_&,XF*"Q
M',`.Y<8([,2AD#&`'D`!_Q0CY_[`"1Q``1('C62'CA8`Y$QF&I^Q$[WQ&^40
M/B3E2=A`-`(@5`0`K,BC`(1GE$IJ5>)*:/ZB8:S-$$J+4=[I+LYQU/A`1,ZQ
M=HH`=H1H6K`BTMS%7'@E`9R"#U3B''E%`);#SS#">/@`"=`Q(?L0'#5R(ZF0
M#23R"7!.1!I@#=Z`"3P+,!P"`!9@ZCR"]B9B`9X@Z]A'(.HD&CEI^4K+E&;"
MJ-9@YPSA:!R`)`<M`)+1*[PIY3JBS1!`[MB`*Y;-+U;R#=;@14JD+02`?B*O
M``B`*44D93CR*\%2"N-1(>!OHUR"*1YPHY9E$@$*,-(">'Z%,R2H-CH$2M:$
M(/\*0#]R0B'N\H(*(5IDPB-@K=<68%I28RTFZ*6TH]C@X`'`+2PA,S*-$$GN
M,H$V+VGV(B.;`V?8DI0`(Z@$XA[!J3;0J"VR4<G*4%=B+C-53'H&`+>,H`R+
M`#Y2)CH^0QJ["YKJ,L1LHP&:X`PE,SB%DP79\CC`[2SXP)-Z8C.':R:)9E&F
MPR+B<E'FLHO\XEI,+'6\Z6?0)%6NA24(`0GVQ`3YA(*L8^+030^'<SW9<P(I
M4R#>JB7/XU#`3"TSIS,AY3.C,S2/DCH1$T^8:2**P`D(E$"?X`F`B[,HIS)H
MB)@*U`F>`$)Q8D<(I0&.H`F4"9H4Z.L<(*,T*"/;,T3_193^V+*GNJ<\E),G
MF%-!R>8KW/)B,&8W."DB`'0@Q$*<*`/HHJU&1$EN"*"CVN[A_N8TM*,\O7(,
M-6[=K'-$F;1)R>\]2T*9MN4/CL.W<*0^E05GIN)ON$-?4'(_)Z@!Y&4B*J0V
MF"GA!L#VK./@$O0C!HA[!,HB&+*<%I,U^.!%$'-I&%0W_@IHG/1/`;6O.G,B
M"(`!'D`T#``G)DI%!44!#<`!MNJIW-),&""KV$!?$B<!R`DQCZ:K_*P_'H`!
M=F5#ZR(A%>0-GNH`'L`!=BK`%!`!5I4=W0M-"B0P7N11'T!$GC)0>;5764:Z
MCL40CL#,!F`E=P,!TJDGGF``_^J2#40N'8^@K:Y"7Q`%"<S,`)X@`4KD`9:I
M)9'`Y6K'`*"-)PA!-.IRN.#B5=2J))X5`9R`K<)B`)+Q3O',M2K.5_$U7WO"
M$.#@[WXH)B6&#X#S)?IU\]@@)N^C5-X`)$\C0M8`QV`(.O1B#4`21!<%A?00
MZPZTXGH.)#NC8(GC[S1V#7147TWV9+70+AA`$U&V95WV$8W#Y<CG96FV9AU1
M+`0@(&UV9WG6#W\H+7LV:(5V:(FV:(WV:)$V:95V:9FV:9WV::$V:J5V:JFV
M:JWV:K$V:[5V:[FV:[WV:\$V;,5V;,FV;,WV;-$V;=5V;=FV;=VV!?6G7O95
M7_=G?__>MFW7(`'T=F_W-B2<-20(H0$<`$M;)O4V3W!9MF4^X__@@'7ZPA!R
ME51#Q$_NA6\3X,&`$W(9P&+O+E<3("@QJ4H20!5YXDY1T!"<@`$NMPD(]VXW
M$BO.<8`$8("8M8%J5XA:5V6L-2UQ5\S."4?QKUAH"*/DK=Q<B"9KAW;QK``>
M\T_*:DN00%_<RUR*)G!K)U0";CQ40H'LD5=VA81<-S+%HC#A0&#AX'P[(SE'
MZXMLR4RC[:/ZZCK^#TDP2$]"*^<R(W-VI)'.%P[6@,B`5F"Y!$WIYPVB-SM5
M#`$>UB2+S')$Q#P'L`!R`][X+7P?,7$/(3'V]0^48JQR3B[_*@8HB.,-"G8W
MCF8'!V)1=R/K@(N2LFXULZXZ"L&!.'@I8K@EP:8A2%@@E0Y$Z;<ORA4ASS4S
MQ&E'W'%1OF)E=X(0+(*).P5P>J(MW'$B@F-)`*I#"N$#*<0\X:DE[M*"_[`0
MA.`%R/@%AJ!UQ>*+]R/?6J.^^.`!#(PJG(#Y".$(/,R]KNTB0J4T./:C^&"?
M9M==%02(Y`Q6=$-8^R:2M''2S(6-]6+)W*L]K&(-#,`(K#4`BI5[#,$QW`NW
M^A!)3.-B`\!=_HF4]%=0+(><[O405'>YL'6W9DP;=8*.Y*02+TA!M.,[$@X1
M,Z-Z@61:4A2,Y=!+PD1,T-BEEM,Y_Y2S'VUC`<[B*GGB*PI@`19@IQ:-$!P+
MXFB)5!Q*-*:YE>YJ#:9+=0LK+]JLZE2.1X95WL15+^#CW\Y"4*!B@!(@G17@
M<2<$G9^J`1*4?O.B7,_D*^XYK)#WB`4"/NPP+5*H-CAI`4KP88#B.``#2G?#
MO*)10P=%13Q"6H39#P6!*(P"*8Z9L5*1`5)Q6YASK,1G+-3--6).NE+*A+.F
M$(ZF$#&)GEQ'EMG`I;?"S1[WF&:$B\1#G-/)$!PE0;%"(8>+'35"(:XR70P,
M3;)(Z_"$5!74U``:YW8J9?(7>>=O(([C7!%F1K[B`-!DD[.'92\U,*%B_O#1
MG3!EA3RB4_\[>I@_P"B.(BE\0BQJ1WB$1P"NI!)5NGK^YY/^X`\R8V:_KA3W
M5R!J5"^N%*,*V[`3F[/FF#)4>8$,`T!*0C><9B>XB*5HJGQ:=#X^`ND.6^HT
M;2=`^30R"DV`^L1(R(BU4ZPOEJPIB#QR=Z>)4EGF#Z,0$Z[')B?HNJ[A<"B*
M(J];-ZEW3NA8LH%XA%2FPGA<PS4,XJL)H@F,H`$\3(3>:4E3>&JFN[JM6U`(
MX0GB2P$,(H6.R5Q4=0U.X[,Y)[@Q94"@`G@'3"7(VS600R?\V;0J)=F^K*OG
M!+OEPRM3^+3<=S?8E[79<93:NB4E2+CCT6@"0#V-NPL+`00B8`+_)"`"]+HG
M-)A11^4A"$'&'B+%'P+!@277?M2['_NF#8!?W4O%4UPKWD#D,-GE4JB!6HG;
M1%"^.6BA+&<[[MLCC%-D;,,`#D#%&0"X?AC`MZ7`-(.("[H^,.(QRW4`(F*E
M:.)*><)>>"NK8J>B4MB\A+L@DNJJKBS#P=`0XD`-U"`-U&`.?B*-DYDLI)LJ
M/BGJ""$Z8,<NU`LD*Q+&31NRRV,JE,O/#8$0/.=%&"`1!597<,)!WJ`)=@M@
MY/?03JD[UB3"O:(C0ON3"H'16?MUJ-,ZVXRQ!$7^9CE#RV1&%KR-V5!89VQF
MG027^Z-F>IDFP'2TT-S-.W'$=R*EI\8L_P2`I9[``?0P,[SR)V$<O!D<D"1#
MV9G]MQ)B=DWH`1:@.FXTG'BB-I+Q.+0"U&/(M`E<;AQ`L164AO3$.D>*5XIX
M66S5NZ_NM%!GVA/4S\RZ3!!X@K![:7XR`!JJ.S9-V#<1*P[>(XP]1]K"`'*#
M^AI,#TWS#?[@%WGE+L4=\\:J+_P,X@4VU'B---I*8)M-WIBD-JX=BF`$*AA@
MAW1"(;928.NH@8\<K$U;NM*Q7]E`)0SZJO?GM2W'S$XY5IP;5VQCE6<+3]"(
MFW/B4K<RZYQ;-S)#`7#."72%XLU3(0[@87M)HQ!^V)&94?7<->2(*]+&(`3`
MMKM9WAK,,AA'*?_:(K7TBIL)`>TYR5PZ9'&ZR[,0S9M0U>U#I2P3+FUL6]+V
M6%^DM7SP^]`QU.UYI=M//90Q"KR90-Z1]WJ%)[2`UI]H]-!;HQ&_HJ_]FGT>
M;<9JY^>=O2R^HKO*.>P[D0T4(P@9@"0*H0Q/@Q":@`$0;21[XA<1X`"*D1",
M0*VH%%GU"LZ*@#5TG_</P/?K!0D4`'&.@`_^5SS>X%`1!PFJ(T0HC">>@/=A
MU9RBR",PG7O80/L5@`FP%`[6YC2VN^(DK?Q-QJ3MOP%<D7`E3:TP'3UN7V<!
MXI!`@4<8&&Q@T""2@7^,)#BPH(FA@137,&!#\=`?)`H.*$!"**/(D23_2YH\
MB3*ERI4L6[I\"3.FS)DT:]J<2:A02D,A21::J+*03I$\31H:FK&HR9\P<]Y\
M"E7@49A3HUJ]BC6KUJU<NWK]"C:LV+%DRYH]BS:MVK5LV[I]"S>NW+ETZ]J]
MBS>OWKU\^_K]"SBPX,&$"QL^C#BQXL6,&SM^##FRY,F4*UN^C#FSYLV<.WO^
M##JTZ-&D2YL^C3JUZM6L6[M^#3NV[-FT:]N^C3NW[MV\>_O^#3RX\.'$BQL_
MCCRY\N7,FSM_#CVZ].G4JUN_CCV[]NW<NWO_#CZ\^/'DRYL_CSZ]^O7LV[M_
M#S^^_/GTZ]N_CS^__OW\^_O_#V"``@Y(8($&_QZ(8((*+LA@@PX^"&&$$DY(
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MRZVZU[X+;[SRLDMMN.76ZVZTZZIK;[OHZIONO]#NF^^\!A\<\,`)KTNPP`PO
M?.^T_=(K[A<53WQM#!IKS,+&'G?L,<<ABSPRR"&;_/'(,:!\LLHDN[PQRRG#
M'#/,,JM\\\LTYYQSRS[_/#/0-9>,<]$[TSRTT4CWK+/-2#<=]-%*.TUTU4)#
MO?+425O--=5:N]PSTUM'_7398'=M=MIJK\UVVVZ_#7?<<L]-=]UVWXUWWGKO
MS7???O\->.""#TYXX88?CGCBBB_.>.../PYYY))/3GGEEE^.>>::;\YYYYZ;
M6^[%&5U\3GKIII^.>NJJ;QS$'4&<`<3JLB\N]NRKUVY[[GQWW,49,6"K>^ZX
M=SZ\VL4'CWSR@?^`QAEZ?*%\]-)/3WWU2P?NPQ=<B&X]X\=WK_CWX(_?MOB`
MG]&\#X6;3W[[[I_._OM^^Q"[_/;?CW_^^N_/?__^_T^^^`%P@`2DFP`+^+X#
6(G"!A%,@YAS(P`A*<'T3K.#A`@(`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g145452moi010.gif
<DESCRIPTION>G145452MOI010.GIF
<TEXT>
begin 644 g145452moi010.gif
M1TE&.#EA2P+*`?8```$!`0L+"Q,3$QP<'"0D)"LK*S0T-#P\/$1$1$Q,3%-3
M4UM;6V-C8VMK:W1T='Q\?!)WB2I?E"-MD2YBEC!DES)EF#9HFCMLG4!OGT!P
MGT1RH4EVI$UZIE!\IU-^J42<HE:`JER%K5:KJURNKF"'KV"(KV2*L6F.M&V1
MMG"4MW.6N7:8NGN<O6.QL6NUM72ZNGZ_OX.#@XR,C)24E)R<G("?OX"@OZ2D
MI*RLK+2TM+R\O(6CPHFFQ(VIQI"LQY.NR9:PRIRTS:"WSZ"XSZ2ZT:F^U(?#
MPXO%Q9'(R)S-S:W!UJ+1T:W6UK#$U[/&V;;(VKO,W;#7U[?;V[G<W,/#P\W-
MS<#/W\#0W\#?W]34U-S<W,32X<G6Y,W9YM#<Y]/>Z<+@X,_GY]?AZ]+HZ-OD
M[>3DY.#G[^#H[^SL[.3K\>GO].WR]O3T]//V^?;X^O[^_@``````````````
M`````````````````````````````````````````````````"'_"TU33T9&
M24-%.2XP&`````QM<T]035-/1D9)0T4Y+C"`\B]6F@`A_PM-4T]&1DE#13DN
M,!@````,8VU04$I#;7`P-S$R`````T@`<[P`+`````!+`LH!``?_@!6"@X2%
MAH>(B8J+C(V.CY"1DH\6DY:7F)F:DI6;GI^@GYVABQ04%A:GJ82IIZ:NL*>#
MJ:BRK*VMBJNDO+V4F*.1P;[$Q<;'R,G*B\/+DY6OKX2JIK2XN8+1IM/5N,[?
MX.'BX^3EYK/GZ<#5MM45M139UO'O\X+SL,WJ^_S]_O\``PK41(W>NVVO1K&C
MA[!=PH<#(TJ<F$P?17X62654MY%50UH+[[F[ARMAMGRMJ'6\"&DERY<P8\J<
MF4AE26\5V)UD5PL=R&[1:`H=JLPE46!'DP[2MG"7QX+PFO$T>%"B4:58"UW-
MRK5KJ'FU<$Z[&5(K4*]HTZI=*XPM(J<Y_['=TFDHGRVW>//*W*J7[=V<JNJ>
M-51R&R^^YA!35-RWL>-TWJ2M^AE/X;614W-M8USWL>=CG#6%_MQXI4YX=@O.
MBN5*9$J;ADF7SCJZK:_:LO?1)0D[JDG>OO_NSDV\N/%+N&.*!<PT&LB<.U/:
M6_WWN/7KV$F[ZG199=-@J%%O%ED=9G+0&B.>SWY\/:G6)[OCDPM8^G9LPVNZ
M9\^_OW]QP4FW5&KRP/7.(?2!LA\K_^VS8(,8D?-@)`GA))=XJ`P83&R%E`?A
MAZ1-"!I5_U6FVB'MQ)42>4OU!.*+,,:('G)-D3C@4QD6R!!\,OHG8H]`6A*+
MBW055MB0Y&UD(/^(/[)D8Y!0@N.=+3A-Z1L\+<(U#(=1=FD;D[TT.=!KTDSI
MG(WV<:,F@V9YZ>:;7@(5UD.JT()(-W`)9YJ'<,Z48)^`^@)+D@K1*5AXA@;J
M5S-+\B>FHHTL)XV*]Y'XFGR[\`GIIHJZF-UR6A94GGS4<,,E,YRFZLFC+2TC
M`:M"#=JBJ;)R@VBM!^7HR).J]NHK5WA.E<]<8>F:6B51-;K:C!'^NIBS+"'+
MG)&E#MC<:IE*MV)-O,88&JRX*0OMN"V:.0JFF`4V"YG#7$BN<J^^*V^'=LGU
M75FXWEL7K/."TFU[_?9#HEWI!1P0O[$:7`Y5>4:E\%L/1XS1OY-41Y7_8;@J
M*%IQ%$OL<4S5@4?=@QU_'"C"@5(0[XAC(;N*0=O*6[+)C:R<%,H<?0N)Q?$8
MEJFZ\N*\Z<PS$>TM(Y>)2_/2!S(M4VHP&X.ST$XWVQ75:O&8I#)&5^TUG%V'
M4EZU7Y=M=J3.G%HHUF>W[?:ZG;'X]MQT<XWBG'5;E?>\#N7W5=AI>;KWX!?!
M[#>@-K=*^.(`,B0XXV9O=RKD3_-YW@28?X/Y!(MD?HSGQ6Q>P>:D"P0Z**?[
MJ\U`G$_PI.BAD`[[N'^B;D$(.R1!1`\I8,"Y,1>LP,(*%R02@@TVA$#*!,4/
MLH(-+&!0C`8L(`^]]=:#`!`'R)^@2?."H("\_P:D9,`"$$,,P4,(%_S>SP4I
M!"&$#R1L>($*-JP@/2'@3U("]M9#@0?\Q3;E``X2('`"&][`P#>XH0LH.`8'
MUO"&-7``$1/H`0.+$(H+G$`(^\,`&1RH/&*$P`T-3&$#@?"/":R`@5OHGR1,
M(`3R5>`"7W"@]T1A@Q&F<`U/V(#[U'$!):"0@4J8E0;2\(8V:$\0%[!!#S#Q
M!!4RT`UK4((-,4$!#?#`!@>$4PA\V,0V-+`-*S`&!]3P!C5<\!`9W"`H,J"$
M-I`AA"-L0PE[00$2'-&*#`3"$-7A0AA>X@)":$,:A'C#'+IAAYY@P1&Q^,<M
M;%$=)V1@%Z[`@HLML?^)(.!<"+C@AB1>HHJ`9*`39#C#+KPA")_ZQ28VD,,W
M>&$'(0@!#WR8AC<2HG6,<)U!*)"Z-;:1`\#\I0=6H((GCNZ7@RQ$ZBJ023*T
M[X8G6$$*6#FZ:&)0$1/(9!KRMX)RFG.`W$J$-P6QSJ5TCITO?,,6[E0*#Y@Q
M#;YKI`Y;U\YD)N("8F#@$U`0`A($P8QOV`$F4M<U8AJBD&_X`@8NT(P+H"`%
MVQR=!M]@2C@RP@E(3$$Y>;"%*YZ`*K.CY^B&P,`@#"R,68&I)3;:A0V\(IQ,
M?$,/AG@!#X0`!-)SWP4T0-0;YG(#@]A`+B]`CPD8TXT7`$$(?`E%#4P4BAO_
ML.H-/5`"J@XB`[F<J@5^=S\4DL$#&BB>5:_*/Y^&8'^$(*H-.1`"#S#U3GY\
M@S5EY[D+;."O=[4`!S)`V$+0-01(/812$?O,0EP@EW8]1$]+,,!XSG,0/0T!
M9>^*"`_>$P1IQ:$.*["!S483`[GT:H=`0,%%"K,"2G#@$P:!@:R"SZ\;:)Y?
MTUH!#?RT>)SS``F<R0C?EB"QF.4!##>0`8J2"`-6+1X&@B#0HHXNJB5`+#<)
M`=*$`A,#7`CD(":``:Y.M7\7R``'*`H"NV*@"`PD@E9S@MJC:@=6%_""`U4P
MQ`G8H`D]("X+MK`&-]@Q"(R<P`G2D(8GF(#`;B`#_PLNT`,RN.&!$13$4U<`
MA0*G00F)G<`.&`S+"J2`P4HH`833$(3F48#"8F##A=,`A1!@3@D4=&`:R,"^
M+>S8F1?@01?6T(8V?*$'X./`%]+PA1(0(0U8A$(H453-:Y9N=!KP<1J&D(H3
MD.$,9V#![TKP!#7,6`GHS,D&A`!E138AS8)@P9"QV(4T$J($'79#&H3``Q3&
M,,Y<*+`;U,`%%B0B"&QD((--4`%'VN#)6-Q""0B!`2!8>-`UQB!K'<B##+S"
M`SQ(P1,O\(0=F^!W/V`P#P3!YG'NP,)MV(('/%#F08-X$2%0`I3U#`5&W[##
M5TR#&#PMCRYR0=AHY0)"]?\<0PI_0=!J@`(D#X'*';AO`D"(+^<H3(8VS!@*
M),A&#TA<A#6LH0EB0*@BH6"!#`!!#(*F\1X=(U-(3&#3:;AD9X,PR2-VP0.8
M2P$#U;!K!JZAI!=6-,`K8,Q!.["!6]C?#Y`X.A8HVLQ_G*(@J.M`;S-0#$B%
M@@K=4`(1DG#;L64@0M\`A;E2T(X/AR$W^VC6$'3``S>?M2]W@$(VF.`")95G
M\2A@@IPF/*)OW$!X'7A$,CBS!T=<ML:I:704YO2RDKSB)&V`B)2G,(*.9./1
MQ6!#4FM=T1DV!-"O^(4@I.""H!/M&T[P.R*TE'.H[/8?Q1#0/S9!$0L^>P4-
M#5#_%:ZA`W_)`!H<"((-Y+2!=^1X$X^H!E]3FX'6QJS(7RF(;#.]Z7#G.)21
MF.,&=B$#\!4\CR?7E\=]8@(H0"$7MCO>K*^A!R%002V?4#R!,Y`+)_!R`Z6]
M@IQFWI@5Y`$(=I#H*4Y@XF\H`N8L#D,4/%B3Q?-`:T7-@ARC@`(E`(+5\V?5
M$;JAA!M-`RY9X$,B:#C1XPR!$%"H1QM1()-O8(.YS:V&-72A[*@$!>GW1!K@
M2J54`BE02R5F=_)T`B70!'[6/B9P3^MC`VS4!I-6`4$G!BL0`JDG3_KD!D&@
M62DG!G!%""$`=16T`RN05K74!KBW`PBU`O%`4RD0`ORF_U?ZQDXFD&@-%&T3
M1E8&"$D,*$@5T`17-((]H&X_@(,HI`8>8'\;X$.]5@)%\(3*8P(,*&';%!L4
MD`%GT$1VA0*HQ`4K<`(><(&X='TLMUVH%`2S!@(H<(4.E`(3H'UOD`;-Q`*)
MQE\3('D1E@8G@`)!!P4K8`(A0$%KP`(A@`)+IP2ZP@E*P7J;,`$J\'NT!T6N
M]`8\L#D>P$2/-`&^MP:AA&V*ADRPU5*C@WS.%T=O,'NN:$K4!X68$WMYB%0;
MP`-"X(<5<`68ASE5QCDF=WX3X'@.E$:88P**.$`-)V83H`$^9(=UD5>IA$_9
M\(D=YT`[0`\I@$)?T#X3\&!.H/]0QN1:S)-#>C0!*<<#$8`YRO4&0G"'+U<"
MF+-V(&B,;L`#Y',!00`$$X8B>)AOV[:)[B<(J/0#Y!50Z8AW=;A.)T!*5K0%
M;W0!0]@Z12@(2`B"YTAQQ0B*]/A0&P6+-Y1R2>1"*&0%T+$+J?!)I*A12`2,
M*+0&^E,!'B`$O-,H&8E%1?9'4*!6NK@"F;-YG5@!'(=&J-4^'!<$F',":)<!
M]S8$/8`"2O,5CB&*LL=-[@,"]X1<J?@&@M2-$05<.V!(.9&4[U=!SA0"6_E\
M<C0!U,<%@V!/>6A#G,,!)\`#3Y!CU@9^9H5'361CMB@&_1-T8I:&H'0/0<=?
M=9%);=#_!$KPF)`)!/UC`W_$>^R4E$(U"&#Y!2=@`B5`9@PT80;(`R7@F93Y
M!EU0`;;8!<WCBO-DCWFX!4!P`M>$"`&96'('E()0A/=V3];GF0Q88BAR`280
M!%Q@9@VT2B&(`G4G7D?(0!IGCS:P;7V7@8:P>=/)3B?0EQ`U3P/36WFD/;$H
M"%-X160@@"50FY<'2(V)7)RS`2;``TV08T/)<:Q)"$EI"AU@=&3P!+@''?76
M'VIYBX9@ET&UG6$Y7ANE!*)(EA4PEF_@!(-@ED[%1FZ45&RT!@"W41SDEF0I
MCP1:`60V>BFTER70EX(PC#9F`P)5"+QIF&J`7$LGC1T2C(M`_Y$J5P(&D7)3
M]TLL>D4QUU+0V$`H]$?X1'U00`B6)0@E0$9L9V>'$)!E-X2#P)L(^G!_]`:S
M]5`W]$P7P`$IL'FDN)%S5Z6!Q#D9.905L'2*:7(8*%E]1W=QV5K(%$]6X%S<
M\$EM@$X<.@A\J$*Q9GF&4(9$4*A"@$O]4P).0*(-5)\4-UXL]4KTL`.E9W`U
MIBGCP"I3&0H98'[,^4OB1P93A*""20@+:F)7.3KON*5$J8H,9Z$+UY$5M*$;
M-'T,E*2"<)OA!'];(`2UI%!\^0:E"IY_Z:$@2`@\6J''!$4S&DTTIU<9P`@E
MX(,=50&IMU,/]:-JL`50L`7<"@50P/\"G^0&7/"MWUH$%T!]ES4ZEM4\'+`#
M6X"<!F>=A2"7^09%CB2G$U"$$8"@L=:M`+L%/3H(*M`$6\!U[-1;`?4&=HBC
MH;B;SME=0VF/;6I^'^E8<>H^NFJG"-)%3*2A@G"J@P`"/S!GD,>52U%MKC->
M*)A3VRH$F]B)?]A2PQ2I+C4(.#AD*31L!92IO!*@A\"`4)!/F`,".>5^AJFA
M[K-Y.^5[<#DZ$+JE,PN/9^D&&38!)ZJ#%2"RZCJR6UD!#*@$;Z2R?61&=Y2B
M>61C64L&R(6C;\!?3X6*%]"LBVE63#5(!J$!2Z=R-.B26II411`$$V:+LT=;
M%U`\#IMV%W#_5>&(HIU'ED.56W8)!#FEE%':6HPD6@\+MF<JI9AUN(C@>5^@
M`4+E2`WK2&F'2BSTG)PX"`BGFQ=@L8B@NN.U`BC$FMT)#88PI`NYH+]36VGE
M`2E`!#DF9H>0INNTKPS4!.O%NHXJJ4LA!'?W#NK57,N$8P[T?8UQ,3O2"]@H
M3RC``1RP`@M+BQ6P>>C*.2E@1FH02BB`B5"K2A,ZO<C7DQ-@`2FWI7UJK+A*
MDZU%/D$WE!S@0R9JM\)H?C8F=ZO[H&:%5'$["&SJK'F5!HWW5Q:<5?,KK-UU
M5L14`O<T0"+V<4.51Q'D5%O`!4[``13`<4UP34#P!5M@:/BH4$[E_T/S%`)+
M)@8`QSDI)YR%@&^D&X)$>*9SJXTI^@1=<*D=XL'+:U=?.G]M!'!%[)68\[U&
MB+PW%'2ZB0'5Z4U9=U:8HW30&6<,=`5V,@UZ^D2^"WMDD`815X]+9[R#BGG=
MPK28,\`,)+,<-P3#)+VOQ#GLUV#@F`%]I[V?T1.1&`HHD&B#)J]NH%""<`(4
MY`9;H(O-)PA.*Y8MNG&J2`$=P,A6P`-.4*0E#'T=2GTHF:L+M$@4D'II\`.6
MUD`:)Y=MT(\>T*DD%&=%^@0\4$<.U$F>;*$J_`XS:G^9I&=I0'`,1G`QI&!F
MY`8JH`$+V\*"T%U?\`.(-L9;.W`VN8E=(/\]V.@&H5P$SYP"\<!Q:V"3M02"
MX,5`9/`#/$"\322H2[$!%T@$0,`^^O5(/<.;%6![2L`#OJA7'=!U/]@%7?!X
MPNG':A`$/T!&0!`/6*R!#%2Q#D2O_!-T9``$/5!+_Y<378LB&F`&8F@*$"JJ
M/P`"/L0%/2#*]U30AR"QW<*`:0`$+RS+H\-Q0O!+&_4%/K`^8B>P/?`$WKB#
M@&("$)E"9H"PSO-X5R0$P)7)JKK)K4JUP=Q$J'1%/R!N'$E]9IP3]BI$*IU"
M;6`%*(2KL/D&*'`!H&AC@D"IAH=D.?')%321;&I_69M*>N57N\=48)E0Y!ET
M1$K-%8`!1J1"8K#_1\6G0FRPU8*@`9MG<*CT9QZPB60]L/P3V6]`/+5T4H*0
M>I9+E"N'=HF``:-L16V@!-$J""'@U%^P=*O;7=@ZQ5MLL>O$`8+=0%P``CUC
M61:AIR$0#X8Y</#IU(K628@@TXG@`4X::W[&R?`X1$SLSAF0`C[80&F0=F[!
M-B\6/T\`!45@`RB;JS^P!63P!4HP;2'PW:L+>]^]:H+`88;XV$H`!2!6`U!`
M!C$,/F$*!0AK`M_M`TG5!."]VA[X!63@!">@`44`!42P/QZ@!'Q78Q=`!%#P
M9@:!@UP@!EU`!/2J`4WP!%J4$Q?P`U#P!,$=I4X`KN#ZW2P.!5!]`D_P_P1.
M@$XE_MTM1E\D]05?\`1!B%DK@&YB(+`H"P+&>=Y*8`+!@`$EVY^>>>*.35H]
M``5B0`8=3L\%6@0\;@4_%P0S[DPL\-U0JII*@.!<`(<W.KQ<8.9$L-94H:A?
MX`5!P`$L`*XJ(`AX"05I!P0G7D(5?N)PIG9A7N50L`-;1'0!;A$98.%-@%PH
MD-]?4`3DXP%`8-ZO'03$90@\`*Z>K6EE+@8#I0%$\`22_L_@:FB%H`+F[05$
M4#PXN`55+IN!SBD7HTZ'FXF7\&+`11`WM.N=M=HW"KH%HW:/P#R%]4]L)5F@
M^R2+RPB+B^O94`&$Q51=<^O040HW-.TK>P@3!?^TX'1#$]5.2/-+SSY>+]9<
M0_<)RRX,S>5.MP[ME!/O8>3M\1XX]7[O'M.S^+[O_-[O_O[O`!_P`C_P!%_P
M!G_P")_P"K\,^K[P#O_P$!_Q$C_QJ!,1XB[Q#8\@W^`2\.Y1DH@=C&()%\\F
M:',/K_<EHG`8Y1#R(D_RZ$`8,,\+$C#S-%_S-G_S.)_S.K_S/-_S/O_S0!_T
M0C_T1%_T1G_T2)_T2K_T3-_T3O_T4!_U4K_T$%#U5G_U6)_U6K_U7-_U7O_U
M8!_V8C_V9%_V9G_V:)_V:K_V;-_V;O_V<!_W<C_W=%_W=G_W>)_W>K_W?-_W
M?O_W@!_X@C_XA%_XAG__^(B?^(J_^(S?^([_^)`?^9(_^91?^99_^9B?^9J_
M^9S?^9[_^:`?^J(_^J1?^J9_^JB?^JJ_^JS?^J[_^K`?^[(_^[1?^[9_^[B?
M^[J_^[S?^[[_^A\0_,(__,1?_,9__,B?_,J__,S?_,[__-`?_=(__=1?_=9_
M_=B?_=J__=S?_=[__>"?_2TP`N1?_N9__N8__N2O_N<__NR/_O"__O(?_^C/
M_N\/__9?_O>?_NT_`OM/_X#0,C(XV")(B$AXF,B8N#CRR&@H"=EH21DY>7EY
M&*G(B=BYZ1A:N>E9"EJ(>EK*^FGY.@J[J#E+:7I;.[H+&^M[F[O*&YQJ3$HK
M_UN\S-SL_`P=+3U-76U]C9VMO<W=[?T-'BX^3EYN?HZ>KK[.WN[^#A\O/T]?
M;W_OW2NX_[GKWP^P4"Y^`O]5$G508$)3!$4Y#+@P(D&)`RL:;%A0(<:%#RD:
M]`AQHDB+(4EF/-D1Y,F$'T>V9+C294E;&%_:G(D3)4R..GG"E!G3I,JA-37N
MW%@4YI@Q89HZ?0HUJM2I5*M:O8HUJ]:M7+MZ_0HVK-BQ9,N:A<KTK-JU;-NZ
MY?HFKMRY=.O:O8LWK]Z]?/OZ_0LXL.#!A`L;/HPXL>+%C!L[?@PYLN3)E"M;
MOHPYL^;-G#M[_@PZM.C1I$N;/HTZM>K5K%N[?@T[MO_LV;1KV[Z-.[?NW;Q[
M^_X-/+CPX<2+&S^./+GRY<R;.W\./;KTZ=2K6[^./;OV[=R[>_\./KSX\>3+
MFS^//KWZ]>S;NW\//[[\^?3KV[^//[_^_?S[^_\/8(`"#DA@@08>B&"""B[(
M8(,./@AAA!).^)<;%%Z(87%DK)!""CNT(9@;.CR@0`(+R)!%:FC$0(.%?*$A
MUXA4#(:&BX91\8`.D,F(V(HSV(B:&S/$`&-=:,@@0Y%[N8'#`@DXH.1B43HV
M98:#;5'!!!-PH$9@9300````A`F```^P<5H5`1B`IEYH.-"`7`\`,$-@;-R0
M0!F(R0!`#)#-6>=A60A00)7_I;%A0``I&CG``'KR10.9!3RJ&!H/-`"DE`TX
M8.5A6UR0)9>!.0#```_DH`,.#0A`YVEHT)!#IG;I`(`"<E%!PZ)_H5&`HWOV
M^2<`-/1X`PZLH7&``+K.=><-;>KE1@(`,*##LHE142MD.`"P0*>&85E!!:+^
M508!`=Q`%Y^%VD9KMX;QZNMA?,H0;*#&(:HL8@D$4,5CM-KZ6`X`Q.DM89]F
MZ<$:@&41P`!:T%4&`@BDF&J4:-R@8QDW5(%&#C'$D,.S<;&A0PP/S+"L%C>4
M006+CVK\`(IHX*"#A3/K&!<:.LAP\HQQ53'G`1N_D<4-#\M5Q0PQ4R'K&V70
M,(``_S/$.O+.)UO[1L<FKRS7O!?'(`/32*\,LPS]0GS#`S'@$.6<P\;E1M)+
M9ZHQV%FPD0/5-]NHL\DHTS6SR;E"FP4-#SQ`P]EQ5:R%X7\SZW$,5*!A@`!'
MT^5&WFA>S'3)#]Q09-$%]+GRQ5ED(</C6JN=@\6>SR`VT4'?,&/1+'^.!N=S
MS1Q[UAY__B@5I")P0XI5&#U7T8M2T?H-(!<9^.>7*ZA&]=4_$6X%&XAA?1H@
MZJ6%N3_2Q4:-;RP``+IRS3!MYK4N0&8`#"A9Q;YBEAI#F^PW0("8QNHP.C$1
M(`8".`",&'8`-&G!?F(2`)3>T(#[#>P-,6C5&]A`P/L)H/\!51+8_=:5!060
MJ4P/4%(6$##"`JB/3PU0@`8?X*((.L``&K37&W)`0S$%X``^>P.@1I;!!G+P
M5CDLU0,&L"XM#,``1:K?"`<@@S:=<(0"R-]=+,4J#<K`0FY`X0/Z)\`<R$4+
M(M3A`RJ'-:<1@``PHL(.P:1#!<"H@A+4@1L7D$,_Z:"(8YI87,I0Q@8^,(+W
M8P`%`["J,5%!!P$`V,\"@``750$!$BR`&-%W/TZ12GUQJ6"=HC4`./HJ!P>0
M(`$XB:`UF&`#&^``!S20/7&UD@,;X`%?8A"`1L*N2CAH9)NB!0!C;:MA#9@!
M`\+T-BV4$@$QF($#!A``/[V!!F/_.@#/RJ"%T2%`!C$PUYK0A$`+1?``S6S`
M`(3U!CP!@``-0)<G.UFF8AX16'3)`@,$$(`%Y`\-E&2F,_OW@#^6DIPS$.$`
M4L2G`!#``3.`7P!P%L$`%`!LE#QH7*@`S6W*H)0%.-H/#RD`!CCSG`ZP4!FT
MR<T"Y!*$`F#3&[1`0W^:,P#T<H,+_7G/`(C1+A4<`$,W&@`!](L-E-PAV&C(
MQ`NB;Z(RV%?#TE@N`NC)C4%=P`P222\=,`":"FA`%F@E49-5(7R-3-T]`<`I
M"`+``.4\9YUP("UVNK.//--9MFX%20O!%``$C6O1I%6`!H@Q@JB<$[W>("T!
MG&B+5#"7_P+,BD]C)4@-&PC7!&(92PID205\88,,SCFF`C``='+A5;Z()@"I
MWK!,.W4#J=Q502O^K`"J91\!=%5!!3PJ"T@]X`[+5P`!]/`&!CALN^34JC)$
M;:=OP$$!JP2O1_'I@7'AK479EZ><H8]>?!J`S]C@0FF.\VB42U]<&#`PZ+DP
MH#Y$IQ)U>BMHS@B[NZ5A$I$(HSG%P$95H&T9E.NPKAG@;8!3P`!PYK31H0N8
M<JRNN6;DQMOF#+VGA1@!?$553E8P`6W:E\\8*0`$WV``"W@6GQ*(K^$6=W%W
MI>!:*?6ON:@IDF_@4X.S!K^W<DLNI"*PBS_IPA+#382HS($`$/\@L@*I@0.8
M;7+V5N"7PBU`I7WL800#Q3Y#KI;#,:J5&]B0K!Q48<Q5L*=YJ>FN-T0K`#U\
M`_M<BD`V$+56Q=M<EQWYPVTMP$8BZEUI>_6P:`D`!Z<;<Q9Z_`87,M=I.M`3
MG]+L9K3&)8*'C0NB3UKA-[C1@.VMTPV\/!=2;5&$"$ZG1&&DA9;*^0`'+K.K
MT=<Z&BX`!UIPPY?Q@H9E(0N=700`<X&IH]C*.*A07>-4UT2_WZH9A1_>H9+8
MD(5G4Y--O4Y`G2_H(D8ZLH)I9;$C-9U7-NRKU%IH='-W;&GSRN6=B5;W2Y=(
M9C(C0*@)6H,'*G`!4($JEOD.%Y0!@X;_EO6OHXL+0`)L+2WUZ7DN,2Y7F7()
M\3`%E'WLS5IP*07NI,;9U&(:`#-U);`T_W!>?4'#A?7$JS%%/)=H->WTYD)R
MN5`SK>@M+#K5=``@E<M7;NLT73[-`'PM2TTL+0`;PJ?RE0-+!F0:0`)0E!<V
M4,&9"@C@L+K(YKFX4$>PWEVOTFARU6+KX'+9.-8_W.(Q.H\!\^8KC&Z018_'
M0'$QAF>EWU#WBT+2XO&JR[8(]@9$KQL`-956#]V8=(C[+T%N^`(7'L^%(&1O
M`U"`_!;(L)<</"YY-`P4Y90UJ$G%95M:+KBMWGL`!!P@]:L76J0K#J_IJ0G.
MRK[A`D!;*N.B_]OG[-Y+[-6XIM1+K/4SB.Y=^"3-N,Q\TNX./#HW#23C__"C
M<B&]T)-'J`,N\>CX;#WK)88N-N#`P/<;@(]EC$(=1HW7S-8Z`'2T=6:AT2Y1
M/3;9JZOLLWN;SS'`O4+YVB8YL`!@5";2]"\N4D%WEW?@AF0[AW%S07IR05AS
M\4XV]7XQ$E2L]WT(T&8+P@79PP$*\Q?H!7AS(4.#-P/4!'@AQW!>MG-WPP9?
M)C(45UKS)Q<"PVF#DD!S`3.E1&\"@V>MPB<55UU4D&1\AW+!!8-R9FLCDRBZ
M1@4/@WQSL7QJ97/#,BA)578#H%HC1T_K@U9@QB\,=VHOI6I1I04Q*/^#32@7
M;E`T,[1.+Y<U_20#M),%TG)U[2<7\3>!I44`F287]0=N]_<&..<B>JAM5$A,
ML%(T:Q4E,(-"])9W"=B"W^9&"<!W4*@G$9AN/F98<1%_>H<`:*"&,1B#$'(P
MXM(E?_%I$L8LTE)I57!D*,1<"W=G:N9"-G1#,_`P-"@7Z&,O;A!!M)=`*U)"
MI45)8G1<<?%#`C.*-3@`BN.'\;)==*$#?P.,$)A/;A!SRB=I:B59Z58GR/)0
M5`@`7-9SC*2%:H:':G5WI`)"2U0CE'1^FO=?A\,WB=*!A>AL8]0_>9AU>WB!
MU,0`-I(#3T5_%]9&`(``V+>#1!60!RB0-E?_C#)`75F3<'C78I3894@&A@UI
M@3YV`_ET;J4G:FT(B^P(`#U4+B%&%S1``X:"(!\8+B$(&&4P4*WS98>&D"/C
M5.L2%P)3>GC72!;2BJ#C!A<3-?WBBXLC``-@-%J`2VL%3K^%*'U2!E]&!<'5
M+\Y8)#]47@^0E67@`)`$7<$E-@<I-34R,P]F:@2@`Z1(!30T+%,H<P#`7GW(
MC.CD8CPD9SDP.H$"EC3D`&.)2Q9%!0(@`#10!JC#*DFD:M.T3DAY,8H9;>+#
MECG`A7(8854@9U0@+>PWA@*I(V25)&XPEV52;&)G</R5?Q[F;6V(/D3B!F7`
M=%0)9GB9E:BI4OU"_RNC:"&]AUKG\I?]0V,C"9>?J6#G=F-O5@6U.96!XD)M
M-B<&$)>UR70&\(`*`BZJ&!BI*5&J=TZ+^9)BTFWG!FFT@HE9@U[A267LU907
M-">E<D[01(QH,I+KI'JL4E+\N"9U\E$Z<$X%@`"C<V!VD9NB18J$1*")@E86
MP@:DLD-MUV!VZ8UII9?M]39E("V0=`!AL@!?:4$"JI^C(P`:UG'U68:AMSF8
M9``(D"@!`$-N%B8$^J'19!?\5"JKAT\`M6P!"8H7.$VY9`#)TBN`^$?&IFGG
M.&P[V&MH]VV1`@`$VC_FHEK.I9]MARF%B$\KQI%P@SX[E"S[0F-L$%&IQ_\J
M#495!X"%_>-QO4))A5>.8U14+]H_YP(A7>`!KG0"(@@86N``P95+!+``^S@H
M\!4C!$"$6PEX1Q*C!40#;7(#!'!W:D8#"$``!M!.14DT!:``;8(#\T:D1#(R
M#H!/>S8#IQ0C"H!/1U9J/V>E>L(&,U`Y&9@DI46KN>13CT(#!.!C.$"IS$@`
MBR8#JOI'7[12I!H7Q<I).L"J084`B^8&-X"I@05W'ED&!L!E62,#C\JFOT0#
MM=I2Q7<756!@T(H#@+EG;C!ETL@_PW6C'*@`!B"'<\AI_56095<`0O8&#%``
MBU(%[,0L,J!2$O4`63!E/D.M^+0FRLH&#W"J0F+_K&.44P,@.:+E(HXZJ-2%
M!JLB/XMSHP:@><;:``70@619L$Y'-0_B!FJP!B];&+E&!56PG7JWCA=4!E%2
MFU,BL]'&+&4@,E7`-&R0LZOE+DEI,5E`!3X[%VY(!2A'BDV;!65VA!"SM'RC
MM$P+.$*+<40;)>4#/5%;6D!KM1Q#/F3;AE-[-S(VM$6[C$[#LUD+77*K%]"V
MM&B"M#GS@&B0E;M39C"2.W>!M%Q4M&T8N'KK(CM;%V4P9H_"M\]BMV8KM4^;
M-6(KM6.E9H=;6ER+.4I+*;EFMD3;)GS;-(P;A55;,(8AC%\(&:PZ/DXC+;J(
M'L>T17_D0I6:NKGK&5E`_R(*5:^,P3X&YP#^RE<U:QXC"4EP@E2_J[O->QE9
M4)^H!!ENT']D(@`*D$;GX5D$V$C9Z[S?6QDZ4#R7H04Y<`,;TS3J40;FNS&H
M"[[O"[_Q*[_S2[_U:[_WB[_YJ[_[R[_]Z[__"\`!+,`#3,`%;,`'C,`)K,`+
MS,`-[,`/#,$1+,$33,$5;,$7C,$9K,$;S,$=O!AKL`4AW`7IVQ>-:2B-2<(H
MK&9:<#309KR>X<)YP<(DW!U:X+V`H[65D@4O_"XYC!K0QKPOH@-B1L.W8<,E
MM\.GP07[Y@&K*!@PM4&9$BVN6!<VY5U.4Z1MI%A<1`72ZQ=/P\,+0P"$"#@'
M0/]PWV$Z?U0`-XL7!.3%AV%DY[D8!'1^-$(#06P863#&18P75>"@HJ<;%W,V
ME`/(>A''I[$%%H`P?AH8,Y!+@`B1TD@7#7``*:)<;%2(!Y!653``W^87:&!@
M>/P7&X>@"X``HDP=98DSH'QC>B%XB\&)C3$#!Q".A,&N]/88AC@82Z5/?/P:
M#X"H:.`D,DD7+&@:2UR33@P8$"E"E2J&DMRT;7+)CW**&@EIGPQHBJ'+=R%G
MX1&*:N:^=/'*BF&+C?%EOERW'WK#AH%SX8P78KAHNM%U(T/,=!'+I-&=XQ(8
MC,2!S]6T*-0O)DP^17+)T(.WVR)'<E8EY4-_2JBSC1G_QJ65Q*1L/M@T,GAK
MN7"3T6A@P_6\.UF@!5]K/KMC/H'K!C9<M;69Q(`#(RIM*"I=:P/]1SF,!M+2
M.CD3MSL,)#UG)`N=M#H]%T*IT4"2E)D";3Y<Q<]&T"N-PVG(@Q\Z.4W;F+][
M=#ML*+FF)PQ#8^_<T<Q"CE'-S5V=HV*-.3-\04HMTQ`#TD:]U!@GS.E3)`S-
M+*>#MJ,W+4J</0DS&!,(/]+ZH3G@`'_(5DI"R0'-A6UD`)Q2K&/"5C$@LG-!
M!0?`KT2T4C>6`PD0->QTPXZ:6@YPD#N8!>3435#$!J;,,HD-)#10`!OJV(II
M3?5<!F?DVN2:3@80HK=R``G`_\((L``A])3$`R0Z<'NIM0"*$S&%.MP&,`,B
M0P4#^)0*P%R@G`#-_8<3!2,1$R8$<``AG0`W!JB5DUH)4#.=N+@)D%U$M*5:
M<$91H[(NPHFTBDK$16!H,,N*:0!BB1>T:BQF>@`C$ESL1"E9P#]/>0#+330Q
M.L:/XJSL7:B[,\OL_=JEU:V=_=GIRR2832@.L"@S0&5K#,W3B@"9W>"XFBR$
M@M_5-V^=7`4.<`!G0\FZXEH&T$-5X-Q.AP,N4MH<..`%<(PUS2K:?3<E\C*R
M'=XK>\^=T09$T`-`T`,]P`+9<P%-_@--_@1]H42J]6E[)A<024.9&B9!MVPK
MJ4:8//]V/A0F084XN^=B<JQIH-52-0)WZU0Y:Y6]9LK8_9,H-!9AA$(`RQU<
M6M"2N@*1&>.#!N"@MVT7RE0FA@ZB@%M*TH23A$<T"O6AM#4F]J*9<GY.!.`S
M9:"8U0U&]C)BI6(`=[JA5MI28.0GV10FJ;7#A_U2A>Z@5ZRA5>Q"-N<G$5,F
M:\PJ+EF2>VE#=@G*NS[G"&"\'P58$D5E8)ZMI&XN>%F(STXH>C(#/U[JI:(^
MKK52!G!..'I![5GJ:P))J.O(<LXJVTU!^%0FM*Z(4\KMZS3(8<KK#'DT<>[E
M!T!#,S)G;1:*F;Y$HQ,`GI<H*E4``110V7KFWF5:>J+K+37_Y[XNU*"Q9%IR
M64VF)5F2`GVQ/SES83!>5#.0L\`:3"IIV&+'I*]RCH"^<^3UH:]Z05D07.8&
MO=$4TB$$:G5QD`/`-F50[0#(I0/S7^7#[0]S97B55,?$`-$6<+=K%^R*2$H/
MF@%_48I9,Q%TVX."[7R+2P3P,">%5G>#L&[G-.?$0WP[3@?4*XS)MY-J42:W
M5G%)EE-:(UI`2493FVLT1^<(]:/#7N,L%UF>L2HU(WR2`!R#!G[\C9Q(?34F
MZ2ZF`)-S^/##YL"NDE"9.XY,;]2$O6N?6K7&6SI5:YQ\2CG+\],.;L.:.V:6
M5+U$`#O?\QY9%[(H`#*0LZ#)+4GY__DYX-2[\Z$QR='HPUZY!?EASRDG%0"%
MV3%W.B/Z1YH)!D5I>#%HF37V!?=;/Y9X"/W9S"<<F#NIF5;E[!E+YF1.]F]U
MJX?M56EN4$HEB&8_:MCK4G=OBUYOXT9`"3B5<S3LH^5)"J1SD8T2"`@`"&QO
M5`$#6F^*:`4"B3H!@XH/``YO60((:(J*6@,'FYR*F`FAHY^A,0$',P$%6:,"
M`32B"@`W;S<`"82+!P$Z;YX!5)R8!&5O,P`RHLK,;V@$`3F<900#L&^VQ6]E
M`\AO.0_:B@X`#>8`M,[>V(GBD6YO.@_=BC$`"XHX``R3ZT3)`!##6X$"R:P9
M"->.THPW;O\20%/$!@&`:@,5)!2G@Y";7]HHX1*5CY:6&",5&2*P:0&`AYP:
M`#C0RUF^=,:PP6(#LEVT`@%NA"IS`Q8CA*+0'!A`-%+-&P&(*4(@E9/+8#0(
M.M/U()J!6]:F55'DLMI/IO0>C.64;]\;'`'<^IQ+MZY=3FDV3)A0@6^%OWW[
M[E5QE]XA&CERX*`$BJ+%8,8$%-A$M=@WEO0`*)BG0Q^G'`$4$,IGR2<C1V3!
MBI*9DA,;`P+*B1-$R)`DBHT2H8%MU`"PV046"%^@8(&`V.UT!1\N7$"V11*C
MIL2$EI.N=.=@<J+4[+(I:>%<(F"^P**":-@V[D;MAINB:PP79='_,>,KSG/L
MVK%6URSI?!H'>/:6/P!I]\9`S1@R`'D+3`.9,PXI(M&#;Y15B```$)"`#%34
MQ%,`:TF4`'D!_L,)&F50<<,"`2#S&G*<]$-3.Q$!0&%[%[W!DP!KZ0=```8T
M<`,\;U1Q"(,#`!/AB4`5XP95/6YCXQLRC<><1`BXL5XY'\'(0(YG$1E-%E0`
M*&`.`A:FYIKMM-'#"BRLL(()@%V0`IQR$E&83`#TZ>>/9E4$8E($L,1&`E+!
MMPDD"2B"YGF+%(#(AQ0F90`B$E;%UDOMP+?1):L08F26)UX*3SX/&6+`)EG]
MZ6<``MS#R3*N^@EC(0'H,T\L!M0TVSY?_^+@S#)=E2&9*=>@)5&M/V8I375>
MP6@+9-XIHL,"C>3:YWT!^03:/F4TR<FUV?KI5C\F+JG(0`6!QBR@/D48D:85
M3NG&#`2\>L`-'O6TV[MQC?+`I=IFB&*AGXZZJR@[RD8E6!\%X#`G6ACG)P$+
MP`()P#C@)TJ-D%7FVK12,ALJ&[FY]LM:+@E[5D)48"N+N?P0R.;-.(NRQ05]
M>:#&S5I,LP`##`R]@$1N?1BE=T\F"LXF5&C&F6:BG'.#(8V9!AL\$SJ373O/
M)KS*/+8MS`BF%VI"25=O9*5`8CGH`+<.IG#BMMQPQTTW)S+DFC6HO8J")K"J
M\0U`5YY,=B+";_\@*L/<B>E03-BN;2WAE-X\G0N&!!R@0`RVI-LMV(UD`=IM
M.7#N^0,NN34X0/D=J%5G!^2M`]YU;\=IC;):^-X-#,#V(RX-Z_@+8G/+#8L6
M7PE@0`(.4((,Y9PHW([2SGQ)_,ITN5%%#`E,(P@:D!@`N=YH>,S)DP`X*3(G
M"OSF4@QQVSZYJ>OW5*]9E*>>X>JMJYF)<D;`-7$!,!Q8P\V6L1EG4&<G%HD=
M)"0A,D\58A>.2A.N%D")@LQE/?`X1W\4P3ZS?.Q]BM"%),KFFI3IB"HZ^`5D
ML.:K:.3.4?)P!AI,007G%.!PNZ*.F/+1C(&4QBI@21RRTO.P$5J#$-3_\\IS
M&E<512DE`#,H0RADPJW8V>0EY_"@H&10AEY0XEPV4]<;PGB)8^D0#0L3Q9(0
M)2M;5`,-5`@%&JH00.RYP26MT1$<99<Q-G"F17!$82YF4D-%?"EVNY'*AR:F
MHRRLA0UEP$&^='",W.WP&4=TAU2:=@^>3&EMG8*BI,JQ(Y:!Z6Q:$%0,M`@0
MUVFP@+BDRQ8L\!<._&Q-%2G<^FS1#/8A("%HL$5!2)DYQ46M49F!E"\$,`U9
MZ=!R\7A%C`XA)L,I8"@6D821#F`V%SXC?JM:A&]D4!,J%.";I,/BPG00G$V4
M(4`SH,(`!.`R3!S.&(TH1@\)T",='&=Y`U#<_R*8"!H"W,,-,2#`0RRH3O:0
MS!TL^0;:Z#$`=*C#BZ*PC;A^<BL=Y`N-)LI'`R^1KX(<JA(UR8(!$-#-`D'$
M(KV;4M\>L#!=[&.2BLB*`5C9``+@XI'6D`AFV@).1OI$%P?82%845[Q.7>JA
M.&T<3(UQ@*@>8RUN&,AOI#1"N$P)$@Y=GPP(T`R4H88B^O/=V;18.DY0X:0"
MS*5>Z<(%7E;`EVQ":TT7"8I@1H(&-)"(`1)20<9!HH%HG4&/!N+4#W[%`3G0
MDBT*((,;.*"C'FQ'%GZ8`,0B`$,S8B%N-IJ%)/W3;C]2``T\V]*Y+",NL_TL
M--P@$WBV`BG^C,L-9/_P0P;,XX\90LD#.NJ`>2@Q+.%`@U(?<`,:Q"]6Z(&6
M6[71.AR@Z&G!+.T-&H`A7;V!$B!UC44J6R,$S,"S'<7@@$P$">'*X%(3`4T`
M$O#>B*(CCKJCQ;QR6@V#XO8&#Y@&\2S2@!RP02D`*`!U$]LB6`RD`"B)P0\!
M@"DMD-:TLB!5IRQB@/<R0!8P`2J-9(+AZKJD,?KE[PTT[`]#4J+%)XY*-P8B
M`.HZ`!N_88-+!N``%\,J&"\B$O;>\"4%>/<TR<#2>QU0W@;V0RY[S;(BMO"7
M"0!V35_"2:>F48U?R""^`#!`-]@WEFIU!IKAZI-<6JN5NIR#PXDH`Z)L]8#_
M1MKU*WT:@"I2ZQ0FO14BMJ`7&\[\IP`TX(84B4%Y^R0`!VP"*@30!AMLT0`W
M8"(XKV+`1LK`HE<]^CUN7&AUM!"_/Q5@)%$\#3Q:\:,\@B,9.D#S3%01./7-
MA;).O.N?#"!IQ:&+(@[05EPZ2$(:Y.M5"X#T>7>G2#LJ8@:Z[O&N\@$`Y&1A
MO7XJ@%GT_*<!#&RL5``TAP?MYTN`F\,RV-62.]5J/ZG9;L_N4UR0V8""+>`7
MW2"WOL&'.5(7+$,WF(>L53:H7&@K!W,M1+[3K`K,'%O+&$^#$I10A"<`N"YN
MP,$,*`F1'$CV+338XP,:0(-/Y:#ET;B!4+R!&&.L_YP&N[H&O4PS@P8\0(\=
M:T`,K.F3,M#`YU5``PU<IG030@0'-/!5%=[;R*DWH`$<NHO5L4Z%79E<5EIX
M+QJRL`HTC/<!#G8&&\;A\ZZ?2.8+8X/,3;'VE;-<R3*O2<AG'O,&."`+<N>7
M(JH@`[\+Q0W5A=K(ZV)TF(LB"X4O,AP3+XP9/&CM#F#YV$]NC*,+O2-TH<+B
MQ>%X:V71&(7G>E)HP``'()/M1?Z4TC._>-&70PM''[K27?;!H,>@"G&$NK2C
ML1C#?^H2GG\`Z-=7#R%)MWTG.CIFW4"?C;!!!S%@`,NY!'5?O3P4B+]Z%A#/
M=\@;'H["]X;E,<[^]KN_+O]HNLW[YT__N6`B</7/O_[WS__^^W\NO/-_`CB`
M!*@F>Q1#05&`"G@SF#`C"_B`$!B!$KA7=#2!%GB!618NN5(*&&B!9(=_'1B"
M(CB"_`<R)'B"*$@1#7``KI>""E@&6/=Q+CB#-%B#HM!S@V6#.CB`[;:#/OB#
M0!B$0CB$1%B$1GB$2)B$2KB$3-B$3OB$4!B%4CB%5%B%5GB%6)B%6KB%7-B%
M[9<%.'!\7CB&9%B&9OB`5G.&:KB&;-B&[+<?;AB'<CB'=!@3PE2'>)B'>@B$
M8W=\?7@B5)`8>50UJJ$%XR<*90!X#%,%B9&#>_B(D!B)\Y=K*S4)`L`.-_`+
M^E;_.W:("Q&1:>NS``.P9CFP9QQF:9*8BJJXBKET&CVR'F,!%9%`'!U%`/"P
M'_,V8(XB"P=`BYHQ?*P8C,(8C,R608-P*%@4"OJD&KBH/Q`A$99Q*8(G#"R2
M7L-XC=@(B32D"#)13%2``WIG$2.!BU`B"A6()@WP8#N$1P+`"]GXCO"HAQ6!
M7=?`(TFA(C)0:NR0AA'3(P&8#P-@``=A``+9(F(8CPB9D&;(+O%P&V7P8\J6
M*^Q`C@UW.<5`";"R3QKI/`>ID![YD5A8!<Z#!MU(0D.F`%B7`Q'$C6`A*%Q2
M@6N3!5I@B#.I!1T)DCB9DT_8'D'1"&LADMJD3MW2C)K"_PC0UP\)$$=N0`6.
MJ)-.^91&F!54<1NJ,A1W-I$08PO-I2.JD"C3(`-ZI`K&!95D699%&#1],D)Q
MQH(.\!6YXD%I^`RA\0`(4"A506ML^0L"4"EFV9=^.8-NP`"'(!N:I&_FUC<+
M,`_)!FO]UB=&%3_=P`;.IFP&P'M_>9F828)EH`-1\AXB-R0Z0@5K,1^FL)2S
M!0MD4C=E8'(TH`,WF9FP&9NR.9NT69NV>9NXF9NZN9N\V9N^^9O`&9S".9S$
M69S&>9S(F9S*N9S,V9S.^9S0&9W2.9W469W6>9W8F9W:N9W<V9W>^9W@&9[B
M.9[D69[F>9[HF9[JN9[LV9Y/Z?\&:1"?OW0S;/!@]8D&]1F%^;E7;F!(^[>?
M.M*#UR.#3`B@(&>@(0B@@X1Q_DE`"_J`#Z:$7<`!&Z`!):!`;((&_W8`!M!5
M!X``#L"72)A,\)0S>&0=^Z)_O(4`1C$BP%@]+"B%@7E,=Y$#K-"!6:`-*PH+
M50"B&$<%!\`V.`,@EEF`R11M2<AE??%E:R(-/P(K4-IM@82$94"0KTD76H``
M*T5$^B<H;58`?U,7/92848@&=4ERH@`50CJ!.2!1))0``S`6ST2@.?,H!*1&
M!>@)F(&$.],S\VF`"I:C.1HS@]F$,DFG==$9TL2E^2<H3F*(B+H^,CF%D'H7
M8_>B!*C_+HE8&_*598I*0*@"@=7"IPCTIX4A#3L'809"0M?3@_UI%XU4GW3Z
MJ@Q#H`V:,PC:#I^*#YRB(W2:JW5AH$W3F:VJ)L`Z%[?J$P)*0@(:JY%:0[1Z
MH)%:JP"XK,[0G\OJ!@"&I]:R7Q3QJ\UJ+;>T)MQ!$<$Z?`]*(\?JJYFSIT?(
M!3SS5QC:I".U&I6`#VI1'GT&$3K``%W5`-:$!C.0``?``%1P+=7`!C$P=.41
M`X1@=`K050HP`WKT`):&`Q&[`)81`P@`HGBWH0U&H.GS<X7``#B0!0W0L0^0
M@S>@5`N`"ZA"!?ZZ(<='!2G;B^`8K#CP;R"J:>68/C&P"5G`_P`TD`5TR8*W
MQP#:L78\ZP!$EQ0W$+$($`.R(0/VL((DZPPRP`!:@+&]F';1\``<4A[Q%@W6
M]:$Q0"0C:W8$J['>0)<(\``)`5$-D!!&BP">(P-$(K,CL2('R[,4^WA'2PXT
MD#%T`7D$VXO3>"`-`(81*UN$H+!?T8MCL;7)$#4*H`5PN[+.4`4.@+<+`+8D
MM+.>DQA4PT<&<B\,0*R\FD__)ENJ.0,1ZSDI]W8\&[))(;MHZS`V>P#\U5H*
M%81NL`500+Q;``2`H0%-8+Q0(`:66DWMX!)=L2,!`B1PI`I/VFTSD'/+DBL#
M(!$%L1N?$!6#D*7ZIBT<*`T"(&E1D?\A.H`HVJ()$,$G[1L`9=LI`X`667$`
MTQ"_!WEG??(/^1`^[?N+)"1IV>MHTI8^N=*^`U`-_2@,;H0F!/DC?1*4<ZHC
M#]#`WCNEB^`2V5L`D/$DF?`C2,$P5-%O]<M3Z$$`;LD+96`+(1QPU+3![6L`
M.D`5V@)/KR$QA?!#!3Q4076O#Y,`LJ`M8UDD0)PK%>QT(;7$#5P:[`._VA*^
M`>(GX`APN%+!-WP/-]!1]>L`O>`&&_RDH>$9G@`MGG`K7Z0`2:(M2'H)5US`
M"Q"Y@IF]`C!"WT9IN4(`)O3%V>O&[@J$:L`!@''(B/P7*Q"IJ&I-=T4-$!$@
M1E4%Q0`7ZTO_R0]P')!Q8T5Q`X#F4E]A5%10#%62`V1BPW<T#03P>S'4;?M2
M!8!<#8;P:E7P/84Z9N'0*@E@RC304:LZ"OEP`#@P%MRF`)S9"I#L<`603UF0
MB1/1#GTC493\)9/AJ.VZ*$Q\LCCP0VSS3$%U"))ELQ%VD#=&`U6@`_&#%.PS
M`%=#=#6R7YS)OL%@E.(FFFN49D6;`[:P6)G3(OFD`U_Q"2<[`[(P.0>`'"YA
ML*9C$:61%:4A$W$AFEU9#"^%`)PD`T?LQ(M@$0O`23++8;#PSO9@LX6*SOX0
MAL-J&/!VSB("-4D"L(27)#`!%7G,TKER'G^4@"D4&@1*"3-Q`[!<_UO(9<QD
MDFQ2`0FO=LK<%`T6P0`Y0,E49HN7\-*CG&P1AJDN6,B)O-45L`)WH8$.@%B(
M553C<U-UAFC/_`9M05(/LHPNA4^N\0`)(!L6\1!&&5K]@%TL20NZ(!JSDK9%
M5RBL$F%$0@D#Y`R[JM9I9@I?\M9Q*@I!$[REDLS1H`!#E=+/U1E3U#:[0`B,
M<E,ZK2,+<&_.4(_WD$R[(Q%KV@X6$56;D@Y&F1]K?-KB*`PR#5N/G1K"\B+C
M]PLFE`5%ED)$W%MC+!&I`B1$(HL:[0U%LT3V(A%B]B^;W"TI75_Y4:5200F=
M9AW66R_:8:9G(C6I\<NZ`XHXM"KIDP!*]O\5N)`59+HNLS0;VVTX161>+"G9
M/UC(?K'5?#$8SVLR+`I7FI(LG_)I>+1?<30_.N(;3]N?F_D5=OU##U(^->$Q
M/20(:/>:E),5AWUQNLK3O+JFRU`0QS`#,C`#)EX?8_5X`A"FG^2ES;0H@K`P
M+.3-P%LW._1Q:.*.UD$U)HBL$A$[!GX:Y=`/TB3<__`-FM(/(L9D`+#;O.'D
M"U*T=>/0+&D@$3+B2?%#R_TQ:*`%7SQ6$N%T5V%3H"VGKE`WW!$QLA))60!+
M`D$U[O`<0?,<_8F?#S8/-\$PW+,^7TY/8&$(D:!\GV+8*8[BR9:493XNB#2$
M:H`"'A#I'F#(?W'_`9(>Z3WPO,OF`)PN`WM#0GU>)&6WY4SQ.B2A%5OB0*!#
M,'T2X?8HKD?N,1!57J[@MH&=RT2<5SZ1V*$Z*_]D".]RA[-QY"@\*%K@1HDM
MZDEY08V2P7>A"Z&$*UF"C$]+0HHT5Q%W;6?=K4FI41MQ9:(0+`ON;>K6XF`Y
MQ`\M3!&B1C72Y4OI``G`ZK\1@$AD%DOR(0*%X*+@T,_23=-R["`X[)S@,;JP
M[/7!H00I++U>[RKQ`);M6A!3QC]"``:;&N^R*LYHVX,,A&VP!AV_!E"`0&3@
M\6O@\99:K\I:CK%`3ELN`*MY2\S&VVD*QI*A`/EBUTR405BF/DLY,.7%_T^!
MK;^Y/E]SH:C;EM9:CE8+&P,/\`!+/S&=@64?PSV9+><J46B?;1MJ8N4A56C0
MV#W7GAY11"R(337?$+S](&9.+BRI'G,-@KZ7-MSJSBGL_AAS@;V'8`#&,>\5
MR/#3EF+ER"AQQ.^2\BDX0@4-6#=1S^BB`4CX<!R03PMX6N:]_"/.8_.JT?/"
MTVW58`L<M+!.S_0IE_&C>H1**J\WXZ35[A@5J:<%?BRVX2O*-.[E@-WVH`5P
M9-S9M1')+NN#-'8MNPL?9T%<K^L?OJA(_T\?B-6XXH#60K68G5`R?N110RJ&
MT"B?YBM4,'3ML.-QY%-3L7,,(Q&MT8`/5O@]_O_>VOX/SV7\:V\\R!&A;K"9
MRP7)7`^'-D7VBX,YSM!#`R!9@*"%5D80H//FE@!`]=;XM@!P^/8`,-/HAA#`
M2`5@@.8X6>EVH`F*5A!0A48P4`9*`[#@B'8PH$-`H-6(EM7;^QD#T&!*FJ55
M&$,ER'8`<(/X^<9+HZC@YE`)JJU@"$H54!"M/4Y>;GZ.GJZ^=5%1P:&F;EK(
M:,Z66>68F.T8;(UF($`.1U0$`(@A[8"`+`0#''!#T*"E4P-T-=(!0`$H;#3>
MX"B`L.$!-N-6$?@$RP$H'``8E,.HL5$P&:!F`'CPAAF_70P6N-)V2N`L!,[>
MX'M39L#)-S"]!4@`D5/_@IS-<#ABHP!`1VV$!-3+F97FO5+E,,42)P.`2HH6
MWV@9("#?+J*6DBYM=$,8*`8`K+(QL)#-`@,,'4%ZEK)1@Z*.*%FJ(H!`X3<S
M`@`8."ZO2T<T`G0S2K915LR.+QW]%N!9(RVH&%%J`!%O`$^/`-"<FQ%4,$6R
MSE$JT#;';#08ISK*8?#9#9"@=`1`X+'3ST8Y$G1,NX!D(VSAY'G_#CZ\HRWN
MWL7[7J;U.4RI5@80$"-+E0<"`EBE#(!`C!PR"``X*`U@DV4!EPSR]?<?311-
MA]$"L872T3?P49&%#EFI-`XA!+B2F",L#4/.-P50X<I,-=W4""P"/$!A#EDE
M_R`.*#($0,`-65`!B0%EL)?/6]TUU1`")$D%D4T$T'#C8L"-<PT`!=BH`R0%
M,,3>5TPJ(@P5\PG@E30$"#"=&XL9`*64KB35'5XM[=57@`N]P1<"./0RPP`#
M,-3A8JHU4IH;D!Q``PX.&"34.,+5>"-]_QVRCY608!;,`EFPP1Y#J"&:`U'9
MO0%9``U0.(-_MSD'WXT+6!93(Y`!D!HZP3RG0Q8T^/=8``,@644,`_S7$:DQ
M5%&A(CBA0=0!-E919U''>$JAHFF*!VVTT9)7P03P@+=*:.2,`H!<E\1@F6>L
MSA`;&PU8]M\`1"'T5P"3-0E`?4[RYF4KQ^7F"$>(@/\;K[P(M&6*G1RJ!4I>
MO8WS%JO#F.B(32&QX4"X!G5BI2GGLNH9`8?HU*-2GP#9R#<(1`6`<6P\8)F\
M`V!6$B3Q6J9Q(_<L8DXBSWF6\E:K@`E*&5F][&0]940V'4N;-0*)7P$QE(4!
MK'+)ZFUY,L8G/V5@^5\!!41"#AI8RFM`,S0U"LIH:K+Z3#.,8&2`(N(>,-D-
MN[['J@/1N#$CQ@)`DBHBBN2"#B4+%!)N`R2QP1?0!1"EDALH/_T?`C]1X330
M`3B@70YS>[9`9#%*"WKHYY!A`PLL]-`&M@XL`#"3,3#0NALY,'#``0Q(HD\.
MJ[-(R3-NO#Z=-#,D8``",6C_H04#,;"!Q@,-B)/%`I8X<L,"DKB!`^UMRQ"\
M*0[8_0:.>W*ZP%;DX)#``0[(O@#+3"UP'R*S'[!]Z]JP<8,"Q3=0&-ZP2].`
M!WPB>M-;S0)NDP4&W"8G.!C,`3YU#C300'\(>,!DWB"#_Y4E$U2@0>T@*#/G
M?0X-,Z"@!6?Q/7&([Q4+R`<;8M"`GV@A!@@(6P-PM\(W5,]*#<0=&JIWP"P@
MX$WD*,,#:IB`&:`!1UO)X`5G("F9R:!VSY"!3]Y`P#(XX``(X)XVJ+#%`R@`
M!]JY1`X6<(`$Y*`*TM.&X-+10QR)\09E1(,,:MC%,A`0(MAC@`$,H(`9!$\+
M,B">_^UR4,;P-8"+,]!""D4'R4A*$I)L2"128C"^-V0%=V6AE"0K^:!)7@4-
MH52'&TCIG4J*\GZ6K)DJP5.EG+1R/9X4I1N8%ZWY6&D5]G)E*;_S2GO,4F:?
MN]\O99:)^,D#E4P*)CE`V<EARG*5U*RF->7QE@#0H`R#`%<!NG?-<(ISG.2\
M1`*T5<YJYB`_.4`#+R#AH'2*TYTW$`!MY(G/?.JSFH[[#P$*X)\!9'*?!"TH
M0<U2,8."SFNL*H`!=E4`;RD4DC%`A38GBM&,:E2""+`3`13`28V*=*2B$Q/<
M2!HM(]9"``7@'TJE52<"R."8+ZVI347'!BUD`9PW[:E/B?_YT^^@`7G%#.HY
M<LI3HRIUJ4QMJE.?"M6H2G6J5*VJ5:^*U:QJ=:M<[:I7OPK6L(IUK&0MJUFM
M2AR)4K4,.K#?6=\*U[B2-0LQF%P`^O94'2PO1023JU__"EBL`J274I'J,0R@
M'2HH8*"!;:QC'VM37OZD.%+-@D.D"=G,:G:S^V1#%>Q$(C=P0B-EH`*)NF;:
M*B32#8)P0Q6H4$<JZ$`9H&!#&<YDVJ*R-5:AS&F,?"L-YQ#&%6S(0HS<4"$J
M?*ZXLTTJ9Y\+W>B20P>[BI>0G+-8B\KT020,"*L0P+(L$*`!@PH`3K18"%81
M`'SA(P`#<K`U<)!K%@\@G``4X"W_S>'$$=0=!@T(-0!9R"TDX5,`H0J@Q)`E
M@%#K=:YT'PSAQ^I`NPI@PS?@4@#B>>8^31(``O3G&=54P58>!I1@`*`N_?T'
M0YS`Q0#2YYGI,?3%"M@:`>J1%Q!1)Q8Z]`\X_-M7*OCGHYD(`$W$VPD%#+$E
M-(VPDY\,5]:R8E),L4P,I0'/1N#@.;"5AMR^R2F#+(]2SHDH1)K7B8]9Y@!5
M..6,P!PI*I5A1@D@28Y!L4Y96'@V9;`SP;`BC!VQH3(G@<4"/L&&6RP)RHQN
M]%L7=!$:M04C0GJ$(2H)RMYAT5;3*<,-..F<I9#J*_M`Y`$D@^E3GC,?=[Y7
M;RP[$KZJ_R0++`V>#&)`0@`@0+F-Z$63'0WL8%]5LB$K&2A&+*1VA:UVM?./
M2D8<:VUH@0HWH&%^/L&):#<B+<?C$K.9O2OEZ,75O19`M!.3YW(0*%X&:,`-
M'"SL>,O[J1J:[%T?A&PWI.=I[_$,EW`"[40J=@#HRMK'\,49M5BV7^^I#Y?$
MK>,WY!DBL-9.7E1R\;)DJN#Z*>J\/P[RGQ*;*<8.TBD+((`<R,<7O7`%LLN(
M9$`V8`:$/CA43A0?<&BI%\#ZA0['O>-77U;6/X^X-,1AX1@DP#\[";G3GU[3
MD8\6WPZYY3DSB095<.HY9:2$W6+#DA_E)WB/.D5<I$UE@YWHU?_FUDYBOG'/
M[1B@K>^^A!$1#O6\ZWVB(W>.<53U'(C`(J*.T,*"!_)RP^R$<M>NLEHR1[0W
M+"8!;:D"0!D2:HLTC<>;1BS1`1*`^3(%+EG`3AEMPH!?[WWUK+?F*6)!`S?`
MA.HCDP91!J`\!VP-`9^`]H-4I$`&$!S%NG`.JQ)@18GTVC\%<``,=Y5ZI&S-
M``_0_=9ZHX7Z-,`J&==A?13P?!2M^P`/2'[*6X_^](OS<:WX1M\L6VDLGNH_
MK%)`82!3^UW,_S\&H$$F#B$R%X-B,E!&5$`*]"<`S^,A3`=[`=`;?O(?(Y$7
M^Z5#6_,?EQ,-\$5_^2%ZZN>!'TA)."#_`S3`/+-E"B9X%1TD`S/09;N`@E>A
M`S,@`^V$13G@"MA%'#)@(R41@R.8!:4D*S/H3BHW"S>@@TA!A([@:2-8,67`
M'S*``VX%@E-(A3<%,E6(A5D(85>HA5WHA9!5'*KWA6-(AF(U9\I4AFFHAFO(
MAFWHAF\(AW$HAW-(AW5HAW>(AWFHAWO(AWWHAW\(B($HB(-(B(5HB(>(B(FH
MB(O(B(WHB(\(B9$HB9-(B95HB9>(B9FHB9L(@FWP!9](!F(803=B7),T")R(
MBF3%!1AP`1?@`6L`+5F@>SAC`#+@<>+!`#>6BKOX55S@#A/@`><!'CC@'^:&
M`*A0,O#F'8J0_U"\Z(Q5Q0[5<BW@H0/:-RFG]!&Q((KID!7-^(S?"%748A[8
M(BRE)!SH9%ONM"VW%4ID8UN8!8[QV%-<T`[O`(O?D7GC8"X,\!5E0$.X8``,
M,!D_M'0$T$7B<$XY,`.G=@"X)H\/:5-NT`1$0)%%L`/E@0%!4)%$L`7I$"G'
M%$IET`PT,GQ3@@B4@&+#IP#1D!698"?_83@0*9,CI08<,`'E@9._^(LKD`Z0
M0&"^43(DXFFT@D5*88-E0(Q"L0\"(`/(,R-$-)-1J5`UF9-5N9/<V'1E43T2
M!0DJ(2*3H0,T8!%9H6,SXSY2B9;Y5),3P)8WB9-MR98K\&MND!4%I/\.ME4%
M.-`,YV5C@<1KYL0UBG>6:4F8Y+0&+'`"B7D"(%`>%U`"BFD"0)`.V(`A3!(C
M5+!(Z;5BU&&!\7(`"?8&S`@*CU*8I9E.;H":J"F.')`&J2F*>:%M!7,`,^41
M!J$4"-``C*.$U8.,!P$1Y\1)I&F:PYE.T6B/X+$L`\50PT`+1F9<)`$).`%<
MT@!&-/()HBF8Q*F=X[2:PN@=E&``5G(R*-8CGD,0NX(30E9G2J@4K@"<HWD9
MVRF?UF2<''"/Z$$4ZY4#.I`_4;,+`=$^.O``U34,A."`GW8#]!*:-).=\^F@
MDT0MUN*=WJ$%^T=_`S`#9=09&]ANND82.<#_@!%8&(H0G/'YH"<J.FD`!"M*
M!*DC'HD6`PN@``IT08B@`PZ0`.7#33)@B[T6HS-Z`^)P`P\0/#AP0BB*I!.U
MC>N1I$WJI$\*I5$JI5-*I55JI5>*I5FJI5O*I5WJI5\*IF$JIF-*IF5JIF>*
MIFFJIFO*IFWJIF\*IW$JIW-*IW5JI\^5/`N@IWO*IWWJIW\*J($JJ(-*J(5J
MJ(>*J(FJJ(O*J(WJJ(\*J9$JJ9-*J95JJ9?JJ.S54]^P@9WJJ9\*JJ$JJJ-*
MJJ5JJJ>*JJFJJJO*JJWJJJ\*J[$JJ[-*J[5JJ[=*J[W44^+%);WJJ[\*K,$J
MK,-*K,5JK,>*K,FJ_ZS+RJS-ZJS/"JW1*JW3*JT-]ZO6ZJO8VJO:RB7<ZG#`
MZJW>2JWC2J[+ZJTZ(G+R407`LJ[MVJ[JJJ[N*J_Q.J_K2J_R:J_XFJ_LJJ_O
MVJ_WNJ\`6Z_Z"J_]ZJ\$NZ\&*[#\NK`'BZ\%:[#\^K`)^Z\5*[$6.[$7B[`4
MN[$9V[`<>[`?J['L>J\K5Z\EJ[$FZZXJZZ\H*[`0J[`6*[(+"[,8.[`S6[$\
M-Z]+>J<]Z[,_"[1!*[1#2[1%:[1'B[1)J[1+R[1-Z[1/"[51*[532[55:[57
MB[59J[5;R[5=Z[5?"[9A*[9C2[9E:[9GB[9IJ[9KR[9MZX<\:TUPJUERZ_^V
M^.0&70`$*8`"*?`#7!!*3<`#/?`%DO0%/<`#3^`(;5`$>KL"3D`&/=`#1$"W
MTM(&Q]0%AJL$Y``%@0L%Z@"X@GM-;D`&0;`">]NWDRL>E=L(;1`$/0`$$VJW
M+HH.6Q"XKSL.4&"X7-`(6V"X'4D.3Q"X@YM/8F"X32");<`#%P"7%7`!-B"[
M*1`!%6"\D40$;,D"EW"1;!D!*D`>$Q`"J!L>;>`$*Y`&Y,`%%C`!&U"^H.`&
M)G"3F9L.*\"6\$M-;=`#&["\%\`#]UE-;?`$*;"^:WD!9$!07\`"B(L.;7`"
M;4F_CF`#;"D$C?`#;-D#Y2"_$U`$^M0$;)D"DDC_!.6Q`1Z@`>4AF8W``A>`
M`0@,24K0BCO0"&FP`>ZP`CW@!%V@`1>``N#['6VP`A6@`>NK#6T0`N[0P&_0
M!<H[C>C0PQ50Q)+4!BP`PAZ``>6Q`SJ<P%#\PXVP!B%P`1Q`P/I$!%,\O>?P
M!?58`2E02CMPDQ'\!D#@#A5,#BQPDQF<3TU0+2H0B5O\QFG0!F0`Q=:ROFE`
M!F0@NZ*S!H-\'F0PQ?9Y"8,,Q.&D!AJ0OK#;"$'@#F@,"CW@#C8@BO++Q-4D
M!.Z@`460!H?,`Q;`O+Y+36D@R1MP'FX@R*&X3REPDRIL#FY<'AKPQ0Y\DT30
M"$!`P>4@QQ5`Q_ADQQ/`_Y-]^$,W0`/-W,PWP,PA]<(QG,4OS`%=W`6-T`5.
MX`1`W`9;L*);<+=-T`3K^P7D3,BX"P3B[`AIP,V#^P5`T`X:0`1/T`9K\`1-
MP,Y:#`5`T`-!T`6E1`9*`+E!L`6R2P;D_`5NP`7^#`4N2@9",,48(`3V/`YB
M,,_>#`(3<`&J_,VMVP-%L,MOX,GPRP5-T,V.T`7D_,AB(`2NNP7\JPUJX`$<
M;<MNX,D\\,).T`1<D`9!$`1?_,T_$+D+K0UB0-#_O,]I(-',6]&5NP5.\-"@
M,-"0JP0C[09;T`1/L`9J0-!!(+SFH`9/X,\_D-)OX+]#7`$VT`0CK0UKL-&N
MZ/\.0:`-:EP!OMS&P1S'[E#,Y9`&30"Y9_T&)RW8;R`&Z.P(:N`$/?`#5PT*
M3U`MR?P&:P`%(.W8<\BIH)I_H`#7-VD#LFS87]":C>#)TZL&*Z"\-\D#"UP!
M3M`(=MT#?\R\/1`;15`MU_O`.(D!:4"/%5`"L<$%0]R6S7N/;E`$(\R6,GR/
MMET!,UPMROT&2I"3`\PDK$V_O0T"+JH&*5`MR:T!KDW:-VF\;G`"[M"YX?W)
MB!`$4YS<)^#6X]$.)5#(AAT$4+"^D.W;"SP!.IT&*9#:LWV?2B#);=G<L*@$
M;ND.`[P&'L"\0@T$(QP!-ZD!01`;;A`"'"T$PCT!WVW_#E^@X3?I`8.;!E-<
M'A/`QN00C2'0!,HKWZ"@QA.`U\!<`7`\#L/<U[?+X,GM`0BLR15`UY>``AQ]
MWEO`F,G-`?1[S'+Y!E]0`L]]DQN@!%;L@2-6<`57,L?4XSY\`CUPT-J@`N*-
M"#R0X";`Q?4(WCQPDQ>@`2?`X*G<"$5@O6T<P^[@`26@!K[HVQ!!!C5=`2&`
M`L@-QU^``1Q]`B90CVS,W*U8`FI-S&\`!1Q0'AP0`N\=W=72P8W0`S=9PFZ`
MYA7@`2B0XZR)WO#+VN=-TF#^!A]<`1BPF-5BY^1@R?N=#OB-D_9,RYY^`I)<
M`3^@S1-M`H;N#A'\Z)$^Z6M@_Y,8\,4]?@&_KKR[#A%"G.8<<`(Q#(R/G+CN
MV^<H`.D3<`*P#.P^[`%C/`XVX`Y`(,3,J[N\?->__,;"/+_F8,/,6P(EH+P8
MD,V"WN<NBN\A`(MD`.E]#NP=W0A)/ME-[NDH(-P"'X=H@`/0[/`/[XW;[>0@
M;KOH[=J*S+Q/X`;V6Q[@?9$^+,YI<.$^_N:WC=:K^`YD`(OT.`&__08]S@)K
MD-7MX`'EZP0><.2H&>O)#.?,&^5KT,,3<+UN\`6M+`8R[0AD,,(;0,#0?@'9
MC-8K(.VMF0:,>0'I7M*(@`+F[0A9#\.K#@5N<)CN@-?:D.D34,+G``7EX0&Q
M_=?N4/\"K?D%#*[+;]`$(`#EZAW9B"`&2_\%L&CLJT[`73#1&I_5,2SPY][G
MH8CR5T\.9&`"&^"\=SO%ZCO904[,,N_7-GD!@WOV-/X&+\[&P#P!H`\*-EX6
MM_X#E4L$[8#&;L#=CO\&EDSR;C#,/%"Y3J"\)Y`Z3K#W99SR:-T#'``"-RZ(
MBIOKSWW)YU':E7[&L;'@M=P(:"[TCD#]<&S;$V`#C:#(P'@>OMCR&W_AG7\)
M3P`%`8T(;J`&8O\%Y#X!E_[!$V`"L2'=[__"2V_M[,O=C<[RW:X/]PP(;FE0
M'A456V]O+!,536]N*(90B6\KC$IO3X8JE%P7$RANE)0]C$'_HZB4FA4878]N
M+(:.B3V&F&]M:FYK7SL5$RF):1H5&VF):AP3&&1OM14]HT"_-K@EMHEN)8R(
MJ8]J;6YD11<5&L=O*HQ.WI1-AB6BGA4>:Y0[C$*)0!,3T=Z+*A1IEV;#A`UJ
M$K7Q</"8DU\\WJP)L:R9&H8:FCW:QNS-PPF<Q)2[D$+)ES1I1+5;R;*ERY<P
M8\J<2;,FRRP)$.C<N=-!2W%/>(0P5$&?&TL5V-7R1\E-BG6)?%4XM8\1D$1%
M?K%(1`;#!`\)W\P+(6A#,73>TA19X:&<H12BLD[8FNCC"E'#SK+4-.&$&WP5
M;F7;TL.$6:*3*EU*%*E"XDJRWO"K_Q""AV46GSRT2<6/*2HW*A-!,01B\R.*
M%518YG%M0L0W:8BP_?0++FR#QI`58N;F!*/';[;``TWQ`I=L)R2U:P-E1PAB
MALXE4I=TI1OJ++ITV5+(,24;C(A4A=9NT03!J.9IV+&:V`5$%[^NF:="E$A6
M["US4&[W44!&%WA@PQ:AV63@@0@FJ.""[5`1```01A@A`@4F,M\37XRRAE0H
M3,>((\]<1<E3U;W!0SZ4_/#+/W+1U54%'-@CUG`O<A!6*ET4,H$%&NP'3")$
M4$/)1YS`1DQN*Z6Q'P;<32!=-CU\,D&`&!C2#5*80/(;)4B!R$@%%X0I)@@W
M#OE+":91TO^%"3]T(<HJP2@T%)ABBKG#&UV`\(LY.L:9%Y+)L$*&&R98.4H7
MGY#EQE`7N/*(;X=XH\8*>P983D:)D,A..V1`1Z=;$]P5%8J2&?)/*K$(U,X6
M%AA2IYC=/+/%9(E]X=:K%V#PQ!OOA&HA$&W]TL\%5#%H[+'()JM@%@<4X.RS
MSS90X1M#M&H;)<)-$(]B%>PJA%9-75,B/A/H4]4$/V#5CXM5@I7(//$$BBE7
M)X&67`4K;)'&.Q7$*5<UB?!5Y#`3<(!6.^!58,(G+(2VQ2<;!/&%&H6^ETB7
MC&WY"(F.?#N7&%^`+`89@Z92$)C=?->/7YF\I1*AEWPA<\ADI'3_;[YI*%&;
M,$>B$U]'U*'W$5QMS.EH;U.F/,JW%8"@!,EF/4G=IMX$250_>^KU!F#B2=;/
MJ:@$A-XHMG[5A1AHTVR:K?@.50]757*P1<@BDV'/T$VEP840;!EBL+*`!R[X
MX(F@8?CAB*/AS16M7J"$2FFDH)4H'`?GMT90N+6KB::D^#56X+[15<$R<G$F
M:(T-9,T%&W!14$6)!+'S&RV:^:.1Q93IC7!$>4>)QP!?9"AD@3V"`JDG%_]P
M!6@FLL4.0#B:RC,>;!'.&D&XU?5HH(S"@R$BOA%$#T*@9%9'XL]^\I-K+-E,
MD'V9=I0A1A5WW*/<>(-4UXB:@PZ)FTM%_QL*A:\@&-"`>E+5&Q+6M<Z`;10!
M*8(H0#-!B11"`QF"#?2>\#+?A`D:*BD:RI"Q@QXX012]6D%P5F""\'4*=H2+
MH0QG*+@V'`],*.@!#Q)X@<10JA&X(&`(B``$3VWJ1%.AQ#0F(**L5(!=7PF+
M)[2%0D-LH`A<^%X4U\"0"O!@;U7JERBL1I>6I08O9G$<%-*4"N$9XFV4<"('
MG+`%%2#F8HOA'#V>L(7&`+$-VW@B%PC1CZZ9S#=3"@$*N@,*T_"E0VJJ$@:"
MT(7L.<ENW=D!&`T1BMM,20E;6,//FI&&[JA@"UM(%0B.4;0I'>U>P%$9\[8`
MA3G-"RD[V()&R/]6I2=1`GXL(U<#&?%`2@3$`R@XP0E0P,P33.(9(7@"%]0!
MC-#HS%493`330/"$+L0B?A[YA0K[=X'H<2%*4:2A.M?)3@.)@9'"(J9*J#D+
M+ABD'Q,P@;@V1:YB_>!SM.L'P,CP"1N]ZQ=D>80-B.(6725"1:XJAE<,6H1U
M#:D?<1K@ES"036^48D6H*"76P*0CJECB/,X+H]^Z>`M[?HDH*9!16B2'3ZRA
M`"V/#(T;+`FF7UR@:Q`ER@:\XBZ8&8*C:S#(!3!W&##U@P/W:Z5QD)._5&PA
MC"-1AN]D1Y1BD:(?HAK%"R^0(?!,8)B>0=75:CJ!"(@G#9#JZ5<Z*E+_4!1H
M#325ZP8<U:M@N$$(M`D3@`+8SL(:]K"C2$,/GH.!"W!`!1RD!`\\4#U*?($%
M'@A!#R;%B,T%@;*S>`,1*-NU)U#V'VD(`3)E]`75-DPA0G@.ZU*0LC;\@`.L
MLX$8>I!95YC6`^ER'F5?(Q838``#'N@HCE0+`N7B"04:P(#3NJ#:'8B"MQYX
MS!-"<-P4?`&[C[DL!S"@@1``0:;M<$,JF;N")J"7.QZXTRC<T(03:.`"&CA!
M9'%Q6_+:@`R\#8&CN&!<Y'ZA#2?P0`G0\H7)'M<#/-CE43P``C%DPP84OE\J
MMGO<$VSAM^9*@PV&J@%S-84M'B"L9"F+"6!Y_V`62O``!TR,"NQ2]L8WWIQB
M0?!@%NQ2B:!M(Q!XC-P59!.^_W##$TZ`6PQP@+:(C;*4"]L&DMFM0FU80SC>
MH`8B\#$-IKEA-W:Q!IVNH<S9.'.:LIPF-[`9%56NV;344+,THWD7;6CSFRD1
M9_2V0\WI)9EIV"P*0H^BRBG!A98+Y`8ZDX&-+MGS9R0]WS2((=&HH#,ZR*Q3
MDLG(T!HBF>X4O66%+'HE<0ZAEO,FYU0`VAN<?L297S;K])Y9S;<^-9]%/2U9
MEUJ`O)YOK5E-!EU,^=C(1O:++K#9??7R8,F.MK2G3>UJ6_O:V)XA++[$@0VX
MA;C9#K>XQTWN<IO[W/^!4P,/O"W4'O@9W?".M[SG3>]Z(U9O3X""Z^S-[W[[
M^]\`#[C`!T[P@AO\X`A/N,(7SO"&._SA$(^XQ"=.\8I;_.(8S[C&-\[QCGO\
MXR`/N<A'3O*2F_SD*$^YRE?.\I:[_.4PC[G,9T[SFMO\YCC/N<YWSO.>^_SG
M0`^ZT(=.]*(;_>A(3[K2E\[TICO]Z5"/NM2G3O6J6_WJ6,^ZUK?.]:Y[_>M@
M#[O8QT[VLIO][&A/N]K7SO:VN_WM<(^[W.=.][K;_>YXS[O>]\[WOOO][X`/
MO.`'3_C"&_[PB$^\XA?/^,8[_O&0C[SD)T_YREO^\IC/O.8WS_G.>_[SH`__
MO>A'3_K2F_[TJ$^]ZE?/^M:[_O6PC[WL9T_[VMO^]KC/O>YWS_O>^_[WP`^^
M\(=/_.(;__C(3[[RE\_\W_>ZZ\^W^Q*F3_WJ6__ZV,^^]K?/_>Y[__O@#[_X
MQT_^)2BA_.A/O_K7S_[VK__\[H^__.=/__K3?P0B&('^1<!__>,?__GW?_O7
M?_L'@`4X@`'X?P28@/S'@`:H@``8@!*8?Q((@108@0?8?Q5X@1RX@`,H@!QH
M@1YH@!MH@1@(@A-X@1"8@?[7@"WX@`Q(@`I8@0CX@B-X@C/X@B18@"%(@2.H
M@3QH@BZ(@A^X@A,(@D)X@D=8@CWX@RI(@S'H@#<X_X0Y*(`XZ(,'>(4P.(-0
M^(1).(1+&(1-V(5(V(-*^(%,:(-("(,>:(96Z(()Z']R.(=62(=T&(=V*(=X
MF(=9R(=^^(>`&(B".(B$6(B&.(=[R(>)F(>+:(>->(B0&(F2.(F4B(B#^(B6
M*(B86(F<V(F>^(F@&(JB.(JD6(JF>(JHF(JJN(JLV(JN^(JP&(NR.(NT6(NV
M>(NXF(NZN(N\V(N0N(F^:(O`&(S$6(RGV`))T`(C@`13D`3&^(S0&(W2.(W4
M6(VAF(@N,`5AT`(O``9&``8P,(R&*(Z>2(ZB:([6Z(A^B(ZZR(Z7V(GNR(CO
MR(KQ"(_1Z`+?V`)&P`0BD-X$SCB.KOB(]4B/=YB.A#B0O(B0PJB)IBB0QKB'
M"JF(@)B-+7`$_.B/$7F.LAB'&2F)'6F-'[F*PQB2.MB.&ZF'`6F*+K`%+0`#
M4]`"46`$)?F+D4B2!EF('=F(-EF0-]F3H+B3/EF**]D"+3`%8``&+C"/T@B4
MT<B4G^B4ZYB00:F14XF2DYB4(\"-6$F056F/E>B071F58>F+4%F-[EB/#CB6
M:KF6I5B6;/F6<!F7-^F633F3<GF7>)F7Q0B6>@F2Y0B(3$F7:\F7?1F,@CF6
0AUF85EF+B0F0=6F-@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g145452moi011.gif
<DESCRIPTION>G145452MOI011.GIF
<TEXT>
begin 644 g145452moi011.gif
M1TE&.#EA2P+*`?<``"H<%C4D&SDL)P\\?A$^?UPJ'$\U+6XX*EI$.7!&-FE=
M6G)42Q,_@!E$@Q)WB2-,B2M3CB]7D#1:DR-MD2YBEC!DES-EF3MIFT1<FDAG
MG4!PGTAVHU1KI%9YIV)\JVQ\L@">10"?2`"@2`>B3`VE41BI62&L7S"Q:D>Z
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M^OKV\_KW^OOZ]O[^_LS,S"'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``A^00!``#_`"P`````2P+*`0`(_P`M"!Q(L*#!@P@3*ES(L*'#AQ`C
M2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FSAS
MZMS)LZ?/GT"#"AU*M*C1HTB3JJ2@M*G3IU"C2IU*M:K5JQ.N:MW*M:O7KV##
MBB6:=:S9LVC3JEW+MJW;MW#CRCU9=J[=NWCS=KR@MZ]?IW7_"AY,N+#APX@3
M*U[,N+'CQY`C2YY,N;+ERY@S:][,N;/GSZ!#BQY-NK3ITZA3JU[-NK7KU[!C
MRYY-N[;MV[ASZ][-NW?*"X%]"Q].O+CQX\B3*U_.O+GSY]"C2Y].O;KUZ]BS
M`];.O;OW[^##B_\?3[Z\^?/HTZM?S[Z]^_?PX\N?3[^^_?OX\^O?S[^___\`
M!BC@@`06:."!"":HX((,-NC@@_X%!^&$1/%%(7(67JCAAAQVZ.&'((8HXH@D
MEFCBB2BFJ.**++;HXHLPQBCCC#36:..-..:HXXX\]NCCCT`&61%39TF`&05$
M\H0D5!4PUN1$&785I4)3FE2E0%<V]&1'21:4Y4U;#M0E1ED:B="7!HT9$9HM
M51#FFAFQ29&<"4F0(9T'O6G0!'SVZ>>?@`8JZ*"$%FKHH8@FJNBBB5K`Z*.0
M1BKII)16:NFEF&:JZ::<"NIHIPZ$*NJHI)9JZJFHIJKJJJRVZNJKL,;_*NNL
MM-9JZZVXYJKKKKSVZNNOP`8K[+#$%FOLL<@FJ^RRS#;K[+/01BOMM-16:^VU
MV&:K[;;<=NOMM^"&*^ZXY)9K[KGHIJONNNRVZ^Z[\,8K[[STUFOOO?CFJ^^^
M_/;K[[\`!RSPP`07_.P$!@^,<,+G+LRPNRI$+/'$%%=LL<0M7*QQQ!EO[/''
M'(-,<<<B6TQRR2BG?/'));.LLL@N>QSSRS//3//+)J^,\\X5V[RQSRD#C;+0
M.Q/-,\A"MZ#TTDPW[?334$<M]=145VWUU5AGK?767'?M]==@ARWVV&27;?;9
M:*>M]MILM^WVVW#'+??<=-=M]]UXYZWWWGSW_^WWWX`'+OC@A!=N^.&()Z[X
MXHPW[OCCD$<N^>241XV,,;/P,HLQF,=2S"R?[^*YY[.('HOFL\P22RRII\ZZ
MZJP?\OGJNZ1>#.NKSSYZZZZ#WOOKO+?^>?"I"R-\Z\@@<_SRR+`^?.O&;YZZ
M\M+[S@OUR`AC3#'**R_,\-@;#W[WWQN??2S=SU*^,.EGWWWR[">/C#+*Q)^\
M,?+?G[PR^^<_?_[TVQ__Y!?``1:P?\I8Q@#G-\!E.'`9^U,@!`.(#`C.3X(,
M3)X%$SA!`V*0@AO\8`,CF,`$:K""#>3?!E'8/P7^CX4NC&`&7\@_$[YPA3%D
MX`3E9T$"(B,9(R3@"O]M6,-E)..&_EO@`(^HQ!_V[W]'?.'^XJ?$9"2CAT]T
MH@']Q\4E.K%_491?&,68OS&6\8M15(85DW=$,Z8QBE94(QG%6(\ZUI$>\8B'
M/>#Q#GK0`QYY#&0>WQ'(=L2C'>Y(9#S>X8YV$-(=Y%`'(]WQ#D9*DAR49.0C
M&;G(>52RDIF<1R=%^8YZX-$>I4RE/.JHQWJLLH[VL,<\9EF/>=C1EO.(92UW
M64=;NM*6^Y#'*^_ARF(&<Y;S(.8L[W&/9"[S'NMH)C.;Z<QZ3#,?TYSF/OJQ
M#WSL(Q_[N`<_N-D/?NQCF^,LYS;[P<YT^D,?[^2'/^9)SW[0DY[RO*<^]\G_
MSW[Z,Q_^#*A`!TK0@AKTH`A-J$(5:L^%\A.>`84H/?4!SXI.=)[ZL"<\\RE/
MBC;TG?#L!T7]P0]^4!2B%35I23'*4HRN=)X=#:D^2GK2C,[4I"2]*4U/*M*2
M[G2D\C2I*04Y2'?0PQWQ2&0B/PE*2"[U'>0`Y3O&@<EN9(,<[2A'.2!)CFR4
M@QQ;)4=4,<E439I5J5']I"?+6LE9OF.6J(S'6MV*S+J^]:UU168M\VI+>>C5
MK[1$)C/K2LU[J`.9Y;C'6[.9S61.,YKY<"PSHWF/?&"SLOGH1V7WH8]O;C.C
M[`QM.\O)SG?VU)ZH)>D\&_K1U;(TGPZ-K6QG2UO:_TKTH;>]Z&O]\5&(:G2U
M%:VH2-]YT8ZR-+@812Y%8YI<DU(4H,&MJ7-K.M/J3I>ZV,WN2?.!W>LZ-Y[5
MI:YSQZM=\FIWN>@-KWKU80\]!A*0]C#J5HVZ5*0J]9.4I*18QY'(:%AB%=MH
M!UC%BDEN8+(<4!5K)J,*2:A6DL&99.1:V4K*>C#5EK*,1SE0V=99ZE&4J(2K
M7>VQU\#N=97+_*4SG6G890I6'8F5IF0ERTQY,+;&S`PG,\M967%Z%IR=I>AG
M.QO:F;;3MR;];3F)R^3?#K2UM8VRE',KY7Y*],H316Z6=8O2EEKTN,2UZ$C#
M#%+EBE?,R8UNF<N\7NM2-_^GY]4N/N*,W3EW5[K+O6YU[5SG-O.9NO@(-)[U
MP5U]U"./@,QC?HWJQTPNLJF-="0E'?E)<21B"I&HQ"JB`0]X"!B37!7K?#%)
M#OXR=<$(CC!;R[I6"[?U'>5XM"P][-97>[+6MPXL8.6!5Q3CDJ_S4$<TRZ$.
MP\IXQHRU\8USG$U\B-/9_0`G/BS;62"S,Z/;Y&R1XUE.(Y/4R:ZU,F^K3.YR
MDQO-9&ZIEW6KSRY[.9]?)G-UY0WFD7YYS!MUZ7GCJ>>:LKG-V=5SOVM:Z.?.
M^>#Z^#.=03KPF@;ZIWL^J9WQ`?%^]_O0[OUC'Y>:U*<.<I*;='!:K6&))TA!
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M.)@ZUK3FU^8XG_"K*YG'6Q,=F2%VJSOX:DV\[A*PS;PE_[`)^TQI1GV:CDW_
M/92M[&F:DYE@UVPXS<G=L7MTN:']-F]%2MJ,ZC.HQ35N<S=N=E>`YX9;ZB9N
MA\=W]^9VL%5XA0=>AS=3$TA<.&51,>5FCV=Q@'9FZ#5=I2=Q=H9ZEA=HFG=Y
M:;=YEX=Y)FAZE'=>"#=3?S9G_7""*UB""&>"@A:"-65*&/<.[04/[A!?&T=?
M0BB$E/8.\%!@+$<-UM`.O/8,B&`$1R`%7C`)EW![XQ!S/\=5D+1\GR16I_9R
M&F9?J\94[85@(%97<F5AM41(KU9BHN2&@957ZU=+]S!KV&>'R51LS^185C=8
M,Z9CVD1QS.1UXG0/X>1--=A-X_\T3A1W?X\H@/U'4P3(6V\74O5D@)SH;K)%
M9:HE;@TH9KE%@2CE;H9'>&%VBLJU>/BV<.DU>*$7>B?H>2NX@CUUBYBG@CK8
MBSOX<"^XBSAHBR5H4K]HC#O8>;YX@YI7#^UU:'^T2*_'2/10A!WW?(A4#MQ@
M"9)P"=P("<\`#N-`#9"`!#Q0A9&0A>-0#MFP#>JPA6G%5N*05F"52#!&AAH6
M:_CU29(4:[&FAWCU27Y%=-+H5M_G2M=75[7D5WA(37^X3'XH8\QD3>J'?N;7
M?ED'?ZCG=:A73F,W=H]83N.$7O8T3@0X>'(7;A3(B2PY6_O@3WC';G<GDWRW
M;@P(4X[_9UQ`E7BKN&89F%T,-XM"68)$&8,W^'4XJ(O+N)2_V(LJ:(L3AXR[
M:(-,R8O+B'HF.'#/2%35N'%%J$A(I4F*9@U38(61,`5/P`2(0`M@A0E,P`,^
M@'*7$`W1D`B5L`W\U0[CX$A1M7P1%E5:!56QAE1;I6%OM7U#6$G^J&%R=5<]
M9V&YEE>5)$RP%@[I`$WK@`XNYDNKY&LNYI"1=7Z.I6S[(%B-=7[9A(C.MG7F
M9(*.N&.958,VY9&/^&;C=E/=AE`#V)+F-F:AJ(`S&9SIEF_QY'=F5I,1V(K^
MYF]>!I3EU7A#"6C.990B2(P.!WK*:)5&R93<R9U)Z8)*6950_ZF=OCB>EH=Q
M>J2$>=25\D6-[B`/3_4.E$8-6G`$52@%3=`$1D`$9?`)XV`-B.`#/R"7B/`$
M79"%NM>78?A@L/9SG*15^?AH\^`.ZJ`.E,28B_E6<O5H;IA*1*=8T^`&9B`&
M+B`&9@`(K=`*G]`*OO`.@#5^>0BC+!:C-V::-(9CVL18WK2(/$IQ%%>#T[5V
M&94/)HE>F!AFZ91DJP5;4,:;+/EW\?9W%R5XOYF`+K5/S,5P.MF3HTB*;_9X
M)[6*T9E="A>,U1F#6/F+G9>=W=FF;IJ#HU>+.:B#Y-F"="J>=L9*[]5>L$=?
M1T4/L69(A*2%T0`)94`%0>`#1O`#1__0!#_``T%0!K7`#64`ER@W!3SP`UY@
M"5`H8%+E#F!X8$DUF(QIF/BU5=`7=(1D2W'88;FF"VZ@``H@`+0J``@@J[BJ
M`)`@#O&@#G*8AX5%?C-ZD8Y%D19YH\F6HP]W#YTE3HT89.6$3==69-\%;\:5
M6DZ:K08E7#,9;^VV3ZFHBKZ9G/*6;]\59],%9]$55!XX:.4U@R0X9UB9G4DI
MKX&V#E;Y=<YF@NN`#_W*G>SPILM(C'8ZL`+KB__JE,`8B8%V:$,52(#:1X!*
M7X0)A[<G3+5@!'"I`$%P``>0J3_`J$$0!(A0!A_[>U+``SSP!.D8#>T`#O(9
M>P^62,57?*/_*GMEU:MLQ6&K2DES)72X!`ZQJ@`&4*NTB@!(BP`&L``+H`!F
M``XOZI""90^"R&+#2@_2I&Q0AYH5J:.*"'^$Z&,^"J1$:F1)9F1%%EHJE5%K
MFYLTJ:U51F7>.E!4ZG;"B:3(>8'EZGC_YI,I!8'N.J9D.IXMF'#3R8(*>[!W
M.K`)ZZ_R<*_HH+@^NK!IB@^/RYV7*[E.:6AYM$=ZQ*>@=%1*I6'CD$<7.P[1
M\)8\4``>:P`>"Y?VR0,>NP,\D)\I>P!&X`67L`K4H&!DU6"@IE1:1;,O!W3^
MR%3EL%:#.:$>JJKS<`UFH``/8+0!(``&@+0)@+U,JP!J``[!2J-\_Z6(@K5,
M.F:L5MM85I=,X41C89MCTW8/LEF#'NF1:M=3U85:;6=O^E=:^`2WY0:*H$BW
M5]J<=NN;]49OWX7`J3B!81IPR_F<Z!IZ)*B=RLB,=%JGW-FOC5NP_"JP4JFY
M`KL.F=N=AO:#>V16>*14]O5HA30.>XD(0G``!3##-/RQL<L#M'N.3W`$M,NR
MN\L-X/!5!`953O55'>>/8?E)_DAL//M)'Z:ATT=+VF`&"&"TM!H`U8L`"3`$
M"I``7KP`M^H&Y;`.Z\!7I;F9LX1-ZMM,[2=9I:F(KL18;MQLA.AU7;>CA@B_
M*D6__,>V'TA:2T:E'[6;_MN)7.:)#OBMQO]9@>2JO[(HIOYVKEX:70`7P7)&
MN&KJ@I6;C""<P>SPK^L0L`';BY&K@Z/<R4OYK_J*#P$KPHJ;</002_&0:*B$
MLZ*;2!/[5*KF#L]0!AU+PS0,NSZ@L@6@LL/\L5"`A:R05;ZK7PQ:<XRTA:"$
MH65HO!(*M$PE#M%;JP$````0`*Z[`$'`!%J`"%;`!$A`!$'0M*TPD'PX#Y$U
MOA*YOFM\D>976,UT6>Y'Q]YDQ^QTB*3%K)]54O974D**B8.G6KXI3TU:R`Z-
MR/!6M\-);Z.HKL>E9GP+5`V<7NI*9\8H9V4JE>`)E4TYN9V\P;Z8N:.,TE5Y
MTKYXRH][RB8HT\O_6`^)ID=#Z$?Q@$>RI\(=YTA&_%4(%@_1H`9%(,,S+,/G
MV`3'7``[4,P>ZP-3@(75$&H)EDACI6H@!VMY-+RFJIBF&G2J^@ZM,*M7[,T"
MD`!!@`13H`61,`F54`F2(`E@H`5(L`!G``YE/'Z?>;YS+$UO;$W&:I$3N6R(
MN'6).&?=%&C1YI'=)+_V6Y(BF7_[=XD-[=!19L#JUHI]EW?@NLA^5ZY<6F99
MZJZ)9V:"BYVJS8NB]Y06')[=R=*]^*^C+,J6NXRRC<I+2=,O'6@C;*<IR$JR
MS$<[#6E'U7%'#&N81`^D5DFU4([#K++G>`1-/<.KR[I'T`6:Q@VWY[L._R95
MSL=(@(F/I?ISI7I745P/S2`&M?K-`8``"\`$4^`%7_#6DT`)J)#?JH`*D8`$
M0_`)ZS=^%(F'\_#&]'S&Z_N]?IW@!6[8B0AD_FQ21$IQG`62\-M.DGRV!,A:
MF*VM>2=1NREX,=EV:V9O*T6ECLS`I)AFD#R4I^UP$ZS:I+>F',S);/JFC8O2
M&AQHK<R4*(W!`INY"4O3O^V=T*AHJ/1RU4BQ[B"$/CU)VJ!@CT1)M8`(3!#=
MT>VQ2.VQ3LT#5G@)P^>I4+5\8ABJS0=*@SE?Q;?DP[N/=717>5#%`M#-[ST$
M\CT%7U#?]TT)E8`*JO#GK)`(5E`&X'!K*K:0??^U8LFT6%9[OLL&3C>JSW:L
M8XC8D9S%D6.'E!NY=GOL?R99G&MKK1T>9?@`G'1;T8&'BG/GB<K)XBF^@90L
MB[$NR>LUG1TXP=M)L&E*L&ZZRAF,L&T:L/)PRK(=KVX*RC.]C#%MRL+NG?B@
MITG57J_G<HVFPD>%8`K6#=J0#=S-W?&PE[1PY<9<W:[[NE6HNZO`EPJ67PH*
M<A%&ADM,AO9UO*PF3-10!'->O0!0`$-`!'?NUF`P"??=YX#."JJ@!45`"_P@
M6.^P#V_E5U*[8A)9M5$WK&^L?LF$B(FX=6#'B.XK4I>N;6A7FR%IB>/%?PL8
M;J/>FYN-G)V-I5BF9>3_VI,1;8&M#J9W]L"SB*;8R<FEEWD&J]LZ*-LP;<K^
M>O0=+/28VXOL<,JV[>N]F`_R@$>!9%2)!JBB*[JDUG'R"0_4(`EP?0G>N`JK
M4`W14`;4'=VRB]1)C;M/X`6:%@TO%PY8)0Y@"(;1_,QE.%_Y^'(TJX^K5@]N
M(.?=O+3^O@1W7M^1``:24`E_#NBJ(`E%X`8=UE:\UDL03UC39'6,SK5JG,\3
M?V/[&DZ:A>F0B'J)^,]S5EGUJW8VY6VYQ=#[=-DKOW?_9UM3.JY]Q\BYGU.N
MF('I&G`,B/.Q'HN#V]IG.M(,NWF;#-NX_:;#SLH\CO1*?["V_<G`GNP&Z[EZ
M_P0//"VZY>#]2M4-W:#"^M4.7Q\%ZN\%7M`%7A`)6C`%::_V7,ZZK[L$F%8)
MS\`-44YJ#6;F`/&.'+EW[L:5<U=.8<)X",O%:]CPW;MX$]_-F]?,A0".```<
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M:8DBQ<D1]D=\L/<AA(?\`P<*&"A0G\<3+9$JK>*&FX$$>D><B<3Q+L&"MHN'
MP7(F<J=!AQZRR"*?8%&@(P`$"(*((HA@8@DHIM#B"S`FD:22EEY2Y9(RRC#P
MIIOD\4G&GVY4:JAR@))*JJAXC*K'J;BZ)Q^KJDHKK'W6V@<KK*Y*LK5^]#F+
MK2G9.NRMMQ(KK$LOOPQL'6#PH",&&%;P8`488GBC#E>(P2>OURZCD\O)+F.L
M3LPF6PPR/"NK+#-`\T&G''3_T%EG,T'9.=0<=-;J;+/61D/+,\@@3>TTV/19
MQYQST''F4=I4VW2UXK9*SKC>5,6''7E<]>U46>5)=2M7A>,M5E%KG6W3>NJ!
M"!YX&G2'GH*P^^X[@<9SIYT'VZ'F&4L2L8())(+P(=LCC.`A"!YXJ`^__'@P
MX@HM)%&%E6JR,;"<@;J#L""""*+G7>[2B3"A!2>JZ<&)[#'#``$\`@`!(3Q$
M@@DFKLCBI!,IJ83%E]"P8II[Y+'HIHEH%`I'HCIN"BB1G6+**9.EPB>K(U/&
MJLA[]M''2'V*7+(J*L>:\BO.VIH2LBWGD@M,H8?NDI@Z7I#@`088&(`!`@@8
MH.FF_QN`@(,8`C'',,3PQ$SKP^KB6K,_]Q0T4$6)R>""#"3HX)S0_*%#;0DL
MH`,TTB8E+;:K-BVUL7[PD""#"B08H[92944.<7E$M155?)*#/#?9$*=<5N=P
M@PU8Z>RQ9R+KLH.0NW:2?6<<[M[Q=YQQH(4$$2)XR#;;('J0+X%PZ^N!B7,C
M7H65:+HC!Z&$#"*(P('4<0=YY(>?$/7M%)JHG&PX&-@C`Q(0XD-K1UI""RU4
MJD1%EU!AA15$JO!%G9NJ6DHG'&\<*BBAU+\'G9+5.:KD'N4YBO^7GZI96(XR
MLYD9*1_YN-*5#LB6>WA&9WS:4EOH=!<)$LV"1(M9(&`0@?\&+,V#2WL:`3S8
M-*8-H`$9&`,Q%,.70"'&,F'+#`S+=AD)\LDRP'C`TP8@`72P15`QB%K48D`:
M(N9--+&)F3[H$,0!>.!RMYD<E7I5N<;MIG*Q0MSD*I<KW/#&BX]S7'&`%2%[
MP*-8^WH'/1!"+.YPXQWM\$ZS"&2@`K6C=.5A0@\.X`,C]#%VX*K/`7J`A/Y(
M@B7IB@8WMC,01I8#00)Q5_(2I`Y[,&]XX4$(.6Q""P403``&&`(1AA"$!)2R
M/@GPP1*Z\(4P@.$+WMM"(E0AB3+X(B@:T]@M?T(4C!3J*/A#"B_S=P_\,25(
M0D(FRJ9R%`.ZK#&O0>`SH_D:OU'_R4H^<XN?@'9!;A+-%1YHP`!"*$(0CO.#
M'PPA!&*@0A8:YH5<FZ!EY"E/0<603YC!H=,((`%EQ%`R8V!B#,H&J,;@K:"C
M64W?8D.'#W9@;UJ<8D01QZOBQ&H=7[2BY$Q%Q2[6)G)@/$XZ9(/%K?Q*<]6)
MA[&R<YUD+5)!P+/CO+:S.G"00W60*$+LC-">]O0Q"=U[V(I6`2!GE:.FQ1-(
M'(^W$'LU;R$*F8<]W%`]`!A@`1\:P@(60,H#&.``"?@!P\#@A23TH`=&@,(6
M$%&&7UQL(O>P2<?X]=:;#$4H\Q/F/(H)%:+83RK^XY__>L25JC"S@8>5&3.I
MN0^9O>8L_VFA$C^J!+2XQ"5HW<0L8-`Q!J5U<)Q1:\`#(!`!"4@@`@_H8-3*
M^30&2*`.<?)'/L#6-;)Y+9[PI&=G[%E0R0A#:4^3@#,$!9D8+$V(DCHHED)C
M&E-IBE2E\1M#F<:`%4!1H1S%U7%(>BOL4A&C/;0-26W#*XC*IHP1B@<\WM$Y
M[M2CI=SI1AS?**_K>*<@=E3=ZFI1!B+T@(_LD<(4!#R%+$"A86&`F%!7D4AW
M:&,@[@H>\.IE+W5,1$$.01WJ'G(&@GTD>Z(40A#P8P"O?E4)K,S"#\Q*R$B\
MR!L_R5B,85R4'=W5KOD+&8Z%Z91U)-/'*2N2D088Y,8V9H`QR_^99"4[ERO1
MUK)XR4<YS/&-9A#C&^BX1V8M*(P.D+"<)WP!'0(!C&&<PQSF:,8P7(&'&'0`
M`JN=&@R^L34Z^]-LE'D,/14UJ;'94#+YP&$((_`-/M$%H/H<PY[OMESE+G=4
M"R5A$PUGF\-U%S@<#0[CA!-%2V<T512E=$GC$1TRNL,>H-N.==CXG='-BY'S
M0M`B5S<>;4"B#$$(@A&6<`0I!/@+(C'P%R:1X)8,E17;"!#P'OQJ<JB#V9DL
M"+2]4PYU=-(C`D!`$11&A`44(``!N![NE"")4T`A`?=)P+BUD(8:S]7=2U%?
MA>=1#AW%KV/J6X=>?SD/+!\EWT+B'S#_!2L5(0?9L/G`QP$->#/&3@DU#[S+
M5]JRY+O@`QF!&,,+.+`V"$"@M!;(@`=B4`=@K$/+77*%!+P<M0A<#1V"P8?1
M.-``'7J0`\TP3`W[<B>>Z]E/+U04:/YDET`#=\Y8DBT0=3B&@1:1T9I*3:9,
M(UVF>0`M"'?N;R`J*UX=1[NM^OJIMOX;BO*&<6%OU6SRP<7?W`,ZIT[CL+3#
MG7J]UR#7B76"!$20<9"C'>(01SOZ[G=;6RO7)2%E#XBPA(9-0D4K8L50JX'L
M92=(V<>K_(.@1Z!Y',/:55T`$XI0A"`LX)1,L,+L>F`%%4'!/@D80@^T4`9(
MZ`1C&].17N,]_P]YT%LA/?X)O>>Q#O5A1!U[5<>_?SG,I_3[98#]WU/6(>29
M'05FKVD@6"KEMYY-ZF=W68<KWL`!"(0S:N/\;-,><`$8Y$&X)_=+(")`3J8]
M8`S#J&#^_X*/0,Q\NDSC@'[2,\G`FYSK&J`CFSRQH9_SAZ+;IW,8**6#&AB@
ME$EYJ(<Z(KXAE:D;(0\0BXW2J*T@#E;)C5<9+WQ@G.#P#;9;E4X[%:^;#7;X
MNN-0C<N!C4K"CNF@N[DCAV[@#D:BHP(ID&9A)#ARM?$8CX%0'6NP!$@P@S)@
M`B'XJAY0`@)[&/%)E\A3%VYH%PA+D%=+"(7P0@WC%VH0`_NH*B&@`O_1(X*0
MV"DGB`(ER#4MB)@O`((?8`)$(!%(F(9T*)1RX!_?\SU^ZR5Z*Y3>NX<=D3?C
M6SYB.KY\&[[CBT1@ZK<>XQ^N6(ZM6+N"NPJK0`OK&Y)*N9)&^PK,Z(=FH(,-
M:(!P.B?TH[\1$B<)B`%7X!+X:T`).*<.`(8NR8>\D*!T@`.E^;\5R+*]J,7:
M<@P$O"=`&3H\TX=]\*T0DH!F\#.`@IH!8#JG*Z+4V#ZIVPRJDS3FVBA.PR[Q
MBD&N`Z--XRCN2D=*\XTG6I5TD)QZ&)9XT!QW&)8?K!?A:2D#^3MW$(>]ZT$#
M\0YM:!8#`;SN$(?N<(=L@`8V4(!2"H(EB`+_$TDPERB?C)R\\7"V=V$D98.D
MI%JD-U(':F""!3BW!"B":E$8`>.U7IN"(^B>2T`%2NB")X@"_[B$9V@'C*B0
MZ)DK&7$WGYPW&PD*><`8GA`*I#2F8!**8.JQB_&WBTJ9'EN'?<`?L'BB?5@2
M?J`F++F4M/`9G7&+9A@#7'2:<U)+=&I%J'D`#PB$"CJY;\B`<XJ!EULA,)$_
MJ5D:.'B,"?(G/!-,>V+`L/D:/C,;WQ*G?:)&>SHTIAFBT#`H;70TZ.+`$G*H
ML7NTV[@B=%P54'/!C,(-$TP[CVK'W,@'S4FO!DDO?ZF7NFLCOQN=^OJ.CR2'
MO9.C\9@(<$`0<M`&_W"H*7IX!--+@(DT%Y4XI"S,R"UD-H%X))$$GI%D%FH@
MO=++'BI8PSR,A.W<3BT(D2FX!)>@A"_P`L=3!3>J$%R*,7XARI],1%Y:RN>3
M2KGJG\`:)OY9!^?SMW@@"DM$N)39"JN8#><X,N=X+-'P!W.``Y4SKK5TT+44
M(7)J@!?8Q9/KA^)2K0:(`=@"##M!1G]P!0XR+@A@)Q=R)P/4DSUAQL\PFQO*
M(:>1@*/C+2`R+H&R(2*:S&V$NGX`QQ5P.-BXDN+0S!,DP=.L2M$4NXE*''/<
M"DT[%=74'(UY!^5I-C2RB(3H32#4AH0$O+SS0C!$$`1I!YSZJB!0@H8!`_]#
MPLCE+)_)X\)&&A`X?3"%"![3L89;\Y8@D`DHG`)$X$Y)B`0M$+!(F`15&"J:
MQ$ANN+U$1)U%E!&HVB7Y040L^Y&G"*R+BDJDE,J+`;*+>@I;`5*S&#X!'5#,
MV8P@A0ROI))\"(2Z_"`O>]!8;<4!@``X*`<MPP-A7)H7V`>ML:!>S(,.\B`8
MF*T#K*TZ&4`:LC,3?:%\HKG@0BY_L$;(?)L<S5&I\\;4`$</',<I&E+O0M)P
M_;03+"\J<HY:P2*J[*C'60?QDI<M%8<M=3!MR`9PR(9[Q09M.`9LP(9CF(9C
MV%>`%=AK$-AC^`6#%=A?4%B%90:%]06`Q0:%[=?_5B@"!$@`*CS.4X`\-E47
M9"-8@/6&7V`&;R#9D2U9;S!9;Q@&:T"$(*@/-62"%RD#/^7.*5@":Q&P24"%
M\,G":G"'<PB'H!7:H/V&H37:<!B'<#@S<]"\<@@'=5"(H$T'IDT'0S&4<#B4
M=%B'<O!#0]%:2424U:&&`$&VBU`'=EA!(*L?Y:B->T@4$9P-KPP'SE(MXQ)6
M6<5;?8*:!N"`"N4F=,@`U1J`#'@_+_&AP-0+&*"_!RC1>\(MKI'+$P6ZRHB4
M&,HGX!+`RE`ZR&PZRD2NR((ZYX*;$:HNXB#'B'JNY?I/T]0-+,(B>&3=$`Q-
MMN45=I2HV?`&7]!=7S"&_V/076/@A5TP!F/(A5S8!5N`A5>(!5B`A5U@7EEH
MWE=(WEAXA>JM7EF07NRUWE?`WE9HA5<0A.\5!$'@7CZH`N(T@C--TY503C:M
MAF>X!>>%A>65!>B5A5C`WUBHWURXWUG0!360C_F(V1=A`A*)A"Z`CP.`'5Y#
MA"^(@D)5EW&(A5F@8&&@X`G>A5E`AF$0AF'@X&%`A@U&!E[88!(>AN%%!F4H
M8156AF5H8196!A5.X1".X1IF!FV(EE1(A56X!$GPTU2@AF]P!F5(AV:06G9(
MAW-PAF:8VC/K%!ED%$3A#6#H@/]3RU>\XKQ%IWW"@VZJ`R][@+C\BUK4ICJ;
M(/]BB``O@P/+DDMM>J?7<`9B<(5`P`,\"(0W00<)FC@5G0R\N5S&5%4J\0<)
M)(#(I-PBDBU\,`=@6+,Z'C-EJ"8D4J)Q<J)*X\Q>@8Q]B.,Y=N0Q,V(0'*_(
M@8T1_"@CG33#80O./%=/(]+6)2_<W858/EY9EN7F=5[H!5]`T.5=UF7P%00^
M``3ES65`$(1@9EY`:`7R+69!B`5DWN57T.4\*`/3,RLEN`*+Q,+>6<YJJ`9H
M0%Y?YF5H#@1!<`5!&&=F=H,HC(\!;LD`DX(C$((0PY8GF`)"E0(HB(1+6(5I
M&-_Q'6?\-818,.=#F(5#Z&>`C@5#,(3Q#>B`%H:'G@7_"Q:&6'CHB7YH@3:$
M0W#HBA8&9/`%4[`$2PC/'D8$W;$$7U@&%T[I%E;I9E!I%V;I=%@&9Z#I9G"&
M0+``UM+BG8Y5$UIC"[H'5V6:%XA<#/+5&!#6`>``D[.S/*$,=,"X#DB:5:1J
MT;*`#GB#0'BYUZC<L6G`!UA,"7";S$BZQ1P`&\51SV`'\>L`"X``U#(AJF$;
M.A"&O>D5.@@A!N!6OL&<U4`'5X"##K@`U.J@PGX`">``&,`#8@"O,%H599B%
M8I#L8D"&XW!26=&'<Q`&8""SS38'63%'1FF<RTX43ED-</#=6,:%6/8%X[4%
MZ+5EY&7>ZMWE/;!MVW:#/>"#_V(&!-T&!&!^!3X`YM_6Y>3=Y>$&A#Q`9C50
M`(L]*RA8)<=;D?;EYFJ(AE[`7G(NYD#(97_6Y3]`YC(0@IN=`C[=-?8P`B0X
M@@'S@GRNADN(`B?H@DE8A5]8Z(7.7V`P9W\^A(2.A7,6!/SN;V$P!`JN8`N>
MA0G.7PK.Z(Z6Z&1`!OWMA6=(A9"NA$NXA%2HA5J@A5H`X62@Z65(X1IFZ65P
M:1(G8F=(!YG.`PAH&BSFZ1CW(`)H@,(AFD!HT`=P!0LZ1CIS!59D``CHISIC
MBUYL"V*(F]2"52L&K0NX/SXCP,J8$M_2IQB-(4,SZT0;#;MI#'.@@YECK5=,
MK0Z"`/\8`(92X0>\AAH&R,Q).QQ],`<\Z`!=Y<L7O\95C``8"(2W#==#,($2
M*`$2`'0]D(U,U"C9@(UP@(&W?H!&YP!D^-;21,'*L<'9T`9IP(9K\(5=P(5-
M-X;5/EY;H.7H_64^V`,W((-45W54!P0W$.[?-G7?W@->AO7;YN56J`4WJ%@$
M.*ON825*8-\UU4AN\`7LKE_\A6;D[NTZ^`,^R`,FR$XJ@,)=>P)N40`%T)8G
M"+`423$I"(-5Z`57P&C_QM\+;FAF)NAR3_`$+W<$M^`4CNA9N.\0AN@01H;C
M-84=7H46N?!)B(14$(<6=H9E2`:85@9F0'$F5@:%9WAS*.+_<!`&"R`A&)=Q
M"+5XIVF`+A8:?G@!J1D`AS+&#@UYVKH+>4!+$]+X9-0+?*@#M%1+P?T_$P(N
M.,#+&R5`?U!,X&H&@QJ#<:+`2#DB/,B`<*(Y])NN(&*:57P#MVD,-5^:ZD+T
MONX_(']YO34AJ9E08%A2/2`!$`B!KR^!/Z@BS%X'##6N"(A+T/3,24\5T]9$
M;>#=4+>%5Q!U6/C>[]W>Y(5F79[U4\?M9J?U5_B$5X=UX39\X=X#,G`#\![N
M0&@%/A`#XC13$@$#\(D889^\R8N&6V#>5N#[:.9E0<`$*E"`[)GV79L"(PBD
M!3Z")O@!(X@"*``"*0"#5)C?<@;?_T!8\`1GYOPE]W@'A@O.7U>@8!&^8$$(
M?@\>AFGHA5K0X540Z19QB4H`U$BPA%3`!IMF!F1@!F/@?A2/X6]8>)=6>&4`
MAR).!V6@`_.[6YZ&\;Q.R[;$>!C`2S`Y!Y4CH;H1^5IT:@H"3'T`"!@0!D*H
MX\\?/WT'_2D\V&Q%`P8#"%`<,(!!`P@2)$!X$%$B`XH4-P#CEY!A0WT*@3T(
M24"",Y0GQUR4&$-?0I4*<_(+!Z,E1@8@&3R`$.&H1XL-1'8@AI..4(H>\.'+
MAT\?U:SYV(UY8-'BT*(1)$2`$/'KV0$%UV6ERM:MCA!R0X`P<8A?6W9M]V:%
M(U3H@`=XL/]F9?N6+SYTB/7JQ<?N'N*J^(Q]`O7*,A\W;O;LX>.9SZ?/HE\!
M*@WH#QG.?/:8_O3J]672@$33=L-G=F?3@#ZA49#@0(\@2ZYD`3.)4J5*J%2I
M8N6<5;7HSV"=_I,'4"M!L5[%ZEXKCP(!"ZA8F3)ER9,E1H(<.2*EBY1(4YYD
MP2+%BR1<LPQQ-]3]?RR';&>(=OX!(\PLQLRRX((`RA++++P,D^`NN^3B2R_/
M1/-,*JNLPAR('JKR82622!()(JE,HPPSRKCH(C$O*M.,,M^$$TXZ.3;3##@T
MIL-C.G5``-9?11IY)))+B:1DD11A]`8^"TDY)94+X=%`30\`4R7_EUU*V=!!
M8*+3##%DHL/00CL=)$P&@`'V0`8QX"$,,>:<T\PL@<#104LB$<``!'CDHQ"A
M*OG3#TLA,2!!.#JA%$--`\2`DDXZ\?--!X"A90$,>+A2IC/#!./'&!PH25$&
MQ/1#QY]2K4,855CIDT\S+YS5`)8-2+`"'8'0228P@=#Q0@18*C5``S$HAL\Z
MD+6%3@YST65",<Q&%NM5^-3QD40/U'$M7XWE)8\\;96[UV-[^=(**)\`\LIJ
M\7KV"BRPT09:O)OMX089>J3VF6F>Z;N9;:NQP<:^>QSL66FMM/*)&U4L<`!P
M1BA!G'''*;=<<\^Q\LPMM_'AAVZOQ5)+_S!F"(``%64L@=[+3+S\A!123!')
M))=4$H878:222RR&!**=+(*\$L@KV@D2B"M&QR(,+PM&C8R$$3*HBRZ^Z)+A
M,ZQXV*&''XX8-MEBC_B,)9;0<@PRP2#CXHYPRVB..3>&\V(SYNR8SHM^%(M1
M34@*WJ1(4?GY9U0/T,&/EXW[0Q-@%\C3.)AIHHE0EX522>CE"A&30>!$>1`(
M.HR'.24^PHP10>$#1!"(H96NZ15%$IQ#J4(T721II;V;TT'H!&10QS<X56I2
M0O(0\L(#%67P#5113745K&[!@"SV`V1`!S'RX$488?S<PPP=&>"*?0-CG"MN
M5NG@("T()Q2#%_^X^/2#!U!"-0!'_8Z=NQ=;&-,_?#B+*MGPQ2Y>(XA[O687
MQ\!&`ND%BV*\8E]DN.`%]X#!?EU0,P0C6,)HH\$1\N$5KK&%+F`!BU:8H0@3
M2T`/C)`$XGPA#!H[Q7(\%AU6[*(8LD`:++HC"UFXPA7@,4#+F"`%F"U!9DLX
M0A/>,XD/3<(+EA@%()8F"$$4K6E;C$4@AO8?8,P"&;/8Q1F%V!T![>(9;BP;
MV9KC(>>LXCDD,M$E/&2):`P#&</8Q3!XP0MD&$,9;\.;C!+Y(F?,B&_,"$2;
M0F<DQ`TN)$QR"0$N28!`F<YQ7,H'\`#S@DYZTDM@JMR44&FY=61J=PS_L``>
M]H$Y-)T$)VC2!S`\X"2A2(`8*`F32A)5.V?(3A^0`LRD'*43?,"@2(&!`S%S
MLDQ+X4-\D!0)#*(7$@\4<%8JP0<<C(6L![RA&?KHQP";$0.O**4!WPH75=*!
M@A',!00H4,95#M.6604B`D:*00'99RZ!"M0MA<E*0:D"#E_X0A:O85B\/K$+
M;+B#'-G`AC&,@0M8K&:#&-S79E+#+]:84#3[0IC"/(,PVYQP%[ZH%Q_J!0DS
M*``!"4A`$(*0!"ADH0M>`$,8*(%#YCRG&M#917=F$0L5ULMA;E"`$,K`!"8\
MH:I0D)EYS!.)2JB"$E^0A"6&%HC3+"T632O:_UA+$XC_&&(__QFB%U]!"UI8
M8A5YG*/'\NJQ$5U"$E_0PA4BL8I*?"$2J8@&.,+Q#1M]@QG-8`8SAC$,15+V
M&SU2QH_2L8Y8;,!-E?SLD0[WDD!PJ1_]**4Y),"M-Y32DRE))6P99R@TC>$O
M%FG*Z6)WR]WZ`QTQX-8`.E!-XQE*&'UZR3=^F0]^'-,FN,,)/[95I$#MHQ^]
MNZZLJJ(,#PCE`1PH$C=AA95\!*)Y9Y%`(+)2/0""#Q_XJXCK7&'0MK`%&2<`
M@;18D`ZWK!>7$D`<EF!@CO72%USZ1"@`KT4.;&`#@;M0H01A<0QMN",>%<U&
M-J!A#&B\PF&7<8W1WO_E4%C(`A:V<"DT>G$+=JDT,WRXQ2V@L0M<X,*!VL"P
M-J2!P%RX`CNTH.D!?N,#G<X0"SX%`QB40U2/;12-L$!C@W21!S-0H0A&.$)5
MGZ#52%SB$I9(!2K`2HNBQ0(8`&(0A``D"`0U"$+"0&/4+)2AL%5C%4;5:U[%
MEAQ)((()/O"!%I*CA4A$PA+MR`>B$7V/<C3C;HG-&SKH9@YG,-(9A\"!(,*Q
MCG2$HVZ:'09W02MJ2E)$21?84I76D8-#E)(90_J+05IKN=-5:;:Y]5*B:M*!
MV\V:<[YFB$GP\=N_-``/P$032RZ"W$+A!%*[NPE"+.4-T(%$,-+\)G:IIY/_
MWX%D=P-8@56^215S<""3%H%`(.@WP+V\UU@O6)9;#J./8MQ76CA(ASX$JH_/
M&:D#YBC@NJV5%X%3A1WZ5#=5K/(.<HB#'`S'AC88?(QL6-2BW=#&AF&QT8W/
MN$*^.,8O&(P-<8B#&C?6!LJQ<0V5&^,:T(`&AB^,87*XH^8-[X;-L=&+7/Q"
M&K0HPP(00#$8_F"&5\`"4"F!BARRHF.F,,4K;J'"(=9"%]:HA26*$)PC."$]
M6Y;$)9ACB5LLB,UHA%#4C"%(M1LCD"QBQB_B[HUC'`,:TH!&-:)19^A$I^]&
MO7,=P\8<2D@B$5^.AAJ&D``D;('P::-%/?+1CWGL_V.YZ[C\.M"!CLP;'//K
M"$<YHB6_<S;K+?PH1PP4)6I1GRI57))G"%!P#T^Z@EL-(*UK32GK4][R>H"1
M`#..W9!:7DZVA$)'*"62@7"8SE#"?(DRBJD[B8SANOSP"V`:0`?B]DZ]UL6V
M3HAQ`4D*-[OWT,>52EULJUR+P'L9@[%P10B$M^7\AS`!?N4R@ASL=Y_G2+Y0
M9$`S9`7`U<^!;5[_7!Y?N$/#N0,X7-0UV$*[?()KP!R&:11L@`(HP(*,^8(T
M2`,U7!0V7)0VB$,V7$,VM$,[,"#%49S#U=P),I@V=(,+BL,#EJ`XE"`XB$,[
MQ(,X0((83,P!V%0/]$#18?^!%W@!<BP9<XC(*J3",]B=-4PA-=!"$00!#_"`
M#W!=S=A,%T0")=C9-!@#,QQ#&?[",,#=+T"6-[2AW80#,WC#`TK#AM19'=%1
M7OD=X(D(<Y1()!C>,XB#]XP#)HC!$&A!&!0:-\1#/MQ#(]Z#/,R#.HR7(\[#
M/5@B)CIB,90`"-3%7?3#^<V*2>0#_$G2ZB$)4R17E2C#"83`"(R`'GA2('P$
MLN#>EV3.+6Y.KS4?;Z$),;P:1N0!K?T:H<C6+36$*^1/L?W22@#%2Y@#I3!.
M;?T%##Q7.%@`D70`.V#7=64+]5`//^1!_DC$"GCC5:`#!WS%`+S`.K!?`A+&
M6]S_@S.8BE+``,$UAE[<PS[\00E("PGH`54XRSEX`)$,``8`@_L5W/\<&,&A
M2[D<!D-FQ3O47,3UPBOPBPN(00JD@`M\PL1=PR[80KW0`BSX`C:`@S;L(,JA
M',DU',/M(#F,`\G5G#O0`X8U7`P>`PIFPPZ.W-PQF#>XI,VY@S2,@A@@@`$8
M`,7T`!`\011P@7&<`A."",=\##2X`S9@0AE@X0'L0!;Z`!`T`1`X`1).`BNT
M0SF``SEP@SJHPSRX0SO0`SG0@SHXG%W")3?H78<TG=@TG5[=H1TQQ])1`B5,
MPA_N$3G4PS[<@R/J0SE``A,@@B2DPCM0A3Q<8B;FPSY4_QYG$A`_5%<_V$,.
MY%\(E,`>F!9J'HH_X`,=>,5?($XF[=+J-0`,A`.7T!MIGH`Z.$X@%$D#N(*L
MT1IL.8XJ-03V481P&>.M<<YNQ0Y6.-N?C!*E($KSA$0$W(XT/4ZDW(3LY`&6
M2,3M<1\W=M\W\@,[9(JB#$!XQ8H^).-?/$`PN&/`[07Z+0662``^'10^R(.X
MZ$$_R@4(_*-.^)8S28`AR"<!\05#"A1_TE=C-"A!.08^3.1%^8(M[($8*,!&
MIH"&NL&)54B)X4(O2(,W,!C)V:4X+!S)O0/)X6!+YF`+9@/*78,T7,/'78,)
M:L,Q^$*)RF"*OJC#O8,UN,$"*/\E</A`$D@!%T"E4"W9<X"(<W0#/2">$/S&
M`60A#W@E6#H!%X3!<D2A&W%#.X@#7.Z0'E9#UX"-V71,7C4'B+SITI7()$S"
M%FQ!(I`"-<Q#/V@F8]J#/>SG.*#-,\0#7MR#8NHC8QHJHBWF9H(F:FZBM)2F
M'IR3Y%F7:>T#'D#`:\(F)0U.X*1/E%3)_47J".R!XUP)L0%G<,[:<,X6<Q[C
M0N!#N8E$K,D6\?F:,AT;/]2>DD1`HX`)2[1*!!0/I?A#<TG*+R6$[PF%-AZ/
MMF&;-RY3K/`#JBJ;<$4K'43*])AC0NX%P'T#Z$Q$L2U&P3&+'M`3@);`'^S#
M.D#.[D#_@!^(V[I%Y'SN4U:0`SA@E#3`@ANXP$9Z@+^Z@!M\@HG9PHDQU([Z
MZ`LZ',FU`\--@S8$Y8O>&$]>5#;L*(:89`EB@S3\@B_\PC1X`\.UI`YF0SG4
M'"0H@`$4P`'\65->01<`%<=TC)NB@B:PPC9L0RI`@A4(81;N@%<VP1/TC,WR
M&5A9PC/T0C1L0S40E9O"Z9N.R%X]Z=*=`F$69F%.`AC\E18@0B(\0SO40\(]
MXCS,0SQ`ADG$0SW0SV=JIMMRIMLR9C_P`VKV@QY$JES\X^R9%MW.K3\$@@0H
M&Z>"5I;`P6E123[LP7_JGUR@0#XTSBS>"B$T#BE1KBI9SN7Z_\,P0(!(0$`S
M^,/CI@3G+)>A)(3Q80Y6@$ZID9:C!&OM%`^ST<2?\(Y*)`0[C-]?+$ZV02M6
MY,0WJD0_A(,$:,H+(%JVG&=-N!->6,6KU*MZZ<Y2Q,!!'=A#QD4]E<`AG$,D
MZ4\L%>!\/J1CO(5AL,7_U`\Y1-S'M8(89*09F`$9Z``9N$&$V4(O?!PV]&@#
MYN"+3BR#06R+/N`U&$.#80@NT._*B<,T>.`#C9R+DBS*,2PL%`$"L&P";&D4
M(!URY%#'H`(KH,(IX*$E,$$"8*D/_$`4A4$8G((*6T$0&%XB%%HJ&)73"J8J
M+!T-1RV4UC`J5`(EA`$8=`$68$$69/^!%G0M(Z0"-<C#8G[F/BAF/93M.UCB
M?E83_9#+H7*F/C;B9MY#WZ)F.M0;NDI+#MQ#:A[*:;G"!;C$*;YG'53N0=@M
M"9`F7>1M,31.[1&;L972:^7B+>YQ;IGN0<PB4YC6JB[$X\X$1E`$':1)/K@N
M`5PG[ACK1-B$\3#$+WZ%EEP;^%F*K&07[RZK>C;O^7U#X':+4X@G[\**?-*/
M2LSB1!!`!S2B@B+8.41+/9W`(0##\"(+'6#+?"I&0I&KA`Y<6Y2#C-HH+$#,
M)[0"O0#"P-(+2_7"`HM#4,8DR4V#-32P-4S#-(C<Q.;K`%NHP6HL@_E"R(Y<
MP[9D.\@D3J[_(#E0`]`E)=$9`7U$90<_APWGF248`=#N0!1Y@0JK\-(YP0Y8
M@25(0A%/)M,^Z0WCL$.C`F%.PA=D010H@1%,E19``BU$PSO<PSJ02R2J;=G.
M0SF4;5NF0R3R0SOV0ST<*J(N)B92'C]H)CK)TB'@;:3B`#B@YCFIYC"DH^%T
MJN"X3B`\+N+>+0B,`'XEM;3HP>QU"3$T#^+$6B%G[D(HYT'PXB_5P6O"P(Y\
M`S&$]8SL"%E_PX[$R(R4R5F3-514!'<VA'&Y1"^9A$HL%Z2TRELKA"#SDC/,
M=*5HV[-F"_AE"S]H$P-,CZPDBD18@"LL0UA/%C$,@UA+MC)(=E@S_P,Q($-8
M:W9D*T,@<&XF60`Q"1Q$"APXL`!IQ@\R?';ZB(L^T&N]BDN#7HM`F6TYT%PV
M5%C-.1PX'$,O0(,OY`(MV(*)ON@XC.G^DBPW<W.+.BS#DMS<Q=TO>`,.2NR+
MCBD[.]R8<H,VT-PXO$,[0((04$R0^0`](QT.<3`'.P>4FFDBA&43-$&7"C0.
MG0(7_``/,($D4`(8;%4U<,,V4&T^1^UR+-T.\S#/9,$57`$3E($B0,(M8(-;
MCO0\R$,\;/$Z[`.%6^([1/&$UX,ZE,LE)NHE+B:)TS3?VG*DRC$*@`-#S.WA
M^H,S`$]L"O61#(`$J"J5J!I.1^H)/#67D/_R+DU*(>OBL56)&Q_$&,!F41C%
M6`Q$61"$E'.$E$LY4FC*"F3G\TE`<IDN3L@N`0S`&$3CMLQN!SBB)G-R]WFR
MK/@#J@K%5("/>X)GE=>YG=\Y02S%1$"`4Y2K?I:K,J``BS,#'B@+?5Y+1+)#
M^=*VM02S8]@#/,"#A<5#/-`#/=!D.5B8.W3X"S9@12T<.:C@<9^O"I)I`SLL
M#^YVPS7<`Z=SJ#OL.L,Z.2S<PHUZJ&_Z=[L#+5`!4BZE$4!!S.+0/1MX/N>L
MSFK!DBXIT1IX5V4!$/Q`%'`55ZG"-G1#@'=P>C,[L5>""A<FSV`!%"R!%20"
M-(A#V3*F)%)X1\O_PQ/G@R4FJB1.WKN/M(;W@XE3'KH;:J)65Q.KPPF$\5P`
M?`B<@#&HYFGY;3G`P))4DO#X$I7T@_OT>*260!UW"3YD@)]T0"<9M7`.IW!:
M]6N[0A@%`D)*R5T?CFU)1*2XTHV;(N!P0*ABA7&)A.UP3D*`^0#`@.RP"N+$
M>?<EQ.\^:RKO:D1@29Q3!3_TII$0B<I[%LM+1$5@4IB7&@$\@"O@!;R!"[WE
M=/\Y;V2\A<'M)SO@8V$X.CZ8K3V4@Z6[0SFH_3M<>J73I-S+_:V_>D7->D6Y
MPW&W`W@?=X>3J:PS(,V!-\U16(JJX*?;)<W!)>'GO:0+*=`-'9)>`5"E__<'
M+T<E@(%4.D?.HD(8)#O1ZO#2A4$7Q'<D1,>'X&S.=C"Q:WMR$";/?`&X,T%&
M1T,\C+0Z1/&&ISN%N_M(DSBB`K\ZZ*.);_&^NZUI;:(<2SRU&+QJ^L,]P)]L
M;BIR!M_#!SK\2#P(Q&*7\,,+^`FC$&=POJJ;>P2N9$"4&,KU^`E8J./*MW_@
M%*0ZJKSVO,J+.S*77U<,B(28YX3D\3Q`,!CPXIX^?OH0)M2'SR!"A@;Q/608
M49^P!P,&,.@0D2$_/`T8"!2(D63)C"91#B"0<L`#0@LYXF,G+R*[F1SU%3,!
M(D3/$3C638PY-&;0B$:))HU(<R@[ADYCVHLW]?\=/7?NWF&UFO5J5Z]>VXW#
MZB[LU7?DVKDC1_9=V';DX)+31FX<W'=BW^9])VYO5[AXL\8E]RYKNWCB(`DY
M4("'CR17P(0Y50E59524NGRIM(K5-GJL4(41[46R952G4'N1<L52MVVL6%7;
MMJWR*4JF*U6B1&ET%RV_(='2-F_=NGGSWAU7KOS>\>;,Y]V3/CWZ=.GS^NV[
MIWU[O^W2]^4+WZ_?GA$]T:=7#\+$(?+]_/F#+Y\.2`8$\.._S^!%N?C__ROF
M!/5"X(DG`G,`4,'XZ,B/@`9<65#"__B1L,+X]`'P0G_&R"BD%>:++X:3&(@@
M@Q-13%%%%3=`L<45,X#_`9^#XK,H/PF^\0<A&CL,:8`8%/*'COT86.&AA(Y,
MLB&'*%((&/L&6(&??A+RHX$&,'H`QA=3U.!$+F$\T<L3@:F)HZ"@BN@>?)H9
M8Y9#2E!/CW*D4ZHHHI`ZRDP]\<DS38[2E*H<JZZRBAYZLHJ'JZ_,0BNK1<=I
MI["ZZ'HKTG8PQ50<3.,29RVR))6TK<'<$2LPN#A52]52"<-%C`4.2,`'):[X
M0A)*<JO$MBRPF$25SEP#;3?)4$-%%=S"Z`*,7V'KK)K+=J,$M=TFF20,+[[0
M8@M&G@DK'G6>6VZY?)Q;[CEPD6NN''7$+?>[?;B[1SSQM!.OGQS2.X_``GL"
M_X$$/>`C3SX,ZX#`P?P:@&&="0\Q0=]^0WB8P!/RF3`^8![(;X`Q+.X8PX\5
MS%!'?^[9("0"&(!CY`QC"(F!!L;0QRFDG())IC/Q06?-=>X)"IV99>(Y0X3\
MP?C&<Q(:>40?8]"1Z#I$(J`#=G94Z""(%H+)(20?"@3*C7#RFJ0,F$'''';,
M0>=G=)QA!YUPV$GG''/*2?OLL\,Y6^USU$:GG#R5FAD&`CA@YH\XT0-!#SOO
M9!RJ/XF:B6HTDZK*G4.]VBH>1LGJ2E3"TNJJK4Q!S<M3LL39U---!5/+K;:N
M>DO5M6`'=2W:R2F'G'BH<4.(!`[H`8DKM@B#$DDFH?\$#"B>T&R5:.JAIYMJ
M5)GL-&.//=8RW5!IMAK94+$V>=["`..+++25)!5JZJEN'G62LR>Y=LV=QY[H
M\(].GN3\OD>===21#G1)QQX$E$X^U@2O\,#+'BC85\0.E!X0^$L/]PB8?`(6
MB`@<K`%PV)""X/1`$8;`!.GHV#HR@#*!6,`<'@.9"_]3L8M=1"4/",1_,D0'
M#PT`!@`2V<B<MC(@$DUD/U2(072$L?L00`+*<%I">H01("7-:R?+@#..R*0L
M9K%),X*:CSP0$WY@#$L#N`#2<#(1F^$C'W9J(^/ZU">D!(6.+4/9"LRA!Q+D
M:W%PM!/-<!:3/P%.D/C@RN;_"%6H=]C#'?$HAUD:*;JV/.I1;"&,6=XRF+3$
MY2WBP,KI2M<53W+J+*4:3*0BY;IQ\.4NN2/,.#!!A04DH`>TT@(8P!")\R7!
M"5&(1#6XD0UR2*\:K-!>]U1Q+-C\*IFP*:9LNL&*:WWA"^;[#2(2L;YP*,>1
MZD"'N,)%O_N!DSGW2$ZX[,&N`^)O.@BLQP'#HX]R#$AB$03!PR(X`AW8XX49
M<H4$$$:'#_ZG'WI`W`@/]+`2%,-C<%!A2/!@L1^"S(@O!*(_^$$#ES'1&2"S
MT@!`TH&#7"AI0Z/HRI!(Q)(^T1\66:($.DI$?[2,:4_DATOQ\P!B7&V+6\M:
MD[;&_P]^+$T@*]!'/I"JCV9(X"00(,8;UPC'-34E<DD!7'T<I#`=X+,$A[`9
M3*;J1XXP!5!S;%Q2I#*5J22R*X92%%9&%ZG1/<J3XSB+[#"%%[6@)2^R&R5A
MSO*ITZ%EKX&%RU[YPA=RL)(PBGV'-=2@@`0$`0E0Z$)FO(`%)QQA"I9H1S1(
M00MN&(8;U>",,5';+-7&9AO<H,<^JA&)S'QA"XBPQ"BH(2EO2H<PR.FMN-I'
MO^>T[QWJN!]Q!^/;=`90'>P:5P$+F+\%&L,$$D3/"")(()[DP(3Q"9&0EMB!
M[\90#]CUB79%2`+W=(P8!D,9`3*`C@E-%(82^@9`ES@&DO_&9Q@/\)$$6GA2
MD\ITP$-+2(4,[+0Q9@P_$FB&@84ZHI-,,4/\"`<&],.`//#TB$?*&C\H(I$9
MH2,#.^S`5]?1@9>!U`]O%*L?%](/.T%E3?FH@WWNTP`Z]`E?B>NJB^$(.4".
M52D\NQE1YC$5^6TN'O2P!R.[LKE&`G:28;ED7_8JED\51BU["0M?1.G)3;E%
ML&OAE*5:MQ<JGX65XECE.[@!"2(<(`A*R$(7LO"%+DR!"9#(;32>80E:4",>
MT>/&:U;;+&:UEA[QD$<]MI$(;%KB&=?`2CSLZMSYS4\>\ZA'<-M5W/<U]SCD
M2,=@&GL,7QCC&L8P1C:R\6I89V/_?OASKCJGHP]C''2$YU4/"DPHL/\8C0!T
MD%`Z<O`PB46LUR,XQ#XZUH_!Y8<!QJZO1(?X'SC8AP`/B!`^@"B/#+BL`3<D
MFA!-BFZ#(!A#YVB&N\]!I9'A@]A,1-J!A[K#IAT8'Q[(ZA%!S.^%</BG.S($
MC@<01J'D&Z0_6A.3@AS(FGR#&!4G!CJ,4IRFK",0_B7W&RB2#ARHYP3%B&H@
M\X0.HI"53Y`#%%'NM];-05G*5Z&UY\P"NK3(E9.N*PSIW"$.<(1E+JF[BJ<6
M>Y?4:2,MF.HR5^ZJYJBK.76G*D<M7M4#(SPA"EV0Q"4H30UK8(H:T2@[^Z1S
MJ&!]SYFL_X5'/?I1CT*3H^RT?@<Z]@?8=:VY.8^61Z?%55Q2EZL<NBM'.K3!
MC%W`XA6@>,4KBF&+8NS"U;[PQ3'*\;YQ/GKP]"H&">S9ZWSR!`78\2Y\B)$Q
M!M1!0GK(+GJONZ\_N!`8!G,9!("![9!=U&*U5\E*8##0^/1((#`PXD0)+$0A
M!D("$8@`!`ARX):JG@%-Q"A"\J&/#I&$P@F!6GZ<RF$U=EB+1X2!RP02QJPA
M1&Q8D@`S9/9B.RDC`\^'0`:$`60^X8/YOP])#,*A240NNTKNY.#(3ZI*'E1N
M'=@!`<VD'M[AD7+''>"A*[HA&PHEDM!"+"P)=/9"=3;E4N`B=?]$<"[B`M:T
M8>D22QRT`1NP01M@4!O<01NR(77:`>D2:[%29P<_<"VTH1Q<P0R$H`=Z(`FR
M@-*BH1VH`1-RBQIR2PE'"RN>C!ZB1^VZH1O@H1NH<$KVX3#>@1\X#]7@YRQT
M!]6HC+@`R[?(4`S5(1R\P1O4H?#2(1N8`1;X8`_P<`]>@0\>[_&,`1:,`?,.
M;]1(K3F:(R?VB%^6C5]&J(3D[3_Z"V583T'Z`0=>3X0NL2?VP(7X80ST(R,V
MH!FN;?>*Z#]2[!-Q3XCZH6(Z[F48P-N""*4^9L""R"#ZH0-.8@`$RFG@@]BJ
M#QT,+$.B:&-J41^(88/RH_MZ:OV2A"+_7`$"T"_A0HPAG*'$,((!0$YKU$C^
M]&%(?*0#5.YF,NX>QN@"5`@_7L`<AD(?O&%`T@,%E,$`Y>\H7.[%YF&QKJ(<
MX@$&KX(<A`D#`<OI.N=V0J=48/`&$ZNOD`X&L2%UR`$;K@$;LD$B6_`87'`7
M/@$0=L$BE\X?LZ$%Q:$AK0$D=U`''3(;P"$8\H`*A("R$*$6:"$X,`$2HB$>
M:H'0,&4J!'+*XH$?/FT?Y,')5E$\ZN'P(K`<PH$<X"<.BS(>["(Y(/`XSE`Y
M(O`XG,L;?D$69L$;R"$IF^$7`&$/W(`,W.`/`.$L7R$6BB$6`"$6C`$<P$$I
MX:><IN,0$K'7_QI1&80*#.6!'_HK)`1*'N)#J/PA!R8(+T=($&#('$H,_3H@
MP$:1]T0&'XA*(-Y@/M+-'_!!Q<+K'C!*AF@D^1),9*I((!SLB3)$B1K,B80*
MBCR$`&)`J+(O(98&/R#`%0A.:WQJ&Q'"'%2LX3!"X;ZJ/AH`97`/Q(0B.1DG
M*+YAW#PD#_2A9XZ,(XB!`S(")`:@`Y0A*7+B!+*+!<+A(/R(D,0QCH[,`5^.
M'?!1+K+!%CX!$&&-'+CA*I@.*[1AE6QG,$9P`_DB5$Q2!X_!%@34%GP!&J[A
M&J3!&*!!U6"A%6CA$]S`#3YA%W9!%G9!&J2A(7<P=;#A#<5A&D`T!?\WM$.)
M828A`1(P(45I`1-2`47_K!8,PS#DP3`^[1ZI@1OB`5[P@3SL@4?C;A[VIPS[
MT1W*@0S3$$CW1RJ/P^^*BS!T!QS*(2L!H16VTAN881;8<@_"$A#X0!!>01#4
M<A=>`1!>`1:.X1@&(QV2P[F68Q=X#3$)Q`3T\N_D81SD(1@\3J#&8:S\P1+A
M5(0.H;Z>T4,$H@.(`8<6)#-YSQ1;QL0$LY_B`P\8#&7T:Q:S;4=&1M[XP3>O
ML=KX(?L^!J>8Z!OR`<%8YAIA<TJ"Q/?R(P,>+."VR,,4XAXJ$XR$(FN&@:E4
MB`.((:K"BJK2*`:P4R.<P4Z:`1=]9``RH%?_[:1ALBL'@D+_YC$F6"YH&"=#
MM4%,/X$/R!(77A`#Y4(&!2-UK,%3]L(%-;3J3-(%?T$:?$$6^&`L(]0-?.$C
M84U,6V%>^8`/R/036N$3_!408`$6>F$:.M3R=L'R;"$7?,$6>B%#CZ%=C\$:
M7"$8@L$5:H$)G3`:4I30J`%&<]+1"DT=L@-4]L$GU6$?WD,\/O4>6J?PMJQ(
M?RNX``_PK!(N=`<;=B$67B$0`$$0``%+8T$6B#86C!9,9X$7*.\7F,$8'D\C
MC4$9PB$<U@4=V"4.PR$==.)/]P4$2B`<Y.$<SL$:K.$<7,'CWH!LQ?8<QJ%/
M#Y-KT4,$U`O:8.@C_T#*92P`#X2/O@9*AOQA&'[31R[@4`?,5#7S!1RD@\!-
M^4J1:-CM'L[/93;@'%#3(&;A(AHLIH)H^P0B9I8$BC1&(]!H&7=3'\)A#+"D
M`2Y`)!*N(";B4VVLC+#$4)$3CJ+JQNS#AOBA'LWA!4+"/BP`&&3,3O1!$-Y4
M!]9!6O&$(\(16/?OY89"U7RA%?B@%4"!#S[!%J0A&XZA!D%2!RW/0:<A)'.!
M%EJ!0,=70\?7&QK6?".4#.!77F$!0W<A7R/T$Q[/7UMA?_GW7__57P74?&D!
M%@94%F"!%BC4?%L!%C#!%2JV%H*A[,RN%E#4&GCG)N,!4[KP'?;AT_BA"_^Q
M`E[J0657D83[81W>\+"PHKG&"4B!M+>@<LU@MO"\@2W=8$J'%A9B(6F1P4J9
M@1F4=AA^`1E^N(B-@1=X]A5V@1F\(6O;,!Q0\H=WP3L9$6Y)B!CDH>*"P1J:
MH16QD6PK[MW<UHKC=J&$;T+XH3Y<YCIA(!C&:S'I0`*B40)RSV/X@1@`2C\2
M1A09=\"@K4*(P7=O+T(<=V14<U2SB*AXJ'(-PADV(,,8@`."H:>4I%2#P0.^
M$75=$6R4$QU68%@98`,"0<240FO,`0XNXG?AP.6"8AR6IJE<0>+641_TB(\`
M)^.J2I;-DQYW>2BP0=6.P1@H5$`I[QJZ%UU=,$#_'986;&$:+.\7>H%"?<%@
ML<&9?0%BK[D7J'=?N9E,80$4(-0-^,!,N=<6%IB`B3EAH5E`>\$7<L$68"$7
MY+F=+^\8M#DC/Z$67"$/\J`6K.'LEA`3:&$<;+(6DC!DW<'33K8?^"%=%&@5
M[4$\CNH>W#!UP&$,(_!(J4PJ"Z\<XA(NP`&(<\%GVW(79F$7>&$6C*&)Z:89
M0OJ'7]H8F"'QX#*DC2$7*,\8?N$8E.$7BH$7>`$9>.$$SB,3$=,$C&$=+':I
M)34DWL!BB<%B1;''R#@$1*"$(K,._.NA6L(#\.`;Z&M!^.$>7.$-+`#]0B(#
MZECY3BH0(.!N,<("ZF`<__P643%*,\^!#BH`_1Y`;Z]/^ESJ/F`*-3E$W[+(
M:81!`D`"_,9`&;+O(*CD<_%A&-Z`J00"][P1(XQ$/&/"&!OS)!X@!LJ$:X`*
MQ,(A$`(796"@'(8BX]X`X2``#V!L(O1`/?Z%C?:DM75[M_>O'O$A)%L0&YC!
MF"TR0Y&Y(5OP\G:PFKU!''R!GJ?9\GJAG7\97:=!0&'A%I@YNW<!G@ET>S$4
M07&A%W#!%A)6N;W!!7TAF=UY%W)A8.59FG7!%W9!%X!AG_,`$_[Y[%*T%@CZ
M8T'6&N!A@SEX//K!M^1!99$*7KP#'!IVU8[A!S&:RL@!',2A2#OZ+]Z0&7ZA
M0O]1>AAX@1F&@<./@1E*_*.5TO#2`4I1LAPLLJ;!H<2-N(B+>!@LT:CQTFN-
MX1LL%H)5TK\:X`.6&JHKL:I[0@0H)C+](1!22"1\I`$BH`/&``\"01B8P>)<
M(1#H``8RX`&*<R1"PE"O;_=>J!^:VA5?1@+&(`^(P1GJ)&>:`1CR``;.6H5:
MH@XPM13S`4]/`D=42A\4>=]ZBOD<)"0B``;P`!C.81WZ)L[QX`4B@'5CNQ]T
MR%;3Z,.$P3G7&`)6H`Y<01G,@=']AAB``0]B(`.PA-Q@P!S>R,@X0JMWZ`'J
MH"C(LRAT0#U*X`]<K%J7,TU\&WHC@LW"%1Q:\"/G`AS_O,'".70'W["ZIZ'#
MG_D7?$':J?T7?J$A77`:I`$:+L_RKAE=LX$:KB'<[94:L,&X87!UQ.$-GYU"
M*?2]T3F>$[87:H&?\]N?HR$:,A83:F$J`)S0QFXJ^&*$5S$['&V$M6-*R.,>
MO$&:7SQWS)`P=-`:.A0;D)V&-]S:72WCF1@NO>%,83HNTV%JFVN%U:'"PP$<
M3BVDX7+DXW!=D%(>:CMQK%A.E>%B":%BS_P-'-B!+78?_-3(<4#)XZ,98"!C
M=FB'7N8!(*#I(>!*?J_02X0.Y$M"&I="EER.P?QW'\`",F`#."`#+B`")A7]
M)""BDH:PE<@T*==P`SU(CB@?_X`AA2`9I!Y``C*``SA``R2`AI(U`OR`/"H]
M)#Q`BX8B'XBA`X:U4^_^1#A@`RZ@[Z$>S!]@#-11EL_<0^"`CN9Q'9+-QPYA
M6G59'J"B>2OGL$X0+M/=(2%^0SD4VW_Y3-,;1)TYO9W=F276VZ$!0UTPW#,4
MUJ@!!B?2!<W=(E,P!7_YF1-V^;V]^5?4#?(;$_2=WU-4%Z;"&FHA^S/8,/8!
ML.!NP;L?[A;H/>+PVE7?'P4C+L"A+CPE+CU%=[QA'*@VY7/'PN,2QH7;Q`L/
M'`+Q3)6AQ0&BG+J!`]^5(R=0X#QT\QK>F[?O$`D0(2I:O(@Q8PEER@(%<N61
MS@,&#?\^N`(9*`\P?S@RNGQ948^_F31KVK3);Y^K#B,9^/SY<X!/H3X)&#WZ
MX`4P?C3S^=/W=*8^J#2G1B4&HT%0H@P&>"5ZE(#/!C"(S60ZU:J_?/R`]1P@
MP5Q:JV.(#HCAC]_<N?W\-8OQ@`#7H5V_#M#ZDP.PM'2&#NB`#]_4R/HD1^X7
M#@X$KPT:"+5K&"AG#G[4W<.W+K)J?($B=/TY1M[JV:LK6Y8<CL5%$">*T4X=
M&;AJ=K/9R1X>/#*ZR,3QO2/GCAPY<=.UN=.631QU<>"F:Q>'+3RV[^*T:3<O
M7ORT8]-\87._/OUX;>:GT=<V#1O]\N*F^:=6WW?[87-,>.S_N8>-?]Y,TXH;
M>;B"22T28D(A)M;P$P\UM41H33O4M".///&T$\\^_.33SSXE\E./B?OTT\\]
MY70G78TV@M,==]*5\XXZY1ST(SGJ2$=0C3@>B6,V/`Z9#3/,-,D,.,RD(TXZ
M!(7SXSTR;OG.//>LTQ`S)\!$ID4E@#,,'AZE=$=/)N41""%Y!,-/2V125-$(
M&9%03%\W_0FH/H'`$(%G@P5%F%T2P+"85(#6I%=540GJP0.<(5946$=!\$(@
M5%FE#UI1^2-,3PQ(T`P_>NG#5@P,'!7#7$_MM2HP+T``U&N(OF8!'7)5QD]C
M0WF`3SZ466:;9;/$4*A=A7EF:+0;_]3AC+&HT19,!%[]!(,YJPE'VVVK*8,"
M".::>X(RR88;V7'(X>,N<\S%&]D[U)'#S737N1/==N!HYXUV\H5''GG>C`>P
M?_&-I]]YXF1S7W_W::.??Q%'7+"`#C/<WS28Y`&R*[I8LR&$M5@C(C711'-R
M.R[+H^*(]?23CXGCE&AB3C#N<P\Y[_PL4#SNE.,.T.30V-U!Z@PM9(\]'B1D
M.N1(;:.0[@SD3CI:IP-..MEPS74XX/Q(=CD/^?C00_EXV1)%>I:9D0G*I`DR
M'GF\H55)(.=A=R#RY(`GW"Z=<,^CAO_Y#1XP9`"!5J%MVP`$%\"0QSF/?@K5
MIXY2594P</]T4.BK1A75P`,2>$`',5#U$^FL>TV%3AVRUX&'/*R&&BHPL]>Q
MTJRK9CX7/_@00T<'$CR`&.0-G(Z',_W8%JHPL],1"#["1W:]:M`/7X<'%R#?
ME:&'/0`!!V,$TAR[^+"#1PPQC#%&#'`TDYSZX=K&CS(ZY*##_CD<PBYW-6<=
MPFE.^I8#+WD-YQWY(D<VH%,CIGD'8!0#CS<.AHT+>H,^T^@/>,B307%LD#S9
M^-=W]#.Q%$[L//O)F`@!QI_T3*,7M`B9A#9$H5J`*$,:JD4T7/:A?:B(1"[:
MQSMPQK,7P6@>!WG.T((4'814#2%DVQ'4@(1%>UQM:D3BVM'$=B3_)8$1'-H8
M&SFP1)"%:&F-^:A'/O9``L&]Q`3&`,8=^&8WO)'D`R![0Q[N6"=S"2YP%LG!
MX0[YIWL0PQ5U@,,88`#)&+R!>L1`AZ3.LKE`S:HJ^G@>3?!Q#E?@H0YT&`,<
MZ%"'0`#C''X"5>8V*151V>25:E&5ZU[WN^`)KQG!&"4<WC`&.N`!&,2P7C\D
M4YFTK$IXV]/>NK!7&6<`@V^_-*4P74&,=>3CF?6[G_K`9;_;*',RJTD?..V'
MP.+09AX0Y%<4W9&-[!PM.P.CSW@@YD+PA"<_X:%8"+G#0O#@IX7V,8]!^7,?
M:^2S8`$+SP6G,8P'`2-"&\I#A$+D,I)%_PA$U*#&BF26HIC)XT0U4R([G_,<
MHKUS1CN23CAJ-"2HV>@@4B.:E09BCX*PM#LX0D@ZPA$.K?F(;&ETB%&]U`]C
MG`!/A!1<"=(1"SH(DPYWR]L'[N#'.^8AD$VUR-M>PB=$'LXI8C4<+6?INDN.
M*I9BM=ZDTNI*X*EJ*KG<B_5>A]>\3H5U<$WF-I$ISG4EDS;-A!ZP^'',M(0+
MG,`!5_IDT]C5?(FPX:QL^LH)6=HLQS@*C(P6W0E!",K3@1G;8':T8\+OM$-@
MZJE8>2@V0GQ2S)[HN0\*]X/;A1KLA.&QAC4P08B31"@EF!A&/.0Q#I61[&3R
ML,:'2A2/>+Q#B?\B>I$02[H/>4`M.CRJT3AJU,2R2?&*0$+(V)(VM71<#:=#
MHMI+N^93=:`Q'3U:B&F\Y"6U:<D>.9"C2TQ@C6#X,:MZ9``?Z3!@"\5`D"ZA
M2%<K@H+"E77"-^%<32P\*@R':JT<QIVCGL*425'%*;0$WBVEDA84QS7%N<Q+
M7?4ZF60^+YDQIK'VCN7,VN"8F]^JS#IXW$W.VL]:E:VL/@C(KG->*UP"9-<[
MW`GE*,NT:MJHVD+[R3"%AG`\&P1'/,MS6VKH)Y[9P$:9<6L>%U[0H>(I,P;%
M,8Q`5&C.KK"&BIS;#FM$PT)`)%&+XE&/F0E11#,+:4Z>(YTH(N0=XW#_1SNB
MHXZ?(;J[XH4:>LV[(^Z60[T$$<A0/>VC3P^D(:-.XSU,<X]BE,"_&#'!(N_V
MAEB_P4VRCG4>Y-$"!K,Z!'K`,(71JE9,!MNLOBZQYD2<E[>".,.8VR3P5GSB
MO,!XVM2>"V`'2V/#ZKC(X13..O:A/LA&-C7D5A\Y+;O8<!DP@>F[[/KH]>0H
MNQ,>_().=/CUZ':\8[70^<X$-79"]!SL8>5QX`.Q`S$RQ]/,X?GR:\G307UF
MT!?3^,4Q+N[0:5CC%ZYX$(6$ZXIQB$C/U-#S1N41C>?&#-!"W+<[6G0/(WX'
MGMD9K<^XZS.@%4W2/:+BCL[[TIJ"XQWV.%H4_XGV(_JJ8QY=*@?3G;[T4J-Z
MU/-8AY;4@8,'PT20)AB'@&M=X`^`?:N`TSJ93I".7ZL=V!7.9+$=%6(4R_TI
M)'ZEL^4ZJDBE>.^@<O8M7TRK:BO6QMD6Y[7%I6UNHWO)DJ7-`->G>&Z#4QX%
M'$YC+YO.U;R#'O)V9SFR<6]WB./>-B)X><K<L?S0]K7]A!@VO%P@;1S#GV5F
M>.VQHQ\4-LR#^L2@@<0#C@Q2S!JN(,3',`&AB]9C1"UK!X?DX2%N0#?0,,-0
M-J@1Z.A2(Q6D2$4TH-'1;"CT2.'XQHY\]&0>27KI!@D2U8PT-9L*)!UD,V-!
M&I+?+2T=':8A2/\9,O\/2R<19I<1YP)@M0!V'X`8'#!V7`4W7Q43:_=K?O(G
M=L=AG'1A'V9WG'-LJV-B=W=W9T57MT17KT.">@%X>85,*FA8-G9CE)$]E*5X
M2E9.W80:CU=DR0)D]N-NJD$OJE%YR/%DG*=2[A1O]/!`-"(=)31/)?0PLU5[
MV7`-4W@-TG`-U``-T%"%OK`+7.@+O8`+OG`,OO`+TE`@TD`@V$`-M<=P]N1"
M`[,>QX!!Z"$+'?<Q$.(*QG5G&N(RM4`+UJ!]'A5=T*4.]=`.SY`*W1`/W/`,
MEO`(B(`(B?`(EF`*IO`,C=@*@!`+O#`-WR5%-85%/G=&Y?!2TJ&$!Z$-FV;_
M$&,S(T%"-C+2?NT7=?Y'BU$'.+L6`B7`#*XP!K7V`3W!@&\@=I,42`^($6@G
M@8?C:VUW.<NH@9*B.28F@GZ78M+V.R3X;'QG@BFHC3"V@L=28_@S6.#X@D4V
M645V6318@^RR@^IS68\%>3XX&_2B9/0`'=G0#?S2#:#'CPI'9KA'9M=@#%.(
M#55X#%F("PF9A=(@#;U@"[#PD+``"Z]P"Q`)D;:P"[9@"V#8"[[@"PR9'M!P
M#&C('OC!6P0C'OXD<=Z@"W)F4<A79R(2#R0S#22R(;5P,QYR1#O4#MS`#:F0
M"%N0":3P"(E0!E9@!450!590!E6P!499!D50!&4`_PFM\`M?=(H\(E/E(`]`
M@R7NEQ!'\R/GA2.DB"58@@[E`(`,\2/\1Q"GAFKY9PPF0(`%N!&!\`$T$&L?
MH(`^$8S`%&OXD'5P0T@C<`C)6($9&&P6]BFMDX%]%XT8J&S3*(V2*7>OE`[%
M4`R%DXV=.8)YE8+6LX+A:'B&%V,R:!DQ&$X]R'@^1AO*4`R'D`Z1AV/FJ([J
M!!SL@(/QJ!KNP`W_B'#9\)O^N'!2>`U:F)"XL`MA"`W2L)"]<`N]()T9"0NM
M\`FM,)&OH)VO@)VMP)T7B9&]D)&XT)%C:`S&,)($H@T*=4("XY[NV3##`!(6
ME7PWLWP:4G(S*2$>E6?Z!O]]/0F4B%`&5U`%!5H$0[``"Z``0\`$2CD$0U`%
M0Y``"U`%9>`&?_@=2',T*?4C7XDE4L1%2U=%9&,E:-FA/V)?7N)IIP8FM*@E
M^*<'$$B8KA8(8R!V-]H9#,"`?`F8@JEK@H,#%(B80YIAEZ1ACVFD:B6"4*%W
MH*(,A^`;M*(#)"`W^_!LJZ)B@J>E+8@L@`6.V"8NM)ENJV$.AW`(R@"$Q?('
M)5`"?\";[%B;ZG,:298:YL1MK&F<PAE/4_B/\40.]%%F`@D-RWD+H&"HMX`+
MT/`>([F<OH`+L/`)>\`'?``(@."=L)`+RIF1&:F1#BF>8>B0RIF>UR`>^B0@
MV&#_#1KW0:C%JG`&(2&C2B)GB"13<GU("]0@(BXS(BIC"8C0H$P0H4BP`$&@
MH`N0`$-`!$JI!,:*``B0`%6@!FH`";T@0N#@#=9Z03J"(]3A#=/A#>.`)$#E
MBEGS(P/A=*1(-@9A$&@SBP$X=:?V$%:G#KKA7R!@`LR`ES9JHWW9`!PPC!\`
M`V]P#[>X=<>8#OM`I!1F@9=#$VC!F&NE%F^%.2&V@=3H#U-J`L7`8?U5`L6`
M@L;6C2LV;:-9>(>G@]S4CG,JIK-Q""4P`GHP&_F@!R0P`GLP'"J[LN&"L[\A
M+[)A3G4*+\VQ6?AP#;M@#%*XI\1)(+.''>71D*^`"X8*_PH3"0O+":G7J9U\
MX`:36JFMX+42F0M=Z)%C.X9C:PQF>+:Q%T\=-""YMT_B$3`O=%KB<`RO"EQY
MH`LOMWRZ<#(=XB&U\"$8LC+10`M&>:`*4`5!\*`+X*P)NJ")^Z!!D`#-F@!3
MB0C2.@SCX`UBTPP!L[F:^T)'\R_7R@S*(#;?H$%G^8H)X30)T99,QQ#F2A"Q
M>P_H\**I-B9R9*_3D`=\Z;M]R0`8\+MBMPY95Y<5`0(D<)@).V'.V(%HQ8%G
M$;'3>YEN%X)/T0^`T['^,&.AHKW%T)E_IZ7YL$V=%(ZO<P^G>;XK2&0ZJ!H[
M>Z?OH@\2P6N5D3[%H`=[X!N,A_\]Y!BFMT%D[_LM0$B#Z\9DYO0*G,`'H'`+
MM_"1QL"<RPD*K_`)K[`+'6D+7%@,?+`'DMK!;N`&9&`&9$#"E$JIEOH*$BD+
MMN"=&+D+7?@+`WEQ'NE/]70?_M%;!<)/6T8P'W0PN[@W'Y&W@.8.^]DA\$"K
MCQ8-D``)`EH%12`$"2K%C$NYQVJL"R"AD2O%4YD(:D`+W.&)9N129[2Y9A0.
M4Z)!U]JM+Q4.:TQ%96.N3,1$H2:B:11J`N&6]Y`')6!VYV(N)<"[PPN\_OJ[
M;U"\#*9UYO*RS(M(#YM)#,MV%Q:9$FNQ%"MBV0L")6`,M[0/.I#)R+`66N.9
MBJ4U^"#_;7M!OJM2RJ^3#^F@#.G`%M:&+&F!#LK0#-H4P.NR->S0CN$T%?2K
M`X1U;JN1#^O@RFC*8U.1#QPQF[VL/NE$+^R@9,0A!BE0!6(@J9WP":/@"=?Y
M"6R0!F1P!F1PPFX@J2$L!NE<S06:`NE,!FY0J8(@"[*P"V%+AK_@D65X<1A'
M'PZ49OY401RT'SO\M@3S9O:T(-/@#1WG(!^1N='5#D;<(;[EAY"@!E$I!$$0
MQ5-,Q<V*``8`TLZ:`#WPH"6M``E:!&A0!FK0"^!E$)XX94?S<^``5&(#5%+D
MB>0`KB_U(T_#E6;S#N@`-#+B?YX&:EP)1P\V`B?`U">@`BA@_PV]^[L<@!C"
M6\CWH`<HT-0HL&H9,0(@D`-"RLB*^6$7%G=D/9FQ=%806X(@QJ0EQFS^<`@L
M,"8D@`(X<`BOY,D=JP<G8`(G@`/@^VS]D`Y9;0(F@`-Z\&/EJP_LH`,LL`?-
MH`-,K0R_4]@X<`(E<`(HH`?I,'CZ\`<XD`/XZ]<GP`*"`!S)TLI]_=><[=FK
MD0XYD-@Q-M<L,`O7HPPX@`(A(`*`K0/+\<LX@-=`>`_L<`B8W=IZX&[Z4-A:
M_=>G#2ZW^2[7TH/RH)M+)AMGD`+BS`:?,,&WH)&@P,%N,,)B\,YDX,[H30;A
M#,)Z0,)DL`?PS)UAVX7M@7']!*@4`_\QI'H?IV4>$#,Q_L%:*(DPK#5PWS$-
M'1<R>0@=AFC$'^)<F&`&91"54^S1">K1S1K2!E``E$NA0T"L"2#B"0"L8N`&
MN=`.ZN<SE/8.;?Q>!T'3YW5&-<W&,]Y298/C`6B[3F=?;XD.#/'C(3*S@[.Y
MX8`.XS`.OS6\5.T35OV[L)P:/#.P+Y$#]C#6REA6T3M+9UW6:ZVD;E>9_841
M,F$5@&/7(T`"<92+X#MC_I`.NQT"-!L"(X`#L)P6Z;!4++#;F2S8S)T#;^.R
M%<$"X9!M9K[;:!X"%*'<@[7,+8'F<40"+#";JE$,$Y$#RJP/>Q`3PL,/+7N,
MWK)->E`1?]#_V*HQY&BN)W0N%ZKQYA61YE]-`C![/T#+O^XFM#S+'!3\"K:`
M"]>`'=AQ#;YP"Q3\"7SP"=<)""#\"8!PG5Y[G?0,"RN\ZQMYSQ;G"]:0>_U=
M9@"NAC676RU$6U[&4`6#(_]-#GE&?!_C$<!@#>X07<M%T2XCX11>!,RJ`!GN
MK!K^T0+0K`(0`"!]``>P`#TPTD'0`T$0!,E:!&)0!M2`:"L^-$-C1CUU1C3M
M4C@N7DMS-3@N(T*-HJ9A-J?6$+:[$$RD)6"B!WS<:N(`:[(VU1]`U4;AY(0,
M=G30#YY\+GF2`Q)VY9&,UHGI\\+FUM+[R)K3.DOJ#[')`LFK!X>`_PPT`Q5B
M3@(Z$)LXH"<YL$W^L`_LT!(E0/6'\.<AH`/D.Q5XGHM+S3^>/15[,`(C@`)0
M>MPB(`)_P$Q3X<DB0.=0FO)S+@CY,*?%FXLZ8*8Y8.FIK6I@#3U_H">]%AGI
M\`>B#@*0?0C$P<LQ&@)[X&/Z(`AQ=`)Z$)MPK@?ERP^6_S_X2Y<E@`RSX5BK
M&2](QK^1X8_]+1Z.BI$)Z9%H>\'X[(72X!['H/NWOT^JER`3TS#V-&;>OD(/
MAS&ZA5#;ZEO$MS>NP.ZZ^EM]>T.0P/#U3L4*(`#=[]&3:P#>;ZP)X`,$[P,^
M0/Y*<`5:\`53H`53@`1#4`14H`:_T--::?\0_$)_,R(U(O2Y)PH0Y02&*W>/
MG+ITZMPAM'?O7KEW\PK>DUA.HCIUY3!N5/<0X[QU>TJ$($G21#HZ'#IPX/"A
M)4N7'`@T8(`!YLV;'\[I`=$31(@1.O+Y(UK4Z%&D29'J4ZJ4Z5.F1I]*G>I/
M7U2K1*M"M;K5*U1].4*4,,9OJ#Y^_G20%#I4F8D0)_A=]7>(1`@]^9[B&%M,
MK[YT)TBR2)?O[U4=)DX4ZUJL!`@]5_7A"PM"!(YT^ZX>&HF"G>1#(T9$UKL.
M!X@2Q2;W0_881S]\E/>(WJ-O76Q^=B'SB[WNZI\0)/3$QH>.!>IB<_LI$WR"
M.+^U)`[QF[L'!X[_0\2U;R?.COCM[>BZCR^.[UTY=]G`D=.F39PV;-JN&?-E
M[)A]7]*.2<,VS?^T8[#!YCUP!)PF/G$$5%!`<=[+YL'V(HS/O0'?LU`;]MQ[
M3\,$&^RP0@[%`4<<:]JQQI4\\@C$%5VL*='$6ERQIA9,,,FC#"J*6&`!!1!`
M0``!?$0@`2$#"`"!!890X@HNFHSBR2C`F*222BR1Y!)$F"B""BK,&(:<<,@I
M1TQW!"J3''?`;)`<;\`D1TR(#A+H((XP.N\A@?+,\R$\Y;%HGGDR4B?00`\1
M;`223A`GI9=8<M11`@BHZ5%*7?K`&1U\0BVOICKU]%.DYEI**JU*38JN_Z32
MBFHJ5%?MRA]5Z1++!,:ZNBH'$$@HII]\^KGG!!!.2`=6?V959C+?0L-+LL#Z
MFDNRJ](I)IUHE=%C!!%TX(VRRD:H39_2CDM-LEF+P8<=[P1!-#+*'`,A!^+T
MF6V$/_J9+#;==+B7VVM'..1>8TP``8=]\3EDCT,^PX<?/1+5HYAF*./NN^_D
M\6X[\'KC[F)VP'O'G3*S>=,=#Q_$YAJ43UZP0@;AP^:8;!A,4,&9/=1F&FUB
MCA`^"7=VSV>@;1;0&G$.Q,8;^#I\[\04,0FFQ7;B:8<:5S"I&I,WS*!""`5V
M1,``(,,VX.L``#!R2""`X,*+,$YA>Y)()J&$RO]+ZKXD$2O*,*,*-\1Y<TQR
MP`$'O<'S#"?,<A#/<YR-WE&'SHP.\E.C/\N1IR.("I+(H7+0F8>B=0!U7)UB
M<$`T!!.\89321S&(E`";6'_T@W%P[6DQ4'/7G510L3*UU*JTXBHK5K-ZE:Y5
M6RUV+&0D@[6?3%.SJI]Y4`B6VWZL)P&%$[@_X031<NBJ'&"%A5:R?M+Y0P<<
M3H!+!!'TX(W<$<:]*I]U>)+N*GQ8"*Y[`((O!/#2!VL>`R_B_&%=!=/-<,[%
M+]$X,#<A@$S!^!>O=/CO)R0X`0[T\(V)A3`V%ML.Q[HC#WE@[!TCRT8Y'L2>
M!F5C0P^R$`W%X0T/(8W_9M[`X='@XXVCO0=I$<I&>S9D1"0V*$(>.F)[!)0-
M:@CH9D:[88,J%$44Y<$5K@!&B<8QHQI5+0]F$(,"S+@C`P0@;$$R0!L+8*0@
M):`'3E@;&,+@A;C);4I4JD3=5F$)O9FA#-3X6^#&5([US$E/8R*(0-3A.$AN
M!$X9<21%"G(YBCCD<X#BTSTP`CI`"60>X="#P$[`C#>TC@.Q8PD&&D"``4A`
M=H_RP#BBHX-A[4Z73<%*6IS2*=^!Y7>O,A[PBAF59Q6/*+@B"_&8$CW&S`4?
MUCO!4Z9I$A-D4S'9C,Q5V`$L%%#F,'HQ%`GJUT'3Q4\OW,J!",9UC\DP+#C3
M_[&-]5"G37SJ(#;Z:,V[[A&;?"@0+_[`QSV210(0Z*L[^KA6"/ZP3[O@Y8'[
M+!AETJ$'%I@`H4!!@3)$J+';7&RB)-1.QM8!'N]\#$UI2I,X2.:A-Y%C34RD
MJ4QE9B$E#C%I5HSBA)9H1!DV$6A2G`8U8B;%)0:U03P41S:8EH=@!*,6+9I&
M+6J1HCQ@@HQ4Z)K7!```(!F@1U\;&UD-<(`?1&%M7F!;),(P";G1S6Z76`4B
MRJ`&-=!B<.MYD^`*.2?$P0E.8_J(.NIA)T7J"4\0&93G/,>GB%`$4)Q\"#[D
ML0]CY."4=,A`[%CIV5?"SB88(.TJ5TG:6NH`!;OR1_\_=OE:3P5S5,8<9E%<
MQ3OE/454K4+>JYB)#%LQA9F,`=<UG2.9TRPF'<ME;CI\$RW!A+.X]TL'"NJG
M!V7<IH&PB6<[]S<9Q.3J7['A"ZV4P5QS+!<\_'!7#OXI&Y+(+U[YVHZ\$+4'
MB-Y%6]HI!L*HI1W;*.,0>@!?0B>6L1"2-#;B06D*,08R"(-LI6A::8,D7-,&
M@8-#0+0B@F@V(/?$3!I%;").CRC%^!C(:$:C&3>,*-,1>:@=,<NB*Z1:BV'4
M@A:8<$-6QU@$#RQ`2#\"DH\6D``WME$`!2B`#YJ`A;6R-0QO[6,?[::*N@&R
M#(F`A#=&Q->^#DY,82+'.`K_][=T#*Y."QD=)1?9V'F@0[*?TV1'-NF03.*Y
MH,6(QQ@PD('3GI:TI'V=+$<;Z%5FP`/I]25L'?TIWY$JTL*3=/*`E[S=$LM5
MNBT@N5!C#*+8"RW0[`H^FL,MA@9G5Z(N1@YRH)K21!?5DE'&2'+0J\VP99T%
MQ%6VDAF.\OVW'PTKP2&LTJMBZ.#55^%':T*``WSD8V%K<2ALB-/`R7A'+PVM
M#66:43[P``:<%\L?#G!9P'P40V#0_N@)1;HQ\G"''A&FMX0IC*8UR?1-(J(I
M$P>48ILU58DR#=&&+G2AG[4GBMJ@AL\2I-00M4P;XT#1BH*Q15?4HA4VZO$8
M/=`U_P3T2`!C*W)7D<SD`O3@!TZ00I.XT(6U4OD2JL!RW52QBC\B(F^.&%#@
M8HK(18I)Z!HA1SK0DXXRI:GH9LK38`5R'D`U=E`6L<A#XDQG.LLCD_O@QS[>
M,&BPA[T!KX1`V,W.@6^T-M2/9OND9TL47P:OMJ6*NZFP8NG>6GJ9\_2-J)8G
M/<F@("[(<TP(.AJM\BKC+\V2+K2:W9G"Y",=?,'+8?IQ&G<*(J1K>==SW(4"
M9.A%&?ZSG^0%0ZO)%.-0>[`V96*!T!R80SSR,(P"A7.ORH1`!Y])![7911F^
M"&<=^<C-`4MZ?!%V;#ORR)AW+$9">Y"#'A2N-TMCJO1W,/]Q'`7O=]&4^#,E
MMJ,]&7+03+^OC30!34/K]UG,C"H@I$VC'>.011X(X8K[5TV,6!TC!XA$I"(C
MLB#9D03XOR$`@B2`DB[H`B]@0#R:$IJKN9F[N4NP!$2@`C>8AG$X#W(8G<$2
MD_,X#X@8'7M(AX]YG,<Y"!4T)#1!.LJQB(RX.CN;,\BBP4&A"'GP,[,#.PD8
MNP8HNQT<-`X@AJ+8A[5#"M=B.TCC)20LIJ-`IMLBEF)2E=]1'KO+BH89BQ,0
M!.&)'N""E7N@IG6PE88R@>LXE,CHBG60M>":#'M")[@PB6ZZ"KX8`1+8'ARP
M+M0A+O[)0C-L'Q`8C7^Z%VJ#PY'_&"CMJ+5<Z2#?H(R&\99]80Z.RL,1");_
MH@S.R!44N(Z1*+80>C?N4#`$0[#MF#X(ZX9YH[?KZT"9(IGLR[X&:0>9ZCX/
MP1DG0J*$"Y&<8;\(>:F=>8^B0BH%R0;^X(_^Z(\&J3\;VZ(PLA$S,(,Q^@`A
M$!(A([FQ*2L#[($AN`(HF((IZ((H8*MP9"NYN81*H#F;6P6ZLH1$4`-(T,`5
M6B&AZZN8^ILQ03JCTXB-L(<Z20<Q08AW2(A!"91WR(<YVQPZ\R2*\!P9?`<Y
MHP@_ZZP_DTC2ZJP&>(`&D`")/"V*Q``/2#NE2$(E?"TJS!VW`R:J,)[A01Z_
MJXKJNHO1_\@*Z!D!$S"&^U$'ZVH\J\"'4B*)GSB!X7">-1P!%C@?R2@&P?L)
MFE0M"B(8Y!H+/;`NI3R!?V$VRF"'4M(4$]"#S\"]T4.4GT`!/2@!$O@#W,.'
M_#E$%!`/ROB#.ZR-B]&'8F"!N]@@'%"-[?B#`B.)$3B!/9`VXK@'4#0I[FB^
MDO*.VS@I?'"';LB9]%@I=TC%E8+%%?*;#J1%FB(:730X#8DB_VBX*.(/H_I%
MSFPB;%@X^*"&:3#&^*"B!M&%90P$J[F:9QPCK1FRKUFCLC*``DB`(?!-(%""
M)9B"*,`"!VQ`MHJ;N9DK+%/'58"$47C'F`*S>N0K,%L/]1"<1/]Z$W\\")"Q
M$_`<R#A3AW78"(&XAX?,I'EX!_5LSWL8AEC`.&#8(F"HS_B4S_JLA1OC!6`0
MAF$`AF%("]=RK49;.Y%4NY&4PE/9I>`))KPC'MMR0I4\'JWHAW4HAD,X!&K)
MBG0X!'.Q%60H!K_@"L#8`SW0@SW84*A(-Q$]#.=)GP%#4658CA/=%4\K`63H
MT!,]!&5()L=3GQ/]@\B[H*M`AQ@5A.7*T,+8I][`4$$H!H7!AV90TGWQI@'3
M`3TXA$;D#AW%4@V]H(\B-[:<&`=[-Y):!WFLOLR1L'=8(7=P4YEJ4W'(OEFD
M19QI(IS!F=8T&FE835_(#U_HCP-I.`7_4<T\53&&,Y`'*2(6\Y!AN#_97!$;
M&2/;?(.M88"R"JNP(AL#2(`D&0)018(E@`(H&4<&?*MR/$><6]4_<H1W;-,Y
M^2O`.B1[1(]8-;JB<YP2M`=8?:2%2+,\$<&,N`?V'$B'Z`A-4LC/0=9]F(=]
MV`=ZZ+IGK8=[,(Q]6)AGY0=Y&(=Q$%"T4-`D'-`$'==&B[23G#N4O+0J)";G
M,:95T0LGS+MO#:[@2D+':T-;.;9^\!5HX0NR`!>#-$J)`2_#(+Z"!2_PVB??
MJ%:`72<`>Q8F]='ZD@QI>Z]]R8?/*%B,K:AV*Z&)B@U0'-.+245ZF[>/B0=;
M;=,WA4RE>REQ_QB'[O./FP'&F\$&:6!-_]B//@54::"&_#"0ALO3FW$B!>$9
M^(`B(YJ&6A2'8;@XC*L1K8)&K:$"##"KW!RYLC*2(RE`4!T"(E""!'R2XXR"
M/)H$NV'5584$:AB'.*'5P8)5.#F/C'`'I(.3Y6(SCEA/@FR<8,4(/5G/C'"<
M0+&(DZ(L/,.SA,0S@ZQ6@VQ6>>@Z?=",?N`'UT(+*CS0<>T=D_PEWCFF*Y0T
MHXB[JJ@[K7@6"'4>5DG=5Q&UXX$6X3%*V(U=??#78Y$,'T4+V<W=@846B8F7
MCIV8]YI8>-(.P-0.4'P@!#M>!7L@!].8!<.'Z)N^>:,'E:T^EZI'I?^;OW=H
M!Y=M$&O0!J+Q$`/I#_VXV6.`AOS0C_T0$-5<&:+:&3UEN)XRHN^SD`'QCV&P
ML10)!*R26JWA``5H(P$6`#C*32-)HR$YLB0Q@B1X`BEXDBQ@*R^`JW*D.9RK
MAE6MAFIPAW'@(1P"!P]N$S<A,[^RQY]SI'U4!WO0VZCCI(H07#N#L_$<ULE:
MUCN;P4RZP7EHW!TVC,>]A[F07'O95\E5E0$MH%#SI<G-7"4\R7-]0L^%T`7M
MK5&Y.RDN'BKDK=.E8A)52=3M"M*C%M>-W=O-73.6#(J"IRJMK]YE8R;EEM\]
M,,LRWO%@A^9%3+3\6*4CV<B$,.P=&:5[DW;_$`=9?!,.6:)C9#$!*=_U#9";
M[0\).<W2Q%.B1:J#BQ"E_:$3N3\?FU1HM%2N$F`E^ZH@(6"M#8`V&I($"((>
M:.`'CH(%1%6SY:/FQ&!UM(14&&1OF`9O^(5C"!!O8(80AMD.]KGI_,XW;=-(
M"MRH&QVJVXC)6DCU#!1EQ3K)XA6*:-Q[L(=]H(AGO:R"U59I+:#)W=>GV-=]
M;2T"[;0('<D"'5>W*\DG?F<'E5"95";?L1=G\F)^EE=]UCOD.9\VW`,L'4.F
M>)8LQEVP.&/;56C^0=AH@V,P?6,1DK:'CN/"S.,\!@]2-,SCQ8?I(X=NH#"1
MR0:E$QGW(+B<\9LY_UTA#EF9`#F&__"/8V1-;#BJHK7%$,M%^+U%]0.X7\2A
M+PH&+5*1_J6#9Z2"CV,`'R&Y-3(;(-':-BK`'F!@XI0"4@U'68X$KKZ2N<H2
M*W`$$<&A$(:_-AF<P!*ZPL&(A>!5874<?7PDA5AAT1E(\51(N[[!CD!3A<RS
MA#1(?E#<Q;6'R>VZ(-X'O4!G=#YGM%!L41')=VX*S$50)H:M<NW<N6O0=K8*
MT]TTX+'7KJA<=6W=?,V[TN9L(S3C-F0VA?;1,C9CB<8'[DI8VJZHA.W=X@K3
M3Z28[QC%.0;9%%(^<EA4XEY4!;D&8SR&/_W9@1-?;`C4`/&%7Y!N__"%G/\U
M1A)SF4=NS?8]S?Z((M2<$*$ZHO.C7VLXFBQJ&FBTS:0VHR`1P*A6HS1ZHP/N
MS1\`@BMHX"=(`BBX@BSX[RRP`B50`E'-@DCHHTCP@0-(`"OHA7(8A[Y*,S&Y
MVV`M.GXLDS&A6\?)1WW4U85(9KIU!U[=QZBKA_+D1Q5.87MHB!5788.TA\&&
M\8;`LQ5>W%[Q%5ZY\:L0M71>XB%6.]!NPB/LE`*=[,KFW+>+;,YE"GLI2;4C
MW2MNK98D'GTNIG^F4'DE;=0-:%N)%<=C[8!V:#`WRKEX;3?VW7NQ:'WHRC/_
M6./%XQ%:WHP&V8G*AFN`!F-`F3R'AINV#P$Y7YW_]07EMNY`31`@.@:R5B+Q
M=9D5HP;P5A#]L%F:=M\#84U'-UJ?XFDG8B(@BBK^Q2JDIH,\"/4R\I$UBNJ1
M.^4#[M2T28(D6()7?X(E`((AZ`%;[X$$.(`>.((LH(1)F((@"`(%2(-IZ,`1
M!)D,/Y.8LH?O9.O1P5MRB(<+CQQ$`H?N7(^]T@:$D)-`R0A_Q`A[6(==W>9T
M8/%TJ(=H+O=MGO%J;?=[Z&;$[I4;)V+84&PF5[MYE4(C/_+,=;MSC<(I7$)*
M4Q5Z#J8@9U?//EV[(]'BP=U]SKMDZO+456C.7FW8E6@+`JBS/)_?19>,]@Z.
MX>B0TFA2Q`<[MW-HP`5?_X`&/$??F\WS/X>0YYZ&Z?:%7ECN/[W3*;)%)9J0
M(O+YA=,9AC.:T;QIFU40F?T/*6(BB'L/$QGJBZL1K)I4_BNC5`>KL.+---):
MLS&`'@!;*'#U)5@"(\#U`@P"(BC['O`!)_@"2HB$*4""(&`"7$@DE?4Y#*]5
M.K&'<N#'7?7.%'2A-\D(DRDBE\D&F#%ZF!EN]7`';>"KIDO!0GJ379WK02GW
M<E]A?OSK@L4'S>`Z>Q]BRFVMJ`C7(?^4?>?WW0'X!4T+*"?R2>LEV8K0!@US
M?GY==_WBKT!X+1;H,3Z?U_[R9*+HLXPVW/N,*'WCCZ9CY"..,6W>WB"AVRCN
M^?\PAIPQAI;'<_H0=)KA96RH^>7^A5_H#_#WY4!]HI69&:2:HNV>D">*&<.'
M#YU.HOIM#Q>Q!F*(JF"83Q4)A&`(!(`(%"A/'E=T%`@0$`````,&#B1(`-%A
M@``%$@`QL@3*DB1&@O2`F*!'D"%!?/SX\>1+)4E9LC!1)(X<N7<TRY%S5\Z=
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MO_@RS32^_)+@-,=@T^`Q!/K2BR\(2B/-,15B$V"&#6K3H38']H*+A-),XZ$V
M^.%G8H?B:"..BRQZ>&$VUEA#S##!X!B,*X$0X@J.P+@2I"MY<.`00P`(4,`!
M/8240`$&5(1`#T,DL=$21AB1Q!$^,.G#$TQ``8441QPAQ2241/*%),]8\XY.
MY;A9#DX[N?D.3C2=:,PU^^EW_XU9>DZH)Y_Z#:K?+H0B:DPOQNR""Z'9>/74
MGWORN:=22=T5%3AXM767.H#]U5=?^_1UCZF3[=./JHPAYT\^H$4F6VBW@>::
MK;?B>EIEN9JV*Z^Q?N9K:[)6MFMEP\86K&3#(5<<L\8--RMPFBW6W&7/43M9
M<]-5ET^WWV:WG77L;"=NN>R)ARYY^,B3[KKXK!/>NNN9=U@VT/`WGU+[0JK-
M61DRV"""$Q)<8('3).B++@3_,DV`D%X(((`<&JB--!.2R*$V#5)#38/VK6@B
M-AYF<V&`TD`C#8TXUJACD"[KB,F.`HFA@`$",)3DDEQ&9,"3"0R!1)5+/%%T
M%%%``?\$$$YX$4DD7G0QQ1%/9#'))$VG,HV<.L65C38W\;23.^2890LLMX`"
M"RAHXW(H+KY`T_8KAT*SRRNPV&++*W?OTO<NL-C]"BB?[`T+H_IADVF??.)"
MJ:9E<76I7#@!]9<Z]]BS3CZ&K2///9>KL_DZA.F3#V.4W4;;;)71ZBMMOO(:
M^ZVTHD;[:9C9GAKKJGD&[&.8"3M;;:)!2[SQP>MFV6W1+I>9<I=1BUENE$EF
M.K?F8G<N=^2FVWWW[(3WWKSIOJ<NV4J=>(PVX)!]XOH->D6-.-C,[Y7`#4]C
M_W\3&HC---Y4Q4\-"M#&J-&A:5##%Q[SG\=4=)_Z:"QD)=K_F(4J="&P',,:
M.0H&,8(A,QT1Q&4^&H@9J&`SG`G@`#SP`99^T(,$("`!"U`"#3<RA2Q$H0LZ
MY$(4N-`TJT5":F6:1"4J<0E+X&)D_2('@X[A%CR]0QO7P`4N!#<X4&!Q;E0\
ME'YP48R^51$4>QOC&&$!BS%^@@]\(.,KBI$HLT"#48[R(I_^%)6FW*DG>,&<
MJ>Q1F'R(ZB_W*,<]UJ$YS96N,)NA'NXV$QEKZ29WN(*=["KI&E]1DC22M!7M
M,ID\QQP+69YD3/*(%YG&+`LVOHF-]%))'-8XAC;-F\YB\.$MZ]RREMK1QWIX
MZ1WR%=(]Y2-/NZI3S/6T:UWK(AO[_TQ$$_2!8WW:\`;\_-<@"#WH?]2$GS>\
M\3]L>$,<2ID/`3E$OPZ-3$4M6B<Z(86^C7T(G1[3D%<J9!\-UDB#'L21*WH$
M#!WQ4V9$*H!"4L@#C1BA!T!XH0R'H`2-/"$*6=!A%[S@A3`T31*2(&(DBC:%
M*4SB$JI@Q=N\H@TG'B,IS(@F5W!Q1EQ\`A1J%`0H!#$W8]S4%XRR6QIGNL97
M'$*-/UVC&O?`!Z,258QG9",LBN'%MK5-/UE1"E[*D1>\7.YS6:V'(`5YF'D8
MQC"F,E5838<8Q*AJ6ZHZ)6QJ=9M'AF97F[3D)$<#/+J2QI.BH5ZN[LJ[W41+
ME9)!Y6Z<Q_\\WR"6-:V$'G"6LRU:?N>7XOJ.]KSGO7>%3SV8A4]U[*$6?NT+
MGN(<656B0EIL3*Q!9!%',R,'%6/XZUX[C6,<?7$?^RC1:_2YT'S@IB?Z[`E`
M)@M4+^KFB[9!PQO$((8SG-%!(`%#%_QTV3]=`:0\B&$!4!*``7J@$1=RZ84+
M"!I$(SI1BU[4:D6\1"4B(87W2B$2EJA&-5)1"P-=XZ2H;53?SIA&PJGQ;F8T
M5"Z,P0M?V`T0/16J&@%1U#7&XA6`>,51W>`&,K@!J7P01!HIS,9B&`YP?2/4
M,58ZIZ:$ZG.!#%57QRK6L<+X<_?@QQ_OP2K&3$95Q*,=*&>%F]W_*0NO=>75
M7(.<*UG9BI+%>LQJ".L\P9825LEY36X*JQG5)98?V[IRM:YGRUU&-K*5_9YX
MTK,N,QNS.O-R#WO.MXULS`=DZ(3?,2!U'Z6(TVMX)EN>IP$-6_P-%%2TQ2W4
M)KA;/`,7MW@;P8Y!VUW$C8JXL(6B[W8+2B]ZT8.F(MXF?8M"GRT7O%BN<W-4
MBPWF"!C_!*$9Q"`$[08@A49X0D*#\!$FG<0(2%C"1G*8WC,9\1*7F$2:I+"$
M*3CM$JN(1C3^8PP$Z^T5K7C%)Z8MX6EWN'"VD(49`<<H,Q9N;X+@PX3)33A"
MV:W"%TX#AHE*[@E[6,`C'O%8K%J.<(0#_RER*B0?8XR.=VBU5#6&,>?RL0Y3
M'=QZB''E[W##2.'%5<@2'PTF4:/7VN65-,B"\L:--[PC4UDX4:YRLI@3RUDN
M2WHF]_*7LQ?F7Z)+S9;U'O@X*QXXQWF*T,`8;JNY<_JX,T-^JM!QU8;%HR.=
M$T>_14Q?H6E*AZB*A)/I)ZIN]9@V_=)MTSJA1X$WHYM1%LLEQCF(H8M3<S`8
MP*A%D%1-#%77`A*M'L(!H!2``R!A"DOP@0^4@(0@`![P6$I"1+E0T4B$5-FK
M6,6POR!$9`N[&B(2,;;+V#=`./BH/\6;,<P&"UEH!2R$R@^XO^@W7GS;&&=\
M,"`X;%.^+=6,A__:BE9VDI?;KT-.NI=3.ECLEZQ^CI""7(<]\G*/=/#;5%DU
M73[ZT7S4X:;'M2J-7*<_\4H6V?H0%S*22XGDZL=5Y#Z.9&8R2<KA(6M:)5^>
M+&GY6%VV7)?EFBS,U5,=\\0KF=593[S8Q9[RC8=L00/:"-JGW0)L5=,U(%C;
M0-J%&,.D-0JAG4TI6)%,<8)0-0*#72`?5)VEB1':4!L6$0Z%M4('GLT9:5VA
MY<T*:EVCX,(PC%W9J5TPP"`_!4DMJ-HP#`,UI`(:%(%V*81%!`'2&$'?/53@
MV1J6%`T68$$7()Y(+9XJ7$(028'4Q)>P6<(M2!NX61LL%!@L9!Z#[8W_5/4-
M@@2,G55%-/G+VX3%LQW#+N3"+O`"+_R-X3"*O!G#%]FAH7`15)0#7K@#.%C5
M4.R>G%S..@#&I_B%7PB<J<S#P<48YSB?8>C#/BS+L/B5*1W/]GG<]<65Z^!*
M]NE*K5R<K'2?QHU?)@&9E4G2\]1&:QS+DU%9MB1'\T0/[EQB+>GB+?%BF''/
M_LU<9L%+S&5',>&#>;##NEP#OH21)X!"*6A:!:',A$C:+@#:SE'1`Q;:+<3-
MX'"@!?(!&Z@1&Z3!&:3!'K@!'W!"TP$.@FDA!ZY1*TR;/'Z"+?1"B%BC-:Z@
M/4[(+HS(+YR#<XW=,`##<J%:+>"@-90#-W!#_S4D@A4L``+<3$+T0!(X`:\9
MP1%@R4;FFA)<P15@P10X8>)AH14&T4=%0B6D`BV<D1=^W5))VQA-6"Q\WB[H
ME.C9I%2M#Z0((D]X!5B<5%9`"*$P`U&^81^2F%<@3DJ1Q?K(A5#`A9RL0UX`
M'(P%TB**E5@!GXNYV'0@A^W`%2=JG"B*HB<F&<994F"E'RIZ!BRUI6?8CFR4
M9;"8XFL`2V(EBY9-QR728G>$RU^.RW+\HGCX4GK('+H44S&]R[M4AS$4&A89
MH*-T!='UXQ8-6MXTRK>]`J#AU']AD1I=H$P=E3BJ44\1CBT<ERU4G8)16RN<
MD6O:HX3T`FK:),84S/\](@ASE=UR$>3;!4.-\.8P6$,[T$,W;$-])4(9%,$0
M:)=#6.04?`%'/!1'G@006.051,$4>(%Z34(81,*6E`F93($6?($ET(+?H&?@
MO((LR`)Z)@BB2$-0!@PXF452P(D[I(-\.IM.E>%.W22#*(/7,`,SZ)E:;`I9
M,(7N,<7MY46*,6(C`M+F_%XBWA[R;8Z$;@ZKK`ID]`-EY)BV1(OOF.7UY<Y<
M1MR(HL8JG:AHQ.+(M57$N2)>OFA>/MFT+))G5,LB74<MY9*WY-)US!PQQAS_
MV1^1P@<[R,,#NM2E!<H#_63$E&$$,B!FSB8_OJ$*[HT8[8U+[0WAE*""<6#_
M*]#";)9@M;DF2P):HQQ7P6C(,>1/_DQ(+TA#@@Q#,NRF#K[=V"T7C5B#/!1G
M-QCG-CR#*80"(A1!`BA$#SR!14W!$WC$1K80$"A!$D!!=J97&&"4>Y&)`O``
M#R"!%FB!)2"(-S`(.#21,<2"W^1"JLIA@B3(@X#%3VX,62!%@D93-(%%P8P8
M@MUD@*:#59#%2FE%6M1J.NP$[]G;/)1#(C:BY8C*/:!#7]R>C-D#/KB8]5@/
M*N$8DU7+*0$9]=B&7AF+D(%BD%59]NF5))7K8WCKB<KH*;*H7<GKO.9.AQZ'
MBB*6DPT6;I"+<5Q+8_5E+%E/Z>@B96W/_DW6>@AC_Y`.(S#N'YNM"\X]&Z15
M2(O869OZAU;89&U2FL3H*L%T7IJ:S:3EC1G1@CS.(][H(S]2")M>2/]D@P&Y
M"#4@3,$@T"QPT#DT@W`6Y'*=0]G12#O$`ST0+:`"ZC9$0P\.`0)(9`](@0X=
MP0\8`0U!:A)8K1-$5!1<%$9%316*":\APA=\`2G\PC$`$#BPUH`:@R[\`B\,
M`R_$H=\L3,.H#U"6&/L\T1/A;3H@!6MA`S-0$S.T88EEPTHQ0WXB!09!A3(@
MA;'^(8/J7NXM*YP04H,BXJ<P:%Y,I:E8*X;F`S_L@W7HF+:&TJI0!RKIF(F2
M*_4%R^CF1L7AE>DN1H<ZQO]@Y"*\KFB3?=QJ+,]>S2A?P1+RL,8H/5D_"$,?
M+`.4L=*_TF+U1$?+06_!,JS,(>G#QMR9D4]UD(U2#M#(B-,V#5#"@$7^N.E_
M"$R<KF`NY$*:(MCZ1HB$;&R$1(B:4B.!^(^;%@B&R(_76).+-`C"&$@`>\6`
M"J0WP"`,V@@SB`,\P,/0T@,#`RHW!&HJ6$$1V,S=]0#?H<01),%#26H'*P$4
M.$$/791%14W4!)'3(-Z:=%/]V`\S#,,OO&W;ZH(NH*<-,T/9FBHSK`_BZIL@
M(JC7K$]*08S9ZO#=`BY3A(-;\##CWNVFK(\AWIZSRHF=/"M@:)7QJ</FDA7!
M7:C_Z="NLG1H*^5#,@R"'PS"(!#"(`2#,VCHQ46<ZK(&N=AKQ@7+,>K8K8QK
M:FR&,Q#"'_O!'Q>"&A,R(00".W2BE;VE)K&E]QG9)TY?*,4K*.GN:P3"#23#
M8`U++&6+8K7E<SP68`*IPUZ6>+`9D@)@D+)#.>B9`)F3@\RGF](9_+3(^`Y,
M+L1IP<@O@K3-B'R%5OC'!6E(`!^(PYBO.140,1N(BVB#-="L@."I#K(=)F!"
M*_@"`T-P-W`#-G<#/!AG-9`"(U0!`A0`0Q1`#_R`=5IM!ZNS$S@!=OH01N'0
M%%1A?*FP)*0"-9`J!HD>,^C4A+2MJ]KP+#"*+H3>26D#_S.HEE5T2-ZZ15.L
MSZ8H-#@`T$I]EB#>FUR`0[Y=R@#?[?I\"CIHKIT,TB*.%>@<(K3ZQ<&M0SIX
M2Q>'E?-98F8LUF*PPR#(P`W$01S<@`W0@`T,`COD,8I^AB',@3"<W\<UQB#8
MP3*,+NSR<8H*`QSTM`W8P`W,0`W<P%;W-!PD`Y)]WVX05L?Y;EOR6&?T6*RX
M(O'`JW+H`R'40":''"S9*"U!5BY%;V2E<I%Z#SJ01S+""V!7+SZT13;D656,
MC"_,)P3!3_[44Q/Y3\WJLAGJLC%82,!00WS6T\D0W?WF3\=$=F33K/Q,@S5$
M=@!;0P`GT#$,@RQ0,R:X01Y@`O\N=`,];$,[4$,V1,,VP\,#&^TV`+<F,(&3
M`,`YI[/52JJD7@$4?&047`$7@$$81(V65"%*6H(EX+,O>(-^"2Z"\$)`Z^`P
M&'&"%.6K.HC@FBHX'*[A/M&=V`E2)'2)(;%ZRT4ZA$-3X.T2\VV^\>U*Q05>
MB+0Z#&(^>(XC*E\ZH$."LS3"/2*,0:+F9"MP4`]AK8H=R``A.$,R+`,Q"(,<
MR(`="'7L+!G%05P_^,&%DQSUL8,=T(`A<,:(JLHZ.,,RT+@R"$,-Q($PT+B&
M$P.Y)#*)KVCJ"@\G?Q):"P<^4$8I>ISZA48AQ#7'L9)SN)(C:1EWE([!A@OW
M\%+Y['7_]RRF]T"L.BS%B_#O_(A#.+D/VKX(-<WG@@#P_PHP0"OVA%R#/4F#
M?5Q#;E?(GB\C_AQ(@!C(,Y^,-BB0`(^,,I=(A?2"+F!"'HBI/6:#.P`WL^%+
M;K>#!/<V-V0#H%8#(T`DE!Q`.JOSI$[J=6+!<V]M%SB!>#K-=4?")62-:6/#
M+WA%H/Q"#NM@B733+W13KP<N@<IG?I`6K;)/5:B/X#:10OMW52'%V1([@O*W
M4)"TY0BX20^2(88#@\I8C%UKAC:&EK4*[PX6/@Q"#!!#K*C*BM-`(0#Y(O^*
M:#B7CY?UKNA#AH>X'/<*BZ+N*:T#',C!PC5R)XK[^-T*[F*&_S,,PCD(UK9N
M7(K#(B'<@#!0TI0ISR6^'XYA3_R!V?06(S*]A\*VBV&*ATVX"$V\R#DU")NK
ME@M[10`'S(*$-FH1S(%4T_UN2("XZ9Y?#(!(`\U*S)P^LS493`)-@SB4B("@
M-@)=3"^T0C7G0B],0SNT0S0\PS-$`RT\0\=D`S?$@S=O^M%6`RN@@9.$^JJO
M<Q(``11<)W9>01>$07=^01?`EPI/P26XPSO,SWA/R(%]=P[GL#<,:%6$TVJ1
MA:MVQ4J!4S>E?%$&S("NE#*DU.%B-*T^$=^20[8[KNX)!:BPF("CP[W=6[9G
M>X(_8H-'8EE5(F1HZ/""4F.<.#)PJ_^J)`,-X`$^`'GW^57K*S(I[3%H,,M:
MI959BV7#I8:SQ!4[U(`<A'CY,=RYRH:PJ-RYWN7JP&5GT(HAR(`P^'X>.Y^[
MLG5<\0/$)T.+)@MCS5*72<^V8(>W%*Q@)NPOI?+"?OEXO`?>C\V+,'/1UX]C
MTY,WI7SY`@2V:<=^^1+H:]HT@0JQ91.(#1LUAMB.)4SH"R&V7Q:I2:-6T&)(
MC+XV5L1FL.)%DANET<KC2M:T=MRB/7M&BU:M6M2H<>/6#5XWH?2Z;3.:R@J"
M`T::.'&:),D5(%"O7,&"A4N826'"1(HD14H7KY8N<:M7SYW&7\R&\>)EC."O
M7Q2/8?-&5YO_-V_@]'K[98Q9X&/,!LNEZ(V9-VU\]S(#!XY9NFR!%S]^7.YQ
MN'#E.*L+ITY=.7*;RX4N/0_T.\Z<-8<[]QE=.G7KYJU3=Z_VO7OK\N73W5M?
M<.']^.GCQ\\?\G[^]/610<Q?='W,G<69@T\Y<>;1H_=;'MS[<N[<EQ,OO]V?
M]_3JIW>?KGY\_.#IZ;]?_QUY?OK[N>OK9\Z&.=A!C[GWC&LOG_+Z>8^]].8K
MCY_E]"OPON+\6_"[?H21(9CNX%,N'_J0NS`Y"4GLAY`;DH&O/>G0.Y"YX[8+
MSD(+]<'GQN#PP1$?=H33AQT<;]R1R!V#+!(?=(H\DDDBE7Q'G"BC_]0&&VLF
M@@@BC+#$LJZ0Y$H(RX$8$LFD+*5!*"1I+++&RH1^Z>47GG0Y,R,T%TKHS%[T
MQ$@::7Z1II67=)G&IVAPTNF9FGCZZ:>ABC)JFT2JZ,&'IIQR0@D@E$A"B:H\
M]6(2KT3]2M2R[-FGGG>.\<4M8TA*[!B]F-&&F5^.N747N2J2BU=CX+K5+KWX
MLLNRQ@+#)K#''`,GG-'*2:><9LE)Q]G5K.5LGGE4ZXPS=-XA#31T9JMMGMUT
M^^W<>WKKK9]\AE-NN^_\D"$9]+Q+YH9!$M2,'WR2(228Z8)S1IA""A'&Q_62
M8XZ=9`P91)AF+%S'&7;,Z^><APE9YD1TG/]AD#IA#"%$F(_5\XZ=<_#IQYF1
M"4$&'_K$BV\[=FR0`YW^7*18&$(*(::9'_,Q)YQ^V.EY1>_Z34:80(11!KMS
MSO'0GZ,--@1J__!Q9IE!9-@X&6?J$6\=9$869IF8D9-.GWR2"8800I+!,<45
MQYNO/H$+%-BXXI+[\4=\\MEQ2.%\')+(&X]$DLC%V9$'2<AW7`<?**44!QO,
M+X\R\\RCU`LBA0:J*Z6[[@03(2W11/WT@O@,"?9I^MQ(=&RHG";U7FRAQ19;
M>B')35I:J25.;K:QJ1=JHJF%EF>@H48;;L@1JAMZZ-GF458L*<('("YUHBJH
MQ*_*"2F\\$**44?_O60;>]RO1QUQ>OW%&X(&@TRCNVZ5RYMIYO<%+L9@3%\8
M`QF]T(I6DSF&92PC&LZ08S3D>`P$P5$:=+"&'-?JS`5-TRW0T`:$M+E-.GQC
MKG.U33?]V(=_6)BAX."!!O4RD#/D0*]V!:(.R_"##61@AY5I2`XW$.(-XA`P
MI44G&4$4(@WB,`B+`6,.]5I0(>)@@RK:8!#F$`\AYF"R!1EB#C00HA4)L0X&
M"2.*8+2B#6S0AP$UR$7=,<<-<$8S?CC##W&H`1'A((>D5<T/?5B&'7@X"($1
MXPY5U*,-_)`,/]AA'1'2QS+N8`,XW,`&-RC$=-"!AQO40`9B9*1P!LG$_T_>
M@!!J<]`R^B#$.,"!!G9(1B%4])WNW,U%TQD1A>8#N!P)Z9>^%!*.%K<DQE&N
M2$HR$C(K-PYWD&-ST?2&YC`7NKKT#YL/"9-(I/$[UL7.(G3RQ9DL(HYI4,.<
ML$LGGGRQIY&T$R,*L88O7-&*7LBD&S2)!O3.:2A:[),;,VD'4![UJ&ILH0=`
M>,+WG+"$)7#J"IWRU!:ZP)4P4&(2&:W$):H1CWK0XU3V4)4N=I$K9F!D@7JA
MWUVTD5+&$(8PM[H5.1+#P,989C',P(:RPJ$7<>SE,<(:#5\R`XYJ68LTG+%-
M:4`3+G&M@S;ET`T([Y&.<PFN-RO4QPH7)!P'I?^G.%Z#V-L*%H<8.#&L=*R#
MW,P1'$,$*&SF$(8<;"",!#%'&'"(0R'.P34_T,"0;ZV7/_!EAV68@Y4T,$1[
M\N@,[^!C$#:0I3.<D8Q*VN&-^C#$#1))B&:80QDP)(1QO-,BG;&C!G-8!\WT
M$8@X;.RSPJ#C,KYSAQK(H0Z&2`8ZIFB=DG%M$$2DH\4F&8<XE,P<R>@#%G&$
M#&'8009],(0AB+$@?+W6&<F%H1_`0U@ZP&%CYG`&%&]V`V'$L3[I?5%T_,8W
M7][(73PRG(Z`-,QB&K-(R-3O,2%(#G=8+IJ7PY+IZ@*16`GD5F`:DT#4E)"4
M*#AT%ND2EJQDSBA-PYS_VF@3[OR'N]_]J<%6^M)"?-$*5TQC'$+A24\"ZI,5
M\R0;V>`&/()2/>QA;Q$]^,$3GB"%[XDO"5"`"A"JH@4P7)02E5#R)3@*%'N`
MU!ZI`H<Q<J6K8?C/+_RCS`!A.IC`4"8QP5(,8<`Q&6U4!AQYL4PXC/K3O@"5
MS1',X`/'$:W5H&,>\B@'.F"#9]ED"\^XR4VZTA4<=_WH/`O[#AYF0`,9S&`&
MH7SM:I,SB!G$P1DABHXSX(!9A3G##G`PQZ;C4`=G*`P?PFBK8)DS"!HL8SWK
M,,2IF>.'&SC6'\&X@1_>F!YVO-60S#&$#&H@C`L!20YPF)HMT>L/=-Q`M>@%
M_]+'%"8,&RQV0<[!['FJT\63Z2,9<9"!'"S&#CO$@6,.6H<?BEV<?@S[O!<R
M-[J/@[+("F,YYE81R$`M@UKJ;+T4:J][9?0WX0"S<(<[..(8=]\>,9,=1Z)<
MQ.6!S'=`R1V7P["4!ES-:5CCFIP+TTKNA+E5A42;L-,&A!5B80Q_/':I^].7
M1&>1.XWS3("JA3:"PHT5^X3&,_'Y/J.QSZ!LPWI"P5XJE&`IIS0!*DX8'Z>,
M(-$O@"')2JZ$*BZQBFI4`WL@W4<_ZE&.7^B"%[;R'Z^^G"R8RB6F<$=,_9"E
M$8I0R<N.659/O3$.:6G&&Q(T:@0KJ$$-WJ,TFF%-./]00QMTK$,VZ;"J;=:1
M+M^LRS^')@[?%-8<&0S"$(68KC#202)^6)H0I5W0(-X`ZQ<EX]K>8?=@9U8>
M0]`@8/IP-;[M$1[_U/H&RNC'.N00AU&?S&AVN($6^3%L/*@R.(1X-2Y-:[3;
M4KK9S/D..^3`7>;<00;X[@X^0BW%\VCVMKRU=C!&)#!SP,$/:QOV8*,C6VQK
MWQ_5N8-_WDJ(M5'H'.)@!J2(M?BCEW3I1PS.1H0)X0JG1^B+<2*PF)H$2:`$
MF@*,XSC.<[1!Y*[$+EIN(>:)(EZNYLH$=B""&B)BG:9AY1(BG3:"3_3$(FA'
M)-II(WY!%J0A'N#!YSZ"&MK_0>A\0@AI`NB*@BB(`BBB(0N:PNF28"J20.J@
M`@F,(`BL+NLN8:.Z#NS`SLG&IA[(P1=V(>V&X1>&H2UXH:36`C!JA1>8P1C6
MHE9JRBX2HU80@Z;V`C&^+*CZHC4$KS6:A322RLXX8QST3![XS,XVPS,LZ#:>
M:C9NXS8J3S?T05W6!4/:AH4*)+[F9;#^#V_\P6OLACG(SX_,P1S80;P:Y@;L
M(!_F80[(C3S&@Q\*P0:(`3F$X;8,066D0SUL#=:4(5]D43HVY+S\8=@,89>B
MPQ`&4#QFIC_^XV;,*#Y&I$>XAF#B@+N"HY5P+3K,(0[VC]DVC8[6H1]:21C.
MP10K_X8=:$A`I@/>XB6X?@L5Q0O4VG$;VZ\_!J$&Z._W3"L9!6:7VN\`64B8
M%"Y'%LY'(E`A@T1R)L=(Y`&:QD$;W($#`\QS3$=S0@?DJ(0B1C#"Q&1-'@R<
M.$(A&JP%S^R<+&*<1N)W&FP&SPF>X,0:3J(7Q($>VF'%K$&@@H(G@8('?2(>
M9LQZZ"$HKF<+RD<*%LH)IN()@0P(@J#JH"`+OF`2E"S)+*$:A.+KN)`>ZL%]
MW@$;7$4NW,(MQ)`LW]`-X2X.XW#N$F,:@$K,Y#!6WDQ8BJJHZK*_FF4068,U
MH"4=-D,S0D-<[@$=T.$>;H/0SB4?>".KWJNK-L\YZF5$%O_DEO2!$&2`UI!C
M'030N#K3N&Y`!N9`'P"$NYQQ/&B)MOH!'ZCHTNQ@$)3!/H)+&?Q!&&;`$&Z)
M/)9AUZ:C-@F0.^:/0&BF:J(Q.(O#D>9`KUYI!OI`8)2/'+E#&3X/`9N1'>Y`
M#LQ(#O9(KX0K#D#3!A+F':7##F8`VKJ3B+JS!KX3'^)`#E9&/F@S#NQ&;]K#
MM.CS;V:$EWYD`0]2OA2'`1422>JK<9;D'<;A`J=D<Z8)(D1N(;:DI5)BP`2"
M`ST23`["?Y*GG-+$(#;,3:8!3M:NF_PD=B3B3?P$(VSE&*3!'>"!&M"$)P1*
M*'B2QG[R)X;21K>A$J(`+))R*:'_4.JB,`F,@`B,P`@<:@K$(A(R2A60CBBV
MH1I8@0OAP2OG01M<A2RO-##&4`WC$"U/BDO9SE:^K'[:+O#(H1F\H1D,R!N^
M05;R,#'8C%GR\EH^(ZD^`S003QW^K#`IC]!\8X4J,:M\#SPV+Q3CA;6\YM3$
M`QVZ<Q`(81`*H5$)(1`@1A^<H8U^3S@W"SI*ZQR$`0_$#0X6*SKR:#:#80:*
M,3[Z03='BS;#+Y?>C4,\43[^X_H`;C4#!&*681GFRH>^[P8L!CIKP)":<3VX
MC]STP0YJH`_BAED=U0\,X="(<4:2=5D%H5GCQA!PY!57RZL*1+;HCV9FICW^
MD?..PS@*_V0_^;-PYBLA!]1=>P1>\0&J\*'BY'5',DX<_FMS*O*G.*>:2`Q,
M&NPN0`<A$JS`4##"5B=VU&0AS&DF84<BX.1,Y,)/9@=X_.<C2&(DJ"$HGZ$7
MK(1-9JPGJ4<H&J5Z;+1)64$2NJ`+=/12HBX)'&I39-8*E@`*IL#($D$3JN$G
M:LPHJB$5H@%[W,<>P&%5TJX-`X,,_\(8KO3L2`H-T^X7W&(LDY8M$^/-^,XO
M`J--\]"`$J,9V.P;OJ$US"$1V2PP0T,="G-M/T,V9B,QS<5=2L@X`#5!NDL?
M_&`&8$U@3//T:L"QW@,?7M%'NJJ7EF,=YL#3*&0\4L06601(DO]!KT9-]X+/
M'W1S$-9F;8*C-HM16IUQ_BCS/:.#':"-6\=#-^7`B_R!^/!`.`CI=/W!&Q>W
M12IU'/,6#D[M;O$&4\/3'_(AN#[&E[@J'SXU4?LC.(*+'X7S10BNEPQN/M(U
MX8#I`75D<"10(1N2<:`)P"3R<_QU03/G+OZ5P6@.=[K$?PJV!N4)8O'DG$XG
M!4<R(3[B=]ZIFUKTGNK7=62LFP;EG*(''MIA1HFBYWP"**SGR9*N>KAA%2*A
M9;'@":"`QWQT"3KE"[(@$3;!$A)A"R0A%*!T&PP8I)!P*\'.>N#GI(:A:?_B
M2G4!:J=V%V1A%UPX[=CP+6J%A>&0:_7_HAF"14S%U&N_06G?E%F^@5G^,%H`
M4_&8ZC##96TO"/+2I5Q,B!)_PUT,MZOPP(8,E;W2XS)QC86"5S[:1CK8S?4R
MU0:2@2`7IM5LX-1:RXVK1@ZB+3[PP9,"=QG/BS+=D1EQ:3RL[SKE`QABZ(CN
M*`[L0&!:*6>.+1#,BT&$0XL#F19%56_:A6_>L3TV2_P&,D'>[=I:1#Q*=Q_%
M%?_8F'>I;T8$4I@.,C@,DN$8#D"-9$>4*4B>A!S:`8+$81RBR2[(-YT0[.8,
M3'1<YYWP9",>0GX_3B(2PAI6\)RD85#>1$_H9$]:DDYP825TP1?:P1IZ0403
M`@AG5)SA@1Z,_^=D$=A&3Q8>&AA]HD!'>0P*XGD*ON`+M``2FG0K(<4GC,)1
MX,$H6($5C.(LZL$;SM(M?$&;J98LQ=`LFY89D#8.D4$NR#!6VJ[ME,&`=-BB
MW1!KV;0OC/@/P84TH+CRRF$=#//Q=,,>#O.IS(7AW.U`,A$?(K.T1`1!O$;X
MS(.P5K$<NEBS\&!`)FD5:>T[DN$<^($0;*!#5C.5%D8?$FEJ\A;=TH,6`V%`
MNB,?A`&P5D8?.C>]8%4^^<-#TN%FT@&]M+H0PL,?\.$RX^_[OE-T9;?XD.&-
MC&80!/!8V0$.X"#=OF,9\(!CEN/VC*T\V`$Y80U"'*D94&8.Z$UFV/]!BT=Y
M="6$<:,WE_8&7=_KX`CG>@,TEBG078.$<BP0FBAR<SJGF3O'P+:D(DC'P7R!
M((KY(B[B(]=$)#(T))*G1+U9?]LI%W)!3^H7MJ5A57YA%Y*'&GI!%WKARG12
MZ,:9*(469=,9"?UY$L['G=TYGJ-@"A#!"[J;&DX64D*8O+<!&K(2@97NZU*!
M9[LR'&*8RL2P#&MEAF>8ALVR5=SP+=1P+?(P[[YL#9E!&0(#,,!!&3#ZHM%4
M+]A4;(\X')RA3LTA'2[H+Q_OI*4*JJ9J-RH/']*EPP]2DJ8#'SA1]2+DEH"7
M!AP+7BQ3LL*&LB*K#H*ZJ_MHUH"+!OPOJ>O_!;(_CQCZ*D6\+V]M`+%'?!7#
M9AU=K1V-PU1OLV^-<8OWH_KFJ([B@]/J:AV7(1#FH`80N6KN@`9R!CWN*-3P
M8+J"80XD2PZ.%=SVNF36D1#VVO54E;,H"X^MR!#2D1"Z\XS##;RRBV#./(C$
MKXM-DWGUYCYC!`%I9)77E4CN@4<</98!M"$QC@/?H1U.>T*G"7,PDK4!5B3O
M(N8,`IPX<)D[#&*EV4,+PIMPCB7'"77>J19T@1IJ`4Z&01>L`7K<H1UV<(!_
M<KJIFRCCH1LJX7Q:5@JR>PI`Q0NTX!GFX1F0[F=#.)^RY^N&`@FW(1J^#GN^
MD!=F81;,<"Q=F*1F_R$72HJAJ5:%RW!JWQ`.U7*CWYUK`T.(!7SN&)S-PC:D
MB28<]!TPGWAM(3$=3MK"H:KRY.$>)*=?"&<X\L$/8F"P^J8]ON/-3^W_A*V*
MTIP&&.D<&(0?A$&1@L@&\.#4!`$.AF'3^D",BF\5S^$[LARQC2:IV5.)_*"M
MN",8:*`8NRL6ZBH3W]-HX.`Z8O%W#>'CX8`.GJL.8D8?\.`-!D1&UL8<`B&(
MR%,.9NT.HBTXDF$.Z`CD98FT@`0/`@0.7)<YM)[KN].P?J\X2DGF`T08!@$.
MEE=<Q8/S"`1O!DX_%?W08MG1@T1Q(EV6Y?5Q((<=H&27,7!*.+U*#*)_"/_B
MM376?+TA(V:;!I/90TM]F3_TF<<IN(.[U;4$=S!"%H9GUEUX30!89,F9QGQN
MNA,8G=V!*"[!"RS*"Z*`9:DR#)X`$0Q^&TQ!O?GY47Y6VTE6Z;"=9[N!'+"A
MI'@!&:ZT+*-V^:>6[<Q2^GG!%\CPH=?RA^']:R$C,,X43=,T'+Y%,T8C$#5#
MWY,X3TT:-,CV6=;VI'5C1R#]0+HJ/9P!9FJZ'[N#'8@A2+@#(/CU\]?/F3!"
M@X(IPZ?/'T&'^M@='%1H6<.(SO+UVXAOF2%"A)*QTS=0GSEE#0?ZTW?.T*!!
MABPZ?+AN&;Z-#@>>9`>1X,69_?0Y.\=O9=&<0@W_!2)D:*0Y9QM-HE0YDY\^
MC,F<K=.'[XZ<=2HC!B/D)]`RG@_]\6,7;!`A8BG[27Q92&3#G"O9$0,9<B0[
M96BISG185/#*PW>OZBMJE=]1Q?GR06:8#U]E?)@S:\[,;K-GSIC)B1LG3IRV
MTN*PE?:F&IMJ;].P3?,U[5?M7[]\R3XV[;;MVM*D]?9%NW=O:K6-&Y?VB]HO
MYKUM2^_=J]?L7M.K8_?UG#CQ7[E:Z:*F2]>O\KW;<>,6#QX\>O#<=<O6C9[]
M^_COQ[/GCE68_Y%X(>!_DT3Q`R+Z[+.-)=%TLTTUU7#3C8/;;+,>A,](."$]
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M:M"F=EIJJ@TG&S;%T88-;]@>0]MSN.4F77'1`7=<=,A-X]QQS?E2G7.],)=;
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MZJPYB>HX8I$&Y7K@H`Z:S^>3,C[Y17KCCO=5;2IV[.__7!V[;$2;+8ML9NM@
MUBRTTY9V&FNNN3;;--SZXJVWL1E'&W.^2..==]+TXMQW]#9GFR_.A5\;<=)0
MX^[[R@6G[G/AQ^NNOKG`XN^__O:F#3?M<$\\U@,/;F0#8@Z[3\3ZL0]^=$,5
M!"+0)"CAA1_\8`H><P<D$K&*!ZT"0MN8D(4J9"$(5>-#+.N&>U9&#W&,2!>R
MB&$,5:2BG!$'%CB,(2QR5K,2R3"&.$L:+XZ&-!;-8ABS,"*+AH$,(3&C&<R8
MDC*H](UFC*ULX0@3%L=6CC!E<4ML4T<ZUD'&>R0O'V9B4V;B]*H]">2-J8/(
M8HY2&,,91BV4\TFN[F*K7/G1_X]R8EP>=T65R0V&3G_<U><X9P@[6,1.^EB&
M'.9@CL@E"G4],4RL$H.86`5E4:"4U:Y&Z3=-!<I7N`O652)S%<L$STV84>7Q
M\&$\XWEF><P3QS2T<9K61$\YQCG&;F9C&VSEIGWAPI>[?C,_Z,RO>[,)7W/B
MA9W<=,\[Y<)-ONS%'.\19QC`B,7^RE,+:R"G8.QY!S?$X1YJ/*QA^(F8/312
MCWKX)PR4F(0^\RF%'Q@!$>W81SRJ`0E+8.@9J3CAA$`XP@>QXD,AG-![6#8/
M<IR'1++`(2QLH=&,ON(5K7`%S5PABUC(@F8H):DL;&:TI?G,9C&,Q8AX<3,4
M\<(;4/\STA-W1*6P42D<5IS2-[9HCG-P*1Q=*@?;R%0.,J+#C&6J6U#8M)@Y
MXHYRB;FC(%652$QU]:M@W2,@<96HS=5N5YP49>-68@@;Q($09SF',Y(A!QL(
MPT]HA=Q/`F5(0XH5K'N]G>%ZQ:O#]6JO<9)E\(YUE9&T<I;%DT=GUL$.7.:2
ME][HI?2R9YQN4>\7Q_!6=^@7OGQ9\WS?.8[WU.<^=<D+7,O\WO1L4YWP<>^:
MOH`:,7[1KW&.9V#K:4<[Z..."KVC'O!\ISQ#50V,5:(2E,A8/Q%1#7C$HQ_Q
MB`8I3`BAA%J(&ZPXX<)2%J'UK$>B'+*/.XP1"UAXM!7P;<7_*P!!7_BZPKTZ
M_"&)8#0,%/471B^"D7][EM,B%7@8Q)#2E:+8-2@FF!ADRV(6Q^2EMJTC'4TM
M8QG5R*8V92Y8:N$C'LE:QYYL[G(/V>OA+)E(JFA5L'^ME*]&?*BP`A)47!%&
M'=PJAQ[;8`["\%M8;*='LGZU=HI3:V'S&%@F#W:1GE(L0UX9RRG[9;&>J:5F
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M.]_B3G"4^69=W$\7UM%7G6M19^W80CON(F:^2MN][MRO.B\B-#&`X0J3_DL7
MNWQT-JS+C?]G7*-A\KPTIC5MCWZH/!_<0$5TH_N?*$PA%:N.1P/WL8]51R.A
MJTB%)0R:,%B;<+PF'*&$-%0?>KSC&"75KPQ-JFP![R*)+I*I+&*D[%HH6Q9#
M&V)_H9:TI<7H\N79&;:)X>TGAKM*89-2@Z_$I#"A`ZEM2P>9T*%[=IOQ'O+`
MC)GBS1!@-091AA((2>CH5T)%CBI'T;B-+:<2?:.XXQU7LJ&^NCD5%XX@IELE
MG`K3Q[T*)K";+/(@`TDY1.5UD(:]'"=[%:<0YTU8P/,=0T8"69CC0[(P9UE?
ME@VN(6;1(TR<12ZYL3X_5W76!'1[]F;WDG1-IQU#9PNY8(&Y48'_;U8=3Y<O
MNC`,SE!HP:!HLC!.U"`^[>`.'!(-E-8/\O1."M1V]]`/^1`/JS!W&>,%6(!W
M_!`/\2`/_,!W^]`/T6`)J1!K!:50VY"$KT9>(&1>$;4AOX9#[15#N]!L-20T
M`D93+<(B7A=MU58>2V0T*,*%+_)?I7<TW@`.K'<DLM=@;SA4X3!4Y&`.XQ`.
MSM!%2H54%-8EZ<`V\H`.P2</:*(9P8)*&Z<XBR)*@E5BAP18__95?>57I12)
M)O80UG=B`B$J"&=P?9,/(6>)(>=5I.AQ@W1'FH16;+1D3:8I@N-R+4<LM/18
MG9,LLY0\[W`:T^(:Q\!+OW@M8F8<"[@^_Q$(=+L0:+OP9M[1"\MX9^U2@;@0
M:$I'=$[W=/@R=+U@"[7P=/Y":",(3B15"ROU+[[`#1/E@MK0=O*40&O'=O50
MA(M1#:%F,5U@"1LA#_$0C_Q0*W#B#M1@"065"(E@4")D"9<@>-&PD-P%(>?%
M,O#Q:[*0"S'U0SN4,[F0"SJS"S1"-`)60P*FAB^B"[%`AB$H)*+7>D_S-,.@
M8#P513]E)57B)&)R-EP"B&2R#NH@-X1X)O=`-VF46"%6?TYF<70R<%ZU1R0A
M*)@XB7\$8Y=4<*-T2(1U<2N&.Y?2#\)0"(UX&&?U$YHT<O$G<%Y)2C?F#[4B
M..TW<E>E.9V4-_]V<XM4EAG$%W.010Y@-@U?A@U@QDO4X!J^8!JRD2/?\X#-
M2!P:N2_XD@O8N(VU=2_O4X%UAH'L0XVV@(W-N(W<2`NMH&CG\)F?R76RT"^)
M!G;H"!]E!PWET([NR';TH':U4@]7\4"B-FK1((K(!80,M!%\IT%J8`F)H`4<
M5`T3$FN28`FKD)RI\`S)>7@I-"'U,#,B)7F2AU]D:$2AMT3;)D0Q8C/E(5,A
M^5]$1"2B!S5B4VY34H=`)25/XB3JAC9<TC9D,@_R\&Z:L28"47Q+V8IP8G';
M%W#V]S?IEV($X0S+<$?9-U8QEGVB0F.0TWV)M$B&\8E>%13K,`=SP!#__#:5
M8RE*%D>63RE_I1@52QE_249PJ=0F]R=+E?%8PD>7H!&CFL$.G2$/HL%+@MF7
M?/F7@*D<HL6,WY,+OK`+E\F83\>8V[B,&8DO>N8NT'!U4->,EUFD&3BE&+B-
MM$`+E\F9ND`,GSD4YQ`,@<!UY6$+TJ!"\-$.T7`+W,".;NHPK!DQ]#`/=)IJ
M^?!`87`*%/0%U$`20*B;>T>$[8`)EH`(5H`(EJ`*J[`>@W><ER`)D8`(DAH)
ME_!0(<0A$N4+LA`(KW!?R`8+@1!LY#B:^$61$TF&FX=ZW;E2Y;AY_W)M-F4T
MWB:K*.E?I#<EZ)E@8D,E58)%X:`.6U(.&":?_VQC1O49?)N!GU0%+%75*.[W
MH2S&./K6#_C@!W!021SJ5=0G2-AW9%`6H83A?7AD*`G7.,ZG#^O08SQA2B%W
M5N^'*IQ41UV)*0-!H461#\LP",G`EE=I.-\Z8U6%1_CG&<2'B\:2/.SP++R8
M<SS*EV)F@,$T'$`:I.Y"I$?:"T:J3-3H+MY3@8TI"UJJI=VHI;8@"U-:"[0`
M"YSY"?"5"\2`#N?P#4-1:(2`;!-)#0?$(8[V#-*`=NVH:3X;,>U13_Z8#_3`
M"AE#09'0#OGP#NT1A$2X=_UH#9!@!47`!(@@"5I;#9<0"5HP!5KPM4_@!$^0
M!9&@J`K5>/#@"R`E4O_P)0ORE5$J19W4-D/N%5)S.[<D68ZQBAM)TS/8EE-.
M)"7$\`W64+A>$Y-.PH=BHC;F\#;SD)/E,(AH`GS`YY-GLB:^$V*28G![4WV1
MN$B80GWL8`<TX`R0@Y3]UJV#!:Y5F:"`E7T-D:YQP!``IRNGPHAV9)4TIKH7
M(1F$$`-S`'*7J);SETKSQJRM)!F_\Z(%6SPRBAFF\66\E`U^R9?8X$U6-QO>
MTHS/Z`M&ES/.N(S)Z'082QP?*)G:,8V]D*6MD*7P:PONRYGP]0FT\`GXR[*R
M``Q>^J7$\+]BB@F+!D#NH0W4L&B15@^L&;3MZ![RT`[R((0_Z6GX%`:3$&G_
M^NC``E&$<+(/ZM`.U$`%02`$4S`%76#"D5#"*CP%4'`$3S`%7D`)EZ`*Y<4A
M:PL(Q,8'.)P']/4).,RR\(5#K4"WR`9?E/=U)2*&:7@T*,+$_O4C.X(,1_(-
M4>1MLM>K5M(DY+"X8I)4@<A[\GD/3V6(EOM__!"4RU=\]?<X(N9'@F$8+L8.
M=T`#YJ"Z3MFA,2:BE!A60]80^8`,S1`KZ2H'H02B2=97LB*N>=PWGS(0SN`'
M03:@AA58BD@8G\,[U#IEKF09EU&7D&5+ZW"C9#8-PN%:P9&]X&.,V^2,1(>^
MVJ$S%8NQ0CJ9^,*^N)"!6/J^L(`+MWR_K>`&G^`&_Y#`!Y\`"<!\S/L[#'+U
MI>=@#<$0#*X`#-9`0.KQ:,AQ7`J\0.ZXP,&ECT/H&-L`79-@P=&@C_'0#N_`
M=X[!0'QG#R","4*P`$&P!%(@!4<@!2I\PE.P!$:P!%/P!9/P7)?P00?C"\6&
MPSV,T)^0!SP<7\,F7_BU4HR)A:GW(CN3(C!$DDNT(OVU--YV-#P"-6RX(UU3
M10K&GF3S#5OL17R85&VC#F),N60$HW7#8?JY*D&AHDLV*W1$$`AG.86A#Z:+
MNHU8.T.V8OQ&O(H2E7R2*R7GH./:TP(+<OZP#G"`!XV(#W)P`S=12).BNQ4W
M?W&$29>8E'>!2IJX$J*8*O_S%J"%I:)+F8BRU'_(VG^TA`]X*6;4(&;2@`V/
MYHMP]C-/:CWDZXQ"FH'[HICBBPO+B'35T=C>D8+*A`ON0@N^\`S3^`RU<`ND
M(`JC,`J>$-KXVPJ0\+[Y"PB8$`S_^YG6`)K$$`S`L&C4`$#5_&C3L(\PN,"6
M1K39[`[18`W"U0[\"`^7L(-34`WGO`WED`\-Q&GJO`_4$`VU4`9"<`!"<`38
M[<\K;`1!8`1((`4`+="74*DAY`NM$`B<*E^!(%+#)E(@95\GA<-##`O-AC,X
M0U-)-`L=^9%E"-+CN9*SRE-ATV!#)53D$#9>U,45I@YLLP['^F[UZ;SWJ;E5
M-4?_ON*?[,>[X3H8^&`',J`,84$H=M(GVDJ6N>LH`>>NA3)'>'4ZU:=\G2AP
MHHA'ZV`#?<!'[+#5@'(KT(HX#4JB?*5'0L8I'QK4T$J4DN'C;E1BS"<IO3)^
M3ZX8;,2B6,;)R+(L=AE\V``-T/!HT-`^UW`-V2`_JP4-RC38]V,+R>@=0@J^
MYJ%,WD-GU<'+;D8<O(P+MY"EHX`)G@`):O`(GJ`(9R`&9=`(GN`(Q3P*M'`+
MMX#GOC"-T@`,J@V:W_"_EA[;P!U<U&!.T^`.^U%/:8=<EV8?"@R$L):<K08/
M]P`/JS`)7E#/U;`/D0;3)+$/S+T1]60-J5`+9B`$ONX#_SXPS]B-W4^`W4B`
MW5,0T.-="0/]0<_0"K%@;/)%"R`E"//%J31#>2:%4B<E>2UB,]^>1/QU-*9'
M>C:2-#E58+.*4T92TD-%AWF(-ELR[UZD#N'`>_$YB&TCQI>+)L$7;U7U2<'R
M2:!;*!<.$74D&$7!#GU@`Y74BNS@#,HP<2F!#P;J#*GB#V>R$>OP%!FA$A:_
M#.<P$GQENWZS)NR@$O905?C0#%ZZ%9Q4$NEP\5.VSC5A`W9`H_PW!W'@%\N0
M#%R6UH."$<J`\2ON)O=0%!UA$U$1\<O0#&`!B^RP#WFA#$6?\I\T*XYE\!%!
M#,O@#&Q2?:WT%&?Q*HFEO"P72_^742S,ZW]7#G//(`JD8`JD4/=V3PJA#0GV
M^]FC``JC@+^?C;^ES;*C``NC\+Z(#[\H6\Q\[@F=X`B0[PB/T`B+T`9MX`B7
M;_EJH`9IL/EG4`9G<`:;OP9JT`9K$/F.$-J>\`FV``S\"YKG`,"O;0WEA+/:
M,#"/)EROV8Y$^S#UU`U'&*F4>@G5$&G5$`E2T`12(`D1+(1W\I-]MP_S4`_4
M(,"00`6^[NL\<.Q'L`3=OP3\;`1'X`21`&K/I0JJ4`FJ``F>0%^O$`BC*5^Q
M0#/=/GD5^7D_-`L4N0L:R2+7J9T`,8P7KV'$AOT:=I`7LU_,ACE$Z)"9Q&'-
MF'W[ULS_V[=P'3UR)!<.G,=RY<R50X>NG#QT\NZANQ?3I4M\^/C5O(D3GSZ>
M_OKUU.<OJ#^B_8@>)3JTJ%%_^.S8."=4F!]VR)[>B$-57S([<&S<D),L*,^I
MSI;UL3%FCA]S_)+)N7'#AAVQ1X79B8I4GR$\[)H&&W2.:]P;=/7U8ZK/G)\X
M7\$:8H=8V)PY,FI0MK,,WYPXY@K%D6O#CS.C0?GU8V=H#N$ZR?KEXTD,C[)E
M=FC`B6J.$-PX;^(4\LO/GS(\Q)SYD?/5AIQ@^!#STW=<6-#7S@:!EHMGV5#A
MZ?S8L`'G]\[3/,W[-,^SICY\^6J^9\_^_7MV\VO6Q[?N5BA/_Z)(0>JDDT<$
M=,01-]HH$$$W#C2P#3;<4*,--=18<$((TTACP@G;<%!"#3\$<<(R0EQCP@Q#
M_%!"-UQQQ;ASSOG&&F*"(6;&6JRA)D=JIIF&&FW@@8>>>NJQ9\AZA+2''GJZ
MZ:8=;JJQ)!)$IH@DDDLN6:4:>=J)I`DO$6F''S$1ZZ>>?<XT,YYH,*D%DS*$
M6$"(((0X8HDEF'C"SB.,,.*((Z:8I!)!41%4T$0<^2206&+A91=9'LV%(%UR
MD0661V%QI5),6V'Q%4Y?8?%174:-99>!1N4%U8%6)8@@9A:::*)I'GIH(F]N
M]48CC,(9QR-?/3)')958*F>==5;"1_^>=?"YIZ9FF;U'S/>@^ZG:HGP22BCA
M]#D-6[V0<LJ&9H0BY(8^YK##$$/\B*$/0^*0@Q!A!L%*K)\"N6$0..P@Q!"T
M!@DFCG2G@N.&97SBQQ`9DCEJ6S]D,(<G0N(8A(X["C%DXAN404RH93B[H]]!
MY("C+WV$P<..&6JPPP\[V,D'KCZR$F;=Y=!1BIVGTC6$7ANF$RH9&\Z=8Y!`
MV&$'CZ'E)>2I00[SQQ!SDW,W8[@&\2LHH0,Q;QFX[A"F$#_$VTXXG<VM68X9
M`MDIJ?326Z\F]^#;23[Z[,.[OOT@X<^34#J!A)-'&B%\$0<=88/#"#V,T$(0
M3]S00\511!'_C3-,-#%#S=.0$'+&W0@F&&=>=*9&TT,/YD9KIM&%]6E^#-+(
M?HH<DAYXVJ'FF502D7(**JV\1-!+VE%SBA^:0&2<,?,YLQ\TAXRG%DNHJ<4,
M)N"DTTX[?7^"3SZ7F$*22BBIY)1"!94$$DA:@<664FAII15;;($&&EMZ\647
M6"BU-!=+9:$4I63A"DMEZE&BTL4L@/$+8.PB@0012`0'DA"*U"I6MM+(1C;R
MC5YY(QSF\)5)2G*2E+!D'<IZB4N>M4+[W,0\/SG/84XS)J$DIF%(.8I3:D`:
M?A!"!OF*3#_P\1W1^"5H-?##8?8B`QL<C2CX&$0-BD@F810&'T(I_\0,&-8P
M?@QB!N;XR2!^2(AUY.,G0K.#<_SA#)+9"S'E*(1H>,(/9]C@#NR(SSK4-@=D
M'":,-)A.:;Y#B"O^Q!EVN`'#^I&,&<B`+;`12BP"*12=P<$9/C%$#6H0!V)<
M$3KL\,,,".''9-Q@E-%!I!NW`I8@"H,&A/3)<;@V%-.\S3SMV0G>[(8W7M9$
M'OBXA2<\(2#`%:A`A5M$XA(W.<IAKG%J4$3CF!DBR*$(<AB:T!E&I"%LJN%$
MK:#1.=A!NF_,:$:IL\:-AC$J:O2B'>V(W9#L420ET8,;S_@/(K2@A2D@X@M?
M`%XE)B$)2U0C'I:8PA,L(0]YB(D?S#N-F?^&]`XVC0,39J`"G.:$)^U-80E)
M,,+VNA"H\Y4T$HE(1",XP0<W$(X3!A*F)R#AB4^THJ:TF!\M<I&+7>S"%[[X
M15![`8M>W.]^N@#J+_*7"Z0JU1>I\NE!O&&K67EC',2P1JR(X8UAY.H;MVK&
M5G%EU8Z49!PJ*<E*5H*.$YX0'RU)5K+V$9.;G*8T//F)7;.U5Z8813C7^NM8
M[%"#J/3#AR_#ECZ6\<-+^@0U78F,/@HA`SD$T2?+H,$-+@DUG77&'PF;@3".
M,I8[W"`<_>BB#-(HIJ0\)3+Y(`0-@J$4HE3RDJ@I#%[[D0XYR"`0L(':,FR`
M!S\N`PY)[!ABE`'_AZ<M4@9S"&)IR-0Q?1`C#L(PBC!FL+'/=I<?[+@#'`ZV
M2%/FPQ_"L($A$&-&H0##!H0P(R&TB!B>(,T\T($.3X"[GOC@4CWJZ>5\\$.?
M6X@B%)!X1($6D2!(.()##_80&S+G!@Q1V$00@E"$V%"B-90H0R5ZG.8^)&(-
M60X-:,BF&M"0AC-D",5J<$4XQS'C<XR#1J%SQ3I9IPMJZ*(7.0*2D.@QSWD*
M"1YK@L24?#<%+50I$I6XA"0F,=#AM0.AEC"*&?MQCWJ(:1_\J$<\VE&+&]4"
M$AG%'A*6@`0C)&%['G4S%)XL/$&1K\Z20,2AV,"&3/"!#9Q@`^(0QPDW_R#.
M#9YP1"<X(<Q/-/JFHZ#%*"!-"TI+^A.0OG2E*9U36,#"%]C`QC&DX8MC:$,;
MXA`'-;P!#G",51PSGG$XR%$.D9`C).HHASKF,8]WO(.A#&7KLIH5DV3%Q-AT
M?>@^$&.3:CV'.E#SUE&8\E?AZ)`T49,!(7YR%'-8$2G]$*,YL"@#0W3+)^SP
M]E#RX<5S&,406A0.M:,(1LG*0!B!]4D4QX4..4!WKTDII;;UP8ZYM*TI<#D'
M='((+[Q*+1CY58_.*KO(&0Q".!VSJSY@@P]V*,.41,GDTWRRC\^>\0:%$$XI
M!^&/==Q!#LZHVWO,(8<^:$VUR[A':=C[-HC_-__FN(Q;+H7.G@'C31ZC`%R"
M'[%@PR6H$0=2PX,D3"%O8LCJ:5B#U:ON3:Y/J,/<!#N*+[?B$X^([):[W!G0
M4(83GT'M+;:<&X!!C!>]:,98K5$P@%$+7?!]5+WX,3R#-&1Z#M[*B+`"$Q3?
M3R9'(E!7*M0EHD&-:%@B%<"=KD/W$8]XI+/,9L`HG!9`!#LE(<Y02*B=H#!2
M.X]/H)00'R4H@0A%-&+/BLC$GP/-AD78GA,J#32A#91H8PK3$7R8*4T=(4Q(
M.)JFE[[T*!I-"EJ`8M(XQ07@;W&_G^:O^]+X!8]XY`U0'P/4V-`&,U9M:UF'
MHR3OF(>N[_%+G,CDV/?_F`?^F<6L?/1?B7ZT*Z/(*QO"EF6[@R_ZB7<3K<0R
MASBH.:+8%B\2MWY0F&"XEGYH0#M0BL,8!!K@H7?;HM'"@QH(!W*9`6+XK)[P
MA^\X&',8FD+*EL-PAAL@+G]`MSM0(_:0@SA@MJ30H\H2BH>Q@R&T@SZX@R.4
M(G%+AFR[0$,JA#ZP`\J`@QHPA,^J(M?`(>&800WD!V5XKWY8ASBH@3N`PCNP
M@R.T@^<Z#%#2I'@)!CQ"K3D2BOMZF[J1#XT3.O@H.HZ[&Z09A09SA,%QA$;@
M$`>#,`ZQL,29$#/H'*W#I@RAL#2()K!3@S*H)JL[,15C,36XG#)@.[?3)E!4
M_SMO<KNX,PZZ&X=SR#O4"097&!4?([-:D`9K`)+!DZ<C69)H@`0F0`(F\)U]
M^ITI"Q[(NX1JH`;<:0?8.(U\,),S<49Y2"=K2*>+>I,%L$8UTQ[M\9XET`*2
M&A_9`T<[DX1$4(256H1RY`/;*Y#=2T??:P1'X`1S3#0^2#1AXH.88K3GB[[I
MVT=)HX52L+Y2&(5;B+1;&,A;P`6$Q(6$Q(5GP`5HZ`5H,`9?,(91.X9KP$AL
M\`9MP`946S5PL#5;>X?W2ZN2N(=RR#]CFP=FO+_V.!-NR:NQ@+:Q@$`A&JS-
M\J&#4<$93"*DZ*(=0JTL4@;'BJ5\`8I\DX'-`D'OXO^)/J@!(\K);_.'0;"!
M@_%"D4N*&F*'..@+&V096F*''2RDL<`'>$F'SU(9.1A"EU-+.U#+R%B&&2B$
M.?0)?#`$KVB902`$>B&$SY*:9:"O%`R*;M-`?P@XEH.#&9B#.G#+M>PW/W".
M@4N&Z[@!RA(+F103;OF_6V*/N;E#][";^@JPFB@%!7,$PUD$-8"$0U0$QLF<
M##$#1]2<J4N1"`$Q2L20R^'$%1/%WCPQ%C.Q410["@F=&CD':6Q%5R`$3,@#
M5^2[6K"%6L`?'X&';HBG)%&2;D@%*R`"))@"7VR\27`\.KN2*^&&=XH'V$`,
M-''&+X-&:91&2\`H*E``:PS_`C4#*2-@,^_YDR<C'TJ8LDD`1TD`T$18@]QK
MQ][+O9<BG`9U@W@DG'2D1T^(1WQDM.73QT:#!$L;!4^0-$D32.N#M(&$-(.D
M!8)$R!3MA6>0!ORI'VB0!FF`!HR\!FD`-8[L2%-#-7$@AW$@AW<8AY'LM7+H
M-5[K-7G8-9>PAYA8TGW(AWO0LNF:-M.8MJ:XR9_P(2QDB@;$2M.(HL92&$4J
MB@;L`R-*BGD#.7O#(:?0+-3RH=M2BB@:RCJJ.:98"G1+HH&[@3N`&I[80;](
MC+($PBY*)*0QU'4P5,E@0NI8)!NH`\T8BW/XN/.J`0NDRVU3!@>\K!KHRQ]T
M!G9`_X>WXCA#92^'8H=D(`0;B`/2X#E;NL/^"KJ@@]7[>(]EP8=2$!#":0-%
M:$U'H)`V@#JN2X-(O+K8U#H-H4TVP)`]JTW,20.QZ\UH!<43H]9G?3$T,`-,
M8$5K>)'D#(0\`-=:>)1:H#3`HP5JL$Y;K)UNJ(9$((*0NI-?K)(I@[+(NY)H
M>*>&XH?V=!YGW%?X+`=KN*C0TZC[-`(?T$\\40(^>8(N"`,`?=@P"(,I@SW9
M0P0T:`0^P+U%R+U%B$="6X3>\]A,R(25*MEX3+1.8+1/>#X+[="7A;Y&^]!(
MJ[11L(43A85;R-D3G9];Z(6%!%IJB%$8C5%I$#5LN(;SP__1'1T'D"0'<0#2
M7AO2(BW2_%M))LT'>\A:YND_,J')&$08H\"'.X`8H_`A%`Q,GJ2MU!*W?%`8
M8B`3G^@V/D6*=9L!'A(&&4!!"/0'=!!#TC`L&5@&UAH*JB0-?)B9LU1!C1.&
M&IA+ELNMI-B,.`!4ZA!40"VE!:0.'#),)A3`?O`#@V'4ZDHOHM"NU=HKGC`$
M&JA"P[2!I]$'>FFL#4P/"'RV<G&-MQ',_HJ/S[S#]<`C`*-5^SBZ0!Q$PDF0
M1R@1QKFZYLW-8^6F$Y&P#WNF1(@Z97U>%FNQ[956$UN#%=LZU<2Q5@R=JVK%
M;VU.6L"$5F`3,ON$<SW/P1.R)7G_AC*X3RA`/2:P`B<CJ?)4A4OXWVK`5Y>P
MJWHHDR%9SRV1QAFK'D@H@XRRSR`@`C?K$S9+@B-(`BGH@B\``PX&@PZ>V/^4
MDC^SO46@1S_[V';D@Y5RJ9<ZO@(9)@W]A.:C*5$0)NGS4%&0V1'UQQ/%611%
M45M(4:!=2&CPA8C\J:)58FE(6A\YM8[<T9"4XI`4TEVS8BM>TF-C'B=UTFH!
M0(3!MW6X4K==F.3JAQGL@ROJKMB]6RQ=&&\YXQOHR1CLP,9*!D[ECJA9&4`E
MA!H8K[[R@QK@F+V(@3D>"F?@C'9CN;GP(Y83RXZI+7AAA].H(^B:+GU`!V$`
MHT6BPN3*_P=$:BP#UH>'*01NT:Y*=:SR0.0YL&-3XHE@$`TUIB]G$`;R6(9D
MD.6]N`'UHBY7_:_.G`_/%#`^["6D(84"&9QW9`1'Z+#6;`,0:[&JZR9ISA#L
MK:8)H4VJB]ZK0SMI%<5,=#$T^-ZOTU96C#&LLH96!-=`P`3X65]:^(]/H(;X
MC0<A@1Y=+((@8(([`9\I\`+':[U*^-_R+,9VN(<N[M<A.9-]W1)Y&`>&,C-(
M,(,R*`+12X!>W,^04H*/<@(LR((N^&@O`(,P^`**G80MV`(V:%"5S@1%\%@(
M9=",+1!"6ZE..#Z5/;25C2D=UN$._011$`7I"^H/'=$3'87WN?\%@TQJ6UC(
M9UC1GX5(7/`%(UYB\U-:]-O1*)[B'Y5:([WBK[Z')=5:*'U)YGF.;>N);=$A
M,(*M^>HK,MU<H:CC!+2WKW6&K."6&DJMQN*MJB2ZR;B!'?()^=)2`8PB%!RX
M[\":]E"LIY@.LX$#.5B&?,`C/:+<NQ(B28:A=[,#9\##VH"#0&(D;6NV5!V$
M]T"'<LDV\VI<K``&9]BXMT@OZ@BXH("B5XH8R229S?H.R.")9)@#2_H__)JC
M7WZ/N8D;Y)Z/W[V;_!B%1U`ZZ*9'2'"#U7PZQS&1SA'6S7E$-4C--9"PQ+'>
M$!/%,A#%*A#%9]W$%_M><?ZZ-7`%&9'_$1LISAE!WU907_S&A/6AA1_CAB"K
M9R")!OLEO7AM,L<34-<3GH%>A56(!G5H'O9LSWT`TBUIAW%HDX&E@B*PQ@5`
M@L1#@A`/`B-0`B7(@H_^Z"[P@B\X\7\"@RG3`C3HO49H:3Y(QY#E@S[[V(^%
M1TY0V6'"QQE>61W^Z2*7/DD3T4@;!5`02$E3ZEL`A:1.ZJ9^R(B4AH>4T2Q7
MXFRPT1W1!FL0!RA&M:>EXG<0R9%4!W6`/[`6ZV-STO[;!WU0MLSS%O;``P_T
MAWPH!!H`!ALZAWU96S^@`7HSA!C8VXXY!ZZDI2"D@:$4DRK:TT%8C4`8A!@8
M%WX(!,&-0>%X_YC-LD&E&9I!>`HX,`08U(=4E0.7@3G.8#;J6`<X\+>?P(<X
M@H,[$/4X8"XC"H97VI;+D@,:L(-!N`/*B*/FJJ)`>`J!.9?PF"1_"`8X&*6'
M,H<^P`H\&)FO,`1NH:,YF`$'I/9=QJLY).XZ!,U@YJ\`PZ,!L]5;"$3H?@1`
M--YD,L0(NT1D[;JI>V8*`;$2F<2L\V9OKM85&^>!SSHVD`5G*)W3J>_0R0-,
M<'B'IVY(6-]:F&?KM)WL)(4J&((@X&<FHY($ESU!4861#QXH,R@#1HPP&Y)Y
M.!/\8ZAVL(9XH)[]GN@W"8(%*`(KL`(D&`(K"((>Z`$BN((KL(*AU_\"++@"
MD-KH*^!@+=B"->#8WL.]'?]8"N6$3ZA0"N6#'X\IEBWRH"YR4OCI#QWJF9VT
M4I#R6S`%@TQ(A.P%A7Q(:,#RN"]:;+#1\Z,&]./(K)YB=[`U=7`'P"\)>TCS
M-9^')3W\L.:R)X7S*+4K:ADM8B`$=$`,9P@$,!(*96,'80`::9/\R%*&RY]#
MQ+@'0[A,6D+5=2@*?EB&E$GUZ0C]G-,'92"$R-HV?UB&H]E<?)@*(AR$P8VV
MU!A"MCB9;,?LO:CETO"'>U`&Y)"#D*D+X3`'0P#,&C(*9S"$(4SUR3:$!90:
M06"'8$`.="$$SRX/?IA^96#4U#!"M22$B$G_+'8HA,;T@T#Z,E^&&Z"3F[C9
MI=&L#[T!B$>A'A%\M(F@HT6.V+!1U*8-0S9JU#QDTT:-&XAK&$*4>''B&D5J
M1"H2F08-FC1G5K)LN1(ES)-K4J)98U/-&C6-=#GK>>[;N6##@@4C1C08IJ1)
M(;G!U(H6+6K<NE&E1P_>LT1%@BA9PN1*%BU>(DVJ9+9L)56H+EU21>E2M7CV
M]O7;)R]>NW?SZ-Z[RZ_=N'C6:M7"!`E2&2H+%A`I@XA)$"M6B`0)8@2(D<P]
M>OSPX?DR$"A8LEAAPZ=1)CZ9.+%N[9K3)T^L/7GJ1-O3)U&?<NON/>KW[T^_
M08TJ17P4J.2E2KT"__7J%G3HSW#AFMX+&BYIO:3A\@4-FC%IXJ5=$X_M/#9Q
MXK2I;T].'+GXY-Z1*^>N'/YW[]RILZ=N'H#WS',/@03NDP^"^>RC3S_]Z../
M/@\ZV&"$#3K(H(7Y4-B//QURR,^$#4+8883^\,-/A29Z""&''$*HSSKHE/C@
MBR-::.&,*^K#CSSLX'.BAQ/NR,XZ&%;HHC\-YL-@A!CZ@P\[Y[`C83\@ANBB
MB/VLD\Z4&O:CH3_!U&#(COVP<R:#2:;))(8G\@.ECVEV.*(^^*0C(S])5OEB
MA$M&B`\^=?Y9)Z#XY%,HH#[Z""6BC>)S2RBA0+)))Y(B](@CCC3B2!N--/^R
MR")L9-310R%MQ,8B'>$T$JL3370&&FJD,2NM)\$*4TTHK9&&3;K:-!.P?`33
MDS/G$$.,,]841911KB@%"1N08$++4]1(-14\W$0#"1-$(+$$%%-,H<479*%5
MR25FH:)*)6M14DDU]-1C93WUN--.//',>Y<\X^#;#F&%&5;&`@@4844991`Q
MA&165#'$$$$LD$`"!?3@V0\_`+%Q%%ALD0@C?*B6FFNQN0:*;"G?=ALHNHVB
MFW#`C1+S<*/<`APMT-E\BRG14?<S==A]YPMUW(TW7GG2G&<M-MZPUQY\\,D7
MGSKN6#U?.N^HLS6``-HSCSU?YW///O7H<^""#*+_^&*>959YHXM@.CFBGBSF
MR:&$:K(YIYYKZ^.GWBW.F2>)A;>]YH--)DFWX!:RZ&+B*^*M9XHW=GBW@R9.
MWN`^;'^HCS`W"%/YBG;772+FBN>)8IM\)JYZDTT&2BBA@/YM:.V.ZHZ//,]`
MXDFDHD3:R2/$$[0(IIHVPDDFF0#B*2>-/,)'0Z!6Q,9-);51TB*NJA$32-_K
MZFJN-<V:TZ^_.N0&LLX@>\XY[ALU_V!,,=44+4[1\DPTW'`#3S>VQ80A(.$K
M2UC"%+X`ADDPT"QF>1<JT)6NMW"C'OMPTS[V$8][M:->%FP'8/)EC<%0(W^0
M4,`"BH`(1)1A,E7X6"*J_W"%A16L``GP#&>`T`0G1($+6D!$\YJG&DYL@A.=
MX(1L0-&))<*F$[&QS6YHTYO=O`PY,Y,9<6[VFYM!!Q;1^:+/JH,=7`A-&M\Q
M(S22=HUL*.T:Z-'&T]P3M:FY8S[@T(\]W*&?_W1M;`7:BX+FD2`-88A"BSLD
MWR(G)R3QC9%S6B3?5*2CQ$%N3DB:$-UH],A-;@Y)FA1<(@M7HL7E+91T(QS;
M7(=*#TG($*)+$>#\QLH:'8Y&A%/<AVH9NUW&SG:^W)WN%K6H0K'C&:$@!2E"
M(;SA+=$1CT#>(ACAJ45\BIJ?0A5#0+4(141$$9E(1",<(I*'D`0G)<%>^M*I
MSO_T*>)7B5"$&T8Q#&+!#W['NF=1:@$)1V!D6DZ95C2HT3]K1$,11?"65Z8`
MA25DP0MA8."['$B)B3JP+*RHQ]M`A-&RX:6C&Q3'.RP8CW=8HQW6HD41%F`%
M1"2BI2X-A2HTL04F((%B-KS8Q8#@!"QP@0M?V$(;7L.:4!P1%$94(E&7"(HH
MBJ*IOJ%9S61F"N'<+#D\*PYT;'$+:)BB9]#YCM"^0T:P0H,\U[@&-<Y*#6ED
M(QO8R`8UX+@>]KA#/?2)SWW(T1_^5&V/_M&+UP0TMGW<HQ_V4%#:Z-(@*Y%2
MDH[T1^<^R;>[17*5@ZMLX2))HLAM4I.4M&1F0_NZS=+_J;&3TVR:+JG93;)6
MDR`2QI@D-,H:<99&MA4MW>CT(-8]DI>^%)2@\'&/1@T3F/A8!Z!,`8E(,3<4
ME&)$09[YB$8P8@V@X@A$N!DJB[23(]@;R?;$29%Q/F2;ZBS).M/9W>ZZ01;U
M/`<ZXHL.^!ZK*,2H11X<X09(U*(5KL@#+6H1C?YI2RO>HND4LI#@+C@4H@ZL
MQ$09^-!)7((;=,$<73)8CWSEJQTEQ2@_]+5AO+2#8%5(A"52D8I0I-@4K&!%
M*AAA!294[`">\<$/DO"$GC+X"XE8#6N,R@DE+G&)SE6B*(KLB=XL513(:5E4
MBP.<KH*"9UJ$3E?!*%;I;)4Z_\\@:QK+:L:SGG4\YX$C-M@CU_A(#:]XK9H[
M[*$U_GRM:P+ZVC[F0K8#G:TN0MH09=6$(A%%LI*/_5!H1;E:PIT6M)HT968Y
MF]M'K[;2H=R1I15=HTU'Z&XT$@8-@I&W3E-ZE+OEK6W;!J&VL;I)K/,MH0XE
MNRD9M[B,@A.@C)G,YFZBUP?Y5$&T><TUE"H3U]VF=I'MD/!R#[UM4"\[N9D)
M]):DVHHP;[79X(KWP4\>WO:V/8_5#*2XH2D"PP1A!AP-WT&F"#1%8!:RH$`P
M3-@LZ8+P)"@1!B]X01+5:,>2]%27#,:C;"(MJ3OD@5$+,CQ?:E!`&1Z1BFBP
M`IFD4/_Q-C*>BD0PX0`VQA@0GL!3!GLA$:X)!2=0O@E1#+D32$YR)YH:<Y?5
M[#C+^<W-;[$<+IJBRM`IA97!")V?36=H8/X.F=.:5FRLT:W9@*.:U5/7.LJG
M'/6Q&G_VN#7`#FA`=RX0V>Z!H,0N=D^$MBQD$1E91J\ZT9F6[.4N/>G,2=KM
MGF7M:IF42;=/UD9W%ZWB5NTB9P3B''>WK2UO&TG$\XE/:XN[ZV0'W`C9NM:)
M<I2/3-'<S3MW$](KB#0YD4U0,8(3VPU5&T#%S6LO(A%M>&>UNQ>2=M)^]M:V
M"7IM/^V0&)L1F7!#,.!7K&^?8QSGD$<]BP(,^V'"6:VHQ?[_GO$,3&CEH.\&
ME[R_$(8)1Y0M^)Y$&"+A[W@,"$0,RF#9T!]B?^&+X>ZOESP@001$A"(5U:B&
MBUGAXFID?!NI0$,0'`!GY%#(<4$7]-2/+8]0M8;+-2#+A<(G%%E3O8R3`0<H
ME,)P@$+/39551<<H>)4I_(PI/,/0W<*7C14T;`=974,:24-:D9D;,9U;05U[
MC(,VO$<VT-'5V<><]96=!8C7A0UAC1UB_8V0H,Z:7%!N/9:E(=J(J)HD12$B
M$1K>E0YI]9:.F!;=T1UJ31J+-!;DX=:J/9IG[8CBC%:D[=UH2=IN/>'K\!(O
M'4J@3(GL`,IPW4/E&1?OX(/F'1/G__6:<QD$)'#/,WG*M1W/(D3/,TD3031;
M23`")%Z;(UX;(UC;[97$%N">-TU;M66"([0"/9W#B?1+\7T#N!U%'IB!/SD%
M]$$%))A!$0P!$=`4$X#+@GW!)"R0)+2+*K!+)3#0)$2");#"8?5%/&S(PM5%
MP;W#.,#'.V@81ME#/=A#/]0#*10!BIE"QMV?*=@?_TT%*R3"$-C0C?G`QF`!
M3W'!%G@30ZQ&(^Q!\P39D(D"*!11RRR14WU"R^SCRQ"'S6$@<7B5!WX16&49
M-&S55AV==ZS@"Y*9TIQ9>MQ@'+W'U+@9?I1#/-A'U?@''W6-/=S#1QI(/XC=
MV1Q(/IB?&?^JFJE=5A>"UHJLTBU5&A-68=XM'MXQTN0<WN)16FZU)!NJ(1EJ
M#DO.B.+MG8DH4BJ]SJN=(:S]ECY,"1T^Y:WMCC`1TS-<''-I0N<M4:\%FR)$
ME_(01#55DS8I6^RI'B.4Y2-6HB+`'B=.&R?27DEPXCLY0BPX@SETVXG@0SF,
M@S4,`S'LPSF,$+D91AXT'RUX@K0L0DH14`$E5((IT!>4"P3UXO=16"IL`R!E
MD,`M5CT4UDB!T#L47-E4HVE:$#6402(\P_VQPC8^`XSQ'U6D@A54#`[ET!6@
MH\=D(C9E`AL8&Q^T1G)$2LL849(Y55/E1F[<'"E@X,Z!(,^4@D#_?E'/'"0N
M(&1"'ATT>`<+LF`:I54V-!TU/%U;K9DVM`.;N<,-7@W6V8<>J8-^Z$?7=-V`
M?&1(#J&"*`@^X(CC.`AC-5*9.)HD41HJV5+A,!*-X,W=T9W>:5JDW19/!B6E
M;2&=Y.3@E&%KD8BJ!5K@)=+AB%)M':5NH5JJP>&?X,[L]%*AY(X>(A<^I$(R
M[1IS;0)S%41")$)"/!-%>,HT51-#3&);?HIU(0]U05<E0F(ESEXD>M/L?9,W
MM64090(DM`]\C8,\C**Q`$,P6*FQ$$,>N$$K)$4KM,)A0((:I%00'!@3:(&X
MQ!NY3.8"V1LJ4$(D@($DK$(U\`\\Z%EA_RW)VU1CP<F#.UB#.\R#!=%%,E9C
M/5`#BI%")9("*]Q?GJ8"-%#%-G1#*B!!`0@@#^R`QO!0%#C!%9Q*1*S!'H3*
M4`4/RJ4<S"7GS"&G*)!"K!;'<DAGEF$9"0I=T.7J5]T""A(-6'5GF'4G7+G5
M>+95-HA#-H"0-J@G7<$'U5D=UL%G/<#GUGDD@03A/NR%V!W(AL"-Y2P(%ZX:
MJ\7D(WE2WPUH&C:2W'$2B2`H;JG6@=H(XS2HXJ'AII564!IE:RE>@:8AA#ZA
MBIR(&?))BLHA[:0HY9UHBR**/&@>,FV>)C`"C1($6Y8$(G8*JE"3-J6>)(;3
M(D`"=6W3IZ1E-/]98K6E924VCR7ZWCN]I2+0PC#4$S$8WSOP#CJ,`S"X0O"-
M0SD0@QNH(BMB0M#"HA`$P1`8`0)-P15H@1;$&]12IEE(`B5H@B1,W#0*E#A0
MXX&<R&)I%,&!T#C,@SJ@'_K-"T91PR*D@B5400(PP18P0BK@Z?U=JE7`PR,$
MX&;D%*@ZP3JV8SM&:<J%PG`.9\P1&7+B!G*60G/>7*W:JE<!G:YRV5>9PD%^
MV7><8)B%V3:047F\(%R-YWBV`QR1KGJN1YN10QV50U_%9SGXAW_09WV&9#Y\
M)I]Y*X9X22'M2>G(*R(%&F8%+RO=EH7:9%'FZ]]=X6QY84_*5H8"7H'_%BS;
M$"5MW:L;)N4I)24OM5HO!5>@V`X=QDDP4:4\,`K$)A.-3BPD6NPC7.PB%!'J
M0<2QE=>GL)[R;)/'(MN2MFS*HJPB("DCP!XCA((UU%,!^Z4WC(/QC<-0U`(Q
MV!,FY`%3%(89)`P5;$6:=@44,,&X:$$7*%AD3L*<3H(DH$(U=(,Z:,@^N(.U
M%-Q(9I2?69`\Z`>^&.K99I"B\D,M),+<%L&F)D":OM`FI()K5D4UU.8.;,8.
M;$QN.H$6^":H^&:4@D(F@$(H&,<5$V[+/""L=C$I`$=S`L?-F0*M7EE73><7
M48>O2I^OHB"8D<=:40,T4,,T6`O4W?$=4V1%_ZIN.;S#1::#'LFG1W9=GI'-
M8.5GGV;0[E;)C+":B$3.H+FD9CF2N39OA2XA:7%6XQCE\=:KFG!:]7:6]99:
M3V92B!X>A"H2J:'.A>[2DLP.+`^*;\TAK4TEYB%*'T:*)NRR+@M$=#T3]WQ*
M1;#&-%&3-"U"2)2E-D%7)B#I(_:O7,*E[:WERF["-;R)/,R7\<6/\5G#-]37
MS,)/4APF?B4,$V#P#RA!5RQM6"08%#Q!%I0%*DC"G7*#((WD7BQJ-."+E?PI
M/V@8#0.&H?K9P&U4/!B&I"S`IAX`Q6Q&$!Q,(ESQ_25"`@A@$G_J%2R!%9"J
M33`$/`)9\^Q!*&CE'O\P#R?0X_`T52C4QI+91CZ*0BDT%>-^L:S.##)]@G%(
M)W!<V>3^3"_\:@N*F7F<U=/%%=2]E5QE`SA(3398G7RLKGVP+GQJ34?2IV`9
MB($D2)70A5*VR"U1%A5ZUML8I8N@$KP&I87*JRJ?*VUAB;TR[YJHUBC%)&]=
M3HZ`,BG[S8>VW8A"X2H3Y1M*7J,\Y:"(+RPS"J$4EXOB`SKP87-IY6,;Q"-8
MPJ_QJ#0EQ#6A2NKU*.LI<P"?[/\>:31=["-*,\L^HB-H0C.+@CB@"(]L\_$A
MWSA\PSP1!C&,$-&B&R:401$<%!$0068H01(D`10T;19\L$+!\Q?0LRI<ZM?_
MU(LT?E!`Q<.)$-*-E,T]D$->O(,\*-9&9=B&'49+#4%%;P8/]$`"H+=#$X$5
MA((5W%0">*JH7@$4;(%O,L2L,,1&B%[S>`I(&YM),P^E0$*1'5$G.$*!QYP4
MV<;*-+@^TLPG?/'-T,(H4#B%3_@MY$P;?\=/BT<MI"`NK%4;4<-;Q=4T3`,V
MQ)52:P,XD`,XY.`>6YU&:@T>S:<@=9T?^1'9G$V@W(A*ZF1I,3);MZ1-MJNI
MU=9L82BD<7(E45+D7(ANG=(I=Q869K(7YLA2ZO4N1;D9FNCW0DGMR/+W>B]Q
M85Z/``HK+--(9^5`6"R2]EHCP#F/,D]G>PHC;#;'_S(BJ)1LRI+V__ZY?3</
M).ZR^D)B)M#"/&!S-GN;?&GS-P-#(*`B.4,"%0C!;Q/!$AA!$JQSN%P!<D=!
M%&3!%7C!)*1"-QBJ/8A8O5`W7E`#/!QJBXAK!M&''NE+^MUP!F5#*$#7(VR!
MVUZ,#^PMR.78%?2``1S`#B2Q.3[!$RR!?9_&?4=$M#,$:H@>)ZC&R##@)B!X
M,W&"IG![IK#T@2,X@:\,MS.X(^S&8<1&<.P&%3T9+4PGT9$1+FS'4*>X+S`=
MB:/',>"Q-F`#.+#'B[=9.8`#?KA#.OP'UUEU?18681E*73")A3`6B("(4%IH
M*26.2H*HE?_=*<=D45)OX_]1+U*6/*:%*&TI6J?I:ZN):,FW'5*^&IVX=F";
MZ*`H+,,2]N59GNZL@^:M6',11"#^LD'\FN=]BN=Q;*J,=H_Z7B)F`EDB<VA;
M(NDU<S-#UYIK0ONR)364+_$Q>K]TL[+@5Z2[@AL<9AZ(01%8.A(8P;=L^A6(
M:G&/QLAE`19H025L`SRX0SS00T@M'-J:5`7]\[=NM;]P]S.:+0XSW#/X'M1S
MPAH4P0#V0!!LC$[U5$_U0`$40++O@#G&O1)LP1YD.T@O3T1DTV^6-*JT4W`:
MD4N+PI(EU1+5!H,W%6W8!KI[@B/\#FTX@F)"PB<`OV)&D?#O1AI?9]#(L1F)
M!^C_%JNU%.N_CV?4I8=2/YTV>$,.MOC4:&0?+SS8@!V!%&%=$*%B=?GC+4Y.
MCIKUEK+&:YHLN7R[ZNMM$<[J[-9H;7R.V+_]&XXLO?Q=KSQ`Z//'3Z"^@@<'
M$C2X$.%"A0PAZLNG#Q_%B@SQ9=2X$1\[CA4_;F1G*E1)DYI*/MKTZ!$CEH\Z
MO>2TJ5&C139O+FJSZ";.FC@5\>29:9$BHXL8)56:B2@C2R4U:7H45:E+:_TT
MGCN'CJM6K>.L!0L6*$\P3&;<G"U"9"T2)$N6.($R]\I<+%BZ<.G2Y8ND;?#B
M=0,<KUX]>_WV[>,7CQJU>(H5^T/<KYX\<N3>Q7M7+W'G_WV<ZW$3M8DI:4Y5
M>O3X\2,($"!WN<3F\J-`@0,[<`-QXN3*%J9\,G$*SHE3(S9L,@'/M&D14T?$
ME2_O--U3*%&?1(GRE)T[*>^C2&&_GMU3>4^?MH_ZM)[4J%&TVKM?W^H6K5NW
M<.6'EA^7M%[[J8'&EVL:RR8;:K#)1IL%%\P&&W$6%.=!;<#)YC)QQ`'G,G+*
MN:R<<M3Y4)T1YRDQGWGNF<>>>_:YQ\5[\KFGGWSVR:>?&0DB2#)];M3G(1[[
M\4>@((442$A^A/2GR(&2+*C))YUT4L>"IDPRQR(94O(@)!=Z4D<NH7Q(2X,4
M.O+*)GT\R"$FI32H2"2Y5*C,'_\CPLB@C/1AY\Z00O*H3WG862<C5DP*11-+
M'C%II4<@"841FGB:J1%&<L(IIYN8XVD32H5J1)$UUE"$J4P864Z3358:U264
M-&%$$T6J:N03>?C!1QY\T+E55W3.D><<8H8)QI4\AC7#C#+6(H((MY1X`@K>
MKH@VBBBDP*L++[R@A!5ZZ($','KBB8>>>A#;A[)VJ(%'L<EN3$R>=S(+-S'.
MS-W'GL*@09744;<P(H@>C/C!-2=D\X(+(`XH8(<#>/!!-R"J&&Y43D"16#CB
M.`&N8N(Z*4ZX340AKJ:;')F.XTZTNPZ[\*@3I;U/PHNO%/=HKID6FN^S[[[[
M<.F%/VK__(,F0&D:P^8::0XTT$`$)8PP&W'(,9"<!:>^S)URTG'''77F@7=$
M>U!,,>P7660Q1AKSF<C<&_GI9TB"@C3(;;F75!+*)=TLTTHW!0+32(B\O!M*
MOKMD*$<U`><R;S;!G/+P@=RTLNXT"4\S(<OYR9SR.O.T\R*,^`R=(W;8N74C
M4TAQU!*4'K$DJ5-98J2F1W@:>2?9:_^IIDTP1I4F3G+*!%11]U5JTT>8JBHI
M6!-1JA%:RNE('M--MW4<7\$2RQ5,W*""BB*&4/8MN)Z8(MJ[T(\""VS!`",5
M>M[QEIMX!BNLL,ZXH:8=>A.[$;%XVC&.<-%K,N0R8">00BFB_P@/-49PH&NN
M(!LN&"QA!V"8PX"@!"N,BC2C8@K&.!$*5`DG$YH@C@AG8BB3-<(1C>!$R3#&
M0DY,9SJ.*!ES.G$>2$#"/#`KQ2W>8XI1[`R(0R0B?G:&BV<H\3_0@(8TH"@-
MHV5#&M<PFA2!AHT$,>AI2HO:U,#A#G*H`QSV&&,YP-8U>Y#H'24JT3W40;87
MM8A%-2(3WS(7-[KQ"$L[JE*;\(:E*`D23GQCTQW5A*7'I2E.6O+;XGPDR"UE
MR2&#))SB+)=)Q4&N<)SSY)Y`HA$]Z<DB]_B(GS*"RM`%*B,D<11*3,*23HCP
M)2YYQ*1ZLH:1%4<GBV`)\#)ADY$)I?\Y1A$5(X)"*61FPBBD6HI1FJ<41_1"
M*[G2"$5JQ0Y>62,LF,B#L;XWA""(;PE,@,L5L!#!V&`A-GN98!A.L0U[V(,;
M]6P'/-P!#_OQ;Q[Z:T=GZNBN=L1+'N2:UV?FF8U,=7!45?@7:R"(SM@8;`>V
MN0T&ET"\X(RJ8A4K80BAH@E06,<ZHRF4RTBQ'>V$`F6BH*%VJN.(W_#!$>:I
MJ2=&X8E.?*)FIOCA+69V"U(043^W<"(N]H-4:3A1&KZ`(C6.!E5J'&BJ#E(0
MAB"D#0MM=:M;(\?6P*J.=ZAC:^70S!I)M`Y[I,-%*XJ1C-)&([FU+7.:TY';
M=C2W'D%22WW__=$A,4FX0R:2D9*[4ITX";DEV;5R?43<YA0;R2_)*4Y]`UQ$
MWO1)T(423Q#AK.A`JTI\N-)0K8)EZUZ26F%Z2A%M&!E06-@2-A!3*,HT9JB,
MN3QC%J4JR8N5)XBA%3QII%;3VZ98SD(%(0@A?,M2@CFA,`4H2)0+6Y#@!+$5
MAE5TXQ[TY$8[Z@F/=K2#,`4U5SRT<<]X(,9&_:L'O-PAC_5^!C%Q_(PI1J4)
M#V;B#$,`&!"&$-%W>H$V%G68!A_E.^&`0J29*$DI1CK23YRT%*(H12E,X=/[
MH,X[I'`9=UPVB@N/N!0E25E.0SR*['2X9D`$HLZ,B`LD+I'&^H'&_S6<>`T=
M0[6*U\@&@1*$C:H:2*M?W!`]-J2.,9XQ:R,"41O?J"(7U<-%+4I;V?8A-ZSH
MU6T*Z1%>#9E(QP6N;U;2T9$2YR,D!9).EFU2(3?WV#<QEDZ;E&2;$5(FPUDV
M(IK[9#Z&&Y'/&42TH!6E**M7NHZ@(W4E616B0A$[22>E)HP`7D]D!RN;H*IV
M1%G$;)$2%&/FMBK-1$YN$Z&(5&>B>8MP1"NV@HZ,R*AMNM**-;QI!BH@00C*
M$A\3WL*$+&0!?=;=2U[:Z05X;H,>]ZIG_K[[7?+&8QZ@`>_^$B,CQ/`#ONY`
MT63VL=[#O$,4'-074[90!8'UP#5`H*X7P/]PA1X<(`$]4,(2K)"(4'S,.DPQ
MU(-+@M]";:+$%BXQ*4C<X5)X^,+MJ3!X?'KAB",<PQC.\'=$?&&<N?@6&3YB
MQX=H"B4^PXDEO_'0?$P@'1^-:$DS4(4JU*$-S;Q#Y;C:.\KA-;3"L:UD:]'/
M:Y2V_N'#;47G$8]L1,FC1TY,?PNS8QM'ILOA[8Y]5*PBXVRXNE).3H;L>MX<
M4N=*K@DB<!ILV8\^D3I5!-`+"?1"]/19D8R.[AWADRDV\12J**\EM=S43SK5
MJ4:@JB:>!G51C(),:,)**8EG@ZB)EQ1F,D43B5A$*X(K:T"S+7/RP#4F(%$&
M*@![N;YV"UR8,-W_87,!-GKQ`K*5#095--L>].@&->J9#?!V@QS?Y0P_ZM&.
M]+[#'L#O1^;"30[XJ<A>[+77/JBQB5-QT(/J9G>`(1B;]J6;^\W;!$L=G(F0
M>72DAKIP2<IOBO*GKL05MG"'?>J=AB]<_A*W.(DS+&(-STS$1<SP_T?!%#X.
M&I;H%I8(J9KHQIZ(BDYNQW0,::2&R%Y.:;9J0[3&YL1HK-:H:U1$K=:HY^0(
M1NKH'B2"'TQ),7BD;1BBZ(KN[#!I3A3GD<BN(<(.30+KCKBDR[)D2B`+SZ3.
MK@Z+3`(K"+,.D31+L]HNT$*I<PC-T.QNE3)B'00%'Z:0M*K"=6PIM1+E_Y9P
MJ2=J`I@\3=0^#?&&9WF2@K>,B2A$I9B:J9F8J2A&@1FDD"/4;!R(`1-$CPF6
M"PF(H+F6!0GNK2ZN(`MD`WVNZYTJ09YJ#QZX(1H:$??NJ1VB8=KX81_$"[SB
M`?CRJ![B08#<X3'ZP1X2H]K`QA<6:+]&!0V&`(.,0,#:YQ3V3;\,A7=`*A0\
M2A,^`9;.KQ1@*11XL1=#H=&",1CAC_XZC.)(K.+^3QDC+L,L[O\B3AEWQA2>
M@>0(T*BL\<9P[!JV8>5T[,<(A!M\+!NX@0(5I$$TQ$*LQFJ4C*S4`<G6"&RZ
M:QY79&P.0QUB)-OZ@47PH5:.CVUNQ$:23NV6#O\'O0Y-]@:P?'!O$$M*FDX%
M#4+MYB8BC5`BBI`@=;#/(B)MT"Y'./+/U.YS0,(B-@(C2(DB3`DD"JW0#FTC
MIM#N&NUU,L%U6F(E(DT+7T*8,N$1CJ,GVX`-=F(,AP)4$@AW8`6W1DT1'H_4
MVK`16F$8II`KIL='Y*$6\'#T>(T/?6U9F$`)[NV<B$V"6D\VP@`,)&%;N,7V
M\B<:J"$:V%*\[(E>QDM_-B,Q*C'<WD$>W.$=^B<4VVH>;@$5^243TNT'4D-@
M!F9]P*"$2N+[."@4P@\40.'[HJ+]+/,7/6H+-#,1F$+A%@YU4D'^Y,\Z%F[$
MH-&GHA'__J_C3K,U/>[_/I[!J*!!-K=QY;IQ&\`QY;R10+1!'!0D&])QYM9Q
MC-IQ1(Q3'380.=7*1<)&'4S01>**'V@D,3AB(BW2?_8,;\2.D1HRD@AG;GAP
MDHYP(3Z2(0C2/,-NS_:,(\&3D;9S/"]BT-QN3RC"(CKG).LSM)Q04&0M"J.0
M%!KE)*0BEK0PTCA%*96R*-@@5(Z#MGCB.)R)F6#E*(*B.8X#MR145!*/,VFA
M&7I%FZ0R<W"M#)B@"-QB*_^P*_$-+N9"?:Z+NB:J?5*!V=+2'1K#+:/A&;B!
M$=V2O#@C'KBA-Q_C+A,#7C2#+Q&C,N1A'TJD%`1SOU`#"(+@!UHQ"9Q`,25A
M_SE"B(0\B&(RP110HOQ`@1=-PDE990NL8`@68`BJH$T5`99&\S,ISA=1BN*<
MT?Y\L<1\T37YE(@\;C9E$QJZ$<=R3,<&]1MW[,<,)$'.46G$:!U'9,FL9FOL
MP=OFP3C781[4:AU2)`1K9!_P(01?A.WT(<N2SNBZ3G,,JY(<2[/>LR+1\Y,^
M!\]\4-#&,R(F4CXI,C[U@00Y,B-"4E<["S_SQ`E/:2.J!U!4*15,PE5:I5"@
ME788`5348`V`\M-Z$D)GBPU&AB8.[[:.0BB4<O*64D+U"U8XP1IZ11[080[Y
M81SPL$3%YT3=PD0!\=Z28+J@0'W8*3:B@/78Z5^U+_^>Z&$;NF$;F$T;W+(:
MGR%=T(4M'V,?]!)=]J<>B#0>XBLS^N<S.+$P`O-)&\J_@*`'6L/=(JA]/@AD
M*2\J;#$J-($7&<P62TB_,@$-VK0'%D`!V+0*T(`13$R$0B$5VL\[?!'A2"$5
M6*$4A#8933/^_B\53,&)H!%0!=#DK+90=7/EM!$W%56*'(1!9LY`W*$">4_Y
MVG%KQ*I$UJ@>5"2-+C6.[B5%3H0YXZ@<Y,&-XNHCXZH@]:P(P[,(;S5P[;-.
M:I4B-U)7!?<(\>$\Z]-.+"()*X)8W2YR2=)8I2>5J-!/1$O62,%GH2):30(2
M'N%3%@%40D4HLK5V$G33>*?_)F9+$=#`=)D"U$!M7(7G4X)B5#YA',Z!=[5B
M>JQ!U\3G#[62#YG%"KX2"IX@"O:5"P36>:4`8`=6%;:A&JJW&K"W&MRR%FKA
M&2;Q80?*7.K!'<;+1R'C'L)E+S/Q4SF1^.H!&H3'-PAS"]#`-^S7OZ:42H'`
M2J\`93,!.6X7%5UV9@.N_/YM%E$%,F&W3:M`38N@"JS@3?\-)0[N&+TCXGPQ
M@QNN_B1N-9\APS[8J.X#&J(VPZX6:W=3Q[3Q&LK1'"4P:L86AF7X,NA!C-PA
M'8@O'HG/C;YF'M6A'U#D;3\DYUYD'MYJ(JZL5.4FZ8R03CCI!V55L^13<FVU
M<2FB_^VL>"1)=3X=UXH]220Y)SYY==``K20_QR/NA-#LL^Z>D$\\`E`X8@K7
MH71&PBD<I212X2ENTBBI51&JU5JW]?'8`'AP@B@N+4&-8@UB]W\7M$(9N9B0
M4@PS@1:\@AB(P1G.H1:099S<HI,]N9.],@GB0GF7=UJF10K^E5_[=0M.0152
MP957H1HLH1I2P7O=DA:^ERTGL5X80QL``Z#"38`T-MOL@3#PA9G0H'ZK0'[1
M0!$001'4S3#9;6!.=@LTZG8_Q3?TBV8=+*1,PL$\RG="BID2H4W9%!%8]H!-
M[!@[;L2"MN(V&&HON(.KH83M>39-+C9-#F%1V%"U]D"^$?^*&+4"M>$R*/"K
M'I4XKV8OC].-FC..TF%%V#9$/N0>UH%)JRSH2!!&(I(C[Z%6#/)OY03-OKAQ
M1[**UTX^%W>-Z1,E]Z2,Z?.:6CJFNWAR2TF+-0)R@76X8)I8<=IR6W+NJ%`C
M7E(CK%"/;[(EBB+5<#<18M=:'[0H3I>VE+(G$[1TUV"!EE)4M/4X1HU4%H$3
M8,&2K>$.MP=9%.`(_I!X/WD)0KDN=L.4Y3J57?0+ON`44"%H6:$:P"L::($:
M;-FOV1*\`#L;.)8QQDM>J`TOPV5)?RX>"BH4H6$----FVS29Z[=^Y6U*5:,5
MH04,3N&:9]>:.2J_5A:6!GA3OH__A%R6$2R;9UVE3/4T=>3O@]LO3TLA:>EO
MMQMN:EGA-%F!A*N!A$7X:KO1B095`;W10"#0A0_:'<HV'6A8H<GJ0^RAC:X;
MK9"3:Z10N[FFB$50'D3PB/>6(/V,Z\;N(0HWC1$7<6N:O5=ZIL7XI7GUBDF2
MO2&"(.=[<4$B;3J+L^P[=.YDE.HS[H[5T%"I/X<Z(Q1\(TA![PYXTA)HU-A`
M#3XEF'3'4@:/F&9KHY"BF"#4=`/Y?_]W>'B"$5Y-+(C!%<Q`#+XG"(P7"1QH
M7COY")`@"?;7"9Y@-W9#"E"Y";@`R)_W"R9!$D(A&O["6R31>]L21VL!E]&E
M8<67?-,K_V+%&R_CI1)91%X*(QJRV9R'(,QYEC"MX#!3X[^FZPO`8`LH>YFS
M>O*JCW[SJ[2BHH0(^`SSJ\X;.;:%L20ZC!@/^+9]D5"&<1@O#&I?DX0%<-%-
MF!KU^82/>QL%%<<"I!O!T8LJ,!O$R(6'\T,XY,G$:JR^AFN0\VU)1&R8<VS&
M^VS(<_.\^'#RX>O@$[X'MW+;FXR'J[,H@I1(\(IS_;Y]?2+>3M=!1R)T_:=!
M!Z;YNR3#&)2<D"6).JCI>*C[_"2FHN]T*RE[,B<.#].,H@T`^=-.UZM-%U2Z
M&I"7LE-:01B``1CR0`@48+F"8`B,0%D<Z).-X,:7`,=YG,>;@/]:G.#?HV!Y
M90,,*$$5'!$PZH%':0&7G3P:NA='J:$2Y<N?W"';BO1(.^-$Y.4PMH&;0<5F
MZQ?=_"LU?.#DC4"4J[F!VU0SF6*1;99-%R$-*MN#!IC5)@\8,Y@[',5S/;?/
M42(TT]G/4T<6OX]IF[8U,:SDHO:$2TYKE;OD#M50#<0W?S-J!IJ&U9%#)G6L
M1$2LT$J[I8QLPD;5+5HZ6<0B8:16^%MSB,Z3&+?8)W<)KXG8\5-73W();;J*
M+\)/'O>_?5T)A9VG33J-F;"ES3@_Y]O9V7@E-<*4!$50"NTE2:$742(IL+`E
MLOU33%<-@++"U2!VB6E:<Q>0T?U"3??_*#RMF)BB.9R)$S[!%0PA#\I`"!:`
M",:IWHG`7W*?#QW(@8X@"?A]-W;<":+@WYU`"I)?8,-@$BHA%794G]ZAK[VW
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M+RJH:-%'-N,;D=>^)GEW\N*],]KTT7LF3\`PF1&R8$&0_49^[.]A!']&]-=?
M$D`8Z$033BR8H().1/%$%%QT$488E%2R33SQP*,A/-$\<TLTT=3RH8BU6$(B
M-=STLT\][[33#C7NM+@//_O(H^$[\M13SXWOQ,-C/>1X]%$F\!7)B/\5/_C@
M0P].!O%#$DY@@4478$AB9":::/+1EJ$<V5%"H709YD<-B4F1)@LM%)$H*#F$
MD"+,/<)(1Q&1E!))>II"TDLKZ5D*3,^8\DRA-1T*S2W/^.034#QM`Y100VTC
MU%&6:H.44U%IZI17\V#UCCOOC/K.54^-JHY8\YC5UCUBK8/66/?@<\\Z8*GE
M%UYWH5;97I7]VBMC@4DFF+#`%HOLL<H&UAEFPWJF5VJ(M2;:;*PU1JQ@G1GK
MV&F30;M;N+O]-EMPL[$C4Z&#.B1*NR%Y$HJ;I)0TRB@DC>+0**:``HHH^O99
M+TF@D'1+P:5\\A+!MYAR"\%]!MKP2[?H`DS_'F9844;&96",",88;UR&%E98
M@8@6B)2,R!:(?!')%F`(]`48D4BBR2FHL+)*-?"TR.,^\;1C#376``TC->U,
M8\W0X\C##S_]X!B/._$XS4\^_CR]SS[].,UB/?)LS8\],O'ITD(#'X3(QE8P
M,3+))D>22'&KE**H3-"4`F+!()J"*#3%0+,-WS7=PB@TU2!*4]^''G[HHHS;
MM$WD-=$$:>657Y,-I9E'#FGFGA=%:>1%N8,I5=U4U4U4ITN5C52NTQ.5ZU&#
M:L\[J:;ZCEBIVL-[/6/-PWL^/8Z5JJOW](,66OO8E4\_+#J/C_/2/]\/8-7G
M0[7S_.BSM3Y-^T/8_[*\^O77]N-79KZRZ1^[OOCMGU_]K_%7-G_X@KV//K#[
M`(N_LJJ)SYA^?`LP6O.'`0]HHP,><!]74Z`#'PC!"$IP@@K\G@$9Z`]^-/"`
MSIM@!PU8CWX\\(,4S*`&'6C!$E:0@B)\(#WLP4$#VJ.%+;Q:#0\8P@?"T(,W
M?&`](-A#%?ICARHD8@0+Z,`@;E""2BRAU82HP"9"<8I4A*(^*'C%"691A5N,
M8!</^$4#AK&*$!SC&!5X1B!2\(1D;*,;WPA'-<;Q@2F<HP&;J$0IJE"/-N2A
M'?D814#:<9"$+*0A#XG(1"IRD8QLI".IR,9'2G*2E*RD)2^)R4QJ<I.<[/^D
M)S\)RE"*<I2D+.4*38G*5*IRE:QLI2M?"<M8RG*6M*RE+6^)RUSJ<I>\[*4O
M?PG,8`ISF,0LIC&/B<QD*G.9S&RF,Y\)S6A*<YK4K*8UKXG-;&ISF]SLIC>_
M"<YPBG.<Y"RG.<^)SG2J<YWL;*<[WPG/>,ISGO2LISWOB<]\ZG.?_.RG/_\)
MT(`*=*`$+:A!#XK0A"ITH0QMJ$,?"M&(2G2B%*VH12^*T8QJ=*,<[:A'/PK2
MD(ITI"0MJ4E/BM*4JG2E+&VI2U\*TYC*=*8TK:E-;XK3G.ITISSMJ4]_"M2@
M"G6H1"VJ48^*U*0J=:E,;:I3GPK5J/)2'\@0!C'_KIB/9%@UC>L0AC":L<AF
M>!4=Q,S',+R*#ZG*]!P;L$`'R+J.%5Q@`\J08"`N<($8%-(<>"`K^&"`5V#\
M4AEX."$^Y+H!9Z@UIM]HZP;@N@$*7(`8=JU`!?3Z1S]T(+%B?($%+."*7N*C
M#AM801;1$=D+U'6Q+W5&9#=@#G_$E0)T/:(?+$"!&)BQBFRE+3LZ:X$+&&*0
M:;RD,"Y@`=.*,1!U\,,Z9%E<UAK2>X!!X_8J2-WJ@M%["JS18**H73!>5X+Z
M0(<YTEI&\WZQL;2%:P>"2UD%KN.\_@A$!7+[0/.B]X"^ZF(__G*U9CBV&2+4
MAV<M$`CPA>.W#P3,.M*Q_]_M:C`?[(AD/LP+&0<*QH#XH"\$^:'>!H]7C.:[
MFC`^NP)T/!%\82RO.9187O,*4HSH0`>#(7AA<T3RCMK-QWG9R`YT1%BZB-0'
M'5[P@OCZHPY(KD,6A8'D*-?A@,AXP0IB$%M_X,,&47X!E@UX#RZ_(,$&#,0*
M7N"'"*Z#R1O8P`OHD&4#L@,/+VCS"_"PW]["5K8=D"Q8#>@,.&P6S7C`+68-
M"(P8;'8%8UAM?5\``QC451]TOO*<Y1K<,PO#'R^0;"#\4.<.P.'/RU5T:>%P
MC@.R(P973O0&8*!8=,RASJ6%02"RB(\80)JP*RAM'2*L#U#;N0[/E3.KOPR^
M(_^_0+!P6,%G+P#I<^3ZRG%>\PL6C6HP!H+5;5Y!MK4(ZD6_P=$&Y"NM5T`'
MQ8*9RS!@AA]ZO0([\,,98^CUF*-+9#C2@0(4H`.85\#OMX*O#I^-06174.Q]
M4P#!!E3&!21P9LL&0H3(0.YE"QP#?@_W@>;P[,+Y38$5I%JV,<#MQRV`Y2LV
MU@*/M<QK5[L,@"\\TX8^H!\NP&^3;V#CL\UM/Y2Q`<LZ&0XY-WF"#XSISUK@
M!3>N`\X_3H$.(,.`J)4LP%GN#'0<.+@Y]\,5T=&!"D#[`A-0.ASNP>$8/-T"
MEGU!.KZ>VM7RH],42'.GE2YV98!=LLN@>LFAGMP_XV'_[6ROP`I(W6`XF/RS
MM-UTPV7.^*@;0H2'E>S=<8ORJ_/[`H3(=R*)@7/E'O?9F];'"L0.9<D*UL",
MAX,!"6Z!.?C!LJ[WAQ]F#EM]N-;P?D4CT9?N!S/SV_7]H`.*@^]Q.%S1M2R/
M+3L`O@'*]B/C44>^TC&+#,?6(1!P0.X&1BZ,MB+8!I:%`=J!`8>V7H`.=5!&
M/K8>`^8BE^'U]3X>`F&#"QC^N6!7.EYCP`]XP&]CMFVX]0)6PPY!%UPVP%QM
M50%IY@^%EES!5W*7=47LT&><94`9QW#;1G8;0`=]M0X9J%CYH'@3:&:X-0;Z
M8`[J1P>?=GH54'L05&@5T`'W_^=Q+Y!6^/`"%0!\!1AR8#5;+/>")8=;&[!]
MGE4!+X!OGD=&K*<!=54'/OA9>.`/#D<!3"B`%#!ES(=S3*@/&7<!PM""AI=6
M'/A9FQ8(N`4'021@M+5:PK`"WJ8/[-4!L<6"?=8!X>`/[/58LG5UE.5:C7>!
MSI9;5T1T==="<&!9$*@/L+<!.%=;!M18%;`!Z0!<EW5"U$<'W@,#DK5QT[=P
MPX5:N+4"5D4,_,!],3!IR8!S`E>*%F`#)S0'G_4"_3""<'A%<95W_I"`M$5J
MU$=FQQ5R3S2"\.4/+<ARJZ4,<P@'ZP!ZRZA!PA`#,>`'.\9AIW<!P'!%'4=M
MML=V*_]0#G(&`Y_E;W'U67/@#_D0C19@A?Y@",BU`D/FA'/TB)_E!_E0<I%(
M`3``CA;@9$"7A?JPAG,57,F0#@=WAF)'#.C@;)%H`?XV!I\E6`^TAOAU0.O0
M089@B]]@#N;@#!PX7'H66[E86Q=YBV*D<'HU6]O8#,[@#'=U61E)=U6H0&6X
M9W]%`0]X0'/`;_[VBQLP#,IP#NE`</WF#[$(@6"4#^N@#![(<F35?Q<0"P?D
M<,U'C!Z@#!]I#F,@<4GY6L&X<,.(7`=H0,>H6O4WD*I6%_XPB'CU`G40"R\F
M05@XCZJF71SXC@84CR&'#RT96BX77%/W<_IWE_582,.`<UC_%EG52%OF((:E
MUVET]0:T90?(%0AW10&U5VA<.'IT`'`P@($AEPXK=D!U,'P1='N?U69M9G)3
MYH<EV6<7`%:WAY%E5G,MN'`:L`&\B5S%>$#Q:(L1AI-9QGH6L''^H'#^UHZM
MB5>&9AD9Z'@&Q`_4V&L[:5E_^'S`>$`.R7=K&%RMZ8!(F8"6^&=A.)971(R'
MN0[JIPS\8)LS^$!'F7-S!0?J]D"N\(5C=%AB5Y$&](9W>%C!M5JZ.8F@9X/%
MAIB#-%LK<',6X`>W=0&:98:OQV]X`'`O()!C0'07$%K^\(8QH'@7@`Q$MP%^
MH`$4L()TA)J;"4'[((&E-8<SN@()_T:2O@APM!F!N&4#-71;*.=C07<!'4"C
M<Q@#*_:CRZA`;&6)<79W56FAL></%?=91%JDRE=U&O`-"C1X"U=::F>#L56&
MDZ5JL_F4K&FE-&J%&!A<Y\F!9`8,H9=%QQA]X'B;$)1H'?!T;4>/\&B`I@E&
M/;B-"B20&P`<SC99W>A8(]<,^M<!"KJ@=M2A#XD,0)=<R*6.!@1Z(1=94Y9Q
M;19R#-8/DPEP*W`/!8FH9&:1"P<#&-0/$2H,ZZ"9HKD.>=$;U56HL;5W=:J9
MAZF<_,:2IR>4K5$KQW-`Q*"`GP4#^[5[.>D/Y>BAIYF:S$=7?5$;29F!CN:=
M%U`'S:`/`O]FB;\UE:IJJ89Z8EDH9+Q1JW#7B^#C<629A>B%6F*G6)K)A'<4
MH:[P7*AA#L%0!VH77/^I0!47<@KZ:8'P6QE7`7OI#W'JE\_'D.7V6EOJ#YOJ
MJY$Z1\2(8L=S=<$UG3PX<Q90E7A0=O<EGUO(H_W0#!J@=']H8E:E06\XB:,'
M6]0Z:>4`!W!`;/[`5LV7C-D*HNKG>.E@B'J%#V/`;U-F0'X@HHX'LA8``^*G
MM%?H6.%P108VB@>TG%LCJ&3VB#%`!W45E$J&A1U08?47KKXH?@!H0!+X`OQ@
M#K.9#%>$#SD+9]@J=ALGD/2WGB?$BQO0=RNG`?&%K'!H"+JF?-G_Z(.WI@_$
M`+-:=G5D%K>J9WN6A7#&AEOGF*/Q9:`CEWU1!ZD8"T>5QW:U]WLAUWM+-G,"
M-WH4J4#(JG0)-G>,UZ-4%XFPI4&)2("?:`$K^GL.&@M_=[E^Z%Z6^)[\8`,+
MYZ"!4(YLAUEQRG)S8`BDM7"K1W`V^`T/.H:V&USW5U<PX(/320?WE:G@N0%V
M8`AT((F;5HH;,'4`JH!P$`MVT&<^.X)4:`.N0+T0*D+&%W+!E[Q1AX<<6*/"
MEYX5*XF?A@XF&5^_FYD>=Z0">0%P$`BQ0`<L^WT_JZ0[ZE84B&)IY9U+EYG"
M&UN5=P')(+&T-7("^:BB.TA$M[B(9G+R_]FP3X=9E4=;^*EE/6B\4<J_@!9T
M&MAQ1<=O*Z!NW^!QD;<!CG<.DBB;DK5:S>!L_J>$A^9T1!Q[5P0,XI=F^L"[
M+T!684B%#'=WJJIPM:</BI=S]W4![U@.KZ7#XVM91UB_@O6+%W!Z2B>+:"=;
MX#MS_+8!%4F0>AQU,D=F/>>Q^!!W?H?%*\`,X.,'D46%_*8!76R@ZE:WF(=Y
M@6R5SC;)4>>TL\FY+Z>IH=>G+DQ&P&!E,#!RZ``#<RBP6L9J#GJ:<T@'.X:A
MWH9>579F^(D.K`8#O8<.==!KI95N"C3,M"9J2J9UEB;+*P!K!]0,8V!G@6`(
MMKQBS+L"&M`!8_^F048VARLZI596HYIJ<*45""8XA\-@<W.(!RV4#X%P;1O0
M`3&0G.L`S'$F6\1,SS&`#&9&RW\K#,2,Q[^F0/A`9VU6S^\)1N]&SZ,&FBOP
MH0U[;L@P;3!0;?Q\:B.G9<'`;5_*C6<)S#>V#L)66C9`;LFHT=[F:&$(S:OU
MR]#L5\Y@93%PRJA,18)Q0\UC1JBQ77[Q0-)R0M^%1D#M0/B0#LYPRAUF#J&;
M01O&*QJ&#N?`QX6A8>O0#.$`;*MAFH;!1BSH#,5&U%>3&`UF7NE`0BP67AEI
M#AD&/ENCME#,#^S@80]T#Q_IU&!V#NAPM6L-/A^)7AMVU.@0UA#TE]__<`YR
MX4"XXE\=U@P:&4%PJ]1TI!<''5Z*<=,XW5)C5)YI24E-J-FA;4>CJ8&B;=JX
M!'9SA7BGS=K0E0RN(`R`VMJS3=NU;=NWC=NYK=N[S=N][=N_#=S!+=S#3=S%
M;=S'C=S)K=S+S=S-[=S/#=W1+=W33=W5;=W7C=W9K=W;S=W=[=W?#=[A+=[C
M3=[E;=[GC=[IK=[KS=[M[=[O#=_Q+=_S3=_U;=_WC=_YK=_[S=_][=__#>`!
M+N`#3N`%;N`'CN`)KN`+SN`-[N`/#N$1+N$33N$5;N$7CN$9KN$;SN$=[N$?
M#N(A+N(C3N(E;N(GCN(IKN(KSN(M[N(O#N,Q_R[C,T[C&E;C..776M9B8536
M&L;C._Y`/0Y&8I1%7[36753D1>[C:,3D+"9&2S[D4:Y=1H[D33[E4/[D4H[D
M/]Y@7([E_`7D1UWE1=WD67[E9![E9J[D6I3F1%[FX./F<([F6:[F=![G=N[D
M8M[E01[FEKWG>F[E:[Y=;Y[D>'[D@6[H8U[G<C[H;5[HC,YABB[G1_Y%?V#I
MEX[IF:[IF\[IG>[IGP[JH2[JHT[JI6[JIX[JJ:[JJ\[JK>[JKP[KL2[KLT[K
MM>[J+8#KN:[KN\[KO>[KOP[LP2[LPT[LQ6[LQX[LR:[LR\[LS>[LPJX"SR[M
MTT[MU6[MUX[MV:[MV\+.[=WN[=\.[N$N[N-.[N5N[N>.[NFN[NO.[NWN[N\.
M[_$N[_-.[_5N[_>.[_FN[_O.[_WN[_\.\`$O\`-/\`5O\`>/\`FO\`O/\`WO
M\`\/\1$O\0X?[=Q>\1./\1F_[Q>O[1RO\1\/\ACO\?P^\B%O[B5O\BG?ZRBO
M\BWO\B\/\S$O\S-/\S4?["QO\\F.\SG/\S??\^V^\S\O]$,_[4%/]$>/]$E?
>[T:O]$WO]"^/\DS_]%-/]56_[%)O]5G_\3L?$``[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
